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The body of work of 139 published papers contained herein, accompanied by a contextualising 
literature review and section preambles, constitutes a thesis submitted for the degree of Doctor 
of Medical Science. Included in this thesis are 78 high quality peer-reviewed principal 
publications presented in full, relating to clinical, epidemiological and basic scientific aspects of 
human prion disease for which I was first author, senior author or the leader of the Australian 
contribution in multi-national collaborative studies. In addition, are a further 61 publications and 
reports, listed by titles and publication details, dealing with human prion disease for which I was 
a significant contributor. A short overall review at the start of the thesis and a preamble before 
each of the sections dealing with my principal publications are offered to place these published 
studies in the context of extant clinical and scientific literature. 
Abstract 
This thesis is primarily constituted as a compendium of published manuscripts encapsulating a 
substantial volume of work relating to prion diseases, undertaken from 1999 to 2020 through the 
Australian National Creutzfeldt-Jakob Disease Registry based at the University of Melbourne, 
frequently in collaboration with pre-eminent domestic and international scholars in the field of 
prion diseases. 
The thesis is divided into two principal parts. The larger first part comprises 78 peer-reviewed 
papers submitted in full, representing a diverse array of acclaimed, often landmark or pivotal, 
studies published in prestigious general medical and specialist journals where I have been 
either senior and corresponding author, primary author or leader of the Australian contribution in 
major multi-national projects. This body of work is divided into seven sections spanning: normal 
prion protein cellular biology; prion pathogenesis; human prion disease epidemiological studies; 
human prion disease bio-marker studies; clinical aspects of human prion disease; prion disease 
treatment studies; and studies of human prion-like diseases. A short review at the start of the 
thesis and a preamble before each of these sections dealing with my principal publications are 
offered to place these published studies in the context of extant clinical and scientific literature. 
The second part of the thesis is submitted for completeness, comprising four sub-sections 
encompassing 61 publications and reports, listed by title and publication details, dealing with 
human prion disease for which I was a significant contributor.  
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Overview of Prion Diseases 
What are Prion Diseases (also known as Transmissible Spongiform 
Encephalopathies)? 
Generically grouped nosologically as neurodegenerative disorders, prion diseases constitute a 
unique sub-group of such conditions due to the combination of disease transmissibility, 
distinctive neuropathology and affliction of both human beings and animals. Substantial 
evidence supports that all prion diseases are caused by accumulation in the brain of misfolded, 
typically protease-resistant, conformers (PrPSc) of the normal or cellular form of the prion protein 
(PrPC), with PrPSc also constituting the transmissible agent (1, 2). In addition to 
immunohistochemical detection of PrPSc deposits in the brain, the other characteristic 
neuropathological features distinguishing prion diseases consist of vacuolation of the neuropil 
(spongiform change), as well as microgliosis and astrocytic gliosis (3). The spectrum of human 
prion diseases includes Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS), Fatal Familial Insomnia (FFI) and Kuru, while animal diseases include bovine 
spongiform encephalopathy (BSE; “mad cow” disease) in cattle, scrapie in sheep and goats, 
transmissible mink encephalopathy, chronic wasting disease (CWD) in deer, moose and elk, as 
well as the recently recognized disorder affecting dromedary camels (2, 4). The following brief 
overview will almost exclusively focus on human forms of prion disease. 
A (very) Potted History of Human Prion Diseases 
Scrapie is the archetypal prion disease, first clearly recognized by shepherds in the 18th century, 
with affected sheep displaying altered gait and intense scratching, the latter leading to the 
colloquial descriptor “scrapie” for the illness. After approximately two centuries, indisputable 
evidence of transmissibility of scrapie was reported in 1936, albeit inadvertently, during attempts 
to vaccinate sheep against louping ill virus. The first reports of likely human prion disease were 
made independently by a German neuropathologist (Hans Creutzfeldt) and neurologist (Alfons 
Jakob) in the early 1920s although despite the eventual eponymous designation of Creutzfeldt-
Jakob disease (CJD) for the conflated malady of the central nervous system, subsequent 
investigation makes it unlikely that the case described by Creutzfeldt and three of Jakob’s five 
original cases were in fact human prion disease. In the 1950s, an unusual neurological disorder 
known as Kuru, predominantly manifesting as a cerebellar ataxia, was recognized as endemic 
amongst the Fore linguistic group in the Eastern Highlands of Papua-New Guinea, as well as 
neighbouring tribes with whom they inter-married (5). Shortly thereafter, the perspicacious 
observations of a veterinary pathologist (Dr William Hadlow) that scrapie and Kuru shared 
similar clinical and neuropathological features led Carleton Gajdusek and his team at the NIH in 
the USA to undertake transmission studies of Kuru, with Kuru reported to be transmissible to 
chimpanzees through intra-cerebral inoculation in 1966 (6); shortly thereafter CJD was 
confirmed as also transmissible in 1968 (7). Subsequent detailed epidemiological investigations 
concluded that Kuru had arisen and been maintained through ritualistic endo-cannibalism, 
practiced as part of mourning rites of the Fore (8). Further delineating the major phenotypes of 
human prion disease, in 1981 a landmark report suggested unification of a previously disparate 
group of neurodegenerative diseases under the rubric GSS through appreciation of their shared 
neuropathological features, with demonstration of transmissibility confirming their unified 
nosology as prion disease (9). Completing the major phenotypes comprising the spectrum of 
human prion diseases, in 1992 FFI was shown to be tightly linked to a mutation in the prion 
protein gene (10) with transmissibility confirmed 3 years later (11). 
Elucidating the Causative Agent of Prion Diseases 
Early hypotheses concerning the causative agent underlying prion diseases included a “viroid”, 
a “slow virus”, or an “unconventional virus”, albeit posited in parallel with mounting scientific 
observations making a conventional infectious agent harbouring a nucleic acid genome highly 
unlikely (12-14). Despite intensive efforts, there was inability to reproducibly isolate a virus or 
demonstrate virus sub-particles, with other experimental evidence showing the causative agent 
of prion diseases resisted treatments (viz, ionizing radiation and UV light) considered highly 
effective at destroying conventional nucleic acid-containing microbial pathogens (14), while the 
agent was vulnerable to methods denaturing proteins. These data culminated in the “protein-
only” hypothesis for the infectious agent underpinning prion diseases, first clearly articulated in 
1967 (13, 15). Indeed, a mathematician (John Griffith) was the first to offer mechanisms that 
might underlie how a protein could replicate and be “infectious” (16). Nevertheless, it took a 
further 25 years before sufficient scientific data were amassed to strongly support the "protein-
only" postulate (1, 17), with Stanley Prusiner coining the term “prion” to depict a 
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proteinaceous infectious particle as the transmissible scrapie agent. Shortly thereafter, the 
protease-resistant component of the protein (denoted PrP27-30) that tightly correlated with prion 
infectivity was identified and called the “prion protein” (18) and a year later it was shown that 
PrP27-30 was in fact encoded by the normal mouse or host genome (19). 
Rigorous confirmation of the “protein-only” hypothesis was considered to require the de novo or 
in vitro production of infectious prions from pure PrPC. Such proof of the hypothesis took another 
approximately 22 years, with Stanley Prusiner and colleagues in 2004 reporting the in vitro 
production of “synthetic prions” through induction of misfolding of recombinant, truncated, 
mouse prion protein (MoPrP89-230) (20). Successful transmission was achieved through 
intracerebral inoculation of the misfolded recombinant synthetic MoPrP89-230 prions into 
transgenic mice carrying the same truncated prion protein gene, requiring 380-660 days after 
inoculation for mice to develop symptoms of a prion-like disorder. Subsequently, successful 
transmission into wild-type FVB mice was achieved employing the brains of sick transgenic 
mice initially injected with recombinant misfolded synthetic MoPrP89-230 prions. Shortly 
thereafter, it was demonstrated that these synthetic prions harboured strain properties akin to 
what is observed in “natural” prion diseases (21). Over the next six years, a number of 
independent research teams, utilising different experimental approaches, reported the 
successful de novo production of synthetic prions, including those able to directly induce 
disease in wild-type recipient mice, providing essentially indisputable collective final validation of 
the "protein-only" hypothesis (22-25). 
Cellular Biology and Functions of the Normal Prion Protein (PrPC) 
In homo sapiens, PrPC is encoded within a single open reading frame of the single-copy 
housekeeping prion protein gene (PRNP) located on chromosome 20, while in mouse the 
homologous gene (Prnp) is located on chromosome 2. The prion protein gene is highly 
evolutionarily conserved across vertebrates, as is the structure of PrPC in mammals (26) and 
lower species (27), supporting a likely critical biological function (28). PrPC undergoes a  
biosynthetic pathway typical of secreted proteins, involving synthesis on the endoplasmic 
reticulum (ER) and passage through the Golgi apparatus, with packaging into endosomes for 
delivery to specialized detergent-resistant (cholesterol and sphingolipid-rich) microdomains 
(“lipid rafts”) on the external leaflet of the cell’s surface membrane (29, 30). Human PrPC is 
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genetically coded as a 253 amino acid protein from which the first 22 residues (“signal peptide”) 
are co-translationally cleaved shortly after translation commences. Further post-translational 
processing includes addition of a C-terminal glycosylphosphatidylinositol (GPI)-anchor at serine 
residue 230, important for directing glycolipid linkage of PrPc into lipid rafts of the external 
leaflet of the cell membrane (31), while PrPC can also be glycosylated, with the two potential 
sites for attachment of N-linked oligosaccharide chains located at residues 181 and 197. A 
histidine-rich, metal binding domain consisting of a nonapeptide followed by four identical 
octapeptide repeats (OPR) is located between residues 51 and 91.  
PrPC is recognized as a copper binding protein (32) with less than 0.1 nanomolar affinity and in 
fact the histidine residue within each OPR is capable of binding individual copper and zinc ions in 
a co-operative manner (33, 34), with metal binding initiating intracellular translocation of PrPC via 
clathrin-dependent endocytosis (35). PrPC also has two additional Cu2+ ion binding histidines 
located at codons 96 and 111 (36).The tertiary structure of mature, including membrane-bound 
PrPC, displays an ordered globular C-terminus containing three alpha-helices, with helices 2 and 
3 linked by a di-sulphide bridge, while the N-terminal region up to residue 120 is more flexibly 
unstructured (26, 37). PrPC expression commences early in embryogenesis and although 
highest levels in the adult are found in neurons of the central nervous system (38, 39) there is 
almost ubiquitous cellular expression at lower levels, especially within the reticulo-endothelial 
system (40, 41). Codon 129 of PrPC is polymorphic, containing either valine (V) or methionine 
(M) at this site, with polymorphic status influencing both risk of developing human prion disease
(42), as well as disease phenotype (10, 43).
PrPC may undergo constitutive endoproteolytic events, including alpha (at residues 111/112) 
and beta (“ragged”, broadly located around residue 90) (44-46), with such processing generating 
N1-C1 and N2-C2 cleavage pairs, respectively. In addition, PrPC may be cleaved by a-
disintegrin-and-metalloproteinase 10 (ADAM 10) in the region of linkage to its GPI anchor
(“shedding”) liberating full-length protein or post-endproteolysis C-terminal fragments (47). 
Endoproteolysis appears to have importance both physiologically and pathologically, with alpha-
cleavage predominant in non-disease states and protective against misfolding of full-length PrPC 
or the C1 fragment into PrPSc (48, 49), while the C2 fragment is increased in prion disease 
suggesting a role for beta-cleavage in pathogenesis (45). Further circumstantially illustrating
the neuro-biological importance of alpha-cleavage, transgenic mice harbouring mutant PrPC missing 
residues 105-125 (delta105-125), thereby preventing alpha-cleavage, show spontaneous 
neurodegeneration with pathological abnormalities different to those of prion disease (50). 
Putative normal functions of PrPC  
Although the likely primary biological purpose of PrPC in the peripheral nervous system appears 
related to maintaining myelination (51), consensus regarding the predominant role of PrPC in the 
CNS remains to be achieved. Moreover, PrPC has also been reported to have important 
functions outside of neurons and in fact the first functional activity reported for PrPC was in 
lymphocyte activation (52). Despite the original description of PRNP gene-ablated (Prn-p0/0) mice 
claiming no apparent adverse phenotypic outcome when comparing wild-type (WT) and Prn-p0/0 
mice (53), subsequent studies have reported a number of deficiencies in addition to peripheral 
nerve demyelination (51), such as hippocampal synaptic dysfunction (54) and cognate memory 
impairment (55), as well as diverse, more generic failures in protection against oxidative 
stress (56), copper and zinc binding (32, 34), membrane signal transduction (57) and synaptic 
function (58). 
Many reports support that PrPC may have a neuroprotective role, especially against oxidative 
stress (59, 60) but also other noxious insults, including the likelihood that products of PrPC 
endoproteolysis may contribute to safeguarding neurons (61). These observations raise the 
possibility that corruption of normal PrPC function may at least partly underscore pathogenesis 
in animal and human prion disease. Some reported functions of PrPC may at least partly 
overlap. For example, neuroprotection against excitotoxicity may also involve a role in synaptic 
regulation, with PrPC mitigating excessive activation of N-Methyl-D-aspartic acid receptors 
(NMDAR) and cognate calcium ion (Ca2+) entry into cells induced by ischemia (62) via direct 
association with the NR2D subunit, favourably constraining NMDAR activity and attenuating 
potential excitotoxicity (63). In addition to the participation of full-length PrPC in neuroprotective 
activities, the N1 fragment has also been reported to protect against staurosporine induced 
caspase-3 activation in rat retinal cells (64) and also bind to synaptotoxic Abeta oligomers 
thereby preventing Abeta peptide fibrillisation and abrogating their toxicity in vitro and in vivo 
(65). This type of study undertaken by Fluharty and colleagues assessing a protective role of 
PrPC against Abeta peptides was prompted by a landmark report that membrane-bound PrPC 
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acts as a receptor for soluble amyloid-beta (Abeta) oligomers thereby mediating their 
synaptotoxicity (66); however, not all studies have supported a direct role of PrPC mediating 
soluble Abetaβoligomer synaptotoxicity (67) (68). 
Localisation of PrPC predominantly within lipid raft domains on the plasma membrane (like other 
GPI-anchored proteins) supported the likelihood of participation in transmembrane signal 
transduction, possibly as part of a multi-molecular “scaffold”. This property was first definitively 
demonstrated through antibody-mediated cross-linking of PrPC in the 1C11 cell line leading to 
activation of the non-receptor tyrosine kinase, Fyn (57). Subsequent studies reported that 
antibody-induced activation of Fyn through PrPC induced reactive oxygen species production via 
extracellular-regulated kinases (ERK) 1/2 and nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase in both neuronal and non-neuronal cells (69). 
Numerous investigations support that PrPC is involved in synaptic development and function 
(70-74). Early electrophysiological studies in Prnp0/0 mice hippocampal slices revealed that 
long-term potentiation (LTP) was disrupted and receptor-associated fast inhibition involving 
GABA-A receptors was impaired (70), with subsequent investigation supporting that PrPC was 
unlikely to have an intrinsic synaptic ion channel function but more likely acting to stabilise 
synapses (54). Impaired after-hyperpolarisation (through disruption of Ca2+-activated K+ 
currents) has been observed in Prnp0/0 mice hippocampal CA1 and cerebellar Purkinje cells (75, 
76). As a corollary of an important participation in synaptic function, especially in the 
hippocampus, several studies employing transgenic rodent models have demonstrated that 
PrPC appears have a role in memory, with absence of PrPC causing altered short-term memory 
(STM) formation and impairment of long-term memory (LTM) consolidation (55, 77), with 
apparent age-dependency of the deficits given such impairments were absent at age 3 months 
but present at 9 months of age (78). Memory impairments in Prnp0/0 mice were rescued when 
PrPC was selectively re-expressed in neurons (55). 
Pathogenesis of Prion Disease 
Acknowledging the fundamental role of conversion of PrPC to PrPSc (through an auto-catalytic, 
template-directed process) for both successful disease transmission and subsequent 
pathogenesis, it is not surprising that Prnp0/0 mice are completely resistant to development of 
prion disease (79). Moreover, conditional knock-out mice (employing the NFH-Cre/MloxP 
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system) that lose PrPC expression in neurons at ~12 weeks of age are also resistant to disease 
when inoculated at ~4 weeks of age, with early neuropathological changes such as spongiosis 
reversing in these inoculated transgenic mice (80). These studies underscore the critical 
importance of ongoing expression of PrPC serving as a substrate for conversion to PrPSc for 
successful disease pathogenesis.  
Considerable evidence supports that small soluble oligomers of Abeta peptides in Alzheimer’s 
disease (AD) and alpha-synuclein peptides in Parkinson’s disease (PD) are primarily 
responsible for inducing neurotoxicity, with synaptic failure and eventual synapse loss key 
outcomes underpinning progressive cognitive decline in AD (81). Electrophysiological studies 
have demonstrated that small soluble Abeta oligomers extracted from the brains of patients 
with AD can potently inhibit LTP and enhance long-term depression (LTD), as well as reduce 
dendritic spine density, in normal rodent hippocampus (82). As described above, evidence 
supports that PrPC can function as a high affinity receptor for soluble Abeta oligomers 
extracted from various sources, thereby transducing their neurotoxicity with consequent 
blockade of hippocampal LTP, with the latter prevented by anti-PrP antibodies (66, 83). 
Additional in vivo and in vitro studies have demonstrated that soluble Abeta oligomers binding 
tooPrPC activate Fyn causing phosphorylation of the NR2B subunit of NMDARs resulting in 
depletion of NMDARs and synapse loss (84).
Although there is good evidence that small oligomers of PrPSc appear to be the most efficient for 
prion disease transmission (85, 86) much less is known about the bio-physical properties of the 
neurotoxic species driving pathogenesis and their relationship to those entities sub-serving 
transmission. This contrasting level of understanding in prion diseases concerning the 
neurotoxic species and its molecular pathogenic effects stems in large part due to the relative 
lack of tractable, authentic models of acute prion neurotoxicity to redress such knowledge gaps. 
Simple in vitro cell culture models have demonstrated toxic effects of recombinant, soluble, 
oligomeric PrP enriched in beta-sheet content, as well as toxicity from purified ex vivo PrPSc and 
proteinase treated PrPSc extracted from the brains of terminally sick rodents (87-89). In addition, 
an in vivo model of acute neurotoxicity employing stereotaxic injection of recombinant, full-
length, beta-sheet-rich, PrP oligomers into the hippocampal CA2 region has been reported, with 
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toxicity assessed morphologically at 24 hours (90). A model utilising cultured organotypic 
cerebellar slice explants has also been described (91) although this model relies entirely on de 
novo PrPSc propagation to generate neurotoxic species over an extended 5-7 week period, 
rendering it not ideal for assessing direct acute PrPSc neurotoxicity. Another recently reported 
model employed ex vivo PrPSc species, scrutinising for retraction and loss of dendritic spines in 
cultured hippocampal neurons following several hours of exposure to the PrPSc preparations 
(92); however, the reported synaptotoxicity required expression of PrPC leaving uncertainty as to 
whether the neurotoxic PrPSc species were entirely those directly added to the culture or were 
species generated from host PrPC through early PrPSc propagation. Nevertheless, despite 
considerable limitations of extant models, evidence exists in prion diseases supporting an 
analogous situation to AD and PD with the neurotoxic entity most likely small oligomers of PrPSc 
(90, 93), with synaptic failure appearing to be an important feature of pathogenesis (94-96). 
Moreover, studies have revealed that impairment of hippocampal LTP coincides with the earliest 
detection of PrPSc, slightly prior to morphological evidence of synaptic loss or neuropil 
vacuolation (96), supporting that impairment of hippocampal CA1 region LTP is an early, 
sensitive indicator of pathogenesis in prion strains that manifest prominent hippocampal 
damage and suggest that PrPSc is likely to be directly synaptotoxic. 
Once present, however, the molecular mechanisms through which neurotoxic PrPSc species 
induce homeostatic failure in neurons or disrupt critical pathways necessary for cellular integrity 
remain incompletely resolved. Many studies aimed at elucidating prion pathogenesis have been 
published, with data supporting the likelihood of protean deleterious consequences from prion 
infection and the possibility that neurotoxic PrPSc species may simultaneously disturb more 
than one fundamental cellular capacity through a “toxic gain-of-function” mechanism; however, 
these observations do not exclude contributions to pathogenesis from corruption of normal PrPC 
function. Arguably, the best scientific evidence supports enhanced oxidative stress (97), 
sustained translational repression (98), especially triggered as part of the unfolded protein 
response (99), disturbed synaptic calcium ion channels (100) and dysregulation of NMDA 
receptors causing glutamate-induced excitotoxicity (63) as key pathogenic consequences 
contributing to neuronal dysfunction and death. Importantly, these various deleterious 
consequences of neurotoxic PrPSc would initially be expressed as synaptic impairment.       
14 
15 
Human Prion diseases 
Nosologically, clinical human prion disease is primarily classified by phenotype as CJD, GSS, 
FFI or Kuru, with CJD by far the most common form. They can also be concurrently classified 
according to aetiology as sporadic (no known explanation), acquired (horizontally transmitted) or 
inherited (genetic). All genetic forms of prion disease are exclusively caused by various 
pathogenic sequence variations (missense and nonsense point changes, as well as tandem 
polynucleotide repeat insertions) within the open reading frame of PRNP.   
Sporadic Creutzfeldt-Jakob disease 
Sporadic CJD (sCJD) is the most common form of CJD, explaining 85-90% of all CJD cases, 
with genetic CJD accounting of 10-15% (101) and acquired CJD <1%. Likelihood of sCJD 
increases with age with an overall incidence of 1-2 cases/million per year (102). Sexes are 
affected approximately equally with the slight female predominance attributed to longer life 
expectancy. Peak occurrence is between 60 and 79 years (103). Causation is unresolved but 
canonically sCJD is believed to probably represent a stochastic misfolding of PrPC to PrPSc in 
the brain, which may happen throughout life (104), with the age-associated occurrence of 
sporadic CJD due to accumulation of PrPSc to neurotoxic levels in the brain probably arising 
from age-related decline in protein quality control mechanisms. Alternatively, a spontaneous 
somatic mutation in PRNP to produce PrPSc cannot be excluded, with some recent evidence to 
support this from a bovine form of prion disease (105).  
Characteristically, sCJD presents as a rapidly progressive dementia (RPD) accompanied by 
cerebellar ataxia but a diverse range of other presenting symptoms such as myoclonus and 
psychiatric disturbance are possible (106). Although relentless neurological deterioration is 
typical with median survival from first symptoms to death ~4-5 months (107), longer survival is 
well recognized; terminally, patients frequently develop a state of “akinetic mutism”. A definite 
diagnosis requires neuropathological examination, most commonly through autopsy. The 
phenotypic heterogeneity of sCJD appears to correlate with molecular subtype as determined 
by the combination of codon 129 status of PRNP (methionine [M] or valine [V] polymorphism) 
and the size of the unglycosylated, protease resistant PrPSc C-terminal fragment on western 
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blotting (type 1 ~21kDa, type 2 ~19 kDa), with 6 sub-types originally clearly described: 
MM1/MV1, VV2, MV2, MM2-cortical (MM2C), VV1 and MM2-thalamic (MM2T; sporadic fatal 
insomnia) (108). Illustrating the phenotypic diversity across sCJD molecular sub-types, 
MM1/MV1 cases are the most common (~65%) typically manifesting RPD and myoclonus with 
survival of <~4 months, while MV2 cases characteristically manifest ataxia with survival often 
longer than 24 months and have unicentric, Kuru-type (PrPSc-positive) amyloid plaques in the 
cerebellum; VV1 is the most uncommon (~1% of sCJD) and patients may have younger onset 
of clinical disease with the cognitive impairment often fronto-temporal in type, which may 
evolve without significant gross motor impairment. Although a competing molecular sub-typing 
nomenclature was developed based on refinement of the western blot mobility of the 
unglycosylated, protease resistant PrPSc C-terminal type 1 fragment (thereby creating 3 
fragment types) the principle of phenotypic diversity correlating with molecular sub-type 
remained biologically valid (109). Subsequent studies have shown molecular sub-typing to be 
more complicated by the relatively frequent co-occurrence of type1 and type 2 fragments in the 
same brain if multiple cerebral hemispheric sites are sampled (110). 
Further broadening the phenotypic spectrum of sCJD, in 2008 another subtype of disease 
known as “variably protease-sensitive prionopathy” (VPSPr) was reported with such cases 
thought to represent ~1-2% of all sCJD (111). In the seminal study, 11 patients with codon 129 
V homozygosity were reported, and while the brain neuropathology revealed spongiform 
encephalopathy and positive immunohistochemistry for PrP, conventional western blotting of 
brain homogenates after PK digestion employing the 3F4 antibody unexpectedly showed 
absence of protease-resistant PrPSc. Additional immunoblot analyses using another anti-PrP 
antibody (1E4) did detect protease-resistant PrP but in reduced amounts and displaying an 
unusual laddering pattern to the banding. These patients were on average somewhat younger 
than usually observed for sCJD and did not show typical diagnostic features for sCJD on EEG 
and brain MRI, with CSF negative for 14-3-3 protein; none of the patients had parhogenic sequence 
variations in PRNP. Two years later the same group reported an elaboration of their original 
observations with additional VPSPr cases encompassing the codon 129 MM and MV 
genotypes, with all three genotypes sharing similar phenotypic and neurological profiles 
although VV cases harboured PrPSc with the least protease-resistance (112). 
Beyond codon 129 contributing to the molecular sub-type of sCJD, homozygosity for M or V is  
associated with an increased risk of developing sCJD (113). While in normal Caucasian 
populations 52% of individuals are methionine homozygous (MM), 36% are heterozygous (MV) 
and 12% are V homozygous (VV) (114), homozygosity for M or V isipresent in greater 
than≥80% of persons with sCJD. Additional PRNP codon influences on risk are recognised in 
Asian populations, with codon 219 of PRNP homozygous for glutamic acid (G) in >92% of 
Japanese, Han Chinese and Koreans, with heterozygosity with lysine (K) at this site highly 
protective against the development of sCJD (113).  
Acquired prion disease 
Acquired prion disease arises from the typically inadvertent exposure to and consequent 
horizontal transmission of prions to humans and accounts for <1% of human prion disease. The 
first report of transmission in a health care setting (iatrogenic CJD; iCJD) was in 1974 in a 
patient who received corneal grafts unwittingly harvested from a patient dying of CJD (115). 
Subsequently, iCJD has most commonly occurred through use of contaminated human 
cadaveric pituitary hormones as treatments for short stature (116) and infertility (117), as well as 
the use of dura mater grafts in neurosurgery but has also occurred secondary to contaminated 
neurosurgical instruments (118). Clinically, iCJD, especially if related to cadaveric pituitary 
hormone therapy, tends to initially manifest as a progressive cerebellar syndrome with dementia 
occurring late if it develops (119). 
 As explained previously, transmission through participation in endo-cannibalistic mourning 
feasts was eventually shown to be the explanation for Kuru, the unusual neurodegenerative 
cerebellar ataxia observed in the Fore linguistic group in the Eastern Highlands of Papua-New 
Guinea (8). In general, young children and women consumed more infectious tissues such as 
brain and internal organs, while adult men consumed less infectious skeletal muscles. The 
name Kuru comes from the Fore language meaning ‘to shiver’ (or ‘to be afraid’). Although highly 
endemic in the Fore when originally recognized and reported in the 1950s as these remote 
regions came under external scrutiny and control, Kuru is now essentially eradicated due to the 
enforced outlawing of cannibalism albeit with some most recent cases evincing incubation 
periods of more than 50 years since their participation in the morning feasts of relatives dying 
from Kuru (120). Typically, Kuru presents with impaired balance and an ataxic gait although 
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30% of patients report non-specific prodromal symptoms (arthralgias, headache, malaise, cough 
etc). With disease progression, the Kuru victim is eventually unable to ambulate and dies 
anywhere from 6-36 months after onset in a bed-ridden state. Neuropathologically, the brain is 
diffusely affected, with nosologically distinctive features being amyloid ("Kuru") plaques 
composed of PrPSc and spongiform degeneration with neuronal loss and astrocytic gliosis also 
evident. Population genetic studies support that Kuru imposed strong selection pressure on 
PRNP within the Fore, especially at codons 127 and 129, with heterozygosity at these codons 
offering protection against Kuru, over-represented in survivors of the sustained Kuru epidemic. 
 The best known form of acquired prion disease is variant CJD (vCJD), the zoonosis related to 
BSE, first reported in the UK in 1996 (121, 122). Strong evidence supporting the same 
aetiologic prion strain as BSE was provided very shortly after its recognition (122). vCJD 
typically presents with alterations in mood and behavior, as well as unpleasant sensory 
experiences, before more definite neurological symptoms ensue, and primarily occurs in young 
adults under age 50 years (median age at death 28 years) (121, 123). Neuropathological 
findings are distinctive for the presence of “florid plaques” (PrPSc-amyloid cores surrounded by 
vacuoles) spread across the brain, with spongiform change most pronounced in the thalamus 
and basal ganglia (121). In addition, vCJD is associated with more widespread distribution of 
PrPSc across lympho-reticular tissues such as lymph nodes, tonsil and appendix (124), which is 
most likely the pathophysiological explanation for the secondary transmissions of vCJD through 
transfusion of blood products (125, 126). Currently, 232 cases of vCJD have been recognized 
worldwide, spread across 12 countries, with the largest number in the UK (n=178) and the most 
recent case occurring in France in a person possibly contracting their illness through 
professional mis-adventure as a laboratory researcher (127). Until 2016 (128), all cases of vCJD 
had been associated with M homozygosity at codon 129. 
Genetic prion disease 
Inherited prion disease accounts for approximately 10-15% of all human prion disease, with 
essentially all genetic prion disease caused by sequence variations (mis-sense, non-sense, and 
octapeptide repeat insertions) in the open reading frame of the PRNP, which through 
incompletely defined mechanisms is believed to lead to PrPC misfolding and most often PrPSc 
accumulation in the brain.  
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A large number of PRNP mis-sense sequence variations have been claimed as causal of 
genetic CJD (gCJD), with the most commonly reported E200K, D178N[cis-codon129V] and 
V210I (129). Carriers of E200K and D178N[cis-codon129V] display high penetrance with a 
nearly 100% likelihood of developing the disease during life. Genetic CJD due to the most 
common causal mis-sense PRNP mutations is usually clinically indistinguishable from sCJD and 
genetic analysis is required to clarify the aetiology. Shorter (2-7 in length) octapeptide repeat 
insertions have also been reported as a cause of gCJD and similar to mis-sense sequence 
variations, phenotypic variation within kindreds is well recognized (130, 131). Single octapeptide 
repeat insertions (129) and deletions (130) are believed to be normal polymorphisms, while a 2-
octapeptide repeat deletion has been tentatively linked to CJD (132). 
GSS is considered exclusively genetic in aetiology, displaying autosomal dominant inheritance, 
and most commonly manifesting as a chronic progressive cerebellar ataxic syndrome although 
phenotypic variation is recognized. Cognitive impairment usually occurs at some point in the 
illness, with survival often extending over many years. Neuropathologically, multi-centric amyloid 
plaques comprised of PrPSc are characteristic, often with a topological predilection for the 
cerebellum; spongiform change can vary from severe to absent. GSS has also been reported in 
association with a range of mis-sense PRNP sequence variations (such as F198S, Y218N, 
P105L, A117V) with P102L the first described (133) and most common (129). Other recognized 
PRNP changes include larger (8 and 9 in length) octapeptide repeat insertions (134) and non-
sense mutations (135, 136).  
Originally recognised in a large, mutli-generational, Italian kindred as an unusual thalamic 
neurodegenerative disorder of uncertain aetiology (137), similar to GSS, FFI was later revealed 
to be an essentially exclusively genetic disease, associated with the D178N[cis-codon129M] 
sequence variation in PRNP (10); three years later it was confirmed as transmissible (11) firmly 
establishing the malady as a prion disease. The major neuropathological findings are observed 
in the thalamus, especially the medial dorsal and anterior ventral nuclei, with severe neuronal 
loss and astrocytic gliosis but little or no spongiform degeneration although the latter can be 
observed to a varying extent in the cerebral cortex. FFI primarily manifests as a sleep disorder 
associated with dysautonomia but multifarious additional neurological features are reported. Of 
interest and underscoring the important potential disease-modifying influence of other single 
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amino acid substitutions in the primary PrPC sequence, as described above, if the D178N PRNP 
sequence variation is in cis with valine at codon 129 (D178N[cis-codon129V]), then the clinical 
phenotype more often aligns to CJD rather than FFI (43). As alluded previously, the very 
uncommon sCJD molecular subtype MM2T (i.e. in the absence of any underlying D178N[cis-
codon129M] sequence variation in PRNP) can also be associated with an illness recapitulating 
most of the clinical features of FFI and is known as "sporadic FFI(sFI)" (138). The most 
common clinical features of sFI are insomnia, ataxia and cognitive decline but motor 
impairments such as tremor and myoclonus can be present. 
Treatments for Prion Disease 
Some optimism regarding the potential for effective treatment of prion diseases is derived from 
the fact congenital absence of PrPC completely prevents disease occurrence (79), while 
successful post-natal removal of PRNP with total suppression of neuronal PrPC expression soon 
after disease initiation appears to completely arrest disease progression and even allow 
reversal of early neuropathological changes (80). Nevertheless, over many years an extremely 
diverse range of conventional therapies employing various models have been trialed as 
treatments for prion disease with limited or no meaningful success. To claim legitimacy as a 
treatment for sporadic human prion disease the therapy needs to offer significant disease 
modifying effect when commenced around the time of clinical disease onset although this 
imperative is not strictly applicable to genetic prion disease where pre-emptive therapeutic 
intervention may be possible in known mutation carriers.  
Although mechanisms of action are not always clearly understood, treatment strategies have 
broadly tried to target one or more of a few major pathophysiological processes such as: 
depletion of the availability of PrPC as substrate for conversion to PrPSc (eg RNAi); direct 
interference with PrPSc-templated PrPC misfolding (eg Congo red derivatives CR-A, CR-B); 
and/or correction or mitigation of corrupted homeostatic mechanisms linked to pathogenesis (eg 
PERK inhibitor GSK2606414 to inhibit parts of the unfolded protein response). A bewildering 
array of therapeutics spanning small molecules, large molecules, antibodies, nucleic acids, 
chelators, antibiotics etc have been trialed in in vivo models with some prolongation of survival 
reported if given around the time of inoculation of animals with prions. A much smaller number 
of therapeutics have shown some efficacy if administered beyond 50% of the predicted 
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incubation period (eg chemical chaperone GN8, dimethyl sulfoxide, doxycycline etc) with the 
most potent treatments increasing survival compared to controls by ~170% (intra-
cerebroventricular pentosan polysulphate (139)), ~140% (intra-peritoneal polyene antibiotic MS-
8209 (140)); and ~23% (single stereotactic intra-hippocampal injection of RNAi (141)), with 
another promising treatment involving twice-weekly oral gavage of the PERK inhibitor 
GSK2606414 halted at the time when non-treated mice were terminally ill but treated mice 
appeared free of disease (142). Rarely have treatments been studied for benefit when 
administered around the time of clinical onset of disease. 
To date, formal human trials of prion disease therapeutics are very limited with unfortunately 
minimal or no proven benefits demonstrated. The first controlled trial employed the non-opioid 
analgesic flupirtine, and while demonstrating very modest benefit in cognitive performance it 
showed no prolongation of survival (143). Human trials involving the ani-malarial drug 
quinacrine have suffered methodological flaws but no clear efficacy has been apparent (144, 
145). Doxycycline was examined in a good quality, controlled trial and despite previous claims 
of worthwhile benefit in pre-clinical studies and through individual humane use, no efficacy was 
demonstrated (146). A formal review of observational compassionate use of prolonged intra-
cereboventricular infusion of pentosan polysulphate in vCJD patients has suggested possible or 
probable prolongation of survival albeit in a vegetative state thereby questioning the 
meaningfulness of the therapy (147). Despite these cumulative disappointments, a cautious 
positive anticipation surrounds the use of an anti-sense oligonucleotide (ASO) approach, given 
the absolute pathogenic dependence on ongoing availability of PrPC as substrate for conversion 
and the success of this technology in genetically driven diseases such as spinal muscular 
atrophy. The ASO is directed against the mRNA of PrPC, promoting cell-mediated degradation 
prior to translation and hence substantial diminution of expression levels; hopefully human trials 
of this therapeutic approach will commence soon (148).    
Prion-like diseases 
Following Stanley Prusiner’s paradigm shifting report in 1982 firmly establishing the “protein-
only” hypothesis (1), the next approximately 3 decades saw prion diseases progressively 
construed as occupying a unique nosological category amongst neurodegenerative disorders. 
Over recent years, however the concept that prion diseases are biologically unique, given the 
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transmissible agent is constituted primarily if not exclusively by misfolded prion protein (PrPSc), 
has been increasingly questioned. Tentative evidence was presented many years ago 
suggesting the transmissibility of Abeta in animal (primate) models (149) and during the 
provision of human health care (150) but really gained no traction; it is only during the last 
approximately 5-10 years that the unparalleled biological standing of prion diseases has been 
seriously challenged. Although many issues in relation to this blurring of the margins between 
prions and other proteins underpinning non-prion neurodegenerative diseases, such as AD 
(Abetaβand tau) and PD (alpha-synuclein) remain to be resolved, there seems little doubt that 
the previous neat and unassailable demarcation of prion diseases from other neurodegenerative 
disorders has been relegated to history. Over recent years numerous basic scientific and clinical 
research studies have undermined the exceptional biological standing of prion diseases. Prion-
like mechanisms of propagation, inter-cellular transfer and inter-organismal spread have been 
reported for other proteins, especially Abetaβ(151, 152) and alpha-synuclein (153-156), as well 
as more limited data for tau (157) and huntingtin (158). This growing body of work has prompted 
provisional new descriptors for these transmissible non-prion proteins, including 
“propagons” (159) or “proteopathic seeds” (160).
Probably the most compelling evidence for inter-organismal transmissibility and propagation of 
non-prion proteins pertains to the use of human cadaveric pituitary hormones (161) and dura 
mater grafts (162) as treatments. One of the important issues to resolve is whether following 
transmission, the propagation and accumulation of non-prion proteins such as Abeta in a new 
host culminate in a disease phenotype or remain sub-clinical. Although the initial observation of 
transmitted Abeta being propagated and deposited in the brain as parenchymal plaques and in 
cerebral blood vessels as cerebral amyloid angiopathy (CAA) was in those succumbing to iCJD, 
subsequent reports have demonstrated these neuropathological findings in people undergoing 
identical treatments who did not develop iCJD (163) and also in patients receiving peripheral 
dura mater grafts for non-neurological reasons (164) or simply undergoing childhood 
neurosurgery many years previously (165). Moreover and very importantly, these very recent 
reports (164, 165) support the pendulum has swung towards the likely eventual development of 
overt disease in at least some individuals undergoing such treatments (eg dura mater grafts; 
neurosurgery with instruments presumably contaminated with Abeta), with the propagated Abetaβ 
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deposited as CAA causing spontaneous, often severe, intra-cranial haemorrhage in relatively 
young people with no genetic or other risk factors for premature CAA. 
Section 1: Normal Prion Protein Cellular Biology 
As outlined in the literature review, considerable progress over the last four decades has been 
made in understanding the cellular biology of PrPC, such as synthetic pathways, cellular 
locations of the mature protein, constitutive processing events, turnover mechanisms and 
potential normal functions. Achieving a good understanding of the normal cellular biology of 
PrPC informs fundamental issues such as likely principal function(s) in the CNS, as well as any 
role in the pathogenesis of prion disease; both likely to illuminate or facilitate therapeutic 
avenues. Despite such progress however, our understanding is far from complete and we are 
still without a consensus understanding of the principal biological role(s) of PrPC in the CNS 
although many putative functions have been reported. Over many years I lead my research 
team to undertake numerous important studies, providing worthwhile new insights into the 
cellular biology of PrPC and how this may relate to normal function and impact prion disease 
pathogenesis. These studies provided insights into the structural biology of membrane 
interactions and the factors influencing signal transduction of PrPC, as well as showed that
constitutive endoproteolysis, including generated fragments, are likely to have important roles in 
attenuating oxidative stress and mitigating conversion of PrPC to PrPSc. Our studies also
demonstrated a new type endoproteolytic (“gamma”-) cleavage, which remains incompletely 
defined as far as the precise site and biological significance but underscores the constitutive 
processing diversity open to PrPC, as well as determined a role for PrPC in regulating neuronal
stem cells, including that mediated throughβbeta-amyloid.
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Prion diseases are transmissible neurodegenerative disorders causally
linked to abnormal conformers (termed PrPSc) of the cellular prion
protein (PrPC). The role of PrPC within the cell has proved difficult
to resolve, with suggested functions including copper homeostasis
and trafficking, signal transduction, cellular adhesion and attenuation
of oxidative stress (Brown and Besinger, 1998; Brown et al., 1999;
Schmitt-Ulms et al., 2001; Spielhaupter and Schätzl, 2001; Stuermer
et al., 2004). Protection against oxidative stress or reactive oxygen
species (ROS) has been proposed to be enzymatic, wherein PrPC itself
would have superoxide dismutase-like activity (Brown et al., 2001),
or alternatively, mediated by signal transduction cascades, whereby
the resultant reaction protects the cell (Watt et al., 2005). The regions
of PrPC involved in such protection have been investigated and both
the C- and N-termini have been determined to be involved (Rambold
et al., 2008).
The C-terminal amyloidogenic region has been more widely
studied than the N-terminal region due to its propensity to misfold
and so have a more prominent association with disease. However,
mutations within the N-terminus are found in hereditary prion
diseases, consisting of insertions or deletions within the copper-
binding octameric repeat domain (Kovács et al., 2005). The N-
terminal region, although not constituting part of the amyloid core
of PrPSc, is thought to be biologically active, associated with
clathrin-mediated internalisation and intracellular trafficking of PrPC
(Nunziante et al., 2003; Shyng et al., 1995; Sunyach et al., 2003),
and with PrPC movement at the cell surface (Taylor et al., 2005).
In particular, the most N-terminal amino acids of PrPC are highly
conserved across mammalian species (Wopfner et al., 1999) and
contain a polybasic domain (residues 23-28) shown to function as
a glycosaminoglycan (GAG)-binding site (Pan et al., 2002). PrPC
binding to cellular receptors, including low density lipoprotein
receptor-related protein 1 (Parkyn et al., 2008) and the 37 kDa/
67 kDa laminin receptor (Gauczynski et al., 2001), involves the N-
terminal region. Further, the latter of these PrP receptors requires
heparan sulphate to mediate binding and has additionally been
shown to be involved in the internalisation of PrPSc (Morel et al.,
2005; Gauczynski et al., 2006).
PrP cleavage fragments, corresponding to two internal cleavage
sites, can be detected in both cell culture systems and brain tissue.
In non-disease states the α-cleavage fragments (N1/C1) usually have
a higher prevalence than the β-cleavage fragments (N2/C2). The
latter cleavage fragments are increased in the brains of Creutzfeldt-
Jakob Disease (CJD) patients and mice generated as models of prion
disease (Chen et al., 1995; Yadavalli et al., 2004). This increase
has mainly been considered a pro-pathogenic event, but equally
might represent a neuronal protective response, attempting to
compensate for increased stress during disease progression.
Consistent with this hypothesis, cell lines expressing mutant PrP
species that do not undergo N2/C2 cleavage are rendered unable
Beta-cleavage of the neurodegenerative disease-associated prion
protein (PrP) protects cells from death induced by oxidative
insults. The beta-cleavage event produces two fragments,
designated N2 and C2. We investigated the role of the N2
fragment (residues 23-89) in cellular stress response,
determining mechanisms involved and regions important for
this reaction. The N2 fragment differentially modulated the
reactive oxygen species (ROS) response induced by serum
deprivation, with amelioration when copper bound. Amino acid
residues 23-50 alone mediated a ROS reduction response.
PrP23-50 ROS reduction was not due to copper binding or direct
antioxidant activity, but was instead mediated through
proteoglycan binding partners localised in or interacting with
cholesterol-rich membrane domains. Furthermore, mutational
analyses of both PrP23-50 and N2 showed that their protective
capacity requires the sterically constraining double proline motif
within the N-terminal polybasic region. Our findings show that
N2 is a biologically active fragment that is able to modulate
stress-induced intracellular ROS through interaction of its
structurally defined N-terminal polybasic region with cell-
surface proteoglycans.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/122/10/1518/DC1
Key words: Prion, N-terminus, Oxidative stress, Beta-cleavage, GAG,
Copper
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to respond to oxidative stress insults (Watt et al., 2005). Further
studies have shown that, in the context of full-length PrP, tethering
the N-terminus abolishes protective responses against various
cellular stressors (Dupiereux et al., 2008; Zeng et al., 2003).
The enigmatic nature of the hereditary disease-associated, highly
conserved N-terminal region of PrPC prompted us to look more
closely at its function. Our specific aim was to elucidate if and how
the N-terminal β-cleavage product (N2) of the prion protein
modulates intracellular ROS under conditions of enhanced stress.
Copper co-ordination of a representative murine N2 fragment,
encompassing residues 23-89, favourably influenced intracellular
ROS produced in response to serum deprivation. The most N-
terminal region (23-50), independent of copper coordination, also
conferred a cellular protective effect resulting in reduced
intracellular ROS. This effect was shown to be dependent on cell-
surface, heparan-sulphate-containing proteoglycans, which are
either localised to, or require interaction with, lipid-raft domains.
Furthermore, the two proline residues within the polybasic region
at the N-terminus of mature PrPC (residues 26 and 28) were found
to exert a dominant effect over the cellular association of this region
and the redox-protective activity of PrP23-89.
Results
N2 differentially modulates the production of intracellular ROS
in response to serum deprivation depending on copper
occupancy
β-Cleavage of PrPC is reportedly ragged. Amino acid 89 was
selected for the C-terminal residue, as this approximates the mid-
point of the β-cleavage range (Fig. 1A) and ensures that the
octapeptide repeat domain is intact, which is likely to be important
for the biological functions of N2. To investigate potential protective
effects, PrP23-89 was applied to CF10 cells manifesting increased
intracellular ROS. CF10 cells were the primary cell line used in
this study, as they represent a PrPC-null background to avoid
potentially confounding effects caused by the activity of full-length
PrP, the complementary C2 fragment or endogenously produced
N2. Cellular ROS insults were induced using serum deprivation to
avoid the peptides contacting serum proteases that might degrade
them. Intracellular ROS levels were assayed using the DCFDA
assay, which detects H2O2 (in the presence of endogenous metal
ions), HO˙, ROO˙, and ONOO- (Martin et al., 1998). The ROS
generated and viability data in response to decreasing serum
concentrations are shown in supplementary material Fig. S1. When
applied in a log10 dilution series from 0.01-10,000 nM the N2
fragment increased the intracellular ROS in serum-deprived CF10
cells to a plateau at 1 nM peptide (Fig. 1B,C). By contrast, when
10 μM peptide was applied with equimolar followed by 2-6 molar
equivalents of CuCl2-6glycine, a protective effect compared with
‘no peptide’, ‘peptide’ and ‘copper alone’ treatments was seen from
2-4 molar equivalents (Fig. 1B,D). One to six molar equivalents
(10–60 μM) of copper alone showed progressively increasing ROS
up to 5 equivalents and a lesser effect at 6 equivalents; the latter
effect is most likely due to a reduction in cell viability caused by
copper toxicity. A peptide corresponding to the amino acid sequence
of PrP23-89 scrambled was also assayed and showed no variation
from baseline ROS production in response to serum deprivation or
serum deprivation with 1-6 molar equivalents of CuCl2-6glycine
(supplementary material Fig. S2).
PrP23-50 attenuates the intracellular ROS response
To explore the PrP domains responsible for the activity of the N2
fragment, a peptide encompassing only the copper-binding octameric
repeat domain (PrP51-89) and an N-terminal peptide lacking this
domain (PrP23-50) were employed. These were applied to the CF10
Fig. 1. PrP23-89 (N2) modulates intracellular
oxidative stress conditional upon copper saturation.
(A) Schematic representation showing the defined
regions of PrP and the approximate internal cleavage
site producing N2 and C2 fragments. (B-D) N2
reduces ROS induced by serum deprivation only
when pre-loaded with copper. Synthetic N2
encompassing murine amino acids 23-89 was
applied to serum-deprived CF10 cells in a log10
serial dilution from 0.01-10,000 nM. The 10,000 nM
concentration was also applied after pre-mixing with
1-6 molar equivalents of copper; 1-6 equivalents of
copper were applied without peptide for comparison.
(B) Example of intracellular ROS curves obtained
using the DCFDA fluorescent dye. Initial rates were
calculated as the linear tangent to the curve and are
shown as the percentage change from the baseline
rate obtained for the serum-free environment.
(C) ROS rate changes induced by the apo-PrP23-89
peptide over the dilution series. Significantly
increased intracellular ROS production is seen from
0.1 nM peptide (one-way ANOVA, F=11.22,
P=0.001, *P<0.01). The effect of copper-loading the
PrP23-89 peptide on intracellular ROS is shown in
D, with black bars indicating the copper-loaded
peptide and white bars indicating the equivalent
copper-alone condition. For comparison, the grey
bar shows the intracellular ROS response to the
peptide alone. Conditions significantly different
from both the copper- and peptide-alone controls, as
determined by two-way ANOVA (F=45.49,












cells in the same log10 serial dilution as used for PrP23-89 and, as
51-89 is a characterised copper-binding domain, the PrP51-89 peptide
was also applied with 1-6 equivalents of CuCl2-6glycine. PrP51-
89 showed increased intracellular ROS at low concentrations and
with 1-3 equivalents of CuCl2 (Fig. 2A), whereas the PrP23-50
fragment decreased the intracellular ROS produced by serum
deprivation at the lowest concentration used (0.01 nM), significant
at 10 nM peptide (Fig. 2B). To check for specificity of the PrP23-
50 reaction, a scrambled peptide corresponding to the amino acid
composition of PrP23-50 (PrP23-50scram) was also assayed and
showed no significant ability to decrease (or increase) the intracellular
ROS produced by serum deprivation (Fig. 2B).
Neuro2a cells show copper-dependant PrP23-89 ROS
reduction and PrP23-50 ROS reduction at higher peptide
concentrations
Wild-type PrP-expressing cells are likely to be influenced by
endogenous expression of full-length PrP and the N2/C2 cleavage
fragments. However, to ascertain whether a response could still be
elicited by increased N2 at the membrane, Neuro2a (N2a) cells were
exposed to 10 μM PrP23-89 with and without 4 molar equivalents
CuCl2-6glycine. Both the apo PrP23-89 and the copper-loaded
peptide were able to reduce intracellular ROS in response to serum
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deprivation, with the copper-loaded PrP23-89 showing a lesser
response than the apo PrP23-89 (Fig. 3A). The reason for such a
discrepancy most likely arises from the basal copper content of the
cells, as the brains of null mice have been shown to have reduced
copper concentrations compared with their wild type counterparts
(Brown, 2003). To confirm this we incubated the cell lines with the
copper-reactive fluorescent dye Phen Green Fl, which is quenched
by both Cu+ and Cu2+ and also has a lesser reactivity with iron and
cobalt (Chavez-Crooker et al., 2001). This confirmed greater basal
metal ion concentrations in the N2a cells compared with the CF10
cells (Fig. 3B). The N2a cells showed no response to the PrP51-
89 fragment (Fig. 3A); however, when PrP23-50 was assayed by
dose titration, there was a specific and significant ROS reduction
at 1 µM peptide (Fig. 3C). This is a higher concentration than seen
for the CF10 cells and most likely indicates that the endogenous
PrP is exerting an effect that mutes the reaction. As shown for the
CF10 cells, the response of the N2a cells to decreasing serum
concentrations and to PrP23-89scram are included in supplementary
material Figs S1 and S2, respectively.
Fig. 2. Amino acids PrP23-50 alone reduce the ROS response to serum
deprivation. Synthetic PrP51-89 and PrP23-50 were added to serum-deprived
cells in the log10 serial dilution from 0.01-10,000 nM and the intracellular
ROS response measured by DCFDA assay (A and B, black bars). PrP51-89
(10 μM) was also assayed with 1-6 molar equivalents CuCl2-6glycine (white
bars). Changes in the rate of ROS production are represented as the percentage
change from the rate induced by serum deprivation alone. PrP51-89 at
0.01 nM and when loaded with 1-2 molar equivalents CuCl2-6glycine shows
no significant difference from when copper alone is applied (two-way
ANOVA; F=1.225, P=0.2738). Cells treated with PrP23-50 show significantly
reduced intracellular ROS in response to serum deprivation from 10-10,000
nM peptide (one-way ANOVA; F=4.774, P=0.0018, *P<0.05, **P<0.01). To
eliminate the possibility of non-specific effects, a scrambled peptide (PrP23-
50scram) was also assayed (B; white bars). No significant change in the rate of
ROS production is seen for the PrP23-50scram peptide (one-way ANOVA,
F=0.4482, P=0.8615).
Fig. 3. Wild-type N2a cells show ROS reduction in response to PrP23-89 and
PrP23-50. (A) PrP23-89 and PrP51-89 (10 μM) were added to N2a cells with
and without 4 molar equivalents of CuCl2-6glycine and assayed for the ROS
produced in response to serum deprivation by the DCFDA assay. Changes in
the rate of ROS production are represented as the percentage change from the
rate induced by serum deprivation alone. PrP23-89 both with and without
copper significantly reduced the intracellular ROS induced by serum
deprivation (one-way ANOVA F=6.298, P=0.0021, *P<0.05, **P<0.01).
(B) Phen green quenching experiments show that N2a cells have higher basal
concentrations of copper compared with CF10 cells (Student’s t-test, t=4.148,
**P=0.0025), possibly explaining the ROS-reducing activity of apo PrP23-89
in these cells compared to that seen in the CF10 cells. (C) PrP23-50 (black
bars) and PrP23-50scram (white bars) were added to serum-deprived cells in
the log10 serial dilution from 0.01-10,000 nM. Cells treated with PrP23-50
show significantly reduced intracellular ROS in response to serum deprivation
from 1000-10,000 nM peptide (one-way ANOVA, F=4.774, P=0.0018,
*P<0.05, **P<0.01). No significant change in the rate of ROS production is












PrP23-50 does not mediate its protective response by copper
binding or direct antioxidant activity
Although the octameric repeat copper-binding domain has been well
characterised, the PrP23-50 region has been less rigorously
investigated. To clarify how this fragment mediates the intracellular
ROS reduction effect, we investigated its ability to coordinate copper
or to directly act as an antioxidant molecule. Electron paramagnetic
resonance (EPR) spectroscopy indicated that both PrP23-50 and
PrP23-50scram were able to coordinate copper upon addition of 1
molar equivalent of CuCl2; however, both peptides readily
surrendered their copper load to 2.5 molar equivalents of the weak
copper chelator glycine (Fig. 4A). This indicates that the copper
binding of PrP23-50 is non-specific at pH 7.0 (Kd>1 μM) and
unlikely to be biologically meaningful in the cell-protective effect.
When PrP23-50 and PrP23-50scram were assayed for their ability
to reduce ROS produced by the Fenton reaction, with the radicals
produced detected by fluorescent spin trapping, neither peptide
showed any antioxidant ability (Fig. 4B). Circular dichroism (CD)
spectroscopy confirmed that PrP23-50 adopts a predominantly
random coil structure, indistinguishable from that of PrP23-50scram,
indicating that the assumption of altered secondary structure in the
absence of the octameric repeat domain is unlikely to be relevant
to the PrP23-50 ROS reduction effect (Fig. 4C).
PrP23-50 mediates its intracellular ROS-attenuating effect
through a proteoglycan binding partner found within, or
requiring, intact cholesterol-rich domains
In the absence of a direct biochemical explanation for the ROS
reduction response of PrP23-50, cellular interactions were
investigated. First trypsin was used to crudely remove all cell-
surface protein and the production of intracellular ROS induced by
serum deprivation monitored by the DCFDA assay as before with
and without PrP23-50 applied in the log10 serial dilution.
Trypsinising the cells did not significantly alter the rate of ROS
produced in the absence of serum (Fig. 5A, left panel), but the
PrP23-50 fragment no longer significantly reduced ROS levels (Fig.
5A, right panel), indicating that the PrP23-50 response most likely
involves a protein-binding partner as opposed to lipid-membrane
interactions. Filipin III complex, an antibiotic that binds and
sequesters cholesterol, was used to disrupt cholesterol-rich lipid-
raft domains within the cell membrane. Lipid-raft domains are
known to be important signalling platforms, and so potential
binding partners may reside in, or mediate their response through,
resident proteins. Treatment with filipin III showed a trend toward
a reduced ROS rate in response to serum deprivation in the absence
of peptide, but this was not significant (Fig. 5B, left panel). Filipin
III-treated cells showed no response to any concentration of the
PrP23-50 fragment, indicating that lipid-raft domains are involved
in mediating the PrP23-50 ROS reduction response (Fig. 5B, right
panel). The transferrin receptor, which is excluded from lipid-raft
domains, was used as a control to show preserved location of non-
raft proteins (supplementary material Fig. S3).
The most N-terminal amino acids of PrP23-50 contain a polybasic
GAG-binding site. Therefore to more closely examine the nature of
a PrP23-50-binding partner, two GAG-catabolising enzymes were used
to selectively remove cell-surface GAGs of interest from their protein
cores. Cells were treated with heparin lyase III to remove heparan
sulphate or chondroitinase ABC to remove chondroitin A, B and C,
and were then assayed for their intracellular ROS response to serum
deprivation with and without addition of the log10 dilution of PrP23-50.
The removal of GAGs by both enzymes induced a significant increase
in intracellular ROS production in response to serum deprivation (Fig.
5C,D, left panels): however, the chondroitinase ABC-treated cells were
still receptive to reduction of intracellular ROS by PrP23-50 (Fig. 5D,
right panel). The heparin lyase III-treated cells showed no reduction
in ROS when incubated with PrP23-50 (Fig. 5C, right panel),
indicating that the PrP23-50 response is dependant on proteoglycans
containing heparan sulphate. The effective removal of over 40% of
cellular heparan sulphate was confirmed by dot blotting, as shown in
supplementary material Fig. S4.
The PrP octarepeat domain, with and without bound copper,
influences N-terminal peptide cell association or internalisation
and half life
The N-terminal polybasic region (amino acids 23-28) has been
shown to be essential for PrPC internalisation (Sunyach et al., 2003).
Fig. 4. The PrP23-50 region has limited copper-binding ability, is not an
antioxidant and assumes no specific secondary structure. (A) EPR spectra of
PrP23-50 (i,iii) and PrP23-50scram (ii,iv) with 1 molar equivalent of Cu2+ in
the absence (i,ii) and presence (iii,iv) of 2.5 molar equivalents glycine. Both
peptides readily surrender their bound copper to the low-affinity chelator
glycine, indicating that PrP23-50 binds copper non-specifically like any
unstructured peptide, with the N-terminal amine, backbone amide(s) and water
molecules being the likely ligands. The principal g|| and A|| parameters
characterising the spectra (g||~2.23, A||(65Cu)~170-18010–4cm–1) are
compatible with a 3N1O or 2N2O coordination sphere of equatorial ligands.
Spin quantification by double-integration of the spectra indicates that PrP23-50
and PrP23-50scram bind around 1/3 and 1/2, respectively, of the observable
Cu2+ bound in the presence of glycine; the unbound Cu2+ fraction forms EPR-
silent copper hydroxide at pH 7 (Drew and Barnham, 2008). (B) The ability of
PrP23-50 to act as an antioxidant was assessed by response to the Fenton
reaction caused by H2O2 and FeSO4, with the fluorescent radical trap proxyl
fluorescamine used to capture hydroxyl radicals produced. In comparison with
the positive control, neither PrP23-50 nor PrP23-50scram showed any ability
to reduce the radicals reaching the trap. Shown are the mean rates with s.e.m.
for three independent experiments. (C) CD spectroscopy shows that both












Therefore, to address whether the PrP23-50 effect might be a result
of internalisation by its protein-binding partner(s), cells were
treated for 0-60 minutes with 10 μM peptide (PrP23-50 alone and
PrP23-89 with/without 4 molar equivalents CuCl2-6glycine) and
both cell lysates and media western blotted for the peptides. Peptide
within the cell lysate fraction may be internalised or membrane-
bound (referred to as ‘cell-associated’). The strongest cell-associated
signal was seen in cells treated with PrP23-89 without copper. Even
1 minute post-exposure the peptide can be seen clearly within this
fraction and already seems to have reached its plateau (Fig. 6A,B).
When PrP23-89 is applied pre-loaded with copper, the initial signal
is much weaker and increases over time to an overall lower level.
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This indicates that in the absence of copper the octarepeats can
mediate binding to the cell surface and/or internalisation, which is
disconnected to protection against intracellular ROS, whereas when
copper is bound the octarepeat site is less cell-accessible or binding
becomes more specific. PrP23-50 shows almost no cell association,
indicating that low levels of cell association are sufficient to achieve
protection or that the response must be the result of a rapid, transient
linkage. When the rate of disappearance of PrP23-50 from the media
and the overall rate of disappearance of the fragment are considered
(Fig. 6C,D), PrP23-50 is seen to disappear much faster than the
PrP23-89 peptide (with or without copper), indicating that PrP23-50
is turned over much more rapidly. Rapid destruction at the
membrane or within the cell may explain the lack of PrP23-50 signal
within the cell-associated fraction. Copper binding to PrP23-89
appeared to slow the overall loss of this peptide, possibly as a result
of more gradual binding to its cellular partners at the membrane,
resulting in a slower catabolic processing.
Mutational analysis of the N-terminal polybasic region
indicates that proline residues 26 and 28 are required for
specific interaction and generation of the intracellular ROS
protective effect
It has previously been shown that the internalisation response of
PrPC is diminished if the positively charged amino acids of the
N-terminal polybasic region are mutated to more neutrally charged
residues (Sunyach et al., 2003). The charge of this region,
however, is not its only feature. Within the charged residues are
two prolines: a motif that functionally is highly significant.
Proline motifs are known to impart a degree of structure onto
proteins due to the steric constraints of the rigid pyrrolidine ring
(reviewed by Vanhoof et al., 1995). Proline motifs are very often
found in association with positively charged amino acids, and
therefore we hypothesised that these two proline residues were
likely to be an essential part of the functional moiety and crucial
for the biological activity of PrP23-50 and PrP23-89. To test this
hypothesis, the PrP23-50 fragment was synthesised with prolines
26 and 28 mutated to alanine. Alanine was substituted for proline
because of its similar size and charge properties but lack of rigid
structure. The ability of PrP23-50 P26/28A to reduce the ROS
induced by serum deprivation in the CF10 cells was tested using
the log10 serial dilution of peptide. The PrP23-50 P26/28A peptide
showed no ability to modulate intracellular ROS induced by serum
deprivation (Fig. 7A). Furthermore, when cell lysates and media
were probed to look for internalisation/cell association it was
Fig. 5. Removal of cell membrane proteins or heparan sulphate, or disruption
of lipid rafts, abolishes the PrP23-50-mediated intracellular ROS reduction
response to serum deprivation. The effect of the cell surface environment on
the protective function of PrP23-50 against intracellular ROS was assessed
using the DCFDA assay. The log10 serial dilution of PrP23-50 was applied to
the cells after treatment with (A) trypsin before the start of the assay, (B) 1 μM
filipin III for the duration of the assay, (C) heparin lyase III at 10 mU/ml for
1 hour before the start then at 5 mU/ml for the duration of the assay, and (D)
chondroitinase ABC as for the heparin lyase III treatment. For each condition
the left panel shows the effect of the treatment on the production of
intracellular ROS compared with serum-free media only, and the right panel
shows the effect of the PrP23-50 peptide on the cells after they have been
exposed to the treatment. Alterations in the rate of ROS production before
PrP23-50 treatment have been compensated for in the analysis. The results of
PrP23-50 treatment (in the absence of other treatment) are shown as empty
grey bars in panel A for comparison. Significant results as determined by
Student’s t-test for changes in the rate caused by the treatment or by one-way













shown that this mutation enhanced signal in the cell-associated
fraction (Fig. 7B,C). Complementary to the increase in cell
association, a rapid decrease in the culture medium and in the
overall detected peptide was observed (Fig. 7D,E). Additionally
the peptide displayed altered physical properties, now showing a
tendency to aggregate, with both the monomer and the aggregates
showing cell association (Fig. 7B). CD spectroscopy, however,
did not reveal any overt alteration in secondary structure from
that of wild-type PrP23-50 (supplementary material Fig. S5).
Proline residues 26 and 28 exert a dominant influence over the
properties of N2
To determine the importance of the proline residues within the
polybasic region of the N2 fragment on the intracellular ROS
protective activity and, further, if the polybasic region could exert
a dominant effect over the octarepeat region, PrP23-89 with the
P26/28A mutations was synthesised. The production of intracellular
ROS in response to serum withdrawal was assessed in the presence
of PrP23-89 P26/28A with and without copper as described for wild-
type PrP23-89. When applied to the serum-deprived cells without
pre-loading with copper, minimal variation was seen from baseline
in the rate of ROS production up to 1 μM peptide, where the
tendency is toward increased ROS production as seen for PrP23-89
(Fig. 8A). When PrP23-89 P26/28A was applied with equimolar,
followed by 2-6 molar equivalents of CuCl2-6glycine, a
pronounced difference was seen from PrP23-89 (Fig. 8B). One to
three equivalents of copper induced a sizable increase in the rate
of ROS production compared with copper alone or the PrP23-89
Fig. 6. The octarepeat region modulates cellular association and peptide turnover. 10μM of the PrP23-89 fragment with and without premixing with 4 molar
equivalents of CuCl2-6glycine, and the PrP23-50 fragment were added to cells at 0 (background control) to 60 minutes. After this time cell lysates and media
were harvested and western blotted to detect the fragments. (A) Example blots showing the cell-associated (upper plate) and media (lower plate) fractions
compared to the original inoculums (OI). Band signals were quantified densitometrically and the signal represented as a percentage of the OI signal. Graphs show
the mean and s.e.m. of (B) the cell-associated fraction, (C) the media fraction and (D) the sum of both fractions as an indicator of total loss of the peptide from the
system, derived from three independent experiments. Where appropriate the single exponential rate curves for association or decay are shown (unbroken line) with
the 95% CI (broken lines). Copper binding reduces the rate of cellular association of the PrP23-89 fragment and the intensity once association has reached
equilibrium, but also reduces its loss from the media and the overall system. The PrP23-50 fragment shows almost no cellular association but a rapid, overall












copper-loaded fragment. Full saturation, at 4 equivalents of copper,
was no different in ROS production from the cellular response seen
for this concentration of copper alone. Five to six equivalents of
copper was not significantly different from the PrP23-89 response.
As the increased intracellular ROS seen at the lower equivalents of
copper may have been a result of cellular toxicity by the peptide
delivering copper into the cell, an MTS assay for cell viability was
performed on the cells 24 hours after treatment (Fig. 8C).
Significantly reduced viability was seen at the 2 equivalent copper
concentration for cells treated with the PrP23-89 P26/28A fragment,
but no significant difference in viability was seen at 1 equivalent,
where the highest ROS were seen or at any of the higher
concentrations of copper. Cells were treated for 0-60 minutes with
the apo or copper-loaded PrP23-89 P26/28A and lysates and media
western blotted for the presence of the fragment as described
previously. Like the PrP23-50 P26/28A, the PrP23-89 P26/28A
fragment showed increased tenancy to aggregate compared with
the wild-type PrP23-89 (Fig. 8D,E), with two dominant oligomeric
forms evident. When a 4 molar excess of copper was premixed
with the PrP23-89 P26/28A fragment the oligomers were reduced,
with the monomer band becoming the dominant species (Fig. 8D,F).
This suggests that mutating the N-terminal prolines to less
structurally constraining amino acids allows the octarepeats to
associate with each other, forming aggregates sensitive to copper
binding. This, however, is not the only region responsible for the
aggregation, as the PrP23-50 P26/28A fragment without the
octapeptide repeats aggregates and oligomeric species remain in
the copper-loaded sample. The dominant aggregated species in the
unloaded sample shows the greatest propensity to internalise, with
the monomer showing much less cellular association; this is
reversed in the cell fraction treated with the copper-loaded peptide.
Cell association and rate of disappearance from the media curves
are shown in supplementary material Fig. S6. Overall, the eventual
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cellular association concentration plateau of copper-loaded PrP23-
89 P26/28A is no greater than that of copper-loaded wild-type
PrP23-89. However, at 1 minute post-exposure, only approximately
4% of the copper-loaded PrP23-89 was associated with the cellular
fraction, whereas approximately 15% of the copper loaded PrP23-
89 P26/28A was seen in this fraction. This rate of cellular association
may place cells under extra stress, resulting in the increased ROS
seen in these treatments. Alternatively, the increased oxidative stress
seen when cells are exposed to this fragment may be due to a mis-
association of the fragment or the remaining oligomeric species.
Furthermore, despite the differences in intracellular ROS production
when PrP23-89 P26/28A was applied with 1 molar equivalent
copper, EPR data on the binding of 1 molar equivalent copper shows
there was no difference in copper coordination between the PrP23-
89 and PrP23-89 P26/28A fragments, and CD spectra confirm there
were no significant differences in secondary structure (Fig. 8G;
Fig. 7H).
Discussion
β-Cleavage of the prion protein occurs internally around the C-
terminal end of the octameric repeat domain (Chen et al., 1995)
and has been shown to protect against ROS induced by copper and
hydrogen peroxide (Watt et al., 2005). Our results significantly
extend this knowledge by showing that the N-terminal β-cleavage
product specifically modulates intracellular ROS occurring in
response to cellular stress, with the protection mediated by both its
copper-binding and non-copper-binding regions. Further, copper
saturation facilitated the attenuation of intracellular ROS
concomitant with altered cellular association properties of the N2
peptide. Hence, differences in intracellular ROS between cells
treated with the apo-N2 and the copper-loaded-N2 peptide are very
likely due to different interactions at the cell membrane. The PrP
octameric repeat domain has been shown to bind to membranes in
Fig. 7. Mutation of the proline residues 26 and 28 to alanine
abolishes the activity of PrP23-50 and alters its cellular
association. PrP23-50 was synthesised with proline residues 26
and 28 mutated to alanine. (A) Percentage changes in the rate of
ROS production from the rate induced by serum deprivation
alone as determined by DCFDA assay for the log10 serial dilution
of the PrP23-50 P26/28A fragment (black bars), the PrP23-50
fragment results are shown for comparison (empty grey bars).
10 μM of the PrP23-50 P26/28A fragment was added to cells at 0
(background control) to 60 minutes. Cell lysates and media were
harvested and western blotted to detect the fragment.
(B) Example blots showing the cell-associated (upper plate) and
media (lower plate) fractions compared to the original inoculum
(OI). Band signals were quantified densitometrically and the
signal represented as a percentage of the OI signal. Graphs show
the single exponential rate curves for association or decay
(unbroken line) with the 95% CI (broken lines) of (C) the cell-
associated fraction, (D) the media fraction and (E) the sum of
both fractions as an indicator of total loss of the peptide from the
system, derived from three independent experiments. The PrP23-
50 P26/28A fragment shows a greater propensity to associate
with the cell than the PrP23-50 fragment and decays from the
media and the overall system faster. Further it shows a tendency












model systems and the addition of copper to this region, although
still allowing binding, changed the conformational arrangement
(Dong et al., 2007). A change in peptide conformation, peptide-
lipid orientation or peptide position in relation to the cell membrane
may allow the far N-terminal residues to interact with differing
binding partners, or at different locations on the cell membrane,
resulting in distinct cellular responses. This is not the case for the
PrP23-50 fragment, which, without the octarepeat domain, is free
to interact directly with its binding partners independent of any
stress-sensing or modulating role of copper binding. Proposed
models of N2 interactions with itself and the lipid membrane
environment are depicted schematically in Fig. 9B.
Fig. 8. Mutation of the polybasic region prolines results in altered properties of PrP23-89. The PrP23-89 fragment was synthesised with prolines 26 and 28 mutated
to alanine. The ability of this peptide to modulate the ROS response to serum deprivation with and without copper loading was monitored by DCFDA assay. All
plots represent the mean and s.e.m. of four independent experiments, except panel F, where n=3. (A) The apo-23-89 P26/28A fragment was applied to cells in the
log10 serial dilution. The ROS response compared with cells not exposed to the peptide is shown (black bars) in comparison to the PrP23-89 peptide response
(empty grey bars). (B) Intracellular ROS response to serum depletion when applying 10 μM peptide with 1-6 molar equivalents CuCl2-6glycine (black bars),
compared with the response of the peptide alone (grey bar) and the response of CuCl2-6glycine alone (white bars). Two-way ANOVA finds that the change in
ROS rate at 1 and 2 equivalents copper are significantly different from the results obtained for wild-type PrP23-89 (F=14.74, P<0.0001, **P<0.01, ***P<0.001).
(C) Viability of cells treated with 10 μM PrP23-89 P26/28A peptide and increasing equivalents of copper for 24 hours (circles and solid line) expressed relative to
the no-copper condition, and compared with equivalent wild-type PrP23-89 (triangles and dashed line) and copper alone (squares and dotted line). Decreased
viability is seen for the PrP23-89P26/28A peptide against both PrP23-89 and copper alone at 2 equivalents copper and relative to just the PrP23-89 peptide at 5 and
6 equivalents of copper (F=4.83, P=0.0422, *P<0.05, **P<0.01). (D) Cells were treated for 0 (background control) to 60 minutes with 10 μM PrP23-89 P26/28A
with and without 4 molar equivalents of CuCl2-6glycine. Cell-associated and media fractions were western blotted for the presence of the PrP23-89 P26/28A
fragment compared with the original inoculum (OI). (E) Densitometric profiles measured vertically from the top to the bottom of the PrP23-89 P26/28A (solid line)
and the wild-type PrP23-89 (dashed line) original inoculums. The PrP23-89 P26/28A fragment showed enhanced aggregation compared to the wild-type PrP23-89,
with several dominant species appearing. (F) Densitometric quantification of the three most dominant species in the original inoculum lanes expressed as a
percentage of their sum indicates copper saturation induces a shift from the dominant upper band (white bar segments) to increased dominance of the middle (pale
grey bar segments) and monomeric bands (dark grey bar segments). Changes in the upper and monomeric band intensities are significant by two-way ANOVA
(F=7.018, P=0.0269, *P<0.05, **P<0.01). (G) EPR spectra of (i) PrP23-89 and (ii) PrP23-89 P26/28A in the presence of 1 molar equivalent 65CuCl2 at pH 7.0.
Multiple coordination modes exist in equilibrium for PrP23-89 that are very similar to those of isolated octapeptide repeat fragments at physiological pH (Drew and
Barnham, 2008). These are unchanged upon mutation of prolines 26 and 28 to alanines. The co-ordination observed in PrP23-50 (Fig. 3A) does not occur here due












The N-terminal polybasic region has previously been shown to
be crucial for internalisation of PrPC; this was dependent on its strong
positive charge (Nunziante et al., 2003; Sunyach et al., 2003). In the
current study the polybasic region was also involved in the ROS
reduction response, requiring the proline residues 26 and 28 within
this charged region. Proline residues induce small structural motifs
due to the steric constraints imposed by their rigid cyclic structure.
It is probable that the charge of the 23-28 polybasic region mediates
N2 binding to proteoglycans and the structure imparted on the N-
terminus by the double proline motif produces the selectivity of this
reaction. The net result is specific recognition of target-binding
partners most likely within the cholesterol-rich lipid-raft domains
in which PrPC is resident. Mutation of the prolines within the
polybasic region, producing a less rigid N-terminus, permitted the
N2 peptide to interact more readily with the cell while simultaneously
abolishing its specific protective properties and producing potentially
deleterious effects. This was exemplified by the PrP23-89 P26/28A
ROS response in the presence of copper. Here, cellular association
was significantly increased compared with the wild type PrP23-89
fragment, indicating that the mutant peptide probably moves copper
inside the cell or to an incorrect membrane location, causing
increased cellular stress at low concentrations of copper.
Among many other functions, proteoglycans can be cellular
receptors and co-receptors (reviewed by Raman et al., 2005). The
specific function of the proteoglycan is determined by its protein
core. PrPC has several putative GAG-binding sites that might
differentially mediate binding to proteoglycans, which are located
at amino acid positions PrP23-50, 53-93 and 110-128 (Warner et
al., 2002). The GAGs bound by cell-free recombinant PrP include
heparin, heparan sulphate, chondroitin sulphate A and B, hyaluronic
acid and dextran (Andrievskaia et al., 2007; Pan et al., 2002), and
cellular PrP expressed by transfection binds heparin (Pan et al.,
2002). Heparan sulphate has been shown to be a cell surface receptor
for PrPSc (Horonchik et al., 2005) and preincubation of infectious
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inoculum with heparin delays the onset of prion disease (Hijazi et
al., 2005), indicating that uptake of PrPSc can be decreased by
exogenous GAGs competing with endogenous GAGs. Furthermore
GAGs mediate PrPC binding to cell-surface receptors including the
37 kDa/67 kDa laminin receptor (Gauczynski et al., 2001). The
regions involved in 37 kDa/67 kDa laminin receptor binding have
been characterised and the N2 fragment and the octameric repeats
alone, in the presence of heparan sulphate, can bind to and are
outcompeted by antibodies against the laminin receptor (Hundt et
al., 2001). Receptor binding such as this may transduce the ROS
protective effect seen in response to the PrP N-terminus in this study;
this is depicted in Fig. 9C.
Copper binding to the octameric repeat domain alters GAG
binding (Andrievskaia et al., 2007; Warner et al., 2002). Increased
octarepeats, as seen in some genetic prion diseases, increases the
binding capacity and affinity for GAGs, and both increased repeats
and increased GAG binding decrease the ability of the cell to
respond to ROS (Yin et al., 2006; Yin et al., 2007). Moreover,
increased GAG binding is associated with increased aggregation
of full-length PrP (Yin et al., 2007), and aggregation of PrP is also
associated with a decreased response to oxidative stress. These
observations are consistent with those reported here, wherein
altering the two N-terminal prolines resulted in enhanced cellular
association and increased aggregation but with a concomitant loss
of the protective response against intracellular ROS. Further, the
current data support a biologically meaningful role for GAG
binding in the protective function of the N-terminus, and identify
the importance of structure within the polybasic region in addition
to any electrostatic contributions to this interaction. By contrast,
aberrant association with the cell membrane could induce an
intracellular ROS insult, which might potentially contribute to the
pathogenesis of prion disease.
The cellular location of the β-cleavage event has not yet been
established; however the N-terminus has been shown to be important
Fig. 9. Scheme depicting hypothetical modes of
action of the N2 fragment. It is probable that
the flexible N-terminus is bound to GAGs via
the polybasic region even when resting at the
cell membrane (A). Upon release of the N2
region by ROS the fragment is free to instigate
further interactions. As N2/C2 cleavage most
likely occurs when the octarepeats are already
occupied to some extent with copper, new
interactions might include metal-ion induced
dimerisation of N2 fragments (B) or, as the
octarepeats also bind lipids, coordination with
GAGs and the lipid membrane environment,
also transducing a protective effect via lipid
signalling pathways. An alternative result of
N2/C2 cleavage might be to deliver the N2
fragment to a cell-surface receptor such as the
laminin receptor (Gauczynski et al., 2001),
where binding to the receptor could initiate a
protective signal transduction cascade (C). In
the event the N2/C2 cleavage occurs when
copper levels are depleted or if the fragment
was outcompeted for copper by another protein,
different interactions may occur with GAGs or
with the lipid membrane environment,
preventing the N2 fragment from interacting
with the appropriate receptor and resulting an












in mediating protective effects from the cell surface. Tethering of
the N-terminus of full-length PrP to the membrane effectively
prevented PrP-mediated protection against ROS insults induced by
hydrogen peroxide (Zeng et al., 2003) and paraquat (Dupiereux et
al., 2008). In the current study synthetic N-terminal fragments were
added exogenously to the extracellular surface to investigate stress
protection mediated from outside the cell. Given that PrPC is an
extracellular cell-surface protein and that both N-terminal (N1 and
N2) cleavage fragments have been found in higher concentrations
in conditioned medium than within cell lysates (Mangé et al., 2004;
Vincent et al., 2001), with the N2 fragment increased especially
after treatment with hydrogen peroxide and copper (McMahon et
al., 2001), it is reasonable to assume that at least part of the N-
terminal function is mediated from the outer leaflet of the cell
membrane. Rapid degradation following internalisation of these
fragments may explain their higher prevalence in the extracellular
environment. This is common for peptide ligands that activate signal
transduction pathways, because prolonged signalling can result in
activation of detrimental cellular pathways, including apoptosis
(reviewed by Junttila et al., 2008). The rapid turnover of signalling
ligands probably explains the lack of PrP23-50 detected in cell
lysate, as without the octarepeat region its effects are more potent
than the N2 fragment, so it must be removed before its presence
becomes harmful to the cell. Further experiments will reveal
whether production of the N2 fragment inside the cell can initiate
a differing effect from that seen when it is produced at the cell
surface, or whether interaction with the complementary C2 and/or
full-length PrPC can modulate function.
β-Cleavage of PrP is increased during disease, as evidenced by
increased N2/C2 cleavage products in the brains of CJD patients
and in the brains of scrapie-infected mice (Chen et al., 1995;
Yadavalli et al., 2004). ROS markers, such as lipid peroxidation,
are also linked with early stages of prion disease (Brazier et al.,
2006). The β-cleavage event is caused by ROS (McMahon et al.,
2001; Watt et al., 2005), and furthermore, an inability to undergo
β-cleavage renders the cell susceptible to oxidative attack (Watt et
al., 2005). Impaired β-cleavage is seen for certain disease-associated
PrP mutations, including expansion of the octameric repeat region
(Watt et al., 2005). Cells expressing PrP mutations with increased
repeats are more susceptible to oxidative-stress-induced cellular
damage and death (Watt et al., 2005; Watt et al., 2007). Taken
together, this indicates that the β-cleavage event is unlikely to be
an irrelevant epiphenomenon of PrPC to PrPSc conversion but,
instead, part of a cellular response to stress that is compromised by
certain pathogenic mutations.
Overall, the current study has shown that through binding to
extracellular proteoglycans, in association with lipid-raft domains,
the N-terminus of PrPC is active in favourably modulating
intracellular ROS changes caused by cellular stress. Further, we
postulate that the octapeptide repeat, through variable copper
binding, may function as a biosensor for activation of the protective
N2 region, with the structure and charge specificity of the polybasic
domain ensuring the correct transducing receptor engagement.
Materials and Methods
Cell culture
Reagents were purchased from Invitrogen (VIC, Australia) unless otherwise stated.
CF10 (murine neuronal PrP knockout) cells and Neuro2a (N2a) cells were cultured
in Dulbecco’s modified Eagle’s media supplemented with 10% (v/v) fetal bovine
serum and 50 U/ml penicillin/50 μg/ml streptomycin solution (Sigma). Cells were
maintained at 37°C with 5% CO2 in a humidified incubator. For microtitre plate assays,
cells were plated to be 90-95% confluent at the start of the assay.
Preparation of synthetic peptides
The following synthetic peptides based on the N-terminal sequence of murine PrP –
(23)KKRPKPGGWNTGGSRYPGQGSPGGNRYP(50)PQGGTWGQPHGGGWG -
QPHGGSWGQPHGGSWGQPHGGGWGQ(89) – were purchased from the peptide
synthesis unit of the Bio21 Institute (Victoria, Australia), which uses microwave-
assisted peptide synthesis; PrP23-89; PrP23-50; PrP23-50 P26/28A; PrP23-89
P26/28A; PrP23-50scram (GKPWSGRGTPGGRGPRKYGSNKYRNGPQ); and
PrP23-89scram (KQSQYGGGPSWGNYWGWPGHGRGPGPRGQPGGTRGPGG -
TQSWKPGGGHWPSGGHQGGPKHWGQNPGG). Peptides were solubilised in
distilled water before addition to cell culture media with concentrations determined
by UV spectroscopy.
DCFDA assay
Cells were incubated in Dulbecco’s phosphate-buffered saline (dPBS) containing 5 μM
5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, acetyl ester (CM-
H2-DCFDA) at 37°C for 20 minutes, then probe solution was removed and replaced
with prewarmed Opti-MEM I Reduced-Serum Medium (without phenol red) with or
without test reagent added. Readings were taken every 5 minutes for 12 hours using
490 nm excitation and 520 nm emission filters in a Fluostar Optima (BMG Labtech,
Victoria, Australia), and initial rates were calculated using tangents to the curve.
Phen Green Fl assay
Cells were incubated in prewarmed Opti-MEM I Reduced-Serum Medium (without
phenol red) containing 10 μM Phen green FL diacetate for 20 minutes and residual
cellular fluorescence compared with the cell-free control solution. Readings were
taken using 490 nm excitation and 520 nm emission filters in a Fluostar Optima.
Cell viability (MTS) assay
Five μl of one solution MTS reagent per 100 μl media (Promega; VIC AUS) was
added to test and medium-only background control conditions, and incubated under
normal culture conditions for 90 minutes. Reaction product was quantified using
absorbance at 462 nm in a Fluostar Optima.
GAG digestion
Cells were digested for 1 hour at 37°C in OptiMEM1 culture media using 10 mU/ml
of heparin lyase III or chondroitinase ABC (Seikagaku, Japan) before the start of
each assay. The enzyme concentration was reduced to 5 mU/ml during the assay.
Negative controls were treated identically except for omission of the enzyme.
Circular dichroism
CD spectra were recorded at room temperature on a Jasco J-815 spectropolarimeter.
Peptides were solubilised in distilled water to a concentration of 10 μM. Spectra were
obtained in a 2 mm path length quartz cell from 190–240 nm using a 1 nm bandwidth
and a scan rate of 50 nm min–1. Background correction was performed by subtraction
of the protein-free spectrum.
Electron paramagnetic resonance
Peptides were solubilised in distilled water at a concentration of 100 μM. A 10 mM
65CuCl2 stock was prepared by dissolving 65CuO (Cambridge Isotope Laboratories)
in concentrated HCl, followed by dilution in distilled water. From this stock,
1 equivalent 65Cu was added to each peptide solution. For Cu2+-binding competition
studies, 2.5 equivalents glycine was further added from a fresh 10 mM stock prepared
in distilled water. The final pH was measured using a micro-probe (Hanna Instruments,
Italy) and adjusted to pH 7.0 using concentrated NaOH. Samples were transferred
to quartz EPR tubes (Wilmad) and snap-frozen in liquid nitrogen.
X-band CW-EPR was performed using a Bruker ESP380E spectrometer fitted with
a rectangular TE102 microwave cavity and a quartz cold finger insert. Experimental
conditions were: microwave frequency, 9.42 GHz; microwave power, 10 mW;
modulation amplitude, 4 G; modulation frequency, 100 kHz; temperature, 77 K; sweep
time, 168 seconds; time constant, 164 milliseconds; receiver gain, 105; 8-15 averages.
Background correction was performed by subtraction of the sample-free spectrum.
Displayed spectra were normalised with respect to their maximum peak-to-peak
intensity.
Fluorescent spin trapping
Of each peptide, 10 μM was incubated with 10 μM proxyl fluorescamine, 10 μM
H2O2, 5 μM FeSO4 and 5% (v/v) DMSO in PBS. Reagents were added into wells
of a black microplate with the FeSO4 added last. Readings were begun immediately
using 360 nm excitation and 480 nm emission wavelengths in a Fluostar Optima.
Assays were run over a period of two hours to collect the linear rate of radical
generation. Readings were taken every 30 seconds following 5 seconds mixing.
PAGE and western blotting
Media were removed from the cells and replaced with pre-warmed Opti-MEM I
Reduced-Serum Medium at the beginning of the assay. At the appropriate time point,
10 μM peptide was added to the cells and at the end of the incubation media was
removed and kept for analysis. Cells were lysed in RIPA buffer [50 mM Tris-HCl











NP-40] supplemented with 0.5 U/ml benzonase (Sigma Aldrich), at 37°C for
20 minutes. Lysates and media were mixed with appropriate volumes of 3 LDS
loading dye (containing 5% v/v beta-mercaptoethanol), denatured for 10 minutes at
80°C and electrophoresed in MES buffer using 12% NuPAGE Bis-Tris gels, at 200V
for 35 minutes, with the dye front not allowed to reach the end of the gel. Protein
was then transferred onto nitrocellulose membranes (BioRad, NSW AUS) using a
BioRad wet blotting system for 30 minutes at 100V, and subsequently blocked in
PBS containing 0.1% v/v Tween (PBS-t) and 5% non-fat milk. Synthetic PrP fragments
were detected using 1 in 10,000 dilution of 8B4 monoclonal antibody (against murine
amino acids 37-44; Alicon, Switzerland) in 1% milk PBS-t, anti-mouse HRP
secondary antibody (GE Healthcare, NSW AUS) was used at 1 in 10,000 dilution
and blots were visualised using ECL-plus detection reagent (GE Healthcare).
Densitometry and statistical analyses
Luminescent signal of the bands on the western blots was captured using a Las-3000
intelligent darkbox (FujiFilm; Berthold, VIC AUS) and the intensity quantified, after
the subtraction of background, by ImageJ 1.38. Statistical analyses were carried
out using GraphPad Prism 5 statistical software. Graphs show the mean and s.e.m.
of four independent experiments unless otherwise stated.
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 The copper-binding, membrane-anchored, cellular prion protein (PrPC) has two constitutive cleavage sites pro-
ducing distinct N- and C-terminal fragments (N1/C1 and N2/C2). Using RK13 cells expressing either human PrPC, 
mouse PrPC or mouse PrPC carrying the 3F4 epitope, this study explored the influence of the PrPC primary sequence 
on endoproteolytic cleavage and one putative PrPC function, MAP kinase signal transduction, in response to exoge-
nous copper with or without a perturbed membrane environment. PrPC primary sequence, especially that around the 
N1/C1 cleavage site, appeared to influence basal levels of proteolysis at this location and extracellular signal-regulat-
ed kinase 1/2 (ERK1/2) phosphorylation, with increased processing demonstrating an inverse relationship with basal 
ERK1/2 activation. Human PrPC showed increased N1/C1 cleavage in response to copper alone, accompanied by spe-
cific p38 and JNK/SAPK phosphorylation. Combined exposure to copper plus the cholesterol-sequestering antibiotic 
filipin resulted in a mouse PrPC-specific substantial increase in signal protein phosphorylation, accompanied by an 
increase in N1/C1 cleavage. Mouse PrPC harboring the human N1/C1 cleavage site assumed more human-like profiles 
basally and in response to copper and altered membrane environments. Our results demonstrate that the PrPC pri-
mary sequence around the N1/C1 cleavage site influences endoproteolytic processing at this location, which appears 
linked to MAP kinase signal transduction both basally and in response to copper. Further, the primary sequence ap-
pears to confer a mutual dependence of N1/C1 cleavage and membrane integrity on the fidelity of PrPC-related signal 
transduction in response to exogenous stimuli.
Keywords: Prion, copper, endoproteolytic cleavage, signal transduction, lipid raft
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Introduction
Cumulative experimental evidence supports that ab-
normal isomers of the prion protein constitute the caus-
ative agent in transmissible spongiform encephalopathies 
(TSEs, also known as prion diseases) [1, 2], with neu-
ronal expression and membrane anchorage of wild-type 
PrP being essential for efficient pathogenesis [3-9]. The 
disease-associated conformer, termed PrPSc, is a structur-
ally altered form of the normal cellular protein, PrPC. 
PrPC is a glycosylphosphatidylinositol (GPI)-anchored 
cell surface glycoprotein, which has been shown to bind 
copper within an N-terminal octameric repeat region and 
also at one or more sites slightly more C-terminal of the 
repeat region [10-13]. 
Despite much investigation and characterization of the 
properties of PrPC and PrPSc, the primary function of PrPC 
and the principal pathogenic pathways of TSEs remain 
unresolved. One suggested role for PrPC is the transduc-
tion of signals from the external environment into the 
cell interior, a function circumstantially supported by the 
localization of PrPC within plasma membrane detergent-
resistant microdomains (also known as lipid rafts), which 
are now widely recognized as membrane-signaling plat-
forms [14]. The plasma membrane constitutes a critical 
site for the activation of intracellular, and transduction of 
extracellular, receptor-mediated signaling, and the lipid 
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environment itself appears to play an extensive role in 
modulating the activation of signaling pathways [15, 16]. 
PrPC has been thought to have a role in lymphocyte sig-
nal transduction for some time [17], with suggested out-
comes including T-lymphocyte activation or the initiation 
of a proliferation response [18, 19]. PrPC crosslinking in 
lymphocytes results in mitogen-activated protein kinase 
(MAPK) activation and subsequent extracellular signal-
regulated kinase 1/2 (ERK1/2) activation [20]. 
PrPC has been shown to interact with several proteins 
that lead to signal transduction. Co-immunoprecipitation 
identifies Grb2, an adaptor protein that putatively func-
tions to link extracellular receptors to intracellular sig-
naling molecules, as directly interacting with PrPC [21]. 
Interaction with stress-inducible protein 1 (STI-1), which 
occurs at the cell surface mainly on the cell body, has 
been shown to induce neuritogenesis and neuroprotection 
via the MAPK pathway [22]. Additionally, clustering of 
PrPC at the cell surface activates ERK1/2 [23-25]. This 
may be mediated by epidermal growth factor receptor 
(EGFR [23]) or by the signaling molecule Fyn tyrosine 
kinase, recruited in turn by the interaction of caveolin-1 
and PrPC [25, 26]. 
PrPC is highly conserved across mammalian species, 
both at the primary amino acid sequence and the tertiary 
folded structure levels [27]. PrPC constitutively under-
goes two well-defined endoproteolytic cleavage events. 
The first cleavage site, termed α-cleavage and producing 
fragments designated N1/C1, is at amino acids 111/112 
of the human PrPC sequence (110/111 of the mouse se-
quence) and is known to be a site for the enzymes A Dis-
integrin And Metalloprotease 10 (ADAM10) and Tumor 
necrosis factor α-Converting Enzyme (TACE) [28]. The 
second cleavage site, termed β-cleavage and producing 
N2/C2 fragments, is around the end of the octameric re-
peat region, amino acid 91 of the human sequence (residue 
90 of the mouse sequence), and can be caused by reac-
tive oxygen species (ROS) without the need for enzymes 
[29, 30]. Enhanced N2/C2 cleavage is associated with 
disease [31]. Increased prominence of the C2 fragment 
is found in the brains of sporadic Creutzfeldt-Jakob 
disease patients and progressive central nervous system 
accumulation of this cleavage product occurs during the 
incubation period of rodent disease models [32]. Given 
the evolutionary conservation of PrP and the apparently 
ubiquitous occurrence of cellular endoproteolytic pro-
cessing, especially alpha cleavage in the non-diseased 
state, it is plausible that cleavage events may be integral 
to both normal PrPC function and pathogenesis.
Mouse PrPC is often substituted for human PrPC in 
studies of prion diseases due to its ability to propagate in-
fection within cell culture systems and the availability of 
a bioassay to properly confirm cell culture results. There 
are, however, differences in the protein sequence across 
the two species, notably at the N1/C1 cleavage site 
where the human sequence contains a methionine residue 
at amino acid 111 as opposed to the valine residue at the 
equivalent position (amino acid 110) of the mouse se-
quence. With the exception of human, chimpanzee, ma-
caque and some hamster species, which have the methi-
onine residue, all characterized mammalian species have 
the valine residue at the N1/C1 cleavage site [27]. Since 
single amino acid substitutions at certain positions within 
the PrPC sequence are sufficient to cause hereditary prion 
disease, it seems likely that even small differences in the 
protein sequence homology could be highly influential in 
PrPC processing, function and cellular membrane interac-
tions.
To explore potential relationships between PrPC en-
doproteolytic processing and signal transduction, we 
developed a model in which different primary sequences 
notably varying around the N1/C1 cleavage motif were 
expressed in the same cell line. The rabbit kidney epithe-
lial (RK13) cell line was chosen because of the absence 
of detectable levels of potentially confounding endoge-
nous PrPC and the ability to reproducibly achieve similar 
expression levels upon transfection of the various PrPC 
constructs. For our model, intermediates of the MAP 
kinase signal transduction pathway were chosen for 
analysis because of the specific evidence for involvement 
of this cascade in PrPC-related cellular activities and the 
general centrality of this pathway across a range of cel-
lular signaling events. Employing this paradigm, the spe-
cific aims of the present study were: (1) to assess basal 
and copper-induced PrPC cleavage profiles, especially 
around the N1/C1 cleavage site, and the corresponding 
activation states of key MAP kinase intracellular signal-
ing intermediates and (2) to assess the effect of perturba-
tions to plasma membrane integrity on endogenous PrPC 
cleavage and the activation of key MAP kinase-signaling 
intermediates in response to copper across different PrPC 
primary sequences. Overall, our results demonstrated a 
significant influence of PrPC primary sequence around 
the N1/C1 cleavage site on endoproteolytic processing at 
this location, which appeared linked to MAP kinase sig-
nal transduction both basally and in response to copper. 
Further, the primary sequence appeared to confer a mu-
tual dependence between N1/C1 cleavage and membrane 
integrity on the fidelity of PrPC-related signal transduc-
tion in response to exogenous copper.
 
Results
Generation of cell lines expressing human or mouse 
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Human and mouse PrPC share 89% (full-length 
sequence) or 91% (minus signal peptides) sequence 
identity (Supplementary information, Figure S1A). To 
investigate the influence of the species-specific differ-
ences in PrPC amino acid sequence on cellular process-
ing and signaling responses, basally and in response to 
membrane perturbations, human and mouse PrPC genes 
were transfected into RK13 cells (referred to as huRK13 
and moRK13 cells, respectively). The results presented 
encompass experiments using clones from three indepen-
dent transfections where clones of equivalent expression 
levels were selected (Supplementary information, Figure 
S1B and S1C), and were, additionally, verified using an 
unselected mixed population. The RK13 cell line is a 
rabbit kidney epithelial line, which shows no detectable 
PrPC and therefore represents a neutral or “null” back-
ground for expressing these genes. Furthermore, RK13 
cells have been used as an effective host for the propaga-
tion of infection using transfected PrPC sequences from 
various species [33, 34]. The empty vector was also 
transfected and selected to act as an appropriately treated 
control cell line (referred to as vecRK13). No difference 
in PrPC detergent solubility or cell membrane localiza-
tion/orientation (as determined by phosphatidylinositol-
specific phospholipase C digestion) was seen between 
the huRK13 and moRK13 cell lines (data not shown); 
however, a slight difference in the mobility of the smaller 
fragments is apparent by western blot (Supplementary 
information, Figure S1B).
Human and mouse PrPC show different basal C1 cleav-
age in RK13 cells 
To look at the quantity of the C1 and C2 cleavage 
fragments compared to the full-length PrPC molecule, 
PNGase F-digested cell lysates were analyzed by west-
ern blot. Blots and graphical results are shown in Figure 
1A. The C2 fragment is not clearly seen in the example 
blots due to the much lower levels present. Densitomet-
ric quantification of the bands showed that basal N1/C1 
cleavage of moPrPC is significantly greater than that of 
huPrPC. This was not true for the N2/C2 cleavage, which 
was not significantly different across the cell lines.
Expression of human and mouse PrPC in RK13 cells in-
fluences ERK activation 
Since PrPC cleavage may be linked to its cellular func-
tion, and one suggested function is signal transduction, 
the effect of expressing human and mouse PrPC in the 
RK13 cell line on basal signaling protein activation was 
investigated. Assessment of basal levels of phosphoryla-
tion of central signaling molecules was made by western 
blotting lysates of the huRK13, moRK13 and vecRK13 
cells with antibodies against p-ERK1/2 and ERK1/2, 
p-JNK/SAPK and JNK/SAPK, and p-p38 and p38. For 
each antibody pair, the phosphorylated form was blotted 
first to avoid dephosphorylation by membrane stripping. 
Expression of mouse PrPC significantly reduced basal 
p-ERK1/2 levels compared to those of the human PrPC 
and vector-only cells (Figure 1B and 1C). Only faint 
signal was seen for basal phosphorylation of p38 and 
JNK/SAPK, and no significant alterations were observed 
across the three RK13 cell lines (Figure 1B). Addition-
ally, expression of human or mouse PrPC in the RK13 
cells did not alter steady state expression of any of the 
signaling proteins studied. 
Expression of PrPC in RK13 cells does not alter intracel-
lular ROS levels
Since PrPC is linked to protection against ROS insults 
and ROS have been shown to be involved in PrPC cleav-
age, the basal levels of ROS within the RK13 cell lines 
were assessed by DCFDA assay.  The CM-H2-DCFDA 
assay detects the ROS H2O2 (in the presence of endog-
enous metal ions only), HO˙, ROO˙ and ONOO- [35]. 
Under basal conditions there was no difference in the in-
tracellular ROS production between the PrPC-expressing 
RK13 cells and the vector-only control (Figure 1D). 
Exogenous copper and altered membrane fluidity exerts 
a greater influence on huRK13 N1/C1 cleavage than 
moRK13
Since PrPC is a plasma membrane, lipid raft-associated 
protein, and its localization is considered important for 
normal function and pathogenesis factors that alter mem-
brane fluidity or lipid raft integrity were deemed likely 
to alter PrPC membrane position, and therefore cleavage 
and/or PrPC-associated intracellular signaling events. 
Several well-characterized conditions for altering mem-
brane fluidity were utilized, including 10 mM benzyl al-
cohol (BA), to increase membrane fluidity and lowering 
cell temperature to 25 ºC, with or without the stiffening 
agent DMSO (0.5% v/v), to decrease membrane fluidity 
[36-38]. In addition to these conditions, 1 μM Filipin, 
an antibiotic that binds and sequesters cholesterol, was 
employed to specifically disrupt the more densely packed 
cholesterol-rich lipid raft domains, with the decrease in 
membrane cholesterol also leading to increased mem-
brane fluidity. To confirm that these treatments were hav-
ing the expected effects, we used an ANS-based assay 
to verify membrane fluidity (Supplementary informa-
tion, Figure S2). The huRK13 and moRK13 cells were 
exposed to increased exogenous copper and each of the 
conditions altered membrane fluidity both with and with-
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Figure 1 Basal PrPC cleavage, MAPK activation and intracellular ROS in moRK13, huRK13 and vecRK13 cells. (A) Basal 
PrPC cleavage of huRK13 and moRK13 cells. Lysates were PNGase F digested and western blotted with mab ICSM18 to 
detect the C1 fragment. β-Tubulin was blotted as a loading control. Western blots are shown on the left and densitometric 
quantification on the right (shown are the mean and s.e.m. of four repeats from three independently selected clones and an 
unselected mixed cell population).  Quantification of the untreated C1 and C2 fragment band intensities is shown as a ratio to 
full-length PrP and reveals that moRK13 cells show significantly greater C1 cleavage compared with the huRK13 
cells (t = 5.671, P = 0.0048, n = 4). No significant difference is seen between the cell lines for the C2 cleavage fragment (t = 
0.368, P = 0.7328, n = 4). Western blots of basal activation of the intracellular signaling proteins ERK1/2, JNK/SAPK and p38 
are shown in (B) and quantification of the ratio of p-ERK1/2 to ERK1/2 is shown in (C). The densitometric quantification of 
ERK1/2 phosphorylation depicts the mean and s.e.m. of five replicates using three clones. A significant decrease in the basal 
level of ERK1/2 activation (phosphorylation) is observed for cells expressing moPrPC (F = 8.713, P = 0.0029, **P < 0.01, *P < 
0.05). To assess if the expression of PrPC within the RK13 cells alters basal ROS production, the DCFDA assay was used to 
quantify basal ROS (D). Cells were loaded with CM-H2-DCFDA and fluorescence was monitored at the assay start and after 
30 min incubation. The plot shows the mean and s.e.m. change in fluorescence from the time 0 reading for three indepen-
dently selected clones. No significant differences were seen between the cell lines by one-way ANOVA (F = 0.681, P = 0.5413). 
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Figure 2 PrP N1/C1 cleavage profiles of the huRK13 and moRK13 cells treated with the membrane perturbing conditions with 
and without increased exogenous copper. HuRK13 cells (A) and moRK13 cells (B) PrP N1/C1 cleavage profile in response to 
treatment with each condition for 30 min before harvesting cells. Lysates were PNGase digested before electrophoresis and 
western blotting with mab ICSM18. Left plates show example blots and right plates show the corresponding densitometric 
quantification of the full-length PrP and C1 band signals with graphs representing the mean and s.e.m. of three independently 
selected clones. Significant differences, as determined by one-way ANOVA, are indicated by *P < 0.05 and ***P < 0.001.
out copper. PrPC is widely accepted to be a copper-bind-
ing protein. Exposing the cell lines to copper resulted in 
a selective increase in N1/C1 cleavage restricted to the 
huRK13 cells (Figure 2A); a trend toward increased N1/
C1 cleavage is seen for mouse PrP but this is not signifi-
cant (Figure 2B). Using BA to non-specifically increase 
membrane fluidity significantly altered huRK13 PrPC N1/
C1 cleavage (Figure 2A). The huRK13 N1/C1 cleavage 
is also increased above untreated cells for the BA plus 
copper treatment; however, this increase is not signifi-
cantly different to the copper-alone treatment, suggesting 
that there is no cumulative cleavage response. The only 
condition to induce a significant change in moRK13 N1/
C1 cleavage was the combined copper and filipin treat-
ment; this was also significant for the huRK13 cells. Sig-
nificant N1/C1 cleavage within huRK13 was also seen at 

















–   +    –   +   –    +    –    +    –    +
–    –    +    +    –    –    –    –    –    –
–    –    –    –    +    +    –    –    –    –
–    –    –   –    –    –    –    –    +    +
–    +    –    +    –    +    –    +    –    +
–     –    +     +     –    –    –    –    –    –
–     –    –     –    +    +    –    –    –    –
–     –    –    –     –    –    –    –    +    +
lncubation at 37ºC
lncubation at

















–    +   –    +    –   +     –   +    –   +
–    –    +    +     –    –    –     –    –    –
–     –    –    –    +    +     –     –     –     –
–     –     –    –     –     –   +   +  +   +















































–    +   –    +    –   +     –   +    –   +
–    –    +    +     –    –    –     –    –    –
–     –    –    –    +    +     –     –     –     –
–     –     –    –     –     –   +   +  +   +
















 Cell Research | www.cell-research.com 
PrP alpha cleavage and cellular signaling
6
npg
Increased exogenous copper activates PrPC-specific sig-
nal transduction in huRK13 cells only 
Copper treatment increased ERK1/2 phosphorylation 
in all of the cell lines including the vecRK13 cells, indi-
cating that copper induces a non-specific reaction via this 
pathway (Supplementary information, Figure S3A and 
S3B). A significant huRK13-specific increase in phos-
phorylation was seen for JNK/SAPK and p38 (Figure 3). 
Global increases or decreases in membrane fluidity re-
duce huRK13 signal fidelity in response to copper
Increasing membrane fluidity eliminates the fidelity of 
the JNK/SAPK and p38 signaling response seen in the 
huRK13 cells (Figure 3). The phosphorylation of these 
intermediates under conditions of increased fluidity is 
not significantly different to the vecRK13 control cells. 
Lowering the cellular temperature decreases membrane 
fluidity and the addition of DMSO allows phase transi-
tion of membranes (into the gel phase) to occur at 25 ºC, 
resulting in reduced mobility of membrane proteins.  No 
clear trends in signaling were observed for the 25 ºC 
(without DMSO) condition across the cell lines, either 
with or without exogenous copper (Supplementary in-
formation, Figure S4). The addition of DMSO increased 
the huRK13 phosphorylation of p38 and JNK/SAPK in 
the presence of copper but only the p38 phosphorylation 
is significantly raised when compared with the vecRK13 
control. Thus, under conditions of reduced protein mo-
bility due to gel phase transition of cellular membranes, 
huPrP is still able to elicit a PrPC-specific response to 
copper through p38 signaling (Supplementary informa-
tion, Figure S4). As observed previously ERK1/2 phos-
phorylation appeared to be a non-specific response to gel 
phase promoting conditions, with the vector control cells 
responding equivalently to the PrPC-expressing cells 
(Supplementary information, Figure S3C).
Lipid raft disruption has a pronounced effect on moPrP-
induced signal transduction in the presence of copper
 The filipin III complex is an antibiotic that acts by 
binding and sequestering cholesterol. This makes it an ef-
ficient disruptor of lipid raft (cholesterol rich) membrane 
domains. The filipin treatment caused a non-specific in-
crease of signal protein phosphorylation in all of the cell 
lines (Figure 4A-4C). When the cells were treated with 
filipin and copper together, the moRK13 cells showed a 
dramatic and significant increase in phosphorylation of 
all the three signal transduction proteins.
Activation of signal transduction in response to copper 
and filipin is dependent on the presence of moPrP
Figure 3 JNK/SAPK, and p38 activation in huRK13 and 
moRK13 cells exposed to increased exogenous copper and 
benzyl alcohol. HuRK13, moRK13 and vecRK13 cells were 
treated with increased exogenous copper for 30 min, both in 
the presence and absence of the membrane fluidizing agent 
benzyl alcohol. Lysates were western blotted with antibody sets 
against p-JNK/SAPK and JNK/SAPK (A), p-p38 and p38 (B). 
Bands were quantified densitometrically and huRK13, moRK13 
and vecRK13 cells are shown as black, white and gray bars, 
respectively. Graphs represent the mean and s.e.m. (from four 
independent experiments) of the phosphorylated form to the 
total signaling protein ratio, and are expressed relative to the 
untreated cell control. Example blots are shown above the cor-
responding graph. Conditions that significantly changed the ratio 
of phospho-signaling molecule to signaling molecule, compared 
by one-way ANOVA within each cell line and by two-way ANOVA 
with the vecRK13 cell controls, are indicated by *P < 0.05, **P 
< 0.01 and ***P < 0.001. Copper induces a huPrP-specific in-
crease in JNK/SAPK and p38 phosphorylation, the specificity of 
which is lost when the membrane fluidity is increased.
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To check that the dramatic cellular signaling responses 
seen in response to the copper and filipin treatments were 
not due to clonal drift from selection pressure, the RNAi 
system described in Daude et al. [39] was employed 
to knock down the expression of PrPC in the moRK13 
cells, and by doing so to allow the innate responses of 
the cell line to be assessed in the setting of attenuated 
PrPC expression. ERK1/2 signaling was assessed in the 
knockdown cells following treatment with copper and fil-
ipin. ERK1/2 signaling was chosen for analysis because 
ERK1/2 phosphorylation was altered in these cells ba-
sally and, whilst ERK1/2 responses to copper alone were 
non-specific, significant increases were observed in the 
moRK13 cells when the copper was applied with filipin. 
Further, Daude et al. [39] used ERK as a loading control, 
so we were confident that ERK1/2 levels would not be 
altered by the siRNA transfection. Since the moRK13 
cells are transfected to overexpress PrPC, a complete 
knockdown of PrP proved difficult; however a ~30% re-
duction in protein expression was reproducibly achieved 
(Figure 5A and 5B), and this corresponded with a ~48% 
decrease in ERK1/2 phosphorylation when treated with 
copper and filipin (Figure 5A and 5C) compared with 
cells expressing unaltered levels of moPrP. Therefore, 
it is unlikely that the cell line has suffered clonal drift 
that would account for the signaling responses. Instead 
moPrPC seems essential for these signaling responses to 
occur. To further ensure that the cell lines used had not 
drifted from the original population, the untransfected 
RK13 cells were treated with the copper and filipin con-
ditions. The results obtained were not significantly differ-
ent from the vecRK13 cells (Supplementary information, 
Figure S5).
Figure 4 Induction of signal transduction in huRK13, moRK13 
and vecRK13 cells by copper when lipid rafts are disrupted. The 
cholesterol-sequestering antibiotic filipin was used to increase 
membrane fluidity by disrupting the cholesterol-rich lipid raft do-
mains and cells were treated for 30 min with and without copper 
before lysis and western blotting. Example blots of p38 activa-
tion† are shown above the corresponding graphical data in (A) 
and graphical data only for ERK and JNK/SAPK are shown in (B) 
and (C), respectively. Graphs represent the mean and s.e.m. of 
four independent experiments of huRK13 (black bars), moRK13 
(white bars) and vecRK13 (gray bars) cells. MoRK13 cells show 
a dramatic and significant response (in contrast to hu/vecRK13 
cells) of all of the signaling proteins to the filipin and copper 
treatment (ERK, F = 12.86, P < 0.0001; p38, F = 3.506, P = 
0.0494; JNK/SAPK, F = 7.663, P = 0.0003; *P < 0.05, **P < 0.01, 
***P < 0.001). †These blots are separated between the filipin 
and non-filipin treatments, as these conditions were originally 
run on the same blot (for quantification purposes) with bands for 
other treatments between the two conditions; these have been 
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Figure 5 Dependence on moPrPC expression and time frame of the copper- and filipin-mediated signal transduction event. 
(A -C) RNAi knockdown of the overexpressing moRK13 cell line was carried out using transient transfection of siRNA duplex-
es targeted against PrPC or scrambled as a control for non-specific responses to transfection. (A) Western blots of PrP and 
ERK1/2 signaling in the untransfected, siRNA-transfected cells and scrambled siRNA controls, when treated with and without 
100 μM copper and 1 μM filipin III. (B) Densitometric quantification of the PrPC western blots. Expression of PrPC is signifi-
cantly reduced in the cells receiving the siRNA directed against PrPC (black bar; t = 5.549, P = 0.0051, n = 3) but not in those 
receiving the scrambled siRNA (white bar; t = 2.81, P = 0.107, n = 3). (C) Induction of ERK1/2 signaling, shown as the ratio 
of p-ERK1/2 to total ERK1/2, by 100 μM copper and 1 μM filipin III is reduced in cells transfected with siRNA directed against 
PrPC (F = 40.23, P < 0.0001, n = 3,  *P < 0.05; black, white and gray bars represent no siRNA, PrP-targeting siRNA and 
scrambled control siRNA, respectively). (D, E) Activation of ERK1/2 when moRK13 cells were treated with 100 μM copper 
and 1 μM filipin III was followed over a period of 1 min to 1 h. Blots are shown in the left plate (D) and densitometric quantifi-
cation of the p-ERK1/2 to total ERK1/2 ratio in the right panel (E). Phosphorylation of ERK1/2 is seen from immediately post 
treatment and plateaus after 10 min of treatment. Statistical significance is achieved at 30 min and maintained until 60 min (F 
= 4.831, P = 0.0165, n = 4, *P < 0.05). Graphs show the mean and s.e.m..
Copper- and filipin-induced signal transduction occurs 
rapidly and peaks around 30 min after exposure
To make certain that the 30 min time point at which 
the various treatments were assessed was not limiting the 
responses seen, especially as many ERK1/2 signal trans-
duction events occur within minutes of stimuli, a time 
course was performed on the moRK13 cells. Cells were 
treated with the copper and filipin treatments from 1-60 
min and western blotted for ERK1/2 phosphorylation. 
Activation of signaling can be seen as early as 1 min post 
exposure to copper and filipin, and phosphorylation con-
tinues to increase until 30 min, after which it appears to 
start decaying (Figure 5D and 5E). Significant difference 
is achieved at the 30 and 60 min time points.
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Cell lines endogenously expressing PrPC show similar 
profiles to the transfected RK13 cell lines
Whilst PrPC transfection into a neutral host spe-
cies provides a convenient background for looking at 
protein sequence-specific responses, the behavior of 
endogenously expressed proteins may still vary. The 
human SH-SY5Y and mouse Neuro2a (N2a) cell lines 
were used to look at the responses of cells endogenously 
expressing PrP, and the mouse PrP-null CF10 cell line 
[40] was additionally considered to identify PrP-specific 
responses. These cell lines are derived from neuronal 
lineages, whereas the RK13 cells are epithelial, and 
would, therefore, identify distinct reactions observed due 
to cell origin differences. Each of the cell lines were as-
sayed with the copper and filipin conditions as described 
for the RK13 cell lines and western blotted for ERK1/2 
(Figure 6A), p38 (Figure 6B) and JNK/SAPK (Figure 
6C), and the SH-SY5Y and N2a cells were additionally 
western blotted for PrP following PNGase F digest-
ing (Figure 6D). The signaling trends seen in the RK13 
cells are mostly preserved across the cell lines, with the 
mouse N2a cells showing significant increases in phos-
phorylation of all signal transduction intermediates in 
response to the combined copper and filipin condition. 
The human SH-SY5Y cells, whilst retaining the reduced 
phosphorylation response to copper and filipin, do not 
show the increase in phosphorylation of p38 and JNK/
SAPK in response to copper alone that was seen for the 
huRK13 cells. This may indicate that the copper-induced 
signaling by huPrP when lipid raft integrity is preserved 
is influenced by cell lineage or that overexpression of 
huPrP in the RK13 background renders it more poised to 
respond to copper than when expressed at endogenous 
levels. The cleavage profiles are not identical to those 
seen in the RK13 cells, with the SH-SY5Y cells showing 
very limited cleavage responses but the N2a cells show-
ing a significant increase in N1/C1 cleavage in response 
to combined copper and filipin treatment.
Introduction of the human N1/C1 cleavage region motif 
into mouse PrPC results in mixed cleavage and signaling 
responses
The region encompassing the human N1/C1 cleavage 
site has two methionines, which are lacking in the mouse 
sequence (Supplementary information, Figure S1A, 
boxed); this is known as the 3F4 site, as this sequence is 
detected by the 3F4 anti-PrP antibody. To further inves-
tigate how the N1/C1 cleavage site influences the mouse 
PrPC response to increased exogenous copper and the 
membrane-perturbing conditions, this motif was cloned 
into the mouse sequence and stable mixed population 
cell lines were selected, referred to as 3F4moRK13 cells. 
Basally, 3F4moRK13 cells showed less N1/C1 cleavage 
than moRK13 but more than huRK13 cells (Figure 7A 
and 7B), and N1/C1 cleavage in 3F4moRK13 cells was 
not significantly affected by copper and/or filipin treat-
ment (Figure 7C). No significant difference in the basal 
levels of the C2 fragment was observed (data not shown). 
A basal difference is also apparent for ERK1/2 phospho-
rylation, with 3F4moRK13 showing decreased levels 
of phosphoERK1/2 compared to huRK13 but greater 
levels than moRK13 cells (Figure 7D and 7E). The N1/
C1 cleavage correlates inversely with the basal phospho-
rylation levels (r2 = 0.88, P < 0.0001). The 3F4moRK13 
cells were treated with copper and/or filipin in parallel 
with the mixed population moRK13 and huRK13 cells as 
described previously. The PrPC-independent response of 
ERK1/2 phosphorylation to copper treatment was main-
tained in the 3F4moRK13 cells (Figure 7D and 7F); con-
versely, the specific response of the moRK13 cells to the 
combined filipin and copper treatment was lost, with the 
3F4moRK13 cells showing no significant difference from 
the huRK13 cell response. The huRK13-specific phos-
phorylation of p38 and JNK/SAPK in response to copper 
was also abolished (Figure 7G-7I), and all phosphoryla-
tion appeared reduced. The consistency of the cellular 
responses did, however, show that, although attenuated, 
the increase in JNK/SAPK phosphorylation that was 
observed for moRK13 cells after treatment with both fil-
ipin and copper was still significant for the 3F4moRK13 
cells, but this was not the case for p38 phosphorylation.
Discussion
Our results suggest PrPC alpha cleavage and PrPC-
mediated signal transduction may be linked events. 
Further, both events are influenced by cell membrane 
and particularly lipid raft integrity. In the context of the 
neutral RK13 cell background, the primary sequence of 
PrPC, specifically the N1/C1 cleavage site, exerts a domi-
nant influence over signal transduction through MAPK 
intermediates both basally and in response to membrane 
perturbation in the presence of copper. These effects are 
summarized in Figure 8.
In the current study, increased basal N1/C1 cleavage 
was associated with lower basal ERK phosphorylation, 
but increased N1/C1 cleavage in response to perturbation 
resulted in increased signal transduction through MAPK 
intermediates. This may indicate that N1/C1 processing 
preceded PrPC localization at the cell surface, and that 
sequestration of the cleavage fragments in lipid raft do-
mains renders them inactive. Release from the lipid raft 
domains by cholesterol depletion or other cellular pertur-
 Cell Research | www.cell-research.com 
PrP alpha cleavage and cellular signaling
10
npg
Figure 6 Human SH-SY5Y and murine Neuro2a cell responses to copper and filipin treatments. To consider how the 100 
μM copper and 1 μM filipin III treatments may alter signaling and cleavage in cell lines endogenously expressing PrPC, and, 
hence not subject to overexpression or selection pressure artifacts, the aforementioned treatments were carried out on SH-
SY5Y and Neuro2a (N2a) cell lines as described for the RK13 cell lines. The murine neuronal PrP-null CF10 cell line was 
also compared to look for PrP-specific responses. (A -C) Western blot and densitometric quantification (mean and s.e.m.) of 
SH-SY5Y (black bars), N2a (white bars) and CF10 (gray bars) cells treated with copper, filipin, or copper and filipin together 
to disrupt lipid rafts. Shown are the changes in ERK1/2 (A), p38 (B) and JNK/SAPK (C) signal transduction as ratios of the 
phosphorylated form of the signal protein to the total expression levels and normalized to untreated cells.  Significant differ-
ences, as determined by two-way ANOVA with Bonferroni secondary testing, were seen between the N2a and both the SH-
SY5Y and CF10 cell lines (ERK1/2 F = 67.39, P < 0.0001, n = 4; p38 F = 3.96, P = 0.018, n = 4; JNK/SAPK F = 12.50, P = 0.0001, 
n = 4; *P < 0.05, **P < 0.01, ***P < 0.001). (D) PrP N1/C1 cleavage of SH-SY5Y (black bars) and N2a (white bars) cells 
following treatment with copper, filipin, and copper with filipin. Shown are western blot of the PNGase F-treated cell lysates 
and densitometric quantification of band intensities. Two-way ANOVA with Bonferroni secondary testing identifies that the cell 
lines are significantly different from each other (F = 9.314, P = 0.0055, n = 4, *P < 0.05).
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bations may allow rapid activation of signal transduction 
pathways in response to stimuli such as copper. Raft se-
questration is a known control mechanism for the activa-
tion/deactivation of certain enzymes. An example of this 
is TACE, where raft sequestering suppresses its catalytic 
activity until released [41]. Alternatively, release from 
rafts may allow TACE to cleave PrP at the N1/C1 site 
and once a threshold is reached the N1/C1 cleavage frag-
ments produce dramatic cellular response. The former 
suggestion is supported by a recent study from Walmsley 
et al. [42], where alpha cleavage appears to occur along 
the secretory pathway, probably in the Golgi, on the way 
to the cell surface. The increase in PrPC N1/C1 cleavage 
may, therefore, follow the signal transduction event to 
replenish PrPC C1 at the cell surface. The activation of 
signal transduction intermediates by human PrPC where 
no response was seen for mouse PrPC, despite the higher 
basal levels of alpha cleavage, may reflect differing abili-
ties of the two proteins to engage the signal transduction 
machinery.
The 3F4 epitope alters the structure of the alpha cleav-
age site as shown by the recognition specificity of the 
3F4 antibody. The sulfur-containing methionines, as 
found in the human sequence, are substantially different 
from the charged histidine with its imidazole ring and 
the small aliphatic valine of the mouse sequence. PRNP 
point mutations within the structured C-terminal region 
are associated with human prion diseases, therefore 
supporting the likelihood that introduction of the 3F4 
epitope into murine PRNP may have significant biologi-
cal consequences. The difference in sequence may result 
in a different presentation of the alpha cleavage site to 
processing enzymes, resulting in the observed different 
cleavage patterns, which in turn influences PrPC function. 
These potential downstream biological consequences 
of this sequence variation may impact on studies that 
use the 3F4 epitope to differentiate between human and 
mouse PrPC when overexpressing one in the cellular 
background of the other. Researchers using these con-
structs in the future may wish to consider the bearing this 
may have on conclusions about the function of PrPC.
N1/C1 cleavage is partially under the control of 
ADAM10 and TACE activities [28]. Unlike ADAM10, 
TACE has a very narrow substrate specificity [43]; 
TNFα, its preferred substrate, is cleaved between alanine 
and valine residues as found at the mouse N1/C1 cleav-
age site but not at the human. TACE may therefore have 
a greater role in the N1/C1 cleavage of mouse PrPC than 
human, particularly under altered cellular conditions. 
The intermediate extent of the N1/C1 cleavage of the 
3F4moRK13 cells also indicates that, whilst the N1/C1 
site is clearly influencing this cleavage, further sequence 
differences appear to be involved, perhaps by modulating 
binding partner interfaces, membrane interaction or cel-
lular trafficking.  
Regardless of primary sequence, copper loading ap-
peared to play an important role in PrPC-mediated MAPK 
signal transduction. The activation of signal transduc-
tion in the moRK13 cells following lipid raft disruption 
was not due to the potential toxicity of copper, since a 
lesser reaction was observed following copper treatment 
alone. Copper binding has been reported to be essential 
for PrPC protection against oxidative stress [44, 45], and 
this protection may be via activation of signal transduc-
tion pathways and the subsequent cellular response [30]. 
Furthermore, there is recent evidence for MAPK activa-
tion by signaling endosomes [15]. PrPC is internalized 
in response to copper [46], and this reaction requires the 
octameric repeat domain and the palindromic sequence 
starting at the N1/C1 cleavage site to be intact [47, 48]. 
Signaling endosomes have been especially associated 
with clathrin and dynamin mediated internalization [15, 
49, 50], and these are both pathways with which PrPC 
has been shown to interact [51, 52]; hence, the role of 
copper in these reactions may be to promote the internal-
ization of PrPC to facilitate engagement with signaling 
intermediates. This is further supported by the findings 
of Caetano et al. [53], who show that signaling by STI-1 
through ERK1/2 requires internalization of PrPC and was 
inhibited by a dominant-negative mutant of dynamin.
Although multiple binding partners for PrPC have 
been suggested to have a role in the activation of cellular 
signal transduction, including Grb2, EGFR and caveolin 
[21, 23, 25], the part PrPC processing plays in relation 
to such events is uncertain. N1/C1 cleavage has been 
shown to play a role in apoptosis through modulation of 
caspase-3 activation. The C1 fragment is able to increase 
p53 transcription and induce caspase-3 activation [54]. 
In transgenic mice overexpressing a truncated PrP spe-
cies (lacking amino acids 32-134), caspase-3 activation 
is via ERK1/2 and p38 activation [55]. The finding that 
ERK1/2 and p38 signal protein activation correlated 
with the changes in mouse C1 cleavage suggests that the 
mouse PrPC may be able to interact more efficiently or 
with a greater number of intermediates involved in acti-
vating these pathways. The human PrPC-expressing cells 
demonstrated more restricted associations by showing 
a significant linkage only between N1/C1 cleavage and 
p38 activation. The consistency of the PrPC signal across 
the western blots also shows that the alteration in signal-
ing is not due to significant amounts of PrPC dissociating 
from the cell surface due to shedding of the GPI anchor, 
as has previously been reported in response to filipin 
and copper [56, 57]. This could be due to species or cell 
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Figure 8 Schematic depiction of PrP N1/C1 cleavage and MAPK-signaling relationships. (A) The relationship between PrP 
N1/C1 cleavage and ERK1/2 phosphorylation in the RK13 cells in the unperturbed state, showing the inverse relationship. 
(B) The relationship between the PrP cleavage and intracellular signaling when an increased amount of exogenous copper 
is available to PrP. In the presence of copper, a direct relationship is observed between N1/C1 cleavage and signaling. Open 
arrowheads show how lipid raft disruption enhances these effects and blocked arrows indicate how non-specific changes in 
fluidity alter the specificity of the reactions.
Figure 7 Introduction of the 3F4 epitope into moPrP alters cleavage and signaling profiles both basally and in response 
to copper and filipin treatments. Example PNGase-F-digested basal PrP blots (A) and densitometric quantification (B) of 
huRK13, moRK13 and 3F4moRK13 cells. C1 cleavage of the 3F4moPrP falls between the levels of moPrP and huPrP, and 
is significantly different from moPrP. Cells were treated with copper and the lipid-raft disrupting antibiotic filipin for 30 min. 
Alterations in PrP N1/C1 cleavage are shown in (C). Example ERK1/2 blots are shown in (D). Densitometric quantification 
of this data show that basal ERK1/2 phosphorylation differs across the cell lines with the 3F4moRK13 levels greater than 
the moRK13 but lower than the huRK13 cells, and statistically different to both (E) (F = 29.86, P = 0.0002, n = 4). The abil-
ity of 3F4moRK13 cells to induce ERK1/2 signaling in response to the filipin and copper treatment is significantly reduced 
compared to moRK13 cells (F) (F = 34.83, P < 0.0001). p38 (blots are shown in G and quantification in H) and JNK/SAPK 
(blots are shown in G and quantification in I) signaling of the 3F4moRK13 cells are significantly different from both huRK13 
and moRK13 cells(p38, F = 3.385, P = 0.0284, n = 3; JNK/SAPK, F = 3.805, P = 0.0142, n = 3), with the 3F4moRK13 cells 
showing a lesser ability to signal through these molecules; however, JNK/SAPK phosphorylation is still significantly increased 
above untreated cells in response to filipin and copper together (F = 9.376, P = 0.0054, n = 3; *P < 0.05, **P < 0.01, ***P < 
0.001). All plots represent the mean and s.e.m. of four independent experiments and black, grays and white bars represent 
the huRK13, 3F4moRK13 and moRK13 cell line results, respectively.
culture model differences. Rabbit PrPC varies from hu-
man and mouse PrPC around the site of the GPI anchor; 
consequently, the rabbit host enzymes involved in cleav-
age at the GPI anchor may have a lower recognition for 
human and mouse PrPC, resulting in less shedding within 
this system.
The N2/C2 cleavage event was also considered during 
this study (Supplementary information, Figure S6); how-
ever, alterations in N2/C2 cleavage did not correlate with 
any PrP-related selective change in the MAPK-signaling 
intermediates studied. Overall, there was no difference 
between moRK13, huRK13 or 3F4moRK13 basal N2/C2 
processing. This is to be expected if the primary cleavage 
mechanism at the N2/C2 cleavage site is ROS-related, as 
there was no difference in intracellular ROS production 
between the cell lines, nor in the N2/C2 site motifs of hu-
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man and mouse PrPC. Moreover, it shows that the N1/C1 
cleavage has no direct influence on the N2/C2 cleavage.
Transfecting different PrP primary sequences into 
identical host cells with negligible endogenous expres-
sion allowed focused research and detection of potential 
species-related differences in processing, particularly at 
the alpha site, and consequent activation of MAPK sig-
naling. Further studies are required to confirm that the 
associations we found between PrPC processing and ac-
tivation of MAPK signaling are mechanistically directly 
linked steps in a cellular pathway, rather than simply 
occurring as unrelated parallel events. Further, while 
the RK13 cells afforded a permissive and conveniently 
manipulable system for the expression of PrP constructs 
of interest, the applicability and translation of our find-
ings from these overexpressing cells of epithelial origin 
to the situation occurring in neuronal cells endogenously 
expressing PrPC is supported by data with SH-SY5Y and 
N2a cell lines. 
In conclusion, the data presented here relate PrPC pro-
cessing to signal transduction, and show the inter-depen-
dence of the PrPC primary sequence, particularly the N1/
C1 cleavage site, and the cell membrane in these events. 
The PrPC primary sequence influences the predominant 
type of proteolysis likely to occur in response to specific 
cellular perturbations, and to what extent consequent sig-
nal transduction will occur. Generally, membrane integ-
rity appears important for the fidelity of signal transduc-
tion occurring in relation to PrPC processing, although 
under certain conditions membrane disruption may allow 
proteolytic processing not normally accessible to the 
particular PrPC primary sequence. For huRK13 cells, the 
selectivity of signal transduction activation due to copper 
treatment was often lost when membrane integrity was 
compromised, becoming similar to non-PrPC-expressing 
cells. Independent of the overall PrPC primary sequence, 
increased N1/C1 cleavage of PrPC appears linked to the 
MAPK pathway, with alterations in amino acid sequence 




All cell lines were cultured in Dulbecco’s Modified Eagles Me-
dia (DMEM; Gibco – Invitrogen, Victoria, Australia) supplement-
ed with 10% fetal bovine serum (Invitrogen), 50 U/ml penicillin 
and 50 μg/ml streptomycin solution (Sigma-Aldrich; New South 
Wales, Australia). Cells were maintained at 37 ºC with 5% CO2 in 
a humidified incubator. For microtitre plate assays, (used unless 
otherwise stated) cells were plated to be 90%-95% confluent at the 
start of the assay.
Constructs and transfection
pIRES-puro2 (Clontech – Scientifix, Victoria, Australia) con-
tain the full-length human or mouse PrPC open reading frame, as 
well as the vector alone was transfected into RK13 cells using Fu-
Gene 6 transfection reagent (Roche, New South Wales, Australia) 
as per the product protocol for a 3:1 reagent:DNA ratio. A total of 
2.5 μg/ml puromycin (Sigma-Aldrich) was used for cell selection 
and both stable clones of equivalent expression levels and mixed 
populations were selected. Cells were maintained in 2.5 μg/ml 
puromycin during routine culture. A further mixed population cell 
line expressing moPrP with the 3F4 epitope (human N1/C1 cleav-
age site motif) was created by transfection using Lipofectamine (as 
per the product protocol: Invitrogen). The mixed population was 
selected and maintained as described above.
RNAi
The siRNA duplexes described by Daude et al. [39] were pur-
chased from Sigma-Aldrich. Cells were plated 1 day prior to treat-
ment with the siRNA at approximately 50% confluence. siRNA 
duplexes were delivered into the cells using FuGene HD trans-
fection reagent in a 4:1 reagent:siRNA ratio as described in the 
product protocol. The final concentration of duplexes delivered to 
the cells was 400 nM. Cells were then incubated for 2 days under 
standard conditions before treatment and extraction as described 
below.
Western blot
Cells were treated for 30 min with appropriate test reagent 
before lysis in 20 μl RIPA buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 
1% (v/v) NP-40) supplemented with 0.5 U/ml Benzonase (Sigma-
Aldrich) for 20 min at 37 °C. Lysates were mixed with 10 μl of 
3× LDS loading dye (Invitrogen) supplemented with 5% (v/v) 
β-mercaptoethanol (Sigma-Aldrich) and denatured gently at 80 
°C for 10 min. A total of 20 μl of lysate was loaded into 15-well 
12% NuPAGE Bis-Tris gels (Invitrogen). Gels were run at 200 
V for 35-40 min (until the dye front reached the bottom) in the 
Invitrogen NuPAGE gel tank system, using MES running buffer 
(Invitrogen). Gels were transferred onto a nitrocellulose mem-
brane (BioRad, New South Wales, Australia) in a Bio-Rad wet 
blotting system at 100V for 45 min. Membranes were blocked for 
1 h in 5% (w/v) fat-free milk powder in PBS-0.1% (v/v) Tween-
20 (PBS-t). For PrPC detection, western blot incubations used a 1 
in 30 000 ICSM-18 primary monoclonal antibody (mab; mouse 
epitope 142-152, human epitope 143-153 (DGen, London, UK)) in 
1% milk PBS-t;  with anti-mouse HRP secondary (GE Healthcare, 
New South Wales, Australia). Signaling antibodies phospho(T202/
Y204)-p44/42 (p44/42 is more commonly known as ERK1/2, 
therefore, p-ERK1/2 is used to refer to this antibody); p44/42 
(ERK1/2); phospho(T180/Y182)-p38 (p-p38); p38; phospho(T183/
Y185)-JNK/SAPK (p-JNK/SAPK); and SAPK/JNK were all used 
at 1 in 1 000 dilution (Cell Signaling – Genesearch Pty, Queen-
sland, Australia) in 1% (w/v) bovine serum albumin (BSA; Sigma-
Aldrich) in PBS-t, with 1 in 5 000 anti-rabbit HRP secondary (Cell 
Signaling) in 1% (w/v) BSA in PBS-t. Anti-β-tubulin (Sigma-
Aldrich) was used as a loading control and blotted using a 1 in 20 
000 dilution with anti-mouse-HRP secondary used at 1 in 10 000. 
Membranes were stripped between probing with each antibody by 
incubation in low-pH stripping buffer (25 mM glycine-HCL, pH 2; 
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1% (w/v) SDS) for 10 min at room temperature with agitation, and 
then washed once in PBS-t before incubation in blocking solution 
for 1 h.
PNGase F digestion
Media were removed from the cells and 20 μl RIPA buffer plus 
0.5 U/ml Benzonase were added per well. Plates were incubated at 
37 °C for 20 min. A total of 2 μl 10× denaturation buffer (5% (w/v) 
SDS, 5% (v/v) β-mercaptoethanol, 50 mM EDTA, 0.02% (v/v) so-
dium azide in PBS, pH 8.0) was added per well and samples were 
heated at 80 °C for 10 min to denature. The plate was allowed to 
cool to room temperature, and 2.5 μl 10% (v/v) NP-40 and 5.5 μl 
incubation buffer (50 mM EDTA and 0.02% (v/v) sodium azide 
in PBS, pH8.0) plus 1 U PNGase F (Sigma-Aldrich) were added 
per well. Plates were incubated overnight at 37 °C in a humidified 
chamber. 3× NuPAGE LDS sample loading buffer supplemented 
with 5% (v/v) β-mercaptoethanol was added to the wells and sam-
ples were denatured at 80 °C for 10 min. A total of 20 μl of sample 
was loaded per well, with PrPC detection as described above.
DCFDA assay
Media were removed and replaced with 50 μl of dPBS contain-
ing 5 μM 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein 
diacetate, acetyl ester (CM-H2-DCFDA, Invitrogen). Cells were 
incubated at 37 °C for 20 min, then the probe solution was re-
moved and replaced with 100 μl of Opti-MEM® I Reduced-Serum 
Medium (without phenol red) with or without test reagent added. 
Readings were taken at time 0 and 30 min, using 488 nm excita-
tion and 530 nm emission filters in a Fluostar Optima (BMG 
Labtech, Victoria, Australia).
Densitometry and statistical analyses
Luminescent signal of the bands on the western blots was cap-
tured using a Las-3000 intelligent darkbox (FujiFilm – Berthold, 
Victoria, Australia), and the intensity was quantified after the sub-
traction of background, by ImageJ 1.38×. Statistical analyses were 
carried out using GraphPad Prism 4 or Minitab15 statistical soft-
ware. Two-way ANOVA with Bonferroni secondary tests was used 
to determine different cell line responses to the same conditions 
(these are tabulated in Supplementary information, Table S1) and 
one-way ANOVA with Tukey’s secondary test was used to identify 
differences within a single cell line. The graphs shown through-
out show the mean ± s.e.m. of all of the data; blots from replicate 
clone/mixed cell line data were averaged and treated as one repeat.
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Victoria Lewis, PhD, Andrew F. Hill, PhD, Cathryn L. Haigh, PhD,
Genevieve M. Klug, PGradDip(Epi.Biostats), Colin L. Masters, MD,
Victoria A. Lawson, PhD, and Steven J. Collins, MD
Abstract
Prion disease pathogenesis is linked to the cell-associated propa-
gation of misfolded protease-resistant conformers (PrPres) of the
normal cellular prion protein (PrPC). Ongoing PrPC expression is
the only known absolute requirement for successful prion disease
transmission and PrPres propagation. Further typifying prion disease is
selective neuronal dysfunction and loss, although the precise
mechanisms underlying this are undefined. We utilized a single prion
strain (M1000) and a range of neuronal and nonneuronal, PrPC
endogenously expressing and transgenically modified overexpressing
cell lines, to evaluate whether PrPC glycosylation patterns or consti-
tutive N-terminal cleavage events may be determinants of sustained
PrPres propagation. Our data demonstrates that relative proportions of
full-length and C1 truncated PrPC are the most important character-
istics influencing susceptibility to sustained M1000 prion infection,
supporting PrPC >-cleavage as a protective event, which may con-
tribute to the selective neuronal vulnerability observed in vivo.
Key Words: Endoproteolytic cleavage, N-linked glycosylation,
Prion infection, Prion protein, PrPC, PrPres.
INTRODUCTION
Prion diseases are fatal neurodegenerative diseases of
humans and animals that are characterized by the accumu-
lation of misfolded protease-resistant conformers (PrPres) of
the normal cellular prion protein (PrPC) (1). PrPC is a ubiq-
uitously expressed glycoprotein (2), and like many structural
and functional classes of membrane-bound proteins (3), it
undergoes posttranslational proteolytic cleavage to generate
distinct species. There are 2 predominant truncated PrPC
species, C1 and C2. PrPC >-cleavage producing C1 occurs
at Residues 111 or 112 (human PrPC sequence nomencla-
ture) (4); significantly, this is within a domain shown to be
neurotoxic and amyloidogenic in in vitro studies of a
synthetic peptide fragment (5). PrPC >-cleavage is thought
to be carried out at least in part by a-disintegrin-and-
metalloprotease 10 (ADAM-10) and ADAM-17 (also known
as tumor necrosis factor->Yconverting enzyme) (6). C2 is
produced from A-cleavage and is found at low levels in
normal human (4, 7, 8) and cultured cells (9). A-Cleavage
occurs around the C-terminus of the PrPC octapeptide repeat
domain (8, 9) and is mediated by reactive oxygen species
(10). The functional significance of endogenous PrPC cleav-
age is unresolved.
A defining feature of prion diseases is their trans-
missibility; this reached epidemic proportions in the United
Kingdom during the outbreak of bovine spongiform ence-
phalopathy (11). Ongoing expression of PrPC is an absolute
requirement for the successful transmission and continuing
pathogenesis of prion diseases (12, 13). In animal species
such as rabbits and dogs, the precise molecular determinants
of their apparently very high resistance to natural and
experimental prion disease are not clearly defined (14, 15),
although PrPC primary sequence incompatibilities have been
suggested to provide protection for rabbits (16). Importantly,
rabbit kidney epithelial cells that have been engineered to
express exogenous PrPC can be infected with cognate prion
strains derived from the same foreign species, and thereafter
propagate PrPres and infectivity (17). These data highlight
that the innate resistance of rabbits is linked specifically to
endogenous rabbit PrPC, as opposed to the cellular machinery
required for infection or propagation.
Neuropathologic features of prion diseases include
vacuolation of the neuropil, astrocytic gliosis, neuronal loss,
and extracellular PrPres deposits. For a single prion strain,
the pattern of neuronal involvement and topographic distri-
bution of these abnormalities can vary among host species
and importantly, across different inbred host strains of the
same animal species harboring the same PrP gene (Prnp)
allele (18). These observations suggest nuances in PrPC
biology or intrinsic cellular factors unrelated to PrPC, that
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differ across neuronal populations in a manner peculiar to
each host, significantly impact pathogenesis. Such phenom-
ena exemplify selective neuronal vulnerability and focus the
broader concept of innate prion disease resistance to the
cellular level.
Cell lines can be persistently infected with prions and re-
tain the biologic and biochemical features of the strain (19, 20).
Analogous to observations in animal models, individual cell
lines have variable susceptibilities to prion infection (Table 1).
In view of the absolute requirement for PrPC in prion disease
transmission and pathogenesis, cellular PrPC expression
profiles may influence susceptibility to sustained prion
infection. Here, we used cell lines, endogenously or trans-
genically expressing the same murine Prnp allele, to correlate
PrPC glycosylation patterns and constitutive endoproteolyic
cleavage profiles with inherent susceptibility or resistance to a
well-characterized mouse-adapted human prion strain
(M1000). We found that expression of proportionately higher
levels of full-length PrPC correlated with susceptibility to
sustained M1000 prion infection, while relatively higher levels
of the C1 C-terminal fragment of PrPC were associated with
resistance to sustained M1000 prion infection. Overall, these
results suggest that >-cleavage of PrPC is protective against
stable PrPres propagation.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
The following murine cell lines expressed endogenous
PrPC from the Prnpa allele (data not shown): 2 cognate hypo-
thalamic GT1-7 cell lines (21) obtained from the same
laboratory approximately 2 years apart, designated GT1-7C
and GT1-7H; uncloned N2a neuroblastoma cells (American
Type Culture Collection [ATCC] CCL-131); NIH/3T3 fibro-
blast cells (ATCC CRL-1658); and OBL-21 olfactory bulb
cells (22). MoRK13 cells, rabbit kidneyYderived epithelial
cells (RK13; ATCC CCL-37) stably transfected with the
murine Prnpa coding sequence as previously described (23),
were also used. Cells were maintained in either Dulbecco
modified Eagle medium (OBL-21, NIH/3T3, MoRK13) or
OptiMEM (N2a, GT1-7) (Invitrogen, Carlsbad, CA) contain-
ing 10% (vol/vol) heat-inactivated fetal bovine serum (Thermo
Fisher Scientific, Rockford, IL) and 1% (vol/vol) penicillin-
streptomycin (Invitrogen), in a humidified incubator, 37-C,
5% carbon dioxide. The medium of MoRK13 cells was
supplemented with a final concentration of 2.5 Kg/mL
puromycin dihydrochloride (Sigma-Aldrich, St Louis, MO).
Prion Strain and Cellular Prion Infection
M1000 prions from mouse brain homogenate (10% wt/
vol, prepared in sterile PBS; 140 mmol/L NaCl; 2.7 mmol/L
KCl; 1.8 mmol/L KH2PO4; 10 mmol/L Na2HPO4), mean lethal
dose (LD50) of approximately 10
9 LD50 per gram of tissue, as
determined by end point titration in Tga20 mice (24), were
used for all infections. To infect cells, subconfluent mono-
layers were overlaid with M1000 brain homogenate (or
uninfected BALB/c brain homogenate as a negative control)
diluted in media to between 0.1% and 2% (wt/vol) final
dilution. After overnight incubation, the homogenates were
removed, cells were then washed twice with sterile Dulbecco
PBS (Invitrogen), and fresh medium was added. Cells were
grown to confluence and subcultured routinely, with the first
passage postYprion exposure designated Passage 1 (P1).
Cell Blot Detection of PrPres
A sensitive cell blot technique was used to detect PrPres in
M1000Yinfected cell cultures, as described elsewhere (23, 25),
with minor modifications. Proteinase K ([PK] Invitrogen)
digestion was at a final concentration of 10 Kg/mL in lysis
buffer (50 mmol/L Tris-Cl pH 7.4, 150 mmol/L NaCl, 0.5%
sodium deoxycholate, 0.5% Triton X-100) for 90 minutes at
37-C and was stopped by incubating for 15 minutes in
2 mmol/L phenylmethylsulfonyl fluoride (Roche Applied
Science, Penzberg, Germany). Phosphate-buffered saline
Tween-20 ([PBST] 140 mmol/L NaCl, 2.7 mmol/L KCl,
1.8 mmol/L KH2PO4, 10 mmol/L Na2HPO4, 0.05% Tween-20
in H2O) was used to make the block buffer (5% [wt/vol]
nonfat milk in PBST) and for all washes. A 1:10,000 dilution
in block buffer of both the antiYprion protein primary antibody
ICSM18 (overnight at 4-C; D-Gen, London, UK) and antiY
mouse-horseradish peroxidase secondary antibody (1 hour at
room temperature; GE Healthcare, Buckinghamshire, UK) was
used for all cell blots.
Detection of M1000 PrPres
To detect PrPres in M1000 brain homogenate, samples
were digested with 50 Kg/mL PK for 1 hour at 37-C. The PK
was stopped by the addition of Pefabloc SC (Roche Applied
Science) to a final concentration of 4 mmol/L.
TABLE 1. Summary of Reported Cellular Susceptibilities to Different Prion Strains
Cell Line
Mo-Adapted Scrapie Prions Mo-Adapted Human Prions
Chandler/RMLa 22La 139Aa ME7a 87Vb 22Ab SY MU-02 FU/M1000
GT1-7 S (34) S (34) S (34) V R (34) R (34) S (32) V S (23, 32)
N2ac S (34, 35, 51, 52) S (34) R (25); S(34) R (25) R (34) R (34, 51) V V S (52)d
OBL-21 R (53) V V V V V V V V
NIH/3T3 V S (43) V V V V V V V
MoRK13 S (17) S (17) V R (17) V V V S (54) S (23, 54)
References are indicated.
Mo-adapted, prion strain adapted by serial passage into mice; SY and MU-02, sporadic CJD strains; FU, Fukuoka-1 GSS strain; M1000, isolate established from FU strain; a,
Prnpa allele; b, Prnpb allele; c, American Type Culture Collection (ATCC) parental line or derived subclones (e.g. N2a 58); d, PrPres detection not attempted but positive in vivo
transmission indicates successful infection; S, susceptible to prion infection; R, resistant to prion infection.
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Cell Lysate Preparation
Confluent cell cultures were harvested, lysed, and as-
sessed for total protein content using the Pierce BCA protein
assay (Thermo Fisher Scientific), as previously described
(26). Cell lysates were used directly or treated, as described
later, before sodium dodecyl sulfateYpolyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blotting.
FIGURE 1. Representative cell blots of MoRK13 (A), GT1-7H (B), OBL-21 (C), GT1-7C (D), N2a (E), and NIH/3T3 (F) exposed to
the specified inoculum (M1000, Balb/c normal brain homogenate (NBH)), or left uninfected (UN). The 2 GT1-7 cell lines were
exposed to lower concentrations of inocula (that is, 1% homogenate), as higher percentage homogenates were toxic to these
cells. The cells were seeded onto coverslips and grown to 90% to 100% confluence before cell blotting for PrPres as an indicator of
successful M1000 prion infection. Passage numbers (post prion infection) are indicated.
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Deglycosylation of PrPC
The glycosidase PNGaseF (Roche Applied Science)
was used to remove N-linked glycans from PrPC in cell
lysates, as previously described (26).
Immunoprecipitation
Zymed rec-Protein GYSepharose 4B conjugate (PGS)
beads (Invitrogen) were equilibrated by washing with PBST.
Cell lysates were precleared by diluting into 1 mL PBST and
then incubating with 40 KL of prewashed beads for 1 hour
with gentle mixing. Beads were collected by centrifugation
(2 minutes, 336  g). The supernatant was transferred to
fresh tubes containing 1 KL SAF32 (Cayman Chemical, Ann
Arbor, MI) and again mixed gently for 1 hour before the
addition of 40 KL of fresh equilibrated beads and overnight
incubation at 4-C with gentle mixing. Beads were collected
as before, washed 3 times in PBST, and then used for PAGE
and Western blot analysis.
PAGE and Western Immunoblotting
Untreated, PNGaseF-treated, or PK-treated samples
were mixed with an appropriate volume of 4 SDS-PAGE
sample buffer (170 mmol/L Tris-Cl pH 6.8, 0.5 mol/L gly-
cine, 8% [wt/vol] SDS, 0.02% [wt/vol] bromophenol blue,
12% [vol/vol] A-mercaptoethanol), boiled (100-C) for 10
minutes, resolved by tris-glycine SDS-PAGE (percent self-
made gel [26] as indicated in figure legends), and Western
blotted as previously described (26). Immunoprecipitated
samples on PGS beads were mixed with NuPAGE loading
dye (Invitrogen), boiled (100-C) for 10 minutes, resolved on
12% Bis-tris NuPAGE gels (Invitrogen) using MES running
buffer (Invitrogen), and subjected to Western blotting. The
anti-PrP antibodies used were monoclonal antibodies
ICSM18 (1:40,000), SAF32 (1:3000) and 8B4 (1:10,000;
Alicon, Schlieren, Switzerland), and polyclonal antibody
03R19 (24) (1:5000). AntiYA-tubulin primary antibody
(1:15,000; Sigma-Aldrich) and the appropriate horseradish
peroxidaseYconjugated secondary antibodies (i.e. anti-mouse
or anti-rabbit; 1:10,000; GE Healthcare) were also used.
Detection was via enhanced chemiluminescence (ECL Plus
Western Blotting Detection Reagents; GE Healthcare) using
Kodak Biomax film (Sigma-Aldrich) or digital capture using
a Fujifilm LAS-3000 Intelligent Dark Box or Syngene
GeneGnome Bioimager.
Densitometric and Statistical Analyses
Digital and scanned x-ray film images were quantita-
tively assessed for signal intensity using ImageJ software.
Statistical analyses were carried out using GraphPad Prism
v4.0a or Minitab 15 as required and as specified in the Re-
sults section.
RESULTS
Determination of Susceptibility to M1000 Prions
The abilities of each cell line to sustain M1000 prion
infection and propagate PrPres over multiple passages after
exposure to M1000 brain homogenate were assessed. Control
cells were either left uninfected or exposed to the equivalent
dilution of normal BALB/c brain homogenate. Cells were
tested a minimum of 3 passages postYprion exposure for de
novo PrPres production to indicate successful establishment
of M1000 infection. As previously reported (23), MoRK13
cells were highly susceptible to M1000 prions, with increas-
ing propagation of prions over time as seen by the increase in
PrPres signal with sequential passages (Fig. 1A). The GT1-7H
cells and the OBL-21 cells (Figs. 1B, C, respectively) were
also susceptible to M1000 prions, but they produced lower
levels of PrPres compared with MoRK13 cells. In both of
these cell lines after an initial slight increase in PrPres pro-
duction, a loss of PrPres propagation was observed. Impor-
tantly, this is the first report PrPres propagation in an olfactory
bulb cell line. PrPres was never detected in the other cell lines
(Figs. 1DYF). Table 2 summarizes the cellular susceptibility
or resistance to M1000.
Cellular PrPC Glycosylation Profiles Do Not
Correlate With Susceptibility to M1000
Prion Infection
The prion protein has 2 conserved potential N-linked
glycosylation sites (27). None, one, or both of these sites can
be occupied by a polysaccharide chain of variable length,
which is visualized as 3 different band sizes (i.e. unglycosy-
lated, monoglycosylated, and diglycosylated PrPC) on a West-
ern blot. As shown in Figures 2A and B, the cell lines display
markedly different PrPC glycosylation profiles; this was high-
lighted when these patterns were quantified (Fig. 2D). Den-
sitometric measurements were obtained by determining the
intensity of the bands at the predicted molecular weights of
diglycosylated, monoglycosylated, and unglycosylated PrPC,
and expressing each relative to the total PrP signal intensity.
Undefined truncated PrPC species were not included for anal-
yses. Unexpectedly, the 2 GT1-7 cell lines had noticeably dif-
ferent PrPC expression profiles (Fig. 2B). Validation of the
authenticity of the common origin of GT1-7C and GT1-7H
FIGURE 2. Prion protein (PrP) expression profiles and glycoform ratios in uninfected cells (PrPC) and M1000 brain homogenate
(PrPres). Representative Western blots (WB) of PrPC expression profiles in cell lines (A) and specifically comparing the GT1-7C and
GT1-7H cell lines (B); 50 Kg total protein per lane, 12% Tris-glycine sodium dodecyl sulfateYpolyacrylamide gel electrophoresis,
WB with ICSM18, and A-tubulin primary antibodies. (C) Representative WB of M1000 brain homogenate pre (j) and post (+)
proteinase K digest. (D) Quantification (mean T SEM) of glycoform ratios of PrPC in the different cell lines and of M1000 PrPres.
Numbers of replicates for each individual cell line or homogenate (n) are indicated on x axis labels. In all cases, based on apparent
molecular weight, di, diglycosylated PrPC or PrPres; mono, monoglycosylated PrPC or PrPres; un, unglycosylated PrPC or PrPres;
truncated, undefined endogenously cleaved PrPC species. (E) Correlative analysis of PrPC glycosylation profiles with susceptibility
to M1000 prion infection. Data points represent the replicates obtained from WB quantification of diglycosylated,
monoglycosylated, and unglycosylated PrPC as shown in (D). Susceptible, evidence of PrPres propagation in cell line after
M1000 exposure; resistant, no evidence of de novo PrPres production after M1000 exposure; susceptible*, susceptible cell lines
excluding MoRK13 from analysis. Binary logistic regression (Minitab 15) was performed; no significant differences were seen.
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cells (i.e. by assessing expression of SV40-T antigen and
finding no glial fibrillary acidic protein expression) showed
no differences between the lines, although they had slightly
different morphologies; the GT1-7H cells were always
stellate in appearance and predominantly grew in clusters,
whereas the GT1-7C cells were fusiform single cells but
became stellate when they approached confluence (not
shown). Differences observed in these originally identical
cells are most likely caused by clonal drift, possibly ex-
plained by the intrinsic or extrinsic models of spontaneous
generation of phenotypic heterogeneity (28).
A previous study indicated that glycosylation of PrPC
might be protective by inhibiting the propensity of PrPC to
misfold and form A-sheet conformations (29). To correlate
M1000 susceptibility with glycosylation pattern, the cell lines
were grouped by their susceptibility or resistance (Table 2)
and the proportion of each PrPC glycoform (Fig. 2D) was
separately plotted against susceptibility or resistance (Fig. 2E).
To assess the effect of glycosylation in an entirely endogenous
expression system, the susceptible group was also separated
to exclude MoRK13 PrPC overexpressing cells from the
analysis. PrPC glycosylation profiles were not a significant
predictor of susceptibility or resistance to M1000 infection.
There is evidence suggesting that similarity between
host PrPC glycosylation pattern and prion strain PrPres
glycosylation pattern can increase the likelihood of PrPC to
PrPres conversion (30). Therefore, the glycosylation pattern of
M1000 PrPres was quantified (Figs. 2C, D) and compared
with each cell line PrPC glycosylation profile (Table 3). Only
the GT1-7H and NIH/3T3 cell lines had PrPC glycosylation
profiles that were not significantly different from M1000
PrPres. Although the GT1-7H cells were susceptible to
M1000 infection, the NIH/3T3 cells were not; this argues
against similarities of PrPC and PrPres glycoform profiles
having a dominant influence on susceptibility to infection
with this prion strain.
One limitation of the glycosylation analyses is that the
Western blot PrPC glycosylation profiles were obtained using
the ICSM18 antibody; the epitope for this antibody is within
the C-terminus of PrP, allowing detection of N-terminally trun-
cated PrP species as well as full-length PrP. Therefore, bands
seen at the presumed relative molecular weights of diglycosy-
lated, monoglycosylated, and unglycosylated full-length
PrPC may actually be a composite of the different glycosylated
full-length and truncated species. To accurately visualize rel-
ative levels of glycosylated full-length PrPC and assess the
influence of these levels on susceptibility to M1000 infection,
N-terminal antibodies were used to immunoprecipitate and
then detect by Western blot exclusively full-length PrPC spe-
cies from cell lysates. The glycosylation profiles of full-length
PrPC species (Fig. 3A) are generally different from the profiles
in Figure 2A, thereby further indicating that the bands in
Figure 2A are most likely a composite of glycosylated full-
length and truncated PrPC. When comparing the different cell
lines, the apparent sizes of the different glycosylated full-
length PrPC species are diverse; however when the proportions
of each PrPC species are quantified and graphed, they were
remarkably similar (Fig. 3B). We have therefore shown that
full-length PrPC glycosylation profiles are not a significant
predictor of susceptibility or resistance to M1000 infection
(Fig. 3C). Furthermore, when comparing the cell line PrPC
glycosylation profiles in Figure 3 to the M1000 PrPres profile
(Figs. 2C, D), all of the cell lines (both susceptible and
resistant) had different proportions of all their PrPC glycoforms
to M1000 PrPres, with the exception of GT1-7H cells for
which the relative proportion of unglycosylated PrPC was not
significantly different from the relative proportion of unglyco-
sylated M1000 PrPres (not shown). These data further argue
against a predominant influence of PrPC glycosylation in de-
termining susceptibility to M1000 prion infection.
Expression of Lower Proportions of Full-Length
PrPC Correlates With Resistance to M1000,
Largely Influenced by Increased PrPC >-Cleavage
PrPC contains 2 well-characterized constitutive internal
cleavage sites: around residues 111/112 (4) and at the C-
terminus of the octapeptide repeat region (8, 9) (Fig. 4A).
The PrPC cleavage profile of each cell line was determined
by Western blot epitope mapping of deglycosylated PrPC
(Fig. 4A). PrPC endoproteolysis varied dramatically among
the cell lines. The C1 and C2 fragments were present in all
cell lines (Figs. 4BYE), however with the exception of the
GT1-7C and MoRK13 cells, the lines had proportionately low
C2 levels (Fig. 4F) requiring overexposure of the Western
blots for detection. The OBL-21 cell line was the only line
with full-length unglycosylated PrPC (FLUG) as the clearly
dominant species compared with the C1 and C2 fragments
(Fig. 4F). Collectively, these data indicate that constitutive
PrPC cleavage was variable among the cell lines, but was
ubiquitous, suggesting that it may have functional significance.
Similar to the PrPC glycosylation profiles previously
described, there were significantly different truncated PrPC
profiles in the 2 GT1-7 cell lines (Figs. 4E, F). Moreover,
there were 2 anomalies in the GT1-7C cells. The first was an
immunoreactive band detected with SAF32 at the electro-
phoretic mobility of the C2 fragment (Figs. 4D, E),
suggesting that a proportion of A-cleavage in this line
occurred slightly more N-terminally than in the other cell
TABLE 3. Differences in the Relative Proportions of Each
Cellular PrPC Glycoform Compared With the M1000 PrPres
Glycoform Profile
Cell Line
Cell Line PrPC:M1000 PrPres
Di Mono Un
Resistant to M1000 infection
GT1-7C *** ** NS
N2a ** ** NS
NIH/3T3 NS NS NS
Susceptible to M1000 infection
GT1-7H NS NS NS
OBL-21 * * NS
MoRK13 NS *** NS
*p G 0.05; **p G 0.01; ***p G 0.001; NS, not significant.
Statistical analysis by 2-way ANOVA with Bonferroni posttests (GraphPad Prism
v4.0a).
Di, diglycosylated PrP glycoform; Mono, monoglycosylated PrP glycoform; PrP,
prion protein; Un, unglycosylated PrP glycoform.
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lines. The second anomaly was the apparent doublet band of
BFLUG[ PrPC in the GT1-7C cells (Fig. 4E). Because this
faster migrating band was not detected with 8B4 (and
consistent with the approximate 2- to 3-kd molecular weight
difference between the 2 bands of the doublet), it likely
resulted from N-terminal truncation of full-length PrPC up to
at least some point within the 37-44 8B4 epitope. A PrPC
doublet has been reported, but was not characterized (31). On
close inspection of the blots, this fragment may also have
been present in the N2a line (Figs. 4B, C), suggesting that it
might occur in various cells but may be overlooked depend-
ing on PAGE resolution and Western blot conditions.
After characterization of PrPC endoproteolytic cleavage
profiles in each cell line, correlative analyses comparing these
profiles with the innate susceptibility to M1000 prions were
performed. The cells were grouped according to their
susceptibility or resistance (Table 2), again including and
excluding the MoRK13 cells to allow for any influence of
exogenous overexpression of PrPC. The relative proportion of
each PrPC fragment (data points obtained from quantification
of FLUG, C2, and C1, as shown in Fig. 4F) was then sep-
arately plotted against susceptibility or resistance (Fig. 5).
The cells that were more likely to be susceptible to M1000
infection expressed a higher proportion of full-length PrPC,
(analysis including MoRK13; p = 0.003; odds ratio [OR],
1.08; confidence interval [CI], 1.03Y1.14; and excluding
MoRK13; p = 0.003; OR, 1.09; CI, 1.03Y1.15). Furthermore,
the analyses also indicated that truncation specifically at the
>-cleavage site was protective against M1000 infection, with
the OR predicting decreased susceptibility with expression of
FIGURE 3. Full-length cellular prion protein (PrPC) glycoform profiles in uninfected cells. Representative Western blot with N-
terminal antibody 8B4 after immunoprecipitation with N-terminal antibody SAF32 (A) and quantification (mean T SEM, n = 3) of
glycoform ratios of PrPC (B). In all cases, based on apparent molecular weight, di, diglycosylated PrPC or PrPres; mono,
monoglycosylated PrPC or PrPres; un, unglycosylated PrPC or PrPres. IgG heavy chain (IgG-H) and light chain (IgG-L) as indicated.
(C) Correlative analysis of full-length PrPC glycosylation profiles with susceptibility to M1000 prion infection. Data points represent
the replicates obtained from Western blot quantification of diglycosylated, monoglycosylated, and unglycosylated PrPC as shown
in (B). Susceptible, resistant, and susceptible* are as defined in Figure 2. Binary logistic regression (Minitab 15) was performed; no
significant differences were seen.
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higher proportions of the C1 fragment (analysis, including
MoRK13; p = 0.027; OR, 0.94; CI, 0.89Y0.99; and excluding
MoRK13; p = 0.029; OR, 0.94; CI, 0.88Y0.99). C2 cleavage
was not protective despite any bias caused by the bimodal
distribution of the data (the cluster of data points with 950%
C2 was exclusively from the GT1-7C cells).
DISCUSSION
Differential susceptibility of cell lines to individual
prion strains is well described (Table 1), and a number of
cellular properties unrelated to PrPC may influence the inter-
cellular variations in susceptibility and resistance to long-
term propagation of PrPres. The apparent subsequent loss of
prion infection, shown here for the GT1-7H and OBL-21
cells, has also previously been described (32Y35). The cause
of this phenomenon was not specifically investigated but
might represent an adaptive cellular response to the ongoing
unfavorable PrPres propagation. Such cellular changes may
reflect diminished PrPC/PrPres interactions and conversion,
and/or enhanced PrPres clearance or degradation, with evi-
dence suggesting that the steady state levels of misfolded
conformers are determined by the equilibrium between their
production and degradation (36). Furthermore, anecdotal evi-
dence for a finely balanced equilibrium comes from cells that
have a propensity to clear prion infection where simple
changes in the batches of culture media or serum used re-
sulting in subtle differences in serum proteins or the con-
centration of salts, amino acids, trace metals, or other additives,
can lead to a loss in prion infection. Finally, although most
prion-infected cells display no obvious detrimental phenotype,
changes in iron metabolism (37), copper binding (38), synaptic
functions, (39) and responses to oxidative stress (40) have all
been described; loss of infection may result from effects of
these subtle changes, if healthier uninfected cells outcompete
or outgrow the infected cells.
The primacy of PrPC in the transmissibility and path-
ogenesis of prion diseases (12, 13) supports the likelihood
that subtle differences in PrPC biology (e.g. posttranslational
processing, trafficking, or specific subcellular localization)
may also constitute important susceptibility determinants in
addition to the presence of expression levels of PrPC. Whilst
PrPC expression levels modulate incubation period in animal
models of prion disease (41, 42), it seems that in vitro, PrPC
expression levels are less critical in influencing susceptibility
to prion infection (36, 43). Therefore, we used the M1000
human-derived prion strain and a range of cell lines encom-
passing anticipated susceptibility or resistance to prion in-
fection to explore PrPC posttranslational processing as a
determinant of sustained PrPres propagation.
A previous study examined the heterogeneity of PrPC
glycosylation and reported that PrPC glycoform patterns in
mouse and rat brain and neuronal cell lines vary but are
distinct (31). We also demonstrated diversity of PrPC gly-
cosylation across different cell types. Because each of the cell
lines investigated has different origins, the likelihood that
different glycans are available for N-linked glycosylation,
FIGURE 4. Cellular prion protein (PrPC) cleavage profiles of cell lines determined by Western blot (WB) epitope mapping. (A)
Schematic representation of endogenous PrPC cleavage and alignment of antibodies used for epitope mapping. (BYD)
Representative WB of PrPC fragments in the different uninfected cell lines; 15% Tris-glycine sodium dodecyl sulfateYpolyacrylamide
gel electrophoresis (SDS-PAGE), WB with ICSM18 (B), 03R19 (C), and SAF32 primary antibodies (D). PGF, PNGaseF digested
samples. (E) Comparison of PrPC fragments in the 2 cognate GT1-7 cell lines (C and H); all samples were PNGaseF treated; SDS-
PAGE and WB conditions were as in (BYD); WB with 8B4 antibody is indicated. For all WBs, the amounts of total protein loaded in
each well depended on relative PrPC expression levels and were adjusted to enable visual identification of PrPC truncated
fragment/s. Based on apparent molecular weight and epitope mapping, diglycosylated PrPC (di), monoglycosylated PrPC (mono),
full-length unglycosylated PrPC (FLUG), and the C1 and C2 truncated PrPC species are indicated. (F) Quantification (mean T SEM)
of relative levels of unglycosylated PrPC species in the different cell lines, as seen in ICSM18 WB images as this is the only antibody
that detects all 3 PrPC species. The replicate numbers for each cell line (n) are indicated on x axis labels.
FIGURE 5. Correlative analysis of relative susceptibility to M1000 infection and constitutive cellular prion protein (PrPC) cleavage
profiles. Data points represent the replicates obtained from Western blot quantification of full-length unglycosylated PrPC (FLUG),
C2, and C1 as shown in Figure 4F. Susceptible, resistant, and susceptible* are as defined in Figure 2. Binary logistic regression was
performed (Minitab 15); significant results are as indicated.
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and varied activities of the enzymes or transferases involved
in oligosaccharide processing, might explain the diversity. N-
linked glycosylation sites are conserved in all mammalian
prion genes (27), possibly indicating an important functional
role for this posttranslational modification; however the
significance of PrP glycosylation in either normal PrPC
function or in prion disease pathogenesis has not yet been
determined. Nonetheless, transgenic mice that express only
unglycosylated PrPC can be infected with a mouse-adapted
scrapie prion strain, propagate only unglycosylated PrPres,
and transmit disease to wild-type mice (44). This indicates
that glycosylation of PrPC or the infectious prion is not al-
ways essential for transmission. We also found that glyco-
sylation profiles were not important determinants of inherent
cellular susceptibility to M1000 prions and sustained PrPres
propagation, a finding that is broadly congruent with pre-
vious studies (45Y47).
There is both in vivo (44) and in vitro (30) evidence that
prion strains may preferentially convert host PrPC with a more
comparable glycosylation state. This phenomenon was not
observed in the current study, suggesting that for the M1000
strain, there are alternative factors that override any influence
of host PrPC glycosylation patterns in determining suscepti-
bility to infection. There is also a suggestion that glycosylation
of PrPC may be protective against prion infection by preventing
the natural tendency of PrPC to form a A-sheet or PrPSc-like
conformation (29). Our results argue against this because all of
the cell lines investigated (both susceptible and resistant)
expressed higher proportions of diglycosylated PrPC com-
pared with the monoglycosylated and unglycosylated species.
The N-terminus of PrPC is not required for production
of PrPres in cultured cells (48). Mice that express only N-
terminally truncated PrPC (lacking residues 32Y80) on a Prnp
null background generated PrPres after scrapie infection and
succumbed to disease after an apparently extended incubation
period (41), although the significance of the longer scrapie
incubation was not determined because of experimental
variations in that study. In a cell-free conversion assay, prog-
ressively longer N-terminal deletion mutants (up to Residue
124) served as a template for production of PrPres, with
decreasing efficiency compared with full-length PrPC, the
more C-terminal the deletion (49). That purely in vitro assay,
however, does not allow for possible disruption of cellular
trafficking of mutant PrPC resulting in altered conversion of
PrPC to PrPres. We found that when the C1 fragment con-
stituted a higher proportion of the total expressed PrPC, there
was reduced susceptibility to M1000 infection with sustained
PrPres propagation; there was increased susceptibility to
infection if greater relative proportions of full-length PrPC
were expressed. Taken together, these results suggest that
although truncated PrPC can be induced to misfold, con-
version and propagation of PrPres are more efficient when
there is a full-length PrPC substrate. This theory also provides
the most likely explanation for why the GT1-7C cells were
resistant to M1000 infection because only 10% of the total
PrPC found in these cells was full-length. Furthermore, the
doublet PrPC band in the GT1-7C and possibly the N2a cell
lines may represent a novel truncated PrPC species that might
also influence susceptibility to M1000 prion infection.
Endoproteolytic >- and A-cleavage of PrPC somewhat
parallels the cleavage of the Alzheimer diseaseYassociated am-
yloid precursor protein (APP) (50). Alzheimer disease patho-
genesis is related to aberrant endogenous proteolytic cleavage
of the transmembrane glycoprotein APP and accumulation
of the resultant amyloid-A peptide. Distinct from the patho-
genic switch of >-secretase APP processing to predominant
A-secretase APP cleavage, our results suggest that it is not a
switch from 1 PrPC processing pathway to another that is a
precursor to pathogenesis, but that it is the depletion of avail-
able full-length PrPC as the optimal substrate that is protective
against prion infection. Interestingly, some of the cell lines
used herein that were resistant to M1000 prions have pre-
viously shown susceptibility to other prion strains (Table 1).
Therefore, analogous studies using additional prion strains
would provide further insight as to whether the observations
made in this study are more broadly applicable or M1000
strain specific.
Overall, the results described herein highlight the
complexity of PrPC biogenesis and how aspects of this,
especially constitutive endoproteolytic cleavage of PrPC, are
important cellular characteristics that contribute to suscepti-
bility to nontransient M1000 prion infection, with increased
>-cleavage offering protection. Thorough analysis of trun-
cated PrPC species within different brain regions may provide
insight into the selective neuronal vulnerability and topo-
graphic distribution of neuropathologic abnormalities char-
acteristic of prion diseases.
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Anionic Phospholipid Interactions of the Prion Protein N
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the Octapeptide Repeat Domain*
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Although theN terminus of the prion protein (PrPC) has been
shown to directly associate with lipid membranes, the precise
determinants, biophysical basis, and functional implications of
such binding, particularly in relation to endogenously occurring
fragments, are unresolved. To better understand these issues,
we studied a range of synthetic peptides: specifically those
equating to theN1 (residues 23–110) andN2 (23–89) fragments
derived from constitutive processing of PrPC and including
those representing arbitrarily defined component domains of
the N terminus of mouse prion protein. Utilizing more physio-
logically relevant large unilamellar vesicles, fluorescence stud-
ies at synaptosomal pH (7.4) showed absent binding of all
peptides to lipids containing the zwitterionic headgroup phos-
phatidylcholine and mixtures containing the anionic head-
groups phosphatidylglycerol or phosphatidylserine. At pH 5,
typical of early endosomes, quartz crystal microbalance with
dissipation showed the highest affinity binding occurred with
N1 andN2, selective for anionic lipid species.Of particular note,
the absence of binding by individual peptides representing com-
ponent domains underscored the importance of the combina-
tion of the octapeptide repeat and the N-terminal polybasic
regions for effective membrane interaction. In addition, using
quartz crystal microbalance with dissipation and solid-state
NMR, we characterized for the first time that both N1 and N2
deeply insert into the lipid bilayer with minimal disruption.
Potential functional implications related to cellular stress
responses are discussed.
Prion diseases (also known as transmissible spongiform
encephalopathies) include a diverse group of neurodegenera-
tive disorders that share a number of unifying features, includ-
ing salient neuropathological changes and transmissibility.
Creutzfeldt-Jakob disease, fatal familial insomnia, and Gerst-
mann-Sträussler-Scheinker syndrome constitute the more
common human disorders, and scrapie in sheep and goats,
bovine spongiform encephalopathy, and chronic wasting dis-
ease of mule deer, elk, and moose are the predominant animal
forms of prion disease (1). A key event in prion disease patho-
genesis is themisfolding of the normal formof the prion protein
(PrPC)3 into isomeric, typically protease-resistant -sheet rich
conformers (designated PrPres), with the latter also posited to
predominantly, or perhaps exclusively, constitute the transmis-
sible agent (“prion”) (2). According to the protein-only hypoth-
esis of propagation, PrPres recruits and converts natively folded
PrPC into de novo PrPres via an autocatalytic process (2).
Mature, full-length mouse PrPC (moPrP) is a 208-residue
variably N-linked glycosylated protein, attached to the outer
membrane leaflet via a C-terminal glycosylphosphatidylinosi-
tol (GPI) anchor (3). Similar to other proteins, theGPI anchor is
important for directing PrPC to detergent-resistant microdo-
mains (DRM; also known as lipid “rafts”), although the N ter-
minus of PrPC has also been shown capable of independently
performing this function (4, 5). Structural analyses of unglyco-
sylated, non-GPI-anchoredmammalian PrPC fromvarious spe-
cies, when analyzed in aqueous environments, have demon-
strated a globular C-terminal region, dominated by three
-helical regions, two of which are linked through a disulfide
bridge; the N-terminal region, encompassing residues 23 to
125, appears largely unstructured (6). TheN terminus of PrPC
can be construed as composed of three sequential subdomains
as follows: a polybasic, charged glycosaminoglycan binding
region (residues 23–50; unless otherwise stated, all references
to amino acid sequences are to murine PrP) (7); an octapeptide
(PHGGGWSQ) repeat domain, with hydrophobic and copper-
binding properties (8); and a hydrophilic, copper binding
domain (approximately residues 90–110) (9), which also
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1 Supported by National Health and Medical Research Council fellowships
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Program Grant 400202.
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appears to have some capacity to bind glycosaminoglycans
albeit with lesser affinity (10).
As part of its normal cellular biology, PrPC, upon binding
Cu2 (11) and/or Zn2 (12), can exit DRMs and move laterally
though detergent-soluble membrane zones to allow endocyto-
sis mediated by clathrin-coated pits (13), with the polybasic
region (residues 23–28) essential for this trafficking (14, 15). In
addition, PrPC can be cleaved near its C terminus or within the
GPI anchor and be secreted or “shed” into the extracellular
milieu (16, 17). As for the cell-associated trafficking of PrPC, the
significance of shedding is poorly understood, but it clearly lib-
erates PrPC to potentially participate inmembrane associations
not readily available to it while tethered through a GPI anchor
at its C terminus.
Notably, PrPC can undergo two constitutive cleavage events,
with their true biological significance yet to be fully elucidated.
Cleavage between residues 109/110 or 110/111, -cleavage
(18), gives rise to the N1 (23–110/111) and C1 (110/111–231)
fragments. Alternatively, cleavage around residue 90, -cleav-
age, produces the N2/C2 combination (19).
A complete understanding of themolecular basis and cellular
location of PrPC to PrPres conversion remains elusive as does
the normal function of PrPC. Several biomolecules have been
implicated in the structural conversion of PrPC into its patho-
genic isoform. These include RNA (20), transition metals such
as copper, zinc, and manganese (21), glycosaminoglycans (22),
and membrane-associated lipids, with the latter potentially
serving as a platform to facilitate structural transitions (23, 24).
Interactions of soluble PrPC with the core of the lipid bilayer
have also been proposed as directly contributing to prion-me-
diated neurotoxicity (25). In addition to these likely deleterious
associations, there are less explored interactions between PrPC
and membrane lipids, which may be important for either con-
trolling or subverting normal physiological activities. Certainly,
induced membrane lipid perturbations can unfavorably influ-
ence protective properties and intracellular signaling associ-
atedwith PrPC processing or cognate peptide exposure (26, 27).
Localization of proteins to the exoplasmic face of DRMs
through a GPI anchor is often associated with receptor or cell-
signaling properties, with evidence to support this function for
PrPC (28, 29).
Extending the lipid associating capacity of PrPC independent
of the GPI anchor, PrP(23–145) and full-length PrPC have both
been shown to also bind to model non-DRM lipid membranes,
specifically to small unilamellar vesicles (SUV) containing
POPS (30), with greater affinity at acidic pH. The specificity of
the membrane lipid binding is of interest. No binding affinity
was observed in relation to POPC, the dominant lipid in non-
DRM membrane segments, with a consistent and significant
pH-dependent association found with POPS. This contrasts
with full-length hamster PrP, which was shown to be capable of
binding to POPC at pH 5, suggesting there may be differing
species affinities for specific phospholipids perhaps most easily
appreciated for the restricted regions of the prion protein (31).
Anionic lipids such as POPS and POPG are expressed in low
quantities compared with bulk phospholipids such as POPC.
However, these charged lipids have been associated with func-
tional roles such as mediating intracellular signaling (32), pro-
motion of phagocytosis (33), and induction of changes to the
outer face of the lipid membrane (34), including those preced-
ing the formation of endocytic pits (35). These observations are
consistent with the hypothesis that it is these minor phospho-
lipid species that determine meaningful biological activities,
such as protein activation or signaling processes, within a dom-
inant but biologically inert PC membrane scaffold (36).
Preliminary studies have suggested theN terminus of PrPC is
capable of binding to non-DRM lipid membranes. However,
there remain many fundamental issues, such as the precise
determinants, biophysical basis, and functional relevance, espe-
cially in relation to the constitutively producedN1 andN2 frag-
ments. Using a range of biophysical approaches, we have been
able to provide novel and important insights into these funda-
mental questions. Through fluorescence and QCM-D studies,
we were able to demonstrate for the first time that the highest
affinity binding occurred with fragments equivalent to N1 and
N2, selective for anionic lipid species. Of particular note, our
detailed characterization of the determinants of non-DRM
lipid binding underscored the need for a combination of the
octapeptide repeat region and an N-terminal polybasic domain
for effectivemembrane interactions to occur. In addition, using
QCM-D and solid-stateNMR,we determined that bothN1 and
N2 deeply insert into the lipid bilayer but with minimal disrup-
tion. As a corollary to more clearly characterizing the determi-
nants and biophysical underpinnings of the binding of N1 and
N2 peptides to model non-DRM lipid membranes, we offer
tentative insights into the possible biological relevance of such
interactions.
EXPERIMENTAL PROCEDURES
Lipids and Synthetic PrP Peptides—All phospholipids were
purchased from Avanti Polar Lipids, Alabaster, AL, and used
without further modification. Synthetic N-terminal peptides
based on the mouse PrP sequence were utilized in this study.
These were synthesized by the Peptide Technology Laboratory,
Research Transfer Facility, Bio21 Institute, University of Mel-
bourne. The peptides are summarized in Fig. 1 and consisted of
the following: PrP(23–50); PrP(23–89); PrP(23–110); PrP(51–
89); PrP(50–110); PrP(23–110)51–89 (i.e. 23–110 with the
octapeptide repeat region deleted); and PrP(90–110). Peptide
sequence and purity (95%) were verified by HPLC and mass
spectrometry. Full-length recombinantmoPrP was also used in
initial experiments as a positive control to assist optimizing
conditions, with its production as described previously (37).
Unless otherwise stated, the following buffers were used: for pH
5, 50 mM acetate, 100 mM NaF; and for pH 7.4, 20 mM phos-
phate, 100 mM NaCl.
Preparation of Lipid Vesicles—Large multilamellar vesicles
(MLV) were produced from POPC or mixtures of POPC with
either POPG or POPS in 2:1 and 4:1 molar ratios as described
previously (38). Chloroform/methanol (9:1 v/v)was used to dis-
solve the lipids in a round bottom flask. The solvent was
removed by rotational film evaporation to leave a thin film.
Vesicles were formed by resuspending the lipid film with the
appropriate buffer prior to 4–6 freeze-thaw cycles using liquid
nitrogen and water at 37 °C.
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Large unilamellar vesicles (LUV)were produced by 11 passes
of theMLV suspensions though a 0.1-mpolycarbonate mem-
brane filter (GE Healthcare) using a manual extruder (Avestin,
Ottawa, Canada). LUV were stored at room temperature and
used within 24 h of preparation. Small unilamellar vesicles
(SUV) were produced by the sonicationmethod of Koenig et al.
(39)
Fluorescence Spectroscopy—Intrinsic tryptophan fluores-
cence of the peptides was measured using either a Thermo-
Electron Varioskan multimode plate reader equipped with
onboard liquid dispenser, a Varian Eclipse spectrophotometer,
or a Cary 100 fluorimeter using 1-cm path length quartz
cuvettes. For plate reader experiments, initial peptide concen-
trations were 12.5M. Fluorescence was excited at 295 nm, and
a spectrumwas recorded between 315 and 460 nm. A point was
recorded every 1 nm with an averaging time of 200 ms. Effects
of dilution on the samples were accounted for in the analysis of
the spectral data.
Circular Dichroism—A Jasco 810 spectropolarimeter was
used to record CD spectra with wavelength analyses between
195 and 260 nm. Samples at 15 M peptide in the appropriate
buffer were contained in a 0.1-cm path length quartz cuvette,
with all experiments conducted at room temperature. Back-
ground spectra (buffer or LUV solution) were subtracted from
the peptide spectra.
Solid-state NMR—All solid-state NMR experiments were
preformed on aVarian Inova-300 spectrometer (Palo Alto, CA)
using a 5-mm Doty (Columbia, SC) magic angle spinning
(MAS) probe at 30 °C. Experiments and analysis were adapted
from Pukala et al. (40). For 31P experiments, the probe was
tuned to a frequency of 121.5MHz and referenced to H3PO4 (0
ppm). To maximize signal/noise, 31P relaxation experiments
were performed under MAS conditions at a spin rate of 4 kHz.
The inversion recovery pulse sequencewas used tomeasure the
longitudinal relaxation time (T1) with internal delay times
0.01–2.0 s. Transverse relaxation times (T2) were measured
using the Hahn spin-echo experiment with internal delay times
of 0.2–160 ms. 2H experiments were performed at 46.1 MHz
using a solid-echo sequence.
Peak intensities were measured using the integration func-
tion of the VNMR software package (Varian Inc.). Peak inten-
sity was plotted in relation to the delay time in the inversion
recovery or Hahn spin-echo pulse sequences using Prism 4
(GraphPad Software Inc.) and a single exponential curve fitted
to the data. The relaxation times are presented as the average of
at least two experiments, and the range between the values was
calculated.
NMR samples contained a 10-mg mixture of POPC/POPS
(2:1)MLVprepared as described above and suspended in 100l
of 10 mM MES, 50 mM sodium chloride, pH 5. Peptides were
added to the lipid film from stock solutions to a 20:1 lipid/
peptide molar ratio prior to MLV formation.
Quartz Crystal Microbalance with Dissipation—QCM-D
monitoring experiments were performed in parallel using a
Q-Sense E4 quartz crystal microbalance (Q-Sense AB, Fröl-
unda, Sweden) using methods previously published (41).
Briefly, AT-cut quartz crystals with a fundamental resonance
frequency of 5 MHz (Q-Sense) were used. Frequency and dis-
sipation changes were recorded at the fundamental 1st, 3rd,
5th, 7th, 9th, 11th, and 13th harmonics. Unless stated other-
wise, changes to the resonance frequency (f) and dissipation
(D) reported here are those for the 7th harmonic (or 35MHz).
Experiments were performed under temperature control at
22 °C.
The dissociation constant of the peptide-lipid complex was
calculated from the kinetic binding constants extracted from
the frequency curve via least squares fitting of the following
Equations 1 and 2 (42),
f  f0e
kont  t0 (Eq. 1)
where f is the frequency at time t; f0 is the frequency change






1  e  kon	P
  kofft  t0 (Eq. 2)
where kon is the on rate, [P] is the concentration of the experi-
mental peptide, and fmax is the resonance frequency of the crys-
tal at maximum coverage. Data were analyzed using the
Q-Tools (Q-Sense) software. Averages for each experiment
were derived from a minimum of three trials.
RESULTS
TheN-terminal region of PrPC, residues 23–110, can be arbi-
trarily construed as composed of three relatively distinct sub-
domains in relation to amino acid composition, and copper and
glycosaminoglycan binding capacity (8). To model the binding
affinity of the three individual N-terminal subdomains, and the
potential influence of interactions between certain combina-
tions of segments in relation to synthetic membranes, the fol-
FIGURE 1. Schematic illustration of the N-terminal region of mouse PrP encompassing residues 23–110, with the various peptides utilized in the study
depicted below. The peptides used in this work are schematically represented by the black bars. The gray region shows the residues deleted from the
PrP(23–110)51– 89 peptide.
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lowing peptides based on murine PrPC were utilized: PrP(23–
50), PrP(51–89), PrP(90–110), PrP(23–89) (representative of
the N2 endoproteolytic fragment), PrP(23–110) (equivalent to
the N1 endoproteolytic fragment), PrP(50–110), and PrP(23–
110)51–89;moPrPwas also used as a positive control in initial
synthetic membrane binding studies.
Three mono-unsaturated diacyl phospholipids were used to
probe the interactions between the peptides and lipid mem-
branes. POPC represents the bulk phospholipid of the cell
membrane, with POPS andPOPGanionic lipids that have func-
tional roles in neurons. LUV and supported bilayers were cho-
sen as model membranes, in preference to the SUV used in
previous studies (30). The metastable nature of SUV and the
high degree of membrane curvature they exhibit can cause
anomalous lipid-peptide interactions that are not representa-
tive of the cell membranes; LUV and supported membranes do
not suffer from these issues (43). All experiments were per-
formed above the liquid lamellar (L) phase transition temper-
ature of the lipid mixtures.
Intrinsic Tryptophan Fluorescence—The aromatic amino
acids tyrosine and tryptophan are fluorescent, with excitation
maxima around 280 nm, with tryptophan providing the stron-
ger emission signal. Given that PrP(23–50) and PrP(90–110)
each only contain single tryptophan residues, whereas PrP(51–
89) contains five, peptide concentrations were optimized to
obtain the best spectra from each of the peptides (43). Under
fully hydrated (polar) conditions, tryptophan has an Em,max
350 nm, although in a hydrophobic environment Em,max is
shifted to a shorter wavelength. In addition, the relative fluo-
rescence intensity of tryptophan is increased in hydrophobic
media when compared with the value in a polar solvent.
TheEm,max values observed formoPrP and all of the synthetic
peptides in buffers without added lipid at both pH 5 and pH 7.4
fell within the range 346–349 nm indicating that the trypto-
phan residues are in a polar environment, consistent with pre-
vious observations of full-length PrP (30) and with the expecta-
tion that the peptides are unfolded in solution (6). Incubating
moPrP and the various peptideswith increasing concentrations
of LUVcomposed only of the zwitterionic POPCdid not induce
any consistent change to Em,max or relative fluorescence inten-
sity at either pH (Fig. 2, A and D). This indicates that moPrP
(especially the N-terminal region) does not interact with the
bulk lipid of the cell membrane over the physiological pH range
5–7.4. At higher lipid concentrations, there was minor binding
of moPrP to POPC/POPG at pH 7.4 but no observable spectral
change for any of the various PrP peptides with titration of
either POPC/POPG or POPC/POPS at around neutral pH (Fig.
2, B and C). The limited affinity of moPrP for anionic lipid
membranes at pH 7.4 contrasts with previous studies using
wild-type humanPrP,where considerable binding to SUVcom-
posed of POPC/POPS (2:1) at pH 7 was observed but with
decreased affinity compared with the lower pH (30). However,
it is to be stressed that our experiments were conducted using
LUV rather than SUV. Therefore, this discrepancy may be
caused by the smaller membrane radius of the SUV allowing
easier access to the hydrophobic core of the membrane result-
ing in less physiologically relevant binding to SUV (44). Alter-
natively, the sequence difference between human and mouse
PrP may be sufficient to cause a difference in affinity.
At pH 5, LUV suspensions of POPC/POPG and POPC/POPS
at themolar ratio 2:1, revealed a distinct blue shift ofEm,max and
an increase of fluorescence intensity for the spectra of moPrP,
PrP(23–89), and PrP(23–110), with greater changes observed
for POPC/POPG LUV (Fig. 2, E and F). The fluorescence spec-
tra of PrP(50–110) and PrP(23–110)51–89 showed no
change of Em,max and relative fluorescence intensity at pH 5
with both POPC/POPG and POPC/POPS LUV (Fig. 2,E and F).
Intrinsic fluorescence binding experiments using PrP(23–50)
and PrP(90–110) did not show a change of fluorescence inten-
sity or Em,max under any experimental conditions (data not
shown). The lack of change to these parameters indicates that
neither of these shorter peptides has any affinity for POPC or
anionicmembranes irrespective of pH. Furthermore, in parallel
with the above experiments, we also screened the peptides for
binding to LUV containing a 4:1 ratio of zwitterionic/anionic
lipids (results not shown). In these experiments, none of the
peptides showed systematic changes to eitherEm,max or fluores-
cence intensity, indicating that they did not bind to the lipids.
Cumulatively, these findings suggest N-terminal peptide-lipid
binding will only occur under relatively specific circumstances.
Given the intrinsic net charge of segments of the various
peptides, for example the polybasic region 23–28, and the ani-
onic nature of POPG and POPS, we assessed the role of electro-
static forces in the peptide-lipid interactions. Sodium chloride
titration experiments (to a final concentration of 1 M) indicated
electrostatic interactions did not cause the membrane binding
of the peptides (results not shown).
Quartz Crystal Microbalance with Dissipation—QCM-D
monitoring is a highly sensitive gravimetric technique that is
able to detect changes tomass in the subnanogram range, and it
has been extensively used to study the membrane binding and
disruption properties of various peptides (41). Fundamentally,
alterations in the resonant frequency of theQCM-D sensor (f)
can be related to changes in the mass of the sensor consequent
to the material deposited. Fig. 3 is a sensorgram of a typical
QCM-D experiment, depicted from the solution-only base line
to the final wash-off of the peptide.
Subsequent to the positive results of the initial fluorescence
studies, we undertook detailedQCMassessment of the binding
of the synthetic peptides to supported bilayers consisting of
POPC/POPS or POPC/POPG at a 2:1 ratio at pH 5 (Fig. 4).
Identical experiments were also conducted with pure POPC
bilayers, and consistent with the fluorescence analysis, no bind-
ing of the any of the peptides was observed (data not shown).
The peptides PrP(23–89), PrP(23–110), PrP(50–110), and
PrP(23–110)51–89 demonstrated different levels of binding
to both POPC/POPG and POPC/POPS bilayers, with PrP(23–
89) and PrP(23–110) showing the greatest binding. All of the
binding peptides showed greater deposition on POPC/POPG
membranes. Peptides PrP(23–50), PrP(51–89), and PrP90–
110 did not show significant changes to f (Fig. 4), indicating
that they do not bind to the lipids.
All experiments showed a reproducible profile, with the sen-
sorgram trace being consistent with SUV binding to the QCM
sensor before rapidly fusing to form a stable bilayer. A wash
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with buffer caused a very small increase in f, indicating extra-
neous SUV being removed from an otherwise intact bilayer.
When peptide was present, deposition was indicated by a rapid
decrease inf before reaching a plateau. Upon starting the flow
of buffer into the QCM cell, the sensorgram indicated a loss of
mass from the chip. In no case was the loss of mass from the
chip initiated prior to the buffer wash or was the loss greater
than the increase in mass due to peptide binding. From this we
suggest the loss of mass is due to the dissociation of peptide
from the lipid bilayer rather than the removal of a lipid-peptide
complex from the QCM sensor in a detergent-like manner.
Changes to the resonance frequency of the QCM chip at
different overtones provides insight into the condition of the
membrane at various distances from the chip, with higher over-
tones indicating activity closer to the chip surface (41). None-
theless, in analyzing QCM-D data, it is usual to discard the first
harmonic, as this senses the chip coupledmolecules of the bulk
solution above the chip, and thus the trace is not relevant to the
behavior of the deposited lipid and peptides. In this study, we
used the 3rd, 5th, 7th, 9th, 11th, and 13th overtones. All mea-
sured harmonics of the QCM chip responded in a similar way
for each of the peptides for both the POPC/POPG and POPC/
POPS membrane compositions. The similar effect for each
overtone is consistent with the peptides inserting into the
bilayer in a transmembrane manner (41). The modest differ-
ence between the 3rd and 13th harmonics for the interaction of
PrP(23–110) with POPC/POPS and for each of the binding
peptides with POPC/POPG suggests that a small excess of the
peptide may associate with the bilayer surface only.
The amount of peptide bound to the outer leaflet of the
bilayer was calculated in stoichiometric terms and expressed as
the number of lipids per molecule of peptide bound (summa-
rized in Table 1). The association rate (kon) and dissociation
rate (koff) of the peptides can be calculated from the binding and
elution phases of the QCM-D experiment (42). The calculated
values of kon, koff, and Kd are given in Table 2.
All of the peptides that bind to the membranes have a mod-
estly higher affinity for the POPC/POPG bilayers than for
POPC/POPS and bind at a lower lipid/peptide ratio. The differ-
ence in the required number of lipidmolecules was particularly
noticeable for two peptides: PrP(23–110)51–89, 10 for
POPC/POPG comparedwith 20 for POPC/POPS; and PrP(50–
FIGURE 2. Intrinsic tryptophan fluorescence intensity change of full-length wild type recombinant mouse PrP and various cognate N-terminal syn-
thetic peptides in response to different LUV lipid environments. The peptides presented are as follows: PrP(23–110) (f); PrP(23– 89) (Œ); PrP(50 –110) ();
PrP(23–110)51– 89 (); and recombinant moPrP (F). The panels show the results of titration as follows: A, POPC, pH 7.4; B, POPC/POPG (2:1), pH 7.4; C,
POPC/POPS (2:1), pH 7.4; D, POPC, pH 5; E, POPC/POPG (2:1), pH 5; and F, POPC/POPS (2:1), pH 5. Experiments were performed at room temperature in either
50 mM sodium acetate, 100 mM NaF, pH 5, or 20 mM phosphate, 100 mM NaCl, pH 7.4. f/f0 is the ratio of tryptophan fluorescence intensity of the peptide in the
presence of LUV to the fluorescence intensity of the peptide in buffer.
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110), 20 for POPC/POPG and 80 for POPC/POPS. Each of the
peptides that demonstrated binding had Kd values in the sub-
micromolar range for membranes containing either POPS and
POPG. These are composed of “on-rates” in the region of
40,000 M s1 with “off-rates” around 0.004 s1. These figures
would indicate that the PrP peptide-lipid complexes both asso-
ciate and dissociate an order of magnitude faster than other
peptides that have been studied by QCM (42).
Solid-state 2H and 31P NMR Studies—2H and 31P solid-state
NMR of phospholipid bilayers are additional noninvasive
methods to study protein-lipid interactions using deuterated
phospholipids. The use of these two nuclei is complementary
with 2H favoring studies of themembrane hydrophobic core via
the acyl chains, although 31P studies probe the headgroup
region of the lipids.
The NMR studies concentrated on the N-terminal peptides
that show the most significant membrane binding by fluores-
cence andQCM-D experiments, PrP(23–89) and PrP(23–110).
Furthermore, although both PrP(23–89) and PrP(23–110)
bound to phosphatidylglycerol with modestly higher affinity
than phosphatidylserine, we chose to undertake theNMR stud-
ieswith the latter because PS is found at higher levels thanPG in
mammalian neural cells (45) and has been previously reported
to selectively interact with other peptides such as A (38, 46).
Moreover, PS is found in significant amounts in the cell plasma
membrane and on the surface of endosomal compartments
(47), locationswhere PrPC is found,whereas PGheadgroups are
mostly found in themitochondrialmembranes as a precursor of
cardiolipin (48). Therefore, the NMR experiments were only
performed with a mixture of POPC and POPS.
31P Solid-state NMR—Phospholipid headgroups can be
probed using 31P solid-state NMR (40). In particular, the order
of the headgroups can be ascertained from broad line 31P NMR
(49), although relaxationmeasurements give an insight into the
rates of motion of the headgroup (50). The width of the 31P
powder pattern indicates the phase of the lipids, with broader
components corresponding to greater order, and narrow com-
FIGURE 3. Typical QCM-D sensorgram. The lower line represents changes to
the vibrational frequency of the QCM chip (f, left-hand axis), and the upper
line is the dissipation of energy through the adsorbed lipid (D, right-hand
axis). Progress of the experiment is delineated by alternating light and dark
gray shading corresponding with the symbols a–f. a, base-line condition
under acetate buffer 50 mM, pH 5, with NaCl, 100 mM; this is the condition to
which changes to f or D are referenced. b, addition of lipid in the form of
SUV (lipid in this example is POPC/POPS (2:1), pH 5), leading to the coating of
the chip with the SUV (rapid decrease in f to around 60 Hz) and their
breaking open to form a bilayer in contact with the QCM chip (rapid increase
in f to a value around 30 Hz). c, wash with acetate buffer to remove extra-
neous SUV (slight increase in f and decrease in D). d, injection of
moPrP(23– 89)-peptide leading to the absorbance of the peptide to the
bilayer (rapid decrease in f to c, 40 Hz). e, incubation of peptide with
bilayer with no resulting change to f or dissipation over time, indicating that
the bilayer is not disrupted by the peptide. f, wash with acetate buffer causing
dissociation of the peptide from the lipid rapid increase in f.
FIGURE 4. Summary of values of f for the 3rd, 5th, 7th, 9th, 11th, and
13th overtones derived from QCM-D measurements of supported lipid
bilayers in 50 mM sodium acetate, 100 mM sodium chloride, pH 5. The
graphs show the change in f induced by the addition of synthetic peptides
derived from the N terminus of mouse a and h, PrP: PrP(23–50); b and i,
PrP(23– 89); c and j, PrP(23–110); d and k, PrP(23–110)51– 89; e and l, PrP(50 –
110); f and m, PrP(51– 89); g and n, PrP(90 –110) interacting with supported
composite lipid bilayers consisting of (2:1) POPS/POPS (a– g) or POPC/POPG
(h–n). Greater negative values indicate a larger deposit of mass to the QCM
chip. Data are shown as the mean of three experiments  S.E.
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ponents indicate highly mobile species such as micelles under-
going isotropic motion. In contrast with the broad line 2H of
acyl chains, 31P NMR allows differentiation between different
phospholipid populations by changes in the chemical shift of
the membrane components (40).
The spectra in Fig. 5 are of POPC/POPS mixtures with and
without PrP(23–89) and PrP(23–110) peptides. All of the spec-
tra have a 31P powder pattern consistent with the lipids forming
homogeneous lamellar bilayer vesicles. The chemical shift ani-
sotropy (CSA) of the 31P signal is related to distance between
the outer edges of the powder pattern; the results are summa-
rized in Table 3. The addition of the PrP(23–89) and PrP(23–
110) peptides caused a slight increase in the 31P CSA from 42.2
to 44.5 and 43.7 ppm, respectively. An increase inCSA indicates
that the phospholipid headgroups undergo less extensive
motions in the presence of the peptides, although the change is
small, suggesting a weak interaction with the headgroup. The
lack of a second CSA in the 31P spectra with the peptides indi-
cates that the peptide interaction does not cause phase separa-
tion of the POPC and anionic lipids.
2H Solid-state NMR—Broad line 2H NMR of chain deuter-
ated phospholipids is a method of probing the order of the
acyl chains in phospholipid bilayers. The technique probes
the environment within the core of the lipid bilayer, with
greater splitting between the wings of the 2H spectrum cor-
relating with greater order of the chains within the mem-
brane. We utilized the 2H31-palmitoyl chain of POPC to act
as the probe of the bilayer. Fig. 6 shows the 2H solid-state
NMR spectra of MLV with and without PrP(23–89) and
PrP(23–110). The spectra show that the peptides increased
the outer 2H splittings from 23.5 kHz for the POPC/POPS
(2:1) MLV to 25.6 and 24.3 kHz with PrP(23–89) or PrP(23–
110), respectively. The changes indicate an ordering of the
lipid acyl chains by the peptides, with PrP(23–89) causing a
greater increase than PrP(23–110). The ordering of the acyl
chains is consistent with the QCM-D experiments, suggest-
ing that the peptides insert deeply into the membrane core
andmay be entirely transmembrane. Themore defined split-
FIGURE 5. 31P broad line solid-state NMR spectra of MLV composed of
dPOPC/POPS (2:1) suspended in MES buffer (10 mM, pH 5) with 50 mM
NaCl. The spectra are the accumulation of 25,000 transients processed with a
line broadening function of 50 Hz. Bottom solid line represents the lipids
alone; the middle dashed line represents the lipids plus PrP(23– 89), and the
top dot-dash line represents the lipids plus PrP(23–110). CSA values are sum-
marized in Table 3. The vertical lines are not representative and are added to
aid the reader.
TABLE 1
Lipid/peptide binding ratios for various synthetic peptides based on the N terminus of mouse PrP
Binding was to support composite lipid bilayers. Ratios are calculated fromQCM-Dmeasurements as the ratio between f upon lipid deposition and bilayer formation, to
f associatedwith peptide addition. Values are themean S.D. number of lipidmolecules (POPC and POPGor POPS) associatedwith the binding of one peptidemolecule.
All experiments were performed in 50 mM acetate buffer, 130 mM NaCl, pH 5.
Total lipid/peptide molar binding ratios
POPC/POPS, 2:1 POPC/POPG, 2:1
PrP(23–89) 16.6 4.0 9.8 0.4
PrP(23–110) 15.2 0.9 13.3 0.3
PrP(23–110)51–89 21.8 1.9 10.7 3.1
PrP(50–110) 79.1 3.7 18.0 5.6
TABLE 2
“On” (kon) and “off” (koff) rate constants and dissociation constants (kd) for the association of synthetic peptides (based on the N terminus of
mouse PrP) to supported composite lipid bilayers, calculated from QCM-D measurements
koff was first calculated by fitting a exponential function to the dissociation phase of the QCM-D experiment. kon was then calculated using the method of Christ et al. (42)
by substituting the value of koff into a binding function. Values are given as themeans S.D. of three experiments. All experiments were performed in 50mM acetate buffer,
130 mM NaCl, pH 5.




PrP(23–89) 35,000  20,000 0.005  0.004 100  200
PrP(23–110) 38,000  23,000 0.003  0.003 100  140
PrP(23–110)51–89 4300  15,000 0.005  0.001 100  100
PrP(50–110) 8000  10,000 0.004  0.006 500  600
POPC-POPG (2:1)
PrP(23–89) 40,900  21,000 0.004  0.002 100  70
PrP(23–110) 41,300  5000 0.004  0.001 100  280
PrP(23–110)51–89 53,000  41,000 0.003  0.003 100  80
PrP(50–110) 54,300  27,000 0.006  0 120  0
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tings seen in the spectra of the MLV with peptides is due to a
change in the dynamics of acyl chains, which would also
suggest the peptides interact strongly with the membrane
core.
31P Solid-state NMR Relaxation—The 31P MAS NMR longi-
tudinal and transverse relaxation time constants (T1 andT2) are
presented in Table 3. To determine values for T1 and T2, an
exponential functionwas fitted to the intensity (integrals) of the
31P NMR spectra. The spectra showed a single peak, indicating
that the presence of the peptides does not lead to the formation
of separate peptide bound and unbound lipid populations.
TheT1 or longitudinal 31PNMR relaxation time constant for
the phospholipid MLV was 338 ms. Following addition of the
PrP(23–89) and PrP(23–110) peptides, the relaxation time
constants decreased to 268 and 271 ms, respectively. Because
T1 reports on faster lipid headgroup motions, such as long axis
rotation, the changes indicate the peptides cause the lipids to
slow on the microsecond-nanosecond time scale (51). The
spin-spin (T2) NMR relaxation time constants also were deter-
mined by fitting a single exponential to the 31PNMRsignal. The
T2 of the MLV increased from 5.3 to 7.5 ms with PrP(23–89)
and 9.9 ms with the PrP(23–110). These values are consistent
with the increase in the 2H order parameter and suggest that
both peptides have a similar effect on rates of slowermotions of
the lipids, for example lateral translation.
Circular Dichroism—The peptide with the highest overall
anionic membrane affinity as shown by fluorescence spectros-
copy and QCM-D was studied using CD to determine whether
membrane lipid binding induced changes in secondary struc-
ture.We have previously demonstrated (26) that PrP(23–89) is
primarily random coil in solution at both pH 7.4 and 5. After
addition of a 100-fold molar excess of the lipid mixture, 1-(9Z-
octadecenoyl)-sn-glycero-3-phosphocholine (LPC) and 1-(9Z-
octadecenoyl)-sn-glycero-3-phospho-L-serine (LPS) (2:1), no
significant change in the CD spectrum was observed at pH 7.4
(Fig. 7A). However, at pH 5, the addition of LPC/LPS led to a
significant change in the CD spectrum (Fig. 7B). The shift in
negative intensity from below 200 nm to around 205 nm and
increased intensity between 210 and 225 nm suggests that the
presence of the lipid caused the peptide backbone to adopt a
more ordered secondary structure.
DISCUSSION
Fundamental questions in relation to the normal function
of PrPC and the principal pathogenic pathways involved in
prion disease remain unanswered, although the lipid mem-
brane has been implicated in both roles (4). The residence
of PrPC within lipid rafts and the number of reported binding
partners in this topographical context support the likely
importance of these specialized plasmalemma microdo-
mains in the cellular biology of the prion protein (4, 52).
Much less explored has been the role of non-lipid raft do-
mains, a consideration underscored by the endogenous traf-
ficking and internalization route followed by PrPC, especially
in response to complexing of copper. Furthermore, recent
studies have shown that the constitutive endoproteolytic
fragments N1 and N2 both harbor intrinsic neuroprotective
properties when delivered exogenously to physiologically
stressed cells (26). The precise site of generation and mech-
anism of action of these N-terminal fragments have yet to be
determined, and although intact lipid rafts appear to play at
least some part in relation to the protective effects of N1/C1
cleavage (27), it is quite plausible that non-raft environments
may also be important components. To further explore such
possibilities, we undertook a series of experiments, with our
studies providing a number of novel insights into the deter-
minants and structural basis of the binding of PrP N-termi-
nal peptides with non-DRM lipid membranes, especially in
relation to those equivalent to the N1 and N2 fragments.
The peptides we studied were chosen to exploit the compo-
sitionally distinct regions of the N terminus, to determine the
relative contribution of each in isolation, and in various combi-
nations, to binding to synthetic non-raft membranes. Our
TABLE 3
Effect of PrP(23– 89) and PrP(23–110) on the 2H and 31P broad line solid-state NMR spectra and 31P MAS solid-state NMR experiment
relaxation times of dPOPC-POPS (2:1), pH 5
CSA and quadrupolar splitting values increase whenmotion within the detected group decreases, in this case both the headgroups and acyl chains are only weakly affected
by the presence of the peptides.
31P CSA (1 ppm) 2H CSA (0.1 kHz) T1 relaxation T2 relaxation
s ms
POPC-POPS 42 23.2 0.34(0.01) 5.3(0.1)
PRP(23–89) 44 25.6 0.27(0.01) 7.5(0.1)
PrP(23–110) 44 24.4 0.27(0.01) 9.9(0.1)
FIGURE 6. 2H broad line solid-state NMR spectra of MLV composed of
dPOPC/POPS (2:1) suspended in MES buffer (10 mM pH 5) with 50 mM
NaCl. The spectra are the accumulation of 250,000 transients processed with
a line broadening function of 100 Hz. Bottom solid line represents the lipids
alone; the middle dashed line represents the lipids plus PrP(23– 89), and the
top dot-dash line represents the lipids plus PrP(23–110). Quadrupolar splitting
values are summarized in Table 3. The vertical lines act as an aid to the eye
indicating the similarity between the outer edge of the 2H spectrum with and
without PrP(23– 89) or PrP(23–110).
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QCM-D and fluorescence results were entirely congruent, with
PrP(23–89) and PrP(23–110) showing the greatest binding to
supported bilayers, whereas the constituent peptides (PrP(23–
50), PrP(51–89), and PrP90–110) showed no binding, and
PrP(50–110) and PrP(23–110)51–89 displayed intermediate
association. Although consistent with previous results (53), the
lack of binding of the terminal region (PrP(23–50)), especially
to the anionic lipids phosphatidylserine and phosphatidylglyc-
erol, is somewhat unexpected given the high concentration of
lysine residues that are positively charged at neutral pH. Our
results also revealed that the octapeptide repeat region alone
does not directly bind to planar lipid bilayers, indicating that a
combination of the octapeptide repeat and either of the two
polybasic regions (23–50 or 90–110) is needed for effective
membrane interaction. These observations suggest another
insight into the relevance of the evolutionary conservation of
constitutive processing of PrP, which has preservedN-terminal
fragments (N1 andN2) harboring at least both of these compo-
nent regions.
As alluded, we believe it is noteworthy that of all the possible
constituent peptide combinations assessed, the highest mem-
brane affinity observed was for peptides equivalent to N1 and
N2.Despite hypothetical considerations suggesting that each of
the octapeptide repeat and polybasic regions alone could bind
to anionic lipid membranes, our results suggest a synergy is
required between the individual peptide segments for this to
occur, which is especially prominent for the 23–50 polybasic
region when combined with the octapeptide repeat domain.
The precise physicochemical basis for this synergism and the
structural form of the bound peptide remain to be determined.
Previous work from our group has also shown the PrP(23–50)
peptide to have only very limited ability to associate with lipid
membranes despite mediating cytoprotective effects (26). We
find the negligiblemembrane binding of PrP(23–50) somewhat
counterintuitive given the theoretical potential for electrostatic
interactions between the seven amino groups in this region to
drive anionic membrane association. Nevertheless, our salt
titration experiments suggest that electrostatic forces are
unlikely to be operating in the membrane association of pep-
tides containing the 23–50 segment. Regarding the octapeptide
repeat domain, Raman spectroscopy studies of PrP-CuII bind-
ing suggest that at pH 5, the histidine residues of PrP will exist
in a mixture of the protonated and unprotonated copper-bind-
ing states (54). As unprotonated histidine has a slight hydro-
phobic character, it could be speculated that the octapeptide
repeat would take on this hydrophobicity because of the com-
bination of several hydrophobic residues per repeat (proline,
tryptophan, and histidine) broken only by a single hydrophilic
residue (glutamine), with this characteristic serving to facilitate
membrane insertion of peptides harboring this domain. Never-
theless, as for PrP(23–50), the octapeptide repeat segment
alone did not bind to our synthetic membranes demonstrating
that the combination of hydrophobic and polar driving forces is
apparently critical to this type of lipid binding. The presence of
some membrane interaction by PrP(23–110)51–89 suggests
that the number of repeats required to facilitate bindingmay be
as few as one.
As described, contrary to previous claims (55), we found the
octapeptide segment alone is not sufficient to drive binding to
contiguous lipid membranes. Dong et al. (55) reported that
binding of the octapeptide region to dodecylphosphocholine
micelles may be driven by insertion of the tryptophan residues
into the acyl chain region of the membrane. However, this
region may not be as accessible in a less tightly curved mem-
brane structure such as LUV or a cellular membrane. Further-
more, from our studies, it is clear that the N terminus does not
drive binding to predominantly phosphatidylcholine mem-
branes, as would be found in the exoplasmic face of nonstressed
cellular and neuronal membranes (30). In fact, contrary to
Morillas et al. (30), we did not observe binding at either higher
pH or at lower anionic lipid ratios. Our results suggest that,
even at acid pH, the N1 and N2 fragments of PrP will not
directly interact with the bulk lipid of the cell membrane in the
synaptic cleft without the presence of a cofactor. Conversely,
the results suggest the peptides will interact directly with the
cell membrane under acidic conditions similar to those found
in endocytic compartments if anionic phospholipids such as
phosphatidylserine are present in significant amounts (56).
FIGURE 7. CD spectra of PrP(23– 89) in the following: A, in phosphate buffer, pH 7.4, without (thin solid line) and with (dashed line) LPC/LPS (2:1) with
the thick solid line representing the difference between the two spectra; B, in acetate buffer, pH 5, without (thin solid line) and with (dashed line)
LPC/LPS (2:1) with the thick solid line representing the difference between the two spectra. The point (a) indicated in B indicates the difference in the CD
spectra around 220 nm, suggesting PrP(23– 89) assumes a greater proportion of -sheet structure in the presence of lipid. The peptide/lipid molar ratio was
1:100.
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In addition to facilitating a greater understanding of the
determinants of non-DRMmembrane binding of the N termi-
nus of PrP, our results have also provided important new
insights into the structural basis of these interactions. All pep-
tides that bound to the lipids affected all of theQCMharmonics
equally, suggesting membrane insertion rather than surface
association. Furthermore, solid-state NMR of the membrane
interaction of the highest affinity peptides, equivalent to the
biologically relevant N1 and N2 fragments, indicated that the
peptides bind by inserting into the lipid bilayer but in a mini-
mally disruptive manner. The 31P and 2H solid-state NMR data
indicate that the peptides insert into the membrane without
strong interactions with the headgroup region, with the small
increase in the order of the acyl chains showing that the pres-
ence of the peptide does not substantially perturb the freedom
ofmotion of the palmitoyl acyl chains of POPC. Static andMAS
31P experiments showed only a single peak, supporting the con-
tention that the addition of N1 and N2 peptides did not cause a
separation of the lipids into distinct micro-domains. The NMR
data also showed that PrP(23–89) and PrP(23–110) have simi-
lar effects on the phospholipid membrane despite the consid-
erably greater length of the peptide equivalent to N1. In addi-
tion, CD demonstrated a structural change in PrP(23–89)
because of interaction with phosphatidylserine lipids, with a
change from exclusively random coil to a significant portion of
-sheet structure.
Clearly, our results suggest that the N terminus of PrP does
not interact directly with the bulk of the lipid membrane under
unperturbed cell surface conditions. In contrast to previous
results of wild type PrP with SUV, interactions in our studies
were only seen at acidic pH, with similar pH dependence
reported previously (30). Given the number of potential bind-
ing partners reported for PrPC while in lipid rafts (7, 10, 29), the
neutral pH usually present at the synaptic cleft appears to add
further support for the reduced likelihood of a direct mem-
brane interaction at this specific location. Nevertheless, as a
corollary, amodel is proposed to try to summarily contextualize
many of our key findings, focusing on the interaction of the N
terminus with membrane regions containing high concentra-
tions of phosphatidylserine in conjunction with acidic pH.
Under conditions of heightened oxidative stress, especially per-
oxidation of the lipid membrane as reported to occur in prion
disease (57), a neuroprotective response is elicited that encom-
passes PrPC while resident as a GPI-anchored protein in lipid
rafts (58). As the protective response evolves, perhaps as a req-
uisite for eliciting specific signaling cascades (59), PrPC moves
from lipid raft domains into the early endosome compartment.
Simultaneously, the ATP-dependent enzyme aminophospho-
lipid transferase, responsible for maintaining the normal mem-
brane asymmetry of the lipid phosphatidylserine (60), is inhib-
ited by lipid peroxidation (61), leading to increased expression
of phosphatidylserine in the external leaflet of the plasma-
lemma, which is generally envisaged as an early marker of apo-
ptosis (62), although other functional implications have been
suggested (63, 64). Surface expression of phosphatidylserine is
not in itself sufficient to inevitably cause a cell to enter apopto-
sis (64), and surface expression of this moiety is reversible (65)
and nonhomogeneous, with regions showing disproportion-
ately higher concentrations (47), perhaps reaching the ratios
used in our study. Once trafficked, the acidic pH of the early
endosome would favor the loss of any histidine-bound copper
associated with PrPC and concomitantly provide a milieu more
favorable to the N-terminal binding to recently externalized
phosphatidylserine, with this organelle shown to be enriched in
this lipid and thereby offering a potentially important cationic
protein sorting capacity (47). Endoproteolytic cleavage of PrPC
could occur at some point along this pathway and facilitate
binding of liberated fragments to phosphatidylserine, but the
absence of proteolysismay not preclude functionally significant
binding of full-length PrPC. Although our model is more
aligned to the postulate that binding of the N terminus of PrPC,
or cognate fragments, to phosphatidylserine may serve to con-
solidate or promote a neuroprotective response, we cannot
exclude the possibility that the loss of membrane asymmetry
may serve to attenuate or abrogate PrPC function through
sequestration akin to N-terminal “tethering” (52) or perhaps
indirectly such as through generic inhibition of endocytosis
(67).
The peptides we studied showed a subtle but consistently
higher affinity for PG- compared with PS-containing lipids.
Lipids containing these headgroups have significantly different
distributions within the cell with PG predominating in mito-
chondria. Recently, recombinant PrP has been converted into
de novo infectious prions in association with RNA and POPG
(66). Whether the differences in affinity of the N terminus of
PrP for PS- and PG-containing membranes, in association with
RNA, suggest a role for this region in the propagation of infec-
tion in vivo remains to be explored.
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Glockshuber, R. (1997) FEBS Lett. 413, 277–281
7. Pan, T., Wong, B. S., Liu, T., Li, R., Petersen, R. B., and Sy, M. S. (2002)
Biochem. J. 368, 81–90
8. Viles, J. H., Cohen, F. E., Prusiner, S. B., Goodin, D. B., Wright, P. E., and
Dyson, H. J. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 2042–2047
9. Jones, C. E., Abdelraheim, S. R., Brown, D. R., and Viles, J. H. (2004) J. Biol.
Chem. 279, 32018–32027
10. Díaz-Nido, J., Wandosell, F., and Avila, J. (2002) Peptides 23, 1323–1332
11. Pauly, P. C., and Harris, D. A. (1998) J. Biol. Chem. 273, 33107–33110
12. Brown, L. R., and Harris, D. A. (2003) J. Neurochem. 87, 353–363
13. Shyng, S. L., Heuser, J. E., and Harris, D. A. (1994) J. Cell Biol. 125,
1239–1250
14. Taylor, D. R., Watt, N. T., Perera, W. S., and Hooper, N. M. (2005) J. Cell
Sci. 118, 5141–5153
15. Sunyach, C., Jen, A., Deng, J., Fitzgerald, K. T., Frobert, Y., Grassi, J., Mc-
Caffrey, M. W., and Morris, R. (2003) EMBO J. 22, 3591–3601
16. Parkin, E. T., Watt, N. T., Turner, A. J., and Hooper, N. M. (2004) J. Biol.
PrP N1 and N2 Phospholipid Interactions

















17. Caughey, B., Race, R. E., Ernst, D., Buchmeier, M. J., and Chesebro, B.
(1989) J. Virol. 63, 175–181
18. Harris, D. A., Huber, M. T., van Dijken, P., Shyng, S. L., Chait, B. T., and
Wang, R. (1993) Biochemistry 32, 1009–1016
19. Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P., and Au-
tilio-Gambetti, L. (1995) J. Biol. Chem. 270, 19173–19180
20. Deleault, N. R., Lucassen, R. W., and Supattapone, S. (2003) Nature 425,
717–720
21. Wong, B. S., Chen, S. G., Colucci, M., Xie, Z., Pan, T., Liu, T., Li, R.,
Gambetti, P., Sy, M. S., and Brown, D. R. (2001) J. Neurochem. 78,
1400–1408
22. Caughey, B., and Raymond, G. J. (1993) J. Virol. 67, 643–650
23. Wang, F., Yang, F., Hu, Y., Wang, X., Wang, X., Jin, C., and Ma, J. (2007)
Biochemistry 46, 7045–7053
24. Kazlauskaite, J., Sanghera,N., Sylvester, I., Vénien-Bryan, C., and Pinheiro,
T. J. (2003) Biochemistry 42, 3295–3304
25. Wang, X.,Wang, F., Arterburn, L.,Wollmann, R., andMa, J. (2006) J. Biol.
Chem. 281, 13559–13565
26. Haigh, C. L., Drew, S. C., Boland, M. P., Masters, C. L., Barnham, K. J.,
Lawson, V. A., and Collins, S. J. (2009) J. Cell Sci. 122, 1518–1528
27. Haigh, C. L., Lewis, V. A., Vella, L. J., Masters, C. L., Hill, A. F., Lawson,
V. A., and Collins, S. J. (2009) Cell Res. 19, 1062–1078
28. Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Leh-
mann, S., Launay, J. M., and Kellermann, O. (2000) Science 289,
1925–1928
29. Gauczynski, S., Peyrin, J. M., Haïk, S., Leucht, C., Hundt, C., Rieger, R.,
Krasemann, S., Deslys, J. P., Dormont, D., Lasmézas, C. I., and Weiss, S.
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Abstract Misfolded conformers of the prion protein are
aetiologically implicated in neurodegenerative conditions
termed prion diseases (also known as transmissible spon-
giform encephalopathies). Two constitutively expressed
N-terminal peptides corresponding to human residues
23–90 and 23–111 are thought to serve normal physio-
logical roles related to neuronal protection with membrane
binding possibly playing a part in their mechanism of
action. These peptides, along with several derivatives up to
111 residues in length, have been produced by microwave
assisted peptide synthesis. HPLC and MS characterisation
showed that the peptides were manufactured in good yields
at high purity. Peptides were assayed by fluorescence
spectroscopy for synthetic lipid-membrane binding activity
and by dichlorodihydrofluorescein diacetate assay for the
amelioration of reactive oxygen species production.
Results of these assays were similar to those reported for
the wild type recombinant PrP, demonstrating that these
synthetic peptides are useful for biological and chemical
assays of PrP activity. Further, the longest peptide 1–111
was dimerised via a single internal cystine residue with
good yield. The high yields and low purification burden of
the microwave assisted synthesis method lends itself to the
production of difficult to produce peptides for such studies.
Keywords Microwave synthesis  Prion protein 
Peptide synthesis
Introduction
Diseases such as Creutzfeldt–Jakob disease (CJD) in
humans, scrapie in sheep and bovine spongiform enceph-
alopathy (BSE) in cattle are members of a family of related
neurodegenerative conditions termed prion diseases. Prion
diseases are aetiologically linked to changes in the con-
formation of a constitutively expressed protein called the
prion protein (Prusiner 1982). The pathogenically defining
event for the development of prion disease is believed to be
the transformation of the normal cellular prion protein
(PrPC), into the altered pathogenic isoform, PrPSc, which is
insoluble, has extensive b sheet structure, and is charac-
teristically resistant to protease degradation. Recombinant
full-length PrPC NMR structures have been reported for
several different species, namely human (Zahn et al. 2000),
mouse (Riek et al. 1997), bovine (López Garcia et al. 2000)
and Syrian hamster (Donne et al. 1997). Such studies have
shown the C-terminal half of PrPC to be highly ordered,
containing three a-helices, and a short pleated b-sheet.
Furthermore, the C terminus is GPI-anchored to the
external surface of cellular membranes (see Fig. 1) (Stahl
et al. 1987). The inherent physiochemical properties of
PrPSc, in particular its insolubility, make its chemical
synthesis and biological study difficult. Consequently, to
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date, the structure of PrPSc remains unsolved and there is
limited tertiary or quaternary structural information avail-
able (Wille et al. 2002).
The normal function of PrPC remains incompletely
defined. It has been implicated in copper and zinc binding,
signal transduction, reduction of oxidative stress (Brown
and Besinger 1998; Milhavet and Lehmann 2002; and
Stuermer et al. 2004) and most recently, maintenance of
peripheral nerve myelination (Bremer et al. 2010). Pro-
tection against oxidative stress has been shown through the
N-terminal region of PrPC (Watt et al. 2005; Haigh et al.
2009), and the C-terminal region of PrP, via interaction
with anti-apoptotic Bcl-2 (Kurschner and Morgan, 1995,
1996); however precise mechanistic details remain to be
determined.
PrP amyloid deposition is found in some forms of prion
disease, including a rare form of prion disease known as
Gerstmann–Sträussler–Scheinker syndrome (GSS) (Col-
lins et al. 2001). Characteristically, the amyloid fibrils and
deposits are constituted by an N- and C-terminally trun-
cated fragment of PrP comprising approximately residues
58–150 (Giaccone et al. 1992, Tagliavini et al. 1991). In
part based on peptide fragments of PrP appearing asso-
ciated with pathogenesis, numerous cognate peptides of
PrP have been synthesised and studied (Tagliavini et al.
2001). Of these, PrP106–126 is the most studied synthetic
peptide fragment of human PrP as it recapitulates some
properties of PrPSc, such as amyloidogenicity (Tagliavini
et al. 1993) and neurotoxicity (Forloni et al. 1993).
Although these studies have provided insights into the
amyloidogenic and toxic properties of PrP, the lack of an
in vivo correlate leaves some uncertainty regarding path-
ogenic relevance.
Longer peptide sequences, especially those approxi-
mating full length PrPC and the products of constitutive
endoproteolytic cleavage such as the N1 (23–89) and N2
(23–110) fragments, are intuitively considered more likely
to recapitulate authentic biological or biophysical proper-
ties compared to hypothetical polypeptide sequences not
found in vivo. Unfortunately, generation of longer peptides
in sufficient quantity and purity can be challenging. The
chemical synthesis of PrP106 (or ‘‘miniprion’’), a 106
amino acid peptide spanning PrP23–231 with two deletions
(D23–88 and D141–176), has been reported as difficult and
low yielding (Ball et al. 2001; Bonetto et al. 2002). Nev-
ertheless, a potential advantage of chemical synthesis is
that compared to recombinant peptide generation, the latter
often requires demanding sequential purification strategies
to achieve satisfactory purity for biological studies, often
associated with substantial losses with each step.
Due to the accumulation of N-terminally truncated PrP
in prion disease, the N terminus of PrPC has been relatively
less studied. Despite being structurally less ordered, its
importance is underscored by implicated roles in the bio-
logical activity of the protein, such as neuroprotection
against oxidative stress, as seen in vivo (Mitteregger et al.
2007) and in vitro (Haigh et al. 2009), and the fact that
mutations in this region are found in hereditary prion dis-
ease (Mead et al. 2006). Insertion mutations of the octa-
peptide repeat region of PrP (51–89) are associated with
the development of familial CJD (Owen et al. 1989;
Gambetti et al. 2003; and Kovacs et al. 2005) and neuro-
logical illness in transgenic mice (Chiesa et al. 1998). The
N terminus is highly conserved across mammalian species
(Wopfner et al. 1999), and the natural absence of post-























Octapeptide repeat region Lipid bilayer
Fig. 1 Schematic of mouse
prion protein. The sequence–
structure relationship of the
prion protein can broadly be
divided into two domains: the
less structured N terminus
(residues 23–130) and the
globular C terminus
(*130–231). The former
contains binding sites for an
estimated six divalent metal
ions (principally Cu2?) while
the latter can be post-
translationally modified by the
addition of up to two sugar
chains at either or both of
residues 180 and 198 and the
formation of a disulphide bond
between Cys178 and 218, as
well as the addition of a
C-terminal GPI anchor
22 Int J Pept Res Ther (2012) 18:21–29
123
Author's personal copy
and disulphide bridges (as occurs in the globular, far, C
terminus), additionally renders the N-terminal peptides
more likely to represent or harbour their true biological
properties. Therefore, as in the case of the C-terminal
PrP106 syntheses described above, long synthetic poly-
peptide fragments of the N terminus offer promise as
desirable tools to help elucidate the biological role of PrP.
The aim of the present investigation was to synthesise a
series of peptides spanning large sections of the PrP
23–111 N-terminal region and verify that such peptides
would be suitable for studies of biological activity. To
achieve this aim, microwave-assisted peptide synthesis was
utilised. In our hands, we have found the major advantages
of microwave peptide synthesis to be short cycle times and
crude peptide products of reasonable purity (50–70% pur-
ity) that present few difficulties in HPLC purification. For
example, we have achieved the total synthesis of Apo C I, a
57 amino acid, 6.6 kDa protein by microwave synthesis
technology together with three alanine mutants of the
native sequence (James et al. 2009). Synthesis and purifi-
cation of the four sequences was achieved in less than
3 weeks. Microwave peptide synthesis, could potentially
assemble much longer polypeptides and was therefore used
to assemble PrP polypeptides ranging in length from 20 to
111 amino acids, including the N-terminal (1–111) region
of PrPC.
Materials and Methods
Fmoc-L-amino acids and coupling reagents O-(6-chlor-
obenzotriazol-1-yl)-N,N,N0,N0,-tetramethyluronium-hexa-
fluorophosphate (HCTU) and N-hydroxy-benzotriazole
(HOBt) were obtained from GLBiochem (Shanghai, China).
Fmoc-Pal-PEG-PS resin was obtained from Applied Bio-
systems (Melbourne, Australia). Solvents dimethylform-
amide (DMF), dichloromethane (DCM), acetonitrile, and
diethyl ether were obtained from Ajax Pty Ltd (Melbourne,
Australia). Trifluoroacetic acid, 3, 6-dioxo-1,8-octanedithi-
iol (DODT), triisopropylsilane (TIPS), piperidine, diiso-
propylethylamine (DIPEA), N-methylpyrrolidone (NMP)
were obtained from Sigma Aldrich (Sydney, Australia).
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine]
(POPS) were from Avanti (AL, USA). DCFDA, Dulbecco’s
modified Eagle’s medium, penicillin and streptomycin were
from Sigma. OptiMEM was from Invitrogen (CA, USA).
Solid-Phase Peptide Synthesis
Solid phase synthesis was performed on a CEM Liberty
Microwave peptide synthesizer (CEM Inc. NC, USA) on a
50 lmol scale (250 mg resin, 0.20 mmol/g) using standard
CEM cycle procedures. The coupling solution was 0.5 M
HCTU in DMF. The base activator was 2 M DIPEA in
NMP. The Fmoc deprotection solution was 20% piperidine
in DMF containing 0.1 M HOBt. Fmoc protected amino
acids were made up as 0.2 M solutions in DMF and tenfold
excess of activated amino acid was used in each coupling.
All couplings were performed for either 5 min (standard)
or 20 min (long) at 75C and 25 W microwave power.
Exceptions were Arginine couplings, which were long
double couple cycles (with the microwave turned off for
the first 15 min of the first coupling cycle), and cysteine
and histidine couplings, which were standard double cou-
ple 50C cycles at 25 W microwave power. In general long
couplings were used after 30 cycles for all the larger
fragments.
Peptide Cleavage from the Resin
The peptide was cleaved from the resin by treatment with
a solution of TFA/DODT/TIPS/H2O (92.5/2.5/2.5/2.5,
10 ml) for 2 h. The mixture was filtered and aspirated with
a stream of dry nitrogen until the solution volume was
reduced to 2 ml. The crude peptide was then precipitated
by the addition of cold diethyl ether (40 ml). The peptide
slurry was centrifuged (3,500 rpm, 3 min) and the crude
material was isolated by decanting the ethereal supernatant.
The peptide was then dissolved in 30% acetonitrile/water
and the solution lyophilized.
Crude Peptide Analysis
Crude peptides were analysed on an Agilent 1100 HPLC
system (Agilent Technologies, CA, USA) using a Gemini
C18 5 lm analytical HPLC column (Phenomenex Inc, CA,
USA) ((Dimension: 150 9 4.3 mm, Flow: 1.0 ml/min).
Theoretical monoisotopic molecular weights were calcu-
lated with Peptide Companion software and the molecular
weights confirmed on an Agilent QTOF LCMS 6200
(Agilent Technologies, CA, USA) with an electrospray
source.
Peptide Purification
Crude peptides were dissolved in 30% acetonitrile/water
(5–10 mg/ml) and purified sequentially in a two step HPLC
protocol utilizing two reversed phase packings with dif-
ferent selectivities. The peptides were initially purified on a
Phenomenex Hydro C18 5 lm semi-prep HPLC column
(Dimension: 50 9 21.2 mm, Flow: 5 ml/min (Phenomenex
Inc, CA, USA). Fractions containing the target peptide
were identified by mass spectrometry and then further
analysed by analytical RP-HPLC. Pure fractions were
pooled, lyophilized and weighed with yields in the range of
Int J Pept Res Ther (2012) 18:21–29 23
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5–50 mg depending on the length of the peptide. A second
purification step was then performed on an Agilent C18
5 lm semi-prep column (Dimension: 250 9 9.4 mm,
Flow: 5 ml/min (Agilent Technologies, CA, USA). Frac-
tions were collected, analysed and lyophilized in the same
manner as described above, with final yields in the range
1–20 mg.
All peptides were subjected to a final QC process in
which 100–200 lg of peptide was dissolved in 30% ace-
tonitrile/water (200 ll) and analysed by RP-HPLC and
mass spectrometry in order to confirm molecular weight
and quantify purity.
Dimerization of PrP1–111
PrP1–111 was dissolved in 25 mM ammonium acetate
buffer pH 6.5 (2 mg, 0.5 mg/ml) and treated with half an
equivalent of 2,20-dithiodipyridine. The reaction was
monitored by mass spectrometry and found to be complete
within 1 h (Fig. 5e). RP-HPLC analysis of the reaction
showed the dimer as the major product together with a
small amount of the thiopyridyl derivative. The dimer was
isolated by semi-preparative RP-HPLC , yielding the syn-
thetic protein (0.5 mg) of molecular weight 23,292 Daltons
at high purity.
Measurement of Phospholipid Binding Properties
of PrP Peptides
As described previously (Boland et al. 2010), PrP peptides
and the WT recombinant PrP23–231 were dissolved in
acetate buffer (pH 5) with NaCl to an ionic strength of
180 mM. The solutions were excited at 295 nm and the
fluorescence emission spectrum was recorded between 315
and 450 nm. The data was recorded on a Varioskan Flash
(ThermoFisher Scientific, MA, USA) plate reader at room
temperature.
The spectra were recorded in buffer alone and also in the
presence of POPC and a 2:1 molar mixture of POPC–
POPS. All lipids were freshly extruded at a concentration
of 100 mM large unilamellar vesicles (LUV). The usual
centre of the fluorescence emission spectrum of the aro-
matic amino acids is around 350 nm. Interaction of the
peptide or protein with lipid causes a blueshift of the
fluorescence maximum. The data-points are the mean peak
centres calculated by non-linear fitting of a Lorentzian
function to the fluorescence spectra. The error bars repre-
sent the standard deviation between three experiments. The
fitted binding curves represent the best fit of the experi-
mental data to either: a linear function or an exponential
decay function.
Cell Culture and DCFDA Assay for Reactive Oxygen
Species (ROS)
SH-SY5Y cells were routinely cultured in Dulbecco’s
modified Eagle’s media supplemented with 10% (v/v) fetal
bovine serum and 50 U/ml penicillin/50 lg/ml streptomy-
cin solution. Cells were maintained at 37C with 5% CO2
in a humidified incubator. The dichlorodihydrofluorescein
diacetate (DCFDA) assay for intracellular ROS has been
described previously (Haigh et al. 2009). Briefly, cells were
loaded in 5 lM CM-H2-DCFDA (Invitrogen, CA, USA) in
phosphate buffered saline (PBS) for 20 min under standard
culture conditions. The DCFDA reagent was removed and
replaced with fresh medium OptiMEM with or without
serum or peptides of interest. Assays were run over 12 h
with fluorescence intensity measurements made every
5 min. Rates were calculated, after correcting for equiva-



























Fig. 2 PrP peptide fragments
synthesised. The black bar
represents the full length wild
type prion protein, including the
N-terminal ER signal
recognition sequence (residues
1–22). The grey bars represent
the peptides that were made for
this project. The C–C symbol
represents the location of the
disulfide bond linking the two
1–111 peptides in the dimer. In
addition to those represented








All prion protein peptides synthesized on the CEM Liberty
microwave peptide synthesizer by Fmoc solid phase syn-
thesis protocols are summarized in Fig. 2. The preferred
resin used for all microwave syntheses was low loading
Fmoc-Pal-PEG PS resin. Yields of crude peptide obtained
on a 50 lmol scale were quantitative. For example, pep-
tides 50 amino acids long yielded approximately 250 mg of
crude peptide, ensuring that after the two step purification
protocol between 5 and 20 mg pure peptide was obtained.
All syntheses recorded relatively high crude purities and,
even in the case of the high MW peptides, the quality and
quantity of peptide isolated using these protocols was
ample to perform the necessary bioassays.
N-Terminal PrP Peptides
The suite of peptides displayed in Fig. 2 was synthesised
sequentially starting with the 28 residue sequence
PrP23–50. Later, longer sequences were synthesised cul-
minating in PrP1–111. The peptides were assayed for both
their ability to reduce oxidative stress in human neuro-
blastoma cells plus their interaction with POPC and POPC/
POPS phospholipids.
Synthetic PrP23–50 Reduces Oxidative Stress in Serum
Deprived Human Neuroblastoma Cells
It is known that both the N- and C-terminal parts of the
prion protein are implicated in the reduction of oxidative
stress. Therefore, a series of synthetic N-terminal peptide
fragments was tested for their ability to reduce oxidative
stress in SH-SY5Y human neuroblastoma cells.
The SH-SY5Y human neuroblastoma cell line was put into
oxidative stress by withdrawal of serum resulting in a highly
increased rate of production of intracellular ROS (Haigh et al.
2009). The serum withdrawal insult was followed by chal-
lenge with synthetic PrP fragments PrP23–50, PrP51–89 and
PrP90–111. In every case the extent of the ROS insult was
reduced (Fig. 3), with the result most significant for the
PrP23–50. PrP23–50 was shown by serial dilution to signif-
icantly attenuate intracellular oxidative stress down to a
concentration of 10 nM. A comparison of PrP23–50 with a
scrambled PrP23–50 peptide sequence, illustrated in Fig. 3,
confirmed that this effect was Pr23–50 peptide specific.
Analogous results have already been reported using these
peptides in other cell lines (Haigh et al. 2009).
Interaction of N-Terminal PrP Peptides with POPC
and POPC/POPS Phospholipids
The peptides were further screened for biophysical activity
in a POPC, POPC/POPS phospholipid binding assay. Two
short peptide fragments from the N-terminal region of
PrP1–111, namely PrP23–50 and PrP30–50, were synthe-
sized and tested in the assay and showed no synthetic
membrane association. More regions of the N-terminal
peptide sequence were synthesised including PrP51–89
(the octapeptide repeat region), PrP90–110 and
PrP23–111(D51–89), the latter assembled without the
octapeptide repeat region. Once again none of the synthetic
peptides demonstrated binding activity in the phospholipid
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Fig. 3 Synthetic PrP23–50 significantly reduces oxidative stress in
serum deprived human neuroblastoma cells. a Withdrawing serum
from the SH-SY5Y human neuroblastoma cell line results in a highly
increased rate of production of intracellular ROS. When the serum
withdrawal insult is applied with synthetic PrP fragments 23–89,
23–50, and 51–89, the extent of the ROS insult was reduced,
significant for the 23–50 fragment (One-way ANOVA, F = 24.99,
*P \ 0.05, ***P \ 0.001). b Applying the 23–50 fragment in a log10
serial dilution shows this effect is significant down to 10 nM
PrP23–50 and comparison with a peptide corresponding to the amino
acid composition of PrP23–50 scrambled confirms this effect is
peptide specific (Two-way ANOVA, F = 44.18, *P \ 0.05,
**P \ 0.01). Graphs show the mean and s.e.m. derived from four
independent experiments
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binding assay. Since these peptides were synthesized in
high purities and yields, up to 60 amino acids long, we
therefore decided to undertake the synthesis of the
complete mature N-terminal protein region, namely
PrP23–111, an eighty-nine amino acid peptide. PrP51–111
was assembled on a 50 lmol scale, and half the resin was
cleaved and the resulting crude peptide purified in good
yield. The remaining 25 lmol of resin was extended to
position 23 to isolate PrP23–111. Although all shorter
peptides within the PrP23–111 region showed no binding
activity in the POPC/POPS phospholipid binding assay, the
full length mature fragment PrP23–111 showed similar
binding to the PrP wild type recombinant protein as shown
in Fig. 4. Similar results utilising analogous peptides have
been previously reported (Boland et al. 2010).
Synthesis of PrP1–111 and Dimeric PrP1–111
To further test the capabilities of the Liberty microwave
peptide synthesizer, the synthesis of PrP23–111 was
repeated and the synthesis extended to the N terminus of
nascent PrP (i.e. PrP1–111). The aim was to assess the
synthetic tractability of this fragment under microwave
conditions, as well as producing an even longer fragment
for comparative bioassay. The progress of the synthesis
was checked by cleaving a small resin sample at positions
50 and 23 and monitoring the product by analytical RP-
HPLC and mass spectrometry, before extending the peptide
chain to position 1. The crude analytical data for PrP1–111
(Fig. 5a, b) shows the parent sequence as the major prod-
uct. The crude material was purified twice by semi-pre-
parative RP-HPLC as described in the ‘‘Materials and
Methods’’ section, in good yield and high purity (see
Fig. 5c, d).
Position 22 in the sequence which is a cysteine residue,
provided the possibility of producing a synthetic 23 kDa
disulfide-bridged polypeptide dimer. It was thought that
this would be an interesting addition to the suite of peptides
already synthesised especially with regard to its activity in
comparative bioassays.. Therefore PrP1–111 was treated
23-50











































































































(A) Buffer only (B) POPC (C) POPC : POPS 2:1 
Fig. 4 Fluorescence emission wavelength changes due to membrane
interaction of prion protein peptides. (a and b) Diluting the peptide
(a) and mixing PrP23–50, PrP23–111 or wild type PrP with the
zwitterionic lipid POPC (b) do not produce any association effects.
c In the presence of a 2:1 molar ratio POPC/POPS mixture at pH 5,
the EmMAX of a 10 lM solution of 23–111 undergoes a blueshift, in
common with wild type PrP. Lipid/peptide is expressed as a mol/mol
ratio
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with 2;20-dithiodipyridine in 25 mM ammonium acetate at
pH6.5 which enabled the reaction monitored by mass
spectrometry. Within 1 h the reaction was determined to be
essentially complete (Fig. 5e, f). The dimer was isolated by
semi-preparative RP-HPLC , yielding the synthetic protein
product of molecular weight 23,292 Daltons at high purity
(Fig. 5g, h.
The activity of these two molecules is currently being
assessed in further biological studies.
Conclusions
Peptide fragments from the N-terminal region of PrPC have
been assembled in high yield and purity through the use of
microwave assisted Fmoc solid phase peptide synthesis.
The successful synthesis of challenging and lengthy pep-
tide fragments such as PrP23–89, PrP23–111 and in par-
ticular PrP1–111 highlights the utility of this technology in
enabling the characterization of peptides in biologically














































Fig. 5 HPLC and mass
spectrometry data from the
synthesis of PrP 1–111 and the
PrP 1–111 dimer. a and b:
Crude C18 RP-HPLC trace and
ESI MS of PrP 1–111 monomer.
c and d: Pure C18 RP-HPLC
trace and ESI MS of PrP 1–111
monomer. e and f: Crude C18
RP-HPLC trace and ESI MS
analysis of the reaction products
from the PrP 1–111
dimerisation reaction performed
in the presence of 2,20-
dithiodipyridine. The mass
spectrum shows a major product
with the correct dimer MW
23292.8 plus a small impurity of
monomer derivatised with a
pyridyl group MW 11756.7
(monomer ? 109.5). g and h:
C18 RP-HPLC trace and ESI
MS of purified PrP 1–111 dimer
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relevant assays such as phospholipid binding activity and
ROS reduction activity of the N-terminal sequence of PrPC.
The ability of microwave technology to synthesize long
and difficult polypeptide fragments, as demonstrated for
PrPC, will enable the synthesis of large discreet high purity
fragments of many proteins, facilitating important insights
into their protein–protein interactions and biological
function.
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Abstract
There is increasing evidence of molecular and cellular links between Alzheimer’s disease (AD) and prion diseases. The
cellular prion protein, PrPC, modulates the post-translational processing of the AD amyloid precursor protein (APP), through
its inhibition of the b-secretase BACE1, and oligomers of amyloid-b bind to PrPC which may mediate amyloid-b
neurotoxicity. In addition, the APP intracellular domain (AICD), which acts as a transcriptional regulator, has been reported
to control the expression of PrPC. Through the use of transgenic mice, cell culture models and manipulation of APP
expression and processing, this study aimed to clarify the role of AICD in regulating PrPC. Over-expression of the three major
isoforms of human APP (APP695, APP751 and APP770) in cultured neuronal and non-neuronal cells had no effect on the level
of endogenous PrPC. Furthermore, analysis of brain tissue from transgenic mice over-expressing either wild type or familial
AD associated mutant human APP revealed unaltered PrPC levels. Knockdown of endogenous APP expression in cells by
siRNA or inhibition of c-secretase activity also had no effect on PrPC levels. Overall, we did not detect any significant
difference in the expression of PrPC in any of the cell or animal-based paradigms considered, indicating that the control of
cellular PrPC levels by AICD is not as straightforward as previously suggested.
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Introduction
Alzheimer’s disease (AD) and prion diseases fall within the
spectrum of neurodegenerative diseases which are causally linked
to misfolded and aggregated proteins. Due to similarities in various
structural elements and proteolytic processing events involving the
major proteins involved in these diseases, potential links and
parallels in both disease mechanisms and possible therapeutic
avenues have been proposed [1,2,3,4]. Increasingly, recent studies
have shown more direct molecular links between AD and prion
diseases, and the proteins at the centre of these diseases; namely
the amyloid precursor protein (APP) and its proteolytic cleavage
product the amyloid-b (Ab) peptide which deposits as plaques in
the AD brain, and the normal cellular prion protein (PrPC) and the
disease-associated isoform PrPSc, which accumulates in prion
diseases. A substantive molecular link was provided when PrPC
was shown to modulate production of Ab from wild type APP,
through an interaction with the b-secretase BACE1 [5], later
demonstrated to be a mechanism for altered trafficking and
localisation of BACE1 resulting in reduced Ab production [6].
Additionally, several groups have now presented evidence that
PrPC can bind oligomeric forms of Ab [7,8,9,10], although there is
conflicting data regarding the downstream consequences of this
binding. Some results suggest that Ab oligomer synaptic toxicity is
mediated through its binding to PrPC [7,11,12], whereas others
have reported that Ab oligomer neurotoxicity is independent of
PrPC expression [8,9]. Whilst perhaps explained by methodolog-
ical differences, these opposing results underscore the complexity
in the possible interactions between these two key proteins and
diseases.
In addition to Ab, a number of other proteolytic fragments are
generated from APP. Cleavage of the full length APP by either a-
secretase or BACE1 produces large soluble N-terminal ectodo-
mains, and C-termimal membrane-bound stubs, denoted C83 and
C99, respectively. Both C83 and C99 can be cleaved by the c-
secretase complex to produce the APP intracellular domain
(AICD) [13]. This latter fragment appears to act as a transcrip-
tional regulator after forming a complex with Fe65 and Tip60
[14]. In particular AICD has been shown to regulate the
expression of the Ab degrading enzyme neprilysin [15,16].
Interestingly, it appears to be only the AICD produced from the
combined action of BACE1 and c-secretase on APP that is
transcriptionally active [17,18,19].
There are three major isoforms of APP expressed in the brain,
APP695, APP751 and APP770, which are produced via alternative
splicing of the single mRNA [20]. Of the three, APP695 is the
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major neuronal splice variant. Recently, we reported that only the
AICD produced from the b- and c-secretase cleavage of APP695,
and not that produced from the other two isoforms, is
transciptionally active as assessed by its ability to upregulate
neprilysin expression [19]. This transcriptionally active AICD was
only produced in neuronal (SH-SY5Y and N2a) cell lines and was
not functional in non-neuronal human embryonic kidney
(HEK293) cells [19]. Further, AICD produced from the familial
AD associated Swedish mutant form of APP695, known to be
subject to increased BACE1 cleavage compared to wild type
APP695 [21], was more transcriptionally active relative to wild type
APP695 [19].
The molecular and cellular links between APP and PrPC were
extended recently when PrPC expression was reported to be
regulated by AICD [22]. Overexpression of APP751 in HEK cells
triggered a significant increase in PrPC immunoreactivity, while a
reduction in PrPC was observed in APP deficient fibroblasts. The
c-secretase inhibitor DAPT significantly reduced PrPC levels in
primary neurons, implicating a role for AICD in controlling the
expression of PrPC [22]. The aim of the present study was to
clarify the role of AICD in the regulation of PrPC and to
specifically determine whether, similar to the control of neprilysin
expression [19], there was an APP isoform effect.
Results
Over-expression of APP does not alter endogenous PrPC
protein expression
Initially we sought to replicate the findings of Vincent et al. [22]
by expressing APP751 in HEK cells. In addition, we looked to
advance this research by determining whether the control of PrPC
expression by AICD was specific to a particular APP isoform.
HEK cells stably over-expressing either APP695, APP751 or
APP770, alongside a vector only control were assessed for total
cell associated PrPC and APP protein levels by western blotting
(Fig. 1A and B). Surprisingly, in contrast to previously published
results [22], although there was a significant 2–3-fold increase in
APP in the cells transfected with any of the three APP isoforms,
there was no significant difference in PrPC level in any of the APP
isoform expressing cells when compared to the Hyg vector-only
controls.
We have recently shown that transcriptionally active AICD is
only produced by the BACE1 and c-secretase cleavage of the
Figure 1. Over-expression of APP isoforms in HEK cells does not alter endogenous PrPC. (A) Representative western blot of APP and PrPC
(antibody 3F4) in HEK cells stably transfected with either the vector alone (Hyg) or one of the APP isoforms (APP695, APP751, APP770), and subsequent
b-actin staining to allow adjustments for equal protein loading. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and
PrPC protein levels expressed relative to Hyg control cells (dashed line). Data from 4 independent experiments. Statistical analysis by one way ANOVA
with Dunnett’s post test comparison to the Hyg cells, ***p,0.001, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g001
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APP695 isoform in neuronal cells [19]. In light of this, and the
negative result observed in the non-neuronal HEK cells, we
utilized mouse neuronal N2a cells over-expressing human APP695
or APP751 to again assess total PrP
C and APP protein levels
(Fig. 2A and B). Despite a significant 2.5-fold increase in APP
expression in the N2a cells transfected with the cDNAs encoding
either APP695 or APP751, there was no difference in endogenous
PrPC levels when comparing the APP over-expressing cells with
each other or the vector only controls.
To further examine the effect of APP over-expression on PrPC
levels, two transgenic mouse models were investigated. PrPC and
APP protein levels were evaluated in brain homogenates from I5
mice which over-express wild type human APP, J20 mice which
over-express human APP containing the Swedish/Indiana familial
AD mutations [23] and non-transgenic matched genetic back-
ground control mice (Fig. 3A and B). Despite a significant 2.8 -fold
increase in APP in the transgenic I5 mice, as compared to the non-
transgenic mice, there was no difference in brain PrPC levels.
Figure 2. Over-expression of APP isoforms in N2a cells does not alter endogenous PrPC. (A) Representative western blot of APP and PrPC
(antibody 6H4) in N2a cells stably transfected with either the vector alone (Hyg) or one of the APP isoforms (APP695, APP751), and subsequent b-actin
staining. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrPC protein levels expressed relative to Hyg control cells
(dashed line). Data from 3 independent experiments. Statistical analysis by one way ANOVA with Dunnett’s post test comparison to the Hyg cells,
*p,0.05, n.s. not significant.
doi:10.1371/journal.pone.0031754.g002
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Analysis of the J20 mice, although only involving two animals,
reinforced this conclusion. Collectively these over-expression
experiments indicate that control of PrPC expression does not
appear to involve AICD in either cell-based or transgenic animal
paradigms.
Reduction of AICD production through APP gene
silencing or c-secretase inhibition does not alter
expression of endogenous PrPC
In light of the above results, we considered whether the level of
AICD required to regulate PrPC expression in the cell lines or the
transgenic mice were already maximal from the endogenous APP,
such that the AICD produced from the over-expressed APP was
not having any additional affect on PrPC expression. Thus we
sought to investigate a possible role for endogenous AICD in the
control of PrPC expression. First, to reduce endogenous APP levels
and thereby remove the substrate for AICD production, N2a cells
were treated with siRNA against murine APP. Cells were
harvested, lysed and PrPC and APP levels measured by western
blotting (Fig. 4A and B). After directed siRNA treatment there was
a significant 70% decrease in total APP levels (endogenous AICD
level is below the limits of detection by immunoblot; data not
shown). However, the amount of PrPC remained unchanged
following siRNA knockdown of endogenous APP.
In order to test further for a possible involvement of endogenous
AICD in controlling PrPC expression, both HEK and N2a cells
were treated with DAPT, a cell permeable c-secretase inhibitor.
Again, whole cell lysates were assessed for PrPC and APP
expression, as well as the levels of C83 and C99, by western
blotting (Fig. 5A and B). Although DAPT treatment inhibited c-
secretase activity, as shown by the significantly increased C83 and
C99 levels (9.4-fold in the HEK cells and 17.8-fold in the N2a
cells), there was no difference in endogenous PrPC protein levels in
the DAPT treated cells as compared to the untreated cells (Fig. 5C
and D). Together these results indicate that in both a neuronal and
a non-neuronal cell line, endogenous AICD is also not involved in
the control of PrPC protein expression.
Figure 3. Unaltered PrPC protein levels in transgenic mice over-expressing human wild type or familial AD mutant APP. (A) Western
blot of APP and PrPC (antibody 6D11) in I5 (n = 3) and J20 (n = 2) transgenic, and age-matched non-transgenic control, mouse brain homogenates,
with membrane re-probing for b-actin. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrPC protein levels
expressed relative to the control mice (dashed line). Error bars represent 6 SD. Statistical analysis by unpaired t-test, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g003
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Discussion
Similarities in the pathogenesis of the protein-misfolding
neurodegenerative illnesses, especially AD and prion diseases,
and possible connections between these diseases have long been
contemplated [1,2,3,4]. Elucidation of any functional links
between these diseases is an important research goal, with
determination of the most appropriate protein or process to target
for development of therapeutics being paramount. Links in the
pathologies of AD and prion diseases have been determined, with
various reports of AD features in prion disease brains [24,25,26],
and PrPC localised in Ab plaques in AD brain [27,28]. In addition,
a polymorphism at codon 129 of the prion protein gene, known to
influence susceptibility to sporadic and iatrogenic human prion
disease [29,30], may also influence susceptibility and the
pathophysiology of AD [31,32,33]. Interestingly there is some
indication of a more direct interaction between Ab and PrPSc, with
the finding of an acceleration and exacerbation of both AD and
prion disease pathologies in animals engineered to have both of
these diseases, and enhanced protein misfolding due to cross-
seeding events stimulating oligomerization in vitro [34]. This
propensity for cross-seeding highlights the importance for a more
complete understanding of interactions between these key proteins
and any resultant downstream consequences.
Recent studies have provided evidence of direct interactions
between the proteins central to AD and prion diseases. Various
studies have determined that the cellular prion protein can act as a
receptor for Ab, with Ab oligomers binding to PrPC with high
affinity, although there are conflicting views as to the physiological
significance of this binding. Some results suggest that Ab synaptic
toxicity is mediated through its binding to PrPC [7,11,12], which
specifically impacts on spatial learning and memory in vivo [35],
whereas others have reported that Ab oligomer neurotoxicity
occurs independently [8,9]. Confounding the relationship between
these key proteins, and in apparent contrast to PrPC mediating Ab
neurotoxicitiy, PrPC has been shown to decrease production of Ab
from wild type APP through its interaction with the b-secretase
BACE1 [5]. This interaction, mapped to the BACE1 pro-domain,
leads to slowed BACE1 trafficking following exit from the ER,
thereby increasing its localization in the trans-Golgi network and
reducing levels at the cell surface and consequently in endosomes
where APP b-cleavage occurs [6]. Importantly, these studies also
ascertained links in the pathology of AD and prion diseases. It was
found that human prion disease-associated mutations in PrPC did
not inhibit BACE1, and scrapie infected mice brains contained
dramatically higher Ab levels [5], suggesting a loss of PrPC
function perhaps as a result of PrPC-PrPSc conversion during prion
disease progression.
PrPC may be a key therapeutic target for sporadic AD, and the
recent report that PrPC expression was controlled by AICD in a c-
secretase dependent manner [22] presented a potential avenue for
achieving this. Further, a possible feedback model reconciling the
control of APP processing and PrPC expression in both normal
conditions and in the presence of increased Ab such as that seen in
AD was proposed [36]. Therefore our study was carried out to
further understand the relationship between AICD production
and PrPC expression. However, utilizing a range of experimental
approaches we found no evidence for AICD involvement in PrPC
expression. This is despite using a cellular system (N2a cells
expressing APP695) in which we have proven that AICD is
transcriptionally active [19]. If AICD is involved in regulating the
transcription of PrPC, then the mechanism underlying this is more
complex than that involved in regulating the expression of
neprilysin and is not readily reproduced in cultured cells or
transgenic mice over-expressing human APP. Our findings have




All experimental procedures performed on mice were approved
by the Roslin Institute (University of Edinburgh) Ethical Review
Process Committee and carried out under the UK Home Office
License 60/3478. Human embryonic kidney (HEK) cells were
obtained from the European Collection of Cell Cultures and
Figure 4. Knockdown of APP expression in N2a cells has no effect on PrPC protein levels. (A) Representative western blots of APP and
PrPC (antibody 6H4) in N2a cells treated with APP directed siRNA, non-coding control siRNA, and a no RNA transfection control (H2O control), and
subsequent b-actin staining. Approximate molecular weights (kDa) are indicated. (B) Quantification of APP and PrPC protein levels expressed relative
to the H2O control cells. Data from 3 independent experiments. Statistical analysis by one way ANOVA with Dunnett’s post test comparison to the
H2O control cells, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g004
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murine neuroblastoma (N2a) cells were obtained from Dr
Lehmann, Université Montpellier, France [37].
Cell culture
HEK cells and N2a cells stably over-expressing the human APP
isoforms (APP695, APP751 and APP770), alongside the vector-only
(Hyg), were generated by electroporation as described previously
[19]. Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Lonza, Basel, Switzerland) containing 10%
(v/v) fetal bovine serum (FBS; Biosera, East Sussex, UK) and 1%
penicillin/streptomycin (Lonza), in a humidified incubator at
37uC, 5% CO2.
APP gene silencing
To ablate endogenous APP expression in the N2a cells, cells
were grown to 80% confluency in growth medium prior to
treatment with 50 nM final concentration of murine APP directed
siRNA, non-coding siRNA or siRNA-free controls following the
manufacturer’s instructions (Thermo Fisher Scientific, Lafayette,
CO, USA). Briefly, sub-confluent cell monolayers were washed
gently with OptiMEM (GIBCO, Invitrogen, Glasgow, UK), before
further incubation in OptiMEM for approximately 30 min (37uC,
5% CO2) during siRNA preparation. A 10 mM siRNA solution in
16 siRNA buffer of either murine APP directed siRNA (ON-
TARGETplus SMARTpool) or non-coding siRNA control (ON-
Figure 5. Inhibition of c-secretase activity does not alter the expression of PrPC. Representative western blots showing total cell-associated
APP, PrPC (antibody 6H4) and C-terminal APP fragments (C83/99) in control (2) and DAPT treated (+) HEK (A) and N2a (B) cells, with membrane re-
probing for b-actin. Approximate molecular weights (kDa) are indicated. Quantification of C83/99, APP and PrPC protein levels in DAPT treated HEK
(C) and N2a (D) cells, expressed relative to control cells (dashed line). Data from 3 (HEK) or 4 (N2a) independent experiments. Statistical analysis by
one way ANOVA with Dunnett’s post test comparison to the control cells, ***p,0.001, **p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0031754.g005
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TARGETplus Non-targeting pool) was prepared, and diluted to
1 mM in OptiMEM. For the RNA-free control, sterile RNase-free
water was diluted 1:10 in OptiMEM. DharmaFECT Transfection
Reagent-1 was diluted 1:40 in OptiMEM, mixed gently and
incubated for 5 min at room temperature. Equal volumes of the
diluted siRNA/control and DharmaFECT solutions were then
mixed and incubated for 20 min at room temperature, prior to the
addition of 46 volumes of OptiMEM containing 10% (v/v) FBS.
The OptiMEM was then removed from the cells, and replaced
with the OptiMEM/FBS/siRNA complexes (or control) for 72 h.
Inhibition of c-secretase
To inhibit endogenous c-secretase activity, HEK or N2a cells
were grown to 90–95% confluency prior to treatment. The cell
monolayer was then washed twice with PBS prior to incubating
the cells in serum-free OptiMEM containing a final concentration
10 mM N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT; Sigma-Aldrich, Dorset, UK), or an equal
volume of dimethyl sulfoxide (DMSO, as the control) for 24 h.
Cell lysis, SDS-PAGE and immunoblotting
When confluent and/or after appropriate treatments as
described above, cells were washed twice in phosphate-buffered
saline (PBS with Ca2+ and Mg2+; Lonza), harvested by scraping
into PBS, and pelleted at 5006g for 3 min. Cell pellets were lysed
for 30 min on ice in cold lysis buffer (25 mM Tris/HCl, pH7.5,
150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100) containing
CompleteTM protease inhibitor cocktail (Roche, West Sussex,
UK), prior to centrifugation for 5 min at 10006 g. Post-nuclear
supernatants were assessed for total protein content using a
bicinchoninic acid protein assay (Sigma-Aldrich). Cell lysate
containing 50 mg total protein was resolved on 7–17% (APP and
PrPC) or 16.5% (C83/99) polyacrylamide SDS gel, then electro-
transferred to Hybond-P polyvinylidene difluoride membrane
(PVDF; Amersham Life Sciences, Buckinghamshire, UK). PVDF
membranes were blocked for 1–2 h at room temperature in PBS
containing 0.1% Tween-20 (PBST) and 5% (w/v) skimmed milk
powder, prior to incubation with primary antibody overnight at
4uC. For detection of APP the membrane was incubated with the
monoclonal antibody 22C11 (Millipore, Billerica, MA, USA), and
for detection of PrPC the membrane was incubated with either the
monoclonal antibody 3F4 (Covance, Princeton, NJ, USA), 6D11
(Eurogentec Ltd, Hampshire, UK) or 6H4 (Prionics, Zurich,
Switzerland), as indicated in the figure legends. For detection of
C83/99, a polyclonal anti-C-terminal APP antibody A8717
(Sigma-Aldrich) was used. After washing off non-specifically
bound primary antibody with PBST, membranes were incubated
in peroxidase-conjugated rabbit-anti-mouse or goat-anti-rabbit
secondary antibodies (Sigma-Aldrich), before further washes with
PBST and detection using enhanced chemiluminescence (Pierce
ECL substrate; Thermo Fischer Scientific). To assess and correct
for protein loading, membranes were stripped at low pH (1% (v/v)
aqueous HCl) for approximately 30 min, re-blocked and probed
with an anti-b-actin antibody (clone AC-15, Sigma-Aldrich) and
the secondary antibody described above. All chemiluminescent
images were captured by a Fujifilm LAS-3000 Intelligent Dark
Box.
Transgenic mice and tissue homogenisation
Animals were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA), and all care was carried out in strict
accordance with institutional guidelines. Transgenic I5 mice (Line
B6.Cg-Tg(PDGFB-APP)5 Lms/J, stock number 004662), which
over-express wild type human APP, and J20 mice (Line B6.Cg-
Tg(PDGFB-APPSwInd)20 Lms/2J, stock number 006293), which
over-express human APP containing the Swedish (K670N/
M671L) and Indiana (V717F) familial AD mutations [23], were
crossed with inbred 129P2 mice, and genotyped to confirm the
APP gene sequence. Brain hemispheres from the I5 (8 weeks old),
J20 (5–9 weeks old) and age-matched non-transgenic littermate
controls were homogenized in 2% (w/v) SDS solution containing
protease inhibitors, and homogenates centrifuged at 100,0006 g
for 1 h at 4uC. The resultant supernatant was assayed for total
protein and assessed for PrPC and APP protein by SDS-PAGE and
western blotting as described above for cell lysates.
Densitometry and statistical analysis
Quantification and densitometric analyses were carried out
using Image J v1.42q. Within each experiment, data was
normalised to b-actin, and expressed relative to the control
samples. Statistical analyses were performed in GraphPad Prism
v5.03. All quantitative data are expressed as the mean 6 SEM,
unless stated otherwise.
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Misfolding of PrPC (cellular prion protein) to β-strand-
rich conformations constitutes a key event in prion disease
pathogenesis. PrPC can undergo either of two constitutive
endoproteolytic events known as α- and β-cleavage, yielding
C-terminal fragments known as C1 and C2 respectively. It is
unclear whether C-terminal fragments generated through α-
and β-cleavage, especially C2, influence pathogenesis directly.
Consequently, we compared the biophysical properties and
neurotoxicity of recombinant human PrP fragments recapitulating
α- and β-cleavage, namely huPrP-(112–231) (equating to C1)
and huPrP-(90–231) (equating to C2). Under conditions we
employed, huPrP-(112–231) could not be induced to fold into
a β-stranded isoform and neurotoxicity was not a feature for
monomeric or multimeric assemblies. In contrast, huPrP-(90–
231) easily adopted a β-strand conformation, demonstrated
considerable thermostability and was toxic to neurons. Synthetic
PrP peptides modelled on α- and β-cleavage of the unique
Y145STOP (Tyr145→stop) mutant prion protein corroborated the
differential toxicity observed for recombinant huPrP-(112–231)
and huPrP-(90–231) and suggested that the persistence of soluble
oligomeric β-strand-rich conformers was required for significant
neurotoxicity. Our results additionally indicate that α- and β-
cleavage of PrPC generate biophysically and biologically non-
equivalent C-terminal fragments and that C1 generated through
α-cleavage appears to be pathogenesis-averse.
Key words: α-cleavage, neurotoxicity, peptide modelling, prion
protein (PrP), prion protein cleavage.
INTRODUCTION
Prion diseases are neurodegenerative disorders associated
with accumulation of misfolded, typically protease-resistant,
prion protein conformers (PrPres), generated post-translationally
through conversion of the normal cellular isoform of the
protein (PrPC) [1,2]. PrPC can undergo either of two constitutive
endoproteolytic events [3,4], termed α- and β-cleavage [5]
(Figure 1). PrPC α-cleavage results in fragments referred to as
C1 and N1 [3,5,6]. C1 is the predominant C-terminal fragment
found in healthy human brains [3,5,7,8] and numerous cultured
cell lines [4,5,9–11], suggesting that α-cleavage is an important,
evolutionarily conserved, biological event. Indeed, evidence
supports a direct link between the α-cleavage of PrPC and normal
function [12–14], with increased C1 expression appearing to be
protective against prion transmission [9,15]. PrP (prion protein)
β-cleavage, occurring around residue 90, is also evident in normal
brains, albeit at lower levels, yielding fragments known as C2 and
N2 [3,5]. Overall, C2 approximates the primary sequence of the
PK (proteinase K)-resistant core of PrPres [16,17]. In contrast
with C1, the C2 fragment is prominently increased in the brains
of patients with CJD (Creutzfeldt–Jakob disease) [3,7], as well
as in cell lines chronically infected with prions [18], with the
majority of this fragment demonstrating reduced solubility in
non-denaturing detergents and/or protease-resistance similar to
PrPres. However, it is uncertain how much of this biochemically
altered C2 occurs through direct conversion of nascent α-helical
C2 or via intracellular proteolytic N-terminal trimming of pre-
formed unglycosylated and glycosylated PrPres. Notwithstanding
this uncertainty, cell-free systems [19], infected cell lines [20]
and transgenic mouse models [21] have demonstrated that C2,
in contrast with C1, can still serve as an efficient substrate for
conversion by PrPres into conformers approximating the protease-
resistant core of PrPres, PrP-(27–30). Overall, these observations
suggest that β-cleavage may be an unfavourable processing event,
especially in the setting of prion infection. Furthermore, studies
of recombinant PrP fragments equating the C2 fragment support
its potential to form neurotoxic conformers [22–24].
Therefore, collectively, evidence suggests that β-cleavage of
PrP may be a potentially detrimental metabolic event, whereas
α-cleavage appears to be more aligned to normal function and
perhaps circumvents a pathogenic isoform. To test this hypothesis,
we therefore investigated the possible differential consequences
of endogenous α- and β-cleavage of PrPC, by directly comparing
the biophysical properties and neurotoxicity of recombinant
hu (human) PrP-(112–231) (C1) and huPrP-(90–231) (C2).
To corroborate and extend the recombinant peptide studies,
our investigations also utilized synthetic peptides modelled
on α- and β-cleavage of a pathogenic mutant form of PrPC
[Y145STOP (Tyr145→stop)] associated with GSS (Gerstmann–
Sträussler–Scheinker) syndrome [25]. We found huPrP-(112–
231) could not be induced to fold into a β-sheet rich isoform
that was neurotoxic. In contrast, huPrP-(90–231) readily adopted
β-strand conformation, with thermostability comparable with
Abbreviations: Aβ, amyloid β-peptide; AD, Alzheimer’s disease; CJD, Creutzfeldt–Jakob disease; D-PBS, Dulbecco’s PBS; E14, embryonic day 14;
ERK, extracellular-signal-regulated kinase; GSS, Gerstmann–Sträussler–Scheinker; hu, human; MRE, mean residual ellipticity; PK, proteinase K; PrP, prion
protein; PrPC, cellular PrP; PrPres, protease-resistant PrP; SELDI–TOF, surface-enhanced laser-desorption/ionization–time-of-flight; ThT, Thioflavin-T.
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Figure 1 Schematic representation of endogenous PrP cleavage
As part of its normal metabolism, PrP undergoes proteolytic processing, described as α- and β-cleavage, resulting in characteristic N- and C-terminal fragments [5]. Depicted are the C-terminal
fragments pertinent to the present study. PrP-(112–231) is equivalent to the C1 fragment following α-cleavage and PrP-(90–231) is equivalent to the C2 fragment following β-cleavage.
PrPres [26], demonstrating structure-dependent neurotoxicity.
Synthetic PrP peptides corroborated the differential toxicity
observed for recombinant huPrP-(112–231) and huPrP-(90–231)
and additionally suggested that persistence of soluble oligomeric
β-sheet-rich PrP conformers was required for neurotoxicity.
EXPERIMENTAL
Recombinant PrP C1 and C2 fragments
Human C-terminal recombinant PrP peptides encompassing
residues 90–231 [huPrP-(90–231)] and 112–231 [huPrP-(112–
231)] were expressed and purified as described in detail previously
[27]. Fresh recombinant protein working stock solutions were
prepared by dissolving freeze-dried protein in ice-cold sterile
Milli-Q water to 1–10 μg/μl and incubated on ice for 5 min.
Unless specified otherwise, the peptide solution was then
centrifuged at 13200 g for 5 min on a benchtop centrifuge
(Eppendorf) at 4 ◦C, and the supernatant was kept on ice
and used for experiments. The concentration was verified by
UV absorbance spectrophotometry at 280 nm using the molar
absorption coefficient values of 21890 M− 1 · cm− 1 for 90–231
and 16390 M− 1 · cm− 1 for 112–231, as calculated by ExPASY
[28]. The proteins were adjusted to the desired final concentration
by diluting with ice-cold Milli-Q water and 10× desired buffer.
Refolding of recombinant huPrP-(112–231) and huPrP-(90–231)
into the β conformation using disulfide bond reduction and low pH
The refolding of recombinant huPrP by reduction of the disulfide
bond in a low-pH acetate buffer has been described previously
to yield high concentrations of a monomeric form of PrP rich
in β-strand secondary structure [29]. This method was applied
to HPLC-purified huPrP-(90–231) and huPrP-(112–231). The
huPrP C-terminal fragment was reconstituted to 0.04 mg/ml in β-
unfolding buffer (100 mM DTT, 10 mM sodium acetate, 10 mM
Tris acetate and 6 M guanidinium chloride, pH 8) and incubated
on a rocking platform or rotating wheel at room temperature
(21 ◦C), unfolding overnight. The unfolded huPrP C-terminal
fragment was then refolded through dialysis with β-PrP refolding
buffer (1 mM DTT, 10 mM sodium acetate and 10 mM Tris
acetate, pH 4). Typically, 50 ml of protein at 0.04 mg/ml was
dialysed with four or five changes of refolding buffer (5 litres).
The β-refolded protein was concentrated with Vivaspin® 20 spin
columns, 5 kDa molecular-mass cut-off PES (polyethersulfone)
(Sartorius), to 2 ml followed by centrifugation at 13200 g at
4 ◦C overnight in order to spin down precipitated material from
soluble β-huPrP. Soluble β-huPrP was collected in the supernatant
and the concentration was quantified with UV absorbance at
280 nm using the molar absorption coefficients noted above.
CD spectroscopy was performed on refolded protein to verify
conformation (described below).
CD spectroscopy
HuPrP peptide solutions were prepared as outlined above
and diluted to 10 μM (recombinant) or 30 μM (synthetic PrP
peptides) in 10 mM phosphate buffer (pH 7.4). Sample spectra
were measured from 190 to 260 nm in 1 nm increments either
immediately or after incubation for various times at 37 ◦C,
employing 1-mm-pathlength quartz cuvettes (Starnez) in a Jasco
J-810 spectropolarimeter. The baseline acquired in the absence
of peptide was subtracted, and the resulting spectra were
smoothed using a Fourier transform. The direct CD measurements
(θ , in millidegrees) were converted into MRE (mean residual
ellipticity), using the relationship MRE = θ /(10×cR×l), where cR
is the mean residue molar concentration and l is the pathlength.
Thermal stability experiments
Thermal stability experiments were performed at a protein
concentration of 10 μM, following changes in ellipticity at
222 nm or 218 nm as a function of temperature. The heating rate
was 1 ◦C/min. The measurements were performed using a Jasco
J-810 spectropolarimeter equipped with a 1 mm water-jacketed
cell and a computer-controlled water bath.
Proteinase K digestion
Samples (15 μl) of recombinant huPrP C-terminal fragment
at 65 μM (146 pmol) or 13–16 μg were digested with 0.005–
50 μg/ml PK (Invitrogen) for 60 min at 37 ◦C. The PK digest
was stopped by the addition of Pefabloc SC (Roche) (final
concentration of 3 mM). Samples were heated to 100 ◦C for 5 min
in LDS (lithium dodecyl sulfate) sample buffer (Invitrogen) before
electrophoresis in 12% NuPAGE Bis-Tris gels (Invitrogen) at
200 V for 45 min (until the dye front reached the bottom) using
MES running buffer (Invitrogen). Protein bands were stained
using the rapid Coomassie Blue staining protocol [30].
c© The Authors Journal compilation c© 2014 Biochemical Society
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Primary neuronal cultures
Primary cortical neuronal cultures were prepared as described
previously under sterile conditions [31]. Briefly, cells from
cerebral cortices of E14 (embryonic day 14) C57BL/6J×Sv129 or
Prnp-ablated (PrP− / − ) (matched genetic background) mice were
removed, dissected free of meninges and dissociated in 0.025%
trypsin (Sigma) in Krebs buffer (124 mM NaCl, 5.1 mM KCl,
1.0 mM NaH2PO4 · H2O, 14.4 mM D-glucose, 0.001% Phenol
Red, 25 mM Hepes, 0.3 % BSA and 2.6 mM MgSO4, pH 7.4).
Cortical neuronal cells were plated on to poly-D-lysine-coated
(0.5 mg/ml) 48-well plates at a density of 150000 cells/well
in plating medium. After 2 h, the plating medium was replaced
with fresh NeurobasalTM medium containing B-27 supplements,
gentamicin and 0.125 mM glutamine. After 6 days in vitro, the
NeurobasalTM medium was replaced, containing B-27 minus
antioxidants, gentamicin, 0.125 mM glutamine and 2.5 μg/ml
cytosine arabinoside. This method resulted in cultures highly
enriched for neurons (>95% purity) with minimal astrocyte and
microglial contamination [31]. All cultures were maintained in an
incubator at 37 ◦C with 5% CO2. All tissue culture reagents were
purchased from Invitrogen unless stated otherwise. All animal
experiments were approved by the University of Melbourne
Animal Ethics Committee and were in accordance with the
National Health and Medical Research Council of Australia
guidelines for animal experimentation.
Cell viability assays
Primary cerebral cortical neurons were allowed to mature for
6 days in culture before undergoing treatment. Freshly prepared
recombinant or synthetic PrP peptide stock solutions were diluted
to the final concentration in the cell culture medium. Primary
neuronal cells were treated with either the recombinant or
synthetic PrP peptides for 4 days. Cell survival was monitored
by phase-contrast microscopy, and cell viability was quantified
after 4 days using tetrazolium reduction with the Cell Counting
Kit-8 (Dojindo Molecular Technologies) according to the
manufacturer’s instructions. Data were normalized and results
are calculated as a percentage of vehicle control values. Data are
shown as means +− S.E.M. Statistical comparisons between groups
were performed using one-way ANOVA with Tukey’s multiple
comparison post-test (GraphPad Prism 4 statistical software).
Synthetic PrP peptides
Table 1 summarizes the peptides used: PrP-(111–144), PrP-(112–
144) and PrP-(90–144). All peptides were chemically synthesized
by the Bio21 Research Transfer Facility, Melbourne, Australia
[32]. Purity and composition were verified by reverse-phase
HPLC, MS and amino acid analysis. Accurate determination of
amino acid content (excluding contaminating salts from synthesis)
allowed the molar absorption coefficient of each peptide at 214 nm
to be quantitatively determined (Table 1). All peptides studied
were soluble in water and were dissolved in sterile Milli-Q water at
1 μg/μl, and then divided into suitable working aliquots followed
by freeze-drying and storage at − 80 ◦C until needed.
Preparation of PrP synthetic peptide stock solutions
Fresh synthetic peptide working stock solutions were prepared
by dissolving freeze-dried peptide in ice-chilled sterile Milli-
Q water to 1–10 μg/μl and sonicating in a cool water bath for
15 min. The peptide solution was then spun in a microcentrifuge
Table 1 Synthetic PrP peptides used in the present study
Amino acid sequences (based on human) and molar absorption coefficients at 214 nm (see the
Experimental section).






for 5 min at maximum speed at 4 ◦C, and the supernatant was kept
on ice and used in experiments. The concentration was verified
by absorbance spectrophotometry at 214 nm using the molar
absorption coefficient values (Table 1) determined by peptide
mass and amino acid analysis (Auspep). The peptides were
adjusted to the desired final concentration by diluting with ice-
cold Milli-Q water and 10× D-PBS (Dulbecco’s PBS) (Gibco).
This method was adapted from Ciccotosto et al. [31] and is
associated with increased peptide solubility and reproducibility
between experiments.
Aggregation assays
Synthetic PrP peptides were prepared fresh, diluted to 30 μM in
D-PBS with excess ThT (Thioflavin-T) (50 μM), and aggregation
was monitored as described previously [33]. Samples were used
immediately or incubated at 37 ◦C with agitation at 1200 rev./min
until the aggregation reached a plateau. Aggregation was
quantified at various time points using a PerkinElmer LS55
fluorescence spectrophotometer measuring fluorescence emission
across a 1-cm-pathlength quartz cell at 480 nm when excited at
444 nm. To assay total aggregation, a discontinuous 90◦ light-
scattering assay was used. Samples were measured in a quartz
cell with a 1 cm pathlength. The ability of the solution to scatter
light was quantified using a PerkinElmer LS55 fluorescence
spectrophotometer employing an excitation wavelength of 300 nm
and scanning the emission wavelengths from 580 to 620 nm.
Maximum light scattering was observed and recorded at 600 nm.
Transmission electron microscopy
Carbon-coated grids (ProSciTech) were glow-discharged and
aliquots from the end points of the aggregation assays described
above were immediately spotted in the centre of the grids and
incubated for 15 min. The grids were then washed twice with
Milli-Q water and blotted dry to remove excess NaCl. The
peptides were negatively stained with 0.5% uranyl acetate by
inverting the grid on a uranyl acetate droplet for 15 s followed by
blotting off the excess. Images of the samples were taken using a
Siemens ELMI-SKOP 102 electron microscope with a voltage of
60 kV (Bio21 Institute EM Facility).
SELDI–TOF-MS detection of PrP peptide oligomers
SELDI–TOF (surface-enhanced laser-desorption/ionization–
time-of-flight)-MS was used to detect oligomers of synthetic PrP
peptides using H50 ProteinChip arrays (Bio-Rad Laboratories),
prepared as described previously [34]. In brief, arrays were
washed twice with 5 μl of 10 mM phosphate buffer (pH 7.4) on
a shaking table for 2 min. Phosphate buffer was then removed,
and 10 μM peptide samples (prepared as described above) were
c© The Authors Journal compilation c© 2014 Biochemical Society
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loaded on to the arrays and allowed to incubate for 5 min while
shaking. Peptide samples were removed and arrays were washed
twice with phosphate buffer (pH 7.4), followed by two 1 min
washes with 1 mM Hepes (pH 7.2). The arrays were air-dried and
1 μl of 50% (w/v) CHCA (α-cyano-4-hydroxycinnamic acid)
matrix in 50% (v/v) acetonitrile and 0.5% TFA (trifluoroacetic
acid) was applied twice to each array, which were air-dried
between each application [35]. Arrays were then analysed by
SELDI–TOF-MS, and resulting spectra were examined using
ProteinChip software (version 3.2.1).
RESULTS
huPrP-(112–231) does not form a soluble β-sheet PK-resistant
thermally stable isoform
We have established previously a protocol to generate huPrP
of exact native sequence [27]. As reported previously, when
reconstituted in phosphate buffer (pH 7.4), huPrP-(90–231) and
huPrP-(112–231) adopt primarily α-helical secondary structure
as determined by CD [27,29] (Figures 2A and 2E). α-
Helical huPrP-(90–231) was first unfolded in a reducing
buffer containing a high concentration of guanidine. Gradually,
the reductant and guanidine were dialysed out, with pre-
formed oligomers or aggregates removed through high-speed
centrifugation overnight, yielding a soluble predominantly β-
stranded secondary structure (Figure 2A) with β-huPrP-(90–231)
displaying increased resistance to PK digestion (Figure 2B) and
existing largely as a soluble monomer as described previously
[29]. Thermal stability studies of β-huPrP-(90–231) revealed
the novel finding that this recombinant isoform is very heat-
stable, retaining β-strand structure at 90 ◦C (Figures 2C and 2D).
Refolding of huPrP-(112–231) into a β-stranded structure has
not been reported previously. The same protocol was applied
to huPrP-(112–231), but, despite repeated attempts, notably, no
soluble β-stranded isoform could be generated, with the protein
predominantly remaining random coil (Figure 2E).
Structure-dependent toxicity of huPrP-(90–231)
huPrP-(90–231) and huPrP-(112–231), homologous with PrP C2
and C1 fragments respectively, in native α-helical conformation,
were tested for toxicity by application to cultures of murine
primary cortical neurons. Cortical neurons were prepared from
E14 mice and allowed to mature for 6 days. The proteins were
applied to the cultures and thereafter maintained for 4 days
before cell survival was determined. Native α-helical huPrP-(112–
231) and huPrP-(90–231) showed no toxicity towards cultures of
cortical neurons (Figure 3A), with huPrP-(90–231) unexpectedly
causing modest, but significantly increased, cell viability at 3 μM
(Figure 3A). In contrast, soluble β-huPrP-(90–231) was found to
be toxic to cultured cortical neurons from 1 μM (Figure 3B).
Insoluble huPrP-(112–231) and huPrP-(90–231) produced under
reducing and acidic conditions are not toxic
The low-pH-reducing refolding protocol for recombinant PrP
resulted in considerable loss of protein, which we estimate
for huPrP-(90–231) to be approximately 80 % of the total
protein forming an insoluble pellet. huPrP-(112–231) lost even
more protein, which was estimated at approximately 98%
of the total protein. To assess the potential toxicity of the
aggregated recombinant proteins under more physiological
cellular conditions, the insoluble pellets were completely
resuspended by mixing vigorously in phosphate buffer (pH 7.4).
Acknowledging that PK-resistance generally correlates with β-
strand structure, a change in secondary structure was investigated
by determining the relative susceptibility to digestion by PK.
No significant increase in PK-resistance was observed in the
resuspended pellets of huPrP-(112–231) with only a modest
increase observed for huPrP-(90–231) (Figure 4A) compared with
soluble α-helical huPrP-(90–231) (Figure 2B). These findings
suggest that resuspended insoluble huPrP-(90–231) may harbour a
small amount of β-stranded structures, but resuspended insoluble
huPrP-(112–231) appears unlikely to harbour any β-stranded
structures, underscoring the relative resistance of huPrP-(112–
231) to misfolding into soluble conformations with this secondary
structure under the conditions we employed. Furthermore,
insoluble huPrP-(90–231) and huPrP-(112–231), resuspended in
phosphate buffer (pH 7.4), were not toxic to cultured primary
neurons (Figure 4B).
Synthetic peptides based on α-and β-cleavage of PrP Y145STOP
form random coil fresh in solution, but change to form β-strand
secondary structure when incubated under physiological conditions
Numerous studies have been carried out employing synthetic PrP
peptide segments to determine those region(s) of the protein
critical for recognized biochemical and biological properties,
including the neurotoxicity of misfolded disease-associated
isoforms of the protein (reviewed in [36]). Arguably the most
studied are peptides constituted by residues 106–126 (human
sequence), with such studies demonstrating increased propensity
to β-strand secondary structure, PK-resistance [37] and toxicity to
PrP-expressing neuronal cultures [38,39], collectively emulating
some properties of PrPres.
In view of the significant insights gained from examining
synthetic peptides based on human PrP, further characterization
of the consequences of α- and β-cleavage of PrPC were
modelled using synthetic peptides based on the PrP Y145STOP
mutation [25]. The peptides we studied equate to human
PrP amino acid residues 112–144, 111–144 (representing α-
cleavage) and 90–144 (representing β-cleavage) (Table 1).
Two peptides representing α-cleavage were studied as it has
been demonstrated previously from radio-sequencing that the
C1 fragment N-termini begin at either His111 or Met112 [3],
with His111 binding copper [40] and reportedly playing a
role in governing structure [41,42]. Although the presence of
peptides approximating PrP-(90–144) have been demonstrated
previously in the presence of the Y145STOP mutation [43], to
increase the relevance of our synthetic peptides, we verified the
likely occurrence of α-cleavage (Supplementary Figure S1 at
http://www.biochemj.org/bj/459/bj4590103add.htm).
CD spectroscopy was used to qualitatively determine secondary
structure of each of the peptides. Freshly prepared peptides
in phosphate buffer (pH 7.4) displayed a single minimum
at ∼200 nm, indicating predominantly random coil structure.
Incubation of the synthetic peptides overnight at 37 ◦C caused
a progressive change in secondary structure with a notable
increase in a single minimum approximating 220 nm, suggesting
an increase in β-strand structure. Incubation at 37 ◦C for extended
periods also induced aggregation accounting for the reduced CD
signal observed (Figure 5A).
Synthetic peptides based on α-and β-cleavage of PrP Y145STOP
form amyloid fibrils with various kinetics
The self-aggregation capacity of the synthetic peptides was
assessed by monitoring ThT fluorescence and light scattering over
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Figure 2 Biophysical properties of PrP-(90–231) and PrP-(112–231)
(A) Secondary structure of PrP-(90–231) in α-folded and β-folded isoforms. PrP-(90–231) (10 μM) oxidized in 10 mM phosphate buffer (pH 7.4) displays a typical predominant α-helical structure
(grey). Reduced PrP-(90–231) in 1 mM DTT, 10 mM sodium acetate and 10 mM Tris acetate (pH 4) (black) displays a predominantly β-sheet structure with a single minimum at approximately
218 nm. (B) PK digestion of β-PrP-(90–231) and α-PrP-(90–231). Samples of 15 μg of α-PrP-(90–231) and β-PrP-(90–231) were incubated with PK at 0, 50, 5, 0.5, 0.05 or 0.005 μg/ml for 1 h
at 37◦C. Digestion was halted with Pefabloc. α-PrP-(90–231) is completely digested by PK at 5 μg/ml and displays partial resistance from 0.5 μg/ml. β-PrP-(90–231) has partial PK-resistance
from 50 μg/ml with most undigested at 5.0 μg/ml. Molecular masses are indicated in kDa. (C) Thermal stability of human recombinant β-PrP-(90–231). β-PrP-(90–231) was diluted to 10 μM. The
fraction of molecules folded was determined by CD at 218 nm. The heating (grey) profile of β-PrP-(90–231) is superimposed with data for cooling (black). (D) Secondary structure of β-PrP-(90–231)
before thermal melt at 20◦C (light grey), at 90◦C (dark grey) and post-thermal melt at 20◦C (black). Before thermal melt, at 90◦C, and after thermal melt (20◦C), β-PrP-(90–231) displays a
predominantly β-sheet structure with a single minimum at approximately 218 nm. (E) Secondary structure of PrP-(112–231) under α-fold and β-fold buffer conditions. PrP-(112–231) oxidized in
10 mM phosphate buffer (pH 7.4) displays a typical predominant α-helical structure (grey). Reduced PrP-(112–231) in 1 mM DTT, 10 mM sodium acetate and 10 mM Tris acetate (pH 4.0) (black)
displays predominantly random coil spectra, with a single minimum at approximately 195 nm.
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Figure 3 Effects of recombinant PrP C-terminal fragments on primary (E14)
mouse cortical neuronal cultures
Cortical cells were plated in 48-well plates at a density of 1.5×105 cells/well and grown for
6 days before treatment. Each PrP fragment, i.e. 112–231 and 90–231 (α- or β-folded), was
cleared of pre-formed aggregates, diluted to a stock solution in D-PBS and incubated directly
on cell cultures for 96 h. Cell viability was determined using the Cell Counting Kit-8. (A)
α-PrP-(112–231) and α-PrP-(90–231). (B) α-PrP-(90–231) and β-PrP-(90–231). Results
are means +− S.E.M. (n = 3, in triplicate). Differences were compared with and normalized to
vehicle controls. *P < 0.05 compared with control group using two-way ANOVA with Bonferroni
post-test correction.
time. An increase in ThT fluorescence indicates the formation
of β-strand-rich amyloidogenic structures, whereas an increase
in light scattering indicates the formation of macromolecular
structures, either amyloid fibrils or amorphous aggregates. Each
peptide was prepared fresh in D-PBS (pH 7.4), incubated with
excess ThT at 37 ◦C and fluorescence, and light scatter were
measured over time until the signal reached a plateau (Figure 5B
and Supplementary Figure S2 at http://www.biochemj.org/bj/459/
bj4590103add.htm). Lag times were calculated by averaging the
first time point greater than 10% normalized ThT fluorescence.
The aggregation kinetics of PrP-(112–144) and PrP-(111–144)
were rapid, with ThT fluorescence reaching a plateau in
less than 60 and 120 min, with mean lag times of 20 and
82 min, respectively (Table 2). This was in contrast with PrP-
(90–144) which, comparatively, aggregated at a significantly
lower rate, reaching a fluorescence maximum within 500 min
(Figure 5B) with a mean lag time of 240 min (Table 2). All
experiments showed concordance between light-scatter kinetics
and ThT fluorescence, indicating a low likelihood of amorphous
aggregates. To confirm that the peptides were indeed forming
fibrils, the aggregates were analysed further by TEM (Figure 5C).
At time points when each of the peptides displayed a high ThT
signal, the TEM images show that all peptides readily formed
amyloid fibrils, albeit with differences in morphology observed.
SELDI–TOF-MS analyses of synthetic peptides based on α- and
β-cleavage PrP Y145STOP
The aggregation kinetic assays combined with TEM analyses
of the α- and β-cleavage of PrP Y145STOP demonstrated that
Figure 4 Insoluble huPrP-(112–231) and huPrP-(90–231) produced under
reducing and acidic conditions
(A) Coomassie Blue-stained gels of resuspended pellets, produced under reducing low-pH
refolding conditions, of PrP-(90–231) and PrP-(112–231), after digestion with PK at various
concentrations. Pellets of 16 μg of PrP-(90–231) (146 pmol) and 13 μg of PrP-(112–231)
(146 pmol) were incubated with PK at 0, 50, 5, 0.5, 0.05 or 0.005 μg/ml for 1 h at
37◦C. Digestion was halted with Pefabloc. Molecular masses are indicated in kDa. (B)
Resuspended pellets generated using a reducing low-pH refolding protocol of PrP-(90–231)
and PrP-(112–231) are not toxic to primary embryonic (E14) mouse cortical cultures grown
for 6 days in vitro followed by 96 h of direct treatment. Results are means +− S.E.M. (n = 3, in
triplicate). Differences were compared with and normalized to vehicle controls. No significant
difference was found by two-way ANOVA with Bonferroni post-test correction.
Table 2 Comparison of lag times to aggregation for α-and β-cleavage PrP
Y145STOP peptides
Delay times were calculated by extrapolating the aggregation curve down to zero absorbance at
the first time point greater than 10 % normalized ThT fluorescence. Results are means +− S.D.
(n = 3–5). Statistical significance was determined by ANOVA.
(a)
PrP peptide Average lag time (min)
112–144 20 +− 7
111–144 82 +− 62
90–144 240 +− 60
(b)
Statistical comparison P value
112–144 with 111–144 >0.05
112–144 with 90–144 <0.001
111–144 with 90–144 <0.01
PrP-(112–144) and PrP-(111–144) aggregate rapidly into amyloid
fibrils, and it is plausible most of the available soluble peptides
concatenate rapidly to form fibrils. PrP-(90–144), in contrast,
aggregates more slowly and it is therefore reasonable to consider
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Figure 5 Biophysical properties and TEM of PrP-(112–144), PrP-(111–144) and PrP-(90–144)
(A) CD analysis of PrP-(112–144), PrP-(111–144) and PrP-(90–144) peptides (30 μM) in 10 mM phosphate buffer (pH 7.4) at 37◦C. Sample spectra were measured from 185 to 260 nm in 1 nm
increments in 1-mm-pathlength quartz cuvettes. (B) Aggregation kinetics of PrP peptides (30 μM) in D-PBS and 50 μM ThT at 37◦C with agitation at 1200 rev./min. Aggregation was measured
at various time points in a 1-cm-pathlength quartz cell. Results are means +− S.E.M. (n = 3–5). (C) TEM of aggregated PrP peptides (30 μM in D-PBS and 50 μM ThT) on glow-discharged
carbon-coated grids. The images confirm fibril formation of PrP-(112–144), PrP-(111–144) and PrP-(90–144) peptides.
that perhaps less of the total peptide concentration is channelled
directly into amyloid fibrils. To investigate this further, SELDI–
TOF-MS was utilized. SELDI–TOF-MS can detect monomers
and oligomers on the basis of their differential molecular masses, a
technique used previously to characterize Aβ (amyloid β-peptide)
glycine-substituted-to-leucine peptides [34]. As with Aβ, the α-
and β-cleavage PrP Y145STOP peptides studied are hydrophobic
and could therefore directly interact with the carbon molecules
on the surface of an H50 Protein Chip array.
In addition to the monomer, a dimeric species was found
in equal abundance in a fresh solution of PrP-(90–144), as
well as comparatively smaller peaks consistent with trimers
and tetramers (Figure 6). PrP-(112–144) and PrP-(111–144)
also briefly displayed dimeric species, although in much lower
abundance compared with their monomeric peaks. No higher-
order oligomeric species were observed for PrP-(112–144) and
PrP-(111–144) (Figure 6). When the peptides were incubated
at 37 ◦C for 24 h, the relative monomeric peak of PrP-(90–144)
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Figure 6 SELDI–TOF-MS profiles of PrP-(112–144), PrP-(111–144) and PrP-(90–144) peptides (10 μM) in 10 mM phosphate buffer on H50 arrays over time
PrP peptides were loaded on spots coated with 10 mM phosphate buffer (pH 7.4) alone and incubated for 5 min. Spots were washed to remove non-specifically bound components. CHAPS was
applied to each spot and arrays were subsequently subjected to SELDI–TOF-MS. Analysis of resulting spectra revealed that all PrP peptides form dimers immediately; however, PrP-(90–144) also
forms trimers and tetramers, and the oligomers remain for up to 72 h. Inset: SELDI–TOF-MS profiles of PrP peptides on H50 arrays at zero time. Spectra reveal that all PrP peptides form dimers
immediately; however, PrP-(90–144) also forms trimers and tetramers.
decreased in intensity in contrast with that of the dimer. The
oligomeric peaks observed when PrP-(90–144) was fresh also
decreased in intensity. In contrast, no change in the MS profile
was observed with PrP-(112–144) and PrP-(111–144) at 24 h.
With increased time, only a monomeric species was observed
in the spectra of PrP-(112–144) and PrP-(111–144). In contrast,
the spectrum of PrP-(90–144) still showed an abundant dimer
peak relative to the monomeric peak after 120 h, with trimer
still present until 120 h, whereas tetramer was detectable for
72 h. This result, in combination with the aggregation kinetic
assays and TEM data, suggest that PrP-(112–144) and PrP-(111–
144) aggregate so rapidly that the relative concentrations of
smaller soluble oligomers present in solution is extremely low,
whereas PrP-(90–144) aggregates more slowly and consequently
has a higher steady-state concentration and persistence of soluble
oligomers. These oligomeric species found with PrP-(90–144)
may relate directly to the consistent toxicity detected for this
peptide (Figure 7C).
Synthetic peptides based on α-cleavage and β-cleavage of PrP
Y145STOP demonstrate differential neurotoxicity similar to that
observed for huPrP-(112–231) and huPrP-(90–231)
The biological activity of the α- and β-cleavage peptides based on
the PrP Y145STOP mutant was investigated using mouse primary
cortical neurons. It is noteworthy that the β-cleavage peptide PrP-
(90–144) retains the entire 106–126 sequence shown previously
to be neurotoxic [38,39]. Conversely, in the α-cleavage peptides
PrP-(112–144) and PrP-(111–144), the 106–126 sequence is
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Figure 7 Effects of PrP-(112–144), PrP-(111–144) and PrP-(90–144) peptides on primary (E14) mouse cortical neuronal cultures
Cortical cells from wild-type mice (A–C) were plated in 48-well plates at a density of 1.5×105 cells/well and grown for 6 days before treatment. Each peptide [112–144 (A), 111–144 (B) and
90–144 (C)] was cleared of pre-formed aggregates, diluted to a stock solution in D-PBS and incubated directly with cell cultures for 96 h. Cell viability was determined using the Cell Counting
Kit-8. Differences compared and normalized to vehicle controls. Results are means +− S.E.M. (n = 3, in triplicate) **P < 0.05, ***P < 0.01 by one-way ANOVA with Tukey’s multiple comparison
test; post-test for linear trend. (D) Effects of PrP-(112–144), PrP-(111–144) and PrP-(90–144) peptides (50 μM in D-PBS) on primary (E14) mouse cortical neuron survival from wild-type and
PrP − / − mice. Results are means +− S.E.M. (n = 3, in triplicate). Differences were compared between PrP− / − and wild-type cortical neuron viability. No significant differences were seen. Two-way
ANOVA Bonferroni post-test correction.
disrupted, prompting speculation that these peptides may be less
toxic. Treatment of murine E14 primary cortical neuronal cultures
with PrP-(90–144) demonstrated dose-dependent neurotoxicity,
significant from 25 μM (Figure 7C). Each concentration of PrP-
(112–144) assessed did not show significant toxicity to cultured
primary cortical neurons; however, decreasing cell viability was
seen with increasing peptide concentrations. This linear trend was
significant, suggesting that the peptide does have modest, less
consistent, effects on cell viability in a dose-dependent manner
(Figure 7A). PrP-(111–144), with an N-terminal histidine residue
rather than methionine, did not demonstrate any significant
compromise of cell viability, including with post-ANOVA trend
analysis (Figure 7B).
The mechanism of PrP-(106–126) peptide toxicity has been
reported to be dependent on PrP expression [37,38,44], but not
invariably [45]. To investigate whether any biological effect
exhibited by PrP-(112–144) and PrP-(90–144) also depends on
PrP expression, E14 primary cortical cultures from genetically
matched PrP− / − mouse embryos were treated with the peptides.
At each concentration of PrP-(112–144), PrP-(111–144) and PrP-
(90–144) tested, no significant difference was observed between
treated PrP− / − and WT cortical neuronal viability (treatment at
50 μM shown in Figure 7D).
DISCUSSION
Determining the biological significance of constitutive
endoproteolytic processing of PrPC, especially in relation
to prion disease pathogenesis, is an important goal. Investigations
in the present study were on the basis of the overarching
hypothesis that the two apparently mutually exclusive processing
events (α- or β-cleavage) are not equivalent in their inherent
pathogenic predispositions. This hypothesis was formulated from
a number of observations, which include that the C1 fragment
is the predominant C-terminal fragment found in healthy human
brains [3,5,7,8] and numerous cultured cell lines [4,5,9–11] with
the C2 fragment prominently increased in the brains of patients
with CJD [3,7], as well as in cell lines chronically infected with
prions [18]. We have compared directly the biophysical and
neurotoxic properties of C-terminal fragments generated from
alternative processing events, thereby extending the observations
of previous studies and further strengthening the argument that α-
and β-cleavage of PrPC generate biophysically and biologically
non-equivalent C-terminal fragments that harbour different
pathogenic implications for host cells, with α-cleavage appearing
more favourable and the likelihood that C2 generated through
β-cleavage may contribute directly to prion pathogenesis.
We found cognate peptides of PrP, modelled on endogenous
processing, have differences in their susceptibility to form
neurotoxic species. This is broadly similar to what is recognized
in relation to APP (amyloid precursor protein) processing in AD
(Alzheimer’s disease), wherein α- and β-cleavage prevents or
conserves respectively the occurrence of a pathogenic peptide,
Aβ, central to the pathogenesis of AD [46]. huPrP-(90–231)
readily adopted a β-stranded conformation under reducing and
acidic conditions, importantly displaying properties reminiscent
of PrPres, particularly enhanced protease-resistance as shown pre-
viously [29], and, remarkable heat-stability, further highlighting
that β-folded recombinant huPrP-(90–231) correlates well with
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the protease-resistant core of PrPres [26]. Soluble β-huPrP-(90–
231), in contrast with α-huPrP-(90–231), was toxic to cultured
primary cortical neurons at very low micromolar concentrations.
The low concentrations required for toxicity enhance the likely
relevance of β-PrP-(90–231) to pathogenesis. We observed no
dose-dependent toxicity over the narrow concentration range
explored. Absence of a dose–response toxicity curve for β-PrP-
(90–231) has been observed before with recombinant Syrian
hamster PrP-(90–231) applied to rat PC12 cells [24]. Interestingly,
in this study, higher doses restored viability [24]. The reason for
our lack of dose–response toxicity is uncertain, but could relate to
either a ceiling effect in relation to toxicity, which occurs at low
micromolar concentrations, or existence of a substantially broader
dynamic range than explored requiring much greater increments
in concentration or absolute amounts of β-PrP-(90–231) to
achieve commensurate increases in toxicity; examination of the
latter was precluded by insolubility at higher concentrations of β-
PrP-(90–231). A broader dose-dependent dynamic range for tox-
icity was observed with the synthetic PrP peptides studied, albeit
requiring higher concentrations up to 50 μM for maximal toxicity.
Other studies using synthetic PrP peptides have also reported
that toxicity is only observed at higher concentrations, such as
100 μM [38,39,47], prompting concerns regarding physiological
relevance.
Congruent with previous studies assessing PrP-(90–231)
toxicity, the ability of PrP-(90–231) to cause cell death correlated
with its secondary structure [22,23,48–50]. Distinct from huPrP-
(90–231), huPrP-(112–231) could not be manipulated to adopt
a soluble β-strand structure under the conditions we employed,
but rather remained predominantly random coil. Discrepant with
our findings, another group has reported His-tagged murine PrP-
(113–231) folds into a β-stranded intermediate at pH 3.9 [51].
Different refolding methods were employed, and notably the
recombinant fragment analysed was not the exact native sequence
as we have studied. Predominant C1 expression has been shown to
be protective against prion transmission in cell line and transgenic
mouse models [9,15], with our studies reinforcing these previous
observations wherein α-cleavage generates a fragment serving as
a suboptimal substrate for misfolding into PrPres-like neurotoxic
conformers, in contrast with β-cleavage, where C2 has been
demonstrated in cell-free systems [19], infected cell lines [20]
and transgenic mouse models [21] to serve as a relatively efficient
substrate for conversion by PrPres into conformers approximating
PrP-(27–30) [52].
Previous studies have reported the toxicity of thermally
refolded β-PrP-(90–231), inducing SH-SY5Y cell death by
promoting activation of pro-apoptotic cascades, p38 MAPK
(mitogen-activated protein kinase) and caspase 3 [22,49],
interestingly through the unbalancing of ERK1/2 (extracellular-
signal-regulated kinase 1/2) and p38 activities [48]. PrPC has a
postulated neurotrophic role (reviewed in [53]). Unexpectedly,
in our neurotoxicity model, we found that α-PrP-(90–231)
significantly increased neuronal cell survival at low micromolar
concentrations, whereas, in contrast, α-huPrP-(112–231) did
not. Preliminary observations have found α-huPrP-(90–231)
activates ERK (V. A. Johanssen, unpublished work) alluding
to the possibility of a signalling function for the fragment and
we therefore cannot exclude the possibility that β-cleavage of
PrPC could occur as a compensatory response to mitigate cell
stress, including from prion infection [12], but the present results
emphasize the need for this to be tightly constrained in the cell
to forestall inadvertent misfolding into a potentially neurotoxic
conformer.
A large loss of protein due to aggregation occurred using the low
pH/reducing β-refolding protocol. Investigations of the insoluble
pellets of both proteins, however, did not reveal a ‘PrPres’-like
aggregate, as their PK-resistance was much the same as that
of α-huPrP-(90–231) and quite different from soluble β-huPrP-
(90–231). Importantly, the resuspended insoluble pellet of both
protein fragments was not toxic to cultured neurons, discounting
a toxic conformer of huPrP-(112–231) coming out of solution
in the refolding process, and supporting further the predominant
correlation of toxicity with soluble β-strand-rich conformers. The
non-toxic solubilized pellets of huPrP-(90–231) and huPrP-(112–
231) demonstrated that aggregates of PrP are likely to represent
benign ‘junk’, rather than toxic species, and offer further support
for the lack of toxic predisposition of α-cleaved PrPC, with huPrP-
(112–231) under the conditions we employed appearing to largely
bypass or avoid a soluble toxic β-strand rich conformation along
its aggregation pathway. To explore this hypothesis further, our
additional studies utilized synthetic PrP peptides modelled on
endogenous processing in the context of the nonsense Y145STOP
mutation found in a single case of GSS syndrome [25]. Enhancing
the relevance of our choice of synthetic peptides, parallel cell
biological studies as part of our research endeavours validated
that both α- and β-cleavage of Y145STOP PrP are likely to occur
(Supplementary Figure S1).
In good agreement with the recombinant PrP fragment studies,
PrP-(90–144) was found to be quite toxic to cultured primary
neurons, notably contrasting with the toxicity observed in relation
to the synthetic α-cleavage peptides. A modest concentration-
dependent decline in primary neuronal viability was observed for
PrP-(112–144), suggesting that His111, which has been found to
govern the structure of PrP-(106–126) [44], also has an impact
on biological activity. Other synthetic PrP peptides similar to
PrP-(112–144) and PrP-(111–144), albeit truncated at the C-
terminus, for example PrP-(112–126) [resembling α-cleaved PrP-
(106–126)] were found to be more toxic to cultured cerebellar
neurons than PrP-(106–126) [54]. Furthermore, another peptide,
PrP-(113–126) (lacking Met112) was toxic to neurons although
less toxic than PrP-(112–126) [54]. Although our data and those
from previous reports do not provide a clear explanation, these
observations collectively suggest that Met112 at the N-terminus as
a consequence of α-like cleavage generates a peptide more likely
to harbour modest neurotoxicity perhaps unrelated to soluble β-
strand-rich oligomeric species.
Biophysical characterization of our synthetic peptides revealed
that toxicity of PrP-(90–144) correlated with the presence of a
soluble β-strand-rich structure, but, arguably more importantly,
correlated with the presence of longer-lasting or stable oligomeric
species, such as dimers, trimers and tetramers. These observations
broadly align with previous studies of PrP, in which it has been
postulated that, during the aggregation of PrP, toxic oligomers are
also generated [47,55–58]. Similar evidence has been found for
other peptides associated with neurodegeneration, in particular
Aβ, wherein SELDI–TOF-MS and other techniques have been
employed to delineate putative toxic oligomeric species [34,59–
61]. In our studies, accelerated aggregation rates of the synthetic
peptides corresponded with reduced detection of small oligomers,
as seen with PrP-(112–144) and PrP-(111–144). The populations
of PrP-(90–144) oligomers, however, appeared to be reasonably
stable, present for up to 120 h when a small trimer peak
was still visible. These data, along with the CD spectra and
aggregation analyses, suggests that PrP-(112–144) and PrP-
(111–144) form fibrils very rapidly, appearing to largely bypass
sizeable pools of stable soluble β-strand-rich oligomers, which
are potentially significantly neurotoxic, an observation analogous
to our inability to generate toxic soluble β-strand-rich huPrP-
(112–231) conformers. In contrast, PrP-(90–144), with slower
aggregation kinetics, established a longer-lasting equilibrium
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with various oligomeric species. Hence there appears to be a
correlation between a sustained population of soluble β-strand-
rich conformers, which may include small oligomeric species,
and neuronal toxicity. In support of this, PrP-(106–126) and PrP-
(82–146) toxicity is partially rescued when these peptides are pre-
incubated with a β-strand-rich oligomer specific antibody [47,62].
Additionally, different transgenic mouse models with a fatal
neurodegenerative phenotype correlate with small oligomeric
species [63,64] and evidence has been provided indicating that
the most infectious prions are constituted by small oligomeric PrP
species [65,66]. The present study demonstrates that differential
processing of the parent protein offers cognate peptides of various
toxic predisposition, mainly determined by their ability to form a
soluble β-strand-rich isoform.
Conclusions
Consistently employing a direct comparative approach to
highlight potential differences in biophysical properties and
neurotoxic predilections of C-terminal fragments consequent to
α- and β-cleavage of PrPC was an integral component of our meth-
odology. As such, the principal aim of our experimental design has
served to unify a number of previous studies assessing individual
peptides broadly recapitulating either C1 or C2 [22,23,48–51,67].
In addition, acknowledging the significant influence that even a
small number of additional amino acids can have on protein or
peptide behaviour, such as Aβ40 compared with Aβ42 [68,69],
another intended positive attribute of the present study was the
utilization of recombinant peptides of exact primary sequence
when assessing the biophysical and biological properties of C-
terminal fragments modelled on α- and β-cleavage of PrPC [27].
Future studies of interest would include investigations into what
contributions there may be, if any, from other post-translational
modifications of PrP C-terminal fragments such as glycosylation
and the presence of a glycosylphosphatidylinositol anchor.
We have demonstrated that the C-terminal fragments generated
through alternative α- and β-cleavage of PrPC appear to harbour
different pathogenic potential for host cells, particularly in the
setting of prion infection. Most significantly, α-cleavage produces
a C-terminal fragment that is resistant to folding into soluble β-
strand-rich toxic isoforms. In contrast, β-cleavage produces a
fragment with greater vulnerability to misfolding into soluble
β-strand-rich toxic conformers. Consequently, the present study
contributes further support for the proposition that strategies to
promote α-cleavage may be a useful approach for the treatment
prion disease.
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C-terminal peptides modelling constitutive PrPC processing demonstrate
ameliorated toxicity predisposition consequent to α-cleavage
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Figure S1 Immunodetection of a fragment equivalent to N1 from RK13 cells expressing mouse PrP W144STOP (Trp144→stop)
To investigate the possibility of α-cleavage occurring within the mutant protein, transiently transfected wild-type mouse PrP (wt), mutant mouse PrP W144STOP (144) and vector only (VO) RK13
cells were harvested after 72 h. The conditioned media, lysate and insoluble proteins were immunoprecipitated by incubating with the polyclonal antibody, 03R19.2 [1] and Dynabeads® Protein A
(Invitrogen) overnight. Dynabeads were then isolated and boiled in SDS sample buffer, and proteins were separated on a Bis-Tris NuPAGE gel followed by Western blot analysis using 03R19.2 to
detect PrP protein fragments; (A) 10 s exposure, (B) 5 min exposure. The double-headed arrow in (B) denotes a PrP band with immunoreactivity and electrophoretic mobility indicating it to be N1,
as has been characterized previously in wt PrP-expressing cells [2]. SDS/PAGE and Western blot analysis revealed low levels of a fragment from the conditioned media (M) and soluble cell lysate
(L) of PrP W144STOP transiently transfected cells, which migrated at approximately 9 kDa and ran equivalent to synthetic PrP-(23–111) (used as a positive control) and a fragment observed in wt
PrP cells, indicating the N1 fragment derived from α-cleavage. Molecular masses are indicated in kDa.
1 To whom correspondence should be addressed (email stevenjc@unimelb.edu.au).
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Figure S2 Aggregation kinetics of PrP peptides: individual experiments
Each peptide was cleared from pre-formed aggregates, diluted to 30 μM in D-PBS and incubated at 37◦C with constant agitation (1200 rev./min) with excess ThT (50 μM). Amyloid fibril formation
was determined by ThT fluorescence (excitation at 444 nm and emission at 480 nm) in a fluorescence spectrophotometer using a 1-cm-pathlength quartz cell.
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Wales, Kensington, New South Wales, 2052, AustraliaABSTRACT The prion protein (PrP), widely recognized to misfold into the causative agent of the transmissible spongiform
encephalopathies, has previously been shown to bind to lipid membranes with binding influenced by both membrane composi-
tion and pH. Aside from the misfolding events associated with prion pathogenesis, PrP can undergo various posttranslational
modifications, including internal cleavage events. Alpha- and beta-cleavage of PrP produces two N-terminal fragments, N1
and N2, respectively, which interact specifically with negatively charged phospholipids at low pH. Our previous work probing
N1 and N2 interactions with supported bilayers raised the possibility that the peptides could insert deeply with minimal disruption.
In the current study we aimed to refine the binding parameters of these peptides with lipid bilayers. To this end, we used neutron
reflectometry to define the structural details of this interaction in combination with quartz crystal microbalance interrogation.
Neutron reflectometry confirmed that peptides equivalent to N1 and N2 insert into the interstitial space between the phospholipid
headgroups but do not penetrate into the acyl tail region. In accord with our previous studies, interaction was stronger for the N1
fragment than for the N2, with more peptide bound per lipid. Neutron reflectometry analysis also detected lengthening of the lipid
acyl tails, with a concurrent decrease in lipid area. This was most evident for the N1 peptide and suggests an induction of
increased lipid order in the absence of phase transition. These observations stand in clear contrast to the findings of analogous
studies of Ab and a-synuclein and thereby support the possibility of a functional role for such N-terminal fragment-membrane
interactions.INTRODUCTIONTransmissible spongiform encephalopathies (TSEs) or prion
diseases are fatal neurodegenerative diseases affecting hu-
mans and animals. Misfolded conformers of the prion
protein (PrPSc) are widely recognized as the causative agent
of TSEs with expression of wildtype or cellular prion
protein (PrPC) indispensable for disease transmission
and pathogenesis (1,2). During disease the predominantly
alpha-helical PrPC becomes misfolded into beta-sheet-rich
conformers that can template further misfolding of PrPC re-
sulting in propagation of pathogenic PrPSc.
The misfolding process has been replicated in vitro utiliz-
ing recombinant PrP (rPrP), and the development of a serial
protein misfolding amplification assay (PMCA) has made
production of misfolded rPrP highly efficient (3). However,
initial experiments with misfolded rPrP could only generateSubmitted July 7, 2014, and accepted for publication September 19, 2014.
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0006-3495/14/11/2313/12 $2.00a transmissible prion species if the PMCA reaction was
‘‘seeded’’ with infectious PrPSc taken from a disease source
(4). Such observations raised questions over the potential
role for cellular cofactors in PrPSc propagation. Various
anionic species have been suggested as cofactors in the pro-
duction of infectious prions; these have included nucleic
acids, glycosaminoglycans, and lipids (reviewed in (5,6)).
In the first study to report use of the PMCA to produce genu-
inely infectious (transmissible in animal bioassay) rPrP spe-
cies in the absence of an infectious disease-derived seed, a
combination of 1-palmitoyl-2-oleoyl-sn-glycero-3-[phos-
pho-rac-(1-glycerol)] (POPG) and nucleic acid cofactors
were required (7). In addition to the inclusion of pure phos-
pholipid species in misfolding reactions, synthetic mem-
branes of mixed lipid composition have also been
employed to mimic rPrP binding to cellular structures.
These studies have demonstrated the affinity of rPrP for
lipids, with binding invariably influenced by lipid composi-
tion, metal ion binding, and pH (8–10) and often resulting in
structural changes to rPrP that might predispose it to or
initiate misfolding (9–12).
Phospholipid-PrP binding interactions may have a
wider significance beyond protein misfolding. Although a
‘‘normal’’ PrPC function is still undetermined, suggestionshttp://dx.doi.org/10.1016/j.bpj.2014.09.027
2314 Le Brun et al.have included trafficking and signal transduction (reviewed
in (13)), functions intimately linked with membranes.
Mature PrPC is a glycosylphosphatidylinositol (GPI)-
anchored membrane protein directed to cholesterol-rich
membrane domains on the outer leaflet of the cell plasma-
membrane (14). These membrane domains are often associ-
ated with cellular signaling reactions and the control of
signal protein activation; such a localization may support a
role for PrPC in these functions. Part of the reason that eluci-
dating one individual function of PrPC has been challenging
is likely to be the influence of its posttranslational modifica-
tions. Protein cleavage is a cellular mechanism of functional
activation and deactivation. PrPC is known to undergo well-
characterized alpha- and beta-cleavage events as well as
secretory cleavage from the cell surface (14–17). Alpha-
cleavage occurs either side of residue 111 (15) producing
N1 and C1 fragments and the b-cleavage site is located
around residue 90 (18) producing N2 and C2 fragments.
The N1 and N2 fragments contain a far N-terminal polybasic
region and an octameric repeat, metal ion binding domain.
The fragments differ at their C terminus by one further poly-
basic region containing an additional metal ion binding site
that is only present in theN1 fragment. PrPC, therefore, exists
as a minimum of six different species before other posttrans-
lational modifications (such as complex glycosylation) are
considered, with the potential for differing functions of
different fragments depending on cellular environment. As
stated, posttranslational cleavage may be used for protein
activation or deactivation and, therefore, the fragments pro-
duced by these cleavages could be functional and may alter
the functional capacity of full-length PrP. Both the N1 and
N2 cleavage fragments have been demonstrated to have
neuroprotective functions (19,20), but the cleavage events
that produce them are thought to occur at different cellular
locations, with N1 produced in the Golgi (21) and N2 at
the cell surface (16), indicating their production may be
stimulated by different signals.
Our previous studies using synthetic N1 and N2 have
shown that the peptides have a propensity to interact with
anionic lipid membranes independent of the PrP globular
C terminus region (22). These studies suggested that the
liberated peptides could interact with the acyl chain core
of the bilayer membrane without substantially disrupting
the homogeneity of the lipid system and thus our previous
work raised the possibility that the peptides may insert
benignly through the bilayer. Our recent work aimed to
expand these findings by directly probing the peptide-lipid
interactions using neutron reflectometry (NR). NR directs
a beam of neutrons into a sample, measuring the intensity
of reflected neutrons as a function of momentum transfer.
The pattern of reflection in the context of membranes pro-
vides information on the thickness and composition of the
surface and from these the fluidity can be inferred by
deriving the area per lipid molecule. This technique was em-
ployed specifically for its capacity to accurately probe theBiophysical Journal 107(10) 2313–2324depth that a peptide penetrates into the bilayer, which can
be measured using isotopic labeling. Furthermore, NR is
nondestructive and nonperturbing, therefore giving a more
valid insight into the interactions within the sample. Our
findings show that both N1 and N2 interact with anionic
membranes at pH 5 as originally proposed without pore-
forming or lytic capacity but neither peptide penetrates
deeply into the membrane.MATERIALS AND METHODS








were purchased from Avanti Polar Lipids (Alabaster, AL) and used without
further purification. Lipids were dissolved in chloroform/methanol (4:1 by
volume) in glass vials to give POPC only, POPC/POPG (2:1 molar ratio),
POPC/POPS (2:1 molar ratio), and DMPC/DMPG (2:1 molar ratio) lipid
mixtures. The same lipid ratios were used for preparing vesicles with
lipids containing the d31-palmitoyl chain. The solvent was evaporated
first by blowing nitrogen over the lipid solutions and then by storing under
vacuum overnight to remove any residual solvent. The dried lipid thin films
were hydrated with a buffered solution of 10 mM MOPS, 150 mM NaCl
pH 7.0 (in 100% D2O for NR experiments) with vortex mixing to a
concentration of 0.5 mg/mL. The hydrated lipid solutions were incubated
at 25C for PO-containing lipids and 30C for DM-containing lipids
for 1 h before small unilamellar vesicleswere prepared by sonicating the lipid
solution until clear.
Fluorescent large unilamellar vesicles (LUVs) for calcein release assays
were prepared as follows. Chloroform solutions (10 mg/mL) of 1-palmi-
toyl-2-oleoyl-sn-Glycero-3-phosphcholine (POPC) and 1-palmitoyl-2-
oleoyl-sn-Glycero-3-[phospho-rac-(1-glycerol)] (POPG) were combined
(2:1 w/w) in a round-bottom flask and the solvent removed by rotary
evaporation. The lipid film was hydrated in 10 mM Tris-HCl pH 7.4
(150 mM NaCl) containing 70 mM calcein (Sigma-Aldrich Pty Ltd,
Sydney, Australia) for 1 h at 40C with gentle agitation. The multilamellar
dispersion was freeze-thawed in liquid nitrogen five times, then extruded
through a 100 nm polycarbonate membrane 11 times. The resultant cal-
cein-loaded LUVs were passed through a column of Sephadex G25 resin
(Sigma) preequilibrated with 50 mM Na/K acetate pH 5.2 (130 mM
NaCl) to remove free calcein from the solution. Calcein-loaded LUVs
were diluted to a concentration of ca. 50 mM in acetate buffer immediately
before use.
The mouse PrP amino acid sequence was used to generate peptide frag-
ments corresponding to N1 (23-111) and N2 (23-90) cleavage fragments.
The Peptide Technology Laboratory (Bio21 Institute, University of
Melbourne) used microwave synthesis to prepare the peptides as previously
described (23). Verification of the peptide sequence and purity was per-
formed by HPLC and mass spectrometry. Freeze-dried peptides were dis-
solved in buffer (17 mM sodium acetate, 150 mM NaCl pH 5.0) to a
concentration of 10 mM immediately before use.Neutron reflectometry experiments and data
analysis
Polished n-type circular silicon wafers 100 mm in diam. and 10 mm thick
(El-Cat Inc., Ridgefield Park, NJ) were cleaned for 1 h at 85C in a strongly
Neutron Reflectometry of PrP Peptides 2315acidic ‘‘piranha’’ solution of H2O/H2SO4/H2O2 (4:3:1 by volume) to re-
move surface impurities. After cleaning in the corrosive acid solution, the
silicon wafers were rinsed in Milli-Q water and dried before being UV-
ozone cleaned for 20 min. A final rinse with Milli-Q water and propan-
2-ol was carried out before drying under a stream of nitrogen. The silicon
wafers were assembled in aluminum cells with a silicon backing plate,
which had a 50 mm deep solvent reservoir and inlet and outlet tubes to allow
for solvent/sample exchange.
Neutron reflectivity data were measured using the Platypus time-of-
flight neutron reflectometer and a cold neutron spectrum (2.8 Å % l %
18.0 Å) at the OPAL 20 MW research reactor (Sydney, Australia)
(24,25). Neutron pulses of 20 Hz were generated using a disc chopper sys-
tem (EADS Astrium GmbH, Munich, Germany) in the low resolution
mode (Dl/l ¼ 8%), and recorded on a two-dimensional 3He neutron de-
tector (Denex GmbH, Lüneburg, Germany). Reflected beam spectra were
collected for each of the surfaces at 0.45 for 15 min (0.72 mm slits), 1.6
for 45 min (2.56 mm slits), and 4.5 for 2 h (7.2 mm slits), respectively.
Direct beam measurements were collected under the same collimation
conditions for 1 h each. The data were reduced using the Slim reduc-
tion package, which stitches the three data sets together at the appro-
priate overlap region, re-bins the data at instrument resolution and
corrects for background and detector efficiency (26). The final scaled re-
flectivity, R, is presented as a function of momentum transfer, Q, defined
as follows:
Q ¼ 4p sinq
l
where q is the angle of incidence and l is the neutron wavelength. The re-
flectivity data was multiplied by Q4 to remove the Fresnel reflectivity andthus final reflectivity data presented as RQ4 versus Q.
Structural parameters for the native oxide layer on the silicon blocks,
lipid bilayer, and peptide layers were refined using the MOTOFIT reflectiv-
ity analysis software (27). In the fitting routines, the genetic algorithm was
selected to minimize c2 values by varying the thickness (t), roughness (s),
and neutron scattering length density (nSLD) of each layer. Model fitting of
the resulting reflectivity profiles yields information on the real space
neutron scattering length density profile normal to the surface, from which
the structure of a lipid bilayer may be deduced. The nSLD, r, can be consid-
ered as a neutron refractive index and is a function of the chemical compo-







where NA is Avogadro’s number, pi is the mass density, Ai is the atomic
mass, and bi is the nuclear scattering length of component i. The errorsgenerated in the analysis software are51 standard deviation of the param-
eter value from which the percentage error was calculated. The advantage
of using neutrons, particularly for soft matter and biological systems, is the
difference in scattering length between hydrogen (bH ¼ -3.74 105 Å)
and its isotope deuterium (bD ¼ þ6.67 105 Å). By selective deuteration
of molecules (in this case the palmitoyl tails) different segments of the lipid
bilayer can be probed by choosing a suitable solvent contrast. We used
either a pure D2O solvent contrast (r ¼ 6.35 106 Å-2) to highlight the
protonated peptide or pure H2O (r ¼ -0.56 106 Å-2) to highlight the
partially deuterated lipid chains. When changing between different sub-
phase contrasts, the physical structure of the system is assumed not to
change. This means that the thickness and roughness parameters in the
models are constrained to be the same between each subphase while
only letting the scattering length density vary. This form of simultaneous
fitting provides for a unique solution to the model. The nSLD on each










where 4 is the volume fraction of each component. Once the volume
fraction has been determined the surface excess, G, of each component
(in mol m2) can be calculated from the following:
G ¼ 4t
VNA
where V is the molecular volume. From the surface of excess the lipid to
peptide ratio can be deduced.For consideration of changes in lipid order, the area per lipid molecule,




where V is the molecular volume of the lipid (1230 Å3 for POPC/POPG
bilayers and 1226 Å3 for POPC/POPS bilayers (28–30), 4 is the volumefraction, and t is half the total bilayer thickness. The values used to calcu-
late parameters can be found in Table S1 in the Supporting Material.Quartz crystal microbalance (QCM) experiments
and analysis
The Q-senseE4 instrument (Q-Sense, Gothenburg, Sweden) fitted with a
peristaltic pump (Ismatec SA, Glattbrugg, Switzerland) used a flow rate
of 100 mL min1, a constant temperature of 22C, and silicon dioxide-
coated sensor crystals (QSX-303, Q-sense). The sensor crystals were
cleaned by UV-ozone for 20 min, rinsing with 2% (v/v) Hellmanex fol-
lowed by copious rinsing with > 18 MU water and drying under nitrogen.
The sensors underwent a final clean using UV-ozone for 20 min immedi-
ately before use. The piezoelectric quartz crystal was excited at its
fundamental frequency (5 MHz) and the change in frequency (Df) was
observed for the third, fifth, seventh, ninth, eleventh, and thirteenth over-
tones. Data was collected using QSoft401 software and processed into fre-
quency and dissipation versus time data using Q-Tools 301 v2.1. A decrease
in frequency corresponds to an increased mass on the surface of the sensor.
For rigid films with little water content that have minimal changes in dissi-
pation (< 1), the Sauerbrey equation can be used to relate mass (Dm) and








where rq is the density of quartz (2648 kg m
3), vq is the speed of sound
through quartz (3340 m s1), F is the fundamental frequency (5 MHz),and n is the overtone number. For each overtone the change in dissipation
(DD) was also measured. The dissipation is the proportion of energy dissi-
pated during one cycle of the frequency oscillation and provides informa-
tion on the viscoelastic properties of the materials deposited on the
sensor surface. For films that are nonrigid and have a dissipation that is
large (> 1), the Sauerbrey equation is no longer valid.
Vesicles prepared in buffer (50 mM sodium acetate/acetic acid pH 5.2,
130 mM NaCl) were deposited onto the silicon dioxide surface. Once the
vesicles had ruptured and the bilayer formed, the excess lipid was removed
with a buffer wash. Peptide at 10 mM prepared in the same buffer was added
and incubated on the bilayer for 60 min after which the excess peptide was
removed with a buffer wash.Calcein Release Measurements
For each condition, 95 mL of calcein-loaded LUVs was added to a black
96-narrow-well plate and the initial fluorescence (f0) monitored using a
POLARstar OPTIMA microplate reader (BMG LABTECH, Ortenberg,
Germany) using 480 5 10 nm excitation and 520 5 20 nm emission fil-
ters. Following addition of 5 mL peptide (100 mM N1, N2, or melittinBiophysical Journal 107(10) 2313–2324
2316 Le Brun et al.dissolved in MQ grade water), the solution briefly mixed by pipetting up
and down the fluorescence signal was further monitored as a function of
time. Finally, 5 mL Triton X-100 (10% v/v) was added to determine the
maximum fluorescence response (f1). The normalized fluorescence (f’)
was obtained from the raw fluorescence signal (f) using the following
expression:
f 0ðtÞ ¼ ½f ðtÞ  f0=½f1  f0:
RESULTS
NR is an established technique for studying the structure
of solid-supported phospholipid bilayers along the axis
perpendicular to the plane of the bilayer (the z-axis)
(31,32). The bilayers were generated using the vesicle depo-
sition technique (33) onto silicon oxide surfaces typically
15 5 1 Å thick and with an interfacial roughness of 3 Å.
In these experiments we used mono-unsaturated diacyl
phospholipids where the palmitoyl chain was deuterated
so that there was contrast against the hydrogenous peptides.
For modeling the bilayer data, the bilayers were separated
into three discrete layers: headgroup one (closest to the
silicon oxide surface), acyl tails, and headgroup two (closest
to the bulk solvent). A 3 to 7 Å solvent layer between the
silicon oxide surface and headgroup one was included in
the model for each bilayer as previously described
(34,35). The experiments were conducted at room tempera-
ture, which is above the phase transition temperature of
POPC, POPG, and POPS (Tm of -2
C, -2C, and 14C,
respectively) and thus the bilayers were in the fluid (La)
phase. The thickness of the bilayers ranged from 38 5




(no peptide) / Å 4lipid (no peptide)
Thickness (peptide
bound) / Å
d31-POPC/d31-POPG (2:1) bilayer þ N1 peptide
Headgroup 1 15 5 1 0.94 5 0.02 18 5 1
Tails 20 5 1 1.00 5 0.02 23 5 1
Headgroup 2 10 5 1 0.41 5 0.02 7 5 1
Peptide - - 21 5 2
d31-POPC/d31-POPS (2:1) bilayer þ N1 peptide
Headgroup 1 7 5 1 0.94 5 0.06 8 5 1
Tails 20 5 1 1.00 5 0.02 29 5 1
Headgroup 2 11 5 1 0.94 5 0.03 9 5 1
Peptide - - 21 5 1
d31-POPC/d31-POPG (2:1) bilayer þ N2 peptide
Headgroup 1 7 5 1 0.56 5 0.01 7 5 1
Tails 27 5 1 1.00 5 0.02 31 5 1
Headgroup 2 11 5 1 0.86 5 0.03 12 5 1
Peptide - - 27 5 3
d31-POPC/d31-POPS (2:1) bilayer þ N2 peptide
Headgroup 1 13 5 1 0.89 5 0.02 12 5 1
Tails 26 5 1 0.98 5 0.01 27 5 1
Headgroup 2 18 5 1 0.24 5 0.02 16 5 1
Peptide - - 20 5 2
Biophysical Journal 107(10) 2313–2324area per lipid molecule ranged from 35 to 47 Å2 in the tail
region. These observations are consistent with molecular
dynamics simulation data of POPC bilayers in the fluid
phase (28).
For all NR experiments a peptide concentration of
10 mM in a pH 5.0 buffer was employed, which has been
previously shown to be effective for binding to anionic bi-
layers (18). The approach used was bilayer formation and
characterization after which peptide was incubated on the
surface and then the excess removed with a pH 5.0
buffer wash in either D2O or H2O. When both the N1
and N2 peptides were added to zwitterionic d31-POPC bi-
layers, no change in reflectivity was observed (Fig. S1)
and no presence of peptide is observed in the correspond-
ing real space nSLD profile. This corresponds with previ-
ous data that the N1 and N2 peptides do not bind to
zwitterionic bilayers (22).
When the N1 peptide was added to the negatively
charged d31-POPC/d31-POPG (2:1 molar ratio) bilayer, a
reduction in the intensity of the fringe at Q ¼ 0.101 Å-1
was observed along with a slight shift in fringe position
to a lower value of Q by 0.01 Å-1 (compare black and
red reflectivity profiles in Fig. 1 A). These changes indicate
that the N1 peptide bound to the d31-POPC/d31-POPG
bilayer without dramatic structural changes to the bilayer.
A similar effect was observed when the N1 peptide was
added to a d31-POPC/d31-POPS (2:1 molar ratio) bilayer;
however, the reduction in the intensity was less than
for d31-POPG-containing bilayers suggesting that less
peptide was bound to the bilayer (Fig. 1 B). The modeling
of the data to produce the real-space nSLD profiles
provided more details on the membrane-bound peptideth and without N1 and N2 peptide bound from the fitting of the
4lipid (peptide
bound) 4peptide Glipid / mmol m
2 Gpeptide / mmol m
2
0.75 5 0.01 - 7.46 5 0.12 -
1.00 5 0.01 - 4.11 5 0.01 -
0.10 5 0.01 0.47 5 0.01 0.39 5 0.01 0.07 5 0.01
- 0.15 5 0.01 - 0.08 5 0.01
0.99 5 0.03 - 4.58 5 0.16 -
0.97 5 0.01 - 4.85 5 0.05 -
0.08 5 0.01 0.47 5 0.01 0.42 5 0.01 0.07 5 0.01
- 0.25 5 0.01 - 0.08 5 0.01
0.56 5 0.02 - 2.30 5 0.09 -
1.00 5 0.02 - 5.38 5 0.12 -
0.14 5 0.05 0.33 5 0.01 0.90 5 0.03 0.08 5 0.01
- 0.20 5 0.03 - 0.12 5 0.01
0.78 5 0.02 - 5.44 5 0.11 -
0.89 5 0.01 - 4.17 5 0.05 -
0.20 5 0.01 0.53 5 0.01 1.90 5 0.03 0.18 5 0.01
0 0.28 5 0.01 - 0.12 5 0.01
FIGURE 1 Neutron reflectometry of the N1
peptide binding to solid-supported phospholipid
bilayers on silicon: (a) d31-POPC/d31-POPG (2:1)
bilayer, (b) d31-POPC/d31-POPS (2:1) bilayer, the
symbols with error bars are the data and the solid
lines the fit. The corresponding real-space nSLD
profile from the fits is also shown: (c) d31-POPC/
d31-POPG (2:1) bilayer, (d) d31-POPC/d31-POPS
(2:1) bilayer. The dashed vertical lines delineate
the different layers in the peptide bound state. In
all panels black (B) is bilayer before N1 peptide
addition in D2O, red (,) is bilayer with N1 pep-
tide bound in D2O, and green (6) is bilayer with
peptide bound in H2O. To see this figure in color,
go online.
Neutron Reflectometry of PrP Peptides 2317(Fig. 1 C and D). There was no change in the nSLD of the
acyl tails region before peptide addition or when peptide
was bound to both the d31-POPG- and d31-POPS-contain-
ing bilayers in the D2O contrast. This shows that the N1
peptide does not penetrate into the bilayer acyl tail layer.
Additionally, changing the isotopic contrast to H2O in the
presence of the N1 peptide also showed no isotopic-depen-
dent change in the nSLD of the bilayer tails region, which
further confirms the acyl tails layer is devoid of peptide
and that there is no detectable pore-formation by the pep-
tide. The calculated volume fractions of the lipid tails
before and after peptide addition showed that there was
no loss of lipid from the surface (Table 1), also suggesting
no detectable peptide action through the membrane lysis
process known as the ‘‘carpet mechanism’’ (36). The
most profound effect that the N1 peptide had on both
bilayers was in the outer headgroups of the phospholipids.
The N1 peptide was present in this region along with
solvent. Using the volume fractions of lipid and peptide,
the surface excess and lipid-to-peptide ratio for the outer
headgroup was calculated. From the lipid-to-peptide ratios
in Fig. 2 it can be seen that a higher amount of peptide is
bound to the d31-POPG-containing bilayer than the d31-
POPS-containing bilayer, indicating a stronger interactionbetween d31-POPG and the N1 peptide than for d31-
POPS. Both bilayers have a 21 Å layer of peptide above
membrane. The peptide layer is not dense; having a
peptide volume fraction of 0.15 and therefore a high sol-
vent content (Table 1). A further observation was that the
thickness of the acyl tail zone was increased on peptide
binding, indicating a potential increase in lipid ordering
(Table 1). This was also evident as a contraction of the
area per lipid molecule of the membrane following peptide
addition (Table 2), but no phase transition of the lipids was
seen.
NR showed the N2 peptide displayed similar behavior to
the N1 peptide when binding to negatively charged phos-
pholipid bilayers. As with the N1 peptide, when N2 was
bound to solid-supported bilayers the intensity of the fringe
at Q ~ 0.1 Å-1 decreased suggesting that the N2 peptide
bound to the bilayer (Fig. 3 A and B). For the H2O contrast
in the d31-POPC/d31-POPS bilayer with N2 bound (Fig.3
B) the background of the data points did not match the
fitted curve; however, the fit is still within a reasonable
c2 value of 1.24. When the background was constrained,
a poorer fit that was not biologically credible resulted.
The real-space nSLD profile showed no presence of pep-
tide in the acyl tail region for both d31-POPC/d31-POPGBiophysical Journal 107(10) 2313–2324
FIGURE 2 The lipid-to-peptide ratio of N1 and N2 peptides in the outer
headgroups in anionic phospholipid bilayers as determined from neutron
reflectometry data.
2318 Le Brun et al.bilayer and d31-POPC/d31-POPS bilayers (Fig. 3 C and D).
The d31-POPS-containing bilayer showed an isotopic
dependent change in the tail layer when changing between
the D2O and H2O contrasts, highlighting the presence of
solvent in the tail region (Fig. 3 D). The volume fraction
of the solvent in the tail region of the d31-POPC/d31-
POPS bilayer was 0.11 with the lipid volume fraction
reducing down to 0.89 indicting some loss of lipid material
from the surface. This marginal loss of lipid material over
the period that the peptide was bound to the bilayer (~ 7 h)
makes it unlikely that the N2 peptide has any lytic or pore-
forming mechanism. The predominant binding of the N2
peptide was at the outer headgroups forming a peptide
layer above the bilayer in both negatively charged mem-
branes. The lipid-to-peptide ratio of the N2 peptide in the
outer headgroup region for each bilayer was calculated.
Fig. 2 shows that there was essentially no difference in
the lipid-to-peptide ratio between d31-POPG- or d31-
POPS-containing bilayers. However, the lipid-to-peptide
ratio of N1 was higher than N2 in both cases indicating
less N2 bound to the bilayer than N1.
The NR data clearly indicates that the N1 and N2 pep-
tides do not insert into the hydrophobic tail region of a
phospholipid bilayer. To further confirm the absence of
tail insertion by the N1 and N2 peptides (and to ensure
the current results were not because of batch variation in
peptides), we conducted QCM-D experiments comparingTABLE 2 The change in area per lipid molecule upon binding






POPC / POPG (2:1) N1 55 5 4 51 5 4
POPC / POPS (2:1) N1 65 5 7 54 5 4
POPC / POPG (2:1) N2 55 5 5 49 5 4
POPC / POPS (2:1) N2 44 5 3 50 5 3
Biophysical Journal 107(10) 2313–2324the N1 and N2 fragments with melittin from bee venom, a
peptide known to insert into the hydrophobic tails of anionic
phospholipid bilayers (37). Fig. S2 shows that when melittin
is added to a bilayer of POPC/POPG (2:1) or POPC/POPS
(2:1) the dissipation increases, the overtones no longer over-
lap, and the Sauerbrey equation is no longer valid as is
consistent with recent publications (38). This is indicative
of the vibration of the bilayer no longer being in concert
with the vibrations of the oscillating quartz crystal because
of the increased hydration of the bilayer. Although the
mass of the bound melittin cannot be determined through
the use of the Sauerbrey equation, the frequency of each
overtone remains more negative than the frequency of the
bilayer. This shows that there is an overall mass gain sug-
gesting the increased hydration of the bilayer rather than
loss of lipid material from the surface (which would result
in a less negative frequency than the initial bilayer). As
can be seen, the QCM-D trace for the addition of melittin
was very different from that of either the N1 or N2 peptides
binding to anionic bilayers (Fig. 4). The QCM-D traces for
the N1 and N2 peptides (N2 trace presented in Fig. 4 and
tabulated results shown in Table S4) show an overall mass
gain on the bilayer indicating no lytic action by the peptides
and all the overtones overlap with a low dissipation indi-
cating that the bilayer was intact and had not changed its
hydration state. Control QCM-D experiments were also
conducted with DM lipids with no differences found from
the PO lipids (Table S4). By plotting Df versus DD, time
is excluded as a parameter and the plot shows how the lipid
bilayer structure changes per unit of peptide mass added.
This provides a ‘‘finger print’’ of the mechanistic action of
peptides with lipid bilayers (39). Fig. 5 shows the Df-DD
plots for N1 and N2 binding to both the POPG and
POPS-containing bilayers. The origin of the each graph in
Fig. 5 is the point of peptide addition (the point marked
PA in Fig. 4 A). In all cases there is a linear increase of
DD with increasing mass (i.e., a more negative Df) as the
peptide is binding to the bilayer until the lipid bilayers are
saturated with peptide and there is no further change in
Df or DD resulting in the large cluster of data points on
the right-hand of each graph. The shape of data in Fig. 5
is indicative of peptides that have minimal structural impact
on lipid bilayers and is similar to the nonlytic peptides api-
daecin (40) and oncocin (41). Finally, to further ensure min-
imal membrane perturbation and no lytic activity of the
peptides calcein release from LUVs in response to the N1
and N2 peptides was compared with the action of melittin
in POPC and POPC/POPG (2:1) vesicles (Fig. 6). No
change from baseline fluorescence was seen for the POPC
LUVs and minimal fluctuation was measured for the
POPC/POPG LUVs when exposed to the N1 and N2 pep-
tides compared with melittin, which demonstrated rapid
and almost complete release. These results further exclude
pore-formation by N1 or N2 and confirm our previous
findings.
FIGURE 3 Neutron reflectometry of the N2 pep-
tide binding to solid-supported phospholipid bila-
yers on silicon: (a) d31-POPC/d31-POPG (2:1)
bilayer, (b) d31-POPC/d31-POPS (2:1) bilayer, the
symbols with error bars are the data and the solid
lines the fit. The corresponding real-space nSLD
profile from the fits is also shown: (c) d31-POPC/
d31-POPG (2:1) bilayer, (d) d31-POPC/d31-POPS
(2:1) bilayer. The dashed vertical lines delineate
the different layers in the peptide bound state. In
all panels black (B) is bilayer before peptide addi-
tion in D2O, red (,) is bilayer with N2 peptide
bound in D2O, and green (6) is bilayer with N2
peptide bound in H2O. To see this figure in color,
go online.
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The NR data presented in the current study confirm the bind-
ing capabilities of the N1 and N2 endogenous cleavage frag-
ments to phospholipid model membranes and further defines
the specific engagement and changes to the lipid environ-
ment upon peptide binding. Our previous work showed in-
teractions of the N1 and N2 peptides with anionic lipids
that were consistent with either benign uniform insertion
of the peptide across the bilayer or no insertion with peptide
bound to the surface of the bilayer causing lipid ordering
(22). Previous studies using 2H-solid-state NMR with only
the palmitoyl chain of the POPC lipid labeled with deute-
rium in a 2:1 mixture of POPC:POPS were only able to
report on the ordering effect on 33% of the tails in the lipid
mixture. The 2H chemical shift anisotropy increased from
23.2 kHz for lipid only to 25.6 and 24.4 kHz in the presence
of N1 and N2, respectively, indicating an ordering of the
palmitoyl tails in POPC. This modest increase in ordering
could reflect peptides inserting into the lipid tails; however,
the increases did not account for a substantial perturbation
in the freedom of movement of the palmitoyl tails associated
with bilayer disruption and could suggest that the N1 and N2
peptides do not interact with the bulk lipid bilayer (22). In
the study all parts of the lipid bilayer and the peptide wereobserved providing a complete picture and strong support
that the latter situation is true, finding that binding was pri-
marily in the outer headgroup region with no penetration
into the acyl tails, and also confirmed that the binding affin-
ity is greater for N1 than N2 on both the POPS/POPC and
POPG/POPC bilayers, most likely because of the additional
polybasic region at the C terminus of the N1 peptide (15).
Therefore, these data continue to support a nonperturbing
PrP N1/N2-lipid interaction and are not consistent with
the peptide causing bilayer damage by other lipid disrup-
tions such as the carpet mechanism (36).
Our findings contrast with NR studies of the neurotoxic
peptide amyloid-beta (Ab) found in Alzheimer’s disease
that, in combination with atomic force microscopy, shows
globular aggregates of freshly prepared Ab1-40, Ab1-42,
or both are adsorbed to the membrane and disruptively pene-
trate into the core increasing hydration (42). Further, once
the Ab has initially inserted into the hydrophobic core of
negatively charged lipids, causing disordering of the lipids,
an induction of folding and template assembly of Ab fibrils
occurs (43). As with the N1 and N2 peptides, Ab forms a
peptide layer on the surface of the lipid bilayer. However,
with Ab, a thicker (~ 40 Å), more crystalline layer is formed
than observed with N1 and N2 (43). The binding parameters
of the N1 and N2 peptides also differ from those ofBiophysical Journal 107(10) 2313–2324
FIGURE 4 The QCM-D of 10 mM N2 peptide
binding to a phospholipid bilayer of POPC/POPS
(2:1). The upper panel shows the Df trace on the
left (black trace) and the DD trace is shown on
the right (red trace). The 3rd, 5th, 7th, 9th, 11th,
and 13th overtones are shown but are indistin-
guishable as all overtones overlap. The lower panel
shows the corresponding Sauerbrey mass at
each step of the measurement with final masses
deposited indicated. VD—vesicle deposition,
VR—vesicle rupture, BF—bilayer formation,
BW—buffer wash, PA—peptide addition. To see
this figure in color, go online.
2320 Le Brun et al.a-synuclein, which forms intracellular aggregates called
Lewy bodies in Parkinson’s disease. Similar to N1 and
N2, a-synuclein mainly embeds in the outer headgroups
of mixed lipid bilayers containing anionic lipids, with a
greater binding affinity seen at lower pH (44), but its mem-
brane interaction causes thinning of the bilayer rather than
the thickening effect seen for the PrP fragments. Also, bind-
ing to lipid membranes is known to induce a helical second-Biophysical Journal 107(10) 2313–2324ary structure of a-synuclein (45), although we previously
observed the formation of increased beta-sheet secondary
structure on binding of N2 to PC/PS (22). The structural
change of a-synuclein and its lipid interactions is thought
to be involved in disease pathogenesis (46). A similar situ-
ation is unlikely to be true for N1 and N2 given these frag-
ments do not contain the amyloidogenic region of PrP and
the data presented indicate that the membrane binding
FIGURE 5 Df-DD plots from the QCM-D data
of (a) 10 mM N1 or (b) N2 binding to POPC/
POPS (2:1) bilayers, or binding to (c and d)
POPC/POPG (2:1) bilayers. The data shown is
from the 3rd (black), 5th (red), 7th (green), 9th
(blue), 11th (magenta), and 13th (cyan) overtones.
To see this figure in color, go online.
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mally perturbing and would not be expected to be directly
toxic to cells. Indeed viability studies in cells have shown
that these peptides do not cause lysis and are not toxic
but instead demonstrate cytoprotective properties (19,20).
Considering these properties, and that the N1/N2 binding
events show no evidence of being acutely damaging to
membranes, these interactions may be relevant to the
cellular functions of these fragments and/or full-length PrP.
Analysis of the NR data of N1 and N2 peptide binding to
POPG and N1 binding to POPS containing membranes
showed that there was a thickening of the lipid bilayer,
reducing the area per lipid. Such changes are indicative of
an ordering of the lipids in the absence of a phase transition.
Changes in lipid order are required for the formation of scaf-
folds for protein binding and the assembly of multimeric
protein complexes, such as those associated with Annexin
A6 (47), which through structuring membrane domains
and linking with actin were found to be involved in mem-
brane repair. Interestingly, PrPC has been reported to bind
to a number of proteins, with the N-terminal region (resi-
dues 23–32) also containing a tubulin binding site (48), indi-
cating that full length PrPC and the N1 and N2 fragments
could link a protein scaffold to lipid membrane domains
and result in membrane ordering events under specific cir-
cumstances. The membrane ordering changes were not
observed for the N2 peptide with the POPS-containingmembrane. This may have a technical basis, most likely
because of the small loss of lipid from the bilayer over the
time of the experiment. We do not believe that this neces-
sarily represents a biologically relevant event as the NR ex-
periments were run over a period of hours but we have
previously shown that the half-life of this peptide in cell sys-
tems is very short, approximately minutes (20), and there-
fore it is unlikely to persist for sufficiently long times to
cause such an effect in vivo.
The N-terminal domain of PrPC has been shown to con-
trol PrPC membrane relocalization from lipid rafts and
subsequent clathrin mediated internalization (49). The for-
mation of protein scaffolds supporting tubule formation
for budding of trafficking vesicles requires organization of
the lipid membrane domain to which the protein scaffold
attaches. The ability to engage a lipid scaffold may be
highly important for the trafficking of full-length PrPC and
potentially the N-terminal cleavage fragments. However,
the absolute dependence on low pH for the observed mem-
brane interactions suggests that any physiological role of N1
or N2 interaction with anionic lipids is likely to occur inside
the cell in organelles of increased acidity. N-terminal inter-
actions may also direct trafficking once inside the cell. A pH
of 5 is representative of the pH within late endosomes, from
which PrPC might undergo retrograde transportation to the
Golgi (50), be transferred to recycling endosomes or multi-
vesicular bodies, or it may be targeted to lysosomes forBiophysical Journal 107(10) 2313–2324
FIGURE 6 Calcein release from (a) POPC or (b) POPC/POPG (2:1)
LUVs when exposed to N1 (blue), N2 (green), or melittin (red) peptides.
Triton X-100 was added to demonstrate maximum release. To see this
figure in color, go online.
2322 Le Brun et al.destruction. N-terminal engagement with intracellular
membranes may therefore be as part of an endosomal sort-
ing signal and direct the final destination of PrPC and/or its
N-terminal cleavage fragments. A role in membrane interac-
tion that directs intracellular trafficking might also account
for intricate changes that alter exosomal membrane struc-
ture during prion disease (51). Exosomes are formed
through membrane fission from multivesicular bodies (52)
to which PrPC may become directed by endosomal traf-
ficking. Notably, N-terminal processing of PrPC is altered
in exosomes from prion-infected cells (53).
Ordering of lipids is also seen in the formation of mem-
brane signaling complexes. An alternative hypothesis to
N1 and N2 being involved in dictating intracellular traf-
ficking is that their endocytosis is required to permit the for-
mation of membrane signaling complexes. Endosomes are
known to have a role in cellular signaling, controlling the
‘‘off’’ and ‘‘on’’ of some pathways (54). The pathways acti-
vated or deactivated are influenced by their type, maturity
and cellular location (55). We have found that the protectiveBiophysical Journal 107(10) 2313–2324signaling of N2 is transduced through MEK1 only after
correct engagement of its internalization pathways (C. L.
Haigh, unpublished observations). Therefore, endocytosis
of N1 and/or N2 may instigate a lipid-protein engagement
that facilitates intracellular signaling.
Although the observed membrane interactions of the
N-terminal peptides did not indicate that such contact could
be responsible for toxicity during disease, they may still be
relevant to pathogenesis in the context of PrP misfolding.
The involvement of POPG in the formation of genuinely in-
fectious misfolded rPrP (7,56) suggests that the ability of
PrP to bind these lipids as a full-length protein could be
important for the generation of prions. Misfolding during
prion disease is significantly more efficient if the N-terminal
regions of PrP are present (57), and it has been shown that
POPG binding to rPrP results in a structural change that ex-
poses a cryptic binding site for the N-terminal polybasic
region that may enhance further rPrP recruitment and tem-
plated misfolding (58). In cell cultures, high levels of PrP
a-cleavage confer resistance to prion infection (59), most
likely because the C1 fragment serves as a suboptimal sub-
strate for misfolding; however, b-cleavage is seen to be
increased during disease (18). In a cellular context, a greater
ratio of C2 to full length PrP could result in aberrant mem-
brane binding of C2, permitting conformational change and
thus enhanced production of misfolded PrP during disease.
b-cleavage leaves the core of misfolded PrP intact and C2
retains the second polybasic site that might substitute for
23-28. Studies considering rPrP fragments equivalent to
the C2 region of PrPC have shown that the ability to bind
lipids and misfold is maintained (60). Additionally, the
central domain has a significant role in lipid binding in
full-length PrPC and is influenced by disease-associated
mutations of the proline residues at 102 and 105 (mouse
sequence) to leucine residues (61). This supports that the
N1 peptide should have a greater capacity to bind lipids
than the N2 fragment that lacks this central domain,
although disruption of lipid membranes is only observed
for misfolded and aggregated rPrP, not for monomeric
rPrP (60), supporting that N1 or N2 are unlikely to be mem-
brane disruptive in vivo. When the N2 peptide was added to
cells in culture at high concentrations (10 mM), a very small
amount of dimer could be visualized by western blotting
but no higher molecular weight oligomers, which were
observed for a peptide with the prolines of the 23-28 poly-
basic region mutated to alanines (20). This indicates that
the propensity for the N-terminal fragments to oligomerise
and for any putative oligomers to cause membrane damage
is also low.
Much previous work looking at PrPC and lipid binding
has focused on full-length recombinant PrP, thus remaining
open to the criticism that, because rPrP is not GPI-anchored
or complex glycosylated, it may not be accurately represen-
tative. The peptides used in the current study are representa-
tive of genuine cleavage fragments that occur in the brain
Neutron Reflectometry of PrP Peptides 2323(18), separating the N-terminus from the structured, glyco-
sylated, and membrane-anchored C terminus, and the data
therefore present a stronger argument for how these
cleavage fragments interact with cell membranes. Both
N-terminal cleavage fragments have been shown to have
neuroprotective functions and therefore lipid binding
interactions could be crucial for these peptides to effect
protection. The binding parameters of full length PrPC,
especially in the context of membrane anchoring, remain
to be determined; however, the data presented herein sug-
gest that specific lipid binding interactions could potentially
be corrupted during prion disease, when the cleavage events
shift toward greater b-cleavage.CONCLUSION
The new data generated by NR support our previous findings
that endogenous PrP N-terminal cleavage fragments can
interact with negatively charged supported phospholipid bi-
layers at low physiological pH. We further show that this
interaction lies predominantly at the level of the phospho-
lipid headgroups with no clear penetration into the acyl
tail plane and without damage to the structural integrity of
the membrane but with induction of a domain ordering
effect. These observations stand in clear contrast to the find-
ings of analogous studies of Ab and a-synuclein and thereby
support the possibility of a functional role for such N-termi-
nal fragment-membrane interactions.SUPPORTING MATERIAL
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Abstract The prion protein (PrPC) when mis-folded is
causally linked with a group of fatal neurodegenerative
diseases called transmissible spongiform encephalopathies
or prion diseases. PrPC normal function is still incompletely
defined with such investigations complicated by PrPC post-
translational modifications, such as internal cleavage, which
feasibly could change, activate, or deactivate the function of
this protein. Oxidative stress induces b-cleavage and the
N-terminal product of this cleavage event, N2, demonstrates
a cellular protective response against oxidative stress. The
mechanisms by which N2 mediates cellular antioxidant
protection were investigated within an in vitro cell model.
N2 protection was regulated by copper binding to the oc-
tarepeat domain, directing the route of internalisation, which
stimulated MEK1 signalling. Precise membrane interactions
of N2, determined by copper saturation, and involving both
the copper-co-ordinating octarepeat region and the structure
conferred upon the N-terminal polybasic region by the
proline motif, were essential for the correct engagement of
this pathway. The phenomenon of PrPC post-translational
modification, such as cleavage and copper co-ordination, as
a molecular ‘‘switch’’ for activation or deactivation of cer-
tain functions provides new insight into the apparent multi-
functionality of PrPC.
Keywords CJD  N-terminus  PrP23-89  Beta-cleavage 
Reactive oxygen species  Signal transduction 
Mitogen-activated protein kinase
Introduction
Prion diseases, fatal and transmissible neurodegenerative
diseases of humans and animals, are causally linked with the
prion protein (PrP). The disease-associated isoforms of the
prion protein (PrPSc) are conformationally altered forms of a
‘normal’ cellular protein (PrPC). The predominant central
nervous system function of PrPC is as yet undefined; however,
various studies have reported a neuroprotective role [1–7].
PrPC undergoes at least two internal cleavage events, termed
a- and b-cleavage, producing N1/C1 and N2/C2 fragment
pairs, respectively [8, 9]. Diversity in functionality of the
different PrP fragments, may contribute to the difficulties in
assigning one single function to PrPC with each fragment
potentially exerting unique effects on the cell. Hence, the
possibility that PrPC cleavage acts as a post-translational
molecular ‘‘switch’’ has been suggested [10, 11].
The products of PrPC b-cleavage are increased in human
prion-diseased brains and mouse models of prion disease,
concurrent with the appearance of PrPSc, and therefore, PrPC
b-cleavage has been mainly considered a likely pathogenic
event [9, 12, 13]. However, inability to undergo b-cleavage
has been shown to render cells in culture more vulnerable
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during times of oxidative stress, when an imbalance
between reactive oxygen species (ROS) production and
detoxification causes cell damage leading to death [14].
During the course of prion infection, oxidative damage
occurs in the brain paralleling increased deposition of PrPRes
(a protease-resistant species of PrP considered a biochemi-
cal marker for PrPSc; [12]) and cellular compensation
responses are essential for maintaining homoeostasis and
viability in chronically infected cultured cells [15, 16].
Significantly, the b-cleavage event, itself, is caused by ROS
[17] and, therefore, in contrast to being a toxic event of prion
disease, this endoproteolysis may form part of a cellular
protective response against heightened oxidative stress.
Recently the N-terminus of PrP has received consider-
able attention with diverse findings demonstrating that it is
integral to PrPSc-mediated toxicity [18, 19], influences
conversion of PrPC to PrPSc [20–22], exerts a neuropro-
tective function [23, 24] and binds to soluble oligomeric
amyloid-b (Ab) peptides [25, 26] mediating the toxic sig-
nalling of oligomeric Ab in Alzheimer’s disease, unless
PrPC undergoes a-cleavage, whereby the N1 fragment is
reported to be protective against Ab toxicity [27, 28].
Our previous work has shown that the N-terminal b-
cleavage fragment (N2) is able to reduce intra-cellular ROS
induced by serum deprivation, a reaction requiring copper
saturation of the eight amino acid repeat (octarepeat)
domain [24]. When the regions of N2 that are important for
the transduction of the protective signal were investigated,
it was found that amino acid residues 23–50 alone were
sufficient to initiate the reaction, indicating that the octa-
meric repeat region (residues 51–89) played a restraining
role with inhibition of signalling when present in its apo
form. Transduction of the protective effect additionally
required cell surface proteins, the glycosaminoglycan
(GAG) heparan sulphate (HS) and intact lipid-raft domains,
and was dependent upon a proline motif within the far
N-terminal polybasic region. To investigate the mechanism
of neuroprotective signal transduction by N2 from the
exterior of the cell, this study followed N2 trafficking and
assessed candidate signal transduction pathways. Our
results show that MEK1 signalling is the primary mediating
pathway, which is dependent upon intra-cellular trafficking,
a process highly influenced by N2 copper saturation.
Materials and methods
Generation of PrP peptide sequences
The synthetic peptides derived from the mouse PrP23-89
sequence have been described previously [24] and were
made as described in Karas et al. [29].
Cell culture
CF10 (PrP null, mouse neuronal; [30]), Neuro2a (N2a;
mouse neuroblastoma) and OBL-21 (mouse olfactory bulb)
cells were cultured in Dulbecco’s Modified Eagle’s Med-
ium (DMEM; Lonza, AUS) supplemented with 10 % (v/v)
foetal bovine serum (Lonza) and 50 U/ml penicillin/50 lg/
ml streptomycin solution (Sigma, Melbourne, VIC, AUS).
Cell cultures were maintained at 37 C with 5 % CO2 in a
humidified incubator.
DCFDA assay
The DCFDA assay using 5 lM 5-(and-6)-chloromethyl-
20,70-dichlorodihydro-fluorescein diacetate, acetyl ester
(CM-H2-DCFDA; Invitrogen, VIC, AUS) was performed
as described previously [24, 31].
MTS viability/metabolism assay
Five microlitres of one solution MTS reagent (Promega;
VIC AUS) per 100 ll media was added to test and med-
ium-only background control conditions, and incubated
under normal culture conditions for 90 min. Reaction
product was quantified using absorbance at 462 nm in a
Fluostar Optima (BMG Labtech, VIC, AUS).
CyQUANT DNA assay
The CyQUANT assay (Invitrogen) was carried out as per
the manufacturer’s product protocol for CyQUANT NF.
Cytosolic redox potential
Cells were incubated in Opti-MEMI reduced serum cul-
ture medium (phenol red free; Invitrogen) containing 5 lM
RedoxSensorTM Red CC-1 probe (Invitrogen) and 1 lM
MitoTracker Green (Invitrogen) for 10 min. Media was
removed and cells were incubated in fresh media with or
without serum and test peptides.
Fluorescence and confocal microscopy
Fluorescence microscope images were visualised with a 609 oil
immersion lens and captured using a Nikon Eclipse TE2000-E
epi-fluorescence microscope (Nikon-Roper Scientific).
Confocal images were collected on a Leica SP8 using a
609 oil immersion lens. For quantification, all image
parameters were maintained throughout an experiment,
across all conditions, and the channels of probes sensitive
to photo-oxidation were collected before other channels.
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For imaging data, the ‘n’ represents independent experi-
ments, which each included capturing sufficient fields to
analyse [50 cells per experiment. Cell intensity and co-
localisation analyses were performed using Nikon NIS-
elements 3.0 software with regions of interest used to gate
individual cells.
Indirect immunofluorescence
Cells were grown on 13 mm glass coverslips in standard
media with immunofluorescence (IF) performed when cells
were 80 % confluent. Plates were incubated in the dark at
all light-sensitive stages during this protocol. Cells were
fixed in 4 % (v/v) paraformaldehyde/PBS for 20 min and
then permeabilised in immunodiluent (ID; 1 % w/v BSA in
PBS) with 0.1 % (v/v) Triton-X 100 for 5 min. Coverslips
were blocked with ID containing 10 % FBS (v/v) for
30 min. Primary antibodies against PrP Saf32 (1 in 200;
Cayman Chemical, Sapphire Biosciences, AUS) and 8B4
(1 in 200; Alicon Switzerland), LAMP-1 (1 in 100; Abcam,
AUS), SOD2 (1 in 100; Abcam), and pMEK1 (1 in 100;
Abcam) were diluted in ID and applied overnight at 4 C.
Alexafluor488/647-conjugated goat anti-rabbit/mouse sec-
ondary antibodies (Invitrogen) diluted 1 in 250 in ID were
applied for 1–2 h at room temperature. Coverslips were
mounted onto glass slides with mowiol or Pro-Long anti-
fade (Invitrogen) mounting media.
Laurdan live cell imaging assay
Cells were incubated with a 5 lM solution of laurdan
probe (Invitrogen) in normal media for 30 min prior to
beginning the assay. At time 0, normal media was replaced
with serum-free, phenol red-free OptiMEM. Peptide was
added to a final concentration of 10 lM at the start of
imaging and images were collected every minute for
10 min using a near UV excitation and blue emission filter
set.
MitoSOX assay
Cells were labelled with 5 lM MitoSOX fluorescent indi-
cator probe (Invitrogen) in standard media for 10 min
under routine incubator conditions (as described above).
Media was then replaced with fresh, phenol red-free Op-
tiMEM for the duration of the experiment.
Pull-down assays
Dynabeads amine (Invitrogen) were resuspended by brief
vortexing. Two hundred and fifty microlitres of bead sus-
pension was transferred into microfuge tubes. Beads were
washed twice, by magnetic separation, in conjugation
buffer (0.1 M MES, 0.5 M NaCl, pH 6) and resuspended in
200 ll of conjugation buffer. One hundred and fifty
micrograms of each peptide was resuspended in 800 ll
conjugation buffer and added to the beads, with brief
vortex mixing. Ten milligrams EDC and 15 mg NHS
(Sigma-Aldrich) were dissolved in 1 ml cold deionised
H2O immediately prior to use and 15 ll EDC/NHS solu-
tion per reaction added with brief vortexing. Samples were
incubated for 2 h at room temperature with slow tilt rota-
tion. Hydroxylamine, to a final concentration of 10 mM,
was added to quench the reaction and incubated for 15 min
at room temperature with slow tilt rotation. Beads were
washed three times with PBS-BSA followed by a final PBS
only wash. Coated beads were resuspended in 250 ll PBS.
Cells were lysed either mechanically in PBS (by freeze-
fracture followed by needle aspiration) or using detergent
(0.1 % Triton-X-100 in PBS). One milligram total cell
lysate (protein quantification was achieved using BCA
assay—Pierce) was diluted into 950 ll PBS and added to
the coated beads. Lysates and beads were incubated at
room temperature with slow tilting rotation for 1 h. Beads
and supernatants were separated magnetically and super-
natants were kept. Beads were washed three times with
PBS and once in a detergent wash (0.1 % Triton-X-100 in
PBS) before elution. Elutions were carried out in the order
of deceasing pH followed by increasing salt and finally the
beads were boiled to remove anything still bound. For each
elution, 100 ll of elution buffer was added to beads, which
were briefly vortexed then incubated at room temperature
for 2 min of gentle mixing before collecting. The elution
buffers used were 0.01 M MES, pH 6 (1.95 g/L MES,
8.75 g/L NaCl); acetate buffer pH 5 (0.6 g/L acetic acid,
8.75 g/L NaCl); acetate buffer pH 4 (0.6 g/L acetic acid,
8.75 g/L NaCl); 0.1 M citrate buffer, pH 3 (21 g/L citric
acid); 300 mM NaCl; 1 M NaCl.
Dot blotting
Two microlitres per spot was dotted onto dry nitrocellulose
and spots dried for 1 h at 37 C. Membranes were then
blotted as per the western blot procedures using 1 in
100,000 CTXb-HRP (Sigma-Aldrich) and 1 in 1,000 10E4
primary antibody (Jomar Bioscience, SA) with 1 in 2,000
anti-mouse-HRP secondary antibody.
Western blotting
Cells were lysed in RIPA buffer [50 mM Tris–HCl pH 7.4,
150 mM NaCl, 0.1 % (w/v) SDS, 0.5 % (w/v) sodium
deoxycholate, 1 % (v/v) NP-40] with 1 in 2000 benzonase
(Sigma) at 37 C for 20 min. Samples were electrophore-
sed using the NuPAGE system (Invitrogen), transferred
onto PVDF membranes (millipore) and blocked as
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described previously [32]. Protein of interest detection was
made using the following dilutions of primary antibodies; 1
in 1,000 37/67 kDa laminin receptor (Abcam), pMEK1
(Abcam), pMEK2 (Abcam), pAKT (Abcam), pERK1/2
(Cell Signalling Technologies, Genesearch, AUS), 1 in 400
p-p38 (R&D Systems, Sapphire Biosciences); and 1 in
5,000 Actin (Sigma-Aldrich) in phosphate buffered saline
with 0.1 % (v/v) Tween-20 (PBS-t). Secondary antibodies
(Dako, Melbourne, VIC, AUS) were used at 1 in 2,000 for
the signalling proteins and 1 in 5,000 for actin. ECL-
advance (GE-Healthcare) was used to visualise bands with
images collected using a Las-3000 intelligent dark box
(FujiFilm, Berthold, Victoria AUS). Following blotting,
total protein levels on all gels were assessed to ensure even
loading by Coomassie brilliant blue staining [0.1 % (w/v)
Coomassie Brilliant Blue in 50 % (v/v) methanol and 7 %
(v/v) acetic acid] for 2 min at room temperature with
agitation. Membranes were rinsed briefly in destain [50 %
(v/v) methanol and 7 % (v/v) acetic acid], then washed in
de-stain for 10 min before drying for image capture.
Statistical analyses
Statistical analyses were carried out using GraphPad Prism
5 statistical software. Data are represented as mean ± -
SEM. The numerical value for each independent
experiment (‘n’) is the average of the technical replicates.
Primary statistical tests are stated in the text and tested with
95 % confidence intervals. For ANOVA analysis Tukey’s
(comparisons of all conditions) or Dunnett’s (comparisons
with control values) secondary tests were applied.
Results
We have previously shown that a synthetic peptide
equivalent to the PrPC N2 fragment (PrP23-89 and frag-
ments thereof, Fig. 1a) can reduce intra-cellular ROS
burden in response to the stress of serum deprivation [24].
Copper coordination was important for the action of full-
length PrP23-89. Serum deprivation was used as a mild
insult that induces intracellular ROS and changes cellular
metabolism but does not cause acute cell death (Sup Fig. 1
[24]). To extend our previous work, we performed a dose–
response following the activity of copper and zinc-satu-
rated (four molar equivalents) PrP23-89 on the intracellular
ROS production in CF10 cells (prnp gene ablated [30];
these cells are used throughout unless otherwise stated).
The response showed significant ROS reduction by the
copper-saturated PrP23-89 fragment at 1 and 10 lM
(Fig. 1b; One-way ANOVA, F = 5.327, p = 0.019,
n = 3; copper-only responses are shown in Sup Fig. 2), but
no significant decrease was observed when zinc loaded
(One-way ANOVA, F = 2.26, p = 0.07, n = 4). A dose–
response curve of the apo PrP23-89 ROS response has
previously been published [24]. Further analysis of the
metabolism of these cells showed that the ROS reduction
seen when copper-bound is not due to a loss of cellular
viability; however, viability is reduced when zinc-bound
(Fig. 1c; 2-way ANOVA, F = 6.833, p \ 0.001, n = 3).
No zinc toxicity was observed in the absence of the N2
peptide (Sup Fig. 2).
The peptides were applied exogenously, therefore, the
cell surface interactions of the apo- and copper-saturated
PrP23-89 were investigated by IF localisation. Peptides
were added to the serum-free media and cells incubated for
15 min before fixing. Two antibodies, 8B4 and Saf32
(recognising different epitopes, Fig. 1a) were used to probe
peptide binding to the cell surface in unpermeabilised cells
and throughout the cell, using Triton-X-100 permeabilisa-
tion after fixing. The cell surface (unpermeabilised)
staining with the 8B4 antibody showed no difference in the
pattern of staining or total intensity between the copper-
loaded and apo-PrP23-89 applications (Fig. 1d). However,
the PrP23-89 showed altered cell surface interactions when
detection was performed with the Saf32 antibody (directed
against the octameric repeat region). Here, when the cop-
per-loaded PrP23-89 peptide was examined, slides were
almost completely devoid of antibody signal (Fig. 1d; One-
way ANOVA, F = 10.27, p = 0.0003). In permeabilised
cells, no significant differences in the intensity of cell
staining were seen across any condition (Fig. 1d; One-way
ANOVA, F = 1.391, p = 0.276, n = 3). Control staining
of permeabilised CF10 cells showed signal is specific for
PrP23-89 (Fig. 1e). When cells were exposed to PrP23-89
with and without copper-loading for a longer time period,
90 min, the intra-cellular staining pattern was visibly
cFig. 1 Copper saturation of N2 influences its anti-oxidant function,
cell surface interactions and trafficking. a Schematic of the PrP N2
cleavage fragment (residues 23–89) with antibody binding sites and
the P26/28A mutation shown. The octarepeat (copper-binding) region
is indicated in blue. b Log10 dose–response of the intracellular ROS
reduction activity displayed by copper-saturated (filled bars) and
zinc-saturated (hollow bars) PrP23-89 following serum deprivation.
c Measurement of MTS metabolism 24 h after serum deprivation and
peptide addition. d Antibody detection of the PrP23-89 fragment at
the cell surface (non-permeabilised cells) and inside the cell 15 min
after peptide addition with or without copper saturation. Antibody
signal is shown in green and blue staining indicates DAPI within the
nucleus. Graphs show quantification of the detected PrP23-89 signal
with white bars indicating apo-PrP23-89 and blue bars indicating
copper-saturated PrP23-89 staining. e Staining of CF10 cells in the
absence of peptide addition to control for non-specific antibody
binding. f Immunofluorescent detection of PrP23-89 inside of cells
90 min post-peptide addition with or without copper. g Immunofluo-
rescent detection of PrP23-89P26/28A at the cell surface, with and
without copper saturation, 15 min after peptide addition. Scale
bars = 25 lm. *p \ 0.05, **p \ 0.01, ***p \ 0.001
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different between the two conditions; the apo-PrP23-89
appeared more diffuse with greater cell surface staining
and the copper-loaded PrP23-89 showed a punctuate,
vesicular, and sometimes perinuclear staining pattern
(Fig. 1f).
To explore whether the lack of Saf32 immuno-reactivity
with the copper-loaded PrP23-89 was due to copper co-
ordination changing epitope availability, PrP23-89P26/
28A, a peptide with the two proline residues at positions 26
and 28 mutated to alanine (Fig. 1a), was incubated with the
CF10 cells under the same apo- and copper-saturated
conditions. This mutant peptide, previously shown to co-
ordinate copper in an identical way to PrP23-89 [24], was
clearly detectable at the cell surface with Saf32 in both the
apo- and copper-saturated states with signal no longer
significantly different from 8B4 detection or the apo-pep-
tide (Fig. 1g; One-way ANOVA, F = 0.1595, p = 0.9209,
n = 3).
As the intracellular trafficking and sub-cellular locali-
sation of the PrP23-89 peptide was influenced by its copper
saturation, we investigated whether altering trafficking
pathways would alter antioxidant activity. First, we asses-
sed the influence of internalisation inhibition on intra-
cellular ROS production using the DCFDA assay. The
results showed that serum deprivation causes a large
increase in intracellular ROS production (student’s t test;
t = 12.7, p \ 0.001, n = 3; Fig. 2a; Sup Fig. 1F) and this
was significantly reduced when internalisation was impe-
ded using inhibitors of clathrin-mediated (T-A23) and
dynamin-mediated (Dynasore) pathways (Fig. 2b; One-
way ANOVA; F = 52.7, p \ 0.001, n = 4). For all inter-
nalisation (and signalling) pathway inhibition studies, a
dose–response curve of the inhibiting compound for both
ROS production and cellular viability was tested (Sup
Fig. 3) from which a concentration of compound that might
influence the pathway, without causing gross cell death,
was determined.
To assess the involvement of internalisation pathways in
PrP N-terminally mediated intra-cellular ROS reduction
response, a C-terminally truncated fragment of PrP23-89,
PrP23-50, was used. The PrP23-50 fragment was previ-
ously shown to reduce intracellular ROS in the absence of
the octarepeat region [24], thus not requiring copper and
the use of this peptide, therefore, eliminates any con-
founding effects of adding redox-active copper to these
reactions. Results are shown relative to the internalisation
inhibitor action on serum-deprived cells; a decrease is
indicative of the inhibitor and PrP23-50 effects being
additive (suggesting different pathway engagement) and
where no change or an attenuated response is seen the
effects of the peptide may be competing with the inter-
nalisation inhibitor for engagement of the same pathway or
mechanism, with overall negation of any additional effect
of the PrP23-50. Inhibition of internalisation significantly
reduced the ROS mitigating action of PrP23-50 with both
T-A23 and dynasore-treated cells showing significantly
different responses from the PrP23-50 action without
inhibitors, and for the dynasore-treated cells, ROS reduc-
tion was no longer significantly different to that of the
serum-deprived cells alone (Fig. 2c; One-way ANOVA;
F = 4.908, p = 0.0407, n = 3). We have previously
detected PrP23-50 in cell lysates harvested after exogenous
application [24], indicating that the peptide is taken up by
cells. As such we considered if cell membrane changes
were occurring in real time. Laurdan fluorescent membrane
probe was loaded into cells before addition of PrP23-50, or
a random sequence (RS) peptide to control for random
peptide uptake effects on membranes, and a time course of
images to 10 min were collected. Cells exposed to PrP23-
50 showed increased movement and retraction of their
membranes into a smaller area, which was not seen for the
RS peptide.
Elucidating the localisation of ROS production was
considered important for identifying the site of PrP23-89
activity. To determine the site(s) of ROS production within
the cell following serum deprivation and whether this site/
these sites were the target of N2 action, intracellular ROS-
localisation probes RedoxSensor Red (cytosolic and lyso-
somal ROS [33]) and mitoSOX (mitochondrial superoxide)
were incubated within live cells throughout serum depri-
vation and peptide treatments. Increased ROS production
upon serum deprivation was detected by RedoxSensor Red.
RedoxSensor Red partitions into mitochondria if it is oxi-
dised in the cytosol otherwise it is transported to lysosomes
where it is oxidised. We analysed the contributions of
cytosolic and lysosomal ROS to oxidation of this probe
using co-localisation with MitoTracker [33] (Fig. 3a),
which indicated the significant increase was not contributed
by cytosolic ROS (Fig. 3b; One-way ANOVA; F = 2.395,
p = 0.0937, n = 4) but instead by lysosomes (Fig. 3c;
One-way ANOVA; F = 5.31, p = 0.0072, n = 4). Copper-
loaded N2 significantly reduced the ROS produced in the
lysosomes. Mitochondrial superoxide production was also
significantly increased in response to serum deprivation and
PrP23-89 was able to reduce superoxide production back to
insignificance against that produced by cells incubated in
serum-containing media both when applied apo and copper-
loaded (Fig. 3d, e). The same ROS reduction response was
reproduced by the PrP23-50 peptide for both the Redox-
Sensor Red and MitoSOX probes (Sup Fig. 6 and 7).
Despite being sites of ROS production neither lysosomal
nor mitochondrial function, as determined by acidity and
ATP levels, respectively, were altered (Sup Fig. 4). How-
ever, incubation with the PrP23-89 peptide (either with or
without copper saturation) did increase cell viability at 24 h
post-exposure (Sup Fig. 5).
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To test if the effects on cellular ROS producing systems
were directly due to the actions of the N-terminal peptides
(the peptides themselves have no intrinsic anti-oxidant
activity [24] ), cytosolic ROS and lysosomal ROS pro-
duction were investigated using inhibition of NADPH
oxidase (NOX; a cytosolic signalling protein that generates
superoxide to signal) and inhibitors of lysosomal acidity/
acidification. The inhibitors were incubated with the
serum-deprived cells and ROS production measured by
DCFDA assay. No significant changes in ROS response to
serum deprivation were seen with any of these inhibitors
(Fig. 4a; One-way ANOVA; F = 2.528, p = 0.0941,
n = 5). The model PrP23-50 peptide was used to look at
capacity to reduce the serum deprivation-induced ROS in
the presence of the NOX and lysosomal acidity/
acidification inhibitors. PrP23-50 treatment of the serum-
deprived cells treated with the NOX and lysosomal inhib-
itors showed no significant difference from the serum-
deprived no inhibitor control (One-way ANOVA;
F = 2.202, p = 0.1453, n = 3); however, the bafilomycin-
treated cell response was variable and no longer signifi-
cantly different from the no peptide control serum-deprived
ROS production (Fig. 4b; student’s t test; t = 2.794,
p = 0.0682, n = 4). We additionally investigated the co-
localisation of PrP23-89 when applied both copper-satu-
rated and in the apo form with the lysosomal marker Lamp
1 and the mitochondrially localised superoxide dismutase
(SOD)-2. The peptides were incubated with the cells for
90 min before fixing to allow significant internalisation to
occur. Whilst a small amount of co-staining was seen for
Fig. 2 Inhibition of
internalisation reduces stress-
induced intracellular ROS and
inhibits the protective action of
PrP23-50. a DCFDA assay for
the detection of intracellular
ROS produced in response to
serum deprivation. b Cells were
stressed by serum deprivation
with or without the
internalisation inhibitors T-A23
and Dynasore. Changes are
shown normalised to 0 % (v/v)
serum control values as 100 %
ROS production.
c Measurement of the
percentage ROS reduction
exerted by PrP23-50 with and
without internalisation
inhibition. Results are shown as
percentage reduction from the
serum-deprived ; inhibitor
control. Asterisks denote
significantly different from no
peptide control (*p \ 0.05,
**p \ 0.01, ***p \ 0.001) and
hash shows significantly
different from the no inhibitor
action of PrP23-50 (# \ 0.05).
d Incorporation of the lipophilic
dye laurdan into cell membranes
before treatment with PrP23-50
(or a RS peptide control) in
serum-free media
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copper-bound PrP23-89 with SOD2, the staining did not
suggest a pronounced co-localisation of PrP23-89 with
either of these organelle markers (Fig. 4c, d).
We next considered if we could detect a putative
receptor for N-terminal PrP that might be involved in
mediating the N2 protective signalling. To look for
N-terminal binding partners, we conjugated PrP23-50,
PrP30-50 (lacking the N-terminal polybasic domain), and
PrP51-89 to magnetic beads. The beads were incubated
with whole cell lysate prepared by mechanical disruption
or detergent lysis. Lysate was separated from the beads and
beads were washed four times. Elution of bound proteins
was done using decreasing pH (6, 5, 4, 3), followed by two
high salt washes (0.3 and 1 M NaCl—to disrupt GAG-
Fig. 3 Copper-saturated PrP23-89 reduces the lysosomal and mito-
chondrial ROS caused by serum deprivation. a Representative plates
of RedoxSensor Red changes due to serum deprivation and as
influenced by PrP23-89 with and without copper saturation. Redox-
Sensor Red fluorescence was co-localised with MitoTracker green to
indicate compartmental partitioning. Scale bars = 25 lM.
Quantification of the cytosolic [co-localised with MitoTracker; (b)]
and lysosomal (c) ROS fractions shown relative to 10 % (v/v) serum
control. d Representative plates of mitoSOX fluorescence production
in response to serum deprivation. Scale bars = 25 lM. e Quantifica-
tion of mitoSOX fluorescence intensity. *p \ 0.05, **p \ 0.01
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binding interactions). Both HS and lipid rafts were previ-
ously identified as essential for PrP23-50 ROS reduction;
therefore, we determined if either had been pulled down by
spotting 2 ll of each wash and elution onto nitrocellulose
and blotting for HS content (using 10E4 antibody) and for
the lipid-raft marker GM1. For the mechanically disrupted
cell lysates, both HS and GM1 were detected in the
elutions but eluted under different conditions with HS
eluting at high salt concentrations and GM1 eluting as pH
dropped (Fig. 5a). No HS or GM1 pull-down was observed
when lipid domains were disrupted by detergent lysis (Sup
Fig. 8).
The 37/67 kDa laminin receptor has previously been
shown to bind to the N-terminus of PrP in an interaction
Fig. 4 Downstream targeting
of lysosomes does not play a
prominent role in 23–50 ROS
reduction and PrP23-89 is not
trafficked to this destination.
a Effect of the inhibition of
NADPH oxidase ROS
signalling and lysosomal acidity
on serum-deprived ROS
production as assayed by
DCFDA fluorescence. Data are
plotted as a percentage of the
serum-deprived control.
b 23–50 ROS reduction
response after inhibition of
NADPH oxidases or lysosomal
acidification. Results are shown
as percentage reduction from
the serum-deprived ; inhibitor
control. *p \ 0.05. Co-
localisation of 1 lM PrP23-89
(; copper saturation) with
lamp-1 lysosomal marker
(c) and SOD2 mitochondrial
marker (d). Blue = DAPI
nuclei staining. Scale
bar = 20 lm
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that also requires GAGs. Therefore, samples from the
elutions were electrophoresed and western blotted for the
37/67 kDa laminin receptor. This was found most strongly
in the elutions from beads conjugated to PrP51-89 but was
also found for PrP23-50 and very weakly for PrP30-50,
which lacks the charged region thought to bind GAGs
(Fig. 5b). Other bands of differing molecular weight are
seen in the blots and whilst these are most likely non-
specific it cannot be ruled out that they are modified species
of the laminin receptor. To test if the 37/67 kDa laminin
receptor might be involved in the ROS reduction action of
the PrP N-terminus we used anti-37/67 kDa antibodies to
sterically block interaction with the cell surface laminin
receptor. Blocking the receptor reduced the ROS produced
in response to serum deprivation (Fig. 5c; student’s t test,
t = 4.006, p = 0.016, n = 5) as well as reducing the
efficiency of the PrP23-50 ROS reduction response
(Fig. 5d; student’s t test, t = 2.953, p = 0.042, n = 5).
Fig. 5 The PrP N-terminus pulls down a complex containing heparan
sulphate, lipid rafts and the 37/67 kDa laminin receptor. a Dot blots
for HS and GM1 of pull downs from cell lysate using PrP N-terminal
fragments. b The fractions were western blotted for the 37/67kDA
laminin receptor (expected size of the 37/67 kDa laminin receptor
band is indicated by arrows). c DCFDA assay of the effect of
blocking the 37/67 kDa laminin receptor with antibodies on the
induction of ROS during serum deprivation. d Assessment of the
activity of PrP23-50 in reducing intracellular ROS produced in
response to serum deprivation following targeting of the 37/67 kDa
laminin receptor with antibodies. *p \ 0.05
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To investigate candidate signal transduction intermedi-
ates that might be recruited into the pathway by which
copper-saturated PrP23-89 exerts its influence, we first
considered the effect of signalling intermediate inhibition
on the production of ROS in response to serum deprivation.
Inhibitors were directed against key signalling
Fig. 6 PrP23-50 influences MEK-1, ERK1/2, and PI3K signalling
pathways and copper-saturated N2 shows increased co-localisation
with pMEK1. a Inhibitors of cellular signalling pathways were
assayed for their ability to interfere with the ROS produced in
response to serum deprivation. The inhibitors used were as follows;
Src kinases—500 nM PP2; MEK—10 lM U0126; ERK—10 lM
3-(2-Aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedi-
one hydrochloride; p38—10 lM SB203580; PI3K—1 lM
wortmannin; TOR1/2—1 lM rapamycin; DMSO control—0.1 % (v/
v); the target protein is indicated in the graph; DCFDA assay results
are shown relative to the serum-deprived 100 % control value.
b PrP23-50 ROS reduction was assessed by DCFDA fluorescence and
shown as percentage reduction from the serum-deprived ± inhibitor
control. *p \ 0.05 from the no peptide control, #p \ 0.05 from the no
inhibitor action of PrP23-50. c Western blots and d corresponding
densitometry of changes in phosphorylation (activation) of central
signal transduction intermediates in response to serum deprivation
with and without PrP23-50. Graphical data are presented relative to
serum control. e Co-localisation of PrP23-89 with pMEK1. PrP23-89,
as detected by saf32, is shown in red and pMEK1 staining is shown in
green, with DAPI staining of the nuclei in blue. The heat map (right
plates) shows co-localising pixels. Scale bars = 10 lM. f Pearson’s
product moment correlation co-efficient analysis of the apo- and
copper-saturated PrP23-89 co-localisation. **p \ 0.01. g Quantifica-
tion of pixel intensity for the pMEK1 staining. **p \ 0.01
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intermediates from well-defined pathways within the cell.
Only inhibition of MEK1/2 and PI3K were observed to
change the ROS produced in response to serum depriva-
tion, with both reducing the ROS produced (Fig. 6a; One-
way ANOVA; F = 5.677, p \ 0.001, n = 3). Since these
experiments were undertaken in PrP knock-out cells for the
purpose of excluding confounding effects from endogenous
PrP, the cellular responses may be influenced by their lack
of PrP expression. Therefore, select inhibitor assays were
also performed with two cell lines, N2a and OBL-21,
which express detectable levels of endogenous PrP [32].
Significant differences were seen between the CF10 and
N2a/OBL-21 cells in the intra-cellular ROS production
upon serum starvation only when NADPH oxidases were
inhibited with DPI (Sup Fig. 9). The identified candidate
pathways for copper-loaded PrP23-89 function responded
consistently across the cell lines regardless of PrP expres-
sion. When the ROS-reducing action of PrP23-50 was
assessed in the presence of these inhibitors, MEK1/2 and
PI3K inhibitors suppressed the action of PrP23-50 signifi-
cantly compared with the control, no inhibitor condition,
and MEK1/2 and ERK1/2 inhibition reduced the ROS
reduction such that it was no longer significantly different
from the control serum-deprived condition (Fig. 6b; Two-
way ANOVA, F = 18.69, p \ 0.001, n = 3).
To confirm the involvement of the identified pathways,
cells were incubated with serum and without serum plus or
minus PrP23-50 for 15 min, then western blotted for cen-
tral signal protein phosphorylation changes. PrP23-50
inclusion in the serum-free media induced phosphorylation
of MEK1 (but not MEK2) and ERK1/2. AKT showed
significantly increased phosphorylation in the serum-
deprived cells, but PrP23-50 did not appear to additionally
influence this pathway (Fig. 6c, d). Co-localisation of the
apo- or copper-loaded PrP23-89 peptides with phosphory-
lated MEK1 (pMEK1) were conducted. Greater co-
localisation of copper-saturated PrP23-89 is seen compared
with the apo-peptide (Fig. 6e, f; student’s t test, t = 3.989,
p = 0.0013, n = 3). Additionally, concordant with the
PrP23-50 responses, intensity quantification of the pMEK1
IF demonstrated significantly increased staining in the cells
treated with copper-loaded PrP23-89 as compared with the
apo-PrP23-89 (Fig. 6g; student’s t test, t = 6.58,
p = 0.001, n = 3).
Discussion
Conditions of heightened ROS cause b-cleavage of PrPC at
the cell surface [14, 17] and the b-cleavage event and its
N-terminal cleavage product, N2, have been shown to be
protective against cellular stress [14, 24, 34, 35]. Herein,
we have shown that the copper-saturated N2 b-cleavage
product initiates a cellular protective response through
binding to a lipid-raft membrane complex containing the
37/67 kDa laminin receptor, engaging its internalisation
and stimulating MEK1 signal transduction pathways. The
precise membrane interactions of N2, within lipid rafts and
with its GAG-binding partners, and also involving both the
copper-co-ordinating octarepeat region and the structure
conferred upon the N-terminal polybasic region by the
proline motif, were also shown essential for the correct
engagement of this pathway. Figure 7 provides a schematic
overview of the postulated membrane binding, internali-
sation mechanism and protective modulation pathway for
copper-saturated N2.
A critical role for the PrP N-terminus in cellular pro-
tection is becoming well established [14, 22–24, 27, 28,
34]. The N-terminus is also required for PrPC internalisa-
tion [36–38]. A requirement for PrP internalisation as part
of ERK1/2 signalling by full-length PrPC has previously
been reported for stress signalling through STI-1 [39, 40].
Mutation of the N-terminal polybasic region, which abol-
ishes internalisation [38], also eliminated the associated
signal transduction [40]. Whilst an interaction with STI-1 is
unlikely to be involved in the N2 ROS reduction pathway
presented in the current study, as STI-1 binds PrP at resi-
dues 113–128 [41] beyond the N2 cleavage site, our finding
that the N-terminus is able to instigate such pathways on its
own suggests that PrPC cleavage at the cell surface may be
an important and deliberate event for initiating protective
cellular signalling pathways. Earlier studies have also
shown that copper stimulates full-length PrPC internalisa-
tion [42, 43] and that copper-induced internalisation of full-
length PrP requires the N-terminus and at least two oct-
arepeats and is lost when the a-cleavage site is mutated
[37, 44]. Copper has been linked with PrPC a-cleavage and
signal transduction in the context of an altered membrane
environment [32]. Therefore, it is probable that copper-
binding interactions modulate the specific function(s) of
the PrP23-89 peptide.
Zinc is also known to co-ordinate to the octameric
repeat domain [45] and, therefore, could have a functional
influence on the N2 fragment. However, in the presented
experiments we only observed heightened toxicity of zinc
when bound to N2 rather than a functional outcome in the
context of these experiments. During prion disease, brain
metal levels are known to be altered [46, 47], and this may
have significant implications for cellular functions that
require copper as a molecular ‘‘switch’’. To the best of our
knowledge, this study is the first to show that the N2
fragment intracellular ROS protection response requires
copper-induced internalisation to effectively engage its
downstream signalling pathways.
Whilst this study identified the 37/67 kDa laminin
receptor as part of a complex that is pulled down by
1624 C. L. Haigh et al.
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N-terminal fragments of PrP, we hypothesise that this is
one part of a much larger complex and we cannot state
from the data presented herein that it is the definitive
receptor for N2. However, there is significant evidence in
the literature to support a functional role for the 37/67 kDa
laminin receptor in the PrP N2 interaction; the 37/67 kDa
laminin receptor binds to PrPC through GAG interactions
with the N2 region of PrPC [48, 49], in a pathway that is
also linked with internalisation of PrPSc during disease
[50–53]. Other reported PrP receptors were not investi-
gated in the current study but include low-density
lipoprotein receptor-related protein 1, with binding in
conjunction with GAGs [54], Glypican-1, an HS containing
proteoglycan that co-internalises with PrPC [55, 56], and a7
nicotinic receptors [57]. The latter have been shown to
form a functional complex with PrPC that mediates STI-1
signalling in a pathway which is known to require inter-
nalisation for signal transduction [57]. Potentially N2 may
be modulating any or all of these pathways depending upon
its membrane environment and copper saturation.
Our presented data indicated that peptide-partner bind-
ing interactions might be masking the octarepeat epitope at
the cell surface, thus preventing antibody binding. Further,
the differing binding pattern of the PrP23-89P26/28A
peptide when compared with the wild-type PrP23-89
showed that the cell surface interaction of the octameric
repeat domain is influenced by the proline motif within the
N-terminal polybasic region. The observations might be
due to interactions with the signalling complex through
which the N2 fragment mediates its function or, alterna-
tively, as the N-terminal amino-acids alone were able to
instigate the same ROS reduction response to serum
Fig. 7 Schematic representation of intracellular signalling pathways
influenced by N2 during cellular protection against oxidative stress.
Upon serum withdrawal, an intracellular ROS increase is stimulated
within mitochondria and lysosomes. The ROS reaction is signalled
through internalisation/trafficking of membrane complexes and
involves central intermediates of the AKT and MAPK signal
transduction pathways. Correct engagement of a lipid-raft membrane
complex containing glycosaminoglycans and the 37/67 kDa laminin
receptor by copper-loaded the PrP N2 fragment modulates intracel-
lular trafficking and activates MEK1 signalling to oppose ROS
production
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deprivation, the function of this region may be orientation
of the interaction within/at the cell membrane. Our previ-
ous findings have shown the importance of the octarepeat
for membrane engagement under specific conditions [58],
and therefore, the context of the cell membrane lipid
binding interactions may also modulate correct pathway
engagement for signal transduction in the present study.
The rapid retraction of the cell membrane that was shown
on addition of PrP23-50 could indicate that changes are
occurring at the cell membrane and could have occurred
due to a rapid formation of membrane domains required for
internalisation. Furthermore, the PrP N-terminus has also
been shown to bind to the cytoskeletal protein tubulin [59].
The observed rapid rearrangement of the cell membrane
could in theory be due to cytoskeletal restructuring either
through direct N2-tubulin interaction or via N2 activation
of MEK1 signalling, in similarity with pathways previously
reported for actin cytoskeletal rearrangements [60].
Herein, two signalling pathways were shown to be
especially involved in modulating the intracellular ROS
produced in response to serum deprivation, the PI3K/AKT
and the MEK1/ERK1/2 pathways, with the latter influ-
enced by PrP23-50 to act against the ROS increase. Our
results showed that direct inhibition of ERK did not pro-
duce the same cellular responses as MEK1/2 inhibition and
so MEK1 might be acting to stimulate further downstream
targets to exert its full protective function. The vesicular
internalisation pattern presented for copper-co-ordinating
PrP23-89, co-localising with pMEK1, shows this peptide is
found in close proximity to the signalling intermediates in
the pathways with which it interacts; therefore, copper-
loaded PrP23-89 may be part of an internalised complex
that acts directly to influence the activity of specific sig-
nalling pathways, such as MEK1.
Whilst the ability to engage signalling pathways appears
important for N2 function, the properties of this amino acid
sequence also affect full-length PrP. Studies using cells
expressing full-length PrP have shown that PrP expression
is regulated by signalling through the MEK1 pathway [61]
and PrP expression is increased in response to conditions of
oxidative stress [62]. An environmental stress-induced
increase in paracrine N2 signalling could be able to initiate
these events even in cells with low endogenous PrP
expression. b-cleavage may also prevent signalling of full-
length PrP or permit signalling of the C-terminal cleavage
fragments. Previous studies have found that PrP can signal
through NADPH oxidase [63], which was not seen for the
truncated N2 fragment in the current study, and that the C2
fragment is able to initiate signalling through p38 and
ERK1/2 in astrocytes and microglia [64]. This highlights a
difficulty of attributing functions to full-length PrP as many
cells and tissue display more cleaved PrP than full length
[65, 66], and further supports the role of cleavage as a
functional event for controlling PrP activity.
Our findings are consistent with interactions at the cell
surface, in the first phases of internalisation being able to
influence the downstream ROS production sites, supporting
the importance of correct engagement of a receptor com-
plex at the cell surface by the N2 fragment. We showed
that engagement of the N2 peptide at the cell surface was
determined by the synergy between the polybasic proline
motif and the copper-co-ordinating octarepeats. A pre-
dominant PrPC function has remained elusive despite many
years of intensive investigation, with many studies con-
vincingly suggesting the likelihood of many different
cellular roles. Whilst the choice of model used in each such
study may lead to differing results and, therefore, add to the
contention around this issue, post-translational modifica-
tion to PrPC itself is unlikely to represent an irrelevant
epiphenomenon in all systems. The hypothesis that PrPC
post-translational modification occurs as a molecular
switch for activation or deactivation of certain functions
facilitates the beginning of our understanding of its multi-
functionality. The apparent contextual dependence of the
protective effects offered by the N-terminal cleavage pro-
ducts, as shown in our data, demonstrates the finely
balanced nature of certain functions. The role of such
protective functions and their potential to be corrupted
during disease processes will provide new insights into
both prion disease pathogenesis and other stresses delete-
riously affecting the brain.
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Steven J Collins1,2,3*, Carolin Tumpach3, Qiao-Xin Li3, Victoria Lewis1, Timothy M Ryan3, Blaine Roberts3,
Simon C Drew4, Victoria A Lawson1 and Cathryn L Haigh1*Abstract
The beta-amyloid (Aβ) peptide and the Aβ-oligomer receptor, prion protein (PrP), both influence neurogenesis.
Using in vitro murine neural stem cells (NSCs), we investigated whether Aβ and PrP interact to modify neurogenesis.
Aβ imparted PrP-dependent changes on NSC self-renewal, with PrP-ablated and wild-type NSCs displaying increased
and decreased cell growth, respectively. In contrast, differentiation of Aβ-treated NSCs into mature cells was unaffected
by PrP expression. Such marked PrP-dependent differences in NSC growth responses to Aβ provides further evidence
of biologically significant interactions between these two factors and an important new insight into regulation of NSC
self-renewal in vivo.Findings
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. The core components of the senile plaques
that characterise AD pathologically are beta-amyloid
(Aβ) peptides cleaved from the amyloid precursor pro-
tein (APP). Various Aβ species exist as a result of dif-
fering N- and C-terminal processing sites and these
species can aggregate, forming oligomers that are im-
plicated in Aβ toxicity [1]. Most Aβ species are found
in healthy brain tissue but the relative amounts shift
during AD [2,3]. In health, Aβ1-40 predominates and
during AD Aβ1-42, Aβ4-42 and pyroglutamated Aβ3-
42 (3(pE)-42) are increased [3]. Many other species
also exist with their relative amounts changing during
disease.
Neurogenesis, whilst declining significantly in the adult
organism, continues throughout life. Adult neural stem
cells (NSCs) are confined to specific protected sites within
the brain, including the sub-granular zone (SGZ) of the
dentate gyrus and sub-ventricular zone of the lateral ven-
tricle [4]. Adult NSCs can self-renew and are multipotent;
they can differentiate into cells of any central nervous* Correspondence: stevenjc@unimelb.edu.au; chaigh@unimelb.edu.au
1Department of Pathology, The University of Melbourne, Melbourne Brain
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unless otherwise stated.system lineage. In the brains of AD patients, markers of
neurogenesis are increased [5,6] indicating potential
neurogenic dysregulation or stimulated compensation
for neuronal loss. AD pathology typically begins in the
transentorhinal and entorhinal cortex. [7] This region
lies adjacent to the SGZ and, therefore, NSCs in their
normally protected niche environment may be exposed
to hostile conditions that stimulate them to change their
behaviour [4]. There is significant evidence that Aβ pep-
tides are able to modulate neurogenesis [8-10]. Various
discrepancies exist in the literature as to whether neuro-
genesis is enhanced or suppressed by Aβ exposure,
which is most likely due to the manner in which the Aβ
was prepared (that is, if monomeric, oligomeric or fibril-
lar Aβ species were used) and the model system for
NSC study (for example, in vivo, in vitro, mouse strain);
however, the consensus is in favour of changed NSC be-
haviour following exposure to Aβ species.
Neurogenesis is also modulated by another neurode-
generative disease-associated protein, the prion protein
(PrP) [11,12]. Increased PrP expression is associated with
increased cell cycling at the expense of differentiation
[13]. Recent studies found that PrP is an essential recep-
tor that transduces soluble Aβ1-42 oligomer signals
from the plasma-membrane through the NMDA recep-
tor via the signalling molecule fyn to tau, with this sig-
nalling thought to cause cellular toxicity [14-16]. Based
on the knowledge that both Aβ and PrP can individuallyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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binding partner necessary for the transduction of toxic
signals, we hypothesized that PrP might also transduce
the Aβ peptide signals that alter neurogenesis. The
present study therefore investigated the ability of various
Aβ peptides to modulate in vitro self-renewal and differ-
entiation of adult NSCs harvested from PrP gene-ablated3
Figure 1 Beta-amyloid (Aβ) peptide modulation of neural stem cell (NSC) s
of NSC colonies grown in a collagen matrix with or without Aβ for 21 days
(WT) cells. (C) Neurosphere volume following Aβ treatment calculated from
phase analysis by DNA content; an example experiment from four repeats
*P < 0.05, **P < 0.01, ***P < 0.001.(knock-out (KO)) or from wild-type (WT; normal PrP
expression) mice.
Methods
Aβ-amyloid peptides (China Peptides, China) were pre-
pared as described previously [17]. NSC harvest and
routine culture was as described previously [18,19]. Forelf-renewal is prion protein (PrP) dependent. (A) Representative images
. (B) Neurosphere volume of untreated knock-out (KO) and wild-type
colony diameter (D) and number (E). (F) Flow cytometry cell cycle
is shown. Scale bars = 100 μm. Data are represented as mean ± SEM.
Figure 2 (See legend on next page.)
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Figure 2 Prion protein (PrP) expression has minimal influence on how beta-amyloid (Aβ) affects neural stem cell (NSC) differentiation. Example
plates of western blots for lineage protein markers from knock-out (KO) and wild-type (WT) NSCs treated for either 7 days during differentiation
(A) or 24 hours prior to differentiation for 7 days (B) with 1 μM Aβ. Quantification of the western blots (A & B) for the stem cell marker nestin
(C, F), mature neuronal marker, NF-L (D, G), and GFAP astrocytic marker (E, H). Data are represented as mean ± SEM. Example immunofluorescent
images of NSCs treated with Aβ during (I) and before (J) differentiation with NF-L, GFAP and DAPI nuclear staining shown in red, green and blue
respectively. Scale bars = 15 μm.
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semi-solid gel matrix made with a 2:1 solution of prolifer-
ation medium and collagen. After day 21, neurospheres
were counted and their diameter measured using NIS-
Elements (Nikon, Adelaide, Australia) software. Cell cycle
analysis was performed using the Muse Cell Cycle Kit
(Millipore, Bayswater, Victoria, AUS). For plate and blot-
ting assays cells were cultured as an adherent monolayer
on a 1:1 poly-D-lysine-laminin matrix. Cellular ATP con-
tent was measured using Life Sciences’ATP assay (Invitro-
gen, Mulgrave, Victoria, AUS). Immunodetection methods
have been described previously [18-20]. Expanded meth-
odology is provided in Additional file 1.
Results and discussion
Potential Aβ-PrP signalled changes in neurogenesis
were assessed using four Aβ species; Aβ1-40, Aβ1-42,
Aβ4-42 and Aβ3(pE)-42, representing those that are
found ‘normally’ in health and those that have been
linked with cellular toxicity in AD [21,22]. Previous
studies have shown that fibrillar Aβ has no effect on
neurogenesis [23] and soluble oligomeric Aβ42 is toxic;
therefore, Aβ peptides were prepared using an estab-
lished protocol for producing soluble monomeric spe-
cies [17]. One μM Aβ peptide was used based on results
of previous studies that demonstrated this concentration
induced neurogenic effects [24]. No toxicity was observed
at this concentration throughout the duration of the as-
says (Additional file 2).
NSCs are defined by their properties of self-renewal
and differentiation into mature cells of any central ner-
vous system lineage. First we assessed the role of PrP in
modifying NSC self-renewal using a neural colony-
forming assay, which considers both the number of cells
able to form new clonal colonies and the size of the col-
onies formed as an indication of clonal growth rate. As
previously reported, PrP expression positively influenced
NSC self-renewal (two-way analysis of variance (ANOVA),
F = 7.84, P = 0.006, n = 4; Figure 1A & B) [11-13]. To de-
termine whether PrP has a role in transducing Aβ-
mediated changes in NSC growth, WT and KO NSCs
were incubated with the Aβ species described above.
The KO cells showed a significantly greater proliferation
volume when compared with the carrier buffer alone and
equivalently treated WT NSCs for all Aβ species (two-way
ANOVA, F = 53.75, P < 0.001, n = 4, see Additional file 3for complete statistical analyses; Figure 1A & C). The dif-
ference was primarily due to increased diameter of the
Aβ-treated KO colonies (Figure 1D) in contrast to a de-
creased diameter of the WT NSCs exposed to Aβ (two-
way ANOVA, F = 63.43, P < 0.001, n = 4), as the number
of colonies formed was not significantly different be-
tween the WT and KO NSCs (Figure 1E). Proliferation
of Tga20 (PrP overexpressing) NSCs treated with Aβ
showed similar changes to those observed for WT cells,
with no apparent PrP dose-effect at the concentration
of Aβ used (Additional file 4). The presence of PrP did
not confer a greater susceptibility to any one species of
Aβ, indicating that neither the N- nor C-terminal trunca-
tion of Aβ is important for induction of growth changes
or interaction with PrP but that the core of the peptide ap-
pears sufficient.
To further assess differences in NSC growth, Aβ1-42
was used to assess the number of cells in each phase of
the cell cycle 24 hours post-Aβ addition to liquid cul-
ture. More KO cells rested in G0/G1 basally than WT
(two-way ANOVA, F = 22.99, P = 0.003, n = 4) but after
treatment with Aβ the number of KO cells actively cycling
(S, G2/M phases) was significantly increased (two-way
ANOVA for S phase, F = 39.18, P = 0.003, n = 4; for G2/M
phases, F = 24.91, P = 0.003, n = 4; Figure 1F). There was
no significant change for the WT cells, suggesting that the
changes that slow the growth and reduce the diameter of
neurospheres may occur after a longer period of exposure
to Aβ.
NSCs can be induced to differentiate into neurones,
astrocytes and oligodendrocytes. The lineage to which
an individual cell commits is influenced by its extracellu-
lar environment both before and during stimulation to
differentiate. Therefore, NSCs can be manipulated to dif-
ferentiate into a specific mature cell by their environ-
ment. To assess the influence of Aβ-PrP signalling on
NSC differentiation, KO and WT NSCs were either ex-
posed to the Aβ species for 7 days (one treatment only)
whilst induced to differentiate or were exposed to the
Aβ species for 24 hours before induction of differenti-
ation as an Aβ-priming event. When the effect of Aβ on
WT and KO cellular differentiation was considered, no
significant changes were observed in lineage preference
regardless of whether Aβ was present during differenti-
ation (two-way ANOVA for nestin, F = 4.707, P = 0.043
(no individually significant condition), n = 3; for NF-L,
Collins et al. Stem Cell Research & Therapy _#####################_ Page 5 of 8F = 1.597, P = 0.226, n = 3; for GFAP, F = 1.514, P = 0.223,
n = 3; Figure 2A,C-E) or if the cells were primed by treat-
ment before differentiation (two-way ANOVA for nestin,
F = 0.616, P = 0.442, n = 3; for NF-L, F = 0.816, P = 0.377,
n = 3; for GFAP, F = 0.266, P = 0.611, n = 3; Figure 2B,F-H;Figure 3 Beta-amyloid (Aβ) peptide influences on mitochondria and cell m
Saf32 in the proliferating cells treated for 24 hours and in differentiated cel
with 1 μM of each of the Aβ species. (B) Cell metabolism as determined by
outer membrane translocase protein TOMM22. (E) Densitometry of the TO
protein Pin1. (G) Densitometry of Pin1 western blots. (H) Densitometry of p
**P < 0.01. (I) Immunofluorescent images of Aβ1-42 (1 μM; WO2 red) and P
cells for 0 to 60 minutes. Background red staining is endogenous amyloid
these cells; data not shown). DAPI nuclear staining is shown in blue, ScaleAdditional file 5). However some morphological changes
in WT astrocytes treated with Aβ1-42, Aβ4-42 and
Aβ3(pE)-42 were observed when cells were treated during,
but not when exposed before, differentiation, indicating
an influence of the C-terminal two residues (Figure 2I,J).etabolism. (A) PrP expression in wild-type (WT) cells detected with
ls treated for 7 days. (B-I) Proliferating cells were treated for 24 hours
MTS. (C) Cellular ATP content. (D) Western blots for the mitochondrial
MM22 detection in Aβ-treated cells. (F) Western blots for the cell cycle
53 western blots. Data are represented as mean ± SEM. *P < 0.05,
rP (03R19 green) incubation with kock-out (KO) and WT neural stem
precursor protein reactivity (endogenous Aβ cannot be detected in
bars = 25 μm.
Figure 4 Schematic of beta-amyloid (Aβ) peptide influences on
prion protein (PrP) knock-out (KO) and wild-type (WT) neural stem
cell (NSC) growth. Representation of NSC neurosphere formation
without Aβ and when Aβ is added to KO and WT NSCs.
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WT cells throughout 7 days of Aβ treatment may indicate
that developing astrocytic maturity and the changes in cel-
lular protein expression associated may be required for ac-
tivation of Aβx-42 signalling pathways.
With the most striking Aβ observations relating to op-
posing changes in self-renewal of the KO and WT cells, it
was next considered how these effects might be trans-
duced. Contrary to previous reports [25,26], in the time
frames examined no significant influences of Aβ on PrP
expression levels were measurable (Figure 3A; Additional
file 6). Whilst chronic exposure may reduce expression
over time, in the context of the experiments performed,
PrP was present to perform its function.
Changes in the rate of cell cycling are likely to require
energy. Therefore, markers of cellular metabolism and
mitochondrial function, as well as cell cycle, were com-
pared in WT and KO NSCs following Aβ treatment. For-
mazan metabolism was significantly increased in NSC KO
cells compared with the WT cells when cells were treated
with Aβ1-40 and Aβ4-42 (two-way ANOVA, F = 16.55,
P < 0.001, n = 3, see Additional file 5 for basal data and
Additional file 7 for full statistical analyses; Figure 3B).
Cellular ATP levels were generally unchanged between
the KO and WT NSCs, only showing a decrease in WT
cells treated with Aβ4-42 (two-way ANOVA, F = 5.95,
P = 0.021, n = 4; Figure 3C). This steady-state ATP
measurement does not preclude increased production
balanced by increased use. Contrary to decreased growth,
TOMM22, a mitochondrial outer membrane translocase,
was increased in WT cells when treated with Aβ1-40,
Aβ4-42, and Aβ3(pE)-42 (two-way ANOVA, F = 16.45,
P < 0.001, n = 3; Figure 3D,E). Potentially, this might
indicate that Aβ can exert an effect on mitochondria
signalled through PrP that could be detrimental to
their function, thus limiting growth. The cell cycle
marker Pin1 has also been shown to protect against
tau hyperphosphorylation and subsequent changes to
the cellular cytoskeleton [27]. Pin1 was globally in-
creased in the Aβ-treated WT compared with the KO
cells, although only the Aβ4-42 condition was individu-
ally significant (two-way ANOVA, F = 21.98, P < 0.001,
n = 4; Figure 3F,G). The overall increase in Pin1 could re-
flect a failed effort to increase cell cycling in these cells or
might represent a cellular protective response against Aβ.
p53 is linked with cell cycle and also with cell death.
When activated, the half-life of this protein increases
resulting in increased protein detection over time. No
changes in p53 protein were observed upon treatment
with Aβ in either the KO or WT NSCs (Figure 3H). We
additionally considered other previously PrP-linked Aβ
signalling pathways (fyn, GSK-3β and calcium) finding no
changes in Aβ-induced responses that relate to PrP ex-
pression (Additional file 8).When the localisation of Aβ added to cells was consid-
ered relative to PrP, surface staining of Aβ was observed
to be more intense on the WT cells after 1 hour and PrP
surface staining appeared less with greater signal inside
the cells (Figure 3I). These findings are consistent with
previous studies that have shown Aβ preferentially binds
to cells expressing PrP causing internalisation [28] and
also supports the hypothesis that Aβ stimulates different
pathways in KO and WT cells.
It remains to be determined how NSCs are affected by
PrP-linked Aβ signalling in vivo, where the context of
their support cells and scaffold may lead to more diverse
outcomes. However, the clear responses of the cells cul-
tured in vitro indicates that sufficient cellular machinery
and environmental factors to transduce PrP-Aβ signal-
ling cascades are present. The details of these pathways
will be revealed by future investigation, but it is of inter-
est that the classical Aβ signalling pathways evaluated
here were unaffected. Hypothetically, as PrP-Aβ studies
to date were performed in neuronal cultures or mice,
different pathways could be engaged in NSCs and post-
mitotic neurones or, alternatively, differing pathways
may be activated when Aβ levels reach toxic concentra-
tions. Furthermore, during sporadic AD, brain PrP ex-
pression reduces [26], inversely correlating with Aβ
burden. Reduced PrP expression (akin to KO NSCs) may
Collins et al. Stem Cell Research & Therapy _#####################_ Page 7 of 8permit Aβ stimulation of NSC proliferation, resulting
in the increased neurogenic markers seen in AD brain
tissue [5,6].
Conclusions
This study has validated the hypothesis that the previ-
ously observed, Aβ-signalled changes in neurogenesis
can be transduced through the Aβ-oligomer receptor,
PrP. In addition, we demonstrated that this signalling is
more complex than PrP acting as a simple ‘on’ or ‘off ’
switch for the pathway (summarised in Figure 4). Our
data indicate that: i) congruous with studies using neur-
onal cells and mice [16,29], differing Aβ pathways are
activated in the NSCs depending upon the presence and
absence of PrP; ii) Aβ-PrP signalling inhibits NSC pro-
liferation signals, although possibly monomeric forms
of Aβ act in contrast to the synaptotoxic soluble oligo-
mers; and iii) variations in the basal expression levels of
PrP might also account for some of the previous variability
in, and disagreements over, NSC growth responses to Aβ.
This dynamic and complex interplay of key factors regu-
lating NSC growth provides significant new insight into
the control of NSC self-renewal and further evidence of
biologically significant interactions between Aβ peptides
and PrP.
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Abstract
Internal cleavage of the cellular prion protein generates two well characterised N-terminal
fragments, N1 and N2. These fragments have been shown to bind to anionic phospholipids
at low pH. We sought to investigate binding with other lipid moieties and queried how such
interactions could be relevant to the cellular functions of these fragments. Both N1 and N2
bound phosphatidylserine (PS), as previously reported, and a further interaction with phos-
phatidic acid (PA) was also identified. The specificity of this interaction required the N-termi-
nus, especially the proline motif within the basic amino acids at the N-terminus, together
with the copper-binding region (unrelated to copper saturation). Previously, the fragments
have been shown to be protective against cellular stresses. In the current study, serum dep-
rivation was used to induce changes in the cellular lipid environment, including externalisa-
tion of plasma membrane PS and increased cellular levels of PA. When copper-saturated,
N2 could reverse these changes, but N1 could not, suggesting that direct binding of N2 to
cellular lipids may be part of the mechanism by which this peptide signals its protective
response.
Introduction
The prion protein (PrPC) is most widely recognised for its causative association with the trans-
missible spongiform encephalopathies or prion diseases. During disease PrPC becomes mis-
folded in a self-templating event that results in its transmissibility. PrPC is a membrane bound
(by a glycosylphosphatidylinositol [GPI] anchor), copper-co-ordinating glycoprotein [1].
Aside from GPI-anchor attachment and N-linked glycosylation, PrPC is recognised to undergo
further post-translational modifications including at least two endoproteolytic cleavage events
termed alpha- and beta-cleavage that result in the formation of N-terminal (N1 and N2) and
C-terminal (C1 and C2) fragments respectively [2, 3].
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PrPC is localised within cholesterol-rich lipid rafts on the external leaflet of the cell mem-
brane and its interactions with specific lipid species have been linked with both its function
and mis-folding [4–9]. The lipid membrane environment is highly important for the control of
cellular signal transduction [10] and association of PrPC with lipid raft domains has been
shown to be important for its signalling functions [7–9]. The N-terminus of PrPC is known to
bind to synthetic lipid membranes [11–13], to target full-length PrP to lipid rafts [14] and to
control the movement of PrPC out of lipid raft domains during its copper-induced clathrin
mediated internalisation [15, 16]; therefore, the endoproteolytic cleavage events that separate
the N and C-termini of PrPC might have a significant impact on its cellular function.
Both the N1 and N2 fragments have been shown to have neuroprotective properties. N1
protects against staurosporine toxicity in cell cultures and ischemia in the rat retina via the p53
pathway [17]. N2 reduces intracellular reactive oxygen species (ROS) production in response
to starvation through stimulation of MEK1 signalling in a sequence that depends upon cell sur-
face glycosaminoglycans, intact lipid rafts and copper-dependent endocytosis [18, 19].
Our work has previously shown that synthetic N1 and N2 can bind to lipid membranes con-
taining anionic phospholipids at low pH [12]. Binding is primarily with the lipid head group
and does not extend significantly into the acyl tail region, but appears to induce a change in
lipid ordering [13]. There is no evidence that these peptides insert into the membrane in such a
way as to disrupt membrane integrity, therefore, the peptide-lipid interactions might represent
a functional event. This study aimed to determine if N1 and N2 could bind other lipid species
and in particular whether such lipid interactions might have a functional influence on the
activity of these fragments under the conditions where we have previously seen a neuroprotec-
tive action of N2. We identified a previously unknown binding interaction of both N1 and N2
with PA and demonstrated that changes in the cellular lipid environment are associated with
cellular stress and the protective action of N2.
Materials and Methods
Peptide synthesis
The peptides used and their synthesis have been described previously [13, 18, 20, 21]
Lipid strip western blotting
Lipid strips were purchased from Life Technologies (Invitrogen; AUS). The protocol provided
by the manufacturer was used with the following modifications. Lipid strip incubations were
performed in phosphate buffered saline (PBS; Gibco, Invitrogen Life Sciences AUS) at pH 7.0
or in acetate buffer (0.06 g acetic acid, 0.875 g NaCl per 100 ml dH2O) at pH 5.0 with 0.5 μg/ml
peptide. Equilibration in a sandwich/double blot of new nitrocellulose membrane and blotting
paper was assembled in Tris buffer at pH 8 to ensure that if binding to the lipids was pH-
dependent the peptide was not washed off the spots during antibody incubations: in this case
the peptide would have transferred to the fresh membrane and been detected by blotting. To
ensure any lack of detection was not because of epitope masking by the lipid-peptide interac-
tion, western blotting was carried out with two antibodies, SAF32 (1 in 5000; SPI Bio) targeting
the octarepeat region residues 79–92 and 8B4 (1 in 1000; Alicon, Switzerland) targeting the N-
terminal residues 37–44. Blots and densitometry were carried out as previously [21, 22].
Shorter exposures are shown in S1 Fig to permit comparison of the intensities of the heavy sig-
nals in some spots.
PrP N-terminal Lipid Interactions and Function
PLOS ONE | DOI:10.1371/journal.pone.0134680 August 7, 2015 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
Cell culture
Amurine PrP-null neural cell line (CF10) was used throughout. These cells and their culture
have been described in detail previously [18, 22, 23].
Generalised polarisation
Cells were labelled with 5 μM Laurdan (Invitrogen; AUS) in the dark for 30 mins under normal
incubator conditions. Fluorescence emission intensity (I) was measured using excitation at 355
nm and emission at 460 and 520 nm. Generalised polarisation (GP) was calculated using the
following equation; GP ¼ ðI460I520ÞðI460þI520Þ. Benzyl alcohol (Sigma-Aldrich, AUS) and filipin III (Sigma-




serine (ammonium salt; 18:1–12:0 NBD-PS), referred to as NBD-PS throughout, was pur-
chased from Avanti Polar Lipids Inc (USA) and methanol stocks made as per the
manufacturer's instructions. Cells were labelled with NBD-PS to a final concentration of 20 μM
in ice cold PBS (Gibco, Invitrogen, AUS) with 1 mg/ml bovine serum albumin (BSA; Sigma-
Aldrich, AUS) for 2 minutes. Cells were washed once in PBS-BSA before incubation in phenol-
red free OptiMEM (Gibco).
NBD-PS emission spectra
Emission spectrum scans were done following NBD-PS labelling, using 480 nm excitation and
500–600 nm emission in a Cary Eclipse spectrometer (Agilent Technologies, AUS).
NBD-PS polarisation
Anisotropy was measured following NBD-PS labelling using 470–10 nm excitation and
matched 520 nm emission filters in a PolarSTAR Optima plate reader (BMG Labtech AUS).
Fluorescence microscopy
Cells were imaged as described previously [21].
Magnetic cell sorting
Cell sorting and counting were performed as previously described [24, 25]. Briefly, cells in sus-
pension were labelled with AnnexinV (which binds with high affinity to externalised phospha-
tidylserine) magnetic microbeads (Miltenyi Biotech, AUS) and separation in a magnetic field
performed as described in the MACS protocol (Miltenyi Biotech). Both labelled (positive) and
unlabelled (negative) fractions were transferred into fresh media for counting.
DCFDA assay
Assays were performed as described previously [22].
Phospholipase D activity assay
Cells were plated, assayed and harvested in 96-well plates. Lysates were prepared using 20 μl/
well 0.1% (v/v) Triton X-100 in assay buffer, followed by three freeze-thaw cycles. Lysate was
PrP N-terminal Lipid Interactions and Function
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diluted in a further 30 μl of assay buffer before 1:1 addition of assay reagents as per the Amplex
Red Phospholipase D Assay Kit (Invitrogen) product protocol.
Phosphatidic acid measurement
Cellular PA concentrations were measured using Total Phosphatidic Acid Fluorometric Assay
Kit (Cayman Chemical, Sapphire Bioscience, AUS) as per the manufacturer's product protocol
with fluorescence measured using a PolarSTAR Optima (BMG). Determination of cellular pro-
tein concentration was achieved using the BCA assay as described previously [26].
Statistical analyses
All graphs represent the mean and SEM. The numerical value for each independent experiment
'n' was the average of the technical replicates. Student's t-test was used for analysis of data with
two variables and one-way ANOVA with Tukey's secondary test used for more than two vari-
ables. Confidence intervals of 95% were applied for all analyses.
Results
Our previous studies using model membranes have shown that N1 and N2 (illustrated in Fig
1A) bind anionic phospholipids at low pH [12, 13]. Such studies are relatively laborious and
expensive. Hence to streamline the identification of further interactions with lipids involved in
cellular signalling functions we used nitrocellulose spotted with individual lipid species (Fig
1B/2A) and incubated these with synthetically produced N1 (Fig 1) and N2 (Fig 2) at neutral
(7) or low (5) pH. The membranes showed that, in accord with results obtained previously, N1
and N2 bound to anionic phosphatidylserine (PS) with limited binding to the neutral phospha-
tidylcholine (PC). The peptides further showed a strong affinity for phosphatidic acid (PA;
Figs 1C&1D, 2B &2C, shorter exposures are shown in S1 Fig). In this assay no pH dependence
or loss of peptide binding as membranes were equilibrated to neutral pH was observed (S2 Fig)
and binding was identical when detection was made using the octameric repeat region target-
ing SAF32 antibody and the N-terminally targeted 8B4 (S3 Fig). In our prior studies, N1 bound
PS with higher affinity than N2. The densitometry showed that the signal magnitude was
higher for the N1 peptide than for the N2, however, the overall binding patterns did not differ
(Figs 1D, 2C; plots are shown on the same axis within each peptide analysis for ease of visual
comparison of absolute densitometry, for alternate scaling see S4 Fig for N1 and S5 Fig for N2).
We additionally assessed the effect of copper binding on these interactions by pre-incubating
the N1 and N2 peptides with four molar equivalents CuCl2 before incubation with the mem-
branes. These results indicated that copper and pH together may weakly, but not significantly,
enhance binding to some lipid species but significantly decrease N2 binding to PS at pH 7.
To examine the importance of each region of the N-terminal fragments for PS and PA bind-
ing we incubated the membrane with peptides containing residues 23–50 (Fig 3A) and 51–89
octameric repeat region (Fig 3B), plus a peptide representing N1 minus the 51–89 copper-bind-
ing domain (Fig 3C) and a peptide representing N2 with the proline residues at amino acids 26
and 28 mutated to alanine (PrP23-89P26/28A; Fig 3D). The octameric repeat region alone was
unable to bind to any lipid regardless of whether it was loaded with Cu2+ (Fig 3B/3E; a longer
exposure of these strips alongside the P26/28A peptide for comparison is shown in S6 Fig and
alternatively scaled axes are shown in S7 Fig). Absence of the octameric repeat region from N2,
leaving only residues 23–50 (Fig 3A/3E) or deletion of the octameric repeat region from N1
(Fig 3C/3E) Fig led to a greater number of interactions with different lipids. Mutation of the
two proline residues within the polybasic N-terminus (Fig 3D/3F) also resulted in a promiscu-
ity of lipid binding with significant changes from the wild type N2 sequence seen for
PrP N-terminal Lipid Interactions and Function
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Fig 1. Lipid spot blots identify N1 fragment binding to PS and PA. A. Diagram showing full length PrP and the regions comprising the N1 and N2
cleavage fragments. B. Schematic indicating the lipid spot arrangement on the membrane. C. PrP23-111 (N1) incubation with the lipid spot blots at pH 7 and
pH 5 with and without pre-loading with four molar equivalents CuCl2 followed by western blotting with SAF32 antibody (directed against amino acids 51–89).
D. Densitometric quantification of spot intensity, n = 3, significance over blank control is shown as *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0134680.g001
Fig 2. N2 binds PS and PA lipid spots. A. Schematic indicating the lipid spot arrangement on the membrane. B. PrP23-89 (N2) incubation with the lipid
spot blots at pH 7 and pH 5 with and without pre-loading with four molar equivalents CuCl2 followed by western blotting with SAF32 antibody (directed against
amino acids 51–89). C. Densitometric quantification of spot intensity, n = 3, significance over blank control and between conditions is shown as *p<0.05,
**p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0134680.g002
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Fig 3. Lipid binding specificity is determined by regions of N1 and N2. Lipid spot blots (incubated at pH
7) of peptides corresponding to regions of N1 and N2, including residues 23–50 (A), residues 51–89
PrP N-terminal Lipid Interactions and Function
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phosphatidylinositol (4)P, (3,5)P2, (4,5)P2, (3,4,5)P3 and PS. From these observations, we may
conclude that the specificity of lipid binding by N1 and N2 requires the full complement of N-
terminal and octarepeat residues.
Our previous studies have found that copper-bound N2 normalises cellular responses to the
stress of nutrient starvation [18, 21]. To assess whether alterations in the lipid membrane envi-
ronment may be involved in the cellular response to starvation, changes in the fluorescence
profile of an environmentally sensitive probe, Laurdan, were assessed using generalised polari-
sation (GP; the principle of this assay is described in [27, 28]). The GP value upon serum depri-
vation showed that decreased phospholipid order within the cell membrane occurred in
response to nutrient withdrawal (Fig 4A). As both peptides were shown to bind PS and PA,
changes to each of these lipids were also specifically assessed. Incorporation of PS containing a
NBD fluorescent label within the fatty acid chain (NBD-PS) into cultured CF10 cells and
microscopic examination of the NBD-PS cells following serum withdrawal revealed a broader
spatial distribution of NBD-PS fluorescence (Fig 4B). Furthermore, using this same probe it
was found that upon serum withdrawal the fluorescence intensity of the probe and its anisot-
ropy are decreased (Fig 4C & 4D). In similarity with the environmentally sensitive Laurdan
probe, NBD is quenched in more aqueous environments [29], therefore, these results indicate
that during serum deprivation the cell membrane is becoming less ordered and more fluid.
It is also known that an early indicator of apoptosis is loss of membrane asymmetry at the
cell surface, which results in abnormal external exposure of PS and might contribute to some
of the changes detected by NBD-PS. Using the affinity of Annexin-V for PS, binding of
Annexin-V coated magnetic beads was employed to separate cells with exposed PS from those
cells maintaining membrane asymmetry. These separations revealed a significant increase in
the number of cells exposing PS in the nutrient deprived population after 15 minutes of starva-
tion (Fig 4E).
PA is generated from catalysis of PC by phospholipase D (PLD) at the plasma membrane
and acts as a second messenger in various signalling pathways [30, 31]. Therefore to look for
the role of PA in signalling the cellular response to serum starvation, butan-1-ol was used to
inhibit the action of this enzyme. Our previous studies have shown that serum deprivation
induces a large and rapid production of reactive oxygen species (ROS) within cells [18, 21]. We
confirmed this production and assessed the effect of butan-1-ol on ROS production, finding
that the butan-1-ol stimulated an even greater increase in intra-cellular ROS (Fig 4F). Butan-
1-ol might elicit non-specific cellular actions and therefore, to confirm whether cellular PA
production was changed following serum deprivation, we examined the cellular concentration
of PA thirty minutes after serum withdrawal. At this time PA concentrations in the serum
deprived cells were almost double those of the cells incubated under normal conditions (Fig
4G). Measurement of PLD activity showed no significant change in enzyme activity (Fig 4H),
indicating that the changed levels of PA measured might be a result of decreased degradation
of PA.
comprising the copper-binding region and therefore tested with and without copper saturation (B) and an N1
fragment lacking the residues of the copper-binding region, Δ51–89 (C). For 23–50 and N1Δ51–89, copper
saturation was not tested as neither fragment contains the octarepeat copper-binding domain and blotting
used the N-terminally targeted 8B4 antibody as SAF32 targets residues 79–92. D. Lipid spot blots of a mutant
N2 P26/28A fragment with and without copper saturation at pH 7 detected with SAF32. E. Densitometric
quantification of spot intensity for the domains of N1 and N2, n = 1. F. Densitometric quantification of spot
intensity of the P26/28A mutation of N2 with and without copper saturation. Apo N2 intensities are shown for
comparison of differences between the mutated and wild-type (WT) sequence, n = 3. Significance over blank
control is shown in black and significant differences in detection from the wild type sequence of N2 are shown
in red, *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0134680.g003
PrP N-terminal Lipid Interactions and Function
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Fig 4. Serum deprivation causes changes to PS and PA in CF10 cells. A. Laurdan GP changes following serum deprivation for 30 minutes as compared
with benzyl alcohol (BA) and filipin III controls. n = 3. B. Live cell imaging of NBD-PS labelled CF10 cells. Image intensity is thresholds have been selected to
view detail in the staining pattern and do not represent a comparison of fluorescence intensity. Scale bars = 20 μm.C. Fluorescence emission spectra of
NBD-PS labelled cells following transfer into serum-free medium, scans were taken immediately after media replacement. D. Anisotropy of NBD-PS in CF10
cells with and without serum present. n = 3. E. Counts frommagnetic separation of cells that have lost membrane asymmetry allowing them to bind PS at 5
and 15 minutes post serum withdrawal. n = 4. F. ROS production detected by DCF fluorescence when cells are serum-starved and with exposure to butan-
1-ol to inhibit PLD activity. n = 4.G.Measurement of cellular phosphatidic acid concentration 30 minutes after commencing serum deprivation. n = 3. H.
Measurement of phospholipase-D activity following 15 minutes serum starvation. n = 3. For all panels, *p<0.05, ***p<0.001.
doi:10.1371/journal.pone.0134680.g004
PrP N-terminal Lipid Interactions and Function
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To determine if the protective actions of copper-loaded N2 [18] or the previously observed
neuroprotective actions of N1 [17] might involve or affect the membrane lipid environment,
the Laurdan GP assay was repeated comparing the effects of N1 and N2 (+/- copper saturation)
with the GP values of serum deprived cells alone. Neither peptide significantly influenced laur-
dan GP (Fig 5A), showing they are unable to influence overall membrane fluidity. To more spe-
cifically look at PS and PA we assessed the influence of serum deprivation in the presence or
absence of N1 and N2 (with and without pre-loading with copper). Annexin-V separations of
cells following serum deprivation showed that copper-saturated N2, but not N1, reversed the
loss of asymmetry induced by serum deprivation (Fig 5B). Despite the influence of copper satu-
rated N2 on PS externalisation, but in agreement with the results seen for laurdan generalised
Fig 5. N2, but not N1, reverses PS externalisation and PA increase in the absence of further membrane changes. A. Laurdan GP of serum starved
cells alone and when treated N2 (23–89), N1 (23–111), N2 with the two prolines within the N-terminal polybasic region mutated to alanines (23-89P26/28A,
the octarepeat region (51–89), copper-saturated (four molar equivalents) N1, N2, 23-89P26/28A and 51–89, 23–50 and equivalent copper without peptide,
measured under the same conditions used in Fig 4. n = 3. B. Annexin V magnetic separation of N1 and N2 with and without copper saturation. Filled bar
indicates 10% (v/v) serum and hollow bars show conditions with 0% serum. n = 3. C. NBD-PS anisotropy of N2 with and without copper saturation. n = 3. D.
Phospholipase-D activity within N1 and N2 (+/- copper), and 23–50 (no copper) serum starved cells. n = 3. E. Relative PA concentrations within N2 treated
(+/- copper) serum starved cells. n = 3. Fig *p<0.05.
doi:10.1371/journal.pone.0134680.g005
PrP N-terminal Lipid Interactions and Function
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polarisation, NBD-PS anisotropy was unchanged (Fig 5C). Such findings indicate that whilst
the externalisation of the PS is restored in response to copper-loaded N2, the changes in fluidity
caused by serum deprivation are not reversed.
In contrast with the unchanged PLD activity in response to serum deprivation, copper
loaded N2 significantly increased the activity of PLD under these conditions (Fig 5D). Apo-N2
and 23–50 produced highly variable (not significant) fluctuations in PLD activity and N1
showed no change from baseline, regardless of copper saturation. To assess the consequences
of the increased PLD activity stimulated by copper-saturated N2, cellular concentrations of PA
were assessed. Despite the increased enzymatic activity of PLD, copper-saturated N2 counter-
acted increases in PA induced by serum deprivation (Fig 5E) suggesting an increased turnover
of PA, which requires enzymatic compensation. An alternative interpretation of the data is that
N2 binding to PA impairs its enzymatic digestion into the end products detected in the analy-
sis, resulting in an apparently reduced PA level due to artefactual under-detection.
Discussion
Whilst the binding of the N1 and N2 fragments to PS is well established in model membrane
systems [12, 13], to the best of our knowledge an interaction between any region of PrPC and
PA has never been reported. Both the 51–89 amino acid copper-binding region and the proline
motif within the basic amino acids at the far N-terminus were required for the specificity of the
interaction with PS and PA. This observation could be highly significant in view of the fact that
the previously reported protective effect of the N2 fragment also required both of these
domains [18]. Weak binding was seen for several of the other lipid species, however this is
unlikely to be of relevance in a cellular context where higher affinity binding partners would be
able to out-compete and dominate.
Our previous studies into N1 and N2 lipid binding found that interactions with PS-contain-
ing bilayers could only occur at low pH [12, 13], which was not the case for the lipid strip assays
in the current study. A potential explanation for the discrepancy between the data lies in the
methodology. The lipid strips are prepared from pure spots of a single lipid species, immobi-
lised on a nitrocellulose membrane [32, 33]. Consequently they are intended as a screening
tool and are not designed to give specific information on interactions that require free move-
ment of lipids such as that provided by the complex biophysical techniques used in our previ-
ous studies. However, they did correctly detect the previously indentified interaction with PS
and inability to bind PC; therefore, it is highly likely that the interaction with PA will occur
under the right conditions. The specifics of these conditions remain to be investigated.
Assessment of the serum deprived cells showed that the lipid environment was consistently
perturbed and that such changes occurred rapidly. As there is no evidence of membrane lysis
during starvation (despite externalisation of PS these cells do not die [21]), such results are
indicative of changed lipid order. Therefore, under conditions of nutrient withdrawal, PS exter-
nalisation may not be entirely a pro-apoptotic event but a cellular compensation to the stress of
starvation and it is in this context that N1 and N2 binding could be significant. Under normal
cellular conditions PS is localised to the inner leaflet of the cell membrane and PrPC is on the
outer leaflet, where the N2 cleavage is proposed to occur [34, 35]. Further, the N1 and N2 frag-
ments are consistently found to be secreted from cells into the surrounding milieu [17, 36–39].
Therefore, the localisation of each molecule is usually so disparate that they would be unlikely
to interact. However, during cellular stress, an opportunity exists for N1 and/or N2 to bind and
modulate PS function.
Within the current study copper-saturated N2 reduced the percentage of cells with external-
ised PS. Whilst the data presented herein cannot rule out that N2 directly binds to and blocks
PrP N-terminal Lipid Interactions and Function
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the annexin-V binding site, resulting in an apparently reduced detection, our data suggests that
this is unlikely as the same response was not seen for N1, which has a stronger affinity for PS
membranes than N2 [12, 13] and the bound N2 would have to survive trypsin digest. The dif-
ference in cellular response to N1 and N2 suggests that they mediate their protective effects by
engaging different pathways or that the protective actions of each peptide are induced by differ-
ent stimuli. Such differences likely stem from the additional charged domain of N1, which may
increase its affinity for a non-lipid target in preference and/or addition to functionally binding
the identified lipid species.
The interaction of N1 and N2 with PA is of special interest since PA is a known signalling
intermediate that feeds into the ras-MEK-ERK pathway [30]. The changes in PLD activity and
PA levels following treatment with the copper-saturated N2 suggest that it could be modulating
this pathway through cellular PA changes. N2 stress-protective signalling has recently been
shown to be transduced through MEK1 and requires copper-induced internalisation of the
peptide [21]. PA production is also associated with endocytosis through its stimulation of
membrane curvature, fission and fusion [40] and it has further been shown to regulate clathrin
induced endocytosis [41]. Clathrin induced internalisation of full-length PrPC is mediated by
its N-terminus [15, 16], with this region being present in both the N1 and N2 fragments.
Therefore, membrane association of N2 and PA could represent a genuine functional engage-
ment activating a larger signalling complex or cascade.
Within the lipid spot binding assay copper appeared to have very subtle effects on the inten-
sity of peptide binding. However N2 copper saturation was required for significant changes to
be observed in both the annexin-V positive counts and in changes to PA production and levels.
This suggests that, whilst not altering N2 affinity for lipids, acts as an essential co-factor, medi-
ating the interactions between N2, lipids and other receptors involved in the transduction of
cellular stress responses.
Conclusions
The findings of the current study showed that the N-terminal endoproteolytic cleavage prod-
ucts of PrP, N1 and N2, demonstrated marked binding to PS and PA and that this interaction
required the full complement of N-terminal and octarepeat residues. Additionally, copper-sat-
urated N2 demonstrated some capacity to normalise starvation-induced cellular changes to
both lipids. Therefore, PS and PA feasibly represent direct targets or pathway intermediates by
which N2 transduces its neuroprotective functions.
Supporting Information
S1 Fig. Lipid strip staining as revealed by shorter exposure times. A. Schematic showing the
spot arrangement on the membrane. Eight second exposure of B)N1 membranes, C)N1 mem-
branes andD)N1/N2 domain fragment membranes (30 second exposures are shown in the
main text).
(PDF)
S2 Fig. Double blots of N2 spot blots following equilibration to neutral pH.Membranes
were equilibrated in Tris buffer (pH 8) in a blotting paper—lipid spot membrane-fresh mem-
brane—blotting paper sandwich before western blotting for N2 on both the original and new
membranes with saf32 antibody. Almost no detectible transfer onto the new membrane
(shown) was evident indicating the peptide remained bound to the lipid spot membrane as pH
was changed.
(PDF)
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S3 Fig. N1 and N2 lipid spot blots probed with 8B4 antibody. Blots were carried out exactly
as for Saf32 blotting with 8B4 used as the detection antibody. The similarity in staining pattern
using SAF32 (Fig 1B and 1D) and 8B4 (below) shows that detection of an interaction is not
being missed by epitope masking.
(PDF)
S4 Fig. Rescaled N1 lipid spot binding plots. Plots shown in Fig 1 of the main text have been
re-scaled on an axis appropriate to their signal intensity. No bars indicates no detectable signal
on any repeat, n = 3.
(PDF)
S5 Fig. Rescaled N2 lipid spot binding plots. Plots shown in Fig 2 of the main text have been
re-scaled on an axis appropriate to their signal intensity. No bars indicates no detectable signal
on any repeat, n = 3.
(PDF)
S6 Fig. Extended exposures of lipid spot blots incubated with the PrP 51–89 peptide. All
blots shown in the main text are 30 second exposures. For incubations with a peptide compris-
ing residues 51–89 (the octarepeat copper-binding region), membranes were blank after 30 sec-
onds so a further 5 minute exposure was done alongside the strongly labelled mutant 23-
89P26/28A peptide. After the five minute exposure a small degree of labelling was evident for
the 51–89 peptide was comparatively very weak against the signal seen for the 23–89 P26/28A
peptide.
(PDF)
S7 Fig. Rescaled plots of N1/N2 domain fragments. Plots shown in Fig 3 of the main text
have been re-scaled on an axis appropriate to their signal. No bars indicates no detectable sig-
nal, n = 1.
(PDF)
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PERSPECTIVE
Endoproteolytic cleavage as a 
molecular switch regulating and 
diversifying prion protein function
The prion protein (PrP), through misfolding, is widely known for 
its causative role in prion diseases, which are transmissible neurode-
generative diseases of humans and animals. There is still no defined 
function assigned to PrP, especially in the central nervous system, 
despite many studies in this area. Proposed functions are protean 
and include signal transduction, neuroprotection, neurogenesis, 
neuritogenesis, metal-ion homeostasis, memory formation and con-
solidation, as well as circadian rhythms (Nicolas et al., 2009). Part of 
the difficulty in assigning a specific function to PrP could perhaps be 
that it does not have one single function. Instead it might be able to 
perform many functions and influence various pathways depending 
upon contextual post-translational modification.
PrP has been shown to undergo various post-translational mod-
ifications including glycosylphosphatidylinositol (GPI)-anchor 
attachment at its C-terminus, N-linked glycosylation at either or 
both of two locations, phosphorylation, metal ion co-ordination at 
no less than six sites, secretory cleavage close to the GPI-anchor and 
endoproteolytic cleavage at three or more sites (Haigh et al., 2010). 
Whilst all of these modifications may change mature PrP in ways 
that potentially alter its function or site of function, endoproteolyt-
ic cleavage creates new peptides with distinct features that are likely 
to contribute to the diversity of functions reported for this protein.  
Alpha-(α-) and beta-(β-)cleavages of PrP were first characterized 
as constitutive processing events in both normal and diseased human 
brain twenty years ago (Chen et al., 1995). The cleavage sites and re-
sultant fragments are shown schematically in Figure 1. The C-termi-
nal fragments persist at detectible levels in cells post-cleavage, where-
as the N-terminal fragments are likely secreted or released from cells 
and are detectible in the culture media. PrP cleavage differs depend-
ing upon cell type. In certain cells PrP can be over 50% α-cleaved 
suggesting that this processing may be part of its normal functioning 
(Lewis et al., 2009). The different properties and fates of the cleavage 
fragments further support that this cleavage is unlikely to represent 
a mere degradation step in the turnover of PrP but instead produces 
functional proteins. Indeed the different ratios across cell types may 
reflect the different functions of CNS cells. The β-cleavage event has 
traditionally been thought to be pathogenic as the relative amounts 
of cognate fragments are increased during prion disease (Chen et 
al., 1995). However, a cellular inability to undergo β-cleavage was 
found to result in a heightened susceptibility to cellular stress, which 
indicated that the produced N2/C2 fragments were also likely to be 
functional (Watt et al., 2005). For both α- and β-cleavages the specif-
ic site of cleavage is “ragged” with these cleavages located either side 
of a charged cluster domain, defining which new peptide contains 
this basic domain.  
Recently a further cleavage event has been extensively charac-
terized (Lewis et al., 2015). Referred to as “gamma-cleavage”, this 
event occurs in the C-terminal structured domain and therefore 
produces fragments with very different features to both the α- and 
β-cleavages. A functional significance is yet to be assigned to this 
processing event but its presence in multiple cells and tissues, and 
in disease, suggests that the fragments produced are likely to exert 
cellular effects distinct to those produced by the other PrP constitu-
tive processing events.
Our prior research has shown that the N2 fragment (and shorter 
fragments thereof that include the far N-terminal residues) dis-
play an anti-oxidant, neuroprotective function in response to the 
mild stress of serum starvation (Haigh et al., 2009a). This function 
required the N-terminal amino acids to be intact, including the 
structure conferred on the first charged cluster domain (residues 
23–38) by the two proline residues at positions 26 and 28. Anti-ox-
idant function was further influenced by the octarepeat region 
and its copper-saturation, requiring a minimum of two copper 
molecules available for co-ordination into this site. N2 interaction 
with the cell surface required intact lipid rafts and heparan sulphate 
containing proteoglycans and if these were absent transduction of 
the protective effect was abolished. It was later shown that the cell 
surface engagement of N2 was also influenced by copper binding, 
directing the N2 internalisation pathway, which in turn permitted 
the specific activation of MEK1 in the absence of MEK2 or ERK1/2 
activation (Haigh et al., 2015a). The outcome of the MEK1 activa-
tion was lower lysosomal and mitochondrial reactive oxygen spe-
cies production. Therefore, two post-translational modifications of 
PrP, specifically β-cleavage and metal ion co-ordination, appear to 
co-operatively regulate and orchestrate N2 signalling, underscoring 
that the various permutations of post-translational modifications 
may determine PrP functional modulation. Further illustrating 
this, combinations of post-translational PrP modifications is not 
restricted to influencing MEK1 but has also been shown to alter 
other signalling pathways. For example, copper ion binding alters 
α-cleavage profiles as a function of membrane fluidity and lipid 
raft integrity and this correlates with downstream activation of the 
ERK1/2, p38 and JNK signalling pathways (Haigh et al., 2009b). 
Therefore, not only may cleavage be a function modifying event 
but the cellular consequences may be highly dependent upon the 
precise micro-environment context in which PrP exists.
Like the N2 cleavage fragment, N1 has also been shown to exert 
neuroprotective functions, counteracting staurosporine toxicity and 
hypoxia by reducing caspase-3 activation through modulating p53 
protein levels and activity (Guillot-Sestier et al., 2009). Of interest, de-
spite acting on different pathways, both N1 and N2 bind anionic syn-
thetic lipid membranes at low pH. They integrate between the lipid 
head groups but do not significantly penetrate between the acyl tails 
and so the interactions are non-disruptive (Le Brun et al., 2014). The 
N1 peptide demonstrates a greater affinity for lipids than the N2. The 
lipid binding propensity of these peptides may function to sequester 
them, possibly to quench their function or alternatively to protect 
them from degradation and preserve their functional life-time. Addi-
tionally, lipid intercalation may serve to order membrane micro-do-
mains for signal protein activation or to direct peptide trafficking, 
ensuring activation of specific signalling pathways. In anionic model 
membranes N1 and N2 peptide binding indeed results in alterations 
in lipid order (Le Brun et al., 2014). Despite N1 demonstrating a 
higher binding affinity for lipids, in a cellular context lipid changes 
appear to be influenced to a greater extent through N2 neuroprotec-
tive activity (Haigh et al., 2015b). Serum starvation of cells induces 
a number of changes in their lipid environment, including changes 
affecting phosphatidylserine and phosphatidic acid, with which both 
N1 and N2 interact. Through unresolved mechanisms, the N2 pep-
tide (but not N1) was able to normalise these cellular changes during 
serum starvation. This could indicate that the extra poly-basic region 
alters engagement of membrane binding partners to such an extent 
that N1 and N2 exert their neuroprotective effects in different ways. A 
stronger binding affinity of N1 for membrane lipids may result in it 
being bound sufficiently tightly to prevent release for performing its 
function or ensure preferential binding to other partners to instigate 
transduction through a different signalling cascade.
Understanding the precise mechanisms underpinning the link be-
tween PrP functions and constitutive cleavage may prove valuable for 
understanding failing processes in disease and aging. Whilst C2 levels 
are increased during prion disease, possibly pathogenically (Chen et 
al., 1995), increased levels of C1 or PrP secretory cleavage have been 
shown to be protective against the uptake of prion infection (Lewis 
et al., 2009). The protective nature of C1 is thought to arise due to 
the α-cleavage site being located in the middle of a ‘toxic domain’ 
(amino acids at 106-126), which is thought to be important for effi-
ciency of conversion into misfolded PrP. Whilst C1 may be protective 
in the context of prion disease, it has also been linked with signalling 
cellular death through p53 and caspase 3, in a pathway opposed by 
its counterpart N1 (Sunyach et al., 2007; Guillot-Sestier et al., 2009). 
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No function has yet been found for C2, with an assumption that it is 
an inert substrate available for pathogenic misfolding during prion 
disease. With so many potential influences and different pathways to 
consider when attempting to discern functions of these fragments it 
could be a long time before a definitive function, or lack thereof, can 
be assigned to this fragment.
Beyond the causative role of PrP misfolding in prion diseases, 
cellular PrP has also been implicated in transducing the toxic signals 
that cause Alzheimer’s pathology. Of special interest, the N1 fragment 
has been shown to bind to the soluble beta-amyloid (Aβ) peptides 
associated with AD pathogenesis offering neuroprotection (Guil-
lot-Sestier et al., 2012). N1 binding to soluble Aβ oligomers is thought 
to block their engagement with PrP at the cell surface and thereby 
prevent damaging signal transduction through fyn and tau. The N1/
C1 cleavage event may be doubly protective as the important Aβ 
binding domain is thought to fall within the amino acids between the 
α- and β-cleavage sites. As a result, the membrane attached C1 frag-
ment lacks the soluble Aβ-oligomer binding domain and so should 
be unable to transduce any toxic signals. The C2 fragment, however, 
contains this amino acid region and so the β-cleavage event may still 
be detrimental during Alzheimer’s disease, permitting toxic signalling 
to occur. The lack of the N-terminus when soluble Aβ oligomers bind 
C2 however, may also result in different cellular engagements thereby 
modulating signal transduction and neuronal outcome. 
Understanding the influence of PrP cleavage on pathways regu-
lating neuronal function are likely to not only provide significant 
information on the cellular failures that underscore or correlate 
with neurodegeneration but also produce insight into the role 
these cleavage fragments may have in the regenerative processes 
of the brain. Endogenous expression of PrP stimulates the activity 
of adult neural stem cells (Steele et al., 2006) yet the role of PrP 
cleavages within these cells remains to be determined. Clarifying 
the importance of PrP cleavage events and the resulting fragments, 
either as autocrine or paracrine intermediates, in neural stem cell 
growth and differentiation will enable us to judge whether there is 
potential to preserve, rescue or enhance regenerative processes by 
modifying PrP processing events.  
In conclusion, there are many more regulatory influences both 
singly and in combination that must be considered before we can 
claim a thorough understanding of the functional roles of con-
stitutive or inducible PrP cleavage within the cell. Nevertheless, 
cumulative data to date strongly suggests that constitutive PrP pro-
cessing is not an irrelevant epiphenomenon of cellular turnover but 
regulated, precise and controlled events for specific ends. Cleavage 
profiles differ across different cell types (Lewis et al., 2009) and ev-
idence so far suggests functional outcomes of cleavage are likely to 
differ and be context specific. The precise cellular locations of the 
cleavage events and of the resulting fragments, whether processing 
occurs at the cell surface and whether N-terminal fragments act in 
cis or trans, the enzymes controlling these events, the membrane 
micro-milieu, and dynamic rather than absolute cleavage levels 
may all potentially impact functional consequences. Until the var-
ious nuances of combined post-translational modifications of PrP 
coupled with cleavage events in different contexts and in different 
tissues are fully elucidated, PrP appears destined to remain an enig-
matic “actor” playing in many apparent functional roles. 
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Figure 1 Schematic representation of the prion protein (PrP) cleavage sites.
Linear representation of the PrP primary sequence based on murine amino 
acid numbering. Shown are major domains within the protein and their 
location following cleavage (note that cleavage events are ragged). Metal ion 
binding sites, potential N-linked glycosylation sites and the locations of the 
cysteines forming the di-sulphide bridge are also indicated (S).
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Abstract The cellular prion protein (PrPC) is a ubiq-
uitously expressed protein of currently unresolved but
potentially diverse function. Of putative relevance to
normal biological activity, PrPC is recognized to undergo
both a- and b-endoproteolysis, producing the cleavage
fragment pairs N1/C1 and N2/C2, respectively. Experi-
mental evidence suggests the likelihood that these
processing events serve differing cellular needs.
Through the engineering of a C-terminal c-myc tag onto
murine PrPC, as well as the selective use of a far-C-
terminal anti-PrP antibody, we have identified a new
PrPC fragment, nominally ‘C3’, and elaborating existing
nomenclature, ‘c-cleavage’ as the responsible proteoly-
sis. Our studies indicate that this novel c-cleavage event
can occur during transit through the secretory pathway
after exiting the endoplasmic reticulum, and after PrPC
has reached the cell surface, by a matrix metalloprotease.
We found that C3 is GPI-anchored like other C-terminal
and full length PrPC species, though it does not localize
primarily at the cell surface, and is preferentially cleaved
from an unglycosylated substrate. Importantly, we
observed that C3 exists in diverse cell types as well as
mouse and human brain tissue, and of possible patho-
genic significance, c-cleavage may increase in human
prion diseases. Given the likely relevance of PrPC pro-
cessing to both its normal function, and susceptibility to
prion disease, the potential importance of this previously
underappreciated and overlooked cleavage event war-
rants further consideration.
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Introduction
The cellular prion protein, PrPC, is a ubiquitously
expressed glycosylphosphatidylinositol (GPI) anchored
cell surface glycoprotein, with highest levels found in
neurons and central nervous system tissues [1–4], and is
causally linked to the group of fatal neurodegenerative
disorders known as prion diseases. Surprisingly, engi-
neered PrPC gene ablated (knockout) mice were initially
reported as normal with no overt phenotypic abnormali-
ties [5], which at the time suggested the prion protein
could be functionally redundant. Subsequent studies,
however, demonstrated various deficits and implicated
PrPC in a diverse range of biological activities, with
increasing evidence for roles in important cellular pro-
cesses such as neuroprotection [6–9], cell signaling [10–
13], neurological development and neuritogenesis [14,
15], and synaptic function and plasticity [16–20]. Further,
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prion proteins from different mammalian species show
high sequence identity, especially in the far C-terminus,
with several post-translational modifications and struc-
tural features conserved across species [21–25],
supporting the likely significant evolutionary and bio-
logical importance of this protein.
Like many other proteins, PrPC is subject to constitutive
and selective proteolytic processing, producing several
membrane-bound and soluble fragments of different sizes
and features. PrPC may be cleaved at its GPI-anchor,
allowing shedding of PrPC species from a cell by both
protease and phospholipase mediated mechanisms [26–28].
PrPC is also subject to two well-described internal cleavage
events known as a- and b-cleavage [29]. The dominant
PrPC processing event, a-cleavage, occurs at the start of the
hydrophobic core region (after residues 111/112, human
PrP numbering) [30], producing the C-terminal C1 frag-
ment and corresponding N-terminal N1 fragment. Adding
complexity, a recent study suggests a-cleavage may actu-
ally be multifaceted, with multiple neighboring cleavage
sites targeted by different proteases [31]. b-Cleavage,
predominantly associated with prion disease and misfolded
prion protein conformers (PrPSc) [30, 32], but also reported
to befall PrPC in uninfected cells and tissues [30, 33–36],
involves ‘ragged’ cleavage at the end of the metal-binding
octapeptide repeat region, around residue 90, producing the
C2 and N2 fragments [34, 35]. The precise biological
reasons for PrPC proteolysis are not entirely elucidated,
although PrPC proteolytic fragments, especially the C-ter-
minal fragments, are abundant in cells and tissues, and
there is increasing evidence for separate roles for the dif-
ferent PrP molecular species [29]. In addition, the influence
of PrPC proteolytic processing on disease transmission
susceptibility, pathogenesis and toxicity is recognized [33,
37, 38].
Herein we report the discovery of a novel small PrPC
C-terminal fragment, ‘C3’, observed in various cultured
cell lines, as well as in murine and human brain extracts.
Our primary aim was to characterize the basic cellular
biology of this previously unrecognized PrPC endoprote-
olytic event, which based on an elaboration of existing
nomenclature, we have named ‘c-cleavage’. This aim was
achieved through the uncovering of intrinsic C3 features, as
well as identification of a time-line for c-cleavage in
relation to the normal PrPC lifecycle within the cell and the
likely cellular location of proteolysis, the approximate PrPC
c-cleavage site, the family of proteases responsible, and
potential links to human prion disease. These findings
increase our understanding of PrPC cell biology and add
further complexity to the multi-faceted PrPC proteolytic
processing pathways.
Materials and methods
Animal and human tissue (ethics)
The animal brain tissue utilized herein was obtained during
a previous study [39], where all animal experiments were
carried out with approval from the University of Mel-
bourne Animal Ethics Committee (AEC #04154). The
detection of C3 in human brain tissue occurred during
routine surveillance and classification activities carried out
by the Australian National Creutzfeldt-Jakob Disease
Registry (ANCJDR) [40], under contract to the Australian
Government Department of Health, and with the approval
of The University of Melbourne Human Research Ethics
Committee (HREC #1136882.2). All human control tissue
was purchased from the Victorian Brain Bank Network
(VBBN), and sporadic Creutzfeldt-Jakob Disease (CJD)
tissue was supplied by the ANCJDR.
Cell culture
The cell lines used in this study were mouse neuroblastoma
cells, N2a (#CCL-131), human neuroblastoma cells,
SHSY5Y (#CRL-2266), both purchased from the ATCC
biological resource center, human embryonic kidney
(HEK) cells obtained from the European Collection of Cell
Cultures and the rabbit kidney epithelial cell line, RK13, a
kind gift from Dr Victoria Lawson, The University of
Melbourne. All cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM; Lonza) containing 10 %
(v/v) fetal bovine serum (FBS; Bovogen), in a humidified
incubator in 5 % CO2 and at 37 C, unless otherwise
indicated.
Generation of Myc-tagged wild-type and mutant
PrP constructs
To generate wild-type murine Prnp (WTPrnp) from a 3F4-
epitope tagged murine Prnp (3F4Prnp) in pIRESneo tem-
plate [41], primers 3F4-WT-F and 3F4-WT-R and the
Quikchange II XL Site-Directed Mutagenesis kit
(Stratagene) were utilized, following the manufacturer’s
instructions. Insertion of the c-myc tag with repetition of
murine Prnp codons 226–230 into WTPrnp to produce
‘‘PrP-myc’’, as well as EcoRI (50) and BamHI (30)
restriction sites for ligation into the plasmid pIRESneo, was
via a three-stage modified overlap extension PCR process,
previously shown to be useful for generation of a chimeric
gene [42]. First, WTPrnp was used in two separate PCR
reactions (A) and (B), with these two PCR products puri-
fied (QIAquick PCR Purification Kit, Qiagen) to remove
leftover primers from the solution. Next, a ‘fusion’ PCR
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reaction (C) was carried out, combining PCR products
(A) and (B) as template DNA and no additional primers.
Lastly, the primers EcoPrPF and BamPrPR and PCR pro-
duct (C) as template were utilized in a final PCR to
generate the full PrP-myc open reading frame (D). PCR
product (D), as well as empty pIRESneo vector, were
subject to a double restriction digest with EcoRI-HF and
BamHI-HF (both NEB) for 2 h at 37 C, and the digested
vector was also treated with antarctic phosphatase to pre-
vent re-ligation of vector ends. The digested DNA was
resolved on a 1 % agarose gel, purified (QIAquick Gel
Extraction Kit, Qiagen) and ligated to form a circular PrP-
myc in pIRESneo plasmid, which was then transformed
into XL1-Gold Ultracompetent bacteria (Stratagene).
Ampicillin resistant colonies were selected and myc-tag
insertion was confirmed by sequencing. The above multi-
step process was also carried out using 3F4Prnp as a
template, to produce 3F4-myc. To generate D177NMyc,
E199KMyc and V209IMyc, site-directed mutagenesis with
the Quikchange II XL Site-Directed Mutagenesis kit
(Stratagene) was carried out with the appropriate primers
and PrP-myc in pIRESneo as the template DNA, following
the manufacturer’s instructions. All primer sequences and
PCR cycling conditions are listed in supplementary mate-
rial (Online Resource 1 and 2, respectively). PCR reactions
included a final concentration of 0.2 mM dNTP mix, 1 mM
MgSO4 and 1.25 Units (0.5 ll) of Platinum Pfx polymerase
(all Life Technologies), except the ‘fusion’ PCR (C), where
double the dNTPs (0.4 mM) and Platinum Pfx polymerase
(2.5 Units) was added.
Transfection of mammalian cells
Transient transfections and the RK13 cells stably
expressing PrP-myc (MycRK) were created using Lipo-
fectamine 2000 (Life Technologies), following the
manufacturer’s instructions. Transient transfections were
all approximately 72 h. All other stable cell lines were
created by electroporation of appropriate cDNA as
described previously [43].
Live cell treatments
Cells were treated in culture with compounds (all Sigma)
or the compound diluent as controls, for the length of time
and concentrations as indicated in figure legends. All
treatments were carried out in OptiMEM (Life Technolo-
gies) containing 10 % FBS unless otherwise indicated.
Briefly, E64d treatment was at a final concentration of
40 lg/ml for 72 h, with reagent added fresh every 24 h.
Prinomastat and Brefeldin A (at indicated concentrations),
and Tunicamycin (10 lg/ml final concentration) treatments
were for 24 h. PIPLC treatment (0.05 U/ml final concen-
tration) was for 1 h in serum free OptiMEM.
Temperature block experiments
MycRK cells were seeded into 12-well plates and grown to
confluence. Cell monolayers were washed gently with 1X
PBS, and then incubated for 4 h in 1 ml of OptiMEM with
or without 10 % (v/v) FBS. All incubations were carried
out in non-humidified conditions, at ambient O2/CO2: 37
and 15 C incubations were constant and regulated in
incubators; 20 C incubation was at room temperature.
Cell lysate and brain homogenate preparation
and treatments
Tga20 mouse brain tissue (half brain, sectioned sagittally),
and approximately 50 mg of human brain tissue taken from
the occipital cortex of six sporadic Creutzfeldt-Jakob dis-
ease patients and six age-matched non-neurological
controls, were prepared as a 10 % (w/v) homogenate in 1X
PBS as described previously [44]. Where indicated, human
brain homogenates were proteinase K (PK) digested
(100 lg/ml final PK concentration, 1 hour at 37 C, as
described [44]) prior to PAGE and western blot analyses.
Cell monolayers were washed with 1X PBS, prior to either
harvesting (scraping into PBS and pelleting at 10009g for
3 min) and lysing, or lysing directly in wells. Cells were
lysed in ice-cold lysis buffer (25 mM Tris/HCl, pH 7.5,
150 mM NaCl, 5 mM EDTA, 1 % (v/v) Triton X-100)
containing a final concentration of 1X Complete Ultra
protease inhibitors (Roche) as described previously [45].
Post-nuclear supernatants were assessed for total protein
content using a bicinchoninic acid protein assay (Pierce).
Where required, cell lysates were treated for 2.5 h at 37 C
with 0.02 U final concentration PIPLC or PIPLC treated
and then PNGaseF [46] digested, as described previously.
PAGE and immunoblotting
Samples were mixed with the appropriate PAGE sample
buffer containing a final concentration of 3 % b-mercap-
toethanol, and resolved on either 4–12 % acrylamide
NuPAGE (Life Technologies) or 15.5 % acrylamide tricine
SDS-PAGE gels, then electrotransferred to Hybond-P
polyvinylidene difluoride membrane (PVDF). PVDF
membranes were blocked for 1–2 h at room temperature in
PBS containing 0.05 % Tween-20 (PBST) and either 5 %
(w/v) skim milk powder, or 2 % (w/v) ECL blocking
reagent, prior to incubation with the indicated primary
antibody overnight at 4 C (as indicated in figure legends).
Online Resource 3 summarizes relevant antibody
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information. After washing off non-specifically bound
primary antibody with PBST, membranes were incubated
in peroxidase-conjugated anti-mouse or anti-rabbit sec-
ondary antibodies (GE), before further washes with PBST
and detection using enhanced chemiluminescence (Pierce
ECL substrate; Thermo Fischer Scientific, or ECL
Advance; GE Healthcare). Where necessary (i.e. when
quantifying a difference in total PrPC expression), to assess
and correct for protein loading, membranes were stripped
at low pH [1 % (v/v) aqueous HCl] for approximately
30 min, re-blocked and probed with an anti-b-tubulin or b-
actin antibody and the secondary antibody described above,
or were stained with Coomassie blue solution [50 % (v/v)
methanol, 10 % (v/v) acetic acid, 0.25 % (w/v) Coomassie
Brilliant Blue R-250 (BioRad)] for 1 min and de-stained
[40 % (v/v) methanol, 10 % (v/v) acetic acid] for 10 min
prior to quantification. All chemiluminescent and digital
images were captured by a Fujifilm LAS-3000 Intelligent
Dark Box.
Cell surface biotinylation and NeutrAvidin
precipitation
Cell surface proteins were biotinylated for 30 min at 4 C
with the Pierce Cell Surface Protein Isolation Kit as per
the manufacturer’s instructions, with all solutions and
reagents utilized scaled down to suit T25 cm2 flasks. Cells
were harvested and pelleted at 500 9 g for 3 min, imme-
diately after biotinylation (T0) or were cultured for a
further 6 h prior to collection of the cells (T6) and condi-
tioned media (T6 M). Cell pellets were stored at -20 C
overnight, and media proteins were precipitated overnight
at -20 C in 4X volumes of 100 % methanol, and then
pelleted at 45009g max speed for 1 h at 4 C. Cell and
media pellets were lysed in 300 ll lysis buffer containing
protease inhibitors as described above. Ten microlitres of
lysates mixed with 10 ll of 2X NuPAGE sample buffer
containing 100 mM dithiothreitol (DTT) (final DTT con-
centration of 50 mM) were utilized for ‘input’ samples in
PAGE and western blotting. Lysates were diluted by
mixing 150 ll of lysate with a further 150 ll of lysis buffer
containing protease inhibitors, and then subjected to pre-
cipitation using 200 ll NeutrAvidin-coated agarose beads,
as per the Pierce Cell Surface Protein Isolation Kit
instructions. Samples were eluted in 85 ll of 1X NuPAGE
sample buffer containing 50 mM DTT for 1 h at room
temperature, with 30 ll of this preparation used for PAGE
and western blotting.
Density gradient ultracentrifugation
MycRK cells were harvested, lysed and subjected to
Nycodenz density gradient flotation assay as described
previously [39]. Fifteen microlitres of collected fractions
was utilized for PAGE and western blotting as described
above.
Densitometry and statistical analysis
Densitometric semi-quantitative analyses were carried out
using Image J v1.42q, and routinely included background
subtraction. C3 levels were always first adjusted for the
total PrPC detected within a lane/sample, and then
expressed relative to control samples. When total PrPC
expression levels were compared, these were normalized to
the relevant loading control (b-tubulin or Coomassie total
protein, as indicated), and then expressed relative to the
control samples. Statistical analyses were performed in
GraphPad Prism v6.0d. All quantitative data is expressed as
the mean ± SEM, with the number of independent exper-
iment replicates (n) as indicated in figure legends.
Results
PrPC is cleaved in the far C-terminus, producing
a novel cleavage fragment, C3
The addition of epitope tags into proteins is a commonly
utilized and relatively simple and effective way to study
their cellular biology, exploiting the convenience of high
affinity antibodies, or intrinsic fluorescence of the tag. The
introduction of epitope tags into PrPC which is then
expressed in cells or animal tissues has been achieved
several times, with different tags, and into different regions
of the protein [47–51]. The nucleotide sequence encoding
the 10 residue human c-myc epitope (EQKLISEEDL),
along with the sequence encoding PrPC residues 226–230
duplicated immediately after the myc-tag, was engineered
into murine PRNP immediately 50 to the GPI-anchor signal
sequence, generating ‘PrP-myc’. This PrP-myc construct
has previously been shown to generate a PrPC fusion pro-
tein (MycPrP) with unaltered cellular behavior or function
in vivo or in vitro, including glycosylation, proteolytic
processing, trafficking, localization, membrane anchoring,
and incorporation into PrPSc aggregates [52]. When whole
lysates from the N2a cell line, transiently transfected with
the PrP-myc construct (see Fig. 1a) were analyzed by
PAGE and western blotting, in addition to the expected
full-length and truncated MycPrPC species, a small, less
than 10 kDa, myc-immunoreactive fragment was observed
(Fig. 1b). This unexpected finding indicated there may be
another PrPC endoproteolytic cleavage site towards the
C-terminus, producing this small fragment, nominally
‘C3’. The PrP-myc construct was stably transfected into
three other routine laboratory cell lines, human embryonic
670 V. Lewis et al.
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Fig. 1 A far C-terminal PrPC fragment, C3, in cells and tissues of
neuronal and non-neuronal origin. a Schematic representation of the
constructs and alignment of the antibodies utilized in this study. Wild-
type murine PrP (WT-PrP), containing the C-terminal Myc epitope-
tag (Myc-PrP), the 3F4 epitope tag (3F4-Myc-PrP), the sites of three
murine equivalents of familial CJD mutations D177N, E199K, V209I
(Mut-Myc-PrP), the N-terminal anchor (NTM) in double anchored
PrP (DA-PrP), the expected endoproteolytic cleavage sites (a, b, c),
and some key conserved features (octarepeat and hydrophobic
domains, N-linked glycans, GPI-anchor), are depicted. PAGE and
western blotting, with the anti-Myc (b) and anti-PrP (c–e) antibodies
as indicated, of: b lysates from different cell lines (N2a, HEK,
SHSY5Y, RK13) transfected with PrP-myc (Myc), the empty vector
(Neo), wild-type mouse PrP (WT), or those left untransfected (UN);
c lysate from untransfected N2a cells; d PBS brain homogenate from
Tga20 (WT murine PrPC over-expressing) mice; e PNGaseF digested
(?) or undigested control (-) lysates from SHSY5Y cells expressing
wild-type (PrP) or double-anchored (DA) murine PrPC. The different
full length (FL) and truncated PrP species are indicated, with the
products of c-cleavage highlighted with closed arrows, and all other
cleavage events with open arrows. Membranes in b were stripped and
re-probed with b-actin (Act) or b-tubulin (Tub) as indicated by the
small arrows
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kidney (HEK), human neuroblastoma (SH-SY5Y) and
rabbit kidney epithelial (RK13), to determine whether this
processing was restricted to the N2a cells. In all cases,
MycPrPC was also processed to C3 (Fig. 1b), indicating
that cells derived from various mammalian species, and of
neuronal and non-neuronal origin are capable of what we
have designated PrPC ‘c-cleavage’ and C3 production.
In order to establish whether this processing was an
artifact of myc tag engineering, lysates from naı̈ve N2a
cells were analyzed by PAGE and western blotting utiliz-
ing a commercially available antibody, EP1802Y, raised
against the PrP far C-terminus residues 214–230 (Fig. 1a).
Once again, a small approximately 6–7 kDa fragment was
observed (Fig. 1c), but this fragment was not seen when
utilizing an antibody (ISCM18) directed against a com-
paratively more N-terminal region of the protein (Fig. 1a,
c). To further confirm this observation, murine brain
homogenates were also analyzed by PAGE and western
blotting. Tga20 mouse brains were utilized as they over-
express murine PrPC approximately six fold, therefore
increasing the likelihood of detection of what appears to be
a relatively low abundance fragment. When mouse brain
proteins transferred to PVDF membranes were probed with
antibodies to the PrPC N-terminus (SAF32) and mid-region
(ICSM18), various PrPC species are observed, including
the a- and b-cleavage products N1 and N2 when probing
with SAF32 (Fig. 1d). However, it was only probing with
EP1802Y that allowed detection of an approximately
6–7 kDa C-terminal fragment in these mouse brains
(Fig. 1d).
The presumed N-terminal fragment, N3, based on the
apparent size of C3, is predicted to be approximately
20 kDa. In the Tga20 mouse brains there was no obvious
detection of N3 using the N-terminal PrPC antibody SAF32
with a short exposure, however upon prolonged exposure,
an immunoreactive fragment of this approximate size was
apparent (Fig. 1d, far right panel). Furthermore, the band
attributed to C2 in the ICSM18 blot could potentially
contain N3. Attempts to detect N3 in conditioned media
from cultured cells were unsuccessful (data not shown). To
increase the likelihood of detecting N3 in cell lysate, which
may otherwise be rapidly secreted and/or degraded, we
utilized SH-SY5Y cells expressing a ‘double anchored’
(DA) murine PrPC [43] (Fig. 1a), and wild-type murine
PrPC expressing cells as controls. In the DA-PrPC con-
struct, the N-terminal PrPC signal sequence has been
replaced with the uncleaved signal sequence and trans-
membrane domain of murine aminopeptidase-A [43],
thereby resulting in the tethering of the PrPC N-terminus to
the cell membrane. When whole cell lysates from the DA-
PrPC expressing cells were subject to PAGE and western
blotting after PNGase digest to remove N-linked glycans,
immunoreactive fragments consistent with N3 containing
the aminopeptidase-A transmembrane domain (DA-N3),
were detectable with all three anti-PrP antibodies utilized
(Fig. 1a, e). N3 was not detectable in the control wild-type
PrPC expressing cells consistent with rapid degradation of
this fragment.
Collectively, these results strongly support that PrP c-
cleavage is a bona fide PrP processing event, prompting
us to investigate further. Note, given MycPrP has been
shown to behave the same as untagged (wild-type) PrP
[52], including, as shown in Fig. 1, undergoing endopro-
teolysis producing the various PrP fragments, for ease of
C3 detection we continued to utilize cells expressing
MycPrP. From this point, MycPrP and its truncated spe-
cies are for simplicity referred to without the prefix
‘Myc’.
PrPC c-cleavage occurs late in the secretory
pathway, preferentially from an unglycosylated
substrate
The cellular prion protein is a cell surface protein, and
follows a typical pathway of trafficking and endocytosis. In
order to determine at which stage during this secretory
pathway c-cleavage occurs, we first carried out temperature
block experiments [53, 54], where RK13 cells stably
expressing PrP-myc (MycRK) were incubated for 4 h at
15 C [slowing protein traffic from the endoplasmic retic-
ulum (ER)], 20 C (slowing protein traffic from the Golgi
apparatus) and 37 C, in the presence or absence (to slow
cell division and simulate oxidative stress) of serum. When
compared to cells in optimal/normal conditions
(37 C ? serum), cells where protein traffic was slowed
through the ER showed no change in C3, while under
stressed conditions, when protein traffic was held up in the
Golgi network, there was a significant increase in C3
production, with a similar trend when cells were not
stressed (Fig. 2a). To further investigate the cellular site of
PrPC c-cleavage we treated MycRK cells for 24 h with
Brefeldin A, a reversible inhibitor of protein translocation
from the ER to the Golgi complex [55]. As predicted, given
PrPC N-linked glycosylation starts in the ER with attach-
ment of high-mannose oligosaccharides, but continues in
the Golgi with modification of these to more complex
sugars [56], Brefeldin A treatment dramatically altered the
glycosylation pattern of PrPC (Fig. 2b). Importantly, we
found that Brefeldin A treatment significantly reduced C3
production.
The well-described PrPC C-terminal proteolytic frag-
ments C1 and C2 are known to be glycosylated like the
full-length protein [36]. This can make interpretation of
their abundance difficult, as glycosylated but truncated
PrPC may have the approximate same molecular weight as
unglycosylated full-length PrPC. Enzymatic removal of
672 V. Lewis et al.
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N-linked glycans from PrPC, through PNGaseF treatment
of cell or tissue extracts is routinely used to more clearly
visualize these fragments. To this end, we used PNGaseF
to visualize all C-terminal PrPC fragments, including C3, in
N2a cells transiently expressing myc-tagged wild-type
murine PrPC, or 3F4 epitope containing murine PrPC,
which is often utilized as a substitute wild-type murine
sequence (Fig. 1a). It is interesting to note that in this cell
line, irrespective of which construct was transfected, after
PNGaseF treatment it becomes clear that there is very little
full length (compared to truncated) PrPC, which has been
described previously in some cultured cells [33]. This is
unlikely to be due to the cells expressing myc-tagged PrPC,
and rather reflects more the pattern of endogenous PrPC
proteolytic processing in these cells (Online Resource 4).
As expected, there is an increase in detectable C1, as
glycosylated species have been reduced and all of C1 now
migrates as a single band (Fig. 3a). However, there is
neither the appearance of a smaller than the 6–7 kDa
species that would indicate C3 had (prior to PNGaseF
treatment) been glycosylated and therefore was resolving
slower in PAGE, nor is there an increase in intensity of the
6–7 kDa C3 band that would indicate some of the C3
present in cells is ordinarily glycosylated and upon enzy-
matic deglycosylation becomes visible. Also of note, after
PNGaseF treatment, with prolonged exposures we can
observe a previously unrecognized faster moving species
below C1 (closed arrow), which we have coined C30.
From experience, and as evident in Figs. 1, 2 and 3a,
most PrPC species in cultured cells and tissue extracts are
heavily glycosylated. As C3 is not glycosylated and, sim-
ilar to unglycosylated PrPC, is in low abundance relative to
other PrPC species, we questioned whether C3 is cleaved
preferentially from an unglycosylated source. When
MycRK cells were treated with tunicamycin, a compound
that blocks de novo N-linked glycosylation, we observed a
significant increase in relative C3 levels (Fig. 3b). Inter-
estingly, in the tunicamycin-treated cells there is again
evidence of a PrPC fragment which is a few kilodaltons
smaller than C1, which we postulate is the same C30
fragment described in Fig. 3a.
The C-terminal fragment C3 is GPI-anchored,
but does not reside primarily at the cell surface
To further understand this PrPC c-cleavage event, we next
aimed to characterize the C3 fragment itself. It is well
established that GPI-anchored proteins, such as PrPC,
localize within lipid raft domains of cellular membranes
[57]. In order to establish whether C3 was also GPI-an-
chored, we subjected lysates from MycRK cells to a
floatation assay, whereby buoyant membranes (i.e. lipid
Fig. 2 c-cleavage occurs after
PrPC has exited the ER, in the
Golgi/TGN. Representative
PAGE and western blot with an
anti-Myc primary antibody (left
panels) and C3 quantification
(right panels) of cell lysates
from: a MycRK cells incubated
in the presence (?) or absence
(-) of 10 % v/v fetal bovine
serum for 4 h at the
temperatures indicated (n = 4);
b duplicate wells of MycRK
cells treated with Brefeldin A, at
the concentrations indicated
(100 ng/ml and 10 lg/ml
n = 3; 1 lg/ml n = 2), or
diluent only controls (CTL).
Statistical analyses were by one
way ANOVA with a Tukey’s
multiple comparison post-test of
all groups and b Dunnett’s
multiple comparison post-test of
each treatment to the control.
*p\ 0.05, **p\ 0.01,
****p\ 0.0001
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raft domains) float to the top of a density gradient, fol-
lowing an established protocol [39]. When fractions from
the MycRK cells were analyzed by PAGE and western
blotting, the C3 fragment was localized predominantly in
the more buoyant fractions where other PrPC species were
also enriched (Fig. 4a), consistent with C3 containing a
GPI moiety. The lipid raft (Flotillin-1), ER (Bip) and
mitochondria (Bcl2) marker proteins localized predomi-
nantly in the lighter/buoyant (Flot1) and denser (Bip/Bcl2)
fractions as expected [39]. Next, lysates from HEK cells
transiently expressing MycPrP were reacted with bacterial
phosphatidylinositol-specific phospholipase C (PIPLC), an
enzyme capable of catalyzing hydrolytic cleavage of the
phosphoric ester bond within the GPI anchor. When the
GPI anchor is enzymatically removed from a protein,
empirically on PAGE separation the GPI-minus protein
resolves slower than its undigested counterpart [58]. To
this end, a small characteristic upward shift in PAGE
mobility of the C3 fragment, as well as the other PrPC
species, was observed in the PIPLC and PNGaseF treated
lysate (Fig. 4b), indicative of GPI-anchor removal.
Treating cells in culture with PIPLC induces cleavage of
GPI-anchored proteins from the cell surface. When
MycRK cells were treated for 1 h with PIPLC, as expected
there was an increase in the detection of PrPC in the con-
ditioned media; however, this was not observed for the C3
fragment (Fig. 4c). Interestingly, levels of C3 in condi-
tioned media were in fact significantly decreased. To
further confirm whether C3 is localized at the cell surface,
we carried out cell-surface biotinylation of MycRK cells.
Using NeutrAvidin-coated agarose beads to bind and pull
out all labeled cell surface proteins from whole cell lysate
or conditioned media, Fig. 4d shows that whilst the cell
surface transferrin receptor and many PrPC species were
biotinylated, C3 was not. Online Resource 5 shows the full
biotinylation experiment result depicted in Fig. 4d,
Fig. 3 C3 is not glycosylated and is preferentially cleaved from an
unglycosylated substrate. a Lysates from N2a cells transiently
transfected with wild-type or 3F4-epitope myc-tagged PrP construct
as indicated, were left untreated (-) or digested with PNGaseF (?)
prior to PAGE and western blotting with an anti-Myc antibody. The
bottom panel is the same blot as the top panel, after a longer digital
exposure time to enable visualization of additional cleavage frag-
ments as indicated. b Representative PAGE and western blot with the
anti-Myc antibody and re-probe with anti-b-tubulin antibody (top
panel) and quantification (bottom panel, n = 4) of relative total PrPC
and C3 levels in duplicate wells of MycRK cells treated with
tunicamycin (TM), compared to diluent only controls (CTL). The
various full length unglycosylated (FLUG) and truncated PrPC species
are indicated. Statistical analyses by paired t test. *p\ 0.05,
**p\ 0.01
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including some relatively low level non-specific NeutrA-
vidin pull down of unlabelled proteins (both PrPC and
transferrin receptor), seen only on longer exposure, and no
precipitation of biotinylated proteins from the conditioned
media. Online Resource 5 also shows that upon longer
exposure, both C3 and C30 can be detected in the whole cell
lysate (input), but not in the NeutrAvidin pull down
samples.
A matrix metalloprotease is responsible for PrPC c-
cleavage within the highly conserved C-terminus
The observations of C3 approximate molecular mass at
6–7 kDa, and the C3/N3 immuno-reactivities, suggested
that the c-cleavage site was in the far-C-terminus of PrPC.
Interestingly the C-terminus of PrPC is highly conserved in
mammals [59], with substantial sequence identity in the
various species listed in the National Center for Biotech-
nology Information (NCBI) Conserved Domains Database
[60] (Online Resource 6). In order to define the sequence
identity of C3 and clarify the c-cleavage site, several
attempts, including the use of size-exclusion and
immunoprecipitation techniques to increase relative
detection/yield of Myc-C3 for downstream mass spec-
trometry or Edman degradation analyses, as well as
antibody affinity based SELDI-TOF–MS, unfortunately all
yielded negative or inconclusive results (data not shown).
Therefore, we employed site-directed mutagenesis to
potentially introduce either slight structural/steric changes
or loss of a protease consensus sequence motif, in order to
hinder and/or alter any interaction of PrPC with the
responsible protease, altering the efficiency of C3 pro-
duction and narrowing down the putative region of the c-
cleavage site. Specifically, the murine equivalents of three
inherited human prion disease mutations which are spread
across the far-C-terminus of PrPC were created, with all
containing the myc tag (see Fig. 1a); MycD177N,
MycE199K and MycV209I. After transient transfection
into RK13 cells, we observed a significant reduction in C3
levels in cells expressing MycD177N and MycE199K
compared to wild-type MycPrPC (Fig. 5a), whilst there was
no significant difference seen for the MycV209I mutation.
A single previous report does identify and describe a
small C-terminal PrP fragment of similar apparent molec-
ular mass, which the authors also referred to as ‘C3’ and
may be the same C3 described herein [50]. Taguchi and
colleagues determined their fragment to result from cys-
teine protease cleavage, as a 72 h treatment with a pan-
cysteine protease inhibitor E64 inhibited its production. In
order to test whether our C3 was also generated by a
cysteine protease, MycRK cells were treated for 72 h with
E64d, a more membrane permeable synthetic analogue of
E64. Surprisingly the MycRK cells had increased total
PrPC expression after E64d treatment, and when adjusted
for the increase in PrPC, C3 levels were also significantly
increased (Fig. 5b). We considered whether the increased
C3 was due to E64d increasing the proportion of a pre-
cursor fragment. Lysates from E64d treated and untreated
cells were PNGaseF digested prior to PAGE and western
blot analysis, in order to clearly see the relative levels of
the different full-length and truncated MycPrPC species. As
seen in Fig. 5c, there is no apparent change in proportion of
the C1 fragment, although there is again the appearance of
a faster moving MycPrPC species with E64d treatment. We
believe this is consistent with C30, observed in the various
experiments described above.
Having ruled out a cysteine protease as the likely
enzyme involved in PrPC c-cleavage, we utilized the
MEROPS database (http://merops.sanger.ac.uk) [61] to
perform low stringency searches of residues around the
highly conserved residues of the PrPC far C-terminus.
Numerous proteases were identified, and of interest were
several matrix metalloproteases (MMP), due to recent
evidence that prion protein fragments can be digested by
membrane-type MMP proteases [62]. To investigate the
possibility of MMP mediated c-cleavage of PrPC, we
treated MycRK cells for 24 h with the MMP inhibitor
Prinomastat, which is selective for MMPs-2, 3, 9, 13 and
14 [63]. We observed a significant decrease in relative C3
levels for all concentrations of Prinomastat tested (Fig. 5d),
suggesting an MMP is involved in PrPC c-cleavage.
Prion disease-associated PrP conformers are
also susceptible to c-cleavage
During a routine diagnostic characterization of PrP spe-
cies detectable in a suspected Creutzfeldt-Jakob disease
(CJD) patient brain for the ANCJDR, a fragment consis-
tent with C3 was detected when utilizing the EP1802Y
antibody, but not the mid-region 3F4 antibody (Fig. 6a),
which indicated the human prion protein may be suscep-
tible to c-cleavage. In order to further characterize this,
and also address whether prion disease associated PrP
species are also subject to c-cleavage, we assessed C3
production in non-neurological control and sporadic CJD
patient brain tissue. While we found no clear evidence of
c-cleavage in control tissue, this was not the case in CJD
brains, with detection of C3 (2/6 cases) and C30 (6/6
cases) (Fig. 6b, top panels). Additionally, after high
concentration PK treatment successfully digested away all
PrPC species, in addition to the typical profile of di-
mono- and un-glycosylated partially protease-resistant
(PrPres) species, C3 becomes readily detectable in all the
CJD brains (Fig. 6b, bottom panels). Interestingly, C30 is
also still detectable after PK digestion. Collectively this
indicates that in the context of disease-associated PrP
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misfolding, C3 represents a highly protease-resistant
unglycosylated fragment, with c-cleavage of disease
associated PrP (PrPSc) occurring, and the likelihood that
the C3 seen in non-PK-treated CJD brain tissue is resul-
tant from endoproteolysis of PrPSc rather than processing
of the PrPC present.
Fig. 4 C3 is GPI-anchored, and does not localize primarily at the cell
surface. Representative PAGE and western blot with anti-Myc
antibody of: a Density gradient fractionated lysate (fractions
numbered 1–10) from MycRK cells, also probed with the marker
protein antibodies (Flot1, Bip, Bcl2) as indicated; b lysates from HEK
cells transiently expressing MycPrP, left untreated, digested with
PIPLC, or PIPLC and PNGaseF. PrPC species [full length (FL) and
truncated] with the GPI-anchor successfully removed are indicated
with the dashed arrows; c cell lysate (Ce) and conditioned media
(Me) from triplicate wells of live MycRK cells exposed to PIPLC or
diluent only (CTL), and total protein (Coomassie) stained PVDF
membrane (after completed western blotting), with quantification
(bottom panel, n = 3) and statistical analyses by two way ANOVA
with Bonferroni’s multiple comparison post-test. ns not significant,
*p\ 0.05, ****p\ 0.0001; d whole cell lysate (Input) or NeutrA-
vidin-coated agarose bead precipitated (Avidin) proteins from cell
surface biotinylated MycRK cells, immediately (T0) or 6 h (T6) after
labeling, re-probed for the cell surface transferrin (Trf) receptor
protein




Prion protein endoproteolysis, a phenomenon observed in
cultured cells as well as human and various animal tissues,
has been reported for many years, with a focus on a- and b-
cleavage and proteolysis at the GPI anchor resulting in
shedding of PrPC from the cell surface [29]. Despite this,
the biological or physiological significance of PrPC prote-
olytic processing has not been entirely elucidated, with
emerging, but sometimes conflicting evidence of separate
functions of the full length [14, 64, 65], and different
truncated PrPC species [6, 10, 66–68]. Importantly, there
are often more truncated PrPC species than full-length PrPC
present in cells and tissues [33, 35, 69], underscoring the
likely cellular requirement for these processes to occur.
Through the utilization of Myc-tagged PrPC expressed
in cells we discovered a novel, approximately 6–7 kDa,
Myc-tagged ‘C3’ fragment, and then confirmed the pres-
ence of endogenous C3 in both human and animal brain
tissue, indicating the fragment was not produced as an
Fig. 5 An MMP not a cysteine
protease is responsible for c-
cleavage within the conserved
PrPC far C-terminus.
Representative PAGE and
western blot with anti-Myc
antibody of: a lysates from
RK13 cells transiently
expressing wild-type (WT) or
mutated, myc-tagged PrPC, with
quantification (right panel,
n = 4); b lysates from MycRK
cells treated for 72 h with E64d
or diluent only control (CTL),
re-probed for b-tubulin
detection, with quantification of
total PrPC levels and C3 levels
adjusted for PrPC (right panel,
n = 4); c PNGaseF digested
whole cell lysates from
duplicate wells of E64d or
diluent control (CTL) treated
MycRK cells (as in b), with full
length unglycosylated (FLUG)
and truncated PrPC species as
indicated; d lysates from
Prinomastat (concentrations as
indicated, 100 pM n = 2,
100 nM n = 3, 10 lM n = 4)
or diluent control (CTL) treated
MycRK cells (in some cases in
duplicate wells), with
quantification (bottom panel).
Statistical analyses in a and
d were by one way ANOVA
with Dunnett’s multiple
comparison post-test of each
mutant or treatment to the
control, and in b were by paired
t test. *p\ 0.05, **p\ 0.01,
****p\ 0.0001
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artifact of epitope tag insertion, and thus the unequivocal
existence of a PrPC c-cleavage event. Extensive literature
searching has found that the most commonly utilized anti-
PrP antibodies are directed to epitopes in the middle region
of PrPC, and unlikely to be within the C3 fragment. Fur-
thermore, published western blot images are often
trimmed, underscoring the possibility that the occurrence
of PrPC cleavage events, especially those producing small
far-C-terminal fragments such as C3, may be easily over-
looked. The apparent approximate molecular weight of C3
seen on PAGE and western blotting, along with the sig-
nificant reduction in C3 production with the mutation of
two residues within the PrPC far C-terminus, are highly
suggestive of the c-cleavage site being within this region,
potentially somewhere between residues 176 and 200.
Interestingly the C-terminus of PrPC is highly conserved in
mammals [59], with 100 % amino acid sequence identity in
residues 190–202 and 54 % identity in the larger region
spanning residues 170–230 (human PrP numbering) in the
various species listed in the National Center for Biotech-
nology Information (NCBI) Conserved Domains Database
[60], including humans and other primates, cervids, bovids,
equids, felids, cetaceans, lagomorphs and rodents, further
pointing to the likely biological significance of c-cleavage.
Additionally, if our predictions of the c-cleavage site hold
true, and when direct cleavage to C3 occurs, the resulting
potentially secreted N3 fragment could represent approxi-
mately 70 % of the span of previously described secreted
GPI-anchorless PrPC species, including important struc-
tural features such as the copper binding octapeptide repeat
and the hydrophobic core (Fig. 1a), which may have bio-
logical/functional relevance [70–72].
After synthesis, the majority of immature PrPC produced
may undergo post-translational modifications en route to
the cell surface, including addition of its GPI-anchor in the
ER, and simple, followed by more complex, glycosylation
of one or two asparagine (N) residues (codons 181 and 197
on human PrPC; 180 and 196 on murine PrPC) in the ER
and Golgi, respectively [56], resulting in predominantly
highly glycosylated PrPC species. Later in the secretory
pathway, after transiting the Golgi apparatus, a large pro-
portion (in most cell types) of PrPC is subjected to the
dominant endoproteolytic processing event, a-cleavage, in
the trans-Golgi network (TGN) [54]. Our results indicate
that PrPC also needs to exit the ER for efficient c-cleavage,
and that this endoproteolysis occurs in the Golgi complex
or TGN. Furthermore, our observation of reduced cellular
C3 levels in PIPLC treated cells is consistent with the
phospholipase-induced loss of GPI-anchored PrPC species
from the cell surface diminishing an available substrate for
Fig. 6 C3 is present in human
sporadic CJD brains. PAGE and
western blot analysis of human
brain tissue utilizing the anti-
PrP far C-terminal EP1802Y
(a) and (b) or 3F4 (a) antibodies
as indicated. Five microliters of
10 % (w/v) CJD (a) and (b) or
non-neurological control
(b) brain homogenate was
utilized untreated (a and bupper
panel), or PK digested (bbottom
panel), prior to analysis. The
various full-length and
truncated PrP species detectable
(PrPC, PrPres, C1, C2, C3, C30)
are highlighted
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c-cleavage. Collectively, this indicates c-cleavage also
occurs after PrPC has transited to the cell surface, perhaps
during endocytic recycling and/or retrograde transport of
PrPC to the Golgi/TGN, trafficking pathways that PrP
isoforms are known to follow [73, 74]. Our data also
suggest the C3 fragment itself is not glycosylated, and
consistent with this, the protease responsible for c-cleavage
favors an unglycosylated substrate. Intriguingly, as the
appearance of another C-terminal fragment, apparently
slightly smaller than C1, sometimes coincided with
increased C3 detection (for example after tunicamycin or
E64d treatment), we believe c-cleavage does not occur
downstream of a-cleavage, and that C3 may not always be
cleaved directly from full length PrPC, but perhaps some-
times from an intermediary or precursor fragment, which
we have coined C30. Collectively these results may partly
explain the apparently relatively low levels of the C3
fragment observed; we propose that proportionately low
levels of PrPC remain unglycosylated, and/or escape either
a- or b-cleavage and remain full length, are not shed or
recycled back to the cell surface, and could therefore per-
sist long enough to be transported back to the Golgi/TGN
where c-cleavage is then able to occur. Importantly, as is
the case with many other low abundance proteins, we
believe the relatively low levels do not militate against the
potential importance of this fragment or cleavage event.
Similar to full length PrPC, the a- and b-cleavage
C-terminal fragments C1 and C2 are known to be GPI-
anchored [30]. After treatment of cells with the bacterial
enzymes PIPLC and PNGaseF, a subtle size shift char-
acteristic of GPI-anchor removal was observed in C3,
along with the other PrPC species expressed in the cells. It
is unclear why PIPLC treatment alone did not result in
this same discernible shift, though this may be related to
the GPI-anchor attachment residues and PIPLC cleavage
recognition motif being more accessible once the sub-
strate protein has been denatured, which does occur
during the conditions of PNGaseF digestion. These
results, along with the detection of C3 in buoyant density
gradient fractions suggest that C3 does retain its GPI-
anchor. However, the lack of an observed C3 increase in
conditioned media after PIPLC treatment of live cells,
coupled to the lack of detection of labeled C3 after cell
surface biotinylation, together indicates this fragment is
unlikely to reside predominantly at the cell surface. These
results are also consistent with c-cleavage occurring after
retrograde transport to the Golgi or TGN, but do not
exclude contributions from nascent PrPC coming directly
from the ER. The possibility that the C3 fragment itself
does not contain enough lysine residues, with amine side
chains to react with the biotin, is unlikely given the pre-
dicted c-cleavage region, although this cannot be
excluded.
A single report does identify and describe a PrPC-
derived C-terminal fragment which we originally hypoth-
esized may be the same C3 described herein [50]. The
fragment described by Taguchi and colleagues was dis-
covered during the development of a biarsenical cell
surface protein labeling technique, using PrP as the model
protein. This, along with our conflicting finding that c-
cleavage was not reduced by inhibition of cysteine pro-
teases using E64d, collectively indicates the C3 fragment
we have characterized is in fact not that which has been
described previously, and further highlights the complexity
of proteolytic processing of the prion protein far C-termi-
nus. Whilst this study has ruled out the involvement of a
cysteine protease in c-cleavage, we have elucidated that a
member/members of the matrix metalloproteinases (MMP)
family of proteases are involved. Interestingly a recent
report describes the proteolysis of various synthetic PrP
fragments with MMP7, MMP14 (membrane-type MMP1,
or MT1-MMP) and MMP16 (MT3-MMP), with some of
the reported cleavage sites mapping to the far C-terminus
of PrPC between residues 169–192 [62], consistent with the
region we predict to contain the c-cleavage site. The
determination of which specific MMP/s are involved is the
subject of ongoing investigations.
Although prevalence of PrPC c-cleavage is not high, the
lack of C3 seen in human control brain tissue was sur-
prising. One explanation may be that c-cleavage does not
occur in cells of the brain region we sampled from, as
cleavage profiles have been shown to vary in different
tissues and regions [69]. Alternatively, C3 may be below
the limits of detection by PAGE and western blotting.
Whatever the explanation, our results indicate that whilst
human cells are capable of accommodating c-cleavage of
murine PrPC (e.g. the HEK and SHSY5Y cells in Fig. 1b),
in vivo human PrPC is perhaps less susceptible to this
cleavage event compared to murine PrPC. Surprisingly, PK
resistant C3 and C30 species were relatively abundant in
CJD brain, indicating PrPSc may be more susceptible than
PrPC to c-cleavage. Small, approximately 7–15 kDa, PK
resistant fragments have previously been detected in
human prion brain tissue (and as illustrated by Fig. 6a),
particularly in the inherited Gerstmann–Sträussler–
Scheinker (GSS) disease cases [75, 76], although these are
typically characterized as both N- and C-terminally trun-
cated, and are therefore not the C3 species we describe.
There is published evidence of small far-C-terminal PK
resistant fragments in sporadic CJD, but not control brain
tissue [77], which the authors designate as PrP-CTF12/13
to reflect their approximate size. Similar to our PrPC-
derived C3, PrP-CTF12/13 are also GPI-anchored. More-
over, the N-terminus of the PrP-CTF12 fragment mapped
to residues 162 and 167, which is consistent with our
estimates of the c-cleavage site, and which based on amino
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acid sequence alone (i.e. codons 162–230 and 167–230) are
predicted to result in C-terminal fragments of approxi-
mately 8.3 and 7.6 kDa, respectively (excluding the GPI-
anchor, which when attached should actually result in
slightly faster than expected resolution [58]). With PAGE
protocol differences (e.g., acrylamide concentrations) and
the inherent inexact nature of molecular weight standard
alignment for predicting actual protein size (especially
when the smallest marker is larger than the protein of
interest) accounting for discrepancies, we believe these
PrP-CTF12/13 species may be the same PrPSc derived PK
resistant C3 and perhaps also C30 that we have detected.
In the context of prion disease pathogenesis, experimental
evidence has proven that expression of the normal cellular
prion protein, PrPC, is an absolute requirement [78, 79],
where it aberrantly folds to the disease associated prion
protein isoforms (PrPSc). Although the mechanisms under-
lying initiation of PrPC misfolding are not understood,
convention proposes the continued hetero-dimeric interac-
tion, templating and conversion of PrPC to PrPSc with
eventual propagation of sufficient neurotoxic and infectious
species ultimately causing cell death and neurodegeneration.
Whilst it is known that the N-terminus of PrPC is not
required for production of PrPSc [80], we and others [33, 37,
38, 81, 82] have linked reduced susceptibility to prion
infection or efficiency of conversion/misfolding, to PrPC
cleavage/truncation, probably due to the depletion of full-
length PrPC which is the optimal substrate for conversion to
PrPSc. Interestingly, a recent report has also linked decreased
expression and activity of MMPs 2 and 9 to increased prion
propagation [83]. Given the likely involvement of MMPs in
PrPC c-cleavage, it remains possible that c-cleavage may be
relevant in cellular mechanisms of susceptibility to prion
propagation. Indeed, the apparent increase in c-cleavage as
indicated by the proportionally higher amounts and the PK
resistance of C3 and C30 in the brains of CJD patients may
reflect increased and ultimately failed cellular attempts at
managing the ongoing prion propagation through efforts to
cleave and therefore degrade PrPSc.
Many areas of prion biology remain enigmatic, with
considerable conflicting data published, perhaps in part due
to the under-appreciation of processes such c-cleavage.
The primary objective of this study was to characterize the
cellular biology of this novel PrPC c-cleavage processing,
and further contribute to the understanding of currently
incompletely answered questions in prion research. Whilst
the exact biological and/or pathophysiological significance
of c-cleavage remain to be determined, the results we have
presented herein, along with mounting evidence of the
relevance of prion protein cleavage to both its normal
function, and the important influence exerted in suscepti-
bility to prion disease, underscore that this previously un-
appreciated cleavage event warrants further investigation.
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Abstract Eight-hydroxyquinolines (8HQs) are a class of
compounds that have been identified as potential therapeu-
tics for a number of neurodegenerative diseases. Under-
standing the influence of structural modifications to the 8HQ
scaffold on cellular behaviour will aid the identification of
compounds that might be effective in treating dementias. In
this study, we describe the action of 2-[(dimethy-
lamino)methyl]-8-hydroxyquinoline (DMAMQ) on adult
murine neural stem cells (NSCs) cultured in vitro. Treatment
of NSCs with DMAMQ resulted in enhanced self-renewal
and increased neurite outgrowth. Concurrent with the posi-
tive growth effects was an increase in intracellular reactive
oxygen species, with the growth being inhibited by inacti-
vation of the NADPH oxidase (Nox) enzyme family. Our
results indicate thatDMAMQcan stimulate neurogenesis via
the Nox signalling pathway, which may provide therapeutic
benefit in treating dementias of various types by replenishing
neurones using the brain’s own reserves. The narrow con-
centration range over which these effects were observed,
however, suggests that there may exist only a small thera-
peutic window for neuro-regenerative applications.
Keywords 8-hydroxyquinoline  Neural stem cells 
Neurosphere  Proliferation  NADPH oxidase  Reactive
oxygen species  2-[(dimethylamino)methyl]-8-
hydroxyquinoline  DMAMQ  PBT2
Introduction
Endogenous neural stem cells (NSCs) are an as-yet
untapped resource in combatting dementia. Low levels of
NSCs persist in the brain throughout adult life, maintaining
the ability to self-replicate and to differentiate into mature
brain cells. During dementia, neurogenesis (the ability to
form new neurones) is seen to become dysregulated [1, 2].
In rodent models of Alzheimer’s disease (AD), production
of beta-amyloid, one hallmark of AD, changes the growth
and differentiation of these cells [3–7]. Neurogenesis has
been extensively linked with both learning and forgetting
[8–10]; therefore, changes in these processes might con-
tribute significantly to the cognitive changes that occur
during neurodegenerative diseases, including AD. Com-
pounds that modulate or normalise the functions of NSCs
represent a prime target for alleviating the symptoms
associated with, or delaying the course of, neurodegener-
ative diseases.
Unbiased chemical screening of substituted 8-hydrox-
yquinolines (8HQs) and a range of investigations in yeast,
nematodes, mice and humans have highlighted the variable
mechanisms by which they may act. Side-chain modifica-
tions to the 8HQ backbone may lead to functional differ-
ences in vivo, with applications of substituted 8HQs as
anti-microbial agents [11, 12], anti-cancer agents [13, 14],
epigenetic modulators [15, 16], dementia treatments
[17–20], artificial nucleobases [21] and medical imaging
agents [22, 23]. Moreover, biosynthesis of substituted
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8HQs has been identified in mammals (e.g. xanthurenic
acid [24]), bacteria (e.g. quinolobactin [25]) and insects
(e.g. 2-carboxy-8HQ [26]). In dementia applications,
studies utilising 5,7-dichloro-2-[(dimethylamino)methyl]-
8-hydroxyquinoline reported an increased neurite number
following treatment of cultured PC12 cells and a restora-
tion of hippocampal dendritic spine density (but not num-
ber) in transgenic mouse model of AD [18].
In the current study, we sought to further understand the
action of this class of 8HQ by treating adult murine NSC
cultures with 2-[(dimethylamino)methyl]-8-hydroxyquino-
line (DMAMQ; Fig. 1). We specifically assessed the ability
of these cells to self-renew, essential for maintaining their
numbers in the brain throughout life, and to differentiate
into new CNS lineage cells. Our findings show that whilst
neurogenesis is unchanged, NSCs treated with DMAMQ
demonstrate an increase in NSC proliferation and an
increased neurite outgrowth during neurogenesis that was
signalled by increased production of reactive oxygen spe-
cies (ROS) signalling intermediates by the NADPH oxi-
dase (Nox) enzyme family. These effects were only
observed within a narrow concentration range, suggesting a





was synthesised as described previously [27].
Cell Culture
Murine NSCs were harvested from the brains of 6–8 week-
old Balb/c mice and grown without modification as neu-
rospheres in liquid culture as described previously [28].
DMAMQ Treatments
DMAMQ was included in the culture medium at the con-
centrations indicated. For all assays, the compound was
added as a single treatment at the start of the assay and was
not replenished when the media was changed.
Neural Colony Forming Assay (NCFA)
The NCFA has been described previously [29]. For each
independent experiment over 50 colonies were measured.
As stated above, DMAMQ was included in the matrix once
only at the start of the incubation.
Neurite Outgrowth Assay
Neurite outgrowth was measured using a neurite outgrowth
staining kit (Merck-Millipore) as per the manufacturer’s
instructions with the following modifications. One hundred
thousand cells per condition were incubated in high FGF
(20 ng/mL), no EGF, growth media before seeding
100,000 cells per well insert (1 lm pore size) in differen-
tiation medium with or without test compound. Neurite
outgrowth was permitted for 2 days before the assay.
Dichlorofluorescein (DCF) Intracellular ROS Assay
The DCF assay has been described previously [30]. Cells
were seeded at a density of 3.6 9 104 cells/well 24 h
before the start of the assay in poly-D lysine coated 96-well
plates. Fluorescence intensity was measured every 5 min
for 12 h using a FLUOstar Optima (BMG Labtech) fitted
with 490 nm excitation and 520 nm emission filters, and
initial rates were calculated using tangents to the curve.
MTS Metabolism Assay
Five microlitre of one solution MTS reagent (Promega) per
100 lL media was added to test and media only back-
ground control conditions, and incubated under normal
culture conditions for 90 min. Reaction product was
quantified using absorbance at 462 nm in a FLUOstar
Optima.
b-Galactosidase Staining and Quantification
The cells were stained using a Cell Signalling Technolo-
gies’ b-galactosidase staining kit as per the manufacturer’s
instructions. To solubilise the stain for quantitation by
spectrometry, the staining solution was removed from the
wells and replaced with 350 lL of DMSO. The plate was
warmed with agitation at 50C for 1 h before 100 lL of
dissolved dye was transferred to three wells of a 96-well
plate for triplicate reads.
Immunofluorescence Staining
The immunofluorescence staining protocol for NSC lineage










Fig. 1 Structure of DMAMQ
(2-[(dimethylamino)methyl]-8-
hydroxyquinoline)
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Ki67 Flow Cytometry
Ki67 expression in proliferating cells was quantified using
the Muse Ki67 Proliferation Kit (Millipore) as per the
manufacturer’s instructions. For the final analysis, the
number of unstained cells gated as positive was subtracted
from the stained cells and the percentage change was cal-
culated from the control cells.
Cell Cycle Phase Flow Cytometry
Cell cycle phase analysis by DNA content was determined
using the Muse cell cycle analysis kit (Millipore) as per the
manufacturer’s instructions.
PAGE and Western Blotting
Polyacrylamide gel electrophoresis and western blotting
were conducted as described previously [32]. Primary
antibodies and concentrations were as follows; pMEK1,
pMEK2 and pGSK-3b (Abcam) 1 in 1000; nestin
(Sigma) 1 in 1000; GFAP (Stem Cell Technologies) 1 in
5000; and Neurofilament-L (Invitrogen) 1 in 1000. Rel-
ative densitometric comparisons were normalised for
total protein loading as shown in Coomassie-stained
images.
Calcium Assay
Cells were seeded in 96-well plates as mentioned above. At
the beginning of the assay, 50 lL of culture media was
removed from each well and replaced with calcium assay
working buffer as per manufacturer’s instructions (Invit-
rogen). Plates were incubated for 1 h under normal incu-
bator conditions protected from light before test reagent
addition. Readings were taken using 488 nm excitation and
530 nm emission filters in a FluoSTAR Optima (BMG
Labtech) every 60 s for 1 h from addition.
Statistical Analyses
Statistical analyses were carried out using GraphPad
Prism 5 statistical software. The relevant statistical test
applied is indicated in the figure legend. Where signifi-
cant differences were found, Dunnett, Bonferroni and
Dunn’s tests were used for multiple comparisons of one-
way, two-way and non-parametric ANOVA, respec-
tively. Graphs show the mean and standard error of the
mean (SEM) of n independent experiments unless
otherwise stated.
Results and Discussion
Herein we investigated the potential for DMAMQ to
enhance the regenerative capacity of NSCs cultured
in vitro. NSC cultures were established using cells har-
vested from the sub-ventricular zone of adult wild type
Balb/c mice and grown in suspension culture as neuro-
spheres. We first examined the influence of DMAMQ on
proliferating neurospheres using a colony forming assay.
Cells were exposed to one single treatment included in the
media matrix at the start of the assay. Exposure of neuro-
spheres to DMAMQ was observed to have a profound
effect on the morphology (Fig. 2a) and volume (Fig. 2b) of
the growing neurospheres. Significant toxicity of DMAMQ
was only observed at the highest concentration tested
(100 lM; Figure S1), whereas NSC growth was stimulated
in the low lM concentration range. The observed prolif-
erative effect was due to both the number of new neuro-
spheres/colonies being increased (Fig. 2c) and the
distribution of neurosphere sizes shifting towards larger
diameters (Fig. 2d). Since the greatest proliferative effect
was observed at 2.5 lM DMAMQ, this concentration was
used for subsequent assays.
To investigate the increased growth further, Ki67, a
marker expressed only in actively proliferating cells, was
assessed by flow cytometry. An approximate 4 % increase
in proliferating cells was seen after 24 h of exposure to
DMAMQ in normal culture media (Fig. 3a, b). Cells that
are not proliferating may be quiescent (resting in G0 until
stimulated to re-enter the cell cycle) or senescent (an
irrecoverable G0 state where cells are unable to re-enter the
cell cycle but are not dead). b-galactosidase staining is
characteristic of senescent cells. Following 3 days of
DMAMQ treatment, administered as a single dose, the
number of senescent cells in the culture was decreased by
almost 20 % (Fig. 3c). Analysis of cell cycle phase by
DNA content also showed that cells were cycling more
rapidly following DMAMQ treatment, with a lower per-
centage of cells resting in the G0 and G1 phases of the cell
cycle following 24 h DMAMQ treatment (Fig. 3d, e).
These results indicate that the observed increase in NSC
proliferation was due to a shift towards active proliferation
coupled with protection against senescence.
In addition to heightening the ability of NSCs to
proliferate in the colony forming assay, we observed a
distinct pattern of outgrowth from NSCs cultured in
response to DMAMQ suggesting that DMAMQ also
promoted neurite outgrowth in the proliferating cultures
(Fig. 2a). To determine whether this was a significant
event, the number of neurospheres demonstrating this
morphology were counted and showed increased fre-
quency in the DMAMQ-treated colonies (Fig. 3f). The
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ability of DMAMQ to stimulate neurite outgrowth dur-
ing differentiation was assessed using a colourimetric
neurite staining protocol and showed that, over 2 days of
differentiation, DMAMQ-treated cells displayed ca.
10 % more neurite outgrowth than was observed for
control cells (Fig. 3g).
To ascertain whether enhanced neurite outgrowth could
be linked with enhanced neurogenesis (the capacity to form
new neurones), the influence of DMAMQ on neuronal or
astrocytic lineage preference following differentiation of
NSCs was considered. Lineage commitment of NSCs can
be influenced by factors present both when stimulated to
differentiate and before they are stimulated to differentiate.
Therefore, we considered the effect of including DMAMQ
in the culture media during differentiation and also before
cells were differentiated as a ‘priming’ event. For the dif-
ferentiating culture, DMAMQ was added at the induction
of differentiation and remained in the media for 7 days. For
the primed culture, NSCs were treated for 24 h prior to
differentiation and then transferred into differentiation
medium and cultured for 7 days in the absence of further
exposure to DMAMQ. Subsequent immunofluorescence
staining indicated that DMAMQ incubation did not alter
the resulting cell lineages or overtly change the morphol-
ogy of the differentiated neurones and astrocytes (Fig. 4a).
In addition, western blot analysis (Fig. 4b) confirmed no
changes in expression of nestin (Fig. 4c), neurofilament-L
(NF-L; Fig. 4d) or GFAP (Fig. 2e) either when cells were
primed or differentiated with DMAMQ. Therefore, neu-
rogenic potential of NSCs treated with DMAMQ was
neither enhanced nor compromised.
Inactivation (by phosphorylation of Ser9) or pharma-
cological inhibition of GSK-3 leads to both increased
proliferation and enhanced neurogenesis in neural stem cell
cultures [33, 34] and this phosphorylation has previously
been reported in some studies using the 5,7-dichlorinated
analogue of DMAMQ [18]; however, we did not observe
any change in the phosphorylation status of GSK-3b fol-
lowing treatment with concentrations of DMAMQ that
induced NSC growth (Fig. 5a). Indeed, a significant
increase in phosphorylation was only observed at 100 lM
DMAMQ (Figure S2), the same concentration at which
DMAMQ cytotoxicity was significant (Figure S1). There-
fore, signalling through GSK-3b is unlikely to be of rele-
vance to DMAMQ-stimulated NSC growth. Additionally,
no detectable changes in AKT and MEK1/2 phosphoryla-
tion were observed (Fig. 5a), indicating these redox-sen-
sitive signalling pathways were not involved in the
induction of cell growth.
Many neuronal signalling processes involve calcium flux,
and stem cells utilise these pathways [35]. Changes in cal-
cium mobilisation are also linked with redox signalling [36]
and increased cytosolic Ca2? can directly activate some Nox
enzymes [37]. Therefore, intracellular calcium levels were
measured in the NSCs. Following DMAMQ treatment, a
reduction in intracellular calcium was detected (Fig. 5b).
Redox signalling pathways have been linked with NSC
growth and an increased ROS burst has been linked with
induction of proliferation [38–40]. A ‘cellular redox cycle’
has been shown to occur within the cell cycle and is
thought to control cycle phase progression [41, 42]. Mea-



















































































(a) (b) (c) (d)
2.5 μM DMAMQ
Control
Fig. 2 DMAMQ promotes the proliferation of NSCs. a Representa-
tive field of view showing neurosphere morphology with and without
2.5 lm DMAMQ treatment for 21 days. Scale bar = 35 lm.
b Colony volume measurement of increasing DMAMQ doses.
Dissociated cells (single cells) were seeded at equal density with/
without DMAMQ, and the growth of neurospheres present at 21 days
post-plating was measured (change in volume is expressed relative to
the no DMAMQ control; one-way ANOVA, n = 3). Neurosphere
volume at 2.5 lm DMAMQ is increased both because of c increased
colony formation (students t test, n = 3) and d a shift in the size of
the neurospheres towards larger diameters (with significant differ-
ences being obtained for diameters in the 30–59 and 90–199 lm
range; two-way ANOVA, p\ 0.001, n = 3)
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fluorescent probe DCFDA showed increased ROS pro-
duction when NSCs were treated with DMAMQ in the
micromolar range (Fig. 6a). There are various sources of
intracellular ROS including the Nox family of signalling
proteins. The Nox family, which generates ROS as a sig-



























































































































































Fig. 3 DMAMQ reduces the non-proliferative population of NSCs
and increases NSC growth. a Flow cytometry analysis of Ki67
proliferation marker expression in NSCs after 24 h treatment with
2.5 lm DMAMQ. Both populations were gated identically using the
unstained background control populations shown in grey behind the
Ki67 negative (blue) and Ki67 positive (red) populations. b Quantifi-
cation of the percentage increase in Ki67 expression from the profiles
in a; students t test, p = 0.025, n = 4. c Quantification of b-
galactosidase staining following three days incubation with 2.5 lM
DMAMQ, change is expressed relative to control cells; students t test,
n = 4. d Flow cytometry profiles of DNA content as an indication of
cell cycle phase after 24 h treatment with 2.5 lm DMAMQ. Control
and DMAMQ samples were gated identically based on the control
distribution and phases are shown as G0/G1 in blue, S in red, G2/M in
pale green and debris in dark green. e Quantification of the
percentage cells in each phase of the cell cycle from the profiles in
d; two-way ANOVA, p\ 0.05, n = 4. f Quantification of the number
of neurospheres grown in the colony forming assay with outgrowths
in response to DMAMQ; students t test, n = 3. g Quantification of the
ability of differentiating NSCs to form neurite outgrowths in the
presence of DMAMQ expressed relative to control cell outgrowths;
students t test, n = 6. *p\ 0.05, **p\ 0.01
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NSC proliferation [43–45]. To examine the role of Nox
signalling in the ROS produced in response to DMAMQ, a
Nox isozyme inhibitor (DPI) was co-administered with
DMAMQ in the DCFDA assay. Inclusion of DPI was
sufficient to block the DMAMQ-induced ROS response in
the NSCs (Fig. 6b), implicating Nox in the observed
intracellular ROS burst.
If the ROS produced by the addition of DMAMQ to the
cells was signalling the increased growth of the cells, then
inhibition of this pathway with DPI would be expected to
inhibit the increased colony growth in the NCFA. DPI was
included in the media matrix as a single dose at the start of
the NCFA with or without NNAMQ and growth was deter-
mined as described previously. DPI alone reduced colony
growth, primarily affecting the number of colonies formed
(Fig. 7a–c). When DPI and DMAMQ were co-incubated in
the media matrix (single treatment at the start of the assay),
the growth of the spheres was stunted with fewer colonies
formed (Fig. 7a–c) and decreased the diameter at the 2.5 lM
treatment concentrations of DMAMQ.
Whilst our results concur with previous literature that
increased ROS increases NSC growth and suggest that
Fig. 4 Effects of DMAMQ on NSC differentiation. a Immunofluo-
rescence staining demonstrates that NSCs treated with DMAMQ
throughout 7 days differentiation retain their capacity to differentiate
and are multipotent. Green, NF-L (neuronal marker); Red, GFAP
(astrocytic marker); Blue, DAPI (nuclear stain); Scale bar = 20 lm.
b Example western blot images of cells either differentiated after 24 h
priming with DMAMQ or differentiated in the presence of DMAMQ.
Densitometric quantification of western blot intensity for c nestin,
d NF-L and e GFAP relative to the total protein (coomassie) loading
control. No differences are observed in lineage preference as a result
of DMAMQ exposure either before or during differentiation; one-way
ANOVA n = 5
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modulation of Nox to increase ROS signalling initiates
such growth, the data presented cannot exclude intrinsic
ROS production by DMAMQ that mimics, but does not
outcompete inhibition of, this pathway. In any case, the
generation of ROS in response to DMAMQ treatment
contrasts with the mainstream view that 8HQs can be of
therapeutic benefit by reducing aberrant metal-mediated
ROS production associated with neurodegenerative disease
[46].
The identification of compounds that regulate neuroge-
nesis holds great promise for treating neurodegenerative
conditions. AD-associated Ab peptides have been shown to
decrease neurogenesis using both in vivo and in vitro
models, including murine NSC cultures [3, 47, 48] and
Fig. 5 DMAMQ signalling is not through GSK-3b, AKT or MEK
signalling pathways. a NSCs were incubated for 30 min with
DMAMQ and assessed for activation of signal transduction pathways
by detection of changes in phosphorylation of several signalling
intermediates (GSK-3b, AKT, MEK1 and MEK2). No significant
differences were seen in phosphorylation; students t test, n = 4.
b Intracellular calcium measured by fluorescence change per minute
for 1 h post-DMAMQ addition. Students t test, n = 4, *p\ 0.05
Fig. 6 DMAMQ mediates its
effects through stimulation of
NADPH oxidase to increase
intracellular ROS production.
a Intracellular ROS increases in
response to DMAMQ treatment
in proliferating NSCs treated
with DMAMQ in the low lM
range, as measured by DCF
fluorescence. b Co-treatment
with DMAMQ and the NOX
inhibitor, DPI, prevents the
DMAMQ ROS burst,




n = 4, *p\ 0.05, **p\ 0.01
(significantly different from
untreated control)
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hence, restoration of NSC function by 8HQs could be of
value in treating AD. The picture is far from clear, how-
ever, because markers of increased neurogenesis can be
found in post-mortem analysis of AD brains [2] and also in
some animal models of disease [4, 49]. Increased neuro-
genesis may represent a compensatory response by the
NSCs within the brain to replenish lost neurones. In such a
context, the current findings suggest that compounds that
stimulate neurogenesis during AD may be able to augment
these compensatory mechanisms. The caveat, however, is
that neurogenesis has also been linked with forgetting [8];
in theory, stimulating neurogenesis may therefore inad-
vertently exacerbate the symptoms of memory loss. In
addition to these complications, which may arise even from
a targeted stimulation of neurogenesis, Nox signalling
regulates diverse processes in vivo such as contractile
functions of heart muscle [50, 51] and systemic immune
responses [37, 52], whilst acute and chronic Nox activity is
associated with neuroinflammation [53]. Moreover, sub-
stituted 8HQs can have anti-proliferative/cytotoxic prop-
erties depending on their local concentrations (Figure S1)
[13–15] or have the potential to cause neuronal damage by
interfering with epigenetic regulation (e.g. clioquinol [54]).
Some of these considerations may explain why clioquinol
and 5,7-dichoro-DMAMQ have not shown evidence of
clinical benefit in treating AD [55].
Conclusions
This study demonstrates that DMAMQ modulates NSC
growth and neurite outgrowth during differentiation when
cultured in vitro by stimulating ROS production and Nox
signalling. This suggests that DMAMQ and similar 8HQs
may have neuro-regenerative potential in vivo; however,
the very narrow concentration range in which DMAMQ
modulates NSC growth presents some challenges for
therapeutic administration. In particular, the potential
benefits of replenishing damaged brain tissue must be
balanced against the possibility of overstimulating neuro-
genesis and the propensity for undesirable ‘‘off-target’’



























































































































Fig. 7 Nox inhibition with DPI blocks DMAMQ-induced growth.
a Representative colonys grown in the presence or absence of Nox
family inhibitor DPI and DMAMQ. Scale bar, 100 lm. b Total
volume of growth at 21 days calculated from the number of colonies
formed c and the diameter of the colonies. d. Two-way ANOVA,
n = 3, *p\ 0.05, **p\ 0.01
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action of substituted 8HQs in vitro and in vivo is required
to determine whether this class of compound will be a
viable therapeutic intervention in countering disease pro-
gression in any dementia.
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Abstract
Neurogenesis continues in the post-developmental brain throughout life. The ability to stimulate the production of new 
neurones requires both quiescent and actively proliferating pools of neural stem cells (NSCs). Actively proliferating NSCs 
ensure that neurogenic demand can be met, whilst the quiescent pool makes certain NSC reserves do not become depleted. 
The processes preserving the NSC quiescent pool are only just beginning to be defined. Herein, we identify a switch between 
NSC proliferation and quiescence through changing intracellular redox signalling. We show that N-terminal post-translational 
cleavage products of the prion protein (PrP) induce a quiescent state, halting NSC cellular growth, migration, and neurite 
outgrowth. Quiescence is initiated by the PrP cleavage products through reducing intracellular levels of reactive oxygen 
species. First, inhibition of redox signalling results in increased mitochondrial fission, which rapidly signals quiescence. 
Thereafter, quiescence is maintained through downstream increases in the expression and activity of superoxide dismutase-2 
that reduces mitochondrial superoxide. We further observe that PrP is predominantly cleaved in quiescent NSCs indicating a 
homeostatic role for this cascade. Our findings provide new insight into the regulation of NSC quiescence, which potentially 
could influence brain health throughout adult life.
Keywords NADPH oxidase · Nox2 · DRP1 · Superoxide dismutase · SOD2 · Reactive oxygen species · Mitochondria · N1 · 
N2
Introduction
It is now firmly established that the adult brain contains cells 
that demonstrate ‘stemness’, i.e., are capable of self-renewal 
and formation of new brain cells (reviewed in [1]). Neural 
stem cells (NSCs) have been detected in human brain tissue 
from donors up to the age of 72 years [2] and markers of 
neurogenesis detected into the ninth decade [3], indicating 
the likely importance of these cells throughout adult life. 
The adult brain contains different populations of NSCs. Type 
1 NSCs are quiescent and can be stimulated to become type 
2 NSCs, which are actively replicating. Type 2 cells in turn 
progress to be type 3 migratory cells or neuroblasts [1, 4]. 
NSC growth and differentiation have been linked with hip-
pocampal learning and memory as well as forgetting [5–9], 
and changes in neurogenesis correlate with various mental 
health issues and neurodegenerative diseases [3, 10].
Neurogenesis is modulated by several neurodegenerative 
disease-associated proteins or peptides including the prion 
protein (PrP) [11, 12], which is most widely recognised for 
its causative role in transmissible neurodegenerative diseases 
of humans and animals [13]. Research into the role of PrP 
in neurogenesis has found that PrP expression is linked with 
enhanced NSC proliferative capacity [12], associated with 
increased cell cycling at the expense of differentiation [14]. 
In addition, PrP has been shown to be part of a receptor com-
plex for soluble neurotoxic Alzheimer’s disease-associated 
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amyloid-beta peptides [15, 16] and the presence or absence 
of PrP changes NSC self-renewal in response to amyloid-
beta peptides [17], thereby suggesting that a putative neu-
rogenic function of PrP may become corrupted during neu-
rodegenerative disease.
Despite much interest in the role of PrP during disease, 
there is still no defined function for this protein. However, 
PrP is known to be involved in cellular redox balance, both 
protecting against detrimental disturbance in health and 
causing damage during prion disease [18–27]. The cellular 
biology of PrP is complex; mature PrP is a glycosylphos-
phatidylinositol membrane-tethered glycoprotein, known 
to undergo various other post-translational modifications 
including internal cleavage at three or more sites, termed 
alpha-, beta- and gamma-cleavages [28–30]. The alpha- and 
beta-cleavage events remove the flexible, unstructured N-ter-
minus from the structured C-terminal region, producing N1/
C1 and N2/C2 fragments, respectively (Fig. 1a). Various 
cellular locations of cleavage have been proposed including 
the secretory pathway and cell surface, and the N-terminal 
fragments have predominantly been found as extracellular 
soluble peptides [31, 32]. As alluded to above, PrP is asso-
ciated with cellular redox homeostasis and the N1 and N2 
fragments alone have been shown to reduce intracellular 
reactive oxygen species (ROS) and protect against oxida-
tive damage [32, 33].
Redox balance has a regulatory role in NSC growth and 
differentiation [34, 35]. Adult NSCs are not dispersed evenly 
through the brain but situated in specialised regions, referred 
to as neurogenic niches [36]. In the neurogenic niche, the 
environment is highly important for the preservation of the 
NSC populations and is maintained as a low ROS environ-
ment [37]. Increased NSC ROS are associated with stimula-
tion of increased growth, possibly at the expense of deplet-
ing the quiescent pool in favour of the actively proliferating 
cells [34, 35, 38]. In neurodegenerative diseases, such as 
prion diseases and Alzheimer’s disease, where redox bal-
ance is compromised resulting in increased ROS, increased 
markers of neurogenesis are detected in brain tissue [39]. We 
hypothesized that the ability of the N-terminal PrP peptides, 
N1 and N2, to modulate cellular ROS levels could exert sig-
nificant regulatory effects on NSC growth and maintenance 
of the quiescent NSC pool.
Methods
Prion N‑terminal peptides
The prion N-terminal peptides were generated by micro-
wave synthesis and quality controlled by HPLC and mass 
spectrometry as previously described in Karas et al. [40]. 
Peptides were also purchased from China Peptides (China).
Adult neural stem cell extraction
NSCs were harvested from the brains of three 8-week-old 
PrP gene (prnp)−/− (PrP knock-out), C57/B6 wild-type, and 
Tga20 (PrP over-expressing by approximately eightfold) 
mice, and transferred into suspension culture as described 
previously in Haigh et al. [24]. All animal procedures were 
performed in accordance with University of Melbourne 
animal ethics committee approval (ethics ID: 1413198.1), 
operating under the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes.
NSC culture
Routine NSC culture has been described previously [24]. In 
brief, cells were grown as neurospheres in complete prolif-
eration medium (Stem Cell Technologies, VIC, AUS), sup-
plemented with final concentrations of 10 ng/ml fibroblast 
growth factor (FGF) and 20 ng/ml epidermal growth factor 
(EGF) cytokines, and 2 μg/ml heparin (Stem Cell Technolo-
gies). Cultures were maintained in a 5%  CO2 humidified 
incubator.
Cell counts
Cells were mixed 1:1 (v/v) with Trypan Blue reagent (Life 
Technologies, VIC, AUS) and counted using a Countess cell 
counter (Life Technologies).
Fig. 1  N1 and N2 change NSC growth, migration, and neurite out-
growth. a Schematic of PrP cleavage events, the cut positions pro-
ducing the N1 and N2 fragments, and the putative site of gamma-
cleavage. Also shown are the epitopes of the antibodies used to target 
PrP. b Representative images of neurosphere colony morphology in 
the NCFA with and without peptide treatments. Two images each 
are shown to illustrate the varied morphology. Scale bar = 100 μm. c 
NCFA colony counts of NSCs incubated with and without N1 and N2 
included in the assay matrix. n = 4. d Diameter measurements of col-
onies formed in the NCFA with and without peptide incubation. n = 4. 
e Immunoblots for Pin1 of NSCs treated for 24 h with N1 or N2. f 
Densitometric quantification of e. n = 4. g NCFA colony counts of 
NSCs incubated with fragments corresponding to regions of N2 and 
an N2 peptide with the prolines of the N-terminal polybasic region 
mutated to alanine. n = 3. h Diameter measurements of the NCFA 
described in G. n = 3. i NCFA colony counts of N1 and N2 incubated 
with prnp knock-out (KO) and over-expressing (Tga20) NSCs. n = 3. 
j Diameter measurements of the NCFA described in I. n = 3. k Rep-
resentative images of neurosphere migration as influenced by N1 and 
N2 taken 3 and 7 days after peptide addition. Scale bar = 100 μm. l 
Quantification of the area migrated after 3 days incubation as shown 
in k. n = 3. m Neurite outgrowth of NSCs incubated with N1 and N2 
relative to control cells. n = 3. All data within the figure panels are 
presented as mean and SEM with significance indicated by *p < 0.05, 




Neural colony forming assay (NCFA)
The colony forming assay is described in Collins et al. [17]. 
Briefly, neurospheres are dissociated into single-cell sus-
pension and seeded in a semi-solid gel matrix made with a 
2:1 solution of proliferation medium and collagen (Sigma-
Aldrich, VIC, AUS) in 24-well plates at a density of 50,000 
cells/ml (25,000 cells/well). Wells were supplemented with 
80 μl of fresh proliferation medium every 5 days. Treatments 
were included at the start of the assay only. Colonies were 
counted and diameters measured at 21 days post the start 
of the assay. All colonies at all depths through the matrix 
were calculated and measured for a minimum of 5 fields or 
50 colonies (for conditions where few colonies were found 
per field of view).
Migration assay
Neurospheres of 80–100 μm diameter were seeded into wells 
pre-coated with 5 μg/ml poly-d lysine (PDL; Sigma-Aldrich) 
in  H2O solution (for a minimum of 1 h at room temperature) 
and grown in complete proliferation medium. After 3 days, 
migration from the central neurosphere was calculated by 
application of contour ROIs around the surface area into 
which the cells had spread using NIS Elements 3.0 (Nikon) 
software package. The area covered after 7 days could not 
be calculated as migration had proceeded beyond the imag-
ing area.
Neurite outgrowth assay
One hundred thousand cells/well were cultured in complete 
proliferation medium supplemented with 20 ng/ml FGF for 
24 h before transferral into complete differentiation medium 
(Stem Cell Technologies). The neurite outgrowth assay (Mil-
lipore, Thermo-Fisher, VIC, AUS) was carried out as per 
the manufacturer’s instructions. Well inserts (1 µm pore 
size) were coated on their under-side with 10 µg/ml laminin 
in  H2O solution for 2 h at 37 °C before NSCs were trans-
ferred into the insert. Cells were cultured for 2 days in dif-
ferentiation medium before assaying outgrowth. To assay 
neurite extension onto the laminin coated under-side, well 
inserts were first washed in PBS, then fixed in methanol for 
20 min at room temperature, washed again by transferring 
the insert into PBS, and then stained with neurite stain solu-
tion for 30 min. Inserts were washed again in PBS, excess 
dye removed from the inside of the insert, and cell somas 
removed by swabbing the inside of the insert. The neurites 
extending over the under-side of the well insert were then 
solubilised in extraction buffer and the absorbance read in a 
Spectrostar (BMG) at 562 nm. Neurite outgrowth, indicated 
by absorbance of the neurite stain as compared with extrac-
tion buffer alone, was calculated using MARS software 
(BMG).
Immunofluorescence staining
The standard immunofluorescence protocol used has been 
described previously [24, 41]. Briefly, cells were fixed in 
4% (v/v) paraformaldehyde for 30 min, followed by per-
meabilization in 0.1% triton-X-100, before blocking in 10% 
(v/v) FBS, 0.1% (w/v) BSA in PBS for 30 min. Primary and 
secondary antibody incubations were carried out in 1% (v/v) 
FBS, 0.1% (w/v) BSA in PBS blocking buffer, with details 
and relevant concentrations listed in Sup Table 1.
Microscopy
Confocal images were collected using a Leica SP8 (Leica 
Microsystems, NSW, AUS) and wide-field fluorescence or 
bright-field images captured using a Nikon Eclipse TE2000-
E epi-fluorescence microscope with a Roper Scientific CCD 
camera (Nikon, Coherent Scientific, SA, AUS). Image analy-
sis was performed using Fiji imaging software [42] or NIS 
Elements 3.0 (Nikon). Mitochondrial parameters (minimum 
of six fields from three independent experiments) were cal-
culated using the mito-morphology macro for image J cre-
ated by Ruben K. Dagda at the University of Pittsburgh. 
Image enhancements, despeckling, were performed for inset 
digital zooms to increase picture clarity.
Pharmacological inhibition of pathway activity
Diphenyleneiodonium chloride (DPI; Sigma-Aldrich) stocks 
were prepared in water and stored at room temperature. 
N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesul-
fonamide dihydrochloride (H89; Abcam, VIC, AUS) stocks 
were prepared in water and stored at -20°C.
Cell plating
Cells were seeded at a density of 3.6 × 104 cells/well in 5 μg/
ml PDL in  H2O solution-coated 96-well plates and allowed 




fophenyl)‑2H‑tetrazolium (MTS) metabolism assay
Five microlitres of one-solution MTS reagent (Promega, VIC, 
AUS) was added per 100 μl of media in each well. Plates were 
incubated under normal incubator conditions for the duration 
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of the assay. Developed colour was measured at 492 nm in a 
FluoSTAR/PolarSTAR Optima (BMG Labtech, VIC, AUS).
Lactate dehydrogenase (LDH) cell death assay
Cellular and extracellular LDH was measured using a Cytotox-
icity Detection kit (LDH; Roche, VIC, AUS) and cytotoxicity 
calculated as per the manufacturer’s instructions.
Caspase 3/7 assay
Caspase 3/7 staining and 7-amino-actinomycin D (7-AAD) 
staining were carried out and quantified using a Muse™ Cas-
pase-3/7 Kit (Roche-Sigma, USA) and a Muse™ Cell Ana-
lyzer (Roche-Sigma) with software version 1.4. The cells 
were loaded as per the manufacturer’s instruction with 5 µl 
of Caspase-3/7 working solution added to 50 µl cells (diluted 
to approximately 1 × 106 cells/ml). Cells were incubated for 
30 min at 37 °C before addition of 150 µl of 7-ADD working 
solution and then analysed for apoptotic (but not dead) and 
dead cells.
Ki67 assay
Ki67 was assayed using the  Muse® Ki67 Proliferation Kit 
(Roche-Sigma) and a Muse™ Cell Analyzer (Roche-Sigma). 
Cells were fixed and stained as per the manufacturer’s instruc-
tions and the negative control staining (shown in grey shading 
on the plots) was used to gate the background unstained cell 
population for analysis using the Muse v1.4 software.
Adenosine triphosphate (ATP) assay
Cellular ATP content was measured by luminescence using 
Life Sciences ATP assay (Life Technologies) as per the 
product protocol and normalised for total protein levels 
determined by BCA assay (Pierce, Thermo-Fisher).
Dichlorofluorescin diacetate (DCFDA) assay
The DCFDA assay for intracellular ROS production has 
been described previously [33]. Briefly, cells were loaded 
with CM-H2-DCFDA reagent (Invitrogen) by incubating 
cells with a 5 µM probe solution in PBS for 20 min at 37 °C. 
Basal fluorescence was then read to provide a well-back-
ground control and test conditions added to start the assay. 
Fluorescence intensity was monitored for 12 h.
Nicotinamide adenine dinucleotide phosphate 
(NADPH) consumption assay
NADPH (Arbor Assays, Bio Scientific, VIC, AUS) was 
diluted to 250 mM stock in sterile water, and aliquoted and 
stored at – 20 °C until use. At the start of the assay, 1 μM 
peptide was included in the culture media; then, 25 mM 
NADPH was added to each well and decay of the NADPH 
absorbance monitored at 340 nm every 60 s for 10 min and 
gradients calculated to show consumption of substrate.
Superoxide dismutase (SOD) activity assay
Total SOD activity of cell lysates was determined using a 
WST-1-based competitive inhibition assay (Abcam), as per 
the manufacturer’s instructions, with normalisation of activ-
ity to total protein as determined by BCA assay.
Peptide:N‑glycosidase F (PNGase‑F) digests
Pre-denatured lysates were digested using 1 µl PNGase-F 
per 20 µl protein sample with overnight incubation at 37 °C.
Western/dot blotting
Western blotting was carried out using the Invitrogen 
NuPAGE/Bolt gel system (Life Technologies) with Criterion 
(BioRad, VIC, AUS) or iBlot (Invitrogen) transfer and devel-
oped as described previously [41, 43]. Coomassie membrane 
staining was performed as previously described [44]. Total 
protein staining was used to monitor gel loading/transfer 
efficiency, because the housekeeping proteins often used as 
loading controls are involved in the cellular processes being 
investigated and are, therefore, considered unreliable. Dot 
blotting was performed by dotting 2 μl of whole-cell lysate 
onto nitrocellulose membranes. Membranes were blocked 
and blotted as for standard western blotting procedure. 
Antibody information is shown in Sup Table 1. Percentage 
change was calculated by first normalising band signal to 
total protein and then applying the following equation:  % 
change = (test band signal intensity/control band signal 
intensity) × 100.
Senescence staining and quantification
Senescence was determined using a β-galactosidase stain-
ing kit (Cell Signaling Technologies, Sapphire Biosciences, 
VIC, AUS), following the manufacturer’s instructions and 
the blue product solubilised in DMSO by agitated heating 
as described in Haigh et al. [44].
Redox‑sensor Red ROS assay
Redox-sensor Red (PF-H2TMRos; Life Technologies) at a 
final concentration of 5 μM in Opti-MEM I reduced serum 
culture medium (phenol red-free; Invitrogen) was loaded 
into cells for 10 min and cells were imaged in fresh medium 




MitoSOX fluorescent indicator probe (Life Technologies) 
was loaded into cells at a final concentration of 5 μM in 
normal media for 10 min under standard incubator condi-
tions and imaged in fresh, phenol red-free Opti-MEM as 
described previously [45].
Small interfering RNA (siRNA) transfections
Pre-validated siRNA duplexes were purchased from Life 
Technologies. Single-cell suspensions were prepared in 
proliferation media and sufficient cells seeded into 1-well 
of a 6-well plate for all test and control assays. Transfec-
tions were achieved using Fugene HD transfection reagent 
(Roche) as per the manufacturer’s protocol. Plates were 
returned to the incubator until cells were used for assay. 
Prior to assay, cells were re-suspended as single cells, 
counted and seeded into the NCFA as described previously. 
Pre-screening of knock-down efficiency found that knock-
downs of both Nox2 and SOD2 were optimal (~ 50%) at 
2 days using 30 μM siRNA for Nox2 and 50 μM for SOD2 
(example western blot images of knock-downs are shown in 
Sup Fig 1). Therefore, all assays began 2 days post-treatment 
with these concentrations of siRNA and the equivalent of 
non-silencing control (Life Technologies). At the start of 
every assay, a dot blot was performed on cells from the start-
ing culture to confirm the knock-down had been consistent. 
Quantifications of these quality control spots are shown in 
Sup Fig 1.
Statistical analysis
Statistical analyses were accomplished using GraphPad 
Prism 5 statistical software. Students t tests were used for 
comparison of two parameters and ANOVA or Kruskal–Wal-
lis analyses used for > two parameters. Where significant 
differences were found, Dunnett, Bonferroni, or Dunn tests 
were used for multiple comparisons of one-way, two-way, 
and non-parametric ANOVA, respectively. p < 0.05 was used 
as the cutoff for significance and ≥ 95% statistical power. All 
stated “n” values indicate independent repeats.
Results
N1 and N2 alter NSC growth
To assess the ability of the soluble N-terminal fragments to 
influence NSC growth, adult NSCs (harvested from wild-
type mice at 8 weeks of age) were incubated with 1 μM syn-
thetically produced N1 and N2 peptides (Fig. 1a) included 
in the matrix of a neural colony forming assay (NCFA; 
Fig. 1b). The 1 μM concentration of each peptide was based 
upon our previous studies showing functionality at these 
concentrations [33, 41, 46]. Exposure of the NSCs to either 
the N1 or the N2 fragment resulted in decreased growth, 
reducing the number of colonies formed (Fig. 1c) and, for 
the N2 fragment, the diameter of the colonies (Fig. 1d). 
The N2 growth reduction was accompanied by a signifi-
cant reduction in protein expression of the cell prolifera-
tion regulatory protein Pin1 (Fig. 1e, f). Using further syn-
thetic fragments corresponding to shorter regions of the N2 
fragment, and also an N2 peptide with mutated N-terminal 
residues, it was found that wild-type full-length N2 is the 
minimum needed to cause overall growth change, especially 
with respect to colony formation (Fig. 1g, h). A fragment 
representing the most N-terminal region, amino acids 23–50, 
could elicit a small effect on colony diameter, but, whilst this 
was significantly different from the untreated control, it was 
not statistically different from a scrambled control peptide 
suggesting an artefactual result (Fig. 1h). The consequence 
of N-terminal mutation was less clear. Whilst the effect of 
wild-type N2 on reducing the number of colonies formed 
was clearly abolished by mutation of the N-terminal proline 
residues to alanine (P26/28A), there was a persisting capac-
ity to reduce colony diameter similar to that observed with 
un-mutated N2 fragment.
During prion disease, ongoing PrP expression is an 
absolute requirement for pathogenesis [47]. Therefore, we 
investigated whether the influence of the N1 and N2 pep-
tides on cell growth was changed in cells of differing PrP 
expression levels. The effect of the fragments, especially 
for N2, did not depend upon the underlying expression of 
PrP in the NSCs, with both the prnp knock-out (KO) and 
Tga20 over-expressing cells showing reduced growth when 
the peptides were included in their matrix (Fig. 1i, j). How-
ever, in contrast with the wild-type cells, the KO and Tga20 
cells demonstrated a changed influence of the N1 peptide, 
with colony diameter more influenced than the number of 
colonies formed.
N1 and N2 reduce migration and neurite outgrowth
Other processes that occur following division in actively 
replicating NSCs include migration of cells to their site of 
integration and the extension of neurite outgrowths, and both 
of these processes have been found to be influenced by cellu-
lar PrP expression levels [48, 49]. Congruent with the colony 
forming assay results, both migration and neurite outgrowth 
were reduced by the N1 and N2 peptides (Fig. 1k–m). By 
observing the migration of cells from the neurospheres for 
longer, it was apparent that the inhibitory effects of N1 and 
N2 were transient with migration of the N1-treated cells 
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indistinguishable from control cells and migration resumed, 
albeit at an attenuated level, for N2 by 7 days (Fig. 1k).
N1 and N2 do not cause cytotoxicity or senescence
To ascertain whether cell death was the cause of the reduced 
NSC growth in response to the N1 and N2 peptides, cytotox-
icity and cell metabolism assays were performed (Fig. 2a, b) 
after 24 h, which found no discernible changes. To ensure 
that death was not delayed or increased over the time of the 
NCFA and migration assays, caspase 3 and 7 (executioner 
caspase) activation and cell death as indicated by uptake 
of 7-AAD were monitored weekly using the more potent 
N2 fragment. These measurements also found no significant 
effect on long-term viability as a result of peptide expo-





































































































Fig. 2  Reduction in growth is not due to reduction in cell viability. 
a Cytotoxicity of N1 and N2 as measured by cellular LDH release 
24  h post-exposure. n = 4. b MTS measurement of cellular metabo-
lism as an indicator of viability 24  h post-exposure to N1 or N2. 
n = 4. c Active caspase 3/7 detection in cells cultured for 3-week post-
treatment with N2. n = 3. d Uptake of 7-AAD as an indicator of dead 
cells in the same time series as c. n = 3. e Beta-galactosidase staining 
intensity, as an indicator of cell senescence, 3-day post-exposure to 
N1 or N2. n = 3. f Immunoblots for the cell quiescence/senescence-
associated protein p21. g Densitometric quantification of f. n = 3. h 
Ki67 flow cytometry analysis of proliferating cells 3 days following 
treatment with the N2 peptide. Representative plots from n = 4. i Cel-
lular ATP concentration relative to total protein 24 h after exposure 
to N1 or N2. n = 4. j Immunoblots for the mitochondrial transporter 
protein TOM22 24  h after exposure to N1 or N2. k Densitometric 
quantification of e. n = 4. Data are presented as mean and SEM. Sig-
nificance is indicated by *p < 0.05
 S. J. Collins et al.
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indicator of cellular senescence, was not increased in these 
cells (Fig. 2e). Assessment of the, quiescence/senescence-
associated marker p21 showed no change in response to N2 
treatment over 3 days (Fig. 2f, g); however, Ki67, a marker of 
cell proliferation, was reduced to half of the levels detected 
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growth might indicate perturbed cellular energy demands; 
therefore, cellular ATP and mitochondrial protein expression 
levels were examined. Despite no changes in cellular ATP 
levels (Fig. 2i), a small decrease in the mitochondrial trans-
porter TOM22 was detected following 24 h exposure to the 
N2 fragment (Fig. 2j, k), which indicated that mitochondrial 
mass was influenced by this peptide.
N1 and N2 reduce intracellular ROS production
In our previous studies, we found that the N2 fragment could 
protect secondary cell lines from oxidative stress and simi-
lar protective actions have been reported for the N1 frag-
ment [32, 33, 41]. In addition, redox signalling is known 
to alter NSC growth [34, 35, 44]. To determine whether 
the influence of the N1 and N2 peptides on redox balance 
might underpin the NSC growth changes, we analysed the 
production of intracellular ROS using the DCFDA assay. 
The DCFDA assay is a fluorometric assay wherein cells 
are loaded with DCFDA; the intracellular form of DCFDA, 
 DCF−, is non-fluorescent until it is oxidised to DCF by free 
radicals, and therefore, an increase in fluorescence signal 
over the control cells indicates increased radical produc-
tion and vice versa. Performing the DCFDA assay found a 
significant reduction of ROS production in cells incubated 
with either peptide (Fig. 3a). We have previously found that 
inhibiting NADPH oxidase (Nox) activity using the pharma-
cological inhibitor DPI reduces NSC growth in the NCFA 
[44]. Therefore, intracellular ROS levels were further con-
sidered in the NSCs using Redox-Sensor Red. Redox-Sensor 
Red is a partitioning probe; fluorescing when it binds ROS 
in the cytosol, which are primarily produced by the Nox 
family, or, if cytosolic ROS are not met, it then accumulates 
in lysosomes where its fluorescence increases as influenced 
by lysosomal redox balance. Redox-Sensor Red was loaded 
into whole neurospheres prior to addition of N1, N2, or DPI 
and spheres were imaged at 90 min. Fluorescence inten-
sity showed a similar significant reduction in ROS detected 
for the N1-, N2-, and DPI-treated conditions (Fig. 3b, c). 
We next measured cellular usage of NADPH, finding that 
N2 and DPI showed a significant decrease in the utilisa-
tion of NADPH indicating a lesser activity of this family of 
enzymes (Fig. 3d). To further assess the potential for N1 and 
N2 to modulate Nox family function, we competed the pep-
tides against ATP, which activates Nox signalling increas-
ing cellular ROS production, and used the DCFDA assay to 
monitor changes within the cells. The peptides were overlaid 
on the cells first and then ATP was included in the assay 
media. ATP increased cellular ROS production significantly 
from the basal control and both peptides were able to inhibit 
this effect (Fig. 3e).
To directly investigate the role of Nox signalling, siRNA 
knock-down was used to target Nox2. Nox2 was selected 
as it is a central catalytic subunit of the Nox complex and 
known to have a role in the maintenance of NSC populations 
within the brain [50]. Nox2 has also previously been linked 
with PrP signal transduction and to prion disease pathogen-
esis [51–53]. Western blotting confirmed that the stem cells 
do express this subunit and showed no significant changes 
in the expression levels of Nox2 after 24 h incubation with 
N1, N2 or DPI (Fig. 3f, g). Confocal imaging of PrP and 
Nox2 showed altered cellular morphology and localisation 
of Nox in response to the peptides (Fig. 3h). Using siRNA to 
knock down the expression of Nox2, a significant decrease 
in cellular growth was seen in the NCFA (consistent with 
the previously reported effects of DPI treatment) and this 
completely negated the effects of both N1 and N2 (Fig. 3i, j).
Reduced redox signalling causes increased mito‑
chondrial fission
We next wished to determine how N1/N2-redox signalling 
could be transduced through the cell to change cell growth. 
Nox signalling is linked with many of the central signal 
transduction pathways of the cell. We investigated several 
of these, including ERK1/2, AKT1, GSK-3β, and p38, but 
found no obvious activation or deactivation of any of those 
tested (Sup Fig 2). Since the central cellular signalling 
pathways were not seen to be influenced by the peptides, 
but mitochondrial involvement was indicated by TOM22 
reduction in response to N2 (Fig. 2j, k), direct changes to 
mitochondria were considered. Mitochondrial fission and 
fusion are linked with cell cycle control [54]. Furthermore, 
in times of heighted oxidative stress, including that caused 
Fig. 3  N1 and N2 reduce intracellular redox signalling through 
the Nox pathway. a DCFDA assay detection of intracellular ROS 
production in NSCs treated with N1 and N2. n = 6. b Representa-
tive images of Redox-Sensor Red staining of whole neurospheres 
90  min after exposure to N1, N2 or the Nox inhibitor DPI. Scale 
bar = 50 μm. c Quantification of fluorescence intensity in B. n = 3. d 
Cellular NADPH consumption rate within 20  min following expo-
sure to the peptides. n = 3. e DCFDA assay detection of intracellular 
ROS production in NSCs treated with N1 and N2 with or without 
the inclusion of ATP in the assay media. n = 4. Hash denotes signifi-
cantly different from the equivalent peptide condition without ATP. 
f Immunoblots for cellular expression of Nox2 24 h following expo-
sure to the N1 and N2 peptides. g Quantification of E. n = 4. h Rep-
resentative confocal images of Nox2 cellular staining 90  min after 
peptide treatment. Scale bar = 10 μm. i Colony counts of the NCFA 
where NSCs were incubated with and without N1 and N2 and with 
siRNA targeting Nox2 expression or a control non-silencing siRNA 
(inset shows dot blots of remaining Nox2 expression in a representa-
tive experiment). n = 3. Hash significantly different from non-silenc-
ing siRNA control, p < 0.05. j Diameter measurements of colonies 
formed in the NCFA described in  i. n = 3. Hash significantly differ-
ent from non-silencing siRNA control, p < 0.05. All data within the 
figure are presented as mean and SEM with significance indicated by 
*p < 0.05, **p < 0.01, ***p < 0.001 from respective control values 
unless otherwise stated
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by Nox and exogenous  H2O2, mitochondria fuse to form long 
networks protecting themselves from autophagy [55].  H2O2 
activates PKA, which results in inhibitory phosphorylation 
of dynamin-related protein-1 (DRP1), a core component of 
the machinery involved in mitochondrial fission and linked 
with dynamic control of the cell cycle by mitochondria [54, 
56]. Therefore, the localisation of DRP1 in relation to mito-
chondrial morphology was examined by confocal micros-
copy. Following treatment with N1, N2, DPI, and H89 (an 
inhibitor of PKA and, therefore, inhibitory phosphorylation 
of DRP1), mitochondrial morphology appeared more punc-
tate (Fig. 4a). Whilst no significant increase in DRP1 pixels 
localising to whole mitochondria was observed (Fig. 4b), 
DRP1 clustering at the ends of the puncta was qualitatively 
more apparent than seen in control cells (Fig. 4a). Measure-
ment of mitochondrial morphology showed a significantly 
reduced mitochondrial size, perimeter, and length with 
greater mitochondrial circularity in cells treated with N1 and 
N2 (Fig. 4c–f). A decrease in the percentage of the cytosol 
occupied by mitochondria was also seen for N2 (Fig. 4g) 
consistent with the decrease in TOM22 previously observed 
following treatment (Fig. 2j, k). The increase in punctate 
mitochondrial morphology was also observable in live cells 
using Mitotracker-Green staining (Sup Fig 3). After 2 h, a 
small but significant decrease in detectible DRP1 was also 
noted for N1 and N2 (Fig. 5a, c) and this was maintained at 
24 h (Fig. 5b, c). Decreased DRP1 detection might indicate 
that this protein is undergoing increased turnover to maintain 
homeostasis. No change was observed for the mitochondrial 
fusion protein, mitofusin-1 (MFN1), at 24 h in response to 
N2 or DPI (Fig. 5d, e).
N1 and N2 cause changes in SOD2 expression 
and SOD activity
To ascertain whether the changes in mitochondrial structure 
caused by the N1 and N2 peptides could also affect their 
redox balance, mitochondrial antioxidant defence and ROS 
production were evaluated. Superoxide dismutase-2 (SOD2) 
is the central mitochondrial antioxidant, and therefore, cel-
lular levels of SOD2 were evaluated by western blotting. A 
significant increase in expression was seen following treat-
ment with the N2 peptide and inhibition of Nox signalling 
with DPI (Fig. 6a, b). This was also reflected in the cellular 
total SOD activity, which showed significant increases in 
response to N1 as well as N2 and DPI (Fig. 6c). Following 
24 h exposure to N1, N2, or DPI, staining of live neuro-
spheres with MitoSOX (a mitochondrially localised fluores-
cent superoxide probe) showed that the production of mito-
chondrial superoxide is reduced throughout the sphere and 
in individual cells surrounding the sphere (Fig. 6d). Using 
siRNA to knock down SOD2 abrogated the effect of N1 and 
DPI on reducing colony formation in the NCFA but did not 
prevent N2 reducing the number of colonies formed (Fig. 6e) 
suggesting effects of N2 beyond SOD2. However, the size 
of the colonies produced when incubated with N2 was no-
longer reduced (Fig. 6f).
NSCs show altered PrP N‑terminal detection 
depending upon whether they are actively growing 
or quiescent
To ascertain whether endogenous cleavage of PrP correlates 
with NSC growth changes, we probed the profiles of N- and 
C-terminal PrP antibody reactivity in growing neurospheres 
(antibody-binding sites are shown in Fig. 1a). NSCs in the 
centre of a healthy neurosphere are quiescent, whereas 
those at the periphery are actively proliferating and this is 
reflected by the expression of the proliferation marker Ki67. 
The N-terminal fragments are rarely found in cell lysates but 
instead are detected as secretory fragments in conditioned 
media [31, 32] and, in addition, they have a predicted short 
cellular half life due to vulnerability to digestion. Therefore, 
while we cannot rule out saf32 (N-terminal) antibody reac-
tivity due to the N-terminal fragments, the N-terminal signal 
in cells is more likely due to the presence of full-length, 
uncleaved PrP. The C-terminus of PrP has a predicted slow 
turnover post-cleavage and remains membrane anchored, 
permitting its detection in cells post-cleavage, and, there-
fore, saf70 (C-terminal) antibody reactivity could be due 
to full-length PrP, C1, or C2. N-terminal labelling of PrP 
was detected mostly at the periphery of the cultures, with 
only ~ 25% of the total signal detected in the core (Fig. 7a, b; 
individual channels and control nestin staining are shown in 
Sup Fig 4 and Sup Fig. 5, respectively). In contrast, signifi-
cantly greater C-terminal labelling of PrP could be detected 
in the neurosphere core (Fig. 7a, c), indicating that more 
full-length PrP is found in cells that are actively growing and 
that PrP is predominantly cleaved in cells that are not grow-
ing. Cells at the periphery and within the core are shown at 
increased magnification in Sup Fig 6. Furthermore, when 
NSCs that were grown as neurospheres (where their core 
Fig. 4  N1 and N2 increase mitochondrial fission. a Representative 
confocal images of DRP1 and mitochondrial (TOM22) morphology 
90 min following addition of N1, N2, DPI, and PKA inhibitor H89 to 
NSCs. Scale bar = 10 μm. Boxes indicate the region shown in higher 
magnification on the right. b Measurement of percentage DRP1 
stained pixels localising within mitochondria. n = 3. c Measurement 
of mitochondrial size under the conditions described in a. n = 3. d 
Measurement of mitochondrial perimeter length under the condi-
tions described in a. n = 3. e Measurement of mitochondrial length 
(measurement of longest axis) under the conditions described in a. 
n = 3. f. Measurement of mitochondrial circularity under the condi-
tions described in a. n = 3. g Measurement of cytosolic  % occupied 
by mitochondria under the conditions described in a. n = 3. All data 
within the figure are presented as mean and SEM with significance 
indicated by *p < 0.05, **p < 0.01 from respective control values
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is quiescent) were compared with those grown as dissoci-
ated cells in suspension (where access to the mitogens in 
the media stimulates their growth) for 24 h, both the C1 and 
C2 cleavage fragments (detected after PNGase-F digest to 
remove N-linked complex glycans) were increased in the 
neurospheres (Fig. 7d).
Discussion
Difficulty assigning a single or predominant function to 
PrP may have arisen, at least in part, from the numerous 
post-translational modifications to which it is subjected and 
the biochemically distinct protein/peptide species that are 
produced as a result. The data presented herein show that 
the N-terminal cleavage fragments, N1 and N2, can reduce 
intracellular redox signalling, with the N2 peptide directly 
reducing Nox catalytic activity. The reduced ROS increases 
the activity of DRP1, which mobilises to the mitochondria 
resulting in their fission within a few hours and later increas-
ing protein levels of SOD2. The increased SOD2 levels and 
activity in turn maintain a low ROS environment within the 
mitochondria preserving cells in a quiescent state (Fig. 8).
The enzymes responsible for N1/C1 cleavage are still 
a matter of contention. It was first reported that A Disin-
tegrin and metalloproteinase domain-containing protein 
10 (ADAM10) was the candidate alpha-cleavage enzyme 
[31], although later work found that this enzyme was pri-
marily responsible for secretory cleavage of PrP near the 
GPI anchor [58]. ADAM17 (alternatively known as tumour 
necrosis factor-α-converting enzyme [TACE]) and ADAM9 
have also been implicated in N1/C1 cleavage, but a defini-
tive identification has not yet been made; a detailed review 
of this work can be found in [59]. The N2/C2 cleavage event 
has been demonstrated to be mediated by ROS [60] and, 
during scrapie infection, by the calpain family [61]. Con-
ditions that change the expression or activity of cleavage 
enzymes may shift the balance between full-length PrP and 
its cleavage fragments or shift the ratio of alpha- and beta-
cleavage resulting in changed cellular outcomes. Therefore, 
the apparent cellular function of PrP may be as related to 
cellular protease expression levels as it is to total PrP levels.
The alpha-cleavage event producing N1 is generally 
considered constitutive, whereas the beta-cleavage event 
is thought to be primarily induced during disease [30] and 
caused by ROS. The N1 fragment, whilst demonstrating 
changes in each of the pathway components examined, was 





































Fig. 5  N1 and N2 change DRP1 detection but not MFN1. a Immu-
noblots of DRP1 2  h following addition of N1, N2, DPI, and PKA 
inhibitor H89 to NSCs. b Immunoblots of DRP1 24 h post-treatment 
as described in a. c Densitometric quantification of DRP1 immunob-
lots at 15 min, 2 h  (a) and 24 h (b). n = 4. d Immunoblots of MFN1 
24 h post-treatment with N2 or DPI. e Densitometric quantification of 
d. n = 3. All data within the figure are presented as mean and SEM 
with significance indicated by *p < 0.05 from respective control values
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less potent in producing cellular changes than the N2 frag-
ment and its potential to modulate Nox signalling less evi-
dent. The more aggressive action of N2 on this pathway 
may reflect differing functional requirements for the N1 and 
N2 fragments. For example, during times of stress, mito-
chondria fuse into tubular networks to avoid being destroyed 
by autophagy [55] and, in stem cells, autophagy becomes 
activated to prevent senescence [62]. Mitochondrial fusion 
is associated with G1-to-S-phase transition through the 
cell cycle [54], and therefore, the role of N2 in decreasing 
ROS signalling and maintaining a less fused mitochondrial 
population may function to preserve quiescence at times 
when the NSC pool is at risk of depletion. However, the 
converse could also be true that, as a result of N2 being more 
efficient at stimulating this pathway, such changes could be 
detrimental. Counteraction of mitochondrial fusion by N2 
could lead to a loss of mitochondrial mass as mitochondria 
are engulfed by mitophagy, leaving cells struggling with 
energy demand. A slight decrease in mitochondria was seen 
for the N2 fragment, which might indicate that the fission 
event is causing a degree of mitochondrial loss even without 














































































Fig. 6  Decreased growth correlates with increased SOD2 protein and 
activity. a Immunoblots for SOD2 24 h following treatment with N1, 
N2 or DPI. b Densitometric quantification of a. n = 4. c SOD activ-
ity assay in cell lysates 24-h post-treatment with N1, N2 or DPI. 
n = 4. d Representative images of MitoSOX staining of whole-live 
neurospheres 24  h following treatment with N1, N2, or DPI. Scale 
bars = 50 μm. e Colony counts of the NCFA where NSCs were incu-
bated with and without N1 and N2 and with siRNA targeting SOD2 
expression or a control non-silencing siRNA (inset shows representa-
tive dots of SOD2 detection after knock-down). n = 3. f Colony diam-
eter as measured for the NCFA described in e. n = 3. All data within 
the figure are presented as mean and SEM with significance indicated 
by *p < 0.05, **p < 0.01, ***p < 0.001 from respective control values
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Alternative explanations may exist for the observed dif-
ferences in biological effects between the N1 and N2 frag-
ments. The N1 fragment contains a second charged cluster 
domain (resulting in charged domains at both ends of the 
peptide); this may endow it with extra properties such as 
the ability to bind and engage pathways that N2 cannot. 
Such putative-binding capacity may result in less N1 being 
available for modulation of the tested pathways. We have 
also observed aggregation of the 23-89P26/28A mutant in 
the previous studies [33] and the second charged domain 
within N1 may facilitate greater dimerisation/oligomerisa-
tion as compared with N2 thereby rendering less N1 peptide 
effectively available for interactions. Furthermore, only a 
single peptide concentration was compared in the current 
study; therefore, it is possible that higher concentrations of 
N1 could elicit the same intensity of reaction of the tested 
concentrations of N2. It is also unclear from the presented 
data why a difference should exist in cellular responses to 
N1 as a result of endogenous PrP expression; this could be 
related to the basal levels of N1 within these cells or lack of 
N1 and/or the pathways compensating for changed expres-
sion levels of the full-length protein. As the knock-out and 
Tga20 over-expressing NSCs demonstrate changed growth 
properties from the wild-type, which is especially apparent 
for the number of colonies generated by the Tga20 cells, 
basally changed pathways could influence how N1 is able to 
interact with and modulate cellular growth pathways.
PrP has been linked with increased ROS generated by 
Nox in the context of prion disease [52] and oxidative dam-
age caused by overstimulation of Nox signalling was found 
Fig. 7  Characterisation of 
PrP cleavage in the quiescent 
core of neurospheres and in 
human brain precursor cells. 
a Representative confocal 
images of serial slices through 
a neurosphere and merger 
(right) when immuno-stained 
with Ki67 proliferation marker 
and N- (Saf32) or C- (Saf90) 
terminal PrP antibodies. Scale 
bar = 20 μm. b Quantification 
of peripheral and core staining 
of PrP as detected by Saf32. 
n = 3 independent repeats with 
a minimum of 20 spheres. c 
Quantification of peripheral and 
core staining of PrP as detected 
by Saf70. n = 3 independent 
repeats with a minimum of 20 
spheres. d PNGase-F digests 
and PrP immunoblots compar-
ing NSCs grown as neuro-
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to be mediated by interaction of the N-terminus at the cell 
membrane in an antibody-stimulated model of toxicity 
[51]. Tethering the N-terminus of PrP to the cell membrane 
reduces the capacity of PrP to undergo normal N2/C2 cleav-
age, as well as cellular resistance to oxidative stress [63], 
possibly by preventing the N2 fragment from modulating 
Nox function. How exactly the N-terminal fragments or 
N-terminus of full-length PrP interact with Nox is unknown. 
Both our previous in vitro studies that indicated no intrinsic 
antioxidant activity of N2 [33] and, herein, the decreased uti-
lisation of NADPH substrate in response to N2 argue against 
an indirect ‘mopping up’ of the superoxide radicals. Other 
possibilities include direct interaction with one or more of 
the Nox subunits or modulation of the lipid membrane envi-
ronment in which the Nox complex forms. The latter is a 
reasonable possibility as we have shown that both of these 
peptides bind to lipids under specific conditions [64, 65] 
and changes in the lipid environment are observed during 
N2 protection against oxidative stress [46].
From the data presented, we cannot rule out a direct effect 
of the peptides on the mitochondria themselves. Whilst N1 
did not significantly change Nox activity or cellular SOD2 
expression it did alter mitochondrial fission and knock-
ing down SOD2 completely counteracted the effect of this 
peptide on cellular growth. Of interest, it has recently been 
reported that a population of PrP resides in the mitochon-
dria of normal disease-free cells and is endoproteolytically 
cleaved similar to total brain PrP [66]. This might offer 
the N-terminal peptides, especially N1 as the predominant 
N-terminal cleavage product, unhindered access to the mito-
chondria from inside the cell, directly facilitating an influ-
ence of the peptide on this organelle. Consequently, this 
might also have a bearing on the apparent lower efficacy 
of N1 in stimulating these responses. We have previously 
shown that N2 traffics from the cell surface to the mitochon-
dria [41], but this has not, to our knowledge, been examined 
for N1. The N1 fragment may be more functionally effective 
in stimulating quiescence if generated at the site of action 
Fig. 8  Schematic illustration of 
the redox signal transduction by 
N1 and N2 to induce quiescence 
in neural stem cells
 S. J. Collins et al.
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(the mitochondria) rather than when it requires trafficking 
from the cell surface.
The role of SOD2 in regulating the cell cycle has become 
well characterised [67, 68]. Increased cellular levels of 
SOD2 are known to facilitate cellular transition to quies-
cence, whereas loss of SOD2 protein or increased superoxide 
signalling favours increased cellular growth [69, 70]. PrP has 
additionally been linked with SOD2 in the context of prion 
pathogenesis. During prion disease or prion infection of 
cells, changes of expression and activity of the SOD family 
of enzymes are seen, including a decrease in SOD2 protein 
levels [45, 71]. Correspondingly, neurogenesis during prion 
disease increases [39]. A further point to note when con-
sidering an influence of PrP-mediated signalling on SOD2 
is that aberrations in SOD2 expression are linked with the 
uncontrolled cell cycling of cancer cells [68, 72]. Recently 
PrP expression has been linked with several cancers as well 
as the risk of metastases [73–75]. In addition to changes in 
mitochondrial SOD2, changes in mitochondrial fission and 
fusion have been linked with the uncontrolled cell cycling 
during cellular adaptation to the energy demands of cancer 
[76]. Regulation of SOD2 expression and mitochondrial 
dynamics by the N-terminal cleavage fragments of PrP or 
putatively the N-terminus in association with the full-length 
protein may explain why such disparate maladies are linked 
with this protein.
From our data, it would appear that detection of full-
length PrP is predominantly observed in proliferating cells 
or cells residing alongside those that are actively prolif-
erating, with quiescent cells staining only for C-terminal 
PrP. This might suggest that the signals stimulated by the 
N-terminal fragments can function in an autocrine or parac-
rine manner. Alpha-cleavage of PrP has been demonstrated 
to increase when PrP homodimerises at the cell membrane 
[77] and this may represent a mechanism for initiating intra/
intercellular signalling. Questions remain as to the actions of 
full-length PrP, secretory (GPI-anchorless) PrP, C1, C2, or 
gamma cleaved PrP fragments in this pathway or cross-inter-
actions with N1 and N2, but it seems highly likely that these 
proteins will be functional in their own right, bringing many 
more layers of complexity to the PrP function narrative.
Cross-talk between cellular redox signalling pathways 
and the mitochondria, and between the mitochondria and the 
nucleus, have been the subject of much study, but the role of 
the PrP N-terminal cleavage fragments as upstream modula-
tors of these pathways has not previously been considered. 
As increased PrP expression levels are linked with increased 
growth of NSCs and herein we have linked the N-terminal 
cleavage fragments with reduced cell growth/increased cell 
quiescence, dynamic modulation of PrP cleavage may be 
part of an important cellular homeostatic mechanism. The 
modulation of redox signal transduction appears to be the 
first event influenced by the PrP cleavage fragments, after 
which the reduced intracellular ROS indicates that cells 
should enter a resting phase of life as modulated and main-
tained by their mitochondria. The diversity of the poten-
tial outcomes resulting from up-steam regulation of central 
redox signalling pathways in different cell types could have 
wide-reaching implications for many of the reported func-
tions of PrP as this small protein begins to reveal its func-
tional complexity.
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Section 2: Prion Pathogenesis 
Analogous to contemporary knowledge concerning the cellular biology of PrPC, our 
understanding of the molecular factors influencing the risk of occurrence of sporadic prion 
disease and the primary cellular derangements or homeostatic failures that drive prion 
pathogenesis has advanced but remains incomplete. A more thorough understanding of these 
factors is an important facet of our progress in developing effective preventative and disease 
modifying therapies. To further assess for genetic risk factors outside of PRNP contributing to 
the occurrence of sCJD, I lead Australian collaborations in genome-wide association studies 
(GWAS) with the first suggesting involvement of the glutamate receptor metabotropic 8 gene 
while the more recent larger study implicated the syntaxin-6 and galactose-3-O-
sulfotransferase-1 genes. The latter GWAS was more adequately powered through the larger 
number of disease and control chromosomes assessed and for the first time achieved genome-
wide significance proving that loci outside of PRNP also influence the risk of sporadic CJD, 
thereby highlighting cellular pathways or processes likely to be pivotal to early pathogenesis.  
For studies concerning the molecular mechanisms of pathogenesis, my research emphasized 
two streams: the role of prion infection in enhancing oxidative stress, with a number of original 
observations made; and characterization of the biophysical properties of neurotoxic PrPSc, along 
with the temporal occurrence of neurotoxic species during prion disease evolution, acute 
synaptic molecular derangements and the relationship between neurotoxic and transmitting 
PrPSc species. To undertake these latter studies, I designed and oversaw the development of a 
novel synaptic electrophysiology model that allowed these new insights regarding the biological 
impact and biophysical and infectious properties of neurotoxic PrPSc.  
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The transmissible spongiform encephalopathies (TSEs) con-
stitute a group of neurodegenerative disorders, which includes
Creutzfeldt–Jakob disease (CJD) and its variant form (vCJD) in
humans, as well as scrapie in sheep and bovine spongiform
encephalopathy (BSE) (Prusiner, 1997). After the onset of clinical
disease, all are invariably fatal disorders sharing neuropathological
hallmarks such as spongiform change, neuronal loss, gliosis, and
accumulation of abnormal isoforms of the host encoded prion
protein. An underlying feature of TSEs is the conversion of the
normal cellular form of the prion protein (PrPc), a glycosylphos-
phatidylinositol-anchored cell surface protein, into a protease-
resistant conformer (PrPres; considered hereafter as equivalent to
PrPsc, the abnormal protease-resistant conformers found in scrapie),
a process intimately linked to infectivity and neurodegeneration
(Prusiner, 1997). Much progress in clarifying the molecular details
of this conversion process has been made, but a complete and
detailed understanding remains to be achieved. Notwithstanding
this, the detection of abnormal isoforms of PrP serves as a very
useful and reliable marker of disease and infectivity, both for
diagnostic and experimental purposes in humans and animals.
CJD is the most common human TSE, but remains rare, with
an incidence of only 1–1.5/million/year in comprehensive national
S.J. Collins et al. / Neurobiology of Disease 20 (2005) 336–346 337surveillance studies (Collins et al., 2002b). Only a small
proportion (10–15%) of CJD can be accounted for by mutations
in the prion protein gene (PRNP) or as a consequence of
recognizable transmission events (1–2%), with the majority
(approximately 85%) occurring without identifiable cause (spo-
radic). Although uncertainty persists, the prevailing concept is
that sporadic CJD arises as a consequence of either rare so-
matic mutations in the neuronal PRNP pool or secondary to a
spontaneous conformation change in PrPc (Prusiner, 1997). An
alternative hypothesis is that a proportion of apparently sporadic
CJD may be due to unrecognized, low-level, contamination events.
Large risk factor case-control studies lend some support to this
postulate (Collins et al., 1999; Ward et al., 2002), but detailed
analysis of spatiotemporal clustering of sporadic CJD has been
unable to substantiate plausible transmission pathways (Collins et
al., 2002a). Although convincing evidence for either of these two
etiological explanations is lacking, additional circumstantial
support for the covert transmission hypothesis is derived from a
number of studies, including primate and mouse paradigms,
showing evidence of TSE infection for lengthy periods prior to
the onset of overt disease.
A common theme in murine models of prolonged asympto-
matic TSE infection is that ‘‘inefficient’’ introduction of the
infectious inoculum, by using peripheral (Collis and Kimberlin,
1985; Dickinson et al., 1975; Zlotnik, 1965) or low-titer
(Thackray et al., 2002) inoculations, donor–host species barriers
to the particular TSE strain (Asante et al., 2002; Hill et al., 2000;
Race et al., 2001, 2002), or more resistant recipient transgenic
mice (Büeler et al., 1994; Frigg et al., 1999), results in very
prolonged incubation periods (preclinical infection) or complete
failure to induce clinical disease during the normal lifespan of the
host animal (subclinical infection). A possible additional intra-
species explanation for inefficient transmission is that despite
development of TSE, the PrPres produced may not be physically
competent to subserve PrPc conversion. Irrespective of the
mechanism, for much of the extended asymptomatic phase,
peripheral organs such as the spleen, as well as the brain, harbor
levels of infectivity often comparable to those seen in terminally
sick animals (Büeler et al., 1994; Collis and Kimberlin, 1985;
Dickinson et al., 1975; Frigg et al., 1999; Thackray et al., 2002).
Acknowledging that the extended incubation period may exceed
the lifespan of the host (Dickinson et al., 1975), differentiation
between preclinical and subclinical infection may be impossible,
but does not detract from the fundamental importance of this
phenomenon, especially as it relates to potential unrecognized
transmission during the provision of health care. Recent reports of
PrPres detection in the skeletal muscles and spleens in some
patients with sporadic CJD (Glatzel et al., 2003), as well as the
likely secondary transmission through blood transfusion from a
presymptomatic vCJD patient (Llewelyn et al., 2004), further add
to the concerns generated by previous studies. Of these, the
demonstration of PrPres in peripheral lymphoreticular organs of
living vCJD patients (Hill et al., 1999; Wadsworth et al., 2001) is
of particular interest and supports the hypothesis that transmission
is possible for a lengthy period before the onset of clinical disease
(Hilton et al., 1998, 2002, 2004).
We undertook the present study to assess the prevalence of
asymptomatic TSE infection in a model that in part simulates
hypothesized neurosurgical contamination events in the health care
setting, such as may occur through intracranial surgery performed
unwittingly on a patient with early symptomatic sporadic CJD.Based on the premise that health care transmissions most likely
involve very low infectious doses, we employed a standard quantal
dose-titration paradigm using a human-derived TSE strain in non-
transgenic host animals. A concomitant aim of the study was to
carefully compare bioassay with the utility of standard biochemical
and histopathological methods for detection of presymptomatic
TSE infection, which is of relevance to screening for potential
infectivity in at risk populations such as dura mater and human-
derived pituitary hormone recipients. In comparative studies, we
found that a high sensitivity Western blot technique utilizing a
metal-enhanced (sodium phosphotungstic acid [NaPTA]) precip-
itation method nearly approximated the sensitivity of bioassay, as
recently reported when used in a different in vitro technique (Safar
et al., 2002; Wadsworth et al., 2001). Similar to others (Hill et al.,
2000; Lee et al., 2000; Race et al., 2001), we determined that
bioassay using highly susceptible recipient animals was clearly
superior to conventional biochemical PrPres detection methods and
routine neuropathological examination. Finally, we also assessed
factors affecting the sensitivity of the NaPTA Western blot
technique as a screening method for potential asymptomatic TSE
infection.Methods
Mice and inoculations
The strain (M470) used for all experiments is a mouse-adapted
form of human TSE derived from a patient dying from probable
Gerstmann–Sträussler–Scheinker syndrome (GSS) (Tateishi et al.,
1979). For initial calculation of infectious titer, a 10% homogenate
(w/v) in phosphate-buffered saline (PBS) of pooled whole brains
from mice dying from TSE was serially log diluted in PBS with
concentrations spanning 101 to 109. Prepared dilutions of
inocula were immediately used for intracerebral inoculations of
groups of six random outbred weanling female Balb/c mice (except
the 109 dilution when only three mice were used). Approximately
30 Al of the appropriate dilution was injected into the left parietal
region under methoxyflurane anesthesia. Unused inocula were
stored at 80-C until subsequent use for Western immunoblot
studies. Titer estimations were according to the method of Reed
and Muench (1938).
Prior experiments employing an analogous human TSE strain
(M1000) in Balb/c mice had demonstrated the earliest presence and
highest amounts of PrPres occurred in brain regions approximating
the telencephalic subcortical gray nuclei and thalamus (authors’
unpublished data). For bioassays assessing asymptomatic infection,
30-Al aliquots of 1% homogenates made from this brain region
from individual Balb/c mice were inoculated intracerebrally into
groups of 3–5 male and female weanling Tga/20 transgenic (PrPc
overexpressing) mice (Fischer et al., 1996). Brain tissues from
Balb/c mice receiving the original 109 inoculum dilution were not
subject to bioassay.
Inoculated Balb/c and Tga/20 mice were observed daily for
signs of TSE. Animals were sacrificed under methoxyflurane
anesthesia when persistent signs consistent with murine TSE were
evident, such as reduced motor activity, weight loss, hunched
posture, hind limb paresis, and ataxia. Mice were given food and
water ad libitum, with all handling according to prescribed national
guidelines, and ethical approval from the University of Melbourne
Animal Ethics Committee.
S.J. Collins et al. / Neurobiology of Disease 20 (2005) 336–346338Histology and immunohistochemistry
Brains were sagittally hemi-sectioned, with one-half fixed in
10% buffered formalin and the other homogenized to 10% (w/v) in
PBS. Fixed brains were immersed in 99% formic acid for 1 h prior
to routine processing and staining. Half-brains were paraffin
embedded and 6-Am sections cut and mounted on glass slides.
Sections were de-paraffinized and rehydrated through a graded
ethanol series to de-ionized water, and either stained with
hematoxylin and eosin or treated by hydrolytic autoclaving for
20 min at 132-C. Once cooled, autoclaved sections were washed
and treated with 96% formic acid for 5 min, then exposed to 4 M
guanidine thiocyanate for 2 h at 4-C. After blocking with 20%
normal rabbit serum (Dako, Carpinteria, CA) for 30 min, sections
were incubated with ICSM 18 anti-PrP monoclonal antibody 1:500
overnight at 4-C (White et al., 2003). Following sequential
incubation in biotinylated rabbit anti-mouse secondary antibody
(1:500) and HRP-conjugated streptavidin (1:1000) (Dako) for 30
min each at room temperature, diaminobenzidine (Dako) was
added.
Only the more specific and reliably quantifiable neuropatho-
logical findings of spongiform change and PrP-positive plaque
deposition were scored. The degree of brain vacuolation and the
presence of PrPres immunostaining were visually graded: 0 =
normal; + = mild; ++ = moderate; +++ = severe/prominent
(equivalent to what is seen in mice with terminal TSE).
Western immunoblots
Conventional Western blots were performed as described
previously with minor modifications (Lewis et al., 2003). Briefly,
to 50-Al aliquots of 10% brain homogenate, 0.5 Al Benzonase
(25 U/Al) (Novagen, Merck, Damstadt, Germany) and 0.5 Al of 1 M
MgCl2 were added and incubated for 5 min at 37-C, followed by
digestion with proteinase K (PK; Sigma, St Louis, MO) (final
concentration 100 Ag/ml) for 1 h at 37-C. Digestion was halted by
adding Pefabloc (final concentration 5 mM) (Roche Diagnostics,
Mannheim, Germany) and the same total volume of 2 sample
buffer (containing 6% beta-mercaptoethanol) and boiling for 10
min. Samples were briefly centrifuged at low speed (1000 rpm)
(Eppendorf 5415C, Hamburg, Germany) and electrophoresed on
precast 12% tris-glycine gels (Invitrogen Novex, San Diego, CA).
Proteins were transferred to nitrocellulose membranes (Trans-Blot;
BIORAD, Hercules, CA) at 380 mA for 45 min, with the filter then
blocked for 1 h at room temperature in 5% non-fat milk in PBS-T
(PBS containing 0.5% Tween 20). Membranes were incubated
overnight at 4-C using the anti-PrP monoclonal antibody ICSM
18 (1:25,000 in PBS-T) (White et al., 2003). Signal was detected,
after incubation for 1 h at 37-C with an HRP-conjugated anti-
mouse secondary antibody using ECL or ECL Plus (Amersham,
Buckinghamshire, UK).
NaPTA precipitation prior to Western immunoblot was under-
taken according to a previously reported method (Wadsworth et al.,
2001). To 500 Al of 10% (w/v) brain tissue homogenates in PBS,
an equal volume of 4% (w/v) Sarkosyl (Sigma) in PBS pH 7.4 was
added, vortexed, and incubated for 10 min at 37-C with constant
agitation. Benzonase (Novagen) and MgCl2 were added to 50 U/ml
and 1 mM, respectively, and incubated at 37-C for 30 min with
vigorous agitation. To this, 81.3 Al of a pre-warmed (to 37-C) 4%
(w/v) NaPTA/170 mM MgCl2 solution (pH 7.4) was added,
vortexed, and incubated with vigorous agitation for 30 min at37-C. Samples were then centrifuged at 15,000  g for 30 min,
after which supernatants were carefully removed and the remaining
pellets resuspended in 20 Al of PBS/0.1% Sarkosyl (pH 7.4),
followed by PK digestion, electrophoresis using the entire sample,
and Western blotting as described above, except proteins were
transferred to polyvinylidine difluoride membranes (Immobilon-P;
Millipore Corporation, Bedford, MA). ECL Plus was used for
signal detection. Often, for individual mice, sufficient brain tissue
was available to allow only a single Western blot using NaPTA
precipitation. In occasional mice, less than 500 Al of 10% brain
homogenate was available, prompting proportional adjustments of
the various treatment steps, including the resuspension of pellets
and amounts loaded onto resolving gels after the addition of
sample buffer. Brain tissue spiking experiments determined
reproducible lower limits of sensitivity, which were then used as
an internal control for each NaPTA Western immunoassay,
whereby 1 Al of a 1% whole brain homogenate from a mouse
dying from TSE was always clearly detectable in a 500-Al aliquot
of a 10% homogenate of normal mouse brain.
To determine levels of detection sensitivity, the brain of a Balb/
c mouse confirmed to have died from TSE was made into a 10%
homogenate (w/v) in PBS. In one experiment, a series of samples
equivalent to 50, 10, 6, 3, 1, and 0.6 Ag wet weight diseased brain
were added to separate 500-Al aliquots of 10% brain homogenate
from uninoculated mice for subsequent Western blot analysis
following NaPTA precipitation. In a separate experiment, 2 Al of a
1% diseased brain homogenate was added to 500-Al aliquots of
PBS, a 10% normal brain homogenate, and a 10% brain
homogenate from a mouse with the PRNP gene ablated (PrPo/o)
(Büeler et al., 1993), with the samples subjected to NaPTA
precipitation and Western blotting (as described below); half of
each sample was digested with proteinase K (PK) (as described
below). In addition, 1-Al aliquots of a 1% diseased brain
homogenate were added to 9 Al of PBS for Western blotting both
without and after digestion by PK. These were not subject to
NaPTA precipitation and served as a baseline to assess the
comparative efficiency of PrPres retrieval from the equivalent of
1 Al of a 1% disease brain homogenate spiked into different
diluents, as well as more directly assess the issue of whether an
altered ratio of protease to total protein concentration was a
significant factor contributing to any reduction in signal when
using PBS as diluent.Results
Titer of infectivity in Balb/c mice based on clinical disease
To facilitate a comparative assessment of markers of asympto-
matic infection and to more thoroughly determine the extent and
frequency of asymptomatic disease after low titer intracerebral
inoculation, we generated asymptomatic infection in Balb/c mice
using a standard quantal end-point titration assay. Based on the
development of clinically apparent disease (Table 1), infectivity of
M470 was calculated as 2.5  107 ID50 units/g brain. Not
unexpectedly at higher dilutions, occasional Balb/c mice man-
ifested TSE after extended incubation periods, including the deaths
of two from the 104 inoculum dilution cohort at 391 and 399 days
post-inoculation (PI). Prompted by these late deaths (approxi-
mately 21/2 times the mean incubation period for highest titer
intracerebral inoculation), we considered it an appropriate time to
Table 1
Summary of quantal, end-point, dose-titration of the M470 strain in Balb/c
mice




101 6/6 162 T 3.4
102 6/6 171 T 4.4
103 6/6 177 T 5.5
104 5/5 291 T 38.8c





SEM, standard error of the mean.
a Dilutions of 10% (w/v) brain homogenate.
b Four remaining healthy mice from each initial dilution of 105 to 108
and the three healthy mice from initial dilution 109 were sacrificed for
assessment of preclinical TSE: 105 and 106 dilutions on day 401 PI, and
the others on day 402 PI.
c Two mice developed signs of TSE and died at 391 and 399 days PI,
respectively; mean incubation period (TSEM) for the other three mice was
221 (T11.8) days.
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mice. For this purpose, four healthy mice from each group
inoculated with initial dilutions of 105 to 108 and the three
healthy mice from the initial dilution 109 were sacrificed; mice
from the 105 and 106 dilutions on day 401 PI, and the others on
day 402 PI (Table 1 and Fig. 1). Two further healthy mice from the
106 dilution that were culled at day 496 PI, and one from the 107
dilution culled at day 498 PI, were inadvertently discarded and not
subjected to further analysis. The last remaining mouse from the
original 108 inoculation group was observed for TSE over its
normal lifespan. This single mouse died suddenly without
preceding illness at 740 days PI with the brain negative for PrPres
on Western blot (data not shown). Using a combination of PrPres
detection techniques, we then undertook assessment of these longFig. 1. Kaplan–Meier survival plots of Balb/c mice used for M470 titer estima
generation of asymptomatic infection. *Inoculum dilution cohorts ranged from
inoculation) at which remaining healthy mice were sacrificed for assessment of psurviving Balb/c mice for evidence of asymptomatic disease, none
of which had demonstrated any definite or fluctuating clinical signs
of murine TSE prior to sacrifice.
Assessment of asymptomatic infection and comparison of
biochemical techniques, routine neuropathological markers, and
bioassay
Tables 2 and 3 summarize the results of investigations to assess
the presence of asymptomatic infection in long surviving healthy
Balb/c mice from the original quantal end-point titration. Morpho-
logical examination of the brains of these mice showed typical
spongiform change and PrP-positive plaques in three of four mice
(numbers 5.1, 5.3, and 5.4) from the 105 dilution and one of four
mice (number 6.4) from the 106 dilution, with remaining mice,
including all those from the higher dilutions, not revealing any
neuropathological abnormalities (Table 2). The neuropathological
changes observed in asymptomatic mice were stereotyped and
qualitatively similar but less developed than those seen in
terminally sick mice (Figs. 2A, B, and E–G), although there were
exceptions in which the changes approached this level of severity
(compare Fig. 2C with D). Spongiform change was always first
evident and most marked in the hippocampus and peri-hippo-
campal regions but could be widespread throughout the cerebral
hemispheres and brain stem, often emphasized in the thalamus.
Vacuolation and PrP-positive plaques always occurred concur-
rently in asymptomatically infected mice. In contrast to spongiform
change, however, the plaque deposition was most prominent, and
often restricted to, the thalamus. In asymptomatically infected
mice, regions prone to substantial neuronal loss in this murine
model (the stratum pyramidale of the hippocampus and dorsal
thalamic area) showed only equivocal reductions, with this only
observed in those animals with prominent vacuolation and PrP-
positive plaques.
Conventional Western blots showed complete concordance with
the neuropathological findings. PrPres was only detected in those
brains displaying typical morphological abnormalities and PrP-tion employing quantal dose-titration and clinical outcome, as well as the
101 to 109. The arrow depicts the time point (day 401 or 402 post
reclinical TSE.-
Table 2
Summary of conventional and NaPTA precipitation Western blot results and morphological investigations to assess the presence of subclinical infection in

















5.1 105 Pos ++ + ND
5.2 105 Neg 0 0 Neg
5.3 105 Pos +/++ ++ ND
5.4 105 Pos ++/+++ +/++ ND
6.1 106 Neg 0 0 Pos
6.2 106 Neg 0 0 Pos
6.3 106 Neg 0 0 Pos
6.4 106 Pos ++/+++ ++ ND
7.1 107 Neg 0 0 Neg
7.2 107 Neg 0 0 Neg
7.3 107 Neg 0 0 Neg
7.4 107 Neg 0 0 Neg
8.1 108 Neg 0 0 Neg
8.2 108 Neg 0 0 Neg
8.3 108 Neg 0 0 Neg
8.4 108 Neg 0 0 Neg
9.1 109 Neg 0 0 ND
9.2 109 Neg 0 0 ND
9.3 109 Neg 0 0 ND
ND, not determined; Pos, positive; Neg, negative; NaPTA, sodium phosphotungstic acid; IHC, immunohistochemistry.
a The degree of brain vacuolation and the presence of PrPres immunostaining were visually graded: 0 = normal; + = mild; ++ = moderate; +++ = severe/
prominent (the latter changes equivalent to what is seen in terminally sick mice).
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surviving mice (determined by incubation time interval assay in
indicator Tga/20 mice and regression analysis using the method of
least squares) was found to fall within the range of 3.2–7.0  104
ID50 units per 30 Al of inoculum (Fig. 3). Surprisingly, the
infectivity in some asymptomatic M470-infected Balb/c mice was
almost equivalent to that in terminally sick mice when a mean
survival of 56 days corresponds to inoculation with 1.9  105 ID50
units.
Despite the absence of PrPres by conventional Western
immunoblot assay and lack of morphological evidence of pre-
clinical infection, bioassay in Tga/20 mice confirmed infectivity
in all remaining mice from the 105 and 106 dilution cohorts, and
also in two mice from the 108 dilution cohort. The more sensitive
Western blot method incorporating NaPTA precipitation was then
used to assess the presence of PrPres in those brains considered
normal neuropathologically and negative for PrPres by the conven-
tional Western immunoblot. In contrast to the negative findings
with the conventional Western blot, the NaPTA precipitation
method was able to detect faint but definite PrPres signal in all three
remaining mice (numbers 6.1, 6.2, and 6.3) from the original 106
dilution cohort (Fig. 4A, lanes 6–8). We were not convinced of a
definite PrPres signal for the single 105 mouse (number 5.2)
examined (Fig. 4A, lane 5) despite the presence of infectivity by
bioassay. PrPres was not detected in any of the mice from each of
the 107 group and 108 groups (data not shown). These results
show that in this model of preclinical disease, a conventional
Western blot is able to reliably detect PrPres when infectivity is
>3.2  104 ID50 units per inoculum, whereas methods employing
NaPTA precipitation can often detect PrPres when the infectivity is
<2.0  102 ID50 units. Hence, when working at the lower limits of
infectious titers in brains harboring preclinical disease, detection of
PrPres by immunoblotting after NaPTA precipitation shows a muchbetter correlation with transmissibility in a sensitive bioassay than
conventional Western immunoblot and routine morphological
markers, and at a practical level detects almost all brains with
potential infectivity.
Western immunoblots and neuropathological examination of
recipient Tga/20 mice and revised titer estimate based on
asymptomatic transmissions
Deaths from murine TSE in Tga/20 mice were confirmed by
Western blot detection of PrPres in the brains of all mice dying
beyond 100 days PI (Fig. 4B, compare lane 8 with lanes 9 and 10).
Tga/20 mice dying from typical TSE less than 100 days PI were
not routinely examined. Whole brain homogenates of Tga/20 mice
dying from TSE displayed abundant amounts of PrPres with typical
banding patterns and the characteristic mobility shift following PK
digestion (Fig. 4B, lanes 6, 7, and 9–11). The remaining
inoculated but long-term surviving Tga/20 mice originally receiv-
ing the 106, 107, and 108 inocula were sacrificed at 218, 234,
and 241 days PI (Table 3), and their brains assessed for evidence of
murine TSE. Characteristic histological and immunohistochemical
features of murine TSE were absent in these Tga/20 mice.
Supplementing the morphological exclusion of preclinical
transmissions in inoculated but long-term surviving Tga/20 mice,
the brains of all healthy animals at time of sacrifice were subjected
to NaPTA precipitation and Western immunoblot. Unexpectedly,
despite treatment with PK (100 Ag/ml final concentration), two
protease-resistant bands of variable intensity were often detected in
the brains of these healthy Tga/20 mice (Fig. 4B, lanes 5 and 8).
The two bands seen were always much less intense than those
observed in mice dying from TSE (Fig. 4B, compare lane 8 with
lanes 9–11). Further, the banding pattern could be clearly
differentiated from that seen in terminally ill mice, with the upper
Table 3






























5.1 105 ND 4/4 ND 62 (61–65) 7.0  104
5.2 105 Neg 2/3c 2/3c 114 (107–120) <2.0  102
5.3 105 ND 4/4 1/1 68 (65–72) 3.2  104
5.4 105 ND 4/4 1/1 65 (63–68) 5.1  104
6.1 106 Pos 3/4d 3/4 133 (98–202) <2.0  102
6.2 106 Pos 3/4d 3/4 140 (123–154) <2.0  102
6.3 106 Pos 4/4 2/2 83 (79–86) 3.3  103
6.4 106 ND 3/3 ND 64 (62–65) 6.0  104
7.1 107 Neg 0/5e 0/5
7.2 107 Neg 0/5e 0/5
7.3 107 Neg 0/5e,f 0/5
7.4 107 Neg 0/5e 0/5
8.1 108 Neg 1/5g 1/5 142 <2.0  102
8.2 108 Neg 0/4g 0/4
8.3 108 Neg 0/5g 1/5h
8.4 108 Neg 1/4g 1/4 129 <2.0  102
9.1 109 ND ND ND
9.2 109 ND ND ND
9.3 109 ND ND ND
ND, not determined.
a This column of data repeated from Table 2.
b Based on incubation time interval assay using the linear regression equation log X = ( Y  135.98/15.07) derived from quantal dose-titrations in Tga/20
mice using the same prion M470 strain.
c The third mouse was culled 214 days PI because of illness, with brain negative for PrPres on Western immunoblot.
d Single remaining healthy mouse culled 218 days PI; brain negative for PrPres on both Western immunoblot and immunohistochemistry, with no evidence of
vacuolation.
e Remaining mice were healthy when culled 234 days PI.
f Single mouse found dead at 228 days PI; brain negative for PrPres on Western blot.
g Remaining mice were healthy when culled at 241 days PI.
h The brain of a single healthy mouse at time of cull was positive for PrPres on Western blot.
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lated PrP, approximately 35 kDa (consistent with incomplete
protease digestion), and the second band displaying a relative
mobility (approximately 25–26 kDa) between those of the di- and
mono-glycosylated bands seen after PK digestion in brain
homogenates from terminal mice. These findings were confirmed
in conventional Western blots, and also in brain homogenates from
age-matched, uninoculated, and sham brain-inoculated Tga/20
mice (Fig. 4B, lane 5), and when probing with a different anti-
PrP monoclonal antibody (6H4; Prionics, Switzerland) (data not
shown); secondary antibody alone gave no signal (data not shown).
Nevertheless, the quantitative and qualitative differences allowed
confident differentiation of normal or sham brain-inoculated mice
from those dying of TSE. Despite the absence of neuropathological
features of murine TSE, a single healthy Tga/20 mouse culled at
241 days PI, inoculated with the brain of a mouse receiving the
original 108 dilution (Table 3), was clearly positive for PrPres
(data not shown). Although the banding pattern was typical, the
intensity was considerably less than seen in animals dying from
terminal illness, consistent with incubating disease.
Based on this evidence of asymptomatic infection using more
sensitive detection methods, a revised estimate of the original
M470 inoculum titer in Balb/c mice is at least 1.3  109 ID50 units/
g brain. This value is two orders of magnitude greater than the ID50
based solely on the development of clinical disease and is a likelyunderestimate because not all surviving Balb/c mice were subject
to bioassay in Tga/20 mice.
Comparison of bioassay with biochemical indicators of potential
infectivity in the original inocula and in ‘‘spiked’’ normal and other
brain homogenates
Given the increased sensitivity using Western immunoblots
after NaPTA precipitation to detect PrPres at levels correlating with
very low titers of infectivity in the brains of mice harboring
asymptomatic prion disease, we undertook a series of additional
experiments to assess the utility of this technique in other
situations. The original inoculum dilution series was assayed
biochemically for the presence of PrPres using both Western blot
methods and compared with bioassay. At best, conventional
Western blot analysis showed a very faint signal at the 101
dilution (representing a 1:100 final dilution, approximating 100 Ag
brain loaded onto each lane of a gel) after prolonged exposure,
which was more evident using enhanced chemiluminescent (ECL
Plus) detection (data not shown). Using the NaPTA pre-treatment,
PrPres was detectable at the 102 dilution (equating 1:1000 final
dilution; approximating 250 Ag brain loaded onto each lane of a
gel) (Fig. 5A, lane 6), but not the 103 dilution (equating 1:10,000
final dilution; approximating 25 Ag brain loaded onto each lane of
a gel), with further titration showing a detection limit at a final
Fig. 2. (A–H) Representative photomicrographs demonstrating the range of morphological changes present in Balb/c mice assessed for the presence of
asymptomatic infection in comparison to those seen in animals dying from terminal TSE. (A–D) Hematoxylin and eosin-stained sections of the hippocampal
regions of individual mice demonstrating varying amounts of spongiform change. (E–H) Immunohistochemistry of the thalamic regions of individual mice
demonstrating varying levels of PrP-positive plaque deposition using the monoclonal antibody ICSM 18 as described in Methods. Panels A and E depict mouse
6.3 from the 106 original inoculation cohort showing no evidence of spongiform change and no evidence of PrP plaques. Panels B and F depict mouse 5.3
from the 105 original inoculation cohort showing mild (+) spongiform change and mild–moderate (+ to ++) PrP-positive plaque formation. Panels C and G
depict mouse 5.4 from the 105 original inoculation cohort showing moderate-to-severe (++ to +++) spongiform change and mild (+) PrP-positive plaque
formation. Panels D and H depict a Balb/c mouse with terminal TSE showing severe (+++) spongiform change and severe (+++) PrP-positive plaque
formation. Final magnifications: A–C, 200; D–H, 100.
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Fig. 3. Relationship between inoculation doses and incubation periods for
the prion strain (M470) in Tga/20 mice. Regression analysis using the
method of least squares was used to construct the fitted (dotted) line with
the regression equation; Y = 135.98  15.07(log X), where Y equals mean
incubation period (days) and X equals dose (ID50 units). Slope = 15.07,
where P < 0.0005, 95% CI (17.59 to 12.53), where the slope
corresponds to a log scale estimate. The strength of the association was
tested by calculating Spearman’s correlation coefficient, q = 0.9787,
P < 0.0005.
Fig. 4. (A and B) Western blots of mouse brains to assess the presence of
PrPres using the monoclonal antibody ICSM 18 as described in Methods.
Sodium phosphotungstic acid (NaPTA) precipitation and proteinase K (PK)
digestion (100 Ag/ml final concentration) prior to Western blotting were
performed as indicated (+). PrPres is indicated by bracket marked with an
asterisk. Approximate molecular weight weights (kDa) are given alongside.
(A) Lanes 1 and 2, uninoculated Balb/c mouse; lane 3, 5 Al, and lane 4, 1 Al
of a 1% brain homogenate from a terminal Balb/c ‘‘spiked’’ into 500 Al of
10% normal mouse brain homogenate; lane 5, surviving Balb/c mouse 5.2
from the 105 inoculation cohort culled 401 days PI, negative for PrPres;
lanes 6–8, surviving Balb/c mice 6.1, 6.2, and 6.3, respectively, from the
106 inoculation cohort culled day 401 PI, positive for PrP-res. (B) Lanes 1
and 2, uninoculated Balb/c mouse; lane 3, 5 Al, and lane 4, 1 Al of a 1%
brain homogenate from a terminal Balb/c ‘‘spiked’’ into 500 Al of 10%
normal mouse brain homogenate; lane 5, sham brain-inoculated, age-
matched Tga/20 mouse; lanes 6 and 7, Tga/20 mouse culled day 74 PI with
typical signs of TSE; lane 8, Tga/20 mouse dying from non-TSE
intercurrent illness at day 214 PI; lane 9, Tga/20 mouse dying with typical
TSE at day 154 PI; lane 10, Tga/20 dying from typical TSE at day 202 PI;
lane 11, Tga/20 mouse dying from typical TSE at day 82 PI. PI, post-
inoculation; TSE, transmissible spongiform encephalopathy.
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(approximating the equivalent of 50 Ag wet weight diseased brain
loaded per lane for immunoblotting) (Fig. 5A, lane 8). The results
were replicated using an analogous fresh brain homogenate
dilution series to eliminate any deleterious effects of long-term
storage of the original inocula. Hence, when diseased brain is
serially diluted in PBS, the NaPTA precipitation method appeared
approximately twice as sensitive as the conventional technique for
detecting PrPres, with the advantage that the former method can
load equivalent total brain weights from a substantially more dilute
sample.
Our previous experiments indicated that the sensitivity of
NaPTA precipitation and Western blotting approached the sensi-
tivity of bioassay for the detection of PrPres in asymptomatically
infected Balb/c mice. However, detection of PrPres diluted in PBS
by the NaPTA precipitation method was 200–2000 times less
sensitive than routine bioassay in Balb/c mice. Clinical disease
invariably developed (5/5 mice) at the 104 dilution (equivalent to
inoculating approximately 0.3 Ag wet weight infected brain per
mouse) and reproducibly occurred (2/6 mice) at the 105 dilution
(equivalent to inoculating approximately 0.03 Ag wet weight
infected brain per animal). Acknowledging the reduced sensitivity
of NaPTA precipitation for detecting potential infectivity compared
to bioassay when brain tissue is progressively diluted in PBS, we
assessed the influence of higher ambient mouse brain protein
concentrations on PrPres detection using this method. To achieve
this, progressively smaller amounts of a whole brain homogenate
from a Balb/c mouse dying from TSE (ranging from 50 Ag to 0.6
Ag) were spiked into 500-Al aliquots of 10% (w/v) normal mouse
brain homogenates. In this situation, PrPres could be detected from
a spike equating to 3 Ag whole brain (Fig. 5B), whereas the limit of
detection of the abnormal isoform when brain was diluted in PBS
occurred at around 50 Ag. The former was nearly 20 times moresensitive but still around 10- to 100-fold less sensitive than
bioassay.
To examine whether this effect reflected an inability of NaPTA
to precipitate PrPres from a low total protein concentration
homogenate, 500 Al of PBS, 10% (w/v) normal brain, or PrPo/o
brain homogenates were spiked with 2 Al of 1% terminal Balb/c
brain homogenates and treated with NaPTA precipitation. The
precipitated protein was analyzed with and without subsequent PK
digestion; non-spiked 10% normal brain homogenate served as
control. Facilitating comparisons of PrPres retrieval as well as
assessing any effect of an altered protease to total protein
concentration ratio, an equivalent (1 Al) amount of 1% terminal
Balb/c brain homogenate was added to PBS and sample buffer for
direct gel loading without NaPTA precipitation. After Western
blotting, we observed complete absence of PrP signal in larger-
volume PBS-spiked samples, including without PK digestion,
whereas abundant signal was seen in the spiked brain homoge-
nates, including after PK digestion (data not shown). Despite
digestion with the same concentration of PK, PrP banding of
equivalent intensity to that observed in spiked larger volumes of
brain homogenates was seen in those samples where 1 Al of a 1%
terminal Balb/c brain homogenate was added to 9 Al of PBS. This
Fig. 5. (A and B) Serial dilutions of terminal mouse TSE brain homogenate
aliquoted into (A) PBS and (B) 10% normal brain homogenate (w/v in
PBS). Weights of diseased brain (Ag) loaded into each lane from which
PrPres is detected are provided. Detection was by Western blot using the
monoclonal antibody ICSM 18 as described in Methods. Sodium
phosphotungstic acid (NaPTA) precipitation and proteinase K (PK)
digestion (100 Ag/ml final concentration) prior to Western blotting were
performed as indicated (+). Approximate molecular weights (kDa) are
given alongside. (A) Lanes 1 and 2, uninoculated Balb/c mouse; lane 3, 5 Al,
and lane 4, 1 Al of a 1% brain homogenate from a terminal Balb/c ‘‘spiked’’
into 500 Al of 10% normal mouse brain homogenate. Lanes 5–9, serial
dilutions using PBS of a 10% brain homogenate (w/v in PBS) from the
terminal Balb/c mouse used for the original quantal, dose-titration
inoculations. Final inoculum dilutions were: lane 5, 1:100; lane 6,
1:1000; lane 7, 1:2000; lane 8, 1:5000; and lane 9, 1:10,000. PrPres
detection limit appears at around 50 Ag diseased brain per lane. (B) Lanes 1
and 2, uninoculated Balb/c mouse; lanes 3–8, serial dilutions of brain
homogenate from a terminal Balb/c mouse ‘‘spiked’’ into 500 Al of 10%
normal mouse brain homogenate (w/v in PBS). The PrPres detection limit
occurs at around 3 Ag diseased brain per lane.
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tration ratio as being the predominant explanation for absence of
PrP signal when PBS is used as diluent and is more in keeping with
a reduced capacity of NaPTA precipitation to selectively concen-
trate PrPres in a larger-volume, low-protein milieu.Discussion
Our study confirmed that asymptomatic prion infection occurs
commonly after low dose inoculation when using a human-derived
TSE strain in non-transgenic hosts, free from a species barrier.
Similar findings in previous murine scrapie (Asante et al., 2002;
Büeler et al., 1994; Collis and Kimberlin, 1985; Dickinson et al.,
1975; Frigg et al., 1999; Hill et al., 2000; Race and Chesebro,
1998; Race et al., 2001, 2002; Thackray et al., 2002; Zlotnik, 1965)
and other models (Masters et al., 1976) reinforce the likelihood that
extended periods of asymptomatic infection may be a generic
property of many, possibly all, TSE strains. In the current
assessment of asymptomatic infection, an incubation period of
approximately 400 days was chosen because immediately prior to
this there were two late deaths from TSE. We construed this as agood indication that asymptomatic infection may exist in other
surviving mice, with this time point representing a more than
doubling of the incubation period observed with high dose
inoculations, and ensuring mice were in the latter half of their
lifespan. We found asymptomatic infection to be very common,
with infectivity detected in all mice receiving up to 100-fold lower
inoculum doses than that which induced consistent clinical disease,
and even in some mice receiving 1000-fold less infectivity. Our
findings are consistent with other studies demonstrating the
presence of high levels of infectivity in mice manifesting
preclinical infection following inoculation with dilutions up to
100-fold higher than those causing consistent clinical disease
(Dickinson et al., 1975; Thackray et al., 2002). In contrast to
previous reports (Taylor et al., 2000; Thackray et al., 2002), we did
not observe fluctuating or reversible signs of murine TSE in these
groups of mice.
The deaths from TSE of two mice just prior to sacrificing most
of the healthy survivors make it likely that clinical disease may
have ensued in some mice had we allowed them to live longer. It is
noteworthy that those asymptomatically infected mice displaying
neuropathological abnormalities differed only in the severity of
lesion burden, demonstrating a stereotyped and very similar
distribution of changes, similar to that seen in mice dying with
terminal disease. However, other asymptomatically infected mice
did not show neuropathological abnormalities and had very low
infectivity titers, and it is unclear whether these mice would have
ever developed clinically overt disease. Although the very low
titers of infectivity found in some of our asymptomatic mice may
simply represent residual inoculum, this is not a tenable
explanation in those mice harboring titers approximating those
found in mice with terminal disease.
The infectious titer of our original inoculum, estimated by the
development of lethal clinical disease, was 2.5  107 ID50 units/g
of brain. A re-estimation of this titer, determined from the presence
of asymptomatic infectivity using ‘‘blind’’ bioassay in Tga20 mice,
increased this value by two orders of magnitude to 1.3  109 ID50
units/g brain. We believe this re-scaling offers a more genuine
assessment of true overall transmission risk, which is of relevance
to modeling studies such as efficacy of clearance of residual
infectivity on surgical instruments. However, in order to routinely
detect preclinical TSE infectivity, it would be necessary to perform
second passage bioassay in sensitive indicator mice or at the very
least observe mice over their entire lifespan for very late deaths.
Such options would be a considerable burden and be generally
considered impracticable. As an alternative approach, we under-
took a detailed assessment of the utility of biochemical and
histological methods to detect asymptomatic infections, thus
alleviating the need for time and resource consuming animal
studies.
The present study is the first to undertake a detailed
comparative assessment for presymptomatic TSE infection using
a number of techniques, including animal bioassay and a more
sensitive Western immunoblot preceded by NaPTA precipitation of
PrPres (Wadsworth et al., 2001). Bioassay in appropriate host
animals has previously been demonstrated to be superior to
conventional Western blot detection of PrPres (Hill et al., 2000;
Race et al., 2001). We found conventional Western blot to be
equivalent in sensitivity to histopathological markers such as
spongiform change and the presence of PrP-positive plaques on
immunohistochemistry, with good concordance between these
techniques, but all three were clearly inferior to bioassay. NaPTA
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superior to conventional immunoblot and morphological markers,
and approached that seen with bioassay. Although some caution is
required in the absence of formal end-point titer estimates of
asymptomatically infected Balb/c mice, the results from incubation
time interval assays suggest that in our model of presymptomatic
infection, conventional Western blot and routine histopathology are
able to reliably detect PrPres when infectivity is >3.2  104 ID50
units per standard 30-Al inoculum, whereas methods employing
NaPTA precipitation can detect PrPres when the infectivity is <2.0
102 ID50 units. Our ability to detect PrP
res in brain homogenates
when infectivity is <6.7  103 ID50 units/ml (equivalent to <2.0 
102 ID50 units per inoculum) is similar to the detection limit of
approximately 3  103 ID50 units/ml found in a prior report
comparing higher performance Western blots with hamster bio-
assay (Lee et al., 2000). There was only one mouse that did not
demonstrate PrPres using NaPTA precipitation when we would
have expected its presence based on the titer seen with bioassay.
We are uncertain of the explanation for this but suspect it
represents a false-negative result stemming from technical factors.
Nevertheless, given the detection of PrPres in three other mice with
comparable titers on bioassay, we believe the technique is clearly
superior to conventional Western blot and at a practical level
detects nearly all brains harboring potential transmissibility.
Our assessment of the utility of the NaPTA precipitation
method for depicting potential infectivity in other situations was
less favorable, appearing mainly related to lower ambient protein
levels. In contrast to using PBS as sample diluent, the situation of
using a 10% normal brain homogenate would be more comparable
to the detection of the abnormal isoform in preclinically infected
brains, as spiking experiments demonstrated a 10- to 20-fold
improvement in sensitivity when using the latter to dilute aliquots
compared to PBS. The influence of sample diluent on the
sensitivity of Western blot detection of PrPres has been reported
previously and suggests benefits from inclusion of higher protein
concentrations may be generic and not specific to brain-derived
polypeptides (Lee et al., 2000). Precisely how a higher protein
milieu assists PrPres detection with NaPTA precipitation is
speculative but probably relates to selectively facilitating the
segregation and aggregation of the abnormal isoform. It is
noteworthy that a recent report of the in vitro conformation-
dependent immunoassay technique showing equivalence to bio-
assay using sensitive host animals also used spikes of brain
homogenates from terminal mice diluted in 10% normal brain
homogenates for the comparisons (Safar et al., 2002). It would be
of interest to know how sensitive this detection method remains in
a more dilute protein environment. Another possibility for the
improved detection sensitivity of the NaPTA precipitation method
in comparison to bioassay in asymptomatically infected animal
brains may be a modest but critical amount of PrPres propagation
(of the order of 10 to 100-fold) sufficient to just allow detection,
whereas only bioassay is able to detect the extreme limits of
potential infectivity in our model.
In contrast to the experience of others (Thackray et al., 2002),
we always found abundant PrPres in whole brain homogenates from
terminal Tga/20 mice using both conventional and NaPTA
precipitation Western blot methods. A somewhat unexpected
finding, similar to what has been reported previously in other
transgenic mice over-expressing PrPc (Telling et al., 1996), was the
frequent presence of positive bands after PK digestion from brain
homogenates of long-term surviving inoculated healthy Tga/20mice. This was not observed in our wild-type (Balb/c) mice. The
observation was confirmed in age-matched, uninoculated Tga/20
mice and Tga/20 mice inoculated with brain from healthy animals.
Given the similarity of findings with two monoclonal anti-PrP
antibodies, we assume the banding represents PrPc and is related to
the markedly increased expression of the protein in these transgenic
mice. The banding pattern, nevertheless, was both qualitatively and
quantitatively quite different to that seen in Tga/20 mice dying of
TSE, always allowing confident differentiation of the two patterns.
In conclusion, the present study has demonstrated that chronic
asymptomatic infection, to varying extents, is a common finding
when wild-type mice are intracerebrally inoculated with low titer
inocula just insufficient to induce reproducible clinical disease over
extended incubation periods. Although unproven, extrapolation to
a human equivalent appears likely given the very long incubation
periods now recognized for kuru (Collinge, 1999) and the evidence
that PrPres deposition, as detected by conventional techniques,
occurs in the appendixes of vCJD patients for a considerable period
before the onset of symptoms (Hilton et al., 1998, 2002, 2004).
The application of higher-sensitivity diagnostic methods is
important to facilitate screening for potential infectivity in tissues
from at risk populations such as dura mater and human-derived
pituitary hormone recipients, and eventually when suitable
methods are available, serum samples from all asymptomatic
blood and organ donors. Comparative studies of the type described
here are needed to define more accurately limitations and situations
where individual tests are best applied. Further, similar to the
sentiments expressed in other comparative studies (Safar et al.,
2002), this knowledge coupled with other recent findings (Bosque
et al., 2002; Glatzel et al., 2003) may suggest the need to re-assess
the transmission risks of tissues and populations previously
deemed not to harbor any infectivity.Acknowledgments
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To assess whether heightened oxidative stress plays an early and primary pathogenic role in transmissible spongiform encephalop
e undertook detailed correlative studies using a mouse-adapted model of human disease. The spatio-temporal evolution of the abnorm
esistant isoform of the prion protein (PrPres) and neuropathological changes were correlated with the occurrence and type of oxidativ
eightened oxidative stress was demonstrated, but restricted to elevated levels of free aldehydic breakdown products of lipid pe
ffecting all brain regions to varying extents. The increase in lipid peroxidation was highest over the mid-incubation period, with
howing close temporal and general topographical concordance with the first detection of PrPres with both pre-empting the typical neuropathol
cal changes of spongiform change, gliosis and neuronal loss. Further, prion propagation over the disease course was assessed
ioassay. This revealed that the initial rapid increase in infectivity titres was contemporaneous with the abrupt onset and maxim
ipid peroxidation. The present results are an important extension to previous studies, showing that heightened oxidative stress in
ipid peroxidation is likely to constitute an early primary pathogenic event in TSE, associated temporally with the integral disease
f prion propagation and PrPres formation, and consistent with causal links between these events and subsequent typical neuropa
hanges.
2005 Elsevier Inc. All rights reserved.
eywords: Neuropathology; Oxidative stress; Prion propagation; Transmissible spongiform encephalopathy
. Introduction
Transmissible spongiform encephalopathies (TSE; also
nown as prion diseases) are a group of neurodegenerative
isorders, which includes Creutzfeldt–Jakob disease (CJD),
erstmann–Sträussler–Scheinker syndrome (GSS) and fatal
amilial insomnia in humans, as well as scrapie and bovine
pongiform encephalopathy in animals. Transmissibility is a
undamental differentiating feature from other neurodegener-
tive disorders such as Alzheimer’s and Parkinson’s diseases,
hat share the common feature of accumulation and aggregation
∗ Corresponding author. Tel.: +61 3 8344 1945; fax: +61 3 8344 4004.
E-mail address: stevenjc@unimelb.edu.au (S. Collins).
of constitutively expressed cellular proteins, which are beli
to be integrally related to disease pathogenesis. The conf
tional change of the wild type isoform of the prion protein (PrC)
to the disease-associated, partially protease-resistant con
(PrPres) appears a crucial event for successful transmission
pathogenesis in TSE. PrPres principally differs from PrPC by
containing a much greater ratio of-sheet to-helical conten
[33], contributing directly to its protease resistance and pro
sity for aggregation. Although PrPres appears to be the main
perhaps sole constituent of the TSE infectious agent (“prio
disease pathogenesis requires expression of PrPC [2,27]. Con-
sequently, prion protein gene (PRNP) ablated mice (PrP0/0) are
unable to be infected[8] and their neurons are resistant to
deleterious effects of direct exposure to PrPres [2,27].
361-9230/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
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Despite the apparent primacy of PrPC expression and PrPres
propagation in TSE pathogenesis, the normal function of PrPC
and the predominant mechanisms involved in pathogenesis
remain uncertain. PrPC and cognate synthetic peptides have
been shown to bind Cu2+ ions and internalise the transition
metal in a redox inactive state[4,30,32,36]. In cell culture mod-
els, neurons devoid of PrPC expression have been shown to
have an increased vulnerability to the superoxide anion[5],
hydrogen peroxide[43] and Cu2+ ions [6] compared to con-
trols and other models have shown that the presence of PrPres
appears to enhance susceptibility to pro-oxidants[29]. The brain
and other tissues of PrP0/0 mice have been shown to have
decreased superoxide dismutase (SOD) activity compared to
that in wild-type mice, as well as increased malondialdehyde
(MDA) and 4-hydroxyalkenals (HAE), reactive aldehydic prod-
ucts of lipid peroxidation[22,48]. Further, a reduction of total
SOD activity in brain homogenates after immuno-depletion of
PrPC has been demonstrated when compared to non-depleted
homogenates, while the Cu/Zn-SOD and Mn-SOD activities
remained unchanged[49]. Infected cell culture systems have
revealed evidence of oxidative damage, appearing to be a con-
sequence of unfavourable perturbations to Cu/Zn SOD and
Mn-SOD, as well as to glutathione peroxidase and reductase
activities[29]. Microglia may also have an effector role in the
oxidative damage observed as a consequence of exposure to a
































between these events and subsequent typical neuropathological
changes.
2. Materials and methods
2.1. Mice and inoculations
The M1000 strain used represents a mouse-adapted human TSE originally
isolated from a patient most likely dying from Gerstmann–Sträussler–Scheinker
disease[38]. For correlative studies over the disease course, Balb/c wean-
ling mice were intracerebrally (ic) inoculated with 30l of either 1% brain
homogenate from a mouse dying from TSE (approximating 2.7× 104 ID50
units) as previously described[12] or with 1% brain homogenate obtained from
a normal animal (control mice). Unless otherwise stated, morphological and bio-
chemical studies utilised groups of four to five diseased and four to five control
mice, sacrificed at 21, 42, 64, 82, 104, 123, 137 days post-inoculation (dpi) and at
the terminal stage of disease, the latter occurring at a mean incubation period of
145 dpi (±2 d). Mice generally began displaying symptoms of TSE from around
136 dpi. After this time point, mice demonstrated typical symptoms including
coat ruffling, reduced spontaneous mobility, hunched posture, hind limb paresis
and gait ataxia with occasional myoclonus.
Tg20 transgenic, PrPC over-expressing mice[16] were used to assess the
brain infectivity of inoculated Balb/c mice across the time-course of dis-
ease. Mice were inoculated as described above with 30l of 1% brain tissue
homogenates (w/v in PBS) prepared from the “diencephalic” regions of pre-
viously inoculated Balb/c mice. This diencephalic region consisted of the tha-
lamus, telencephalic deep gray nuclei, hypothalamus and brain stem, and was
chosen for inoculations because preliminary studies had indicated that the high-
est levels of PrPresand spongiform change occurred within these sites, especially



































w batedatively, this data and the ability of PrPC to bind Cu2+ and
emonstrate SOD-like activity[3,7] contribute to the propos
ion that PrPC acts as a protective and anti-oxidant molec
ith beneficial effects probably extending beyond SOD-
atalysis[43]. In parallel with this evidence, in vivo models
SE have demonstrated the presence of heightened oxi
tress[20] with damage to proteins[11,19] nucleic acids[18]
nd lipids[10,46] in terminally ill animals, and similar dama
as been detected in the brains of patients dying from spo
JD[47].
To date, however, the mounting in vivo evidence that he
ned oxidative stress may contribute to the pathogenesis o
as been derived primarily from studies of the terminal st
f disease. With a single exception[1], reports have failed t
ddress the temporal development of oxidative insults and c
ate them with conventional neuropathological changes or
ntegral features of TSE pathogenesis[10,11,19,20,46]. Data
rom terminal disease may not accurately represent the
athological relevance of oxidative stress in TSE and le
pen the possibility that oxidative damage is a relatively
nd non-specific contributor to the degeneration of neu
lready irrevocably damaged by other primary insults. To a
hether oxidative stress constitutes a primary pathogenic m
nism in TSEs, spatio-temporal correlation of various mar
f oxidative damage with classic neuropathological hallma
he presence of PrPres and prion propagation was perform
n a murine model of human disease. Our findings dem
trate that heightened oxidative stress in the form of
eroxidation is an early and likely primary pathogenic me
nism in TSE, with this change closely associated with Pres









noculated with 1% diencephalic region homogenates from Balb/c mice c
t 0 and 1 h, and 1, 7 and 14 dpi. Bioassay mice were culled once signs o
ere consistently evident, and those with lengthy incubation periods (>10
ere assessed for the presence of PrPres. rior quantal dose-titrations of t
1000 strain had been performed in both Balb/c and Tg20 mice. All mice
ulled by cervical dislocation, unless otherwise specified. Animal handling
n accordance with national prescribed guidelines and ethical approval f
tudy was granted by the University of Melbourne Animal Experimenta
thics Committee.
.2. Western immunoblot analysis of the spatio-temporal
volution of PrPres
To demonstrate PrPres, the brain regions were assayed by Western blot. D
ephalon tissue was isolated by macroscopically removing the cerebellu
he cerebral cortices and the three separate regions were homogenised to
BS. Fifty microlitre aliquots of these homogenates were treated with Benz
Merck, Darmstadt, Germany), 50 U/ml, in the presence of 1 mM MgCl2, and
ncubated for 5 min at 37◦C. Proteins were digested by Proteinase K (PK; Sig
astle Hill, Australia) at 100g/ml final concentration, incubated for 1 h
7◦C. Digestion was halted by the addition of Pefabloc (Roche, Basel, Sw
and) to 8 mM final concentration and 50l of 2× sample buffer containin
% 2-mercaptoethanol (Sigma) followed by boiling for 10 min. Samples
riefly centrifuged at 5000 rpm, prior to resolving on 10% pre-cast tris/gly
els (Novex, San Diego,California), then transferred to nitrocellulose me
ranes and blocked with 5% non-fat milk powder in PBS-T. Membranes
ncubated at 4◦C overnight with the ICSM18 monoclonal anti-PrP antib
44] (1:25,000 in PBS-T), with detection utilising an HRP-conjugated
ouse secondary antibody at 1:5000 (DAKO, Carpinteria, California), enh
hemiluminescence (ECL; Amersham, Castle Hill, Australia) and Kodak
ax film, developer and fixative (Sigma).
Western blot detection of PrPres across the time course of disease was
ndertaken using sodium phosphotungstic acid (NaPTA) precipitation of
omogenates prior to PK digestion[41]. In summary, 500l of 10% dien-
ephalon homogenates were mixed 1:1 with 4% Sarkosyl (Sigma) in PB
ncubated at 37◦C for 10 min with constant agitation. Benzonase and Mg2
ere added at 50 U/ml and 1 mM final concentrations, respectively and incu
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for 30 min at 37◦C with agitation. To this, 81.3l of a solution containing 4%
NaPTA (Sigma) and 170 mM MgCl2 was added (pre-warmed to 37◦C) and the
reaction mixtures vortexed then incubated for 30 min at 37◦C with agitation.
The samples were then centrifuged at 15,000× g for 30 min; supernatants were
carefully removed and the remaining pellets resuspended in 20l of PBS 0.1%
Sarkosyl ready for PK digestion and western blotting as described above.
2.3. Histology and immunohistochemistry
For morphological studies, mice were sacrificed by transcardial perfu-
sion. Mice were exsanguinated with wash buffer (2000 IU/l heparin, 0.028 M
sodium nitrite (Clyde Industries, Sydney, Australia) 0.005% butylated hydroxy-
toluene (BHT; Sigma) in PBS) followed by perfusion with 4% paraformaldehyde
(ProSciTech, Kirwan, Australia) in a 0.1 M phosphate buffer for approximately
10 min. Fixed mice were then incubated at 4◦C for 30 min before brains were
removed for further immersion fixation in either 10% neutral buffered formalin
or methacarn[35] for 1 h at room temperature (RT); brains were stored in 70%
methanol until processing. All fixed brain tissue was treated with 99% formic
acid for 1 h at RT to reduce tissue infectivity. Half-brains were paraffin embed-
ded and 6m sagittal sections were cut and mounted on Superfrost Plus slides
(Menzel-Glaser, Braunschweig, Germany). Mounted sections from each time
point were deparaffinised in Shellex and rehydrated through 100, 90 and 70%
dilutions of ethanol to deionised water and stained with hematoxylin and eosin
(H&E).
For immunohistochemical (IHC) assessment of neuropathological changes,
adjacent serial sections from mice culled across the time course were used.
After rehydration, all tissue sections were incubated in 3% hydrogen perox-
ide for 5 min at RT, then washed with PBS (pH 7.4). As appropriate for the
subsequent secondary antibody, sections were blocked with either 20% normal







































2.4. Biochemical assessment of oxidative stress
For all biochemical assessments of oxidative damage, mice were exsan-
guinated by transcardial perfusion as described above, with 0.005% BHT in PBS
included as anti-oxidant to prevent superimposed post-mortem contributions.
Mice were culled by lethal injection of Nembutal (Merial Australia, Paramatta,
NSW) (200l intraperitoneally) and brains were macroscopically dissected as
above, with each of the three principal regions (cerebral cortex, cerebellum and
diencephalon) individually homogenised to 10% in PBS containing 0.005%
BHT, snap frozen in liquid nitrogen and stored at−80◦C. Prior to analyses,
the protein concentration of homogenates was quantified using the BCA pro-
tein assay (Pierce, Rockford, Illinois), with samples equalised for total protein
content.
To assess for lipid peroxidation, the three brain regions were analysed
across the time course of disease using the Bioxytech LPO586 (Oxis, Portland,
Oregon) colorimetric assay. Aliquots of brain homogenates (protein concentra-
tion adjusted to 8 mg/ml) were analysed as per manufacturer’s instructions and
described previously[45].
Brain regions were analysed for levels of total carbonylated proteins
using the OxyBlot carbonyl detection kit (Intergen, Purchase, New York).
Brain homogenates (10g protein each) were derivatised with 10 mM 2,4-
dinitrophenolhydrazine in 2 M HCl and assessed by western blot as per kit
instructions.
To assess levels of inducible nitric oxide synthase (iNOS), normalised brain
amples from each of the three brain regions were analysed by western blot for
iNOS expression using anti-iNOS polyclonal antibody diluted 1:2000 (Affinity
Bioreagents, Golden, Colorado) with mouse derived iNOS (Cayman Chemicals,



























t dentabbit anti-GFAP polyclonal sera (DAKO) was applied (1:50) for 1 h at 37C.
etection of neurons (neuronal nuclear protein (NeuN) and neurofilamen
nhanced by boiling sections in sodium citrate buffer (pH. 6.0) for 5 min
o application of primary antibodies. Anti-NeuN (1:500; Chemicon, Teme
alifornia) and anti-neurofilament (1:50; Sigma, detecting all three sub
ouse monoclonal sera were incubated overnight at 4◦C before washing in PBS
he appropriate biotinylated secondary antibodies (swine anti-rabbit and
nti-mouse (DAKO)) were applied at 1:500 dilution for 1 h at RT, then wash
BS followed by incubation with HRP-conjugated streptavidin (DAKO) dilu
:1000 for 30 min at RT. Visualisation utilised the diaminobenzadine (DA
ubstrate-chromagen system (DAKO). A 1 min hematoxylin counterstain
lso employed.
To enhance PrPres epitope detection, sections were autoclaved for 20
t 132◦C, followed by cooling and washing twice in deionised water and
reated with 96% formic acid for 5 min[23]. After washing, sections were trea
ith 4 M guanidine thiocyanate for 2 h at 4◦C, then washed before blockin
rP was detected using the monoclonal antibody ICSM18 diluted 1:500 in
ith overnight incubation at 4◦C. Sections were then sequentially incuba
ith biotinylated rabbit anti-mouse IgG secondary antibody (1:500 for 30
RP-conjugated streptavidin, (1:1000 for 30 min), and finally DAB+.
Heme oxygenase-1 (HO-1; StressGen, Victoria, Canada), nitrotyr
NT; Upstate Biotechnology, Waltham, Massachusetts) and 4-Hydroxyno
HNE) (Calbiochem) polyclonal antisera pre-treatments included rep
icrowave boiling (up to five cycles) for 2, 3 and 4 min in 10 mM or 100
odium citrate buffer (pH 6.0), as well as exposing slides to either 0.1%
us Trypsin, Saponin, or Triton X 100 pre-warmed to 37◦C. Trialled primary
ntibody concentrations varied from 1:50 to 1:400. Carrier protein conc
ions for these primary antibodies were also varied, including use of 1%
nd 0.1, 5 and 10% fetal calf serum in PBS, and the 20% serum blockin
as extended to overnight. Positive controls for NT utilised pre-treatme
ections for 20 min at RT with peroxynitrite (Sigma), while general neg
ontrols consisted of: (1) omitting the primary antibody; and (2) substit
f the primary antibody with pre-immune serum from the same host a
pecies. As further negative controls for NT immunostaining, we pre-tr
issue sections with three 20 s exposures to 100 mM sodium hydrosulphi
.0) prepared immediately prior to use in 100 mM sodium bicarbonate
naerobic conditions, as well as pre-adsorption of the anti-NT antibody







Comparisons of the means of the levels of MDA/HAE at each time poin
ontrol and M1000-inoculated mice were estimated and tested for signifi
sing two-way analysis of variance (ANOVA).
. Results
.1. Western immunoblot analysis of the spatio-temporal
volution of PrPres
Using conventional western blots, PrPres was first consis
ently detectable at 82 dpi in the diencephalic region of Ba
ice, with the signal increasing thereafter. This region was o
ionally weakly positive at 64 dpi. In contrast, NaPTA prec
ation of the same brain region prior to electrophoresis affo
eliable detection of PrPresjust prior to the mid-incubation poi
t 64 dpi (Fig. 1), with occasional mice displaying a weakly po
ive signal at 42 dpi. Using NaPTA precipitation prior to wes
lotting, we were also able to consistently detect PrPres in the
omogenates of the cerebral cortex and cerebellum from 6
hereas conventional western blot only occasionally reve
eak PrPres signals from these same brain regions at 64
estern blots of the diencephalic region appeared to sh
lateau in PrPres levels after day 104 post-inoculation (Fig. 1).
.2. Histopathological findings through the incubation
eriod
.2.1. Spongiform change and astrocytic gliosis
Onset and progression of neuropathological changes
ssessed over the incubation period for comparison with o
ive damage and infectivity. Spongiform change was first evi
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Fig. 1. Western blot detection of protease-resistant prion protein (PrPres) within
the diencephalic brain regions of M1000 infected Balb/c mice. The time points
following intracerebral inoculation at which brains were harvested for assess-
ment are shown as days post-inoculation (dpi) and at terminal disease (terminal).
In the long exposures shown, the earliest detection of PrPreswas at 64 dpi, which
was more clearly and consistently seen with western blotting preceded by sodium
phosphotungstic acid (NaPTA) precipitation (on right). Conventional western
blots (left) show that there is a rapid increase in signal from 64 to 104 dpi with
plateauing thereafter. Note that in the M1000 strain, the unglycosylated (lowest)
band of PrPres is much less abundant than the glycosylated (upper) bands, and
is only clearly seen from 104 dpi using the conventional western blots and at
82 dpi for NaPTA treated samples. Brains were treated (+) with proteinase K
(PK), with the brain homogenate from a terminal animal also not treated with
PK (−) to verify complete PK digestion and demonstrate overall levels of PrPc
and PrPres. A 30 kDa molecular mass marker is provided at right.
simultaneously in the thalamus and hippocampus, immediately
after the mid-incubation point, at 82 dpi (Fig. 2A and D), and this
progressed to severe vacuolation at the terminal stage (Fi . 2B
and E). The hippocampal microvacuolation was diffuse, evi-
dent in both the radiate and oriens strata, but accentuated in the
CA2 segment. There was widespread but less severe spongi-
form change in the cerebral subcortical white matter from
104 dpi, with the occipital lobe usually the most affected. Brain
stem spongiform change was evident from 123 dpi, sometimes
becoming the most severely affected region in terminal animals.
The cerebellar cortex never displayed vacuolation in any of the
animals.
In control brains, modest GFAP immunoreactivity was
present in the hippocampus (in the stratum lacunosum-
moleculare and fimbria), corpus callosum, stria terminalis and
occasionally the thalamus, which did not change throughout the
time course (Fig. 2I and L). Closely paralleling the spongiform
change, the hippocampus and thalamus of mice inoculated with
M1000 were the first regions to demonstrate increased GFAP
signal at 82 dpi (Fig. 2G and J, respectively). Gliosis was patchy
but diffusely distributed in the thalamus, and in the hippocampus
Fig. 2. Evolution of the typical neuropathological changes observed in the mo
strating the earliest evidence of spongiosis occurring simultaneously in the hipp
to severe vacuolar degeneration in these same regions in terminal animals (B
(controls) were free of such changes (C and F, respectively). Astrocytic gliosi
82 dpi in the hippocampus (G) and thalamus (J), and progressively increased s
(H) and thalamus (K), compared to unchanged levels in age-matched, sham-i
marker anti-neuronal nuclear protein (NeuN) monoclonal antibody. Subtle neu
at 82 dpi, which progressively worsened at subsequent time points with the hi
severe depletion of neurons compared to sham-, age-matched controls (O an
monoclonal antibody first demonstrated occasional PrP-positive plaques juxta
mice with terminal disease showing very prominent plaque deposition (T and W
mice (U and X, respectively). Original magnifications: (C, D–F, M–X) 200×; all othuse-adapted model of TSE. Hematoxylin and eosin staining of brain sections demon-
ocampus (A) and the thalamus (D) at 82 days post-inoculation (dpi), wh ch progressed
and E, respectively); age-matched mice at a similar time point post-shaminoculation
s demonstrated using anti-GFAP polyclonal sera was first evident simultaneously at
o that terminal mice demonstrated dense astrocytic gliosis throughout the hippocampus
noculated brains (I and L, respectively). Neurone loss was assessed using th n uronal
ronal loss was first evident simultaneously in the hippocampus (M) and thalamus (P)
ppocampal CA1–CA3 (N) and dorsal thalamic (Q) regions of terminal mice showing
d R, respectively). Immunohistochemical staining for PrP using the anti-PrP ICSM18
posed to the hippocampus (S) and within the thalamus (V) at 82 dpi, withthe brains of
, respectively) but absence of staining in the brains of age-matched, sham-inoculated
ers: 400×.
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both the stratum oriens and stratum radiatum were affected.
Thereafter, the hippocampus and thalamus progressively dis-
played widespread and markedly increased GFAP reactivity
compared to controls, with the expansion most dramatic from
104 dpi through to the terminal stage (Fig. 2H and K). The occip-
ital subcortical white matter was the first neocortical region to
display GFAP reactivity at day 104 post inoculation at which
time sparse staining was also seen in the brain stem. These areas,
and the other cerebral subcortical white matter regions, progres-
sively developed widespread but less marked increases in GFAP
staining. The cerebellar cortex remained free of gliosis even in
terminally ill animals.
3.2.2. Neuronal loss
Neuron-specific immunostains confirmed neuronal loss in
M1000 inoculated mice relative to age matched, sham inocu-
lated controls. Subtle thalamic neuronal loss was evident from
82 dpi (Fig. 2P) and progressively worsened thereafter, with
the lateral thalamic (including pars posterior) through to the
pre-tectal nuclear areas the most affected, frequently displaying
complete neuronal loss in terminal mice (Fig. 2Q), when com-
pared to controls (Fig. 2R). The CA1–CA3 pyramidal neurons
of the hippocampus also displayed similar findings from day
82 post inoculation (Fig. 2M) with the loss greatly pronounced
by 123 dpi. The CA1–CA3 regions of the hippocampus showed






























Summary of bioassay results of M1000-inoculated Balb/c mice culled at pre-











0 10/10 82± 8 1.8× 106
0.1 8/8 82± 6 1.8× 106
1 14/14 81± 8 2.2× 106
7 8/8 111± 18 4.1× 103b
14 7/7 86± 4 7.6× 105
21 16/20 118± 36 9.5× 102b
42 20/20 79± 5 3.3× 106
64 20/21 75± 6 7.6× 106
82 17/17 68± 4 3.3× 107
104 18/18 59± 2 2.2× 108
123 19/19 63± 3 9.3× 107
137 23/23 60± 2 1.8× 108
145± 2 12/12 58± 4 2.7× 108
S.E.M. = standard error of the mean; dpi = days post inoculation.
a Calculated using regression equation derived from dose titration assay of
M1000 whole brain homogenates inoculated into Tg20 indicator mice: incu-
bation period = 111.18 + (−11.02) Log dose of inoculum (Spearman coefficient
p < 0.0001).
b Notional titre; incubation period fell outside interpolatable data range.
post-inoculation, and 1, 7 and 14 dpi revealed transmission rates
and incubation periods consistent with low titres of infectivity,
which are assumed to reflect residual inoculum. The nadir of
infectivity occurred at 21 dpi, suggesting maximal clearance of
the inoculum, with an 80% transmission rate and mean incu-
bation period of 118± 36 days. Thereafter, infectivity rapidly
increased to day 42, as reflected by shorter incubation peri-
ods and 100% transmission rates, followed by a more gradual
increase to reach maximal levels around 104 dpi when mean
incubation periods approximated 60 days for this and subse-
quent time points.
3.4. Assessment of oxidative stress through the incubation
period
3.4.1. Immunohistochemistry
Immunohistochemistry employing various markers of oxida-
tive damage was intended to provide a detailed topographical
analysis over the disease course for correlation with conventional
europathological changes. Despite varying numerous param-
eters of the immunohistochemical protocol, we were unable to
detect consistent and convincing differences in the staining pat-
terns of diseased and control tissue for NT modified proteins,
HNE adducted proteins and HO-1. All three primary antibod-








p hiteompared to controls (Fig. 2O). The occipital cortex was seen
ose NeuN reactivity around day 104 while, in contrast but
ordant with other morphological findings the cerebellum
ot display any definite neuronal loss even in terminally ill
als, including Purkinje cells as demonstrated by neurofila
taining (data not shown).
.2.3. PrP immunohistochemistry
PrP-positive plaques were occasionally detectable by
t 64 dpi, at the junction of the corpus callosum with the s
um oriens of the hippocampus but remained an incon
nding at 82 dpi (Fig. 2S). At 82 dpi the thalamus often b
ot invariably demonstrated modest numbers of PrP-po
laques (Fig. 2V). However, throughout the time course,
ippocampus and thalamus demonstrated the greatest
f PrP immunostaining, which often became very pro
ent in terminally ill animals (Fig. 2T and W, respectively
rom day 104 post-inoculation, PrP plaques were also pr
n the neocortical white matter, with the occipital reg
ost affected. Even in terminal mice, the brain stem
evealed occasional plaques and the cerebellum was free
eposits.
.3. Bioassay determination of transmissibility over the
ncubation period
Prion propagation over the disease time course was ass
y “blind” bioassay using Tg20 mice. For each pre-sched
ull of Balb/c mice at the various time points, incubation t
nterval assay estimates of infectious titres were calcu
Table 1). The diencephalic regions from mice culled 0 anded
ontrol brains (data not shown). The most intensely staining
ones were usually in the brain stem, a region generally sho
elatively less severe conventional histopathological cha
he anti-NT antibody caused a uniform hazy staining of the
opil, which appeared to be non-specific. Although encour
y some of our results, such as the absence of immuno
ng when omitting the primary antibodies and for NT, a
re-treatment of sections with 100 mM sodium hydrosulp
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Fig. 3. Comparative assessment of brain levels (nmol/mg protein) of free HAE
and MDA aldehydic breakdown products of lipid peroxidation in M1000 inocu-
lated Balb/c mice and controls using the Bioxytech LPO586 (Oxis) colorimetric
assay as described in Section2. The diencephalic regions of the infected mice
were found to contain the most significantly elevated levels of free HAE and
MDA (two-way ANOVA p = 0.0071), increased from 42 dpi and continuing over
the entire disease course but highest over the mid-incubation period. dpi = days
post-inoculation.
(dithionite) under anaerobic conditions, pre-immune serum gave
very similar staining patterns to that observed with polyclonal
primary antisera (data not shown).
3.4.2. Biochemical assessment of lipid peroxidation
Given the limitations of immunohistochemistry to assess for
a spatio-temporal pathogenic link between heightened oxidativ
stress, and prion propagation and the typical neuropathologica
changes, we undertook biochemical analyses. Free aldehyd
lipid peroxidation breakdown products from the three prin-
cipal brain regions were assessed across the disease cour
Observed was an elevation of free MDA and HAE in all brain
regions of mice inoculated with M1000 compared with con-
trols. The most striking and significant elevation of the aldehydic
breakdown products was in the diencephalon (two-way ANOVA
p = 0.0071). MDA and HAE levels rose from background con-
centrations at 21 dpi to increased levels at 42 dpi, remaining
elevated thereafter over the entire time course, but highest ove
the mid-incubation period (Fig. 3). It is notable that the onset of
heightened lipid peroxidation in the diencephalic region closely
correlated with both the rapid rise in prion titres as well as the
earliest evidence of PrPres(42 dpi), and immediately pre-empted
the appearance of typical neuropathologic changes, which even
tually were often most marked in this same brain region.







analysis did not reveal a consistent difference between M1000
and sham inoculated mice at any of the time points during the
incubation period, nor in terminal mice compared to age matched
controls (data not shown). Also, for total protein carbonylation
there was no evidence of a trend to higher levels with time over
the disease course nor with ageing in sham inoculated mice.
For assessment of iNOS expression, analysis was restricted to a
protein band with a relative mobility of 130 kDa (in accordance
with the positive control). An additional, often more prominent
band was observed at around 117 kDa with similar results in
both M1000 inoculated mice and controls.
4. Discussion
The findings of the present study represent an important
extension to previous in vivo studies assessing oxidative stress
in animal models of TSE pathogenesis[1,10,11,19,20,46], and
support a generic role for heightened oxidative damage across a
range of neurodegenerative disorders[51]. Previous in vivo stud-
ies demonstrating increases in lipid peroxidation products have
either been restricted to non-topographical assessments of the
brains of terminally ill animals[10,11,46]or have used immuno-
histochemistry over a time course but only found noticeable
elevations of 4-hydroxynonenal (HNE) restricted to astrocytes
late in the incubation period[1]. None have correlated their find-































r notxide synthase (iNOS) expression
To determine if other cellular indicators of brain oxidat
tress were also increased during the disease course, total
arbonylation and levels of iNOS were assessed. The o
esults for both carbonyl modification and iNOS expression w








he present results demonstrate that peroxidative lipid da
ccurs as an early and relatively selective pathogenic e
losely linked temporally and more broadly topographic
ith the hallmark features of TSE pathogenesis; de novo p
ropagation and the presence of PrPres. The observed increa
n lipid peroxidation early in disease evolution militates aga
he likelihood that such changes represent a less relevant e
omenon occurring secondarily in non-neuronal cells late i
isease course[1,11] or in neurons already compromised fr
ther primary insults. Exemplifying our speculations regar
ausality is the observation that although all brain regions
ffected, the most significant peroxidative damage was se
he diencephalic region, corresponding to where neurop
ogical changes were first evident and where the most s
europathologic findings generally eventuated (Table 2).
Support for a direct link between increased oxidative s
nd spongiform neurodegeneration also comes from a t
enic mouse model in which the mitochondrial form of S
MnSOD) has been genetically ablated[28], as well as othe
nimal models of TSE where mitochondrial damage has
escribed[10]. Precisely how PrPres or the conversion proce
s linked to lipid peroxidation is uncertain; however evide
xists to suggest that the conformational change of PrPC to
rPres probably occurs within a lipid membrane environm
nd may involve formation of redox active, copper complex
etastable PrP intermediates[39]. Ultrastructurally, conversio
f PrPC is most likely to be within detergent-resistant lipid-ra
f the plasma membrane or early endosomes[13,40], both of
hich are rich in easily peroxidisable arachidonic acid[34].
A detailed topographical insight into precisely which br
egions and cell types displayed oxidative damage was
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Table 2
Summary of neuropathological changes and biochemical evidence of oxidative stress in the diencephalon of M1000-inoculated Balb/c mice culled at pr-det rmined
time points and at terminal illness
Number of days post-intracerebral inoculation
21 42 64 82 104 123 137 145± 2
Transmissibility +a ++ ++ +++ ++++ ++++ ++++ ++++
Lipid peroxidation 0 ++ +++ +++ ++ + + +
PrPresb 0 0c ++ +++ ++++ ++++ ++++ ++++
Vacuolation 0 0 0 ++ +++ +++ ++++ ++++
Neuronal loss 0 0 0 + + ++ +++ +++
GFAP 0 0 0 + ++ ++ ++++ ++++
PrP plaques 0 0 0 + ++ ++ +++ +++
a For illustrative comparative purposes, the various analysed features over the time course of disease were arbitrarily graded: 0 = normal/absent; + =very minor;
++ = mild; +++ = moderate; ++++ = severe or marked. Neuropathological gradings were qualitative, based on a composite average of observations from single,
mid-sagittal, whole brain sections from three or four mice at each time point, using a high power field (200× original magnification) centred on the thalamus.
b Determined by western blot analysis of brain homogenates as described in Section2.
c Occasional weak positive signal at 42 dpi.
achieved in our study. We suspect this inability may at least
partly relate to a technical problem regarding tissue preparation.
In contrast to previous studies reporting immunohistochemical
evidence of oxidative damage or stress in animal models of prion
disease[1,11,19,20], we subjected tissue sections to concen-
trated formic acid. Such pre-treatment may deleteriously affect
the antigenic specificity of epitopes found in HNE, HO-1 and
NT, and may also lead to an artefactual, diffuse increase in non-
specific neuronal staining (including similarly pre-treated con-
trol tissues), overwhelming any genuine signal from oxidative
damage. Consequently, we were not able to clearly reproduce the
previous findings of increased HNE immuno-reactivity within
astrocytes in the later incubation period[1]. Utilising a sensitive
biochemical approach, however, our study did demonstrate sig-
nificantly heightened lipid peroxidation in the diencephalon. The
importance of the biochemical assay employed in our study is
that it detects free MDA and HAE as evidence of lipid peroxida-
tion, with these unbound aldehydes known to quickly dissipate
due to very rapid reactions with other biomolecules. In contrast,
immunohistochemical detection of HNE (one important HAE
breakdown product) utilises antibodies that specifically recog-
nise chemically reduced amino acid-(4)-HNE adducts, which are
stable end products of reactive HNE molecules. Once formed,
these would remain and accumulate in an affected tissue, allow-
ing subsequent detection but not necessarily reflecting active














o control levels. The reduction in lipid peroxidation may relate
to glial proliferation, which although posited as a generic pro-
tective response[50] against many different insults including
oxidative stress[14,15,37], does not impede the continuing prop-
agation of PrPres. It may be that in our in vivo model of TSEs,
such a protective effect was achieved to some degree against
oxidative attack on membrane lipids, but failed to mitigate the
deleterious effects of additional pathogenic pathways induced
as a consequence of the continued production and accumula-
tion of PrPres[50]. Additionally, certain neuronal subpopulations
may have increased vulnerability to oxidative stress and are lost
early, leaving surviving neurons such as seen in the cerebel-
lum of our mice and in those infected with other prion strains
[9], perhaps because of better innate anti-oxidant defences
[25].
The present study found no convincing evidence of increased
total protein oxidation, nor elevation of iNOS in the brains of
infected mice. Our observed lack of up-regulation of iNOS
accords with the findings of a recent report[42] but is discrepant
with another in vivo animal study[20]. Prion strain-host animal
differences are unlikely as the explanation for the discrepancy
given the use of a similar combination in the two previous
studies of iNOS with strikingly divergent observations. Further,
although reports have described increased gene transcriptional
activity and expression levels of NF-, and pro-inflammatory













a n af stable HNE adducts later in the disease is not neces
ncompatible with our finding of highest free reactive aldeh
evels earlier in the incubation period. Differing sensitivities
he two techniques may underlie a situation in which the m
hological method requires greater absolute amounts of
efore a detection threshold is reached, with progressive
ulation only achieving this by late in the incubation period[1],
hereas despite lessening production of HAE and MDA
ore sensitive biochemical detection is still possible even
he terminal phase of illness.
Despite inexorable progression of the disease
istopathologically and clinically, lipid peroxidation lesse
n the latter stages of the incubation period but did not rey
-
l
nfected with TSE agents[21,24] (the latter most likely
hrough reactive oxygen species inducing increased leve
F-, a major transcriptional activator regulating TNF and
nterleukins-1 and 1), this has not been an invariable find
42]. It is possible that NF- is not activated in our model
rion disease. Free HNE, likely to be considerably incre
rom relatively early in the incubation period in our study,
een shown to bind and inhibit the activation of NF- and
revent iNOS expression in cell culture models[26,31]. Also,
hile the observed up-regulation of GFAP but not iNOS
ur model appears contradictory, it must be noted that G
an be expressed in the absence of NF- activation. NF-о
nd NF- can differentially regulate GFAP expression i
M.W. Brazier et al. / Brain Research Bulletin 68 (2006) 346–354 353
number of situations, including maturation and as a response to
a wide variety of perturbations to the cellular environment[17].
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Neuronal loss is a pathological feature of prion diseases for which increased reactive oxygen species (ROS) and
consequent oxidative stress is one proposed mechanism. The processes underlying ROS production in prion
disease and the precise relationship to misfolding of the prion protein remain obscure. Using cell culture
models of prion infection we found that cells demonstrate a rapid, prion protein (PrP) dependent, increase in
intracellular ROS following exposure to infectious inoculum. ROS production correlated with internalisation
and increased intracellular protease resistant PrP (PrPRes). The ROS increase was predominantly lysosomal in
origin but not sustained, with cells adapting within 48 hours. Overall ROS levels remained normal in the
chronically prion infected cell population; however a subpopulation characterised by loss of membrane
phosphatidylserine asymmetry exhibited highly peroxidised intracellular aggregates that localised with PrP
and intense caspase activation. These apoptotic cells showed increased ROS closely correlating with increased
PrPRes. Our findings demonstrate that a PrP-dependent, transient, increase in intracellular ROS is characteristic
of acute cellular prion infection, while chronic phases of prion infection in vitro are associated with a
significant subpopulation manifesting apoptosis accompanying heightened oxidative stress and increased
PrPRes burden. Such observations strengthen the direct links between heightened ROS and ongoing prion
propagation with eventual cellular demise.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Transmissibility is a fundamental feature of prion diseases
separating them from other neurodegenerative disorders such as
Alzheimer's disease. Transmission and neuronal degeneration only
occur when the native prion protein (PrPC) is expressed, allowing
ongoing formation of abnormal conformers with increased beta-sheet
content [1,2]. Generally in animal models, the abnormal conformers
can be detected in the brains, by means of their increased protease
resistance, well before overt disease is evident. At the earliest time
point when these abnormal, protease resistant conformers (referred
to as PrPRes) can be weakly detected there is also a significant
elevation in lipid peroxidation, a marker of increased ROS [3]. This
finding raises the possibility that conversion of PrPC to the abnormal
isoform occurs concurrently with elevated ROS production, especially
before any cellular compensatory responses can be established.
Recent studies have highlighted the role of methionine oxidation,
caused by ROS, in destabilising PrPC conformation and so indicate that
oxidation of PrPC itself might be part of the conversion mechanism to
PrPRes[4].
PrPC has been linked with cellular anti-oxidant capacity. This
protection may arise through an intrinsic superoxide dismutase-like
activity of PrPC[5,6], or through the activation of signal transduction
pathways that stimulate anti-oxidant defence by other means [7].
Transgenic mice with the PrP gene ablated (Prnp PrPo/o) appear to have
no significant impairment of central nervous system function [1,8];
however such mice do show heightened levels of oxidative stress
markers in the brain and peripheral organs [9]. Further, when
challenged with large insults, such as transient cerebral ischemia,
PrPo/omice displaymuch greater oxidative damage than theirwild-type
counterparts [9–11]. Prion diseased mice with ongoing PrPRes propaga-
tion show compromised antioxidant function and, specifically, attenu-
ated cellular superoxide dismutase activity [12,13]. The implication
being that, during prion disease, a PrPC-related ROS protective function
is lost either as a direct or indirect result of conversion of PrPC to PrPRes.
An alternative to such ‘loss of function’ theories is the possibility that
PrPC to PrPRes conformational changebrings about an innate toxic gainof
function directly contributing to increased cellular oxidative stress.
Increased ROS have been found due to activation of NADPH oxidase
when cells are exposed to PrPRes or the amyloidogenic and toxic 106–
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126 peptide derived from the core of PrP [14]. The authors reported that
exposure to the ‘toxic’ agent initiates deleterious signalling through PrP,
fyn and NADPH oxidase thereby promoting pathogenesis.
Considerable evidence exists supporting the occurrence and likely
pathogenic role of heightenedoxidative stress inpriondisease evolution
although whether this is a primary or initiating event or a later
contributor after the development of neuronal dysfunction remains to
be confidently resolved. Further, the processes underlying ROS
production in prion disease and the precise relationship to misfolding
of the prion protein remain obscure. At the earliest time point when
protease resistant conformers were detected in the brains of prion
infected mice, increased lipid peroxidation was detected concurrently
[3]. The purpose of the present studywas therefore to better understand
the associations between PrPRes propagation, ROS production and
toxicity at the cellular level. Accordingly this study investigated the ROS
changes associated with acute and chronic phases of prion infection in
cell cultures. We found that cellular adaptation quickly restores
increased ROS levels following acute prion infection but appears to be
progressively overwhelmed in a significant subpopulation with resul-
tant toxicity and apoptosis during chronic propagation.
2. Materials and methods
2.1. Cell culture
Rabbit kidney epithelial (RK13) cells, transfected (using FuGene 6;
Roche, AUS) with empty vector, mouse PrP or human PrP, mouse
olfactory bulb (OBL-21) cells [15,16] and the GT1-7 mouse hypotha-
lamic neuronal cell line were cultured in Dulbecco's Modified Eagle's
Medium (DMEM; Invitrogen AUS) supplemented with 10% (v/v)
foetal bovine serum (Lonza Australia Pty) and 50 U/ml pencillin/
50 μg/ml streptomycin FBS; solution (Sigma, AUS) and maintained at
37 °C with 5% CO2 in a humidified incubator.
2.2. Stem cell harvest and culture
The brains of three eight week-old Prnp wild-type and knock-out
mice (C57BL/6 x SV129 background) were harvested, post-anaes-
thetising with methoxyfluorane and cervical dislocation, and the sub
ventricular zone (SVZ) dissected from the whole brain. All procedures
were approved by an animal ethics committee operating under the
Australian code of practice for the care and use of animals for scientific
purposes. Stem cells were harvested from the SVZ using the Neurocult
enzymatic cell dissociation kit (Stem Cell Technologies - Canada), as
per the product protocol. Neurospheres were expanded in complete
proliferation media (Stem Cell Technologies; see the Neurocult ‘In
vitro proliferation and differentiation of mouse neural stem cells’
manual for more details) and used for experiments at passages three
and four. Neurospheres were differentiated into neural lineage cells
by transfer into differentiation media (Stem Cell Technologies). For
assays cells were seeded at a concentration of 5×104 cells/cm2.
2.3. Preparation of infectious lysates and cell infections
The M1000 mouse-adapted prion strain was utilised for all cell
infection experiments throughout this study [3]. Infections with
M1000 brain homogenate were established using a standard overlay
technique described previously [17]. Cell lysates were prepared by
centrifugation at 300 x g for 5 minutes, washed in Dulbecco's
phosphate buffered saline (dPBS), and centrifuged again. Pellets
were weighed and resuspended in dPBS to make a 10% wet-pellet-
weight/volume suspension. Cells were lysed by repeated freeze-thaw
cycles and vortex mixed thoroughly to ensure an even suspension
before overlay techniques. De novo cell infections were performed by
exposure of cells to cell lysates that were M1000-infected or mock-
infected (cells that had been exposed to normal brain homogenate in
parallel with those exposed to M1000-infected brain homogenate).
Cell-to-cell contact and media exchange infections were carried out
utilising M1000-infected and mock-infected cells grown on cover-
slips. At the start of the assay, test cells grown in 24-well culture plates
were loaded with DCFDA reporter reagent (see below), with the
coverslips, which fit snugly in the well, positioned over the top of the
test cells either face-up (media exchange) or face-down (cell contact)
and readings taken 1.5 mm from the centre of the well.
2.4. DCFDA assay
The DCFDA assay using 5 μM 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2-DCFDA,
Invitrogen) was employed as described previously [18]. Cells were
loaded with CM-H2-DCFDA ROS-activated fluorescent dye (fluores-
cence yield progressively increases as ROS react with the dye) and
fluorescence readings recorded from the addition of inocula for 12
hours. The rate of fluorescence change, indicating increased oxidative
flux and defined as the linear tangent to the initial rate curve, was
quantified relative to time 0 signal.
2.5. TEMPO-9-ac assay
For plate based assays 50 μM TEMPO-9-ac (Invitrogen) was
included in the cell media (media in empty wells – no cells – was
used as a negative control) and fluorescence changes monitored from
the addition of test lysates. The fluorescent signal initially accumu-
lates and linear tangents to the initial rate curve were used to monitor
radical detection. For microscope assays 50 μM TEMPO-9-ac was
loaded onto cells in normal media for 30 minutes, prior to imaging
cells after transfer into phenol-red-free media.
2.6. MTS viability assay
Five μl of one solution MTS reagent (Promega; VIC AUS) per 100 μl
media was added to test and medium-only background control
conditions, and incubated under normal culture conditions for 90
minutes. Reaction product was quantified using absorbance at 462 nm
in a Fluostar Optima.
2.7. CyQuant viability assay
The CyQuant viability assay (based on total DNA; Invitrogen) was
performed as described in the product protocol. Readings were taken
using 490 nm excitation and 520 nm emission filters in a Fluostar
Optima.
2.8. Bodipy staining
Stock solutions of Bodipy581/591 C11 (Invitrogen) were made by
dissolving 1 mg of probe into 50 μl chloroform. The probe-chloroform
solutionwas then diluted into 10 ml of foetal bovine serum to produce
a 0.2 mM concentration of probe. Cells were cultured in normal media
containing 2 μM of Bodipy581/591 C11 for 24 hours prior to the start of
the assay. Bodipy581/591 C11 displays red fluorescence emission until it
becomes oxidised when emission shifts into the green range;
therefore the ratio at time 0 was taken as the control basal levels of
lipid peroxidation.
2.9. Cytosolic redox potential
Cells were incubated in Opti-MEMI reduced serum culture
medium (phenol red free; Invitrogen) containing 5 μM PF-H2TMRos
(Invitrogen) probe and 1 μM mito-tracker® green (Invitrogen) for 10
minutes. Media was removed and cells were washed in fresh media
then incubated in fresh media with or without test inocula.
595C.L. Haigh et al. / Free Radical Biology & Medicine 51 (2011) 594–608
Author's personal copy
2.10. pHrodo labelling
Fifteen mg total protein (based on determination of concentration
by BCA assay) fromwhole cell lysates of mock or M1000 infected cells
was prepared in 100 mM sodium bicarbonate buffer (pH 8.5) then
incubated with 0.25 mM pHrodo dye (Invitrogen; prepared as a
10 mM solution in DMSO) for 1 hour at room temperature protected
from light. Protein was separated from unbound dye by methanol
precipitation and resuspended in culture media before use. Protein
concentration and pH fluorescence curves were determined as quality
control measures before use (Sup Fig. 3).
2.11. Immuno-depletion of PrP
After determining protein concentration in cell lysates (by BCA
assay), 1 mg was diluted into 500 μl dPBS, then incubated with 1 μl
Saf32 primary anti-PrP antibody (epitope: murine residues 79–89;
Sapphire Biosciences, AUS) for 1 hour with 3 rpm rotational mixing at
4 °C. Twenty-five μl of protein G dynabeads (Invitrogen) was added
per separation and mixing continued for a further 2 hours at 4 °C.
Separations were performed using a Dynabeads magnetic separation
rack (Invitrogen); the supernatant was kept as the depleted fraction.
Beads were boiled in dPBS to collect the PrP enriched fraction.
Depleted samples were treated identically to the enriched fraction.
2.12. Indirect immunofluorescence
Cells were grown on 13 mm glass coverslips in normal media then
treated with Bodipy581/591 C11, as described above for 24 hours at
37 °C, with immunofluorescence (IF) performed when cells were 80%
confluent. Plates were protected from light at all stages during this
protocol. Cells were fixed in 4% (v/v) paraformaldehyde/PBS for 20
minutes and then permeabilised either in immunodiluent (ID; 1% w/v
BSA in PBS) with 0.1% (v/v) Triton-X 100 for 5 minutes or ice-cold
100% methanol for 20 minutes. Coverslips were blocked in ID with
10% FBS (v/v) for 30 minutes. Primary antibodies Saf32 and mouse
monoclonal anti-vimentin (Abcam, AUS) were diluted in ID and
applied for 2.5 hours at room temperature. Alexafluor350-conjugated
goat anti-mouse secondary antibody (Invitrogen) also diluted in ID
was applied for one hour at room temperature. Coverslips were
mounted onto glass slides with mowiol mounting media.
2.13. Caspase imaging
A 600 μM stock solution of SR-VAD-FMK (Immunochemistry
Technologies, USA) was prepared in sterile PBS (pH7.4; Invitrogen)
containing 20% (v/v) high quality sterile-filtered DMSO (Sigma-
Aldrich). Cells were plated 24 hours before the start of the assay.
0.6 μM of the SR-VAD-FMK solution was added to Opti-MEMI reduced
serum, phenol red free media and cells were incubated for 30 minutes
under normal growth conditions. The cells were then washed and
incubated in fresh Opti-MEMI for the duration of the assay.
2.14. Phen green Fl assay
Cells were incubated in pre-warmed Opti-MEMI reduced-serum
medium (without phenol red) containing 10 μM Phen green FL
diacetate for 20 minutes and residual cellular fluorescence compared
with the cell-free control solution. Readings were taken using 490 nm
excitation and 520 nm emission filters in a Fluostar Optima.
2.15. Cell blot assay
The cell blot assay is a variation on that developed by Bosque &
Prusiner [19] as described in Lewis et al [17].
2.16. Slot blotting
Slot blots were performed using a Bio-Rad Bio-Dot SF apparatus as
described in the recommended product protocols using nitrocellulose
membranes. Five μg of total protein (as determined by BCA assay) was
loaded per sample. Membraneswere dried and treated as for cell blots
to detect PrPRes.
2.17. MACS separation
Cells were brought into solution using trypsin and gently pipetted
up and down to remove cell clumps. 107 cells, as determined by
haemocytometer cell count, were labelled with AnnexinVmicrobeads
(Miltenyi Biotech, AUS) and magnetic separation was performed as
described in the MACS protocol (Miltenyi Biotech). Both labelled and
unlabelled fractions were transferred into fresh media for use in
ensuing experiments, which were carried out within 2 hours whilst
the cells expressing phosphatidylserine were still viable.
2.18. PK digest and western blotting
Cell fractions from MACS separations were centrifuged at 300 x g
for 10 minutes to collect the cells, followed by lysis in RIPA buffer
[50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% (w/v) SDS, 0.5% (w/v)
sodium deoxycholate, 1% (v/v) NP-40] at 37 °C for 20 minutes. Total




































































moRK13 vecRK13 huRK13 moRK13 (PrP 
depleted innocula)
Fig. 1. Intracellular ROS increases in PrPC-expressing cells upon exposure to infectious
prions. (A) MoRK13 (black bars), vecRK13 (white bars) and huRK13 (chequered) cells
were exposed to lysate derived from M1000 infected or mock infected (normal brain
homogenate) moRK13 cells and intracellular ROS response determined by DCFDA
assay. Shaded bars represent moRK13 cells treated as above but following immuno-
depletion of PrP from the lysate inoculum. Significantly increased intracellular ROS
response is seen for the moRK13 in response to the M1000 infected lysates only (2-way
ANOVA F=5.487, p=0.004, n=4, *pb0.05 significance comparing M1000 to mock
lysate and #pb0.05 significance comparing M1000 treatments) and this reduced to
baseline when PrP is depleted from the inoculum. (B) Cell blot for infection at passage
four post-treatment with infectivity. Following PK digestion, PrPRes was detected by
mab ICSM18. Growing the cells post DCFDA assay slowed the uptake of infection in the
DCF treated cells compared to untreated counterparts (representative of n=3).
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protein was split into two aliquots with the first incubatedwith 10 μg/ml
proteinase K (PK) for 90 minutes. The second 50 μg of lysate was
treated identically but without addition of the PK. Equal volumes of
digested and undigested samples were electrophoresed using the
NuPAGE system (Invitrogen), transferred onto nitrocellulose mem-
branes and blocked as described in [20]. PrP was detected using 1 in
10,000 dilution of ICSM18 monoclonal antibody (murine epitope
142–152; D-Gen, UK) in 1% milk PBS-t. Anti-mouse HRP secondary
antibody (GE Healthcare, NSW AUS) was used at 1 in 10,000 dilution
and blots were visualised using ECL-plus detection reagent (GE
Healthcare).
2.19. Oxyblot
Cells were lysed in RIPA buffer supplemented with 2% (v/v) β-
mercaptoethanol and 20 μg derivatised as per the Oxyblot product
protocol (Millipore). Two μg of each derivatisation and controls (no
derivatisation negative control and derivatisation of cell lysates
treated with 3% v/v H2O2 plus 1 mM CuCl4 as a positive control)
were spotted onto nitrocellulose membranes and blotting was
continued as per the product protocol with visualisation using ECL-
plus detection reagent (GE Healthcare).
2.20. Densitometry and statistical analyses
Luminescent signal of the bands on thewestern blots was captured
using a LAS-3000 intelligent dark box (FujiFilm – Berthold, Victoria
AUS) and the intensity quantified, after the subtraction of background,
by ImageJ 1.38x. Statistical analyses were carried out using GraphPad
Prism 4 or Minitab15 statistical software. Graphs represent the mean
and s.e.m. of four independent experiments unless otherwise stated.
Primary statistical tests are stated in the text; for ANOVA analysis
Tukey's secondary test was applied. Microscope images were
visualised with a 60x oil immersion lens and captured using a Nikon
Eclipse TE2000-E epi-fluorescence microscope (Nikon-Roper Scien-
tific). All image parameters were maintained throughout an exper-
iment, across all conditions, and the channels of probes sensitive to
photo-oxidation were collected before other channels. For imaging
data the ‘n’ represents independent experiments, which each































































































































































Fig. 2. Increased intracellular ROS occurs when uninfected cells directly contact infected cells and is also observed in murine neuronal cell lines and differentiated NSCs. The moRK13
(black bars) and vecRK13 (white bars) cells were incubated either in direct contact with M1000-infected or mock-infected cells (A) or allowed to exchange media with these cells
(B). Significantly increased intracellular ROS as determined by the DCFDA assay is seen in moRK13 cells in direct contact with M1000 infected cells (2-way ANOVA, F=9.409,
p=0.0154, n=3); this does not reach significance in cells allowed to media exchange (2-way ANOVA, F=1.189, p=0.3072, n=3). (C) OBL-21 and GT1-7 cells treated with normal
mouse brain homogenate (white bars) and M1000 infected mouse brain homogenate (black bars) show increased ROS in response to the infectious inoculum (students t-test; OBL-
21 t=3.719, p=0.0338, n=3; GT1-7 t=7.106, p=0.0192, n=3). (D) Wild-type (black bars) and Prnp knock-out (white bars) NSCs were differentiated for 6 days then assayed
with mouse brain homogenate as described for the neuronal cell lines. The wild type cells treated with the M1000 infected homogenate showed significantly increased intracellular
ROS compared with the control homogenate treated and null cells (Two-way ANOVA, F=25.53, p=0.001, n=3).
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experiment. Cell intensity, intensity variation, co-localisation or
ratiometric analysis (with percentage peroxidation calculated using
%=I510/(I510+I570) *100) was done using Nikon NIS-elements 3.0
software with regions of interest used to gate individual cells.
3. Results
3.1. Exposure to M1000 infectious inocula induces a rapid, PrP-
dependent, increase in intracellular ROS in moRK13 cells
The RK13 cell system used in this study has previously been
characterised in detail [17,18]. RK13 cells transfected withmouse PrPC
readily propagate the M1000 mouse-adapted Gerstmann-Sträussler-
Scheinker syndrome (GSS) prion strain [17,21,22]. Mixed population
stable cell lines expressing mouse PrP (moRK13), human PrP
(huRK13) and the empty vector control (vecRK13) were created by
transfection. Infection of moRK13 cells with M1000 prions derived
from the brains of mice in the end-stages of disease was established as
described previously [17]. For subsequent infectivity assays, estab-
lished propagating moRK13 (M1000-infected) lysates were used as
the source of infectious prions, to mitigate any species barrier to prion
infection, with mock-infected, equal passage moRK13 lysates used as
controls.
To assess the oxidative response to infectious inocula, moRK13 and
vecRK13 cells were exposed to 0.2% (wet-cell-pellet-weight/volume)
M1000-infected or mock-infected lysate and subject to the DCFDA
assay as outlined in the methods, whereby the ROS activated CM-H2-
DCFDA fluorescence yield progressively increases as ROS react with
the dye. A significant increase in the implied intracellular ROS was
seen in themoRK13 cells exposed to infectious inocula comparedwith
the non-infectious control (Fig. 1A). An increase in ROS was not seen
for the vecRK13 cells, indicating a PrP-specific effect. The difference
was not due to higher basal oxidative stress levels in the vecRK13 cells
restricting a potential increase, as basal ROS production is not
significantly different across the cell lines [20]. The DCF responses of
the moRK13 and vecRK13 cells were confirmed using a fluorescence
spin-trapping assay with TEMPO-9-ac detection (Sup Fig. 1). A similar
DCF response was not seen when huRK13 cells were exposed to the
same treatments, indicating a species barrier to the response. Since it
has not been possible to establish prion infection in the humanised
RK13 cells to date [22], and prion toxicity is widely thought to be
linked to converted host PrP oligomerisation, this finding was to be
expected. Additionally, when PrP was immuno-depleted from the
inocula and the assays repeated, no significant increase in ROS was
observed for the M1000-infected compared with the mock-infected
inoculum (Fig. 1A). Following the DCFDA assay, selected cells were
collected and cultured until significant de novo propagation of
infection beyond residual inoculums could be established (passage
4, approx 20 days). Control cells were equivalently treated with the
exception of DCFDA loading. A cell blot assay was used to confirm
prion propagation by the presence of PrPRes. Loading the cells with the
ROS-reactive DCFDA dye slowed, but did not prevent, the appearance
of PrPRes compared with the unloaded cells (Fig. 1B).
3.2. MoRK13 Intracellular ROS is increased by cell-to-cell contact with
M1000 infected cells
Whilst overlaying cells with infectious brain homogenate or lysate
may mimic the later stages of disease, when PrPSc deposits surround
neurones, during the establishment of early disease this is unlikely;
therefore to simulate an expected early in vivo situation, we sought to
determine if either media or direct cell-to-cell contact with infected
cells could produce the same effect. Using cells grown on coverslips, to
allow either direct cell interfacing or indirectmedia exchange over the
top of DCFDA-loaded test cells, the rates of ROS production in
response to infected versus uninfected cell exposure were measured.
ROS production was significantly increased in the moRK13 cells
directly contacting infected cells but not in moRK13 cells contacting
uninfected cells or in vecRK13 cells contacting M1000 infected cells,
indicating that juxtaposition with cell-surface infectivity is sufficient
to cause this effect in PrP expressing cells (Fig. 2A). A similar trend
was observed in cells submitted to media exchange but this was not


































Fig. 3. ROS changes are transitory and cells compensate by 48 hours. (A) moRK13 (dots/
solid line) or vecRK13 (squares/dashed line) cells were treated at various intervals up
to 5 days with the M1000-infected or mock-infected lysates and intracellular ROS
determined by DCFDA assay at the indicated time points up to 5 days. Significantly
increased intracellular ROS in the moRK13 cells in response to the M1000 infected
lysate is observed up to 24 hours post-infection after which it decreases to be non-
significant (2-way ANOVA, F=9.618, p=0.003, n=3, *pb0.05). (B) Slot blotting of
proteinase-K treated moRK13 and vecRK13 cell lysates from the above assay shows that
the quantity of PrPRes increases in the moRK13 cells, plateauing at 24–56 hours (2-way
ANOVA, F=2.785, p=0.0298, n=3) before declining to background, whereas the
vecRK13 cells show a steady decrease in PrPRes, which is almost undetectable by 5 days.
The 0 time point represents immediate binding to the cells as soon as the infectious
inoculum is added and C is the un-treated background control.
Fig. 4. Increased ROS production occurs predominantly in the lysosomal compartment. (A) Fluorescence images of moRK13 cells stained with Bodipy581/591 C11 and exposed to
M1000 infectious or mock lysate for 3 hours, showing individual channels, merged channels and ratio view. Scale bar=20 μm. (B) Ratiometric analysis of the images in A shows
significantly increased lipid peroxidation in the moRK13 cells exposed to M1000-infected cell lysates compared to the mock-infected lysates (students t-test, t=2.891, p=0.0043,
n=4) and (C) identifies increased numbers of peroxidised vesicular structures within the cells exposed to M1000-infected cell lysates (students t-test, t=5.647, p=0.011, n=4).
(D) Fluorescence images of cells stained with PF-H2TMRos and co-stained with mito-tracker green. Shown are split and merged images; scale bar=20 μm. (E) Quantification of PF-
H2TMRos intensity indicates a specific increase in moRK13 cells exposed to M1000-infected cell lysates, which is significantly different from mock-infected inoculum by 1 hour and
from the vecRK13 cells exposed to the M1000-infected lysates at 2 hours (2-way ANOVA, F=15.03, ***pb0.001, n=4, ). (F) Using mitotracker co-localisation to quantify
partitioning indicates that the increase in signal in the moRK13 cells is predominantly lysosomal (shown are data from 3 hours of treatment), with significant differences seen from
both the mock treated and the vecRK13 cells treated with the infectious lysate (2-way ANOVA, F=4.631, p=0.0036, n=4, *pb0.05, **pb0.01). For graphs, grey bars and black bars
show moRK13 cells and white and pale grey bars show vecRK13 cells treated with mock and infected cell lysates respectively.
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3.3. Induction of increased intracellular ROS by M1000 infectivity is also
observed in murine neuronal cell lines and differentiated neural stem
cells
To ensure that the ROS increase seen in the moRK13 cells exposed
to the M1000 infectious lysate was not a cell line peculiarity or
artefact, OBL-21 cells (a murine olfactory bulb-derived neuronal cell
line) and GT1-7 cells (a murine hypothalamic neuronal cell line),
which endogenously express PrPC and were previously shown to
propagate the M1000 prion strain [17], were exposed to whole brain
homogenates taken from mice with terminal prion disease or their
age-matched uninfected controls. Brain homogenates (0.1% brain
weight/volume) rather than cell lysates were used for the OBL-21 and
GT1-7 assays as there was no need to passage the brain homogenates
through the cell line to avoid a species barrier. Both the OBL-21 and
GT1-7 cells acutely exposed to infectious inocula also showed a
heightened ROS response compared with their mock treated
counterparts (Fig. 2C). To further relate this to the in vivo situation
differentiated neural stem cells (NSCs) were also subject to the same
assay. Both proliferating and differentiated NSCs have been shown to
propagate prion infection ex vivo [23,24] and NSCs in culture
differentiate into neurones, astrocytes, oligodendrocytes and neural
precursor cells in mixed culture, thus mimicking the cellular
constituents of the brain. NSCs were differentiated for 6 days prior
to assay (See Sup Fig. 2 for images of neurosphere/differentiated cells
then loaded with DCF as assayed as for the OBL-21 and GT1-7 cell
lines. The neural stem cells showed a greater ROS response than the
cell lines (Fig. 2D), with this change shown relative to viability as a
drop in viability of approximately 40% of the NSCs was observed
within the duration of the assay. Not surprisingly, this indicates that
the response is more pronounced and toxic in primary cells than cell
lines.
3.4. Cells exposed to M1000 inocula adapt to the intracellular ROS
increase within 48 hours
Intracellular ROS rates were measured at various time points from
the addition of the infectious lysate for up to five days. The
significantly increased cellular ROS was no longer detected 48 hours
after exposure (Fig. 3A). The highest ROS production was seen 24
hours post-exposure to the infectious inoculum. Following DCFDA
assay, cells were lysed and slot blots prepared to look for PrPRes levels.
The 24 hour time point corresponds with the peak transient increase
in detectable PrPRes within the cells before it reduces to background
levels prior to the establishment of persistent infection (Fig. 3B).
When the ROS rates of the moRK13 cells are correlated with the
corresponding PrPRes densitometry, a significant non-zero correlation
is seen between increased ROS and increased PrPRes (r2=0.60,
p=0.04). The vecRK13 cells do not show the same increase in ROS
and the PrPRes levels steadily decrease over time to be barely visible at
5 days post-exposure.
3.5. Acute moRK13 increased intracellular ROS is predominantly
lysosomal
To identify the site of intracellular ROS production concomitant
with initial exposure toM1000 prions, Bodipy581/591 C11 fluorescently
tagged lipid dye was included in cell growth media and allowed to
disperse through the cell. This dye displays low toxicity, is virtually
insensitive to environmental changes such as pH and exhibits red
fluorescence emission until it becomes oxidised when the spectrum
shifts to green emission [25]. Hence relative lipid peroxidation within
a cell can be determined using ratiometric analysis. Increased lipid
peroxidation was seen in cells exposed to M1000-infected lysate
compared with the mock treated cells (Fig. 4A and B) and increased
numbers of cells showed intracellular punctate staining that might be
due to lipid containing aggregates or vesicular organelles (Fig. 4A and
C). VecRK13 cells do not show the same lipid peroxidation response
(Sup Fig. 3). For further characterisation, the PF-H2TMRos fluorescent
dye was loaded into the cells prior to exposure to M1000 or mock-
infected lysates. This dye preferentially localises to mitochondria
upon reacting with ROS in the cytosol; if ROS are not met in the
cytosolic compartment the dye will accumulate in lysosomes, where
fluorescence increases with increased ROS [26]. The cells were
counterstained with mito-tracker green so that the partitioning
could be differentiated. Cells were followed for three hours following
the addition of lysates. An increase in overall fluorescence from the
probe is significant from 2 hours (Fig. 4D and E) and when mito-
tracker co-localisation was used to determine partitioning, the
predominant increase was lysosomal (Fig. 4F). Cytosolic ROS also
appeared increased; however this did not reach significance.
To confirm the lysosomal origin of the intracellular ROS increase
observedwith DCFDA, the DCFDA experiments were carried out in the
presence of the lysosomal inhibitors NH4Cl and chloroquine. Both
inhibitors reduced the ROS increase associated with the M1000
infectious lysate in the moRK13 cells and this was significant for cells
treatedwith chloroquine (Fig. 5A). VecRK13 control data are shown in
Sup Fig. 4.
The ROS responses detected by DCFDA and PF-H2TMRos were
predominantly lysosomal, suggesting that at least some of the
infectious inoculum must be directed to lysosomes; to verify this,
lysates were conjugated via NHS esters to a pH sensitive rhodamine
derivative (pHrodo). The pHrodo dye increases in fluorescence
intensity as its environmental pH decreases; therefore as it accumu-
lates in acidic vesicles increased fluorescence is observed. The tagged
inocula (10 μg total protein as determined by BCA assay) were applied
to the cells and images collected at 0, 3, 24, 48 and 72 hours. Intensity
quantification indicates that lysates containing PrPRes were targeted
to acidic vesicles faster than mock inocula, regardless of PrP
expression of the underlying cell (Fig. 5B & C, vecRK13 images can
be found in Sup Fig. 5), although the signal intensity begins to decline
in the vecRK13 control cells before themoRK13 cells. Fig. 3 shows that
the ROS increase following exposure to infectious inocula correlates
with increased cell-associated PrPRes; however PrPRes levels decline
from 24 hours, before the pHrodo signal (which declines from 48
hours), indicating that cells begin degrading PrPRes by the time the
maximum inoculum uptake had been internalised to lysosomes.
Confirmation that PrP can be detected in lysosomes is shown in
Sup Fig. 6.
The pHrodo tagged inocula were separated, by magnetic immuno-
depletion, into PrP-depleted and PrP-enriched fractions and the time
course experiments repeated. The PrP-rich fractions showed much
greater internalisation than the depleted fractions and, as for whole
cell lysate, there was no significant difference between the PrP-null
and wild-type cells. Therefore, although different rates of internalisa-
tion are not responsible for the ROS response (Fig. 5C & D),
internalisation does appear to be important for the ROS responses as
cellular ROS reactions are reduced in the presence of inhibitors of
internalisation (Sup Fig. 7).
Previous studies have used lysosomal inhibitors to look at the role
of these organelles in clearing infection with chloroquine shown to
reduce prion propagation in cell culture [27]. The ability to reduce
prion propagation was also seen when persistently M1000-infected
cells were treated with lysosomal inhibitors although it was not
sustained, with PrPRes levels returning to levels seen prior to
treatment by 20 days (Fig. 6A–C). Interestingly, when these chloro-
quine treated cells were monitored for ROS production following
treatment, there was a rapid and significant reduction in intracellular
ROS, which returned to baseline levels at approximately 48 hours
(Fig. 6D). Therefore, it is likely that there is a very prompt reduction in
PrPRes propagation correlating with transiently reduced ROS levels
with a brief lag period before pre-formed PrPRes can be cleared by the







































































































































Fig. 5. Lysosomal inhibition reduces the ROS response to infected cell lysates, which are rapidly internalised into acidic compartments. (A)moRK13 cells were treated with lysosomal
inhibitors andmock/M1000-infected lysate at the start of the DCFDA assay. ROS rates are expressed relative to untreated cell controlswith black bars showing no lysosomal inhibition,
white bars show 50 mMNH4Cl and grey bars 25 μM chloroquine responses. Incubation with lysosomal inhibitors results in a loss of the ROS response to the infectious lysate, which is
significant for the cells treated with chloroquine (2-way ANOVA, F=4.335, p=0.0222, n=4). Mock and M1000-infected cell lysates were labelled with pHrodo, which exhibits pH
dependantfluorescencewith increasedfluorescence at lower pH; representative images ofmoRK13 cells exposed to these lysates and followed for up to 72 hours are shown; scale bars
represent 20 μm (B). (C) The M1000-infected cell lysate is internalised more rapidly and reaches a higher fluorescence intensity in acidic vesicles than in cells exposed to the mock-
infected cell lysate (2-way ANOVA, F=140.1, pb0.001, n=4); this is significantly different between the moRK13 and vecRK13 cells only at 48 hours when the vecRK13 intensity
appears to have begun to decline before the moRK13 signal (2-way ANOVA, F=22.28, pb0.001, n=4). (D & E) Magnetic separation of the pHrodo labelled lysates into PrP-depleted
and enriched fractions shows the PrP-enriched fraction internalises and is directed to acidic vesiclesmore rapidly than the depleted lysate (2-way ANOVA, F=39.12, pb0.001, n=3).
Graph and sample images show the 24 hour time point (scale bar=20 μm). (D) D – PrP-depleted inocula fraction and E – PrP enriched fraction. Internalisation into acidic vesicles is
independent of PrP expression in the recipient cell with the vecRK13 cells showing no significant different to the moRK13 cells (secondary t-test, t=0.1731, p N0.05).
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cells. The clearance of PrPRes within this system is unlikely to be due to
a shortened half-life of PrPC through redirection to, and increased
turnover of, PrP by the proteosome as total levels of cellular PrP
increased upon lysosomal inhibition by chloroquine (Sup Fig. 4).
Instead, it would appear that inhibiting lysosomal function renders
the PrPC substrate less available for conversion into PrPSc or lysosomal
inhibition directly or indirectly impairs conversion.
3.6. A significant sub-population of cells stably propagating M1000
prions contain peroxidised aggregates that are not lysosomal
When assayed by DCFDA assay, the long-pass chronically infected
cells (N50 passages) overall do not show increased rates of
intracellular ROS production despite high levels of PrPRes, indicating
that the rapid adaptational responses to ROS within the general
population are maintained over time (Fig. 7A); this is also true of the
NSC cultures when grown in the presence of infectious inoculum
(0.1% brain weight/volume) over 8 days (1 passage) before assaying
(Sup Fig. 8). To ascertain whether there was evidence of ROS damage
occurring in these cells, long-pass mock and M1000 infected cells
were incubated with the Bodipy581/591 C11 dye. Although lipid
peroxidation was not significantly increased in cells that had been
propagating infection for at least fifty passages (Fig. 7B), approxi-
mately 10% of cells (significantly more than the uninfected equiva-
lent-pass cells) showed dense, intracellular peroxidised aggregates of
larger diameter than the previously observed punctate staining
patterns (Fig. 7B and C); these aggregates were also reactive with
TEMPO-9-ac (Sup Fig. 9) and could be seen using phase-contrast
microscopy. When equivalent experiments were performed with
OBL-21 cells, increased lipid peroxidation and large peroxidised
aggregates were observed in PrPRes propagating cells (Sup Fig. 10).
Incubating the equivalent passage mock and infected moRK13 cells
with the PF-H2TMRos dye confirms that these aggregates are not
clearly lysosomal. Where the aggregates were observed, some
individual lysosomes could be discerned but these were relatively
scant and therefore unlikely to result in the intensity of signal seen
with the Bodipy581/591 C11 dye (Fig. 7D). These aggregates also did not
co-localise with the GFP-tagged early endosome marker Rab5a and
showed no convincing ThT binding by plate and microscopic analysis
that would indicate they contain amyloid (data not shown).
3.7. The peroxidised intracellular aggregates observed in chronically
infected cells co-localise with active caspases
To investigate whether the sub-population of cells containing
peroxidised aggregates were undergoing apoptosis, the long-pass
mock and infected cells were incubated with SR-VAD-FMK, a
rhodamine labelled, cell permeable, pan-caspase inhibitor that
irreversibly binds the active site of caspases. Caspase-positive
aggregates were observed in approximately 10% of the infected cell
population, similar to what was observed for the lipid peroxidation





































































































Fig. 6. Lysosomal inhibition in chronically propagating cells temporarily reduces PrPRes
and intracellular ROS. (A) Long-pass M1000-infected cells were treated with varying
concentrations of the lysosomal inhibitors chloroquine and NH4Cl and cell blots for
PrPRes performed after 1, 3, 10 and 20 days post treatment. Shown are the blots from
three days post-treatment. Chloroquine reduces the detectable PrPRes, however NH4Cl
has no effect on propagation. The blots from the chloroquine treated cells have been
quantified densitometrically only up to the 25 μM dose as toxicity was seen at higher
concentrations (Sup Fig. 1) and the PrPRes dose response at three days is shown
(B) along with the 25 μM dose over each of the time points (C). At three days treatment
with chloroquine a significant reduction in PrPRes is seen from 6.25 μM (1-way ANOVA,
F=11.82, p=0.0026, n=3, *pb0.05, **pb0.01) and this is significant from 3 to 10 days
(1-way ANOVA, F=7.506, p=0.0136, n=3, *pb0.05, **pb0.01). (D) DCF measure-
ments over time from treatment with the lysosomal inhibitors shows there is an initial
decrease in intracellular ROS that returns to normal levels by 48 hours (2-way ANOVA,
F=43.32, pb0.001, n=3).















































































































































Fig. 7. Chronically M1000 infected moRK13 cells contain highly peroxidised aggregates with concentration of active caspases. (A) Late passage moRK13 cells (N50 passages) show
significant production of PrPRes detected by cell blot assay in M1000 infected cells, which is not seen in mock brain homogenate exposed cells, but show no significant difference in
intracellular ROS production (students t-test, t=0.6061, p=0.5772, n=4). (B) Late passage M1000 infected or mock-infected moRK13 cells were incubated with Bodipy581/591 C11
and imaged after 24 hours (scale bar=20 μm). Ratiometric analysis shows lipid peroxidation is not significantly increased in the infected cells compared with the uninfected
controls (students t-test, t=1.775, p=0.0784, n=4); however large peroxidised aggregates are seen in higher numbers of the infected cells than the uninfected (C; students t-test,
t=3.18, p=0.0191, n=4). (D) PF-H2TMRos staining (red) shows that whilst some lysosomal ROS is the cause of this signal it is not dense enough to account for the whole
aggregate, which also excludes mitochondria (counterstained in green). Scale bars=10 μM. (E) Incubation with the cell-permeable, irreversible, pan-caspase inhibitor SR-VAD-FMK
shows aggregates within the infected cells contain high concentrations of active caspases. (F) Quantifying this based on intensity variation, a cell size independent measure, shows a
distinct population of the infected cells with high caspase activation, n=3.
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caspase activation with recruitment to these aggregates (Fig. 7E & F,
Sup Fig. 11).
3.8. PrP localises to the sites of activated caspase-positive, peroxidised
intracellular aggregates and deposits adjacent to vimentin
PrP has previously been shown to localise to aggresomes during
chronic prion infection when proteosome function is compromised
[28,29]. To determine if these peroxidised, caspase reactive aggregates
localised with PrP and were classical aggresomes we fixed the
Bodipy581/591 C11 or SR-VAD-FMK labelled cells and used indirect
immunofluorescence to localise PrP and vimentin. PrP surrounds both
the peroxidised and caspase reactive aggregates with some co-
localisation observed (Fig. 8 A & B). This halo staining may be due to
dense packing of the aggregated material excluding the anti-PrP
antibodies but allowing detection on the periphery or due to PrP being
directed only to the exterior of the aggregates. PrP and vimentin also
appear to partially co-localise and lie adjacent to each other. This
suggests the formation of an aggresome-like structure with vimentin,
a structural protein, forming a cage-like scaffold around peroxidised
aggregates of lipid moieties.
3.9. Separation of M1000 chronically infected cells by annexinV binding
shows a significantly increased subpopulation of apoptotic cells
manifesting increased intracellular ROS
Increased expression of phosphatidylserine (PS) on the outer
leaflet of the cell membrane occurs early in apoptosis. The recruitment
of active caspases to the peroxidised aggregates suggested that this
subpopulation of cells was undergoing apoptosis. Exploiting the high
affinity of annexinV for PS, annexinV coated magnetic beads were used
to separate the apoptotic cells with externalised PS from non-
apoptotic cells. Approximately double the number of chronically
M1000 infected cells were annexin-V positive (~6%) compared with
the mock-infected or the vector control cells of equal passage. The
background rate of annexinV reactivity is most likely due to growing
cells under constant selection pressure (Fig. 9A). Loading the
separated fractions with DCFDA to look at the rates of intracellular
ROS production showed significantly increased ROS in the M1000-
infected annexinV-positive cell fraction compared with the annexinV-
negative cells and the annexinV positive fraction of mock treated cells
(Fig. 9B). Proteinase-K digestion and western blot analysis of these
cells showed the annexinV-positive sub-population contains more










Fig. 8. In chronically infected moRK13 cells, PrP localises in and around aggregates and with or adjacent to vimentin. Indirect immunofluorescence of PrP following fixing and
staining of late passage M1000 infected moRK13 cells with Bodipy581/591 C11 (A) and SR-VAD-FMK (B). Arrows indicate areas of localisation of PrP with each probe. (C) Indirect
Immunofluorescence of PrP and vimentin for aggresomal staining. PrP and vimentin are found both together and adjacent to each other. In C nuclei, stained with DAPI, are shown in
blue. Images can be compared with localisation of staining in uninfected cells found in supplementary Fig. 3. Scale bar=20 μm.
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solution and therefore most of the signal is probably from intracellular
PrP and may under-estimate cellular PrPRes; Fig. 9C). Incubation of
these cells with Bodipy581/591 C11 or SR-VAD-FMK prior to separation
showed that lipid peroxidation and caspase activation are increased in
the annexinV-positive cells with the infected cells showing high
numbers of the large peroxidised aggregates and active caspase sites
(Fig. 9D & E).
Preliminary experiments examining the basis of the failure in
apoptotic cells found that the infected cells display reduced metal ion
levels when assayed with Phen Green (a dye that has a preference for
copper), which might lead to anti-oxidant enzyme dysfunction (Sup
Fig. 13). Treatment with TEMPO-9-ac to scavenge the ROS being
produced or with the pan-caspase inhibitor VAD-fmk for 24 hours,
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Fig. 9. AnnexinV separation yields a distinct population of M1000 infected moRK13 cells. Using annexinV conjugated magnetic microbeads to separate cells in the early phases of
apoptosis from healthy cells shows a significantly increased apoptotic population in the M1000 infected cells than in uninfected or vector control cells (A; 1-way ANOVA, F=7.034,
p=0.0267, n=3). The rate of ROS production of the M1000 infected moRK13 apoptotic cells is significantly higher (adjusted for equal time 0 signal) than in the non-infected
apoptotic cells (B; 2-way ANOVA, F=7.465, p=0.0341, n=3). No significant difference is seen between the non-apoptotic cells regardless of infection. Western blot analysis using
ICSM18 anti-PrP mab shows greater concentrations of PrPRes in M1000 infected cells that are apoptotic compared with those that are not (C). Staining with Bodipy581/591 C11 (D) or
SR-VAD-FMK (E) prior to separation shows that theM1000 infected apoptotic cells have a greater concentration of large peroxidised/caspase reactive aggregates than the uninfected
or non-apoptotic populations. Scale bars=20 μm. (F) Oxyblot, for detection of oxidative modification of protein, was performed on dot blots of the separated samples. Whilst no
difference is evident between the infected and uninfected cells that do not show PS externalisation, both cell lines showed increased protein oxidation in the apoptotic fraction and
this is greater again in the M1000 infected cells.
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infected cells (Sup Fig. 14). Further, treatment with the TEMPO-9-ac
for four hours, a sufficient time to prevent the externalisation of PS,
found no significant difference in the number of infected cells
displaying externalised PS; however the infected cells do differ from
the uninfected in that the number of uninfected cells with PS
externalisation unexpectedly doubles to levels equivalent to those
in infected cells when exposed to this treatment (Sup Fig. 14). We
hypothesise this probably occurs due to an unintended sub-lethal
disruption of normal protective cell signalling in uninfected cells,
possibly suggesting extant perturbations in these pathways within
infected cells, with the lack of further increase in the infected cells
possibly representing a partial restoration of redox homeostasis and
relative protection through the radical scavenger. Considerable
further investigation is underway to clarify these points.
4. Discussion
This study has shown that intracellular ROS production changes in
acute, adaptive and chronic phases of prion infection in vitro and
further links ROS with prion propagation and cellular demise. Upon
initiation of prion infection cellular adaptation to increased intracel-
lular ROS occurs quickly within the overall cell population, a response
probably essential for maintaining viability. The cells progress to a
chronic phase of infection where the ROS response is kept below
levels that would damage the cell. Eventually the adaptational
responses fail in a significant subpopulation of chronically infected
cells, with these cells showing activation of apoptosis. This progres-
sion is shown schematically in Fig. 10. As such, in addition to further
strengthening the direct mechanistic and pathogenic associations
between PrPRes generation and heightened ROS production, these
findings prompt reconsideration of the prevailing opinion that
chronic PrPRes propagation is a generally innocuous circumstance
for host cells in vitro.
There is considerable evidence linking PrP and ROS in vivo in
normal and disease states: altered metal ion and Cu/Zn superoxide
dismutase activity with increased superoxide and nitric oxide in
scrapie-infected mouse brain [12]; alterations in mitochondrial
numbers and morphology in PrP-null mice [30]; alteration in
superoxide from Complex 1 in PrP-null mice [31]; increased lipid
peroxidation products correlating with the appearance of PrPRes in the
brains of M1000-infected mice [3]; and prolongation of survival of
infectedmice by an adaptive response to oxidative stressed evoked by
low-dose radiation [32]. The underlying cellular pathogenic mecha-
nisms linking PrP and ROS in vitro are still widely debated. The loss of
PrP superoxide dismutase-like function is one possibility [6]. Another
possibility is metal ion dysregulation (PrP has the capacity to bind
copper and to a lesser extent several other metal ions [33,34] as a
cause or result of PrP aggregation. Iron has been shown to induce the
formation of protease-resistant PrP aggregates within cells [35,36]
and brain levels of copper and manganese become disturbed during
disease [37]; therefore metal ion imbalancemay play a significant role
in oxidative stress seen during prion disease, possibly by essential
metal ions being sequestered from anti-oxidant enzymes into redox-
active aggresomes. Observations within our model concur with this
hypothesis with copper levels reduced in chronically M1000-infected
cells (Sup Fig. 13), suggesting that metal ion dysregulation may play
an important role in the failure of cellular oxidative stress responses.
Cell lines such as RK13 have proved invaluable for a range of
studies dealing with PrPRes infectivity because they will propagate
infection indefinitely with apparently no adverse morphological or
biochemical consequences. Our observations contradict the belief that
such cells are propagating infection free of adverse effects even when
they appear phenotypically normal. The results presented show
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Fig. 10. Schematic of the progression of prion infection and ROS response in vitro. Representative increases in PrPRes, ROS, oxidative damage and caspase activation are shown in both
overall and terminal (annexin V positive – dashed lines) populations. A represents the acute phase of infection, B is the adaptive phase and C shows chronic infection.
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interesting parallels with those reported by Schatzl et al. [38], who
found that the GT1-7 cell line shows cytopathology in approximately
20% of cells chronically infected with the scrapie derived RML prion
strain, with apoptosis being initiated in these cells. In combination
with our findings, this raises the possibility that chronic prion
infection in vitro is more frequently associated with low-level but
ongoing cell damage and loss than currently appreciated, and may
offer greater utility for studies of prion related toxicity and
pathogenesis than acknowledged. In cell cultures, cytopathology in
a small number of cells could be easily overlooked, especially when
cells are transfected and constantly under antibiotic selection
pressure. By analogy, such heightened apoptotic cells loss may not
be inconsequential if it were to occur in vivo, where steady loss of even
a small percentage of neurones over time would eventuate in
devastating compromise of the function of the whole organ.
By separating the apoptotic population from the healthy (normal
PS membrane asymmetry) cells, we have shown that a small but
significant sub-population is manifesting heightened intracellular
ROS levels and oxidative damage that cannot be detected when
assessing the overall population. Furthermore, the increase in
intracellular ROS in these cells is concurrent with increased PrPRes
and activation of caspases. The structures simultaneously showing the
highest intensity of oxidative damage, activated caspases and PrP
localisation appear similar to previously reported vimentin-contain-
ing aggresomes, which were shown to be temporally associated with
activated caspases 3 and 8 post-exposure to PrPSc in the GT1-7 cell
model following inhibition of the proteosome [29]. Lipid peroxidation
is a feature of these structures, and it is known that lipid peroxidation
end-products are capable of inducing apoptosis by mechanisms
involving signalling through JNK and c-jun, and by impairing
mitochondrial function through altering glutathione (GSH) metabo-
lism and calcium uptake (reviewed in [39]). Therefore, adaptational
failure during the ongoing intracellular ROS production related to
chronic PrPRes propagation could inflict oxidative damage on the
interior of the cell, with subsequent recruitment and activation of
caspases, which would effect the eventual demise of the cell.
Previously, it has been proposed that the ‘toxic’ species of PrP is able
to cause oxidative injury in cells by over-stimulation of signalling
pathways that generate ROS as a signalling intermediate [14].Whilst the
majority of the intracellular ROS response to M1000-infected lysates
reported here was lysosomal, increased ROS from NADPH oxidase
signalling is associated with phagosome production [40] and could
perhaps accompany the transit of the infectious inoculum into the cell. A
toxic gain of function such as this would need to be transduced through
PrPC signalling or initiated by the structural conversion to PrPRes, as the
PrPC-null cells do not exhibit the same ROS responses.
The data presented do not allow discrimination between the ROS
event as a cause or effect of PrPC to PrPRes conversion although
conceivably both could occur simultaneously. Recent interest has focused
on increased ROS directly causing the conformational change of PrP by
modification of the protein itself. Studies of methionine oxidation have
indicated that increases in cellular ROS that cause oxidation of the helix 3
methionines destabilise PrP, potentially permitting a switch of confor-
mation that facilitates a seeding event [4,41]. This event, combined with
thedestabilising environment of the lysosomes,might favour conversion
and a seeding event by PrPRes, with sustained PrPRes production
thereafter. Other recent studies have identified various co-factors that
are required for efficient prion conversion and infectivity including
certain lipids [42] and nucleotides [43,44]; the assays used to generate
these data contain sonication or rapid shaking steps, conditions that
produce ROS [45] and, therefore, ROS modification of co-factors might
equally contribute to the misfolding events.
In the RK13 cell systememployed, lysosomeswere important for the
turnover of PrP, with increased total cellular PrP levels observed when
lysosomal function was inhibited. This supports that, whilst total levels
of PrP are clearly important for prion propagation and the evolution of
prion disease in vivo, specific sub-cellular trafficking and the precise
micro-environment of the infectious PrP species are also likely to be
important for maintaining infection inside the cell. The reduction in
detected PrPRes is not likely to be due to the redirection of PrPRes to the
proteosome for degradation given the increase in PrP inside the cell
population upon lysosomal inhibition and previous investigation of
proteosomal involvement in this systemhas not shown any evidence of
impairment in infected cells (Lewis et al., unpublished data).
Lysosomes have long been implicated in prion disease pathogenesis
due to providing a destabilising environment that might favour
unfolding of PrPC allowing more efficient conversion into PrPSc [46],
although quinacrine, a lysosomal inhibitor that had promising effects in
cell culture, was not effective in a murine treatment paradigm [47].
Nevertheless, in support of previous postulates, lysosomes were not
only involved in establishing infection but also inmaintainingpersistent
infection. From a therapeutic perspective however, non-sustained
lysosomal inhibition to slow PrP propagation has only transient and
limited effects with PrPRes levels returning to those observed pre-
treatment very quickly once ROS levels have normalised. The increased
toxicity of chloroquine to infected cells may suggest that the cells with
the highest PrPRes burden die rapidly as a result of inhibiting PrP
turnover, producing a greater effect on overall PrPRes levels with much
less impact on the number of infected cells. The tendency of the cells
with highest PrPRes to die first is tentatively supported by the annexin V
separation data which shows that the infected cells with early signs of
apoptosis contain comparatively higher levels of PrPRes than those that
do not show signs of progression to cell death.
The observation that endosomes/lysosomes are oxidising compart-
ments is not new. Redox-sensitive variants of the green fluorescent
protein fused to endocytic proteins have shown that recycling
endosomes, late endosomes and lysosomes are oxidising environments
[48]. These are all organelles to which PrP is targeted during trafficking
and have been suggested as sites of PrPC to PrPRes conversion [49,50].
Inhibition of lysosomes has also been shown to protect cells against cell
death from glutamate induced ROS [51]. Here the authors proposed that
lysosomal ROS had a role in regulating the later burst of mitochondrial
ROS that initiates apoptosis. Aggresomal structures seen during prion
infection are surrounded by mitochondria [52] and so the oxidative
stress balance of the organelles caught in the aggresomesmight activate
apoptosis through disturbed mitochondrial function.
In conclusion, exposure of naïve PrPC-expressing cells to PrPRes
induces a rapid lysosomal ROS response concurrent with the
internalisation and accumulation of the infectious inoculum in acidic
vesicles. This lysosomal ROS burst initiates or is part of an early
adaptive response that quickly restores redox equilibrium despite
ongoing PrPRes propagation, with lysosomes appearing to play an
important role in maintaining chronic PrPSc production. Eventually,
failure to maintain adaptational responses occurs in a significant sub-
population of chronically infected cells with consequent peroxidative
damage to lipids and activation of the cellular pathways that initiate
cell death. Overall, heightened oxidative stress in chronic prion
disease is clearly detrimental and the formation of ROS is closely
coupled to the formation of misfolded PrP. Increased ROS, possibly
due to a combination of destabilising intracellular environments,
aberrant signalling and even PrP itself, are all likely to contribute to
damage of cellular components, with consequent activation of
apoptosis effector enzymes and eventual progression to cell death.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.freeradbiomed.2011.03.035.
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Victoria Lewis1,2, Cathryn L Haigh1,2, Colin L Masters2, Andrew F Hill2,3, Victoria A Lawson1,2 and Steven J Collins1,2*
Abstract
Background: Prion disease transmission and pathogenesis are linked to misfolded, typically protease resistant
(PrPres) conformers of the normal cellular prion protein (PrPC), with the former posited to be the principal
constituent of the infectious ‘prion’. Unexplained discrepancies observed between detectable PrPres and infectivity
levels exemplify the complexity in deciphering the exact biophysical nature of prions and those host cell factors, if
any, which contribute to transmission efficiency. In order to improve our understanding of these important issues,
this study utilized a bioassay validated cell culture model of prion infection to investigate discordance between
PrPres levels and infectivity titres at a subcellular resolution.
Findings: Subcellular fractions enriched in lipid rafts or endoplasmic reticulum/mitochondrial marker proteins were
equally highly efficient at prion transmission, despite lipid raft fractions containing up to eight times the levels of
detectable PrPres. Brain homogenate infectivity was not differentially enhanced by subcellular fraction-specific co-
factors, and proteinase K pre-treatment of selected fractions modestly, but equally reduced infectivity. Only lipid
raft associated infectivity was enhanced by sonication.
Conclusions: This study authenticates a subcellular disparity in PrPres and infectivity levels, and eliminates
simultaneous divergence of prion strains as the explanation for this phenomenon. On balance, the results align
best with the concept that transmission efficiency is influenced more by intrinsic characteristics of the infectious
prion, rather than cellular microenvironment conditions or absolute PrPres levels.
Keywords: Prion protein, Prion infectivity, Prion disease, Protease resistance, Subcellular localisation, Fractionation
Background
Prion diseases constitute a group of unique neurodegen-
erative disorders, which naturally afflict a number of
mammalian species including humans. Although our
understanding remains incomplete, considerable evi-
dence supports the “protein-only” hypothesis, which
purports that the agent (“prion”) responsible for both
transmission and consequent pathogenesis is predomi-
nantly composed of misfolded conformers of the normal
cellular prion protein PrPC [1]. Additional discriminat-
ing features of the aberrant prion protein include
increased b-sheet content [2,3], reduced solubility and
increased tendency to aggregate, and typically heigh-
tened protease resistance [4-6]. Due to the characteristic
protease resistant core, limited proteolysis with protei-
nase K (PK) truncates the N-terminus of the misfolded
protein, producing PrPres, whilst PrPC is completely
degraded, allowing a convenient biochemical differentia-
tion of these two prion protein isoforms.
An intriguing but somewhat perplexing aspect of prion
biology is the several instances in transmission studies,
encompassing many prion strains, where infectivity titres
and PrPres levels (as detected by biochemical assessment
of inocula) do not faithfully correlate. Illustrating this are
pre-clinical prion infections after low dose transmissions
[7], BSE infectivity in tongue and nasal mucosa [8] and
slowly sedimenting high titres of infectivity separated
from PrPres in ‘fast’ prion strains [9]. Further examples
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have occurred during cross species transmissions includ-
ing intracerebral inoculation of hamster prions to mice
[10], primary passage of bovine prions to rodents [11,12],
scrapie prions peripherally introduced into mice [13] and
transmission of three distinct prion strains (human, ham-
ster scrapie, murine scrapie) into transgenic mice expres-
sing the murine equivalent of a human prion protein
gene mutation [14]. In addition, PrPres generated through
protein misfolding cyclic amplification (PMCA) evinces a
longer incubation period (indicative of a lower titre)
despite western blot detection levels equivalent to those
observed in the original seeding inoculum [15]. This
PMCA study suggests that a component within the origi-
nal inoculum, which perhaps does not propagate or
amplify as well as PrPres, may contribute to the more effi-
cient transmission. Although PrPres is inextricably linked
to prion infectivity, these numerous examples clearly
illustrate the poorly understood complexities of this
relationship.
The precise cellular location of PrPC misfolding and
conversion also remains speculative (reviewed in [16]), as
does the contribution of cellular co-factors to conversion
efficiency, although the participation of a species-specific
protein [17-19], or negatively charged macromolecules
such as nucleic acids [20-24] and glycosaminoglycans
[25-29] has been posited. In contrast, evidence exists cor-
relating the efficiency of prion propagation and transmis-
sion with the size of prion multimers serving as templates
for conversion [30,31]. Acknowledging the aforementioned
uncertainties, the current study investigated whether such
observed disparities between infectivity titres and PrPres
levels could be resolved to a subcellular level and thereby
provide a useful model for insights into the molecular
basis of this observation. To address this aim, we utilized
fractionation of MoRK13 cells infected with M1000 prions
to explore the contributions of subcellular co-factors
and cognate prion protein species to the efficiency of
transmission.
Results
Prion protein conformers reside predominantly in lipid
rafts in MoRK13 and MoRK13-inf cells
Characterisation of the MoRK13-M1000 prion infection
model (MoRK13-inf) determined that per detectable
‘PrPres unit’, MoRK13-inf cell lysate was approximately
90 times more efficient than crude M1000 brain homoge-
nate at prion transmission to recipient MoRK13 (Addi-
tional file 1: Figure S1). This finding, perhaps an example
of strain adaptation into a rabbit cell line, highlighted a
discrepancy between PrPres and infectivity levels, and indi-
cated that MoRK13-inf cells may be an appropriate model
to study this phenomenon. PrP isoforms have been shown
to localise to various subcellular environments, including
those of the secretory and endocytic pathways, and at the
cell surface [32-34]. Figure 1 shows the localisation of
organelle markers Bcl-2 (mitochondria; MT), Bip (endo-
plasmic reticulum; ER), and EEA1 (early endosome; EE) in
the MoRK13 cells. As expected, the lipid raft marker Flo-
tillin 1 was enriched within fractions at the buoyant end of
the gradient, consistent with the high cholesterol:protein
ratio resulting in a significantly lower density of lipid rafts
compared to other solubilised membrane proteins [35].
This was confirmed by dot blot analysis of the lipid raft
marker GM1, detected by the cholera toxin subunit B
(CTB). Figure 1 also indicates that the subcellular localisa-
tion of PrPC in MoRK13, and total PrP (PrPC and PrPres,
indistinguishable from each other under the conditions of
these western blots) in MoRK13-inf is predominantly in
the buoyant, lipid raft fractions. There were no substantial
differences in organelle or membrane markers or PrP loca-
lisation when comparing the MoRK13 and MoRK13-inf
cells, and also comparing vector-only transfected RK13
(vecRK13), GT1-7H and GT1-7H-inf cells (Additional file
2: Figure S2); therefore over-expression of PrPC, prion
infection and cell line origin (neuronal/non-neuronal/mur-
ine/rabbit) do not appear to alter localisations, or create
artefacts in this system of subcellular fractionation. Pre-
vious reports indicate PrPres is also localised in lipid rafts
[36]. Figure 2A shows the localisation of MoRK13-inf
PrPres to be principally in lipid raft fractions, with a similar
distribution to total PrP (Figure 1) as determined by both
western blot and dot blot. Quantification of relative PrPres
levels (Figure 2B) highlights that the lipid raft enriched
fractions contain up to eight times the detectable PrPres
levels than the ER/MT marker enriched fractions (eg com-
pare fractions #3 and #8). By way of comparison to the
original prion strain, Nycodenz gradient distribution of
PrP isoforms and marker proteins from M1000 brain,
homogenised in a comparative manner, was also similar to
that observed in cell lysates (Additional file 3: Figure S3).
High levels of prion infectivity are present in lipid raft
and ER/MT marker enriched fractions of MoRK13-inf cells
In order to determine whether detectable subcellular
PrPres levels correlate with infectivity, an in vitro cell
culture transmission study was carried out of equivalent
volumes of fractions obtained after density gradient flo-
tation assays of MoRK13-inf cell lysate using the highly
susceptible MoRK13 as recipient cells. Levels of PrPres
produced by recipient cells after exposure to fractions
were quantified and used as a surrogate indicator of
relative infectivity titres contained within the subcellular
fractions. The representative cell blot and quantification
(Figure 3A, B) clearly show that infectivity was con-
tained within all fractions derived from MoRK13-inf
cells, albeit to varying degrees. The EE enriched frac-
tions (predominantly #9 and #10) contained consider-
ably less infectivity compared with the lipid raft
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Figure 1 MoRK13 and MoRK13-inf PrP localises predominantly to lipid raft fractions. Representative immunoblots of subcellular fractions
(1-10) obtained from MoRK13 and MoRK13-inf. Equivalent volumes of each fraction were resolved on gradient gels. Proteins were transferred to
PVDF, which was sectioned based on the predicted molecular weight of the protein of interest, with each PVDF strip probed with the relevant
antibody. CTB dot blot - 3 μl of fraction was dried onto nitrocellulose membrane, and blotted as described in the methods. LR = lipid raft; ER =
endoplasmic reticulum; MT = mitochondria; EE = early endosome; CTB = cholera toxin subunit B (LR marker); Flot1 = Flotillin 1 (LR marker); Bcl-2
= anti-apoptotic MT marker protein; Bip = ER lumen chaperone protein; EEA1 = EE antigen 1.
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enriched fractions (predominantly #3 and #4), and the
ER and MT marker enriched fractions (predominantly
#7 and #8), although the comparison of fraction #7 and
fraction #9 did not reach significance. Interestingly,
there was no significant difference in the amount of
infectivity contained within the lipid raft enriched frac-
tions (#3 and #4), and the ER and MT marker enriched
fractions (#7 and #8). As shown in Figure 3A, fractions
were also diluted in a 1/2 log series, to ensure there was
no limiting sensitivity of the in vitro assay truncating the
upper end of the dynamic range. Importantly, neat frac-
tions that elicited the highest production of PrPres by reci-
pient MoRK13 cells (for example fractions #4 and #8),
were infectious to the same dilutions (1:100), thereby vali-
dating the use of PrPres produced by recipient cells as a
measure of relative infectivity contained within fractions.
ER and MT marker enriched fractions show disparity
between PrPres levels and infectivity titres in vitro and
in vivo
Correlation of the percentage of PrPres present in each
fraction with the level of in vitro infectivity produced by
each fraction (Figure 4A) revealed a discrepancy in the
ER/MT enriched fractions. The relative levels of PrPres
present in the lipid raft enriched fractions (#3 & #4) and
the early endosome enriched fractions (#9 and #10) cor-
respond with the relative levels of PrPres produced by the
recipient MoRK13 cells. In contrast, the ER/MT enriched
fractions (#7 and #8) that display low detectable PrPres
levels, contained high infectivity levels similar to the lipid
raft enriched fractions, with the discrepancy at fraction
#8 highly significant (p < 0.001; two way ANOVA).
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Figure 2 PrPres is enriched in lipid raft fractions of MoRK13-inf cells. (A) Equivalent volumes of PK treated MoRK13-inf fractions resolved on
10-20% Tris-glycine SDS PAGE and immunoblotted (top panel), and representative fraction PrPres dot blot (bottom panel). (B) Quantification of
PrPres from dot blots of six separate cellular fractionations. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial (MT)
and early endosome (EE) marker proteins are highlighted. Comparison of relative PrPres levels by one way ANOVA; *** p < 0.001, ns = not
significant.
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divergence between PrPres and infectivity levels within
ER/MT marker enriched fractions.
To confirm genuine prion infectivity, selected fractions
were bioassayed in Tga20 PrPC over-expressing mice. The
fractions were chosen to provide a range of PrPres and
infectivity level combinations; ie high PrPres and infectivity
levels (fraction #4), low PrPres and infectivity levels (frac-
tion #10), and low PrPres but high infectivity levels (frac-
tion #8). Controls included inoculating mice with whole
cell lysate from naive MoRK13 and MoRK13-inf cells, as
well as M1000 brain homogenate, in order to make com-
parisons with the original prion strain. Figure 4B depicts
the incubation periods for the selected fractions and con-
trol mice. Mice exposed to uninfected MoRK13 cell lysate
were symptom free at 245 days post-inoculation. Mice
inoculated with 0.01% M1000 brain homogenate had a sig-
nificantly shorter incubation period than mice inoculated
with MoRK13-inf whole cell lysate. Importantly, concor-
dant with the in vitro cell culture transmissions, mice
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Figure 3 All MoRK13-inf fractions contain infectivity. (A) Representative cell blot showing PrPres levels produced by recipient MoRK13 cells at
passage 4 (P4) post-exposure to equal volumes of each fraction at the ‘neat’ dilution (N) or further serially diluted (1/10-1/1000). (B)
Quantification of infectivity from three independent MoRK13-inf fractionations (n = 3); fractions enriched in lipid raft (LR), endoplasmic reticulum
(ER), mitochondrial (MT) and early endosome (EE) marker proteins are highlighted. Statistical analysis by one way ANOVA; only the statistical
findings for relevant comparisons are indicated: *** p < 0.001, ** p < 0.001, * p < 0.05, ns = not significant.
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Figure 4 Disparity in subcellular fraction PrPres levels and relative infectivity in vitro and in vivo. (A) Relative amounts of PrPres contained
within MoRK13-inf fractions (dot blot - top panel, also Figure 2; red line) plotted against relative infectivity of each fraction (PrPres produced by
recipient MoRK13 - bottom panel, also Figure 3; blue line). There is a highly significant separation of relative PrPres and infectivity levels observed
in fraction #8; statistical analysis was by two way ANOVA; *** p < 0.001. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER),
mitochondrial (MT) and early endosome (EE) marker proteins are highlighted. (B) Mean survival (horizontal bar) of Tga20 mice inoculated with
0.01% (w/v in PBS) M1000 brain homogenate, whole cell lysate from MoRK13 and MoRK13-inf cells, and selected subcellular fractions from
MoRK13-inf. Each data point represents the number of days post-inoculation (PI) that a terminally ill mouse was sacrificed, with the exception of
Tga20 mice inoculated with MoRK13 cell lysate (#) which were symptom free when culled at 245 days PI. Mice inoculated with 0.01% (w/v)
M1000 brain homogenate had a significantly shorter incubation period than those exposed to all other inocula. Mice inoculated with fraction
#10 had a significantly longer incubation period compared to mice exposed to all other infectious inocula. Statistical analysis was by one way
ANOVA; *** p < 0.001.
Lewis et al. Molecular Neurodegeneration 2012, 7:18
http://www.molecularneurodegeneration.com/content/7/1/18
Page 6 of 17
incubation periods, despite the significantly different PrPres
levels contained within these fractions. Mice inoculated
with fraction #10 had significantly longer incubation peri-
ods than mice infected with the other two fractions, again
concordant with the relative infectivity levels determined
by the cell culture transmissions. For illustrative purposes,
this 35 day extension in incubation period approximates a
3 log reduction of infectious titre when modelled on a
time interval assay developed in Tga20 mice inoculated
with M1000 brain homogenate derived prions (Additional
file 4: Figure S4). In summary, the in vivo findings faith-
fully recapitulate and validate the MoRK13 in vitro model.
Infectious prions from different subcellular fractions do
not induce unique disease in vivo
Neuropathologically, prion diseases are characterised by
the presence of neuronal loss, spongiform change, prolif-
eration of astrocytes and extracellular PrP deposits [37].
Further, for different prion strains the topographical dis-
tribution of neuropathological changes is distinctive,
creating characteristic lesion profiles [38,39]. All diseased
mice displayed symptoms typical of M1000 prion infec-
tion and brains were harvested to assess neuropathologi-
cal changes. As expected, control mice inoculated with
MoRK13 whole cell lysate showed no neuropathological
abnormalities (Additional file 5: Figure S5). Figure 5 dis-
plays the quantification of the neuropathological features
mentioned above within different brain regions, clearly
indicating that each inoculum produced very similar
lesion profiles (for representative photomicrographs of
the histological and immunohistochemical findings see
Additional file 5: Figure S5). This distribution pattern of
the pathological features, with predominant involvement
of the thalamus, midbrain and pons, and minimal invol-
vement of the cerebellum is consistent with previous
observations of the M1000 strain [40,41]. The only signif-
icant difference detected in lesion profiles was between
MoRK13-inf whole cell lysate and fraction #10 inocula,
with the former having significantly more reactive astro-
cytes in the occipital cortical region. The explanation for
this is uncertain, but may suggest an additive effect of the
individual fractions, which contribute to the whole-cell
lysate profile. Different prion strains often have distinc-
tive PrPres glycoform ratios and mobilities on western
blot analysis [42-46]. To further evaluate the possibility
of different MoRK13-inf subcellular fractions associating
with distinct prion strains, the brain PrPres profiles from
Tga20 mice inoculated with selected fractions were
examined by western blot. Similar to the lesion profiling,
there were no significant differences in PrPres patterns
when comparing MoRK13-inf whole cell lysate with each
of the selected fractions, in keeping with them all being
the same prion strain (Additional file 6: Figure S6).
The efficiency of M1000 prion transmission is not
enhanced by exogenous fraction specific co-factors in
vitro or in vivo
In order to explore whether subcellular fraction specific
co-factors might contribute to the observed transmission
efficiency spectrum, M1000 brain homogenate was
spiked into fractions derived from uninfected MoRK13
or vecRK13 cells, prior to use as inocula in vitro. Figure
6A shows that even at the lowest dilutions of M1000 in
MoRK13 fractions, PrPres was produced by recipient
MoRK13 cells. However, quantification (Figure 6B)
shows there were no significant differences in amounts of
PrPres produced when comparing the various MoRK13
subcellular fraction diluents. Notably, there was a general
trend for MoRK13 subcellular fractions to enhance
M1000 transmission efficiency to MoRK13 cells com-
pared to lysis buffer alone. A similar result was observed
using fractions obtained from vecRK13 cells (Additional
file 7: Figure S7), suggesting this trend is not PrPC speci-
fic or dependent.
To further evaluate the possible contribution of cellular
co-factors on the efficiency of prion infection, M1000
brain homogenate was diluted in PBS or selected subcel-
lular fractions from uninfected MoRK13 cells (fractions
#4, #8 and #10), and bioassayed in Tga20 indicator mice.
M1000 was also diluted in ‘empty’ Nycodenz fractions
(#4, #8 and #10), in order to control for any affect the
Nycodenz gradient material itself may have on incubation
period or the neuropathology. Neither the exogenous cel-
lular co-factors in the selected fractions, nor Nycodenz
alone, had any significant affect on the incubation time
(Figure 6C) or overtly affected the neuropathology (Add-
tional file 8: Figure S8) of M1000 in Tga20 mice.
Discrepancies between PrPres and transmission efficiency
are not due to protease-sensitive prions, and only in lipid
raft enriched fractions is infectivity enhanced by
sonication
There is experimental evidence that some disease asso-
ciated [47-50], and synthetic [51] prions, may be protease
sensitive. To test whether the infectious prions within the
MoRK13-inf fractions may differentially contain significant
amounts of protease sensitive species, selected fractions
were digested mildly with PK prior to using them as a
source of infectivity. There were no significant differences
in PrPres levels produced by MoRK13 infected with PK
digested fractions #4, #8 or #10 compared to cells infected
with the untreated fraction counterpart (Figure 7A, B).
However there was a modest general trend towards
reduced PrPres production by recipient cells after PK treat-
ment of each fraction inoculum.
Evidence suggests misfolded prion protein aggregate
size correlates with efficiency of conversion or prion
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Figure 5 Lesion profiles from Tga20 mice intracerebrally inoculated with M1000, MoRK13 and MoRK13-inf whole cell lysates and
selected MoRK13-inf fractions. Lesion profiles generated by quantification of the degree of vacuolation, reactive astrocytosis and PrP plaques
in each brain region (HI - hippocampus, TH - thalamus, OP - occipital pole, CE - cerebellum, MB - midbrain, PO - pons) in Tga20 mice inoculated
as indicated. n = 3 or 4 for all brain regions except in MoRK13-inf whole lysate HI H&E and 0.01% M1000 HI PrP plaque deposition, where n = 2.
Statistical analysis comparing lesion profiles was by two way ANOVA. The only significant difference was comparing MoRK13-inf and Fraction #10
in OP region (*p < 0.05).
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Figure 6 Exogenous cellular co-factors do not modify the efficiency of M1000 infection in vitro or in vivo. (A) Representative cell blot showing
PrPres levels produced by recipient MoRK13 cells exposed to M1000 brain homogenate diluted to three different final concentrations (as indicated)
with either 1:4 lysis buffer (LB):medium or 1:4 MoRK13 fraction:medium mix. (B) Quantification of PrPres produced by MoRK13 cells exposed to M1000
brain homogenate diluted in subcellular fraction relative to the equivalent % M1000 brain homogenate diluted in lysis buffer; data is from M1000
spiked into three independent fractionations of MoRK13. For quantification purposes, the three different % M1000 spikes into the same MoRK13
fractionated lysate were considered a triplicate of the same experiment. Fractions enriched in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial
(MT) and early endosome (EE) marker proteins are highlighted. Analysis of relative levels of PrPres produced after infection was by one-way ANOVA
with Tukey’s multiple comparison test; no significant differences found comparing subcellular fractions. (C) Survival of Tga20 mice inoculated with
M1000 brain homogenate diluted to 0.01% with either PBS, selected fractions from an empty Nycodenz gradient, or selected subcellular fractions from
MoRK13 cells. Each data point represents the number of days post-inoculation (PI) which mice were sacrificed because of terminal prion disease.
Statistical analysis was by one way ANOVA, with no significant differences in survival seen between any inocula.
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Figure 7 Sonication but not PK treatment alters efficiency of in vitro infection with fraction #4 only. (A) Representative cell blot (left
panel) of PrPres produced by MoRK13 cells exposed to selected MoRK13-inf fractions which were PK digested (PK) or left untreated (UN) and
western blot (right panel) of MoRK13-inf inocula before and after PK treatment. (B) Quantification of cell blot PrPres levels (n = 3 independent
experiments), with PrPres produced after infection with PK treated inocula expressed relative to untreated MoRK13-inf fraction inocula. (C)
Representative cell blot (left panel) of PrPres produced by MoRK13 cells exposed to selected MoRK13-inf fractions which were sonicated (SON) or
left untreated (UN) and western blot (right panel) of MoRK13-inf fraction inocula before and after sonication. (D) Quantification of cell blot PrPres
levels expressed relative to untreated MoRK13-inf fraction inocula (n = 3 independent experiments). Note, levels of total PrP in fractions #8 and
#10 are at or below the limits of detection by standard immunoblotting. Comparison of relative PrPres levels by one way ANOVA and Dunnett’s
post-test for specific comparisons to a control (ie untreated fraction) found no significant differences in any PK treated inocula, and only
sonicated MoRK13-inf fraction #4 was significantly different compared to its untreated control, *p < 0.05.
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infection [30,31]. As a consequence, in vitro conversion
assays such as PMCA may be most efficient when incor-
porating sonication steps [52,53]. To assess this possibi-
lity, selected fractions (#4, #8 and #10) were subjected
to sonication (equivalent to one ‘round’ of PMCA) prior
to using them as a source of infectivity in the MoRK13
cell culture model. As demonstrated by the representa-
tive cell blot in Figure 7C, quantified in Figure 7D, only
subcellular fraction #4 had significantly increased levels
of infectivity compared to its untreated fraction.
Discussion
The protein-only hypothesis states that misfolded confor-
mers of the normal cellular prion protein are the principal
component of the agent responsible for transmitting prion
disease [1]. However, previously observed examples of
high infectivity titres associated with very low or undetect-
able PrPres, the commonly utilized surrogate prion marker,
suggest a poorly understood spectrum of infectious prions.
Assessing the subcellular environment of the most infec-
tious prions may provide information about optimal pH or
metal content conditions, implicate membrane domains,
or subcellular co-factors involved in localisation of highly
efficient prions. Investigation of the subcellular distribu-
tion of prion infectivity and corresponding PrPres levels
has been previously reported, albeit to a limited extent.
However, absent in prior studies were attempts to explore
what determines the intracellular topographical diversity
of prions or the molecular basis of any observed discre-
pancies in PrPres and infectivity levels.
The present study clearly indicates that not all prion
infectivity is associated with lipid rafts, although the sig-
nificance of the lipid raft microenvironment in PrPC mis-
folding and prion conversion is yet to be resolved, with
experimental evidence both for and against lipid raft
localisation as an optimal site (reviewed in [16]). In com-
plete agreement with the protein-only hypothesis, lipid
raft and EE marker associated infectivity and PrPres were
shown to correlate in the MoRK13-inf model. In contrast
however, ER/MT marker enriched fractions contained
much greater infectivity when reported to relative PrPres
content. That lipid raft and ER/MT enriched fractions
contain the same infectivity levels indicates some biologi-
cal redundancy or relative inefficiency of the lipid raft
localised prions, and/or higher efficiency of ER/MT loca-
lised prions, prompting further investigation.
Cell-free conversion studies have shown there is a role
for cellular co-factors, such as nucleic acid or other poly-
anionic molecules, in the efficiency of prion conversion
and propagation [21-23,29,54]. Perhaps militating against
a prominent role of specific co-factors contributing to
the transmission efficiency of the MoRK13-inf subcellular
fractions, infectivity of brain derived M1000 prions was
not significantly differentially enhanced by dilution across
various subcellular fractions. However, an explanation for
this result is that the transmissible prions within M1000
brain homogenate were already largely in an optimal
state, pre-formed and associated with the necessary co-
factors required for infection. Therefore additional exo-
genous co-factors supplied via the MoRK13 or vecRK13
subcellular fractions were somewhat superfluous. Alter-
natively, the fractionation procedure itself may have inac-
tivated any critical co-factors, such that they were not
able to significantly enhance the infectivity of M1000
brain homogenate. In fact, there was a clear trend for
increased PrPres propagation by recipient cells after infec-
tion with M1000 diluted in subcellular fractions com-
pared to the lysis buffer only control, independent of
whether the fractions contained PrPC. This may indicate
that incompletely defined but relatively ubiquitous ‘cellu-
lar co-factors’ contribute to the efficiency of in vitro
prion transmission, which would be consistent with pre-
vious studies.
Numerous prion strains exist, evident in both naturally
occurring human [55,56] and animal [38,57-60] prion dis-
ease, as well as those adapted to laboratory based animal
models. One hypothesis for what determines different
strains is the tertiary structure of the prion conformer,
possibly affected by metals, co-factors or binding partners
[61]. It is also believed that prions may adopt various
stable tertiary conformations, and there is evidence of
simultaneous propagation of more than one prion strain
within the brain [55,62,63]. Furthermore, super-infection
experiments indicate that the more infectious strain will
predominate and determine disease expression [64-66].
Prion strains can be classified by their distinctive neuro-
pathological lesion profiles, incubation periods, PrPres gly-
cosylation patterns and electrophoretic mobilities
[39,42,43,46]. As RK13 cells are capable of supporting and
maintaining propagation of many prion strains [67], and
each fraction represented different subcellular localisations
and potential binding partners, we explored the possibility
that MoRK13-inf fractions contained structurally distinct
prions of variable transmission efficiency. However histo-
logical and western blot analyses failed to detect any evi-
dence of a subcellular divergence of prion strains, strongly
militating against this as the explanation for the apparent
increased relative infectivity in the ER/MT marker
enriched fractions.
Previous experiments have shown that PrPres aggregate
size affects the efficiency of conversion and prion infec-
tion, perhaps through effects on optimising the available
templating surface [30,31], with oligomers of five or fewer
PrPres molecules and larger fibrillar aggregates of PrPres far
less efficient than non-fibrillar particles of 14-28 molecules
[30]. There is also experimental evidence that a proportion
of disease associated prions are protease sensitive [47-49],
which may form low molecular weight aggregates [47,49].
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The results presented herein show that only a minor pro-
portion of prion infectivity within MoRK13-inf fractions is
protease sensitive, and is unlikely to account for the dis-
connect observed between PrPres levels and infectivity in
the ER/MT and lipid raft enriched fractions. Rather, the
sonication results are in keeping with a greater proportion
of multimeric assemblies, fibrils or aggregated species of
prions existing in the lipid raft compared to ER/MT mar-
ker enriched fractions, with sonication increasing the
number of replication-competent prion oligomeric strand
ends which are then more efficient at transmission and
inducing prion propagation. Recent publications provide
credence to this hypothesis [68,69], with direct visualisa-
tion of the fragmentation of recombinant PrP after sonica-
tion. However, the current study does not exclude any
positive effect that sonication may have had on other cel-
lular components contained within the fraction mileu or
interactions between the prion protein and other mole-
cules. In fact another recent publication [70] found that
sonication also fragments purified liver RNA, to a size that
has previously been shown to stimulate prion conversion
in PMCA assays. However the RNA sonication produced
optimal (sized) RNA after approximately 8 cycles, whereas
our sonication experiment was equivalent to one cycle,
giving some support to the plausibility of our former
hypothesis. Ongoing studies, including the utilisation of
techniques such as the conformation dependent immu-
noassay (CDI) to measure prions in the fractions [71], and
sophisticated size fractionation techniques, will help clarify
the exact biophysical nature of the variably efficient prion
species in the lipid raft and ER/MT enriched fractions.
The association of prion infectivity with MT and ER has
been previously investigated with conflicting results. One
study showed that purified mitochondria and mitoplast
fractions from scrapie infected hamster brain contained
infectivity titres equivalent to those determined for crude
brain homogenate, yet mitoplast fractions were not asso-
ciated with detectable levels of PrP [72], in keeping with
the findings of the present study. These results, which sug-
gested an association of high levels of scrapie infectivity
with the inner mitochondrial membrane or mitochondrial
matrix, are broadly consistent with the characteristics of
MoRK13-inf ER/MT enriched fractions, which co-loca-
lised with the mitochondrial membrane marker Bcl-2 [73].
An integral and unique (to mitochondria) lipid component
of the inner mitochondrial membrane is cardiolipin, a
form of dimeric phosphatidylglycerol [74]. Interestingly,
utilizing serial PMCA, researchers have recently been able
to produce protease resistant, infectious prions from
recombinant PrP mixed with RNA and the synthetic phos-
phatidylglycerol, POPG (1-palmitoyl-2-oleoylphosphatidyl-
glycerol) [75]. The authors state that the POPG and RNA
additives to their PMCA may be mimicking factors which
facilitate the conversion process in vivo, which is entirely
consistent with the results presented here implicating
mitochondrial component enriched fractions as containing
highly efficient infectious prions.
Somewhat incongruent with these observations, a
much earlier study examined the infectivity of scrapie
within membrane fractions and found that brain derived
purified mitochondrial fractions were associated with
very little infectivity [76]. Nevertheless, similar to our
results, Millson and colleagues [76] did find both brain
and spleen derived subcellular fractions containing ele-
vated enzyme activities usually associated with the ER
and plasma membrane were associated with high scrapie
infectivity. Conversely, Alais and colleagues [77] found
fractions enriched in the ER marker Bip harboured no
infectivity, despite containing moderate levels of PrPres.
This result, whilst presenting another example of discre-
pancy between PrPres levels and infectivity, clearly con-
trasts with what was observed in the MoRK13-inf
fractions, perhaps reflecting the different methods and
prion strain-cell model employed.
Conclusions
Through the use of both in vitro and in vivo transmis-
sion studies, we have corroborated previously reported
discrepancies between absolute PrPres levels and infectiv-
ity and provided insight into the basis of this phenom-
enon. Through subcellular separation of infectivity, our
data indicates that a substantial amount of infectivity is
contained outside of buoyant lipid raft fractions and
importantly showed that the most transmission efficient
prions per detectable PrPres unit were associated with
either ER and/or MT membranes or proteins. We estab-
lished that the high transmission efficiency shown by
the ER/MT containing fractions was not due to the
simultaneous separation of a more potent prion strain.
As critical co-factor enrichment could not be completely
excluded, it remains to be determined whether cellular
microenvironments directly but variably contribute to
the transmission efficiency of resident prions, or only
passively serve as sequestration sites for the different
prion species. Overall the current study broadly aligns
with the notion that rather than absolute levels of PrPres,
intrinsic prion properties may dictate or be dictated by
the ultimate subcellular localisation of infectious prions,
with transmission efficiency likely correlating best with
optimal prion oligomeric state for template directed
conversion. Importantly, through the development and
validation of a tractable model, further detailed explora-
tion of these fundamental aspects of prion biology,
including assessment of other cell line-prion strain com-
binations to determine the breadth of applicability of
our observations, can be undertaken.
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Methods
Cell culture
Rabbit kidney epithelial cells which have no detectable
endogenous PrPC protein, were stably transfected to over-
express murine PrPC (MoRK13) or the empty vector
(vecRK13) [78] and mouse hypothalamic GT1-7H cells
were maintained as described previously [79], in a humidi-
fied incubator at 37°C with 5% CO2.
Subcellular fractionation
A method of non-toxic/non-detergent cell lysis and sub-
cellular separation was necessary to allow subsequent use
of fractions for infecting recipient cells or mice. Also, due
to the possible involvement of lipid rafts in prion conver-
sion, a lysis method was chosen in order to maintain lipid
raft integrity and buoyancy [35], with minor modifications.
Briefly two confluent T175 cm2 flasks (approximately
4 x107 cells) were washed twice with 20 mls ice cold lysis
buffer (20 mM Tris-Cl pH 7.8, 250 mM sucrose, 1 μM
CaCl2, 1 μM MgCl2) and harvested by scraping into a
further 20 ml of lysis buffer and pelleting at 700 × g for
3 minutes. The cell pellet was re-suspended in 500 μl cold
lysis buffer. Cells were lysed on ice, by passing the cell sus-
pension through a 22 g needle exactly twenty times, and
the crude lysate was centrifuged at 1000 × g, 10 minutes
at 4°C. The post-nuclear supernatant was retained on ice
and the extraction repeated on the pellet. The lysate was
then assayed for total protein content by performing a
bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific,
Scoresby, VIC, AUS) as per the manufacturer’s instruc-
tions, and adjusted with lysis buffer to 1.8 mg/ml. The
Nycodenz (HistoDenz™, Sigma-Aldrich, Castle Hill,
NSW, AUS) density gradient fractionation method was
adapted from a published protocol [80], to suit a Beckman
Optima Max-E Benchtop Ultracentrifuge and MLS-50
rotor. Nycodenz solutions were prepared in TNE (25 mM
Tris-Cl pH 7.5, 150 mM NaCl, 5 mM EDTA) and an 8-
35% linear step Nycodenz gradient was poured (400 μl of
each of 8%, 12%, 15%, 18%, 20%, 22.5% and 25%) with 1.1
ml of a 35% Nycodenz cushion consisting of equal parts
ice cold 70% Nycodenz and cell lysate (1 mg total protein)
pipetted to the bottom of the gradient. In some cases, an
‘empty Nycodenz’ gradient was poured, whereby the 35%
Nycodenz/lysate cushion mixture was substituted for 35%
Nycodenz alone. Nycodenz gradients were centrifuged at
200,000 × g (average) for 342 minutes at 4°C. Following
centrifugation, 10 equal volume fractions of 390 μl were
collected and stored at -80°C or kept on ice for immediate
use.
Prion strain and cell infections
The M1000 prion strain used in this study was derived
from a well characterised stock of pooled mouse brain
homogenate [81]. Recipient MoRK13 or GT1-7H cells
were infected using an overlay technique as described
previously [79]. For comparisons of cell lysate and brain
homogenate M1000 infectivity, cell lysates were pre-
pared by harvesting and lysing in sterile phosphate buf-
fered saline (PBS; Invitrogen, Mulgrave, VIC, AUS) by
three cycles of freezing (10 minutes at -80°C) and thaw-
ing (3 minutes at 37°C), and centrifugation at 1000 × g
for 3 minutes at 4°C to obtain a post-nuclear superna-
tant. The total protein content of the PBS supernatant
and M1000 brain homogenate were determined by BCA
assay, and the lysates and homogenate were balanced to
the same protein concentration with PBS. Following this
100 μl of lysate or homogenate was mixed with 400 μl
of complete medium and this was used to infect recipi-
ent cells. For fraction infections 100 μl fraction (’neat’)
or, where indicated, fraction which had been serially
diluted in medium, was mixed with 400 μl complete
medium, and used to infect recipient MoRK13 cells. For
‘spiking’ experiments, M1000 brain homogenate was
diluted in 400 μl media and mixed with 100 μl MoRK13
or vecRK13 fraction (or as a control the lysis buffer
used to prepare cells prior to fractionation) to give a
final concentration of 0.05%, 0.025% and 0.0125%
M1000, prior to being used to infect recipient MoRK13
cells.
Subcellular fraction pre-treatments
For PK digestion, 100 μl of a fraction was treated with a
final concentration of 1 μg/ml PK for 8 hours at 37°C,
conditions found to reduce PrPC by approximately 80%
when tested on control fractions (data not shown). For
sonication pre-treatment, 100 μl of a fraction in a 1.5 ml
microfuge tube was subjected to 60 seconds at amplitude
70 in a S4000 sonicator (Misonix, Farmingdale, NY, USA)
with microplate horn adapter in 300 mL water maintained
at 37°C. The PK digested or sonicated fractions (and
untreated controls) were mixed with 400 μl of complete
medium and used for in vitro infections as described
above.
Immunoblotting
For determination of subcellular localisation of PrP and
other proteins, fractions were mixed with 4X sample buf-
fer and subject to PAGE (using either 4-20% or 10-20%
Tris-glycine SDS or 4-12% Bis-tris NuPAGE pre-cast gels
(Invitrogen), depending on the size of the proteins to be
detected, and then transferred to PVDF membrane for
western blotting of PrP as described previously [79] and
organelle marker proteins using antibody dilutions as out-
lined in the manufacturer’s instructions (BD Pharmin-
gen™ Organelle Sampler Kit, BD Biosciences, North Ryde,
NSW, AUS). For detection of the ganglioside GM1 (lipid
raft marker), 3 μl of each fraction was spotted onto nitro-
cellulose membrane, and allowed to dry for 20 minutes at
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37°C. The membrane was blocked for a minimum of 1
hour in 5% skim milk powder in PBS containing 0.05% (v/
v) Tween-20 (PBST) and then incubated in 1:100,000 cho-
lera toxin B subunit (CTB)-horseradish peroxidise (HRP)
conjugate (Sigma, stock concentration 0.45 mg/ml CTB
and 1 mg/ml HRP in H2O) solution in block for 1.5 hours
at room temperature prior to chemiluminescent detection
(ECL Plus, GE Healthcare, Rydalmere, NSW, AUS). For
PrPres detection, fractions, cell lysates or brain homogenate
were digested with a final concentration of 50 μg/ml PK,
1 hour at 37°C before SDS-PAGE and western blotting.
Dot blots of fractions were also carried out for PrPres
detection, whereby 5 μl of fraction was spotted onto nitro-
cellulose membrane, which was dried 30-60 minutes at
37°C and then treated in exactly the same manner as the
cell blot assay nitrocellulose membrane. Cell blots for the
detection of PrPres in recipient cells, at four passages (P4)
post-infection were carried out as described previously
[79]. All immunoblotting (western blots and cell blots) for
PrP species used the monoclonal antibody ICSM18, (D-
Gen, London, UK). All chemiluminescent images were
captured by a Fujifilm LAS-3000 (Berthold Australia,
Bundoora, VIC, AUS).
In vivo prion transmissions
All animal experiments were carried out in strict accor-
dance with the ‘Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes (NHMRC)’,
with approval from the University of Melbourne Animal
Ethics Committee (AEC #04154). Tga20 PrPC over-
expressing mice [82] were anesthetised using methoxy-
fluorane and inoculated intracerebrally with 30 μl of
0.01% M1000 brain homogenate diluted in PBS or the
appropriate fractions as indicated, or with 30 μl of ‘neat’
fraction or whole cell PBS lysate. Mice were provided
food and water ad libitum and housed following routine
animal husbandry practices. Mice were examined daily
for symptoms of prion disease. Once mice developed per-
sisting features of advanced prion disease, including
impaired righting reflexes, hunched posture and hind
limb paresis, they were culled by cervical dislocation
under anaesthesia and the number of days post-inocula-
tion was recorded. Brains were removed and sagittally
hemi-sectioned, with half the brain fixed and stained to
allow scoring of vacuolation, astrocytic gliosis and PrP
deposition as described previously [40], and the other
half made to 10% (w/v) homogenates in PBS, with homo-
genates stored at -80°C until required. Neuropathological
scoring was performed on two separate occasions,
blinded as to the inoculum group, to provide a semi-
quantitative comparison of lesion profiles between the
groups of animals. Stained sections were visualised using
a Zeiss Axioskop 50 microscope with images captured
using a Zeiss AxioCam HRC camera (Carl Zeiss, North
Ryde, NSW, AUS).
Densitometry and statistical analysis
All densitometric analyses used the public domain ImageJ
software (National Institutes of Health, USA). For deter-
mining relative levels of PrPres in fractions, each fraction
PrPres dot blot signal intensity was measured, with the
sum of the 10 individual PrPres levels providing the ‘total
PrPres’; each individual fraction was expressed as a percen-
tage of the total PrPres. For determining relative levels of
infectivity contained within MoRK13-infectious fractions,
PrPres produced by MoRK13 cells exposed to each ‘neat’
fraction was measured at passage 4 (P4) post-exposure by
cell blot signal intensity, with the sum of the 10 individual
PrPres levels providing ‘total PrPres’. Once again, each indi-
vidual fraction was expressed as a percentage of the calcu-
lated total PrPres. All statistical analyses were performed in
GraphPad Prism 4, with one way ANOVA and Tukey’s
multiple comparisons or two way ANOVA and Bonfer-
onni post-tests used as indicated, unless stated otherwise.
Additional material
Additional file 1: Figure S1. Disparity in PrPres levels and relative
infectivity in the MoRK13-inf cell prion infection model. Representative
western blot (A) and quantification (B) of PrPres levels in MoRK13-inf
whole cell lysates relative to M1000 brain homogenate (n = 3). Samples
were balanced for total protein; 5 μg total protein was resolved in
untreated (-) lanes; 50 μg total protein was proteinase K (PK) digested (+)
and resolved on 4-12% Bis-tris NuPAGE gels. Very long exposures were
required to visualise the PrPres within cell lysates, hence the loss of
distinction between M1000 PrPres glycoforms. Representative cell blot (C)
and quantification (D) of PrPres produced by recipient MoRK13 cells
infected with equivalent total protein amounts of M1000 or MoRK13-inf
cell lysate (n = 3). Note infections utilised the corresponding lysate/
homogenate shown in (A). NBH = Balb/c normal brain homogenate.
Statistical analysis by one way ANOVA; *** p < 0.001, ** p < 0.01.
Additional file 2: Figure S2. Localisation of PrP, organelle and membrane
markers in Nycodenz density gradient fractions of alternative cell lines.
Representative immunoblots of subcellular fractions obtained from vector
only transfected RK13 cells (vecRK13), GT1-7H and (M1000 infected) GT1-7H-
inf, subject to SDS-PAGE and western blotting as described in the methods.
CTB dot blot - 3 μl of fraction was dried onto nitrocellulose membrane, and
blotted as described in the methods. LR = lipid raft; ER = endoplasmic
reticulum; MT = mitochondria; EE = early endosome; CTB = cholera toxin
subunit B; Flot1 = Flotillin 1; Bcl-2 = anti-apoptotic MT marker protein; Bip =
ER lumen chaperone protein; EEA1 = EE antigen 1.
Additional file 3: Figure S3. Localisation of PrP isoforms, organelle and
membrane markers in Nycodenz density gradient fractions of M1000
brain. Representative immunoblots of subcellular fractions obtained from
terminal M1000 brain. Brains were homogenised in a comparative way to
the detergent-free cell lysis described in the methods, and then subject
to Nycodenz gradient fractionation. Briefly, whole brains (snap frozen in
liquid N2 and stored at -80°C) were homogenised in TNE buffer by
passing the tissue through an 18 g and then a 20 g needle until an even
homogenate was formed, followed by exactly 20 passes through a 22 g
needle. The homogenate was centrifuged at 1000 × g, 10 minutes at 4°
C, the post-nuclear supernatant was retained on ice and the extraction
repeated on the pellet. The supernatant was then subject to Nycodenz
gradient floatation, fractions were collected and analysed by SDS-PAGE
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and western blotting as described. PrPres and CTB dot blots - 3 μl of
fraction was dried onto nitrocellulose membrane, and blotted as
described in the methods. CTB = cholera toxin subunit B; Flot1 = Flotillin
1; Bcl-2 = anti-apoptotic mitochondrial marker protein; Bip = ER lumen
chaperone protein.
Additional file 4: Figure S4. Illustration of the reduction of infectious
titre in a 35-day extension of incubation period in Tga20 mice.
Regression analysis (modelled on the results of an incubation time
interval assay based on quantal end-point dose titration of M1000 brain
homogenate in Tga20 mice) was used to plot the relationship between
incubation period and titre (V.A. Lawson, unpublished data). The red and
blue lines highlight an incubation period of 35 days and the
corresponding titres.
Additional file 5: Figure S5. Assessment of neuropathology in the
brains of Tga20 mice inoculated with 0.01% (w/v) M1000 brain
homogenate, MoRK13 and MoRK13-inf whole cell lysates and selected
MoRK13-inf fractions. Representative photomicrographs demonstrating
the degree of (A) vacuolation in hematoxylin and eosin-stained (H & E)
sections, (B) astrocytic gliosis in glial fibrillary acidic protein (GFAP)
stained sections, and (C) PrP plaque deposition in ICSM18 stained
sections of various brain regions as indicated. Magnification = 50 × for all
sections/stains except H & E stained hippocampus and occipital pole,
where magnification = 100 ×.
Additional file 6: Figure S6. PrPres profiles in Tga20 mice inoculated
with 0.01% (w/v) M1000 brain homogenate, MoRK13-inf and selected
MoRK13-inf subcellular fractions. Representative western blot (A) and
quantification (B) of PrPres glycoform ratios in terminal mice brains after
intracerebral inoculation as indicated. (A) 10 μl of PK digested (100 μg/ml
final concentration PK, 1 hour at 37°C) 10% (w/v in PBS) homogenate
was resolved on 12% Bis-tris NuPAGE and probed with ICSM18 primary
antibody and (B) quantified using ImageJ. Di = di-glycosylated PrPres,
mono = mono-glycosylated PrPres, un = unglycosylated PrPres. Statistical
analysis by two-way ANOVA with Bonferroni post-tests; ns = no
significant differences; #M1000 in Balb/c mice was significantly different
to all other inocula; ^0.01% M1000 in Tga20 mice was significantly
different to all other inocula.
Additional file 7: Figure S7. Exogenous cellular co-factors from vecRK13
do not differentially increase the efficiency of M1000 infection in vitro. (A)
Cell blot showing PrPres levels produced by recipient MoRK13 cells
exposed to M1000 brain homogenate diluted to three different final
concentrations (as indicated) with either 1:4 lysis buffer (LB):medium or
1:4 vecRK13 fraction:medium mix. (B) Quantification of PrPres produced
by MoRK13 cells exposed to M1000 brain homogenate diluted in
subcellular fraction relative to the equivalent % M1000 brain
homogenate diluted in lysis buffer; for quantification purposes the three
different % M1000 spikes into the same vecRK13 fractionated lysate were
considered a triplicate of the same experiment, with the error bars
representing this intra-experiment variation, and analysis of this variation
(one way ANOVA) showing no significant differences. Fractions enriched
in lipid raft (LR), endoplasmic reticulum (ER), mitochondrial (MT) and early
endosome (EE) marker proteins are as marked.
Additional file 8: Figure S8. Lesion profiles from Tga20 mice
intracerebrally inoculated with M1000 brain homogenate diluted in PBS
and high density Nyocodenz with or without MoRK13 cell lysate content.
Lesion profiles generated by quantification of the degree of vacuolation
(H&E), reactive astrocytosis (GFAP) and PrP plaque deposition in each
brain region (HI - hippocampus, TH - thalamus, OP - occipital pole, CE -
cerebellum, MB - midbrain, PO - pons). n = 3 or 4 for all brain regions
except in 0.01% M1000 diluted in PBS HI PrP plaque deposition, where n
= 2. Statistical analysis comparing lesion profiles was by two way ANOVA.
For astrocytic gliosis and PrP plaque deposition, *p < 0.05 comparing
M1000 diluted in PBS and Nycodenz fraction #10 in TH region only. No
other significant differences seen.
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INTRODUCTION
The transmissible spongiform encephalopathies (TSEs; also known
as prion diseases) encompass a group of fatal neurodegenerative
diseases that differ from other dementias, such as Alzheimer’s
disease, because of their transmissible nature. The causative agent
is composed wholly or largely of misfolded conformers of the prion
protein (PrP) (Prusiner, 1982; Weissmann et al., 1994). These
misfolded conformers (PrPSc) form a template for the cellular
isoform of PrP (PrPC) to misfold and in this way propagate
themselves, resulting in the transmissibility of the TSEs.
Similar to other neurodegenerative diseases, prion disease in mice
and humans is associated with markers of oxidative stress in the
brain (Wong et al., 2001; Freixes et al., 2006), which increase
concurrently with disease-associated PrP burden (Brazier et al.,
2006). The oxidative stress has been attributed to an increased
production of reactive oxygen species (ROS) due to metal ion
dyshomeostasis and resulting redox activity (reviewed in Singh et
al., 2010), changed redox signalling through NADPH oxidase
(Schneider et al., 2003; Mouillet-Richard et al., 2007) and alterations
in nitric oxide synthase (Park et al., 2011). PrP itself has been linked
with an antioxidant function; possibly due to an inherent superoxide
dismutase (SOD)-like activity (Brown et al., 1999) or by modulation
of protective signal transduction pathways (Mouillet-Richard et al.,
2007; Rachidi et al., 2003). Aside from a potential PrP SOD-like
function, the cell has two further intracellular SODs: SOD1
(CuZnSOD) and SOD2 (MnSOD). SOD2 is localised within the
mitochondria, whereas SOD1 has a more ubiquitous localisation
(Kawamata and Manfredi, 2010). Reduced SOD activity is reported
in prion protein knockout mice and cell cultures (Brown et al., 1997;
Brown and Besinger, 1998; Klamt et al., 2001; Sakudo et al., 2005),
and a loss of SOD function is one proposed mechanism of prion
disease pathogenesis. Alterations in activity and redistribution to
mitochondria is reported for SOD1 mutants associated with genetic
amyotrophic lateral sclerosis (ALS) in humans and mice (Carrì and
Cozzolino, 2011; Goldsteins et al., 2008) indicating that
mislocalisation and altered activity of the SOD enzymes can have
deleterious consequences for neurons.
Our previous work defined four stages of oxidative response
in cultured cells exposed to infectious prions: acute, adaptive,
chronic and terminal (Haigh et al., 2011). In these phases the
oxidative state of the cell changes from oxidative stress to
adaptational response to ‘normal’ oxidative capacity to loss of
normal oxidative metabolism and increased ROS preceding death.
The terminal subpopulation of cells accounts for ~6% of the
chronically infected population and these cells show markers of
apoptosis [phosphatidylserine (PS) externalisation] that correlate
with detrimental oxidative stress, suggesting a possible failure of
antioxidant compensatory responses. This apoptotic response is
associated with the formation of aggregates of highly peroxidised
lipid and activated caspases to which PrP is targeted. In this
terminal phase of infection, the cells seem to be unable to
maintain a defensive response to the increasing ROS burden, with
a higher density of these aggregates appearing in apoptotic cells.
We therefore sought to further investigate the role of the cellular
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SUMMARY
Oxidative stress as a contributor to neuronal death during prion infection is supported by the fact that various oxidative damage markers accumulate
in the brain during the course of this disease. The normal cellular substrate of the causative agent, the prion protein, is also linked with protective
functions against oxidative stress. Our previous work has found that, in chronic prion infection, an apoptotic subpopulation of cells exhibit oxidative
stress and the accumulation of oxidised lipid and protein aggregates with caspase recruitment. Given the likely failure of antioxidant defence
mechanisms within apoptotic prion-infected cells, we aimed to investigate the role of the crucial antioxidant pathway components, superoxide
dismutases (SOD) 1 and 2, in an in vitro model of chronic prion infection. Increased total SOD activity, attributable to SOD1, was found in the overall
population coincident with a decrease in SOD2 protein levels. When apoptotic cells were separated from the total population, the induction of SOD
activity in the infected apoptotic cells was lost, with activity reduced back to levels seen in mock-infected control cells. In addition, mitochondrial
superoxide production was increased and mitochondrial numbers decreased in the infected apoptotic subpopulation. Furthermore, a pan-caspase
probe colocalised with SOD2 outside of mitochondria within cytosolic aggregates in infected cells and inhibition of caspase activity was able to
restore cellular levels of SOD2 in the whole unseparated infected population to those of mock-infected control cells. Our results suggest that prion
propagation exacerbates an apoptotic pathway whereby mitochondrial dysfunction follows mislocalisation of SOD2 to cytosolic caspases, permitting
its degradation. Eventually, cellular capacity to maintain oxidative homeostasis is overwhelmed, thus resulting in cell death.
Cytosolic caspases mediate mislocalised SOD2
depletion in an in vitro model of chronic prion infection
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antioxidant defence mechanisms in chronic and terminal prion
infection in vitro. Primarily, we aimed to define the failure(s) in
the adaptational response to chronic infection that result in the
infected cells progressing to apoptosis. Our results suggest that
chronic prion infection is associated with SOD2 mislocalisation,
for which increased SOD1 activity compensates. The mislocalised
SOD2 is directed to redox-active aggregates in the cytosol where
it is degraded by caspases, resulting in a reduction of SOD2
protein levels. Eventually, mitochondria fail to cope with the lack
of SOD2, which manifests as increased superoxide production,
and ultimately mitochondrial numbers decline such that the cell
can no longer maintain viability, resulting in the activation of
apoptosis.
RESULTS
SOD1 activity increases in chronically infected cells and SOD2
protein levels decrease
moRK13 cells [rabbit kidney epithelial (RK13) cells expressing full-
length murine PrP] readily propagate infectious prions and the line
remains viable indefinitely, allowing the study of chronic cellular
infection. Our previous work has shown that chronically infected
cells do not show a difference in the overall production of
intracellular ROS; however, increased ROS production is seen in
a subpopulation of infected cells expressing apoptotic markers when
separated from the predominant population (Haigh et al., 2011).
To investigate the possibility that the greater population was
maintaining normal ROS levels by increased antioxidant defences,
we looked at intracellular total SOD activity in the infected and
mock equal-passage moRK13 populations. All experimental data
presented herein are generated using the moRK13 cell model unless
otherwise stated. The SOD activity assay showed an increased
activity in the infected cells (Fig. 1A); this activity was approximately
double that seen in the mock cells. Confirming that the results were
not a cell-specific effect, we also assayed differentiated murine
neural stem cells (NSCs) for changes in total SOD activity after 5
days of exposure to infectious mouse brain homogenate (Fig. 1B).
Increased SOD activity was found in these cultures, which displayed
a PrP expression dependence. The NSCs were treated for only 5
days with infectious homogenate owing to the pronounced toxicity
to these cells (Fig. 1C-E) (Haigh et al., 2011). In order to determine
whether the increase in total SOD activity in the moRK13 cells was
predominantly due to SOD1 or SOD2 or both, we used
pharmacological intervention to inactivate each of the SODs
individually. The doubled SOD activity in the infected cells is
maintained when SOD2 is removed by precipitation out of the
lysate but is lost when SOD1 is inactivated, indicating that SOD1
is contributing the increased SOD activity (Fig. 1F).
SOD1 and SOD2 protein levels within the mock and infected
moRK13 cells were analysed by western blotting. Protein detection
indicated that SOD2 levels were significantly decreased by around
50% in the infected cells (Fig.  1G), but SOD1 levels remained
unchanged. When compared with the detected protein levels of
each SOD, SOD2 activity was not changed relative to its expression
levels. SOD1 activity was significantly increased but a concurrent
increase in protein expression was not detected, indicating a
possible allosteric modulation of SOD1 function (supplementary
material Fig. S1).
Overall mitochondrial superoxide production is not changed in
chronically infected cells
SOD2 is mitochondrially localised. With the protein levels of
SOD2 decreased in the infected moRK13 cells as compared with
the mock cells we sought to determine whether the mitochondria
of these cells were experiencing greater oxidative stress. To
measure the levels of superoxide within the mitochondria,
MitoSOX fluorescent sensor probe was incubated in the live
moRK13 cells and intensity levels determined. No significant
difference between the mock and infected cells in mitochondrial
superoxide production could be detected (Fig. 2A). This is
consistent with our previously obtained results in these cells,
which showed no difference in ROS production or evidence of
oxidative stress between the mock and infected cells (Haigh et
al., 2011). However, given the significant decrease in SOD2
protein levels, we queried whether other cellular changes might
account for the apparent lack of change in mitochondrial
superoxide; for example, rather than being due to maintenance
of homeostasis, it might be a result of decreased numbers of
TRANSLATIONAL IMPACT
Clinical issue
Prion diseases are aggressive, transmissible neurodegenerative disorders that
often have long incubation periods. The causative agent of prion diseases,
which can be transmitted through surgical procedures, blood transfusion or
ingestion, is misfolded conformers of the normal cellular prion protein (PrPC).
These misfolded conformers (PrPSc) propagate themselves within their host by
forming a template for the misfolding of PrPC. The function of PrPC and the
mechanisms of toxicity during infection and prion propagation remain
undefined, although both have been linked with cellular redox homeostasis.
There is currently no effective treatment for prion diseases.
Results
Previous work by this group in a cellular model of prion infection showed
distinct oxidative responses to infection that culminated in toxicity and cell
death. Interestingly, in this model, despite an acute and damaging oxidative
response to initial infection, prion propagation occurred in the bulk of the
cellular population over a long period with only a subpopulation progressing
to death, thereby emulating a long, asymptomatic incubation period. In the
current study, the authors investigate the cellular response mechanisms that
compensate for prion infection in their model and how these mechanisms fail
in the cells that progress to death. Although the bulk population of prion-
infected cells has an increased level of superoxidase dismutase (SOD; the SOD
family helps to protect cells against oxidative damage) activity that is
attributable to SOD1, this increased SOD activity is absent in the
subpopulation of cells progressing to apoptosis. Interestingly, SOD2
(mitochondrial SOD) protein levels are reduced in the whole population as a
result of mislocalisation to the cytosol and to aggregates containing caspases
(enzymes involved in the execution of apoptosis) before progression to
apoptosis and concomitant mitochondrial loss is observed. Notably, inhibition
of caspases restores cellular levels of SOD2 in the infected cells.
Implications and future directions
These findings suggest that a failure of the cellular antioxidant response
occurs during prion infection when SOD2 becomes mislocalised and available
to cytosolic caspases. Although an increase in SOD1 activity can initially
compensate for diminished SOD2 levels in mitochondria, subsequent failure of
the SOD1 compensatory response results in mitochondrial damage, loss and
ultimately cell death. These new insights into the cellular response
mechanisms to prion propagation might help to explain why these diseases
can have long asymptomatic incubation periods, and could also provide
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stressed mitochondria resulting in a ‘normal’ fluorescent signal
(i.e. a lower quantity of mitochondria with a higher fluorescent
signal). We therefore utilised two further mitochondrial probes:
MitoTracker and Mito-RFP. The mitochondrial importation of
both of these probes might be altered by the mitochondrial state
of health (probe metabolism or active transport of probe), so both
Fig. 1. Chronically infected cells demonstrate increased SOD1 activity and decreased SOD2 protein levels. (A)Chronically infected moRK13 cells show a
heavy PrPRes burden as detected by cell blot when compared with their mock-infected counterparts and increased total SOD activity (Student’s t-test, t=3.46,
**P=0.0028, n=10). (B)NSCs derived from prnp knockout (−/−), wild-type (wt) and PrP overexpressor (Tga20) mice were differentiated into mature cultures and
incubated for 5 days with mock or infectious brain homogenate. Tga20 cells exposed to infectious homogenate showed significantly increased SOD activity as
compared with mock brain lysate controls (results are shown as ratios of infected to mock cell responses; Kruskal-Wallis K=6.038, *P=0.0488, n=4). The magnitude
of the SOD response correlated with PrP expression level, shown in the western blot above the SOD activity graph for comparison [duplicate lanes, proliferating
cells left (P), differentiated cells right (D)]. (C)Wild-type NSCs were differentiated into mature cultures and exposed to mock or infectious inoculum for 24 hours.
Cells exposed to infectious inocula demonstrate significantly reduced metabolic activity, as measured by MTS metabolism, relative to untreated or mock cells
(t=2.421, *P=0.036, n=3). (D)At 5 days post-addition of prion-infected inoculum, changes in cellular morphology were observed using fluorescence labelling of
neuronal cells with antibodies targeting neurofilament-L (red); blue, DAPI. Scale bars: 25 μm. (E)Altered cellular morphology was also visible using brightfield
microscopy. Scale bars: 50 μm. (F)SOD1 and SOD2 activities were differentiated using chloroform precipitation (CP) to isolate SOD1 from the lysate and addition of
diethyldithiocarbamate (DDC) to inactivate SOD1. The results are shown as ratios of the infected to mock cell activities and show that SOD1 is primarily responsible
for the increased activity observed (one-way ANOVA, F=5.796, *P=0.012, n=3). (G)SOD protein levels were determined by western blotting and show SOD1 levels
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were considered together. No difference was found between the
mock and infected moRK13 cells for either probe (Fig. 2B,C). As
a further indication of mitochondrial stress, cellular metabolism
of formazan was considered. Formazan metabolism occurs in both
the mitochondria and the cytosol, so two inhibitors (rotenone,
which indicates mitochondrial contribution by inhibiting NAD-
linked substrate oxidation at the oxygen side of NADH
dehydrogenase and DPI, an inhibitor of NADPH oxidase enzymes
in the cytosol) were used to differentiate the mitochondrial
contribution. Neither the cellular rate of formazan metabolism
nor the mitochondrial contribution was altered in the infected
moRK13 cells (Fig.  2D,E). Finally, we considered the
mitochondrially localised anti-apoptotic protein Bcl-2, which has
previously been linked with PrP binding and toxicity (Kurschner
and Morgan, 1995; Rambold et al., 2006). This protein was
decreased significantly in the infected moRK13 cells (Fig.  2F).
Overall, it would seem that mitochondrial numbers, superoxide
levels and function are maintained during chronic prion infection
but with selective loss of SOD2 and Bcl-2.
SOD activity is increased in non-apoptotic infected cells only
In our previous study ROS levels were only found to be increased
in the apoptotic subpopulation of infected moRK13 cells (Haigh et
al., 2011). This population was only a small proportion of the entire
culture population and changes in such a small number of cells
might easily be missed; therefore, it was possible that SOD-activity
was increased to compensate for the ROS insult in the dying cells
only. Mock and infected moRK13 cells were separated based upon
Fig. 2. Chronic prion infection does not influence
mitochondrial superoxide production, numbers or
metabolism but does reduce Bcl-2 protein levels.
(A)MitoSOX, (B) MitoTracker and (C) Mito-RFP
fluorescence (images) and intensity quantification,
expressed as a ratio of infected to mock average cellular
fluorescence (right of images), shows no change in
mitochondrial superoxide production or mitochondrial
numbers in the prion-infected cells compared with
controls [Student’s t-test; (A) t=0.027, P=0.98, n=4; 
(B) t=2.123, P=0.101, n=4; (C) t=0.179, P=0.869, n=4].
(D)MTS metabolism was unchanged in the prion-
infected population compared with the mock control
population (Student’s t-test, t=0.749, P=0.466, n=4).
(E)1 nM rotenone and 10 μM DPI were used to inhibit
mitochondrial and cytosolic metabolism, respectively.
The mitochondrial (mito) and cytosolic (cyto)
contributions to MTS reduction are not significantly
different between the fractions (two-way ANOVA,
F=0.0229, P=0.883, n=4). (F)Western blot analysis of Bcl-
2 protein levels shows a reduction in prion-infected cells
compared with controls (Mann-Whitney, U=0.00,
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PS externalisation, a marker for apoptosis, and the SOD activity
assays repeated. The opposite response to that hypothesised was
observed, with increased SOD activity only observed in the non-
apoptotic population of infected cells but not in the cells separated
by their externalised PS and therefore committed to apoptotic cell
death (Fig. 3A).
In the apoptotic subpopulation of infected cells, mitochondrial
superoxide levels are increased and total mitochondria are
decreased
Because the increased total SOD activity was not maintained in
the apoptotic infected cells, it was plausible that, in the absence of
appropriate antioxidant control, the mitochondrial superoxide
production could be increased. Therefore, we tested the superoxide
production in these cells using the MitoSOX probe. Although
mitochondrial superoxide was increased in both populations of
apoptotic moRK13 cells (mock and infected), the infected apoptotic
cells showed significantly higher levels than the non-infected
apoptotic cells (Fig. 3B). Examining these cells with the MitoTracker
and Mito-RFP probes indicated that the apoptotic infected cells
had lower numbers of mitochondria, as determined by lower
fluorescence levels (Fig.  3C,D). Relatively, in the pro-apoptotic
infected cells, fewer mitochondria were generating considerably
more superoxide.
Mitochondrial SOD2 depletion is caused by SOD2 mislocalisation
to the cytosol
Various pathways by which mitochondria can be lost are reported
within the literature. Mitochondria can be extruded from cells by
being engulfed in vesicles that are similar to autophagic vacuoles,
with release into the surrounding milieu (Lyamzaev et al., 2008;
Nakajima et al., 2008). To look for evidence of mitochondrial
extrusion as the cause of their loss in the pro-apoptotic infected
cells, conditioned media from the whole, unseparated moRK13 cell
populations was western blotted for SOD2 and Bcl-2 as evidence
that mitochondria were located outside of the cell. Although
significant signal was seen for SOD2 in both the mock and infected
conditioned media, and this was greater for the infected cells, there
was no detectable Bcl-2, suggesting that mitochondria were not
being extruded but SOD2 was being expelled from the cell by some
other means (Fig. 4A).
Another mechanism by which mitochondria are lost in disease
is through mitoptosis, considered the mitochondrial equivalent of
apoptosis (Mijaljica et al., 2010; Tinari et al., 2007). In mitoptosis,
Fig. 3. An apoptotic population of prion-infected cells shows normal SOD
activity but increased mitochondrial superoxide and decreased
mitochondrial numbers. (A)Magnetic separation using annexin V (AV) to
select the population of cells with externalised phosphatidylserine (a marker
of apoptosis) showed the apoptotic fraction of prion-infected cells to have
normal cellular SOD activities as compared with the mock-infected controls;
the increased SOD activity was seen only in the non-apoptotic population
(one-way ANOVA, F=4.402, P=0.036, n=4). (B)The apoptotic fraction of both
the prion-infected and mock control cells showed increased mitochondrial
superoxide over the non-apoptotic fraction and this was significantly greater
in the prion-infected cells over the control cells (two-way ANOVA, F=23.56,
P<0.001, n=4). (C,D)When mitochondrial numbers were considered with
MitoTracker (C) and Mito-RFP (D) probes, signal was significantly reduced in
the apoptotic prion-infected population (two-way ANOVA, F=4.493, P=0.025,
n=4 and F=15.55, P=0.0002, n=4, respectively). * indicates significantly
different to the non-apoptotic fraction, # indicates significantly different to the
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Fig. 4. SOD2 is mislocalised to the cytosol and degraded by caspases. (A)Western blotting of conditioned media shows that SOD2 is expelled from the cell in
the absence of mitochondrial extrusion; this is significantly increased for the infected cells (Student’s t-test, t=13.62, *P=0.0053, n=4). A lack of β-tubulin
detection shows that conditioned media SOD2 detection is not due to cell contamination. (B)Separation of mitochondrial and cytosolic fractions demonstrates
that SOD2 is found in the cytosol in relatively greater proportions in infected cells than uninfected as a result of depletion from the mitochondrial fraction
(Student’s t-test, t=2.702, *P=0.0427, n=4). Bcl-2 blotting shows that the cytosolic fraction is not highly contaminated with mitochondria. (C)Co-staining mock
and infected cells with SR-VAD-FMK (pan caspase inhibitor; red in merge) and SOD1 or SOD2 (green in merge) shows SOD2 to be highly localised to caspase-
reactive aggregates within the infected cells with very low detection elsewhere in the cell. Blue, DAPI. Scale bars: 25 μm. (D)Wild-type NSCs were differentiated
then incubated with mock or infectious lysate for 5 days. After this time cells were incubated with SR-VAD-FMK then immunostained for SOD2. Cells exposed to
infectious innocula display clumps of SOD2 colocalising with the caspase marker. Example mock and infected cell photomicrographs are shown; blue, DAPI;
green, SOD2; red, SR-VAD-FMK; arrows indicate caspase-SOD2 clumps. Scale bars: 25 μm. (E)z-stack of a wild-type neural stem cell, exposed to infectious
innoculum, containing large caspase-reactive aggregates. Colouring as for D; cross-hairs indicates sectioning. (F)Mock and infected cells were incubated with
the pan-caspase inhibitor for 4, 24 or 48 hours and SOD2 protein levels determined by western blotting; left plate shows example blots and right plot shows
densitometrical analysis normalised to mock time 0 expression levels. Incubation of mock and infected cells with the pan-caspase inhibitor for up to 48 hours
significantly increases intracellular SOD2 at 24 hours (two-way ANOVA, F=7.78, *P=0.0038, n=4), restoring detection to that of the mock cells. # indicates that
SOD2 is significantly decreased in the untreated infected cell population (t=6.204, P=0.0084, n=4). Mock and infected cell responses to caspase inhibition are not
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mitochondria can fragment, losing their outer membrane and
releasing their contents into the cytosol, thus losing their
functionality, or suffer fragmentation of the inner membrane
leaving only a dysfunctional outer husk (Mijaljica et al., 2010; Tinari
et al., 2007). Mitochondrial preparations of the whole, unseparated
moRK13 cell populations were examined to look for evidence of
SOD2 in the cytosol of infected cells as a result of leaky
mitochondria. Western blotting showed that SOD2 was increased
relative to total cellular SOD2 detection in the cytosol of the
infected cells compared with their mock counterparts (Fig. 4B). Bcl-
2 blotting confirmed minimal cross-contamination of the cytosolic
fraction with the mitochondrial fraction (Fig.  4B), suggesting a
selective relocalisation of SOD2.
SOD2 is degraded by caspases in the cytosol
Western blotting indicated a mislocalisation of SOD2 into the
cytosol of infected cells, so immunofluorescence was used to image
the location of both SOD1 and SOD2 in the cytosol of mock and
infected moRK13 cells. Acknowledging that a change of location
can be part of an apoptotic pathway, co-staining with a rhodamine-
labelled pan-caspase inhibitor (SR-VAD-FMK) was also performed.
Both SOD1 and SOD2 localise with the previously described (Haigh
et al., 2011) caspase-positive aggregates within the infected cells
but SOD2 shows a more pronounced colocalisation, with decreased
levels of SOD2 elsewhere throughout the cell (Fig.  4C). SOD2
colocalisation with caspase-positive aggregates was also observed
in cultures of differentiated wild-type NSCs exposed to infectious
inoculum for 5 days (Fig. 4D,E). Immunofluorescent staining shows
that cleaved (active forms of) caspases 3 and 9 localise with these
aggregates but that pro-caspase 3 and caspase 6 show very little
localisation (supplementary material Fig. S2). To test the hypothesis
that SOD2 was being degraded by mislocalisation to the cytosolic
caspase aggregates, the caspase inhibitor was used to block caspase
activity for up to 48  hours. This treatment has previously been
shown to increase the viability of these cells (Haigh et al., 2011).
At 24  hours of caspase inhibitor treatment, the level of SOD2
protein within the cell was significantly increased (Fig. 4F), with
detected levels in the infected cells restored to match those
measured in the mock cells. Bcl-2 is also cleaved by caspase 3 to
a Bax-like pro-apoptotic form (Cheng et al., 1997). Therefore, we
also treated the mock and infected cells with the caspase inhibitor
and also a radical scavenger, in case ROS production was also
influencing Bcl-2 loss, at the 24-hour time point to see whether
Bcl-2 also increased following treatment. No significant differences
in Bcl-2 levels were observed in the treated infected cells compared
with the untreated (supplementary material Fig. S3).
DISCUSSION
Previously, we have shown unchanged ROS levels in overall
populations of infected cells compared with their mock
counterparts during chronic prion infection; however, the cells in
the acute or apoptotic terminal phase had higher ROS levels than
the mock control cells (Haigh et al., 2011). Prompted by the
observation that overall ROS levels were ‘normal’ during chronic
infection but the apoptotic subpopulation showed oxidative stress,
we investigated the cellular antioxidant defence pathways
responsible for compensation to the chronic infection and the
adaptational failure(s) associated with progression to apoptosis.
Regulation of, or influence on, cellular SOD activity by PrP has
been an important ongoing theme in prion infection and therefore
SOD1 and SOD2 were the candidate molecules chosen for
examination. SOD1 activity was increased and SOD2 protein levels
decreased in chronically infected cells. SOD2 downregulation has
previously been associated with prion infection in vivo (Choi et al.,
1998; Lee et al., 1999; Park et al., 2011). Although these studies did
not report an increase in SOD1 activity, regulation of SOD1
activity by PrP has also been reported (Brown et al., 1997; Sakudo
et al., 2005) and SOD1 knockout has been shown to significantly
reduce disease incubation time in murine models of prion disease
(Akhtar et al., 2013). In the current system, the increased SOD1
activity might explain how the majority of moRK13 cells are able
to remain viable in culture, despite reduced SOD2 levels, while
propagating infection over long periods of time. The upregulated
SOD response to infectious inoculum was also seen in the NSC
cultures. The NSCs show an acute toxic response of increased ROS
and decreased viability within 24 hours of exposure to infectious
PrP (Fig. 1) (Haigh et al., 2011) and therefore were assayed after 5
days to allow a recovery period after the acute insult. Although it
is not possible to discern whether it is de novo PrPSc propagation
or PrPSc exposure that causes toxicity, those cells that survive to 5
days post-exposure have increased their antioxidant defences to
compensate.
Given that SOD1 activity was increased in chronically infected
cells, the subpopulation of apoptotic cells were separated from non-
apoptotic cells to assess the activity in this apoptotic population,
which has previously been shown to have increased ROS
production (Haigh et al., 2011). The apoptotic population is
relatively small compared with the non-apoptotic population, but
still constitutes ~6% of infected cells, double the 3% of mock cells
(Haigh et al., 2011), and so the responses of these cells can easily
be overlooked because detection of these changes are overwhelmed
by the remaining population. The total SOD activity in the infected
apoptotic cells was not different from the levels seen in the mock
cells (either separated or not); therefore, the overall increase in
SOD1 activity must be due to the non-apoptotic population. This
seems to indicate a relative decline in SOD activity in the infected
apoptotic cells, thereby allowing detrimental ROS production
within these cells, which contributes to their demise.
Mitochondrial respiration is one of the major cellular processes
that produce ROS. Because levels of the mitochondrially localised
SOD2 were decreased in chronically infected cells, mitochondrial
representation within the cell was considered, but no difference
was seen between the overall mock and infected populations. This
lack of change is consistent with the investigations of Sisková et
al., who found no prion-disease-associated changes in
mitochondrial density or expression of mitochondrial proteins
(Sisková et al., 2010). The same study did find changes to the
mitochondrial inner membrane morphology and reduced
cytochrome c oxidase activity, and similar observations were also
made by others (Choi et al., 1998; Lee et al., 1999).
The pronounced loss of mitochondria in the pro-apoptotic
prion-infected cells might indicate a primary contribution to cell
death as part of the apoptotic response. Mitoptosis, the pathways
of mitochondrial death, manifests in various ways (Lyamzaev et al.,
2008; Nakajima et al., 2008). Although we saw evidence of SOD2
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extrusion, indicating that the cytosolic SOD2 was apparently
independently being expelled from the cell. In the absence of other
intracellular molecules, such as tubulin, this was probably a specific
event as opposed to non-specific cell lysis or fragmentation.
Colocalisation with active caspases in the previously reported
oxidised aggregates (Haigh et al., 2011) indicated that SOD2 might
be degraded when located outside the mitochondria. No evidence
of mitochondria has ever been observed in these aggregates,
additionally suggesting that the SOD2 is selectively mislocalised.
Mislocalisation might be a result of mis-targeting of SOD2 to the
cytosol following synthesis or could be due to loss from failing
mitochondria. Furthermore, in the current study and as previously
reported (Haigh et al., 2011), in cells in which the caspase reactive
aggregates are observed there is no apparent depletion of
mitochondria, indicating that the SOD2 relocalisation to the
aggregates occurs while the mitochondria are still present and
intact. Park et al. found reduced mitochondria in an in vivo model
of prion disease, which occurred concurrently with a decrease in
SOD2 (Park et al., 2011). Electron microscopy comparing infected
and uninfected mouse brain tissue found evidence of loss of
internal structures of the mitochondria. The authors correlated this
with increased endothelial nitric oxide synthase (eNOS) and thus
with increased intra-mitochondrial oxidative stress. This is
consistent with our findings, but does not explain the relatively
selective loss of the SOD2 protein from the mitochondria at a stage
before mitochondrial function is apparently significantly
compromised and the presence of this organelle depleted.
A decline in SOD2 protein level and function does not seem to
be a prion-disease-specific pathway. Similar decreases are reported
in other conditions of chronic oxidative stress such as heart failure,
in which mRNA levels are increased but protein levels decreased
(Holley et al., 2011; Sam et al., 2005), and osteoarthritis, in which
SOD2 protein decreases precede erosion of cartilage (Scott et al.,
2010). A paradigm attempting to recapitulate a generic model of
chronic low-level oxidative stress using hydrogen peroxide exposure
did not replicate a reduction in protein levels of SOD2 in the
moRK13 cells (supplementary material Fig.  S4), but rather an
increase in SOD2 protein was instead observed. This might imply
that the reduction in SOD2 protein levels in the chronic phase of
prion infection requires much longer periods of time to manifest,
or is caused by a specific ROS or reactive nitrogen species or
localisation of these species, or that other dysfunctional pathways
are also contributing to SOD2 protein level reduction. Further
investigation is required to resolve these intricacies.
Caspase degradation of SOD2 has been reported as part of the
extrinsic apoptotic pathways, with two caspase 3 cleavage sites
identified within human SOD2 and recombinant caspase 3 shown
to cleave recombinant SOD2 (Pardo et al., 2006). Activation of
CD95 (also known as Fas) apoptotic pathways has been shown to
redistribute PrPC to mitochondria in lymphoid lineage cells (Mattei
et al., 2011). Li et al. found that cytosolic PrP disrupts the proper
formation of the cytoskeleton (Li et al., 2011). Together, the altered
cytoskeleton and the direct PrP (or the disease-associated PrPSc
isoforms) action on mitochondria might serve to mis-target SOD2
to the cytosol, permitting its incorporation into the caspase reactive
aggregates and its loss into the surrounding cellular environment.
Caspase 3 has also been shown to cleave Bcl-2 (Cheng et al., 1997)
and could represent a common pathway, linking the decreases of
SOD2 and Bcl-2. Interestingly, the resulting peptide formed by
caspase 3 cleavage of Bcl-2 has Bax-like death effector function
(Cheng et al., 1997) and might provide an explanation as to why
prion-infected mice that overexpress Bcl-2 succumb to disease
earlier than wild-type mice (Steele et al., 2007), apparently contrary
to the expected anti-apoptotic function of Bcl-2. Although a pan-
caspase inhibitor failed to restore Bcl-2 levels in our cell system
(supplementary material Fig. S3), we cannot rule out that prion-
infected cells downregulate protein expression of Bcl-2 to protect
against deleterious consequences of caspase cleavage producing the
pro-apoptotic form.
Evidence of caspase activation has been detected in brain tissue
obtained post-mortem from human Creutzfeldt-Jakob disease
(CJD) patients (Jesionek-Kupnicka et al., 1997; Puig and Ferrer,
2001) and can be observed in the brains of live mice in the pre-
terminal phases of prion disease (Lawson et al., 2010), with caspase-
reactive aggregates observed inside neurons using the same active
caspase label as in the current study (Drew et al., 2011).
Furthermore, in GT1 and N2a cell models of prion infection,
aggresomes associated with increased caspases 3 and 8 activity are
formed when the proteosome is inhibited (Kristiansen et al., 2005).
The targeting of SOD2 to similar aggregates, with a loss of up to
50% of normal activity in the chronically infected cells, before any
detectable decline in mitochondrial numbers is indicative of this
event forming part of the toxic pathways that ultimately contributes
to mitochondrial loss (as a result of superoxide accumulation) and
cellular demise.
SOD2 knockout mice develop a neonatal lethal cardiomyopathy
and metabolic acidosis within the first week of life; aside from the
heart, post-mitotic tissues with high metabolic requirements
including the brain are the most severely affected tissues (Lebovitz
et al., 1996). Interestingly, if the mice are kept alive beyond the
expected 1 week using antioxidant therapy, they develop an
oxidative-stress-mediated spongiform encephalopathy (Melov et al.,
1998). Complexes I-IV of the electron transport chain were found
to have diminished activity and protein levels, which was
pronounced for complex II, directly correlating with the dose of
antioxidant used to prolong the life of the mouse (Hinerfeld et al.,
2004). PrP knockout mice show increased superoxide production
from complex I (Paterson et al., 2008). During prion disease,
increased superoxide due to the conversion of PrPC to PrPSc,
coupled with a loss of SOD2 and therefore its antioxidant activity,
might begin a cycle of heightened oxidative damage within
mitochondria, eventuating in their loss. SOD2 mimetics have been
proposed as potential therapeutics for prion disease (Fukuuchi et
al., 2006). One such mimetic demonstrated an ability to extend the
lifespan of prion-infected mice with reduced vacuolation within
the hippocampus in early and terminal disease (Brazier et al., 2008),
and therefore might indicate that a restoration of SOD2 function
is crucial for cellular survival in prion disease. A schematic of
potential cell death pathways enhanced by prion infection is shown
in Fig. 5.
A further factor in this scenario is the heightened SOD1 activity
in the non-apoptotic infected cells. As stated, this could represent
a compensatory response that allows prolonged survival of cells in
the same manner as using antioxidant therapy in SOD2 knockout
mice. However, increased SOD1 activity might itself contribute to
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function inadvertently contributing to cellular decline. In a murine
model of ALS, in which mice express a mutant form of SOD1
displaying a toxic gain of function, the absence of PrP leads to
decreased levels of Bcl-2 and vacuolation of motor neurons
(Steinacker et al., 2010). These observations might indicate that an
overactivity of SOD1 caused by or coinciding with a disturbance
of a PrP regulatory function could be responsible for characteristic
prion pathology and cellular demise. We did not observe any
increased localisation of SOD1 in mitochondria of infected cells
(data not shown), but cannot exclude that a gain of function is
adversely affecting this organelle.
The mechanisms by which SOD2 is relocated from mitochondria
and those responsible for the decline in mitochondrial numbers
during terminal prion infection still remain to be revealed. The
relocalisation might be a deliberate redirection by cellular targeting
mechanisms to compensate for increased cytosolic oxidative flux
or might be a side effect of the disease process. Overall, SOD2
mislocalisation seems to be an integral part of SOD2, mitochondria
and ultimately cell loss in terminal prion infection.
In summary, elaborating on previous work, we believe that the
present results support the contention that chronic prion infection
is associated with relatively early loss of SOD2 from mitochondria,
while organelle numbers and functionality are generally maintained.
SOD2 is mislocalised to the cytosol where it is catabolised at least
in part by caspases and also apparently undergoes increased
selective extrusion from the cell through unclear mechanisms;
overall cellular ROS homeostasis is maintained by compensatory
increased SOD1 activity. Eventually, in a subset of chronically prion-
infected cells, a deleterious cycle leads to initiation of apoptosis
that is associated with prominent loss of mitochondria and
heightened superoxide generation in the remaining dysfunctional
mitochondria, culminating in the death of these cells.
MATERIALS AND METHODS
Cell culture
Rabbit kidney epithelial (RK13) cells expressing full-length murine
PrP (moRK13) were generated as described previously (Haigh et
al., 2009). Cells were routinely cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Melbourne, VIC, Australia)
supplemented with 10% (v/v) foetal bovine serum (Lonza,
Australia), 50 U/ml penicillin/50 μg/ml streptomycin solution
(Sigma, Melbourne, VIC, Australia) and 2.5 μg/ml puromycin
(Sigma). Cell cultures were maintained at 37°C with 5% CO2 in a
humidified incubator.
Stem cell culture
Neural stem cells (NSCs) were harvested from c57BL/6×SV129
mice of prnp−/− (prion gene knockout) (Büeler et al., 1993), wild
type or Tga20 (transgenic prion overexpression of approximately
eightfold at the protein level) (Fischer et al., 1996) genetic
background, as described in Haigh et al. (Haigh et al., 2011). NSCs
were maintained in Neurocult complete proliferation medium
(Stem Cell Technologies, Melbourne, VIC, Australia) at 37°C with
5% CO2 in a humidified incubator. Differentiation was induced by
transferral of cells into Neurocult complete differentiation medium
(Stem Cell Technologies) and plating on a poly-D-lysine matrix
(Sigma-Aldrich).
Cell infections
Cells were infected with the M1000 mouse adapted, human GSS-
derived strain of prions or ‘mock-infected’ with normal brain
homogenate (Lawson et al., 2008; Lewis et al., 2009) and permitted
to propagate infection until the infected population was uniformly
laden with protease-resistant PrP (PrPRes; approximately >passage
50), a marker of propagating prions, as determined by cell blot assay
(Fig.  1A). These cells are referred to as ‘mock’ or ‘infected’
throughout. De novo infections with M1000 were prepared by
centrifugal collection of M1000-infected and mock-infected cells
(300 g for 5 minutes), followed by washing in Dulbecco’s phosphate
buffered saline (dPBS; Invitrogen) and centrifugation as before.
Lysate pellets were weighed and a 10% wet pellet weight/volume
homogenate made in dPBS. Naïve cells were overlaid with 0.01 or
0.1% (w/v) of the mock or M1000-infected homogenised lysate.
Cells were returned to the incubator until they were ready to be
passaged. Long-term infection (empirically determined by cell
blotting, see below) is defined as greater than passage 50. New
infections were routinely established to ensure cell drift did not
bias results.
SOD activity assay
Samples were prepared by washing cells in dPBS, followed by lysis
with ice-cold 0.1 M Tris/HCl, pH 7.4 containing 0.5% (v/v) Triton
X-100, and 0.1  mg/ml of Complete Mini, EDTA free, Protease
Inhibitor Tablets (Roche, Melbourne, VIC, Australia). Cell lysates
Fig. 5. Putative cell death pathway hijacked by prion infection. Schematic
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were briefly centrifuged to separate membrane and nuclear debris
and the supernatant collected for use in the assay. Determination
of SOD activity was performed as described by the Superoxide
Dismutase Activity Colorimetric Assay Kit protocol (Abcam,
Sapphire Biosciences, Sydney, NSW, Australia).
Differentiating SOD1 and SOD2 activity
SOD1 and SOD2 activity discrimination utilised chloroform
precipitation of SOD1 (SOD2 does not survive this treatment) and
inclusion of diethyldithiocarbamate (DDC; Sigma) in the sample
buffer to deactivate SOD1. For chloroform precipitation, 96 μl of
ice-cold 37.5/62.5 (v/v) chloroform/ethanol solution was added to
60 μl of cell lysate. Samples were centrifuged for 10 minutes at 1000
g at 4°C and the aqueous phase was removed and stored at 4°C
until use. SOD1 inhibition was achieved by the addition of DDC
to 1  mM final concentration. Remaining SOD activity in these
samples was measured as above.
Preparation of conditioned media
Cells were transferred into serum-free OptiMEM overnight
(16  hours) and incubated under normal conditions. Media was
collected and centrifuged at 150 g for 3 minutes to remove any cell
carcasses. The media was then transferred to a fresh tube and mixed
with four equivalent volumes of ice-cold methanol then stored at
−20°C overnight. The precipitated protein was collected by
centrifugation at 3273 g for 1 hour. Protein pellets were solubilised
in 1× NuPAGE gel loading buffer (Invitrogen) with 5% (v/v) β-
mercaptoethanol.
Mitochondrial preparations
Mitochondria and cysolic preparations were separated by washing
cells briefly in dPBS, then collecting the cell suspension in
phosphate buffered saline (PBS) by centrifugation at 335 g for
5 minutes. The cell pellet was resuspended in hypotonic buffer
(10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris, pH 7.5) and lysed on
ice by needle aspiration 20 times through an 18-gauge needle.
One quarter sample volume of 5× sucrose solution (1.65 M
sucrose, 30 mM EDTA, 43 mM Tris, pH 7.5) was added to the
homogenate and the sample mixed. Nuclei and unbroken cells
were separated by centrifugation at 600 g for 10  minutes. The
supernatant was transferred to a fresh tube and centrifuged for
10 minutes at 10,000 g. The supernatant (cytosolic fraction) was
collected and the pellet (mitochondria) resuspended in 1× sucrose
solution.
Western blotting
Cells were lysed in RIPA buffer [50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v)
NP-40] at 37°C for 20 minutes. Samples were electrophoresed using
the NuPAGE system (Invitrogen), transferred onto PVDF
(Millipore) membranes and blocked as described previously (Haigh
et al., 2009) with the exception of PrP blots, which used 2% (w/v)
ECL Advance buffer with ECL Advance developer (GE Healthcare,
Sydney, NSW, Australia). Protein of interest detection was made
using the following dilutions of primary antibody: 1 in 2000 SOD1
(Abcam); 1 in 5000 SOD2 (Abcam); 1 in 1000 Bcl-2 (GE
Healthcare); 1 in 5000 EP1802Y against PrP (Abcam) and 1 in
10,000 β-tubulin (Sigma-Aldrich) in PBS with 0.1% (v/v) Tween-
20 (PBS-t). Secondary antibodies (Dako, Melbourne, VIC,
Australia) were used at 1 in 5000 anti-rabbit (SOD1, SOD2), 1 in
10,000 anti-rabbit (PrP), 1 in 2000 anti-mouse (Bcl-2) and 1 in
10,000 anti-mouse (β-tubulin). ECL-plus (GE Healthcare) was used
to visualise bands. Following blotting, total protein levels on gels
were assessed by Coomassie brilliant blue staining [0.1% (w/v)
Coomassie brilliant blue in 50% (v/v) methanol and 7% (v/v) acetic
acid] for 2 minutes at room temperature with agitation. Membranes
were rinsed briefly in destain [50% (v/v) methanol and 7% (v/v)
acetic acid], then washed in destain for 10 minutes before drying
and image capture.
Cell blot assay
The cell blot assay is a variation of that developed by Bosque and
Prusiner (Bosque and Prusiner, 2000) as described by Lewis et al.
(Lewis et al., 2009). PrP was detected using 1 in 10,000 dilution of
ICSM18 monoclonal antibody (murine epitope 142-152; D-Gen,
UK) in 1% milk PBS-t. Anti-mouse HRP secondary antibody (GE
Healthcare) was used at 1 in 10,000 dilution and blots were
visualised as above.
MitoSOX assay
Cells were labelled with 5 μM MitoSOX fluorescent indicator probe
(Invitrogen) in normal media for 10  minutes under standard
incubator conditions. Media was then replaced with fresh, phenol-
red-free OptiMEM (Invitrogen) for the duration of the experiment.
MitoTracker staining
Labelling with MitoTracker Green (Invitrogen) was performed with
1 μl MitoTracker in normal media for 30 minutes under standard
culture conditions before transfer into phenol-red-free OptiMEM.
Mito-RFP expression
CellLights BacMAM 2.0 Mito-RFP (Invitrogen) at 50 particles per
cell was included in normal culture media for no less than 24 hours
before cells were to be used.
MTS metabolism assay
5 μl of one-solution MTS reagent (Promega, Sydney, NSW,
Australia) was added per 100 μl of culture media in a 96-well plate
and absorbency change measured at 492 nm for 2 hours at 37°C.
Rates of change were determined from the linear portion of the
curve.
Caspase imaging
A 600 μM stock solution of SR-VAD-FMK (Immunochemistry
Technologies, Sapphire Biosciences) was prepared in sterile PBS
(pH 7.4; Invitrogen) containing 20% (v/v) high-quality sterile-
filtered DMSO (Sigma-Aldrich). Cells were plated 24 hours before
the start of the assay. 0.6 μM of the SR-VAD-FMK solution was
added to Opti-MEM® reduced serum, phenol-red-free media and
cells were incubated for 30  minutes under normal growth
conditions. The cells were then washed and incubated in fresh Opti-
MEM for the duration of the assay.
Annexin-V MACS
Cells were washed in Mg2+/Ca2+-free dPBS and then suspended
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separation was performed as described in the magnetic-activated
cell sorting (MACS) protocol (Miltenyi Biotec, Sydney, NSW,
Australia). Briefly, cells were centrifuged for 10 minutes at 300 g,
resuspended in 80 μl of binding buffer (Miltenyi Biotec) and 20 μl
of MACS Annexin V Microbeads (Miltenyi Biotec) added. After
15 minutes incubation at 4°C, the cells were washed in 10 equivalent
volumes of binding buffer, centrifuged for 10 minutes at 300 g and
resuspended in 500 μl of binding buffer. MS columns (Miltenyi
Biotec) were equilibrated with 500 μl of binding buffer. Labelled
cells were applied to the column in a magnetic field and washed
twice with 1 ml of binding buffer. The columns were removed from
the magnet and cells eluted in 1 ml of binding buffer. These samples
were then centrifuged for 5 minutes at 300 g and resuspended in
OptiMEM media. Both annexin-V-labelled and unlabelled fractions
were transferred into fresh media for use in ensuing experiments,
which were carried out immediately to avoid loss of viability of the
annexin-V-positive fraction.
Indirect immunofluorescence
Cells were grown in chambered coverslips (Nunc, Invitrogen) in
normal media. Transfections or dye incubations were carried out
before fixing. Cells were fixed in 4% (v/v) paraformaldehyde/PBS for
30 minutes and then permeabilised in PBS with 0.1% (v/v) Triton X-
100 for 10 minutes. Coverslips were blocked in PBS with 10% FBS
(v/v) and 1% (w/v) BSA for 30  minutes. Primary antibodies were
diluted in PBS-FBS as appropriate (SOD1, 1 in 500; SOD2, 1 in 250,
Abcam; neurofilament-L, 1 in 50, Stem Cell Technologies) and
applied overnight at 4°C. Secondary Alexa-Fluor-488/647-conjugated
antibodies (Invitrogen) were diluted 1 in 250 in PBS-FBS and were
applied for 1 hour at room temperature. Coverslips were coated with
Prolong-Gold mounting media (Invitrogen). Fluorophore-stained
coverslips were protected from light at all times.
Densitometry and statistical analyses
Luminescent signals of bands on western blots were captured using
a Las-3000 intelligent dark box (FujiFilm, Berthold, VIC, Australia)
and the intensity quantified, after the subtraction of background, by
ImageJ 1.38x. Statistical analyses were carried out using GraphPad
Prism 4 or Minitab15 statistical software. Graphs represent the mean
and standard error of the mean (s.e.m.) of four independent
experiments unless otherwise stated. Primary statistical tests are
stated in the text; for one-way ANOVA analysis Tukey’s secondary
test was applied and Bonferroni’s secondary testing was used for two-
way ANOVA. Microscope images were captured using a Nikon
Eclipse TE2000-E epi-fluorescence microscope (Nikon-Roper
Scientific, Coherent Scientific, Adelaide, SA, Australia). All image
parameters were maintained throughout an experiment, across all
conditions, and the channels of probes sensitive to photo-oxidation
were collected before other channels. For imaging data the ‘n’
represents independent experiments, which each included capturing
sufficient fields to analyse >30 cells per experiment. Cell intensity
analysis was done using Nikon NIS-elements 3.0 software with
regions of interest used to gate individual cells.
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We performed a genome-wide association (GWA) study in 434 sporadic Creutzfeldt-Jakob
disease (sCJD) patients and 1939 controls from the United Kingdom, Germany and The
Netherlands. The findings were replicated in an independent sample of 1109 sCJD and
2264 controls provided by a multinational consortium. From the initial GWA analysis we se-
lected 23 SNPs for further genotyping in 1109 sCJD cases from seven different countries.
Five SNPs were significantly associated with sCJD after correction for multiple testing.
Subsequently these five SNPs were genotyped in 2264 controls. The pooled analysis, in-
cluding 1543 sCJD cases and 4203 controls, yielded two genome wide significant results:
rs6107516 (p-value=7.62x10-9) a variant tagging the prion protein gene (PRNP); and
rs6951643 (p-value=1.66x10-8) tagging the Glutamate Receptor Metabotropic 8 gene
(GRM8). Next we analysed the data stratifying by country of origin combining samples from
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the pooled analysis with genotypes from the 1000 Genomes Project and imputed genotypes
from the Rotterdam Study (Total n=12967). The meta-analysis of the results showed that
rs6107516 (p-value=3.00x10-8) and rs6951643 (p-value=3.91x10-5) remained as the two
most significantly associated SNPs. Rs6951643 is located in an intronic region ofGRM8,
a gene that was additionally tagged by a cluster of 12 SNPs within our top100 ranked re-
sults. GRM8 encodes for mGluR8, a protein which belongs to the metabotropic glutamate
receptor family, recently shown to be involved in the transduction of cellular signals trig-
gered by the prion protein. Pathway enrichment analyses performed with both Ingenuity
Pathway Analysis and ALIGATOR postulates glutamate receptor signalling as one of the
main pathways associated with sCJD. In summary, we have detected GRM8 as a novel,
non-PRNP, genome-wide significant marker associated with heightened disease risk, pro-
viding additional evidence supporting a role of glutamate receptors in sCJD pathogenesis.
Introduction
Sporadic Creutzfeldt-Jakob disease (sCJD), although rare, with a yearly incidence of one to two
cases per million, is the most common form of human prion disease. This group of disorders is
characterized by spongiform changes in the brain, as well as accumulation of misfolded, often
protease-resistant, conformers (PrPSc) of the normal prion protein (PrPC). The PrPC gene
(PRNP) plays a central role in prion disease susceptibility. Expression of PrPC is indispensable
for disease transmission [1] and the polymorphism coding for methionine (M) or valine (V) at
codon 129 (PRNPM129V) has been linked to disease risk [2]. Homozygosity at PRNPM129V
has been consistently associated to sCJD, being one of the strongest common genetic risk fac-
tors reported for neurodegenerative diseases. The remarkable disease-determining effect of this
PRNP polymorphism is observed in variant CJD, a subtype acquired from dietary exposure to
bovine spongiform encephalopathy [3], where all definite and probable clinical cases studied to
date have been PRNP129MM [4].
Similar to other diseases, several genetic association studies with candidate genes have been
performed on sCJD susceptibility [5]. Only one previous genome wide association study
(GWAS) of sCJD risk has been published to date, showing that the PRNP locus was strongly as-
sociated with disease risk, specifically with rs1799990 (PRNPM129V) [6].
To further scrutinize genomic variations related to sCJD risk we have performed a three-
stage GWAS encompassing a total of 1,543 sCJD cases and 4,203 controls, as well as a meta-
analysis encompassing data from the 1000 Genomes Project and imputations from the Rotter-
dam Study.
Results
Demographic and clinical features of the sCJD case populations are shown in S1 Table. The
Q-Q plots for autosomal and X chromosome SNPs are given in S1 Fig; during discovery (stage
one) the genomic inflation factor λ was 1.053 for autosomal and 1.057 for X chromosome
SNPs.
S2 Table shows the top 100 SNPs associated with sCJD at discovery stage, sorted by allelic
differences p-value. A total of 23 SNPs were taken forward to replication. In stage two, we suc-
cessfully genotyped 22 of the 23 SNPs with the Sequenom iPLEx GOLD platform in an indepen-
dent population of 1,109 samples of sCJD. Table 1 shows that five SNPs remained significant
AGWA Study Links Glutamate Receptor Pathway to Sporadic CJD
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Table 1. SNPs genotyped in stage two.
Stage one: Discovery Stage two: Replication in
independent sCJD Cases
SNP CJD risk allele in
Discovery
population
GENE tagged Controls Frequencies
of sCJD risk allele
(n = 1939)
Cases Frequencies
of sCJD risk allele
(n = 434)




rs10061929 A FLJ43080 0.159 0.224 4.58E-
05
0.200 5.89E-05
rs10915708 T NA 0.140 0.207 1.35E-
06
0.158 0.0626
rs11075924 C NA 0.498 0.565 5.52E-
05
0.500 0.8808
rs11245373 T NA 0.037 0.069 2.48E-
05
0.049 0.0238
rs12102156 T NA 0.863 0.912 2.00E-
05
0.849 0.1457
rs12188818 C NA 0.796 0.859 6.44E-
05
0.809 0.2544
rs12419710 A NA 0.210 0.279 2.52E-
05
0.219 0.3746
rs17060736 G NA 0.112 0.160 7.13E-
05
0.121 0.3134
rs17115017 A GRIA1 0.050 0.082 2.23E-
04
0.072 5.00E-04
rs17833759 C GRIN2B 0.085 0.140 7.74E-
07
0.095 0.1955
rs196940 C ERN1 0.758 0.818 6.19E-
05
0.758 0.9631
rs2240344 G NA 0.432 0.600 4.47E-
19
0.443 0.4194
rs2627829 A INPP4B 0.939 0.970 1.83E-
04
0.931 0.2188
rs392184 T MACROD2 0.052 0.096 2.00E-
06
0.07 0.003
rs565559 T NA 0.553 0.618 2.02E-
04
0.579 0.057
rs6027482 C LOC100131710 0.187 0.247 6.69E-
05
0.181 0.5476
rs6107516 C PRNP 0.752 0.827 6.92E-
06
0.804 3.27E-06
rs6463269 G NA 0.084 0.134 3.53E-
06
GENOTYPE FAILED -
rs6496239 T NA 0.805 0.862 4.96E-
05
0.821 0.1195
rs6820644 T NA 0.357 0.433 3.40E-
06
0.647 0.7566
rs6951643 A GRM8 0.507 0.592 8.09E-
06
0.573 6.79E-07
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after Bonferroni correction. In stage three we genotyped those five SNPs in a population of
2,264 independent controls with Sequenom iPLEx GOLD. S2 Fig depicts neatly separated geno-
type clusters of the five SNPs studied in stage three. Only two SNPs were successfully replicated
at stage three and reached genome wide significant p-values after meta-analysis of discovery
and replication results: rs6107516 (p-value = 7.62x10-9) tagging PRNP and in linkage disequilib-
rium (LD) with PRNPM129V (rs1799990), and rs6951643 (p-value = 1.66x10-8) an intronic
SNP withinGRM8 (Glutamate Receptor Metabotropic 8) in chromosome 7. Table 2 shows dif-
ferences in allelic frequencies in the discovery, replication and pooled population sets including
1,543 sCJD cases and 4,203 controls. The A allele of rs6951643 was associated with a 1.27 fold
increased risk of sCJD (95%CI = 1.17–1.38), and this effect was consistently observed across all
tested populations (Table 3).
Rs6107516 (p-value = 3.00x10-8) and rs6951643 (p-value = 3.91x10-5) remained as the two
most statistically significant associations in a meta-analysis of the discovery data adjusted for
PCAs and analysis of replication samples stratified by country. This meta-analysis included
discovery and replication samples plus data from the 1000 Genomes Project and imputed geno-
types from the Rotterdam Study (Total n = 12967), (Table 4). Within the top 100 SNPs, there
Table 1. (Continued)
Stage one: Discovery Stage two: Replication in
independent sCJD Cases
SNP CJD risk allele in
Discovery
population
GENE tagged Controls Frequencies
of sCJD risk allele
(n = 1939)
Cases Frequencies
of sCJD risk allele
(n = 434)




rs9830696 T NA 0.120 0.173 1.02E-
05
0.104 0.0711
sCJD: Sporadic Creutzfeldt-Jakob Disease
In bold SNPs significant after Bonferroni correction (Replication P-value <0.0023)
* P-value for allellic diferences adjusted by Country of origin by PCA
**Chi Squared p-value from comparison between Allele frequencies of independent sCJD cases and stage one controls
NA: SNP in intergenic region.
doi:10.1371/journal.pone.0123654.t001
Table 2. SNPs studied in stage three.
































0.200, 0.196 0.6882 1.03
(0.90–1.17)
0.207, 0.179 0.0007 1.20
(1.08–1.33)




0.072, 0.077 0.4434 1.08
(0.89–1.31)
0.075, 0.065 0.0597 1.17
(0.99–1.37)




























0.173, 0.173 0.9723 1.00
(0.88–1.15)
0.179, 0.157 0.0045 1.17
(1.05–1.31)
* Adjusted by Country of origin by PCA.
doi:10.1371/journal.pone.0123654.t002
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were 12 tagging GRM8 (S2 Table). Pathway analysis using IPA showed that glutamate
receptor signalling was the most over-represented canonical pathway within our top results
(p-value = 8.01x10-5) (Fig 1). Analysis with ALIGATOR software showed (S3 Table) that the
GO category glutamate receptor activity was the 4th most represented amongst our top results.
Three genes from the GO category "glutamate receptor pathway" (S2 Table) were within our
top 100 SNPs (GRM8, GRIN2B and GRIA1). Fine mapping in search for functional variants
linked to rs6951643 was attempted sequencing the 11 exons of GRM8 gene and the corre-
sponding intronic flanking regions in 96 sCJD patients. We found 8 intronic SNPs
(rs73231278, rs62468898, rs1008274, rs111546739, rs17685327, rs6951643, rs2074012,
rs35648111) and one exonic non-coding SNP (rs34182595). Functional prediction analysis of
these genetic variants by FuncPred or RESCUE-ESE showed no indication of regulatory impli-
cations. In the Gtex eQTL database we found no eQTL associated to any of the GRM8 SNPs.
There is no co-expression of GRM8 and PRNP in blood eQTLs in Genenetwork. However,
based on PITA prediction we found that rs34182595, which is an insertion/deletion SNP in
Table 3. - rs6951643 pooled genotypes by country.
Population GG n (%) AG n (%) AA n (%) A allele n (%) G allele n (%)
CONTOLS
UK 364 (24.6) 741 (50.0) 377 (25.4) 1495 (50.4) 1469 (49.6)
NL 118 (22.4) 265 (50.3) 144 (27.3) 553 (52.5) 501 (47.5)
Spain 488 (22.3) 1097 (50.0) 608 (27.7) 2313 (52.7) 2073 (47.3)
CASES
UK 28 (10.5) 155 (58.3) 83 (31.2) 321 (60.3) 211 (39.7)
NL 23 (18.1) 62 (48.8) 42 (33.1) 146 (57.5) 108 (42.5)
Germany 66 (16.7) 217 (54.8) 113 (28.5) 443 (55.9) 349 (44.1)
Italy 43 (15.0) 140 (48.8) 104 (36.2) 348 (60.6) 226 (39.4)
Australia 10 (20.8) 26 (54.2) 12 (25.0) 50 (52.1) 46 (47.9)
France 23 (15.3) 77 (51.3) 50 (33.3) 177 (59.0) 123 (41.0)
Spain 35 (17.2) 110 (54.2) 58 (28.6) 226 (55.7) 180 (44.3)
Austria 11 (20.0) 27 (49.1) 17 (30.9) 61 (55.5) 49 (44.5)
ALL CONTOLS 970 (23.1) 2103 (50.0) 1129 (26.9) 4361 (51.9) 4043 (48.1)
ALL CASES 239 (15.6) 814 (53.1) 479 (31.3) 1772 (57.8) 1292 (42.2)
HapMap Frequencies (CEU) 27 (23.9) 59 (52.2) 27 (23.9) 113 (0.50) 113 (0.50)
doi:10.1371/journal.pone.0123654.t003
Table 4. Meta-analysis by country of origin.
MarkerName Effect estimates of discovery
analysis corrected for
population substructure by PCA
Meta-analysis of effect estimates of replication
analysis stratified by country of origin
Meta-analysis of discovery and
replication
β SE P-value β SE P-value β Direction* β SE P-value
rs6107516 0.4243 0.0944 6.92E-06 0.2327 0.0637 0.000262 ₊₊₊₊₊ 0.2927 0.0528 3.00E-08
rs17115017 -0.5363 0.1453 0.000223 -0.1420 0.1061 0.181 ₋₋₋₊₊ -0.2792 0.0857 0.001123
rs9521699 -0.4087 0.0993 3.84E-05 -0.0233 0.0723 0.7468 ₊₋₊₋₋ -0.157 0.0585 0.007242
rs6951643 -0.3472 0.0778 8.09E-06 -0.1033 0.0545 0.05821 ₋₊₊₊₊ -0.1837 0.0447 3.91E-05
rs10061929 -0.3737 0.0917 4.58E-05 -0.0289 0.0701 0.6801 ₋₋₋₊₊ -0.1562 0.0557 0.005048
* Concordance between discovery population βs and each of the five replication populations; PCA, Principal Component Analysis; SE, standard Error.
doi:10.1371/journal.pone.0123654.t004
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exon 11 in partial LD with rs6951643 (D' = 0.41; r2 = 0.16), is located in a target site for micro-
RNAs (miR-103 and miR-107), a finding that has been previously reported [7].
We then performed an immunohistochemical study in brain samples from 48 sCJD pa-
tients. Immunoreactivity for mGluR8 was observed in neurons and microglial cells (both in the
white and grey matter) While in neurons we did not observe obvious differences we found a
trend towards higher combined score of mGluR8 immunoreactivity in microglia related to the
A allele at rs6951643 (Fig 2); however, these differences were not statistically significant (ordi-
nal regression A-carriers versus A-non-carriers adjusting by c129 and levels of microglia in
temporal cortex; p-value = 0.093). S3 Fig shows semi-quantitative assessments of mGluR8
expression in microglia (0 to 3) in the temporal region across the three rs6951643 genotypes.
We found no association between rs6951643 genotypes and patient’s age of disease onset or
disease duration.
Discussion
In this study we report a non-PRNP genetic risk variant for sCJD, GRM8. Moreover, building
on findings from previous studies [8], pathway analyses yielded glutamate receptor signalling
as one of the main pathways linked to sCJD pathogenesis.
A previous GWAS of prion diseases employed 1,259 sCJD samples, in addition to other dis-
ease subtypes and 6,015 shared controls [6]. In the sCJD sub-group and in a meta-analysis in-
cluding all prion cases only variants in PRNP were found to be significantly associated with
disease risk. Several SNPs outside PRNP were identified, but in contrast to our multi-national
disease cohort the association with sCJD was not homogeneous across the different geographi-
cal groups. Our main novel finding (rs6951643) was not statistically significant in that analysis.
One possible explanation for this discrepancy is the fact that both studies have limited power
to detect small effects due to the overall restricted case numbers included for study and there-
fore a SNP with a relatively modest OR of 1.27 might not be detected by all analyses. The expe-
rience and insights drawn from GWAS performed in more prevalent disorders, such as
Alzheimer’s disease, shows that increasing sample size and performing meta-analysis might be
essential in order to discover and confirm, relatively small-effect genetic risk factors. However,
it is worth re-iterating that in our study, the association with rs6951643 was consistent across
Fig 1. Canonical pathway analysis performed by IPA software including those genes tagged by SNPs with p-value <0.001 in our GWAs analysis.
The horizontal axis represents the pathways identified. The ratio (vertical axis, right) is calculated by the numbers of genes in a given pathway that meet
cutoff criteria, divided by total numbers of genes that make up that pathway. The orange line stands for the threshold above which there are statistically
significantly (by default P<0.05). The vertical axis (left) shows the −log of the p-value calculated based on Fisher’s exact test.
doi:10.1371/journal.pone.0123654.g001
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the geographically diverse sCJD population tested, showing an over-representation of the A al-
lele in cases, and across the different genotyping methods used.
A limitation of our primary analysis was the fact that we were not able to adjust by country
of origin at the replication stage. In order to overcome this caveat we performed a meta-
analysis including control data from the 1000 Genomes Project and imputed data from the Rot-
terdam Study. In the meta-analysis of the stratified analysis by country of origin the association
of both SNPs became less significant suggesting that some signal might be caused by popula-
tion stratification. Despite the fact that both variants were nominally significant in the meta-
analysis of the replication data, the PRNP variant was the only genome wide significantly asso-
ciated to sCJD in the pooled meta-analysis. However, this meta-analysis is not perfect either, as
ideally the cases and controls should originate from the same population and in our analysis
we attempted to match on country of origin (see S4 Table) and this approach is statistically less
powerful because of the uneven distribution of cases and controls, as might reflect the fact that
the PRNP SNP p-value is also less significant in the meta-analysis than in the primary analysis.
Still we acknowledge that the results are a call for caution and the association between GRM8
genetic variants and sCJD should be confirmed in larger analysis with extensive control for
population stratification.
Fig 2. Representative photomicrographs of a sCJD case with AA (a, c) and a sCJD case with GG (b, d) rs6951643 genotype showing differences in
mGluR8 immunostaining of microglial cells in the temporal cortex (a, b) and temporal white matter (c, d). Bar represents 50 μm for all images.
doi:10.1371/journal.pone.0123654.g002
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GRM8 encodes for mGluR8, a protein that belongs to the metabotropic glutamate receptor
family, a family that has recently been linked to the transduction of physiological and cytotoxic
signals mediated by PrPC. MGluR1 and mGluR5 have been shown to interact with PrPC, with
such associations appearing important for promoting neurite outgrowth [9, 10]. Additionally,
a recent study demonstrated that mGluR5 coupled with PrPC mediated the cellular toxicity of
soluble β-amyloid oligomers [10]. Further, in the APPswe/PS1dE9 Alzheimer’s disease mouse
model, altered PrPC processing and a selective increase in cortical mGluR1 expression has been
reported. The authors hypothesized that complex processing of PrPC in connection with
mGluR1 over-expression is triggered by β-amyloid peptides [11]. In the setting of accumula-
tion of PrPSc, our immunohistochemical assessment of a limited sample of sCJD patients
found that carriers of the risk allele at rs6951643 tended to have higher mGluR8 expression in
microglial cells compared to non-carriers. Although our functional prediction analysis for
rs6951643 was uninformative, it is of interest that a nearby variant in partial LD (rs34182595)
is located in a micro-RNA target site and could influence gene expression.
In conclusion, our study has detected a GRM8 genetic variant as a suggestive marker for
sCJD risk mapping outside the PRNP region. Our findings provide evidence supporting a role
for glutamate receptor signalling pathways in sCJD susceptibility. The involvement of gluta-
mate receptor pathway in sCJD should be addressed in future studies in order to provide new
insights in its pathogenesis. Our results underscore the importance of increasing sample sizes
in future studies in order to augment the likelihood of detecting additional non-PRNP genetic
risk factors for sCJD.
Methods
Ethics statement
The present study was conducted according to the revised Declaration of Helsinki and Good
Clinical Practice guidelines. A signed informed consent to participate in genetic research was
obtained from all participants or patients’ relatives. The study was approved by Comité de
Ética de la Investigación y de Bienestar Animal (CEIyBA), National Health Institute Carlos III
and Comité de Ética de Ensayos clínicos de Galicia and Comite de Ética de la Fundación Pú-
blica Gallega de Medicina Genómica (Servicio Gallego de Salud, SERGAS) (Spain); the Lothian
Health Board, Lothian Research Ethics Committee (reference MCO/103/90) (UK); the Ethik-
Kommission der Universitätsmedizin Göttingen (No. 9/6/0) (Germany); the Ethic Committee
of the Istituto Superiore di Sanità (CE-ISS 09/266) (Italy); the Medical Ethics Committee of
The Erasmus MC and the review board of The Netherlands Ministry of Health Welfare and
Sports (The Netherlands); the Ethics Committee of the Medical University of Vienna (396/
2011) (Austria); the Human Research Ethics Committee, based at The University of Melbourne
(941450) (Australia).
Populations and study design
All patients were ascertained by National CJD Surveillance Centers. Only definite or probable
sCJD cases, according to accepted classification criteria, were included [12]. Table 5 summa-
rizes the study design and populations included after quality control. All cases and controls
were of Caucasian origin. Legal representatives gave written informed consent, and all samples
were taken in accordance with the Helsinki declaration.
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Genotyping and quality control
At the discovery stage (stage one) patient’s samples were characterized using the Affymetrix
500k array at the USC node of the Spanish National Genotyping Center. Out of the initially
available 554 sCJD samples there was not enough DNA in 61 (36 samples from the UK and 25
from Germany), leaving 493 for genotyping. Genotypes were called first by the Dynamic
Model (DM) and those samples with an overall call rate>93% were subsequently called by a
Bayesian Robust linear model with Mahalanobis distance (BRLMM). Samples with BRLMM
call rates<95% and with call and discrimination rates of the Modified Partitioning Around
Medoids algorithm (MDR-MCR)>10% were excluded (31 patient samples out of 493 did not
reach these thresholds, leaving in total 462 available for the analysis). Genotype and quality
control of the WTCCC controls have been described elsewhere [13]. The other set of controls
(Rotterdam Study) were genotyped at the Genetic Laboratory, Department of Internal Medi-
cine at Erasmus Medical Center (Rotterdam) also using the Afymmetrix 500K array following
same protocols as those used for cases. After quality control, 28 patients and 25 controls were
excluded resulting in a final discovery population of 434 sCJD patients and 1,939 controls. Rep-
lication was attempted in independent sCJD patients (n = 1,201) (stage two) and control series
Table 5. Study Design and populations tested.
STAGES POPULATION EFFECTIVELY ASSESSED*
sCJD CASES (N) CONTROLS (N)
Stage 1: Discovery Germany (113)
Genotyping method: Affymetrix 500k array UK (269) UK WTCCC controls (1482)
Number of SNPs effectively assessed 279389 Netherlands (52) Netherlands-RS controls (457)
Number of SNPs selected for replication: 23 TOTAL sCJD (434) TOTAL controls (1939)
Stage 2: Replication in independent sCJD Cases Germany (284)
Genotyping method: Sequenom iPLEX GOLD Netherlands (76)
Number of SNPs effectively assessed: 22 Italy (292)





Stage 3: Replication in independent Controls Spain-USC (2193)
Genotyping method: Sequenom iPLEX GOLD Netherlands-RS (71)
Number of SNPs effectively assessed: 5 TOTAL controls (2264)
Number of SNPs replicated: 2
TOTAL controls (4203)
POOLED ANALYSIS TOTAL sCJD (1543)
Netherlands-RS (6192)
British in England and Scotland-10KG (137)
Controls added in analysis stratified by country Toscani in Italy-10KG (385)
Iberian populations in Spain-10KG (217)
Utah residents with Northern and Western European ancestry-10KG (290)
TOTAL sCJD (1543) TOTAL controls (11424)
*Number of samples effectively genotyped that passed quality control
sCJD, sporadic Creutzfeldt-Jakob disease; WTCCC, Welcome Trust Case Control Consortium; RS, Rotterdam Study; USC, University of Santiago de
Compostela; 10KG, 1000 Genome Project.
doi:10.1371/journal.pone.0123654.t005
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(n = 2,264) (stage three) with the Sequenom iPLEx GOLD platform. SNPs for replication were
selected as follows: after excluding outliers, we chose the 10 SNPs with lowest p-values (when a
cluster of SNPs was in LD tagging the same gene we selected only the one with lowest p-value)
and the remainder from the top 100 when a) they were in linkage disequilibrium with other
top 100 SNPs or b) agreed in direction with the previous sCJD GWAS [6], or c) were connected
to pathways of interest based on our previous study [14] (phosphatidylinositol) or based on the
pathway analyses performed with the current data (glutamate receptors).
Statistical analysis of genetic data
The statistical analyses were conducted using GenABEL [15]. For the individual SNP analysis,
we excluded those SNPs: 1) with call rates<98% within either group (n = 219,182); 2) with
minor allele frequency<0.01 (n = 1); 3) with controls not in Hardy-Weinberg equilibrium
(False Discovery Rate for unacceptably high individual heterozygosity<1%) (n = 1,300). The
quality control further included a check of the sex chromosomes against the reported sex and
unexpected sample duplicates (Identity by State, IBS>95%). All quality control was performed
with the ‘check.marker’ function of GenABEL. After quality control, 279,389 out of 499,872
SNPs were included in the analyses. In the discovery analyses (stage one), we conducted a one
degree of freedom additive score test between cases and controls coding the presence of the
minor genotype 0 for non-carriers, 1 for heterozygous and 2 for homozygous carriers. We con-
trolled subpopulation structure using principal components analysis (PCA). In brief, we select-
ed a random set of 10,000 SNPs and calculated a genomic kinship matrix using pair wise
identity by state statistic (function 'ibs'). We then performed PCA analysis (function
'cmdscale'), and adjusted our analysis by the three main IBS matrix principal components
(function 'mlreg'). We calculated the genomic inflation factor lambda (λ) for both autosomal
and X chromosome SNPs. In the replication phase (stages two and three), we compared allele
frequencies in cases and controls by a Chi-squared test implemented in Haploview [16]. We
used a Bonferroni correction to adjust for multiple testing, setting the threshold for significance
to a p-value of 0.0023 (0.05/22 SNPs successfully genotyped). We combined the gene discovery
and replication series of patients for all validated SNPs and used as the criterion for genome
wide significance a p-value of 5x10-8. We attempted to adjust for country of origin after stage
three. We analysed the data from stage two and three with genotypes of the 1000 Genomes Proj-
ect [17] and imputed genotypes from the Rotterdam Study [18]. We extracted the SNPs from
the 1000 Genomes reference set excluding the children and other family members (Version:
phase I v3). Additionally we imputed the same SNPs from the Rotterdam Study (imputations
of the same phase I v3of the 1000 Genomes). Imputed genotypes had a very high quality score
(R2 > = 0.99). Next we paired our cases and controls by country of origin (S4 Table) and calcu-
lated effect estimates of the SNPs per country. The effect estimates of the SNPs from the discov-
ery stage (adjusted by PCAs) and the effect estimates from the replication were meta-analysed
using a inverse variance weighted meta-analysis(METAL version released 2011-03-25). [19].
We performed pathway analyses using ALIGATOR, a method for studying groups of genes by
testing for over-representation of members of those groups within lists of genes containing sig-
nificantly associated SNPs from GWA studies [20]. This analysis used 410 SNPs with a p-value
for significance of<0.001 out of 115,565 within-gene SNPs from a total of 279,389 available.
We found these SNPs were associated with 94 genes from a total of 13,092 genes with GO an-
notation covered in this study. Additionally we used Ingenuity Pathway Analysis (IPA) www.
ingenuity.com) to determine the functional pathways in the genes tagged by our top ranked
SNPs. We again selected those genes tagged by SNPs with p-value<0.001 and selected the ca-
nonical pathway analysis implemented in IPA software.
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Sequencing
We sequenced the 11 exons and intronic flanking areas of the GRM8 gene in 96 sCJD patients
using specific primers (S5 Table). The amplification reactions were carried out with 25 ng of
genomic DNA and 0.5 units of Taq DNA Polymerase in a volume of 25 μl. The final concentra-
tions of other reactants were: 1x Taq DNA Polymerase Buffer, 0.1 mM dNTPs and 0.1 μM of
each primer. The final concentration of MgCl2 was 2 mM for the amplification of exons 1–7
and 10; 4 mM for exons 8 and 9a; 1.5 mM for exon 9b and 1 mM for exon 11. Additionally, the
amplification reactions of exons 1 and 8 were supplied with DMSO 10% and 5%, respectively.
The PCR cycling conditions were as follows: initial denaturation at 96°C for 3 min followed by
30 cycles of 96°C for 30 s, annealing temperature (see S5 Table) for 30 s and extension tempera-
ture of 72°C for 1 min with a final extension at 72°C for 10 min. A 2 μl aliquot of the amplifica-
tion reaction was sequenced using 0.1μM of the above primers.
Functional prediction analysis
Functional prediction analysis of genetic variants was performed by the use of FuncPred online
software (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) [21]. Exonic splicing enhancers
were analyzed by RESCUE-ESE Web Server (http://genes.mit.edu/burgelab/rescue-ese/) [22]
and PITA online software (http://genie.weizmann.ac.il/pubs/mir07/index.html) [23] was used
to assess potential micro-RNA target sites. We searched for correlations between our genetic
variants and eQTL in GTEX [24] and Genenetwork (http://genenetwork.nl:8080/
GeneNetwork/) [25].
Phenotypic correlations
We performed an immunohistochemical study in brain samples from 48 sCJD patients. The
rs6951643 genotype distribution was as follows: 13 AA, 25 AG, and 9 GG. Sections from the
hippocampal region CA1 sub-region, temporal cortex and white matter were immunostained
for mGluR8. The intensity of mGluR8 (1:50; polyclonal rabbit antibody, Novus Biologicals,
Cambridge, UK) immunostaining was evaluated using a scale of 0–3 (0: no; 1: weak; 2: moder-
ate; 3: strong staining). The frequency of mGluR8 positive cells was scored semi-quantitatively
using three categories: 1,<10%; 2, 10–50%; 3,>50% and was evaluated to provide information
about the relative number of mGluR8 positive cells within the tissue. The product of these two
values (intensity and frequency scores) was used to give the overall scores (total scores). In ad-
jacent sections microglial activation using immunostaining for HLA-DP, DQ, DR (clone CR3/
43, 1:00, monoclonal mouse), and spongiosis were also estimated semi-quantitatively. The
analysis was performed (GGK) blinded to rs6951643 genotype. Ordinal regression was em-
ployed to test for association between rs6951643 genotypes and brain semi-quantitative expres-
sion of mGluR8. We adjusted by disease duration, PRNPM129V genotype, gliosis and
spongiosis. We correlated clinical variables (age at death and patient’s disease onset) with the
presence of 0, 1 or 2 sCJD risk alleles. In order to assess rs6951643 influence on age at onset
and disease duration we performed a time to event analysis using Cox regression adjusting by
PRNPM129V genotype and other relevant factors like sex and country of origin.
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Prion acute synaptotoxicity is largely driven by
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Although misfolding of normal prion protein (PrPC) into abnormal conformers (PrPSc) is criti-
cal for prion disease pathogenesis our current understanding of the underlying molecular
pathophysiology is rudimentary. Exploiting an electrophysiology paradigm, herein we report
that at least modestly proteinase K (PK)-resistant PrPSc (PrPres) species are acutely synap-
totoxic. Brief exposure to ex vivo PrPSc from two mouse-adapted prion strains (M1000 and
MU02) prepared as crude brain homogenates (cM1000 and cMU02) and cell lysates from
chronically M1000-infected RK13 cells (MoRK13-Inf) caused significant impairment of hip-
pocampal CA1 region long-term potentiation (LTP), with the LTP disruption approximating
that reported during the evolution of murine prion disease. Proof of PrPSc (especially PrPres)
species as the synaptotoxic agent was demonstrated by: significant rescue of LTP following
selective immuno-depletion of total PrP from cM1000 (dM1000); modestly PK-treated
cM1000 (PK+M1000) retaining full synaptotoxicity; and restoration of the LTP impairment
when employing reconstituted, PK-eluted, immuno-precipitated M1000 preparations (PK
+IP-M1000). Additional detailed electrophysiological analyses exemplified by impairment
of post-tetanic potentiation (PTP) suggest possible heightened pre-synaptic vulnerability
to the acute synaptotoxicity. This dysfunction correlated with cumulative insufficiency of
replenishment of the readily releasable pool (RRP) of vesicles during repeated high-fre-
quency stimulation utilised for induction of LTP. Broadly comparable results with LTP and
PTP impairment were obtained utilizing hippocampal slices from PrPC knockout (PrPo/o)
mice, with cM1000 serial dilution assessments revealing similar sensitivity of PrPo/o and
wild type (WT) slices. Size fractionation chromatography demonstrated that synaptotoxic
PrP correlated with PK-resistant species >100kDa, consistent with multimeric PrPSc, with
levels of these species >6 ng/ml appearing sufficient to induce synaptic dysfunction. Bio-
chemical analyses of hippocampal slices manifesting acute synaptotoxicity demonstrated
reduced levels of multiple key synaptic proteins, albeit with noteworthy differences in PrPo/o
slices, while such changes were absent in hippocampi demonstrating rescued LTP through
treatment with dM1000. Our findings offer important new mechanistic insights into the
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synaptic impairment underlying prion disease, enhancing prospects for development of tar-
geted effective therapies.
Author summary
Misfolding of the normal prion protein (PrPC) into disease-associated conformations
(PrPSc) is the critical initiating step for prion diseases. Similar to other neurodegenerative
disorders, progressive failure of brain synapses is considered a primary deleterious event
underpinning prion disease evolution. Our current understanding of the underlying
mechanisms associated with synaptic failure is rudimentary contributing to difficulties in
developing effective treatments. Herein we report the use of an electrophysiology para-
digm that allowed us to demonstrate that at least modestly proteinase K (PK)-resistant
PrPSc species from two mouse-adapted prion strains (M1000 and MU02) are directly
synaptotoxic causing significant acute impairment of hippocampal CA1 region long-term
potentiation (LTP). Of note, the LTP disruption approximated that reported in prion
animal models. Additional detailed analyses provided novel pathophysiological insights
suggesting possible heightened pre-synaptic vulnerability to the acute synaptotoxicity
through impairment of replenishment of the readily releasable pool of neurotransmitter
vesicles, while biochemical analyses demonstrated reduced levels of multiple key pre-and
post-synaptic proteins. Broadly similar acute synaptic dysfunction and dose-response sus-
ceptibility were observed in slices from mice not expressing PrPC albeit with minor but
noteworthy differences in electrophysiological and biochemical findings. Our study offers
important new mechanistic insights into the synaptic impairment underlying prion dis-
ease, enhancing prospects for development effective therapies.
Introduction
Prion diseases constitute a group of transmissible neurodegenerative disorders with the spec-
trum encompassing several human phenotypes, the most common being Creutzfeldt-Jakob
disease (CJD), as well as a number of animal diseases including bovine spongiform encepha-
lopathy (“mad cow” disease) and scrapie in sheep [1, 2]. Regardless of disease phenotype, mis-
folding of PrPC into disease-associated conformers (herein collectively designated PrPSc), with
their subsequent aggregation and accumulation, appears critical to pathogenesis although the
precise neurotoxic species and how such species provoke neuronal dysfunction and loss lead-
ing to the onset of clinical illness remain unresolved. The precise composition of the infectious
unit or “prion” also remains to be determined, although considerable evidence supports that
PrPSc is the major, if not exclusive, component (the “protein only” hypothesis) [3]. Histori-
cally, PrPSc has been considered to be highly protease-resistant (designated PrPres after prote-
ase treatment) but recent evidence supports the existence of a broader spectrum, including
protease-sensitive conformers, which most likely contribute to pathogenesis and may com-
prise up to 90% of misfolded prion protein in diseased brains [4, 5].
The primary function of PrPC in the central nervous system remains uncertain although a
key role for this glycosylphosphatidylinositol-anchored glycoprotein in synaptic physiology
and memory has been described [6]. Aligned to such functions, PrPC has been reported as hav-
ing a predominant synaptic localisation [7], with important influences on voltage-gated cal-
cium (Ca2+) [8] and N-methyl-D-aspartate receptor (NMDAR) ion channels [9], as well as
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LTP [10]. LTP is a use-dependent neurophysiological process, enhancing the strength of syn-
aptic connection, with hippocampal CA1 region LTP directly correlating with episodic mem-
ory acquisition [11]. Critical to LTP-type synaptic plasticity and episodic memory generated
in the hippocampus are α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor
(AMPAR) and NMDAR ion channels, as well as metabotropic glutamate receptors with signal
transduction mediated through pathways including calcium-regulated phosphorylated extra-
cellular signal–regulated kinase (pERK) and phosphorylated cAMP response element binding
protein (pCREB), which alter DNA transcription with consequent ultrastructural and receptor
changes at synapses [12].
Our group [13] and others [14, 15] have shown in prion animal models evidence of early
selective hippocampal damage, with synapses becoming significantly disrupted and retracted
from the mid-incubation period [15–17]. Of particular relevance, selective and progressive
impairment of LTP in the CA1 region of the hippocampal stratum radiatum has been demon-
strated in vivo in ME7 prion infected mice from 44–70% of the incubation period [14], with
early loss of hippocampal pyramidal neuronal synapses shown to correlate with first evidence
of disturbances in hippocampal-dependent behaviour [15]. Additionally, studies have revealed
that impairment of LTP coincides with the earliest detection of PrPSc, slightly prior to morpho-
logical evidence of synaptic loss or neuropil vacuolation [14, 18], indicating that impairment
of hippocampal CA1 region LTP is a sensitive indicator of synaptic dysfunction in prion
strains that cause early, prominent hippocampal damage and supporting the likelihood that
PrPSc is directly synaptotoxic.
Somewhat limiting our ability to better understand prion pathogenesis is the relative pau-
city of tractable, authentic models of acute prion neurotoxicity. Very simple in vitro cell culture
models have demonstrated toxic effects of recombinant, soluble, oligomeric PrP enriched in
β-sheet content [19], as well as toxicity from highly “purified” PrPSc and proteinase treated
PrPSc extracted from the brains of terminally sick rodents [20, 21]. An in vivo model of acute
neurotoxicity employing stereotaxic injection of recombinant full-length ovine PrP into the
hippocampal CA2 region has been reported, with assessment for acute toxicity requiring mor-
phological analysis approximately 24 hours later [22]. In addition, a model utilizing cultured
organotypic cerebellar slice explants allowing assessment of factors that interfere with PrPSc
replication and abrogate cerebellar granule cell loss has been described [23], although this
model relies entirely on de novo PrPSc propagation to generate neurotoxic species over an
extended 5–7 week period. This ex vivo culture model is arguably therefore not ideal for assess-
ing direct acute PrPSc neurotoxicity because PrPSc propagation can closely correlate with dele-
terious cellular events such as heightened oxidative stress [24] that may also contribute to
pathogenesis thereby potentially confounding the delineation of a directly neurotoxic PrPSc
species. Of particular interest is a recent study demonstrating that PrPSc species cause retrac-
tion and subsequent loss of dendritic spines in cultured hippocampal neurons following
several hours of exposure to PrPSc preparations [25]. This study however, reported that the
synaptotoxicity required expression of PrPC [25] leaving some uncertainty as to whether the
neurotoxic PrPSc species were entirely those directly added to the culture or were different spe-
cies generated through initial PrPSc propagation from host PrPC.
Electrophysiological studies employing techniques to assess LTP are an established method
to explore potential acute neurotoxic effects of ex vivo brain material derived from neurode-
generative disorders such as Alzheimer’s disease (AD) [26]. Herein we report the use of an
electrophysiology paradigm to explore the acute synaptotoxicity of ex vivo prion preparations
derived from terminal disease brains briefly superfused onto hippocampal slices. We found
that PrPSc (for convenience hereafter considered as synonymous with PrPres species with at
least modest PK resistance) is directly deleterious to LTP in the hippocampal CA1 region, with
Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species
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the degree of impairment approximating that observed during the natural evolution of prion
disease in rodent models and independent of age of mice up to 11 months, with lysates from
chronically M1000 prion infected cells (MoRK13-Inf) also inducing analogous acute synapto-
toxicity. Additional detailed electrophysiological analyses suggested possible heightened pre-
synaptic vulnerability to the acute synaptotoxicity, exemplified by impairment of post-tetanic
potentiation (PTP) and correlating with failure of replenishment of the readily releasable pool
(RRP) of vesicles during repeated high-frequency stimulation utilised for induction of LTP.
Size fractionation chromatography demonstrated that synaptotoxic PrP correlated with PK-
resistant species>100kDa, consistent with multimeric PrPSc, with levels of these species
>0.006 μg/ml appearing sufficient to induce synaptic dysfunction. Biochemical studies
confirmed that synaptotoxic PrPSc in WT slices reduces essential proteins required for the
induction and maintenance of hippocampal LTP such as pERK, pCREB, synaptophysin and
vesicular glutamate transporter 1 (VGLUT1), as well as the NMDAR NR2A and NR2B sub-
units and the GluA2 subunit of AMPAR. Importantly, the PrPSc acute impairment of LTP and
PTP was largely PrPC independent, albeit with some noteworthy differences in the changes
in key synaptic proteins and electrophysiological findings between wild type (WT) and Prn-p
gene-ablated (PrPo/o) hippocampal slices, supporting the likelihood of non-PrPC dependent
mechanistic pathways. Dose-response assessments using cM1000 revealed similar sensitivity
to synaptic disruption in PrPo/o and WT hippocampal slices. Our findings offer important
new pathophysiological insights into the synaptic impairment underlying prion disease,
enhancing prospects for development of targeted effective therapies.
Materials and methods
Ethics statement
All animal handling was in accordance with National Health and Medical Research Council
(NHMRC) guidelines. All experimental procedures were approved by The Florey Institute of
Neuroscience and Mental Health Animal Ethics Committee (Ethics number: 13–048) or the
Biochemistry & Molecular Biology, Dental Science, Medicine (RMH), Microbiology & Immu-
nology, and Surgery (RMH) Animal Ethics Committee, The University of Melbourne (Ethics
number: 1312997.1).
Animals
To prepare hippocampal slices for multi-electrode array (MEA) studies, 12-week-old and
11-month-old WT C57 black 6J (C57BL/6J) female mice were used (Animal Resource Centre,
Western Australia), as well as 12-week-old female PrP knockout (PrPo/o) mice on a C57BL/6J
background produced through 10 consecutive back-crossings of C57BL/6JX129/sv mice [27].
Mice were group caged, with 12-hour day-night light cycles and food and water provided ad
libitum.
Brain homogenate and cell lysate preparation for electrophysiology studies. Whole
brains from terminally ill mice inoculated with M1000 and MU02 prion strains [28, 29],
as well as age-matched normal brain homogenate (NBH) “sham” inoculated mice, were
homogenized to 20% (w/v) stocks in artificial cerebrospinal fluid (aCSF; 126mM NaCl, 2.5mM
KCl, 26mM NaHCO3, 1.25mM NaH2PO4, 10mM Glucose, 1.3mM MgCl2.6H2O, 2.4mM
CaCl2.2H2O) by passing through progressively smaller gauge needles (18g, 20g, 22g, 23g, 26g),
sub-aliquoted and stored at -80˚C until required. For each electrophysiology experiment, ali-
quots of 20% (w/v) prion-infected brain homogenate and NBH were diluted to a final concen-
tration of 0.5% (w/v) in aCSF after pre-clearing at 100×g for one minute. These 0.5% (w/v)
brain homogenates were the crude preparations (crude M1000: cM1000; crude MU02:
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cMU02; crude NBH: cNBH). Rabbit kidney epithelial (RK) cells expressing murine PrPC
(known as mouse RK13 or MoRK13; produced by Laura Vella and Andrew Hill as described
in Vella et al. [30]), either mock-infected with NBH (control) or M1000 prion infected were
cultured as described previously [31]. Control and M1000 infected cells were harvested, lysed
in aCSF through needles as described above for brain homogenates to a final concentration
2% (w/v) for the use in electrophysiology experiments (control or mock-infected lysate, MoR-
K13-Un; M1000 infected lysate, MoRK13-Inf). In addition, we performed cM1000 serial dilu-
tion experiments on both WT and PrPo/o hippocampal slices to assess the sensitivity of the
slices. For these experiments we utilised cM1000 brain homogenates (w/v in aCSF) diluted to
1%, 0.5%, 0.25% and 0.1%.
Proteinase K (PK) treatment of brain homogenate preparations for electrophysiological
studies. M1000 brain homogenates and NBH, diluted to 0.5% (w/v) in aCSF and pre-cleared
as above were treated with a final concentration of 5μg/mL PK for one hour at 37˚C. The PK
digested preparations (PK+M1000 and PK+NBH) were used immediately in electrophysiology
experiments. Small aliquots of PK treated homogenates were stored at -80˚C for subsequent
biochemical analyses.
PrP immuno-depletion and PK-elution of PrP species from immuno-precipitated pel-
lets of brain homogenates. In preparation for immuno-depletion, 50% protein-G-sepharose
bead slurry (PGS; Invitrogen) was pre-blocked overnight at 4˚C by incubation (with constant
gentle movement) in 10% (w/v) skim milk powder in sterile phosphate buffered saline contain-
ing calcium and magnesium (PBSCa2+Mg2+; Life Technologies). For each PrP immuno-deple-
tion, 03R19 anti-PrP rabbit polyclonal antibody raised against residues 89–103 [29] was
coupled to pre-blocked 50% PGS at room temperature (RT) for 2 hours. Normal rabbit serum
(NRS) was utilized in the same manner as 03R19 to serve as a negative control. The 03R19 (or
NRS) coupled PGS were incubated with 1% (w/v in aCSF) pre-cleared M1000 brain homoge-
nate or NBH overnight at 4˚C. PGS was pelleted by a pulse spin at 100 x g. Supernatants were
collected as the PrP immuno-depleted samples and were further diluted 1:1 with aCSF to
approximately a 0.5% (w/v) homogenate (PrP immuno-depleted NBH: dNBH; PrP immuno-
depleted M1000: dM1000) prior to use in electrophysiology experiments. The immuno-cap-
tured PrP species bound to the pelleted PGS were resuspended in aCSF to the same starting
volume of 1% (w/v) brain homogenate used for the immuno-depletion. PGS samples were
then digested with a final concentration of 5μg/mL PK at 37˚C for an hour with agitation (two
cycles of 20 minutes agitation at 1400 rpm followed by 10 minutes with no agitation) to pre-
vent the PGS from settling. The PGS was again pelleted (pulse spin at 100 x g) and the superna-
tant containing any eluted at least modestly PK-resistant PrPSc species was collected and
diluted 1:1 with aCSF for use in electrophysiology experiments (PK eluted PrP immuno-pre-
cipitated NBH, PK+IP-NBH; PK eluted PrP immuno-precipitated M1000, PK+IP-M1000).
Small aliquots of PK+IP-NBH and PK+IP-M1000 were retained and stored at -80˚C for subse-
quent biochemical analyses.
Hippocampal slice preparation for electrophysiology studies
Mouse brains were quickly collected following decapitation while under deep anaesthesia
induced by isoflurane. 300μm dorsal horizontal brain slices were prepared using a vibratome
(Leica VT1200S) in ice-cold continuously carboxygenated (5% CO2 and 95% O2) cutting solu-
tion (3mM KCl, 25mM NaHCO3, 1.25mM NaH2PO4, 206mM Sucrose, 10.6mM Glucose, 6
mM MgCl2.6H2O, 0.5mM CaCl2.2H2O). Approximately three optimal mid-hippocampal slices
were collected from each hemisphere for electrophysiology studies. Slices were then allowed to
stabilise at 32˚C by incubation for one hour in continuously carboxygenated aCSF prior to
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mounting onto 60MEA200/30iR-Ti-pr-T multi-electrode arrays (MEA; Multichannel Systems;
Germany) with secure placement achieved using Harp slice grids (ALA HSG-5B, Multichannel
Systems; Germany) to ensure good contact of the CA1 region with the MEA (S1A(1) to S1A(3)
Fig). Three slices were simultaneously mounted in separate recording chambers and were
independently continuously superfused with carboxygenated aCSF (S1A(3) Fig panel i).
Electrophysiology paradigm. Hippocampal field excitatory post-synaptic potentials
(fEPSP) were evoked by stimulating one of the MEA grid electrodes that was best aligned to
the Schäffer collateral pathway while recording from other electrodes placed on the stratum
radiatum of the CA1 region (S1A(3) Fig panel ii). The average number of electrodes recorded
from and utilised for analysis in each slice was seven. The amplitude of fEPSP was recorded as
the synaptic response. The basal stimulus intensity was determined by generating an input-
output (I-O) curve with the intensity chosen sufficient to achieve a fEPSP of ~40% of the
maximum response without causing a population spike and a baseline was recorded with stim-
ulation every 30 secs for 30 mins. After approximately 10 mins of the 30-mins baseline, the hip-
pocampal slice was then treated by superfusion with prion containing or control preparations
for 5 mins, followed by the rest of the baseline recording in aCSF to ensure return of a stable
baseline prior to trains of high frequency stimulation (HFS) (see S1A(4) Fig). The HFS trains
(three 500 millisecond, 100Hz trains, 20 sec apart) were delivered (see S1A(4) Fig), followed by
post-HFS stimulation every 30 sec for 30 mins, wherein the first response was the post-tetanic
potentiation (PTP) and the responses recorded from five mins post-HFS considered the LTP.
Immediately after the recordings, slices were snap-frozen and stored at -80˚C for future bio-
chemical analyses. For each independent experiment (n = 5–10 for each treatment), hippocam-
pal slices generated from the same mouse brain were simultaneously utilized for perfusion
with aCSF (technical control), NBH control preparations and prion infected samples.
Several synaptic neurophysiological parameters were recorded and analysed (see S1A(4) Fig):
1. I-O curve: fEPSP responses to a series of stimuli of increasing strength from 0 mV up to a
stimulus that evoked the maximum fEPSP (ie 3000 mV-5000 mV determined by plateau
responses), with the I-O curve prior to treatments (I-O 1) used to determine the basal stim-
ulus intensity, as well as measure the strength of synaptic transmission before (I-O 1) and
after treatments and LTP expression (I-O 2) (S1A(4) Fig, boxes 1 & 6).
2. PTP: The first fEPSP response at 0.5 sec after the third HFS train (see S1A(4) Fig, box 4;
S1B Fig).
3. LTP: Responses recorded from five minutes following HFS trains represent LTP. The last
10 mins of LTP was used for analyses (S1A(4) Fig, box 5; S1B Fig).
4. Paired pulse facilitation (PPF) ratio can be used to estimate the basal probability of neuro-
transmitter release, which was measured by two identical basal stimuli delivered at a 20 mil-
lisecond interval with the fEPSP amplitude of the second stimulus divided by that of the
first stimulus (see S1B Fig). PPF was measured before (PPF1) exposure to prion containing
or NBH control preparations, as well as after 30 minutes of LTP expression (PPF2) (see S1A
(4) Fig, box 1 and box 6).
5. Readily releasable pool (RRP) depletion: For each HFS train the first 9 evoked fEPSP pulses
were utilised wherein the ratio of the pulse 1 and pulse 2 fEPSP amplitude (pulse 2 divided
by pulse 1) estimates the probability of transmitter release (Pr) in each train (see S1C Fig).
The fEPSP amplitude declined after pulse 2 to the last pulse in a HFS train and the rate of
decline was used to estimate the RRP decays in each train (Further explained in Data analy-
sis section) (see S1D Fig).
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6. RRP replenishment: Relative changes in RRP size were estimated by extrapolating to the Y-
intercept the best-fit straight line of the last 4 pulses (pulse 6 to pulse 9) of the cumulative
fEPSP amplitudes of each HFS train [32–34] (Further explained in the Data analysis sec-
tion) (see S1E Fig).
7. PPF time-course: For the time-course PPF study without LTP induction, the PPF1 was
measured (with basal stimulation) before (PPF1A) and immediately after (PPF1B) expo-
sure to either cM1000 or cNBH; following PPF1B, PPF was measured every 5 minutes for
one hour. The slices were stimulated with basal stimulation during the treatment and at
5-minutely intervals (see S1F Fig).
Note: the omission of specific GABAA receptor antagonists during measurements of fEPSP
to calculate PPF ratios may reduce the accuracy of Pr estimates. Similarly, the omission of spe-
cific GABAA receptor blockade during HFS may render estimates of the RRP based on changes
in fEPSP amplitudes less accurate.
Size exclusion chromatography
Prior to size exclusion chromatography, brain homogenates were solubilized in Sarkosyl (w/v
in 1xPBS), dialysed and filtered. Normal brain homogenates (~10% w/v) were pelleted by
15000xg spin for 10 minutes at 4˚C. The supernatant was discarded and the pellet was recon-
stituted with 4% (w/v in 1xPBS) Sarkosyl, incubated at 37˚C for 30 minutes, and centrifuged
at 10000xg for 10 minutes. The pellet was discarded, and the supernatant was collected and
exhaustively dialysed (using 10kDa cut-off dialysis tubing) four times in 1x PBS dialysate (con-
taining no Mg2+ or Ca2+) that was ~166 fold greater than the sample volume with each dialysis
conducted overnight at 4˚C. Parallel to these procedures, ~1% (w/v) PK+IP-M1000 was pel-
leted by 15000xg, and the pellet was resuspended in 4% (w/v) Sarkosyl with a volume that was
10-fold less than the initial volume to concentrate the PK+IP-M1000 into ~10% (w/v). Similar
procedures were utilized to solubilize ~1% (w/v) dM1000 and concentrate to ~10% (w/v). The
10% (w/v) solubilized and dialysed preparations were filtered using a 0.22-micron filter before
~3mL was injected into a size exclusion chromatography column (HiPreP 16/60 s-100) at a
flow rate of 0.5mL per min. The protein complexes were eluted in 1x PBS (containing Mg2+
and Ca2+) at 0.5mL per min flow rate, wherein the void volume was collected at ~70 minutes
after injection followed by continuous collection of 1mL fractions every two minutes for 80
minutes (~40 fractions in total). The size of proteins or protein complexes fractionated by size
exclusion chromatography and eluted into each fraction was determined following size frac-
tionation of the following size exclusion chromatography markers: bovine erythrocyte car-
bonic anhydrase (~29kDa), bovine serum albumin (~66kDa), yeast alcohol dehydrogenase
(~150kDa), sweet potato beta-amylase (~200kDa), horse spleen apoferritin (~443kDa), and
bovine thyroglobulin (~669kDa). Fractions 1 (the void volume) through 12 were enriched
for proteins, protein complexes or protein oligomers and protofibrils with molecular weight
above ~100kDa, whereas fractions 15 through 30 were enriched for proteins with molecular
weights less than ~100kDa, including monomeric proteins such as PrPC. The levels of prion
proteins in each fraction were determined by western blotting, including before and after treat-
ment with 5μg/mL PK for 60 minutes at 37˚C.
Biochemical analyses
Hippocampal slices (n = 5 for each treatment condition) were analysed after dissection of the
hippocampus from surrounding tissue, homogenization in lysis buffer (50mM Tris-HCl pH
7.4, 150mM NaCl, 0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate, 1% (v/v) NP-40) using
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needles as with whole brain homogenates, methanol precipitation of proteins by adding 5×
volumes of ice-cold 100% methanol and incubating at -20˚C overnight, followed by centrifuga-
tion at (20817xg) at 4˚C for one hour. Supernatants were discarded and pellets were resus-
pended in 50μL lysis buffer and prepared in 4x sample buffer (NuPAGE LDS, Thermo Fisher
Scientific) with a final concentration of 6% beta-mercaptoethanol. As required, aliquots of 1%
brain homogenates (w/v in aCSF) of M1000, MU02 and NBH were also utilised for western
blot analysis, including after digestion using 5 or 50μg/ml PK for 60 minutes at 37˚C as indi-
cated in the figure legends. The 5μg/ml PK digestion was used for all other PK treatments such
as for the PrP-containing preparations used for hippocampal slice treatments (Fig 2D & 2G).
In addition, for quantifying levels of PrP in brain homogenates and other preparations used in
electrophysiology studies, a serial dilution of recombinant full-length mouse PrP (rPrP; made
as described previously [35]) of known concentrations (prepared as described in [36]) was uti-
lized to generate a standard curve of rPrP through probing by western blotting (using 8H4
anti-PrP antibody) and densitometric analysis, which was then used to estimate levels of PrP
in the various preparations loaded onto the same gel. Proteins were analysed by PAGE and
immunoblotting as described previously [37]. Briefly, samples were resolved on NuPAGE
Novex 4–12% Bis-Tris gels (ThermoFisher Scientific), transferred to PVDF membrane (Milli-
pore), blocked in either 5% (w/v) skim milk powder (SkM) or 3% (w/v) bovine serum albumin
(BSA), probed with various antibodies (see S1 Table for a summary of primary and secondary
antibodies utilized, their dilutions, as well as blocking conditions/antibody diluents), with pro-
tein detection using enhanced chemiluminescence (ECL Prime and Select, Invitrogen). Mem-
branes were also stained with Coomassie blue (and de-stained) to determine relative total
protein levels. All chemiluminescent and digital imaging was carried out using a Fujifilm LAS-
3000 Intelligent dark box.
Statistical analyses
Statistical analyses were performed using GraphPad Prism 6 (USA). The PTP and LTP fEPSP
data were exported to Excel files (by LTP Analyzer software from Multichannel Systems)
where they were normalized to average fEPSP recorded over the last five minutes of baseline
recording. An unpaired Student t test (parametric test with Welch’s correction) was used to
compare the average LTP and PTP of the treatment groups, such as NBH controls versus
prion containing (or depleted) preparations. A paired Student t test (parametric test) was used
to compare the average ratio of PPF1 and PPF2. I-O1 and I-O2 were compared using ANOVA
with repeated measures. The fEPSP amplitudes of the HFS trains were quantified using PlotDi-
gitizer software and normalized to the baseline fEPSP amplitude. The slope of decline of fEPSP
amplitude from pulse 3 to the last pulse in each HFS train was compared between treatment
groups by one phase decay exponential function in which the time constant of decay (Tau = 1/
K) measures the rate of RRP decline in each train. The ratio between pulse 1 (P1) and pulse 2
(P2) of each train was compared between trains within a treatment group by paired Student t
test to measure the probability of release per train. Cumulative fEPSP responses of each of the
three trains were compared between treatment groups using a linear fit equation (of the last 4
cumulative fEPSPs/train) comparing Y-intercepts upon the initial stimulus after extrapolating
the linear fit [32, 33]. Acute synaptotoxicity in the form of LTP and PTP change was calculated
as the percentage decrease relative to their appropriate negative controls. The acute synapto-
toxicity estimated in the form of PPF ratio was calculated as the percentage of PPF ratio decline
in PPF2 relative to PPF1. Because the PPF ratio is inversely proportional to the Pr, the percent-
age of PPF ratio decline represents the Pr increase in PPF2. All data are presented as mean
(m) ± standard error of mean (SEM). The western blot bands of interest were quantified by
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densitometry (Image J), after correcting for total protein level and analysed by Student
unpaired t test (parametric test with Welch’s correction).
Results
M1000 and MU02 brain homogenates are acutely synaptotoxic to mouse
hippocampal CA1 region
Brains of terminally sick prion infected mice are presumed to contain all pathogenic species
responsible for the development of prion diseases. To determine if some of these species are
acutely synaptotoxic, independent of de novo propagation of PrPSc given the very short time-
frame of the experiments, crude brain homogenates were introduced onto ex vivo mouse hip-
pocampal slices to determine any deleterious effects on LTP. These crude homogenates were
derived from WT C57BL/6J mice intracerebrally inoculated with normal brain homogenate
(cNBH) and terminally ill mice infected with either of two mouse-adapted human prion
strains, M1000 (cM1000) [28] and MU02 (cMU02) [29]; Fig 1A, 1D and 1G provide examples
of PrPres detection by western blots of brain homogenates pre- and post-PK treatment. The
hippocampal CA1 region LTP of 12-week-old WT mice was significantly reduced by 53 ± 9%
(n = 6) following five-minute exposure to cM1000 (Fig 1B & 1C; see S2A Fig) and by 62 ± 19%
(n = 6) following exposure to cMU02 (Fig 1E & 1F; see S2A Fig) relative to cNBH. There was
no significant difference between the acute synaptotoxicity of cM1000 and cMU02 (see S2A
Fig). Further, there was no significant difference in the degree of LTP disruption of cM1000
in slices generated from 11-month-old WT mice (impaired by 44 ± 7%; n = 7) compared with
12-week-old WT mice (Fig 1H & 1I; see S2A Fig). Consistent with the LTP impairment, the
I-O2 curve was not significantly enhanced compared to the I-O1 curve following exposure to
cM1000 (in both 12-week-old WT and 11-month-old WT mice) and cMU02 compared with
cNBH (see S2E and S2F Fig). In addition, relative to aCSF technical controls, cNBH negative
controls did not affect LTP (S2B & S2C Fig).
Lysates from M1000-infected MoRK13 cells are acutely synaptotoxic
Propagation of bona fide prions in MoRK13 cell lines that express murine PrPC has been well
established through studying M1000 and MU02 ex vivo transmission [29, 31]. PK-resistant
PrPSc detected in these cells (Fig 1J) appears a valid biomarker for successful transmission
of prions. To determine if these cells also propagate acutely synaptotoxic species similar to
cM1000, whole cell lysates derived from MoRK13-Inf were also briefly superfused onto hippo-
campal slices from 11-month-old WT mice, with the amount of biochemically detectable
PrPSc in MoRK13-Inf lysates balanced to equate that in cM1000. Similar concentration MoR-
K13-Un lysates did not affect LTP relative to aCSF controls, demonstrating no background
toxicity of the uninfected cell lysates (see S2D Fig). Following brief treatment with MoR-
K13-Inf lysates, the LTP was significantly impaired by 40 ± 6% (n = 6) (Fig 1K & 1L), with the
degree of LTP disruption similar to that obtained from cM1000 (see S2A Fig). Consistent with
the LTP impairment, the I-O2 also failed to significantly increase relative to I-O1 following
exposure to MoRK13-Inf compared with MoRK13-Un (see S2H Fig).
Acute synaptotoxicity of cM1000 is directly associated with PrP species
PrPSc species are readily detectable in the brains of terminal prion infected mice [38] and
PrPSc species closely correlate with the disruption of neuronal structures including dendritic
spines in prion disease in vivo mouse models [16] and a primary neuronal cell culture model
[25]. To determine the relationship of PrP species to the acute disruption of LTP following
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Fig 1. Crude ex vivo PrPSc containing preparations acutely impair LTP. (A) Western blot of cNBH not treated (-) or
treated (+) with 50μg/ml PK. The PK- cNBH was utilised as control preparations for the treatments of WT
hippocampal slices using prion-containing crude brain homogenates. (B) cM1000 superfused for 5 minutes over
hippocampal slices from 12-week old WT mice approximately 20 minutes prior to HFS caused a significant
impairment of LTP with (C) average LTP reduced by 53 ± 9% (n = 6) compared to cNBH. (p = 0.0087). (D) Western
blot of cM1000 not treated (-) or treated (+) with 50μg/ml PK with PK+ proving presence of PrPSc. (E) cMU02
superfused for 5 minutes over slices from 12-week old WT mice approximately 20 minutes prior to HFS caused a
significant impairment of LTP with (F) average LTP reduced by 62 ± 19% (n = 6) compared to cNBH. (p = 0.0129). (G)
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exposure to cM1000 in our electrophysiology assay, total PrP species were selectively immuno-
depleted from both cM1000 and cNBH under native conditions using the 03R19 antibody [29]
coupled to protein-G conjugated sepharose beads. As shown in Fig 2A, relative to the normal
rabbit serum (NRS) control, the 03R19 immuno-depletion selectively reduced ~77 ± 12%
(n = 9) of PrPC from cNBH (dNBH) and ~77 ± 9% total PrP species and 96 ± 4% PrPres from
cM1000 (dM1000). The immuno-depletion did not introduce any synaptotoxicity, wherein
dNBH did not affect LTP relative to aCSF controls (see S3B Fig). When hippocampal slices
generated from 12-week-old WT mice were treated with dM1000, LTP was not significantly
different to dNBH, and was therefore effectively ‘rescued’ by 74 ± 14% (n = 8) when compared
to cM1000 (Fig 2B & 2C), clearly supporting that PrP species in cM1000 are directly responsi-
ble for the LTP disruption. In addition, I-O2 became significantly increased relative to I-O1
following exposure to the dM1000 compared with dNBH (see S3G Fig), thus verifying substan-
tial rescue of the synaptic transmission concomitant with the recovery of LTP.
At least modestly PK-resistant PrPSc species in cM1000 are responsible for
acute synaptotoxicity
Both PK-sensitive and PK-resistant species have been found capable of transmitting prion dis-
ease [39]. To determine whether any PK-resistant PrPSc species were directly responsible for
the LTP disruption observed with cM1000, cM1000 was treated with PK prior to superfusion
over WT hippocampal slices. The mild PK treatment (5μg/ml for one hour at 37˚C) digested
~90% of total protein from cM1000 relative to before the PK treatment but importantly a
prominent amount of PK-resistant PrPSc was still evident on western blotting after the PK
digestion, demonstrating that the modest PK treatment had considerably enriched for PrPSc
(Fig 2D lower panel; see S3H Fig columns i-ii & S3I Fig). The mild PK treatment digested
~80% of total proteins from cNBH including all PrPC relative to before the PK treatment
(Fig 2D upper panel; see S3H Fig columns v-vi & S3I Fig). Importantly, this mild PK treatment
and possible by-products did not cause any background synaptic impairment when comparing
PK+NBH relative to the aCSF technical control (see S3C Fig). Hippocampi derived from
12-week-old WT mice exposed to PK+M1000 demonstrated significant LTP impairment
of 48 ± 7% (n = 8) relative to PK+NBH (Fig 2E & 2F). Thus, the LTP disruption of the PK
+M1000 was approximately equivalent to that of the cM1000 (see S2A & S3A Figs), indicating
that at least modestly PK-resistant PrPSc species are most likely directly responsible for the
acute synaptic disruptions caused by cM1000. This dysfunction correlated with the failure of
I-O2 to significantly increase relative to I-O1 after treatment with PK+M1000 (see S3E Fig).
To further validate that PrPSc species, in particular PK resistant species, are directly respon-
sible for the acute synaptotoxicity, the total PrP species immuno-precipitated (IP) from
cM1000 (IP-M1000) and cNBH (IP-NBH) (using the method employed for PrP immuno-
depletion) were eluted from the IP pellets by the same modest PK treatment (5μg/ml for one
hour at 37˚C). This PK elution digested ~70% of total proteins from IP-NBH pellets including
Western blot of cMU02 not treated (-) or treated (+) with 50μg/ml with PK+ proving presence of PrPSc. (H) The PK-
cM1000 was superfused for 5 minutes over slices from 11-month old WT mice approximately 20 minutes prior to HFS
caused significant impairment of LTP with (I) average LTP reduced by 44 ± 7%; (n = 7) compared to cNBH.
(p = 0.0006). (J) Western blot of MoRK13-Inf not treated (-) or treated (+) with 50μg/ml PK with PK+ proving
presence of PrPSc. (K) The PK- MoRK13-Inf was superfused for 5 minutes over slices from 11-month old WT mice
approximately 20 minutes prior to HFS caused significant impairment of LTP with (L) average LTP reduced by
40 ± 6% (n = 6) compared to MoRK13-Un (p = 0.0172). (B, E, H & K) The first five-minute fEPSP recordings following
HFS trains have been removed to enhance clarity and the last 10 minutes of post-HFS recordings were used for LTP
analysis. (A, D, G, J) Molecular markers are provided at left. (B, E, H, K) Examples of raw fEPSP traces are provided as
insets. Data are presented as ± SEM. p<0.05, p<0.01, p<0.001, p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g001
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Fig 2. PK-resistant PrP species are responsible for acute synaptotoxicity. (A) PrP immuno-depletion selectively depleted
~77 ± 12% of PrPC (dNBH) from cNBH and ~77 ± 9% total PrP species and 96 ± 4% of PK-resistant PrP (dM1000) from cM1000
relative to the normal rabbit serum (NRS) controls. Controls and depleted preparations were either not treated (-) or treated (+) with
50μg/ml PK to determine the level of PK-resistant PrP. (B) dM1000 superfused for 5 minutes over hippocampal slices from 12-week
old WT mice approximately 20 minutes prior to HFS trains displayed significant rescue of LTP with (C) average LTP increased
74 ± 14% (n = 8), which was no longer significantly different to slices superfused with dNBH. (D) Western blot of cNBH and cM1000
treated with 5μg/mL PK (PK+NBH; PK+M1000), which was sufficient to completely degrade all PrPC in cNBH. (E) PK+M1000
superfused for 5 minutes over slices from 12-week old WT mice approximately 20 minutes prior to HFS significantly impaired LTP
Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007214 August 8, 2018 12 / 37
all PrPC (Fig 2G upper panel; see S3H Fig columns vii-viii, & S3I Fig) and ~80% of total pro-
teins from IP-M1000 pellets, leaving substantial levels of PrPSc in the preparations as revealed
by western blotting (Fig 2G lower panel; see S3H Fig columns iii-iv, & S3I Fig), effectively
enriching the preparations for modestly PK-resistant PrPSc. Following brief exposure of
12-week-old WT hippocampal slices to the PK-eluted IP-M1000 (PK+IP-M1000), LTP was
significantly impaired by 59 ± 5% (n = 8; Fig 2H & 2I). Noteworthy is that the degree of LTP
disruption caused by the PrPSc alone from IP pellets was at least as great as that obtained from
cM1000 and PK+M1000 (see S2A & S3A Figs), strongly supporting that these species were
responsible for the LTP disruption observed with other M1000 preparations. Consistent with
the LTP dysfunction, the I-O2 was also prevented by PK+IP-M1000 from becoming signifi-
cantly enhanced after LTP induction relative to I-O1 (see S3F Fig).
Multimeric PrPSc species present in M1000 preparations correlate with the
acute synapototoxicity to LTP
Similar to misfolded pathogenic proteins responsible for other neurodegenerative diseases
such as amyloid-beta (Aβ) in AD and alpha-synuclein in Parkinson’s disease, the neurotoxic
species in prion diseases is believed to be soluble multimers or oligomers [40, 41]. Consider-
able data supports that PrPSc species accumulate into different size multimers such as oligo-
mers and protofibrils, correlating with the natural evolution of prion disease and the onset of
clinical signs in mice [42, 43]. To determine any correlation between the presence of multi-
meric PrPSc species in M1000 preparations causing acute synaptic dysfunction (especially
cM1000, and PK+IP-M1000), PrPSc species in these preparations underwent size exclusion
chromatography and analysis by western blotting. For the negative control, PrPC species
in cNBH were also fractionated by size exclusion chromatography. Through the use of size
exclusion markers with molecular weights of ~400kDa, ~200kDa, ~66kDa and ~29kDa, pro-
tein complexes larger than 100kDa, including PrPSc multimers, were eluted in fractions 1
through 12, whereas protein species smaller than 100kDa, including PrPC, PrPSc monomers
and endoproteolytic fragments were eluted in fractions 14 through 40. Relative to fractions
of cNBH where most PrPC species were eluted as monomers (Fig 3A and 3B), the fractions of
cM1000 contained mostly multimeric PrPSc species (Fig 3C upper panel and Fig 3D) wherein
significant levels were at least modestly PK-resistant (Fig 3C lower panel and Fig 3D). Inter-
estingly, fractions of PK+IP-M1000 also contained predominantly at least modestly PK-
resistant PrPSc multimers. In contrast, fractions of dM1000 contained significantly reduced
levels of the multimeric PrPSc species, especially fractions 5–10, including at least modestly
PK-resistant multimeric PrPSc species (Fig 3G and 3H), which were present at substantial
levels in cM1000 (Fig 3C & 3D) and PK+IP-M1000 (Fig 3E & 3F). Consequently, the
increased levels of multimeric PrPSc species in fractions 5–10 of cM1000 and PK+IP-M1000
which were relatively depleted in dM1000 appear most strongly correlated with the acute
impairment of LTP (Fig 2).
with (F) average LTP reduced by 48 ± 7% (n = 8) relative to PK+NBH preparations (p = 0.003). (G) Pellets generated through PrP
immuno-precipitation (IP) of total PrP from cNBH and cM1000 were resuspended and western blotted after 5μg/mL PK digestion to
specifically elute at least modestly PK resistant PrPSc, with comparison made to NBH and M1000 resuspended pellets wherein PK-
resistant PrP was eluted by boiling after PK digestion with 5 μg/ml PK. (H) The resuspended, PK-eluted IP pellets from cNBH (PK
+IP-NBH) or cM1000 (PK+IP-M1000) superfused for 5 minutes over slices from 12-week old WT mice approximately 20 minutes
prior to HFS caused significant impairment of LTP measured during the last 10-minutes of post-HFS recording, with (I) average LTP
reduced by 59 ± 5% (n = 8) relative to PK+IP-NBH preparations (p = 0.001). (B, E & H) The first five-minute fEPSP recordings
following HFS trains have been removed to enhance clarity. (A: lower panel, D, G) Molecular markers are provided at left. (B, E, H)
Examples of raw fEPSP traces are provided as insets. Data are presented as ± SEM. p<0.05, p<0.01, p<0.001, p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g002
Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007214 August 8, 2018 13 / 37
Detailed electrophysiological analyses suggests acute synaptotoxicity of
PrPSc may be associated with heightened pre-synaptic vulnerability
PrPSc appears to reduce the probability of release (Pr) following expression of disrupted
LTP. The paired pulse facilitation (PPF) ratio was used to determine if the Pr from docked
neurotransmitter vesicles was disrupted and thereby contributing to the impairment of LTP
in WT hippocampal slices. The PPF ratio is inversely related to the Pr, becoming significantly
Fig 3. Prion acute synaptotoxicity is associated with increased levels of multimeric PrPSc species in ex vivo M1000 preparations. (A)
Representative anti-PrP immunoblots of fractions collected following size exclusion chromatography of 10% (w/v) cNBH after clarifying centrifugation,
solubilization in 4% (w/v) Sarkosyl and exhaustive dialysis. The fractions were immunoblotted before (-) and after (+) mild PK treatment (PK; 5μg/mL
PK; incubated at 37˚C for an hour). (B) Densitometric analysis of the immunoblots of cNBH fractions (n = 3) displayed as the percentage of PrP in each
fraction over the sum of PrP levels in all the fractions. (C) Representative anti-PrP immunoblots of fractions collected following size exclusion
chromatography of 10% (w/v) solubilized, dialyzed, and pre-cleared cM1000. The fractions were immunoblotted before (-) and after (+) mild PK
treatment as described for (A). (D) Densitometric analysis of the immunoblots of cM1000 fractions (n = 3). (E) Representative anti-PrP immunoblots
of fractions collected following size exclusion chromatography of at least modestly PK-resistant PrPSc, extracted from 1% (w/v) cM1000 by
immunoprecipitation (IP) and eluted by a mild PK digestion (5μg/mL PK at 37˚C for an hour) before being concentrated (10-fold to be equivalent to
10% w/v), solubilized, dialyzed, and pre-cleared for the size fractionation (PK+IP-M1000). (F) Densitometric analysis of the immunoblots of PK
+IP-M1000 fractions (n = 2). (G) Representative anti-PrP immunoblots of fractions collected following size exclusion chromatography of solubilized,
dialyzed, and pre-cleared 10% (w/v) M1000 brain homogenates containing only ~30% of the total PrP following selective removal of ~70% by immuno-
depletion (dM1000). The fractions were immunoblotted before (-) and after (+) mild PK treatment (5μg/mL PK at 37˚C for an hour). (H)
Densitometric analysis of the immunoblots of dM1000 fractions (n = 3). (D & H) The levels of fractionated PrP with and without PK treatment were
overlaid for illustration purposes and cannot be compared quantitatively because they were analysed independently. The effective molecular weights of
PrP species collected in fractions one through 12 were larger than 100kDa consistent with multimeric species while those collected in fractions 15
through 40 were smaller than 100kDa (Molecular weight markers are indicated as arrows above B. (A, C, E, and G) Since all 40 fractions could not be
loaded onto one 26-well gel, two 26-well gels were used for immunoblotting of the fractions from one size exclusion chromatography experiment;
importantly the last fraction on the first gel was also loaded as the first on the second gel, thereby allowing the levels of PrP on the second blot to be
normalized to those on the first blot. The PrP species were probed by either anti-PrP 03R19 (in A, C, and G) and 8H4 (in E) antibody. (A, C, E, and G)
Molecular weight markers are provided at left. (B, D, F, and H) The data are presented as mean ± SEM.
https://doi.org/10.1371/journal.ppat.1007214.g003
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reduced following LTP (PPF2) relative to before LTP induction (PPF1) due to an increase in
the Pr. A normal reduction in the PPF2 ratio was demonstrated in all negative controls includ-
ing cNBH similar to that obtained in aCSF technical controls (Fig 4A; see S4A & S4B Fig).
Conversely, the PPF2 ratio did not significantly reduce after exposure to any prion containing
preparations (cM1000, MoRK13-Inf, cMU02 and PK+IP-M1000) (Fig 4A; see S4B Fig). These
data suggest there may be a significant failure of Pr to increase during LTP induction, thereby
contributing to and correlating with the impairment of LTP. There was no difference in the
degree of Pr impairment obtained in 12-week-old WT mice compared with 11-month-old WT
mice (see S4B Fig). Importantly, the PPF ratio decline returned when slices were superfused
with using dM1000, correlating with the rescued LTP (Fig 4A; see S4B Fig).
Because the impairment of PPF ratio decline in prion containing preparations had only
been measured after high frequency stimulation (HFS) trains utilised to induce LTP, it
remained unclear whether the PPF ratio became disrupted immediately following exposure to
PrPSc. To determine if PrPSc may directly impair PPF independent of LTP expression, PPF
was measured before (PPF1A) and shortly after (PPF1B) exposure to cM1000 without HFS.
Baseline recordings were temporarily disrupted during the five-minute exposure to cNBH and
cM1000 (maximal at ~15 minutes of recording) but quickly recovered to normal baseline lev-
els (S4E Fig). Interestingly, the PPF ratio after exposure to cM1000 did not differ from cNBH,
nor did the PPF ratio decline over the next ~ 50 minutes (Fig 4B; n = 8), suggesting that PrPSc
does not appear to directly impair Pr and that the mechanisms underlying disruption of Pr by
PrPSc are only manifested in the context of induction and expression of LTP.
PrPSc appears to disrupt post-tetanic potentiation in WT hippocampal slices by impair-
ing the action potential dependent replenishment of the readily releasable pool (RRP) of
vesicles during HFS trains, while Pr and mechanisms of neurotransmitter release remain
normal. In addition to the PPF ratio, PTP was another pre-synaptic parameter assessed imme-
diately after HFS trains. Relative to appropriate negative controls where PTP was not affected
compared with aCSF controls (see S4C Fig), cM1000, cMU02, and MoRK13-Inf significantly
disrupted PTP, further supporting that pre-synaptic impairment may be a key component of
the acute synaptotoxicity, which was evinced by HFS (Fig 4C). Similar to the LTP impairment,
the PTP disruption was age independent up to 11 months old (see S4D Fig). Further, PTP dis-
ruption was still evident when using PK+M1000 and PK+IP-M1000 (Fig 4C; S4D Fig), support-
ing that this PTP disruption also appears directly associated with modestly PK-resistant PrPSc.
Noteworthy, however, in contrast to the significant rescue of both LTP and PPF, the PTP
remained significantly impaired when exposed to dM1000 (Fig 4C; see S4D Fig), thereby further
suggesting a possible enhanced pre-synaptic vulnerability to the acute synaptotoxicity possibly
linked to the residual PrPSc, including some multimeric species (Fig 3G & 3H) in these prepara-
tions. PTP is strongly influenced by the Pr, RRP size, RRP depletion rate, and RRP replenish-
ment rate, which are all action potential-elicited Ca2+-dependent functions in the pre-synaptic
terminal during HFS trains [44]. Detailed electrophysiological analyses showed the Pr (Fig 4D)
and RRP depletion rate (Fig 4E & 4F) appeared normal across the three HFS trains in both
cM1000 and dM1000 relative to cNBH and dNBH, respectively demonstrating that mechanisms
of neurotransmitter release are probably not impaired in PTP disruption; however, the size of
the RRP, while normal in train 1 (T1) became progressively and significantly diminished in
trains 2 (T2) and 3 (T3) in both cM1000 (n = 17) and dM1000 (n = 7) (Fig 4G & 4H) as a result
of significant disruption of RRP replenishment in T2 and T3 (Fig 4I & 4J), thereby probably
contributing to the disruption of PTP after exposure to both M1000 preparations.
PrPSc acute synaptotoxicity in WT hippocampi is associated with decreased expression
levels of pre- and post-synaptic components crucial for LTP induction and maintenance.
Altered expression levels of core synaptic components integral for maintaining normal
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Fig 4. Prion acute synaptotoxicity demonstrates enhanced pre-synaptic vulnerability in WT hippocampal slices. (A)
Normal PPF ratio reductions (the ratio becomes significantly reduced in PPF2 relative to PPF1) were obtained in slices after
LTP induction and exposure to all negative controls: cNBH (for cM1000 treatments in 12-week old [p<0001] and
11-month old mice [p = 0.0008]; cMU02 treatment [p = 0.0104]); dNBH (p = 0.0017); PK+NBH (p = 0.0182); PK+IP-NBH
(p = 0.0002); and MoRK13-Un (p = 0.0170). Conversely, PPF ratio in slices treated with cM1000 (both in 12-week and
11-month old mice), cMU02, MoRK13-Inf, PK+M1000, and PK+IP-M1000 was not reduced in PPF2 relative to PPF1,
showing poor Pr associated with the LTP disruption. The PPF ratio was normal in dM1000 (p = 0.0013) concomitant with
the recovery of LTP. (B) Treatment of slices with cM1000 without inducing LTP expression did not affect PPF ratios
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synaptic functions, have been frequently reported as features of Aβ42 toxicity [45]. The disrup-
tion we observed, especially the PPF ratio and PTP disruption, suggested the likelihood of
perturbed expression of key pre-synaptic markers. Western blotting of WT hippocampi with
impaired PPF2 ratios revealed a significant down-regulation of the synaptic vesicle proteins
synaptophysin and VGLUT1, relative to hippocampi with normal PPF2 ratios (Fig 5A & 5D).
It is important, however to acknowledge that because PTP reflects short-term synaptic potenti-
ation, which lasts only a few minutes after HFS trains, and the tissues were harvested following
LTP expression, these altered pre-synaptic markers represent the pre-synaptic concomitants of
LTP impairment that persisted throughout the expression of LTP.
Other synaptic proteins including the NR2A- and NR2B-subunits of NMDAR and the
GluA2 subunit of AMPAR, as well as pERK, pCREB (Fig 5B, 5C & 5D) were also down-regu-
lated in WT hippocampi manifesting impaired LTP, thereby supporting that the PrPSc acute
synaptotoxicity is not exclusively pre-synaptic. Although NMDAR are required for both pre-
and post-synaptic functions, they are clearly most abundant post-synaptically [46]. Therefore,
the reduced expression levels of NR2A and NR2B as well as GluA2 suggest post-synaptic dis-
ruptions in hippocampal glutamatergic synapses. The decreased expression levels of pERK and
the transcription factor pCREB that activate pathways for production of synaptic proteins [47]
further supports post-synaptic disruption. This suggests that pERK and pCREB are likely
downstream effectors of PrPSc acute synaptotoxicity contributing to diminished expression of
other synaptic proteins. Procaspase-3 was also down-regulated in hippocampi with impaired
LTP (n = 5; Fig 5E & 5F), although the amount of active caspase 3 was normal (n = 5; Fig 5E &
5F), indicating that intracellular signalling cascades downstream of caspase-3 activation were
probably normal, whereas mechanisms of generating procaspase-3 were conceivably dis-
rupted. Importantly, expression levels of all these synaptic proteins were unaltered in hippo-
campal slices treated with dM1000 (Fig 5A–5F), correlating with the rescue of LTP and PPF
ratio and despite persisting impairment of PTP. Moreover, post-synaptic markers such as
PSD95 and Fyn remained unaltered in cM1000 (Fig 5C & 5D), suggesting that while PrPSc
acutely disrupted post-synaptic function contributing to LTP impairment, it is less likely there
was an acute loss of dendritic spine compartment volume over the very short time-course of
our observations.
PrPSc remains acutely synaptotoxic to PTP and LTP independent of PrPC
expression
Ongoing PrPC expression is required for the sustained propagation of transmissible and neu-
rotoxic PrPSc to cause prion disease [27, 31]. PrPC has also been described as a receptor for
transducing soluble, oligomeric Aβ42 synaptotoxicity [26]. To determine if PrPSc acute
relative to slices treated with cNBH. (C) Relative to appropriate negative controls, PTP was significantly disrupted after
cM1000 treatment of slices from 12-week-old (p = 0.0144) and 11-month-old (p = 0.0006) mice. Similar PTP disruption was
obtained following treatment with cMU02 (p = 0.0391), MoRK13-Inf (p = 0.0172), dM1000 (p = 0.0062), PK+M1000
(p = 0.0359), and PK+IP-M1000 (p<0.0001). (D) The Pr during the HFS trains was normal in both cM1000 and dM1000
relative to cNBH and dNBH controls, respectively where the Pr became significantly increased (determined by the P1 to P2
ratio in each train) in T2 and T3 relative to T1. (E & F) Consistent with the normal Pr, the rate of RRP depletion was normal
across three HFS trains in both cM1000 (E) and dM1000 (F), where the time constant of decay between P3 and P9 in each
train was not different between cNBH and cM1000, as well as between dNBH and dM1000. (G & H) The size of RRP
(determined by the Y-intercepts of the linear fit of the last four pulses of HFS) became significantly diminished at T3 in
cM1000 (G) and dM1000 (H) relative to cNBH (G) and dNBH (H). (I & J) This reduction in RRP size was caused by a
significant impairment of the RRP replenishment (indicated by the increase in the RRP size between trains) to refill the
RRP at T3 in both cM1000 (I) and dM1000 (J) compared with cNBH (I) and dNBH (J). The reduction in RRP size
contributed directly to the impairment of PTP. (A-D) Examples of raw fEPSP traces are provided as insets. Data are
presented as ± SEM. p<0.05, p<0.01, p<0.001, p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g004
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Fig 5. Altered expression levels of key pre- and post-synaptic markers correlate with synaptic dysfunction in WT
hippocampi. Following induction of LTP, hippocampi were homogenized and biochemically analysed for key synaptic
markers. (A & D) Hippocampi treated with cM1000 [c] expressed reduced levels of pre-synaptic markers, synaptophysin
(p = 0.0280) and VGLUT1 (p = 0.0108), relative to those treated with cNBH [c]. Conversely, WT hippocampi treated with
dM1000 [d] were associated with unaltered synaptophysin and VGLUT1 levels relative dNBH [d]. (B & D) NR2A/B-
containing NMDAR were also reduced in hippocampi treated with cM1000 (NR2A: p = 0.0012; NR2B: p = 0.0003) relative to
those treated with cNBH, with unaltered levels when employing dM1000 and dNBH. GluA2-containing AMPAR were also
reduced in hippocampi treated with cM1000 relative to those treated with cNBH (p = 0.0077), with unaltered levels when
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hippocampal synaptic disruption requires PrPC expression, the synaptotoxicity of cM1000 was
assessed using slices derived from 12-week-old PrPo/o mice. The degree of LTP impairment in
these PrPo/o hippocampal slices following exposure to cM1000, was less marked but broadly
comparable to that observed in WT slices (Fig 6A & 6B; see S5E Fig), thereby demonstrating
that PrPC expression is not crucial for the acute synaptotoxic mechanisms underlying disrup-
tion of LTP by PrPSc. Notably though, in contrast to WT slices treated with cM1000 (Fig 4A),
the PPF2 ratio significantly decreased following HFS trains, thereby mirroring what occurred
with exposure to cNBH (Fig 6C; see S5G Fig) although PTP remained significantly impaired
in PrPo/o slices following cM1000 treatment (Fig 6D; see S5F Fig). These findings suggest that
any pre-synaptic dysfunction following HFS trains may also be at least partly PrPC indepen-
dent and that because the Pr was not significantly diminished during LTP expression the
mechanisms of any PrPSc pre-synaptic dysfunction in PrPo/o slices are subtly but notably dif-
ferent compared with WT mice. Of further noteworthiness, the LTP, PTP, and PPF ratio in
PrPo/o slices treated with cNBH were not affected compared with PrPo/o slices treated with
aCSF (see S5 Fig), demonstrating no background synaptotoxicity from crude brain homoge-
nates and importantly, the LTP, PTP, and PPF ratio obtained from PrPo/o and WT slices
superfused with aCSF only were not different (see S5 Fig), in keeping with previous reports of
no significant effect of the loss of PrPC on the Schäffer collateral pathway synaptic functions in
young PrPo/o mice [10].
Different mechanisms appear to underlie PrPSc acute synaptotoxicity in
PrPo/o hippocampal slices relative to WT slices
Given the likely fundamental role PrPC plays in synaptic functions [7, 9], it is possible that the
molecular components of the pre- and post-synaptic compartments are fundamentally altered
to compensate the neuro-developmental absence of PrPC in an attempt to maintain normal
synaptic functions, thereby perhaps supporting the possibility of different or distinct mecha-
nisms for any PrPSc acute synaptotoxicity. The disruption of PTP and LTP in PrPo/o hippo-
campal slices exposed to cM1000 suggested both pre- and post-synaptic impairments,
respectively. The Pr during T2 and T3 of the HFS trains showed a normal decline comparable
to that observed for cNBH (Fig 6E) and similar to what occurred after exposure of WT slices
to cM1000 (Fig 4D). Importantly however, the RRP replenishment also appeared impaired in
PrPo/o slices similar to that observed in WT slices (Fig 6G) leading to a significant reduction
in RRP size during T3 (n = 11; Fig 6H), thereby probably disrupting PTP (n = 11; Fig 6D).
Unexpectedly, the RRP during T1 was minimally but significantly larger in the PrPo/o slices
exposed to cM1000 supporting the possibility of enhanced neurodevelopmental compensation
to the absence of PrPC made apparent in such slices upon exposure to PrPSc (n = 11; Fig 6H)
explaining why a significant impairment of RRP replenishment was not apparent until T3.
Biochemical analysis of the cM1000 treated PrPo/o hippocampi revealed significantly
decreased levels of synaptophysin (Fig 6I & 6J) akin to what was observed in WT slices (Fig 5A
& 5D), further supporting a pre-synaptic component to the PrPSc acute synaptotoxicity in
employing dM1000 and dNBH. (C & D) Expression levels of pERK and pCREB were reduced in slices exposed to cM1000
(pERK: p = 0.0339; pCREB: p = 0.0108) relative to cNBH but were unaltered when employing dM1000 and dNBH. PSD95
remained unaltered after exposure to both cM1000 and dM1000 supporting no loss of pre-existing synapses in prion acute
synaptotoxicity. Fyn levels remained unaffected after treatment with either cM1000 or dM1000. (E & F) Relative to cNBH,
cM1000 reduced expression levels of procaspase 3 (p = 0.0028) with unaltered production of the active form, thereby
significantly reducing the pro- to active caspase 3 ratio (p = 0.0083). The pro-caspase 3 expression level was unaltered after
treatment with dM1000 compared with dNBH with a normal pro- to active caspase 3 ratio. (A-C, E) Molecular weight
markers are provided at right. Data are presented as ± SEM. p<0.05, p<0.01, p<0.001, p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g005
Prion acute synaptotoxicity is largely driven by protease-resistant PrPSc species
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007214 August 8, 2018 19 / 37
Fig 6. Acute PrPSc synaptotoxicity is largely PrPC independent. Hippocampal slices derived from PrPo/o mice were used
for these experiments. (A) cM1000 superfused over slices approximately 20 minutes prior to HFS trains caused significant
impairment of LTP with (B) average LTP reduced by ~37 ± 12% (n = 10) compared with cNBH. (p = 0.0046). (C) A normal
Pr during LTP in slices exposed to both cNBH and cM1000, where PPF2 (after treatment and LTP) became significantly
reduced compared with the PPF1 (before treatment and LTP) (p = 0.0003). (D) PTP was significantly disrupted after
exposure of slices to cM1000 relative to cNBH (p = 0.0133). (E) A normal increase in the Pr during HFS trains despite
treatment with cM1000, demonstrated by a significant increase in the P1 to P2 ratio in T2 and T3 relative to T1. (F) A
normal depletion rate of RRP after cM1000 exposure relative to cNBH across the three HFS trains, wherein the time
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these slices and implying that the disruption of synaptophysin in WT hippocampal slices was
probably PrPC independent. In contrast, PrPSc exposure did not affect expression of VGLUT1
(Fig 6I & 6J), once again supporting that pre-synaptic functions in PrPo/o slices are probably
less and differentially susceptible to PrPSc acute synaptotoxicity compared with WT slices.
Additionally, expression levels of NR2A and NR2B and GluA2 remained unaffected by PrPSc
in PrPo/o hippocampi, also supporting the likelihood of different post-synaptic pathophysio-
logical mechanisms of PrPSc acute synaptotoxicity (Fig 6I & 6J) and implying that the down-
regulation of VGLUT1, NR2A, NR2B, and GluA2 in WT hippocampal slices is PrPC expres-
sion dependent. Nevertheless, importantly both pERK and pCREB were significantly reduced
(Fig 6I & 6J) in PrPo/o slices, underscoring that although there are likely to be nuanced differ-
ences in the pathways sub-serving acute synaptic dysfunction in PrPo/o hippocampi, there
appears to be overlap in the final effector pathway of post-synaptic dysfunction similar to WT
hippocampi. PSD95 remained unaltered in PrPo/o hippocampi again supporting no net loss of
the dendritic compartment associated with this acute synaptotoxicity over the very short time-
frames of our experiments (Fig 6I & 6J). Interestingly, Fyn levels were significantly reduced in
PrPo/o hippocampi after treatment with cM1000 (Fig 6I & 6J), supporting post-synaptic dis-
ruption in PrPo/o slices.
WT and PrPo/o hippocampal slices display similar sensitivity to prion
acute synaptotoxicity
To determine if WT and PrPo/o hippocampal slices display similar sensitivity to prion acute
synaptotoxicity, the dose-response relationships of LTP and PTP were analysed following
exposure to a dilution series of cM1000 including 1% (w/v), 0.5% (w/v; as utilised previously),
0.25% (w/v) and 0.1% (w/v). In addition, the approximate level of abnormal or PK-resistant
PrPSc in various preparations employed in our electrophysiological studies was determined.
The 1% homogenates caused non-specific technical difficulties with electrophysiological test-
ing precluding their use (S6A Fig). In 0.5% cM1000, there was ~0.168 ± 0.020 μg/mL total PrP
including ~0.094 ± 0.020 μg/mL at least modestly PK-resistant PrPSc (n = 3; Fig 7A and 7B). In
0.25% cM1000 (n = 3), there was ~0.066 ± 0.003 μg/mL total PrP including ~0.026 ± 0.002 μg/
mL at least modestly PK-resistant PrPSc, while in 0.1% cM1000 there was ~0.015 ± 0.004 μg/
mL total PrP with ~0.006 ± 0.0003 μg/mL at least modestly PK-resistant PrPSc (n = 3; Fig 7A
and 7B).
For WT hippocampal slices, relative to cNBH controls, the LTP was significantly disrupted
in a dose-dependent manner (p<0.0001; One-way ANOVA with Bonferroni correction for
multiple comparisons) wherein non-PK digested 0.5% (n = 6) and 0.25% (n = 5) cM1000
constant of decay (Tau = 1/K) between P3 and P9 in each HFS train was not different between slices treated with cNBH and
cM1000. (G) The size of RRP (determined by the Y-intercepts) in slices treated with cM1000 were modestly but
significantly increased in T1 relative to slices treated with cNBH (cNBH: 173 ± 16, cM1000: 269 ± 15; p = 0.0111),
demonstrating distinctive mechanisms of the acute synaptotoxicity in PrPo/o hippocampi; however, the RRP size of slices
treated with cM1000 became significantly reduced in T3 relative to cNBH. (H) The RRP refill in slices treated with cM1000
(estimated by the increase in RRP size between trains) was normal between T1 and T2 (significantly increased from
169 ± 15 in T1 to 450 ± 28 in T2; p = 0.0048), but failed to significantly increase between T2 (450 ± 28) and T3 (461 ± 29)
(G), thereby reflecting a significantly reduced RRP size. (I & J) Western blotting of PrPo/o hippocampi treated with cM1000
revealed reduced level of synaptophysin (p = 0.0024), but not VGLUT1. Exposure to cM1000 significantly reduced
hippocampal pERK (p = 0.0432) and pCREB (p = 0.0034) relative to hippocampi treated with cNBH. Expression levels of
NR2A and NR2B-containing NMDAR, and GluA2-containing AMPAR were unaffected by cM1000 treatment. PSD95 and
Fyn levels were unaltered by cM1000 (p = 0.0168). (I & K) Pro-caspase 3 and production of its active form were unaltered in
PrPo/o hippocampi treated with cM1000 relative to cNBH. (I) Molecular weight markers are provided at right. (A, C, D, E)
Examples of raw fEPSP traces are provided as insets. Data are presented as ± SEM. p<0.05, p<0.01, p<0.001,
p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g006
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Fig 7. Crude M1000 brain homogenate acute synaptotoxicity dose-response relationships and estimation of total
PrP and PK-resistant PrPSc in preparations used in electrophysiology experiments. A dilution series of
recombinant full-length mouse PrP was western blotted (probed with 8H4 monoclonal antibody) and analysed with
densitometry to generate a standard curve with aliquots of preparations utilised in electrophysiology experiments run
on the same gel. (A) Quantification of levels of total PrP species (without PK treatment) in 0.5% (w/v), 0.25% (w/v),
and 0.1% (w/v) cM1000, as well as in 0.5% dM1000 (PrP immuno-depleted cM1000). (B) Relative levels of at least
modestly PK-resistant PrPSc (after treatment with 5μg/mL PK for 1 hour at 37˚C) in 0.5% (w/v), 0.25% (w/v), and 0.1%
(w/v) cM1000, as well as in 0.5% (w/v) PK+M1000 and 0.5% (w/v) PK+IP-M1000. (C & D) Percentage of LTP and
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significantly impaired LTP (0.5% p<0.0001, impaired by 53 ± 9%; 0.25% p = 0.0195, impaired
by 30 ± 2%), while it was unaffected by the 0.1% cM1000 (n = 5; Fig 7C). Similarly, PTP in WT
hippocampal slices was significantly impaired in a dose-dependent manner (p = 0.0039; One-
way ANOVA with Bonferroni correction for multiple comparisons) following treatments with
the same dilutions of cM1000 wherein both 0.5% (n = 6) and 0.25% (n = 5) cM1000 were sig-
nificantly toxic to PTP (0.5% p = 0.0073, impaired by 30 ± 6%; 0.25% p = 0.0270, impaired by
26 ± 7%), while 0.1% cM1000 did not adversely affect PTP (n = 5; Fig 7D). Hence, these results
demonstrated a correlation between the levels of PK-resistant PrPSc and the degree of LTP and
PTP dysfunction with a threshold level of at least modestly PK-resistant PrPSc > ~0.006 μg/ml
being toxic to PTP and although acknowledging a probable non-uniform immuno-depletion
across the spectrum of PrP species in dM1000 a level >~0.014 μg/ml was toxic to LTP. Levels
of at least modestly PK-resistant PrPSc in 0.5% PK+M1000 and PK+IP-M1000 that were signif-
icantly toxic to LTP and PTP were ~0.094 ± 0.020 μg/mL (n = 3) and 0.057 ± 0.013 μg/mL
(n = 3), respectively.
For PrPo/o slices relative to cNBH controls, a similar dose-dependent decline in LTP and
PTP was observed (n = 5 each; p = 0.0027; One-way ANOVA with Bonferroni correction for
multiple comparisons). The 0.5% cM1000 reduced LTP significantly by 58 ± 8% (p = 0.0003),
while 0.25% impaired LTP by 48 ± 10% (p = 0.0018); however, 0.1% cM1000 did not signifi-
cantly disrupt LTP (Fig 7E). Parallel dose-dependent dysfunction was observed with PTP fol-
lowing exposure of PrPo/o hippocampal slices to 0.5%, 0.25%, and 0.1% cM1000, respectively
(n = 5 each; p = 0.0027; One-way ANOVA with Bonferroni correction for multiple compari-
sons). Compared to cNBH controls, both 0.5% and 0.25% cM1000 significantly disrupted PTP
(0.5% reduced PTP by 32 ± 8%, p = 0.0135; 0.25% reduced PTP by 39 ± 6%, p = 0.0023); how-
ever, 0.1% cM1000 was not significantly toxic to PTP (Fig 7F). Overall, the results were similar
to those obtained in WT hippocampal slices, thereby implying that the prion acute synapto-
toxicity in PrPo/o hippocampal slices reported in this current study was not due to an altered
sensitivity.
Discussion
Herein we report the acute synaptotoxicity of ex vivo, prion-containing preparations and
provide important new molecular pathophysiological insights. Utilising a number of experi-
mental approaches, our findings revealed that: (1) PrPSc (particularly at least modestly PK-
resistant isoforms most likely as multimeric species) is directly synaptotoxic; (2) that the acute
PTP impairments (calculated as described in Methods) following exposure of 12-week old WT hippocampal slices to
non-PK treated 0.5% (w/v), 0.25% (w/v), and 0.1% (w/v) cM1000 compared to 0.5% (w/v) cNBH controls (One-way
ANOVA with Bonferroni correction for multiple comparisons [LTP: p<0.0001; PTP: p<0.0001]). In 0.5% (w/v)
cM1000, LTP and PTP were significantly impaired by 53 ± 9% and 30 ± 6%, respectively. In 0.25% (w/v) cM1000, LTP
and PTP were significantly impaired by 30 ± 2% and 26 ± 7%, respectively. In 0.1% (w/v) cM1000, LTP and PTP were
not significantly impaired, reduced by only 19 ± 6% and 0.1 ± 9%, respectively. Percentages of LTP and PTP
impairment in WT hippocampal slices following exposure to 0.5% dM1000, PK+M1000, and PK+IP-M1000 were also
compared to 0.5% (w/v) cNBH controls (One-way ANOVA with Bonferroni correction for multiple comparisons
[LTP: p<0.0001; PTP: p<0.0039]). In 0.5% (w/v) dM1000, the LTP was not impaired significantly (reduced by
14 ± 7%) while PTP was significantly impaired by 38 ± 3%. In 0.5% (w/v) PK+M1000, LTP and PTP were significantly
impaired by 48 ± 7% and 26 ± 7%, respectively. In 0.5% (w/v) PK+IP-M1000, LTP and PTP were significantly
impaired by 59 ± 5% and 36 ± 5%, respectively. (E & F) Percentage LTP and PTP impairments following exposure of
12-week old PrPo/o hippocampal slices to non-PK treated 0.5% (w/v), 0.25% (w/v), and 0.1% (w/v) cM1000 compared
to 0.5% (w/v) cNBH controls (One-way ANOVA with Bonferroni correction for multiple comparisons [LTP:
p<0.0002; PTP: p<0.0027]). In 0.5% (w/v) cM1000, LTP and PTP were significantly impaired by 58 ± 8% and 32 ± 8%,
respectively. In 0.25% (w/v) cM1000, LTP and PTP were significantly impaired by 48 ± 10% and 39 ± 6%, respectively.
In 0.1% (w/v) cM1000, LTP and PTP were not significantly impaired (reduced by only 15 ± 7% and 13 ± 5%,
respectively). Data are presented as ± SEM. p<0.05, p<0.01, p<0.001, p<0.0001.
https://doi.org/10.1371/journal.ppat.1007214.g007
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synaptotoxicity was similar across the two prion strains examined and appears independent
of tissue source of prions when balanced for PrPSc levels; (3) the acute synaptotoxicity is not
reliant on hippocampal PrPC expression albeit with noteworthy molecular and electrophysio-
logical differences in the presence or absence of PrPC; and (4) both pre- and post-synaptic
functions are deleteriously affected, with the possibility of enhanced vulnerability of the for-
mer compartment.
Although previous studies have demonstrated clear correlations between the presence of
PrPSc and the onset of neuropathological changes [38], disruption of LTP at the hippocampal
CA1 region of mice inoculated with ME7 [14] and impairment of memory and learning [15],
our studies offer compelling evidence for the direct synpatotoxicity of PrPSc, especially PK-
resistant species derived from brains of terminally sick animals. First, we demonstrated that
modest PK treatment of ex vivo preparations (sufficient to digest all PrPC) did not attenuate
the acute synaptotoxicity, with the impairment of LTP similar to that observed with cM1000.
These protease digested preparations demonstrated substantial selective enrichment of PrPSc
(see S3H Fig columns i & ii) analogous to that recently reported in another model assessing
acute PrPSc synaptotoxicity [25]. Next, we demonstrated that immuno-depletion of PrP species
from cM1000 substantially and proportionally mitigated the acute synaptotoxicity such that
LTP was restored to levels not different to dNBH. Additionally, we demonstrated that the use
of reconstituted, PK-eluted, immuno-precipitated PrPSc generated from crude brain prepara-
tions achieved full acute synaptotoxicity equivalent to that observed for cM1000, with addi-
tional biochemical characterisation of these preparations once again demonstrating significant
selective enrichment of PrPSc (see S3H Fig columns iii & iv). Finally, size fractionation studies
revealed that in addition to reducing total PrP species in dM1000, the spectrum of PK-resistant
PrPSc species was altered and the levels of multimeric PrPSc species specifically decreased in
dM1000 correlating with the rescue of LTP. Notably, the acute synaptotoxicity of cM1000 and
PK+IP-M1000 clearly correlated with elevated levels of multimeric PK-resistant PrPSc species.
Our electrophysiology assay demonstrated that brains from terminally ill mice harbouring
either M1000 or MU02 prions contain acutely synaptotoxic species. Interestingly, the degree
and spectrum of synaptic dysfunction caused by these two different prion strains were indis-
tinguishable, implying that the acute synaptotoxicity may be a generic property of PrPSc spe-
cies and independent of the specific prion strain; the study of additional prion strains would
confirm this speculation. Importantly, the degree of LTP impairment caused by both M1000
and MU02 strains was comparable to that recorded in the hippocampal CA1 region of ME7
scrapie-infected mice between 125 to 160 days post-inoculation [14], underscoring the biologi-
cal validity of our findings. In further support of the biological relevance of our findings, the
estimated level of misfolded or PK-resistant PrPSc in our 0.5% M1000 brain homogenates was
~0.094 ± 0.020 μg/mL, which despite methodological differences, falls well within the range of
modestly (10 μg/ml) PK-resistant PrPSc levels determined by Mays et al. [48] in terminal whole
brain homogenates of several prion animal models; however, uncertainty persists as to what
precise levels would actually be found localised to synapses. Moreover, our results demon-
strated a correlation between the levels of PK-resistant PrPSc and the degree of LTP and PTP
dysfunction with a threshold level of at least modestly PK-resistant PrPSc > ~0.006 μg/ml
appearing toxic to PTP while a level>~0.014 μg/ml appears toxic to LTP.
A recent study by Fang et al describes retraction and depletion of dendritic spines after 24
hours of exposure to PrPSc preparations [25]. In keeping with the importance of LTP in the
generation and maintenance of dendritic spines, our observations may offer insights into
the molecular pathogenesis underpinning at least some of the described dendritic spine mor-
phological changes [12, 49, 50]. Though it is known that cellular expression is not required
for uptake of PrPSc aggregates [51] and in vivo neurons not expressing PrPC develop
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morphological abnormalities typical of prion disease with continued exposure to PrPSc over
many weeks [52], in noteworthy contrast to this and our electrophysiology studies, Fang et al
reported complete dependence on neuronal PrPC expression for toxicity. There are several
potential explanations, which from our cM1000 serial dilution studies do not relate to an
altered sensitivity of PrPo/o hippocampal slices. Firstly, our model assessed synaptic dysfunc-
tion within a period of approximately 45 minutes following exposure to PrPSc containing
preparations, whereas the time-frame for assessment in the study of Fang et al was at approxi-
mately 24 hours. The importance of ongoing neuronal PrPSc propagation to provide continued
PrPSc exposure for effective pathogenesis is exemplified by the reported rapid and complete
reversal of morphological, hippocampal CA1 region neurophysiological and behavioural
abnormalities shortly after neuronal PrPC expression is abrogated in the setting of established
prion infection [53, 54]. The prompt reversibility of synaptic spine loss has also been reported
in relation to AD models employing naturally secreted Aβ oligomers if the toxic species is
completely removed [55]. Such observations support that the CNS has evolved powerful com-
pensatory and recuperative mechanisms and it is highly likely that a single brief exposure to a
synaptoxin only causes transient dysfunction that probably does not inevitably lead to sus-
tained failure and loss of the synapse, especially if the level of toxin exposure is not extreme.
Therefore we speculate in the Fang et al model that an additional approximately 23 hours in
the absence of any de novo PrPSc production from endogenous PrPC may have allowed effec-
tive activation of neuro-protective or adaptational responses in PrPo/o tissues, including pro-
gressive clearance or degradation of exogenous PrPSc, and that persisting neuronal exposure
above threshold levels is required to achieve sustained dendritic retraction and pruning when
assessing synaptotoxicity over the longer 24 hour period. Secondly, other methodological dif-
ferences, such as in the techniques for generating ex vivo PrPSc preparations (eg detergents
plus serial ultracentrifugation versus IP plus PK digestion), the tissues used for toxicity studies
(primary hippocampal neuronal cultures versus ex vivo hippocampal slices) and the primary
metric for assessing toxicity (endogenous dendritic spine size/number versus induced LTP
amplitudes), may collectively contribute to the observed discrepancies. Finally, and notwith-
standing the aforementioned neurobiological and technical considerations, although LTP
impairment was observed in PrPo/o slices, subtle but potentially important differences were
observed in other facets of synaptic function, as well as in changes to key synaptic proteins.
Namely, while PTP was also adversely affected by PrPSc preparations in addition to LTP in
PrPo/o hippocampi, the PPF ratio showed a normal decline after LTP with VGLUT1, NR2A,
NR2B, GluA2 and procaspase 3 levels unchanged. These discrepancies with WT hippocampi
exposed to PrPSc suggest the possibility of PrPC-independent mechanistic pathways contribute
to LTP and PTP impairment, which may not have been easily discerned in the setting of PrPC
expression and further underscore uncertainty of how such differences may relate to the
retraction and loss of dendritic spines over a longer period of 24 hours.
The possible impact of age associated with the lack of PrPC expression were important con-
siderations in our studies. Because the absence of PrPC has been reported to be linked with
age-dependent impairment of hippocampal synaptic function in 8–15-month old mice [10],
we mitigated this potentially confounding phenomenon by only using hippocampal slices
from young PrPo/o mice. Notably, our findings reproduced those previously reported in a
number of studies [10, 56, 57] with young PrPo/o mice exhibiting hippocampal CA1 synaptic
functions congruent with aged-matched WT mice although contrary findings have been
reported [58, 59], which may partly relate to variations in electrophysiology techniques
employed. Also of interest, WT C57BL/6 mice 9–12 months old have been reported to express
age-dependent deficits in learning following treatment with neurotoxic Aβ1–42 [60], thereby
suggesting that older WT mice of this age may also be more susceptible to synaptic impairment
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associated with prion-infected preparations. Our studies however, revealed age-independent
disruption of hippocampal synaptic function by cM1000 up to 11 months of age.
Synaptic physiology is complex and multi-facted making the achievement of precise
understanding of pathophysiological changes through electrophysiological interrogation a
considerable challenge. As part of validating the acute synaptotoxicity of PrPSc, our detailed
electrophysiological analyses suggest a possible enhanced pre-synaptic vulnerability, exempli-
fied by the impairment of PTP, although contributions to LTP disruption from post-synaptic
dysfunction seem likely as discussed below. A technical limitation of our assessments to probe
pre-synaptic impairments was the lack of inclusion of specific GABA receptor antagonists.
The 20 millisecond inter-stimulus intervals used to determine PPF ratios and the 10 millisec-
ond intervals employed for HFS are very short, making contributions from GABAB receptors
quite unlikely but leaves open the possibility that GABAA receptor related inhibitory post-syn-
aptic potentials could have influenced some of the measured synaptic phenomena in ways we
have not fully accounted for. Consequently, the absence of GABAA receptor blockade in our
experiments utilising fEPSP amplitudes to infer pre-synaptic pathophysiology allows for some
potential inaccuracy in the derived measurements of Pr and RRP and precludes our studies
from being definitive in this regard. Nevertheless and notwithstanding such caveats, to try
to offer an understanding of the basis of the impairment of PTP, our analyses are consistent
with impairment of action potential-dependent mechanisms of RRP replenishment, made
obvious by the physiological stress imposed by repeated HFS trains used to induce PTP
whereby there appeared to be a progressive deterioration of RRP replenishment leading to a
significant reduction of RRP size and consequently a reduced PTP. In addition, because the Pr
and the depletion rate of RRP during HFS trains appeared normal these could exacerbate the
dysfunction of RRP replenishment [61] and the reduction of PTP. Further, this suggestion of
pre-synaptic disruption was observed in WT and PrPo/o mice, supporting that PrPC expres-
sion appears irrelevant to this dysfunction. The observation that immuno-depletion of total
PrP species by ~77% only rescued LTP but not PTP with the ongoing PTP impairment also
appearing to be due to deficiency of RRP replenishment leading to a reduction in RRP size,
suggests that the modest amount of PK-resistant PrPSc, including multimeric species, remain-
ing after immuno-depletion appears sufficient to cause this disruption although contributions
from a non-PrPSc factor cannot be completely excluded. These findings raise the possibility
that the mechanisms responsible for RRP replenishment during repeated HFS trains appear
highly vulnerable to PrPSc toxicity and more susceptible than LTP. The reduced PTP we
observed appears discordant with results reported in a previous in vivo study of the ME7 prion
strain in which PTP was reported as unaffected over the mid-incubation period [14]. We
believe this apparent discrepancy is methodological in basis given that careful scrutiny of
the relevant figure from this report reveals consistently lower amplitude initial PTPs in the
prion infected mice similar to what we found. These authors measured PTP at a presumably
varying time point during the first minute after HFS (with the PTP in non-prion infected mice
decreasing rapidly after the first stimulation post-HFS) while we systematically utilised the
first response immediately after serial HFS to estimate PTP.
The apparent disruption of the PPF ratio following HFS in WT slices is consistent with
insufficient Pr during the maintenance of LTP suggesting pre-synaptic impairment following
exposure to synaptotoxic PrPSc [62]. Additionally, expression levels of pre-synaptic markers,
synaptophysin and VGLUT1, were consistently decreased in WT hippocampi manifesting dis-
rupted LTP. Although synaptophsyin has been shown to be less important in neurotransmitter
release [63], previous studies have uncovered that synaptophysin is significantly recruited for
LTP expression and generally required for synaptic plasticity without involvement in Pr main-
tenance [64, 65]. Hence, this reduced level of synaptophysin is somehow directly concomitant
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with the impairment of LTP, but probably not via diminishing Pr. Noteworthy are previous
reports of significantly reduced synaptophysin expression levels in the hippocampi of WT
(C57BL/6) mice inoculated with three different prion strains: ME7, 79A, and 22L [66].
VGLUT1 instead plays substantial roles in the packaging of glutamate into pre-synaptic vesi-
cles and maintaining normal Pr, wherein neurons lacking VGLUT1 have reduced Pr [67].
Therefore, we believe that the reduced expression levels of both synaptophysin and VGLUT1
directly contributed to the disruption of LTP, whereas only the loss of VGLUT1 was probably
associated with our postulated impairment of Pr after LTP induction. Unexpectedly, we
observed decreased synaptophysin levels but preserved VGLUT1 levels in PrPo/o slices corre-
lating with the normal Pr observed following LTP. This suggests that the loss of VGLUT1 in
WT hippocampi was PrPC dependent, whereas the loss of synaptophysin in these hippocampi
is PrPC independent. The preservation of the Pr and PPF ratio following HFS in PrPo/o slices
exposed to synaptotoxic PrPSc suggests that any pre-synaptic impairment associated with dis-
ruption of PTP is a primary pathophysiologic driver of the LTP dysfunction in both WT and
PrPo/o slices. Nevertheless, because HFS also cause post-synaptic changes such as receptor
activation, new receptor insertion and terminal expansion, which may collectively alter post-
synaptic sensitivity to released neurotransmitters [12], contributions from post-synaptic dis-
ruptions are likely in the HFS-dependent synaptic dysfunction such as the impairment of LTP.
Variable transient disruption of the baseline during treatments of the hippocampal slices
was observed in our study. Although we are not able to offer a definitive explanation for this
minor technical issue, possible contributing factors, which are not mutually exclusive and may
have occurred in varying combinations, include: i) slight variation in the temperature of some
of the treatments; ii) slight variation in the pH of some of the treatments or slight pH change
during the treatment; iii) slight variation in the depth of the treatment solution in each MEA
recording chamber across experiments; and iv) minor mouse cohort variation in the sensitivity
of hippocampal slices to the treatments. Another issue that could also contribute to variability,
particularly in association with the above first three speculations is subtle variation in position-
ing of the superfusing solution inflow and outflow and the associated flow of solution within
the MEA recording chamber. The MEA recording chambers are circular and this shape is
known to allow some variation in cross-chamber solution flow as the solution can flow around
the circular walls of the chamber rather than inevitably directly across the centre of the cham-
ber; however, despite the occasional transient baseline disruption during treatments, there is
no evidence this phenomenon impacted our recordings or results as HFS for elicitation of LTP
and PTP was not undertaken until fEPSPs had returned to baseline for at least 5 minutes after
the treatment. In addition, the acute synaptotoxic effects of ex vivo PrPSc preparations reported
in our study were not linked to or affected by whether the baseline recording was temporarily
disrupted (such as in Fig 1B cM1000 and 2H PK+M1000) or not disrupted (such as in Figures
IE cMU02; 1K MoRK13-INF, and 2H PK+IP-M1000).
Notwithstanding controversies concerning the exact mechanisms underpinning hippocam-
pal LTP, it is clear that LTP expression involves significant modifications of post-synaptic
properties, particularly activation of extant post-synaptic NMDAR and externalization of new
AMPAR [12, 68]. Our study demonstrated reduced expression levels of NR2A- and NR2B-
containing NMDAR and GluA2-containing AMPAR in WT hippocampi expressing impaired
LTP following exposure to synaptotoxic PrPSc. Although these receptors can be expressed in
both pre- and post-synaptic terminals [69, 70], their considerable numerical predominance
post-synaptically supports that their overall loss was likely to be primarily post-synaptic
[71]. NR2A/B-containing NMDAR are essential for hippocampal synaptic function and the
expression of CA1 LTP [72]; therefore, their loss supports that the disruption of LTP in WT
mice is at least partly dependent on NMDAR disruption. AMPAR also play a critical role in
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maintaining basal synaptic functions and most importantly in LTP expression, where new
AMPAR are inserted into the post-synaptic membrane as part of LTP induction to enhance
the function of active synapses and activate silent synapses [73, 74]. Because the acute PrPSc
synaptotoxicity we observed was HFS-dependent, we postulate that the loss of AMPAR was
mediated predominantly through silent synapses. Of likely relevance to our findings, parallel
losses of NMDAR and AMPAR have been reported in the brains of AD patients [75] directly
correlating with Aβ synaptotoxicity [76]. Unlike in WT slices, NR2A/B-containing NMDAR,
and GluA2-containing AMPAR remained unaltered in PrPo/o hippocampi following exposure
to synpatotoxic PrPSc, implying different mechanisms are responsible for acute PrPSc synapto-
toxicity in PrPo/o compared to WT slices. Importantly, this result infers that the disruptions of
these receptors in WT mice are probably PrPC dependent with the persistent impairment of
LTP in PrPo/o hippocampi suggesting that the alterations of these glutamate receptors are
not the sole determinant of PrPSc acute synaptotoxicity. This finding also suggests that PrPo/o
mice may have higher innate resistance to PrPSc synaptotoxicity through mechanisms which
mitigate acute synaptic dysfunction when studied over longer time frames than we allowed
[77, 78].
Following exposure to PrPSc the key intracellular proteins pERK and pCREB involved in
synaptic plasticity were also down-regulated in slices. Of note, both pERK and pCREB levels
were significantly rescued following immuno-depletion of PrP, supporting a direct synapto-
toxic effect of PrPSc on their function. Offering mechanistic pathway overlap in the disruption
of LTP, these key intracellular synaptic proteins were also reduced in PrPo/o slices supporting
that PrPC-independent impairment through different mechanisms occurs upstream of ERK
and CREB activation. The sustained expression of NR2A and NR2B subunits in PrPo/o slices,
while observing persistently reduced pERK and pCREB levels, supports the notion that activa-
tion of ERK and CREB during LTP induction and maintenance is likely to be independent of
NMDAR activity in hippocampi of PrPo/o mice [79]. Although the activation of NMDAR is
known to mediate the influx of Ca2+ during LTP induction, the activation of ERK and CREB
has also been demonstrated to be independent of NMDAR activity but dependent on L-type
voltage-gated calcium channel (L-VGCC) activation. PrPC may be either directly or indirectly
involved in Ca2+ influx via neuronal L-VGCCs [8, 80], and interact with Fyn to mediate Ca2+
dependent activation of ERK and CREB [81–83]. The absence of PrPC in PrPo/o slices may
increase the vulnerability of L-VGCCs to PrPSc disruption compared with WT mice.
Phosphorylation of ERK is essential for many synaptic functions such as activation of tran-
scription factor CREB to produce more synaptic proteins. This pathway has been implicated
in structural plasticity by which activation mediates formation of new dendritic spines and
thereby contributes to LTP expression in ex vivo hippocampi [84] and memory formation in
vivo [85]. Hence, the diminished levels of these two-key intracellular post-synaptic markers
suggest that the acute PrPSc synaptotoxicity is likely to be associated with impaired production
of new synaptic proteins with associated difficulties maintaining some spines and/or produc-
ing new spines. Of note, inhibition of ERK activity with MAPK/ERK kinase (MEK) inhibitors
prevents dendritic spine growth and acutely disrupts LTP induction [68]. Additionally, pERK
is directly involved in AMPAR insertion into the post-synaptic membrane following HFS,
which is required for both enlarging synapses and activating silent synapses [47, 68, 73].
Hence, the reduced activation of pERK might have contributed to the down-regulation of
AMPAR in WT mice but supports others factors contributing to this change in PrPo/o slices.
Overall, our observations offer new insights into the pathophysiology underlying the acute
synaptic dysfunction of prion disease, generally aligning with reported synaptic disruptions
demonstrated in other neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Hun-
tington’s diseases, all of which consist of both pre-synaptic and post-synaptic impairments
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[86–88]. Our findings suggest an enhanced vulnerability of the pre-synaptic compartment,
especially replenishment of the RRP of vesicles, to PrPSc acute synaptotoxicity although post-
synaptic impairment is likely to contribute to the disruption of short and/or long-term synap-
tic plasticity. We have demonstrated that PrPSc derived from terminal disease brains, particu-
larly modestly PK-resistant most likely multimeric species, are important direct synaptotoxins
in prion disease, with the likelihood of PrPC-independent pathways contributing to acute
PrPSc acute synaptotoxicity.
Supporting information
S1 Table. Primary and secondary antibodies used for immuno-blottings with their appro-
priate dilutions and comparable block buffer, which was either 5% Skim milk (Skm) or
bovine serum albumin (BSA).
(DOCX)
S1 Fig. Methods and data analysis. (A) A schematic flow diagram of how the MEA experi-
ment was done. (1) Mouse brain was sliced into hippocampal slices, (2) incubated at 32˚C for
an hour, (3) loaded onto the MEA (i) that was set-up with a perfusion system and (ii) stimu-
lated the Schäffer collateral pathway through one of the micro-electrodes (black dots; the best
aligned one) to evoke fEPSPs at the stratum radiatum of the CA1 region, and (4) the ampli-
tudes of the fEPSPs were recorded as input-output (IO) curves and paired pulse facilitation
(PPF) before (baseline) and after repetitive high frequency simulation (HFS) and the treatment
of hippocampal slices with different preparations. (B) Examples of fEPSPs during baseline
recording, PTP, LTP, and PPF. The PPF ratio was measured by employing two identical basal
stimuli delivered at a 20 ms interval and recording the change in the elicited field excitatory
post-synaptic potential (fEPSP); PPF1 recorded during the baseline and PPF2 after HFS and
induction of long-term potentiation (LTP). (C) A series of individual fEPSP responses (P1 to
P9) to each train (T) of the three HFS trains, with the ratio between P1 and P2 representing the
initial probability of release (Pr) in each HFS train. (D) The slope of the curve through which
the P3 fEPSP reduces to the P9 fEPSP signifies the rate of depletion of the readily releasable
pool (RRP) during a single HFS train, with the slope measured as a time constant of decay
(Tau = 1/K) employing a one-phase decay exponential function. (E) The size of RRP was esti-
mated by back-extrapolating to the Y-intercept a linear fit equation based on the last 4 cumula-
tive fEPSPs per train. During repeated trains (T1, T2 and T3) of HFS over a short period, the
increases in RRP size from T1 to T2 and T2 to T3 represent the efficiency of RRP replenish-
ment. (F) For the time-course PPF study without LTP induction, PPF was measured with basal
stimulation before (PPF1A) and immediately after (PPF1B) exposure to either prion contain-
ing or control preparations; thereafter PPF1B was measured every 5 minutes for one hour.
(TIF)
S2 Fig. Acute synaptotoxicity of crude ex-vivoPrPSc preparations. (A) Relative to the appro-
priate negative controls, there was a uniform and similar impairment of LTP (displayed as
percentage change) caused by: 0.5% (w/v in aCSF) cM1000 (in both 12-week-old [related to
Fig 1B & 1C] and 11-month-old hippocampal slices; [related to Fig 1G & 1H]); 0.5% (w/v in
aCSF) cMU02 (in 12-week-old hippocampal slices; related to Fig 1E & 1F); and Two percent
(w/v in aCSF) MoRK13-Inf (related to Fig 1K & 1L). To assess for potential non-PrPSc adverse
synaptic effects in the various test preparations, LTP was compared to technical aCSF controls
(aCSF only), with LTP (displayed as percentage of baseline field excitatory post-synaptic
potential (fEPSP) amplitude over time [left panels] and as average LTP as a percentage of base-
line [right panels]) not affected by: 0.5% (w/v in aCSF) cNBH in both (B) 12-week-old (related
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to Fig 1B & 1E) and (C) 11-month-old hippocampal slices (related to Fig 1H); (D) Two percent
(w/v in aCSF) MoRK13-Un in 11-month-old hippocampal slices (related to Fig 1K). (E-H:
first column i.) Normal I-O curves were obtained in all aCSF-only technical controls and
(A-G, middle column ii.) the relevant negative controls whereby the I-O curves after LTP
(I-O2) became significantly increased relative to the I-O curves before LTP (I-O1). In contrast,
the I-O2 curves failed to significantly increase after exposure to PrPSc contained in: cM1000
(E: column iii—12-week-old hippocampal slices; F: column iii—11-month old mice hippo-
campal slices); cMU02 (G: column iii—12-week old mice hippocampal slices); MoRK13-Inf
(H: column iii—11-month old mice hippocampal slices). Scatterplot: Student’s t test; I-O
curves: Two-way ANOVA with repeated measures; mean ± SEM; p<0.05, p<0.01,
p<0.001, p<0.0001.
(TIF)
S3 Fig. Validation of the prion acute synaptotoxicity model. (A) Relative to the appropriate
negative controls, there was a uniform and similar impairment of LTP (displayed as percentage
change) caused by 0.5% (w/v; in aCSF) PK-treated cM1000 (PK+M1000) (in 12-week-old
hippocampal slices; related to Fig 2E & 2F); and reconstituted PK-eluted PrP immuno-precipi-
tated 0.5% (w/v) cM1000 (PK+IP-M1000) pellets (in 12-week-old hippocampal slices; related
to Fig 2H & 2I). Importantly, immuno-depletion of PrPSc in 0.5% (w/v in aCSF) PrP immuno-
depleted brain homogenate from cM1000 (dM1000) significantly rescued LTP to levels not dif-
ferent to the NBH control (related to Fig 2B & 2C). To assess for potential non-PrPSc synapto-
toxicity in the various test preparations, LTP was compared to technical aCSF controls (aCSF
only), with LTP (displayed as percentage of baseline field excitatory post-synaptic potential
(fEPSP) amplitude over time [left panels] and as average LTP as a percentage of baseline
[right panels]) not affected by (B) 0.5% (w/v in aCSF) PrP immuno-depleted NBH (dNBH) in
12-week-old hippocampal slices (related to Fig 1B); (C) PK treated 0.5% (w/v; in aCSF; with
5μg/ml PK) cNBH (PK+NBH) in 12-week-old hippocampal slices (related to Fig 1E); and (D)
reconstituted PK-eluted immuno-precipitated 0.5% NBH (PK+IP-NBH) pellets in 12-week-old
hippocampal slices (related to Fig 1H). The first five-minute fEPSP recordings following HFS
trains have been omitted to assist clarity. (E-G) Normal I-O curves were demonstrated in aCSF
(column i.) and negative controls (column ii.) wherein I-O2 became significantly increased rel-
ative to I-O1. Conversely, PK-treated cM1000 (PK+M1000) (E: column iii—12-week old mice
hippocampal slices); and reconstituted, PK-eluted immuno-precipitated cM1000 brain homog-
enate (PK+IP-M1000) pellets (F: column iii—12-week old mice hippocampal slices) prevented
I-O2 from becoming enhanced relative to I-O1. The only exception was following immuno-
depletion of PrP (dM1000) wherein the I-O2 was normal compared with the controls (G: col-
umn iii—12-week old mice hippocampal slices). (H) Level of total protein (i, iii, v, vii) and PrP
(ii, iv, vi, viii) in each ex vivo PrP preparation detected by coomassie stain and western blotting
probed with 8H4 antibody. (I) Quantification of the total protein in each ex vivo PrP prepara-
tion. Relative to the total protein level in 0.5% (w/v) cM1000 without PK treatment, modest
PK treatment (5μg/mL PK) of the 0.5% (w/v) cM1000 and IP-M1000 significantly reduced the
total protein level to only 10% and 20% respectively, while containing substantial level of mod-
estly PK-resistant PrPSc (H column ii & iv). Similarly, total proteins in 0.5% (w/v) cNBH and
IP-NBH were significantly reduced to 20% and 30% by modest PK treatment compared with
those in cNBH before PK treatment. However, no PrP detected by 8H4 antibody in modestly
PK-treated NBH preparations (H column vi & viii). Densitometry analysis was performed as
described in [Lewis, 2015 #248] Scatterplot: Student’s t test; I-O curves: Two-way ANOVA
with repeated measures; mean ± SEM; p<0.05, p<0.01, p<0.001, p<0.0001.
(TIF)
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S4 Fig. Presynaptic functions. (A) Relative to aCSF-only technical controls where the paired
pulse facilitation (PPF) ratio after LTP induction (PPF2) was significantly reduced compared
with the PPF before LTP (PPF1), similar normal PPF results were obtained in the cNBH, MoR-
K13Un, dNBH, PK treated NBH, and PK-eluted IP-NBH controls (related to Fig 4A). (B)
Synaptic disruption in the form of altered paired pulse facilitation (PPF) ratios (displayed as
percentage change) was calculated after LTP (PPF2) relative to before LTP (PPF1). Relative to
appropriate negative controls, all preparations containing PrPSc prevented reduction in the
PPF ratio after LTP except dM1000, where the PPF ratio was significantly rescued (related to
Fig 4A). (C) PTP displayed as a percentage of baseline fEPSP amplitude, was not affected by:
Crude 0.5% (w/v in aCSF) brain homogenate from a normal brain (“sham”) inoculated mouse
(cNBH) in both 12-week-old and 11-month-old hippocampal slices; crude 2.0% (w/v in aCSF)
NBH “sham” uninfected RK13 cells lysate (MoRK13-Un) in 11-month-old hippocampal slices;
0.5% (w/v in aCSF) PrP immuno-depleted brain homogenate from a normal brain (“sham”)
inoculated mouse (dNBH) in 12-week-old hippocampal slices; proteinase K (PK) treated 0.5%
(w/v; in aCSF) cNBH (PK+NBH) in 12-week-old hippocampal slices; and reconstituted PK-
eluted immunoprecipitated 0.5% NBH (PK+IP-NBH) pellets in 12-week-old hippocampal
slices (related to Fig 4C). (D) Relative to the appropriate negative controls, all preparations
containing PrPSc, including the dM1000 caused similar PTP impairment (displayed as per-
centage change), thereby suggesting that PTP appears more sensitive to the acute synaptotoxic
effects of PrPSc than LTP (related to Fig 4C). (E) Average baseline fEPSPs at every five minutes
in hippocampal slices treated with aCSF, cNBH, and cM1000 (between the 10 and 15-minute
time points) recorded for ~60 minutes. Scatterplot (A-D): mean ± SEM, Student’s t test;
p<0.05, p<0.01, p<0.001, p<0.0001.
(TIF)
S5 Fig. Additional electrophysiology results from PrPo/o hippocampal slices (related to
Fig 6). (A-D) Analogous to what was observed in WT hippocampal slices, cNBH did not har-
bour non-PrPSc adverse synaptic effects on LTP (displayed as percentage of baseline fEPSP
amplitude over time (A) or and as average LTP as a percentage of baseline (B), PTP (C) or
PPF ratios after LTP induction (PPF2; D) in 12-week-old PrPo/o mice hippocampal slices
relative to aCSF-only technical controls. (E & F) In comparison to cNBH, cM1000 impaired
both LTP (E) and PTP (F) in 12-week old PrPo/o hippocampal slices (displayed as percent-
age change), with the changes comparable in degree to the disruption of LTP and PTP
observed with 12-week-old WT hippocampal slices (related to Fig 6A, 6B & 6D). (G) In
contrast, cM1000 did not impair the PPF ratio of 12-week-old PrPo/o hippocampal slices
(displayed as percentage change) following LTP induction, with results not significantly dif-
ferent to cNBH (related to Fig 6C). (H) Relative to the aCSF-only technical control, cNBH
did not disrupt the I-O curve after LTP expression (I-O2) compared with the I-O curve
before LTP expression (I-O1) in 12-week-old PrPo/o hippocampal slices; however, cM1000
significantly impaired the enhancement of I-O2 relative to I-O1. Scatterplot: Student t test;
Two-way ANOVA with repeated measures; mean ± SEM; p<0.05, p<0.01, p<0.001,
p<0.0001.
(TIF)
S6 Fig. The effects of 1% (w/v) versus 0.5% (w/v) crude normal brain homogenate (cNBH)
on hippocampal synaptic functions (related to Fig 7). Relative to hippocampal slices from
12-week old wild type mice treated with aCSF, (A) slices treated with 1% (w/v) cNBH for five
minutes following an eight to 10-minute stable baseline exhibited a disrupted baseline that
did not recover back to normal baseline before the trains of high frequency stimulation (HFS),
associated with disruption of the long-term potentiation (LTP). (B) However, hippocampal
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slices treated with 0.5% (w/v) cNBH did not affect the baseline and LTP.
(TIF)
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Abstract
Although considerable evidence supports that misfolded prion protein (PrPSc) is the principal
component of “prions”, underpinning both transmissibility and neurotoxicity, clear consen-
sus around a number of fundamental aspects of pathogenesis has not been achieved,
including the time of appearance of neurotoxic species during disease evolution. Utilizing a
recently reported electrophysiology paradigm, we assessed the acute synaptotoxicity of ex
vivo PrPSc prepared as crude homogenates from brains of M1000 infected wild-type mice
(cM1000) harvested at time-points representing 30%, 50%, 70% and 100% of the terminal
stage of disease (TSD). Acute synaptotoxicity was assessed by measuring the capacity of
cM1000 to impair hippocampal CA1 region long-term potentiation (LTP) and post-tetanic
potentiation (PTP) in explant slices. Of particular note, cM1000 from 30% of the TSD was
able to cause significant impairment of LTP and PTP, with the induced failure of LTP
increasing over subsequent time-points while the capacity of cM1000 to induce PTP failure
appeared maximal even at this early stage of disease progression. Evidence that the synap-
totoxicity directly related to PrP species was demonstrated by the significant rescue of LTP
dysfunction at each time-point through immuno-depletion of >50% of total PrP species from
cM1000 preparations. Moreover, similar to our previous observations at the terminal stage
of M1000 prion disease, size fractionation chromatography revealed that capacity for acute
synpatotoxicity correlated with predominance of oligomeric PrP species in infected brains
across all time points, with the profile appearing maximised by 50% of the TSD. Using
enhanced sensitivity western blotting, modestly proteinase K (PK)-resistant PrPSc was
detectable at very low levels in cM1000 at 30% of the TSD, becoming robustly detectable by
70% of the TSD at which time substantial levels of highly PK-resistant PrPSc was also evi-
dent. Further illustrating the biochemical evolution of acutely synaptotoxic species the
synaptotoxicity of cM1000 from 30%, 50% and 70% of the TSD, but not at 100% TSD, was
abolished by digestion of immuno-captured PrP species with mild PK treatment (5μg/ml for
an hour at 37˚C), demonstrating that the predominant synaptotoxic PrPSc species up to and
including 70% of the TSD were proteinase-sensitive. Overall, these findings in combination
with our previous assessments of transmitting prions support that synaptotoxic and
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increasing thereafter, albeit with eventual plateauing of transmitting conformers.
Author summary
Although evidence clearly supports that misfolded prion protein (PrPSc) is the principal
component of “prions”, underpinning both transmissibility and neurotoxicity, consensus
is lacking around the time of appearance and biochemical profile of neurotoxic species
during disease evolution. Employing an electrophysiology model, measuring the capacity
of brain homogenates derived from across the disease time-course to impair CA1 region
long-term potentiation (LTP) and post-tetanic potentiation (PTP) in hippocampal slices,
we observed that synaptotoxic species were present from 30% of the terminal stage of dis-
ease (TSD). Evidence that synaptotoxicity directly related to PrP species was demon-
strated by significant rescue of LTP dysfunction at each time-point through immuno-
depleting >~50% of total PrP species from cM1000 preparations. Moreover, size fraction-
ation chromatography revealed that acute synpatotoxicity correlated with predominance
of oligomeric PrP species in infected brains across all time points, while additional charac-
terisation of cM1000 demonstrated that the predominant synaptotoxic PrPSc species up to
and including 70% of the TSD were quite proteinase-sensitive. These findings in combina-
tion with our previous assessments of transmitting prions support that synaptotoxic and
infectious M1000 PrPSc species co-exist from at least 30% of the TSD, simultaneously
increasing thereafter, with biochemical transformation of synaptotoxic conformers con-
tinuing until late in disease.
Introduction
Prion diseases are transmissible neurodegenerative disorders with human phenotypes includ-
ing Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS) and
Kuru, while the principal animal diseases comprise scrapie in sheep and goats, bovine spongi-
form encephalopathy (“mad cow” disease) and chronic wasting disease in deer, elk and moose
[1, 2]. The key pathogenic event in all prion diseases is believed to be misfolding of the normal
prion protein (PrPC) into altered conformers (PrPSc) with progressive accumulation of PrPSc
in the brain linked to neurotoxicity through incompletely resolved mechanisms [3–8]. PrPSc,
especially that found at the terminal stage of disease (TSD: the advanced stage of disease
requiring animal euthanasia) was previously construed as invariably highly protease-resistant
whereas more recent evidence supports a broader spectrum encompassing a substantial pro-
portion that are protease-sensitive [9–12], with such species evident during disease evolution
[13] and terminal disease [10] most likely contributing to neurotoxicity [12].
Although experimental approaches exploiting successful rodent-adaptation of human and
animal prion diseases such as CJD and scrapie have facilitated our understanding of the patho-
genic evolution of these disorders [14–16], consensus around some fundamental aspects of
pathogenesis has not been achieved. In contrast to various in vivo models consistently demon-
strating rising titres of infectivity from early in disease development, well before overt clinical
features [8, 12, 17] there is controversy over the time of appearance of neurotoxic PrPSc spe-
cies. Reports of electrophysiological [18], morphological [19] and behavioural [20] distur-
bances prior to the mid-incubation point, generally coinciding with the first detection of
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PrPSc, support relatively early production of neurotoxic PrPSc. Conversely, other in vivo and in
vitro studies describe that predominantly transmitting PrPSc species are produced first [21, 22]
with neurotoxic species only propagated later in disease evolution nearer the onset of clinical
disease, appearing to correlate with the plateauing of infectivity and depletion of PrPC levels
[12, 13, 21, 23]. Evidence of significantly increased expression levels of GFAP and active cas-
pase 3, as well as heightened oxidative stress from around the mid-incubation period [8, 24]
further support the likely presence of neurotoxic PrPSc species extant from relatively early in
disease evolution, considerably pre-empting the onset of conventional clinical signs such as
weight loss, ataxia, and hind limb paresis [8, 25].
In addition to uncertainty regarding the time of occurrence and propagation sequence of
neurotoxic PrPSc species across the disease incubation period, it remains unresolved whether
such species are devoid of transmission capacity or harbour both pathogenic properties. Some
findings support that disease transmissibility and neurotoxicity are at least partially discon-
nected and perhaps relate to separate PrPSc species [12, 21, 23, 26]. Part of this apparent dis-
connection however, may relate to the types of techniques deployed to detect neurotoxicity
[27], as well as the innate neuroprotective mechanisms of the host, such as microglial activa-
tion [28, 29] and brain clearance capacity [30], which may successfully mollify neurotoxicity to
sub-threshold levels thereby delaying features evincing the presence of neurotoxic PrPSc over a
prolonged period. Compounding such difficulties is the current lack of detailed understanding
of the biochemical and biophysical characteristics of PrPSc species directly underpinning trans-
missibility and neurotoxicity and whether such properties change over the course of disease
evolution. Recently we reported that acutely synaptotoxic PrPSc species derived from brains at
the TSD appear to be at least modestly proteinase K (PK)-resistant and oligomeric [31] while
other groups utilising size fractionation and sedimentation velocity fractionation with terminal
disease tissue suggest that the most efficient PrPSc species for disease transmission are small
oligomers [32, 33]. The reported predominance of relatively protease-sensitive PrPSc species
until late in the incubation period [12, 34], which appear to be oligomeric [34], supports that
both transmitting and synaptotoxic species extant earlier in disease progression would be likely
to display such characteristics. This observation broadly concurs with the limited available
information suggesting that the most infectious species and conversion to overt symptomatic
disease corresponds with an increasing relative presence of PrPSc conformers found in smaller,
more protease-sensitive oligomers [13]. Also to be determined is whether there is a single or
predominant neurotoxic PrPSc species and if so, does specific biochemical or biophysical
transformation occur during disease progression or conversely does a diverse spectrum of
toxic PrPSc of varied biochemical properties eventuate during disease progression.
As a part of studies comprehensively characterising a new electrophysiological paradigm,
we recently demonstrated the ability to objectively and sensitively detect the presence of
acutely synaptotoxic ex vivo PrPSc derived from brains of mice terminally ill with M1000 prion
infection [31]. The current study aimed to determine whether such synaptotoxic species could
be detected in the brains of mice during disease evolution following precise stereotaxic intrace-
rebral inoculation with M1000 prions. To achieve this, we assessed the acute synaptotoxicity of
ex vivo homogenate preparations derived from the brains of M1000 infected mice (cM1000) at
30%, 50%, 70% and 100% of the TSD, through exploring the capacity of cM1000 to impair hip-
pocampal CA1 region long-term potentiation (LTP), paired-pulse facilitation (PPF), and post-
tetanic potentiation (PTP) in explant hippocampal slices. LTP and PTP are physiological mea-
sures of synaptic plasticity correlating with memory and learning induced by repetitive high
frequency stimulations wherein PTP is a short-term predominantly pre-synaptically mediated
enhancement of synaptic responsiveness followed by LTP, which is expressed as a persistently
enhanced post-synaptic potential generated by a combination of both pre- and post-synaptic
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functions [31]. PPF is a physiological measure of the probability of neurotransmitter release
(Pr), which is frequently used to estimate Pr during expression of LTP [31]. Of particular note,
cM1000 from 30% of the TSD was able to cause significant impairment of LTP, PPF, and PTP.
Evidence that the synaptotoxicity directly related to PrP species was demonstrated by the sig-
nificant rescue of LTP dysfunction at each time-point through immuno-depletion of>50% of
total PrP species from cM1000 preparations. Size fractionation chromatography revealed that
capacity for acute synaptotoxicity correlated with predominance of oligomeric PrP species in
infected brains across all time points, with the profile appearing maximised by 50% of the
TSD. Interestingly, both pooled oligomeric and monomeric PrPSc fractions from across the
time-points were acutely synaptotoxic, with the toxicity of pooled monomeric fractions
appearing associated with likely rapid spontaneous oligomerization of PrPSc monomers in
physiological buffer following their size fractionation. Moreover, the synaptotoxicity of
cM1000 from 30%, 50% and 70% of the TSD, but not at 100% TSD, was abolished by digestion
of immuno-captured PrP species with mild PK treatment (5μg/ml for an hour at 37˚C), dem-
onstrating that the predominant synaptotoxic PrPSc species up to and including 70% of the
TSD appears quite proteinase-sensitive. Overall, these findings in combination with our previ-
ous assessments of transmitting prions support that synaptotoxic and infectious M1000 PrPSc
species co-exist from at least 30% of the TSD.
Materials and methods
Ethics statement
All animal handling was in accordance with National Health and Medical Research Council
(NHMRC) guidelines. Animal handling and experimental procedures were approved by The
Florey Institute of Neuroscience and Mental Health Animal Ethics Committee (Ethics num-
ber: 13–048) or the Biochemistry & Molecular Biology, Dental Science, Medicine (RMH),
Microbiology & Immunology, and Surgery (RMH) Animal Ethics Committee, The University
of Melbourne (Ethics number: 1312997.1).
Animals
The M1000 prion strain has been well described and characterised [8], and was originally
adapted to mice from a person most likely dying from GSS [15]. Mice used for electrophysio-
logical studies and to generate M1000 infected brains at varying stages of prion infection fol-
lowing stereotaxic intracerebral (ic) inoculation were 12-week-old wild-type (WT) female
C57BL/6J mice (Animal Resource Centre, Western Australia). In addition, 12-week-old WT
female Balb/c mice were used to generate M1000 infected brains through routine ic inocula-
tion as described previously [8]. Mice used for bioassay studies were six-week old transgenic
(over-expressing PrPC ~10-fold; [35]) tga20 mice bred at the Florey Institute of Neuroscience
and Mental Health (originally a generous gift from The Scripps Research Institute, La Jolla,
California, USA).
Mice inoculations for electrophysiology experiments
To optimise precision with M1000 inoculations for producing time course ex vivo preparations
for electrophysiology experiments, 12-week old WT C57BL/6J mice were stereotactically ic
inoculated. Briefly, mice were anesthetized with an intraperitoneal cocktail injection of keta-
mine (100mg/kg) and xylazine (20mg/kg) and placed on a small animal stereotactic frame
(Model 940, Kopf, Germany fitted with a Model 5000 microinjection unit) equipped with a
37˚C heating mat. The pedal reflex was monitored every 15–20 minutes to assess the level of
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unconsciousness. A small incision along the sagittal line of the scalp allowed the identifica-
tion of the bregma. A small drill fitted with a blunt burr was then used to make a hole in the
skull, through which a 26-gauge needle (Model 1701, Hamilton, Switzerland) was placed.
Four microlitres of 10% (w/v in sterile PBS) cM1000 was then injected (flow-rate of 0.8μl/
min) just above the dorsal hippocampus (bregma coordinates: -2.5 caudally, +/- 2.5 laterally
and -1.5 ventrally). The needle was then slowly retracted, placed in position above the con-
tralateral hippocampus and the procedure repeated as above. The scalp wound was closed
with Super Glue and Ilium Neocort was applied. The mice were allowed to recover for 1
hour on a 37˚C heating mat and then transferred to single-caging for 3 days. The mice were
checked once daily for physiological parameters such as weight and normal motor behav-
iour and an intraperitoneal dose of carprofen (5mg/kg) given at 0, 24 and 48 hours after sur-
gery to relieve pain. These M1000 inoculated mice reach the TSD (requiring euthanasia) at
a mean of ~170 (±3 SD) days post-inoculation (dpi). Relative to the TSD, mice were sacri-
ficed at 30%, 50%, 70% and at the 100% time points (ie representing ~51, ~85, ~119, and
~170 dpi, respectively), brains were collected and homogenized to 20% (w/v) in 1x PBS, and
stored at -80˚C until use. As negative or sham controls, similar aged WT mice were ic inoc-
ulated as above with normal brain homogenate (NBH; 10% w/v in PBS) and brains were
harvested at the same dpi as the M1000 infected mice. To further assess the presence of
synaptotoxic PrPSc species at an early time point following M1000 inoculation, 12-week-old
WT female Balb/c mice were routinely ic inoculated as described previously [36] with brains
collected at 30% of the TSD (representing ~44 dpi).
Immuno-depletion/-precipitation of PrP
Total prion proteins were specifically immuno-depleted using 03R19 anti-PrP polyclonal anti-
body from 1% (w/v) cNBH and cM1000 as previously described [31] to generate depleted nor-
mal and M1000 brain homogenates (dNBH and dM1000, respectively), with specificity
checked by comparison with “mock” immuno-depletion using normal rabbit serum. Addi-
tionally, the immuno-precipitated prion proteins were eluted from protein-G-sepharose pel-
lets reconstituted to original volumes, by a mild PK treatment of 5 μg/mL at 37˚C for an hour,
with two cycles of 20-minutes of agitation interspersed with 10 minutes without agitation to
generate PK-eluted immuno-precipitated NBH and M1000 brain homogenates (PK+IP-NBH
and PK+IP-M1000, respectively). Aliquots of the ~1% (w/v) depleted and resuspended PK-
treated preparations were taken for analysis by western blotting, prior to further dilution to
0.5% (w/v) in artificial CSF (aCSF: 126mM NaCl, 2.5mM KCl, 26mM NaHCO3, 1.25mM
NaH2PO4, 10mM Glucose, 1.3mM MgCl2.6H2O and 2.4mM CaCl2.2H2O) for use in electro-
physiology studies.
Electrophysiology paradigm
Electrophysiology studies were performed as described [31] with brain homogenates for these
studies pre-cleared by a one minute 100xg spin. In brief, 300μm hippocampal slices were pre-
pared from WT mice utilizing a vibratome (Leica VT1200S) and ice cold cutting solution
(3mM KCl, 25mM NaHCO3, 1.25mM NaH2PO4, 206mM Sucrose, 10.6mM Glucose, 6 mM
MgCl2.6H2O, 0.5mM CaCl2.2H2O) while continuously carboxygenating with 5% CO2 and
95% O2. Following an hour of incubation in carboxygenated aCSF at 32˚C, slices were
mounted on to 60MEA200/30iR-Ti-pr-T multi-electrode arrays (MEA; Multichannel Systems;
Germany) for recording while continuously superfused with carboxygenated aCSF. Harp slice
grids (ALA HSG-5B, Multichannel Systems; Germany) were utilized to ensure optimal contact
of the slices with microelectrodes. Electric stimulation (1500 to 2500 mV) was utilised to evoke
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hippocampal field excitatory post-synaptic potentials (fEPSP) from the Schäffer collateral
pathway while recording from the CA1 region. A 30-minute baseline was recorded at 30
second intervals using a basal stimulus determined by an input-output curve, which was
obtained by stimulating the Schäffer collateral pathway with increasing stimulation intensi-
ties (at 30 second intervals) starting from 500 mV to a stimulation intensity that evoked the
maximum fEPSP as indicated by plateau curve (usually between 4000–5000 mV) wherein
the basal stimulus was declared as the stimulus that evoked ~40% of the maximum fEPSP.
Channels of the MEA grid utilized for analysis were those best aligned to the Schäffer collat-
eral pathway through recording from electrodes placed on the stratum radiatum of the CA1
region and selecting those demonstrating fEPSPs that manifested PPF (as described previ-
ously [31]), generated positive trend input-output curves, produced non-spiky fEPSP
curves, and maintained fEPSP amplitudes above the eight standard deviation threshold of
the noise levels for at least 80% of the total recording time. The average number of elec-
trodes recorded from and utilised for analysis in each slice was seven. The treatments (the
crude homogenates or other preparations) were superfused over the hippocampal slices for
five minutes following 8–10 minutes of stable baseline. For tetanus, three trains of high fre-
quency stimulation (HFS: 100Hz each) were applied (for 0.5 seconds at 20 second intervals)
following the baseline recording to induce PTP and LTP. Each train of HFS evoked serial
pulses of fEPSPs, wherein the first nine of those pulses were recorded to estimate presynap-
tic activity associated with the induction of PTP. Post-HFS recording continued for 30 min-
utes wherein the first response was utilised to estimate PTP and last 10-minute period taken
as representing LTP. LTP and PTP were calculated as the percentage fEPSP increase after
HFS relative to the last five-minute baseline of fEPSPs. PPF was evoked by basal stimuli
delivered 20 ms apart as previously reported [31]. The ratio between the fEPSP amplitude of
the first and the second pulse was the PPF ratio. PPF ratio was measured before treatment
and induction of LTP (PPF1) and after treatments and expression of LTP (PPF2).
Incubation time interval bioassays
To assess levels of prion infectivity contained within the various ex vivo M1000 PrPSc prep-
arations utilized to characterise acutely synaptotoxic species present in cM1000 derived
from terminal prion disease, tga20 mice were ic inoculated with these ex vivo samples
(30μL per mouse) as previously described [8]. In addition, 1% (w/v) cM1000 and NBH
served as positive and negative controls, respectively. The tga20 mice were euthanized
when they become terminally ill as indicated by features including reduced spontaneous
activity, prominent ataxia and hind limb paresis. Total survival in dpi was recorded and
utilized to calculate an approximate, especially relative infectivity titre for each ex vivo
M1000 PrPSc preparation as described [8]. One-way ANOVA was used to compare the
average terminal incubation period of tga20 mice, as well as average infectivity titre of
inocula. The infectivity titres, ID50 units/g brain were converted to log ID50 units/μL 1%
crude M1000 brain homogenate and plotted as a function of percentage of incubation
period to the terminal stage.
Western blotting
PrP levels were analysed by standard PAGE and immunoblotting as described previously [37],
with protease-resistant PrP also detected following the higher sensitivity method of sodium
phosphotungstate (NaPTA) precipitation as previously described [36]. For non-NaPTA
immunoblotting, brain homogenates (1% w/v) from all time points were either not treated or
treated with 5μg/mL PK for an hour at 37˚C, while brain homogenates undergoing NaPTA
Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007712 April 10, 2019 6 / 29
precipitation were treated with 5, 25, and 50μg/mL PK for an hour at 37˚C. Proteins were dena-
tured in 1x sample buffer (containing 6% Beta-mercaptoethanol), resolved on NuPAGE Novex
4–12% Bis-Tris gels (ThermoFisher Scientific), transferred to PVDF membrane (Millipore;
transfer buffer containing 25 mM Tris, 200 mM glycine and 20% methanol), blocked with 5%
(w/v) skim milk then probed with the anti-PrP primary antibodies either 03R19[14] or 8H4
(Abcam) as indicated in the figure legends. For native western blotting, protein samples con-
taining 2% (w/v) Sarkosyl were diluted 1:1 with 2x Novex Tris-Glycine native sample buffer,
resolved on NuPAGE Novex 3% Tris-Acetate gels in 1x Novex Tris-Glycine native running
buffer (at constant 160V; ThermoFisher Scientific), and transferred to PVDF membrane (at
constant 70V for 3 hours) using a transfer buffer containing 25 mM Tris, 200 mM glycine and
10% methanol. A few microliters of a High Marker protein standard (Invitrogen) were resolved
alongside the protein samples on native gels to estimate sizes of native proteins. The PVDF
membranes of native protein samples were blocked and probed with 8H4 antibody to detect
PrP species. Following the appropriate secondary antibody, protein bands were detected by
chemiluminescence (ECL Prime and Select, Invitrogen) and digitized in a Fujifilm LAS-3000
Intelligent dark box. Membranes were stained with Coomassie blue to determine relative total
protein levels. Protein bands of interest were quantified by densitometry (Image J) normalized
for total protein level as previously described [37]. Approximate estimation of PrP quantities in
preparations used for electrophysiology studies was achieved by intra-experimental comparison
to a recombinant full-length mouse PrP (rPrP) standard curve, as described previously [31].
Size exclusion chromatography
As described in detail previously [31], whole brains from infected mice at each time point, as
well as sham-infected control mice, were homogenized at 20% (w/v in 1x PBS), pelleted at a
15000xg spin, solubilized with 4% (w/v in 1x PBS) Sarkosyl into ~10% (w/v) final concentra-
tion, and centrifuged at 10000xg to collect the supernatants. The supernatants were then
exhaustively dialyzed using 10 kDa cut-off dialysis membranes in 1x PBS dialysate (without
calcium) and filtered across a 0.22-micron filter. Approximately 3 mL of each preparation was
slowly injected into a sephacryl-100 column pre-equilibrated with at least 2 column volumes
of 1x PBS containing calcium and magnesium. The protein complexes were eluted in 1x PBS
(containing calcium and magnesium) at a flow rate of 0.5 mL per minute, wherein the void
volume was collected at ~70 minutes after injection. One mL fractions were then collected
every two minutes for 80 minutes (40 fractions) following collection of the void volume. The
relative levels of PrP in each fraction were analysed by western blotting, including before and
after digestion with PK as described [31]. The size of proteins or complexes eluted into each
fraction was determined through size fractionation of size exclusion chromatography protein
markers: bovine erythrocyte carbonic anhydrase (~29kDa), bovine serum albumin (~66kDa),
yeast alcohol dehydrogenase (~150kDa), sweet potato beta-amylase (~200kDa), horse spleen
apoferritin (~443kDa), and bovine thyroglobulin (~669kDa) [31]. Operationally, PrP species
eluted into fractions with molecular weights smaller than 100kDa were considered to be
mostly monomeric PrP while prion proteins eluted into fractions with molecular weights
>100kDa but<500kDa were considered predominantly oligomeric PrP or large protein com-
plexes containing PrP and although not experimentally verified PrP >500kDa was considered
to represent increasingly fibrillar assemblies.
Statistical analyses
The total levels of PrP and levels of at least modestly PK resistant PrPSc were compared across
time points of the disease evolution by One-way ANOVA. Levels of PK-resistant PrPSc across
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the time points detected by NaPTA precipitation after digestion with each PK concentration
(5, 25, and 50μg/mL) were compared by One-way ANOVA with Tukey’s correction for multi-
ple comparisons. The average LTP or PTP in slices treated with M1000 preparations from
across the time points were compared with the appropriate negative controls by One-way
ANOVA with Dunnett’s correction for multiple comparisons (comparing mean LTP and PTP
of M1000 treated slices to those of negative controls). The degree of synaptotoxicity was calcu-
lated as the percentage LTP reduction from that observed in negative controls. The average
degree of synaptotoxicity as either LTP or PTP disruption in slices treated with M1000 prepa-
rations from across the time points were compared by One-way ANOVA with Tukey’s correc-
tion for multiple comparisons (comparing mean degree of toxicity at each time point with that
at every other time point). Unpaired Student t-test was used to compare the average PrP levels
before and after the PrP-immuno-depletion. PPF was calculated as the percentage PPF ratio
decrease in PPF2 relative to PPF1 and compared to that of the appropriate negative control by
One-way ANOVA with Dunnett’s correction for multiple comparisons. The probability of
neurotransmitter release during HFS trains was calculated by dividing the second pulse by the
first pulse of the first 9 pulses evoked by each train. The average probability of neurotransmit-
ter release at the second and third train was compared to that of the first train by One-way
ANOVA with Dunnett’s correction for multiple comparisons. The depletion of the readily
releasable pool (RRP) of neurotransmitter during each train of HFS was estimated and com-
pared between treatment groups using a one-phase decay exponential function to determine
the slope of fEPSP amplitude decline (time constant of decay) from pulse three to the last pulse
as described previously [31]. The size of RRP was estimated and compared between treatment
groups by a linear fit equation of cumulative fEPSP of each train (best fit of the last four cumu-
lative fEPSP) wherein the size of RRP was the Y-intercept of the linear fit (see Methods of [31]
for further details). The efficiency of RRP replenishment following each HFS train was deter-
mined by size of RRP increase at train two and three [31]. One-way ANOVA with Tukey’s cor-
rection for multiple comparisons was used to compare the average incubation period of tga20
mice inoculated with different preparations from the TSD, as well as to compare the average
infectivity titres of these M1000 preparations. Tukey’s correction for multiple comparisons
was used to compare the mean of each group to the mean of every other group (suited for time
point results), whereas Dunnett’s correction for multiple comparison was used to compare the
mean of the control group to the mean of every other tested group.
Results
Acutely synaptotoxic PrPSc is detectable from early in M1000 prion disease
development
Neuropathological features of prion disease such as microvacuolation and astrocytic gliosis are
initially detected in the hippocampus and thalamus of WT Balb/c mice ic infected with M1000
prions at ~57% of the TSD (~83 dpi) [8], which suggests the presence of neurotoxic PrPSc spe-
cies prior to this. To explore whether acutely synaptotoxic PrPSc species are propagated at ear-
lier time points of M1000 prion disease pre-empting these first neuropathological changes, we
used a recently developed electrophysiology paradigm to assess cM1000 prepared from WT
mice at 30%, 50%, 70% and 100% of the TSD following stereotaxic ic infection with M1000 pri-
ons. To biochemically characterise the 0.5% (w/v) cM1000 from each of the time points (n = 3
for each time point) they were initially evaluated by routine western blotting before and after
treatment with modest PK digestion in combination with comparative quantitative analysis
based on a rPrP standard curve. A significant increase in total PrP (p = 0.0019), largely due to
increased levels of at least modestly PK-resistant PrPSc (p<0.0001) at 100% of the TSD relative
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to earlier time points was observed (Fig 1A & S1A Fig) with a trend towards reduced total lev-
els at 70% of the TSD. Moreover, at least modestly PK-resistant PrPSc was not detected at 30%
and 50% of the TSD, with only minimal levels evident at 70% of the TSD (~0.005 μg/mL),
which were approximately 16-fold less than the robust levels observed at 100% of the TSD
(~0.080 μg/mL). As expected, PK-resistant PrP was never observed in cNBH across the time
course, with no difference in PrPC levels across all time points (S1B Fig).
To further characterise the PrP in the 0.5% (w/v) NBH and cM1000 across the time course,
western blotting following NaPTA precipitation and digestion with increasing PK concentra-
tions was performed. In cM1000 preparations, this analysis (Fig 1B & and 1C) revealed barely
detectable levels of very modestly PK-resistant PrPSc at 30% (<< 0.012μg/mL) and 50%
(<<0.012 μg/mL) of the TSD, with significantly higher levels at 70% (~0.059 μg/mL) and
100% (~0.090 μg/mL) of the TSD (p = 0.0043; One-way ANOVA with Tukey’s correction for
multiple comparisons). The 25 μg/mL PK digestion completely abolished PK-resistant PrPSc
species at 30% of the TSD, while minimal levels were detected at 50% (<<0.012μg/mL) of the
TSD and significantly higher levels observed at 70% (~0.035 μg/mL) and 100% (~0.051 μg/
mL) of the TSD (p = 0.0045; One-way ANOVA with Tukey’s correction for multiple compari-
sons). The 50 μg/mL PK completely digested PK-resistant PrPSc species at 30% and 50% of the
TSD, while significantly higher levels remained at 70% (~0.037 μg/mL) and 100% (~0.058 μg/
mL) of the TSD (p = 0.023; One-way ANOVA with Tukey’s correction for multiple compari-
sons). Of note, these data suggest that PK-resistant PrPSc species at 70% of the TSD were ren-
dered more detectable by NaPTA precipitation compared to results of routine western blotting
such that levels of PK-resistant PrPSc species (including at least modestly PK-resistant species)
were no longer significantly different to those at 100% of the TSD (compare Fig 1B and 1C
with S1A Fig). Given PK-resistant PrP was never observed in cNBH across the time points,
only cNBH from 100% of the TSD was utilized as negative control for assessing acute
synaptotoxicity.
Relative to the normal CA1 region LTP obtained in WT hippocampal slices treated with
cNBH (180 ± 7%; n = 5), the CA1 LTP was significantly impaired following exposure to
cM1000 prepared from the brains of C57BL/6J mice at 30% of the TSD following M1000 prion
inoculation through hippocampal stereotaxic injection (154 ± 4%; p = 0.0122; n = 5; Fig 2B;
One-way ANOVA with Dunnett’s correction for multiple comparisons), which was very simi-
lar to the degree of LTP disruption obtained in WT hippocampal slices after exposure to
cM1000 derived from brains of routinely ic inoculated Balb/c mice also culled at 30% of the
disease progression (159 ± 5%; p = 0.0368; n = 5; Fig 2A; One-way ANOVA with Dunnett’s
correction for multiple comparisons). CA1 LTP was also significantly impaired by cM1000
derived from the brains of stereotactically infected C57BL/6J WT mice at 50% (142 ± 4%;
p = 0.0001; n = 5), 70% (141 ± 5%; p = 0.0001; n = 5) and 100% (133 ± 6%; p<0.0001; n = 5) of
the TSD (Fig 2C–2F; One-way ANOVA with Dunnett’s correction for multiple comparisons).
Consistently, the degree of PPF ratio decline in slices with impaired LTP were significantly
lower than those in slices treated with cNBH demonstrating normal LTP, confirming signifi-
cant disruption of the probability of neurotransmitter release associated with LTP dysfunction
(Fig 2G; One-way ANOVA with Dunnett’s correction for multiple comparisons). In addition,
PTP was significantly disrupted in WT slices treated with cM1000 prepared from each time
point (Balb/c at 30% of the TSD, 261 ± 25%, p = 0.0480; C57BL/6J at 30% of the TSD,
255 ± 24%; p = 0.0334; 50% of the TSD: 238 ± 14%, p = 0.0093; 70% of the TSD, 222 ± 19%,
p = 0.0052; and 100% of the TSD: 261 ± 25%, p = 0.0191; n = 5 for each time point) relative to
normal PTP generated in WT hippocampal slices treated with cNBH (344 ± 25%; n = 5; Fig
2H). Interestingly, the degree of PTP impairment did not significantly increase across the time
points (p = 0.3306; One-way ANOVA with Tukey’s correction for multiple comparisons; Fig
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2I upper panel), whereas the degree of LTP impairment significantly increased across the dis-
ease evolution in mice inoculated by stereotaxic injection (p<0.0001; One-way ANOVA with
Tukey’s correction for multiple comparisons; Fig 2I bottom panel). Transient depression of
fEPSPs during and following the brief treatments was frequently observed, but importantly,
they invariably return to baseline before instigation of HFS trains, with potential explanations
for this phenomenon and the lack of implications for assessments of synaptic function dis-
cussed in detail previously [31].
Further analyses of presynaptic events during HFS trains that subsequently induced PTP
were undertaken. Of note, the cNBH negative controls used in these electrophysiology studies
did not affect synaptic functions as compared to the aCSF technical controls (S2A–S2G, S2K &
S2L Fig). Specifically, normal RRP replenishment was exhibited by slices treated with aCSF
and cNBH wherein the size of RRP significantly increased at train 2 and again at train 3 (S2K
& S2L Fig); however, the RRP replenishment was impaired in slices with PTP impairment,
wherein the RRP size failed to significantly increase from train 2 to train 3 across all treatments
with cM1000 from the time course (S2M–S2P Fig). Although the RRP replenishment was
impaired, the probability of neurotransmitter release was normal with the second and third
trains evoking significantly higher neurotransmitter release than the first train (S2D Fig). The
RRP rate of depletion was also normal, whereby the time-constant of decay of the third-to-
ninth pulses were not different when comparing between slices treated with cNBH and those
treated with cM1000 (S2H–S2J Fig).
Acute synaptotoxicity derived from earlier time points of M1000 prion
disease evolution is associated with PrP species
To determine if ex vivo PrP species propagated at earlier time points of the disease evolution
are directly associated with the acute synaptotoxicity of cM1000, we immuno-depleted total
PrP species in cM1000 derived from each time point and assessed the acute synaptotoxicity of
the depleted M1000 preparations using our electrophysiology paradigm. The immuno-deple-
tion removed ~63 ± 18% of total PrP from cNBH (n = 3), ~52 ± 0.6% from cM1000 at 30%
TSD (n = 5), ~60 ± 0.4% at 50% TSD (n = 5), ~58 ± 2% at 70% TSD (n = 5), and ~79 ± 7% at
100% TSD (n = 4; Fig 3A and 3B). In parallel with the ~79% total PrP depletion from cM1000
at 100% of the TSD, ~89 ± 0.3% of at least modestly PK-resistant PrPSc was also depleted
(n = 2; Fig 3C). Importantly, the LTP dysfunction caused by cM1000 preparations from each
time point was abolished following the depletion of PrP species (Fig 3D–3G) wherein the LTPs
generated by slices treated with dM1000 from 30%, 50%, 70%, and 100% of the TSD
(161 ± 7%, 157 ± 6%, 163 ± 5%, and 169 ± 5%, respectively; n = 5 for each) were no longer dif-
ferent from the LTP of slices treated with dNBH (163 ± 6%; n = 5) (Fig 3H). Consistent with
the rescue of LTP, the degree of PPF ratio decline was no longer significantly lower in slices
treated with dM1000 compared to slices treated with dNBH consistent with rescue of the
impairment of the probability of neurotransmitter release during LTP through the immuno-
depletion of PrP (Fig 3I). Further, the PTP was no longer disrupted following treatment with
Fig 1. Levels of total PrP and proteinase K (PK)-resistant PrPSc species across the natural evolution of M1000
prion disease. (A) Quantification of the immunoblots in S1A Fig with the levels of total PrP (without PK digestion:
PK-) and at least modestly PK-resistant PrPSc (PK+) compared across M1000 disease evolution by One-way ANOVA
with Tukey’s correction for multiple comparisons. (B) Western immunoblots of cNBH and cM1000 from all the
disease time points following precipitation of PrPSc species by sodium phosphotungstic acid (NaPTA) and digestion
with 5, 25, and 50 μg/mL PK (at 37˚C for an hour), respectively. The “spike” represents the positive control
demonstrating successful precipitation and detection of PrPSc species in 5μL of 10% (w/v) cM1000 that was spiked into
500μL of 1% (w/v) cNBH. (C) Approximate quantification of PrP levels (in μg/mL) in brain homogenates in B (n = 4).
Results are presented as mean ± standard error of mean. �p<0.05, ��p<0.01, ����p<0.0001.
https://doi.org/10.1371/journal.ppat.1007712.g001
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dM1000 from 30% and 50% of the TSD (n = 5 each; Fig 3J). In contrast, relative to the dNBH
control, the PTP remained impaired after treatment with dM1000 from 70% (p = 0.0221;
n = 5) and 100% (p = 0.0009; n = 5) of the TSD regardless of the significant rescue of LTP by
the immuno-depletion of PrP species (Fig 3J). This inconsistent rescue of PTP aligned with the
significant rescue of RRP replenishment after depletion of PrP when treated with dM1000
from 30% and 50% of the TSD (significant increase of RRP size at train 2 and again at train 3),
while it remained impaired by dM1000 from 70% and 100% of the TSD (failure of RRP size to
significantly increase from train 2 to train 3) (S3M–S3P Fig). Both the probability of release
and RRP depletion during HFS trains were normal in slices treated with dM1000 similar to
those treated with dNBH (S3D, S3H–S3J Fig). Importantly, dNBH negative controls did not
affect synaptic functions as compared to aCSF technical controls (S3A–S3G, S3K & S3L).
Acute synaptotoxicity at earlier time points is associated with PK-sensitive
PrP species
In a previous report, we described that the prion acute synaptotoxicity harboured in brains at
the terminal stage of M1000 prion disease appeared directly linked to at least modestly PK-
resistant PrP species [31]; however, the virtual absence of at least modestly PK-resistant PrP
species at 30% and 50% of the TSD (Fig 1A–1C and S1A Fig) regardless of the link between
total PrPs and acute synaptotoxicity suggests that synaptotoxic species at earlier time points
probably relate to PK-sensitive PrPSc. To verify this speculation, we immuno-precipitated total
PrP species from cM1000 at each time point, digested pellets with the same mild PK treatment
to elute immuno-captured PrP species, and assessed their toxicity using our electrophysiology
paradigm. Using routine western blotting, there was no detectable PK-resistant PrPSc in
immuno-captured PrP species prepared from 30% and 50% of the TSD, while very minimal
levels were detected at 70% of the TSD (<<0.012μg/mL; n = 5) and substantial amounts at
100% of the TSD (~0.057 ± 12 μg/mL; n = 4; p<0.0001; One-way ANOVA with Tukey’s cor-
rection for multiple comparisons) (Fig 4A and 4B). Importantly, the LTP was not impaired by
treatment with PK+IP-M1000 from 30%, 50% and 70% of the TSD relative to the PK+IP-NBH
controls (Fig 4C–4E; n = 5 for each), while congruent with our previous observations the LTP
was significantly disrupted by exposure to PK+IP-M1000 from 100% of the TSD (Fig 4F,
p = 0.0176; n = 5 each; [31]). Overall, similar to the results in cM1000 (Fig 2I), there was a cor-
relation between disease progression and LTP dysfunction due to the presence of at least
Fig 2. Synaptotoxic PrPSc species are propagated from early in the evolution of M1000 prion disease. (A) CA1 region LTP of WT
mouse hippocampal slices was significantly disrupted following a five minute exposure to 0.5% (w/v; in artificial CSF) crude M1000
brain homogenates (cM1000) derived from M1000 infected WT Balb/c mice (infected through routine intracerebral injection [R.ic]) at
30% of the incubation period to the terminal stage of disease (TSD). (B to E) CA1 region LTP of WT mouse hippocampal slices was
significantly disrupted following a 5 minute exposure to 0.5% (w/v; in artificial CSF) cM1000 derived from M1000 infected WT
C57BL/6J mice (infected by stereotaxic intracerebral injection [S.ic]) at 30% (B), 50% (C), 70% (D) and 100% (E) of the TSD. (F)
Average LTP from the last 10 minutes of recordings (fEPSP readings following high frequency stimulation, HFS) after treatments with
cM1000 from 30%, 50%, 70% and 100% of the TSD compared to the negative control 0.5% (w/v) crude normal brain homogenates
(cNBH) derived from sham infected mice at the equivalent of 100% of the TSD. (G) Average percentage paired pulse facilitation (PPF)
ratio decline following treatments in WT mouse hippocampal slices treated with cM1000 compared with cNBH controls as described
in the Methods. (H) The average PTP generated by WT mouse hippocampal slices treated with cM1000 from across the disease
evolution compared to the cNBH control as described in the Methods. (I) The percentage of PTP and LTP impairments (upper and
lower panel, respectively) following treatments with cM1000 from each time point of the disease progression calculated as the
percentage of PTP and LTP decrease compared to the normal PTP and LTP in slices treated with cNBH controls (One-way ANOVA
with Tukey’s correction for multiple comparison). (A to E) The five minute treatments started after 8-to-10 minutes of stable baseline.
The HFS trains were applied following 30 minutes of baseline recordings. (A, C, D) Results are presented as mean ± standard error of
mean. (A-E, F, G & H) Average LTP/PTP/PPF ratio degree of decline in WT mouse hippocampal slices treated with cM1000
preparations from across the time points were compared with NBH controls by One-way ANOVA with Dunnett’s correction for
multiple comparisons. (A-E, G & H) Some examples of raw fEPSP traces are provided as insets. �p<0.05, ��p<0.01, ���p<0.001,
����p<0.0001, ns = not statistically significant (p>0.05).
https://doi.org/10.1371/journal.ppat.1007712.g002
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modestly PK-resistant PrPSc largely driven by the results at 100% of the TSD (Fig 4G,
p = 0.0264; One-way ANOVA with Dunnett’s correction for multiple comparisons). Addition-
ally, relative to the normal PPF ratio decline in slices treated with PK+IP-NBH control, levels
of PPF ratio decline in slices treated with PK+IP-M1000 from 30%, 50%, and 70% of the TSD
also appeared normal (Fig 4H), while the degree of PPF ratio decline in slices treated with PK
+IP-M1000 from 100% of the TSD was still significantly lower (Fig 4H; p = 0.0011: One-way
ANOVA with Dunnett’s correction for multiple comparisons). These PPF ratio results
revealed that synaptotoxic PrPSc species responsible for the disruption of the probability of
neurotransmitter release during LTP expression are highly PK-sensitive at earlier stages of the
disease evolution and acquire resistance to PK as part of biochemical maturation toward the
terminal stage of the disease. Parallel results were obtained with PTP dysfunction wherein only
the PTP of slices treated with the PK+IP-M1000 from 100% of the TSD were impaired
(p = 0.0222), but not with the PK+IP-M1000 from earlier time points (Fig 4I; One-way
ANOVA with Dunnett’s correction for multiple comparisons). The PK+IP-NBH did not cause
any background disruption of LTP, PTP, and PPF ratios relative to aCSF technical controls
(S4A–S4C Fig).
Propagation of oligomeric PrPSc species correlates with the detection of
prion acute synaptotoxic PrPSc during the evolution of M1000 prion
disease
Our previous studies demonstrated that acutely synaptotoxic species at the TSD in M1000
prion infection were strongly correlated with at least modestly PK resistant and oligomeric
PrPSc [31]. To further explore the biophysical status of PK-sensitive, acutely synaptotoxic
PrPSc species from earlier time points of M1000 prion disease we undertook size exclusion
chromatography to fractionate ex vivo preparations from PrPSc from brains at 30%, 50%, and
70% of the TSD and compared them with ex vivo PrPSc fractions prepared from 100% of the
TSD (positive control), as well as PrPC fractions prepared from sham-infected NBH controls
(negative control). Our results revealed that oligomeric PrPSc species were present and pre-
dominant at all the time points of the evolution of M1000 prion disease (Fig 5), which
appeared directly correlated with the detection of the acutely synaptotoxic species at these ear-
lier stages of the disease. Relative to fractions of the sham-infected NBH controls wherein PrPC
species were mostly monomeric (<100kDa in fractions 15 to 40; Fig 5 B), PrPSc fractions of
Fig 3. Acute synaptotoxicity of cM1000 from earlier time points of M1000 prion disease is associated with prion protein species.
(A) Western blotting of 20 μL 1% (w/v) crude M1000 brain homogenates (cM1000) from 30%, 50%, 70%, and 100% of M1000 prion
disease progression to terminal stage disease (TSD) following mock immuno-depletion of total PrP species with normal rabbit serum
(control) or immuno-depletion of total PrP species with 03R19 prion antibody (Probed with 8H4 antibody; molecular weight markers
are provided at left). (B) Quantification of total PrP species in PrP immuno-depleted normal brain homogenate (dNBH) and PrP
immuno-depleted cM1000 (dM1000) from across the disease progression (by densitometry analysis) compared to appropriate negative
controls by Unpaired Student’s t-test (mock immuno-depleted NBH or mock immuno-depleted cM1000). (C) Upper panel: A
representative western blot of PrP levels in 20 μL cM1000 at 100% TSD following a mock immuno-depletion with normal rabbit serum
(NRS) and an immuno-depletion with 03R19 antibody, and mild PK digestion. Lower panel: Quantification of total PrP (n = 4) and at
least modestly PK-resistant PrP (n = 2) immuno-depleted from cM1000 (from 100% of the TSD) by 03R19 relative to the controls
(probed with 8H4 antibody; molecular weight markers are provided at left). (D to G) LTP of WT mouse hippocampal slices following a
five minute treatment with 0.5% (w/v in aCSF) dM1000 from 30% (D), 50% (E), 70% (F), and 100% of the TSD (G) compared with the
LTP of slices treated with 0.5% (w/v in aCSF) dNBH controls (One-way ANOVA with Dunnett’s correction for multiple comparisons).
(H) The average LTPs, (I) the average percentage of PPF ratio decline, and (J) the average PTPs generated by WT mouse hippocampal
slices treated with dNBH and dM1000 from across time points of the disease progression were compared by One-way ANOVA with
Dunnett’s correction for multiple comparisons when comparing across time points. (D to G) The five minute treatment started after
8-to-10 minutes of stable baseline. The high frequency stimulation (HFS) trains were applied following 30 minutes of baseline
recordings. Results are presented as mean ± standard error of mean. (D-G, I & J) Some examples of raw fEPSP traces are provided as
insets. �p<0.05, ��p<0.01, ���p<0.001, ns = not statistically significant (p>0.05).
https://doi.org/10.1371/journal.ppat.1007712.g003
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M1000 preparations were mostly oligomers (>100KDa) wherein most PrPSc species were
eluted in fractions 1 to 10 (Fig 5B, 5D, 5F & 5H). In fact, the most noteworthy change at 30%
of the TSD is the loss of predominance of monomeric PrP species, with the predominance of
oligomers appearing to be maximised by 50% of the TSD (Fig 5B & 5D). No PK-resistant
PrPSc was detected in the fractions from 30% to 70% of the TSD employing routine western
blotting with only fractions from 100% TSD containing at least modestly PK-resistant PrPSc
species (Fig 5A, 5C, 5E & 5G lower panels).
Oligomeric PrPSc species propagated during M1000 prion disease
progression are acutely synaptotoxic to LTP
To assess the acute synaptotoxicity of different sized assemblies of PrPSc (predominantly
monomeric versus mainly oligomeric) at different time-points of the disease progression, we
pooled fractions 1 through 10 to generate oligomer enriched fractions (oM1000) and fractions
15 through 40 to create principally monomeric fractions (mM1000) and assessed their acute
synaptotoxicity on WT hippocampal slices. Similar fractions of NBH pooled together as oligo-
meric NBH (oNBH) and monomeric NBH (mNBH) were assessed for non-specific or back-
ground toxicity of brain homogenates introduced through size exclusion chromatography.
Crude M1000 brain homogenates (~0.5% w/v) from 100% of the TSD, and crude normal brain
homogenates (cNBH, ~0.5% w/v), both processed as for size exclusion chromatography (i.e.
Sarkosyl solubilization and exhaustive dialysis), were also used as positive and negative con-
trols for prion acute synaptotoxicity. PBS (1x) alone served as an additional technical negative
control for all fractions because it was the size exclusion chromatography buffer, as well as the
diluent for PrP fractions. Importantly, cNBH was not toxic to synaptic functions relative to 1x
PBS controls (S5A–S5C Fig). In addition, one-to-one dilution of oNBH and mNBH with
1xPBS did not cause any hippocampal synaptic disruption relative to 1xPBS controls (S5A–
S5C Fig). In contrast, however, one-to-one dilution of oM1000 from all time points appeared
to cause significant impairment of LTP (Fig 6A–6E) and PTP (Fig 6F). Unexpectedly, one-to-
one dilution of mM1000 from all the time points was also significantly synaptotoxic to LTP
(Fig 6A–6E) and PTP (Fig 6F) relative to 1xPBS controls (compared by One-way ANOVA
with Dunnett’s correction for multiple comparisons).
Given evidence that PrPSc exists in dynamic equilibria [38, 39] with the possibility that
monomers separated from oligomers by size exclusion chromatography might rapidly oligo-
merise in a physiological buffer, we checked if the pooled monomeric fractions prepared for
the toxicity assay remained monomers as assessed by native gel western blotting. We found
that monomers separated by size exclusion chromatography spontaneously oligomerised (to a
size approximating those observed in mM1000 pooled fractions) prior to assessing their acute
Fig 4. Acute synaptotoxicity at earlier time points of M1000 prion disease is associated with PK-sensitive prion protein species. (A)
Western blotting of 20μL of preparations obtained following immuno-precipitation of total PrP species from 1% (w/v) crude M1000 brain
homogenates (cM1000) from 30%, 50%, 70%, and 100% of M1000 disease progression to the terminal stage of disease (TSD; in WT C57BL6J
mice) and mild PK digestion (probed with 8H4; molecular weight markers are provided at left). (B) Quantification of at least modestly PK-
resistant PrP species obtained in A (by densitometry analysis) with the levels of PrP in each PK-eluted immuno-precipitated M1000
preparation (PK+IP-M1000) compared across the time points (One-way ANOVA with Tukey’s correction for multiple comparisons). (C to F)
LTP of WT mouse hippocampal slices following a five minute treatment with 0.5% (w/v in aCSF) PK+IP-M1000 from 30% (C), 50% (D), 70%
(E), and 100% (F) of the TSD compared with LTP of slices treated with 0.5% (w/v in aCSF) PK-eluted immuno-precipitated normal brain
homogenate (PK+IP-NBH) controls (One-way ANOVA with Dunnett’s correction for multiple comparisons). (G) The average LTPs, (H) the
average percentage of PPF ratio decline, and (I) the average PTPs generated by WT mouse hippocampal slices treated with PK+IP-NBH and
PK+IP-M1000 from across time points of the disease progression (compared by One-way ANOVA with Dunnett’s correction for multiple
comparisons). (C-F) The 5 minute treatment started after 8–to-10 minutes of stable baseline. The high frequency stimulation (HFS) trains
were applied following 30 minutes of baseline recordings. Results are presented as mean ± standard error of mean. (C-F, H & I) Some
examples of raw fEPSP traces are provided as insets. �p<0.05, ����p<0.0001, ns = not statistically significant (p>0.05).
https://doi.org/10.1371/journal.ppat.1007712.g004
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synaptotoxicity (Fig 6G & 6H), providing a plausible explanation for why pooled mM1000
preparations were also acutely synaptotoxic.
Propagation of transmitting M1000 prions and acutely synaptotoxic prions
display broadly similar temporal profiles
Despite evidence clearly supporting that PrPSc is responsible for disease transmission [8, 13] as
well as neurotoxicity in prion disease, there has been relatively limited exploration of the prop-
agation profiles of neurotoxic species compared with transmitting species [13, 21]. As
described above, the degree of synaptotoxicity in the form of LTP dysfunction across M1000
disease evolution progressively and significantly increased (Fig 2I lower panel; One-way
Fig 5. Size fractionation chromatography of M1000 brain homogenates prepared from different time points of the disease progression to the terminal
stage. (A, C, E, G) Representative anti-PrP immunoblots of fractions collected after size exclusion chromatography and solubilization of 10% (w/v) crude M1000
brain homogenates from 30% (A), 50% (C), 70% (E), and 100% of the terminal stage of disease (G). The fractions were immunoblotted before (top panel) and after
(bottom panel) mild proteinase K treatment (PK; 5μg/mL incubated at 37˚C for an hour). Since all 40 fractions could not be loaded in one 26-well gel, two 26-well
gels were used for the immunoblotting of fractions from one size exclusion experiment wherein the last fraction on the first gel was also loaded as the first lane on
the second gel, thereby allowing the levels of PrP on the second blot to be normalized to those on the first blot. The PrP species were probed by 03R19 antibody.
Molecular weight markers are provided at left. (B, D, F) Densitometric analysis of total PrP in fractions from 30% (B; n = 3), 50% (D; n = 3), 70% (F; n = 3) of the
terminal stage of disease. (H) Densitometric analysis of total PrP (PK-) and PrPSc (PK+) in fractions from the terminal stage of the disease (100%; n = 3). (B)
Densitometric analysis of the immunoblots of fractions from NBH (data were extracted from our previous publication Fig 3A [31]) is superimposed over the
results of M1000 fractions from 30% of the TSD to enhance comparison of PrP species in sham-inoculated mice to those at different stages of prion disease. All
data are displayed as mean ± SEM.
https://doi.org/10.1371/journal.ppat.1007712.g005
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ANOVA with Tukey’s correction for multiple comparisons; p<0.0001), whereas PTP
impairment did not significantly increase across the time points, which may relate to a “ceiling
effect” due to the apparent heightened pre-synaptic sensitivity to prion toxicity [31] (Fig 2I
upper panel; One-way ANOVA with Tukey’s correction for multiple comparison; p = 0.3306).
To qualitatively compare the propagation of acutely synaptotoxic PrPSc species to that of trans-
mitting species, we utilised our previous study of the temporal profile of M1000 infectivity in
WT mice following ic inoculation [8]. The infectivity titre (log ID50 units per μL of 1% [w/v]
M1000 brain homogenate) progressively increased from ~6.5 at ~30% of the TSD (~42 dpi) to
~6.9 at ~44% (~64 dpi) of the TSD to plateau at ~8.3 at ~72% of the TSD (~104 dpi). Hence,
when plotted for illustrative purposes (Fig 7A), there appeared to be broadly similar propaga-
tion profiles for transmitting and acutely synaptotoxic species albeit with plateauing of infec-
tivity noteworthy from ~72% of TSD while synaptotoxic species appear to continue to
modestly increase until terminal disease. Further, despite the degree of PTP impairment not
being significantly increased across the disease evolution, the overall profile of PTP dysfunc-
tion (as illustrated by the best-fit curve) during the disease progression appeared similar to
that of LTP dysfunction but at a higher level (Fig 7A).
Efficiently transmitting minimally synaptotoxic PrPSc species co-exist with
primarily acutely synaptotoxic PrPSc species at terminal disease stage
We previously showed that cM1000 and modestly PK-treated cM1000 prepared from brains at
100% of the TSD were equivalently synaptotoxic to WT hippocampal CA1 region LTP [31].
This acute synaptotoxicity was demonstrated to be directly associated with PrP species present
in cM1000 given the significant rescue of LTP impairment by selective immuno-depletion of
~79% total PrP from cM1000 (Fig 3A; including ~89% of at least modestly PK resistant PrPSc
[Fig 3C] and ~96% of highly protease-resistant PrPSc (resistant to 50μg/mL for one hour at
37˚C) (refer to Fig 2A–2C in [31]) through PrP immuno-precipitation. The direct contribu-
tion of PrPSc to this acute synaptotoxicity was further supported by the return of LTP
impairment following exposure of WT hippocampal slices to reconstituted, immuno-precipi-
tated PrPSc species eluted from pellets by modest PK treatment (Fig 4F and also refer to Fig
2G–2I in [31]).
To determine the infectivity of these various M1000 preparations (cM1000, PK+M1000,
dM1000 and PK+IP-M1000) at 100% of the TSD, we undertook incubation time interval bio-
assays employing routine ic inoculation of tga20 mice, euthanized once they reached the TSD
as reflected by reduced spontaneous activity, severe ataxia and hind limb paresis. Control
tga20 mice ic inoculated with cNBH did not develop features of prion disease by the time the
experiment was terminated (120 dpi). In contrast, the mean time to the TSD of mice
Fig 6. Acute synaptotoxicity of pooled oligomeric and monomeric PrPSc species. (A-D) LTP from WT hippocampal slices induced by
high frequency stimulation (HFS) following treatment for 5-minutes with 1xPBS negative control and M1000 preparations from 30% (A),
50% (B), 70% (C), and 100% (D) of the TSD. These M1000 preparations include crude M1000 brain homogenates (cM1000 positive
controls) and pooled M1000 fractions containing either predominantly PrP oligomers (oM1000) or PrP monomers (mM1000). The last
10-minutes of LTP recording of slices treated with M1000 preparations were compared to the LTP of slices treated with 1xPBS (by One-
way ANOVA with Dunnett’s correction for multiple comparisons). (E) The average LTPs and average PTPs (F) generated by WT mouse
hippocampal slices treated with cM1000, oM1000, and mM1000 from across time points of the disease progression were compared to 1x
PBS controls (by One-way ANOVA with Dunnett’s correction for multiple comparisons). (G) Native western blotting of M1000
preparations (20uL in 2% w/v Sarkosyl) used for treatments of WT slices in A-D revealing that monomeric PrPSc fractionated by size
exclusion chromatography appeared to have spontaneously become oligomers. Molecular weight markers are provided at left. (H)
Densitometry analysis of blots in G showing that most of the PrPSc species are oligomers with molecular weights (MW) of at least
150kDa. The 5-minute treatment started after 8–to-10 minutes of stable baseline. The high frequency stimulation (HFS) trains were
applied following 30 minutes of baseline recordings. Results are presented as mean ± standard error of mean. (A-D & F) Some examples
of raw fEPSP traces are provided as insets. �p<0.05, ��p<0.01, ���p<0.001, ����p<0.0001, ns = not statistically significant (p>0.05).
https://doi.org/10.1371/journal.ppat.1007712.g006
Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007712 April 10, 2019 20 / 29
Early existence and biochemical evolution characterise acutely synaptotoxic PrPSc
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007712 April 10, 2019 21 / 29
inoculated with dM1000 (60 ± 1.7 dpi) was similar to those inoculated with cM1000 (56 ± 1.8
dpi; p = 0.1737), while modestly but significantly shorter than those inoculated with PK+-
IP-M1000 (65 ± 1.3; p = 0.0360; Fig 7B & 7C). The mean time to the TSD of those mice inocu-
lated with PK+M1000 (61 ± 0.4 dpi) was not different from those infected with dM1000
(p = 0.7335), as well as PK+IP-M1000 (p = 0.2034) but significantly albeit minimally longer
than those infected with cM1000 (p = 0.0266; Fig 7B & 7C). The mean time to the TSD was
used to calculate the approximate infectivity titre of each M1000 preparation using a linear
regression formula (y = -11.02x + 111.8) obtained from previous quantal dose-titration of
M1000 prion infectivity in tga20 mice [8]. The estimated average infectivity titre (log10 ID50
units/g brain) of dM1000 (~8.9) was not different to cM1000 (~9.2; p = 0.1736) and PK
+M1000 (~8.8; p = 0.7320) but was significantly although minimally higher than the PK+-
IP-M1000 (~8.4; p = 0.0343; Fig 7D). Further, the infectivity titre of the PK+M1000 was signifi-
cantly lower than the cM1000 (p = 0.0265), but not significantly different from the PK
+IP-M1000 (p = 0.1961; Fig 7D). Noteworthy from these collective observations is the substan-
tially abrogated acute synaptotoxicity of dM1000 while retaining essentially unaltered high lev-
els of infectivity (despite removal of ~77% of total PrP species), which stands in contrast to the
prominent acute synaptotoxicity of PK+IP-M1000 with its modestly albeit significantly
reduced infectivity.
Discussion
The primary purpose of this body of work was to gain insights into the time of occurrence and
biophysical properties of acutely synaptotoxic PrPSc. Employing a combination of experimen-
tal approaches the current study has demonstrated some important observations, especially:
that acutely synaptotoxic PrPSc species related to M1000 prions are generated from early in
disease evolution generally coinciding with the propagation of transmitting species; and that
acutely synaptotoxic PrPSc species most likely constitute small oligomers, appearing to
undergo significant biochemical transformation relatively late in the incubation period, partic-
ularly transition from quite protease-sensitive to at least modestly protease-resistant. The early
presence of synaptotoxic conformers in combination with the relative stability of their size
fractionation profile and only comparatively modest increase in absolute acute synaptotoxicity
from 50% of the TSD suggests that progressive failure of neuro-protective mechanisms is likely
to be an important component of the eventual transition to overt prion disease.
The ability to detect the presence of acutely synaptotoxic PrPSc in the brains of M1000
infected mice at 30% of the TSD was independent of the host animal species (Balb/c or C57BL/
6J mice) and method of inoculation (routine or stereotaxic ic injection). Moreover, in further
contrast to the reported plateauing of the production of infectious PrPSc in the latter phase of
Fig 7. Evidence for efficiently transmitting minimally synaptotoxic PrPSc species co-existing with separate primarily
synaptotoxic species at terminal disease stage. (A) Concomitant representation of the degree of prion acute synaptotoxicity
across the disease progression calculated as the percentage of LTP and PTP decline from normal LTP together with titre of
infectivity (log ID50 units/g brain) across the designated time points as published previously [8]. (B) Kaplan-Meier survival
curves of tga20 mice intracerebrally (ic) inoculated with various 1% (w/v) preparations generated from brains of terminally
sick M1000 inoculated WT mice, including crude M1000 brain homogenates (cM1000), PrP-immuno-depleted cM1000
(dM1000), 5μg/ml proteinase-K (PK) digested cM1000 (PK+M1000), and reconstituted PK-eluted immuno-precipitated PrP
(PK+IP-M1000), as well as tga20 mice sham inoculated with crude NBH (cNBH). (C) Comparison of the average survival (day
post-inoculation; dpi) to the TSD in tga20 mice ic inoculated with cM1000, dM1000, PK+M1000, and PK+IP-M1000 (One-
way ANOVA with Tukey’s correction for multiple comparisons). (D) Comparison of the estimated mean infectivity titres
(log10 ID50 units/g brain) of the cM1000, dM1000, PK+M1000, and PK+IP-M1000 preparations (One-way ANOVA with
Tukey’s correction for multiple comparisons). The mean time to the TSD was used to calculate the approximate infectivity titre
of each M1000 preparation using a linear regression formula obtained from previous quantal dose titration of M1000 prion
infectivity in tga20 mice [8]. Data are presented as mean ± standard error of mean. �p<0.05, ���p<0.001.
https://doi.org/10.1371/journal.ppat.1007712.g007
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the disease [8, 12, 21], possibly related to declining PrPC levels [13], we found propagation of
synaptotoxic PrPSc appeared to increase throughout disease development although the capac-
ity of cM1000 to induce PTP failure appeared maximal even at the earliest stage of disease pro-
gression assessed, in keeping with previous findings suggesting an enhanced pre-synaptic
vulnerability [31]. The explanation for discrepancies in the reported time of occurrence of neu-
rotoxic PrPSc conformers during disease progression is unclear. Some evidence suggests that
the prion strain utilised is unlikely to be a major influence [22] underscoring that methodolog-
ical factors, especially the sensitivity of techniques employed to discern neurotoxicity may be
important contributors. Indeed, we have recently argued that somewhat hindering previous
efforts to detect neurotoxic prion species present in ex vivo preparations from early time points
of disease has been the relative lack of tractable, sensitive, detection paradigms [27]. Congruent
with this speculation is that in vivo studies reporting the late, sequential propagation of neuro-
toxic PrPSc species have relied primarily on the occurrence of typical clinical features of
murine prion disease [12, 21], while those describing findings supporting an earlier propaga-
tion of toxic conformers have utilised techniques such as serial specific electrophysiological or
behavioural interrogation across the incubation period [18, 20]. Of particular note, the obser-
vation of acutely synaptotoxic PrPSc at 30% of the TSD aligns with a study reporting progres-
sive failure of hippocampal CA1 LTP from ~44% of the incubation period during ME7 prion
infection [18] and also correlates with our previous report that in vivo M1000 infection is asso-
ciated with elevated by-products of lipid peroxidation from ~30% of the TSD with typical
neuropathological changes occurring from ~57% of the TSD, well in advance of the plateauing
of infectivity at ~72% of the TSD [8]. Evidence also supports that elevated free radicals in
neurodegenerative diseases are neurotoxic and can impair synaptic functions [40–42]. Because
the levels of free by-products of lipid peroxidation are elevated at earlier stages of M1000 prion
disease [8], we cannot exclude that part of the early synaptotoxicity is due to the presence of
free radicals related to propagation of PrPSc; however, the abrogation of synaptotoxicity with
selective immuno-depletion of PrP coupled to the fact that levels of free lipid peroxidation by-
products progressively decline from around 50% of the TSD [8] appears inconsistent with
heightened oxidative stress being the primary driver of the progressive increase in the synapto-
toxicity across the latter disease progression that we (in this study) and others [18] have
observed.
Previously we reported that acutely synaptotoxic PrPSc at the TSD in M1000 infection were
most likely constituted as small oligomers [31]. The present findings elaborate this observation
and suggest that acutely synaptotoxic PrPSc species are oligomeric from inception as well as
protease-sensitive, which is in broad agreement with previous suggestions regarding the bio-
physical nature of neurotoxic species during disease progression [13, 34]. The observed bio-
chemical evolution of such oligomeric PrPSc relatively late in the incubation period (after 70%
of the TSD) from quite protease-sensitive to at least modestly protease-resistant is consistent
with a previous report using the same prion strain (Fukuoka-1) [8, 34]. Further illustrating the
biochemical transformation of PrPSc in the latter part of the incubation period and similar to
what was reported by Sasaki and colleagues [34] is the apparently altered solubility or interac-
tion of misfolded PrPSc conformers in NaPTA. Notwithstanding the reduced sensitivity of rou-
tine western blot detection, we observed very little PrPSc after modest PK digestion at 70% of
the TSD without NaPTA pre-treatment while substantial quantities were detectable when uti-
lising NaPTA precipitation. Of note though, despite PK-resistant PrPSc levels being substan-
tially increased at 70% of the TSD as determined by employing NaPTA pre-treatment of
cM1000, they do not yet represent the acutely synaptotoxic PrPSc species given that modest
protease treatment is able to completely attenuate the synaptotoxicity of immuno-precipitated
PrPSc derived from this time point. These findings underscore a likely cumulative or step-wise
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maturation of the biophysical properties of synaptotoxic oligomers with protease-resistance
perhaps one of the last hallmark changes to occur.
Acknowledging the reported inherent imprecision of incubation time interval assays (±0.5
log10 median infective dose units) when calculating infectivity [3], we believe only estimates
outside this range are reliably different. Importantly, our bioassays showed that the estimated
infectivity of dM1000 was not clearly different to that of mice inoculated with cM1000, while
PK+IP-M1000 was lower in infectivity with respect to cM1000 and probably significantly
reduced compared to dM1000. It is noteworthy that although a ~0.8 log10 relative decrease in
infectivity between cM1000 and PK+IP-M1000 preparations appears rather modest it equates
to an absolute reduction of the order of 1,300 million ID50 units/g brain. It is also worth
emphasising that while depletion of ~79 ± 7% of total PrP to generate dM1000 at 100% of the
TSD was sufficient to significantly ameliorate synaptotoxicity, the remaining ~21% harboured
infectivity that was not clearly different to that contained in cM1000 brain homogenate. Fur-
ther, employing the same immuno-depletion method, including anti-PrP capture and detec-
tion antibodies, we previously showed that an essentially identical reduction in total PrP
species of ~77 ± 9% from cM1000 at 100% of the TSD was associated with ~96 ± 4% reduction
in highly protease-resistant PrPSc [31] in addition to the ~89% reduction of at least modestly
PK-resistant species we now report, with reciprocal enrichment of PK-resistant PrPSc con-
firmed in PK+IP-M1000 preparations. Consequently, the unaltered infectivity in the presence
of substantial depletion of PK-resistant PrPSc in dM1000 supports that the residual predomi-
nantly PK-sensitive conformers are highly infectious species.
We previously attributed the ongoing impairment of PTP by dM1000 at 100% of the TSD
to an enhanced pre-synaptic vulnerability to the small residual amount of PK-resistant PrPSc
[31]; however, some refinement of this simple explanation appears necessary when trying to
encompass results at earlier time points. At 70% of the TSD, despite similar absolute amounts
of total PrP remaining after immuno-depletion when compared to 30% and 50% of the TSD,
only dM1000 from 70% caused PTP impairment, with modest PK treatment of the comple-
mentary 60% of total PrP captured in the immuno-precipitated pellets able to completely abro-
gate any acute synaptotoxicity. Although alternative explanations cannot be excluded, these
data are compatible with a differential interaction of the immuno-capturing antibody with
PK-sensitive synaptotoxic PrPSc at 70% of the TSD stemming from its evolving biochemical
transformation (akin to the differential interaction of PrPSc with NaPTA at this time point), as
suggested by previous results we reported (Fig 3 [31], compare panel F with panel H), such
that less PTP impairing species are removed by immuno-precipitation leaving sufficient to
impair this pre-synaptic function. In addition, we also reported that PK+IP-M1000 prepara-
tions at 100% of the TSD contained full acute synaptotoxicity equivalent to or even a little
greater than that caused by cM1000 [31]. Collectively we construe these previous and present
findings as supporting the likelihood that pathogenic PrPSc at 100% of the TSD clusters into at
least two overlapping but relatively separable biophysical ensembles: one, PrPSc species that
are minimally or non-synaptotoxic but highly efficient in transmission harbouring little PK-
resistance; and a second group, highly synaptotoxic species replete in PK-resistant conformers
that retain substantial infectivity. Given that the infectivity titres estimated by our incubation
time interval approach for all preparations were within a one log10 of each other suggests that
infectivity is perhaps an integral feature of all PrPSc species at the TSD.
The observation that acutely synaptotoxic PrPSc up to and including 70% of the TSD was
highly protease-sensitive rendered our experimental approach (PrP immuno-precipitation
coupled to elution through modest PK treatment of pellets) impracticable to rigorously assess
whether separable pathogenic species could be verified at earlier time points; consequently
we restricted these evaluations to 100% of the TSD by which stage acutely synaptotoxic
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conformers are sufficiently resistant to the modest PK treatment required to elute them from
immuno-precipitation pellets to allow their subsequent use in electrophysiology experiments.
Also, although size exclusion chromatography profiles appeared generally similar over the dis-
ease evolution albeit with an apparent increase in predominance of higher molecular weight
fractions between 30% and 50% of the TSD, we did not quantify absolute amounts of PrPSc
species. Hence, this leaves unresolved whether acutely synaptotoxic PrPSc species, especially
PK-sensitive species at earlier time points in disease evolution, may harbour greater synapto-
toxicity per notional “toxic unit” and whether the intrinsic synaptotoxicity per “toxic unit” can
change over the course of disease evolution. This concept is similar to that of a previous study
of the M1000 prion strain utilising subcellular fractions containing PrPSc prepared from
M1000-infected mouse RK13 cells wherein some fractions were shown to harbour equally effi-
cient transmissibility despite much lower levels of PK-resistant PrPSc [43].
In summary, the current study is the first practical application of our recently developed
electrophysiological paradigm designed to assess the presence of acutely synaptotoxic ex vivo
PrPSc, demonstrating that synaptotoxic species related to M1000 prions are generated from
early in disease evolution broadly overlapping the propagation profile of transmissible species.
The very short period over which our assay is performed militates against significant propaga-
tion of de novo synaptotoxic PrPSc and also limits the time available for attenuating compensa-
tory or neuroprotective mechanisms thereby enhancing the specificity and sensitivity for
detecting directly synaptotoxic species. Conventional indicators of the presence of neurotoxic
prion species during disease evolution such as the presence of neuropathological changes or
the development of overt clinical signs [12, 27] are arguably less sensitive metrics because they
only become manifest when overall or regional adaptive and/or neuroprotective CNS thresh-
olds have been persistently exceeded by accumulating neurotoxic species [28].
Supporting information
S1 Fig. Routine western blotting of crude brain homogenates from M1000-infected mice
and sham-infected mice. (A) Western immunoblots of 20 μL crude 1% (w/v) M1000 brain
homogenates (cM1000) from 30%, 50%, 70% and 100% of M1000 prion disease progression to
the terminal stage disease (TSD) before (-) and after (+) digestion with PK (5μg/mL) at 37˚C
for an hour (Upper panel: PK-; Lower panel: PK+). PrP species were probed with 8H4 anti-
body. Total protein was stained with Commassie blue stain (Coom.) as a loading control. (B)
Western immunoblots of 20 μL crude 1% (w/v) normal brain homogenates (cNBH) obtained
from mice sham inoculated with uninfected brain homogenates and culled at time points
equivalent to the 30%, 50%, 70% and 100% of the TSD of M1000 disease showed no change in
total PrP or any evidence of PK-resistant PrP. PrP levels before and after PK digestion (5μg/
mL at 37˚C for an hour) were probed with 03R19 antibody.
(TIF)
S2 Fig. Other electrophysiology results related to Fig 2. (A) The average LTPs, (B) the aver-
age PTP, and (C) the average percentage of PPF ratio decline generated by slices treated with
cNBH compared to aCSF technical controls by unpaired Student’s t-test. (D) Average proba-
bility of neurotransmitter release evoked by each of the three HFS trains (T1, T2, & T3; deter-
mined by dividing the fEPSP amplitude of pulse 2 by that of pulse 1) were compared within
each treatment group by One-way ANOVA with Dunnett’s correction for multiple compari-
sons. (E) Readily releasable pool (RRP) depletion during (E) T1, (F) T2, and (G) T3 in slices
treated with cNBH compared to aCSF controls by one phase decay exponential function (com-
paring the time-constant of fEPSP amplitude decay from pulse 3 to pulse 9). RRP depletion
during (H) T1, (I) T2, and (J) T3 in slices treated with cNBH compared to cM1000 from across
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four time-points of the disease progression. Replenishment of RRP following each train of the
three HFS trains was measured in slices treated with (K) aCSF controls, (L) cNBH, and
cM1000 from (M) 30%, (N) 50%, (O) 70% and (P) 100% of the TSD. See Methods for how the
RRP size and RRP replenishment were estimated. Results are presented as mean ± standard
error of mean. �p<0.05, ��p<0.01, ���p<0.001, ns = not statistically significant (p>0.05).
(TIF)
S3 Fig. Other electrophysiology results related to Fig 3. The average LTPs, (B) the average
PTP, and (C) the average percentage of PPF ratio decline generated by slices treated with
dNBH compared to aCSF technical controls by unpaired Student’s t-test. (D) Average proba-
bility of neurotransmitter release evoked by each of the three HFS trains (T1, T2, & T3; deter-
mined by dividing the fEPSP amplitude of pulse 2 by that of pulse 1) were compared within
each treatment group by One-way ANOVA with Dunnett’s correction for multiple compari-
sons. (E) Readily releasable pool (RRP) depletion during (E) T1, (F) T2, and (G) T3 in slices
treated with cNBH compared to aCSF controls by one phase decay exponential function (com-
paring the time-constant of fEPSP amplitude decay from pulse 3 to pulse 9; see Methods for
details). RRP depletion during (H) T1, (I) T2, and (J) T3 in slices treated with dNBH compared
to dM1000 from across four time-points of the disease progression. Replenishment of RRP fol-
lowing each train of the three HFS trains was measured in slices treated with (K) aCSF con-
trols, (L) dNBH, and dM1000 from (M) 30%, (N) 50%, (O) 70% and (P) 100% of the TSD. See
Methods for how the RRP size and the RRP replenishment were estimated. Results are pre-
sented as mean ± standard error of mean. �p<0.05, ��p<0.01, ���p<0.001, ns = not statistically
significant (p>0.05).
(TIF)
S4 Fig. Other electrophysiology results related to Fig 4. The average LTPs, (B) the average
PTPs, and (C) the average percentages of PPF ratio decline generated by slices treated with
dNBH compared to aCSF technical controls by unpaired Student’s t-test. Results are presented
as mean ± standard error of mean. ns = not statistically significant (p>0.05).
(TIF)
S5 Fig. Electrophysiology results related to pooled size fractionated M1000 and normal
brain homogenates displayed in main Fig 6. (A) LTP of WT mouse hippocampal slices fol-
lowing a five-minute treatment with 1x PBS negative technical control compared to ~0.5% (w/
v in 1x PBS) cNBH after processing for size exclusion chromatography, as well as pooled oligo-
meric and monomeric fractions of NBH after size fractionation in 1x PBS. The five-minute
treatment started after eight to 10 minutes of stable baseline. The high frequency stimulation
(HFS) trains were applied following 30 minutes of baseline recordings. The average LTPs (B)
and average PTPs (C) of slices treated with cNBH, oNBH, and mNBH were compared to those
of slices treated with 1x PBS by One-way ANOVA with Dunnett’s correction for multiple com-
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Markers of A1 astrocytes stratify to molecular
sub-types in sporadic Creutzfeldt–Jakob
5 disease brainAQ1
Cathryn L. Ugalde,1 Victoria Lewis,2 Christiane Stehmann,2 Catriona A. McLean,2,3
Victoria A. Lawson,4 Steven J. Collins2,5 and Andrew F. Hill1AQ2
10
Astrocytes are glial cells of the central nervous system that become reactive under conditions of stress. The functional properties of
reactive astrocytes depend on their stimulus that induces the upregulation of specific genes. Reactive astrocytes are a neuropatho-
logical feature of prion disorders; however, their role in the disease pathogenesis is not well understood. Here, we describe our
studies of one polarization state of reactive astrocytes, termed A1 astrocytes, in the frontal cortex region of 35 human sporadic
15 Creutzfeldt–Jakob disease brains encompassing a range of molecular sub-types. Examination of two mRNA markers of A1 astro-
cytes, C3 and GBP2, revealed a strong linear correlation between the two following their log-normalization (P¼ 0.0011). Both
markers were found upregulated in the sporadic Creutzfeldt–Jakob disease brain compared with age-matched control tissues
(P¼ 0.0029 and 0.0002, for C3log and GBP2log, respectively), and stratifying samples based on codon 129 genotype revealed that
C3log is highest in homozygous methionine and lowest in homozygous valine patients, which followed a linear trend (P¼ 0.027).
20 Upon assessing other disease parameters, a significant positive correlation was found between GBP2log and disease duration
(P¼ 0.031). These findings provide evidence for a divergence in the astrocytic environment amongst patients with sporadic
Creutzfeldt–Jakob disease based on molecular sub-type parameters of disease. While more research will be needed to determine the
global changes in the genomic profiles and resulting functional properties of reactive astrocytes in disease, considering the evidence
demonstrating that A1 astrocytes harbour neurotoxic properties, the changes seen in C3log and GBP2log in the current study may
25 reflect differences in pathogenic mechanisms amongst the sporadic Creutzfeldt–Jakob disease sub-types associated with the A1 po-
larization state.
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Abbreviated summary
Two RNA markers of A1 astrocytes were assessed in 35
sporadic Creutzfeldt–Jakob disease brain tissues that rep-
resented various molecular sub-type parameters.
5 Following log-normalization, we show that the A1 astro-
cyte markers C3log and GBP2log stratify to disease
parameters: C3log stratifies to codon 129 genotype and
GBP2log positively correlates to disease duration.
Introduction
10 Prion disorders are a group of transmissible, incurable
neurodegenerative conditions that affect humans and ani-
mals. These diseases are caused by ‘prions’ (Prusiner,
1982) that are composed predominantly, if not entirely
of PrPSc, which is a misfolded isoform of the normal cel-
15 lular prion protein, PrPC. The ability of PrPSc to auto-
catalytically propagate, by inducing the template-driven
misfolding of PrPC, is the central pathogenic event in dis-
ease. Amplification of PrPSc with resultant accumulation
results in neuronal loss in the CNS, as well as wide-
20 spread vacuolation and reactive astrogliosis and micro-
gliosis through unresolved mechanisms.AQ5
In humans, around 85% of Creutzfeldt–Jakob disease
(CJD) cases are sporadic CJD (sCJD) with an unknown
aetiology. An important genetic component in sCJD is
25 the genotype [either valine (V) or methionine (M)] at
codon 129 in the human prion protein gene with homo-
zygous genotypes [homozygous methionine (MM) or
homozygous valine] being over-represented compared
with the heterogeneous methionine/valine genotype after
30 standardization to their frequency in the normal popula-
tion (Palmer et al., 1991; Alperovitch et al., 1999; Parchi
et al., 1999). Historically, sCJD-associated PrPSc was dis-
tinguished from PrPC by its resistance to proteinase K di-
gestion with different banding patterns of the
35 glycosylated and unglycosylated isoforms of proteinase K-
resistant PrP (especially mobility of the unglycosylated
band) constituting identifiable ‘molecular types’ in the
brains of such patients (Collinge et al., 1996; Parchi
et al., 1996; Hill et al., 2003). The presence of proteinase
40K-resistant PrP types suggests that different conformations
of PrPSc exist and, in combination with codon 129 geno-
type, defines various molecular sub-types of sCJD corre-
lating with features of disease including disease duration
and clinical presentation (Collinge et al., 1996; Parchi
45et al., 1999; Hill et al., 2003; Bishop et al., 2010). The
correspondence of distinct clinical features with molecular
sub-types suggests that divergent pathogenic mechanisms
exist, although the neurobiological mechanisms underpin-
ning these associations are not well understood.
50Astrocytes are important glial cells of the CNS that be-
come reactive in states of stress, causing them to adopt
protective or damaging properties (reviewed in Liddelow
and Barres, 2017). Two states of polarization have been
observed for reactive astrocytes whereby specific activa-
55tors cause the upregulation of certain genes (Zamanian
et al., 2012), the combination of which is considered to
dictate the cell’s functional phenotype. This has been
thoroughly characterized for one of these states, termed
A1 reactive astrocytes, that harbour highly neurotoxic
60properties (Liddelow et al., 2017). While more research is
needed to determine the extent of these neurotoxic prop-
erties in disease models, the observation that A1-specific
astrocyte markers C3 and GBP2 co-localize with astro-
cytes in the frontal cortex of sCJD brain (Hartmann
65et al., 2019) confirms that they are present in disease;
however, it is not known whether these cells preferential-
ly occur in disease of a certain molecular sub-type.
In the current study, we measured mRNA expression
of the aforementioned A1 markers in frontal cortex sam-
70ples from a cohort of 35 patients with sCJD , encom-
passing various molecular sub-types, and eight healthy
age-matched controls. In further support of C3 and
GBP2 as specific markers of A1 astrocytes, we report a
strong correlation between the two in human brain and
75confirm both are elevated in sCJD. Critically, we found
that C3log stratified to codon 129 genotype. Moreover,
we report C3log and GBP2log expression levels associated
with glycotype within codon 129 groups and observed a
significant positive correlation between GBP2log and dis-
80ease duration of patients with sCJD. These differences in
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the expression of the A1 astrocyte markers suggest that
the reactive astrocyte environment differs between the
molecular sub-types in sCJD. While further research into
the genetic and functional properties of A1 astrocytes
5 will provide important insight into the nature of these
changes, their reported neurotoxic properties (Liddelow
et al., 2017) suggest that their differential expression may
contribute to divergences in prion disease pathogenesis
amongst the molecular sub-types.
10 Materials and methods
Patient selection
The use of human tissue in this study was with the ap-
proval of La Trobe Human Research Ethics Committee
(HEC18004), and all consent was obtained according to
15 the Declaration of Helsinki. sCJD brain tissues were
obtained from the Australian National CJD Registry, and
control brain tissues were obtained from the Victorian
Brain Bank. Frozen tissue was from the frontal cortex.
For sCJD samples, cases for analysis were chosen from
20 research-consented tissues after the consideration of dis-
ease duration of the patient, proteinase K-resistant PrP
glycotype (Types 1–3) and codon 129 genotype, deter-
mined as described previously (Lewis et al., 2005).
Diagnostic tests that may indicate prion disease ante-mor-
25 tem include the detection of 14-3-3 protein in the CSF,
an abnormal electroencephalogram showing periodic
sharp wave activity and brain magnetic resonance imag-
ing showing increased T2 signal in the basal ganglia and/
or cerebral cortex. Whenever available, the following
30 additional information was collected: age, gender, post-
mortem delay, years of storage and results of ante-mor-
tem clinical assessment for suspected CJD reviewed as
per established diagnostic criteria (Will, 1999; Will et al.,
2000). The control brain tissues used in this study were
35 chosen according to the following criteria: (i) a non-
neurological cause of death as reported from the Coroner
or Full Medical Cause of Death Certificate written by the
donor’s General Practitioner, (ii) no known neurological/
psychiatric history in the donor’s general medical history,
40 obtained from their treating doctor and (iii) absence of
amyloid-b and tau (proteins found aggregated in the
brain in many neurodegenerative proteinopathies, includ-
ing Alzheimer’s disease) deposition in brain tissue sections
following immunostaining to detect these proteins. The
45 sCJD and control cohorts had an M:F gender ratio of
1:1.5 and 1:0.6, respectively.
RNA isolation from human brain
Extraction of RNA from human brain tissues was per-
formed using the QIAzol lysis buffer and the RNeasy
50 RNA isolation kit (Qiagen) according to the manufac-
turer’s instructions with the following adjustments:
5PRIME phase lock gel light tubes were used for phase
separation to physically separate the aqueous from the
interphase and the organic phase. The isolated aqueous
55phase was diluted 2:1:1 with chloroform and RNA-free
water in fresh phase lock tubes, vortexed and centrifuged
again. This was repeated for two chloroform extractions
in total. After phase separation, tubes were checked to
ensure the gel separating the phases resolved below the
60aqueous phase. In cases where the density of the sample
was greater than the gel, RNA-free water was injected
under the gel to reduce the density of the aqueous phase;
the sample was then vortexed and centrifuged again.
RNA was isolated in 60 ll of RNA-free water and purity
65and concentration determined using NanoDrop.
Reverse transcriptase and real-time
qualitative PCR
cDNA was produced using the high-capacity cDNA re-
verse transcriptase kit, gene primers and fast advanced
70master mix by PCR under the following conditions: 25C
for 10 min, 37C for 120 min, 85C for 5 min and then
held at 4C. RT-qPCR (Taqman Fast Advanced Master
Mix; Applied Biosystems) was performed using the fol-
lowing Taqman gene expression array primers (Life
75Technologies): RPLP0: Hs00420895_gH, C3:
Hs00163811_m1 and GBP2: Hs00894837_m1. Samples
were processed using a ViiA7 Real-Time PCR System
(Life Technologies) whereby each biological replicate was
run in triplicate and normalized to the house-keeping
80gene RPLP0. Normalization of Ct values of each gene
and determination of fold differences in gene expression
(normalized to control samples) were calculated by the
2DDCt method. QuantStudioTM Real-Time PCR software
(Applied Biosystems) was used to analyse the data.
85Statistical analysis
All data were assessed for outliers (ROUT Q¼ 1%) and
normality (Shapiro–Wilk test). Pearson r correlation ana-
lysis was performed to determine the relationship between
two normally distributed variables. Disease duration data
90was non-normally distributed and contained statistical
outliers and so Spearman r correlation was used to assess
this dataset. Statistical differences of mRNA between
groups were examined using two-tailed Student’s t-test or
one-way ANOVA with a multiple comparisons test for
95linear trend. All statistical analyses were performed using
GraphPad Prism with a statistical criterion of 0.05. AQ6
Data availability
Upon reasonable request, the data that support the find-
ings of this study are available from the corresponding
100author.
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Results
Assessment of the relationship
between two markers of A1
astrocytes, C3 and GBP2, in human
5 brain
Patient information and molecular sub-type analysis of
the 35 pathologically confirmed subjects with sCJD used
in this study are shown in Table 1. The outcome (when
available) of clinical investigations indicative of CJD is
10 also summarized here. Eight normal brains were used as
controls, which were age-matched to the disease cohort
(Supplementary Fig. 1). Patient information of the control
cohort is shown in Table 2.
The utility of C3 and GBP2 to serve as markers of A1
15 astrocytes in human brain has been confirmed previously
(Liddelow et al., 2017; Hartmann et al., 2019). The
translated proteins co-localize with astrocytes in the
frontal cortex of human prion-diseased brain (Hartmann
et al., 2019). Using fluorescence in situ hybridization, C3



























MM 1 6 1, 5 72 (58–81) 2.2 (1–3) 5/5 5/5 2/5 1.5 (0–3) 11.5 (5–12)
MM 2 6 2, 4 64 (60–82) 4.6 (1.5–9.6) 5/5 6/6 4/5 2 11.5 (9–13)
MM 3 6 4, 2 56.5 (47–85) 8.4 (2–21) 4/4 3/5 1/4 1 (0–2) 11.5 (8–15)
MV 1 2 1, 1 65.5 (58–73) 1.8 (1.5–2.1) 2/2 2/2 1/2 2 (1–3) 14 (11–17)
MV 2 4 2, 2 67 (63–74) 2.7 (2–8) 4/4 3/4 0/4 3 11.5 (7–13)
MV 3 5 1, 4 67 (50–75) 11.5 (6–40.5) 4/4 3/3 1/3 2.5 (2–6) 12 (10–15)
VV 3 6 3, 3 71 (59–78) 4.5 (2–6.5) 6/6 3/3 1/5 4 (2–6) 11 (6–15)
Total 35 14, 21 67 (47–85) 3.5 (1–40.5) 30/30 25/28 10/28 2 (0–6) 12 (5–17)
Disease duration and age are represented as median (range). Wherever performed, outcome of ante-mortem clinical testing results suggestive of CJD are provided. Variables relating
to tissue handling are included as PMD and storage time of tissues prior to experimental use.AQ12
aValues indicate the number of positive outcomes/total number of results available.
bValue indicates number reported, where information is available.
PMD, post-mortem delay; F, female; M, male; VV, homozygous valine; PrPres, proteinase K-resistant PrP; MV, heterozygous methionine/valine.
Figure 1 Correlation analysis of two mRNA markers of A1
astrocytes, GBP2 and C3, following log-transformation.
Symbols represent the following: , control; , sCJD frontal
cortex brain tissues. GBP2log and C3log significantly correlate
(Pearson r test, P¼ 0.0011). Graph shows line of best fit, and
dotted lines show the 95% confidence interval (95% CI¼ 0.2111–
0.6827, r¼ 0.4810); n¼ 43.
Table 2 Summary of control donor information: donor information, including cause of death of control cases
Diagnosis Sex Age (years) Cause of death PMD (days) Storage
(years)
Control M 75 Abdominal aortic aneurysm 1 12
Control M 73 Ischaemic heart disease 0 14
Control M 77 Acute posterolateral myocardial infarction 2 15
Control M 48 Cardiac failure 2 13
Control M 57 Intra-abdominal haemorrhage 0 11
Control F 60 Pancreatic cancer 1 1
Control F 68 Pulmonary thromboembolism 2 14
Control F 81 Metastatic endometrial stromal sarcoma 1 6
Median (range) 70 (48–81) 1 (0–2) 12.5 (1–15)
Variables relating to tissue handling are included as PMD and storage time of tissues prior to experimental use.
PMD, post-mortem delay; F, female; M, male.
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selectively co-localizes with astrocytes and its mRNA is
elevated in a range of neurodegenerative diseases associ-
ated with A1 astrocyte reactivity (Liddelow et al., 2017).
As specific markers for the same cell population and
5 given their low basal expression in the CNS under nor-
mal conditions (Fagerberg et al., 2014), it is expected
that C3 and GBP2 correlate within diseased and healthy
human brain, although this has not been confirmed.
Therefore, we first performed correlation analysis be-
10 tween C3 and GBP2 using all brain tissues. Data were
non-normally distributed and hence log-normalization
was performed for results of all samples. Assessment of
the correlation between C3log and GBP2log was found to
be strongly significant (Fig. 1, n¼ 43, P¼ 0.0011) suggest-
15 ing that either may be used to describe the A1 phenotype
but does not exclude some degree of complementarity.
Accordingly, the A1 astrocyte markers were subsequently
assessed in the sCJD cohort with respect to the molecular
sub-types of disease.
20C3log and GBP2log stratify to
molecular sub-type parameters in
sCJD brains
The expression of C3log and GBP2log was examined in
both sCJD and control brain tissues. C3log was signifi-
25cantly elevated in sCJD brain tissues compared with con-
trol counterparts (Fig. 2A, P¼ 0.0029). Using the sCJD
samples, these data were then divided into groups accord-
ing to the genotype at codon 129 of the patient.
Following this stratification to genotype, a significant dif-
30ference was found in C3log expression between the
groups that exhibited a linear trend whereby MM sam-
ples had the highest and homozygous valine had the low-
est C3log expression (Fig. 2B, P¼ 0.027). Likewise,
GBP2log was also elevated in sCJD brain compared with
35control tissues (Fig. 2C, P¼ 0.0002). Although a similar
trend was observed, unlike C3log, GBP2log stratification
according to codon 129 did not reach significance
(Fig. 2D). The expression of both markers in sCJD tis-
sues was subsequently subdivided according to the pro-
40teinase K-resistant PrP glycotype and the codon 129
genotype (Fig. 3A and C). While no significant differences
were identified amongst the groups, Type 3 patients of
both MM and heterozygous methionine/valine genotypes
exhibited the highest C3log and GBP2log mean values
45compared with Type 1 and Type 2 counterparts. Type 1
cases in both MM and heterozygous methionine/valine
typically have shorter disease durations than Type 3
counterparts (Lewis et al., 2005); hence, correlation ana-
lysis was next performed between C3log or GBP2log and
50disease duration (Fig. 3B and D). A significant positive
correlation was found between disease duration and
GBP2log (Fig. 3D, P¼ 0.031). No significant correlation
was observed between disease duration and C3log
(Fig. 3B). Neither C3log nor GBP2log correlated with
55other patient variables (gender, age, post-mortem delay
or years of tissue storage) in either the control or sCJD
groups (Supplementary Figs 2 and 3).
Discussion
Reactive A1 astrocytes have been reported to exhibit
60powerful neurotoxic properties (Liddelow et al., 2017).
These cells are present in sCJD brain (Hartmann et al.,
2019), as well as brains from a range of other neurode-
generative conditions (Liddelow et al., 2017). In a trans-
genic rodent model of Parkinson’s disease, ablating the
65cytokines that stimulate their production results in neuro-
protection (Yun et al., 2018). Likewise, an A1 profile is
Figure 2 Expression of reactive A1 astrocyte markers in
sCJD and control frontal cortex brain tissues and
stratification to codon 129 genotype in sCJD. Symbols
represent the following: , control; , sCJD brain tissues.
(A) C3log was significantly elevated in sCJD brain tissues compared
with control samples (Student’s t-test, n¼ 8,35, P¼ 0.0029) and (B)
in the sCJD tissues C3log expression stratified according to codon
129 genotype (one-way ANOVA with a multiple comparisons test
for linear trend, n¼ 18,11,6, P¼ 0.027). (C) GBP2log was
significantly elevated in sCJD brain tissues compared with control
samples (Student’s t-test, n¼ 8,35, P¼ 0.0002). (D) Stratifying
GBP2log expression to codon 129 genotype was not statistically
significant (one-way ANOVA with a multiple comparisons test for
linear trend, n¼ 18,11,6).AQ13
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observed in a tauopathy mouse model (Shi et al., 2017).
These studies have led to merited discussion on A1 astro-
cytes as a therapeutic target for neurodegenerative disor-
ders that are associated with their activation [reviewed in
5 Liddelow and Barres (2017)].
It is well established that sCJD is phenotypically high-
ly heterogeneous, with several groups reporting clinical
correlation with molecular sub-type parameters of dis-
ease (Collinge et al., 1996; Parchi et al., 1999; Hill
10 et al., 2003; Bishop et al., 2010). It is not known
whether any given sub-type is particularly vulnerable to
produce an A1 environment. In this study, we confirm
that two markers of A1 astrocytes are significantly
elevated in sCJD brain and that they associate with
15 disease parameters: C3log stratifies to codon 129
genotype while GBP2log positively correlates to disease
duration.
In rodents, A1 astrocytes can be induced by factors
released from activated microglia following exposure to the
20proinflammatory molecule lipopolysaccharide (Zamanian
et al., 2012; Liddelow et al., 2017). Hence, the generation
of A1 astrocytes is intimately related to inflammation.
Their stratification to codon 129 status in sCJD suggests
that disease associated with the 129MM genotype exhibits
25enhanced microglial and inflammatory responses. This is
consistent with another study showing that microglial
(CD11b, CD68) and proinflammatory (TNFa) markers are
elevated in frontal cortex sCJD tissues of 129MM com-
pared with 129 homozygous valine (Llorens et al., 2014).
30However, the relevance of the codon 129 genotype to A1
astrocytes may also be related to astrocyte-specific PrP
propagation. Astrocytes are amenable hosts for prion repli-
cation and astrocytes derived from human stem cells host
prion replication most efficiently when the infecting inocu-
35lum (derived from human sCJD brain) has the same codon
129 genotype as the stem cells (Krejciova et al., 2017).
Given that the astrocyte-specific marker, GFAP, appears
in concert with PrPSc deposition in human sCJD brain
Figure 3 Expression of A1 markers in sCJD frontal cortex brain tissues based on codon 129 and PrPres glycotype and
correlations to disease duration. (A) C3log expression grouped by PrP
res glycotype and genotype at codon 129 (n¼ 6,6,6,2,4,5,6) and (B)
C3log did not correlate with disease duration (Spearman r correlation, n¼ 35). Graph shows line of best fit, and dotted lines show the 95%
confidence interval (95% CI¼0.2817 to 0.4002, r¼ 0.06707). (C) GBP2log expression grouped based on PrPres glycotype and genotype at
codon 129 (n¼ 6,6,6,2,4,5,6) and (D) GBP2log correlated with disease duration (Spearman r correlation, n¼ 35). Graph shows line of best fit,
and dotted lines show the 95% confidence interval (95% CI¼ 0.02573–0.6286, r¼ 0.3648). PrPres, proteinase K-resistant PrP.
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tissues (Muhleisen et al., 1995), this could indicate that
astrocyte-specific propagation is relevant to 129MM
patients. Additional assessment of these A1 astrocyte
markers and PrPSc deposition across brain regions that
5 have differential disease pathology amongst the sCJD sub-
types would provide insight into these notions.
The significant positive correlation of GBP2log to dis-
ease duration suggests that A1 astrocytes may not solely
be necessary for sCJD-associated neurotoxicity. This is
10 consistent with a recent study that reported transgenic
mice lacking the factors that activate A1 astrocytes do
not exhibit neuroprotection following prion exposure
(Hartmann et al., 2019). Collectively, these findings sup-
port the concept that microglia are neuroprotective in
15 disease. The role of microglia in prion disease pathogen-
esis has long been a point of interest, with contrasting
reports of their activation as enhancing or inhibiting dis-
ease progression in various animal models of disease
[reviewed in Aguzzi and Zhu (2017)]. Several compre-
20 hensive in vivo and ex vivo studies using transgenic mice
show a protective role of microglia associated with prion
clearance (Falsig et al., 2008; Zhu et al., 2016). Hence,
it is possible in sCJD, A1 astrocytes may be produced
from activated microglia as a by-product or result of sig-
25 nificant and/or prolonged neuroprotective actions. The
progressive accumulation of these astrocytes in patients
based on the duration of illness could ultimately mean
that microglia can play both protective and damaging
roles in disease, whereby their initial capacity to be pro-
30 tective may switch to damaging neurotoxic properties
over time with corresponding generation of A1 astro-
cytes. Such considerations prompt the need for further
analysis of A1 astrocytes in larger cohorts of sCJD tis-
sues as well as better models to determine the precise na-
35 ture of their generation over disease course. This is
particularly relevant given that, despite the majority of
patients having short disease durations (Table 1), 5–10%
of CJD cases have duration of illness ù 24 months
(Brown et al., 1984). Hence, comprehensive modelling of
40 the role of A1 astrocytes and disease duration requires
large patient numbers.
AQ7 While there are numerous studies detailing the detri-
mental effects of A1 astrocytes and the utility of C3 and
GBP2 to identify them, the genetic and phenotypic
45 changes that astrocytes undergo upon activation are not
well understood. Hence, there may be unknown nuances
to the capacity of C3 and GBP2 to serve as markers for
A1 astrocytes. For example, possibly, multiple polariza-
tion states exist that share a degree of overlap in genomic
50 profiles. Alternatively, the markers themselves may under-
go expression changes in other brain morbidities. Such
notions may explain the variation in the abilities of the
two markers to stratify to disease sub-types in the current
study. However, the positive correlation between the two
55 markers in control and sCJD brain, and their co-localiza-
tion with astrocytes in sCJD brain (Hartmann et al.,
2019) is evidence for C3 and GBP2 reporting a
population of astrocytes that are equivalent or highly
similar. Regardless, further investigations into reactive
60astrocytes and their activator/s will provide important
additional insight into their role in disease and markers
to identify them.
The results of this study may contribute to our under-
standing across the range of broadly related neurodege-
65nerative conditions. Pathogenic mechanisms are shared
amongst the different proteins that aggregate in the brain
causing neurodegenerative disorders, including significant
heterogeneity in the clinical and biochemical features of
the diseases (reviewed in Ugalde et al., 2016; Walker
702016). In the context of A1 astrocytes, it is possible that
their involvement in the range of neurodegenerative disor-
ders depends on patient-specific disease parameters.
Phenotyping of disease, including molecular sub-typing,
could represent an important paradigm for determining
75the best strategies to target A1 astrocytes, with the identi-
fication of patient groups who would most benefit from
therapies aimed at neurotoxic astrocytes across a range
of neurodegenerative conditions.
Supplementary material
80Supplementary material is available at Brain
Communications online.
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ArticlePrPSc Oligomerization Appears Dynamic, Quickly
Engendering Inherent M1000 Acute SynaptotoxicitySimote T. Foliaki,1 Victoria Lewis,1 Abu M. T. Islam,1 Matteo Senesi,1 David I. Finkelstein,2 Laura J. Ellett,3,4
Victoria A. Lawson,3,4 Paul A. Adlard,2 Blaine R. Roberts,2 and Steven J. Collins1,2,*
1Department of Medicine (RMH), 2Florey Institute of Neuroscience and Mental Health, 3Department of Pathology, and 4Department of
Microbiology and Immunology, The University of Melbourne, Parkville, AustraliaABSTRACT Prion diseases are neurodegenerative disorders pathogenically linked to cellular prion protein (PrPC) misfolding
into abnormal conformers (PrPSc), with PrPSc underpinning both transmission and synaptotoxicity. Although the biophysical
features of PrPSc required to induce acute synaptic dysfunction remain incompletely defined, we recently reported that acutely
synaptotoxic PrPSc appeared to be oligomeric. We herein provide further insights into the kinetic and requisite biophysical char-
acteristics of acutely synaptotoxic ex vivo PrPSc derived from the brains of mice dying from M1000 prion disease. Pooled frac-
tions of M1000 PrPSc located within the molecular weight range approximating monomeric PrP (mM1000) generated through
size exclusion chromatography were found to harbor acute synaptotoxicity equivalent to preformed oligomeric fractions
(oM1000). Subsequent investigation showed mM1000 corresponded to PrPSc rapidly concatenating in physiological buffer to
exist as predominantly, closely associated, small oligomers. The oligomerization of PrP in mM1000 could be substantially miti-
gated by treatment with the antiaggregation compound epigallocatechin gallate, thereby maintaining the PrPSc as primarily non-
oligomeric with completely abrogated acute synaptotoxicity; moreover, despite epigallocatechin gallate treatment, pooled
oM1000 remained oligomeric and acutely synaptotoxic. A similar tendency to rapid formation of oligomers was observed for
PrPC when monomeric fractions derived from size exclusion chromatography of normal brain homogenates (mNBH) were
pooled, but neither mNBH nor preformed higher-order NBH complexes (oNBH) were acutely synaptotoxic. Oligomers formed
from mNBH could be reduced to mainly monomers (<100 kDa) after enzymatic digestion of nucleic acids, whereas higher-order
PrP assemblies derived from pooled mM1000, oM1000, and oNBH resisted such treatment. Collectively, these findings support
that oligomerization of PrPSc into small multimeric assemblies appears to be a critical biophysical feature for engendering
inherent acute synaptotoxicity, with preformed oligomers found in oM1000 appearing to be stable, tightly self-associated ensem-
bles that coexist in dynamic equilibrium with mM1000, with the latter appearing capable of rapid aggregation, albeit initially form-
ing smaller, weakly self-associated, acutely synaptotoxic oligomers.Submitted January 10, 2020, and accepted for publication April 24, 2020.
*Correspondence: stevenjc@unimelb.edu.au
Editor: James Shorter.
SIGNIFICANCE Although PrPSc comprise the synaptotoxic species in prion diseases, their biophysical characteristics
remain incompletely understood. Herein, we reaffirmed that oligomerization of M1000 PrPSc is an integral feature for acute
synaptotoxicity. We found that synaptotoxic oligomers can be tightly or weakly aggregated, with size exclusion
chromatography showing tightly assembled oligomers are preformed and the most abundant. Broadly consistent with
monomer-oligomer equilibria, separation of preformed oligomers from PrPSc located within the range of PrP monomers
caused the monomer-like PrPSc to rapidly concatenate in physiological buffer into the loosely aggregated synaptotoxic
oligomers. The antiaggregation compound epigallocatechin gallate was able to disrupt the loosely assembled oligomers
into nonsynaptotoxic species but was ineffective on preformed oligomers, suggesting that more potent epigallocatechin
gallate analogs may have therapeutic potential.
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Prion diseases are neurodegenerative disorders with sub-
stantial evidence supporting that misfolding of normal prion
protein (PrPC) into abnormal conformers (PrPSc) is central
to pathogenesis, with PrPSc constituting the transmitting
and synaptotoxic species associated with these disorders
Synaptotoxic M1000 PrPSc Are Oligomers(1–3). Notably, prion diseases affect both humans and ani-
mals (1), with the most common human phenotype being
Creutzfeldt-Jakob disease, whereas in animals, the spectrum
includes bovine spongiform encephalopathies in cattle,
scrapie in sheep and goats, and chronic wasting disease in
deer and elk (1).
Numerous studies have attempted to determine the
pathway, critical auxiliary factors, and mechanism by which
PrPC is misfolded to PrPSc (4–6), with analytical tech-
niques including the use of cell-free assays such as protein
misfolding cyclic amplification (PMCA), wherein a cocktail
containing abundant PrPC is seeded with ex vivo PrPSc
from prion-infected tissues, facilitating propagation of de
novo PrPSc species. PMCA assays have variably demon-
strated the requirement for cofactors such as nucleic acids,
as well as certain ionic levels, pH, and temperature condi-
tions to successfully misfold PrPC in the presence of PrPSc
(6–9). The fact that misfolding of PrPC requires a physical
templating interaction with PrPSc has also promoted a po-
tential therapeutic approach in which this close association
can be disrupted by drugs that bind tightly to PrPC or PrPSc
(10). In addition, given that disease pathogenesis is highly
dependent on the ongoing presence of PrPC to serve as sub-
strate for conversion (11,12), with complete resistance of
mice devoid of PrPC expression to developing the disease
(13), studies have reported successful delay of disease
progression by depleting PrPC levels either by disrupting
protein synthesis through RNA interference or through com-
pounds that facilitate cellular PrPC removal (5,11,12). One
such procatabolic compound is epigallocatechin gallate
(EGCG), an antioxidant extract of green tea with known
protein antiaggregation properties (14), which has also
been shown to tightly bind to PrPC, preventing self-associ-
ation and facilitating its intracellular degradation (15).
In the M1000 mouse model of human prion disease,
PrPSc propagated during the disease incubation period has
been shown to harbor infectivity and synaptotoxicity, with
acutely synaptotoxic species evident from early in the natu-
ral evolution of M1000 murine prion disease, appearing
coincident with the production of transmitting PrPSc spe-
cies (3,16,17). Further, acutely synaptotoxic species un-
dergo biochemical maturation during disease progression
(especially the acquisition of protease resistance near the
end stage of the disease (3)), whereby there appeared to
be some differentiating emphasis in the biochemical
features of acutely synaptotoxic versus infectious PrPSc at
terminal disease, albeit with the likelihood of overlap in
their biophysical features. As prion disease evolves, a
considerable amount of PrPSc progressively accumulates
as variably sized multimeric aggregates that appear to corre-
late with the development of certain pathogenic features and
neuropathological changes (3,18–20). Indeed, we recently
reported the likely direct relevance of oligomeric PrPSc to
acute synaptotoxicity (3,16). Previous investigators have
additionally shown that ex vivo small oligomers of PrPScare easily internalized by neuronal cells regardless of
PrPC expression (21), efficiently template the production
of nascent PrPSc (22), and can induce intracellular neuro-
toxicity (23), further underscoring their pathogenic rele-
vance. Oligomers of pathogenic proteins such as Ab in
Alzheimer’s disease and a-synuclein in Parkinson’s disease
are also believed to represent assemblies toxic to synaptic
functions (24–27). Cumulatively, experimental evidence
supports that oligomeric species of PrPSc are most likely
responsible for the neurotoxicity in prion diseases, with a
detailed understanding of unique, as well as any shared
biochemical and biophysical characteristics of acutely syn-
aptotoxic and infectious PrPSc, especially across a range of
prion strains, yet to be achieved.
In our aforementioned study assessing the temporal pro-
file of acutely synaptotoxic PrPSc over the course of murine
M1000 prion disease, we also undertook preliminary inves-
tigation of PrP species migrating in the molecular weight
ranges of monomeric and oligomeric prion protein species
generated through size fractionation chromatography. As
hypothesized, we observed that oligomeric species were
acutely synaptotoxic (3) but unexpectedly detected acute
synaptotoxicity of ex vivo M1000 PrPSc fractionating as
apparent monomers. Additional pilot experiments suggested
that such monomeric PrPSc species may rapidly concate-
nate in physiological buffer, presumably forming into toxic
multimeric species, thereby theoretically explaining their
observed acute synaptotoxicity (3). Nevertheless, these pro-
visional findings left some uncertainty as to whether oligo-
merization of PrPSc is a mandatory biophysical prerequisite
for misfolded conformers to harbor acute synaptotoxicity in
M1000 prion disease. Hence, this study primarily aimed to
gain additional insights into critical biophysical properties
underpinning acutely synaptotoxic PrPSc species found in
M1000 prion disease, especially by further interrogating
prion protein species (PrP) within the molecular weight
ranges around the size of monomeric and oligomeric PrP
generated through size fractionation chromatography.MATERIALS AND METHODS
Ethics statement
All animal handling was in accordance with National Health and Medical
Research Council guidelines. Animal handling and experimental proced-
ures were approved by The Florey Institute of Neuroscience and Mental
Health Animal Ethics Committee (Ethics# 13-048) or the Biochemistry
& Molecular Biology, Dental Science, Medicine (RMH), Microbiology &
Immunology, and Surgery (RMH) Animal Ethics Committee, The Univer-
sity of Melbourne (Ethics# 1312997.1).Animals
Mice used for electrophysiological studies and for inoculation to generate
M1000 infected brains at the terminal stage of disease after stereotaxic
intracerebral inoculation were 12-week-old wild-type (WT) female
C57BL/6J mice (Animal Resource Centre, Murdoch, Western Australia).Biophysical Journal 119, 128–141, July 7, 2020 129
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Electrophysiology studies utilizing ex vivo preparations were performed as
described (3,16) with brain homogenates for these studies precleared by a
1-min 100  g spin. In summary, electric stimulation (1500–2500 mV)
was utilized to evoke hippocampal field excitatory postsynaptic potentials
(fEPSPs) from the Sch€affer collateral pathway while recording from the
CA1 region. A 30-min baseline was recorded at 30 s intervals using a basal
stimulus determined by an input-output curve, wherein the basal stimulus
was declared as the stimulus that evoked 40% of the maximal fEPSP.
Channels of the multi-electrode array (MEA) grid utilized for analysis
were those best aligned to the Sch€affer collateral pathway determined
through selecting those demonstrating fEPSPs that manifested paired pulse
facilitation (PPF), generated positive trend input-output curves, and main-
tained fEPSP amplitudes above the eight standard deviation threshold of
the noise levels for at least 80% of the total recording time. The treatments
(crude homogenates or other preparations) were superfused over the hippo-
campal slices for 5 min after 8–10 min of stable baseline. For tetanus, three
trains of high-frequency stimulation (HFS: 100 Hz each) were applied (for
0.5 s at 20 s intervals) after the baseline recording to induce post-tetanic
potentiation (PTP) and long-term potentiation (LTP). Post-HFS recording
continued for 30 min, wherein the first response was utilized to estimate
PTP and the last 10-min period taken as representing LTP. LTP and PTP
were calculated as the percentage fEPSP increase after HFS relative to
the last 5 min of baseline fEPSPs. PPF was evoked by basal stimuli deliv-
ered 20 ms apart. The ratio between the fEPSP amplitude of the first and the
second pulse was the PPF ratio. PPF ratio was measured before treatment
and induction of LTP (PPF1) and after treatments and expression of LTP
(PPF2).Size exclusion chromatography
Size exclusion chromatography (SEC) was performed as described previ-
ously, employing crude homogenates of mouse brains inoculated with
M1000 prions (cM1000) or normal brain homogenate (cNBH), as well as
reconstituted proteinase K (PK)-eluted supernatants of PrP-immunoprecip-
itated pellets generated from M1000 prion-infected brains (cPKþIP-
M1000) (3,16). Briefly, 3 mL of 10% (w/v) brain homogenate preparations
(cM1000, cNBH) and cPKþIP-M1000, after solubilization with 4% sarko-
syl and exhaustive dialysis, were injected into a Sephacryl S-100 column
(Sigma-Aldrich, St. Louis, MO) (47 mm particle size in 16 600 mm col-
umn), wherein different sizes of PrP species were eluted in 1 phosphate-
buffered saline (PBS) at a flow rate of 0.5 mL per minute. One-mL fractions
were collected and analyzed for PrP levels by Western blotting. The size of
PrP species eluted in each fraction was approximately determined by SEC
markers: bovine erythrocyte carbonic anhydrase (29 kDa), bovine serum
albumin (66 kDa), yeast alcohol dehydrogenase (150 kDa), sweet po-
tato beta-amylase (200 kDa), horse spleen apoferritin (443 kDa), and
bovine thyroglobulin (669 kDa) (16). Those fractions containing PrP
larger than 100 kDa were pooled as oligomeric fractions, whereas those
containing PrP smaller than 100 kDa were pooled as monomeric fractions.
For the refractionation of pooled fractions, 3 mL of each pooled fraction
was injected into the S-100 Sephacryl column and fractionated as described
above. In addition, each fraction collected from the refractionation was
spiked into five volumes of ice-cold 100% methanol, incubated at 20C
for overnight and centrifuged at 24,000  g for 1 h to pellet proteins.
The pellets were then resuspended in 20 mL of 0.1% sarkosyl for Western
blotting analysis.EGCG treatment
EGCG (Sigma-Aldrich) was dissolved in milliQ water and added to 1%
(w/v) ex vivo pooled PrPSc preparations (prepared in 1 PBS) to generate
final concentrations of 30, 50, and 100 mM, respectively. These samples130 Biophysical Journal 119, 128–141, July 7, 2020were then incubated at 37C for 30 min with constant agitation at
1400 rpm. After the EGCG treatment, 10 mL from each sample was
analyzed by Western blotting for any change in the quaternary structures
of PrP. The preparations used in electrophysiology assays were treated
with 50 mM EGCG and then diluted 1:1 with 1 PBS immediately before
superfusion onto hippocampal slices.Benzonase treatment
Benzonase (Millipore, Burlington, MA) was added to 1% (w/v) ex vivo
pooled PrPSc fractions (prepared in 1 PBS containing 6 mM MgCl2
and 0.5 mM CaCl2) to create final sample concentrations of 10, 25, and
50 U/mL. Benzonase-treated samples were then incubated for 30 min at
37C with constant agitation at 1400 rpm. After the benzonase treatment,
10 mL from each sample was analyzed by Western blotting for any change
in the quaternary structures of PrP. Samples for electrophysiology assays
were treated with 25 U/mL benzonase, then diluted 1:1 with 1 PBS imme-
diately before being used to treat hippocampal slices.Chemical cross-linking
Disuccinimidyl suberate (DSS) (Sigma-Aldrich) cross-linker was prepared
in 100 mM dimethyl sulfoxide. Brain homogenates or pooled SEC PrP frac-
tions were cross-linked using a 20 mM final concentration of DSS for
30 min at 37C. After treatment, the DSS cross-linking was quenched by
100 mM final concentration of glycine, and 10 mL from each sample was
analyzed by Western blotting after denaturation of proteins.Western blotting
Western blotting and assessment of levels of PrP were by standard PAGE
and immunoblotting as described previously (16,28) unless otherwise
stated. DSS cross-linked samples in 1 sample buffer containing 6%
(v/v) beta-mercaptoethanol were boiled at 100C for 5 min, resolved on
NuPAGE 3–8% Tris-acetate Protein Gels using 1 Tris-acetate running
buffer (Thermo Fisher Scientific, Waltham, MA) transferred to polyvinyli-
dene fluoride (Millipore) and probed for PrP with 8H4 (epitope 145–180;
Abcam, Cambridge, UK)). Molecular weights were determined using
SeeBlue Plus2 prestained (Invitrogen, Carlsbad, CA). Approximate sizes
of PrP species in their quaternary structures were analyzed by Western blot-
ting as described previously (3). For assessment under ‘‘native’’ conditions,
PrP samples containing 2% (w/v) sarkosyl and 1 Novex Tris-glycine
native sample buffer (Thermo Fisher Scientific) were resolved on NuPAGE
Novex 3% Tris-Acetate gels in 1 Novex Tris-glycine native running
buffer (at constant 160 V; Thermo Fisher Scientific) and transferred to a
polyvinylidene fluoride membrane (at constant 70 V for 3 h) using a transfer
buffer containing 25 mM Tris, 200 mM glycine, and 10%methanol. Molec-
ular weights of proteins were determined using High Marker protein stan-
dard (Invitrogen). As described previously, a serial dilution of recombinant
human PrP of known concentrations was immunoblotted alongside PrP
fractions to estimate the approximate relative levels of PrP (16). The total
protein levels were determined by BCA assay (Invitrogen).Data analysis
Unless stated otherwise, the average LTP and PTP of hippocampal slices
treated with ex vivo PrPSc preparations were compared with those treated
with control preparations by one-way ANOVA with Dunnett’s correction
for multiple comparisons. The percentage of PrP species resolved by
Western blotting according to the sizes of their quaternary structures
before and after treatments with the serial concentrations of EGCG
were compared by two-way ANOVA with Dunnett’s correction for multi-
ple comparisons.
FIGURE 1 Levels of total PrP species and total proteins in ex vivo PrPC
and PrPSc preparations. (A) Representative Western blots of 20 mL
of 0.5% (w/v) crude (c; before SEC), oligomeric (o), and monomeric
(m) normal brain homogenates (NBHs; left panel), M1000 brain homoge-
nates (M1000; middle panel), and PK-eluted immunoprecipitated M1000
brain homogenates (PKþIP-M1000; right panel) are shown. Molecular
weight markers are at left. (B) Levels (ng) of PrP species in 0.5% (w/v)
cNBH, cM1000, and cPKþIP-M1000, as well as in 1:1 dilution of
oNBH, mNBH, oM1000, mM1000, oPKþIP-M1000, and mPKþIP-
M1000, are shown. All data are presented as standard error of mean.
TSD, terminal stage disease.








0.5% cNBH 358 5 78 113 5 7
mNBH 844 5 190 71 5 6
oNBH 580 5 125 <<12
0.5% cM1000 359 5 69 187 5 11
mM1000 656 5 27 <<12
oM1000 704 5 90 81 5 8
0.5% cPKþIP-M1000 213 5 64 115 5 18
mPKþIP-M1000 30 5 18 17 5 9
oPKþIP-M1000 75 5 18 55 5 6
Synaptotoxic M1000 PrPSc Are OligomersRESULTS
Pooled oligomeric and monomeric M1000
fractions generated through SEC cause acute
synaptotoxicity that appears independent of
absolute PrP levels
We previously demonstrated that the significant disruption
of hippocampal CA1 LTP correlated with abundant levels
of oligomeric PrPSc species in M1000-infected prepara-
tions from the terminal stage of the disease (16). In
more recent studies, however, we unexpectedly observed
that both pooled oligomeric and monomeric fractions of
cM1000 generated through SEC from across the disease
natural evolution were toxic to hippocampal CA1 LTP,
albeit with preliminary observations suggesting that
pooled monomeric species most likely rapidly concate-
nated into multimers in physiological buffer (3).
To further investigate these preliminary observations,
we first aimed to determine whether the acute synaptotox-
icity of these pooled fractions generated in our previous
studies (3) was influenced by the total protein concentra-
tions or levels of PrP. This study utilized M1000-infected
preparations from the terminal stage of the disease, given
that the apparent degree of acute synaptotoxicity of mono-
meric and oligomeric M1000 was not noticeably different
across the disease incubation period (3). Our most recent
report demonstrated no background synaptotoxicity of
0.5% (w/v) cNBH (after processing for SEC), 1:1
diluted pooled oligomeric NBH fractions (fractions 1–
10; oNBH), and 1:1 diluted pooled monomeric NBH
fractions (fractions 15–30; mNBH) (3); nonspecific back-
ground synaptotoxicity was observed with neat mNBH
containing a total protein concentration of 1688 mg/
mL (i.e., without the 1:1 dilution in 1 PBS; Fig. S1).
Herein, we report that 0.5% (w/v) cNBH contained
358 mg/mL of total protein with 113 ng/mL PrPC.
The 1:1 diluted pooled oNBH contained 580 mg/mL to-
tal proteins with <<12 ng/mL PrPC, whereas 1:1 diluted
pooled mNBH contained 844 mg/mL total proteins with
71 ng/mL PrPC (Fig. 1). By contrast, 0.5% (w/v)
cM1000 contained 359 mg/mL total proteins with
187 ng/mL PrP species, whereas a 1:1 dilution of the
pooled oligomeric M1000 fractions (fractions 1–10;
oM1000) contained 704 mg/mL total protein with
81 ng/mL PrP species, and a 1:1 dilution of the
pooled mM1000 fractions (fractions 15–30; mM1000)
contained 656 mg/mL total proteins with only
<<12 ng/mL PrP species (Fig. 1; Table 1). These results
demonstrate that the acute synaptotoxicity of oM1000 and
mM1000 do not directly correlate with levels of total pro-
teins or PrP species. The previously observed significant
acute synaptotoxicity of pooled mM1000 (3), given the
reduced levels of PrP species, suggests that monomeric
fractions have the capacity to generate highly synapto-
toxic species.Pooled oligomeric and monomeric fractions of at
least modestly PK-resistant immunopurified
PrPSc species exhibit acute synaptotoxicity
analogous to fractions of cM1000
As part of the validation of our prion acute synaptotoxicity
model, we demonstrated that cPKþIP-M1000 PrPSc spe-
cies (immunocaptured by the 03R19 prion antibody from
terminal cM1000 and eluted by a mild (5 mg/mL for 1 h
at 37C) PK treatment) were acutely synaptotoxic, and theBiophysical Journal 119, 128–141, July 7, 2020 131
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PrPSc species by SEC revealed that they consisted of
mostly PrPSc oligomers (16). In this study, we aimed to
determine whether pooled monomers of at least modestly
PK-resistant immunocaptured PrPSc were synaptotoxic
and to provide further insights into the biophysical fea-
tures of such synaptotoxic PrPSc species. Fractions of
cPKþIP-M1000 from the terminal stage of the disease
(16) were pooled, creating preparations mostly containing
PrPSc oligomers (fractions 1–10; oPKþIP-M1000) and
those predominantly containing PrPSc monomers (frac-
tions 15–30; mPKþIP-M1000). First, we demonstrated
that relative to a 1 PBS negative control, 0.5% (w/v)
cPKþIP-M1000 remained acutely synaptotoxic after
treatment with sarkosyl and exhaustive dialysis as under-
taken in the preparation for SEC (Fig. 2 A; see work-flow
diagram summary in Fig. S3). Relative to the normal LTP
and PTP of slices treated with 1 PBS (LTP: 173 5 3;
PTP: 376 5 25), cPKþIP-M1000 disrupted PTP and
LTP by 30 and 35%, respectively (LTP: 151 5 3;
PTP: 277 5 18; Fig. 2, A, D, and E). These results
confirmed that synaptotoxic species of at least modestly
PK-resistant immunocaptured PrPSc were among those
size fractionated. Next, we assessed the pooled fractions
and showed that relative to 1 PBS control, LTP and132 Biophysical Journal 119, 128–141, July 7, 2020PTP were significantly disrupted by oPKþIP-M1000
(LTP: 134 5 9; PTP: 250 5 21) and mPKþIP-M1000
(LTP: 141 5 10; PTP: 281 5 8) after dilution 1:1 in
1 PBS (Fig. 2, B–E), similar to our observations with
size fractionation of cM1000 brain homogenates at the
terminal stage of disease (3). This finding also supports
that the acutely synaptotoxic species in both oM1000
and mM1000 at terminal disease were most likely at least
modestly PK-resistant ex vivo PrPSc. Additional quantita-
tion showed that 0.5% (w/v) cPKþIP-M1000 contained
213 mg/mL total protein with 115 ng/mL at least
modestly PK-resistant PrPSc (Fig. 1; Table 1). oPKþIP-
M1000 after 1:1 dilution contained 75 mg/mL total pro-
tein with 55 ng/mL at least modestly PK-resistant
PrPSc, whereas mPKþIP-M1000 after 1:1 dilution con-
tained 30 mg/mL total protein with 17 ng/mL at least
modestly PK-resistant PrPSc (Table 1). These levels of to-
tal protein were notably lower than the nontoxic levels in
0.5% (w/v) cNBH, mNBH, and oNBH, further supporting
that the acute synaptotoxicity of these PKþIP-M1000
preparations was not due to nonspecific toxic effects of to-
tal protein. The acute synaptotoxicity of mPKþIP-M1000
associated with only 17 ng/mL of at least modestly PK-
resistant PrPSc suggests that such monomeric fractions
harbor potentially highly synaptotoxic PrPSc species.FIGURE 2 Acute synaptotoxicity of oligomeric
and monomeric at least modestly PK-resistant PrPSc
in M1000 preparations from the disease terminal
stage. (A) Hippocampal CA1 LTP in WT mice after
treatments with 1 PBS negative control and
0.5% (w/v in 1 PBS) crude PK-eluted immuno-
precipitated M1000 (cPKþIP-M1000) after solubili-
zation with sarkosyl and exhaustive dialysis in
preparations for the size fractionation of PrP species
by SEC is shown. The hippocampal slices were
treated for 5 min (black solid line) started after an
8–10 min of stable baseline recording, which was
20 min before the induction of LTP by serial trains
of HFS. (B and C) Hippocampal CA1 LTP in WT
mice after treatments with oligomeric and mono-
meric PKþIP-M1000 (B: oPKþIP-M1000 and C:
mPKþIP-M1000) relative to the 1 PBS control is
shown. (D) The average LTPs of slices treated with
cPKþIP-M1000, oPKþIP-M1000, and mPKþIP-
M1000 (i.e., average of the last 10-min recording in
A–C) are shown, statistically compared with the 1
PBS negative control by one-way ANOVAwith Dun-
nett’s corrections for multiple comparisons. The sta-
tistically significant difference of each treatment to
the negative controls obtained by the multiple com-
parisons is presented at the last 10 min of the record-
ings in (A)–(C). (E) The average PTPs of slices
treated with cPKþIP-M1000, oPKþIP-M1000, and
mPKþIP-M1000 are shown, statistically compared
with the 1 PBS negative control by one-way
ANOVAwith Dunnett’s corrections for multiple com-
parisons. All data are presented as standard error of
mean. **p < 0.01, ***p < 0.001, ****p < 0.0001.
To see this figure in color, go online.
Synaptotoxic M1000 PrPSc Are OligomersPrion proteins in monomeric SEC fractions
derived from both cM1000 and cNBH can rapidly
concatenate to generate predominantly
oligomeric species
Our recent report of acute synaptotoxicity of pooled
mM1000 preparations (3) appeared to contradict a previous
observation of the correlation between the abundance of
PrPSc oligomers and prion acute synaptotoxicity (16).
This finding also appears at odds with a previous study
showing only recombinant PrP oligomers, but not mono-
mers, were neurotoxic (29). Preliminary investigations ofpooled mM1000 preparations, however, suggested that
monomeric PrPSc appears to rapidly concatenate in physio-
logical buffer, presumably forming acutely synaptotoxic
oligomers (3).
To further explore this and other potential explanations
for pooled monomeric SEC PrPSc fractions being acutely
synaptotoxic, we first fractionated cNBH and cM1000
preparations (cNBH: Fig. 3, A and D; cM1000: Fig. 3, E
and H; see work-flow summary diagram in Fig. S3) and
then immediately refractionated pooled oNBH and mNBH
preparations, as well as oM1000 and mM1000 preparations,FIGURE 3 Refractionation of PrP species con-
tained in pooled monomeric and oligomeric frac-
tions of NBH and M1000 brain homogenates
generated by SEC. (A and D) Representative West-
ern blot (A) and quantification of the relative levels
of PrPC (D) in crude NBH (cNBH) after size frac-
tionation chromatography are shown, wherein
oligomeric fractions of PrPC were eluted into frac-
tions 1–10, and the monomeric fractions were eluted
into fractions 15–30. (B and D) Representative
Western blots (B) and quantification of the relative
levels of PrPC in each fraction (D) after the refrac-
tionation of the pooled fractions of oligomeric
NBH (oNBH) are shown. (C and D) Representative
Western blots (C) and quantification of the relative
levels of PrPC in each fraction (D) after the refrac-
tionation of the pooled fractions of monomeric
NBH (mNBH) are shown. (E and H) Representative
Western blot (E) and quantification of the relative
levels of PrP (H) in crude M1000 (cM1000) after
the size fractionation chromatography are shown,
wherein oligomeric fractions of PrPSc were eluted
into fractions 1–10, and the monomeric fractions
were eluted into fractions 15–30. (F and H) Repre-
sentative Western blots (F) and quantification of
the relative levels of PrP in each fraction (H) after
refractionation of the pooled fractions of oligomeric
M1000 (oM1000) are shown. (G and H) Representa-
tive Western blots (G) and quantification of the
relative levels of PrP species in each fraction (H)
after refractionation of the pooled fractions of mono-
meric M1000 (mM1000) are shown. The approxi-
mate molecular weights of proteins eluted into
each fraction are listed in (D) and (H). (A–C, E,
and F) PrP species were probed with 8H4 antibody.
To see this figure in color, go online.
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of the crude brain homogenates. The PrPSc species in
pooled oM1000 remained predominantly oligomers after
the refractionation (400 kDa median size in fractions 1–
10; Fig. 3, F and H). Interestingly, the refractionation of
pooled mM1000 revealed that PrPSc species were now
mainly oligomers, albeit with relatively smaller sizes
(200 kDa median size in fractions 3–13) (Fig. 3, G and
H) compared with PrPSc in oM1000, thereby providing a
plausible explanation for pooled mM1000 exhibiting acute
synaptotoxicity. The refractionation of oNBH revealed
that the pooled PrPC species remained as higher molecular
weight complexes and oligomers (400 kDa median size in
fractions 1–8; Fig. 3, B and D). Unexpectedly, PrPC in
mNBH was also detected after refractionation as predomi-
nantly oligomers with a median size of 200 kDa (Fig. 3,
C and D). Attempts at analogous refractionation of pooled
oPKþIP-M1000 and mPKþIP-M1000 were unsuccessful
for unclear but likely technical reasons, with failure to
detect PrP by Western blotting possibly due to the dynamic
equilibrium strongly favoring production of very large PrP
species (probably fibrils) too large to enter the pores of
the SEC column.
To further examine the apparent rapid self-oligomeriza-
tion phenomenon of PrP monomers and assess any technical
limitation of SEC, we utilized a supplementary ‘‘native’’
Western blotting approach to resolve different sizes of PrP
species in our pooled preparations while trying to maintain134 Biophysical Journal 119, 128–141, July 7, 2020their quaternary structures (see work-flow summary diagram
in Fig. S3). Size fractionation of proteins by SEC is primar-
ily dependent on the assumption that proteins enter the pores
of the matrix beads used to fill the chromatography column,
whereas bigger proteins too large to enter the pores of the
beads flow out of the column faster than smaller proteins.
Native Western blotting, on the other hand, attempts to
minimally perturb in situ proteins, including multimeric
assemblies, leaving them natively folded, and assumes
that the overall charges of such normally folded proteins
and assemblies have been rendered negative, thus allowing
electrophoresis to separate them predominantly by size
and shape, thereafter detected by immunoblotting. Hence,
sarkosyl (2% w/v) was used to enhance the negative charges
of proteins to facilitate their resolution in Tris-acetate
NuPAGE gels employing Tris-glycine running buffer. The
quaternary structures of PrP species, as represented by gel
mobility, were detected with 8H4 monoclonal antibody
(Fig. 4). Given the possibility that some PrP species were
folded or aggregated in ways by which epitopes for 8H4
were not accessible, the relative PrP levels detected by
this approach could not be directly compared across PrP
preparations; therefore, levels of differently sized PrP in
each preparation (lane) were normalized as the percentages
of total PrP for that preparation. Similar to SEC of cNBH
(Fig. 3, A and D), the native Western blotting resolved
PrPC in cNBH into species that were mostly monomers or
very small oligomers (55– 117 kDa), albeit withFIGURE 4 Additional evidence that monomeric
PrP fractions of NBH and M1000 brain homogenates
appear able to quickly self-associate to varying ex-
tents and proximity to form predominantly higher
molecular weight complexes or PrP oligomers. (A)
Western blotting after native gel electrophoresis of
PrP species in 10 mL of 0.5% (w/v) crude (c), olig-
omeric (o), and monomeric (m) NBH, M1000, and
PK-eluted immunoprecipitated M1000 (PKþIP-
M1000) is shown. (B) Densitometry analyses of the
sizes of PrP in each lane of the blots in (A) is shown.
(C) Western blotting for denatured structures of PrP
species in 20 mL of o and m NBH, M1000, and
PKþIP-M1000 after a 30-min treatment with DSS
cross-linker is shown. The lower panel is a longer
exposure of the 44 kDa bands of PrP. Molecular
weight (MW) markers are provided at left. To see
this figure in color, go online.
Synaptotoxic M1000 PrPSc Are Oligomersprominent levels of higher-order oligomers or higher molec-
ular weight complexes (117 to 460 kDa) (Fig. 4, A and
B). Approximating the results of SEC of cM1000, the native
Western blotting also resolved PrPSc in cM1000 into spe-
cies that appeared to be mostly oligomers (117 to
460 kDa) with minimal levels of monomers or very small
oligomers (55 to 117 kDa) (Fig. 4, A and B). Interest-
ingly, the Western blotting of pooled oNBH and mNBH,
collected as soon as possible after the SEC, revealed that
PrPC species in both fractions appeared to have relatively
similar sizes between 117 and 460 kDa with oNBH ap-
pearing relatively predominant up to 460 kDa. The native
gel Western blotting showed that PrP species in pooled
oM1000 and mM1000 contained mostly oligomers (from
171 to 460 kDa) with oM1000 appearing to contain
greater amounts of larger oligomers than mM1000 (Fig. 4,
A and B), which was consistent with the SEC results and
our previous findings with native gel resolution and Western
blotting of mice brains across the evolution of M1000 prion
disease. On the other hand, PrPSc species in cPKþIP-
M1000, as well as in its pooled oligomeric and monomeric
fractions, were detected by native Western blotting as very
high molecular weight oligomers (>460 kDa) (Fig. 4, A
and B, right panels). It is noteworthy that the levels of PrPSc
species in the PKþIP-M1000 preparations were generally
quite low as compared to the amounts of PrP detected by
post-denaturation Western blotting in Fig. 1 A. Close inspec-
tion of the Western blotting gels used for pooled fractions of
PKþIP-M1000 performed under native conditions revealed
substantial amounts of PrP located in the loading wells of
the gel, suggesting failure to enter the resolving component
of the gel, thereby offering a likely partial explanation for
the apparent low levels compared to the pooled fractions
of NBH and M1000. As such, this suggests that the process
of probing fractions of cPKþIP-M1000 under native condi-
tions may have allowed further concatenation of pooled
oligomeric and initially monomeric PrP into higher molec-
ular weight species larger than 500 kDa, preventing their
ability to move from the loading wells. A further possible
explanation for the low levels observed under native condi-
tions was that residual PK in these PKþIP-M1000 prepara-
tions may have remained active when the temperature was
between 37 and 50C during the 3–4 h of electrophoresis
and possibly digesting away more PK-sensitive PrP species
with low molecular weights, thereby relatively enhancing
the presence of more PK-resistant, higher-order PrP
oligomers.
To additionally ensure the validity of SEC and native
Western blotting results, we employed DSS lysine-to-lysine
bonding to covalently cross-link proteins interacting very
closely at a distance of %11.4 Å (see a work-flow summary
diagram in Fig. S3). Samples were boiled in the presence of
denaturants to denature proteins as well as disassemble
protein complexes that were not covalently cross-linked,
followed by resolution in low-percentage Tris-acetateNuPAGE gels probed for PrP species using 8H4 antibody.
The Western blot analysis revealed that mNBH contained
mostly PrPC monomers (44 kDa), whereas oNBH con-
tained some PrPC monomers mixed with higher molecular
weight species (111– 210 kDa), supporting the very
close interaction of the latter with other PrPC or non-PrPC
protein partners (Fig. 4 C). Interestingly, all PrP species in
mM1000 and mPKþIP-M1000 appeared to have been
successfully cross-linked into substantial levels of higher
molecular weight complexes with similar sizes to those in
oM1000 and oPKþIP-M1000 (Fig. 4 C). Of note, some
PrP in oM1000 was not cross-linked, suggesting that some
species were not tightly self-associated, or their lysine resi-
dues were not aligned sufficiently closely to be cross-linked
(Fig. 4 C). Moreover, the presence of some PrPSc species
<460 kDa in PKþIP-M1000 preparations is consistent
with digestion of more PK-sensitive PrP species with lower
molecular weights, thereby leaving predominantly more
PK-resistant higher-order PrP oligomers (>460 kDa) as dis-
cussed above in native Western blot experiments, although
this does not exclude the partial disaggregation of larger,
noncovalently linked PrPSc oligomers when boiling in
denaturants.
Importantly, all methods utilized to further interrogate
acutely synaptotoxic pooled mM1000 PrPSc generated
through SEC collectively support that these species were
not predominantly monomers, but oligomers, which may
account for their acute synaptotoxicity. The detection of
predominantly PrPSc oligomers in pooled mM1000 by
native Western blotting performed as soon as possible after
fractionation by SEC (within 1 h) suggests that the conver-
sion of the PrPSc monomers to oligomers occurs relatively
rapidly in physiological buffer.Nucleic acids appear to facilitate the secondary
oligomerization of PrP in mNBH, but not mM1000
The basis of the unanticipated, prominent association of
PrPC monomers into higher molecular weight complexes
in pooled mNBH similar to what occurred for PrPSc mono-
mers in mM1000 was unclear. PrPC may self-associate as
dimers as part of normal function (30), with substantial
evidence supporting that PrPC to PrPSc conversion requires
close physical association and can be enhanced in the pres-
ence of other cofactors, including nucleic acids (31–33).
Exemplifying this, nucleic acids are known to bind PrPC
(34) and have been shown to be essential components of
the reaction to generate de novo PrPSc aggregates in the
PMCA assay (6,33). To determine whether nucleic acids
contributed to the apparent oligomerization of PrP mono-
mers in mNBH and mM1000, we treated the pooled frac-
tions of monomers, as well as the pooled fractions of
oligomers, with serial dilutions of benzonase (10, 25, and
50 units/mL) for 30 min at 37C with constant agitation at
1400 rpm (see work-flow summary diagram in Fig. S3).Biophysical Journal 119, 128–141, July 7, 2020 135
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species revealed that relative to fractions without the
benzonase treatment, only pooled mNBH demonstrated a
benzonase-dose-dependent shift in PrP sizes, whereas 25
and 50 U/mL benzonase appeared to reduce the size of
PrPC complexes from 100 to 200 kDa to less than
100 kDa, respectively (Fig. 5, A and B). Interestingly,
this dose-dependent reduction of the size of PrP higher mo-
lecular weight complexes was not observed in pooled
mM1000 (Fig. 5, A and B) or in oNBH and oM1000
(Fig. 5, C and D). These results, in combination with previ-
ous data, support that nucleic acids were involved in the as-
sembly of PrPC monomers into loosely associated
multimeric assemblies in pooled mNBH but did not appear
to play a role in the higher-order complexes found in
mM1000, oNBH, and oM1000.
Any potential direct contribution of nucleic acids to prion
acute synaptotoxicity was assessed on WT mice hippocam-FIGURE 5 Nucleic acids were significantly involved in the self-assembly of P
icity of monomeric M1000. (A) Western blotting for quaternary structures of PrP
and after the treatment with 10, 25, and 50 units/mL of benzonase is shown. (B) D
blotting for quaternary structures of PrP in oligomeric fractions of NBH and M1
units/mL of benzonase is shown. (D) Densitometry quantification of the Western
after treatment with oM1000, mM1000, and mNBH treated with 25 U/mL benz
line) started after an 8–10 min of stable baseline recording, which was20 min b
at the last 10 min of the recordings in (D) is shown. (G) Average PTPs recorded a
PTP (I) disruptions after treatment of WT hippocampal slices with mNBH, mM
ments with 25 U/mL benzonase. (F–I) Data are analyzed by one-way ANOVAw
standard error of mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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mNBH with 25 U/mL benzonase (see a work-flow summary
diagram in Fig. S3). Relative to the normal LTP and PTP
observed in WT hippocampal slices treated with mNBH
(191 5 9 LTP; 475 5 47 PTP), equivalent to that observed
in the 1 PBS control (Fig. S1), the PTP and LTP of slices
treated with mM1000 and oM1000 were significantly
disrupted (mM1000: 149 5 12 LTP and 224 5 7 PTP;
oM1000: 158 5 6 LTP and 196 5 18 PTP) (Fig. 5,
E–G). Furthermore, the degree of LTP and PTP change in
slices treated with mNBH containing benzonase were not
significantly different relative to slices treated with mNBH
without benzonase (Fig. 5, H and I). Although not statisti-
cally significant, the degree of the LTP disruption caused
by the Benzonase-treated mM1000 and oM1000 appeared
to increase compared with the degree of LTP disruption
caused by mM1000 and oM1000 without the benzonase
treatment (Fig. 5H). The degrees of PTP dysfunction causedrP in monomeric NBH, but not in the self-assembly and acute synaptotox-
in monomeric fractions of NBH and M1000 (mNBH and mM1000) before
ensitometry quantification of the Western blots in (A) is shown. (C) Western
000 (oNBH and oM1000) before and after the treatment with 10, 25, and 50
blots in (C) is shown. (E) Hippocampal CA1 LTP in slices from WT mice
onase is shown. The hippocampal slices were treated for 5 min (black solid
efore the induction of LTP by serial trains of HFS. (F) Average LTP recorded
fter the treatments listed in (D) are shown. (H and I) Degrees of LTP (H) and
1000, and oM1000 are shown, including before (B) and after (Bþ) treat-
ith Dunnett’s correction for multiple comparisons. All data are presented as
. To see this figure in color, go online.
Synaptotoxic M1000 PrPSc Are Oligomersby mM1000 and oM1000 after digestion with benzonase
were significantly increased relative to M1000 fractions
without the benzonase treatment (Fig. 5 I). Collectively,
these results suggest that nucleic acids were not directly
synaptotoxic but appeared to reduce the acute synaptotoxic-
ity of PrPSc oligomers (Fig. 5, H and I).EGCG disrupts PrPSc oligomers in pooled
mM1000 into nonsynaptotoxic species
It is known that PrPSc monomers can tightly self-associate
to form oligomers (35,36). This interaction can be at least
partially disturbed in some complexes by physical forces
such as heating, sonication, and quaking or by chemical
treatments (10,18). PrPSc monomers produced through
physical forces can quickly reaggregate into fibrils (18).
Chemical treatments can disrupt PrPSc oligomerization by
binding individual PrP molecules, thereby interfering with
monomer-oligomer equilibria (10,15). It has also been
shown that PrPSc monomers initially oligomerize into
small, immature or unstable, weakly self-associated com-
plexes, which then mature into highly stable oligomers
(18,37,38).
To test whether PrP oligomers formed in pooled mM1000
were unstable or mature, we treated pooled mM1000 and
oM1000, as well as mNBH and oNBH, with serial dilutions
of EGCG (30, 50, and 100 mM) for 30 min at 37C with
constant agitation at 1400 rpm (see work-flow summary di-
agram in Fig. S3). Through Western blotting analysis of PrP
in EGCG-treated preparations, we found that relative to
mM1000 not treated with EGCG, PrP oligomers in pooled
mM1000 were significantly reduced by increasing EGCG
concentrations (p ¼ 0.0004; n ¼ 3), whereas 50 and 100
mM EGCG prominently reduced PrP oligomers with molec-
ular weights above 238 kDa and coincidently emphasized
species smaller than 117 kDa (Fig. 6, D and H). We also
observed a slight redistribution in sizes of PrP oligomers
in pooled oM1000 after the treatment with 100 mM
EGCG, but not with the 30 and 50 mM EGCG (Fig. 6, C
and G). Further, absolute PrP levels appeared reduced in
both mM1000 and oM1000 after the treatment with 100
mM EGCG (Fig. 6, C, D, G, and H). In contrast, EGCG
treatment did not significantly alter the size of PrPC oligo-
mers in pooled mNBH and oNBH, albeit with a slight loss
of PrPC levels in oNBH after the treatment with 100 mM
EGCG (Fig. 6, A, B, E, and F).
Before assessing the acute synaptotoxicity of EGCG-
treated, pooled M1000 fractions, we first tested for the
optimal nontoxic concentration of EGCG. We found that
relative to aCSF controls, a final concentration of 50 mM
EGCG prepared in 0.5% (w/v in PBS) NBH was signifi-
cantly toxic to hippocampal CA1 LTP, but not a final
concentration of 25 mM (Fig. S2). Hence, we used 50 mM
EGCG to treat the pooled PrP fractions, whereby the subse-
quent 1:1 dilution in 1 PBS provided the optimal nontoxic25 mMEGCG. Importantly, relative to normal CA1 LTP and
PTP obtained in hippocampal slices exposed to EGCG-
treated pooled mNBH (LTP: 180 5 9; PTP: 285 5 22;
n ¼ 4), EGCG-treated pooled mM1000 was no longer toxic
to LTP and PTP (LTP: 178 5 3; PTP: 309 5 37; n ¼ 4),
whereas EGCG-treated oM1000 remained significantly
acutely synaptotoxic to LTP and PTP (LTP: 151 5 6, p ¼
0.0372; PTP: 202 5 7, p ¼ 0.0224; n ¼ 4; Fig. 6, I–K).
The loss of acute synaptotoxicity in pooled mM1000 treated
with EGCG correlated with the significant dose-response
redistribution of the size of PrP complexes with a gradual
decrease of PrP oligomers at molecular weights above
200 kDa and an increase of PrP species smaller than
100 kDa (Fig. 6, D and H). The retained acute synaptotox-
icity of EGCG-treated pooled oM1000 correlated with the
inefficacy of 50 mM EGCG to disrupt PrP oligomers in
oM1000 (Fig. 6, C and G). Overall, these results demon-
strate that PrP oligomers in pooled mM1000 were closely
associated, albeit through relatively weak interactions
compared with PrP oligomers in oM1000, suggesting that
the multimeric complexes in mM1000 were composed of
less stable oligomers apparently rapidly forming after frac-
tionation by SEC but that oligomerization of PrPSc closely
correlates with acute synaptotoxicity.DISCUSSION
The primary aim of this study was to provide additional in-
sights into the biophysical requisites of acutely synaptotoxic
M1000 PrPSc species, especially the role of PrPSc oligo-
merization, which we previously reported as appearing to
clearly correlate with prion acute synaptotoxicity (3,16),
as well as further explore the unexpected synaptotoxicity
of pooled mM1000 preparations (3). Collectively, the find-
ings reported herein support that 1) the acute synaptotoxic-
ity of pooled monomeric and oligomeric PrPSc fractions we
observed previously during M1000 prion disease evolution
(3) was not due to nonspecific toxic effects of total protein
concentration nor directly related to total concentration of
PrPSc species or their resistance to PK digestion; 2) the
acute synaptotoxicity of pooled mM1000 we observed pre-
viously (3) does correlate with apparent rapid concatenation
of PrPSc in physiological buffers to generate mostly oligo-
mers; 3) PrPC monomers in mNBH can form higher-order,
nontoxic aggregates, with aggregation preventable by ben-
zonase treatment; 4) PrPSc oligomerization in pooled
mM1000 fractions resisted the antiaggregation effects of
benzonase treatment but was vulnerable to the aggregation
mitigation properties of EGCG, thereby maintaining PrPSc
as mainly nonoligomeric, nonsynaptotoxic species; and 5)
preformed PrPSc oligomers in pooled oM1000 fractions
resist the antiaggregation effects of EGCG, suggesting these
multimeric assemblies are maintained through stronger in-
teractions than those occurring in nascent oligomers formed
during pooling of mM1000 fractions.Biophysical Journal 119, 128–141, July 7, 2020 137
FIGURE 6 EGCGdisassembled synaptotoxic PrPScoligomers intononsynaptotoxic species. (A–D)Westernblotting is shown for quaternary foldedPrP species
in oligomeric andmonomeric fractions of NBH (A: oNBH;B: mNBH) aswell asM1000 (C: oM1000;D: mM1000) before and after digestingwith 30, 50, and 100
mMEGCG, respectively. (E–H) Quantifications of PrP species as theywere resolved according to their sizes byWestern blotting are shown in (A)–(D); (E) and (F)
are the quantifications of oNBH (n¼ 3) andmNBH(n¼ 3), and (G) and (H) are the quantifications of oM1000 (n¼ 3) andmM1000 (n¼ 3). (I) Hippocampal CA1
LTP in slices fromWTmice after treatmentwith oM1000,mM1000, andmNBHtreatedwith 50mMEGCGis shown.Thehippocampal sliceswere treated for 5min
(black solid line) started after an 8–10 min of stable baseline recording, which was20min before the induction of LTP by serial trains of HFS. (J) Average LTPs
recorded at the last 10min of the recordings in (I) are shown. (K) Average PTPs recording after the treatments listed in (I) are shown. (E–H) Results are analyzed by
two-way ANOVAwith Dunnett’s correction for multiple comparisons. (J andK) Results are analyzed by one-way ANOVAwith Dunnett’s correction for multiple
comparisons. All data are presented as standard error of mean. *p < 0.05, ****p < 0.0001. To see this figure in color, go online.
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Synaptotoxic M1000 PrPSc Are OligomersThe additional studies we report have verified our previ-
ous preliminary findings supporting that although the PrPSc
in mM1000 fractions were initially fractionated as mono-
meric (as per their size exclusion behavior), they are likely
to be misfolded, pathogenic species in a state of unstable
equilibrium, via which they may rapidly become oligomers
(19,37,39,40). The new interrogations of PrP species in
pooled mM1000 in this study through tandem SEC, native
Western blotting, and DSS cross-linking revealed that
mM1000 appeared to quickly form closely self-associated
PrPSc oligomers when pooled in a physiological buffer.
Given the evidence that transition between b-PrP monomers
and oligomers could occur between four to 10 s (37), it is
possible that monomeric PrPSc species in the mM1000
immediately became oligomers as they were eluted from
the SEC column. Importantly, given the absence of acute
synaptotoxicity of multimeric complexes in mNBH and
oNBH, misfolding to form PrPSc appears a fundamental
but insufficient prerequisite for such toxic effects, and
although biophysical differences exist between mM1000
and oM1000 oligomers, as reflected by the effects of
EGCG treatment and the median size of constituent oligo-
mers revealed by densitometry, it appears oligomerization
of PrPSc engenders inherent acute synaptotoxicity not
evident when PrPSc can be maintained as primarily
monomeric.
Although the protection of synaptic function through
EGCG treatment of pooled mM1000 fractions may suggest
this as a potential therapeutic, the primary reason we used
this compound was to more directly assess the role of olig-
omerization as a prerequisite for acute synaptotoxicity,
aware of evidence that EGCG can interfere with the normal
physiological roles of proteins, including PrPC (10,15).
Nevertheless, our finding that EGCG can prevent acute syn-
aptotoxicity by mitigating oligomerization of PrPSc found
in pooled mM1000 verifies this as a potential therapeutic
approach, albeit requiring the discovery or development of
drugs analogous to EGCG but with arguably higher efficacy
and acceptable ‘‘off-target’’ effects. We were not able to
assess for any altered toxicity of ‘‘mature’’ oligomers in
pooled oM1000 fractions after being slightly disassembled
by a higher concentration of EGCG (100 mM) because of
the background synaptotoxicity of such high doses of
ECGC, but a safe, more potent compound with broadened
antiaggregation capacity would enhance the appeal of this
type of therapy.
Although a similar rapid transition to higher-order assem-
blies was observed in PrPC from pooled mNBH, our
evidence of the reduced size of higher molecular weight
complexes only in mNBH, but not in mM1000, after
treatment with benzonase suggests that the intermolecular
interactions of such multimeric PrP in mNBH and
mM1000 were fundamentally different. Further support
for such difference was the resistance of higher-order com-
plexes containing PrP in pooled mNBH to EGCG treatment,but not those in pooled mM1000, as well as the differences
revealed with DSS cross-linker studies wherein the11.4 Å
spacer cross-linked substantial levels of PrPSc oligomers in
mM1000 compared with minimal effects on PrPC within the
multimeric assemblies of mNBH. These observations sug-
gest that relative to PrP oligomers in mM1000, PrP in
pooled mNBH was not aggregated at sufficiently close prox-
imity to be cross-linked. Given the evidence that sarkosyl
alters PrP conformation and promotes PrPSc aggregation
(41), it is possible that the use of sarkosyl in this study
contributed to the self-concatenation and conformations of
PrP in mNBH and mM1000. Collectively, our findings
clearly support that self-concatenation of PrP in mNBH
and mM1000 preparations yielded multimeric PrP species
with different molecular interactions and consequent con-
formations. Further studies are required to clarify whether
SEC fractionation of cNBH, and consequent pooling of
mNBH and oNBH, simply allows irrelevant artifactual
agglomeration of PrPC through unclear mechanisms into
loosely associated multimers or is truly capturing, or
perhaps affording, an opportunity for PrPC to assemble
into biologically meaningful homo- or heteromultimeric
complexes, as suggested by the recognized large number
of potential association partners (42). PrPC may only be pre-
sent as oligomers or higher molecular weight complexes if
they are correctly and closely partnered with other mole-
cules, especially proteins, and the apparent self-assembly
of PrPC monomers into higher-order assemblies facilitated
by nucleic acids may exemplify an artifact of our SEC frac-
tionation utilized in this study.
The molecular interactions that assembled PrPSc
molecules into oligomers, as defined by the sensitivity to
EGCG, appeared different and stronger in oM1000
compared to mM1000, suggesting the possibility that synap-
totoxic PrPSc oligomers biophysically evolve through a
maturation process from ‘‘nascent’’ to ‘‘mature.’’ We specu-
late that ‘‘nascent’’ oligomers are possibly intermediates in
dynamic equilibria between PrPSc monomers and ‘‘mature’’
oligomers, in which monomers can rapidly oligomerize,
whereas oligomers, especially nascent species, can disas-
semble, producing monomers (37). This speculation is
broadly consistent with previous reports of intermediates
determined as ‘‘octamers,’’ which were demonstrated to
exhibit some toxic effects associated with prion disease
(6,29,40,43). Moreover, analogous dynamic equilibria and
underpinning intermolecular interactions and pathways
were not observed in fractions of NBH, as indicated by
the failure of the EGCG treatment to reduce the size of
PrPC oligomers in both mNBH and oNBH. The molecular
interactions that bound PrP multimers in mM1000,
oM1000, and oNBH appeared independent of nucleic acids
because benzonase treatment did not alter them. Impor-
tantly, benzonase and EGCG did not alter oNBH and
oM1000, suggesting that PrP multimers in these prepara-
tions were bound by relatively strong molecular interactionsBiophysical Journal 119, 128–141, July 7, 2020 139
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nisms given differences in DSS cross-linking studies. In
addition, as opposed to the mechanisms of many antiprion
therapeutic drugs (10), the mechanism by which EGCG
altered the sizes of PrP multimers in this study was indepen-
dent of any cellular activity because all the treatments of PrP
preparations were conducted in a cell-free assay.
Our findings further support that M1000 prion acute syn-
aptotoxicity is more dependent on the specific biophysical
properties of constituent PrPSc (especially oligomerization)
rather than just the absolute quantity of PrPSc. The acutely
synaptotoxic level of total PrP (including PrPSc) in
mM1000 was <<12 ng/mL despite our previous report
demonstrating that 15 ng/mL total PrP in 0.1% (w/v)
cM1000 and 35 ng/mL in 0.5% (w/v) PrP-depleted
M1000 were not synaptotoxic to hippocampal CA1 LTP
of WT mice (16). We surmise this discrepancy may be
due to the different ways by which these preparations of
ex vivo PrPSc were prepared, with pooling of monomeric
M1000 fractions after SEC associated with production of
more acutely synaptotoxic species relative to total PrP
present. For example, the smaller average size mM1000
oligomers as compared with those in pooled oM1000 frac-
tions may mean a higher effective concentration of acutely
synaptotoxic entities per total PrPSc in the former. More-
over, this finding is broadly consistent with other reports
of PrPSc infectivity appearing more dependent on certain
species of PrPSc rather than absolute levels (18,22,44).
We have not explored the infectivity of our pooled fractions,
but given previous reports of significant overlap between
synaptotoxic and transmitting PrPSc species at terminal
disease (3), as well as the evidence that highly efficient
transmissibility correlates with smaller PrPSc oligomers
(18,22,44), we speculate that the smaller PrPSc oligomers
in mM1000 may harbor substantial infectivity. Furthermore,
given that we previously showed that prion acute synapto-
toxicity appeared independent of human mouse-adapted
prion strain, the results of this study are likely to be evident
with other prion strains; however, additional experiments
are required to confirm this.SUPPORTING MATERIAL
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association study
Emma Jones*, Holger Hummerich*, Emmanuelle Viré*, James Uphill, Athanasios Dimitriadis, Helen Speedy, Tracy Campbell, Penny Norsworthy, 
Liam Quinn, Jerome Whitfield, Jacqueline Linehan, Zane Jaunmuktane, Sebastian Brandner, Parmjit Jat, Akin Nihat, Tze How Mok, Parvin Ahmed, 
Steven Collins, Christiane Stehmann, Shannon Sarros, Gabor G Kovacs, Michael D Geschwind, Aili Golubjatnikov, Karl Frontzek, Herbert Budka, 
Adriano Aguzzi, Hata Karamujić-Čomić, Sven J van der Lee, Carla A Ibrahim-Verbaas, Cornelia M van Duijn, Beata Sikorska, Ewa Golanska, 
Pawel P Liberski, Miguel Calero, Olga Calero, Pascual Sanchez-Juan, Antonio Salas, Federico Martinón-Torres, Elodie Bouaziz-Amar, Stéphane Haïk, 
Jean-Louis Laplanche, Jean-Phillipe Brandel, Phillipe Amouyel, Jean-Charles Lambert, Piero Parchi, Anna Bartoletti-Stella, Sabina Capellari, 
Anna Poleggi, Anna Ladogana, Maurizio Pocchiari, Serena Aneli, Giuseppe Matullo, Richard Knight, Saima Zafar, Inga Zerr, Stephanie Booth, 
Michael B Coulthart, Gerard H Jansen, Katie Glisic, Janis Blevins, Pierluigi Gambetti, Jiri Safar, Brian Appleby, John Collinge, Simon Mead
Summary
Background Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common 
being sporadic Creutzfeldt-Jakob disease (sCJD). Variants in the PRNP gene that encodes prion protein are strong risk 
factors for sCJD but, although the condition has similar heritability to other neurodegenerative disorders, no other 
genetic risk loci have been confirmed. We aimed to discover new genetic risk factors for sCJD, and their causal mechanisms.
Methods We did a genome-wide association study of sCJD in European ancestry populations (patients diagnosed with 
probable or definite sCJD identified at national CJD referral centres) with a two-stage study design using genotyping 
arrays and exome sequencing. Conditional, transcriptional, and histological analyses of implicated genes and proteins 
in brain tissues, and tests of the effects of risk variants on clinical phenotypes, were done using deep longitudinal 
clinical cohort data. Control data from healthy individuals were obtained from publicly available datasets matched 
for country.
Findings Samples from 5208 cases were obtained between 1990 and 2014. We found 41 genome-wide significant single 
nucleotide polymorphisms (SNPs) and independently replicated findings at three loci associated with sCJD risk; 
within PRNP (rs1799990; additive model odds ratio [OR] 1·23 [95% CI 1·17–1·30], p=2·68 × 10–¹⁵; heterozygous model 
p=1·01 × 10–¹³⁵), STX6 (rs3747957; OR 1·16 [1·10–1·22], p=9·74 × 10–⁹), and GAL3ST1 (rs2267161; OR 1·18 [1·12–1·25], 
p=8·60 × 10–¹⁰). Follow-up analyses showed that associations at PRNP and GAL3ST1 are likely to be caused by common 
variants that alter the protein sequence, whereas risk variants in STX6 are associated with increased expression of the 
major transcripts in disease-relevant brain regions.
Interpretation We present, to our knowledge, the first evidence of statistically robust genetic associations in sporadic 
human prion disease that implicate intracellular trafficking and sphingolipid metabolism as molecular causal 
mechanisms. Risk SNPs in STX6 are shared with progressive supranuclear palsy, a neurodegenerative disease associated 
with misfolding of protein tau, indicating that sCJD might share the same causal mechanisms as prion-like disorders.
Funding Medical Research Council and the UK National Institute of Health Research in part through the Biomedical 
Research Centre at University College London Hospitals National Health Service Foundation Trust.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Prion diseases are fatal neurodegenerative conditions in 
humans and animals caused by the propagation of prions: 
atypical infectious agents comprised solely or predomi­
nantly of host prion protein.1 Prions are thought to 
propagate through a process of binding to normal prion 
protein, induction of conformational change by templat­
ing, and fission of the polymeric assembly. Prion diseases 
can be acquired from exposure to prions in the diet, or 
through medical or surgical procedures, which can result 
in public health crises. The cattle prion disease, bovine 
spongiform encephalopathy (BSE), which transmitted to 
mostly young British and other European adults as variant 
Creutzfeldt­Jakob disease (vCJD),2 led to enhanced clinical 
surveillance for all prion diseases worldwide. Inherited 
prion disease, caused only by mutations of the prion 
protein gene (PRNP), causes approximately 10–15% of the 
annual incidence of all prion diseases in most countries.3 
The most common type of human prion dis ease is 
sporadic CJD (sCJD), a rapidly progressive demen tia with 
a lifetime risk of approximately one in 5000, which occurs 
predominantly in older adults.4,5 Other than age and 
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polymorphisms at PRNP, no risk factors for sCJD are 
known, leaving only speculative explanations for sporadic 
prion formation.
Polymorphisms of PRNP at codons 127, 129, and 
219 alter amino acids and are strong genetic risk factors or 
modifiers of the disease phenotypes.3 Sibling or familial 
concurrence of sCJD has been reported, but not to the 
extent that chance concurrence can be eliminated as an 
explanation. There are no estimates of the heritability of 
sCJD based on family studies.6 Animal studies have 
identified acquired prion disease risk factors in Prnp and 
close by, and provided evidence for susceptible loci on 
other chromosomes, yet elucidating the causal genes has 
proven to be challenging.3 Many other neurodegenerative 
diseases are thought to share fundamental mechanisms 
with prion diseases, including template­based protein 
misfolding and spreading of pathology associated with 
abnormally aggregated proteins in diseased brain tissue. 
If shared mechanisms exist, this might implicate shared 
genetic risk factors for these diseases.
This study follows on from previous genome­wide 
association studies (GWAS) in human prion diseases, 
which have not been powerful enough to discover non­
PRNP risk factors.7–10 We aimed to identify specific causal 
genes at risk loci, to allow molecular causal mechanisms 
for sCJD to be proposed.
Methods 
Study design and participants 
We did a GWAS using samples from patients diag­
nosed with probable or definite sCJD according to 
widely accepted criteria, which were provided by special­
ist or national surveillance centres in countries with 
populations of predominantly European ancestries 
(appendix pp 2, 28–32). Diagnostic criteria for probable 
sCJD varied over the course of sample collection for the 
study. Using modern diagnostic methods, including real­
time quaking­induced conversion assay with CSF, a 
probable diagnosis refuted by post­mortem examination 
is extremely rare; but even more than 20 years ago, 
probable sCJD was a highly accurate term. Patient 
samples were distributed across a two­stage study design: 
samples were genotyped using Illumina Omniexpress 
arrays in the discovery stage, and additional samples were 
genotyped at the lead variant in each hit locus using 
minor groove binding probes in the replication stage. 
Control data from healthy individuals were obtained from 
publicly available datasets matched for country.
Research in context
Evidence before this study
The rarity of sporadic Creutzfeldt-Jakob disease (sCJD) has been 
limiting in previous genome-wide association studies (GWAS) 
for disease risk. We searched PubMed on April 9, 2020, with the 
terms (“prion” OR “creutzfeldt*”) AND (“genome wide 
association” OR “GWAS”), without language or date 
restrictions, and identified four relevant publications, including 
two directly investigating sCJD risk through genome-wide 
analyses. However, the sample sizes in these studies were not 
sufficient to identify statistically significant associations outside 
of the known risk at the prion protein gene (PRNP). Further 
studies into genetic risk factors for sCJD have primarily utilised 
targeted replication of putative risk variants or candidate gene 
studies to propose association.
Added value of this study
Through international collaboration of sample resources, 
this study is, to our knowledge, the first GWAS to identify 
genetic variants associated with sCJD risk outside of PRNP, at 
genome-wide significance. Two of these variants (within STX6 
and GAL3ST1) were statistically robust to replication in an 
independent cohort, with 5208 patients with sCJD in total 
included in the two-stage study design. Through statistical 
fine-mapping and analysis of exome sequencing and gene 
expression data, we propose genes that are likely to be causal, 
and mechanisms for both novel associations. We used patient 
brain samples and cell-based assays to further investigate the 
biological implications of these associations in relevant 
systems. Two further loci at PDIA4 and BMERB1 were also 
associated with sCJD risk in gene-based tests.
Implications of all the available evidence
Identification of two novel non-PRNP loci conferring sCJD risk 
will provide further avenues for research, with increased 
evidence to support a role of modified intracellular trafficking 
and sphingolipid metabolism within sCJD biology, providing 
the potential to inform new therapeutic approaches. With the 
shared genetic risk of variants within STX6 and those previously 
identified for the tauopathy progressive supranuclear palsy, this 
study also supports the notion of a common so-called 
prion-like causal mechanism for related neurodegenerative 
disorders and thus potential for shared treatments.
Figure 1: Manhattan plot for significant variants
The nearest gene to each genome-wide significant locus (significance indicated 
by the red horizontal line [p<5 × 10–⁸]) is labelled, as well as genes that were 
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Procedures and statistical analysis 
Genotypes were imputed using the Michigan Imputation 
Server and standard sample and genotyping quality control 
measures were implemented, to generate 6 314 492 high­
quality autosomal single nucleotide polymorphisms 
(SNPs) for subsequent analysis (appendix pp 28–32). 
SNPTEST version 2.5.2 was used to perform the associ­
ation test using an additive logistic regression model. 
Association statistics for the replication stage were gen­
erated using PLINK version 1.9 in a fixed­effects meta­
analysis of each cohort. The same model was used to study 
genetic association for kuru resistance (older asymptomatic 
individuals who were exposed to kuru compared to 
patients with young onset and those born after kuru 
exposure). Additional exome sequencing was performed 
on 501 CJD samples using the Illumina HiSeq2000 platform.
Further gene­based analysis was performed using 
MAGMA version 1.06 and VEGAS2 version 2.02, and 
SNP heritability estimates were calculated using SumHer 
with standard specifications. CAVIAR and PAINTOR 
were utilised to generate a credible causal set for SNPs 
surrounding each significant locus based on linkage 
disequilibrium and functional annotations.11,12 eCAVIAR 
and eQTL colocalisation analysis was performed using 
48 tissues included in the GTEx portal version 7.13,14
Short­hairpin RNAs targeting Stx6 and Prnp were used 
to knockdown expression in N2aPK1/2 cells suscep tible to 
infection with Chandler RML prions. Prion propag ation 
was measured using the scrapie cell assay, as pre viously 
described.15 Expression of each proposed gene was 
measured by RT­qPCR in cerebellum from ten patients 
with sCJD and ten neurologically healthy controls. 
Immuno histology for syntaxin­6 and protein disulfide 
isomerase family A, member 4 was done on formalin­
fixed paraffin­embedded frontal cortex and cerebel lum of 
19 patients with sCJD and 15 non­neurological disease 
controls.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between 1990 and 2014, we obtained 5208 sCJD samples, 
of which 4110 were used in the discovery stage and 
1098 were used in the replication stage.
In the discovery stage we compared genome­wide 
genotype data from 4110 patients with probable or defi­
nite sCJD from countries of predominantly European 
ancestries with 13 569 control samples from a similar 
range of countries (appendix pp 2–3). Imputation using 
the Michigan server resulted in 6 314 492 high­quality 
autosomal SNPs after quality control, which were used 
for downstream association tests in SNPTEST with 
ten population covariates. Genomic inflation (λ) was 1·026 
(appendix p 16), indicating no significant sys temic bias 
related to population ancestry or platforms, so no further 
correction was done; the threshold for genome­wide 
significance was p<5 × 10–⁸. Estimated SNP heritability 
(LDAK model: h²SNP=0·26 [SD 0·014]; GCTA model: 
h²SNP=0·24 [SD 0·023]) was similar to that of common 
neurodegenerative diseases, in keeping with very rare 
reports of familial sCJD concurrence.6,16,17
Further to the known association at PRNP on chromo­
some 20p13, two loci achieved genome­wide significance 
mapping to 1q25.3 (STX6) and 22q12.2 (GAL3ST1; figure 1; 
table; appendix pp 17–19). Gene­based testing with VEGAS2 
additionally identified PDIA4 (p=0·040) and BMERB1 
(p=0·0014), although testing with MAGMA did not support 
these associations (appendix pp 20–21). No significant gene 
sets were found. A SNP in intron 1 of the BMERB1 gene 
achieved borderline signifi cance (rs6498552, odds ratio 
1·27 [95% CI 1·16–1·38], p=5·75 × 10–⁸, appendix p 21). 
Although we acknowledge that data from multiple SNPs at 
a locus are needed to directly replicate gene­based test 
results, we selected a lead SNP from the three genome­
wide significant loci as well as from PDIA4 and BMERB1 
for the replication stage.
In the replication stage we generated genotype data 
using minor groove binding probes from 1098 patients 
with probable or definite sCJD, again from multiple 
countries of predominantly European ancestries, and com­
pared these with genotypes from 498 016 control samples 
rs1799990 rs3747957 rs2267161 rs9065 rs6498552
Nearest gene PRNP STX6 GAL3ST1 PDIA4 BMERB1
Location (in GRCh37) 20:4680251 1:180953853 22:30953295 7:148700849 16:15539901







Risk allele A A C T T
Minor allele G A T T T
Discovery stage (n=4110 cases, n=13 569 controls)
MAF cases 0·288 0·452 0·289 0·220 0·120
MAF controls 0·340 0·410 0·322 0·191 0·102










p value 2·68 × 10–¹⁵ 9·74 × 10–⁹ 8·60 × 10–¹⁰ 1·66 × 10–⁶ 5·75 × 10–⁸
Replication stage (n=1098 cases, n=498 016 controls)
MAF cases 0·294 0·450 0·302 0·203 0·105
MAF controls 0·328 0·420 0·326 0·204 0·097










p value; replication 
cohorts
0·0049 0·0034 0·042 0·88 0·17
p value; replication plus 
discovery meta-analysis
9·61 × 10–¹⁷ 1·23 × 10–¹⁰ 1·97 × 10–¹⁰ 8·49 × 10–⁵ 6·45 × 10–⁸
PRNP, STX6, and GAL3ST1 SNPs were successfully replicated in an independent cohort (p<0·05). OR is relative to the 
low-risk allele. GRCh37=Genome Reference Consortium human genome build 37. UTR=untranslated region. 
MAF=minor allele frequency. OR=odds ratio. 
Table: Association results of discovery and replication stages
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from the same countries (appendix pp 2–3). Association 
testing provided replication evidence for PRNP (rs1799990, 
heterozygous geno type and to a lesser extent the minor 
allele is protec tive), STX6 (rs3747957, minor allele con­
ferred risk), and GAL3ST1 (rs2267161, minor allele was 
protective; table). Additionally, we explored if those loci 
would show an association in related prion diseases. 
Genotype data was generated for vCJD (acquired from 
exposure to BSE), iatrogenic CJD (caused by exposure to 
cadaveric pituitary­derived human growth hormone), or 
kuru (and resistance to kuru; a former epidemic of orally 
trans mit ted prion disease among people who lived in the 
Eastern Highlands Province of Papua New Guinea). We 
found no evidence for association of rs3747957 in STX6, or 
rs2267161 in GAL3ST1 with these phenotypes (p>0·05), 
implying that these loci might confer risk specific to the 
sporadic form of human prion disease, although all tests 
were underpowered because of small sample size.7,9
sCJD is known to comprise a range of different 
clinical and pathological phenotypes, broadly correlat­
ing with prion molecular strain types, the latter includ­
ing categorisation by different proportions of three 
glyco forms and the apparent molecular weight of abnor­
mal prion protein by western blotting.18 The National Prion 
Clinic London, UK has done longitudinal observa tional 
cohort studies of CJD involving syste matic clinical assess­
ments of patients, resulting in deep phenotype data.19,20 We 
tested rs1799990, rs3747957, and rs2267161 for association 
with age at clinical onset, clinical duration, and the slope 
of decline in a functional measure of disease severity, 
along with 27 other phenotypic variables (appendix p 4). As 
expected, rs1799990 in PRNP showed associations with 
several clinical and biomarker traits (ten associations in 
30 tested hypotheses). We found no evidence for epistasis 
between discovered loci and geno types at rs1799990, which 
is known to be a major determinant of clinical phenotype.
Because association in a genomic region might not 
be mediated through the nearest gene, we investigated 
the potential mechanisms underlying associations with 
PRNP, STX6, and GAL3ST1. We used CAVIAR to fine­
map the association signal at a locus through joint 
modelling of association statistics for all variants at a 
locus and estimation of a conditional posterior probability 
of causality while allowing for multiple plausibly func­
tional SNPs.12 Around PRNP most of the SNPs identified 
tagged rs1799990. Unexpectedly, a cluster of SNPs located 
Figure 2: Statistical fine-mapping using CAVIAR
CAVIAR utilises summary statistics and LD structure to predict the probability of 
each variant being causal, producing a causal set with 95% probability of 
containing the causal SNP, while allowing for the possibility of multiple 
causal SNPs. Each locus was defined as 100 variants upstream and downstream 
of the top SNP. Plots show causal posterior probability of each variant at 
PRNP (A), STX6 (B), and GAL3ST1 (C), coloured by LD (derived from 
1000 Genomes Project European populations data) with the top SNP. Circles 
indicate variants within the 95% causal set. Triangles highlight other SNPs not 
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5ʹ to those tagging rs1799990 (lead SNP rs12624635, not 
an eQTL) with low levels of linkage disequilibrium to 
rs1799990 were also putatively causal, suggesting a 
potential additional signal at this locus (figure 2A). 
Previous studies have reported that variants at the PRNP 
locus might confer an increased risk for sCJD, inde­
pendently of rs1799990.21–24 To further delineate the 
genetic architecture of the PRNP risk locus, we first 
performed an association analysis under a heterozy­
gous model, which is more appropriate for the known 
mechanism, and confirmed rs1799990 as the lead SNP 
(p=1·01 × 10–¹³⁵; appendix p 22). In a conditional analysis, 
adjusting for heterozygosity at rs1799990, the lead SNP 
was rs6139515 (p=8·98 × 10–⁴). This SNP, which is in 
low linkage disequilibrium with rs1799990 (r²=0·04), is 
correlated with PRNP transcript levels in tibial nerve in 
the GTEx eQTL database14 (p=1·8 × 10–⁶; appendix pp 5, 23). 
The conditional analysis provided no substantive evidence 
of an independent association signal at the CAVIAR lead 
SNP, rs12624635 (p=0·03; appendix pp 5, 23).
The region of high linkage disequilibrium surrounding 
rs3747957 in STX6 resulted in a large causal set, making 
identification of a single causal variant more difficult 
(figure 2B). Subsequently, using eCAVIAR13, GTEx14, and 
other eQTL databases, we identified a strong correla tion 
between sCJD risk and increased expression of STX6 
mRNA in multiple brain regions, particularly in the caudate 
and putamen nuclei of the brain (putamen: rs3747957, 
p=2·3 × 10–¹³, GTEx; figure 3). Both the caudate and puta­
men nuclei are key regions implicated in sCJD and are the 
most commonly abnormal brain regions at diagnostic 
brain MRI.25 Correlations between lead SNPs in STX6, 
rs11586493 and rs3747957, and other genes at the locus or 
within other tissues were absent or less strong (figure 3, 
appendix p 12). These results suggest that increased 
expression of STX6 in brain regions confers an increased 
risk of sCJD. Using PAINTOR, a tool that integrates 
functional genomic annota tion with association statistics, 
we next identified three SNPs (rs12754041, rs10797664, 
and rs6425657; each in strong linkage disequilibrium 
with lead SNP rs3747957) with high posterior probability 
of being causal because they were members of one of 
four functional annota tion groups (RoadMap_Assayed_
NarrowPeak; Maurano_Science2012_DHS; RoadMap_
Enhancers; Roadmap_ChromeHMM_15state).11
As the GWAS signal is associated with only two SNPs at 
GAL3ST1 (in strong linkage disequilibrium with each 
other but low linkage disequilibrium with all surrounding 
variants), these SNPs define the causal set, yet they are 
statistically indistinguishable from each other (figure 2C). 
Using GTEx, neither SNP correlated with expression of 
genes at the locus in brain tissues. One of the SNPs, 
rs2267161, is a non­synonymous variant of GAL3ST1 
p.V29M. Close to p.V29M resides p.V34M (rs55674628, 
allele frequency=0·02; linkage disquilibrium with 
rs2267161, r²=0·01, Dʹ=1·00, discovery p=0·18), the only 
common non­synonymous variants in European ances­
tries populations. These polymorphisms form three 
common haplotypes, rs2267161­C/rs55674628­C (CC; 
frequency in the combined case­control dataset of 0·667), 
CT (frequency of 0·018), and TC (frequency of 0·315). We 
found no evidence of an association driven by the 
rs55674628­T allele using a haplotype­based test (appendix 
p 13). Furthermore, analyses of 501 CJD samples by exome 
sequencing26 did not identify addi tional rare variants in 
GAL3ST1 or STX6.
Expression of STX6, GAL3ST1, PDIA4, and 
BMERB1 mRNA was slightly reduced in bulk analysis of 
post­mortem cerebellar brain tissue from patients with 
sCJD, but only to a similar extent as genes that have 
been suggested as good comparators (appendix p 24).27 
Immunohistology of frontal cortex (in 19 patients with 
sCJD and 15 controls) showed that syntaxin­6 expression 
is restricted to neurons of different sizes, although other 
cell types, probably astrocytes or oligodendrocytes, were 
less consistently stained. In the cerebellum, syntaxin­6 
staining was observed in Purkinje cells and in large 
neurons of the dentate nucleus, and a fine granular 
staining was seen in the molecular layer (appendix p 25). 
In all neuron populations of cerebellum and forebrain, 
Figure 3: Colocalisation of GWAS results at STX6 locus with expression quantitative trait loci
Plot of –log10 of p values from the GWAS analysis at the STX6 locus (black) and the expression quantitative trait 
locus association analysis from the GTEx dataset (red) for: STX6 expression in the caudate (A), STX6 expression in 
the putamen (B), STX6 expression in the hypothalamus (C), and KIAA1614 expression in the tibial artery (D). Peaks 
correspond to the colocalisation posterior probability in the expression quantitative trait locus and GWAS CAVIAR 
analysis, with a higher degree of colocalisation with increasing colocalisation posterior probability (appendix p 12). 
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the staining pattern was fine granular, and was located in 
the cytoplasm, but did not extend into the processes. The 
staining pattern was compatible with the predicted target, 
the Golgi apparatus. The pattern for both syntaxin­6 and 
PDIA4 was indistinguishable between patients with CJD 
and controls (appendix p 26).
Based on GTEx data, we hypothesised that increased 
expression of STX6 in deep brain nuclei increases risk of 
prion disease. To test whether this might be conferred 
through facilitating prion propagation in mammalian 
neuronal cells, we depleted prion­susceptible mouse 
neuroblastoma­derived cells (N2aPK1/2)28 of Stx6 expres­
sion using RNA interference. Using the automated scrapie 
cell assay we measured the impact of Stx6 knockdown on 
prion propagation15,28 using Prnp knockdown cells, known 
to inhibit prion propaga tion in this assay, as positive 
controls.29 Figure 4 shows that Stx6 depletion, unlike 
Prnp depletion, does not consistently reduce the ability of 
N2aPK1/2 cells to propagate RML prions.
Discussion 
We report, to our knowledge, the first GWAS in a human 
prion disease powered to detect alleles with the modest 
effect sizes typical of complex diseases. We identified new 
risk factors for sCJD, including variants which appear to 
have pleiotropic effects in neurodegenerative diseases. 
Further to the known effects at PRNP codon 129, we 
report two independently replicated loci and evidence to 
support the conclusion that risk variants modify the 
primary sequence of the encoded protein (GAL3ST1) or 
increase expression in brain tissues (STX6). Although a 
multitude of potential binding partners for prion protein 
and mechanisms for the modification of prion infection 
have been proposed, GWAS discoveries have great value 
because risk variants identified are implicitly causal in 
the human disease.30 Therapeutic targets underpinned 
by genetic evidence have better chances of successful 
drug development, further encouraging research into the 
mechanisms that underpin these signals.30
Risk variants in sCJD might act at different disease 
stages: increasing the chance of the spontaneous generation 
Figure 4: Scrapie cell assay to measure prion propagation in N2aPK1/2 cells 
with modified Stx6 expression
N2aPK1/2 cells were transfected with pRetroSuper vectors containing 
Stx6 (shSTX6 1, shSTX6 2) or Prnp (shPRNP) targeting short-hairpin RNAs or a 
scrambled non-silencing shRNA sequence (shScramble 1, shScramble 2) for 
controls. Samples were taken before scrapie cell assay for immunoblot (n=3) and 
expression normalised to untransfected N2aPK1/2 (indicated by dashed line). 
(A, B) Knockdown of syntaxin-6 protein determined by immunoblot with anti-
syntaxin-6 antibody (A), with band intensity measured relative to β-actin loading 
control (Student’s t test; B). (C, D) Knockdown of cellular prion protein determined 
by immunoblot with anti-prion-protein antibody ICSM18 (C), with band intensity 
measured relative to β-actin loading control (Student’s t test; D). (E) Average spot 
count of infected cell number after fourth split in scrapie cell assay following 
infection with RML at 3 × 10–⁶ dilution (one-way analysis of variance with Tukey’s 
post-hoc test on log-transformed data). Statistical associations of knockdown 
lines relative to controls are indicated; other results have been omitted for clarity. 
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of prions, reducing prion clearance, enabling prion 
propagation throughout brain tissue, or modifying the 
downstream toxic effects of prion propagation on brain 
cells. We did not find any evidence of a role for risk variants 
in the modification of clinical or pathological disease 
phenotypes, or in modified expression of risk genes at the 
end stage of the disease, but it is too early to draw confident 
conclusions in this respect. Altering the expression of Stx6 
in a cellular model of prion infection did not modify 
the susceptibility of mouse cells to infection or the 
accumulation of abnormal forms of prion protein. Our 
functional data therefore point to a role early in the disease 
process, perhaps in altering the risk of spontaneous 
prion formation in the brain, but studies in other models 
are warranted.
STX6 encodes syntaxin­6, an eight exon, 255 amino­acid 
protein that localises to the trans­Golgi network, and 
recycling and early endosomes. Syntaxin­6 is thought to 
form part of the t­SNARE complex involved in the decision 
of a target membrane to accept the fusion of a vesicle.31 
The intracellular location of abnormal prion protein in 
prion­infected cells involves the plasma membrane where 
conversion is primarily thought to occur,29 as well as 
early and recycling endosomes, late endosomes, and the 
perinuclear region.32 Other studies implicate the endocytic­
recycling compartment or multivesicular bodies as sites of 
generation of prions, and dysregulation of trafficking 
genes by sCJD.33,34 Intracellular trafficking has also been 
implicated in the degradation of prions.35 The modification 
of trafficking of normal or abnormal prion protein by 
syntaxin­6 might be a focus for future investigation.36
There has been considerable recent discussion about 
the extent to which neurodegenerative diseases associated 
with the accumulation of misfolded proteins or peptides 
are similar to prion diseases in their pathogenesis.37 This 
concept provokes the suggestion that prion diseases 
and prion­like disorders might share genetic risk factors. 
Progressive supranuclear palsy is an uncommon neuro­
degenerative cognitive and movement disorder associated 
with the accumulation of abnormal forms of microtubule­
associ ated protein tau with four repeats.38,39 Variants in 
STX6 are in a haplotype with SNPs previously identified 
as associated with progressive supranuclear palsy, with 
shared risk alleles (appendix p 14).39,40 Pleiotropic effects at 
this locus shared between prion diseases and a tauopathy 
lend support to the concept of prion­like disorders and 
indicate the possibility of genetically inspired interventions 
across multiple neurodegenerative disorders.
GAL3ST1 encodes galactose­3­O­sulfotransferase 1, a 
423 amino­acid protein that localises to the Golgi network 
in oligodendrocytes, and is the sole enzyme responsible 
for the sulfation of membrane sphingolipids to form 
sulfatides—a major brain lipid and component of the 
myelin sheath.41 Degradation of sulfatides is catalysed by 
ARSA in the lysosome; recessive defects in this enzyme 
cause metachromatic leukodystrophy: a lysosomal storage 
disorder associated with profound central and peripheral 
demyelination.42 Knockout of Gal3st1 in mice results in 
a neurological phenotype associated with abnormal 
myelin maintenance with age, histological abnormalities 
at the paranodal junctions, and abnormal diffusion tensor 
imaging.43 Furthermore, in a GWAS of UK Biobank 
participants, rs2267161 in GAL3ST1 was significantly 
associ ated with multiple changes in white matter micro­
structure measured using brain diffusion tensor imag­
ing.44 Sphingolipid metabolism and myelin maintenance 
have both been previously implicated in prion protein 
function and prion diseases.45,46 Multiple genes in the 
sphingolipid metabolic pathways are dysregulated early 
in the patho genesis of mouse prion diseases, a finding 
consistent between inbred mouse lines and prion strains.47 
Knockout of prion protein in mice, or naturally in goats, 
results in a demyelinating neuropathy, which in goats is 
associated with abnormal sphingolipid metabolism.36,48–50
PDIA4 and BMERB1 loci, identified in the discovery 
stage by gene­based analysis, were not replicated at their 
lead SNPs; however, the replication sample was necessarily 
limited by the rarity of the disease, and the lead SNPs had 
a lower allele frequency than at other risk loci. Further 
attempts to replicate are justified as gene­based test results 
are driven by multiple SNPs at each locus.
In conclusion, we present the first evidence of statistically 
robust genetic associations in sporadic human prion 
disease that implicate intracellular trafficking and sphingo­
lipid metabolism as molecular causal mechanisms. Future 
work might further test the hypotheses derived from these 
discoveries in prion disease model systems, and examine 
the effects of genome­wide genetic variation on clinical, 
pathological, and molecular phenotypes in sporadic and 
inherited prion diseases.
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Section 3: Human Prion Disease Epidemiological Studies 
The basic descriptive epidemiology of human prion diseases as rare, rapidly progressive and 
potentially transmissible neurodegenerative disorders was delineated more than five decades 
ago. In the intervening period since, incremental elaboration of the epidemiology of human prion 
disease has continued, especially the delineation of genetic forms of CJD in addition to GSS 
and FFI, as well as the recognition of various iatrogenic aetiologies such as treatments 
employing contaminated cadaveric pituitary hormones and dura mater grafts. Over the last 
approximately 20 years, I have led or led the Australian participation in large collaborative 
studies that have re-affirmed and further expanded our understanding of the epidemiology of 
human prion disease. These diverse studies have: supported the likelihood that at least some 
apparently sporadic CJD is likely to represent unrecognized, temporally remote, iatrogenic 
transmission events; determined the global experience of iatrogenic CJD; described the 
influence of codon 129 on the risk and phenotype of prion disease; delineated determinants of 
survival in prion disease; more confidently determined the incidence of prion disease and 
influential factors; and clarified the biological significance of spatio-temporal clusters of CJD. 
Information generated from these studies serves important clinical translational needs including 
enhanced awareness of potential iatrogenic aetiology, individual prognostication, and improved 
patient stratification for therapeutic trials. In addition, other studies have contributed to an 
enhanced understanding of the range of sequence variations in PRNP, their likely true biological 
significance and the feasibility of mounting treatment trials for persons harbouring highly 
penetrant disease causing PRNP mutations. Illustrative of the utility of these studies, for genetic 
counselling purposes it was found that many uncommon PRNP sequence variations have very 
low penetrance or are rare normal polymorphisms and reconfirmed that the three most common 
(E200K, P102 and D178N) mutations account for approximately 80-85% of all likely pathogenic 
sequence variations and are highly penetrant.  
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I n t r o d u c t i o n
By contrast with iatrogenic and familial cases of
Creutzfeldt-Jakob disease (CJD), the aetiology of the
most common form, sporadic CJD, which constitutes
85–90% of all cases,1 , 2 is unknown. One hypothesis is
that sporadic disease is caused by a rare (one in a
million) spontaneous somatic mutation within the
cerebral neuronal pool of the prion protein (PrP).3 A n
alternative is low-level contamination events.4 T h e
excess of homozygosity at codon 129 in iatrogenic
d i s e a s e5 has also been found in sporadic CJD, and may
increase the chance of normal PrP (PrPC) converting to
the abnormal, disease-associated isoform (PrPS C) when
the normal and abnormal conformers interact, as could
occur after a contamination event.
Previous case-control studies have investigated
possible causes or risk factors for sporadic CJD, without
identifying any consistent or major influences.7 – 1 4 In our
case-control study of risk factors for sporadic CJD, we
used the Australian National Creutzfeldt-Jakob Disease
Registry to ascertain cases. Controls were recruited from
the general community by random telephone survey,
unlike most previous studies that used hospital-based
c o n t r o l s .9 – 1 4
M e t h o d s
C a s e s
The Australian National Creutzfeldt-Jakob Disease Registry1 5
collected cases retrospectively to Jan 1, 1970, and prospectively
from Oct 1, 1993. 241 patients with sporadic CJD (122 men,
mean age 63·1 years, 119 women, mean age 66·6 years;
combined age range 25–84 years) represented all Australian
cases of sporadic CJD that occurred up to Oct 31, 1997. The
diagnostic subclassifications of this cohort were 151 definite
(neuropathologically confirmed) and 90 probable (clinically
likely) cases of CJD, according to previously published criteria.1
For probable cases, clinical investigation excluded the
possibility of an alternative explanation and triphasic periodic
complexes on the electroencephalogram, the presence of 14-3-
3 protein in the cerebrospinal fluid, or both were usually
present. In all cases, a history of potential iatrogenic
transmission in the form of dura mater and corneal grafts or
exposure to human cadaveric pituitary hormones was sought
and excluded.
The ascertainment methods were approved by an Ethics
Committee of the University of Melbourne. The main sources
of case reporting provided about 91% of the total cases and
were: neurologists (32%) and neuropathologists (20%); death
certificates (25%); searches of separation codes at university-
affiliated hospitals with ICD-9 CM 046.1 (specific for CJD)
and 290.1 (for presenile dementia), or the equivalent codes
from earlier versions of the International Classification of
Diseases when appropriate (12%); and similar systematic
reviews of the Health Information Morbidity Data for each
S u m m a r y
B a c k g r o u n d Apart from the small number of iatrogenic
and familial cases, the cause of most cases of
Creutzfeldt-Jakob disease (CJD) is not known. We aimed
to identify risk factors for sporadic CJD.
M e t h o d s In a case-control study, we compared the
medical history and selected demographic characteristics
of 241 definite (neuropathologically confirmed) and
probable (clinically likely) patients with CJD, ascertained
from the Australian National Creutzfeldt-Jakob Disease
Registry between Jan 1, 1970, and October 31, 1997,
and of 784 controls, recruited from the community by
random telephone interview in August, 1997. Standard
logistic regression was used for the comparisons.
F i n d i n g s Surgical procedures were significantly
associated with the development of sporadic CJD. This
risk progressively increased with the number of surgical
treatments to a maximum for three procedures (odds
ratio 2·13 [95% CI 1·34–3·41], p=0·002). There was also
a significant association between risk of CJD and
residence or employment on a farm (p<0·001) or market
garden (p=0·002) for longer than 10 years. We found no
significant risk associated with a history of blood
transfusion, organ transplantation, major dental work, or
o c c u p a t i o n .
I n t e r p r e t a t i o n Our findings accord with the hypothesis
that a range of surgical treatments may serve as
unrecognised contamination events and account for a
proportion of cases of sporadic CJD. Possible biases in
different methods and times for the acquisition of data on
cases and controls suggest our findings need to be
replicated in independent studies with community
c o n t r o l s .
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State and Territory (2%). The medical histories of all cases,
detected through the death certificate and hospital separation
coding, were reviewed and validated on-site by a field
researcher. Registry staff compiled a medical and demographic
profile of each case of sporadic CJD with a standard
comprehensive questionnaire (72% of cases) that was
completed by the spouse or a first-degree relative (92%) and
occasionally in consultation with the patient’s general
practitioner. Questionnaires were routinely posted to the
appropriate relative or spouse for completion at his or her
leisure, without time constraints; a few case questionnaires
were completed by telephone interview.
The retrospective retrieval of information was more difficult
the longer the time since death; the datasets least likely to be
complete were for cases from the 1970s.
C o n t r o l s
Controls were recruited and interviewed through a random
dialling telephone survey. All interviews were in English and
took place over 3 days at the end of August, 1997. We
developed an abridged questionnaire for controls to find out:
surgical procedures; specific selected non-surgical hospital
treatments (controls were asked about dialysis, chemotherapy,
radiotherapy, and arterial embolisation); temporally separate
episodes of blood transfusion; recipience of organ
transplantation; major dental work (beyond fillings and dental
hygiene); travel outside Australia for longer than 1 month
(including specifically to the UK); residence or employment on
a farm (of any type including a market garden); work in an
abattoir or as a butcher; relative with dementia; and close
personal contact with a person with dementia who was not a
relative. This abridged questionnaire was specifically based on
that used for cases, with the retained questions selected
because of their a priori relevance to transmission of CJD.
However, telephone interviews necessitate more direct
questions, and the responses captured, if possible, through a
restricted series of options rather than through an open-ended
a p p r o a c h .
We intended to interview 750 controls (about three for each
case of CJD), matched to the cases by age (in 5-year age
groups), sex, and urban or rural residence (as defined by the
Australian Bureau of Statistics1 6) and in proportion to the
resident population of each State and Territory. Listed
telephone numbers were called randomly and on answer we
asked for the oldest man in the household to give his verbal
consent to the interview. If the relevant male age stratum was
already completed, or if no man was available in the household,
the oldest woman was asked to give her consent. In each case,
we sought the oldest person in the household because of the
age distribution of CJD cases.5 A person in an incomplete age
and sex stratum who gave his or her consent was directly
questioned. We did not seek independent corroboration of the
volunteered information, nor verify data provided by
respondents from independent sources such as general
p r a c t i t i o n e r s .
Statistical analysis
Cases and controls were compared by standard logistic
regression techniques. All analyses were adjusted for age, sex,
and urban or rural residence. Because of the incompleteness of
datasets in the cases from the 1970s, we did statistical analyses
for the 128 sporadic CJD cases that occurred after 1987, and
all 241 cases from 1970. In view of the similar results, we
mostly present findings for the entire group. However, analyses
of travel abroad and residence in the UK in the 1980s were
based on cases of CJD diagnosed after 1989.
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Cases Controls Odds ratio (95% CI) p
(n=241) (n=784)
Country of birth
Australia 155 598 1·0
UK 32 86 1·44 (0·92–2·23) 0·109
Other European 36 48 2·89 (1·81–4·62) <0·001
Asia 3 19 0·61 (0·18–2·08) 0·430
Other 6 33 0·70 (0·29–1·70) 0·434
Not known 9 0 —
Any surgery
No 38 233 1·0
Yes 153 550 1·71 (1·16–2·51) 0·007
Not known 50 1 —
Any dialysis, chemotherapy, radiotherapy, or arterial embolisation
No 171 758 1·0
Yes 4 24 0·69 (0·23–2·01) 0·494
Not known 66 2 —
Ever lived or worked on a farm or market garden or employed in an abattoir or as a
butcher
No 77 523 1·0
Yes 94 261 2·61 (1·84–3·71) <0·001
Not known 70 0 —
Blood transfusion
No 118 616 1·0
Yes 27 158 0·89 (0·57–1·40) 0·621
Not known 96 10 —
Relative with dementia
No 156 632 1·0
Yes 7 148 0·20 (0·09–0·43) <0·001
Not known 78 4 —
Close personal contact with non-relative with dementia
No 133 695 1·0
Yes 26 85 1·60 (0·99–2·59) 0·055
Not known 82 4 —
Major dental work
No 89 403 1·0
Yes 62 375 0·75 (0·53–1·07) 0·115
Not known 90 6 —
Transplant recipient
No 165 780 1·0
Yes 2 3 2·67 (0·44–16·3) 0·288
Not known 74 1 —
Travel abroad >1 month*
No 48 406 1·0
Yes 29 377 0·70 (0·43–1·15) 0·157
Not known 36 1 —
Lived in UK >1 month in 1980s*
No 97 718 1·0
Yes 4 65 0·46 (0·16–1·30) 0·132
Not known 12 1 —
All factors adjusted for age, sex, and urban or rural residence. *Cases (n=113) since
1990 only.
Table 1: Risk of CJD by medical and demographic variables
Cases Controls Odds ratio (95% CI) p
(n=241) (n=784)
Total number of surgical procedures
0 38 233 1·0
1 55 241 1·36 (0·86–2·14) 0·185
2 43 154 1·67 (1·03–2·71) 0·037
Ä3 55 155 2·13 (1·34–3·41) 0·002
Not known 50 1 —
Type of surgery
No surgery 38 233 1·0
Skin lesions 27 141 1·17 (0·69–2·01) 0·557
Appendix 25 115 1·33 (0·77–2·31) 0·307
Tonsils 9 93 0·59 (0·28–1·28) 0·181
Heart 11 19 3·55 (1·57–8·04) 0·002
Hip/knee 5 41 0·75 (0·28–2·01) 0·565
Hysterectomy 28 58 2·96 (1·68–5·21) <0·001
Thyroid 4 9 2·73 (0·80–9·29) 0·109
Haemorrhoids 8 11 4·46 (1·69–11·8) 0·003
Gall bladder 18 51 2·16 (1·14–4·09) 0·018
Hernia 18 46 2·40 (1·26–4·57) 0·008
Cataract/eye 24 24 6·13 (3·16–11·9) <0·001
Ear 3 5 3·68 (0·84–16·0) 0·083
Varicose veins 10 15 4·09 (1·71–9·76) 0·002
Carpal tunnel 6 4 9·20 (2·48–34·1) 0·001
Prostate 4 16 1·53 (0·49–4·83) 0·466
Other 89 203 2·69 (1·76–4·11) <0·001
Factors adjusted for age, sex, urban or rural residence, except reasons for surgery or
treatment.
Table 2: Risk of CJD by surgical procedures
Copyright © 1999.  All rights reserved.
R e s u l t s
784 controls completed the telephone interview. 12 3 8 7
telephone calls were made, 2577 (21%) of which were
number unobtainable, engaged, or no reply, and in 22
(0·2%) calls an appointment was made to ring back. In
1308 (11%) of the calls, permission for the interview
was refused, and in 7349 (60%), the relevant age, sex,
and urban or rural residence quota was full. Of the 1131
calls in which interviews began, 347 calls were halted—
the respondent did not want to continue in 63 (6%),
there were language or hearing difficulties in 158 (14%),
or for other reasons in 126 (11%) calls. In 784 (69%)
calls the interviews were completed.
Controls and cases were well matched for age, sex,
State or Territory of residence, and urban or rural
residence (data not shown). However, there was some
deficit of controls from non-English speaking European
countries, probably because our interviews were
conducted in English.
Table 1 shows each medical and demographic
variable by risk of CJD. Of the variables analysed,
surgical procedures were the factor most significantly
associated with risk of CJD (table 2). The risk of CJD
progressively increased with the number of surgical
procedures. Mean time from first surgery to death was
29 (SD=17·4) years. Assessment of separate surgical
procedures indicated that the risk of CJD increased over
a range of operations and was not associated with a
specific anatomical site or complexity. There was no
association between the risk of CJD and non-surgical
hospital treatments (dialysis, chemotherapy, radio-
therapy, and arterial embolisation).
Residence or employment on a farm or market garden
(presence of livestock not specified), was associated with
a risk for CJD, which increased with longer duration of
residence or employment (table 3).
Blood transfusion was not associated with subsequent
risk of developing CJD, irrespective of the total number
of infusion episodes, reason for transfusion, or date of
the first procedure (table 4). Other non-predisposing
factors are shown in table 1 and include: major dental
work; organ transplantation; close physical contact with
an unrelated person with dementia and travel to the UK
in the 1980s. A relative with dementia was associated
with a decreased risk of CJD (table 1).
D i s c u s s i o n
In this case-control study, we found a range of surgical
treatments were associated with an increased risk of
sporadic CJD. Two previous case-control studies, also
with community controls, found the risk of CJD was
associated with hospital-related therapy,8 , 9 but this
significance was lost when the data were pooled as part
of a meta-analysis.1 3 The absence of this finding in a
third study1 2 may reflect methodological differences,
since the controls were selected only from hospital
populations and not from the community. One
possibility is that our finding of an association between
surgery and increased risk of CJD may be due to the
more complete ascertainment of surgical histories in
cases than controls as a result of different data-
acquisition methods. The design of this study differs
fundamentally from all previous case-control series.7 – 1 4
In accord with the report by Kondo and Kuroiwa,8 w e
found that increased risk of CJD was significantly
associated with various surgical procedures, but there
was no consensus with regard to anatomical site,
complexity, or postoperative length of stay in hospital.
We also assessed progressive risk of CJD from multiple
operations and found it to be cumulative, independent
of the type of surgery. The mean of 29 years between
first surgery and eventual death from CJD differs from
the results of Kondo and Kuroiwa8 who reported a
significant association for operations performed within 5
years of symptom onset. The explanation for this
difference is unknown, but our results fall within the
range of reported incubation periods for iatrogenic
transmission events.1 7 The exception in our study was
surgery involving tissue transplants, which may reflect
the high level of precaution and screening in relation to
graft donors. There were, however, few transplants
performed among the study population.
Davanipour and colleagues9 also reported a positive
association, although the discerned surgical risk was less
pervasive. The only significant associations were for
procedures involving the head, face, and neck.
However, hospital controls constituted about half of
those recruited, and selection bias may have contributed
to these more restricted findings. The possibility of
similar recruitment bias was also acknowledged in the
largest case-control study by van Duijn and colleagues1 4
who did not find that risk of CJD was related to medical
history, including the limited range of surgical
procedures assessed. However, after they excluded
neurological inpatient controls, the previous inverse
relation for surgery of the vertebral column and other
invasive investigations was lost, which lends support to
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Cases Controls Odds ratio (95% CI) p
(n=241) (n=784)
Residence or employment
Farm 73 205 2·59 (1·78–3·76) <0·001
Market garden 10 21 3·43 (1·54–7·64) 0·002
Abattoir 6 23 1·87 (0·73–4·80) 0·198
Butcher 5 9 3·97 (1·28–12·3) 0·017
Not known 0 8 —
Duration (years) lived or worked on farm or market garden
None 77 523 1·0
<10 12 64 1·33 (0·68–2·59) 0·404
10–19 17 46 2·71 (1·47–5·02) 0·001
Ä20 24 65 2·78 (1·60–4·81) <0·001
Not known 20 30 —
All factors adjusted for age, sex, and urban or rural residence.
Table 3: Risk of CJD by residence and occupation
Cases Controls Odds ratio (95% CI) p
(n=241) (n=784)
Number of transfusions
0 118 616 1·0
1 20 105 0·94 (0·56–1·58) 0·804
2 4 28 0·70 (0·24–2·03) 0·506
Ä3 3 25 0·58 (0·17–1·96) 0·382
Not known 96 10 —
Reason for transfusion
No transfusion 118 616 1·0
Accident 0 14 —
Illness 1 20 0·26 (0·03–1·96) 0·192
Operation 17 109 0·81 (0·47–1·41) 0·462
Childbirth 2 15 0·70 (0·16–3·08) 0·633
Not specified 9 19 —
Year of first transfusion
No transfusion 118 616 1·0
1979 11 70 0·80 (0·41–1·56) 0·510
>1980 13 74 0·81 (0·43–1·52) 0·510
Not known 3 14 —
All factors adjusted for age, sex, and urban or rural residence.
Table 4: Risk of CJD by blood transfusion
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concerns about the selection of controls.1 4 Differences in
study design may contribute to the conflicting findings
of this and previous case-control studies, particularly
with regard to risk of CJD and surgical treatments.
Given the absence of any form of transmissible
spongiform encephalopathy in Australian domesticated
l i v e s t o c k ,1 8 the apparent association between risk of 
C J D and long-term agricultural residence and work is
difficult to reconcile. However, the increasing risk
associated with longer duration of residence or
employment does lend some support to this result.
Nevertheless, this finding contrasts with the more
understandable absence of clear-cut risk seen for
domestic butchers and abattoir workers, and the
generally negative findings for various agricultural
exposures, assessed by van Duijn and colleagues1 4 i n
Europe. Our finding may stem from matching ages of
controls at interview (in 1997) with ages of cases at
death (1970–97). Any trends over this period toward
fewer Australians living and working on farms could
create an association with the risk of CJD. However, our
analysis restricted to cases since 1987 gave similar
results (if anything larger odds ratios). Furthermore, the
persistence of increased risk of CJD in market
gardeners, among whom exposure to commercial farm
animals would seem to be kept to a minimum, indicates
that more generic explanations may account for the
increased risk with farm domicile and employment, as
Cousens and co-workers1 9 suggested for the increased
rates for CJD in dairy farmers from countries with
negligible endemic bovine spongiform encephalopathy.
Given the potential for specious associations when many
risk factors are analysed, circumspection is required
when dealing with implausible or non-intuitive findings.
Despite anecdotal claims to the contrary,2 0 t h e
absence of detectable increased risk of CJD from blood
transfusion accords with previous case-control
s t u d i e s .8 , 9 , 1 2 – 1 4 This lack of association was maintained
despite a detailed analysis that included total number of
transfusion episodes, reason for the resuscitation, and
date of the first infusion. Other pertinent findings were
the lack of association with major dental work and
contact with people with dementia. Although there was
no association between risk of CJD and travel to the UK
in the 1980s, there were probably too few cases to assess
this risk reliably. However, to date, cases of variant CJD
have not been detected in Australia.1 8
The apparent “protective” effect of a family history 
of dementia conflicts with previous findings.1 2 – 1 4 T h i s
apparent effect probably arises from our careful
exclusion of cases with any familial forms of CJD. Since
classification of familial CJD is based largely on family
history, the exclusion of all familial cases could have
also removed some cases with a relative with some 
other form of dementia; the control population was not
selected on this basis.
The retrospective nature of information retrieval for
most of the cases led to predictable limitations of data
completeness, which generally, but not exclusively,
increased with the length of time since the patient’s
death. However, our analysis of cases after 1987, and
separately of all patients, did not qualitatively affect 
the findings, which suggests any lack of information
probably arose unsystematically. The possibility of 
recall bias by surrogate respondents (spouses and close
relatives) who completed the medical demographic
questionnaires relating to patients is unavoidable. 
Other possible biases may have resulted from the way
we selected and interviewed controls, as suggested by
the deficiency of non-English speaking Europeans in 
the controls. Since controls were selected from listed
telephone numbers, they may not represent an entirely
random sample of the Australian population. Controls
were interviewed in person which raises the possibility
of different recall bias compared with cases for whom 
a surrogate supplied information. A similar study1 4
discounted methodological discrepancies in interviewees
for control data, but did not assess the potential for
systematic bias relevant to our study since we used
different data acquisition methods. Another potential
bias is that data were ascertained in August, 1997, for
controls and from 1970 to 1997 for cases, so any time
trends over this period could bias results. Although the
concordance of our results with previous studies in
terms of absence of risk from blood transfusion9 , 1 2 – 1 4 a n d
dental work8 , 1 0 – 1 4 suggest that large or pervasive biases
were not introduced, our results need to be replicated in
independent studies with community-based controls.
We believe our findings should reinforce the
heightened vigilance about infection control at all levels of
care in hospital settings, particularly given the emergence
of the probable zoonotic forms of variant CJD.
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S u m m a r y
B a c k g r o u n d Mifepristone is a highly effective and well-
tolerated emergency contraceptive when given in a dose of
600 mg within 72 h of unprotected coitus. We assessed
whether the same effectiveness can be achieved with lower
doses of mifepristone (50 mg and 10 mg) and a longer
postcoital treatment period (120 h).
M e t h o d s We undertook a multicentre, single-masked,
randomised trial in 11 family-planning clinics in Australia,
China, Finland, Georgia, the UK, and the USA. 1717 healthy
women with regular menstrual cycles who requested
emergency contraception within 120 h of unprotected coitus
were randomly assigned to three treatment groups.
F i n d i n g s 32 women were lost to follow-up and one was
pregnant before treatment. The 600 mg, 50 mg, and 
10 mg groups did not differ in the proportions of pregnancies
(seven [1·3%] of 559, six [1·1%] of 560, and seven [1·2%]
of 565). Two pregnancies (both in the 50 mg group) were
tubal. Among women without further acts of intercourse,
treatment delay did not appear to influence the
effectiveness. No major side-effects occurred, except a
delay in the onset of next menses, significantly (p<0·01)
related to the mifepristone dose. 
I n t e r p r e t a t i o n Lowering the dose of mifepristone sixty-fold
did not decrease its effectiveness as an emergency
contraceptive under typical use, though a study of this size
cannot exclude differences in effectiveness up to almost
three-fold. Lower doses of mifepristone were associated with
less disturbance of the menstrual cycle. Thus, a dose as low
as 10 mg seems preferable to the 600 mg dose.
L a n c e t 1999; 3 5 3 : 6 9 7 – 7 0 2
In t r o d u c t i o n
Two UK randomised controlled trials of emergency
contraception compared a single dose of 600 mg
mifepristone with the Yuzpe regimen of oral
contraceptives (ethinylestradiol 100 mg plus
levonorgestrel 500 mg, repeated after 12 h) given within
72 h of unprotected coitus.1 , 2 Mifepristone seemed to be
a better option—three pregnancies were reported among
597 women who received mifepristone, compared with
nine pregnancies among 589 women who received the
Yuzpe regimen. The difference in proportions of
pregnancies was not significant, but women who
received mifepristone had significantly less nausea and
vomiting, which are major drawbacks of the Yuzpe
regimen. Women who received mifepristone were,
however, more likely to have a delay in the onset of the
next menses, presumably because antiprogestagen
administered in the preovulatory phase of the menstrual
cycle delays or blocks ovulation.3 Such delay can worry
women already fearful of an unintended pregnancy. In
addition, delayed ovulation means a conception risk later
in the prolonged cycle if no contraception is used. In one
of the UK trials,2 the three pregnant women were
reported to have conceived 10–15 days after mifepristone
t r e a t m e n t .
Research on the effects of mifepristone on ovarian and
endometrial functions suggests that doses lower than 
600 mg may confer protection against pregnancy when
used for emergency contraception.4 – 6 Lower doses would
reduce the cost and are consistent with the principle that
the lowest effective dose of a drug should be used.
This randomised controlled trial aimed to compare the
effectiveness and side-effects, including the timing of the
subsequent menstrual period, of single doses of 600 mg,
50 mg, and 10 mg mifepristone when the treatment was
given within 120 h (5 days) of unprotected coitus.
M e t h o d s
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Methionine homozygosity at codon 129 of the prion protein
(PrP) gene is a recognised risk factor for the development of
sporadic Creutzfeldt-Jakob disease (CJD).1 Between 64 and
81% of sporadic cases have this genotype,1 – 3 with an overall
rate, combining the data from three series, of 71%. PrP gene
analysis is now available in 748 out of 1327 cases of definite or
probable sporadic CJD, including data from Australia (5),
France (217), Germany (239), Italy (101), the Netherlands
(36), Slovakia (7), Spain (7), Switzerland (7), and the UK
(129). A current issue is whether cases of variant CJD
(nvCJD), might occur in individuals with a valine homozygous
or heterozygous PrP genotype. To date, all 36 cases of variant
CJD with available genetic analysis have been methionine
homozygotes and died at an early age (mean 29 years). A
small number of cases of sporadic CJD with a relatively early
age at death have been identified in participating countries
including Australia, France, Germany, the Netherlands, and
the UK. We analysed the distribution of genotypes at codon
129 of the PrP gene by 10-year age groups in order to
determine whether there is a relative excess of young valine
homozygote or heterozygote cases of sporadic CJD.
The table shows data on the distribution of PrP genotypes
in the normal white population, pooling data from five studies4
(there are no data on stratification by age in these studies), and
the genotype distribution in sporadic CJD, derived by pooling
data from three studies (table2), are also shown, together with
previous data from the European surveillance project.3 T h e
frequencies of codon 129 PrP genotypes differ significantly
across the age groups (x2=38·2, 8 df, p<0·0001) and there is a
positive linear relation between age and the frequency of the
methionine homozygote genotype (p for linear trend
<0·0001). The valine homozygous genotype is significantly
more frequent in cases aged 49 years or less compared with
those aged 50 years and over (x2=27·9, 2 df, p<0·0001). In
some countries only limited data are available but
comparisons between countries are possible for France,
Germany, Italy, and the UK. Codon 129 distribution in these
countries is not significantly different from previous studies of
sporadic CJD, and within country comparison of cases aged
less than 50 years shows a significant excess of valine
homozygotes in France, Germany, and the UK, but not in
Italy. There is a non-significant excess of heterozygote cases
aged less than 50 years in Italy, the Netherlands, and the UK.
The relative excess of valine homozygotes in sporadic CJD
aged less than 50 years is unexpected. There are a number of
possible reasons. There may be a bias in the surveillance
system for the identification of younger atypical cases of
sporadic CJD, because of increased interest in younger
suspect cases after the identification of variant CJD. Sporadic
CJD with an atypical clinicopathological phenotype may occur
in younger patients, particularly those with a valine
homozygous genotype.4 These cases rarely have the “typical”
electroencephalogram seen in sporadic CJD and might be
over-represented in systematic surveillance data because of
ascertainment bias. It is also possible that CJD is
underdiagnosed in older valine homozygotes because of an
atypical phenotype, although the genotype distribution we
have identified would necessitate underdiagnosis in the 50–59
year age group in which alternative causes of dementia are
fairly uncommon. It is also difficult to understand why there
should be a differential bias in the diagnosis of those aged over
50 years compared with younger cases, when suspect cases are
investigated in a standard manner, independent of age, and
this often includes 14-3-3 cerebrospinal fluid immunoassay
and necropsy examination. The percentages of heterozygote
and valine homozygote cases between the study periods
1993–95 and 1996–98 are not statistically different, and this
finding does not support the hypothesis of an increase in the
ascertainment of younger heterozygote or valine homozygote
cases with time as a result of the identification of variant CJD
in March, 1996.
It is possible that the excess of valine homozygotes in
younger cases is caused by variation in the strain of infectious
agent and perhaps exogenous infection, either iatrogenic or
zoonotic, for example due to bovine spongiform
encephalopathy (BSE). An excess of valine homozygotes has
been found in growth-hormone recipients with CJD,5 b u t
none of the cases in our report were known to have an
iatrogenic exposure. The possibility that the excess of young
valine homozygote cases reflects disease caused by BSE is
unlikely because there is no differential excess of valine
homozygote cases in the UK, the country with the greatest
potential human exposure to BSE, compared with France and
Germany. Furthermore all cases of variant CJD tested to date
in the UK have been methionine homozygotes and it would be
surprising if cases of variant CJD with this genotype were not
identified at the same time, and probably earlier, than valine
homozygote BSE-related cases in other countries, should such
cases actually occur. One methionine homozygote French case
of variant CJD has been identified. It is of note that
widespread florid plaque deposition, which is the
neuropathological hallmark of variant CJD, has not been
found in any of the valine homozygote cases in this series.
Most of these cases have undergone necropsy and PrP
glycoform analysis in a small number of cases, including three
young valine homozygote cases in the UK, has not shown the
PrP subtype identified in variant CJD nor the type 5 subtype
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Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease
A Alperovitch, I Zerr, M Pocchiari, E Mitrova, J de Pedro Cuesta, I Hegyi, S Collins, H Kretzschmar, C van Duijn, RG Will
MM MV VV
<49 years* 43 (23) 17 (9) 41 (22)
50–59 years 65 (97) 16 (24) 19 (28)
60–69 years 75 (227) 13 (40) 12 (36)
70–79 years 73 (148) 10 (21) 17 (35)
80+ years 84 (32) 11 (4) 5 (2)
Total 70 (527) 13 (98) 16 (123)
Previous studies† 71 (60) 17 (14) 12 (10)
European data 74 (252) 11 (38) 15 (51)
1993–95
European data 68 (275) 15 (60) 18 (72)
1996–98
Normal population 39 (156) 50 (198) 11 (44)
*The age of death of the youngest case for each genotype was 28 years for MM, 20
years for MV, and 23 years for VV. †Laplanche J-L, et al. Molecular genetics of
prion diseases in France. Neurology 1994; 44: 2347–51, and Salvatore M,
et al. Polymorphisms of the prion protein gene in Italian patients with
Creutzfeldt-Jakob disease. Hum Genet 1995; 94: 375–79.
Percentage of codon 129 PRP genotypes in sporadic CJD by
10-year age groups in the European study 1993–1998
(numbers of cases in parentheses), and codon 129 distribution
in the normal population and in previous studies of sporadic
CJD
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time of the visit. In addition, parents or guardians received
structured questionnaires that asked for developmental
milestones, various diseases including those of the skin, and
parental smoking. The same modes of data collection were
applied to 137 non-VLBW infants seen in our follow-up clinic
for developmental testing and 318 term healthy newborn
babies who were recruited as controls.
Five (2%) of 331 former VLBW infants examined
presented with atopic eczema, whereas atopic eczema was
present in 18 (4%) of 455 control infants at the time of
examination, and transient atopic eczema before examination
was additionally reported by parents of three control infants.
Both the point prevalence and the calculated 1-year lifetime
prevalence of atopic eczema (1·5% v s 4·6%) were significantly
lower in VLBW infants than in term or near-term infants
(two-sided p=0·045 and p=0·016, respectively). The relative
risk of developing atopic eczema until 1 year (corrected age) in
VLBW infants was 0·33 (95% CI 0·13–0·86), compared with
non-VLBW infants. Development of atopic eczema was not
related to parental smoking or net household income.
There is no obvious explanation for the low prevalence of
atopic eczema in VLBW infants. Possibly early exposure to
antigen may lead to the development of tolerance rather than
sensitise VLBW infants, especially after oral administration. In
mice, continuous feeding with small doses of antigen has been
shown to suppress antigen-specific Th2 lymphocytes and IgE
p r o d u c t i o n .5 VLBW infants surviving the numerous antigens
encountered during initial intensive care are apparently more
resistant to atopic immune deviation than infants born close to
t e r m .
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found in BSE transmissions to laboratory mice expressing
valine at codon 129. Further analysis of temporal trends in
codon 129 genotype distribution, clinicopathological features,
and prion protein glycoform patterns in younger patients with
CJD is being undertaken.
The data in this paper have been accumulated by many people in each
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glycoform analysis in the UK. The study is funded by the European Union,
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Low 1-year prevalence of atopic
eczema in very low birt h we i g h t
i n f a n t s
Christoph Bührer, Ingrid Grimmer, Bodo Niggemann, 
Michael Obladen
Preterm birth is associated with various diseases persisting
beyond the neonatal period or becoming evident only after
discharge from neonatal care units. Premature infants are
potentially liable to early sensitisation to numerous antigens.
Undigested proteins are poorly excluded by the mucous
membranes of the gastrointestinal and respiratory system
during the first weeks of life, and antigenic substances may
penetrate the skin because of immaturity and invasive
procedures. There has been speculation, therefore, that
preterm infants are a high-risk group for asthma and eczema,1
although population-based studies have not confirmed an
association between atopy and prematurity.2 , 3
To address the frequency of atopic eczema in very
immature infants who are presumably at greatest risk to early
sensitisation, we investigated the 1-year prevalence of atopic
eczema in a hospital-based follow-up cohort of very low
birthweight (VLBW) infants. The cohort included all 315
surviving, prematurely born, infants with a birthweight below
1500 g consecutively admitted to our tertiary care referral
centre between Jan 1, 1992, and Dec 31, 1996, of whom 282
infants (90%) underwent total body physical examination by a
trained paediatrician at 12 months (corrected age), together
with 49 VLBW infants initially cared for in two other Berlin
hospitals born in the same period. At examination, the
physician’s diagnosis of atopic eczema was based on itchy
eczema with characteristic (facial, extensor) distribution.4 A n
oral history was taken from the parents or guardians at the
Alcohol injection: a new method of
treating placental chorioangiomas
Umberto Nicolini, Guglielmo Zuliani, Elena Caravelli,
Roberto Fogliani, Andres Poblete, Alistair Roberts
Placental chorioangiomas are benign vascular tumours.
Complications associated with chorioangiomas larger than
4–5 cm include polyhydramnios, maternal and fetal
coagulopathies, preterm delivery, pre-eclampsia, fetal heart
failure, and hydrops.1–3 Chorioangiomas probably act as
peripheral arteriovenous shunts leading to progressive heart
failure. Management is limited to induction of labour once
fetal viability is reached. Fetal blood transfusion has been
used therapeutically in infants found to be anaemic,4 but this
is at best only a temporary solution.
Two women were referred to our department with
ultrasound findings of placental chorioangioma. The tumour
was 633·533 cm at 25 weeks’ gestation in patient 1, and
534·534 cm at 18 weeks in patient 2. Patient 1 had
polyhydramnios at admission, and polyhydramnios had
developed by week 22 in patient 2 (figure 1). Both fetuses
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Article abstract—The causes and geographic distribution of 267 cases of iatrogenic Creutzfeldt–Jakob disease (CJD) are
here updated at the millennium. Small numbers of still-occurring cases result from disease onsets after longer and longer
incubation periods following infection by cadaveric human growth hormone or dura mater grafts manufactured and
distributed before the mid-1980s. The proportion of recipients acquiring CJD from growth hormone varies from 0.3 to 4.4%
in different countries, and acquisition from dura mater varies between 0.02 and 0.05% in Japan (where most cases
occurred). Incubation periods can extend up to 30 years, and cerebellar onsets predominate in both hormone and graft
recipients (in whom the site of graft placement had no effect on the clinical presentation). Homozygosity at codon 129 of
the PRNP gene is over-represented in both forms of disease; it has no effect on the incubation period of graft recipients,
but may promote shorter incubation periods in hormone cases. Knowledge about potential high-risk sources of contamina-
tion gained during the last quarter century, and the implementation of methods to circumvent them, should minimize the
potential for iatrogenic contributions to the current spectrum of CJD.
NEUROLOGY 2000;55:1075–1081
Nearly 30 years have passed since the first case of
iatrogenic Creutzfeldt–Jakob disease (CJD) was rec-
ognized in the recipient of a corneal graft from a
donor who had died of unsuspected CJD.1 Two fur-
ther possible cases of corneal graft–related CJD have
occurred in the last decade: one in a patient with
verified CJD who had received a graft 16 months
earlier from a donor whose cause of death was un-
known,2 and one in a patient with clinically typical
CJD who had received a graft 30 years earlier from a
patient with verified CJD.3 The few cases resulting
from contaminated stereotactic intracerebral EEG
needles4 or neurosurgical instruments5 identified in
the 1970s have not grown in number.
Frequency, distribution, and risk. The two
most important causes of iatrogenic disease are con-
taminated cadaveric human growth hormone and
dura mater grafts, first recognized as risks in the
mid-1980s.6,7 The original hope for a limited number
of cases that would quickly diminish over time has
vanished, as cases continue to occur each year, with
current tallies of 139 (growth hormone) and 114
(dura mater). Table 1 summarizes cases of iatrogenic
disease from all causes, and table 2 shows their in-
ternational distribution. More than half of all growth
hormone–related cases have occurred in France, and
more than half of all dura-related cases have oc-
curred in Japan.
The frequencies of CJD in growth hormone recipi-
ents shown in table 3 make no assumptions about
risk factors other than the absence of risk in subjects
treated after mid-1985 with either recombinant hor-
mone (United States, United Kingdom, and New
Zealand) or urea-treated native hormone (France),
who were excluded from the treated population de-
nominator. However, in the United States, all cases
of CJD have so far occurred in individuals who began
treatment before 1977, when the purification proto-
col was changed to include a column chromatography
step. If this new purification protocol contributed to
the disappearance of new cases, then a more appro-
priate calculation of risk in the United States would
use only cases in the pre-1977 treated population,
with a resulting frequency of CJD of 0.8%. Similarly,
instead of the 5 cases in 184 patients treated in New
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Zealand with hormone prepared in the United
States, the denominator would decrease to 46 indi-
viduals treated before 1977, and yield a frequency of
11%. No plausible reason has yet been advanced to
explain this discrepancy between CJD incidence in
United States and New Zealand hormone recipients.
In the United Kingdom, chromatography purifica-
tion was inaugurated around 1980, but because of
supply shortages, hormone prepared by the earlier
method remained in use, and all of the CJD cases in
the United Kingdom received at least some of this
hormone during treatment. Thus, no limiting dates
can be used for making an alternative risk calcula-
tion. In France, all cases have thus far shared a
treatment period between the beginning of 1983 and
mid-1985, which has been proposed as the most
likely limiting period of risk.8 Using the population
under treatment during this period (1260), the calcu-
lated frequency of CJD rises to nearly 6%.
This clustering of French cases may have resulted
either from a succession of several batches of indepen-
dently contaminated pituitary glands or from one or
two batches that cross-contaminated other batches
during processing. However it happened, the con-
tamination must have been comparatively severe, as
judged by the comparatively short intervals between
infection and the onset of clinical signs in most of the
French cases (in experimental models of disease,
Table 2 International distribution of iatrogenic cases of Creutzfeldt–Jakob disease (July 2000)
Country


























United Kingdom 6 4 35
United States 3 1 22
Worldwide totals 114 5 2 3 139 4










Corneal transplant† 3 Optic nerve 16, 18, 320 mo Dementia/cerebellar
Stereotactic EEG 2 Intracerebral 16, 20 mo Dementia/cerebellar
Neurosurgery 5 Intracerebral 17 mo (12–28) Visual/dementia/cerebellar
Dura mater graft 114 Cerebral surface‡ 6 y (1.5–18) Cerebellar (visual/dementia)
Growth hormone 139 Hematogenous (?) 12 y (5–30) Cerebellar
Gonadotropin 4 Hematogenous (?) 13 y (12–16) Cerebellar
* Calculated from the midpoint of treatment to the onset of disease.
† One definite, one probable, and one possible case.
‡ In two cases, dura was used to embolize vessels of non-CNS tissues, rather than as intracranial grafts.
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higher infectious doses generally produce shorter in-
cubation times).
A consideration of all of this information makes it
clear that no single factor can explain the different
frequencies of CJD in the different countries. The
introduction of a chromatography purification step in
the hormone production process may have been crit-
ical in the United States, but does not appear to have
played any role in the United Kingdom and France,
and it is thus probable that details of chromatogra-
phy purification (e.g., column matrix, fraction collec-
tion) may have been important risk determinants. It
is equally clear that differences in the source of pitu-
itary glands, and the rigor with which donor screen-
ing criteria were employed in the various hospital
collection centers of each country, must also have
been critical to hormone safety. No cases of CJD
appear to have resulted from the administration of
commercially prepared hormone, which may explain
why Japan, which used commercial hormone exclu-
sively, has had no cases among 5000 treated subjects.
Japan, however, had a different problem—that of
dura mater grafts. Although nearly all contaminated
dura mater grafts were produced before 1987 by a
single German company, the absence of precise infor-
mation about the extent of graft usage prevents reli-
able risk calculations. Based on a consensus estimate
that in Japan about 20,000 grafts were used each
year,9 it is possible to estimate a cumulative inci-
dence of 0.025% in neurosurgical patients receiving
grafts during the 13-year period 1979 to 1991, and
an incidence of 0.053% during the peak years of 1984
to 1985. The extraordinary use of dura mater grafts
in Japan almost certainly exceeded its use in any
other country in the world (estimated usage in the
United States, for example, was fewer than 4000
grafts per year, of which less than 10% were sup-
plied by the German company). Thus, even with a
random international distribution of infected grafts,
the number of cases in Japan would be expected to
far exceed that in any other country.
Pathogenesis. Virtually all current pituitary hor-
mone and dura mater cases result from infections
that occurred before the mid-1980s, when native hor-
mone was replaced by recombinant hormone, and
improvements in dura mater donor screening and
processing limited further risk of contamination.
Thus, most of these cases have comparatively long
incubation periods that are at least in part the result
of a very small infecting dose (which cannot now be
quantified), administered by a suboptimal route of
infection.
Whereas the route of entry of the infectious agent
into the CNS is obvious in cases resulting from neu-
rosurgical interventions, the route of entry in cases
resulting from peripheral infections is uncertain.
Contamination from corneal grafts and intramuscu-
lar hormone administration could enter the brain
either along nerves at the site of infection, or
through the bloodstream, and both routes have been
successful in experimental models of disease.
Contamination from dura mater grafts is unusual
in that the infection is intracranial, rather than intra-
cerebral or peripheral, and it is therefore interesting to
ask whether the location of the graft influenced the
clinical presentation of CJD, and by implication, the
site of initial infection. Table 4 summarizes the re-
sults from dural graft recipients in 12 different coun-
tries for whom sufficient information is available to
analyze the question. It is evident that graft place-
ment had little or no effect on the clinical presenta-
tion of CJD, which in three-quarters of cases (32/44)
included symptoms and signs referable to the cere-
bellum. Parenthetically, the presence of myoclonus
among presenting symptoms in four of the cases (one
in each dura placement category) is remarkable, as it is
almost never seen at onset in cases of sporadic CJD.
The preponderance of cerebellar onsets and the
absence of topographically distinctive features asso-
ciated with different dural graft placements has been
taken to indicate that cerebellar onsets are not pecu-
liar to peripheral routes of infection.10 Strictly speak-
Table 3 Frequency and median incubation periods of cases of Creutzfeldt–Jakob disease due to contaminated human cadaveric growth











United States§ 23 8000 0.3 (0.8) 20 (10–30)
United Kingdom 35 1880 1.9 (1.9) 16 (8–22)
New Zealand¶ 5 184 2.7 (10.9) 26 (14–30)
France 74 1700 4.4 (5.9) 10 (6–16)
* Excludes patients who began treatment after mid-1985 with either recombinant hormone (United States, United Kingdom, New Zea-
land) or urea-treated hormone (France).
† Figures in parentheses are based on smaller denominators consequent to assumptions about “at-risk” recipient subsets (see text).
‡ Calculated from the midpoint of treatment to the onset of disease.
§ Includes one case in Brazil in a patient who received hormone processed in the United States.
¶ All patients received hormone processed in the United States, and if listed with the US cases, would increase the US case frequencies
to 0.35 (1.0).
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ing, this may be true; however, it is not surprising to
find brain surface infections behaving more like pe-
ripheral route infections than infections introduced
directly into the substance of the brain (either via
neurosurgical or stereotactic EEG instruments or via
the optic nerve), because infectious material applied
to the brain surface, like peripheral route infections,
would be widely diffused by the CSF, whereas infec-
tions introduced directly into the cerebral cortex would
be more likely to start at the site of contamination.
It might even be argued that the preferred site of
replication of the infectious agent, given equal access
to all regions of the brain, is the cerebellum, and that
only when infection is initiated focally inside the ce-
rebrum is mental deterioration likely to precede
other signs of disease. Moreover, the clinical distinc-
tion between the usually cerebellar onset of brain
surface or peripheral infections and the usually demen-
tial onset of direct intracerebral infections, together
with the clinical similarity of such intracerebral infec-
tions to sporadic CJD, is consistent with the idea that
sporadic CJD arises de novo within the brain itself,
rather than from an external invasion.
Genetic influence. The proportion of alternative
genotypes at polymorphic codon 129 of the PRNP
gene in the normal white population is approxi-
mately 40% methionine homozygosity, 10% valine
homozygosity, and 50% heterozygosity.11 It has been
known for some time that homozygotes are over-
represented in most types of CJD, and the sugges-
tion has been made that the transition from a
normal to pathologic isoform of the encoded protein
may be more easily accomplished by molecules with
an identical amino acid sequence, so that codon 129
homozygosity would act to predispose to disease.12
Table 5 compares the results gathered from pub-
lished and unpublished molecular genetic studies of
Table 5 Proportion of codon 129 genotypes in iatrogenic and other forms of Creutzfeldt–Jakob disease (CJD)







Normal white subjects* 398 156 198 44 50
Iatrogenic CJD 128 73 26 29 80
Corneal transplant 1 1 0 0 —
Stereotactic EEG 2 1 1 0 —
Dura mater graft 43 32 8 3 81
Growth hormone 82 39 17 26 78
US 9 5 2 2 78
UK 20 1 8 11 60
France 53 33 7 13 87
Sporadic CJD* 832 587 112 133 87
New variant CJD* 47 47 0 0 100
* Data cited in reference 11.
Table 4 Clinical presentation of dura mater–related cases of Creutzfeldt–Jakob disease according to location
of dura mater tissue application
Dural graft introduction No. of cases
Clinical presentation*
Cerebellar Visual Mental Additional symptoms
Supratentorial 20 15 4 6 Myoclonus and hemiparesis (1), drowsiness (1),
headache (1)
Infratentorial 17 12 6 4 Myoclonus (1), drowsiness (1)
Infratentorial and cervical 5 3 1 2 Myoclonus and spasticity (1), stiffness and
myalgia (1)
Peripheral vein embolization 2 2 1 0 Myoclonus (1), headache and drowsiness (1)
Total 44 32 12 12
* Some patients had onsets with symptoms in more than one category.
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patients with iatrogenic disease to other forms of
CJD: 102 (80%) of 128 iatrogenic cases were homozy-
gous at codon 129. It is curious that whereas methi-
onine homozygosity is the most important genotype
in dura mater–related CJD (as well as in sporadic
and nvCJD), valine homozygosity makes a dispropor-
tionate contribution to growth hormone–related
CJD, particularly among patients in the United
Kingdom. Conceivably, infected pituitaries in the
United Kingdom might by chance have come mainly
from valine-homozygous individuals, with a result-
ing predilection for similarly homozygous hormone
recipients.
The possible influence of the codon 129 genotype
upon incubation time was also analyzed, with the
implicit assumption that the occurrence of a few ad-
ditional future cases in the studied cohorts will not
materially alter the conclusions. For 43 dura mater
cases (from 11 different countries), the codon 129
genotype had no statistically significant effect on the
length of the incubation period: the median incuba-
tion time of the eight heterozygotes was 94 months
(range, 34 to 197 months), and the median for the 35
homozygotes was 108 months (range, 16 to 195
months).
Analysis of the growth hormone cohorts requires
additional assumptions about both the source and
time of infection, because pituitaries were processed
differently at different periods and in different coun-
tries, and infection in the hormone recipients could
have occurred at any point during the usual several year
period of therapy. Most studies have estimated the time
of infection for each case as the midpoint of the inter-
val during which growth hormone was received.
A previously published study of the French cases
observed that heterozygous cases of CJD occurred
notably later than the homozygous cases.8 Analysis
of this data shows the difference to be statistically
significant ( p 5 0.003), using a lognormal distribu-
tion model, and assuming the period of potential ex-
posure was restricted to the years 1983 to 1985, as
suggested by epidemiologic data. The same restric-
tion cannot be applied to cases in the United States
and United Kingdom, where random contamination
occurred, and consequently, incubation times for
each case had to be estimated using the midpoint of
the total treatment period as the point of infection.
Using this approach, no statistically significant rela-
tionship could be demonstrated between incubation
time and the codon 129 genotype in either the
United States or United Kingdom.
In view of the relatively small sample size in each
country, and despite the different conditions of hor-
mone preparation in each country, we attempted to
increase statistical power by a stratified analysis of
pooled data. If, as before, a lognormal distribution is
assumed, the result is highly significant ( p 5
0.0012), and nearly identical results were found by a
stratified analysis of the data as interval-censored
lognormal values (which avoids having to estimate
the time of infection as the treatment period mid-
point). However, using Cox models that make fewer
assumptions about the form of the incubation time
distribution curve, none of the comparisons cited
above reached statistical significance.
Probably the most serious hindrance to all of this
statistical analysis is the unavoidable need to choose
some point during the period of therapy as the time
of infection. The most plausible choice—the midpoint
of the treatment interval—could create a serious cal-
culation artifact by hiding the possibility that the
more susceptible homozygotes would be more easily
infected and so contract the disease earlier in the
course of treatment than would heterozygotes, thus
leading to underestimates for the homozygotes and
overestimates for the heterozygotes. Analysis assum-
ing interval censoring would be subject to a similar
bias. Given the inconsistency of results using these
different analytic strategies, it is not possible to
draw definitive conclusions about the effect of geno-
type on incubation time.
Glycotying has not been carried out on enough
cases to know whether PrP molecular subtypes exert
a further influence upon the clinical features of iatro-
genic disease. Of five tested cases, two had Type 1
PrP (both homozygous for methionine at codon 129),
and three had Type 2 PrP (all homozygous for valine
at codon 129), and no obvious clinical distinction was
apparent between the two groups.13
Diagnostic laboratory aids. Because many pa-
tients with iatrogenic disease are comparatively
young, the clinical diagnosis of CJD may not be con-
sidered, or be considered unlikely, unless the physi-
cian is familiar with the recognized risk factors.
Periodic sharp-wave complexes in the EEG and hy-
perlucency of the putamen in MRI are frequently
found in both sporadic and iatrogenic forms of CJD,
but are usually not observed early enough in the
illness to help with the initial differential diagnosis.
In contrast, a test for the 14-3-3 kinase-inhibitor
family of proteins in the spinal fluid has proved in-
creasingly valuable as an aid to the diagnosis of CJD
as experience with easily performed Western blot
assays has been gained over the last several years.
In studies of hundreds of patients with sporadic CJD
(many of whom were in the early stages of illness)
compared to non-CJD neurologic controls, the test
has been found to have a sensitivity and specificity of
90 to 95%.14 From both published and unpublished
data, the test was positive in 33/43 (77%) cases of
iatrogenic CJD, including 1/1 corneal graft, 7/8 dura
mater grafts, and 25/36 growth hormone cases.
In many cases, positive test results were an im-
portant early clue to diagnosis.
Anecdotal observations. All proven or probable
cases of iatrogenic CJD have resulted from the trans-
mission of disease either from tissues or instruments
contaminated by brain, or tissues proximate to the
brain. Nevertheless, the literature includes a few anec-
dotal reports of patients with CJD in whom peripheral
October (2 of 2) 2000 NEUROLOGY 55 1079
tissue grafts or transplants had been performed. As
examples, we briefly reiterate two published case re-
ports and add one unpublished observation.
The first report was of a 54-year-old man who
developed visual and mental abnormalities 4 years
after having had a tympanic membrane repair using
a pericardial graft from a patient undergoing open
heart surgery, who died postoperatively.15 The sec-
ond report was of a 57-year-old woman with the on-
set of cerebellar symptoms 2 years after receiving a
liver transplant from a 42-year-old man who died
from rupture of a cerebral aneurysm.16 The recipient
of a renal transplant from the same donor remained
in good health at the time of writing. During the
liver transplant operation, the patient also received
a small amount of albumin from a large plasma pool
that included a contribution from a donor who 3
years later died of sporadic CJD. Contamination
from this source can probably be excluded on the
basis of experimental animal model studies showing
the absence of infectivity in albumin.
The unpublished observation is of a 63-year-old
man whose illness began with memory loss and nom-
inal aphasia 4 years after receiving a bone graft from
a previously healthy 46-year-old man who had died
of a myocardial infarct. Bone from the same patient
was used in grafts for 27 other patients, of whom 13
were reported in good health up to 6 years after-
wards (14 recipients could not be reached). Both cor-
neas were also harvested and both recipients have
remained in good health.
In each of these three examples, the tissue recipi-
ents were verified by postmortem neuropathologic
examination to have died of CJD, and although none
of the donors was known to have a primary neuro-
logic illness, none had undergone autopsy.
In only one of the three cases—that of the liver
transplant recipient—was there a cerebellar onset of
illness, which is the proportion that would be ex-
pected for sporadic CJD, but not for iatrogenic CJD
contracted by peripheral route infection. Whereas it
is likely that these (and other) cases represent the
chance occurrence of sporadic CJD in individuals
with preceding transplantation procedures, their oc-
currence should not be ignored, as any similar future
cases will shift the balance in favor of an iatrogenic
cause, just as happened after the initial case reports
of CJD in recipients of growth hormone and dura
mater grafts. Attention should also be given to anec-
dotal cases of CJD in individuals exposed to other
sources of human or animal tissues, including com-
mercial dietary supplements such as vitamin tablets
compounded in tissue powders, illustrated by the fol-
lowing case.
A 71-year-old American woman experienced a pro-
gressive gait disorder and mental deterioration
beginning in the autumn of 1989. Neurologic exami-
nation confirmed a severe ataxia with features of
both cerebellar and basal ganglion dysfunction,
global disorientation, and memory loss. She subse-
quently developed visual loss, complex involuntary
movements, and myoclonus. EEG was abnormal but
showed no periodic activity. Brain biopsy of the fron-
tal cortex showed spongiform change (no plaques
were seen). She died 18 months after the onset of
illness, and in view of the biopsy diagnosis, no au-
topsy was performed. The patient’s family noted that
she had for many years regularly taken a megavita-
min preparation that, on investigation, was found to
contain large quantities of imported beef liver and
bone meal. The country of origin of these imported
tissues was not specified.
The millennium. For the future of iatrogenic dis-
ease in the 21st century, we are optimistic that be-
cause of an increased awareness in the scientific and
medical communities of the dangers of transmitting
infectious diseases from donors to recipients of tis-
sues, tissue extracts, and fluids (such as blood and
its products), together with knowledge of high-risk
CJD tissue sources and methods to avoid or mitigate
their infectious potential, outbreaks of iatrogenic
CJD will soon fade into memory. Certainly, with dis-
infection techniques now well defined, there is little
likelihood of iatrogenic disease resulting from con-
taminated instruments, although we still have not
solved the problem of potential risk from instru-
ments too delicate to withstand harsh chemicals and
autoclaves, and too expensive to discard, that have
contacted infectious organs in patients who only
later are discovered to have been incubating CJD.
Alternatives to human tissue products, such as
recombinant growth hormone and anti-hemophilic
factor VIII, to name but two examples, are already in
use and will become increasingly common. Where
alternatives are either suboptimal or unavailable, at-
tention to donor screening should eliminate much of
the risk at its source. However, in view of the now all
but certain classification of the new variant of CJD
as a zoonotic disease,17-19 we must concede the possi-
bility that unpredictable infections of humans by
analogous animal diseases could spawn donor groups
whose tissues or blood would be used in complete
ignorance of their potential infectivity. Until a prac-
tical diagnostic test to detect preclinical CJD be-
comes a reality, no method or combination of methods
will guarantee risk-free conditions for recipients, and,
as always, considerations of risk tolerated for benefits
gained will determine the use or discontinuance of hu-
man products for therapeutic purposes.
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Through the Australian National Creutzfeldt-Jakob Dis-
ease Registry, 6 pathologically confirmed sporadic cases
were recognized over a 13-year period in persons who
had been long-term residents of a moderate-sized rural
city, whereas the expected number was 0.923. An exten-
sive investigation could not find any point-source or
case-to-case transmission links. This occurrence is highly
statistically significant (p  0.0027) when viewed in iso-
lation and remains significant (p < 0.02) when only the
cases that arose after the cluster was recognized were
taken into account. However, a more conservative statis-
tical analysis suggests that such a grouping could have
arisen by chance in at least one population group of this
size when the whole country is taken into consideration.
Ann Neurol 2002;52:115–118
Transmissible spongiform encephalopathies (TSEs) con-
stitute a group of invariably fatal neurodegenerative dis-
orders that affect both humans and animals.1 The Eu-
ropean epidemic of bovine spongiform encephalopathy
and the more recently recognized variant Creutzfeldt-
Jakob disease (CJD; first reported in the United King-
dom in 19962) have drawn considerable attention to this
group of diseases. In contrast with variant CJD, classic
CJD typically presents as a rapidly progressive dementia
in the elderly associated with ataxia and myoclonus and
is the most common human TSE phenotype. Systematic
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prospective genotyping detects likely causal mutations in
the prion protein gene (PRNP) in up to 13 to 14% of
CJD patients,3 and iatrogenic transmission appears to
explain only a few additional cases.4 Recognized sources
of iatrogenic transmission are diverse, including contam-
inated neurosurgical instruments, and long incubation
periods of 15 or more years are reported.1,4 For most
cases of CJD, there is no identifiable cause. Although de
novo somatic mutations in PRNP or spontaneous dele-
terious conformational changes in the normal prion pro-
tein are favored to underlie sporadic CJD,1 other postu-
lated mechanisms include unrecognized iatrogenic or
natural transmission events.5,6 Recent reports of spatio-
temporal groupings of variant CJD have rekindled inter-
est in undertaking detailed analyses of such occurrences,
with the outcome that covert or uncertain transmission
mechanisms may be elucidated.7
During the course of systematic Australian National
Creutzfeldt-Jakob Disease Registry surveillance activi-
ties, it was observed that 7 deaths from TSE had been
reported from 1988 to 2000 in persons who had been
long-term residents within or immediately neighboring
a single moderate-sized rural city. We present the find-
ings of our detailed investigation.
Patients and Methods
Australian National Creutzfeldt-Jakob Disease Registry sur-
veillance methods have been reported in detail previously.5
In brief, ascertainment methods include reviews of morbidity
separation coding data from all university-affiliated tertiary
referral hospitals in Australia, as well as the centralized data-
bases of state and territory health departments; regular na-
tional death certificate searches; and semiannual mail-out
questionnaires to all neurologists and pathologists within
Australia. Simultaneously with comprehensive prospective
monitoring since September 1993, all Australian cases have
been retrospectively sought to January 1, 1970. Through the
combination of ascertainment measures, it is believed that
essentially all human cases of TSE within Australia have been
detected, particularly since the late 1980s.
After potential CJD cases are ascertained, a thorough medi-
codemographic profile is collected from medical records and
family members, including the completion of a detailed ques-
tionnaire largely aimed at a priori risk factors for CJD. PRNP
analysis (as described previously8) and autopsy are actively fa-
cilitated and undertaken whenever possible. Final classification
is made once all data are collected and is consistent with in-
ternationally recognized diagnostic criteria, with pathological
verification required for definite CJD.9 The national CJD
mortality data for 1988 to 2000 were used to obtain Austra-
lian mortality rates (adjusted for age and gender) and the ex-
pected CJD occurrence rate among residents for the rural city
over this period (0.923 cases) and after the cluster was first
suspected in 1996 (0.284 cases). Formal semiannual analyses
are performed and reports are generated to monitor patterns
and trends of CJD occurrence, including geographical ones.
The statistical significance of the cluster was assessed by
estimation of relative risk through comparisons of the ex-
pected (following age and gender adjustment) and observed
CJD death rates for the rural city. The comparison was made
first for the entire observation period and then separately for
the period from 1997 after the diagnosis of the earlier cases
had given rise to the suspicion of a cluster. In addition, Pois-
son probabilities were used to assess the likelihood of similar
clusters of CJD cases occurring in any equivalent-sized indi-
vidual cohort (of approximately 73,000) with the entire Aus-
tralian population divided equally into 241 groups. p values
less than 0.05 were considered significant.
Results
During the course of systematic surveillance activities,
it was observed that 5 deaths from pathologically con-
firmed TSE had been reported from 1988 to 2000 in
persons who were residents of a single moderate-sized
rural city (population in 1991 census, 72,976). An ad-
ditional death from Gerstmann-Sträussler-Scheinker
syndrome associated with the proline102valine
(P102L) mutation was confirmed in a person who re-
sided just outside the city. Further investigation, there-
fore, concentrated on the other five patients (Tables 1
and 2; Fig). Patients 1 to 4 were all long-term residents















1 1988 71 M 30 11.0 ND
2 1992 58 M 34 3.5 Nil/MMc
3 1996 58 F 40 7.5 Nil/MM
4 1996 65 F 65 10.5 Nil/MMc
5 2000 73 M 3.5 3.7 Nil/MM
6 1999 53 M 13d 3.8 Nil/MM
aLast city residential address.
bMethionine.
cArchival retrieval of DNA from formalin fixed brain permitted reliable nucleotide sequencing for codons 1 to 133 only in Case 2, and from
1 to 135 only in Case 4.
dOver 3 separate periods spanning 22 years.
ND  not determined.
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of the rural city (30–65 years) and died there. The
most recent case (Patient 5) was a person who lived
only the last 3.5 years of his life in the rural city. In
addition to these 5 deaths among residents, the Aus-
tralian National Creutzfeldt-Jakob Disease Registry as-
certained an additional sporadic case (Patient 6; see Ta-
bles 1 and 2; see Fig) who died while a resident of the
state capital but who previously had been a long-term
resident of the rural city (a total of 13 years over a span
of 22 years). Patient 6 spent an additional 2 years liv-
ing on a small farm 27km from the city center from
which he commuted weekdays to his office located in
the central city. Total residence in the rural city con-
stituted the longest by far in any specific location over
the patient’s lifetime. To explore possible linkages
among the cases, we included this case in the investi-
gation. All 6 cases resided within an approximately
11km radius of the city center, with the shortest dis-
tance between any of their last residences being approx-
imately 3.5km. A family history of similar neurodegen-
erative disorders was absent in all patients, and the
clinical phenotype of the six patients was typical of
sporadic CJD (as outlined in Table 2), with PRNP
genotyping excluding mutations in the five patients in
whom it could be undertaken. The average age at
death in the six patients was 63.0 years, which is sim-
ilar to the national mean of 65.2 years.
Exhaustive medicodemographic analysis, including a
communal meeting with family members of 4 of the
sporadic cases, could not determine any point-source
or case-to-case transmission link between the 7 persons
(including Patient 7 with Gerstmann-Sträussler-
Scheinker syndrome). In particular, no orthodox med-
ical, alternative medical, or dental practitioner was
shared by all nor were invasive procedures or opera-
tions performed on these patients at a single institu-
tion. The only association detected was for Patients 2,
3, and 4 (see Tables 1 and 2), who shared the same
ophthalmologist for 11 years, with all 3 first examined
during a 7-month period commencing September
1983. Aside from a single flourescein angiogram in Pa-
tient 2, the consultations were for routine clinical as-
sessments, which included application tonometry
(Goldman) on two or three separate occasions each,
with the shortest interpatient interval being approxi-
mately 9 weeks.
The simplest assessment of the statistical significance
of the apparent cluster employed the hypothesis that by
chance alone the number of sporadic cases observed in
long-term residents from this city was greater than the
number expected for this period. For the cases dying in
the rural city (Patients 1–5), the relative risk was 5.4
(p  0.0027). However, this approach can be ques-
tioned on the grounds that the hypothesis was gener-
ated from the data rather than being stated a priori. A
more valid test of significance, therefore, applied the
same method to cases arising after the cluster was sus-
pected (represented by the third patient dying of spo-
radic CJD in 1996). On this basis, the observed rate of
an additional 2 sporadic cases during 4 years develop-
ing in residents, compared with the expected (0.284),
still represented a significant excess (p  0.02).
More conservative statistical analysis, however, as-
sessed the likelihood that somewhere in Australia, in a













1 4 No Yes Yes No ND
2 6 No Yes No No ND
3 1.5 No Yes Yes No ND
4 1 No Yes Yes Yes ND
5 1 No Yes Yes No Yes
6 2 No Yes Yes No Yes
CSF  cerebrospinal fluid; EEG  electroencephalogram; ND  not done.
Fig. Temporal summary of rural city residence, illness onset,
and death of all patients: (small vertical line) death, (greater
than symbol) onset, (horizontal line) time periods in rural
city, and (asterisk) patient with Gerstmann-Sträussler-
Scheinker syndrome.
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population unit of the same size as this city, 5 or more
cases of sporadic CJD could occur when 0.923 cases
were expected. With the Australian population divided
equally, there are 241 units of approximately 73,000
people. Under Poisson probability assumptions, the oc-
currence of a cluster of this size or greater in at least 1
of these 241 population groups quite easily could arise
by chance alone (p  0.49), even if the nonresident
case (Patient 6) is included to make a cluster of 6 (p 
0.124).
Discussion
Spatiotemporal groupings of sporadic CJD have been
reported previously,10–12 including in the context of
comprehensive epidemiological studies.6,7,13 Generally,
clusters detected during systematic national surveillance
studies are construed as more valid for detailed analysis
by obviating potential selection and detection biases
that may arise when the cluster itself prompts further
investigation.13
It is acknowledged that the relatively short duration
of rural city residence of the most recent case (Patient
5) appears inconsistent with disease acquisition during
this period given the incubation periods determined to
date for recognized peripheral iatrogenic transmission
events.4 Nevertheless, their inclusion was determined
to be important to facilitate the investigation of poten-
tially novel transmission mechanisms. Despite the high
relative risk and extensive investigation of individual
cases, we were unable to identify a putative transmis-
sion pathway. Three patients infrequently attended the
same ophthalmologist, but no convincing mechanism
of transmission was uncovered, with the role of routine
clinical tonometry being highly contentious.14–17 Fur-
thermore, although this cluster is apparently of high
significance when viewed in isolation, more conserva-
tive statistical analysis demonstrates that such a group-
ing of 5 or 6 cases in at least 1 population unit the
same size as the rural city within Australia would not
be unexpected by chance alone over a 13-year period.
Given the cumulative evidence to date, apparent clus-
tering of CJD above background or expected average
national incidence rates is not rare, and each instance
requires careful epidemiological and statistical assess-
ment to determine its true significance.
The Australian National Creutzfeldt-Jakob Disease Registry is
funded by the Commonwealth Department of Health and Aging.
The authors thank Drs M. Pilbeam and G. Hunter for their gen-
erous support in facilitating the clinicopathological investigation of
the patients in this study and A. Bell for his technical assistance.
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Creutzfeldt–Jakob disease in Australia
1970–1999
S. Collins, MD; A. Boyd, Dip. Gen. Coun.; J.S. Lee, BSc; V. Lewis, BSc (Hons); A. Fletcher, BSc;
C.A. McLean, MD; M. Law, PhD; J. Kaldor, PhD; M.J. Smith, PhD; and C.L. Masters, MD
Abstract—Objective: To ascertain all persons who developed a transmissible spongiform encephalopathy (TSE) within
Australia during the 30-year period 1970 to 1999 through a comprehensive national surveillance program and subject the
group to detailed epidemiologic analysis. Methods: Cases were ascertained through reviews of morbidity separation coding
data from all university-affiliated tertiary referral hospitals, as well as the centralized data bases of state and territory
health departments, regular national death certificate searches, and semiannual mailout questionnaires to all neurolo-
gists and pathologists throughout Australia. Prospective monitoring commenced in September 1993. Results: A total of
387 patients were confirmed as having TSE during this epoch. The majority of cases were sporadic Creutzfeldt–Jakob
disease (CJD) (90.7%), with 7.2% heredofamilial and 2.1% iatrogenic. Over this 30-year period, the national average
annual sporadic CJD incidence rate per million progressively increased from 0.31 for the decade 1970 through 1979 to 0.77
for 1980 through 1989, reaching 1.03 for 1990 through 1999. Death certificates were found to have a false-positive rate of
11.5% and sensitivity of 83.0% for sporadic CJD. Conclusions: Within Australia, there has been a gradual increase in the
incidence of transmissible spongiform encephalopathy over the three-decade period 1970 through 1999, peaking in 1999 at
1.4/million/year for sporadic Creutzfeldt–Jakob disease. This increase is believed secondary to improved case ascertain-
ment. Variant Creutzfeldt–Jakob disease was not identified during this period. Age- and sex-adjusted comparisons showed
a decline in incidence rates in the elderly in both sexes, usually from age 74 years. Death certificates were a useful but
imperfect method of case detection.
NEUROLOGY 2002;59:1365–1371
Classic Creutzfeldt–Jakob disease (CJD) is an in-
variably fatal neurodegenerative disorder with a
mean illness duration of 7 months and a global
distribution.1-3 The disease is recognized to occur on
a genetic basis, as a result of mutations within the
prion protein gene (PRNP) and also from rare hori-
zontal (iatrogenic) transmission events; however, in
the vast majority (85 to 90%) the occurrence is ap-
parently sporadic.1
Over the years, CJD has been the subject of many
systematic national and international epidemiologic
surveys.2-19 Earlier comprehensive ascertainment
studies were generally undertaken to explore mecha-
nisms of causation, including the possibility of unrec-
ognized case-to-case transmissions and natural
reservoirs of infection or to clarify the true incidence
and annual death rate from this rare disease.2-9 Re-
cently, interest in this group of diseases has been
rekindled by the bovine spongiform encephalopathy
epidemic among cattle in the United Kingdom and
the emergence of the zoonotically related human dis-
order, variant CJD (vCJD).20,21 The outbreak of bo-
vine spongiform encephalopathy prompted the
development of a number of European national CJD
surveillance registries that have undertaken large
domestic and collaborative epidemiologic studies, fo-
cused primarily on detecting changes in the inci-
dence or clinical pattern of CJD in the wake of the
bovine epidemic.18,19 It was from such efforts that the
vCJD phenotype was quickly delineated, contrasted
against the reaffirmed background clinicopathologic
profile of classic sporadic CJD.
In Australia, a national CJD register was estab-
lished in September 1993 to undertake prospective
surveillance as well as retrospective ascertainment
of all cases to January 1, 1970. Herein we report the
results of our comprehensive national surveillance
and epidemiologic investigation of CJD over the 30-
year period beginning at the start of the retrospec-
tive ascertainment interval and ending in December
1999. To the best of our knowledge, this is the long-
est national population-based ascertainment epoch
for CJD reported to date.
Methods. Surveillance procedures and all related activi-
ties of the Australian National Creutzfeldt–Jakob Disease
Registry (ANCJDR) have ethical approval from the Uni-
versity of Melbourne and collaborating institutions as ap-
propriate and have been described in detail previously.22-24
There has been no statutory obligation to notify to public
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health authorities in Australia about CJD cases. National
prospective surveillance began in September 1993 with the
aim of identifying all persons within Australia in whom
transmissible spongiform encephalopathy (TSE) had been
diagnosed. In accordance with the recommendations of an
independent inquiry,25 the ANCJDR additionally sought
cases retrospectively to January 1, 1970. Previous reports
have summarized the outcome of evaluation of medical and
other risk factors for sporadic CJD in part of this cohort
and provided limited demographic details and analysis.22,24
At commencement of the Registry’s operation in 1993,
all neurologists and pathologists throughout Australia
were contacted by mail and were requested to notify the
ANCJDR of any patients with CJD encountered during
their practice lifetime. Since then, these two specialist
groups have received semiannual prompts by mail, re-
questing notification of recently deceased or living sus-
pected, likely, or confirmed cases. Searches of the National
Death Index, established in 1980, by the Australian Insti-
tute of Health and Welfare (AIHW) have been undertaken
on an annual basis. In addition, the records of all Austra-
lian university-affiliated or tertiary referral hospitals were
searched for the International Classification of Diseases–9
CM (or equivalent earlier) separation codes 046.1 (specific
for CJD) and 290.1 (presenile dementia), with the latter
accepted only if it constituted the principal diagnosis. The
medical files of all persons with disease ascertained in this
way were reviewed and validated on-site by the ANCJDR.
Annual searches for code 046.1 were also made of the
centralized hospital separation morbidity databases of the
health departments of each state and territory. Cases were
attributed to the initial method of notification if they were
identified via more than one source. Since November 1997,
the ANCJDR has provided testing for the presence of 14–
3–3 proteins in CSF, to facilitate notification of suspected
cases and to heighten awareness of the Registry. The Reg-
istry has also offered PRNP genotyping to determine caus-
ative mutations and codon 129 status for selected patients.
Methods used for these two investigations have been de-
scribed previously.23
Potential case subjects underwent detailed evaluation
using all available medical, demographic, and risk-related
information. Data were sourced from both medical records
and attending medical care providers. A history of poten-
tial iatrogenic exposure from dura mater implants, corneal
grafts, or human cadaveric pituitary hormones was sought
in all cases. A standardized and comprehensive question-
naire that specifically sought information on known and
potential risk factors was posted to the surviving family
member or relative designated as most appropriate by the
treating physician. Postmortem histopathologic examina-
tion was sought for all cases but Western blot immuno-
chemical analysis of brain was not performed as part of the
study. Classification criteria for CJD cases, including
vCJD, were based on previously published criteria.3,26 Def-
inite CJD required typical neuropathologic changes. Prob-
able (clinically likely) sporadic CJD cases did not have
pathologic confirmation but had other causes excluded by
appropriate investigations and manifested the salient fea-
tures of rapidly progressive dementia to death in 2 years
accompanied by two of the following: myoclonus, visual or
cerebellar dysfunction, pyramidal or extrapyramidal signs,
or akinetic mutism. In addition, probable cases typically
had characteristic periodic sharp wave complexes (PSWCs)
on their EEG or the presence of 14–3–3 proteins in their
CSF, or both. However, given the relative insensitivity of
PSWC,27,28 this feature was not invariably used as a crite-
rion for classification as probable. Consequently, the possi-
ble CJD classification category was not used. All patients
with suspected CJD without detectable 14–3–3 proteins in
their CSF were followed up at 9 months, with death in this
period prompting reevaluation.
Population denominators by age, sex, and country of
birth were obtained from the Australian Bureau of Statis-
tics.29 Death rates in relation to sex and age for the Austra-
lian population for the years 1987 through 1998 were
obtained from the AIHW. Age-adjusted rates of CJD were
calculated by calendar period for Australia as a whole and for
each state and territory. Time trends were assessed using
Poisson regression. Country of birth was analyzed as a risk
factor for CJD by comparing numbers of recorded cases with
the number expected on the basis of the age and sex distribu-
tion in the population. All statistical analyses were per-
formed using STATA (version 7; Stata Corporation, College
Station, TX) and p values 0.05 were taken as significant.
Results. Out of a total of 704 suspected cases of TSE
evaluated by the ANCJDR during the calendar years 1970
to 1999, 387 were found to be either definite or probable.
All but 17 of these patients died during the study period.
The overwhelming majority of cases were sporadic (90.7%),
with 7.2% heredofamilial and 2.1% recognized to have an
iatrogenic basis (table 1). Of the 351 sporadic cases, 195 were
definite and 156 probable. There were no cases classified as
vCJD. Specific diagnoses in excluded cases varied consider-
ably and often a precise diagnosis could not be discerned,
leaving exclusion based on a clear failure to fulfill diagnostic
criteria such as recovery from a monophasic illness.
Over half the cases were reported by specialist physi-
cians (neurologists 37.6% and neuropathologists 17.9%),
either on the basis of the reminder cards or on their own
initiative. National death certificate searches by the AIHW
Table 1 Summary of all ANCJDR cases, including mean age at death and duration of illness, according to the major etiologic subtypes
Classification
Cases of CJD in
Australia, 1970–1999, n Average age at death, y (range) Average duration, mo (range)
Men Women Total Men Women Total mean Men Women Total mean
Sporadic 165 186 351 63.9 (25–84) 66.6 (33–89) 65.3 (25–89) 6.1 (1–45) 7.1 (1–60) 6.6 (1–60)
Familial 13 15 28 49.3 (20–68) 58.9 (42–82) 54.6 (20–82) 13.8 (2.3–50) 23.8 (2–156) 19.4 (2–156)
Iatrogenic 3 5 8 40.3 (27–62) 39.8 (26–50) 40.0 (26–62) 5.0 (2–10) 10.7 (3.5–25) 8.6 (2–25)
ANCJDR  Australian National Creutzfeldt–Jakob Disease Registry; CJD  Creutzfeldt–Jakob disease.
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yielded approximately 24.6% of the cases, and hospital medi-
cal record and state and territory morbidity separation cod-
ing searches provided an additional 8.5% of all cases. The
remaining 11.4% cases came from a diversity of sources.
Death certificates were available in 342 persons (97.4%) ulti-
mately classified as having sporadic CJD, with 284 (80.9%)
correctly listing the diagnosis as the cause of death (sensitiv-
ity 83.0%; false-negative rate 17.0%). Conversely, 37 patients
with CJD cited as the cause of death were deemed to have
died from another illness after thorough review of all avail-
able data, giving an 11.5% false-positive death certificate
rate. The positive predictive value of a death certificate list-
ing CJD as the cause of death was 88.5%.
A comparison of definite to probable sporadic CJD cases
showed no differences in their sex distribution (men: defi-
nite 97/197 [49.2%] compared with probable 68/156
[43.6%]; p  0.25) or mean illness duration (6.8 months for
definite cases vs 6.5 for probable cases; p  0.76). How-
ever, there was a significant difference in mean age at
death (64.2 years for definite cases vs 66.8 for probable
cases), which was restricted to men (62.2 years for definite
cases vs 66.3 for probable cases: women 66.2 years vs 67.2,
p  0.45). Nevertheless, we considered the two groups
sufficiently similar to be aggregated for subsequent statis-
tical analysis. The overall ratio of men to women was
1:1.13, with the age-adjusted incidence for men and women
very similar for the study period: men 0.662/million to
women 0.661/million. The excess of women observed in
those dying at age 60 years (p  0.004) was not different
from the predominance of women in the overall Australian
population death rate in this age group (p  0.001). Death
occurred at a mean age of 65.3 years (men 63.9 years;
women 66.6 years; range, 25 to 89 years) (see table 1). For
sporadic cases, there was a significant overrepresentation
of EEGs displaying PSWCs in the probable group (93 with,
vs 59 without, typical EEG changes) compared with defi-
nite cases (81 positive, 88 negative), which is not unex-
pected given the reliance on this feature for categorization
of the former group. EEGs were not performed or not avail-
able in 30 patients. About 70% of patients with sporadic
CJD died within 6 months of illness onset, and 87.5% died
before 12 months. The combined mean illness duration
was 6.6 months (6.1 for men, 7.1 for women).
Age- and sex-adjusted death rates from sporadic CJD
were assessed over three separate periods: 1970 to 1989,
1990 to 1994, and 1995 to 1999. The peak age period for
death was generally 65 to 74 years in both sexes in each
epoch, except for women in the 1970 to 1989 period and
men in 1990 to 1994 period when the incidence did not
clearly decline until after age 79 years (figure 1). A com-
parison of the mean age at death and age distribution of
sporadic cases was made for the 1970 to 1994 and 1995 to
1999 periods. There was no difference in the average age
at death in either sex (1970 to 1994: men 63.2 years com-
pared with 65.3 for the later epoch; women 66.6 years
compared with 66.8). The age distributions were also very
similar, suggesting no major change in these salient demo-
graphic features over the period studied. In contrast, the
28 familial and eight iatrogenic cases were typically
younger patients, with the average ages at death 54.6
years for the former group and 40.0 years for the latter,
and both displayed longer mean illness durations (19.4
months for familial cases and 8.6 months for iatrogenic
deaths). Patients with younger age at disease onset (50
years) accounted for approximately 12% of the total, but of
these, sporadic cases still constituted the majority (54%).
Because of the relatively recent availability of the CSF
14–3–3 protein assay, only 53 of the 387 patients under-
went testing. Of the sporadic cases, 25 of 27 definite cases
were positive, whereas 17 of the 18 probable patients had
detectable 14–3–3 proteins. The two patients with iatrogenic
(dura mater [Lyodura, B. Braun, Melsunger, Germany]–
associated) disease tested both displayed immunodetectable
14–3–3 proteins in their CSF, but this was seen in only five
of six patients tested with a PRNP mutation: 3/3 E200K; 1/1
T188A30; 1/1 V210I; and 0/1 P105T.23
Of the eight patients dying from iatrogenic CJD, four
were exposed through human pituitary gonadotrophin (hGn)
therapy, and four had received Lyodura implants. Incubation
periods for the patients receiving hGn therapy varied from 12
to 15 years (calculated from midpoint of individual treatment
courses) and from 5.5 to 17 years for the dura mater recipi-
ents (figure 2). The most recent recognized iatrogenic expo-
sure was 1986 in relation to a dura mater implant, and the
most recent death occurred in 1999.
There were 14 kindreds in which neuropathologic exam-
Figure 1. Age- and sex-adjusted an-
nual incidence rates for sporadic
Creutzfeldt-Jakob disease over three
different time periods constituting the
duration of the study. 1970 to 1989:
men   , women  Œ ; 1990 to 1994:
men  }, women  E; and 1995 to
1999: men  □ , women  ‚.
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ination (performed in 19 patients) and prion protein geno-
typing have been sufficient to confirm a genetic form of
TSE in a total of 25 patients. The PRNP codon mutations
included six families with E200K; two with P102L; two
with D178N; and one each with V210I, T188A, and P105T.
There was a single pedigree with a seven octapeptide repeat
insert. A further three cases of CJD have been tentatively
classified as familial awaiting genotypic confirmation in fur-
ther symptomatic relatives. PRNP analysis was performed in
30 persons dying from sporadic CJD, confirming 24 (80%) to
be homozygous at codon 129: 20 methionine/methionine, four
valine/valine.
The total annual incidence of TSE within Australia has
shown a steady increase over the observation period. Of
the 30 cases with their onset in 1999, 27 were sporadic,
two familial, and one iatrogenic, reinforcing that the in-
crease in numbers generally conforms to the overall classi-
fication proportions for the study period. For sporadic CJD,
the annual incidence peaked in 1999 at 1.4 per million
(figure 3), with the provisional incidence of 0.67 per million
for the year 2000, suggesting a possible plateauing of case
rates. The national average annual sporadic CJD incidence
rate per million for the decade 1970 to 1979 was 0.31,
whereas for 1980 to 1989 the rate was 0.77 and for 1990 to
1999 it was 1.03. A single spatiotemporal cluster of six
cases in a large rural city was recognized during the course
of the study and is the subject of a separate report.31 The
age-adjusted incidence rate was uniform across all the
states and territories of Australia (ranging from 0.92 to
1.19 cases per million per year for the period 1990 to 1999),
with the exception of Tasmania, where for uncertain rea-
sons the rate over the 30-year period (based on four cases)
has been noticeably lower (0.42 cases per million per year
for the period 1990 to 1999). Time trend analysis was
possible for all states except Tasmania and was found to be
present in all (p  0.001 for Victoria, Queensland, New
South Wales, and Australia as a whole; p  0.004 for
South Australia; p  0.002 for Western Australia).
Country of birth was recorded for all 351 sporadic cases
(table 2). The proportion of patients born in Australia was
65.8%, compared with 68.3% expected after age adjust-
ment. No country of birth was associated with a significant
excess incidence of CJD. All but one of the patients re-
corded as born in the United Kingdom, and none of those
born in continental Europe, had immigrated after 1985.
Limited travel data (principally aimed at country of desti-
nation and not duration of stay) were also available on 246
of the 309 persons dying of sporadic CJD during the period
1980 to 1999. Of the 198 Australian-born patients, 64 had
never left Australia whereas 22 had spent time in the United
Kingdom during the 1980s and 1990s, with a further four
traveling to continental Europe only. There were 46 persons
born in the United Kingdom, of whom 11 returned to their
country of birth for some time during this period. Another
four non–Australian-born patients also traveled to the
United Kingdom over the two decades specified.
Discussion. Arguably the most important finding
of our study was the geographically uniform, steadily
progressive increase in the recorded incidence of spo-
radic CJD over the three decades of ascertainment.
An analogous observation has been reported from
many other countries that have undertaken surveil-
lance over extended periods, and similar to the
present study these other groups have attributed the
increase to enhanced case detection and report-
ing,9,12,15,18 which for the ANCJDR may have become
optimal in the late 1990s, with relative plateauing of
Figure 2. Australian iatrogenic
Creutzfeldt–Jakob disease cases from
1970 to 1999. LD  patients who re-
ceived a dura mater (Lyodura, B.
Braun, Melsunger, Germany) implant.
hGn  patients who were treated with
human cadaveric pituitary gonadotro-
phins. Open boxes represent treatment
and maximal possible exposure peri-
ods to contaminated batches of
human cadaveric pituitary gonado-
trophins. Incubation periods are
calculated from the midpoint of
treatment for patients treated with
hGn and from day of dura mater
implant for patients receiving LD. Straight lines represent incubation periods. Filled boxes represent the period of
symptomatic illness.
Figure 3. Annual deaths for all definite and probable spo-
radic Creutzfeldt–Jakob disease patients for the period 1970
to 1999 and the corresponding national annual incidence
rate per million population. Open part of bar represents defi-
nite cases; filled part of bar represents probable cases.
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incidence rates from about 1996. An increase in case
rates unrelated to enhanced detection only cannot be
completely excluded but is thought less likely given
that our findings closely conform to what is expected
when a comprehensive surveillance system is intro-
duced for a rare disease during the latter part of an
ascertainment period. Consistent with ascertain-
ment bias in our study is the progressive lessening of
retrospective incidence rates as detection becomes
more temporally remote and the relative stabilizing
of incidence rates within a few years of the establish-
ment of the surveillance system. Earlier studies have
reported rates as low as 0.09/million/year,5,13 but gener-
ally the reported overall annual incidence rates have
been about 0.3 to 0.7/million.2,9,11,12,15,19 Some of these
surveys noted increased rates of 0.73 to 1.2/million/
year in their higher-density population centers,2,9,12
consistent with the likelihood of better urban case de-
tection and confirmation compared with rural areas.
The strikingly higher rates seen in certain ethnic
groups such Libyan Jews in Israel4 (31.3/million) have
been found to have a genetic basis.32
The decline in case rate we observed among very
elderly persons (especially those 75 years of age)
has been frequently described2,10,11,13,18,19 and stands
in clear contrast to other neurodegenerative diseases
such as AD, but it raises concerns regarding subopti-
mal surveillance in this age group, as suggested by
previous findings.18 Increased efforts at case ascer-
tainment in the very elderly, including the use of
surveillance targeted at groups such as residents of
nursing homes, would help resolve this issue. Never-
theless, although unexplained at present, the consis-
tency of the observed decline in sporadic CJD rates
in the very elderly (regardless of sex) suggests a
likely further important insight into the cause and
neurobiology of this disease in contrast to other neu-
rodegenerative disorders.
The salient demographic findings of the current
study are in general agreement with prior reports.
Given our findings and those reported previously in
relation to familial cases,12 the aggregation of all (in-
cluding familial) cases for analysis in some reports
may have contributed to their overall slightly
younger mean age at death2,3,9 and longer duration of
illness2,3 in comparison with the current results
when restricted to sporadic CJD. However, even for
the latter group alone other authors have reported
younger mean ages at death of 55.710 and 62.113
years, in contrast to the 65.3 years observed in our
study. With respect to the mean duration of illness of
6.6 months observed in the present study, both longer
(16.6 months10) and shorter (5.3 months,13 5.9
months14) have been described. Importantly, age-
adjusted rates for sporadic CJD were not different for
men and women over the observation period, with the
slight overall excess of women (ratio 1:1.13) accounted
for in our study by their longer lifespan compared with
men, who on average die slightly younger from other
causes. These findings are very similar to those of a
previous UK study,11 in which the excess of women was
essentially restricted to those aged 60 years, with
age-standardized death rates for men and women not
different over the study period.
vCJD was not identified in Australia during the
study period, including in persons potentially at
higher risk because of travel to the United Kingdom
and Europe during the 1980s and 1990s, although
the travel data relating to this are limited. Our ex-
clusion of vCJD cases relied on careful scrutiny of
available clinical and neuropathologic data. It is con-
ceded that use of auxiliary diagnostic techniques
such as examination of brain prion protein glyco-
forms may have been of additional merit, but given
the validated distinctive clinicopathologic phenotype
of vCJD, we are confident that variant cases were
not overlooked. Further, excluding risks from travel,
only one person born in the United Kingdom dying
from CJD emigrated to Australia after 1985 (and
none from continental European countries with bo-
vine spongiform encephalopathy), making it less
likely that we would have seen “imported” cases of
vCJD among these non–Australian born residents.
The proportion of heredofamilial cases observed in
the present study (7.2%) is comparable to other large
surveillance studies, which did not employ PRNP geno-
Table 2 Comparison of country of birth for ANCJDR sporadic
CJD cases and the expected percentage occurrence after age
adjustment for Australian-born and immigrant subgroups based








United Kingdom 11.59 14.53
New Zealand 1.00 0.28
Poland 1.01 0.57
Yugoslav Republics 1.49 2.56
Greece 1.61 2.28





Oceania and Antarctica 0.23 0.00
Lebanon 0.36 0.00
South Africa 0.26 0.28
Malta 0.51 0.57
United States and Canada 0.22 0.57
Former USSR and Baltic States 0.87 0.57
Egypt 0.40 0.85
Other countries combined 5.02 8
* Countries for which age breakdown of immigrant population is
not known.
ANCJDR  Australian National Creutzfeldt–Jakob Disease Reg-
istry; CJD  Creutzfeldt–Jakob disease; USSR  Union of Soviet
Socialist Republics.
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typing.2,10,11 Much higher proportions (26%,9 44.8%,4
and 80%19) have been reported from countries with rec-
ognized heightened occurrences of genetic forms of
CJD,32 but for unclear reasons some countries have
reported no familial CJD.13-15 The Australian propor-
tion is also lower than the 13 to 14% seen in a more
recent series employing systematic PRNP analysis of
all patients in whom CJD was suspected.33 The lower
proportion of genetic cases in the present study most
likely relates to the smaller overall number of cases
genotyped, with consequent underdetection of PRNP
mutations. It is very likely that with increased use of
genetic screening, more PRNP mutations would have
been detected by the ANCJDR, giving an improved
understanding of the frequency of unrecognized genetic
cases, including in people without a recognized family
history of prion disease.30
In Australia, human cadaver pituitary hormone-
related CJD has been uniquely associated with hGn
treatment in contrast with growth hormone, which
has been the source of contamination in all other
countries.34 The four patients with hGn-associated
disease died over a 2-year period, with 10 years
now elapsed since the most recent. Based on this
observation, it would be reasonable to conclude that
a limited number of treatment batches were contam-
inated over a short period. Other countries such as
France continue to report a steady number of new
growth hormone–associated cases, consistent with
more sustained therapy-related contamination. The
four cases associated with Lyodura dura mater im-
plants had comparable incubation periods to the pi-
tuitary hormone–related cases, including one of the
longest recorded anywhere in the world (17 years).
Personal communications and death certificates
were the most important mechanisms of case ascer-
tainment. Not unexpectedly, the single largest refer-
ral group was neurologists (37.6%). Despite a
generally favorable ratio of this specialist physician
group to the adult Australian population (1:62,000
persons aged 14 years),35 wide differences in this
ratio among European countries (varying from
1:177,000 for the United Kingdom to 1:8,117 for It-
aly) has not translated into noticeable differences in
sporadic CJD detection rates, and of further interest
the proportion of neurologist-referred suspect CJD
cases in the United Kingdom is about 65% (R. Will,
personal communication). Death certificates were
shown to be a useful surveillance method for spo-
radic CJD, with a sensitivity of 83.0% and false-
positive rate of 11.5%. These findings are similar to
those observed previously when undertaking system-
atic surveillance for CJD using a combination of as-
certainment methods including death certificates.16
However, inherent slowness always caused a mini-
mum 18- to 24-month delay before such data were
available. Given the false-positive (11.5%) and false-
negative (17.0%) rates we observed in relation to
death certificates and sporadic CJD, additional
mechanisms of surveillance and thorough review of
all available patient medicodemographic information
is still warranted if optimal sensitivity and specific-
ity of case classification are to be achieved.
Note added in proof: The Swiss National Refer-
ence Centre for Prion Diseases has just reported an
unexplained doubling of sporadic CJD incidence for
2001 to 2.7 deaths per million, and a rate of 3.9 for
the first quarter of 2002. Such observations pose a
number of questions and concerns for all national
CJD surveillance programs, and further investiga-
tion and monitoring will be required to clarify the
true significance of this change.36
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CME Sleep deprivation does not affect
seizure frequency during inpatient
video-EEG monitoring
B.A. Malow, MD, MS; E. Passaro, MD; C. Milling, MD; D.N. Minecan, MD; and K. Levy, MD
Abstract—Objective: To determine whether acute sleep deprivation facilitates seizures during inpatient monitoring in a
controlled protocol. Methods: Eighty-four patients with medically refractory partial epilepsy undergoing inpatient moni-
toring were assigned in consecutive blocks to either sleep deprivation every other night or to normal sleep. In both groups,
subjects were requested to stay awake during the day, from 6 AM to 10 PM. In the sleep deprivation group, patients also
stayed awake between 10 PM and 6 AM every other night beginning with Day 2. Patients were removed from sleep
deprivation if they had two or more secondarily generalized seizures within 24 hours. Patients were removed from the
normal sleep group and were sleep deprived if they did not have a complex partial or secondarily generalized seizure by
Day 6 of monitoring. In these patients removed from sleep deprivation or from normal sleep, data were analyzed up to and
including the day of removal from the protocol. Results: The sleep deprivation and normal sleep subjects did not differ in
age, sex, seizure localization, or percent dosage reduction in antiepileptic drugs from baseline at days 1 to 3 of monitoring.
Protocol duration was 6.5  2.4 days (mean  SD) for the sleep deprivation group and 5.8  2.0 days for the normal sleep
group. Seizures per day for complex partial, secondarily generalized, and combined complex partial and secondarily
generalized, calculated from admission until end of protocol, did not differ significantly between the two groups. Conclu-
sion: Acute sleep deprivation did not affect seizure frequency during inpatient monitoring in our patients with intractable
complex partial seizures with secondary generalization.
NEUROLOGY 2002;59:1371–1374
For at least 40 years, sleep deprivation has been
regarded as a precipitant of epileptic seizures.1,2
Data from both case series3-6 and patient surveys7-9
have suggested that sleep deprivation has seizure-
provoking effects. Acute sleep deprivation is used in
some epilepsy monitoring units to facilitate seizure
recordings as part of the diagnostic or presurgical
evaluation for epilepsy.10 The efficacy of acute sleep
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Search strategy: Material used in this article was selected from Medline searches, 
references from reviews and original articles. Search items included the following 
words: vCJD, tissue, distribution and variant Creutzfeldt_Jakob disease. English 




In this article an overview of the Transmissible Spongiform Encephalopathies (TSEs) 
is given, with emphasis on the evidence for the distribution of abnormal prions in 
tissues. The normal prion protein is ubiquitously distributed throughout human body 
tissues. Endogenous expression of the normal prion protein, as well as auxiliary 
proteins play a role in accumulation of the abnormal prion protein. There is growing 
evidence that the host lymphoid system, in particular the follicular dendritic cells are 
involved in prion replication. The route for the disease related prion neuroinvasion is 
likely to involve the peripheral nervous system. An alternative route may involve 
blood constituents. A combination of animal studies and studies on variant 
Creutzfeldt_Jakob disease (vCJD) patients suggest a potential for abnormal prion 
distribution in several peripheral tissues other than the lymphoreticular system. In 
humans the abnormal prion has been reported in the brain, tonsils, spleen, lymphnode, 
retina and proximal optic nerve. Infectivity though present, is at lower levels than that 
of the central nervous system. Animal models suggest that the growth of infectivity is 
likely to be gradual with maximum values during the clinical phase of the disease. 
That tissues may harbour the abnormal prion, at different levels of infectivity, during 
the incubation period of the disease raises concerns of iatrogenic transmission of the 
disease either following surgery, blood transfusion or accidental organ transplantation 








Prion diseases also known as transmissible spongiform encephalopathies (TSE) are 
fatal neurodegenerative disorders of humans and other animals. Variant 
Creutzfeldt_Jakob disease is a transmissible form of spongiform encephalopathy, 
believed to have been contracted from consumption of bovine spongiform 
encephalopathy infected beef products. Of interest is the tissue distribution of prion 
protein which may lead to iatrogenic transmission of prions. The mechanism of prion 
invasion may indicate reservoirs where prions can multiply during the pre-clinical 




Prion diseases: an overview.  
 
The human prion diseases are unique in that they can have a sporadic, inherited or 
transmissible origin (Table 1). 
 
Since the BSE epidemic in the UK, the unique biology of these previously obscure 
brain diseases has been the subject of intense research and controversy. The idea that 
a protein can act as an infectious pathogen and cause degeneration of the central 
nervous system was accepted only after a long and difficult battle.1 Prion diseases 
involve the modification of the prion protein, a constituent of normal mammalian 
cells. The function of the normal cellular prion protein (PrPC) is unknown. The disease 
 6 
related isoform PrPSc is derived from the normal cellular precursor PrPC, by a post-
translational process that involves a conformational change. PrPC is rich in α-helical 
structure, whereas PrPSc seems to be composed mainly of a β-pleated sheet structure. 
According to the protein only hypothesis, PrPSc is postulated to act as a 
conformational template that promotes conversion of PrPC to PrPSc. PrPC exists 
between the two different folding states, and the α (helical structure) and β (sheeted 
structure) forms of PrPC have been shown to interconvert in suitable conditions.2 A 
possible molecular mechanism for prion propagation can be that recruitment of PrPC 
to PrPSc may be initiated by a pathogenetic mutation (resulting in PrPC predisposed to 
form the β sheeted structure) in inherited prion diseases; by exposure to a ‘seed’ of 
PrPSc in acquired disease; or as a result of the spontaneous conversion of PrPC to the β 
sheeted structure in sporadic prion disease.  
 
This structural transition is accompanied by changes in the physicochemical 
properties. Soluble β-sheeted prion protein aggregates in physiological salt 
concentrations to form fibrils with morphological and biochemical characteristics 
similar to PrPSc. 2, 3, 4 Prion diseases of human beings and animals are associated with 
the accumulation in the brain of the partially protease-resistant isoform PrPSc. It now 
seems clear that the pathogenesis of TSE, like other neurodegenerative diseases (eg 
Alzheimer’s disease), is a result of defective processing and accumulation of specific 
proteins in the central nervous system. 5 
 
About 10% of CJD cases have a predisposing mutation (and are considered familial). 
More than 20 mutations of the PrP gene are known to cause inherited human prion 
diseases and genetic linkage has been established for five of these mutations. 6. 
 7 
Sporadic forms of prion disease constitute most cases of CJD and possibly a few cases 
of Gerstmann-Straussler-Scheinker Disease. In these patients mutations of the PrP 
gene are not found. How prions cause disease in patients with sporadic forms is 
unknown. Hypotheses suggest horizontal transmission of prions from humans or 
animals, spontaneous conversion of the normal cellular prion protein into PrPSc or 
somatic mutation of the PrP gene. As attempts to link sporadic CJD to previous 
existing disease in animals and humans have been not been successful, the chances 
that sporadic CJD occurs by transmission is small (Prusiner 1998). Prion strains can 
be distinguished by Western blot analysis with distinct cleavage sites to proteinase K 
and differences in glycoform ratios of the protease-digested PrPSc. Biochemical 
characterisation identified four main types of CJD-the sporadic and iatrogenic forms 
were of types 1-3, and the variant CJD was type 4. 7 
 
Properties of the cellular PrP.  
 
Structure: The normal and cellular form of the prion protein is expressed in many 
tissues, although highest levels are found in the central nervous system in particular in 
association with synaptic membranes. The PrPC is also found in lymphoreticular 
tissues. It is a glycosylated cell-surface protein held in situ by a glycolipid anchor. 8 
The mature PrPC species consists of an N-terminal region of about 100 amino acids, 
which is unstructured in the isolated molecule, and a C-terminal segment also around 
100 amino acids in length which is folded into a largely α-helical conformation and 
stabilised by a single disulfide bond .9  
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Function: Mice lacking prion protein showed no gross phenotypic alterations, 
although they were completely resistant to prion disease following inoculation. 
Amongst the minor abnormalities observed were abnormalities in synaptic physiology 
and altered circadian rhythms. These phenomena are suggestive of certain features of 
TSE and suggest that loss of normal function may cause the disease. 10,11 While none 
of these observations define a molecular role for PrPC, it has been argued that PrPC 
may act as a receptor for as yet unidentified extracellular ligand. Newly synthesised 
PrPC is transported to the cell surface and then cycles via a clathrin mediated 
mechanism, with a transit time of around an hour. This type of behaviour is associated 
with other cell-surface receptors, though a potential protein partner for PrPC has not 
been identified.12, 13 Using transfected cell lines it has been shown that PrPC 
undergoes cleavage at the glycophospholipid anchor, which releases PrPC into 
extracellular space.12a Clues to the function of PrPC can also be given by the cell 
specific distribution of the prion protein. 
 
Evidence for infectivity 
 
Historically, the similarity between scrapie, kuru and CJD was identified because 
spongiform degeneration and astrocytic gliosis was found during histological 
examination of the CNS in all three diseases. The transmissibility of kuru and CJD 
was established by passaging the disease to chimpanzees by intracerebral 
innoculation.14,15 The human to human transmission of prion diseases was 
demonstrated in the Fore people in New Guinea where Kuru was transmitted by 
ritualistic cannibalism.  
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Transgenetic mouse studies also suggest that PrPSc cause TSEs. Introduction of a 
mutation that causes GSS into the mouse PrP transgene, caused spontaneous CNS 
degeneration with vacuolation and amyloid plaques.16 Further evidence that the prion 
protein plays a role in the pathogenesis of prion disease was shown when prion 
protein deficient mice were found to be resistant to prion infection.17 
 
The passage of prions between species is almost always characterised by prolonged 
incubation times during first passage in the new host. Transgenetic mouse studies 
identified factors that contribute to the ‘species barrier’ as the difference in prion 
amino acid sequences between the prion donor and recipient and the strain of the 
prion. On subsequent passage in the same species the incubation time shortens. Mice 
constructed with Syrian hamster PrP transgene, when inoculated with Syrian hamster 
prions, showed abbreviated incubation times, unlike their non-transgene controls. 
Transgenic studies with mice expressing the Syrian hamster transgene also argue that 
the PrPSc acts as a template upon which PrPC is refolded to form the protease resistant 
form. 18, 19 Thus homotypic interactions between identical PrP sequences in the PrPC 
and PrPSc isoforms seem more favourable than the heterotypic alternatives. Further 
studies with transgenic mice suggest that a species specific macromolecule-protein X-
participates in prion formation, and may contribute to the observed species barrier. 20  
 
Link between vCJD and BSE  
 
A novel form of TSE, vCJD, was recognised in the UK in 1995. Differences were 
observed in the clinical presentation of the disease and classical CJD. The median age 
of death in these patients was generally ≈ 28 years, compared to the sporadic forms of 
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the disease ≈ 65 years.21 Psychiatric and behavioural changes, involuntary movements 
and sensory symptoms are observed. During electroencephalography the classic 
periodic wave complexes of classical CJD were not observed in vCJD and MRI brain 
signal hyperintensities differed in frequency and distribution.22, 23, 24 
. 
Laboratory studies provide confirmatory evidence that vCJD and BSE have a 
common origin. Glycosylation patterns of the resistant form of the PrP from the brain 
tissue of patients with vCJD and animals with BSE are similar but are distinct from 
the sporadic and iatrogenic forms of the disease.25 In inbred mouse strains, different 
strains of scrapie have distinct incubation periods and different topographic 
distribution of lesions. Studies show that the prions from BSE and vCJD show 
similarities in the incubation periods and distribution of lesions which are distinct 




Codon 129 of the prion protein gene is the site of a common methionine (ATG)/valine 
(GTG) polymorphism. The polymorphism has also been shown to affect the clinical 
and pathological features of familial and sporadic CJD. In a study of the codon 
polymorphisms in the UK, there were differences in the frequency of the Met/Met 
homozygote (39% vs 69%) as well as in that of Val/Met heterozygote (50% vs 14%) 
in the general population and in people with sporadic CJD.21, 27 All vCJD cases for 
which data were available were Met/Met homozygotes at codon 129 (UK CJD 
surveillance unit). DNA extracted from Kuru patients showed that the first population 
to develop the prion disease shared the common Met/Met genotype. The study also 
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showed that the Met/Val and Val/Val genotypes also developed the disease though 
with longer incubation times. 28 Recent evidence also suggests that DQ7, a gene 
involved in the immune response, is found in 36% of the normal population compared 
to 12% of the vCJD population indicating a protective effect of the gene. 29 
 
Other data suggest that Val/Val homozygosity increases susceptibility to iatrogenic 
CJD transmitted through peripheral (pituitary hormone therapy) exposure. The study 
also reports that Met/Met homozygosity is more frequent in centrally (dura mater) 
infected iatrogenic patients. A putative reason for the increased susceptibility can be 
that homozygous Val/Val individuals were donors of the contaminated growth 
hormone extracts. This conjecture is consistent with the experimental observation that 
amino acid sequence homology facilitates the conversion of PrPC to PrPSc.30, 31 The 
data suggest that depending on the prion strain given genotypes show increased 
susceptibility and/or reduced incubation times for developing clinical symptoms of 
TSE.  
 
Developments in methodology for prion detection 
 
Early studies used bioassays. However the cattle to mouse species barrier limited the 
sensitivity of the assay. Some of the published assays have been reviewed by 
MacGregor .32 (Table II). 
 
 
At the present time, standardisation and validation of assays are at early stages of 
development. A working group has recently been formed under the auspices of the 
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WHO for the development of reference materials. The success of the Delfia, Prionics, 
Enfer and CEA methodology in discriminating between BSE-infected and normal 
bovine tissue was evaluated in a European Commission sponsored study 33. Both the 
Enfer and CEA assays and the Prionics Western blotting procedure showed 100% 
sensitivity and specificity suggesting that the tests had potential for the detection of 
BSE.  
 
Tissue distribution:  
 
Normal prion protein 
 
At first the prion protein was considered to be a protein essentially found in the 
neuron. Subsequent observations have shown that the PrPC can be expressed in 
relative abundance in extraneuronal tissues, some of which are given in Table III 
 
A review of the literature suggests that a large number of cells and tissues express 
PrPC. Endogenous expression of the prion protein is necessary for the replication of 
the abnormal PrPSc protein. PrPC in nonneuronal cells may have important 
consequence for the pathogenesis of prion disease. Tissues that express PrPC are most 
likely to support prion replication. It is also likely that the tissues which express the 
highest level of PrPC are those most likely to accumulate abnormal prion, PrPSc, and 
are the most infective. Thus, the levels of normal PrPC expression can be one of 
several factors that influence the development of prion diseases. 51, 52. PrP was 
expressed under the control of various cell or tissue specific regulatory elements in 
PrP knockout mice. Transgenic mice expressed the PrP in high levels on B and T 
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lymphocytes and in low levels in the brain. Following intraperitoneal inoculation with 
mouse scrapie, these mice propagated prions in the spleen and thymus but infectivity 
was below detectability in the brain at six months post inoculation .53  
 
The expression of PrPC is necessary for replication of the infectious agent but may not 
be sufficient as only a few tissues appear to replicate the agent, namely neurons, and 
follicular dendritic cells. Factors other than the amount PrPC expression (eg the 
presence of auxiliary proteins such as protein X to allow accumulation of prions) can 
determine the tropism of prions to certain tissues. One study showed that during 
human leukocyte differentiation, prion protein was expressed very early in 
hematopoiesis, indicated by its presence on CD34+ stem cells. Differentiation along 
the lymphocyte or monocyte lineages supports the expression of surface PrPC, while 
differentiation along the granulocyte lineage results in a decrease of PrPC surface 
protein. 54 Other studies confirm that PrPC expression on human haematopoietic cells 
correlates with the activation of these cells. 35, 36 Thus, expression of the prion protein 
may also be affected by the developmental stage and physiological status (activation) 
and function of cells.  
 
Abnormal prion protein:  
 
Animal studies: The pathogenesis of natural scrapie was followed in susceptible 
sheep, (bred in an environment with a high incidence of scrapie), using 
immunohistochemistry to monitor the deposition of PrPSc in various tissues. PrPSc was 
present in all lymphoid tissues (spleen, tonsil and lymph node as well as Peyer’s 
patches) at the age of 5 months and older. The authors report the appearance of the 
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scrapie agent at multiple sites within the enteric nervous system before appearance in 
the thoracic spinal cord (at the age of 10 months), and subsequently the brain, 
suggesting a neural spread of the agent. In this study the authors also report the 
presence of PrPSc in the endothelial cells of the capillaries within the thalamus, and 
suggest the possibility of a haematogenous spread of the prion protein as well. 55 The 
spread of PrPSc may depend on a chain of cells which express PrPC. Since prion 
diseases primarily manifest as a disease of the CNS, the mechanism of prion 
spread/invasion from the periphery to the CNS, is of importance (i) in the 
understanding of peripheral pathogenesis and in (ii) assessing risks of iatrogenic 
transmission of vCJD from blood or tissues of preclinical cases. Prions may multiply 
in silent reservoirs (lymphoid tissue, peripheral nervous tissue) during the incubation 
period of the disease.  
 
There is growing evidence that the host lymphoid system is involved in prion 
replication leading to the development of clinical symptoms.51 Studies have reported 
that mice lacking B cells are resistant to PrPSc infection by the peripheral route, 
though later studies reported that the B cells were not the direct targets of infectious 
prions. However, B cells are required for the differentiation of other cell types that 
may be required for the propagation of PrPSc.56, 57 Using irradiated SCID mice Brown 
et al (58) tested the potential of PrPSc replication in mice bearing PrP+/+ or PrP-/- 
follicular dendritic cells derived from the host, along with PrP+/+ or PrP-/- lymphocytes 
derived from bone marrow grafts. When the follicular dendritic cells from the host 
mice did not express PrPC but the bone marrow grafted cells did, PrPSc replication did 
not occur in the spleen and the mice remained healthy. Thus follicular dendritic cells, 
that reside in the spleen and depend on B-cell signals for maturation, are required for 
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the replication of a mouse scrapie strain. Other studies also indicate that other 
dendritic cells (CD11c+ dendritic cells) are also candidate cells in prion 
pathogenesis.59, 60 Dendritic cells capture foreign antigens and may serve to store the 
infectious agent and allow it to replicate. 
 
What then is the mechanism for transporting abnormal prions from the periphery to 
the CNS? Experimental evidence suggests that the transfer of infectivity from the 
spleen to the CNS cannot simply occur by bone marrow transfer and reconstitution of 
the haematopoietic system. Indirect evidence suggests that this compartment may be 
part of the peripheral nervous system.61, 62 
 
The role of B cells in delivering prions to the spleen and follicular dendritic cells is 
speculative. It is possible that additional factors are involved. The finding that PrPSc 
binds to plasminogen may suggest a different route of prion infectivity.63, 64 Radebold 
et al. 65 report the spread, in mice, of the FU prion strain of CJD from the brain to the 
gut by the vascular route, confirming the possibility of the spread of prions by blood. 
Other studies suggest that activation of specific complement components is involved 
in the initial trapping of prions in lymphoreticular organs early after infection. 66 
 
Western blot analysis confirmed PrPC expression in both mice and cattle skeletal 
muscle at a level of about 5-10% of that in brain. The same study reported the 
presence of infectious mouse prions in the hindlimb muscle of mice following intra 
cerebral inoculation with mouse prions. Particular muscles eg hindlimb accumulated 
high levels of the prion. Infectious prion protein level in muscle was about 500 fold 
lower than in the brain.49 In contrast, infectivities in heart and skeletal muscle have 
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been reported to be undetectable in scrapie affected sheep. 67, 68 Thus, this work may 
not be directly relevant to vCJD in humans. 
 
Subclinical infection: Immunodeficient mice harboring brain (prion) infectivity titers 
equalling terminally sick wild-type controls can be healthy on clinical grounds.69 
Hamster prions can persist and perhaps even replicate in a clinically silent fashion 
when transmitted to mice. 70, 70a Similarly, there is a possibility that many humans 
may have developed subclinical infection rather than overt vCJD. 
 
A summary of relevant issues: 
 
• Animal and human studies show that PrPC is ubiquitously distributed throughout 
several tissues, as well as in neuronal tissues; 
• The levels of normal PrPC expression can be one of several factors that influence 
the development of prion diseases; 
• Other factors that influence infectious prion protein accumulation in tissues may 
be the presence of auxiliary proteins that participate in prion replication 
• The distribution of PrPSc in non-neuronal tissues may depend on the prion strain 
as well as the host species; 
• There is growing evidence that the initial phase of infection following peripheral 
transmission involves cells of the immune system in particular B-lymphocytes and 
follicular dendritic cells; 
• The route of prion infection may indicate reservoirs of prion replication; 
• Infection is characterised in its early stages by widespread colonisation of 
lymphoreticular organs , by a mechanism that is dependent on B lymphocytes, 
 17 
follicular dendritic cells and soluble factors. The second phase requires PrPC 
expression in the peripheral nervous system and results in prion dissemination in 
the CNS; 
• A route for prion neuroinvasion, adapted from Nicotera et al. is given in Fig 1. 71 
• Thus the most likely organs for prion replication are Peyers patches, spleen and 
lymphoid organs. Neurons of the sympathetic nervous system and blood may be 
required for prion spreading; 




Extensive studies on prion distribution in the peripheral tissues of vCJD patients have 
not been reported. Bruce et al 72 using a mouse bioassay, calculated the infectivity in 
the brain of a patient with vCJD as approximately 105.1intracerebral mouse ID50 U/g 
of brain. The infectivity was lower in spleen and tonsils. For spleen the estimated titre 
was 102.7 intracerebral mouse ID50 U/g. Because mouse bioassays cross species 
barriers, the assays will be relatively inefficient. Across the same species transmission 
may be 1000 times more efficient .73 Table IV summarises the results from several 
studies. 
 
Wadsworth et al 74 also report that prion concentrations in peripheral nerve, sciatic 
nerve, lymphocytes and monocytes, appendix, heart, lung, pancreas, kidney and skin 
were below the detection limit of the assay (approximately <103 ID50/g tissue), in a 
total of 4 patients with neuropathologically confirmed vCJD. Other studies report the 
presence of prions in the appendix of a single patient, approximately 8 months prior to 
 18 
the onset of clinical disease.75 In a further study, all lymphoreticular tissues (tonsils 
spleen and lymph node) from patients (up to 10 patients), with confirmed vCJD, were 
positive for PrPSc by Western blotting.76  
 
The following point is of relevance: 
 
• There is evidence of extensive lymphoreticular involvement, suggesting a similar 




Brown et al. 77, reviewed the published literature on attempts to detect infectivity in 
the blood of animals with transmissible spongiform encephalopathy. The review 
shows that blood from rodents experimentally infected with the agents that cause 
TSE, (cCJD, BSE and scrapie) show infectivity, in contrast, infectivity has never been 
detected in blood from animals with naturally occurring scrapie or BSE. 
The review also summarises few reports of infectivity in the blood of humans with 
cCJD, in contrast to several reports that failed to find infectivity in human blood.  
In a further article, Brown 78 challenges studies demonstrating infectivity in the blood 
of humans on technical grounds and the absence of reproducible results. Further, these 
studies were conducted on patients with cCJD and may not be applicable to vCJD.  
 
A few studies on blood transmission are discussed in more detail below: 
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(i) Blood components and plasma fractions were prepared from the pooled blood 
of mice that had been infected with the mouse adapted strain of human GSS 
disease. Infectivity bioassays were conducted in healthy Swiss Webster mice. 
The authors report that during the preclinical phase of the disease the 
infectivity was present in the buffy coat at levels of 6-12 Infectious Units/mL 
and was either absent or present in plasma in only trace amounts. Infectivity 
rose following the onset of clinical signs to 100 Infectious units/mL of buffy 
coat and 20 Infectious units/mL of plasma. The authors also observe that 5-7 
times more plasma was needed to transmit disease by the IV (intravenous) 
route than by the IC (intracerebral) route. 79  
(ii) The disease was produced in RIII/Fa/Dk mice by IC injection of a mouse 
adapted strain of vCJD. Preliminary data show that infectivity was detected in 
the buffy coat of mice euthanised during the incubation period. The levels of 
infectivity in blood components were reported as not greater than identified in 
(i). 80 
(iii) Diringer 81 using a hamster scrapie model and IC route of inoculation, reported 
that the blood infectivity during the incubation period was 5-50 infectious 
units/mL. 
(iv) Houston et al.82demonstrated that it was possible to transmit BSE to a sheep 
by transfusion with whole blood taken from another sheep during the 
symptom free phase of an experimental BSE infection. 
(v) Drohan et al 83 describe experiments by Rohwer et al.in which blood from 
hamsters experimentally infected with hamster scrapie contained infectivity 
during the pre-clinical and clinical stages of the disease, though with reduced 
efficiency of transmission by the IV route compared to the IC route.  
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Epidemiological data have not revealed cases of cCJD that could be attributed to 
administration of blood. 78 Explanations for this observation can be the low level of 
infectivity in blood and the need for 5-7 times more prion for transmission by the IV 
other than IC route. Tests with detection limits that are capable of detecting the low 
levels of prion present in blood are yet to be developed and the estimated 
concentration of prions in human vCJD blood have been based on animal models84. 
Comparable information on human vCJD is not available and the relevance of the 
animal models to vCJD infectivity in human blood is not known. Holada et al.85 
report on species differences (between humans, hamsters, and mice ) of PrPC in 
peripheral blood distribution. These differences need to be considered before 
extrapolating rodent TSE transmission studies with blood and blood components to 
humans. 
 
Some assumptions can be made about blood infectivity: 
 
• In the absence of tests with detection limits to be able to detect PrPSc  in blood the 
level of infectivity in human vCJD blood is speculative;  
• Based on animal models the infectivity is likely to be low and approximates to 
≤200 ID50/mL during the clinical phase. 
 
Infectivity of eye tissue.  
 
Much remains to be discovered about the relative infectivity of eye tissue in relation to 
CNS tissue. More is known about prion tissue distribution and infectivity in animals. 
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As a result, animal models are used to demonstrate whether transmission of TSE is 
possible through ocular pathways.  
 
(i) Manuelidis et al. 86)demonstrated the infectivity of corneal tissue using a 
guinea pig model. Cornea from infected guinea pig was placed in the eye of 6 
normal guinea pigs. Four developed clinical signs of CJD and histological 
examination of all six animals revealed spongiform encephalopathy. 
(ii) In 1974, Marsh et al. 87 demonstrated the infectivity of the corneal epithelium 
from hamsters dying of transmissible mink encephalopathy. Infectivity was 
demonstrated by intracerebral innoculation of weanling hamsters. Brains of the 
infected animal contained the highest amount of infectivity, when compared to 
corneal epithelium. 
(iii) In a scrapie infected hamster model, the infectivity in the optic nerve and retina 
were comparable to that in the brain (≈ 108-9 ID50 U/mL by intracerebral 
injection, using a hamster bioassay). Prion titers in the cornea and lens were 
lower (≈ 104-7 ID50 U/mL) than levels in the brain. In this model, infectivity 
was demonstrated in the brain and eye tissue before observation of 
neurological signs. 88 
(iv) Brown et al. 89 demonstrated infectivity in the eye (specimen of retina, 
vitreous, lens and cornea) of patients with spongiform encephalopathy. In most 
cases the inoculated animals were squirrel monkeys.  
(v) Mice inoculated with brain and cornea samples from a patient with cCJD 
showed spongiform changes, glial proliferation and moderate loss of nerve 
cells. The authors  observe that the brain samples transmitted disease more 
frequently with shorter incubation periods.90  
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(vi) In a single experiment, Herzberg et al. 91 failed to transmit CJD to two healthy 
capuchin monkeys, following transplantation of cornea taken from a moribund 
CJD infected capuchin monkey. 
 
A further study compared the prion protein levels in single patients with 
neuropathologically confirmed cases of vCJD and sporadic CJD (Table V).  
 
The authors used a sensitive Western blot method for comparative quantitation. The 
limitation of the method was such that PrPSc could only be detected at a sensitivity 
limit of 1/400 of that present in a brain homogenate. 74 The study did not discuss how 
levels relate to tissue infectivity. 
 
Prion replication and disease progression:  
 
The progression of the TSEs has been investigated in animal models.  
 
(i) In the mouse scrapie model infectivity is observed in the spleen and lymph-
nodes before the brain tissue is infected and long before the clinical stage of 
the disease. Infectivity was detected in the lymph-nodes at 4-8 weeks and 
clinical symptoms at 23 weeks after subcutaneous inoculation with the scrapie 
virus.92 
(ii) Following intragastric infection in mice, scrapie was detected in Peyers 
patches, lymph nodes and spleen prior to replication in the spinal cord and 
brain.93 
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(iii) Using mouse bioassays, infectivity was demonstrated in lymphoid tissue of 
naturally infected scrapie sheep at 10-14 months of age (94), before it occurred 
in the CNS. Schreuder et al 95 conclude that PrPSc could be detected in the 
tonsils of genotype-susceptible sheep at between 1/3rd and half the incubation 
period, about 18 months before clinical signs normally appear. 
(iv) Injection of CJD strain into mice by the intraperitoneal route resulted in the 
detection of the prion protein in the lymphoreticular tissues of the GIT (28-32 
days post inoculation) before the brain and spinal cord (>80 days).65. 
 
Some conclusions can be reached from the literature review:  
 
• Animal and human studies suggest an approximate level of infectivity of 108 
ID50/g could be encountered in the brain. The infectivity level depends on the site 
at which prions are deposited, and the levels refer to material injected directly into 
the brain, hence they are given as intracerebral ID50/g; 
• Posterior eye tissue has a similar potential infectivity as CNS, though the anterior 
part of the eye could be considered to have a potential infectivity which is 1-2 logs 
less; 
• Infectivity is present during the incubation period, the exact time at which 
infectivity becomes relevant is speculative-it is possible infectivity may be present 
during the last half of the incubation period. There have been few studies on eye 
infectivity in the pre-clinical stage of the disease. It is likely that for a peripheral 
route of infection, infectivity in the eye may be encountered in the latter part of the 
incubation period; 
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• It is likely that the growth of infectivity is gradual, to reach maximum values 




This review summarises the current understanding of the biochemistry of the prion 
protein as it relates to the tissue distribution of abnormal prions. The variation in 
distribution of the abnormal prion protein in tissues may have implications for 
iatrogenic transmission of vCJD following surgery, blood transfusion or organ 
transplantation. The potential for infection arises from BSE-exposed individuals who, 
though asymptomatic, may be incubating the disease. It is the potential for 
transmission of the disease, and the appropriate implementation of procedures to 
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Table 1. Prion diseases 
Disease Host Mechanism of pathogenesis 
Kuru Humans  Infection through ritualistic cannibalism 
Iatrogenic CJD (iCJD) Humans Infection from prion-contaminated hGH, 
dura mater grafts etc 
Variant CJD (vCJD) Humans Infection from bovine prions 
Familial CJD (fCJD) Humans Germ Line Mutations in PrP gene 
Gerstmann-Straussler-
Scheinker Disease (GSS) 
Humans Germ Line Mutations in the PrP gene 
Familial Fatal Insomnia 
(FFI) 
Humans Germ Line mutations in PrP gene 
Sporadic CJD (sCJD) Humans ?subclinical case-to-case transmission, 
?somatic mutations or spontaneous 
conversion of PrPC to PrPSc  
Scrapie Sheep Infection in genetically susceptible sheep 
Bovine Spongiform 
Encephalopathy (BSE) 
Cattle Infection with prions from sheep or cattle 
Transmissible Mink 
encephalopathy 
Mink Infections with prions from sheep or cattle 
Chronic wasting disease Mule deer, elk Unknown 
Feline Spongiform 
Encephalopathy 
Cats Infection with prion contaminated bovine 





Infection with prion contaminated meat and 
bone meal 
iCJD, fCJD, sCJD are the classical forms of the disease 
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Table II: Tests for PrPSc detection 
Assay Test sample 
Delfia BSE brain homogenate 
Prionics Western blotting BSE brain homogenate 
Enfer ECL ELISA BSE brain homogenate 
CEA ELISA BSE brain homogenate 
Capillary electrophoresis Brain and blood from scrapie sheep and 
CWD elk. 
BioRad Platelia BSE Bovine Brain sample 
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Tissue Species Prion 
Strain 
Detection method 
Cerebral tissues    
Glial cells eg Astrocytes  Hamsters 
and rats 
PrPC In situ hybridisation 34 
Circulating blood    
B and T Lymphocytes 
and monocytes 
Human PrPC Immunoblot and 
cytofluorometry 35,36 
Platelets Human PrPC Immunoblot, time resolved 
dissociation-enhanced 
immunoassay 37, 38, 39 
Lymphoreticular 
system 
   
Follicular dendritic cell Mouse PrPC Immunocytochemistry 40,41,42 
Gastrointestinal tract    
Parietal cells Hamster PrPC Immunofluorescence 43 
Mucous epithelial cells Human PrPC Anti-PrP antibodies 44 
Epithelial cells of the 
GIT 
Human PrPC Not stated 45 
Skin    
Keratinocytes in basal 
layer (cell culture) 
Human PrPC Western blot 46 
Muscle    
Neuromuscular junction Human PrPC Immunohistofluorescence 47 
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 Western blot 43, 48, 49 
Testes    
Sperm cells Human PrPC Immunoblot detected a 
truncated prion protein. 50 
 
Table III: PrPC distribution in tissues 
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Table IV: Tissue distribution PrPSc in humans 
 









Tonsil 5-15% 107 Technique 
used:Western blotting 
74 
Spinal cord 30% 107 Technique 
used:Western blotting 
“ 






1/50,000 103 Found in a single 
patient with high 








Based on prion concentrations in the brain of 108 ID50/g tissue,. 
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                                       Blood stream? Bound to blood proteins? 
 
 
                                                         









Dendritic cells in 
spleen and other 
lymphoid organs 
Follicular dendritic cells 
in Peyers patches 
Central nervous system 
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Table V: PrPSc distribution in eye tissues. 
 
Eye Component PrPSc concentration 





Cornea ND ND 
Iris ND ND 
Aqueous Humour ND ND 
Lens ND ND 
Vitreous humour ND ND 
Sclera ND ND 
Retina ND 2.5% 
Optic Nerve ND 25% 
ND=not detected 
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Novel prion protein insert mutation
associated with prolonged
neurodegenerative illness
V. Lewis, BSc(Hons); S. Collins, MD; A.F. Hill, PhD; A. Boyd, Grad Dip Gen Coun; C.A. McLean, MD;
M. Smith, PhD; and C.L. Masters, MD
Abstract—Background: Mutations in the prion protein gene (PRNP) are found in approximately 13 to 15% of persons
classified as dying from a transmissible spongiform encephalopathy. Point and octapeptide repeat insert and deletion
mutations are described in the open reading frame (ORF) of PRNP. The authors present a clinicopathologic study of a
patient with a family history of a lengthy and progressive neurodegenerative disorder associated with a novel large
octapeptide repeat insert mutation. Methods: Neuropathologic examination, including immunohistochemistry for the prion
protein, was undertaken. The ORF of PRNP was amplified by PCR, cloned, and sequenced. Homogenate of cerebral tissue
underwent Western blot analysis for the prion protein before and after proteinase K treatment. Results: The proband died
after a 16-year illness commencing at age 29 years. Confident premortem clinical diagnosis was not achieved despite a
brain biopsy. Autopsy examination of the brain confirmed a spongiform encephalopathy. Prion protein immunohistochem-
istry revealed occasional granular deposits in the cerebellar granular layer. The proband was found to harbor a novel
PRNP 168 base pair (bp) insert mutation. Conclusion: The authors have identified a novel 168 bp octapeptide repeat insert
mutation. Prion protein immunohistochemistry differs from previous cases harboring seven octapeptide repeat and other
long insert mutations. Optimization of PRNP analysis, especially PCR conditions, is essential to avoid overlooking this
type of mutation and delay the correct molecular genetic diagnosis.
NEUROLOGY 2003;60:1620–1624
Within the phenotypic spectrum of human transmis-
sible spongiform encephalopathies (TSE), systematic
molecular genetic analyses have confirmed various
anomalies in the prion protein gene (PRNP) on chro-
mosome 20 to be causally associated with 13 to 15%
of cases.1,2 Most commonly, point mutations are
found in the coding region of PRNP, although poly-
morphic deletions of single repeats,3 a pathogenic
two repeat unit deletion,4 and insertions are also
recognized, with insertions the first to be described.5
The N-terminal region from codon 51 to 91 normally
codes for a nonapeptide (R1), followed by four identi-
cal octapeptide repeats (R2, R2, R3, and R4) with
only minor variations at the nucleotide level (table
1). Insert mutations are postulated to arise from un-
equal crossover events,6 and consequently demon-
strate striking sequence similarity to the wild-type
allele. With the exception of a three octapeptide re-
peat insert, interpolations consisting of discrete 24-
base pair (bp) multiples varying in length from one
(24-bp) to nine (216-bp) octapeptides have been
described.6-9,13
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Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the May 27 issue to find the title link for this article.
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A detailed clinicopathologic study of a proband
harboring a novel 168-bp, representing seven repeat
units, PRNP insert mutation is presented. This rep-
resents only the fourth family with this length oc-
tapeptide repeat insert to be reported.6,9-13 Although
the phenotype shows general conformity to previous
descriptions, some deviations in the pathologic find-
ings and the technical difficulties encountered in se-
curing a molecular genetic diagnosis add further
interest and importance to the report.
Methods. Neuropathologic examination. The brain was he-
misectioned longitudinally with the right half frozen at 70 °C
and the left half fixed in 20% formalin. Postfixation sections were
taken from the frontal, parietal, temporal, and occipital cortex,
basal ganglia, diencephalon, thalamus, brainstem, and cerebel-
lum. Sections were treated with formic acid for 1 hour before
normal processing. Sections were stained routinely and immuno-
reacted for the prion protein (PrP), using 3F4 (Signet Pathology
Systems, Dedham, MA) at a concentration of 1/1,000 following the
hydrated autoclaving protocol to enhance antigenicity.14 Immuno-
labeling was visualized using horseradish peroxidase and diami-
nobenzidine (DAB Dako, Carpenteria, CA).
DNA analysis. PRNP analysis was undertaken posthumously
on two separate occasions, with the first showing no apparent
mutations. Comprehensive review of the proband’s clinical details
(for classification purposes) prompted repeat PRNP analysis.
PRNP analyses utilized the same DNA extracted from frozen
brain samples, with the initial analysis using methods described
previously.15 In the second analysis, amplification of the entire
PRNP open reading frame (ORF) was first performed using the
primer pair forward-PrP 106, reverse-PrP 46 (please see table e1
at www.neurology.org for all primer sequence details). PCR reac-
tion conditions were optimized using FailSafe PCR 2X PreMixes
(Epicentre, Madison, WI). Thereafter, PCR mixes were made ac-
cording to manufacturer’s instructions, using 25 
L Mix D with 1

L DNA and 20 pM of each primer and 1 
L Taq Polymerase
(Gibco, Carlsbad, CA) to a final volume of 50 
L using sterile
deionized water. Cycling conditions were 94 °C for 5 minutes,
followed by 35 cycles of 94 °C for 1 minute, 60 °C for 1 minute, and
72 °C for 1 minute. The final extension was at 72 °C for 10
minutes. PCR products were visualized on 1.5% agarose gels con-
taining ethidium bromide. The insertion was confirmed again us-
ing genomic DNA and a second set of primers, which were
internal to the first: forward-PrP 3F, reverse-PrP 2R. Reaction
mixes contained 1 
L DNA, 5 
L 10  dNTP mix, 20 pM of
primers, 5 
L 10  PCR buffer (Gibco), 2.5 
L DMSO, 3 
L 25
mM MgCl2, and 0.5 
L Taq Polymerase (Gibco) to a final volume
of 50 
L using sterile deionized water. PCR cycling conditions
were as above, except during the 35 cycles, denaturation was at 94
°C for 30 seconds, while reannealing was at 60 °C for 45 seconds.
Products were again visualized on 1.5% agarose gels.
Cloning. A TOPO TA Cloning kit (Invitrogen, Carlsbad, CA)
was used to produce transformants from purified PCR product
(Roche Diagnostics High Pure PCR Product Purification Kit;
Roche, Mannheim, Germany), which were plated on LB plates
containing 50 
g/mL ampicillin and Xgal/ITPG. Plates were incu-
bated overnight at 37 °C. White colonies were picked and cultured
overnight in LB containing 50 
g/mL ampicillin. Minipreps follow-
ing the manufacturer’s protocol (Eppendorf Perfectprep Plasmid
Mini; Eppendorf, Hamburg, Germany) were performed to retrieve
the plasmid, and an EcoRI digest was performed to confirm the
presence of the inserted gene in the clone.
Sequencing. Clones were sequenced in the forward and re-
verse directions. Gene sequencing utilized the BigDye Terminator
Cycle Sequencing Ready Reaction, DNA Sequencing Kit (Applied
Biosystems, Foster City, CA), with the following modifications: 20

L reactions were used containing 4 
L BigDye buffer, 10 pM of
primer, 8 
L DNA, 2 
L dilution buffer (250 mM Tris, 10 mM
MgCl2), made up to 20 
L with sterile deionized water. The se-
quencing primers are summarized in table e1 (available at www-
.neurology.org): forward-M13F, PrP 5 and PrP F3, reverse-M13R,
and PrP 6. Sequencing conditions were 25 cycles of 96 °C for 10
seconds, 50 °C for 5 seconds, and 60 °C for 4 minutes. DNA was
further prepared using the DyeEx Spin Kit protocol for Dye-
Terminator removal (Qiagen, Hilden, Germany) with automated
sequencing performed on an Applied Biosystems (ABI) Prism
373XL sequencer.
Western immunoblots. Brain homogenates (10% w/v in
phosphate-buffered saline) were prepared from sporadic
Creutzfeldt-Jakob disease (proven not to have a PRNP mutation),
a normal control, and the proband. Proteinase K (PK) was added
to 20 
L of homogenate (final concentration 100 
g/mL) and incu-
bated at 37 °C for 1 hour. Digestion was stopped with a final
concentration of 5 mM Pefabloc (Roche) in an equal volume of
sodium dodecyl sulfate sample buffer containing 6% beta-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO). Samples were
boiled for 10 minutes before loading 5 
L of PK untreated samples
and 10 
L of PK digested samples on to 12% Tris-Glycine precast
gels (Novex, San Diego, CA). Samples were then transferred to
nitrocellulose membrane and blocked for 45 minutes at room tem-
perature in 5% skim milk powder/PBST. After overnight incuba-
tion at 4 °C in 3F4 (1:5,000 in phosphate buffered saline [PBS]
with 0.05% (v/v) Tween 20 (Sigma-Aldrich)), the filter was incu-
bated at room temperature in anti-mouse-horseradish peroxidase
(1:10,000 in PBST). The membrane was visualized using en-
hanced chemiluminescence (ECL, Amersham, Buckinghamshire,
UK) as per manufacturer’s instructions.
Results. Case report. The proband’s illness commenced at age
29 years, with inappropriate behavior, undue clumsiness, abnor-
mal limb movements, and forgetfulness noted. Gradual physical
and intellectual deterioration prompted hospital evaluation 6
years after symptom onset. Generalized tonic-clonic seizures had
necessitated anticonvulsant therapy with phenytoin 200 mg twice
daily, which was the only prescribed medication. Routine biochem-
ical and hematologic parameters were unremarkable, including
serum copper levels and Venereal Disease Research Laboratory
serology. Muscle biopsy was uninformative. EEG showed a non-
specific excess of slower frequencies, whereas CT scans of the
brain revealed generalized atrophy. Brain biopsy from the right
frontal region was nondiagnostic. The patient was discharged with
a diagnosis of degenerative brain disease.
At 10 years into the proband’s illness, the combination of invol-
untary limb movements and cognitive decline led to diagnostic
speculation of Huntington disease. Examination revealed the pa-
tient to be unable to walk or sit without assistance, with athetoid
movements affecting the proximal limbs and choreiform move-
Table 1 Comparison of the proband with the normal and published codon 51–91 region of PRNP encompassing seven octapeptide
repeat inserts
Repeat unit sequence Reference
R1 R2 R2 .. .. .. .. .. .. .. R3 R4 9
R1 R2 R2c R3 R2 R3 R2 R3 R2 R3g R3 R4 6
R1 R2 R2 R3 R2 R2 R2 R3g R2 R2 R3 R4 9, 13
R1 R2 R2 R3 R2 R3 R2 R2 R2 R2 R3 R4 Proband; current report
Details of the octapeptide repeat insert sequence for the family reported by Dermaut et al.12 were not cited. R1 denotes the nonapeptide
PHGGGGWGQ; R2, R3, etcetera denote octapeptide repeat motifs essentially homologous to R1 but varying slightly at the nucleotide
level.
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ments distally. Mild tetraparesis with generalized hypertonia and
hyperreflexia were present but with flexor plantar responses.
Limb cerebellar-type ataxia was not a feature. Frontal release
signs were elicitable and there was evidence of moderately severe
global cognitive impairment. Repeat EEG and CT head scan
showed results similar to those previously. An MRI scan of the
brain 11 years after symptom onset confirmed generalized,
marked cerebral and cerebellar atrophy, with normal-appearing
caudate nuclear heads. Progressive decline necessitated admission
to long-term institutional care and culminated in the patient’s
death after an illness spanning 16 years.
A family history of similar neurodegenerative disorder was
present. Clinical and investigational details were incomplete but
one parent developed dementia at 32 years and died at age 39,
whereas a full sibling manifested a similar illness from age 24
years and died at age 31. Both underwent postmortem neuro-
pathologic examination in another country without a conclusive
diagnosis, although frontal atrophy and gliosis with no evidence of
plaques or inclusions were reported. Some sections of the lower
brainstem from the propositus’ sibling were obtained for review; a
specific diagnosis remained unachievable. A half-sibling sharing
the affected parent was reported to be alive and well 10 years ago,
with further follow-up not possible since.
Neuropathologic examination. The brain (weight 990 g)
showed generalized atrophy more marked in the frontal lobes with
dilation of the lateral ventricles anteriorly. The caudate nuclei,
basal ganglia, and cerebellar folia appeared atrophic. The cerebel-
lum showed diffuse folial atrophy. The brainstem appeared
normal.
Microscopic examination revealed prominent diffuse spongi-
form changes, neuronal loss, and gliosis in the cerebral cortex
(most marked in the frontal [figure 1A] and temporal cortex), with
similarly severe changes in the basal ganglia and diencephalon.
Atrophy of the molecular and granular layers and patchy Purkinje
cell loss was seen in the cerebellum. Patchy, synaptic-type PrP
immunoreactivity was seen in the inferior aspects of the cerebellar
folia, with occasional granular deposits (see figure 1B), and no
immunostaining in the cerebral cortex and basal ganglia.
Molecular genetic studies. During the optimizing of PCR con-
ditions, the second PRNP amplifications revealed an additional
slower band consistent with a DNA insert of approximately 150 bp
(figure 2, lanes 5, 9, and 10; figure 3, lane 4). However, absence or
a very weak slower band signal in the majority of lanes is evident
(see figure 2, lanes 2 through 4, 7, 8, 12, and 14). A band consis-
tent with the wild type allele at the predicted mobility of ~1000 bp
was also present. The presence of the larger DNA fragment was
confirmed by a second PCR amplification using primers internal
to the first (see figure 3, lane 7). Each allele was cloned and
sequenced. A 168 bp insert in the 51–91 coding region of the ORF
was determined in the expanded allele, equivalent to a seven
octapeptide repeat. The wild type octapeptide repeat region was
confirmed as R1, R2, R2, R3, R4 in cis with valine at codon 129,
whereas the 168 bp insertion constituted a novel seven octapep-
tide repeat with methionine at codon 129 (see table 1).
Western blotting. Figure 4 shows Western blot analysis of
brain tissue from a normal control, sporadic CJD, and the pro-
Figure 1. Photomicrographs of representative brain sec-
tions. Magnification 400. (A) Hematoxylin and eosin–
stained frontal cortex displays diffuse spongiform changes,
neuronal loss, and gliosis. (B) Prion protein immunostain-
ing of the molecular layer of the cerebellum shows occa-
sional nonlinear granular deposits.
Figure 2. Optimization of PCR conditions using proband
DNA with primers PrP 106 and PrP 46 and the Failsafe
PCR PreMixes (Epicentre). Lanes 1, 6, and 11 are a 100
base pair DNA ladder. Lanes 2 through 5 are mixes A
through D, lanes 7 through 10 are mixes E through H,
and lanes 12 through 15 are mixes I through L.
Figure 3. Ethidium bromide–stained 1.5% agarose gel
shows the different-sized PCR products obtained with dif-
ferent primer pairs: lanes 2 through 4, PrP 106 and PrP
46; lanes 5 through 7, PrP 3F and PrP 2R. Lane 1, 100 bp
molecular weight ladder; lanes 2 and 5, sterile deionized
water; lanes 3 and 6, control DNA without PRNP insert
mutation; and lanes 4 and 7, our proband’s DNA. Both
primer pairs clearly show a second slower band consistent
with an allele containing an insert mutation of approxi-
mately 150 bp.
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band, demonstrating the presence of PK resistant PrPSc in the
sporadic CJD and proband samples. The PrPSc type in the pro-
band tissue was determined as type 2 (using the classification in
reference 16), displaying a glycoform ratio similar to that observed
in sporadic CJD, with an abundance of the mono-glycosylated
band.16 In the absence of PK treatment, several bands are ob-
served in the proband sample. Higher molecular weight fragments
are a direct result of the insert, and many lower molecular mass
fragments result from nonspecific cleavage of the mutant allele, as
these are not observed in the normal control or sporadic CJD
samples.
Discussion. This family represents the fourth re-
ported pedigree to harbor a seven octapeptide repeat
insert in PRNP as the explanation for their spongi-
form encephalopathy, with the 168 bp nucleotide se-
quence and arrangement different from those
previously described.6,10-12 Remarkable congruity in
relation to age at onset and duration of illness is
apparent in comparison to previously reported fami-
lies, with general similarity of other clinical features
(table 2). Symptoms commenced in the current fam-
ily at 24 to 32 years of age, with illness duration
Figure 4. Western immunoblot of 10% brain homogenates
before (lanes 1, 3, 5) and after (lanes 2, 4, 6) proteinase K
digestion. The filter was probed with the anti-PrP mono-
clonal antibody 3F4. Lanes 1 and 2, non–Creutzfeldt-
Jakob (CJD) disease control; lanes 3 and 4, our proband;
and lanes 5 and 6, sporadic CJD. Approximate molecular
weights are shown.
Table 2 Comparison of clinical features of illness and PRNP codon 129 status between the proband and other published seven
octapeptide repeat cases
Features/phenotype Proband
Reference 10 Reference 12
Reference 13II-3* III-9* III-8* I-1* II-2* II-4*
Presenting features
Abnormal behavior Y Y
Clumsiness Y Y Y
Depression/mood change Y Y Y
Forgetful/memory problems Y Y




Cerebellar dysfunction Y Y Y Y
Cognitive decline Y Y Y Y Y Y Y Y
Dysphasia Y Y
Epileptic seizures Y Y
Euphoria Y
Extrapyramidal features Y Y Y Y Y
Myoclonus Y Y Y
Psychosis Y
Pyramidal features ?Y† Y
Duration of illness, y 16 11 10 13 7 11 11 7
Age at onset, y 29 31 23 28 32 24 31
Codon 129 status
Normal allele Val Met
Mutated allele Met Met‡ Met‡ Met‡ Met Met Met
* Individual as stated in appropriate reference.
† Described as motor problems only.
‡ Source is reference 21.
Y  feature present; blank  feature not described; Val  valine; Met  methionine.
May (2 of 2) 2003 NEUROLOGY 60 1623
spanning from 7 to 16 years, which is remarkably
similar to the 23 to 35 years for illness onset and 7 to
13 years duration reported in the other seven oc-
tapeptide repeat cases.6,10-12,17 Progressive cognitive
deterioration was evident in the three members of
the current family, as in all previous cases reported.
Additional clinical features vary, but pyramidal and
cerebellar dysfunction are common, and seizures12
and involuntary movements6,10 have been recognized,
as seen in our proband. Given the long illness dura-
tion and diverse clinical features, difficulty with
achieving a specific, premortem clinical diagnosis
has been reported previously for this type of muta-
tion,12 as has the incorrect speculative diagnosis of
Huntington’s disease in patients with large PRNP
octapeptide repeat insert mutations.8
Noteworthy in the current family was the inability
to secure a correct pathologic diagnosis in the pro-
band with brain biopsy and the two first-degree rela-
tives despite autopsy examination. This is consistent
with the significant intra- and interfamily variation
in the neuropathologic findings described in patients
carrying large octapeptide repeat inserts, including
the 168 bp insert mutations, ranging from minimal
nonspecific changes to typical spongiform enceph-
alopathy.6,7,10-12,17-19 The proband described in this re-
port displayed changes similar to some members of two
previously reported seven octapeptide repeat insert
pedigrees, with widespread cortical atrophy, neuronal
loss, spongiform change, and gliosis.10,12 In contrast to
previous cases, immunohistochemistry for PrP re-
vealed no cerebral cortical plaques or synaptic type
positivity.11,12 The distinctive elongated cerebellar mo-
lecular layer PrP deposits perpendicularly orientated
to the pial surface typically evident in previous 168 bp
insert pedigrees,11,12 and other octapeptide repeat in-
sert families,7,17,18 were not evident in our propositus.
Pathologic phenotypic variability may relate in part to
differences in the ability to clear the abnormal prion
protein, with the long duration of symptoms possibly
relating to neuronal dysfunction rather than morpho-
logic change. Expression of the particular expanded
mutant allele, as shown by the Western immunoblots
in our proband, and the specific PrPSc type and glyco-
form ratio, may be germane to these issues.
Technical difficulties in achieving correct molecu-
lar genetic diagnoses have been reported with PRNP
analysis. Polymorphisms in the intron region proxi-
mate to the 5' end of the ORF can cause problems
with primer annealing,20 and suboptimal PCR ampli-
fication of the mutant allele can occur with large
octapeptide repeat insert mutations.8 We postulate
that selective amplification of the wild type allele
occurred in the original PRNP analysis undertaken,
with absence or a weak signal from the expanded
PRNP locus (as shown in figure 2) militating against
correct interpretation. In contrast to one report, we
did not find that utilizing a larger candidate DNA
template for PCR amplification overcame this diffi-
culty.8 Rather, optimizing PCR conditions, especially
in relation to reaction buffers, resolved the problem.
We suspect this experience may be more prevalent
than appreciated, particularly in laboratories less fa-
miliar with this type of mutation analysis, and with-
out appropriate positive controls correct diagnosis
may be overlooked relatively easily. A high level of
suspicion and concerted technical efforts are re-
quired to ensure this type of error is avoided.
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CREUTZFELDT–JAKOB DISEASE (CJD) is a fatal, transmis-
sible, neurodegenerative disorder belonging to the group
known as the transmissible spongiform encephalopathies
(TSEs). CJD can occur without explanation (sporadic),
secondary to mutations in the prion protein gene (PRNP),
or as a complication of medical treatment using contami-
nated therapeutic agents or equipment (iatrogenic).
Although corneal grafts and neurosurgical equipment have
been associated with disease transmission, the most com-
mon causes of iatrogenic CJD have been treatments involv-
ing human-derived cadaveric pituitary hormones or dura
mater.1
Creutzfeldt–Jakob disease and Lyodura
The first identified case of CJD in a dura mater recipient
was reported in the United States in early 1987.2 In
response, the US Food and Drug Authority issued a safety
alert in April 1987, seeking immediate discontinuation of
use of the identified dura mater batch (Lyodura batch
#2105).3 A second patient with CJD linked to Lyodura was
detected in New Zealand in 1988,4 but the specific batch
could not be identified. This has remained a frequent
difficulty when tracing contamination sources.
As of January 2003, over 120 CJD cases related to dura
mater use had been detected globally, with 97 in Japan.5
These cases were predominantly associated with Lyodura, a
commercial product produced since 1969 by B Braun
Melsungen AG (based in Germany). Only a few reports
suggest the possibility of CJD after use of dura mater from
other commercial or non-commercial sources.6-8
Lyodura consists of lyophilised, irradiated human dura
mater sourced post mortem. Additional processing with
immersion in a solution of sodium hydroxide (1 M) was
instituted in 1987, with a noticeable reduction in Lyodura-
related cases thereafter.9 Lyodura has been used in a
number of countries, including Australia, Japan, Canada,
the United States and the United Kingdom, mainly in
neurosurgery, but also in orthopaedic, otological, dental,
urological, gynaecological and cardiac procedures (Box 1)
(Dr L Schonberger, Assistant Director, National Center for
Infectious Diseases, Centers for Disease Control and Pre-
vention, Atlanta, Ga, USA, personal communication).
Most cases of CJD associated with dura mater have
occurred in Japan. In 1996, in response to the growing
incidence, a survey was undertaken of Lyodura use in
almost 3000 Japanese healthcare institutions. This esti-
mated that up to 100 000 people received Lyodura grafts
between 1983 and 1987,9,10 and up to 220 000 between
1979 and 1991 (out of a total of 260 000 who received dura
mater grafts). Use of these grafts greatly declined after 1991
but may have continued until 1997.11,12 Assuming that all
cases of CJD associated with dura mater were a conse-
quence of Lyodura use, the overall risk of Lyodura-associ-
ated CJD in Japan is approximately 0.04%.5
Estimating Lyodura use and risk in Australia
Lyodura was approved by the Australian Therapeutic
Goods Administration for importation and use in Australia
Lyodura use and the risk of iatrogenic Creutzfeldt–Jakob disease 
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in 1972. The product licence was withdrawn in early May
1987, shortly after recognition of the first case of CJD linked
to Lyodura use.
To date, five cases of CJD have been epidemiologically
linked to neurosurgical use of Lyodura in Australia. Their
clinical features have already been described13-15 and are
summarised in Box 2. Patient 1 presented in 1987, about 5
years after implantation of Lyodura. The longest incubation
period was in Patient 4, who presented in 1999 after an
incubation period of almost 17 years.14 The most recent
(fifth) patient died in 2000. Patients 1, 2 and 4 were exposed
in 1982, while Patients 3 and 5 were exposed in 1985 and
1986, respectively.
A number of studies have attempted to determine the
number of people exposed to Lyodura in Australia. We
collated the available information and undertook further
enquiries, as a basis for estimating the risk of Lyodura-
associated CJD in this country (Box 3).
Implications for Australia
Quantifying past use of Lyodura in Australia relies on data
that cannot be fully confirmed. Initial estimates by the
Commonwealth Department of Health and Ageing in dis-
cussion with the Therapeutic Goods Administration placed
an upper limit of between 5000 and 10 000 individuals
potentially exposed to Lyodura. However, from the results
reported here, the true number is likely to be much smaller
— probably fewer than 2500. If so, the risk of Lyodura-
associated CJD is higher in Australia (0.20%–0.23%) than
in other countries that have undertaken similar investiga-
tions, such as Japan.
Although the risk of Lyodura-associated CJD in Japan has
appeared to fluctuate over time, two relatively stable features
are a peak in contaminated grafts between 1983 and 1987,
and the paucity of Lyodura-associated cases after 1987,
when the manufacturer instituted effective decontamination
of the tissue with a 1 M solution of sodium hydroxide.1,5,9
Ninety-seven cases associated with dura mater had been
recognised to 2003,5 with predictions that further cases are
likely until 2020, and that final numbers may reach 160.12
Acknowledging a total of 220 000 people exposed to Lyo-
dura, and assuming all CJD associated with dura mater was
associated with Lyodura (which is reasonable based on
evidence published to date),11 then the cumulative overall
risk of CJD from Lyodura in Japan is currently around
0.04% (95% CI, 0.03%–0.05%) (Box 4). Estimated risk in
Australia is much higher — 0.20% to 0.23% (95% CIs,
0.06%–0.47% and 0.07%–0.53%, respectively). With the
same assumptions, the risk of CJD in the higher-risk period
in Japan (1983–1987) is about 0.08% (95% CI, 0.06%–
0.10%), while that in Australia (1982–1986) is 0.43% (95%
CI, 0.14%–0.99%). Notwithstanding the need for certain
assumptions to facilitate these comparisons, the risk in
Australia appears about five times greater than the analo-
gous point estimates of risk in Japan. The reality of the
differences is further supported by the lack of overlap
between the confidence intervals of the calculated estimates.
Nevertheless, the risk of CJD associated with Lyodura in
Australia is well below the risk associated with exposure to
human-derived pituitary growth hormone (hGH) in France
(Box 4). As of 1999, 55 cases of CJD had been linked to
French-derived hGH, from a cohort of 1361 patients,
representing an attack rate of about 1 in 25 recipients
(4.0%).17 A more recent report suggested the risk could be
much higher, at 81 per 1361 (about 6.0%).18
The reason for the higher estimated risk of Lyodura-
associated CJD in Australia compared with Japan is not
1: Non-neurosurgical uses of Lyodura in the United 
States*
■ Development of ligaments to stabilise shoulder joints
■ Replacement of the tracheal wall
■ Covering pleura defects
■ Securing bronchial stumps
■ Repair of pericardium
■ Repair of diaphragm defects (traumatic or congenital)
■ Arthroplasties of the elbow
■ Reinforcement of fascia in abdominal hernias
■ Reinforcement of tendons or ligaments
■ Plastic enlargement of the urinary bladder
■ Other miscellaneous surgical uses
* Based on information from the US National Center for Infectious Diseases, 
Centers for Disease Control and Prevention, Atlanta, Ga.
2: Features of the five Australian cases of Creutzfeldt–Jakob disease associated with Lyodura
Probable Removal of frontal meningioma Dementia 61
Definite Removal of cerebellar astrocytoma Cerebellar ataxia 32
Probable Craniocervical decompression Cerebellar ataxia 26
Probable Removal of cerebellar astrocytoma Non-specific dizziness, 27
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3: Studies of Lyodura use in Australia
Survey of hospitals in Victoria
In 1987, after notification of the first patient with Lyodura-associated 
Creutzfeldt–Jakob disease (CJD), the Victorian Department of 
Community Services and Health surveyed use of Lyodura in all private 
and public hospitals in Victoria.
Five hospitals responded, out of an uncertain total number. They 
reported use of 40 Lyodura grafts in 1985–1986 and 36 in 1986–1987, 
all in neurosurgical procedures (unpublished data).
Survey of neurosurgeons
In 1995, the Neurosurgical Society of Australasia surveyed 100 
neurosurgeons (comprising all practising neurosurgeons and retired 
surgeons still on their register) about use of Lyodura or other dura 
mater during their practice lifetimes.13 This survey was also used to 
assess the feasibility of tracing recipients.
Sixty-five neurosurgeons responded (response rate, 65%); 35 of these 
(54%) had used dura mater grafts in cranial or spinal procedures at 
some time, with 34 having used Lyodura. Eleven of the 34 (32%) 
believed that they could identify over 90% of recipients from their 
records, nine (27%) that they could identify 50%–90%, and 14 that they 
could identify fewer than 50%. The survey could not determine the 
precise amount of Lyodura or specific batches used, nor the number of 
procedures involving Lyodura. However, all three cases of Lyodura-
related CJD recognised before the survey were in patients of 
respondents who reported using Lyodura. The remaining two 
confirmed cases presented after this survey.
Survey of non-neurosurgical use
In 2001, the Department of Health and Aged Care (DHAC) undertook 
a survey through the Royal Australasian College of Surgeons (RACS) 
to assess non-neurosurgical use of Lyodura. Over 5000 practising and 
retired surgeons across 15 surgical specialties were asked about use of 
dura mater grafts (and specifically Lyodura) over their practice lifetimes.
Responses were received from 172 surgeons (response rate, 3.4%). 
This very poor response rate precluded meaningful analysis. However, 
the survey confirmed that Lyodura had been used in 
otorhinolaryngological procedures, such as tympanoplasty, 
myringoplasty and mastoidectomy, with respondents reporting use of 
about 100 grafts in such applications. Given the poor response rate, 
time elapsed since the product was withdrawn, recall bias and 
retirement of surgeons during this time, this may be a significant 
underestimate of use in non-neurosurgical applications. This possibility 
is supported by the US Centers for Disease Control and Prevention 
report that up to 20% of Lyodura use in the US was in non-
neurosurgical applications (Dr L Schonberger, personal 
communication).
Quantification study
In 2002, the Department of Health and Ageing, in conjunction with the 
Australian National Creutzfeldt–Jakob Disease Registry, undertook a 
study to quantify Lyodura use in Australia and to determine the types 
of procedures in which it was used, as a basis for estimating the risk 
of Lyodura-associated CJD.
Methods: The Registry has ethical approval for its surveillance 
methods and activities from the University of Melbourne Human 
Research Ethics Committee.
As well as collating results of previous surveys, we asked the 
manufacturer of Lyodura, B Braun Melsungen AG, about supplies 
including the Australian Therapeutic Goods Administration and the 
Health Insurance Commission.
Results: Braun Melsungen indicated that:
■ Before 1978, about two to five packs of Lyodura per month were 
distributed nationally.
■ Between 1978 and 1982, 600 packs were distributed in mainland 
Australia.
■ Between 1983 and 1987, 1278 sheets were distributed for use in 
mainland Australia.
According to the 1985 Braun catalogue for Australia, Lyodura was 
available in a range of sizes, with some packs containing up to 6 
pieces. The manufacturer indicated that packs sold in Australia 
contained either one large sheet or two smaller sheets. Its information 
suggests that generally the larger sheets were used for neurosurgery, 
and smaller sheets for other surgical applications. The single-sheet 
packs outsold the double-sheet packs by about three to one. Braun 
did not supply documentary verification of this information.
Neither the Australian Therapeutic Goods Administration nor the 
Health Insurance Commission could furnish further information on 
Lyodura use.
Based on the manufacturer’s information, and assuming that all 
distributed product was used, then a maximum of 750 sheets may 
have been used in Australia between 1978 and 1982. Before 1978, 
assuming the same distribution of pack sizes, then 180–450 sheets 
may have been distributed.
These data suggest a total use in Australia of 2208 to 2478 Lyodura 
grafts. Assuming maximum and equal annual use, then about 1172 
Lyodura grafts were used in the higher-risk period 1982–1986.
Risk estimation: Risk estimates for Lyodura-associated CJD were 
based on data from the manufacturer alone, as survey results were 
very incomplete, and Lyodura use reported in the surveys was likely 
to be encompassed by the manufacturer’s information.
Risk estimates were calculated from the total number of individuals 
exposed and the number of CJD cases detected over defined 
periods, with 95% confidence intervals calculated using the Poisson 
distribution.
Based on the five Lyodura-associated CJD cases detected to 2003, 
the attack rate ranged from 1 in 496 patients who received Lyodura 
(0.20%) to 1 in 442 (0.23%) (Box 4), depending on whether a higher 
or lower estimate of pre-1978 use was used. In the higher-risk period 
(1982–1986), the attack rate may have been as high as 1 in 234 
(0.43%). These calculations were based on exposure through any 
surgical application of Lyodura, assuming that only one sheet was 
used per patient and that all distributed product was used. The latter 
fact cannot be verified, and previous reports suggest that not all 
distributed Lyodura was necessarily used.16 These attack rates are 
therefore likely to be underestimates.
The attack rates after neurosurgery in Australia may be even higher, 
depending on the proportion of Lyodura that was used in this type of 
surgery. Should the proportion be close to 60% of the total product used 
(as suggested by the manufacturer) or 80% (as found in the US), the 
overall neurosurgical attack rate may be as high as 
1 in 397 (ie, 80% of 496) to 1 in 265 (ie, 60% of 442), or 0.25% to 0.38%.
The CJD Registry also recently reviewed all records to determine 
whether any patients on the CJD register might have been exposed 
to Lyodura through non-neurosurgical applications. No potential 
cases were identified.
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program for CJD, with international comparisons of inci-
dence rates for sporadic CJD attesting to the adequacy of
case ascertainment.14
Another potential explanation is genetic difference
between the populations of the two countries. For example,
homozygosity for methionine at codon 129 of the PRNP
gene appears to predispose to iatrogenic CJD.1 However,
contrary to expectations, this homozygosity appears more
common in the Japanese population (about 92%) than in
occidental populations (about 37%).19
Finally, the differences in risk may reflect greater use of
Lyodura in Japanese patients with malignancies, whose
survival was shorter than the lengthy incubation periods
typical of TSEs, or in non-neurosurgical applications, with
attendant lower transmission efficiency. Japanese studies
suggest that Lyodura-related transmissions have been essen-
tially restricted to neurosurgical procedures,10,11and our
comparative risk analysis was predicated on the assumption
that most Lyodura was used in these procedures in both
countries. Although some Lyodura was most likely used in
non-neurological procedures, the proportion is impossible
to quantify in different countries, leaving uncertainty about
our risk comparisons.
In addition to neurosurgery and the non-neurological
applications identified by Australian surveys, additional uses
of Lyodura have been reported in the US (Box 1). Cases of
CJD have been linked epidemiologically to Lyodura used in
the embolisation of the external carotid artery for treating a
nasopharyngeal angiofibroma,20 as well as dura mater used
to embolise intercostal arteries before thoracic surgery.7
This reinforces the likelihood that non-neurosurgical use of
Lyodura can result in transmission.10 Therefore, risk of
Lyodura-associated CJD linked to non-neurosurgical uses
appears a genuine possibility, which may be very difficult to
identify epidemiologically, given the often deficient state of
medical records.
The inability to clearly identify surgical uses of Lyodura,
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Summary
A collaborative study of human transmissible spongiform
encephalopathies has been carried out from 1993 to 2000
and includes data from 10 national registries, the majority
in Western Europe. In this study, we present analyses of
predictors of survival in sporadic (n = 2304), iatrogenic
(n = 106) and variant Creutzfeldt–Jakob disease (n = 86)
and in cases associated with mutations of the prion protein
gene (n=278), includingGerstmann–Sträussler–Scheinker
syndrome (n = 24) and fatal familial insomnia (n = 41).
Overall survival for each disease type was assessed by the
Kaplan–Meier method and the multivariate analyses by
the Cox proportional hazards model. In sporadic disease,
longer survival was correlated with younger age at onset of
illness, female gender, codon 129 heterozygosity, presence
of CSF 14-3-3 protein and type 2a prion protein type. The
ability to predict survival based on patient covariates is
important for diagnosis and counselling, and the charac-
terization of the survival distributions, in the absence of
therapy, will be an important starting point for the assess-
ment of potential therapeutic agents in the future.
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Introduction
Human transmissible spongiform encephalopathies (TSEs)
or prion diseases comprise a number of conditions with vary-
ing aetiology and include sporadic Creutzfeldt–Jakob
disease (sCJD), iatrogenic CJD (iCJD), variant CJD (vCJD)
and cases associated with mutations of the prion protein gene
(PRNP) (gTSE). Within the latter group are genetic forms
of CJD (gCJD), for example cases linked to mutations at
codon 200 and codon 210 of PRNP, Gerstmann–
Sträussler–Scheinker syndrome (GSS) and fatal familial
insomnia (FFI) (Pocchiari, 1994). The clinical phenotypes
of the subtypes of human TSE vary, and this variation is
determined in part by the polymorphism at codon 129 of
PRNP (Collinge et al., 1991; Palmer et al., 1991; Kovacs
et al., 2002) and the type of prion protein deposited in the
brain (Parchi et al., 1996). One important variable is the total
duration of clinical illness, also termed survival, and this
parameter can be useful in clinical diagnosis of the various
forms of human TSE, including sCJD (Brown et al., 1994). In
genetic cases, iCJD cases following human growth hormone
therapy (ihGH) and vCJD, survival is more prolonged than in
sCJD, but considerable variation in survival is seen within all
subtypes of human TSE.
Variables that are thought to influence survival are age
(with a reduction in survival with increasing age in sCJD;
Puopolo et al, 2003), the codon 129 genotype and the type of
prion protein deposited in the brain. There have been sugges-
tions of a gender effect on the incidence of sCJD (Will et al.,
1986; Brown et al., 1987), but this has been inconsistent
between studies (Galvez et al., 1980; Lundberg, 1998). The
identification of significant and consistent predictors/
determinants of survival is a difficult task because of the rarity
of human TSEs, but establishing definitive factors that influ-
ence disease phenotype, including survival, may lead to clues
to the underlying pathogenic mechanisms and to improved
case recognition and clinical discrimination between the var-
ious disease subtypes.
The renewed interest in developing specific therapies for
human TSEs (Brown, 2002; Korth et al., 2002) has high-
lighted the importance of clearly delineating the natural his-
tory of these disorders. Establishing the expected survival and
the variables that influence survival in a cohort of untreated
cases is likely to provide a crucial baseline to assessing the
effectiveness of novel therapies. If, for example, age and gen-
der are important determinants of survival, it may be crucial to
include these variables in the assessment of whether or not an
intervention actually prolongs survival. It is known that sur-
vival is variable in sCJD, with some cases presenting acutely
(McNaughton and Will, 1994) and others surviving for many
years (Brown et al., 1984). The aim of this paper is to define
predictors of survival in all forms of human TSE and to
quantify these effects as accurately as possible.
Patients and methods
Patients with all forms of human TSEs were ascertained by
national surveillance centres as part of a prospective CJD
surveillance programme funded by the European Union.
Those patients fulfilling the validated diagnostic criteria for
definite or probable TSEs were included in a common data-
base. The database contained core medico-demographic
information on all TSE cases who died between 1993 and
2000 for Australia, France, Germany, Italy, The Netherlands,
Slovakia and the UK, and between 1998 and 2000 for Austria,
Spain and Switzerland. Detailed descriptions of the study
methodology have been published (Will et al., 1998a).
TSE patients were classified as sCJD, iCJD, vCJD and gTSE
according to previously published diagnostic criteria. This last
group includes gCJD, GSS, FFI and cases carrying an insert
mutationof thePRNPgene (althoughpatients withgTSEscarry
a mutation of the PRNP gene, it is not yet clear whether the
mutation is the cause of disease or a predisposing factor). Iatro-
genic cases were also divided into two categories according to
whether they developed the disease following therapy with
native human cadaveric growth hormone (ihGH) or after
human dura mater implant (iDM). The protease-resistant
prion protein type (PrPSc) found in the brain was classified
according to the two-type system published by Parchi et al.
(1999). Survival was defined as the interval between disease
onset and death. Dates of death were available from direct
notification by clinicians, from hospital records or from
death certificates. The date of onset of clinical symptoms
was defined in each case after review of hospital records, clin-
ical correspondence and/or interview with the patient’s family.
In the great majority of cases, there was little difficulty in defin-
ing the date of onset, but in some cases a judgement was made
based on information from a range of sources. In Germany,
attribution of the date of onset was dependent solely on infor-
mation from relatives.
Statistical analysis
We investigated the effect on survival of the following demo-
graphic, clinical and laboratory investigation variables: sex,
age at onset, polymorphism at codon 129 of the PRNP gene,
country participating in the study, EEG pattern, presence of
protein 14-3-3 in the CSF and PrPSc type.
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Survival curves were estimated by the Kaplan–Meier
method, both overall and by stratifying for each of the
above variables.
For each form of TSE, we report as descriptive statistics the
median survival times overall and stratified for each variable;
the comparisons of survival curves between groups were car-
ried out by the generalized Wilcoxon test. The Cox propor-
tional hazards model was used to assess the independent
effects of the investigated factors by a multivariate analysis.
Crude relative risk (RR) and adjusted RR with 95% confi-
dence intervals (CIs) were generated. We used the ‘cluster’
function on the STATA program for the categorical variable
‘country’. The ‘cluster’ function is used to specify non-
independent observations, such as all patients observed in
each country, in order to allow robust calculations of stand-
ard errors.
Age (in years) at onset was analysed as a continuous
variable for 10 year increments. The relative risk for codon
129 was estimated by including two dummy variables with
methionine/methionine (MM) as reference.
For sCJD, the multivariate model was used first by includ-
ing only the gender, the age at onset and the codon 129
polymorphism, because this set contained the largest number
of data (n = 1452). The Cox model was then used on smaller
samples with available data for EEG characteristics and pre-
sence of the 14-3-3 protein in the CSF (n = 893) or PrPSc type
(n = 420). The distributions of sex, age at onset and codon 129
status in these different data sets were compared by the x2 test
to confirm that missing values were not selected for any of the
considered variable. The x2 test was also adopted to assess
dependency between categorical variables.
The Bonferroni correction for multiple testing was adopted
within the five subgroups of gTSE (E200K and V210I gCJD,
GSS, FFI and insert mutations) and the two subgroups of iCJD
patients. This correction was not applied for all forms of
human TSEs since sCJD, iCJD, vCJD and gTSEs are distinct
diseases with different aetiology. Thus, the critical level of
significance for gTSE was 0.01 (five subgroups) and for iCJD
0.025 (two subgroups).
Statistical analyses were performed using BMDP and
STATA.
Results
The mean and median survival times for the different forms
of TSEs are summarized in Table 1. SCJD, gCJD and iDM
had the shortest median survival times of <6 months; ihGH,
vCJD, FFI and gTSE with insert mutations had median
clinical durations of 1 year, while that for GSS patients
exceeded 3 years.
Kaplan–Meier survival curves for sCJD, iCJD and vCJD
are shown in Fig. 1A, and for gTSE in Fig. 1B. One year after
clinical onset, only a few patients with sCJD (15%), iDM
(15%) or gCJD (8%) were still alive, while about half the
patients with ihGH (54%), vCJD (55%), FFI (48%) and gTSE
with insert mutations (55%) survived. About 80% of GSS
patients were still alive 1 year after clinical onset.
Sporadic CJD
sCJD patients from Germany had a significantly (P < 0.0001)
longer median duration (6 months, n = 568) of illness than
patients from all the other countries: 5 months for Spain (n =
123), 4.5 months for Switzerland (n = 43), and 4 months for
Australia (n = 149), Austria (n = 29), France (n = 543), Italy
(n = 379), Slovakia (n = 12), The Netherlands (n = 70) and the
UK (n = 388).
Univariate survival analyses of sCJD cases with available data
(see Table 2) showed differences in the duration of illness by
gender (Fig. 2A), age at onset (Fig. 2B) and the polymorphism
at codon 129 of the PRNP gene (Fig. 2C). The multivariate
analysis confirmed that survival is longer in females compared
with males and showed that increments of 10 years in the age at
onset are associated with an 30% increase in risk of death
(Table 3A). Survival was shorter in patients who were MM at
codon 129 of the PRNP gene (Table 3A) compared with that
seen in valine/valine (VV) and methionine/valine (MV) cases.
When we include a dummy variable in the Cox multivariate
model indicating whether patients were from Germany or
other countries, the RR for all the above parameters did
not change, but the clinical duration of German sCJD patients
still remained significantly longer (adjujsted RR = 0.78; CI
0.74–0.83, P < 0.001) than that in other countries.
Two investigational features were considered as possible
predictive markers of survival: periodic sharp wave com-
plexes (PSWC) in the EEG, the ‘typical’ pattern in sCJD,
and the presence of the 14-3-3 protein in the CSF. In the
univariate analysis, survival was significantly shorter in
patients with PSWC than in patients without PSWC and in
patients with a positive versus negative 14-3-3 test (Table 2).
When the EEG pattern and the 14-3-3 test were included in







Sporadic CJD (n = 2304) 7.3 (0.2) 5
Genetic TSE
Genetic CJD (n = 191) 6.3 (0.5) 4
FFI (n = 41) 15.6 (2.2) 12
GSS (n = 24) 42.7 (6.1) 39
Insert (n = 22) 46.9 (12.8) 14
Iatrogenic CJD*
hGH CJD (n = 85) 14.7 (0.9) 13
DM CJD (n = 20) 9.4 (2.4) 5.5
Variant CJD (n = 86) 15.3 (0.8) 13
FFI = fatal familial insomnia; GSS = Gerstmann
Straussler–Scheinker syndrome; hGH = human growth hormone;
DM = dura mater. *A single case of iatrogenic CJD following
corneal transplant had a survival of 11 months.
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the Cox regression model with sex, age at onset and codon 129
polymorphism, the 14-3-3 test, but not the EEG, retained
significance in determining clinical duration of disease
together with the other three parameters (Table 3A and B).
The reason for the lack of significance in the multivariate
analysis for the EEG variable is likely to be because a typical
EEG is more frequently observed in patients with late clinical
onset (78% of patients >80, 73% in age class 71–80, 69% in
61–70, 58% in 51–60 and 47% of patients <50 years, P <
0.0001, x2 test), and in patients homozygous for methionine at
codon 129 (80% of MM, 51% of MV and 31% of VV patients,
P < 0.0001, x2 test), representing groups of patients with the
shortest survival. The missing data for EEG and 14-3-3 were
randomly distributed (x2 tests for the comparison of the dis-
tributions in the two data sets: P = 0.97 for gender,P = 0.54 for
age at onset and P = 0.66 for codon 129).
PrPSc type analysis was available for 450 subjects. Uni-
variate analyses (Fig. 2D) showed that patients with the PrPSc
type 1 had a significantly shorter survival than PrPSc type 2a
(Table 2). When PrPSc type was included with sex, age at
onset and PRNP polymorphism at codon 129 in the Cox
regression model, the genotype lost its effect on survival
(Table 3A and C). This was mostly due to the concomitant
fact that there was an uneven distribution of codon 129 poly-
morphism between PrPSc type 1 (MM = 87.9%, VV = 3.7%,
MV = 8.4%) and type 2a (MM = 21.1%, VV = 47.2%, MV =
31.7%) (P < 0.0001, x2 test), and an increased proportion of
MV and VV patients (with longer clinical duration) in PrPSc
type 2a with respect to type 1. The missing data for PrPSc type
were randomly distributed (x2 tests for the comparison of the
distributions in the two data sets: P = 0.23 for gender, P = 0.80
for age at onset and P = 0.97 for codon 129).
The crude RR for gender, age at onset and codon 129
obtained in the univariate Cox regression models (Table 3)
did not vary when estimated in different subgroups of patients
where data on EEG and 14-3-3 test (n = 893) or on PrPSc type
(n = 420) were available.
Fig. 1 Kaplan–Meier survival curves in (A) sporadic CJD, variant CJD, dura-mater related CJD and human growth hormone-related CJD;
(B) genetic TSEs, including genetic CJD, GSS, FFI and insert mutations.





Overall (n = 2304) 5
Gender
Male (n = 998) 4 <0.0001
Female (n = 1304) 5
Age at onset
11–20 (n = 2) 54, 58* <0.0001
21–30 (n = 6) 21
31–40 (n = 14) 23
41–50 (n = 95) 7
51–60 (n = 425) 6
61–70 (n = 937) 5
71–80 (n = 703) 4
81–90 (n = 120) 3
91–100 (n = 2) 2, 3*
Codon 129
MM (n = 993) 4 <0.0001
MV (n = 227) 9
VV (n = 233) 6
EEG
PSWC (n = 1429) 4 <0.0001
No PSWC (n = 683) 6
14-3-3 in CSF
Positive (n = 1254) 5 <0.0001
Negative (n = 104) 9
PrP type
Type 1 (n = 319) 4 <0.0001
Type 2a (n = 131) 8
*Observed values.
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Genetic TSEs
Survival in gCJD patients differed between the various muta-
tions of the PRNP gene (Table 4). An analysis was only
performed for the two most frequent PRNP mutations (i.e.
E200K and V210I). Median clinical duration (Table 5) for
E200Kand V210I patients was 4 months. In the univariate
Cox analysis, survival of both E200K and V210I patients was
shorter in males than in females. Though both mutations co-
segregate with methionine at codon 129, methionine homo-
zygosity was associated with a shorter survival in E200K
patients, but a long survival in V210I patients (Table 5,
Fig. 3). Survival was significantly shorter in patients with
late age at onset only in V210I patients (Table 5). Multivariate
analyses confirmed the significance of all variables for V210I
patients (Table 5). In E200K patients, the only significant
predictor of survival remained the polymorphism at codon
129. The effect of gender just missed statistical significance
when correcting for multiple testing (Table 5).
In FFI (D178N) patients, only the polymorphism at codon
129 of the PRNP gene significantly affected survival
(Table 6). MV patients showed a longer survival than MM
patients.
In gTSE with insert mutations, survival was influenced by
the age at onset and codon 129 polymorphism (Table 6). The
multivariate analysis with age at onset and codon 129 showed
that only MV patients had a significantly longer survival than
MM patients (adjusted RR for age at onset = 1.88, CI
0.82–4.30, P = 0.133; adjusted RR for MM versus MV,
0.31, CI 0.20–0.48, P < 0.001; adjusted RR for MM versus
VV = 0.81, CI 0.38–1.71, P = 0.583). We did not analyse the
relationship between survival and the size of the insert
because of the small numbers of cases.
3/4
Fig. 2 Kaplan–Meier survival curves in sporadic CJD by (A) gender, (B) age at onset, (C) codon 129 genotype and (D) prion protein
isotype.
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In GSS, methionine homozygous patients at codon 129
showed a median survival time 36 months longer than hetero-
zygous patients. However, due to the small sample size and
to the correction for multiple testing in the gTSE group, the
difference did not reach statistical significance (Table 6).
Iatrogenic CJD
In ihGH CJD cases, a significantly lower risk was found for
females compared with males and a higher risk for patients
with late versus early age at onset. Survival curves were
different in patients carrying distinct polymorphisms at
codon 129 (Table 7, Fig. 3). However, this parameter was
not significant in the univariate Cox analysis when MM
patients were considered as the reference group. The multi-
variate Cox model with gender and age at onset confirmed
these results (adjusted RR for gender = 0.75, CI 0.63–0.89,P =
0.001; adjusted RR for age at onset = 1.56, CI 1.35–1.81, P <
0.001). It is likely that the loss of significance for codon 129
was because the median survival of MM cases was between
those of MV and VV cases. When we used VV cases as the
reference group (those with the shortest median survival), the
MV cases showed a lower risk than VV cases (crude RR =
0.41; 95% CI = 0.26–0.65, P < 0.001).
In iDM CJD cases, no significant effect of gender or age at
onset was found by the Cox univariate model (Table 7). We
did not analyse the effect of the codon 129 polymorphism
because there were only two MV and one VV patients.
Variant CJD
Since all vCJD patients were MM, only the effect of
gender and age at onset as predictors of survival was
analysed. A significantly longer median illness duration
was observed in females compared with males and in patients
with early compared with late age at onset. These findings
were confirmed by the Cox univariate and multivariate
analyses (Table 8).
Table 3 Cox regression model for survival in sporadic CJD patients
Features Crude RR (95% CI) Adjusted RR (95% CI)
for A (n = 1452) for A and B (n = 893) for A and C (n = 420)
A
Gender





































PSWC 1 – 1 –





14-3-3 in the CSF –








Type 1 1 – – 1
Type 2a 0.54 (0.43–0.68)
(P < 0.001)
– – 0.53 (0.43–0.64)
(P < 0.001)
*Crude RR did not change when estimated for A and B and A and C; þcontinuous for increment of 10 years.
Table 4 Clinical duration of disease in genetic CJD patients
carrying different point mutations of the PRNP gene
PRNP mutations Median (months)
D178N-129V (n = 8) 9
T188R (n = 1) 2*
E196K (n = 1) 13*
E200K (n = 123) 4
V203I (n = 2) 2, 4*
R208H (n = 1) 10*
V210I (n = 48) 4
E211Q (n = 5) 4
Observed values.
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Discussion
The findings presented in this paper are generally consistent
with previous studies of survival in sCJD (Wientjens, 1997;
Will et al., 1998a; Parchi et al., 1999; Puopolo et al., 2003),
but the large number of cases included in our analysis allows a
more detailed description of predictors that influence survival
in all forms of human TSE. There are a number of noteworthy
and novel findings, including the influence of gender on sur-
vival in a number of subtypes of human TSE and the effect of
prion protein PrPSc type on survival in sCJD. A reduction in
survival with increasing age has been confirmed in sCJD,
gCJD, cases with insert mutations and vCJD.
In order to allow comparability of data, it is essential to
achieve consistency of data collection between countries.
Details of the methodology of the study have been described
previously (Will et al., 1998a). In this paper, there is a
remarkable consistency in the results from country to coun-
try, for example in the median duration of illness in sCJD.
The exception is a significant increase in the median survi-
val in sCJD in Germany in comparison with the other coun-
tries (4 months in the majority compared with 6 months in
Germany). The reason for this finding may be because of a
systematic difference in classification of the time of disease
onset. However, the analyses are not affected by this anom-
aly. The numbers of cases in this study are larger than any
previous series, allowing firm conclusions on the major
predictors of survival in sCJD. However, the numbers of
cases in the subtype analyses are smaller, and this may
result in insufficient power to assess some parameters
properly.
Assessment of survival by disease type (Fig. 1A and B)
demonstrates differences in illness duration between the var-
ious forms of human TSE. The shortest survival is in sCJD,
iDM and, perhaps surprisingly, in some forms of gCJD. It is
important to stress that the surveillance system depends on
referral of suspect cases from neurologists, and this may result
in a bias in the identification of genetic cases with a phenotype
similar to sporadic cases (Will et al., 1998b). In vCJD, ihGH
and FFI, a small proportion of patients survive to 24 months,
which contrasts with GSS and cases associated with insert
mutations in which a significant proportion survive beyond
24 months. In sCJD, about one in seven cases survives to
1 year and one in 30 to 2 years.
A reduction in survival with increasing age in sCJD is well
known (Wientjens, 1997) but is not well documented. In
this study, survival was found to decrease significantly with
Table 5 Survival times for genetic CJD (E200K and V210I)
Features E200K V210I
Median in months P* Median in months P*
Overall 4 (n = 123) 4 (n = 48)
Gender
Male 3 (n = 48) 0.020 3 (n = 22) 0.060
Female 5 (n = 75) 5 (n = 26)
Age at onset
31–40 14, 20þ (n = 2) 0.067 5þ (n = 1) 0.0047
41–50 6 (n = 20) 4 (n = 10)
51–60 5 (n = 36) 5 (n = 14)
61–70 3 (n = 41) 3 (n = 15)
71–80 3 (n = 20) 2 (n = 7)
81–90 3 (n = 4) 4y (n = 1)
Codon 129
MM 4 (n = 88) 0.002 5 (n = 38) 0.04
MV 8 (n = 23) 3 (n = 9)
VV 4, 7þ (n = 2) – (n = 0)
Cox regression model for survival in genetic E200K and V210I CJD patients
Features E200K (n = 111) V210I (n = 47)
Crude RR (95% CI) Adjusted RR (95% CI) Crude RR (95% CI) Adjusted RR (95% CI)
Gender





























*Generalized Wilcoxon test; þobserved values; ycontinuous for increment of 10 years.
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increasing age in sCJD (Fig. 2B) with, for example, 10% of
cases aged >80 years surviving at 6 months in comparison with
60% of cases aged <50 years. A similar age effect on survival
is seen incasesassociated with mutationsofPRNPat codon 210
and in insert mutations. In ihGH, there is also a borderline
relationship between prolonged survival and younger age,
and there is a trend in a similar direction with vCJD. The
most obvious difference between the ihGH cases and vCJD
in comparison with the other subtypes is the relatively young
age at death (Brown, 1988; Will et al., 2000). It is possible that
shouldcasesof iatrogenicorvCJDoccur in theolderagegroups,
the relationship between survival and age would become more
significant as in the other forms of human TSE. The single case
ofvCJDin theolderagegroupdiedat theageof74yearsandhad
one of the shortest illness durations yet seen of 7 months (Henry
etal.,2002).Thereasonfor the inverserelationshipbetweenage
and survival in the majority of subtypes of human prion disease
is unknown and, although age-related variations in care or
resistance to terminal infection may play a role, there is evi-
dence from laboratory studies of age-related effects on patho-
genesis (Bruce and Fraser, 1982; Manolakou et al., 2001).
The overall female : male ratio in sCJD in this study, based
on sex-specific mortality rates, is 1.24, representing a signific-
ant excess of female cases. A female preponderance in sCJD
has been documented previously, but this finding is not con-
sistent between studies, even in those carried out systematic-
ally (Brown, 1998). Because sCJD is predominantly a disease
in the older age groups (60–79 years) and life expectancy is
longer in females, population demographics may influence the
overall sex distribution. However, this ratio may be affected
by the uneven distribution of cases in different age classes,
and a better estimate is given by the average female to male
Fig. 3 Influence of codon 129 genotype on Kaplan–Meier survival curves in (A) E200K CJD, (B) V210I CJD, (C) FFI, (D) human growth
hormone-related CJD.
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Table 6 Survival times for FFI, GSS and patients with insert mutations













Overall 12.0 (n = 41) 39.0 (n = 24) 14.0 (n = 22)
Gender
Male 12.0 (n = 24) 0.43 1 30.5 (n = 9) 0.59 1 32.5 (n = 11) 0.53 1
Female 12.5 (n = 17) 0.92
(0.69–1.24)
(P = 0.590)
39.5 (n = 15) 0.66
(0.20–2.17)
(P = 0.490)





21–30 – 0.65 0.82
(0.60–1.13)
(P = 0.227)






31–40 11.0 (n = 6) 8, 32y (n = 2) 93.0 (n = 4)
41–50 13.5 (n = 9) 46.0 (n = 9) 86.0 (n = 4)
51–60 12.5 (n = 19) 20.0 (n = 5) 5.0 (n = 4)
61–70 12.0 (n = 6) 29.5 (n = 3) 8.0 (n = 7)
71–80 – 3, 67y (n = 2) 4, 5y (n = 2)
81–90 – – 4y (n = 1)
Codon 129
Met/Met 11.0 (n = 26) 0.0026 1 44.0 (n = 6) 0.19 1 4.0 (n = 7) 0.13 1
Met/Val 20.0 (n = 12) 0.15
(0.06–0.39)
(P < 0.001)
8.0 (n = 6) 2.56
(1.03–6.39)
(P = 0.044)
40.0 (n = 5) 0.28
(0.12–0.66)
(P = 0.003)
Val/Val – – 5.0 (n = 5) 0.52
(0.16–1.71)
(P = 0.280)
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
Table 7 Survival times for iatrogenic-hGH and iatrogenic-DM CJD
Features Iatrogenic-hGH CJD Iatrogenic-DM CJD
Median in months P* Crude RR (95% CI) Median in months P* Crude RR (95% CI)
Overall 13.0 (n = 85) 5.5 (n = 20)
Gender 0.19 0.38
Male 13.0 (n = 62) 1 5.0 (n = 12) 1
Female 14.0 (n = 23) 0.61 (0.60–0.63)
(P < 0.001)
6.0 (n = 8) 0.78 (0.34–1.76)
(P = 0.546)




10 36y (n = 1) –
11–20 25.0 (n = 8) –
21–30 11.5 (n = 59) 7.0 (n = 5)
31–40 12.5 (n = 17) 4.0 (n = 3)
41–50 – 5.0 (n = 4)
51–60 – 4.5 (n = 5)
61–70 – 2y (n = 1)
71–80 – 3, 11y (n = 2)
Codon 129 0.0065 0.70
Met/Met 13.0 (n = 38) 1 6.0 (n = 9) –
Met/Val 17.0 (n = 19) 0.59 (0.30–1.19)
(P = 0.141)
5, 8y (n = 2) –
Val/Val 9.0 (n = 19) 1.46 (0.46–4.63)
(P = 0.522)
5y (n = 1) –
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
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ratios of each 10 year age class interval, weighting for the
number of cases in each age class. The weighted female to
male ratio is 1.08, but this still represents an 8% excess of
female cases. The excess of female cases in sCJD does not
explain the significant difference in survival in sCJD, with
females surviving a median of 1 month longer than males.
Similar gender effects on survival were found in cases asso-
ciated with mutations of PRNP, with the exception of FFI,
and in vCJD.
The effect of gender has been studied in mouse models,
with varying results. One study has shown a major influence
of gender in experimental transmission of bovine spongiform
encephalopathy (BSE), with extended incubation periods in
females (Abiola et al., 2002). In contrast, a recent study of
non-PRNP genetic influences on incubation period showed a
significant reduction in the incubation period in females
(Manolakou et al., 2001), consistent with previous studies
(Bruce and Dickinson, 1985; McLean and Bostock, 2000).
The excess of female cases and the prolonged female survival
in a number of types of human TSE suggest that there are
sex-specific factors that influence the clinical phase of
human disease. Possibilities include genetic determinants
outside the PRNP gene, hormonal effects or neuro-
anatomical factors.
Prolonged survival is one of the variables that distinguish
the subtypes of CJD classified according to the seminal work
by Parchi and colleagues, using PrPSc type and codon 129
genotype (Parchi et al., 1991). The findings in our study
support the hypothesis that the type of protein deposited in
the brain influences the clinical phenotype. There is a clear
and significant effect on survival in sCJD according to PrPSc
type, with more prolonged survival in cases with the type 2a
prion protein. One caveat to this conclusion is that there is
evidence in some cases of sCJD of deposition of more than
one PrPSc type in the brain (Puoti et al., 1999) and in our study
there was no consistency in the brain area from which protein
was extracted. Whether the PrPsc type correlates with different
‘strains’ of infectious agent remains unproven.
There has been a recent resurgence of interest in identifying
potential therapies for human TSEs, including CJD (Brown,
2002; Knight, 2002). Drug trials are likely to pose many
difficulties, not least because of the rarity of CJD, and com-
parison of outcome, including survival, in treated cases in
relation to the natural history may be an important strategy
in assessing the efficacy of potential treatments. The detailed
analyses in this study are likely to constitute important con-
siderations for the assessment of treatment efficacy in human
TSEs because of the identification and quantification of vari-
ables that influence survival in various TSE subtypes. This
study documents the influence of a range of variables on
survival in a population of cases that were not treated with
any therapy known to influence the underlying disease pro-
cess. A number of variables have been identified that have an
influence, and often a major influence, on survival, including
age, gender and codon 129 genotype. Although variables such
as the PrPSc type may be of clinical use in the future by using
nervous tissue taken from the biopsy of the olfactory epithe-
lium (Zanusso et al, 2003), the results of investigations
including the 14-3-3 CSF immunoassay correlate with survi-
val. A ‘typical’ EEG is associated with shortened survival
(Zerr et al., 2000) and a negative 14-3-3 test with relatively
prolonged survival. In this study, the multivariate regression
analysis has shown that only the 14-3-3 result is an independ-
ent predictor of survival, with a positive result probably
reflecting rapid neuronal damage. In the univariate analysis,
patients with a typical EEG had a significantly shorter survival
than patients with non-specific EEG findings. This signific-
ance was lost in the multivariate analysis because the EEG
pattern strongly correlates with the polymorphism at codon
129 of the PRNP gene. A possible explanation is that a typical
EEG is likely to be related to the site of lesions in the brain,
which in turn depends on the polymorphism at codon 129
(Tschampa et al., 2002).
This study underlines the importance of collaborative
research in a rare disease. Some of the findings are novel,
but attaining statistical significance has depended on the pool-
ing of results from 10 countries carrying out national surveil-
lance for human TSEs. The detailed analyses of factors
influencing survival raise a number of scientific questions,
for example the mechanism by which gender influences
Table 8 Survival times for vCJD patients
Features Median in months P* Crude RR (95% CI) Adjusted RR (95% CI)
Overall 13.0 (n = 86)
Gender 0.035
Male 12.0 (n = 45) 1 1
Female 14.0 (n = 41) 0.69 (0.61–0.79) (P < 0.001) 0.76 (0.68–0.85) (P < 0.001)
Age at onsetþ 0.005 1.26 (1.25–1.28) (P < 0.001) 1.22 (1.18–1.26) (P < 0.001)
11–20 14.0 (n = 18)
21–30 13.0 (n = 39)
31–40 12.0 (n = 20)
41–50 7.0 (n = 4)
51–60 11.0 (n = 4)
61–70 –
71–80 7y (n = 1)
*Generalized Wilcoxon test; þcontinuous for increment of 10 years; yobserved values.
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disease expression, and may be critical in assessing the effi-
cacy of novel therapeutic strategies.
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Abstract—Background: An international study of the epidemiologic characteristics of Creutzfeldt–Jakob disease (CJD)
was established in 1993 and included national registries in France, Germany, Italy, the Netherlands, Slovakia, and the
United Kingdom. In 1997, the study was extended to Australia, Austria, Canada, Spain, and Switzerland. Methods: Data
were pooled from all participating countries for the years 1993 to 2002 and included deaths from definite or probable CJD
of all etiologic subtypes. Results: Four thousand four hundred forty-one cases were available for analysis and included
3,720 cases of sporadic CJD, 455 genetic cases, 138 iatrogenic cases, and 128 variant cases. The overall annual mortality
rate between 1999 and 2002 was 1.67 per million for all cases and 1.39 per million for sporadic CJD. Mortality rates were
similar in all countries. There was heterogeneity in the distribution of cases by etiologic subtype with an excess of genetic
cases in Italy and Slovakia, of iatrogenic cases in France and the UK, and of variant CJD in the UK. Conclusions: This
study has established overall epidemiologic characteristics for Creutzfeldt–Jakob disease (CJD) of all types in a multina-
tional population–based study. Intercountry comparisons did not suggest any relative change in the characteristics of
sporadic CJD in the United Kingdom, and the evidence in this study does not suggest the occurrence of a novel form of
human bovine spongiform encephalopathy infection other than variant CJD. However, this remains a possibility, and
countries currently unaffected by variant CJD may yet have cases.
NEUROLOGY 2005;64:1586–1591
Creutzfeldt–Jakob disease (CJD) is one of the trans-
missible spongiform encephalopathies (TSEs), or
prion diseases, which include the animal diseases
scrapie and bovine spongiform encephalopathy
(BSE). CJD occurs in a number of distinct etiologic
subtypes.1 Sporadic CJD (sCJD) occurs worldwide
and is of unknown etiology. Genetic forms of human
TSE (gTSE), including genetic CJD, Gerstmann–
Sträussler–Scheinker syndrome (GSS), and fatal fa-
milial insomnia (FFI), are linked to mutations of the
prion protein gene (PRNP) (although whether the
mutations are causal remains uncertain). Iatrogenic
CJD (iCJD) is caused by the transmission of infec-
tion from person to person in the course of medical
treatment, for example, cadaveric human pituitary
growth hormone and human dura mater grafts. Vari-
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the May 10 issue to find the title link for this article.
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ant CJD (vCJD) is a novel form of human TSE,
which has been linked to transmission of BSE to the
human population.2
The probability that vCJD represents the first
zoonotic transmission of a TSE to the human popula-
tion has political, economic, and social implications,
not least because of the potential threat to public
health in the United Kingdom and other countries.
In 1993, a system was established to coordinate the
epidemiologic surveillance in a number of European
countries with the primary aim of identifying any
change in the characteristics of CJD that might be
attributable to the BSE epidemic.3 In 1996, a new
form of CJD, vCJD, was identified in the UK, and
the hypothesis that this disease might be causally
linked to BSE exposure has been supported by sub-
sequent evidence.4,5
The occurrence of a new form of CJD in one coun-
try, the United Kingdom, and not, initially, in other
countries with similar surveillance methodologies
was an important component of the argument in fa-
vor of a link with BSE, and this depended on the
systematic study of the incidence and case character-
istics of CJD of all types in participating countries.
This article reviews the data from the European,
Australian, and Canadian CJD surveillance systems
from 1993 to 2002 and addresses a number of impor-
tant questions: What is the distribution of CJD by
etiologic subtype, and does this vary by country? Is
the pattern of occurrence of vCJD consistent with a
link with BSE? Does analysis of the temporal trends
in the characteristics of sCJD, including intercountry
comparisons, suggest a change in the characteristics
of sCJD that may be linked to BSE?
Methods. The European Union collaborative study of CJD was
carried out from 1993 to 2002 by France, Germany, Italy, the
Netherlands, Slovakia, and the United Kingdom. National
Creutzfeldt–Jakob disease registry surveillance methods for these
participating countries have been reported in detail previously.3 In
1997, the study was enlarged to other European and non-
European countries where similar registers and surveillance
methods were set up: Australia in 1993, Austria, Spain, and Swit-
zerland in 1996, and Canada in 1998. The aim was to monitor
CJD and the occurrence of vCJD in Europe and in countries where
exposure to BSE is likely to have been minimal. The annual mor-
tality rates and the standardized mortality ratios (SMRs) were
calculated using data collected from 1999 to 2002 when the sur-
veillance system was well established in all countries.
Cases were classified according to shared diagnostic criteria3
updated from January 1998 with the introduction of the 14-3-3
CSF test.6 Cases classified as definite (neuropathologically con-
firmed) or probable that died between January 1, 1993, and De-
cember 31, 2002, have been included in the analyses. For each
case, a data set including diagnostic classification, etiologic sub-
type, year of diagnosis, age at onset and death, results of investi-
gations, and, when available, PRNP analysis and the brain prion
protein type were established using standard methods.7 The data
set was checked for accuracy and consistency by all participants.
Statistical analysis. Crude and age- and sex-specific inci-
dences or mortality rates were calculated using as denominator
population data for 1998 provided from the national or federal
statistics bureau of participating countries. For Canada, popula-
tion data (2001) were taken from the Canadian Statistics Web
site. Six age-interval classes (10 to 39, 40 to 49, 50 to 59, 60 to 69,
70 to 79, and 80) were defined for the analyses.
Differences in mortality from sCJD and gTSE among the coun-
tries were assessed by calculation of the SMR based on the overall
age- and sex-specific mortality rates for the period 1999 to 2002.
SMRs with 95% CIs that did not include 1.0 were considered to be
significant. The CIs were calculated under the assumption that
the observed number of cases followed a Poisson distribution.
Results. There were 4,441 deaths from CJD included in
the study in the period 1993 to 2002. Of these 4,441
deaths, 66% of cases were classified as definite CJD and
34% as probable CJD. The overall proportion of cases clas-
sified as definite or probable did not change over time. The
percentage of human TSE diseases with autopsy, EEG,
measurement of 14-3-3 in the CSF, and PRNP analysis for
the period 1999 to 2002 in each country is given in figure
E-1 on the Neurology Web site (www.neurology.org). Post-
mortem examination was performed in 66% of all cases,
ranging from 100% in Slovakia to 49% in Germany. In all
countries, the EEG was available in the majority of pa-
tients except in Canada (7%). CSF 14-3-3 protein analysis
was performed in 86% of all patients, ranging from 52% in
Slovakia and Canada to 99.6% in Germany. PRNP analy-
sis was carried out in 67%, ranging from 32% in Australia
and the Netherlands to 97% in Slovakia.
The large number of cases collected in the database and
the accuracy in terms of etiologic classification allowed
analysis of incidence and mortality rates according to the
classification as gTSE, sCJD, iCJD, and vCJD. Eighty-four
percent of cases were classified as sporadic, 10% as genetic
(including genetic CJD, FFI, and GSS), 3% as iatrogenic,
and 3% as vCJD. The number of cases by country accord-
ing to the etiologic subtype is shown in table 1. The highest
number of deaths from sCJD was reported in Germany
(n  827), reflecting the largest population by country,
whereas Slovakia reported only 18 deaths from sCJD. The
number of genetic cases was highest in Italy, France, Ger-
many, the United Kingdom, Spain, and Slovakia. The
number of deaths due to iCJD varied markedly by country,
with a peak of 82 cases in France and 33 in the United
Kingdom related mainly to cases of CJD in human growth
hormone recipients (n  105; human dura mater recipi-
ents: n  32; corneal graft recipient: n  1). There were no
such cases in Slovakia, Austria, or Switzerland. vCJD
cases were identified during this study period (1993 to
2002) only in the UK (n  121), France (n  6), and
Canada (n  1). When the clinical subtypes were analyzed
by year of death, apart from the yearly increase in the
absolute number of deaths in each subtype related to new
countries joining the study, the emergence of variant cases
is the most striking feature (see table E-1).
Analysis of the age at death in each etiologic subtype
confirmed previous observations on differences in the age
distribution between the four subtypes: The vCJD and
iCJD cases were mainly in the age class younger than 39
years, the genetic forms mostly distributed between age
groups 50 to 59 and 60 to 69, and sporadic cases predomi-
nantly in age groups 60 to 69 and 70 to 79 (see figure E-2).
The overall yearly number of deaths from TSE (includ-
ing all subtypes) ranged from 209 cases in 1993 to 621 in
2001 with an average yearly mortality rate of 1.67 cases
per million for the period 1999 to 2002 (pooled data from
all countries). The distribution of the etiologic subtypes is
shown in an analysis of yearly mortality rates from CJD by
European country (figure 1). The mortality rates from
sCJD were relatively homogeneous, whereas high mortal-
ity rates from gTSE were reported in Austria, Italy, Slova-
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kia, and Spain and from iCJD in France (0.12 case per
million) and United Kingdom (0.05). Moreover, it is clear
that vCJD is predominantly a disease occurring in the
United Kingdom (0.38).
The distribution of genotypes at codon 129 of PRNP for
all types of TSE is shown in table 2. Overall, about 68% of
cases were methionine (M) homozygotes, with 67% of sCJD
cases and 100% of vCJD cases exhibiting this genotype. In
iCJD and GSS, the relative excess of methionine homozy-
gotes was less marked, and in iCJD, the distribution of
codon 129 genotypes was different between France (61%
MM) and the UK (5% MM).8 There was no significant
difference in the distribution of codon 129 genotypes by
country in sCJD.
sCJD. The SMRs and the 95% CI of SMRs for the
countries in the study, for 1999 to 2002, are reported in
table 3. In this period, France and Switzerland reported an
observed number of deaths higher than expected (n  397
and 57), whereas Slovakia and the UK reported an ob-
served number of deaths lower (n  9 and 241).
The incidence and mortality rates for sCJD are similar
because of the short mean duration of disease, and data
are therefore presented in terms of mortality rates. The
overall annual mortality rate from sCJD in the period
1999 to 2002 is 1.39 cases per million (pooled data from all
countries). The rates in individual countries range from
0.48 in Slovakia to 2.23 in Switzerland, while most of the
countries showed similar rates (figure 2A).










CJD TotalTotal With PRNP analysis
Australia 16,361,803 189 34 22 4 — 215
Austria*† 7,165,559 77 30 13 — — 90
Canada‡ 27,317,369 169 54 16 3 1 189
France 51,904,469 766 571 84 82 6 938
Germany 73,693,100 827 690 68 5 — 900
Italy 51,868,080 544 303 115 3 — 662
Netherlands 13,698,715 136 24 3 3 — 142
Slovakia 4,683,900 18 18 41 — — 59
Spain*† 35,488,954 380 96 44 5 — 429
Switzerland* 6,384,109 84 45 1 — — 85
UK 52,001,000 530 279 48 33 121 732
Total (%) 340,567,058 3,720 (83.8) 2,144 (57.6) 455 (10.2) 138 (3.1) 128 (2.9) 4,441
* Since 1996.
† Including retrospective cases from 1993.
‡ Since 1998, including retrospective cases from 1994.
CJD  Creutzfeldt–Jakob disease; TSE  transmissible spongiform encephalopathy.
Figure 1. Yearly mortality rates from human transmissi-
ble spongiform encephalopathy (TSE) in Europe by clini-
cal subtype (1999 to 2002). CJD  Creutzfeldt–Jakob
disease.
Table 2 Codon 129 distribution by disease type
Human TSE
Codon 129 polymorphism, %
TotalMet/Met Met/Val Val/Val
Sporadic CJD 67.2 16.4 16.5 2,339
Genetic CJD 69.4 23.8 6.8 294
FFI 71.4 28.6 — 63
GSS 51.6 32.3 16.1 31
Iatrogenic CJD 54.0 26.5 19.5 113
Variant CJD 100 — — 119
Total 68.1 17.3 14.6 2,959
CJD  Creutzfeldt–Jakob disease; FFI  fatal familial insomnia;
GSS  Gerstmann–Sträussler–Scheinker syndrome.
Met  methionine; Val  valine.
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Data on age at death and sex were available in 3,716
patients with sCJD, and the age- and sex-specific rates are
shown in figure E-3A. The distribution of the yearly age-
and gender-specific mortality rates for sCJD showed a low
rate in the under-50 age group, a peak in mortality in the
60 to 79 age group, and a decline in the 80 and older age
group. This observation is consistent between countries. A
slightly higher rate of deaths among men was observed for
patients ages 70. The age distribution of cases was simi-
lar in all countries, with the exception of a peak mortality
in the 60 to 69 age group in Slovakia.
Analysis of pooled data from Australia, Austria, France,
Germany, Italy, the Netherlands, Slovakia, Spain, and the
United Kingdom for the three time periods (1993 to 1995,
1996 to 1998, and 1999 to 2002) showed mortality rates
from sCJD increasing with the time in all age groups, most
prominently in patients over age 60 (see figure E-4).
The distribution of codon 129 genotypes in sCJD by
year of death is shown in figure E-5. The distribution with
time shows an overall slight decrease in the proportion of
cases of sCJD with an MM genotype (2 test for linear
trend, p  0.01). Prion protein type is available in 865
(23%) cases of sCJD. Combining the two prion protein
types (type 1 or type 2A) and the three codon 129 geno-
types allows cases of sCJD to be classified into six sub-
groups, with the MM/type 1 cases representing the
majority of cases (see table E-2) of clinically “typical”
sCJD. About 6% of cases have both type 1 and type 2A in
the brain. Eighty-eight percent of MM cases are associated
with PrPSc type 1, whereas 82% of valine/valine (VV) and
62% of MV cases are PrPSc type 2A (2 test, p  0.0001).
Table E-3 shows the number of MM/type 1 and MV/type 2
sCJD cases in the four countries with available informa-
tion. We did not observe any significant (after Bonferroni
correction for multiple testing) temporal trend for patients
with MM/type 1 sCJD (2 test for linear trend, France, p 
0.03; Germany, p  0.12; Italy, p  0.27; UK, p  0.91) or
MV/type 2 (France, p  0.02; Germany, p  0.08; Italy,
p  0.32; UK, p  0.75).
gTSE. The SMRs and the 95% CIs of SMRs for gTSE
in 1999 to 2002 are reported in table 3. In Italy (n  62)
and Slovakia (n  20), there was a relative excess of ge-
netic cases, whereas in Germany, the Netherlands, and the
United Kingdom, there was a relatively low number.
The overall annual mortality rate in the period 1999 to
2002 for gTSE is 0.17 case per million. However, the anal-
ysis of the incidence and mortality rates for gTSE by coun-
tries showed marked differences (see figure 2B). The
yearly mortality rates in individual countries ranged from
0.02 in the Netherlands (1999 to 2002) to 1.07 in Slovakia
(1999 to 2002). Data on age at death and sex were avail-
able in 455 patients with gTSE, and the age- and sex-
specific rates overall (pooled data from all countries) are
shown in figure E-3B. The distribution of the yearly age-
and gender-specific mortality rates was different from that
Table 3 SMRs and 95% CIs of sporadic Creutzfeldt–Jakob




SMR 95% CI SMR 95% CI
Australia 1.11 0.89–1.37 0.85 0.39–1.61
Austria 0.80 0.54–1.13 1.59 0.69–3.14
Canada 0.87 0.72–1.04 0.71 0.38–1.22
France 1.34*1 1.21–1.47* 1.00 0.71–1.38
Germany 0.93 0.84–1.03 0.69*2 0.49–0.95*
Italy 0.95 0.84–1.06 1.60*1 1.23–2.05*
Netherlands 0.82 0.62–1.07 0.11*2 0.00–0.60*
Slovakia 0.44*2 0.20–0.83* 6.84*1 4.18–10.56*
Spain 1.03 0.89–1.18 1.30 0.89–1.84
Switzerland 1.61*1 1.22–2.08* 0.22 0.01–1.21
UK 0.83*2 0.73–0.94* 0.41*2 0.23–0.67*
* Significant increase (1) or decrease (2) in mortality rates with
respect to the estimates for overall Europe.
SMR  standardized mortality ratio; TSE  transmissible spon-
giform encephalopathy.
Figure 2. Yearly mortality rates from sporadic
Creutzfeldt–Jakob disease (CJD) (A) and genetic transmis-
sible spongiform encephalopathy (TSE) (B) by country
(1999 to 2002).
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of sCJD cases, with higher rates in the 50 to 59 and 60 to
69 age groups and a decline in the over-70 age groups. A
slightly higher rate of deaths among women was observed.
There was no increase in mortality from gTSE over the
10-year period in any of the age groups under examination
(data not shown).
Discussion. This is the largest systematic prospec-
tive survey of CJD ever carried out, including de-
tailed information in 3,700 cases of sCJD and
4,400 cases in total. The proportion of cases by
etiologic subtype is similar to previous studies3,9,10
with 80% of cases classified as sporadic, but there
is marked variation in the incidence of gTSE, iCJD,
and vCJD between countries. Overall, there is evi-
dence of an increase in mortality of sCJD with time,
but this is not specific to any particular country or
countries, and no new subtype of CJD, other than
vCJD, has been identified.
Any surveillance system depends on a high-level
ascertainment to allow meaningful results and for
intercountry comparisons to be valid. The efficiency
of case identification and data collection should be
similar in all participating countries. There is varia-
tion in the provision of health care in the countries
in our study, for example, in the number of neurolo-
gists per country11 and in postmortem rates. How-
ever, there is a general consistency in the mortality
rates for sCJD in this study between participating
countries. Furthermore, the increasing temporal
trends in mortality and the changes in the age-
specific incidence rates are also very similar between
countries, arguing that the efficiency of case ascer-
tainment is similar despite the variations in health
care systems and resources available to individual
centers. Complete data sets were available for nearly
all cases included in this study, and there was a high
rate of data consistency, requiring only minor
amendments to the original data set. The proportion
of cases undergoing postmortem examination was
high, at about two-thirds of all cases. PRNP analysis
was available in 60% of cases; although there was
variation in the proportion of tested cases ranging
from 32% in Australia to 97% in Slovakia, in the
majority of countries, the proportions tested were
comparable (see figure E-1). Although there are un-
certainties about the efficiency of case finding of CJD
across time and the age range, for example, in the
first years of the study and in the elderly, the data in
this article suggest that surveillance for all types of
CJD has been carried out efficiently and that inter-
country comparisons are likely to be valid.
One notable finding is the marked variation in the
incidence of etiologic subtypes by country with an
excess of iatrogenic cases in France and the United
Kingdom and an excess of genetic cases in Italy and
Slovakia. The great majority of cases of iCJD in this
study are related to human growth hormone treat-
ment, and the reason for the excess of cases in particu-
lar countries suggests that the treated populations in
these countries were exposed to a higher level of infec-
tion. It is of note that in France and the UK, human
growth hormone was produced locally, whereas in
other countries, commercially produced human growth
hormone was mainly used.12 Cases of gTSE were found
in all participating countries, indicating that the risk of
gTSE is widespread, although the excess of gTSE cases
in particular countries indicates that this risk is not
homogeneous. The variation in mortality rates for gT-
SEs by country is not directly related to differences in
the proportion of cases with available PRNP analysis
(see table 1) and is therefore likely to be a real observa-
tion. Codon 200 mutations account for about 50% of all
PRNP mutations in this series, have been identified in
all participating countries, and represent the majority
of mutations found in France (55%) and Slovakia
(100%) but not in Italy (32%) and Spain (33%). The
worldwide dissemination of the codon 200 mutation
has previously been studied, with haplotype analysis
suggesting a link between the Italian and Spanish
families, but no link between families in Slovakia, Ger-
many, and Austria.13 The possibility of genetic isolation
and/or consanguinity may explain the high incidence of
gTSE in Slovakia14 and perhaps in some Italian cases.15
Previous work from the EuroCJD Group has shown
that a family history of a similar disorder is found in
only about one-third of all mutation-related cases.16
The widespread geographic occurrence of a range of
PRNP mutations may relate to spontaneous mutations
in PRNP, similar to those that have previously been
identified in association with mutations at codon 178 of
PRNP.17
Analysis of SMRs for sCJD by country indicates
some variation with time (data not shown). This may
represent a variation about a mean; for example, in
Austria, a high SMR for sCJD in the period 1993 to
1995 (1.58) was not sustained in subsequent years.
There is a possibility that the fluctuations in mortal-
ity from sCJD may explain the high incidence of
sCJD identified in Switzerland,18 but other explana-
tions must be considered, including a locally efficient
surveillance system and underreporting in other
countries. This hypothesis has been judged to be im-
plausible in view of the similarities between Switzer-
land and other countries such as Austria, in which
there is no equivalent rise in mortality rates, despite
similar population, age structure, and quality of
health care. Furthermore, the proportion of cases
with results of specialist investigations in Switzer-
land (see figure E-1) is similar to that in other coun-
tries and lower than in Austria. However, the
possibility that the variation in mortality rates for
sCJD between countries is related to differences in
the efficiency of case identification or classification
cannot be excluded.
It is clear from our study that vCJD occurs pre-
dominantly in the United Kingdom with a smaller
number of cases in France during the study period,
probably linked to a proportionally lower human ex-
posure to BSE.19 The single vCJD case in Canada
most likely occurred as a consequence of exposure in
the United Kingdom. The hypothesis that improved
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identification of atypical cases of CJD, rather than
BSE, may explain the occurrence of vCJD20 is not
supported by our data. Despite evidence of efficient
surveillance for all forms of CJD in participating
countries, vCJD was not identified during the study
period in a population of 300 million over 4 to 7
years. Single cases of vCJD have subsequently been
identified in Italy21 and the USA,22 but not in the
other countries in the surveillance system. Further-
more, the cases in the USA and Canada had a his-
tory of extended residence in the UK during the
period when human BSE exposure was maximal, a
striking coincidence if these cases had been identi-
fied solely as a result of improved case identification.
Overall, there has been an increase in mortality
from sCJD with time, and it is not possible to be
certain whether this is related to improved efficiency
of the surveillance system with time or some other
cause such as a new environmental source of infec-
tion. However, the increased mortality is related
mainly to increasingly mortality rates in the elderly,
rather than the younger age groups, and the changes
in mortality have been found in all participating
countries, including Australia and Canada, in which
indigenous BSE exposure is likely to have been neg-
ligible. This argues against the possibility that the
rise in mortality may be related to BSE infection in
humans, resulting in a phenotype indistinguishable
from sCJD. Further analyses of trends in subtypes of
sCJD do not support the hypothesis that BSE infec-
tion might result in an increase in the MM/type 1
subtype of sCJD23 or an increase in the MV/type 2
subtype in relation to a novel form of BSE.24 The
proportion of all cases of sCJD with an MM genotype
has decreased, if anything, during the period of the
study; although data are available in only a minority
of cases, there has also been a decrease overall in the
proportion of cases with an MM genotype and type 1
prion protein deposition in the brain. If BSE were to
result in a novel phenotype of sCJD, this is most
likely to occur first and to a greater extent in the
United Kingdom than in other countries. The analy-
ses in this study do not suggest a change in the
characteristics of sCJD in the United Kingdom com-
pared with other countries. Although the phenotype
of BSE infection in individuals with an MV or VV
background cannot be predicted, to date there is no
evidence of a novel phenotype of sCJD in Europe
related to BSE infection.
Acknowledgment
The authors thank the following for their assistance and partici-
pation: in Australia, C.L. Masters, A. Boyd, V. Lewis, and J. Lee;
in Austria, Drs. Christa Jarius, Ellen Gelpi, Christine Haberler,
Thomas Ströbel, and Till Voigtländer, and Dita Drobna, Helga
Flicker, Brigitte Millan-Ruiz, and Monika Richter; in Canada,
Drs. C. Bergeron, M. Coulthart, N. Cashman, and D. Westaway;
in France, reporting physicians and members of the Reseau Na-
tional de surveillance de maladies de Creutzfeldt–Jakob et mala-
dies apparentees; in Germany, reporting physicians, Maja
Schneider-Dominico for help in coordination of surveillance, and
Drs. Otto Windl and Walter Sculz-Schaeffer; in Italy, S. Almonti,
V. Mellina, and L. Ingrosso for advice and help with data collec-
tion; in the Netherlands, colleagues at the Department of Neurol-
ogy at the Academic Medical Centre, Amsterdam and the
Department of Pathology at the University Medical Centre,
Utrecht; in Spain, reporting physicians and members of the Span-
ish TSE study group at Consejo Interterritorial and co-workers at
CNE and ISCIII; in the UK, the staff at the National CJD Surveil-
lance Unit, James Ironside for neuropathologic expertise, and cli-
nicians for their cooperation with the study.
References
1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363–13383.
2. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt–
Jakob disease in the UK. Lancet 1996;347:921–925.
3. Will RG, Alperovitch A, Poser S, et al. Descriptive epidemiology of
Creutzfeldt–Jakob disease in six European countries, 1993–1995. Ann
Neurol 1998;43:763–767.
4. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate
that “new variant” CJD is caused by the BSE agent. Nature 1997;389:
498–501.
5. Scott MR, Will RG, Ironside J, et al. Compelling transgenetic evidence
for transmission of bovine spongiform encephalopathy prions to hu-
mans. Proc Natl Acad Sci USA 1999;96:15137–15142.
6. World Health Organisation. WHO manual for strengthening diagnosis
and surveillance of Creutzfeldt–Jakob disease. Geneva: WHO, 1998:1–
75.
7. Parchi P, Giese A, Capellari S, et al. Classification of sporadic
Creutzfeldt–Jakob disease based on molecular and phenotypic analysis
of 300 subjects. Ann Neurol 1999;46:224–233.
8. Brandel J-P, Preece M, Brown P, et al. A. Distribution of codon 129
genotype in human growth hormone-treated CJD patients in France
and the UK. Lancet 2003;362:128–130.
9. Brown P, Cathala F, Gajdusek DC. Creutzfeldt–Jakob disease in
France: III. Epidemiological study of 170 patients dying during the
decade 1968–1977. Ann Neurol 1979;6:438–446.
10. Will RG, Matthews WB. A retrospective study of Creutzfeldt–Jakob
disease in England and Wales 1970–79 I: clinical features. J Neurol
Neurosurg Psychiatry 1984;47:134–140.
11. Kmietowicz Z. United Kingdom needs to double the number of neurolo-
gists. Br Med J 2001;322:1508.
12. Will RG, Alpers MP, Dormont D, et al. Infectious and sporadic prion
diseases. In: Prusiner SB, ed. Prion biology and diseases. New York:
Cold Spring Harbor Laboratory Press, 1999:465–507.
13. Lee H-S, Sambuughin N, Cervenakova L, et al. Ancestral origins and
worldwide distribution of the PRNP 200K mutation causing familial
Creutzfeldt–Jakob disease. Am J Hum Genet 1999;64:1063–1070.
14. Mitrova E, Bronis M. “Clusters” of CJD in Slovakia: the first statisti-
cally significant temporo-spatial accumulations of rural cases. Eur J
Epidemiol 1991;7:450–456.
15. D’Alessandro M, Petraroli R, Ladogana A, et al. High incidence of
Creutzfeldt–Jakob disease in rural Calabria, Italy. Lancet 1998;352:
1989–1990.
16. Euro-CJD Group. Genetic epidemiology of Creutzfeldt–Jakob disease in
Europe. Rev Neurol (Paris) 2001;157:633–637.
17. Dagvadori A, Petersen RB, Lee H-S, et al. Spontaneous mutations in
the prion protein gene causing transmissible spongiform encephalopa-
thy. Ann Neurol 2002;53:355–359.
18. Glatzel M, Rogivue C, Ghani A, et al. Incidence of Creutzfeldt–Jakob
disease in Switzerland. Lancet 2002;360:139–141.
19. Alperovitch A, Will RG. Predicting the size of the vCJD epidemic in
France. CR Biol 2002;325:33–36.
20. Venters GA. New variant Creutzfeldt–Jakob disease: the epidemic that
never was. Br Med J 2001;323:858–861.
21. La Bella V, Collinge J, Pocchiari M, et al. Variant Creutzfeldt–Jakob
disease in an Italian woman. Lancet 2002;360:997–998.
22. Wiersma S, Cooper S, Knight R, et al. Probable variant Creutzfeldt–
Jakob disease in a US resident—Florida 2002. MMWR 2002;51:927–
929.
23. Asante EA, Linehan JM, Desbruslais M, et al. BSE prions propagate as
either variant CJD or sporadic CJD-like prion strains in transgenic
mice expressing human prion protein. EMBO J 2002;21:6358–6366.
24. Casalone C, Zanusso G, Acutis P. Identification of a second bovine
amyloidotic spongiform encephalopathy: molecular similarities with
sporadic Creutzfeldt–Jakob disease. Proc Natl Acad Sci USA 2004;101:
3065–3070.
May (1 of 2) 2005 NEUROLOGY 64 1591
ORIGINAL INVESTIGATION
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Abstract A total of 10–15% of human transmissible
spongiform encephalopathies (TSEs) or prion diseases
are characterised by disease-specific mutations in the
prion protein gene (PRNP). We examined the pheno-
type, distribution, and frequency of genetic TSEs
(gTSEs) in different countries/geographical regions. We
collected standardised data on gTSEs between 1993 and
2002 in the framework of the EUROCJD collaborative
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Gábor G. Kovács and Maria Propolo Contributed equally
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surveillance project. Our results show that clinicopath-
ological phenotypes include genetic Creutzfeldt–Jakob
disease (gCJD), fatal familial insomnia (FFI), and
Gerstmann–Sträussler–Scheinker disease (GSS). Genetic
TSE patients with insert mutation in the PRNP repre-
sent a separate group. Point and insertional mutations in
the PRNP gene varies significantly in frequency between
countries. The commonest mutation is E200K. Absence
of a positive family history is noted in a significant
proportion of cases in all mutation types (12–88%). FFI
and GSS patients develop disease earlier than gCJD.
Base pair insertions associated with the Creutzfeldt–Ja-
kob disease (CJD) phenotype, GSS, and FFI cases have
a longer duration of illness compared to cases with point
mutations and gCJD. Cerebrospinal fluid 14-3-3
immunoassay, EEG, and MRI brain scan are useful in
the diagnosis of CJD with point mutations, but are less
sensitive in the other forms. Given the low prevalence of
family history, the term ‘‘gTSE’’ is preferable to
‘‘familial TSE’’. Application of genetic screening in
clinical practice has the advantage of early diagnosis and
may lead to the identification of a risk of a TSE.
Keywords Prion protein gene Æ Creutzfeldt-Jakob
disease Æ Fatal familial insomnia Æ Gerstmann-
Sträussler-Scheinker disease Æ Point
mutation Æ Insertional mutation
Introduction
Human transmissible spongiform encephalopathies
(TSEs) or prion diseases are characterised by neurolog-
ical and psychiatric symptoms and a progressive fatal
course. Accumulation in the central nervous system
(CNS) of the pathological prion protein (PrPSc) is a
common disease marker (Prusiner 2001). The most fre-
quent human TSE is Creutzfeldt–Jakob disease (CJD).
The majority of cases (85%) present as a sporadic dis-
order (sCJD) without defined aetiology (Masters et al.
1979; WHO 2003). Acquired forms, including iatrogenic
CJD due to transmission of infection in the course of
medical or surgical treatment, and variant CJD (vCJD),
which has been linked to infection with bovine spongi-
form encephalopathy, are less frequent (Masters et al.
1979; Prusiner 2001; WHO 2003). The familial occur-
rence of cases has been reported with a broad range of
frequency: 6% of TSE cases in France (Brown et al.
1979), 25.5% in Israel (Kahana et al. 1974), 26% in Chile
(Galvez et al. 1980), 53.6% in Slovakia (Mitrova and
Belay 2002), and world-wide 15% (Masters et al. 1979).
Current clinical and neuropathological diagnostic
criteria distinguish familial or genetic TSEs (gTSEs),
including familial/genetic CJD (gCJD), fatal familial
insomnia (FFI), and Gerstmann–Sträussler–Scheinker
disease (GSS) (Budka et al. 1995; Prusiner 2001; WHO
2003). Experimental transmissibility of all the major
subtypes has been established, albeit not with all muta-
tions (Masters et al. 1981; Tateishi et al. 1979, 1995). In
gTSEs, disease-specific point or insertional mutations in
the prion protein gene (PRNP) have been demonstrated
(Goldfarb et al. 1990a, b, 1992; Goldgaber et al. 1989;
Haltia et al. 1991; Owen et al. 1989), with individual
PRNP mutations showing variable geographical distri-
bution and frequency. While certain mutations are rare
(Kovacs et al. 2002), the E200K mutation has been re-
ported not only in Europe but also in Chile, Israel, Japan,
and USA (Goldfarb et al. 1990a, b; Goldgaber et al.
1989; Miyakawa et al. 1998). Geographic or ethnic clus-
ters of cases of gTSEs have been found in Israel, Slovakia,
Chile, and Italy (Chapman et al. 1994; D’Alessandro
et al. 1998; Kahana et al. 1974; Mayer et al. 1977;
Mitrova and Belay 2002; Mitrova and Bronis 1991).
In parallel with the increasing numbers of PRNP
mutations, it has been recognised that, unexpectedly, not
all patients withPRNPmutations appear to have affected
family members (Chapman et al. 1994; D’Alessandro
et al. 1998; EuroCJD group 2001; Goldman et al. 2004;
Mitrova and Belay 2002). Therefore the terms ‘‘familial’’,
‘‘hereditary’’, or ‘‘inherited’’ TSEmay not be appropriate
in cases without a family history and the inclusive term
‘‘genetic TSE’’ may be preferable for cases associated
with a mutation, whether or not there is a family history.
The negative family history in some gTSE cases and
the identification of ‘‘healthy’’ carriers has drawn
attention to the issue of penetrance, i.e., the proportion
of carriers who will eventually develop the disease
(Chapman et al. 1994; D’Alessandro et al. 1998; Gold-
farb et al. 1990a, b; Mitrova and Belay 2002). Pene-
trance of the E200K mutation shows considerable
variability. While in Israeli carriers, penetrance appears
to be almost complete (89%), in Slovakian and Italian
E200K carriers, penetrance is partial (54–59%) (Chap-
man et al. 1994; D’Alessandro et al. 1998; Goldfarb
et al. 1990a, b; Mitrova and Belay 2002).
The EUROCJD project, funded by the European
Commission, started in 1993 and compares data from
national registries in Australia, Austria, Canada,
France, Germany, Italy, The Netherlands, Slovakia,
Spain, Switzerland, and the UK. The present study
analyses the EUROCJD data on gTSE cases. Recently
clinicopathological data of more than 500 published
genetic cases of the literature has been reviewed (Kovacs
et al. 2002) and some of the data on genetic epidemiol-
ogy of CJD in Europe has been published (EuroCJD
group 2001). The present paper includes standardised
data from a large number of cases not previously re-
ported in the context of a study carried out over a period
of years in a defined population. Our aims are: (1) to
describe the distribution and frequency of gTSEs, (2) to
define and describe specific features of subgroups of
gTSEs, (3) to contribute to a better understanding on
how mutations and polymorphisms of PRNP influence
clinical phenotypes, and (4) to assess the terms genetic




The EUROCJD database contains data on sporadic,
variant, iatrogenic, and gTSE cases collected between
1993 and 2002 (for detailed methodology see Ladogana
et al. 2005a). In this paper we have analysed data of 455
gTSE cases from the following groups: gCJD cases
(including patients with PRNP analysis and those with
no available PRNP analysis but positive family history
for TSE), FFI, GSS, and gTSE patients carrying base
pair insertions (insert gTSE): referred to in previous
publications as BPI (Kovacs et al. 2002) because these
mutations are associated with repeat base pair insertions
in the octarepeat region. No deletions in this region were
identified in this study. We evaluated E200K gCJD and
V210I gCJD separately as there were sufficient numbers
of cases to allow statistical analyses. Cases of gCJD
without either an E200K or V210I mutation are classi-
fied as ‘‘other CJD’’. Cases were classified either as
definite or probable according to recent surveillance cri-
teria (WHO 2003), which for the diagnosis of ‘‘familial’’
CJD require definite or probable CJD in the index case
and a first-degree relative or a neuropsychiatric disorder
in association with a PRNP mutation.
Statistical analysis
Differences among distinct forms of gTSE cases with
respect to age at onset or clinical duration were assessed
by Mann–Whitney test; variation in clinical signs by the
chi-square test or the Fisher’s exact probability test. The
Bonferroni correction for multiple testing was adopted
within the six subgroups of gTSE (E200K, V210I, and
other forms of gCJD, GSS, FFI, and insert mutations)
at an experimental probability type 1 error of 0.05.
Age at onset was given as mean, standard deviation
(SD), and range; clinical duration as median and half
interquartile range (IQR) because of highly skewed
distribution of data. Box-plots were used for the graphic
representations of continuous variables. Statistical
analyses were performed using BMDP and STATA.
Crude and sex-specific mortality rates were calculated
using as denominator populations data for 1998 pro-
vided from National or Federal Statistics Bureau of
participating countries. For Canada, population data
(2001) were taken from the Canadian Statistics website.
The annual mortality rates were calculated using data
collected from 1999–2002 when the surveillance system
was well established in all countries.
Results
Distribution of cases and mutations
The distribution and frequency of PRNP mutations
among countries participating in the study are sum-
marised in Table. 1 and 2. The proportion of all gTSE
cases with respect to the total number of TSE cases
(including sporadic, iatrogenic, and variant CJD) was
10.2%, but, this varied significantly among participating
countries ranging from 69.5% in Slovakia to 1.2% in
Switzerland. The overall annual mortality rate of gTSE
cases was 0.17 patients per million people for the period
1999–2002. It is of note that Slovakia had an overall
mortality rate for gTSE diseases 3.5 times that of the
second highest country (Italy). However, while the
E200K mutation was the only mutation present in the
Slovak population, several mutations were present in the
Italian population, including the E200K and V210I
gCJD, FFI, and GSS. Switzerland reported a single
Table 1 EUROCJD 1993–2002: number of reported cases in each EUROCJD country
All genetic TSE diseases gCJD GSS FFI Insert







Australia 22/215 4.8 10.2 0.14 14 3 4 1
Austria 13/90 2.9 14.4 0.28 9 0 3 1
Canada 16/189 3.5 8.5 0.12 7 9 0 0
France 84/938 18.5 9.0 0.18 68 5 6 5
Germany 68/900 14.9 7.6 0.13 31 8 17 12
Italy 115/662 25.3 17.4 0.30 94 8 10 3
Netherlands 3/142 0.7 2.1 0.02 1 0 0 2
Slovakia 41/59 9.0 69.5 1.07 41 0 0 0
Spain 44/429 9.7 10.3 0.23 18 0 25 1
Switzerland 1/85 0.2 1.2 0.04 1 0 0 0
UK 48/732 10.5 6.6 0.07 11 19 1 17
Total 455/4,441 – – 0.17 295 52 66 42
% Total – 100 10.2 – 64.9 11.4 14.5 9.2
Abbreviations: gTSE, genetic transmissible spongiform encephalopathy; gCJD, genetic Creutzfeldt–Jakob disease; FFI, fatal familial
insomnia; GSS, Gerstmann–Sträussler–Scheinker disease; Insert, gTSE patients with insert mutations.
a For the period 1999–2002.
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gTSE patient for the period 1996–2002 while the Neth-
erlands had the lowest mortality rate for gTSE diseases.
More than 90% of FFI and 75% of GSS patients
underwent post-mortem examination and were classified
as definite gTSE cases, while 52% of V210I gCJD pa-
tients did not undergo autopsy (see Table 3) and were
classified as probable gTSE based on clinical and labo-
ratory features. There was an excess of females in gCJD
(more pronounced for E200K than V210I or ‘‘other’’
gCJD patients) and, to a lesser extent, in GSS or insert
gTSE cases, and an excess of males in FFI cases (Ta-
ble 3). Data on the polymorphic codon 129 of the PRNP
gene were available in 87% of all cases (95% in E200K,
97% in V210I, 75% in ‘‘other’’ gCJD, 95% in FFI, 56%
in GSS, and 79% in insert gTSE). The distribution of the
polymorphic codon 129 in all forms of gTSE is shown in
Table 3. Differences between codon 129 distribution in
controls (39% methionine homozygous (MM), 50%
heterozygous (MV), 11% valine homozygous (VV), Al-
perovitch et al. 1999) and in individual gTSE groups
have been evaluated by chi-sqared test with the follow-
ing results: E200K gCJD, V210I gCJD and FFI,
P<0.0001, ‘‘other’’ gTSE, P=0.0010, Insert gTSE,
P=0.0577 and GSS, P=0.3825. The majority of PRNP
mutations co-segregate with methionine at the poly-
morphic codon 129 (see Table 2). Thus, the majority of
gTSE patients overall were either MM (67.9%) or MV
(25.8%) with only a few valine homozygotes (6.3%).
Family history
About 47% of all gTSE cases were reported to have no
TSE or other neurological disorder in family members.
Almost 90% of V210I gCJD patients had a negative
family history implying that a correct classification of
these cases would not have been possible without PRNP
genetic analysis. Interestingly, a positive family history
for TSE was reported in only about two-thirds of GSS
patients (Table 3).
Age at onset
There were significant differences in the age at onset in
gTSE forms (Fig. 1a). Patients with FFI (mean
51.2 years, SD 12.3, range 19–83) and GSS (51.6, 12.8,
26–87) developed disease significantly earlier than
E200K gCJD (60.4, 10.2, 33–84, p<0.0001), V210I
gCJD (59.3, 9.8, 39–82, p=0.0001 and 0.0009, respec-
tively), and ‘‘other’’ gCJD cases (60.4, 14.7, 31–87,
p=0.0004, 0.0036). There was no significant difference
in the age at onset between FFI and GSS patients and
among distinct forms of gCJD. Age at onset in patients
with insert mutations (57.2, 14.8, 32–85) did not signif-
icantly differ from that of gCJD, GSS, or from FFI
(p=0.0193) after Bonferroni’s correction. The youngest
age at onset was 19 years (FFI, MM at codon 129),
while the two oldest were 87 years (gCJD with missing
information on PRNP mutation, and A117V GSS, VV
at codon 129). The age at onset was earlier in valine
homozygotes in comparison to methionine homozygotes
(P=0.0001) and, to a lesser extent, in MV vs MM
(P=0.0059, not significant after Bonferroni’s correction)
in ‘‘other’’ gCJD patients. The codon 129 polymorphism
did not significantly influence the age at onset in all the
other forms of gTSEs (Table 4). Gender did not have
any significant effect on the age at onset (data not
shown).
Duration of illness
The duration of disease varied between different forms
of gTSE (Fig. 1b). Clinical durations of E200K (median
5.0 months, IQR 2.5) and V210I (4.0, 1.5) gCJD
patients were shorter than ‘‘other’’ gCJD (7.0, 7.0,
p=0.0031 and 0.0012, respectively), FFI (12.4, 4.2,
P<0.0001 and 0.0001), GSS (40.0, 25.0, P<0.0001 and
0.0001) and insert gTSE (13.0, 35.5, P=0.0001 and
0.0001). GSS patients had a longer survival than FFI
(P<0.0001) and ‘‘other’’ gCJD (P<0.0001) patients.
Table 2 EUROCJD 1993–2002: number of reported cases and distribution of PRNP mutations in each EUROCJD country
Country gCJD
P105T-129? N171S-129V D178N-129V V180I-129M T188A-129M E196K-129M/V E200K-129M/V V203I-129M R208H-129M V210I-129M E211Q-129M NS
Australia 1 – – – 1 – 8 – – 2 – 2
Austria – – 1 – – 1 5 – – 1 – 1
Canada – – 2 – – – 4 1 – – – –
France – 1 8 1 – 1 46 3 – 6 2 –
Germany – – – – 2 3 15 – 1 9 1 –
Italy – – – – – – 35 1 1 50 1 6
Netherlands – – 1 – – – – – – – – –
Slovakia – – – – – – 40 – – – – 1
Spain – – 4 – – – 14 – – – – –
Switzerland – – – – – – 1 – – – – –
UK – – – – – – 7 – – 1 – 3
Total 1 1 16 1 3 5 175 5 2 69 4 13
% Total 0.2 0.2 3.5 0.2 0.7 1.1 38.5 1.1 0.4 15.2 0.9 2.9
Abbreviations: NS, not specified; others as in Table 1.
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The longest duration of illness was 216 months in an
insert gTSE case, the group with the highest variability
in clinical duration. However, in all other groups there
were a few cases with an exceptional long clinical
duration for their group (outliers in Fig. 1b). This in-
cluded 11 cases in E200K gCJD (five MM at codon 129:
16, 19, 20 and two 24 months; 6 MV: 17, two 18, 19,
and two 36 months), four cases in V210I gCJD (MM:
11, 15, 31, and 34 months), four in ‘‘other’’ gCJD
(43 months, D178N-129VV, 46 months, V180I-129MV,
52 months, V203I-129MV, 59 months, missing muta-
tion and codon 129), and one in FFI (MV: 97 months),
and two in insert gTSE (216 months 120 bp insert-
129MV, and 192 months 168 bp insert-129 MV).
Investigations
Data on CSF 14-3-3 immunoassay were available in
57% of cases (60% in E200K, 72% in V210I, 59% in
‘‘other’’ gCJD, 58% in FFI, 31% in GSS, and 50% in
insert gTSE), EEG in 82% of cases (90% in E200K,
96% in V210I, 86% in ‘‘other’’ gCJD, 77% in FFI, 50%
in GSS, and 67% in insert gTSE), and MRI brain scan
in 43% of cases (38% in E200K, 67% in V210I, 31% in
‘‘other’’ gCJD, 52% in FFI, 33% in GSS, and 36% in
insert gTSE). In the various forms of gTSEs, there were
significant differences in the frequency in positivity of
the 14-3-3 test in the CSF (P<0.0001, Fisher’s exact
test), the EEG (P<0.0001, chi-squared test) and the
MRI brain scan (P=0.0038, Fisher’s exact test) (WHO
2003). A positive 14-3-3 test was present in the majority
of gCJD patients and insert gTSE patients (Fig. 2). A
typical EEG (WHO 2003) was more frequent in gCJD
than in other forms of gTSE diseases. About 50% of
GSS cases had a positive 14-3-3 test in the CSF, while
the EEG showed typical pseudoperiodic activity in only
2 of 26 patients with available information (Fig. 2). In
GSS and FFI, neither the EEG nor the 14-3-3 tests were
of help in the clinical diagnosis of disease. MRI brain
scan was performed in a small proportion of cases and
was positive (WHO 2003) in about 50% of E200K and
‘‘other’’ gCJD and in about 30% of GSS and insert
gTSE cases. In FFI and V210I gCJD patients, the MRI
brain scan was positive in only 18 and 15%, respectively.
Classification of protease-resistant PrP
Results were available in only 43 cases. Twenty-two
E200K, 6 V210I gCJD, 9 ‘‘other’’ gCJD, 1 FFI, 2 GSS,
and 3 insert gTSE cases (Table 5). Thirty-four patients
had type 1 protease-resistant prion protein (according to
the system described by Parchi et al.) (Parchi et al. 1999)
in brain samples, six had type 2A, and three patients had
both type 1 and type 2A.
Discussion
EUROCJD has data on 23 specified PRNP mutations.
Currently more than 30 mutations have been reported in
the world literature, but many of these mutations are
very rare or are restricted to specific populations (Kov-
acs et al. 2002). Comparison of genetic and sporadic
TSEs shows striking differences in their frequency and
geographic distribution. While sCJD has a similar inci-
dence in all participating countries (Ladogana et al.
2005a), PRNP mutations show significant variability.
Some mutations (P105L, N171S, V180I, T188A, E196K,
R208H, V203I, 168 BPI) are extremely rare, while
E200K is recognised in 9 out of 10 reporting countries.
The high absolute and proportionate incidence of the
V210I mutation in Italy is striking; most affected fami-
lies lived in three adjacent areas (Ladogana et al. 2005b).
It is a pertinent point that a single report on the N171S
mutation suggested a psychiatric phenotype, whereas in
our series this mutation was associated with CJD
(Samaia et al. 1997). A high proportion of all cases in
each category underwent genetic analysis. The three
lowest percentages of PRNP tests were 42.3% (Canada),
32% (Australia) and 31.7% (Netherlands). The vari-
ability in the frequency of mutations countrywise is
unexpected and is not related to variation countrywise in
GSS FFI Insert
P102L-129M A117V-129V G131V-129M NS D178N-129M NS 24-129M 48-129M 72-129? 96-129M/V 120-129M/V 144-129M 168-129M 192-129M/V NS
1 – 1 1 3 1 – – – – – – 1 – –
– – – – 3 – – – – – – 1 – – –
1 – – 8 – – – – – – – – – – –
3 2 – – 6 – 2 – – 1 – 1 – 1 –
3 5 – – 17 – 1 – 1 2 8 – – – –
8 – – – 10 – 2 – – 1 – – – – –
– – – – – – 1 – – – – – – 1 –
– – – – – – – – – – – – – – –
– – – – 24 1 – 1 – – – – – – –
– – – – – – – – – – – – – – –
8 5 – 6 1 – – – – 1 4 9 1 – 2
24 12 1 15 64 2 6 1 1 5 12 11 2 2 2
5.3 2.6 0.2 3.3 14.1 0.4 1.3 0.2 0.2 1.1 2.6 2.4 0.4 0.4 0.4
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the availability of genetic data. Focal accumulations of
genetic patients (Mayer et al. 1977) may be due to ge-
netic isolation but the explanation for the overall inter-
country variability in this study is uncertain.
The ratio of female to male mortality rates in Table 3
indicates that there is an excess of females in all mutations
except FFI. Taking account of varying distribution by
age, the weighted female to male ratio (1.59 for E200K,
1.62 for V210I, 1.90 for other gCJD, 1.43 for GSS, 1.62
for insert gTSE, and 0.62 for FFI) strongly confirms the
excess of female cases in all forms of gCJD except FFI.
Although consistent with similar findings in sporadic
CJD (Ladogana et al. 2005a), the explanation for this
gender bias in mortality is uncertain. Possible explana-
tion include sex-linked genetic factors influencing disease
expression, bias in case ascertainment linked to gender or
differential susceptibility/exposure to a co-factor.
Clinical and laboratory parameters show consider-
able similarity between the most frequent gCJD (e.g.,
E200K mutation) and sCJD cases. Although gCJD cases
with point mutations have an earlier mean age at death,
there is no difference between gCJD cases with point
mutations and sCJD in the mean duration of the disease
(Alperovitch et al. 1999; Pocchiari et al. 2004). As in
sCJD (Zerr et al. 2000), analysis of CSF 14-3-3 protein,
EEG, and MRI is helpful in the diagnosis of gTSEs and
Table 3 Characteristics of genetic transmissible spongiform encephalopathies
Forms of gTSE n Percentage of
definite cases
(n)




F M F/M ratios
of mortality
ratesa
MM % (n) MV % (n) VV % (n)
E200K gCJD 175 68.0 (119) 107 68 1.69 78.3 (130) 19.9 (33) 1.8 (3) 49.1 (114)
V210I gCJD 69 47.8 (33) 39 30 1.42 73.1 (49) 26.9 (18) – 12.3 (57)
Other gCJD 51 58.8 (30) 28 23 1.38 36.8 (14) 34.2 (13) 29.0 (11) 75.9 (29)
FFI 66 92.4 (61) 29 37 0.62 71.4 (45) 28.6 (18) – 88.0 (50)
GSS 52 76.9 (40) 29 23 1.17 51.7 (15) 34.5 (10) 13.8 (4) 69.7 (33)
Insert gTSE 42 69.0 (29) 21 21 1.23 48.5 (16) 30.3 (10) 21.2 (7) 48.0 (25)
Abbreviations: gTSE, genetic transmissible spongiform encephalopathy; gCJD, genetic Creutzfeldt–Jakob disease; FFI, fatal familial
insomnia; GSS, Gerstmann–Sträussler–Scheinker disease; Insert, gTSE patients with insert mutations.
a For the period 1999–2002.
Fig. 1 Box- and whisker-plots of age at onset (a) and clinical
duration (b) in different forms of genetic TSE diseases. The line in
the middle of the box represents median. The box extends from the
25th percentile (x[25]) to the 75th percentile (x[75]), the so-called
interquartile range (2IQR). The lines emerging from the box are
called the whiskers and they extend to the upper and lower adjacent
values. The upper adjacent value is defined as the largest data point
less than or equal to x[75]+1.52IQR. The lower adjacent value is
defined as the smallest data point greater than or equal to x[25]
1.52IQR. Filled circles represent values more extreme than the
adjacent values (referred to as outliers)
Table 4 Influence of codon 129 polymorphism of the PRNP gene
in determining the age at onset







E200K gCJD 60.4 (10.8) 60.7 (8.6) 55.7 (9.0)
V210I gCJD 59.3 (9.7) 57.9 (9.8) –
Other gCJD 70.9 (7.5) 56.2 (14.2) 48.1 (12.6)
FFI 50.8 (13.4) 52.5 (10.0) –
GSS 54.0 (11.1)a 49.0 (12.1) 66.2 (17.9)
Insert gTSE 60.9 (14.0)a 56.2 (15.2) 62.7 (11.3)
Abbreviations: gTSE, genetic transmissible spongiform encepha-
lopathy; gCJD, genetic Creutzfeldt–Jakob disease; FFI, fatal
familial insomnia; GSS, Gerstmann–Sträussler–Scheinker disease;
Insert, gTSE patients with insert mutations.
a Two patients had missing data on age at onset.
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in particular in gCJD cases with point mutations, while
in other gTSE cases these laboratory examinations are
less sensitive. Our data confirm previous studies that
insertional mutations often present atypically with a
relatively protracted duration of illness (although less
protracted than a previous study which included larger
numbers of cases and with a unique type of PrP
immunoreactivity in the cerebellum (Kovacs et al. 2002;
Vital et al. 1999).
We also demonstrate that, except for some specific
mutations like D178N-129M, protease-resistant PrP
may be variable within the same brain in some gTSEs as
in sCJD (Puoti et al. 1999).
It is of great importance that a positive family
history of a human TSE is absent in a high proportion
of cases overall and with all the mutations. Although
this has been reported previously by this group and
others (EuroCJD group 2001; Goldman et al. 2004;
Mitrova and Belay 2002), this is the first study to
provide a detailed analysis of the frequency of a po-
sitive family history in a range of PRNP mutations.
Possible explanations include lack of knowledge of the
family history in the relatives of index cases, premature
death in antecedents prior to the development of a
TSE, and non-paternity. However, there must be some
doubt that the very high frequency of a negative family
history in this study can be explained by these mech-
anisms and there remains the possibility that a
minority of mutations arise de novo (Dagvadorj et al.
2003) or that the mutations are not fully penetrant
(Mitrova and Belay 2002).
As cases considered as sCJD often lack full-length
PRNP analysis, accurate diagnosis of gTSEs may de-
pend on more widespread genetic screening, particularly
as some mutations, e.g., E200K and V210I, are associ-
ated with a phenotype indistinguishable from sCJD. The
negative family history in a high proportion of cases
indicates that mutations may be identified unexpectedly
in cases thought to have sCJD or indeed some other
neurological disorder and this may have important
implications for other family members.
At present gTSEs are the only sub-group of human
TSEs in which the diagnosis can be supported by
genetic screening in life. There is the potential for
early diagnosis and the risk of developing a TSE can
be identified before the onset of disease in asymp-
tomatic carriers. This may be an important advantage
in the application of potential therapies as treatment
could be instituted before severe and irreversible
damage to the CNS occurs, or perhaps, as a means to
prevent iatrogenic transmission of CJD from at-risk
patients.
Fig. 2 Percentage of cases
showing positive 14-3-3 protein
in the CSF, typical EEG
pattern, and positive MRI brain
scan in different forms of
genetic TSE disease. The
number of patients with
available data is shown on top
of each column
Table 5 Type of the pathological PrP in the brain of genetic TSE cases
PrP type gCJDa FFIa GSSa Inserta
N171S D178N E196K E200K V203I R208H V210I E211Q D178N P102L
Type 1 – 2 VV 1 MM 17 MM 1 MM 1 MM 5 MM 1 NA – 2 MV 1 MV
1 MV 1 MV 1 MV
Type 2A 1 VV – – 1 MV 1 MV – – – – – 1 VV
1 VV
Type 1–2A – – – 2 MM – – – – – – 1 MV
Type 2B – – – – – – – – 1 MV – –
Abbreviations: gTSE, genetic transmissible spongiform encepha-
lopathy; gCJD, genetic Creutzfeldt–Jakob disease; FFI, fatal
familial insomnia; GSS, Gerstmann–Sträussler–Scheinker disease;
Insert, gTSE patients with insert mutations; MM, methionine
homozygous; VV, valine homozygous; MV, heterozygous patients;
NA, not available.
a Number of cases of codon 129 polymorphism.
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The occurrence of asymptomatic carriers of PRNP
mutations (Mitrova and Belay 2002) underlines the
importance of genetic testing in all suspect cases of hu-
man TSEs and, in positive cases, relatives may be offered
genetic testing, provided appropriate ethical protocols
are followed. Although there may be incomplete pene-
trance and an absence of presymptomatic neuropatho-
logical changes or accumulation of disease-associated
PrP (Sasaki et al. 2003), healthy carriers of PRNP
mutations are at greater risk of developing a TSE and
may be subject to restrictions, such as donating blood
and tissues (e.g., cornea, dura mater), because of the risk
of iatrogenic transmission.
It is not known why there is partial penetrance in
some mutations, or why there is marked variability in
clinical phenotype, including age at onset, both between
and within pedigrees. There is a need to analyse events
preceding the onset of clinical manifestation in carriers
of PRNP mutations as possible triggering factors. In
E200K, psychological stress (divorce, death of a close
relative, retirement, loss of a job), complicated surgery
with prolonged anaesthesia, serious accidents, or current
infectious disease have been frequently noted (Brandel
and Delasnerie-Laupretre 1997; Mitrova and Belay
2002).
In conclusion, the term gTSE, which includes gCJD,
FFI, and GSS, is more appropriate than familial TSE
for all patients with TSE-specific genetic marker,
regardless of the number of affected family members,
while familial TSE designates only genetic cases with
other (one or more) TSE-affected relative. The distri-
bution of gCJD is geographically heterogeneous. The
codon 129 polymorphism influences phenotype. In
gTSEs, PRNP analysis may allow early or pre-symp-
tomatic diagnosis and this may be important if specific
therapies become available. Further studies are required
to identify whether PRNP mutations are sufficient in
themselves to cause disease.
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Abstract
Background: The objective of this study was to describe the diagnostic panorama of human transmissible
spongiform encephalopathies across 11 countries.
Methods: From data collected for surveillance purposes, we describe annual proportions of deaths due to
different human transmissible spongiform encephalopathies in eleven EUROCJD-consortium countries over the
period 1993–2002, as well as variations in the use of diagnostic tests. Using logistic models we quantified
international differences and changes across time.
Results: In general, pre-mortem use of diagnostic investigations increased with time. International differences in
pathological confirmation of sporadic Creutzfeldt-Jakob disease, stable over time, were evident. Compared to
their counterparts, some countries displayed remarkable patterns, such as: 1) the high proportion, increasing with
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BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278time, of variant Creutzfeldt-Jakob disease in the United Kingdom, (OR 607.99 95%CI 84.72–4363.40), and France
(OR 18.35, 95%CI 2.20–152.83); 2) high, decreasing proportions of iatrogenic Creutzfeldt-Jakob disease in France,
(OR 5.81 95%CI 4.09–8.24), and the United Kingdom, (OR 1.54 95%CI 1.03–2.30); and, 3) high and stable ratios
of genetic forms in Slovakia (OR 21.82 95%CI 12.42–38.33) and Italy (OR 2.12 95%CI 1.69–2.68).
Conclusion: Considerable international variation in aetiological subtypes of human transmissible spongiform
encephalopathies was evident over the observation period. With the exception of variant Creutzfeldt-Jakob
disease and iatrogenic Creutzfeldt-Jakob disease in France and the United Kingdom, these differences persisted
across time.
Background
Human Transmissible Spongiform Encephalopathies
(HTSE) constitute a group of rare, fatal central nervous
system disorders [1]. A general characteristic of HTSE is
deposition of a pathological isoform (termed prion pro-
tein; PrPSc) of the normal cellular prion protein (PrPC).
Diverse aetiological factors and pathogenic mechanisms
underlie the development of HTSE. The sporadic form of
Creutzfeldt-Jakob disease (sCJD), which is of unknown
aetiology, represents the most common form of HTSE,
with an estimated yearly incidence of 1–1.5 per million
population. An inherited form, caused by mutations in
the gene encoding PrPC (PRNP) is known as familial or
genetic Creutzfeldt-Jakob disease (gCJD), or genetic HTSE
(gHTSE) when other recognized entities are included.
Acquired forms of HTSE, such as iatrogenic Creutzfeldt-
Jakob disease (iCJD) or variant Creutzfeldt-Jakob disease
(vCJD), are caused by exposure to infectious prions, be it
through contaminated medical products (iCJD) or uptake
of bovine spongiform encephalopathy (BSE) prions,
(vCJD) [2,4]. The period 1993–2002 witnessed an histor-
ically exceptional situation, inasmuch as eleven countries
(the EUROCJD consortium) conducted co-ordinated epi-
demiological HTSE surveillance, using harmonised meth-
ods against a rapidly changing medical HTSE background.
New entities, such as vCJD, were identified and reported
in a number of countries [5]. Diagnostic tests were devel-
oped and case definitions modified [6,7] and infrequent
forms of HTSE were documented [8]. The descriptive epi-
demiology of HTSE in these populations, plus time inter-
vals and details about HTSE survival, iCJD and gHTSE
have recently been reported [9-12].
Taking into account that individual countries are facing
country-specific risk factors, the need for a comparison of
national registries and temporal analysis of national sur-
veillance data is imperative, highlighted by recent research
indicating that the incidence of HTSE by aetiological sub-
type varies widely geographically [9,13,14]. The fact that
BSE exposure may result in sCJD-like phenotypes, as sug-
gested by experiments performed on rodents, further
underlines the need for in-depth temporal analysis of
HTSE [15,16]. We analysed variations in defined epidemi-
ological parameters in the EUROCJD-consortium HTSE
cohort over a ten-year period. Through this analysis we
have been able to describe variations in the annual
national panorama of investigations used to evaluate
patients and in aetiological HTSE subtypes over a defined
timeframe, both overall and by country.
Methods
Cases included in this study were those registered in the
national databases of constituent countries of the Euro-
pean Union's and Allied countries' prospective CJD sur-
veillance programme (EUROCJD). National registers
started collecting prospective data in 1979 in Slovakia,
1990 in the UK, 1992 in France, and 1993 in Germany,
Italy, The Netherlands and Australia. Spain followed in
1995, as did Austria and Switzerland in 1996, and Canada
in 1997. In 1993, a standardised protocol was introduced
for diagnosing cases for epidemiological surveillance pur-
poses. After the introduction of a diagnostic test based on
detection of 14.3.3 protein in cerebrospinal fluid (CSF) in
1997, this protocol was updated in 1999. Diagnostic cat-
egories were based on application of shared specific diag-
nostic criteria for HTSE [17,18] adapted from those
originally proposed by Masters and colleagues [19],
updating in 1998 for surveillance purposes diagnostic cri-
teria for sCJD [7,9,20]. The study included all patients
with a diagnosis of probable or definite sCJD, gHTSE,
iCJD or vCJD, who died in the period 1993–2002 and
were reported to their respective national surveillance cen-
tres. All information was centralised in Rotterdam.
The patients from each country' included in the study is
summarised in Table 1. The pooled dataset comprised
4441 patients: sCJD n = 3720 (2461 definite, 1269 prob-
able); gHTSE n = 455; iCJD n = 138; and vCJD n = 128.
Iatrogenic forms were due to dura mater grafts (n = 32),
growth hormone (n = 105) and corneal transplantation
(n = 1).
Whenever possible, all diagnostic investigations were
reviewed by a member of the surveillance system. Infor-
mation on electroencephalogram (EEG) records was
available in 3825 cases. Typical periodic sharp and slow
wave complexes (PSWCs) were deemed to be present
when periodic complexes had a bi- or triphasic morphol-Page 2 of 10
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nous, generalised or lateralised on the EEG and persist for
at least 10 seconds [21]. Cerebral magnetic resonance
imaging (MRI) data was available in 2013 individuals,
and was considered positive for sCJD when high signal
changes were present in striatum [22]. Analysis of results
according to specific pulse sequences used for MRI studies
(such as diffusion weighted imaging) was not undertaken.
Information on 14.3.3 protein in CSF was available in
2890 cases, with 14.3.3 Western blotting was performed
in single, national centres within each country with con-
siderable expertise in the assay [4,7]. Genetic analysis was
performed by sequencing the entire open reading frame of
PRNP and was available for 2967 patients.
While time trends of diagnostic patterns of a group of
entities may refer to a varied type of approaches, in this
paper we describe distributions by year of death and pro-
portions of aetiological HTSE type or diagnostic test used
in clinical workup. Changes across time in HTSE inci-
dence or mortality have been reported in prior papers
[9,18]. Therefore, differences between individual coun-
tries and changes across time were explored here by com-
bining national HTSE death ratios for different diagnostic
categories: 1) for each aetiological subtype of disorder; 2)
for sCJD, by pathological or non-diagnostic confirmation,
i.e., probable/definite ratios; and, 3) for different entities
by available specific diagnostic CSF or genotype informa-
tion. The statistical significance of the variation in distri-
butions was assessed using chi-square statistics. Logistic
regression was used to calculate odds ratios (OR) for each
country compared to the other 10, with adjustment for
age at death and year of death: 1) for specific aetiological
subtypes of disorder versus all remaining HTSE; and 2) for
definite versus probable sCJD. For the purposes of compa-
rability, the vCJD death ratios for the remaining 9 coun-
tries were taken as reference for France and the UK alike.
OR time trends were ascertained by introducing time as a
continuous independent variable in the models. In order
to judge the additional contributions made by EEG pat-
terns and presence of 14.3.3 protein in CSF to sCJD diag-
nosis, and by identification of mutations in PRNP to any
gHTSE diagnosis, we calculated the annual proportions of
positive findings in each of these auxiliary tests in cases
where the corresponding findings in EEG, 14.3.3 protein
test, or family history of HTSE were absence of PSWCS or
negative.
The information used in the paper is grouped and mortal-
ity grouped data for each country is publicly available at
the web at the CJD surveillance unit in Edinburgh. The
study underwent evaluation by the Medical Committee
on Ethics of the Rotterdam Academic Hospital, MEC
127.071/1993/71, and by the Carlos III Institute of
Health Committee on Bioethics, report number Pub-102/
06.
Results
Shown in Figure 1 are graphs depicting the population
under surveillance (Figure 1-a) and annual data in the
EUROCJD consortium countries for major HTSE catego-
ries in terms of number of clinical onsets (Figure 1-a),
number of deaths (Figure 1-b), average age at death (Fig-
ure 1-c), as well as the proportion of HTSE deaths for
which EEG, CSF 14.3.3, cerebral MRI and genotyping
results were available (Figure 1-d). The most remarkable
general feature was that at no period was the death or inci-
dence rate stable from year to year. For most entities, the
highest annual number of HTSE onsets occurred early in
the second half of the observation period (Figure 1-a). The
increase in onsets from 1993 to 1998 was mainly in evi-
dence for vCJD (0 to 18 cases), gHTSE (22 to 47 cases) and
Table 1: Number of cases studied by diagnostic entity and country
Sporadic CJD Variant CJD Iatrogenic 
CJD
Genetic TSE All categories
CJD GSS FFI Insert
Australia 189 - 4 14 4 3 1 215
Austria* 77 - - 9 - 3 1 90
Canada** 169 1 3 7 9 - - 189
France 766 6 82 68 5 6 5 938
Germany 827 - 5 31 8 17 12 900
Italy 544 - 3 94 8 10 3 662
Netherlands 136 - 3 1 - - 2 142
Slovakia 18 - - 41 - - - 59
Spain* 380 - 5 18 - 25 1 429
Switzerland 84 - - 1 - - - 85
UK 530 121 33 11 19 1 17 732
All countries 3720 128 138 295 53 65 42 4441
* Since 1996, including retrospective cases from 1993. ** Since 1998, including retrospective cases from 1994Page 3 of 10
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between onset and death was observable for both sCJD
and other entities at the end of the study period, a finding
consistent with selecting cases by death up to 2002, for
inclusion in a database. While a statistically significant
linear trend for increased average age at death was
observed for sCJD (0.30 95%CI 0.14–0.46 years per year),
and iCJD (1.15 95%CI 0.26–1.95 years per year), no such
trend was suggested for gHTSE or vCJD (Figure 1-c).
The use of ancillary tests, such as MRI, 14.3.3 or genetic
analysis, in diagnosis of HTSE (Figure 1-d) increased with
time up to 2002. Overall, the most frequently used inves-
tigation was the EEG, yet in recent years the use of the CSF
14.3.3 protein analysis increased significantly, attaining
levels comparable to EEG analyses in 2000. While rising
time trends were seen for 14.3.3 tests and MRI, stable val-
ues for PRNP genotyping and decreasing figures for EEG
examination were in evidence.
Annual distribution by HTSE type (Figure 2) changed sig-
nificantly, both overall (p < 0.001) and in the UK, p <
0.001, and France p = 0.009 (Pearson χ2). Furthermore,
country- specific patterns were observable, i.e., an increase
in vCJD in the UK and a decrease in iCJD in France. In the
comparative inter-country analysis focusing on specific
diagnostic groups, remarkable differences in magnitude
and linear time trends were found. Of interest were: 1) an
increase over time in vCJD in the UK (OR 607.99 95%CI
84.72–4363.40; time trend OR 1.21, 95%CI 1.11–1.31),
and France (OR 18.35, 95%CI 2.20–152.83; time trend
OR 1.64 95%CI 1.02–2.62), as against other countries; 2)
a decrease over time in iCJD in France, OR 5.81 95%CI
4.09–8.24; time trend OR 0.84, 95%CI 0.80–0.90), and in
the UK, (OR 1.54 95%CI 1.03–2.30, time trend OR 0.85
95%CI 0.79–0.90); and 3) a high proportion of gHTSE in
Slovakia, (OR 21.82 95%CI 12.42–38.33) and Italy, (OR
2.12 95%CI 1.69–2.68), with stable time trends in both
countries, (OR 0.99 95%CI 0.95–1.03).
Annual histopathological confirmation of sCJD (definite
cases) is depicted in Figure 3. There was considerable var-
iation between individual countries, with proportions of
definite sCJD varying from 100% in Slovakia to as low as
61% in France, 59% in Italy, 57% in Germany and 52% in
Spain. Noteworthy was the annual variation in diagnostic
confirmation of sCJD statistically significant, both overall,
p < 0.001, and for specific countries, such as France, p =
0.007, Germany, p < 0.001, Spain p = 0.002, UK p = 0.038
and Austria (Fisher's exact test, p = 0.019). When compar-
ing national, definite versus probable confirmation ratios,
statistically significant low values were found for Spain
(OR 0.50, 95%CI 0.41–0.62), Germany (OR 0.60
95%0.52–0.70), Italy (OR 0.68 95%CI 0.58–0.81), and
France (OR 0.75 95%CI 0.65–0.88), with no differences
in time trend being identified for the four countries (com-
parative time trend OR 1.00 95%CI 0.98–1.03).
The yearly distribution patterns of diagnostic tests -such as
14.3.3 protein detection in CSF, EEG and genetic analyses
in all HTSE- are shown for all countries in Figure 4. During
the study period, the proportions of definite and probable
sCJD deaths with available EEG results in which PSWCS
were identified were 58% and 73% respectively. The
annual variations proved statistically significant, p <
0.001 in both cases, suggesting a rising time trend in atyp-
ical EEG patterns in sCJD since 1997. The proportions of
definite and probable sCJD with 14.3.3 tests were 62%
and 74% respectively for the whole period; annual varia-
tion was not statistically significant, with 88% and 95% of
such tests proving positive. Genetic analyses were per-
formed on 64% of all HTSE. Mutations could be detected
in 8.5% of all HTSE (7.04% missense mutations, 1.04%
insert mutations). The annual proportion of methionine
homozygous cases in PRNP 129 codon for all genetically
examined HTSE patients did not vary significantly, p =
0.116.
The annual proportions of probable sCJD cases having
exclusively positive EEG or 14.3.3 test results, along with
the proportion of gHTSE identified by genetic analysis
only (without family history of prion diseases) are listed
in Table 2. The annual proportion of probable sCJD solely
having a positive EEG declined evenly with time, from
95% to 3% across the period. Up to 1998, few probable
sCJD cases solely had a positive 14.3.3 test (diagnostic cri-
teria changed in 1998), but in that year the annual
number rose sharply, after which it fell slightly to remain
at a mean proportion of 46%. The annual proportion of
gHTSE identified by mutation alone was fairly stable over
the study period, with a mean of 51%.
Discussion
In terms of case numbers, this study constitutes the larg-
est-scale observation of HTSE ever conducted. Prior
reports on this clinical population are sparse [10]. Taking
into account that neither mortality of HTSE nor popula-
tion denominators are considered in this study, the results
suggest that: 1) the panorama of HTSE, as seen from
deaths for all or part of the 1993–2002 period in 11 coun-
tries, varies within and between countries, sometimes
exhibiting characteristic features; 2) there is an expected,
overall rising time trend in annual deaths and proportions
of patients studied using ancillary tests other than EEG; 3)
characteristic national patterns, as seen from the magni-
tude of and time-trends for proportions of specific enti-
ties, were particularly relevant in the UK and France for
vCJD and iCJD, and in Slovakia and Italy for gHTSE; 4)
pathological confirmation of sCJD varied but interna-
tional differences persisted across time; and, 5) the addi-Page 4 of 10
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BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278tional contribution of ancillary tests to sCJD diagnosis
decreased to almost nil for EEG, increased to stable figures
for the 14.3.3 test, and was high and stable across time for
genetic assay insofar as gHTSE was concerned. The inter-
pretation of these results is complicated by several param-
eters, due to the fact that use of methods for diagnosing
HTSE, particularly CSF 14.3.3 test and MRI, improved sig-
nificantly over the course of the study period.
The eligibility of cases for this study based on vital status
after death proved most appropriate, since diagnostic cri-
teria for probable sCJD may require measurement of dis-
ease duration, <2 years, and quality of diagnosis is
frequently determined by post-mortem examination.
Diagnosis classification for probable cases is therefore nei-
ther conditional to a specific disease course nor provisory.
A rising time-trend in sCJD incidence or mortality has
been observed over the last decade in Austria, France, Ger-
many, Italy, Switzerland, the UK, and other countries
[9,23-25] and has mainly been attributed to progressive,
persistent, improvement in sCJD diagnostic ascertain-
ment [26, 27] or has gone unexplained [9]. This large
dataset makes the EUROCJD countries the most stable ref-
erence population for comparing HTSE incidence, e.g.,
that of sCJD in specific age-groups. Nonetheless, under-
counts due to poor reporting or case ascertainment before
1998, likely due to different awareness and clinical man-
agement of dementia prior to 14.3.3 CSF test, and incom-
plete case-finding after 2001 by observation at death,
suggest that the optimal time interval for incidence meas-
urements using this material should be carefully selected,
e.g., 2000–2001 for sCJD.
Variation across time for four major HTSE groupsFigure 1
Variation across time for four major HTSE groups in: a) annual number of cases by year of clinical onset, with study population 
shown in millions; b) annual number of cases by year of death; c) annual average age at death and; d) proportion of cases, all 








































































































































gHTSE iCJD vCJD sCJD 
b
Page 5 of 10
(page number not for citation purposes)
BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278With regard to changes across time, differences due to the
presence of vCJD in the UK and France are most remarka-
ble. Abrupt changes in 1997 and 1998 for sCJD suggest a
strong impact of the first vCJD report [4] on diagnostic
practices and the updating of diagnostic criteria. Yet, inter-
pretation of comparative linear time trends can some-
times prove problematic. For instance, changes in average
age at death might reflect improved ascertainment for
sCJD and an exposure-related cohort effect with increas-
ing duration of incubation period for iCJD.
Changes across time reported here may, among other
things, reflect clinical management and reporting, and
variations in pre- and post-mortem laboratory diagnostic
practices and diagnostic criteria updates. The increasing
use of MRI might explain rising trends for CJD since spe-
cific patterns of abnormality on diffusion-weighted and
fluid-attenuated inversion recovery images are highly sen-
sitive and specific for CJD [28]. In EUROCJD countries,
the use by clinicians of the 14.3.3 protein test in sCJD
diagnosis first became significant in 1997. Accordingly,
the 14.3.3 protein in CSF, identified for the not inconsid-
erable annual proportions of HTSE patients who died
from 1993 to 1996 (Figure 1, bottom right) -with test
results shown for definite and probable sCJD (Figure 4,
centre) and probable sCJD (Table 2)- should have been
determined post-mortem, in most cases on frozen CSF
stored for research purposes. This policy might have had:
a) positive effects, in terms of increasing the average
amount of information per registered HTSE case, some-
thing that is particularly interesting for definite sCJD cases
with date of death prior to 1998; and b) bias in research,
due to inclusion of 14.3.3-test results in the database for
probable sCJD being made conditional upon the presence
Annual distribution by type of HTSE in eleven countriesFigure 2
Annual distribution by type of HTSE in eleven countries. Different study intervals for the period, 1993–2002.
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Annual proportion of histopathologically-confirmed sporadic CJDFigure 3


















































































































































Table 2: Additional contribution of: positive results in EEG and CSF examination (14.3.3 protein test) to diagnosis of probable sporadic 
CJD; and identified PrP gene mutation to diagnosis of genetic HTSE.
Year of death Cases solely with positive EEG
Number and percentage of probable 
sporadic CJD cases
Cases solely with positive CSF 14.3.3 test
Number and percentage of probable 
sporadic CJD cases
Cases with mutation and negative or 
missing data on family history.
Number and percentage of genetic TSE 
cases
1993 52 (95) - 13 (48)
1994 60 (70) 7 (8) 16 (50)
1995 61 (68) 4 (4) 15 (45)
1996 62 (64) 13 (14) 23 (55)
1997 30 (30) 21 (21) 20 (53)
1998 32 (18) 65 (36) 26 (55)
1999 15 (9) 67 (38) 24 (49)
2000 11 (6) 79 (41) 23 (40)
2001 8 (5) 95 (58) 30 (44)
2002 4 (3) 69 (54) 40 (65)
BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278of PSWCs in EEG, a requisite for such diagnosis before
1998. The study of associations similar to those reported
[29, 30, 31] using this large database may benefit from
stratification by period of death or diagnostic criteria for
probable sCJD.
Identifying a time-related increase in sCJD incidence in
populations with valine in PRNP codon 129 which have
been considerably exposed to BSE has been a key goal of
EUROCJD-sponsored public health HTSE surveillance,
reinforced by results of recent laboratory research [15,16].
The frequent lack of PRNP codon 129 data for age-specific
national populations makes it impossible to calculate the
incidence figures required as denominators for such anal-
yses. Hence, a surrogate index is currently used, compar-
ing proportions of sCJD with a valine allele in the UK
versus those in other countries and their changes across
time [31]. Our study results for the general population
suggest that there have been no changes over time in this
proportion since 1996 (Figure 4, bottom right). Due to
frequent atypical clinical features [32], probable sCJD is
particularly liable to being misdiagnosed in patients with
valine in codon 129, and as a result expected improve-
ment in sCJD diagnosis internationally is not reflected as
a trend. Monitoring international changes across time in
clinical-geno-phenotype with this extensive and unique
Annual distribution of positive results in ancillary testsFigure 4
Annual distribution of positive results in EEG and 14.3.3 protein tests in sCJD, and for all HTSE, PRNP mutations identified (in 
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BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278material might require stratification by variables poten-
tially associated with misdiagnosis and codon 129 struc-
ture, e.g., EEG pattern.
Conclusion
This study reveals remarkable international differences in
the HTSE panorama that change with time, as seen from
deaths in eleven countries in the period 1993–2002.
Knowledge of possible biases in the study cohort is vital
for future applications of this dataset, both in clinical/epi-
demiological research and in public health surveillance.
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Novel prion protein gene mutation
presenting with subacute
PSP-like syndrome
D.B. Rowe, PhD; V. Lewis, BSc(Hons); M. Needham, MB, BS(Hons); M. Rodriguez, MB, BS;
A. Boyd, Dip Gen Coun; C. McLean, MD; H. Roberts, MB, BS; C.L. Masters, MD; and S.J. Collins, MD
Abstract—A 62-year-old Indonesian woman presenting with a progressive supranuclear palsy–like syndrome was con-
firmed post mortem as dying from a spongiform encephalopathy. Despite an illness duration of only 4 months, brain MRI,
EEG, and CSF analysis for 14-3-3 proteins all failed to disclose changes typical of Creutzfeldt–Jakob disease. Neuropatho-
logic examination revealed multicentric, prion protein–positive, amyloid plaques as typically seen in Gerstmann–
Sträussler–Scheinker syndrome. Prion protein gene analysis revealed a previously unreported A133V mutation.
NEUROLOGY 2007;68:868–870
Genetic Creutzfeldt–Jakob disease (CJD) and other
phenotypes are linked to a variety of mutations
within the prion protein (PrP) gene (PRNP).1 Re-
gardless of etiology, the clinical features found in
prion disease are diverse, and whereas dementia,
myoclonus, and cerebellar ataxia are particularly
common in CJD, additional findings may include cor-
tical blindness, extrapyramidal dysfunction, insom-
nia, and psychiatric disturbances.2 Rarely, sporadic
CJD may even manifest a clinical profile, especially
the presence of supranuclear vertical gaze abnormal-
ities, prompting misdiagnosis as progressive su-
pranuclear palsy (PSP).3 To date, supranuclear gaze
palsy has only been clearly described in two pedi-
grees with familial prion disease.4,5
We report a patient who presented with a sub-
acute PSP-like syndrome, confirmed to be a spongi-
form encephalopathy at post mortem, who, despite a
negative family history for CJD or other neurodegen-
erative disorder, revealed a hitherto unreported
A133V mutation.
Methods. DNA analysis. Genomic DNA was extracted from a
frozen (stored at 80 °C) muscle biopsy specimen. Open reading
frame (ORF) sequence analysis and subsequent bacterial cloning
were performed as described previously.6 To assist the selection of
clones for DNA sequencing, plasmid DNA was subjected to restric-
tion fragment length polymorphism analysis, using the restriction
enzyme BspH1, which cuts at a site just upstream of the ampicil-
lin resistance gene on the vector (i.e., linearizing both wild-type
and mutant plasmids) and additionally at the sequence introduced
into PRNP with the A133V mutation. Three representative wild-
type clones and five mutant clones were sequenced.
Neuropathology. The brain and spinal cord were examined
after 17 weeks’ fixation in 10% formalin. Sections taken from a
number of cerebral cortical sites, as well as hippocampus, stri-
atum, lentiform nucleus, thalamus, brain stem, cerebellum, spi-
nal cord, and dorsal root ganglia were stained with hematoxylin
and eosin (H-E) and examined. Tissues were not pretreated
with formic acid. Sections of cerebellar vermis and thalamus
were immunostained for PrP using the monoclonal 3F4 anti-
body (Signet), whereas tau immunostaining using a polyclonal
rabbit anti-human antibody (DakoCytomation) and Congo red
staining were performed on frontal, parietal, and occipital cor-
tices, as well as the striatum, thalamus, and cerebellar
hemisphere.
Fresh-frozen brain was not available to allow western blot
analysis of PrP.
Results. Case report. A 62-year-old woman was ad-
mitted to hospital because of 1 month of difficulties with
upper limb coordination and an unsteady gait with falls.
Originally from Indonesia, the patient had resided in
Australia for 16 years. There was a history of diet-
controlled type 2 diabetes mellitus, hypercholesterol-
emia, and essential hypertension but no family history
of dementia or other neurologic disorder. Neurologic ex-
amination shortly after admission was remarkable for a
severe abnormality of conjugate eye movements, with no
vertical saccades to command and slow, stepwise hori-
zontal saccades. Pursuit eye movements to target were
broken and incomplete. Oculocephalic reflex eye move-
ments were normal, consistent with a predominantly
supranuclear deficit of ocular movements. Cranial nerve
examination was otherwise normal. Tone was normal in
the limbs but increased at the neck and trunk. There
was marked postural instability, with gait possible only
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with the support of two people. Repeated MRI of the
brain, including diffusion-weighted imaging, fluid-
attenuated inversion recovery sequences, and gadolin-
ium enhancement, demonstrated only nonspecific
periventricular white matter changes thought to be on
an ischemic basis (figure 1). EEG revealed a nonspecific
excess of slower frequencies but no periodic activity, and
aside from a mild elevation of total protein, CSF was
unremarkable, including negative for 14-3-3 proteins.
The patient progressively deteriorated over the next 4
weeks, sleeping up to 18 hours per day. Disorientation,
dysarthria, dysphagia, and language difficulties became
evident, but myoclonus was never observed. Truncal and
nuchal rigidity became more marked. Eventually, saccadic
and pursuit eye movements were lost, and oculocephalic
reflexes were suppressed. There was no clinical response to
trials of IV pulse methylprednisolone (1 g daily for 3 days)
or levodopa/carbidopa (2  100/25-mg tablets three times
daily). The patient died 4 months after presentation; a
confident clinical diagnosis was not achieved premortem.
Neuropathology. The brain weighed 1,319 g prior to
fixation. No macroscopic abnormalities were identified ex-
ternally or following sectioning. Microscopic examination
demonstrated widespread, multifocal, spongiform encepha-
lopathy with neuropil vacuolation, neuronal loss, gliosis,
and increased numbers of activated microglia in the cere-
bral cortex, basal ganglia, thalamus, brainstem, and cere-
bellar cortex. Findings were most severe in the thalamus
and the brainstem tegmentum, with only mild focal
changes in the head of the caudate nucleus and the cere-
bral cortex, the latter most marked in the deeper layers of
the occipital cortex. Multifocal spongiform change, micro-
glial proliferation, patchy loss of Purkinje cells and inter-
nal granular neurons with associated gliosis, and scattered
small amyloid plaques, without peripheral vacuoles, were
noted in the molecular layer of the cerebellar cortex (figure
2A); morphologic features of granular cell lysis and necro-
sis were not evident. Amyloid plaques were not identified
in the cerebellar internal granular layer or anywhere else
in the brain. There was no evidence of encephalitis.
3F4 immunostaining demonstrated PrP-positive
plaques confined to the cerebellar molecular layer (figure
2B). Most of the deposits formed cluster or multicentric
plaques. More plaques were identified with immunostain-
ing than with H-E and Congo red. In the thalamus, there
was a predominantly synaptic pattern of PrP immunoreac-
tivity with some larger patches of immunoreactivity and
occasional perineuronal granular staining but no plaque-
like or definite perivacuolar staining. Tau immunostaining
was negative in all brain regions.
Molecular genetic studies. DNA analysis revealed a
C-to-T transition at the second nucleotide position of codon
133 of the PRNP ORF, resulting in a predicted amino acid
change from alanine to valine. The patient was methionine
homozygous at codon 129 and also carried the E219K poly-
morphism.7 Sequencing of representative wild-type and
mutant clones determined that the codon 133V mutation
was in cis with the uncommon 219K allele.7
Discussion. In addition to expanding the spec-
trum of PRNP mutations associated with spongiform
encephalopathies, our proband extends the range of
specific mutations associated with supranuclear gaze
palsy. Although nonspecific limitations of upward
gaze have been described in Gerstmann–Sträussler–
Scheinker syndrome,8 to the best of our knowledge,
this is only the third PRNP mutation to be clearly
associated with a supranuclear gaze palsy as a
salient or presenting clinical feature4,5,8 and reaf-
firms the phenotypic heterogeneity that may be
encountered in genetic prion disease. In contrast to
affected family members harboring the S198F mu-
tation, the vertical restriction of gaze in our pa-
tient was not just limited to supraduction and
evident only in the advanced stages of long-
duration illnesses5 but was more akin to that ob-
served in the pedigree with the E200K mutation.
Despite general similarities in the clinical find-
ings, the rapidity of the patient’s neurologic de-
cline to death over 4 months made a diagnosis of
PSP untenable,9 and notwithstanding awareness
that vertical supranuclear gaze palsy can occur
uncommonly in sporadic CJD,8 the absence of char-
acteristic findings on EEG, CSF analysis for 14-3-3
proteins, and brain MRI militated against this di-
agnosis. The lack of typical clinical features such
as myoclonus and the absence of periodic sharp
waves on EEG have also been observed in the pre-
vious family with genetic CJD due to the E200K
Figure 1. Representative fluid-attenuated inversion recov-
ery sequence MRI brain scans, showing midline sagittal
(A) and midhemisphere (B) coronal views. Only minor ar-
eas of increased signal are seen in the periventricular re-
gions thought to be on the basis of coincidental,
nonspecific chronic white matter ischemia.
Figure 2. Photomicrographs of the cerebellar cortex show-
ing evidence of minor microvacuolation and occasional
eosinophilic, multicentric amyloid plaques confined to the
molecular layer (A), with substantial numbers of prion
protein (PrP)–positive plaques, also restricted to the molec-
ular layer, confirmed on immunohistochemistry (B). He-
matoxylin and eosin (A) and immunohistochemistry using
the 3F4 monoclonal antibody specific for PrP (B); 40.
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mutation manifesting supranuclear gaze palsy.10
This stands in clear contrast to most E200K pa-
tients and other PRNP mutations associated with
genetic CJD, wherein routine investigations usu-
ally show typical findings as seen in sporadic CJD.
Although the short duration of the patient’s ill-
ness was more in keeping with CJD, the combined
clinical and neuropathologic findings did not clearly
conform (especially for a codon 129 methionine ho-
mozygote) to a specific subtype within a recently re-
ported classification scheme for sporadic CJD.2 The
pathologic changes observed in our patient, particu-
larly multicentric PrP-positive plaques in the cere-
bellar molecular layer, are perhaps more in keeping
with those observed in patients with Gerstmann–
Sträussler–Scheinker syndrome, although typically
in the latter disease subgroup, the PrP-positive amy-
loid plaques are more widespread, additionally ob-
served in the cerebrum and diencephalon. We
conjecture that our patient’s phenotypic uniqueness
relates specifically to the novel A133V mutation it-
self, but the possible disease-modifying influences of
polymorphisms such as E219K should not be dis-
missed, as suggested for patients harboring the
P102L mutation.7
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Spatio-temporal clustering of sporadic Creutzfeldt-Jakob disease (sCJD) has been recognized and investigated previously in
various global settings including Australia. Generally, despite often extensive investigation, explanations such as point source
outbreaks and plausible case-to-case transmission links have not been identified to explain the apparently higher case rates than
expected. In the context of national surveillance during the period 1993–2006, an increased number of cases of sCJD were
recognized in a circumscribed coastal region of eastern Australia. To assess the significance of this apparent clustering, the
Spatial Scan Statistic was used to examine for geographic excess of CJD mortality at spatial and temporal combined, spatial only
and temporal only levels. A significant spatial cluster was confirmed, encompassing three contiguous statistical local areas
within the state of New South Wales (NSW). Detailed epidemiological analysis did not reveal a plausible cross-over or point
source transmission event. Further evaluation prompted the conclusion that vigilant and motivated managing clinicians in this
geographically circumscribed area of NSW evinced a sustained higher level of clinical awareness for the broad phenotypic
spectrum of CJD with reliable referral of suspect cases for further investigation. In addition, these physicians established and
maintained a well-coordinated and active approach to suspect CJD autopsy. This combination of factors translated into a higher
intensity of surveillance at approximately twice the rate per population observed in the entire state, culminating in twice the
incidence of sCJD at around 2.28 cases/million population/year. The hypothesis that intensity of surveillance for rare disorders
can be objectively measured and that this can positively correlate with disease incidence deserves further exploration. It may
prove to be an important insight into the varying incidence rates over periods of time within individual nations and between
different countries.
Keywords: CJD; cluster analysis; epidemiology; surveillance; incidence
Abbreviations: CJD = Creutzfeldt-Jakob disease; NSW = New South Wales; PRNP = prion protein gene; RRMH = Mantel–Haenszel
rate ratio estimate; sCJD = sporadic CJD; SLA = statistical local area
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Introduction
In reported large national surveillance studies, the majority of
Creutzfeldt-Jakob disease (CJD) cases are sporadic, occurring with-
out apparent aetiology, while the remaining proportions have a
genetic or iatrogenic aetiology (Masters et al., 1979; Brown et al.,
1987; Ladogana et al., 2005). Genetic CJD is linked to various
mutations in the prion protein gene (PRNP) (Kovacs et al.,
2005b), while iatrogenic CJD has been recognized in association
with neurosurgery, corneal transplants, dura mater grafts and
human-derived pituitary hormone treatments (Brown et al.,
2006). The origin of sporadic CJD (sCJD) remains enigmatic.
Hypotheses include spontaneous conversion of the normal isoform
of the prion protein to a disease-related conformer (PrPres) with
progressive accumulation in the CNS thereafter, somatic PRNP
mutations within brain neurons predisposing to misfolding to
PrPres, and covert transmission events during the provision of
health care (Collins et al., 1999; Lewis et al., 2002; Ward et al.,
2002, 2008). Unidentified environmental factors and susceptibil-
ity to an environmental trigger may also be involved in disease
aetiology. To date, there are very few proven risk factors for
sCJD; the covariates of codon 129 methionine homozygosity,
increasing age (Ladogana et al., 2005) and surgical history
(Collins et al., 1999; Ward et al., 2002, 2008; Mahillo-
Fernandez et al., 2008) have been shown to be associated with
increased risk of disease in sporadic cases.
Long-term national surveillance units report differing annual
sCJD incidence rates, ranging from 0.44 to 1.61 per million popu-
lation (Ladogana et al., 2005), but occasionally much higher rates
can occur for unclear reasons, even if only for short periods of
time (Glatzel et al., 2002). The explanation for these differences
and fluctuations in national incidence rates is uncertain although
variation in case ascertainment is one potentially contributing
factor. Spatio-temporal clustering of CJD has also been recognized
and investigated previously in various global settings. These
unusual geographical and temporal patterns of disease also tend
to create public health interest and explanations are frequently
sought. Attention is often directed towards potential environ-
mental factors, and in relation to this rare, neurodegenerative
disorder, this includes potential transmission events through
medical interventions. However, intensive investigation of spatio-
temporal clustering can lead to unexpected yet important insights,
such as the delineation of the genetic basis, through inheritance
of PRNP mutations, as the explanation for the high rates of dis-
ease in Slovakia (Mayer et al., 1977; Goldfarb et al., 1990; Kovacs
et al., 2005b), Chile (Galvez et al., 1980), Israel (Kahana et al.,
1974) and Italy (D’Alessandro et al., 1998). In contrast, a number
of smaller sCJD clusters have been described in other countries,
including Australia (Collins et al., 2002a), England (Matthews,
1975; Will and Matthews, 1982), Japan (Arakawa et al., 1991;
Doi et al., 2008), France (D’Aignaux et al., 2002) and the USA
(Farmer et al., 1978), and despite extensive evaluation, plausible
explanations for the apparently higher case rates than expected
have not been delineated.
In this study, formal geostatistical analysis confirmed an
unusually high sCJD incidence rate in a geographically restricted
coastal region of the Australian state of New South Wales (NSW).
This area had been suspected to harbour an excessive number of
sCJD from 1997 through local observation (Cohn et al., 2000),
and routine national surveillance activities. Detailed epidemiologi-
cal assessment did not disclose any likely horizontal transmission
events but instead uncovered a heightened intensity of surveil-
lance. This more intense level of surveillance was reflected by
the significantly higher rates of referrals of suspect sCJD cases
for evaluation and diagnostic testing of CSF for 14-3-3 protein
detection by the Australian National CJD Registry, as well as
higher neuropathological examination rates in suspect sCJD
patients. We postulate this sustained, enhanced level of surveil-
lance was due to the vigilance and motivation of local neurolo-
gists, culminating in higher CJD, and particularly sCJD, detection
and consequently incidence rates. Overall, we believe this pro-
tracted period of more intense surveillance may offer a more
accurate sCJD incidence rate in the Australian population rather




The data collected, and the analyses undertaken in this study, were
subsumed under national surveillance activities of the Registry. The
aims and methods of the Registry have been reported in detail
previously, as has the study population in part (Collins et al.,
2002b). In brief, ascertainment methods include: review of morbidity
separation coding data from all university-affiliated tertiary referral
hospitals in Australia, as well as the centralized data bases of
State and Territory health departments; regular national death certifi-
cate searches; and semi-annual mail-out questionnaires to all neurol-
ogists and neuropathologists within Australia. In addition, the Registry
offers a national diagnostic service, predominantly for detection of
CSF 14-3-3 proteins, but also prion protein genotyping and specialized
ancillary neuropathology techniques. CSF testing for 14-3-3 proteins
has been available from September 1997, and has provided the
overwhelming majority of annual notifications of suspected CJD
since 1998. The Registry has a non-systematic approach to prion
protein genotyping and this may lead to under-ascertainment of
genetic CJD cases. Complementing the comprehensive prospective
monitoring of human transmissible spongiform encephalopathies
(TSEs) by the Registry since inception in 1993, all Australian cases
have been retrospectively sought to January 1, 1970. The classification
of definite and probable CJD cases by the Registry is in accordance
with internationally recognized WHO diagnostic criteria (WHO, 2003).
Through the combination of ascertainment measures, it was believed
that the overwhelming majority of all human sporadic, genetic and
iatrogenic cases of TSE within Australia were detected, particularly
since 1993.
During the prospective surveillance period, restricted geographical
regions of apparently higher sCJD incidence rates have been recog-
nized, one of which has already been reported in detail (Collins et al.,
2002a). The present cluster analysis was prompted by an ongoing
seemingly disproportionate spatio-temporal grouping of sCJD in a cir-
cumscribed coastal region of NSW, Australia. As health care delivery
in Australia is devolved to the State and Territory level with variations
between these jurisdictions, the study was restricted to all suspect
sCJD cases occurring in NSW during the period 1993–2006, as well
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as all definite and probable sCJD cases whose death occurred in NSW
during the same period. For the purposes of this study, ‘suspect CJD’
is defined as any person referred to the Registry for evaluation or on
whom a CSF sample was received for 14-3-3 protein analysis. To be
included, referral to the Registry of both suspect and confirmed CJD
cases must have been made during the 1993–2006 epoch. This time-
frame aligns with prospective ascertainment by the Registry and con-
fidence in the surveillance of the majority of Australian CJD cases.
Suspect cases that were referred or retrospectively ascertained within
the designated period but died prior to or after 1993–2006, were
excluded. Confirmed and suspect CJD cases must have lived within
NSW with a known residential address for at least 1 year before
death. This temporal criterion of one year was based on the shortest
known incubation time between exposure to contaminated instru-
ments or therapeutics and the onset of reported iatrogenic CJD
(Brown et al., 2006). One definite CJD case was excluded from ana-
lysis on this basis.
Rates of suspect CJD referrals, and their neuropathologic examina-
tions and CSF 14-3-3 protein testing, were determined for NSW and
the area of significant geographical clustering. The rate of neuropatho-
logical examination for the NSW suspect CJD group was calculated
on the basis of either a brain biopsy or post-mortem examination. For
the assessment of geographical referral patterns of CSF for 14-3-3
protein analysis in NSW, all NSW-laboratory originating referrals
from the commencement of the Registry’s diagnostic testing in
September 1997 to December 31, 2006 were included, regardless of
test outcome. Geographical groupings of the referrals were based
on residential address at the time of referral.
Age adjustment for rates of suspect CJD and CSF test referrals was
based on notification age, except when notification occurred after
death and death age was utilized. One suspect CJD case with an
unknown birth date was not included in adjustment calculations.
For neuropathologic examination rates in suspect CJD referrals, adjust-
ment was based on age at death or age at notification, when death
was not known to have occurred.
Estimated resident population by age group for NSW and statistical
local areas (SLAs) for the period 1993–2006 was obtained from
the Australian Bureau of Statistics (Australian Bureau of Statistics,
1994–1995, 1996–2006). For this period, the mean estimated resident
population of NSW is 6 437 459 and from 2001, NSW consisted
of 199 SLAs. The standardized mortality ratio was calculated for
NSW and the specified SLAs based on all TSE deaths and separately,
sporadic only CJD deaths occurring between 1993 and 2006 and
with a NSW residential address at time of death. The single case
that was excluded from the cluster analysis due to residential reloca-
tion to NSW less than 1 year before death was included in the CJD
mortality rates calculation. The rationale for this inclusion is that the
case is still attributed to NSW as a sCJD death and would have
been clinically assessed and treated in the region with the possibility
of posing a transmission risk.
As described previously (Collins et al., 2006), EEGs were considered
typical for sCJD when displaying periodic sharp wave complexes. CSF
14-3-3 protein detection methods have been reported previously
(Collins et al., 2000; Zerr et al., 2000). MRI brain changes considered
characteristic of sCJD included increased T2-weighted signal in the
basal ganglia, thalamus and/or cerebral cortical regions, with greatest
sensitivity achieved when using diffusion weighted imaging (DWI)
and/or fluid attenuated inversion recovery (FLAIR) pulse sequences
(Meissner et al., 2004; Shiga et al., 2004; Tschampa et al., 2005).
A review of employment, residential, surgical, dental, and ophthal-
mic procedure histories (based on medical records and a detailed ques-
tionnaire completed by relatives) was undertaken on all sCJD patients
within the specified cluster SLAs, as part of routine case investigation.
A questionnaire had not been completed for two cases. Data was
compared for any linkage between cases.
Statistical analysis
Analysis was conducted at two levels: first, an image plot of the NSW
CJD cases was created as a smooth bivariate function of the geo-
graphical data (longitude and latitude); second, statistical evidence of
disease clustering was sought using a spatial, temporal and space–time
scan statistic based on a Poisson model, using SaTScan software
(Kulldorff, 2006). Input data on the NSW cases included geographical
location, age group and sex while population data for the estimated
populations at risk in NSW and the SLAs 1993–2006 was obtained
from the Australia Bureau of Statistics (Australian Bureau of Statistics,
1994–1995, 1996–2006). Place of residence at death was utilized
as residence history and stratified by geographical location, age
groups (565, 65–74, 75+) and gender. Geographical data coordinates
of longitude and latitude for residential suburbs were obtained from
the Australian Geoscience website (http://www.ga.gov.au/map/
names/). Suburbs were then grouped according to SLA for analysis.
Analyses were performed for the entire 1993–2006 epoch and then
repeated for the 1993–1996 and 1997–2006 periods to allow compar-
isons to be made based on the premise that suspicions of a cluster
(from 1997) had prompted enhanced surveillance thereafter.
As an initial step, we used geostatistical type models to construct
an image plot over the entire NSW state by mapping the mean of a
response of interest, y, based on data
ðCJDi, longitudei, latitudeiÞ, 1  i  n
where CJDi corresponds to sCJD cases in a particular region (image
plot not shown). We applied the methodology (Kulldorff, 2002) by
controlling for confounding effects of the other covariates such as
age, which is known to be associated with higher CJD incidence
rates regardless of other environmental exposures, and gender.
In recent years, Kulldorff’s scan statistic has become the most
widely used test for analysis of clustering, both because of its efficacy
in detecting single ‘hot spots’ as well as the availability of the SaTScan
software (Kulldorff, 2006) for implementing the test. The basic idea
of the scan statistic is to allow circular windows of various sizes
to range across the entire NSW state, centring on a large number of
different locations. At each location, the rate of disease inside the
window is compared to that outside the window. For an analysis
of a rare disease in a case-only setting, such as CJD, we chose the
Poisson probability model. A ‘hot spot’ is characterized by a higher
localized rate of disease. For a given zone (circular window), the
methodology calculates the probability of a data point being a case
inside and outside the circle under evaluation. For each circle, a like-
lihood ratio is computed for the alternative hypothesis that there
is an increased risk of disease inside the circle against the null hypoth-
esis that the circle contains the same risk as the risk outside (Kulldorff,
2006). A ‘cluster’, in this context, is said to be detected within a
defined geographical area during a specific time-frame if the area
has a disproportionate excess in CJD mortality, when compared to
the neighboring areas under study. By meeting the statistical assump-
tions of a set of statistical models, the unusual rise or reduction
of mortality in a specific spatial and temporal window (with adjust-
ments of age and gender) can be characterized by statistical signifi-
cance. In this analysis, three options were tested; purely spatial, purely
temporal and a combined spatial and temporal dimension. As a sec-
ondary analysis, any potential clusters were assessed for differences
in gender proportions or age distribution using Fisher’s exact test.
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Statistical analysis of the proportions and rates of referrals (suspect
sCJD cases, CSF 14-3-3 protein analysis, and neuropathological exam-
ination) between the entire NSW study population and the specified
SLAs, was performed using STATA (Intercooled Stata 7, Stata
Corporation, College Station, TX). In order to adjust for potential con-
founding by age, rate ratios were adjusted using the Mantel–Haenszel
estimate (RRMH) and test for heterogeneity.
Results
For the period 1993–2006, there were 102 eligible definite and
probable sCJD patients in NSW, drawn from 51 mutually exclusive
geographical SLAs. SaTScan analyses performed on these 102
cases tested for spatial, spatial-temporal and temporal only clus-
tering. Only one spatial cluster (designated ‘Cluster 1’), comprising
three contiguous geographical SLAs and 14 sCJD cases was found
to have a significantly greater than expected number of cases
(Table 1) (P = 0.012). Cluster 1 corresponded exactly to the geo-
graphical region previously recognized to have an apparently
increased rate of sCJD during the course of routine national sur-
veillance, which prompted the more formal cluster evaluation.
Analyses for potential temporal clustering showed the most not-
able finding to be a non-significant grouping of cases during
the 1997–2001 period (Table 1). Similarly, when combining the
analysis to account for both temporal and spatial clustering,
sCJD case numbers were in excess by five in Cluster 1 during
the 1997–2001 period; however, this was again not significant.
The residential history of the 14 cases indicated that all had
resided in the Cluster 1 area for two or more years (range, 2–43
years) and had moved to the area between the ages of 15–85
years. Four cases were long-term residents, having lived in the
region for 25 or more years, while the remaining cases were
either shorter-term residents (n = 5, 2–8 years) or medium-term
(n = 5, 15–19 years). Ten cases moved to the area after the age
of 55 and resided for an average of 11 years (range, 2–25 years).
Selected clinical features and investigation findings of the
Cluster 1 cases are presented in Tables 2 and 3. The majority
displayed rapidly progressive dementia (14/14) and myoclonus
(12/14), and of those tested the EEG was typical in 71% and
CSF positive for 14-3-3 proteins in 100%. There was a low rate
of brain MRI scans reported as typical for sCJD (Table 3).
However, of the 10 cases that were investigated by MRI, the
type of pulse sequences were unknown for four cases but the
initial radiologist reports described two patients with non-specific
abnormalities only and two with normal findings. For the remain-
ing six cases undergoing MRI, DWI and/or FLAIR sequences
were performed and the images for four cases were available
for independent review by two neurologists of the Registry. At
review, MRIs were considered to have changes characteristic
of sCJD in three cases, while the fourth was considered normal.
The remaining fifth and sixth cases did not have images available
for review but were officially reported as displaying features that
were non-characteristic for CJD. Codon 129 genotype and/or
prion protein glycotype was available for eight Cluster 1 cases
with a mixture of subtypes identified (Table 3). Only 3 of the
14 cases had undergone PRNP genetic testing with no mutations
found. In one case there was a family history of non-specific
dementia in a first degree relative (parent) and in another case,
non-specific psychiatric illness in a sibling. For the single case
with a family history of non-specific psychiatric illness, ethnicity
was linked to a European country with increased genetic human
prion disease incidence (Kovacs and Majtenyi, 2005; Kovacs et al.,
2005a) but in the absence of PRNP genetic analysis the case
is classified as sCJD.
A comparison of the gender and age distributions of sCJD
cases in Cluster 1 and the remainder of NSW (outside Cluster 1)
showed a similar gender ratio but marked age differences
(Table 2). In Australia, NSW and outside Cluster 1, the death
age for the majority of cases was below 75 years (80%, 77%
and 82%, respectively) (Table 2). Within the Cluster 1 group,
however, 50% of the cases were 75 years or older, with the
difference in the age distributions inside and outside Cluster 1
significant (P = 0.0325). Given this significantly older age of the
sCJD cases in Cluster 1, and the recognition that this disease
is age-related, an assessment for age biases in the Cluster 1 gen-
eral population was undertaken. Between 1993 and 2006,
the population in Cluster 1 was older compared to outside
Table 1 Summary of SaTScan cluster analyses
Cluster analysis type Unadjusted Adjusteda






1993–2006 Cluster 1 14/4.46 0.012 14/5.01 0.032
1997–2006 Cluster 1 13/4.23 0.020 13/4.65 0.059
Temporal only
1993–2006 1997–2001 47/41.19 0.142 47/41.15 0.144
1997–2006 1997–2001 47/42.04 0.325 47/42 0.338
Spatial Temporal
1993–2006 1997–2001 (Cluster 1) 8/2.39 0.10 8/2.64 0.156
1997–2006 1997–2001 (Cluster 1) 8/2.52 0.242 8/2.72 0.832
a Age (565, 65–74, 75+) and gender.
b Analysis was performed on the 1993–1996 period for comparison to the 1997–2006 period. No significant clusters were identified for this
epoch most likely due to the small sample size, n = 17, distributed into 15 SLAs.
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Cluster 1, particularly in the 565 years age group (P50.00001).
Nevertheless, even after adjustment for gender and age by strati-
fying definite and probable sCJD cases into 565 years, 65–74
years and 575 year groups, spatial SaTScan analysis still
showed a significant excess of cases in Cluster 1 (P = 0.032)
(Table 1).
To further explore the significance of the increased number
of cases in the Cluster 1 area, a review of all of definite and
probable CJD cases (sporadic, familial and iatrogenic) that died
in NSW between 1993 and 2006, regardless of their previous
residential history was performed. Based on the total NSW and
Cluster 1 cohorts, CJD mortality rates were still significantly higher
in Cluster 1 compared with NSW [standardized mortality ratio
(SMR) = 1.68, 95% CI = 1.04! 2.70] (Table 4). This excess
was also observed for sporadic CJD deaths (SMR = 1.68, 95%
CI = 1.01!2.80).
Acknowledging the significant excess of sCJD in Cluster 1, we
investigated potential explanations starting with possible case-
to-case transmissions or point-source contamination events. An
assessment of surgical (including ophthalmological) and other
invasive medical procedures undertaken on the Cluster 1 cohort
identified numerous interventions from 1938 to 2006 for all cases
except one, where no surgical history was known. Only two pos-
sible cross-over events were recognized, although it is considered
quite unlikely that any transmission would have occurred. The first
episode relates to a neurosurgical procedure and a gastroscopy
performed 4 days apart on two separate patients in the same
institution. The second episode relates to two cases that were
admitted to the same hospital within a 10-year window for
minor pelvic and general surgical procedures; however specific
procedure dates were unavailable to provide a meaningful insight
into the possibility of a transmission event. There were a further
Table 2 Age and gender distributions of sCJD in Cluster 1 compared with NSW and Australia
1993–2006 Spatial - only cluster (1993–2006)
Australia NSW Inside Cluster Outside Cluster P-value
N 300 102 (100%) 14 (14%) 88 (86%)
Gender (% female) 165 (55%) 63 (62%) 9 (64%) 53 (60%) 0.810
Age (years)
565 (%) 36 33 21 35 0.0325
65–74 (%) 43 44 29 47
575 (%) 20 23 50 18
Mean age at death (years) (SD) 66.5 9.9 67.2 9.8 71.8 9.9 66.5 9.6
Median age at death (years) (IQR) 67 (60–73) 67 (62–73) 73 (65–79) 67 (59.5–72)
Mean duration (months) (SD) 6.2 7.0 5.56.0 3.82.4 5.8 6.4
Median duration (months) (IQR) 3.5 (2–7) 3.25 (2–6) 2.8 (2–4.25) 3.25 (2–7.1)
Population over 65 years (%)a 12.4 13.0 16.4 12.7 50.0001
Inside versus outside cluster.
a Based on the average 1994–2006 estimated resident populations. (Australian Bureau of Statistics, 1994–1995, 1996–2006).




















1a 75 4 Probable Y Y ND ND Y Y
2a 52 2.8 Definite Y Y ND N Y Y
3a 82 2 Definite Y Y ND ND Y Y
4a 69 2 Definite Y Y ND N N Y
5 65 9 Definite Y Y ND Y N MV Y
6 79 2.5 Definite Y N Y ND Y N
7 62 9 Definite Y Y Y N N Y
8 76 4 Definite Y Y Y N Y VV Y
9 88 2.5 Definite Y NK ND N Y MM 2 Y
10 60 2 Definite Y Y Y N Y MM 2/3 Y
11 67 4.25 Definite Y Y ND ND N VV 3 Y
12 79 2.75 Definite Y Y ND N Y MM 2 Y
13 71 4.75 Definite Y Y Y Y Y MM 1/3 Y
14 81 2 Definite Y Y Y Y Y MM 1 Y
RPD = rapidly progressive dementia; NK = not known; ND = not done; MM = methionine homozygous; MV = methionine/valine heterozygous; VV = valine homozygous.
aIndicates cases previously published. (Cohn et al., 2000).
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four patient pairs where admissions to hospital for acute care
or non-CNS procedures (two hysterectomies, one colonoscopy
and one gastroscopy, one lymph node removal/colonoscopy and
one chest pain, one pan-endoscopy with gastric biopsy and
one cardioversion for cardiac arrhythmia) occurred in the same
year, raising the possibility of potential cross-over events; lack
of information on the specific institutional locations of the care
or procedures limited our ability to further evaluate and determine
the significance of these potential linkages. Additional evaluation
of surgical and non-surgical procedures performed on all
Australian CJD cases (sporadic, genetic and iatrogenic) undertaken
at institutions where Cluster 1 cases were admitted for health care,
did not detect any convincing likelihood of transmission events.
Other potential linking mechanisms were examined for Cluster 1
cases but no apparent or plausible connections were found. These
included: treating general practitioners; occupational history; and
history of optometric assessments, dental procedures, blood dona-
tion or blood transfusion. Information pertaining to optometry was
very poorly completed by family members and medical practi-
tioners in our questionnaire; however, from the limited informa-
tion available, no optometrist was found to have treated more
than one patient. There was one case pair that may have attended
the same ophthalmologist, however a linkage was not plausible
due to a 417-year period between treatments. No overlap in
general practitioners, including at disease onset, was found. Four
cases were reported to have received a blood transfusion in their
lifetime. In one patient where two transfusions were received,
autologous blood was used for one transfusion, while the other
was performed 3 days before death. In another case, a suggestion
of a possible transfusion was reported by family but we were
unable to confirm this through available medical records. The
blood donation history of the 14 Cluster 1 cases showed that
only four had donated blood. In an additional patient, it was
unclear whether a donation had been made. Of the known dona-
tions, the last donation was in the 1970s.
Referral biases can lead to increased detection rates, especially
when dealing with rare disorders like sCJD. Given the local recog-
nition of an apparent increased incidence of sCJD in 1997, we
considered the possibility that enhanced awareness and referral
for evaluation were more likely thereafter, leading to increased
incidence rates. Consequently, we performed comparative second-
ary SaTScan analyses for the periods 1993–1996 and
1997–2006 (Table 1). No significant clusters were identified for
the earlier period but case numbers were small (n = 17). For
the latter period, the spatial analysis identified Cluster 1 as the
most likely cluster, almost achieving significance (P = 0.059);
temporal and spatial-temporal analyses were non-significant,
similar to the results for the overall period.
With the results of the secondary analyses suggesting potential
detection bias, this issue was further explored. Ten neurologists
were involved with one or more (eight involved with two or
more) of the Cluster 1 cases and two geriatricians were involved
with two or more cases. When comparing the referral patterns
of the 14 sCJD cases from Cluster 1, we found that clinicians
were an over-represented factor in notifying the ANCJDR of
potential cases either through direct contact (six), semi-annual
mailout cards to neurologists/neuropathologists (two) or through
referrals for CSF 14-3-3 protein detection (six). Analysis of the
proportions of neurologists per population based on 2007 esti-
mates (MDA, 2007; Australian Bureau of Statistics, 2008) indicate
that NSW and the Cluster 1 population have the equivalent
proportions of neurologists (1 neurologist per 50 000 persons),
which is within the range observed for other Australian States
and Territories (0.6–1.05 neurologists per 50 000 persons).
Excessive referrals of suspect cases in the Cluster 1 area are there-
fore unlikely to be related to an excessive number of neurologists
servicing the population.
Further investigation of potential referral biases in Cluster 1,
included examining overall suspect sCJD referrals and CSF referrals
for 14-3-3 protein testing. From the CSF referrals originating
Table 4 Comparison of rates of CSF 14-3-3 protein test-
ing, suspect CJD referrals, neuropathological examinations








14-3-3 CSF test referrals
1997–2006
N 576 78 (13.5%)
Crude referral rate
(ref/mil/yr)
8.76 16.19 1.59 (1.25! 2.02)
Suspect case referrals
1993–2006
N 648 93 (14.4%)
Crude referral rate
(ref/mil/yr)





N 138 28 (20.3%)
Crude examination
rate (exam/mil/yr)





























b Includes sporadic, familial and iatrogenic CJD cases.
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from NSW between 1997 and 2006, 13.5% were from patients
that resided in the Cluster 1 geographical region at the time of
referral. For the same period the referral rate for Cluster 1 was
59% greater than the NSW rate (age-adjusted RRMH: 1.59, 95%
CI = 1.25!2.02) (Table 4). In conjunction with the increased
CSF referrals from the Cluster 1 region, the rate of suspect CJD
case referrals from Cluster 1 was also found to be significantly
higher than case referrals for NSW for the 1993–2006 epoch
(age-adjusted RRMH, 1.68, 95% CI = 1.36! 2.10). The likelihood
of referred suspect cases being confirmed as probable or definite
CJD (all CJD types) was examined and found not to be different
between the Cluster 1 area and NSW. This was also the case
for sporadic CJD cases alone. Neuropathological examination
of the brain was performed in a greater proportion of sCJD
patients from Cluster 1 (13/14) (Table 3), compared to proportion
of cases outside Cluster 1 (53/88). Of all suspect NSW case
referrals, 21.3% underwent neuropathological examination,
while in Cluster 1 the proportion of cases examined was 30.1%,
with the difference between the rates not significant. However,
when comparing the population-based rates, the rate of neuro-
pathological examination was found to be almost two and half
times greater in Cluster 1 compared with NSW (age-adjusted
RRMH, 2.34, 95% CI = 1.56! 3.51).
Discussion
Despite the overall rarity of CJD, clustering of apparently sCJD
has been repeatedly identified (Matthews, 1975; Farmer et al.,
1978; Will and Matthews, 1982; Arakawa et al., 1991;
D’Aignaux et al., 2002; Collins et al., 2002a). Given the transmis-
sion risk of these disorders, an important priority is to investi-
gate any geographically confined excess occurrence, to identify
whether transmission events or other circumstances have been
extant that may pose risks to the general public. Illustrating
this principle was the outcome of the detailed epidemiological
investigation of a small United Kingdom cluster of the bovine
spongiform encephalopathy related disorder variant CJD, wherein
local butchering methods may have lead to contamination of
meat products destined for human consumption (Bryant and
Monk, 2001). In contrast however, such as in the present inves-
tigation, extensive analysis may highlight surveillance parameters
and health care management that appear to lead to significantly
improved case ascertainment.
Our analyses confirmed a disproportionate geographical group-
ing of 14 cases of sCJD between 1993 and 2006 in a NSW coastal
area. This greater than expected number of cases was dependent
on spatial dimensions, rather than temporal determinants, suggest-
ing that the cases were evenly distributed temporally throughout
the epoch. However, our secondary analyses based on dichoto-
mizing the entire epoch around the point in time when an
increased number of cases were first recognized in the region,
showed that the vast majority (13/14) of Cluster 1 cases occurred
in the 1997–2006 period. As a corollary, spatial analysis on this
time period again yielded Cluster 1 as the most likely cluster,
almost achieving significance. The increased case numbers and
almost significant spatial clustering for the latter time period
alone is consistent with the postulate that the sustained higher
than expected incidence of sCJD in this circumscribed region of
NSW, is most likely due to a more intense level of surveillance
from 1997, which appeared to be directly facilitated by the local
managing clinicians. This hypothesis is entirely consistent with the
operation of the Registry wherein the Registry relies predomi-
nantly on the clinical perspicacity of the managing physicians to
suspect CJD and then their motivation to refer these cases for
diagnostic testing and clinical evaluation. The enhanced ongoing
detection of cases after a few have been identified is not neces-
sarily surprising and has been recognized previously, such that
once an initial case is confirmed in a given geographical location,
the potential to identify another case increases (Raubertas et al.,
1989).
There was clear evidence to support the postulate of a physician
driven enhanced surveillance. Both the rate of referral for CSF
14-3-3 protein testing and the rate of referral of suspect CJD
cases per population notified to the Registry were significantly
higher in the Cluster 1 area, suggesting that clinicians were
more readily referring cases to the Registry compared to NSW
overall, even after adjusting for age differences. The positive
trend could not be explained by an elevated level of service by
neurological specialists in the area as there was no difference
between NSW and Cluster 1. Another measure of the interest
and motivation of the region’s clinicians to confirm CJD cases
could be gauged by the likelihood that a given suspect CJD case
would undergo neuropathological examination. Although the pro-
portions of suspect CJD referrals that were examined neuropatho-
logically were similar in Cluster 1 and NSW overall, when analysed
as a rate per the general population, Cluster 1 had over double
the rate to that of the whole state. Given that the rate of referral
of suspect CJD cases and neuropathological assessments in
Cluster 1 were approximately twice that of the entire state, the
similar case confirmation ratios observed in the Cluster 1 area and
NSW translated into approximately double the incidence of sCJD.
Simply stated, double the rate of referral of suspect CJD cases
combined with double the rate of neuropathological examinations
equated to double the incidence of sCJD. On a national level,
a greater number of ante-mortem referrals have been shown to
correlate with an increased number of case confirmations (Klug
et al., 2007). Although seeming somewhat intuitive that more
intense surveillance will most likely culminate in higher ascertain-
ment, this is the first study of sCJD to offer actual quantification
of any potential correlation between the level of surveillance
intensity (measured as a composite of clinical referrals and diag-
nostic test rates per population) and disease incidence. As such,
we posit that the incidence of sCJD in Cluster 1 may be a more
accurate measure of the true disease incidence in the Australian
population, similar to the sCJD mortality rates of 42 cases/million
population/year observed in some European countries (Glatzel
et al., 2002; Gelpi et al., 2008), and contend that more intense
surveillance may lead to even higher rates as already reported for
brief periods by other national surveillance units (Glatzel et al.,
2002).
A distinguishing clinical feature of the Cluster 1 cases was their
older age at death, when compared to both NSW and the entire
Australian cohort of sCJD. While this may have reflected the older
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age population of the area, it is consistent with a greater than
usual capacity to detect older age sCJD. Other European countries,
including Austria where autopsy in suspect CJD cases is manda-
tory, have found that an increased incidence of sCJD (42 cases/
million population/year) has been associated with increased detec-
tion of older age cases (Glatzel et al., 2002; Ladogana et al.,
2005; Van Everbroeck et al., 2006; Gelpi et al., 2008). This sug-
gests that systematic under-ascertainment of sCJD in the older
age population is possible in many countries due to a number of
factors, including diagnostic difficulties due to the early sympto-
matic phase of CJD imitating other dementias and restricted med-
ical resource allocation to the elderly.
Although our strongest suspicion is that the managing clinicians
in the Cluster 1 area were well-primed to investigate and confirm
CJD cases, it remains possible that other factors unrelated to
enhanced surveillance may have contributed to, or explain, the
increased number of sCJD in the region. It is conceivable that
the cluster could have occurred by chance alone, as apparent
clusters are inherent in randomness. This has been seen previously
in Australia (Collins et al., 2002a) and with variant CJD in the
United Kingdom (Cousens et al., 1999). In Australia, a cluster
of six cases in a rural city was identified between 1988 and
2000 and was concluded to have been a chance occurrence.
Since this time, no further cases have been confirmed in the
area (personal communication, S. Collins) which supports the
initial conclusion. In this study, our analysis of case records did
not support a definite or likely instance of causal transmission
linkage between any cases; however, it cannot be completely dis-
missed that the Registry’s case record details may be incomplete
or influenced by recall error from those completing case question-
naires. This leaves the possibility that some of the excess cases
may have arisen through covert transmission events. A further
limitation of the cluster cohort is the low proportion of cases
with complete PRNP genetic analysis, thereby limiting our ability
to rule out the possibility of an underlying genetic aetiology in
some cases. Finally, a comparison of the age groups of NSW
and the Cluster 1 area revealed a small but significant difference
between the age structures of the areas with a trend towards
an older age population in Cluster 1. Since the disease is age-
dependent, it could be speculated that the higher rate simply
reflected the older age population. We are confident this is
not the explanation given that age-adjustment did not alter the
finding that there were significantly more cases of sCJD than
expected in Cluster 1.
In conclusion, we believe that vigilant and motivated managing
clinicians in a geographically circumscribed area of NSW evinced
a sustained higher level of clinical awareness for the broad phe-
notypic spectrum of CJD with reliable referral of suspect cases
for further investigation. In addition, these physicians established
and maintained a well coordinated and active approach to suspect
CJD autopsy. The combination of these factors translated into
a higher intensity of surveillance at approximately twice the rate
per population observed for the entire state, culminating in twice
the incidence of sCJD at around 2.28 cases/million population/
year. The hypothesis that intensity of surveillance for rare disorders
such as sCJD can be quantified and correlates positively with
disease incidence deserves further exploration and may prove
to be an important insight into the varying incidence rates over
periods of time within individual nations and between different
countries, particularly in light of declining variant and iatrogenic
CJD case numbers and a potential waning of awareness of CJD
in the years to come. This type of improved understanding could
provide strategies to maintain optimal national and potentially
global surveillance.
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Prion protein gene multiplication
a b s t r a c t
Precedent of causative multiplication of key gene loci exists in familial forms of both Alzheimer’s and
Parkinson’s diseases. Genetic Creutzfeldt-Jakob disease (CJD) is often clinically indistinguishable from
sporadic disease and inexplicably, a negative family history of a similar disorder occurs in around 50–90%
of patients harboring the most common, disease-associated, prion protein gene (PRNP) mutations. We
undertook semi-quantitative analysis of the PRNP copy number in 112 CJD patients using quantitative
polymerase chain reaction. All included cases satisfied classification criteria for probable or definite spo-
radic CJD, ascertained as part of longstanding, prospective, national surveillance activities. No examples
of additional copies of the PRNP locus as an explanation for their disease was found in any of the 112
sporadic CJD patients. Hence, contrasting with more common, age-related neurodegenerative diseases,
the genetic aetiology in human prion disease continues to appear entirely restricted to small scale muta-
tions within a single gene, with no evidence of multiplication of this validated candidate gene locus as a
cause.
© 2010 Elsevier Ireland Ltd. All rights reserved.
Creutzfeldt-Jakob disease (CJD) constitutes the most common
human phenotype of the rare, transmissible neurodegenerative dis-
orders known as prion diseases, with this disorder characterized by
rapidly progressive dementia with a median survival of only 4–5
months [4]. In contrast to variant CJD, a zoonosis related to bovine
spongiform encephalopathy, most CJD (approximately 85%) occurs
without explanation (sporadic), with detectable mutations in the
prion protein gene (PRNP) accounting for only 10–15% of cases
(genetic) and the very small remainder due to inadvertent health
care related transmissions (iatrogenic) [4]. Although unrecognized
or covert horizontal transmission related to surgery or other med-
ical procedures is presumed to explain some apparently sporadic
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CJD [3], this contentious mechanism is quite unlikely to be the basis
for all such cases.
Analogous to the much more common neurodegenerative disor-
ders Alzheimer’s disease (AD) and Parkinson’s disease (PD), which
are also patho-aetiologically linked to the accumulation of neuro-
toxic protein species within the CNS [9,12] sporadic CJD evinces a
notable increase in incidence with age [7]. Diverse evidence sug-
gests a decline in proteasomal function occurs with advancing age
[1], with the likely compromise in protein clearance thought to
be one pathogenic factor contributing to the progressive build-up
of certain abnormal polypeptides, such as A and -synuclein so
commonly observed in the brains of older individuals. Further illus-
trating age-related effects on protein homeostasis and the capacity
of neurons to maintain a critical balance between protein syn-
thesis and the maintenance of quality control are examples of
overexpression such as Down’s syndrome due to trisomy of chro-
mosome 21 and carriers of duplications of the Amyloid Precursor
Protein (APP) gene. The presence of an extra copy of the APP gene
is almost invariably associated with the early development of AD
brain pathology [11,13]. Similarly, the PARK 4 autosomal dominant
form of genetic PD is explained by either duplication [5] or tripli-
cation [10] of the -synuclein gene (SNCA) locus, which results in
0304-3940/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2010.01.043
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Table 1
Summary of cases undergoing semi-quantitative analysis of the PRNP locus.
Country Definite sCJD Probable sCJD Male Female Total Age range, yearsa (mean) sCJD aged <61 years
Australia 48 19 29 48
Netherlands 41 23 26 38 64
Combined 89 23 67 45 112 34–87 (65.4) 35
a Ages are at time of death.
the invariable development of disorders either recapitulating PD or
dementia with Lewy bodies, with gene dosage directly correlating
with younger age of onset and greater neuropathological severity.
Current diagnostic criteria for sporadic CJD require the absence
of mutations in the PRNP or exclusion of a positive family history
of prion disease in first degree relatives. Analogous to phenotypes
observed in some PARK 4 kindreds in comparison to idiopathic
PD [5], genetic CJD is often clinically indistinguishable from spo-
radic disease. Of further importance, the penetrance of many PRNP
mutations appears to be low, as a negative family history of a sim-
ilar disorder occurs in around 50–90% of patients harboring the
most common PRNP mutations associated with the CJD phenotype
[6]. To date, only point mutations and polynucleotide insertions
and deletions restricted to the open reading frame of PRNP are
recognized as causally related to genetic CJD [4]; no gene locus
multiplications have been reported, which contrasts with the find-
ings in PD and AD. Acknowledging the aforementioned, and the fact
that conventional genetic analytical techniques are insensitive for
detecting disease-associated large scale chromosomal rearrange-
ments [10], we undertook the present study to semi-quantitatively
assess whether multiplication of the PRNP locus was an occa-
sional explanation for disease in a cohort of classified sporadic CJD
patients, especially in younger age at onset cases.
Many of the Australian and Dutch patients included in the
present study have been reported on previously [2,7]. All included
cases satisfied classification criteria for probable or definite spo-
radic CJD, ascertained as part of longstanding, prospective, national
surveillance activities with case definitions and surveillance meth-
ods described previously [2,7]. In brief, definite cases were
pathologically confirmed, while probable cases had alternative
diagnoses excluded and manifested rapidly progressive demen-
tia (of less than 2 years duration), accompanied by any two of
myoclonus, visual or cerebellar dysfunction, extrapyramidal or
pyramidal signs or akinetic mutism, with an EEG showing typical
periodic discharges or the presence of 14-3-3 proteins in the CSF.
Permission for inclusion in research studies was obtained for all
patients.
For Dutch cases, genomic DNA was extracted from whole blood
samples according to a standard non-phenol:chloroform method
[8]. For Australian cases, genomic DNA was extracted using a phe-
nol:choloroform extraction method. Briefly, approximately 50 mg
frozen brain tissue was homogenised in 450 l DNA extraction
buffer (100 mM NaCl, 10 mM Tris–Cl pH 8.0, 25 mM EDTA pH 8.0,
0.5% (w/v) SDS), by passing through 18 g, then 20 g needles. Proteins
were digested overnight at 37 ◦C by addition of proteinase K (final
concentration 1 mg/ml). An equal volume of phenol:chloroform
(phenol:chloroform:isoamyl alcohol, 25:24:1, Pierce) was added,
samples mixed gently, and centrifuged for 5 min, maximum speed
in a bench top microfuge (approximately 13,000 rpm). The aqueous
(top) layer was removed to a fresh tube, and the phenol:chloroform
extraction was repeated twice more, or until there was no white
precipitate at the interface between the organic and aqueous
layers. The extraction was then repeated, substituting the phe-
nol:chloroform with chloroform. DNA was precipitated from the
final aqueous layer by the addition of 2.5 times the volume of
ice cold 100% ethanol, which was pelleted by centrifugation at
maximum speed in a bench top microfuge at 4 ◦C. The DNA pel-
let was then washed with 70% ethanol, allowed to air dry, and
re-suspended in an appropriate volume of sterile Milli-Q H2O.
PRNP gene locus copy number variation was analysed by qPCR
(Hydrolysis Probes). For the PRNP locus, we used a FAM labeled
Applied Biosystems TaqMan probe (Hs01940892) located in exon 2
of the PRNP gene (NM 000311) and the RNase P Control Reagents Kit
(VIC labeled, Applied Biosystems) as reference locus. Both probes
(final concentration 1×) were tested in one single reaction, total
volume 20 l, containing 1× qPCR MasterMix Plus w/o UNG (Euro-
gentec) and 15 ng of genomic DNA using an Applied Biosystems
7300 Real Time PCR System. The amplification protocol was as
follows: initial denaturation for 10 min at 95 ◦C followed by 40
cycles of denaturation at 95 ◦C for 15 s and annealing, extension
and data collection at 60 ◦C for 60 s. Relative quantification was
performed using the RQ-Study Application from the Sequence
Detection (SDS) software V1.3.1 (Applied Biosystems). The linear
amplification phase for analysis of PRNP was generally observed
between 25 and 27 cycles.
A total of 112 sporadic CJD patients (89 definite, 23 probable)
underwent PRNP locus quantification by qPCR; in three additional
cases amplification was attempted but was unsuccessful (two due
to degraded DNA; one for unclear reasons). Table 1 summarizes
the demographic features of analysed cases. The ages of the 112
patients at time of death ranged from 34 to 87 years (mean 65.4
years), with 67 females (59.8%). Thirty-five individuals (31.3%) were
60 years of age or younger at their time of death, with 12 (10.7%) less
than 56 years. None of the 112 successfully, semi-quantitatively,
assessed sporadic CJD cases showed evidence of a definite increase
in PRNP locus copy number with the relative quantification range
0.76–1.39 (normal: 0.7–1.3); two patients each had copy ratios just
above the normal range on a single occasion, which were within
the reference range on repeat testing.
Despite precedent in other age-related neurodegenerative dis-
eases, albeit with more overt genetic associations, our study of
112 sporadic CJD patients failed to disclose any examples of addi-
tional copies of the PRNP locus as an explanation for their disease.
Although investigation of familial CJD occurring in the absence of
PRNP mutations would perhaps, a priori, be considered more likely
to uncover locus copy number multiplication, such pedigrees were
not available. We speculated that given the insensitivity of con-
ventional analytical techniques to gene locus multiplication and
through extrapolated analogy to the unexplained but very frequent
occurrence of a negative family history despite probands harbor-
ing causative PRNP mutations, it was reasonable to investigate a
sizeable cohort of apparently sporadic CJD patients.
Even though the number of cases included in our study is per-
haps comparatively small, this finding certainly militates against
undetected duplication or triplication of this genetic locus consti-
tuting a relatively common cause and possibly excludes this type
of genetic basis as even a rare cause of apparently sporadic dis-
ease. From previous reports of PARK 4 kindreds, age of disease onset
correlates with gene dosage, although for SNCA duplications ages
at onset were only modestly or equivocally reduced in compari-
son to idiopathic PD [5] with the most dramatic effects observed
in relation to triplication of SNCA [10]. With nearly one third of
our sporadic CJD cohort below the mean age at death reported for
this disease (around 65–70 years) [2], we believe our studied group
Author's personal copy
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included optimally aged patients to detect this type of underlying
genetic disorder.
In conclusion, contrasting with the more common, age-related
neurodegenerative diseases AD and PD, the genetic aetiology in
human prion disease continues to appear entirely restricted to
small scale mutations within a single gene, the PRNP, with no evi-
dence of multiplication of this validated candidate gene locus as a
cause.
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For Debate
between hGH therapy and the development of Creu
disease (CJD) in a young hormone recipient in the U
CJD is an incurable and rapidly progressive neur
disorder and one of the transmissible spongiform 
thies. As of mid 2010, 25 years after the morato
AHPHP, and 20 years since an Australian recipient de
we present a likely, and we hope, final assessment of 366 MJA • Volume 193 NumbeABSTRACT
• From 1967, the Australian Human Pituitary Hormone Program 
offered treatment for short stature and infertility using human 
cadaver-acquired pituitary hormones (human growth 
hormone [hGH] and human pituitary gonadotrophin [hPG]). 
The program was suspended in 1985 when a growth-hormone 
recipient in the United States developed Creutzfeldt–Jakob 
disease (CJD), an incurable and rapidly progressive 
neurodegenerative disorder.
• Since this time, recipients have lived with the significant 
anxiety that they have an elevated risk of developing CJD. 
Furthermore, additional CJD infection control measures are 
required when recipients undergo some types of surgery.
• As it is 20 years since the last Australian pituitary hormone 
recipient developed CJD, we evaluated the risk for Australian 
recipients of developing iatrogenic CJD, and compared 
Australian data with data from New Zealand and selected 
other countries who had pituitary hormone programs.
• Our evaluation indicates that pituitary hormone recipients in 
Australia have the lowest risk of developing iatrogenic CJD, 
and that Australia is the only country not to have experienced 
ongoing CJD-related deaths. Thus, we believe that:
in the Australian hGH recipient cohort, the risk of 
developing CJD is sufficiently low for this cohort to no longer 
require additional infection control measures in the health 
care setting; and
in the Australian hPG recipient cohort, if another 5 years 
elapses with no further occurrence of CJD in this group, the 
hPG recipient cohort could also be considered as not 
requiring additional infection control measures in the health 
care setting.
• These recommendations should not be misunderstood as 
implying that there is no ongoing risk, but that the risk is 
acceptably low and generally in keeping with guidelines that 
MJA 2010; 193: 366–369
stratify the risk.n A
an
(hI ustralia, from 1967 to mid 1985, treatment for short statured infertility with cadaver-acquired pituitary hormonesuman growth hormone [hGH] and human pituitary gonado-
trophin [hPG], respectively) was provided through the Australian
Human Pituitary Hormone Program (AHPHP).1 The program was








experience of medically transmitted CJD from human-derived
pituitary hormone therapy, and compare our experience here with
that in other countries.
The Australian experience
In total, four Australians have had their deaths from CJD attributed
to pituitary hormone therapy, with the most recent occurring in
early 1991. Unique to Australia, these four deaths were related to
treatment with hPG: three had CJD confirmed at autopsy and the
fourth was classified as “probable CJD” after evaluation by the
Australian National Creutzfeldt–Jakob Disease Registry (ANCJDR)
using World Health Organization surveillance criteria.3
The death of an Australian hGH recipient in 1991 is considered
unlikely to be the result of CJD, as this person had numerous
confounding comorbidities. However, in the absence of relevant
premortem investigations and an autopsy, this case was conserva-
tively classified as “possible CJD” and, as such, is excluded from
formal epidemiological analyses and incidence data.
The Box summarises the total number of hPG and hGH
recipients in Australia and in selected, larger national human
pituitary hormone programs in other countries. It also shows the
number of deaths from CJD among these recipients, and the
relative risk of developing CJD for recipients in each country. Each
national pituitary hormone treatment program has only ever
confirmed iatrogenic CJD in either hPG (Australia only) or hGH
recipients, never in both. This is an empirical observation, the
reasons for which are not understood; however, it spans many
countries and thousands of recipients over a period of 25 years. The Australian figures are presented in two sets. The first gives
the recipient numbers reported in the 1994 Report of the inquiry
into the use of pituitary derived hormones in Australia and Creutz-
feldt-Jakob disease (known as the Allars report),1 and the second
gives the recipient numbers published in 1999 by the Australian
Government Department of Health and Ageing (DoHA).4 Both
sets of recipient numbers are included for transparency. Discrep-
ancies between the sets could be attributed to early audits of
program lists providing the number of patients approved for
treatments, and later figures representing only those recipients
confirmed by DoHA as having received treatments.
Abbreviations
AHPHP = Australian Human Pituitary Hormone Program
ANCJDR = Australian National Creutzfeldt–Jakob Disease Registry
CJD = Creutzfeldt–Jakob disease
hGH = human growth hormone
hPG = human pituitary gonadotrophin
PRNP = prion protein gene ◆r 6 • 20 September 2010
FOR DEBATEThe four Australian hPG recipients who developed CJD all had
disease onset in the period 1987–1990, which is consistent with
a single, discrete contamination event and, most likely, effective
removal of prions through routine pituitary processing methods.
The now 20-year interval since an Australian recipient developed
CJD offers some reassurance to recipients, who have, since 1985,
lived with the anxiety that they have an elevated risk of
developing CJD. It is considered unlikely that national surveil-
lance has missed identifying a further CJD illness in an Australian
hGH or hPG recipient, especially given the heightened awareness
of this possibility among AHPHP recipients and their families,
and the significant improvements in premortem diagnostic tests
since 1993, when CJD surveillance commenced in Australia.
Annual incidence rates of CJD reported by the ANCJDR have
increased over time,9 in line with anticipated improvements in
case ascertainment afforded by a dedicated national surveillance
unit and better diagnostic tools.10,11 Families of all patients with
CJD ascertained by ANCJDR are also routinely asked for details




In Australia, there has been a 20-year interval since a pituitary
hormone recipient developed CJD. This contrasts with the
ongoing occurrence of CJD in hGH recipients in other countries,
where, with the exception of New Zealand, hGH-related CJD
cases have continued to be diagnosed and deaths reported (Box).
The most recent death from CJD of an NZ recipient occurred in
2004 after an incubation period of 37 years (the incubation
period is calculated from the mid-treatment point to the onset of
symptoms). The most recent death from CJD of a US recipient
occurred in 2007 (reported in 2008), with 30 years elapsing
before the onset of symptoms — the longest US incubation
period to date. In both the United Kingdom and France, there
were deaths of recipients in 2008, and these cases represent the
longest incubation periods reported for each country, 32 and 24
years, respectively (Professor R G Will, The National CJD Surveil-
lance Unit, Edinburgh, UK, personal communication, February
2009). Overall, the longest incubation period is currently
believed to be 38 years, occurring in a recipient in the Nether-
lands who received several doses of hGH for diagnostic pur-
poses.12 By comparison, the longest incubation period reported
in an Australian recipient is 15.3 years, with incubation periods
in Australia ranging from 12 to 15.3 years.
Risk in relation to pituitary hormone source country
Both the total risk (hPG and hGH) and the hGH-only risk of
pituitary hormone-related CJD in NZ and the UK are similar (Box),
although the hGH product used in NZ until the late 1970s was
predominantly manufactured in a laboratory in the south-eastern
US. Earlier reports recorded 46 of a total of 184 hGH recipients in
NZ13 as receiving hormone product processed in the US before
1977, the year when the hormone extraction method in the US
was changed.13 The total number of hGH recipients on the NZ
CJD Registry (159 individuals)7 was recently confirmed by the
Medicines and Medical Devices Safety Authority (Medsafe), Minis-
try of Health, NZ, in February 2009. Up to the end of 2008, the six
NZ hGH recipients who subsequently died of CJD all received US-
sourced hormone product. The risk rate of CJD for the NZ
recipients of US-sourced hGH (6/49) is 12.2%.
The explanation for the striking difference between US and NZ
hGH risk rates — less than 0.5% compared with close to 4% — is
Summary of the number of recipients of cadaver-acquired human pituitary gonadotrophin (hPG) and human growth 
hormone (hGH) in five countries; the number of related deaths from Creutzfeldt–Jakob disease (CJD); and the relative risk 




No. of hPG 
recipents hPG risk (%)
No. of hGH-
related deaths
No. of hGH 
recipients hGH risk (%) 
Total risk (%) 
(hGH and hPG) 








13634 0.29% 6084 0.16%‡ 0.20%
France 0 0 0 115 1700 6.76% 6.76% 2008
New Zealand 0 154§ 0 6¶5 159**7 3.77% 1.92% 2004
United States 0 0 0 28 ~ 7700 0.36% 0.36% 2007
United Kingdom 1† ~ 300†† 0 576 18498 3.08% 2.65% 2008
* The two recipient totals for Australia are derived from two different reports,1,4 and most likely represent the difference between patients approved for treatments 
(larger number) and those confirmed as having received treatments. Two corresponding risk calculations are given.
† One Australian hPG recipient is reported by both Australia and the UK; treatment took place in Australia, but disease onset and death occurred in the UK. This case is 
not included in Australian incidence figures, but for the purpose of this risk assessment, this recipient is analysed with the Australian hPG recipients only.
‡ This “possible CJD” case does not appear in Australian CJD incidence figures, and calculations of total risk exclude this case.
§ This total comprises nine hPG recipients with hormone source unknown; 37 recipients of Australian hPG; 29 recipients of US hPG; and 67 recipients of NZ hPG. A 
further four recipients received Australian and NZ hPG, three received Australian and US hPG, and four received US and NZ hPG. One recipient received hPG from all 
three sources (Medicines and Medical Devices Safety Authority [Medsafe], Ministry of Health, NZ, February 2009).
¶ These NZ recipients received US-sourced hGH (Medsafe, Ministry of Health, NZ, January 2010).
** This total comprises 34 recipients of US hGH, 15 recipients of US and Australian hGH, 94 recipients of NZ hGH, 12 recipients of Australian and NZ hGH, and four 
recipients of Australian- and/or Swedish-sourced hGH (Medsafe, Ministry of Health, NZ, February 2009).
†† Professor R G Will, The National CJD Surveillance Unit, Edinburgh, UK, personal communication, February 2009. ◆MJA • Volume 193 Number 6 • 20 September 2010 367
FOR DEBATEnot entirely clear;13 however, the US hormone product received by
NZ patients is not thought to be identical to that received by US
patients.14 Potential differences include the final post-purification
processing steps performed in the two countries; that is, the final
pooling and filtering of material to eliminate bacterial contamina-
tion before placing the hormone product in sterile ampoules (Dr A
Parlow, Director, National Hormone and Peptide Program, Harbor-
UCLA Medical Center, Torrance, Calif, USA, personal communica-
tion, February 2009). For example, these final post-purification
steps were performed manually in NZ on much smaller volumes
than those used in the US.
As in Australia, in NZ, hPG was administered for infertility.
There were a total of 154 NZ recipients of hPG Medsafe, Ministry
of Health, NZ, January 2010). The risk analysis for these recipients
can be differentiated into four groups, based on the source of the
hormone administered: Australia only (37 recipients), the US only
(29), NZ only (67 — from 1978),1 and mixed sources (12). The
risk for nine NZ recipients is unknown, as the hPG source was not
recorded.
Recalculating the risk of developing CJD after adding the
number of NZ recipients of any Australian-processed hPG to the
total number of Australian hPG recipients results in no significant
change in Australian risk rates; the risk of CJD in recipients of hPG
processed in Australia is 0.24%–0.28%, a negligible shift of 0.01%
(Box).
The risk for NZ recipients of US- and NZ-sourced hPG can be
considered zero, as no CJD-related deaths have occurred in either
recipient group. In contrast, combining the number of recipients
of US-processed hGH in the US and NZ (7749) with the total
number of CJD deaths in those countries (34) increases the US risk
rate for iatrogenic CJD to 0.44%.
Risk in relation to pituitary hormone purification processes
As described by Huillard d’Aignaux15 et al and Brown et al,13
higher-risk periods apparently exist for recipients of hGH in
France and the US. Acknowledging the unusual biophysical
properties of prions, including their resistance to conventional
sterilisation measures,16,17 these higher-risk periods are consid-
ered to relate to differences in extraction and purification
methods of human-derived pituitary hormones altering the
infectivity of contaminated preparations.18-20 As a potential
example, through to the end of 2008, all hGH recipients who
developed CJD in the US received their hGH treatment before
1977, the year a column chromatography purification processing
step was introduced; this step was considered to have signifi-
cantly reduced, but not necessarily eliminated, contaminating
prions.21 The risk estimate for US recipients treated before 1977
is 1%.13 The progressively lengthening intervals of absence of
iatrogenic CJD cases in US hGH recipients treated after 1977
suggest that, as in Australia, this recipient group may have a
considerably lower, perhaps a negligible, risk of developing
iatrogenic CJD.
The overall risk of human pituitary hormone-related CJD in
France is calculated at 6.8%. The higher-risk period for French
hGH recipients occurred between 1982 and mid 1985; all
iatrogenic CJD cases occurred in hGH recipients treated in that
period. As in the US, processing changes were implemented from
mid 1985, especially universal urea-inactivation of hGH, which
is believed to have significantly lowered the prion transmission
risk. In this higher-risk period, Huillard d’Aignaux et al15
reported that 1361 people were treated with hGH in France
between January 1982 and July 1985, with an 8.4% risk of
developing CJD, while Brown et al13 reported 1260 individuals
receiving hGH in France between January 1983 and July 1985,
with a 9.1% risk.
Limitations to further refinement of the risks for Australian 
recipients
The information available for UK hGH recipients8 and Australian
hPG and hGH recipients does not clearly identify higher-risk
periods. The UK has reported deaths from CJD in recipients
treated over the entire program period — without temporal
clustering. Unfortunately, the information available about the
treatments administered to Australian pituitary hormone recipi-
ents is incomplete: batch numbers of hormones and the number of
treatments from each batch administered are not available for all
recipients. The absence of complete treatment details for all
AHPHP recipients precludes further refinement of the risk for
Australian recipients. In addition, the polymorphic codon 129
status of the prion protein gene (PRNP) is generally considered a
risk factor for hGH-related iatrogenic CJD.22 However, PRNP
genotyping of the four Australian hPG recipients who developed
CJD showed no clear association: two were homozygous for
methionine, one for valine, and the fourth was heterozygous.23
This mixed result reduces the utility of codon 129 assessment for
determining the risk of developing CJD in other Australian hPG
recipients. Notwithstanding such limitations, the combined total
risk of iatrogenic CJD for AHPHP recipients is relatively low at
0.16%–0.20%.
Time to re-evaluate the need for infection control 
measures for Australian recipients?
Our assessment shows that the Australian recipient community
has the lowest risk of developing iatrogenic CJD of all the countries
studied, and Australia is the only country not to have experienced
ongoing CJD-related deaths. This is positive news for the AHPHP
recipient community. Beyond any emotional or psychological
benefits stemming from the confirmed, low absolute number and
low relative risks of pituitary hormone-related CJD in Australia, as
well as the absence of further occurrences of CJD among the
treated cohort over the past 20 years, we believe these data prompt
reconsideration of the current infection control measures for the
Australian recipient community.
For Australian hGH recipients: given the absence of confirmed
iatrogenic CJD in hGH recipients in Australia, and the freedom
from any instances of pituitary hormone-related CJD over the past
20 years, we believe that the risk of developing CJD for members
of the Australian hGH recipient cohort is sufficiently low for them
to no longer require additional infection control precautions in the
health care setting.24
For Australian hPG recipients: a revision of infection control
measures is less clear-cut and more contentious, principally due
to the long incubation periods reported among hGH treatment
cohorts in other countries where there is an established risk.
Nevertheless, if another 5 years elapses25 with no further occur-
rence of CJD in this Australian recipient group, we believe that an
absence of iatrogenic CJD over a 25-year period would suggest
that the residual risk is acceptably low, and that the Australian368 MJA • Volume 193 Number 6 • 20 September 2010
FOR DEBATEhPG recipient cohort could also be considered as not requiring
additional infection control measures in the health care setting.
These recommendations should not be misunderstood as imply-
ing that there is no ongoing risk, but that the risk is acceptably low
and generally in keeping with guidelines that stratify the risk.26
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In 2009, a pathologist with sporadic Creutzfeldt–
Jakob Disease (sCJD) was reported to the Spanish reg-
istry. This case prompted a request for information on 
health-related occupation in sCJD cases from coun-
tries participating in the European Creutzfeldt Jakob 
Disease Surveillance network (EuroCJD). Responses 
from registries in 21 countries revealed that of 8,321 
registered cases, 65 physicians or dentists, two of 
whom were pathologists, and another 137 healthcare 
workers had been identified with sCJD. Five countries 
reported 15 physicians and 68 other health profession-
als among 2,968 controls or non-cases, suggesting no 
relative excess of sCJD among healthcare profession-
als. A literature review revealed: (i) 12 case or small 
case-series reports of 66 health professionals with 
sCJD, and (ii) five analytical studies on health-related 
occupation and sCJD, where statistically significant 
findings were solely observed for persons working at 
physicians’ offices (odds ratio: 4.6 (95 CI: 1.2–17.6)). 
We conclude that a wide spectrum of medical speci-
alities and health professions are represented in sCJD 
cases and that the data analysed do not support any 
overall increased occupational risk for health profes-
sionals. Nevertheless, there may be a specific risk in 
some professions associated with direct contact with 
high human-infectivity tissue.
Introduction 
Creutzfeldt–Jakob disease (CJD) is a fatal neurodegen-
erative disease characterised by deposition of a path-
ological isoform of the normal cellular prion protein 
(PrPC) [1]. The annual CJD incidence worldwide is 1–2 
per million population [2]. CJD exists in various forms: 
genetic, caused by mutations in the PRNP gene encod-
ing PrPC, acquired (variant and iatrogenic) and spo-
radic. Most cases have sporadic CJD (sCJD) – the cause 
of which is unknown. Occupational risk related to sCJD 
has been assessed in several case–control studies as 
a secondary study objective, with inconsistent results 
[3-7] and there have been occasional reports of health 
professionals with sCJD [8-12].
Occupation has not been included as a variable in all 
CJD surveillance protocols [13]. Nonetheless, there is 
concern about potential occupational excess risk of 
sCJD among health professions, as shown by a recent 
study on guidelines in European Union (EU) Member 
States and Norway for the prevention of CJD transmis-
sion in medical settings. This study showed that 12 of 
the 17 contributing countries had specific recommen-
dations targeted at minimising occupational exposure; 
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eight of the 12 had systems for reporting or registering 
work-related incidents at hospitals or laboratories [14].
In March 2009, a CJD case was reported to the Spanish 
CJD registry, who was classified as having sporadic 
CJD. As the patient was an experienced general pathol-
ogist and neuropathologist, it was speculated that the 
disease might have been a result of the person’s pro-
fessional activities. The event was commented on in 
medical, scientific and mass media in Spain and else-
where, e.g. [15]. The patient died after a four-month dis-
ease course, characterised mainly by cognitive decline, 
ataxia and myoclonus. The disease prion protein sub-
type, i.e. strain, was confirmed histochemically and 
biochemically as MM1, the most common subtype [2]. 
Risk factors for developing CJD, including blood trans-
fusion, iatrogenic exposure (e.g. to dura mater, cadav-
eric pituitary-derived growth hormone) and mutations 
in the PRNP gene, were not identified. Assessment of 
the patient’s routine hospital work indicated that the 
patient had had a history of minor injuries during post-
mortem examinations (personal communication, E. 
García-Albea, April 2009).
Following notification of this patient, the Spanish 
registry circulated a request for information to 
each national surveillance team participating in the 
European Creutzfeldt Jakob Disease Surveillance 
Network (EuroCJD), which dates back to 1993 and cur-
rently encompasses 25 collaborating centres in EU 
Member States and European Free Trade Association 
(EFTA) countries and a further eight in countries around 
the world, including Australia, Canada and Japan [16]. 
These centres provide data from national registries 
either through the EuroCJD website or, as with Japanese 
data, at regular network meetings. The request asked 
for the following: (i) information on the diagnosis 
(year of birth and death, sex and place of residence) of 
reported cases of sporadic CJD among active or retired 
pathologists from 1996 onwards; and (ii) comments 
based on personal experience of occupational risk and 
CJD among health professionals, including technicians 
working at pathology laboratories.
There has been limited systematic research targeted at 
identifying occupational risk factors for sCJD in health-
care settings. This paper reports on the data supplied 
to the Spanish CJD registry in response to the request, 
and on the results of two literature reviews of sCJD – 
one on case reports involving health professionals and 
the other on epidemiologically assessed healthcare-
related occupational risk of sCJD.
Methods
Individualised occupational data from 
national CJD surveillance teams
The Spanish CJD registry obtained answers in English 
to at least one of the requests for information from 21 
national surveillance teams. The amount of information 
provided varied: in general, only data that had already 
been registered was reported; with regard to occupa-
tional history in CJD – recorded by profession or activ-
ity branch – several countries provided information on 
people in whom CJD had been excluded or on controls.
The data received were divided into two groups, for 
further analysis – one describing health professionals 
who were sCJD cases and the other describing health 
professionals among controls or non-cases. We did 
not attempt a formal epidemiological assessment of 
healthcare-related occupational risk of sCJD based on 
this information, for instance using a case–control 
design.
Case reports of sCJD among health professionals
Countries with available registry data on cases’ occupa-
tions sent individualised data on physicians with neu-
ropathologically confirmed or probable sCJD or other 
types of CJD [17,18]. Some countries provided such 
data on other health professions. In the few instances 
in which occupation as a pathologist was identified, 
professional experience or job duration at a laboratory 
or department was specified. The results were tabu-
lated, using the original definitions from the countries’ 
Box
Search terms used in first step of two literature searches 
on sporadic Creutzfeldt–Jakob disease (sCJD) in health 
professionals and analytical studies on occupational risk 
of sCJD for health professions and selection criteria used 
in a second step, reported 1 January 1989–1 October 2011
MEDLINE




groups/occupations/occupational dentistry/case control 
studies. 
Embase
The search strategy was based on the following Emtree 
thesaurus terms:
•		prion/prion	disease/prion	protein/Creutzfeldt	Jakob	disease/
Creutzfeldt Jakob disease agent; and 
•		occupation/occupation	and	occupation-related	phenomena/
medical profession/nursing as a profession/nursing 
career/paramedical profession/professional development/
occupational accident/occupation and occupation-related 
phenomena/occupational accident/occupational disease/
occupational exposure/occupational hazard/occupational 





Either specific reference to the subject (Creutzfeldt–Jakob 
disease and health profession) or analytical study design 
(either case–control or cohort), regardless of the study’s stated 
objective. 
Exclusion
Identification of the document as a letter or review, news, 
comment, congress abstract, when reference to health 
professions was not explicitly made. 
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reports. No standard occupational classification was 
used for grouping response results and each case was 
assigned to one occupational category. Frequently, the 
occupational categories corresponded to a combina-
tion of professional profiles, e.g. specialities and work 
types (clinical, administrative, laboratory, etc.). In such 
cases, the category most likely to involve direct con-
tact with human tissue or patients was selected.
Healthcare-related occupations among 
controls and non-cases
Some CJD surveillance teams with a sufficient sample 
size provided data on occupation of people with sus-
pected sCJD who were finally classified as not having 
CJD (non-cases) and also of those in control groups. 
Five EuroCJD countries with large populations – 
Germany, Italy, Japan, Spain and the United Kingdom 
(UK) – provided this type of data, both published 
and unpublished. These countries supplied data on 
physicians who were controls Italy and Japan also pro-
vided information on other health professionals who 
were non-cases. Information on different categories 
of health professionals was available for British con-
trols. Occupation was usually categorised on the basis 
of original records at registries. In a few instances, 
reporting physicians or relatives were consulted about 
the predominant activity, e.g. general practice vs radi-
ology, of the non-cases.
Literature reviews
The first step in the literature reviews sought to identify 
reports of sCJD among health professionals, whether 
reported as case studies or drawn from analytical 
studies published during 1 January 1989 to 1 October 
2011. We carried out several searches in MEDLINE and 
Embase using the medical subject headings (MeSH) 
and Emtree thesaurus terms listed in the Box, to iden-
tify case studies on CJD in health professionals and 
Different documents identified
n=715
Failed to meet inclusion criteria  n=671 
No prion/CJD disorders                 n=170
Not occupation related                 n=214
Hospital/public health                  n=89
Secondary publication                  n=198










Occupational term-based search Case–control study-based search
n=6
Case-study reports                                         n=4
















Analytical studies with no (n=33) or 
insufficiently described (n=1) individual health 
occupational data  
Reports assessing occupational health risk 
excluded due to non-validated diagnosis or 
devoid of sCJD cases among health professionals    
Reports issued before 1989 included 
f rom personal records
Reviewed case and case-series reports on sCJD 
among health professionals 
sCJD: sporadic Creutzfeldt–Jakob disease.
Figure 1
Literature review of case reports of sporadic Creutzfeldt–Jakob disease among health professionals, 1979–1 October 2011
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sCJD: sporadic Creutzfeldt–Jakob disease.
Different documents identified
n=715
Failed to meet inclusion criteria  n=671 
No prion/CJD disorders                 n=170
Not occupation related                 n=214
Hospital/public health                  n=89
Secondary publication                  n=198
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Excluded reports on case studies only 
n=4
Included from personal files before 1989
 n=2
Potentially valid risk-based reports
 n=40
Reviewed reports on occupational risk assessment      
n=9
Excluded as the study focused on non-occupational 
exposures (genetic, biochemical, diagnostic, etc.) 
n=33
Reports possibly addressing but not reporting 
results on healthcare-related occupations 
n=4
Risk not assessed due to lack of health professions 
among cases
n=1




Literature review of analytical studies on occupational risk of sporadic Creutzfeldt–Jakob disease for health professionals, 
1982–1 October 2011     
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analytical studies on occupational risk of CJD for health 
professions. The initial searches yielded a total of 715 
different documents.
In a second step, two independent assessors applied 
predefined sets of inclusion and exclusion criteria 
(Box) to the titles of the retrieved documents or, where 
available, to their abstracts.
Documents that met the inclusion criteria were pro-
cessed further for full-text analysis in order to obtain 
the case description or to assess health-related occu-
pational risk of sCJD.
After the selection criteria for had been independently, 
though not always unanimously, applied to the 715 
documents by two reviewers, EAC and JPC, 671 were 
rejected and 44 selected for further analysis by both 
reviewers (Figures 1 and 2).
Case reports of sCJD among health professionals
Of the 44 documents selected for full-text review, 34 
were excluded as the studies did not examine health-
related occupations (Figure 1). Four studies that failed 
to include specific categories of health professionals 
with sCJD or in which the diagnosis of CJD was not vali-
dated were also excluded [3,6,7,19]. Six studies – four 
case reports [10-12,20] and two case–control studies, 
which provided information on health-related occu-
pations in sCJD case series [5,21] – were selected for 
data extraction. Five case studies and one case-control 
study retrieved from personal records before 1989 were 
also included [4,8,9,17,22,23]. Thus, the final analy-
sis of 12 reports included data on individual health 
professionals from case reports [8-12,17,20,22,23] 
and numbers of health professionals with sCJD from 
three reports on case–control studies [4,5,21]. These 
12 reports included sCJD cases fulfilling diagnostic 
criteria for neuropathologically confirmed sCJD or for 
probable sCJD (people in the latter category were only 
included in case–control studies) [5,24]. Where health 
professions were listed in the case series of a large 
case–control study and numbers were not reported, 
only one individual, e.g. a dentist, was counted [5].
Epidemiologically assessed healthcare-
related occupational risk of sCJD
Of the 44 documents selected for full-text review (the 
same 44 mentioned above), 40 fulfilled the inclusion 
criteria. After analysis of the texts, seven analyti-
cal studies on occupation and risk of sCJD remained 
for potential data extraction [3,5-7,19,21,25].Those 
excluded were multipurpose case–control investi-
gations that made no mention of occupation in the 
results, occupation-unrelated meta-analyses, genetic 
case–control studies and public-health occupational 
profiles derived from empirical data. Four analytical 
studies reported before 1989 were reviewed: two were 
included [4,26] and two rejected [27,28]. Nine docu-
ments [3-7,19,21,25,26] provided data on occupational 
risk but only five of these addressed healthcare-related 
occupations [5-7,19,26]. Due to the low numbers 
(absence of exposed cases) in one study [26], risk-
based data for health professions were only avail-
able from four case–control studies [5-7,19]. Reported 
associations for healthcare-related occupational risk 
obtained from these four epidemiological studies and 
raw negative findings from the above-mentioned study 
[26] were tabulated.
Results
Individualised occupational data from 
national CJD surveillance teams
Health professionals among registered sCJD cases
A total of 202 health professionals were listed among 
8,321 cases of sCJD registered by 21 respondent coun-
tries participating in EuroCJD (Table 1). Of these, 65 
(32%) were physicians and 137 were other healthcare 
workers. The highest numbers by medical special-
ity were general practitioners (n=9), surgeons (n=7), 
internists (n=7), dentists (n=4), ophthalmologists 
(n=3) and pathologists (n=2). The proportion of physi-
cians or dentists among all registered sCJD cases was 
65/8,321 (0.8%).
Health professionals among non-cases or controls
Table 2 shows individual data reported for health pro-
fessions among non-cases or controls in five countries 
(Germany, Italy, Japan, Spain and the UK). Among 83 
healthcare workers, 15 were physicians, six of whom 
had unknown specialisations, and three were sur-
geons. The percentage of physicians and dentists 
among CJD cases in Germany, Italy, Japan, Spain and 
the UK combined was 0.7% (34/4,949 (Table 1). This 
was similar to the proportion in the combined controls 
0.5% (15/2,968).
Literature reviews
Reported sCJD in health professionals
Individual occupational profiles of reported health-
related professionals with sCJD are outlined in Table 3. 
The data are derived from 12 studies, three of which 
were case–control studies. In these 12 studies, a 
total of 66 health workers with sCJD were reported, at 
least eight of whom were physicians [4,5,8-12,17,20-
23]. One report described genetic CJD with phenotype 
resembling sCJD in three Slovakian health workers 
(two nurses and one dermatologist) with a mutation in 
codon 200 of the PRNP gene [11].
The following professions have been reported in sCJD 
cases: dentists (n=5), dental surgeon (n=1), neurosur-
geons (n=2), pathologist (n=1), internist with training 
in pathology (n=1) and orthopaedic surgeon who had 
worked with sheep and human dura mater for indus-
trial purposes (n=1) [12]. The majority of the remaining 
health professionals were nurses, two of whom had 
worked in neurosurgery and neurological care. Two 




Occupational profile of sporadic Creutzfeldt–Jakob disease cases reported to the European Creutzfeldt Jakob Disease 
Surveillance Network (EuroCJD), 1965–2010 (n=8,321)
Occupation Number of sCJD cases, by countrya, in the specified time period




























































































































   Cardiovascular surgeon 0 0 0 - - - - - 0 0 0 0 1 0 0 0 0 0 - 0 0 1
   Surgeon/urologist 1 0 0 - - - - - 1 0 0 0 0 0 0 0 0 0 - 0 0 2
   Surgeon and neuropathologist 0 0 0 - - - - - 1 0 0 0 0 0 0 0 0 0 - 0 0 1
   Traumatologist/surgeon 1 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   Ophthalmologist 0 0 0 - - - - - 0 1 0 1 0 0 0 0 0 1 - 0 0 3
   Surgeon (not specified) 0 0 0 - - - - - 0 0 0 0 0 0 0 0 0 1 - 0 0 1
   Pathologist 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1
   Neuropathologist’s assistant 0 0 0 - - - - - 1 0 0 0 0 0 0 0 0 0 - 0 0 1
   Forensic medicine 0 0 0 - - - - - 0 0 0 1 0 0 0 0 0 0 - 0 0 1
   Dentist 1 0 1 - - - - - 0 0 2 0 0 0 0 0 0 0 - 0 0 4
   Traumatologist 1 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   Plastic surgeon 0 0 0 - - - - - 0 0 0 0 0 0 0 0 0 1 - 0 0 1
   Paediatrics/anatomy 0 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 1 1
   Cardiologist 0 1 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   Internist 0 0 2 - - - - - 2 0 0 3 0 0 0 0 0 0 - 0 0 7
   Clinical oncologist 1 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   Toxicologist 0 1 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   General practitioner 0 3 0 - - - - - 0 0 1 3 0 0 0 0 0 1 - 0 1 9
   Psychiatrist 0 0 0 - - - - - 0 0 0 0 1 0 0 0 0 0 - 0 0 1
   Paediatrician 1 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 1
   Radiologist 0 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 1 1
   Scientist 0 0 0 - - - - - 0 1 0 0 0 0 0 0 0 0 - 0 0 1
   National service medical corps 0 0 0 - - - - - 0 0 0 0 0 0 0 0 0 0 - 0 1 1
   Alternative medical practitioner 0 0 0 - - - - - 2 0 0 0 0 0 0 0 0 0 - 0 0 2
   Epidemiologist 0 0 0 - - - - - 0 0 0 0 0 0 0 1 0 0 - 0 0 1
   Geriatrician 0 0 0 - - - - - 0 0 1 0 0 0 0 0 0 0 - 0 0 1
   Virologist 0 0 0 - - - - - 0 0 1 0 0 0 0 0 0 0 - 0 0 1
   Other (specialisation not specified) 0 0 0 - - - - 9 0 0 0 4 0 0 0 0 0 4 - 0 0 17
   Number of sCJD cases 
   among physicians or dentists 6 5 3 - - - - 9 7 2 5 12 2 0 0 1 0 9 - 0 4 65
Other health professionals
   Laboratory technician 0 - 0 - - - - - - 0 0 1 1 1 - 0 0 - - - 2 5
   Sterilisation department 0 - 0 - - - - - - 0 0 0 0 1 - 0 0 - - - 0 1
   Veterinarian 1 - 0 - - - - - - 1b 0 1 0 0 - 0 0 - - - 0 3
   Hospital employee 1 - 0 - - - - - - 0 0 2 0 0 - 0 0 - - - 5 8
   Other 0 - 0 - - - - - - 1b 0 17 17 0 - 2 2 - - - 45 84
   Number of sCJD cases among all   
   other health professionals 2 - 0 - - - - 36 - 2 0 21 18 2 - 2 2 - - - 52 137
Number of sCJD cases among all 
healthcare professionals 8 5 3 - - - - 45 7 4 5 33 20 2 - 3 2 9 - - 56 202
Total number of  















































AR=Argentina, AU= Australia, AT=Austria, BE=Belgium, CA=Canada. CY=Cypus, DK=Denmark, FR=France, DE=Germany, HU=Hungary, IL=Israel, IT=Italy, 
JP= Japan, NL=Netherlands, PT=Portugal, SK=Slovakia,SL=Slovenia, ES=Spain, SE=Sweden, CH=Switzerland, UK=United Kingdom. 
    sCJD: sporadic Creutzfeldt–Jakob disease. The dashes represent years for which there are no data.
       a There were no reports of sCJD among Polish pathologists, clinicians or medical technicians (personal communication, Dr J. Kulczycki, May 2009)./ 
b The two (non-medical) health workers were pathology assistants./ c Data for countries reporting presence versus absence of sCJD among pathologists 
(Belgium, Canada, Cyprus, Denmark and Sweden) are not included in the total number./ d Confirmed or probable cases./ e Austria reported 233 sCJD cases 
during 1969 to 2009 (one genetic transmissible spongiform encephalopathy excluded), including 84 cases of sCJD with occupational data (1993–2008). / 
f  sCJD deaths obtained from the EuroCJD website [16].Otherwise different categories of registered sCJD on request./ g sCJD cases with occupational data 
only./ h Occupational data not registered.
7www.eurosurveillance.org
Only one of three case–control studies [4,5,21] pro-
vided data on specialities but gave no indication of the 
numbers involved [5]. It is likely that most cases men-
tioned in the EuroCJD study by Van Duijn et al. [5] were 
included in country-specific occupational counts of the 
case set obtained from the extended EuroCJD consor-
tium in response to the current request.
Health-related occupational risk of sCJD
The nine analytical papers on occupations and sCJD 
identified [3-7,19,21,25,26] tended to focus on health-
care and animal care-related occupations, with Cocco 
et al.’s study furnishing detailed data on other occupa-
tions [19]. This study used a large number of non-vali-
dated CJD diagnoses from death records in the United 
States and controls selected after exclusion of persons 
with neurological diseases reported as the cause of 
death [19]. The main findings for healthcare-related 
occupations from five papers are summarised in Table 
4. While three of four studies on health professions 
did not demonstrate excess risk [5-7], statistically sig-
nificant findings – for persons working at physicians’ 
offices – were solely reported by Cocco et al. [19].
Discussion 
Despite a number of case reports of sCJD in physicians 
and technicians, the findings of this EuroCJD survey do 
not suggest an increased risk of sCJD in health profes-
sionals, nor do analytical studies show a clear excess 
risk for health-related professions. Methodological 
limitations of analytical studies in which occupational 
data were frequently provided by informants who were 
probably aware of the sCJD diagnosis [3-7,26] argue in 
favour of a cautious interpretation of the positive asso-
ciation reported for persons working at physicians’ 
offices [19]. Consequently, the main finding of this 
literature review and complementary EuroCJD obser-
vation is that health professionals, including medi-
cal staff, are not at greater risk of developing sCJD. 
However, this cannot exclude the possibility that there 
may be an occupational risk in specific circumstances, 
for example, for people in contact with high-risk cen-
tral nervous system tissue, and appropriate precau-
tions, as recommended by national authorities, should 
therefore be followed, particularly regarding labora-
tory work.
Although in some studies occupation was specifically 
analysed [19,25] and occupation may be the subject of 
specific inquiry in some surveillance systems, a limi-
tation of some registries and scientific studies is that 
occupation may not have been systematically recorded. 
When occupation was recorded, it is unlikely that a 
framework for consistent occupational data collection 
was used, so that neither registries nor case–control 
studies have incorporated the classic epidemiologi-
cal double approach. Recording of occupation may 
not identify specific chemical or biological exposures, 
which would require data for professions (job titles, 
medical specialisations) being cross-referenced with 
branches of activity (laboratory, administrative or 
clinical patient-contact work). The lack of registered 
surveillance data that combine profession with activity 
(e.g. contact with human tissue), when compared with 
the descriptions from previous case reports and the 
incident in Spain, illustrates the limits of the validity 
of available data for analytical purposes and precludes 
formal use of statistical testing. Although our study 
does not provide evidence of an excess risk of sCJD in 
health professionals, the fact that the data collected 
were mainly linked to medical speciality rather than 
actual activity might have concealed an excess risk of 
sCJD for some specific health professionals.
A case–control study seeking to examine the putative 
occupational risk posed by surgical injuries should 
have a biologically clear working hypothesis and a 
custom-tailored methodology. Matrices designed 
by linking medical speciality and surgical/forensic-
anatomical/pathological activity, in which the health 
Table 2
Occupational profile of non-cases or controls obtained 
through the European Creutzfeldt Jakob Disease 
Surveillance Network (EuroCJD), 1980–2009 (n=2,968)
Occupation Number of professionals, 
by country, in the 
specified time period
































Traumatologist/surgeon 0 1 0 0 0 1
Surgeon (not specified) 0 1 0 0 1 2
Internist 0 1 0 0 0 1
General practitioner 0 1 0 0 1 2
Psychiatrist 0 0 0 1 0 1
Paediatrician 1 0 0 0 0 1
Scientist 0 0 0 0 1 1
Other (specialisation not specified) 6 0 0 0 0 6
Number of physicians 7 4 0 1 3 15
Other health professionals
Laboratory technician - 2 - - 5 7
Hospital employee - 1 - - 13 14
Other - 10 - - 34 44
Number of other health  
professionals - 13 3 - 52 68
Number of healthcare professionals 7 17 3 1 55 83
Total number of  















DE=Germany; IT=Italy ; JP=Japan; ES=Spain; UK=United Kingdom.
The dashes represent years for which there are no data.
a  Controls from own case–control study.
b  Only persons with occupational data.
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professional can come into direct contact with high 
human-infectivity tissue by accident might not provide 
a sufficient background for analysis, without appro-
priate control being made for the influence of PRNP 
genotype, surgical or laboratory work history and long 
latency. Assuming that among non-cases or controls 
the proportion of medical specialities with potential 
exposure (surgeons, forensic surgeons and other sur-
gical specialists, pathologists) may be low, i.e. approx-
imately 1 per 1,000 (based on the figures of 3/2,968 in 
Table 2), the study size that would afford the necessary 
statistical power for a proper examination of the spe-
cific practices of health professions is higher than that 
provided by existing CJD registries in any one country. 
Since complementary analyses would be needed for 
professional and activity categories defined in terms 
of temporal references that have not been explored to 
date, such as ‘ever employed’ or ‘currently employed’, 
as well as duration of employment, requirements for 
study size and collaboration would be even higher.
In conclusion, a wide spectrum of medical specialities 
and health professions are represented in sCJD regis-
tries. Although selection due to higher ascertainment 
may lie behind the case reports of certain professions 
involved in clinical management or care of patients 
with sCJD, the biological significance of these obser-
vations remains uncertain and available data do not 
indicate an increased risk of sCJD in health profession-
als. However, the methodological issues mentioned 
above indicate the need for caution in drawing con-
clusions from the data and large-scale studies with 
specific causal hypotheses are needed in order for fur-
ther research to be undertaken into the potential link 
between health professions and sCJD
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2 assistant nurses [22]
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1 dentist
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neuropathologist; nurse; laboratory technician; 
dentist and ambulance worker
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1 nurse, gastrointestinal section [21]a
1 nurse and 1 ambulance driver without E200 
mutation 
2 nurses, 1 physician (dermatologist) with  
sporadic-like forms, carriers of E200K mutation 
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Summary of methods and main results of analytical epidemiological research into healthcare-related occupations and 
sporadic Creutzfeldt–Jakob disease, literature review, 1982–1 October 2011  
CJD: Creutzfeldt–Jakob disease; EuroCJD: European Creutzfeldt Jakob Disease Surveillance Network; GP: general practitioner; OR: odds ratio
UK: United Kingdom; USA: United States of America.
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Background Prospective national screening and
surveillance programmes serve a range of public health
functions. Objectively determining their adequacy and
impact on disease may be problematic for rare disorders.
We undertook to assess whether objective measures of
disease surveillance intensity could be developed for the
rare disorder sporadic Creutzfeldt–Jakob disease (CJD)
and whether such measures correlate with disease
incidence.
Method From 10 countries with national human prion
disease surveillance centres, the annual number of
suspected prion disease cases notified to each national
unit (n=17 610), referrals for cerebrospinal fluid (CSF)
14-3-3 protein diagnostic testing (n=28 780) and the
number of suspect cases undergoing diagnostic
neuropathological examination (n=4885) from 1993 to
2006 were collected. Age and survey year adjusted
incidence rate ratios with 95% CIs were estimated using
Poisson regression models to assess risk factors for
sporadic, non-sporadic and all prion disease cases.
Results Age and survey year adjusted analysis showed
all three surveillance intensity measures (suspected
human prion disease notifications, 14-3-3 protein
diagnostic test referrals and neuropathological
examinations of suspect cases) significantly predicted the
incidence of sporadic CJD, non-sporadic CJD and all
prion disease.
Conclusions Routine national surveillance methods
adjusted as population rates allow objective
determination of surveillance intensity, which correlates
positively with reported incidence for human prion
disease, especially sporadic CJD, largely independent
of national context. The predictive relationship between
surveillance intensity and disease incidence should
facilitate more rapid delineation of aberrations in disease
occurrence and assessment of the adequacy of disease
monitoring by national registries.
INTRODUCTION
National screening and surveillance programmes
encompass a broad range of diseases, which collect-
ively serve a diverse spectrum of important public
health objectives. Examples of national screening
programmes are those aimed at the early detection
of cancers or precancerous states, such as in
relation to cervix,1 breast2 3 and bowel,4 5 while
infectious or transmissible diseases like HIV,6 hepa-
titis C7 8 and Creutzfeldt–Jakob disease (CJD)9 are
a frequent focus of national surveillance centres.
Evaluation of national screening and surveillance
programmes, using objective measures of the
adequacy of screening and the consequent impact
on disease incidence, is important for measuring
the utility of these public health initiatives.
In relation to national screening for certain
malignancies, the ‘at risk’ group can often be
defined by age and/or sex, with national census
data delineating the size and geographical distribu-
tion of the target population. Consequently, the
adequacy of screening and impact on disease inci-
dence over time can be determined reasonably
easily and accurately, including providing insights
into how completeness of disease screening impacts
disease incidence.1 Objective assessment of the
adequacy and consequent impact of national sur-
veillance is arguably more difficult for rare disor-
ders like sporadic CJD, where screening is not
possible and surveillance largely based on the suspi-
cion of disease.
CJD is the most common human phenotype of
the rare, transmissible neurodegenerative disorders
known as prion diseases. Over the last 15 years,
there has been substantial improvement in premor-
tem diagnostic capacity, mainly through CSF
14-3-3 protein detection and brain MRI.10–12 With
a reported sensitivity of 85%–90%,11 13 the utilisa-
tion of the 14-3-3 protein CSF test has greatly
increased since its introduction during the 1990s.14
Sporadic CJD incidence is frequently quoted as
1/million population/year,15 16 implying a fixed and
always maximal incidence, perhaps secondary to
intrinsic biological features of the disease, yet offi-
cially reported national incidence rates vary from
0.48 to 2.23/million population/year.9 Small popu-
lations, more vulnerable to incidence variation,
may partly explain such disparities but the question
remains as to why countries with inherent similar-
ities in surveillance methodologies and population
sizes have varied reported incidence rates. A recent
report has suggested that surveillance intensity,
measured through assessment of population inter-
rogation rates, correlates with disease incidence.17
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This is an intuitively appealing but hitherto unsubstantiated
hypothesis, particularly in a multi-national setting.
The primary aim of the current study was to examine within
a multi-national context the relationship between reported
disease incidence and surveillance intensity, the latter measured
through adapting relatively simple monitoring methods into
objective metrics.
METHODS
National surveillance centres constituting the European and
Allied Countries Creutzfeldt–Jakob Disease Surveillance
Consortium (EUROCJD) were invited to participate in the
study. In addition, based on analogous prospective national
human prion disease surveillance programmes and similar data
collection mechanisms, the Czech Republic and Hungary were
also included in the study. Details concerning the EUROCJD
participating countries and their ascertainment and data collec-
tion methods have been published previously.9 11 Overall,
10 countries (Australia, Austria, Canada, Czech Republic,
France, Germany, Hungary, Republic of Ireland, Netherlands
and the UK) provided data for the 14-year period of 1993–
2006, with a key requirement being their ability to undertake
detailed age-stratification of the annual national populations for
each year of study data supplied. Surveillance activities in the
majority of countries involved began in 1993 and the timeframe
of data collected was chosen to reflect this fact and the introduc-
tion of the CSF 14-3-3 test in 1997, providing a long-term per-
spective of the study measures assessed. Data requested for
analysis were annual counts for each category of: persons
referred to national surveillance units with suspected prion
disease; those referred with suspected prion disease undergoing
neuropathological assessment; and persons referred for CSF
14-3-3 protein testing. For countries commencing national pro-
spective surveillance prior to 1998, CSF 14-3-3 protein detec-
tion was available from 1997, while in countries where
prospective national surveillance commenced after 1997
(Canada and Czech Republic), data were limited to the available
years within the epoch (refer table 1).
Three variables were selected as potential objective predictors
of disease incidence: notification of suspected prion disease to a
national registry; referrals for diagnostic CSF 14-3-3 protein
testing; and referrals for neuropathological examination in sus-
pected prion disease cases. Suspected prion disease notifications
included all referrals made to each national surveillance centre
between 1/1/1993 and 31/12/2006, regardless of the notification
source and the perceived prima facie likelihood of prion
disease; the latter was to mitigate potential selection biases.
Specific practices for CSF 14-3-3 protein testing varied between
countries; some national surveillance centres were notified by
multiple delegated diagnostic laboratories of all testing results,
while in other countries only positive results were notified by
external laboratories and not all samples were tested. In many
countries, surveillance centres undertook all testing within their
own laboratory and were therefore aware of all referrals, regard-
less of result. Although this variation in CSF referrals introduces
a potential source of bias, it was tolerated to accommodate
minor differences in national surveillance formats and to
enhance the broader applicability of the study and its findings
across the authentic range of national surveillance practices.
Referrals for neuropathological examination included all sus-
pected cases of prion disease referred to national surveillance
centres undergoing autopsy examination of the brain or brain
biopsy, offering a ‘gold standard’ for prion disease diagnosis.
Cases where onset and notification occurred within one
country but death occurred elsewhere were excluded from the
analysis, as were CSF 14-3-3 protein samples referred from
outside the country in question. Within each country, data for the
three predictor variables were collected as total numbers and
were stratified by survey year into 5-year age groups by: year and
age at notification or death (if dead at time of notification) for
the suspected prion disease referral variable; year and age at CSF
14-3-3 protein sampling for CSF referrals; and year and age at
notification (or death if dead at time of notification) for neuro-
pathological examination of suspected prion disease referrals.
Three outcome variables were determined: the annual
number of definite and probable cases of sporadic CJD; non-
sporadic CJD (encompassing variant CJD, genetic and iatro-
genic prion disease); and all prion disease cases (sporadic plus
non-sporadic CJD plus other prion diseases). Human prion
disease evinces a heterogeneous phenotype, such that a case
may be referred as being suspected variant CJD but ultimately
classified as a different form of prion disease. The national sur-
veillance units involved in the study use the same referral
systems for all types of prion disease, with final classification of
definite and probable cases based on internationally recognised
clinical and/or neuropathological criteria. To assess the potential
influence of the numerical predominance of sporadic CJD on
the all prion disease groups, non-sporadic CJD cases were ana-
lysed as a separate group.
After data auditing, the Netherlands was excluded from
the modelling analyses due to incomplete data sets for the
study period.
Statistical analysis
Adjustment for age structure differences in the nine countries
was performed by direct age-standardisation, with data adjusted
to a standard population; the Australian 2000 population was
chosen due to it being the median size and midpoint of the data
set collected. Crude rates of disease incidence (per million popu-
lation) were initially calculated for each country. Trends in rates
overall and within each country for referrals of CSF 14-3-3
protein detection, suspect CJD cases and neuropathological
examinations postmortem were assessed. To investigate the pre-
dictors for sporadic, non-sporadic and all prion disease cases,
incidence rate ratios (IRRs) were estimated with 95% CIs using
random-effects Poisson regression methods to take into account
within-country variation for repeated measures across the survey
years: reported suspect cases, CSF referrals and performing
neuropathology in suspected cases. The test for heterogeneity
using the random-effects variance parameter estimate was signifi-
cant (p<0.01), confirming the appropriateness and suitability of
the random-effects model. Stata, V.10.0 (StataCorp, College
Station, Texas, USA) statistical software was used in all analyses.
RESULTS
For the period 1993–2006, 17 610 persons with suspected prion
disease were notified to national surveillance centres across the
nine countries, with 28 780 CSF 14-3-3 protein referrals for
diagnostic testing, and 4885 cases of suspected prion disease
undergoing neuropathological assessment (table 1). For the same
period, there were 4235 (definite and probable) sporadic CJD
cases (approximately 84% of the total) among 5054 cases classi-
fied with any form of prion disease. Overall, 70% of the 5054
definite and probable CJD cases and 73% of all suspect prion
disease referrals who underwent neuropathological examination
were classified as definite cases. For the nine countries, national
crude annual referral rates of suspected prion disease cases
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ranged between 0.20 and 26.62 cases per million per year
(annual average 1.55–12.32 referrals/million/year), while CSF
referrals ranged from 0.20 to 29.41 per million per year (annual
average 0.92–17.25 referrals/million/year) and neuropathology
examination in suspect cases ranged from 0.19 to 4.84 examina-
tions per million per year (annual average 0.88–2.64 examina-
tions/million/year) (table 2, see online supplementary tables 1
and 2). For sporadic CJD, the crude annual incidence rates
varied from 0.19 to 2.29 cases per million per year (annual
average 0.77–1.42 cases/million/year) (table 3) and for all prion
diseases, the crude annual incidence rates varied from 0.19 to
2.58 cases per million per year (annual average 0.87–1.73 cases/
million/year) (see online supplementary table 3).
Temporal trend analysis of each age-adjusted, predictor and
outcome variable over the 1993–2006 period was undertaken
for the pooled national data. Overall, there was a significant
increase in suspect case referrals (IRR 1.09 (95% CI 1.08 to
1.10)), diagnostic CSF 14-3-3 protein detection referrals (IRR
1.18 (95% CI 1.17 to 1.19)), sporadic CJD (IRR 1.03 (95% CI
1.01 to 1.04)) and all prion disease cases (IRR 1.02 (95% CI
(1.01 to 1.03)) but no increase in neuropathological examina-
tions of suspect cases at postmortem (IRR 1.00 (95% CI 0.99 to
1.01)) over time (see online supplementary table 4). Differences
between countries in terms of the temporal trends and the cor-
relations between surveillance intensity predictor variables and
disease incidence were observed over the study period. Seven of
the nine countries displayed congruence with the principle that
significant increases in the average annual trend of suspect prion
disease notifications combined with diagnostic CSF 14-3-3
protein detection referrals correspond with increases in disease
incidence (sporadic CJD and/or all prion disease) over the study
period. Increasing surveillance variables in Hungary was asso-
ciated with an increase in only the ‘all prion disease’ category,
and in one country (Czech Republic) the conformity to this
principle was that no increase in surveillance intensity variables
over the study period corresponded with a lack of observed
increase in disease incidence. In only two countries (Australia
and Republic of Ireland) was there no correspondence between
a significant increase in the average annual trend in suspect
prion disease notifications and diagnostic CSF 14-3-3 protein
Table 2 National crude annual suspect human prion disease referral rates (per million population)
Country Australia Austria Canada Czech Republic France Germany Hungary Ireland UK
1993 1.25 1.10 0.36 0.68 0.30 1.35
1994 1.29 1.57 1.64 0.98 0.30 2.06
1995 2.10 1.95 1.58 1.18 0.30 1.50
1996 2.84 2.14 3.47 2.11 1.67 0.55 2.29
1997 2.86 4.39 5.12 2.18 1.78 2.46 2.78
1998 4.17 4.26 1.42 7.89 2.22 0.80 2.97 2.63
1999 5.76 7.88 2.07 10.13 1.73 1.30 3.47 2.90
2000 10.08 10.86 2.66 0.19 13.98 1.85 1.91 1.85 2.99
2001 11.23 14.55 3.24 1.08 18.61 2.10 3.09 3.64 3.03
2002 10.99 13.48 3.27 1.76 17.54 1.88 1.59 3.83 2.75
2003 11.81 14.66 2.36 2.25 18.12 2.06 1.69 1.51 2.72
2004 12.67 15.66 2.80 1.76 14.66 2.08 2.39 9.39 1.90
2005 13.14 21.01 2.96 1.95 15.24 2.35 3.17 6.77 2.03
2006 12.41 26.62 2.38 1.85 21.38 3.51 4.86 6.84 1.83
Average 7.33 12.32 2.57 1.55 10.77 1.97 1.94 3.16 2.34






























who had NP that
were confirmed
with CJD (%)
Australia 1993–2006 2017 1740 412 302 340 235 69 57
Austria 1996–2006 1102 1016 235 101 122 113 93 48
Canada 1998–2006 731 918 472 284 311 261 84 55
Czech
Republic
2000–2006 111 154 111 55 62 62 100 56
France 1993–2006 8998 8148 1272 1177 1432 874 61 69
Germany 1993–2006 2273 15 640 1008 1366 1493 973 65 97
Hungary 1993–2006 273 83 241 115 165 162 98 67
Republic
of Ireland
1993–2006 175 77 86 42 49 44 90 51
UK 1993–2006 1930 1004 1048 793 1080 825 76 79
Totals 17 610 28 780 4885 4235 5054 3549 70 73
*Includes both probable and definite (pathologically confirmed) sporadic CJD.
†Includes all forms of probable and definite prion disease: sporadic CJD, variant CJD, genetic prion disease and iatrogenic prion disease.
CJD, Creutzfeldt–Jakob disease.
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detection referrals over the study period and increases in either
sporadic CJD and/or all prion disease incidence; this lack of cor-
relation did not clearly correspond with the magnitude of the
IRRs for surveillance intensity.
The test for heterogeneity using the random-effects variance
parameter was significant (p<0.001), indicating suitability for
employing random-effects Poisson modelling. After age adjust-
ment, the analysis showed highly significant correlations
between each predictor variable and the incidence of disease
(sporadic CJD, non-sporadic CJD and all prion disease groups)
(table 4), with the association between the neuropathological
examinations of suspect cases as predictor and disease incidence
less substantial than the other two predictor variables.
By age and survey year adjusted analysis, the associations
between the predictor and outcome variables (table 4) showed
suspect case notifications, diagnostic CSF 14-3-3 protein detec-
tion referrals and neuropathological examination each inde-
pendently predicted sporadic CJD, non-sporadic CJD and all
prion disease incidence. The only exception was a modest nega-
tive association between diagnostic CSF 14-3-3 protein detec-
tion referrals and non-sporadic CJD. In comparison with the
level of significance of our other analyses we believe this modest
result may imply a lack of meaningful correlation. We suspect
the outcomes observed for the all prion disease group most
likely represent a carryover effect through the numerical pre-
dominance of sporadic CJD in this group.
COMMENT
This is the first study to directly address and verify previous sug-
gestive findings17 and prevailing assumptions that greater scru-
tiny of a population may lead to higher rates of human prion
disease detection and thereby reported disease incidence. Integral
to the more objective assessment approach described in our study
is the adjustment of surveillance detection methods as population
interrogation rates. Employing this method, we have shown that
relatively simple, accessible measures (clinical case recognition
with notification made to a national surveillance centre combined
with a routine diagnostic test like CSF 14-3-3 protein detection
and neuropathological examination) can be adjusted to generate
metrics of surveillance intensity, which correlate sufficiently with
sporadic CJD incidence to be predictive. The broad multi-
national context, very large number of cases included and the
extended time period of the study all add support for the robust-
ness of the findings. As such, our observations provide important
insight into factors that contribute to variations in reported prion
disease incidence, particularly for sporadic CJD.9 Nevertheless,
in the absence of universal autopsy, some uncertainty inevitably
persists regarding the ascertainment of all human prion disease
cases and the absolute incidence of CJD.
The observed predictive relationship between surveillance
intensity and sporadic CJD incidence was present despite the
recognised clinical profile variations across the sporadic CJD
subtypes,11 18 suggesting that national surveillance can be
Table 4 Overall incidence rate ratios after adjustment for age and survey years
Outcome Predictor
Incidence rate (95% CI) ratio
(age-adjusted) p Value
Incidence rate (95% CI) ratio (age and survey
year adjusted) p Value
Sporadic cases Suspect cases 1.007 (1.005 to 1.01) <0.001 1.005 (1.004 to 1.006) <0.001
CSF referrals 1.002 (1.001 to 1.003) <0.001 1.001 (1.0008 to 1.002) <0.001
Neuropathology performed in
suspect cases
1.08 (1.06 to 1.09) <0.001 1.056 (1.05 to 1.061) <0.001
Non-sporadic cases Suspect cases 1.007 (1.003 to 1.01) 0.003 1.004 (1.002 to 1.007) <0.001
CSF referrals 1.0003 (1.0002 to 1.0004) <0.001 0.998 (0.997 to 0.999) 0.03
Neuropathology performed in
suspect cases
1.05 (1.04 to 1.07) <0.001 1.05 (1.03 to 1.07) <0.001
All prion disease
cases
Suspect cases 1.008 (1.005 to 1.01) <0.001 1.013 (1.012 to 1.014) <0.001
CSF referrals 1.002 (1.001 to 1.003) <0.001 1.002 (1.001 to 1.003) <0.001
Neuropathology performed in
suspect cases
1.07 (1.06 to 1.09) 0.006 1.06 (1.05 to 1.07) <0.001
Table 3 National crude annual incidence rates (per million population) for sporadic Creutzfeldt–Jakob disease for each country
Country Australia Austria Canada Czech Republic France Germany Hungary Ireland UK
1993 0.96 0.61 0.31 0.39 0.66
1994 0.62 0.79 0.87 0.59 0.92
1995 1.05 1.03 0.93 0.49 0.60
1996 1.37 1.13 1.18 1.01 1.18 0.55 0.69
1997 1.08 0.50 1.38 1.23 1.09 0.55 1.03
1998 1.34 0.75 0.73 1.40 1.38 0.30 1.62 1.08
1999 1.32 0.88 0.85 1.58 1.20 0.50 0.27 1.06
2000 1.46 0.75 1.04 0.19 1.48 1.26 0.90 0.79 0.82
2001 1.03 1.12 0.87 0.78 1.86 1.44 1.69 1.30 0.98
2002 0.92 0.62 0.99 0.59 1.81 1.18 0.69 1.28 1.21
2003 1.11 1.85 0.85 0.78 1.80 1.28 0.80 0.50 1.33
2004 0.84 0.86 1.31 1.08 1.60 1.62 0.80 1.73 0.84
2005 1.13 1.70 1.23 0.98 1.36 1.59 0.79 1.21 1.10
2006 1.55 2.29 1.13 0.97 2.02 1.30 1.19 0.94 1.14
Average 1.13 1.13 1.00 0.77 1.42 1.19 0.81 0.98 0.96
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achieved for a disease through primarily relying on clinical
detection even when there is a somewhat diverse phenotypic
spectrum. It is also of interest that advanced age, well beyond
that more typically associated with sporadic CJD, does not
appear to impede clinical recognition, with previous studies sug-
gesting that increased incidence appears to correlate with
increased referrals of suspect cases in the very elderly.17 19
The epidemiological history of human prion diseases, espe-
cially acquired forms such as those related to the therapeutic use
of cadaveric dura mater explants and pituitary hormones20 as
well as variant CJD21 and ongoing concerns regarding transmis-
sion risks posed by routine surgery, including non-
neurosurgery,22 23 should serve as a sobering precaution against
any public health complacency in relation to this group of dis-
eases. The key objectives of prospective national surveillance pro-
grammes are to ensure adequate detection of the disease and
accurate depiction of the epidemiological profile so that signifi-
cant departures in disease incidence or demographic characteris-
tics can be recognised.24 Our findings should subserve both of
these objectives. As described for variant CJD,21 an altered
phenotype can indicate important epidemiological changes with
respect to disease aetiology. Notwithstanding this influence, a
more accurately defined and predictive relationship between
population surveillance intensity and disease recognition rates
(with 95% CIs) should facilitate more rapid and confident delin-
eation of significant deviations in national disease incidence for a
given surveillance intensity and serve to prompt more detailed
evaluation of why this change has occurred, possibly leading to
more expeditious deployment of public health responses.
Our study revealed major variations, approximately two
orders of magnitude, in annual crude notification rates of
persons with suspected prion disease across the study period in
the countries assessed. Although some of this variation may be
a natural finding based on variable population sizes, it demon-
strates the likely underappreciation of true differences when only
drawing comparisons of unadjusted, average disease incidence
rates from countries with varied population sizes. Over the study
timeframe, CJD awareness and recognition increased markedly
both nationally and globally due to factors including the bovine
spongiform encephalopathy (BSE) epidemic, improved surveil-
lance systems and advances in diagnostic capabilities, in particu-
lar the CSF 14-3-3 diagnostic test. These influences have
contributed to improved notification and diagnostic assessment
of suspected cases, a feature reflected in the positive temporal
trends observed for suspect case and 14-3-3 CSF test referrals
and, to a lesser degree, with neuropathological examination in
the participant countries. Although temporal variation in pre-
dictor and outcome variables was significant between the coun-
tries over the study period, the analysis of pooled data, adjusted
for time and age, demonstrated that time was independent of the
association between surveillance intensity measurements and
incidence, further underscoring the strength of this study.
Referrals for 14-3-3 CSF analysis in France and Germany were
noticeably higher than in other countries. We surmise this may be
due to subsidisation of the costs of testing and/or the strong trad-
ition of employing CSF surrogate biomarker detection in the
evaluation of dementias, including CJD. In Hungary and the
Czech Republic, the lower number of referrals for 14-3-3 testing
is due to the later point at which 14-3-3 testing was introduced
and adopted into the criteria in comparison with France and
Germany. However, despite the higher levels of CSF testing in
Germany and France, incidence was not increased in comparison
with other countries, suggesting that the correlation with spor-
adic CJD incidence also relies on referral of suspect cases to a
national reference centre, as well as neuropathological examin-
ation. Furthermore, this finding argues against a potential mis-
conception from this study that widespread 14-3-3 CSF testing is
required for optimal case ascertainment. The negative association
observed between CSF referrals and non-sporadic CJD cases may
relate in part to modest increases in prion protein gene (PRNP)
testing observed over the study timeframe, translating into a
reduced likelihood of non-sporadic CJD cases (mainly genetic)
undergoing 14-3-3 CSF testing. This is a plausible explanation,
however, unverified in this study, with the negative association
also possibly related to the fact that CSF 14-3-3 protein detection
was primarily developed for sporadic CJD detection.
The multi-national context of the present study was an
intended and important design feature by which it was ensured
relatively minor but ‘real life’ variations in specific mechanisms
of national prion disease surveillance were encompassed.
Despite this, the findings clearly demonstrate overall support for
a positive and predictive correlation between surveillance inten-
sity and sporadic CJD incidence; however, we note that this pre-
dictive association was not observed in two of the nine
countries. The reason for this is uncertain but may relate to
unapparent variations in surveillance methods employed within
these countries or a potential saturation point where no new
cases are identified despite increasing surveillance intensity.
Although the public health and epidemiological context of
each disease undergoing national screening or surveillance is
relatively unique, and therefore of limited direct comparability,
the finding that observed population diagnosis rates can be influ-
enced by testing and resourcing issues is not unique to CJD.
HIV infection diagnosis in the UK is estimated at 74% of all
infections, while in Australia, the estimate is 85%–90%.25 26
The Australian epidemic remains largely transmitted through
male homosexual contact, a well-informed group with a high
rate of HIV testing.27 In contrast, the epidemic in the UK is
more heterogenous and often associated with migration to the
UK from high prevalence countries.28
So, in conclusion, our study has confirmed that routine
national surveillance methods adjusted as population rates allow
objective determination of surveillance intensity, which corre-
lates positively with reported incidence for human prion
disease, especially sporadic CJD, largely independent of national
context. The predictive relationship between surveillance inten-
sity and disease incidence should facilitate more rapid delinea-
tion of aberrations in disease occurrence and permit objective
assessment of the adequacy of disease monitoring by national
registries. Further, the approach outlined in our study could
extend to other rare disorders, and should allow more objective
assessment of the adequacy of population scrutiny by extant or
potential members of surveillance consortia.
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Unusual Clinical and Molecular-Pathological Profile
of Gerstmann-Sträussler-Scheinker Disease Associated
With a Novel PRNP Mutation (V176G)
Marion Simpson, MBChB; Vanessa Johanssen, PhD; Alison Boyd, DipGenCouns; Genevieve Klug, BSc;
Colin L. Masters, MD; Qiao-Xin Li, PhD; Roger Pamphlett, MBChB, MD, FRCPath, FRACP; Catriona McLean, MD;
Victoria Lewis, PhD; Steven J. Collins, MD
G erstmann-Sträussler-Scheinker (GSS) disease is arare, almost exclusively genetically determinedprion disease, typically characterized clinically by
progressive cerebellar ataxia and dementia and neuropatho-
logically by diffuse, prion protein (PrP)–containing amyloid
deposits.1 Although the P102L mutation in the prion protein
(PRNP) gene is the most commonly observed in GSS
disease,2 numerous insertion, missense, and point muta-
tions, including P105L, A117V, H187R, F198S, D202N, Q212P,
Q217R, and Y218N, have been detected, probably contribut-
ing to the notable clinical and pathological diversity.2,3 Typi-
cally, GSS disease follows an autosomal-dominant inheri-
tance pattern4 and manifests a prolonged clinical course,
with median illness duration of 39 months reported in large
patient series.5 In addition to progressive cerebellar ataxia
and dementia, clinical findings in GSS disease may include
myoclonus, extrapyramidal features, and evidence of pyra-
midal tract dysfunction.3 Cognitive decline usually follows
cerebellar ataxia as a later symptom in the clinical course,
especially in P102L GSS disease,4 and may be absent in
patients with certain mutations such as Q212R6; however,
early prominent dementia without cerebellar ataxia has
been described in some less-common mutations such
as G131V.7,8 Neuropathological findings are also variable
but generally there is evidence in the cerebrum and cerebel-
lum of widespread, PrP immunopositive, unicentric and/or
multicentric amyloid plaques, associated with differing
degrees of spongiform change, neuronal loss, and astrocytic
gliosis; tau-positive neurofibrillary tangles may also be
observed.6,9-11
Herein, we report a patient with neuropathologically
confirmed GSS disease associated with a novel PRNP
mutation, displaying an unusual combination of clinical
and molecular-pathological features, which overall sub-
serve to further broaden an already diverse phenotypic
spectrum.
IMPORTANCE Here we describe the unusual clinical and molecular-neuropathological profile
of a case of Gerstmann-Sträussler-Scheinker disease associated with a novel prion protein
(PRNP) gene mutation.
OBSERVATIONS This case report from the Australian National Creutzfeldt-Jakob Disease
Registry concerns a 61-year-old British-born woman with no history of neurodegenerative
disorder in first-degree relatives. Rapidly progressive dementia, altered behavior, and
cerebellar ataxia dominated the clinical picture in the period immediately following minor
elective surgery, with death 1 month later in an akinetic-mute state. Brain histopathological
examination revealed neuronal loss, scant foci of spongiform change, and diffuse multicentric
amyloid plaques, selectively immunoreactive for prion protein, within the cerebral and
cerebellar cortices and deep gray matter. Tau immune-reactive neurofibrillary tangles and
neuritic threads were present in the cerebral cortex. PRNP sequencing demonstrated a valine
to glycine mutation at codon 176, with valine homozygosity at polymorphic codon 129.
Western-blot analysis of frozen brain tissue displayed a nonclassic protease-resistant prion
protein banding pattern, with a prominent approximately 8-kDa protease-resistant fragment.
CONCLUSIONS AND RELEVANCE Reported is a proband with a novel PRNP mutation associated
with neuropathologically confirmed Gerstmann-Sträussler-Scheinker disease displaying a
somewhat unusual constellation of clinicopathological features, which overall subserve to
further broaden an already diverse phenotypic spectrum.
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Methods
The proband was a white, British-born woman whose first defi-
nite neurological symptoms occurred at age 61 years, around
the time of elective surgery for removal of a dislodged breast
implant. However, during a period of years prior to surgery, the
patient had become increasingly estranged from all relatives.
Infrequent, irregular involvement with family precluded con-
fident delineation of any specific neurological or psychiatric
symptoms and their chronological evolution but a sister main-
tained some contact, describing 6 months of “low mood” and
possible memory problems. In addition, posthumously, the sis-
ter of the proband became aware of some apparently unusual
behavior, such as buying inappropriately sized underwear and
the likely hoarding of large supplies of cleaning products, al-
though in contrast, financial affairs and housework had been
maintained in good order. In the immediate postoperative pe-
riod, the patient developed what was thought to be an acute
confusional state with delusional ideation, for example, claim-
ing that she had swallowed a 5-cent coin and that staff mem-
bers had been forcing her to swallow jewelry. The proband’s
sister affirmed that the postoperative demeanor was com-
pletely uncharacteristic.
Following surgery, gait unsteadiness was also notewor-
thy and 2 falls occurred while she was in the hospital. Mental
status assessment in the postoperative period confirmed cog-
nitive impairment (Mini Mental State Examination score, 20
out of 30), especially defective short-term recall and mild ex-
pressive and nominal dysphasia. Neurological examination re-
vealed cerebellar ataxia with bilateral intention tremor, gen-
eralized hyperreflexia, and myoclonus. The patient never left
institutional care following her surgery, experiencing rapid,
steady cognitive and gross motor decline and dying in an aki-
netic-mute state around 1 month following surgery.
There was no known family history of neurodegenera-
tive disease in first-degree relatives (Figure 1), with the pro-
band’s mother dying aged 88 years of cancer and the father
aged 92 years as a consequence of a head injury sustained from
a fall. Scant, imprecise information existed for nonfirst-
degree relatives, especially in the patrilineage, but there was
a history of a maternal aunt dying (age unknown) in a mental
hospital after an illness of only a few months’ duration. The
patient had migrated to Australia at the age of 37 years, around
the time of onset of the United Kingdom bovine spongiform
encephalopathy epidemic. There was no history of recog-
nized risk factors for iatrogenic prion disease.
Routine blood test results were unremarkable. Cerebro-
spinal fluid test results were normal aside from the presence
of 14-3-3 proteins. Magnetic resonance imaging of the brain
showed mild generalized atrophic changes (consistent with age)
and a few, nonspecific, deep white matter hyperintensities in
the cerebral hemispheres, but there were no findings more typi-
cal of sporadic Creutzfeldt-Jakob disease such as areas of gray
matter restricted diffusion nor increased signal on fluid-
attenuated inversion recovery sequences (Figure 2). Electro-





Family tree depicting the proband (solid fill) and first-degree relatives with
current ages or ages at death (in years). No first-degree relative was reported to
have had any neurological disease with the exception of 1 son (line fill) with
schizophrenia. Circles indicate females; squares, males; strikethrough,
deceased.
Figure 2. Representative Proband Brain Magnetic Resonance Images
A B C
Fluid-attenuated inversion recovery (A), diffusion-weighted (B), and apparent
diffusion coefficient map (C) images demonstrate mild age-appropriate cerebral
atrophy, associated with some nonspecific T2 hyperintensities, but absence of
changes typically found in human prion disease, especially sporadic
Creutzfeldt-Jakob disease.
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encephalography findings showed attenuated alpha rhythms




Routine hematoxylin and eosin stains of frontal, temporal, and
occipital cortical sections showed numerous (densely eosino-
philic) amyloid plaques (Figure 3A), neuronal loss, and astro-
cytic gliosis. The amyloid plaques, sometimes appearing mul-
ticentric, were extensively deposited, most marked in the lower
laminae, with immune-peroxidase studies showing reactiv-
ity with both 3F4 and 12F10 anti-PrP monoclonal antibodies
(Figure 3B); plaques did not demonstrate amyloid-β immu-
noreactivity. Many of the amyloid plaques showed an associ-
ated microglial response but did not resemble florid plaques
(Figure 3A). The basal ganglia showed a similar prominent dep-
osition of closely packed, granular deposits, again immuno-
reactive with 3F4 and 12F10 anti-PrP monoclonal antibodies.
Scant spongiform change was seen focally in the cerebral cor-
tex, basal ganglia, and cerebellar cortex. Hippocampal sec-
tions displayed numerous tau immunoreactive neurofibril-
lary tangles in association with extensive neuropil thread
formation and areas of neuritic plaque formation (Figure 3C).
In the cerebellum, there was extensive immunopositive prion
protein deposition within the molecular layer, patchy Pur-
kinje cell loss, and a moderately intense microglial response
within the cortex. This extensive PrP-positive amyloid depo-
sition in association with prominent tau pathology was felt to
be most consistent with a neuropathological diagnosis of GSS
disease.
PRNP Genotyping
Appropriate consent for genetic examination was obtained. Ge-
nomic DNA was extracted from the brain, and the PRNP open
reading frame was sequenced in the forward and reverse ori-
entations with overlapping primers (PrP106 and PrP46 se-
quences described previously12; PrPF2 5′-CCGAGTAAGC-
CAAAAACCAAC -3′ and PrPR2 5′-TCACTGCCGAAATGTATGATG
-3′). Sequencing revealed the patient to be homozygous for va-
line at the polymorphic codon 129. A guanine to adenine
nucleotide substitution was found in a 5′ noncoding region,
at position -21 relative to the start codon, and a synonymous
adenine to guanine substitution was seen at the third posi-
tion of codon 117, transitions both previously described as PRNP
polymorphisms.13 A thymine to guanine transversion was de-
tected at the second position of codon 176, resulting in a pre-
dicted amino acid change from a valine to glycine. This mu-
tation has not previously been reported. A diagrammatic
representation of these sequence variations is shown in
Figure 4A.
PrPres Analysis
Frozen post mortem brain specimens from the cerebellum and
occipital pole were homogenized to 10% (weight/volume) in
phosphate-buffered saline. Aliquots were analyzed by West-
ern blot with or without proteinase K (PK) digestion, as pre-
viously described.12 Briefly, samples were digested with 100
μg/mL PK for 1 hour at 37°C, before mixing with the appropri-
ate polyacrylamide gel electrophoresis (PAGE) sample buffer.




Temporal cortex showing numerous plaques (A, encircled) in combination with
neuronal loss and astrocytic gliosis (A, arrowheads) (hematoxylin and eosin,
original magnification x 200). The plaques are immunoreactive with the
anti-PrP monoclonal antibody 12F10 (B, original magnification x 100) and
associated with tau-immunoreactive neurofibrillary tangles and prominent
neuropil threads (C, original magnification x 200).
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Samples (using double the volume of PK digested compared
with undigested) were resolved on 16% Tris-glycine or 12%
NuPAGE (Invitrogen) gels and transferred to polyvinylidene
difluoride membrane (Millipore) before incubation with the ap-
propriate primary and secondary antibody and visualization
using enhanced chemiluminescence (ECL Plus; Amersham).
Initially, before PRNP sequencing results were known,
samples were subjected to sodium dodecyl sulfate–PAGE and
Western blot analyses of protease-resistant PrP (PrPres) follow-
ing PK digestion alongside glycotype 1-4 controls, using the
commonly used 3F4 antibody as previously described.14 As
seen in Figure 4B, the characteristic di-, mono-, and un-
glycosylated triple banding pattern of PrPres was not present
in the proband. Rather, a prominent immunoreactive, PK-
resistant fragment of less than 15 kDa was observed. Numer-
ous additional minor bands, creating a ladder spanning from
greater than 15 kDa to at least 50 kDa, often superimposed on
subtle lane smearing, were also observed.
Epitope mapping using antibodies spanning the length of
the prion protein (Figure 4C and Table) was carried out to fur-
ther characterize the small fragment. As seen in Figure 4C, the
PrPres fragment, resolving at approximately 8 kDa, was not im-
munoreactive with antibodies to the far N-terminus (8B4) or
those with epitopes beyond codon 143 (ICSM 18) toward the
C-terminus of the prion protein, leading to the conclusion that
the 8-kDa fragment resulted from combined N- and C-
terminal truncation of PrPres. Based on its apparent molecu-
lar weight and the known antibody epitopes, we predicted the
8-kDa fragment resulted from PrP cleavage around residues
60 and 140. Furthermore, the higher molecular weight bands
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A, Schematic representation of the prion protein open reading frame and
protein, with the nucleotide changes, codon positions, and resulting amino acid
changes detected in the proband as indicated. B, Proteinase K (PK) digest and
polyacrylamide gel electrophoresis/Western blot analysis (using 3F4 antibody)
of frozen brain tissue from 2 brain regions of the proband (cerebellum [Ce] and
occipital pole [OP]) compared with glycotype controls (T1, T2, T3, and T4:
protease-resistant prion protein [PrPres] glycotypes 1, 2, 3, and 4).14 C,
Characterization of the small amyloidogenic PrPres fragment by polyacrylamide
gel electrophoresis/Western blot epitope mapping, using anti-prion protein
antibodies spanning the length of the protein as specified. Schematic
representations of the small fragment and oligomeric species and of the
potential N- and C-terminal truncation sites based on antibody epitopes are
highlighted on the right and below, respectively. WT indicates wild type.
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were thought to represent aggregation of the 8-kDa fragment
into highly stable, higher-order species.
Tau Analysis
Cerebrospinal fluid was examined by enzyme-linked immu-
nosorbent assay (Innotest hTau Ag and Phospho-Tau [181P],
Innogenetics NV Belgium), according to the manufacturer’s in-
structions, and showed both total tau and tau phosphory-
lated at threonine 181 were elevated (total tau, 1409 [normal,
<412 pg/mL], with phospho-tau, 126 [normal, <82 pg/mL]). Ref-
erence ranges were determined from 71 well-characterized,
healthy elderly volunteers participating in the Australian
Imaging Biomarker Lifestyle Study.16
The cerebellum and hippocampus were homogenized (10%
[weight/volume] in phosphate-buffered saline) and analyzed
by Western blotting for the different tau isoforms using 4% to
12% NuPAGE gels and probed with a rabbit anti-human tau an-
tibody (1:3000; Dako). In the cerebellum (absence of tau pa-
thology), there was no difference in the tau isoform profile
when comparing the proband with age-matched control and
Alzheimer disease brains. In the hippocampus (abundant tau
pathology), the tau isoform profile of the proband did not re-
semble that seen in either the control or Alzheimer disease
brain (data not shown).
Discussion
Characteristically, GSS disease is inherited in an autosomal-
dominant manner,4 therefore, usually occurs in the setting of
a known family history of similar neurodegenerative disor-
der. No history of similar neurological disease was known
among first-degree relatives; however, the absence of family
history can occur in up to 30% of GSS disease pedigrees.2
Awareness of a maternal aunt dying in a mental hospital from
a poorly characterized illness of apparently only months in du-
ration is of uncertain but possible relevance.
Our proband manifested rapid cognitive and gross
motor decline following her minor elective surgery, dying
approximately 1 month after the procedure. The proband’s
limited contact with her family prior to surgery rendered
precise determination of presenting symptoms and their
duration impossible. However, notwithstanding the long-
standing estrangement from her family, the information
available suggests a relatively brief duration of cognitive
and behavioral changes for up to 6 months prior to hospital
admission. Although limited survival after first symptoms
has been reported in GSS disease, it is uncommon that dura-
tions of this length occur in patients with GSS disease.5,6,10,11
Typically, GSS disease follows a prolonged clinical course,
evincing a median duration of more than 3 years.5 Our
patient aligned more to the contrasting relatively short
median survival observed in sporadic Creutzfeldt-Jakob
disease.5 In addition, molecular pathological evaluation of
our propositus using the 3F4 antibody demonstrated promi-
nent, low-molecular-weight, protease-resistant PrPres bands
on Western blots of the brain, a feature more usually associ-
ated with much longer survival.6,10 Similarly, although
valine homozygosity at codon 129, as seen in our patient,
has been reported in GSS disease, it is most unusual; fur-
thermore, it also appears to usually correlate with pro-
longed symptomatic illness.4,6,10,11
Predominance of shorter (<15-kDa) PK-resistant PrPres frag-
ments on Western blots has been observed in GSS disease in
association with numerous mutations, including those clus-
tered toward the C-terminus of the prion protein (H187R, F198S,
D202N, Q212P, Q217R, and Y218N), as well as those situated
more in the middle of the protein (P102L, P105L, A117V, G131V,
and S132I).6,10,17 It remains to be determined how PrP-
containing mutations within the C-terminus, including V176G,
engender processing such that the core of amyloid deposits ap-
pear to be constituted by truncated species that do not actu-
ally harbor the mutation.10
Aligned to previous reports for the G131V, S132l, Y160X,
H187R, F198S, D202N, Q217R, Y218M, and Q227X
mutations,6,9,10,17 the presence of shorter, nonclassic PrPres frag-
ments on Western blots in our proband was associated with
the neuropathological profile of high amyloid plaque bur-
den, neurofibrillary degeneration, and relative paucity of
spongiform change in the brain; however, some mutations,
such as P102L, P105L, and A117V, despite the presence of shorter
PrPres fragments on Western blots and considerable amyloid
deposition in the brain, do not consistently display neurofi-
brillary degeneration.17 It is noteworthy that those patients with
GSS disease displaying predominance of longer 21-kDa to 30-
kDa PrPres fragments on Western blots, as exemplified by some
P102L carriers, generally have more prominent neuropil vacu-
olation, usually associated with synaptic-type PrP immuno-
staining rather than mainly amyloid plaque burden.10 The pres-
ence of tau-positive neurofibrillary tangles and neuropil
threads, as frequently observed in GSS disease cases includ-
ing our proband, underscores the likelihood that accumula-
Table. Panel of Anti-PrP Antibodies Used for Epitope Mapping
1° Antibody 1° Dilution
2° Antibody (HRP Conju-
gated) 2° Dilution Supplier
8B4 (monoclonal) 1:10 000 Anti-mouse 1:10 000 Alicon
SAF32 (monoclonal) 1:3000 Anti-mouse 1:10 000 Caymen Chemical
03R19 (polyclonal) 1:5000 Anti-rabbit 1:10 000 V Lawson15
3F4 (monoclonal) 1:5000 Anti-mouse 1:10 000 Covance
ICSM 18 (monoclonal) 1:40 000 Anti-mouse 1:10 000 D-Gen
5B9-biotin (monoclonal) 1:50 000 Streptavidin 1:40 000 Abcam
EP1802Y (monoclonal) 1:10 000 Anti-rabbit 1:5000 Abcam
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tion of aberrant tau in the brain may be a relatively nonspe-
cific secondary consequence to certain primary cerebral
amyloidoses, as typified by Alzheimer disease.
In summary, in addition to expanding the range of PRNP
mutations found in neuropathologically confirmed prion dis-
ease, our case is of interest and informative through display-
ing a constellation of clinical, genetic, molecular, and patho-
logical features, which although individually recognized across
the spectrum of GSS disease, are unusual in their co-
occurrence in a single person. Consequently, our proband
serves to further broaden the already diverse genetic and phe-
notypic spectrum recognized for GSS disease.
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ARTICLE
Ascertainment Bias Causes False Signal
of Anticipation in Genetic Prion Disease
Eric Vallabh Minikel,1,2,3,* Inga Zerr,4,5 Steven J. Collins,6 Claudia Ponto,4 Alison Boyd,6
Genevieve Klug,6 André Karch,4 Joanna Kenny,7 John Collinge,7 Leonel T. Takada,8 Sven Forner,8
Jamie C. Fong,8 Simon Mead,7,9 and Michael D. Geschwind8,9
Anticipation is the phenomenon whereby age of onset in genetic disease decreases in successive generations. Three independent reports
have claimed anticipation in Creutzfeldt-Jakob disease (CJD) caused by the c.598G>A mutation in PRNP encoding a p.Glu200Lys
(E200K) substitution in the prion protein. If confirmed, this finding would carry clear implications for genetic counseling. We analyzed
pedigrees with this mutation from four prion centers worldwide (n ¼ 217 individuals with the mutation) to analyze age of onset and
death in affected and censored individuals. We show through simulation that selective ascertainment of individuals whose onset falls
within the historical window since the mutation’s 1989 discovery is sufficient to create robust false signals both of anticipation and of
heritability of age of onset. In our data set, the number of years of anticipation observed depends upon how strictly the data are limited
by the ascertainment window. Among individuals whose disease was directly observed at a study center, a 28-year difference between
parent and child age of onset is observed (p ¼ 0.002), but including individuals ascertained retrospectively through family history
reduces this figure to 7 years (p ¼ 0.005). Applying survival analysis to the most thoroughly ascertained subset of data eliminates the
signal of anticipation. Moreover, even non-CJD deaths exhibit 16 years anticipation (p ¼ 0.002), indicating that ascertainment
bias can entirely explain observed anticipation. We suggest that reports of anticipation in genetic prion disease are driven entirely by
ascertainment bias. Guidelines for future studies claiming statistical evidence for anticipation are suggested.Introduction
Prion diseases are uniformly fatal, progressive neurodegen-
erative disorders caused by the conversion of the cellular
prion protein, PrPC, to a misfolded conformation known
as the prion, or PrPSc, in which Sc stands for scrapie, the
prion disease of sheep and goats.1 In humans, prion dis-
eases have an incidence of approximately 1 death per 1
million individuals per year,2 and usually occur as simplex
cases in individuals with two wild-type (WT) copies of the
prion protein gene (PRNP [MIM 176640]), commonly
referred to as sporadic cases. A minority of cases are genetic
and, very rarely, prion disease can be environmentally
acquired.1 Creutzfeldt-Jakob disease (MIM 123400) caused
by the c.598G>A (dbSNP id rs28933385) mutation, which
encodes a p.Glu200Lys (E200K) substitution in PrP, is the
most common genetic form of prion disease worldwide.3
This point mutation was first identified in 19894 and was
established as a dominant Mendelian cause of disease by
1991.5–7 Disease penetrance inmutation heterozygotes ap-
pears to reach 80%–100% by age 80.8,9 Reported estimates
of the mean age of onset in individuals with this mutation
range from 537 to 63,10 and the mean survival after disease
onset is 7 months.11
Three reports12,13 (see also Web Resources) have claimed
statistical evidence that this genetic prion disease exhibits1Prion Alliance, Cambridge, MA 02139, USA; 2Broad Institute, Cambridge, M
General Hospital, Boston, MA 02114, USA; 4National Reference Center for TS
for Neurodegenerative Disease (DZNE), 37073 Goettingen, Germany; 6Australia
Parkville, Australia 3010; 7MRC Prion Unit, Department of Neurodegenerative
National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL
of Neurology, Memory and Aging Center, University of California, San Franci
9These authors contributed equally to this work
*Correspondence: eric.minikel@prionalliance.org
http://dx.doi.org/10.1016/j.ajhg.2014.09.003. 2014 by The American Societ
The Americanticipation, a phenomenon in which successive genera-
tions exhibit progressively earlier disease onset or more
severe presentation.14 These studies reported a 7 to 14
year younger age of onset or death among children in
affected parent-child pairs, suggesting implications for
genetic counseling.
The only genetic mechanisms known to cause anticipa-
tion are the germline expansion of unstable repeats in
disorders such as Huntington’s disease and type 1 myoto-
nic dystrophy,15,16 and telomere shortening in disorders
such as dyskeratosis congenita and breast cancer.17,18
Anticipation in a genetic prion disease might raise the
question of whether disease in children is accelerated by
exposure to infectious material during their parents’
illness, however, the only known routes of human-to-hu-
man prion transmission are cannibalism19 and iatrogenic
exposure.20,21
Because a variety of sources of ascertainment bias are
known to contribute to false statistical signals of anticipa-
tion,14,22–25 we set out to determine whether the anticipa-
tion reported for Glu200Lys genetic prion disease could be
a statistical artifact. An individual’s observed age of onset
cannot be greater than the age at interview or ascertain-
ment, and previous studies have modeled the effects of
this right truncation of age of onset22 and provided
methods of correction.23–26 These methods of correction,A 02142, USA; 3Analytical and Translational Genetics Unit, Massachusetts
E, Georg-August University, 37073 Goettingen, Germany; 5German Center
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however, require either a consistent, known set of ascer-
tainment criteria23 or the use of only a subset of available
data.26 In rare diseases, data may be too sparse for subset-
ting, and may not represent a unified ascertainment effort,
but rather consist of a mix of data points ascertained retro-
spectively (through family histories of varying depth and
quality), directly (symptomatic individuals seen clinically),
and prospectively (asymptomatic individuals with a muta-
tion, followed for varying amounts of time). We therefore
sought to model ascertainment bias due to left- and right-
truncation not of the age of onset per se, but of the year of
onset. Because the Glu200Lys substitution was discovered
only 25 years ago and most prion surveillance programs
and clinical centers have been established even more
recently, we hypothesized that the selective ascertainment
of parents and children whose deaths both occurred
within this 25-year window could explain the reported dif-
ferences in parent and child age of death.
To test this hypothesis, here we combine data from
four national prion study centers to assemble the largest
Glu200Lys cohort (n ¼ 217 individuals) yet reported. We
first create a simulation of the ascertainment of parent-
child pairs with a mutation to identify conditions under
which naive paired t tests will detect a false signal of antic-
ipation. We explore methods for detecting and controlling
for this ascertainment bias. We then apply our analytical
framework to our Glu200Lys data set and successfully
reproduce the anticipation reported by other groups but
demonstrate that this anticipation is a false positive due
to ascertainment bias.Material and Methods
Data Collection
We combined data collected on Glu200Lys individuals and their
families from four research centers with data collection practices
as follows.
Australian National Creutzfeldt-Jakob Disease Registry
Details of Australian National Creutzfeldt-Jakob Disease Registry
(ANCJDR) surveillance mechanisms, as well as data collection
and analysis methods, have been reported previously.27,28 In brief,
prospective national surveillance of CJD has been undertaken
since 1993 with CJD a Notifiable Disease throughout Australia
since 2006. ANCJDR collects detailed medico-demographic infor-
mation on suspect cases, including family histories, and provides
diagnostic tests including PRNP genotyping. Year and age of death
are primary variables with information on age at onset of first
symptom collected if available. Informed, written consent was
obtained from participants or legal next of kin. Ethical approval
was obtained from the Office of Research Ethics and Integrity at
The University of Melbourne.
German CJD Surveillance Unit
Details of German CJD surveillance have been reported previ-
ously.29–31 In brief, the Surveillance Unit in Goettingen has
collected data on all suspected prion disease cases in Germany
since 1993. Diagnostic information is obtained from reporting
hospitals and where possible, confirmation by autopsy is sought.
The Surveillance Unit also accepts clinical referrals, provides diag-372 The American Journal of Human Genetics 95, 371–382, Octobernostic tests including PRNP genotyping, and, where possible, col-
lects family history. Age of onset is defined from first symptom of
a progressive neuropsychiatric disorder by interview with family
members. Informed, written consent was obtained from partici-
pants or legal next of kin. Ethical approval was obtained from
the Ethical Committee at the University Medical School, Georg-
August University Goettingen.
MRC Prion Unit/NHS National Prion Clinic
The UK has had a centralized tertiary clinical referral service for
CJD since 1991. Since 2004, all suspected CJD cases from the UK
are referred to the NHS National Prion Clinic at the National Hos-
pital for Neurology and Neurosurgery (NHNN) at University Col-
lege London Hospitals NHS Trust. Age of onset was defined from
first symptom of a progressive neuropsychiatric disorder and fam-
ily history was obtained by interview with family members. Other
details of data collection have been described previously.32
Informed, written consent was obtained from participants or legal
next of kin. Ethical approval was obtained from the NHNN/Insti-
tute of Neurology Joint Research Ethics Committee.
Memory and Aging Center, University of California San Francisco
The UCSF cohort comprises symptomatic and asymptomatic indi-
viduals fromGlu200Lys families referred from the U.S. and abroad
to the rapidly progressive dementia and Prion Disease research
program since August 2001.33–35 PRNP genotyping36 was per-
formed at the National Prion Disease Pathology Surveillance
Center (Cleveland, OH), or by outside laboratories in some of
the individuals who were tested prior to UCSF referral or
lived abroad. Symptom onset was determined as previously re-
ported.37 A detailed, usually three generation, family pedigree
was made by a neurologist and/or clinical genetic counselor for in-
dividuals participating in research. Further data were collected
from medical records sent by referring physicians and/or from
direct contact with family members (by email or telephone).
Informed, written consent was obtained from research partici-
pants or legal next of kin. The UCSF data included in this study
have been collected through UCSF Institutional Review Board-
approved research protocols.
Data Annotation
Directly observed individuals were defined as those either seen
clinically at one of the four centers or officially reported to one
of the centers in its prion disease surveillance role. Indirectly
observed individuals were those ascertained through interview
with family members. Individuals were considered to have the
c.598>A mutation if they (1) had either a genotyping test indi-
cating the presence of the mutation or were related to someone
with a positive test and (2) had a diagnosis of CJD or (3) were
deemed to have died of CJD based on information obtained
from interviewed family members. Individuals were considered
to not have the mutation if they (1) had a genotyping test indi-
cating the absence of the c.598G>A mutation or (2) were related
to the family only by marriage and thus lacked a blood relation-
ship to any affected individual. The Glu200Lys substitution causes
CJD with nearly 100% penetrance,8,9 but individuals with twoWT
PRNP alleles have a very low disease incidence of only about 1 in 1
million per year.2 This incidence translates into a lifetime risk
roughly on the order of 1 in 10,000 for a WT individual. By Bayes’
rule, the high penetrance of themutation and rarity of nongenetic
CJD cases mean that any CJD case in a Glu200Lys pedigree is over-
whelmingly likely to be genetic. Therefore, we assumed that all
CJD cases in these pedigrees were due to the c.598G>A mutation.
Data on four individuals with CJD were flagged as questionable2, 2014



















of onset slope a
Slope
significant b
1 1989–2013 None 16.4 100% 93% 100% 0.67 100%
2 1950–2013 None 4.9 98% 19% 16% 0.22 100%
3 1880–2013 None 1.6 23% 3% 5% 0.06 100%
4 1989–2013 Declining 5%/year 10.7 100% 59% 83% 0.55 100%
5 1950–2013 Declining 5%/year 3.4 79% 14% 11% 0.18 100%
6 1880–2013 Declining 5%/year 1.4 18% 3% 6% 0.05 98%
7 1989–2013 Declining 1%/year 2.0 33% 6% 5% 0.26 100%
8 1950–2013 Declining 1%/year 0.9 12% 4% 5% 0.12 100%
9 1880–2013 Declining 1%/year 0.4 6% 1% 4% 0.04 85%
10 1989–2013 Exhaustive 0.2 5% 1% 5% 0.20 99%
Ascertaining only those individuals with disease onset within a historical window creates false signals of anticipation and heritability (Simulation 1). These false
signals are reduced, but not eliminated, by expanding the ascertainment window (Simulations 2 and 3). Probabilistic retrospective ascertainment (see text)
reduces these signals further (Simulations 4–9). Only when retrospective ascertainment is 100% exhaustive does anticipation become reliably nonsignificant
(Simulation 10).
aAverages from 1,000 simulations.
bPercentage of 1,000 simulations in which this figure was statistically significant at p < 0.05.due to uncertain diagnosis, uncertain relatedness to other individ-
uals or uncertain age at death; none of the results reported here
differed when the analysis was re-run excluding these individuals.
Missing PRNP codon 129 information was imputed from affected
family members when possible. For the purpose of assessing rates
of predictive genetic testing, ‘‘at-risk’’ individuals were defined
as those who were not symptomatic at last follow-up but who
did have a parent deemed to have the mutation, per the above
criteria. Recursively, individuals were also considered at-risk if
they had a parent who qualified as at-risk according to the above
definition.
Simulation
We hypothesized (see Introduction) that the selective ascertain-
ment of individuals with disease onset within a specified window
(for instance, 1989–2013) might explain reported anticipation in
Glu200Lys prion disease. To assess whether such an ‘‘ascertain-
ment window’’ was sufficient to create a false signal of anticipa-
tion, we created a simulation model in which parent and child
ages of onset are drawn from the same specified distribution but
ascertainment of parent-child pairs is selective based on year of
onset. For each round of simulation, we generated n ¼ 100,000
parent-child pairs. We only simulated parents and children with
the causative mutation. We wished to model a situation in which
individuals have been falling ill of prion disease continuously
throughout history, and will continue to do so into the future,
whereas our data are limited only by an artificial ascertainment
window. We therefore generated parents with a year of birth uni-
formly distributed from 1700 to 2000, in order to ensure that (1)
the density of disease onsets over our largest ascertainment win-
dow (1880 to 2013) would be uniform and that (2) observed years
of onset would effectively be left-truncated only according to our
ascertainment criteria and not according to the underlying simu-
lated distribution. We set the child’s birth to occur 28 5 6 years
after the parent’s birth, per the actual distribution from our data.
To simulate an age of onset distribution while accounting forThe Americcensoring due to deaths due to other causes (‘‘competing risks’’),
we first created a normally distributed 64 5 10 year age of onset
to approximate the distribution in our real data (see Results) and
then randomly censored individuals according to the U.S actuarial
life table for 2009 (see Web Resources). We did not model changes
in the life expectancy over the time periods considered here.
Further details of the specific simulations are explained in Results
and in the legends of Tables 1 and 2.
Statistical Analyses
All simulations and analyses of Glu200Lys pedigree data
were conducted in R 3.0.2. In order to demonstrate the effects
of ascertainment bias on the evidence for anticipation reported
by previous studies of genetic prion disease, we adopted methods
from those studies when possible. For paired t tests, all possible
parent-child pairs were generated from Glu200Lys pedigree struc-
tures using a SQL join operation. This results in multiple-counting
parents of multiple affected children and counting both as par-
ents and as children those individuals in the middle of pedigrees
with three or more affected generations. Multiple counting
means that pairs are not independent; this mirrors the methods
from at least one prior study of prion disease anticipation.13
Based on these paired lists of parents and children, differences
in parent and child age of onset were assessed using two-tailed
paired t tests (the R t.test function) for naive comparisons of
observed age of onset distributions. Correlation between parent
and child age of onset was assessed using linear regression (the
R lm function). Survival analysis utilized the R survival package.
For survival analysis, to avoid multiple-counting and ensure
independence of all pairs, we randomly selected one parent-child
pair from each pedigree and compared the survival curve for all
parents to that of all children using a log rank test (the R survdiff
function). Because we randomized which pairs were included, we
repeated this analysis for over 1,000 iterations and have reported
aggregate statistics. Source code and output are available online
(see Web Resources).an Journal of Human Genetics 95, 371–382, October 2, 2014 373
Table 2. Stratification of Simulated Data
Cohort Name Inclusion Criteria Anticipation p
Child early birth year Child born < 1939 16 years 0.009
Child late birth year Child born R 1939 18 years <0.0001
Child early death year Child year of onset
< 2000
26 years 0.0004
Child late death year Child year of onset
R 2000
15 years <0.0001
Child early death age Child age onset < 61 21 years <0.0001
Child late death age Child age onset R 61 11 years 0.003
Parent early death age Parent age onset < 70 12 years 0.01
Parent late death age Parent age onset R 70 20 years <0.0001
In n¼ 26 simulated parent-child pairs with independent and identically distrib-
uted ages of onset but ascertaining only those pairs whose onsets both fall
within 1989–2013, all subsets of data stratified according to the variables
defined in Table 3 of Pocchiari et al.13 still show significant anticipation.Results
Simulated Effects of Ascertainment Window
We generated 100,000 parent-child pairs with all individ-
uals harboring a dominant genetic mutation and ages of
onset for all individuals independent and identicallydistrib-
uted, corresponding to a scenario in which no anticipation
or heritability of age of onset are present (see Material and
Methods and Figure 1A). Themean age of onset without ac-
counting for censoring was 62, whereas the median age of
onset in survival analysis accounting for censoring due to
intercurrent deathswas 64.When considering all simulated
individuals, therewasnodifference inageofonset (p¼0.91,
two-tailed paired t test), no correlation between parent and
child age of onset (p¼ 0.53, linear regression), andno corre-
lation between the year of birth and age of onset for all indi-
viduals (p ¼ 0.59, linear regression).
Next we considered the effects of selectively ascertaining
individuals whose disease onset occurs within an ‘‘ascer-
tainment window,’’ which we define as a range of years
in which disease onsets can be observed. It is impossible
to ascertain ages of onset after 2013, the last year in which
our data were collected. Right-truncating the year of onset
at 2013 and considering all affected pairs introduced only
a very small difference between parent and child age of
onset (0.37 years, p < 0.0001, two-tailed paired t test).
Because we had generated parent-child pairs with years
of birth as early as 1700, only a minority of pairs was
affected by this right truncation. Spreading the simulated
pairs out over an even greater range of years of parent birth
(year 0–2000) made this anticipation cease to be significant
(p ¼ 0.31, two-tailed paired t test), indicating that right
truncation of year of onset is not sufficient cause a false
signal of anticipation. In practice, any real data set will
be both left-truncated (when researchers began to study
the disease) and right-truncated (at the present year
or when the study stopped, whichever is earlier). For374 The American Journal of Human Genetics 95, 371–382, OctoberGlu200Lys CJD, we reasoned that ascertainment rates
would be higher after the discovery of the disease’s causal
mutation in 1989,4 so we next considered the effects of
ascertaining only those individuals whose year of onset
occurs between 1989 and 2013 inclusive.
When only those simulated pairs in which parent and
child disease onset both occurred within this window
were considered (Figure 1A), we observed 17 years of antic-
ipation (p < 0.0001, two-tailed paired t test, Figure 1B).
Because parents were born, on average, 28 years earlier
than their children, yet the window of observation was
only 25 years long, the ascertained pairs were vastly en-
riched for those in which the child dies at least 3 years
younger than the parent. Under these conditions, we
also observed an artifactual correlation between year of
birth and age of onset, with slope of 0.67, (p < 0.0001,
linear regression, Figure 1C). This relationship is intuitive
because an individual born in 1970, for instance, can
only be included in the data set if onset occurs by age 43
(year 2013), and an individual born in 1940 can only be
included if onset occurs at age 49 or later (year 1989).
Year of birth/age of onset correlation is therefore a conse-
quence of ascertaining only individuals with the year of
onset within a particular window. This problem has previ-
ously been noted in Huntington’s disease pedigrees.38
Among the ascertained pairs, parent and child age of onset
were also correlated with a slope of 0.48 (p< 0.0001, linear
regression, Figure 1D). In single parent-offspring regres-
sion, the slope can be doubled to obtain an estimate of
phenotypic variance explained by additive genetic herita-
bility plus environmental effects.39 Applying this formula
to the ascertained data would suggest that age of onset
is up to 96% heritable. Because the true distributions of
parent and child ages of onset in our simulation were
neither different nor correlated, this shows that the year
of onset ‘‘windowing’’ simulated here is sufficient to create
false signals of both anticipation and heritability. We
confirmed this finding through 1,000 iterations with the
same set of simulation conditions and n ¼ 100 ascertained
pairs to simulate a realistic sample size for a rare disease
(Table 1, Simulation 1).
Because we knew the anticipation and heritability
identified in our above simulation to be false signals, we
asked whether improved ascertainment or simple analyt-
ical methods could disprove them. We considered a two-
step ascertainment model; in the first step, we ascertained
all individuals with disease onset between 1989 and 2013
(simulating clinical visits), and in the second step we ascer-
tained any and all individuals still alive and well as of 2013
who were parents or children of the individuals ascer-
tained in step 1 (simulating genetic testing and prospective
follow-up of individuals with the mutation). When we
compared parent and child survival curves under this
two-step ascertainment model in Kaplan-Meier survival
analysis, the median age of onset of children was greater
than that of parents (64 versus 62 years, p < 0.0001, log
rank test). This counter-intuitive finding of later child2, 2014
Figure 1. Simulation of Ascertainment
Bias Due to Year of Onset Windowing
(A) Visual representation of a subset of
simulated data. Parent-child pairs are ar-
ranged along the y axis. Parent is born on
orange square and has disease onset on or-
ange X; child is born on blue square and
has disease onset on blue X. Age of onset
distributions are identical, but in Simula-
tion 1, only those pairs in which both indi-
viduals have onset between 1989 and 2013
inclusive (red vertical lines) can be ascer-
tained. In the above example, only one
pair (#49) meets these criteria.
(B) Among ascertained pairs in Simula-
tion 1, children have almost categorically
younger onset than their parents, leading
to 17 years of observed anticipation (p <
0.0001, two-tailed paired t test). For visibil-
ity, a subset of simulated points is shown.
(C) Ascertainment windowing introduces
an artifactual correlation between year
of birth and age of onset, slope ¼ 0.67
(p < 0.0001, linear regression).
(D) Ascertainment windowing also leads
to a correlation between parent and child
age of onset and thus a false signal of heri-
tability (slope ¼ 0.48, p < 0.0001, linear
regression).
(E) Ascertained pairs are supplemented
with those pairs where one individual’s
onset occurs in 1989–2013 and the other
is alive and well as of 2013. The plot shows
that the median survival of parents and
children in Kaplan-Meier curves depends
upon what proportion of alive and well in-
dividuals are included. If 0% are included,
then 17 years anticipation are observed,
just as in (B). As ascertainment increases,
the anticipation is reduced. As inclusion
of alive and well individuals approaches
100%, children have longer survival than
parents. This is because more of the chil-
dren are censored, so their age of onset dis-
tribution better reflects the hypothetical
distribution of age of onset without the
influence of competing risks.onset can be explained as follows. Because parents are born
earlier than children, pairs in this two-step ascertainment
model are predominantly ones in which the parent dies
of genetic prion disease between 1989 and 2013 while
the child is alive and well in 2013. In such pairs, the par-
ent’s age of onset distribution is truncated by competing
risks (parents who would have had older disease onsets
were never ascertained because they died of other causes
first, thus making disease onset appear younger). The
child’s age of onset distribution, however, is less affected
by competing risks (children who would have older disease
onsets are ascertained through genetic testing even if they
will never develop the disease in their lifetimes).The American Journal of Human GRecall that in the two-step ascer-
tainment model above, an affected
individual is ascertained in step 1,and if that individual has a parent or child alive and well
in 2013, then that parent or child is always ascertained.
In practice, however, it is difficult to ascertain 100%
of asymptomatic relatives of an affected individual. We
therefore also modeled incomplete ascertainment of asymp-
tomatic individuals. When we did so, we saw that the false
signal of anticipation from naive t tests was not fully cor-
rected (Figure 1E). The difference in median survival ac-
cording to the log rank test was 17 years when no censored
individuals were included, and this difference shrunk to 7
years when 20% of individuals alive and well in 2013 were
included, and 2 years when 50% of such individuals were
included. This indicates that accounting for censoredenetics 95, 371–382, October 2, 2014 375
observations is not sufficient to remove false signals of
anticipation unless ascertainment of censored individuals
is exhaustive. In long-term studies of predictive genetic
testing for neurodegenerative diseases, it has been
reported that only 3% to 24% of individuals with risk of
having inherited a mutation pursue predictive genetic
testing.40–45 Survival analysis including asymptomatic in-
dividuals with a mutation is therefore unlikely to mitigate
false signals of anticipation and heritability in this disease
setting.
We also asked whether including year of birth as a
covariate could eliminate the false signal of heritability
we observed in our simulation. When both parent age of
onset and child year of birth were used in a linear model
to explain child age of onset, only the child’s year of birth
proved to be correlated (slope ¼ 0.72, p < 0.0001, linear
regression), whereas parent age of onset was no longer sig-
nificant (p ¼ 0.73, linear regression). When we simulated
an age of onset that truly was heritable, this method
reduced, but did not eliminate, the estimate of heritability
(see Table S1 available online).
Simulated Effects of Different Ascertainment Criteria
In Simulation 1 (Table 1) we assumed that it was only
possible to include individuals directly ascertained within
the window from 1989 to 2013. In reality, some Glu200Lys
families have been followed since as early as 19637 and it is
also possible to obtain information on deceased individ-
uals retrospectively through interview with family mem-
bers, though it can be more difficult for individuals whose
year of death is long past.46 We therefore asked whether
false anticipation and heritability would still be observed
with larger or more flexible ascertainment windows. In
this analysis, we limited the number of ascertained pairs
to 100 in order to simulate a realistic sample size for a
rare disease. Expanding the size of the direct ascertainment
window back to 1950 or 1880 (but still not adding indirect
ascertainment) decreased the strength of the false signals
quantitatively, but did not reliably eliminate them,
even when the window was longer than a human lifespan
(Table 1, Simulations 1–3).
Next, we considered including some indirectly ascer-
tained individuals. To simulate retrospective ascertain-
ment, we first directly ascertained individuals with onset
within the window, then ascertained any parents or chil-
dren thereof whose onset had already occurred prior to
the beginning of the window. We hypothesized that it
might be more difficult to ascertain individuals who died
long ago, so for indirectly ascertained individuals we
applied a linear reduction in ascertainment probability ac-
cording to how many years prior to the beginning of the
ascertainment window the individual had disease onset.
In Simulation 4 (Table 1), for instance, direct ascertain-
ment from 1989-2013 is exhaustive, but the probability
of indirect ascertainment declines by 5% for each year
prior to 1989 that an individual has onset so that, for
instance, an individual with onset in 1988 can be retro-376 The American Journal of Human Genetics 95, 371–382, Octoberspectively ascertained with 95% probability, in 1987
with 90% probability, and so on. Including some indi-
rectly ascertained individuals in this manner further
reduced the magnitude of anticipation but did not
completely eliminate it in most scenarios tested (Simula-
tions 4–9). The false signal of heritability was weaker
than that of anticipation and could be reliably reduced
to statistical insignificance in the most extreme scenarios
tested (Simulations 6–9). Only when indirect ascertain-
ment was 100% exhaustive and independent of the year
of onset (Simulation 10) did a signal of anticipation cease
to be detected, though a year of birth/age of onset correla-
tion still existed.
Together, our simulations demonstrate that ascertaining
individuals over a larger time window or including some
indirect ascertainment (retrospective phenotyping) can
quantitatively reduce the false signals of anticipation and
heritability but that these false signals are still likely to be
observed as statistically significant under anything other
than almost complete ascertainment. Our results indicate
that whenever retrospective ascertainment is less than
exhaustive, there is a risk of observing false signals of antic-
ipation and heritability of age of onset.
Stratification of Simulated Data
One recent report of anticipation in Glu200Lys genetic
prion disease13 argued that the observed anticipation
must be real because anticipation was observed, using
paired t tests, within every subset of 26 parent-child pairs
when these were stratified by age of death, year of birth,
or year of death. To determine whether such an analysis
could indeed rule out a false positive due to ascertainment
bias, we stratified 26 simulated parent-child pairs with
onset between 1989 and 2013 in the same way described
in the previous report (Table 2). In our simulation, antici-
pation is not real, yet a strong signal of anticipation is
nevertheless observed in all eight strata. Therefore, these
methods of stratification do not eliminate spurious signals
of anticipation due to ascertainment bias.
Characteristics of Glu200Lys Pedigree Data
We combined data on Glu200Lys families from four inde-
pendent study centers worldwide (Table 3). Each individ-
ual data set reflected a different method of ascertainment
(see Material and Methods) and accordingly, the propor-
tion of individuals ascertained indirectly or asymptomatic
as of last follow-up varied considerably (Table 3).
Of individuals whose disease onset or death was directly
observed by one of the study centers, 65% had no reported
family history of prion disease. This figure might reflect
some combination of (1) incomplete reporting of family
history, (2) underdiagnosis of affected individuals in earlier
generations, (3) censoring of asymptomatic individuals
with the mutation upon death due to other causes, and
(4) de novo mutations. Similarly, we knew the genotypes
of only 22% of at-risk individuals (see Material and
Methods) in our data sets. Together, these figures suggest2, 2014














ANCJDR 1993 24 7 42% 8%
German CJD Surveillance 1993 32 3 38% 3%
MRC Prion Unit 1991 57 29 25% 23%
UCSF 2001 104 58 73% 37%
All 217 97 52% 25%
Data from the four study centers varied in terms of the length of time for which data had been collected, the degree of indirect ascertainment, and the ascertain-
ment of asymptomatic individuals with the mutation. See Material and Methods for details.that neither retrospective ascertainment nor prospective
following of individuals with the mutation are exhaustive
in our data set.
Disease Duration and Genotypic Influence
Disease duration was defined as time from first symptom
(see Data Collection in Material and Methods) to death.
Disease duration followed a nonnormal distribution (p <
0.0001, Shapiro-Wilk normality test) with a median of
162 days (n ¼ 61, interquartile range 205 days), similar
to the figure reported elsewhere.11 Disease duration did
not differ by study center (p ¼ 0.35, Kruskal-Wallis test,
n¼ 61) or between directly and indirectly ascertained indi-
viduals (p¼ 0.08, Kruskal-Wallis test, n¼ 38 and 23 respec-
tively). PRNP codon 129 information was available for a
subset of individuals with known disease duration. Among
individuals with a haplotype encoding Glu200Lys cis
129Met, disease duration was shorter for individuals
with a trans allele encoding 129Met (median of 137 days,
n ¼ 25) than a trans allele encoding 129Val (median of
426 days, n ¼ 7) and this difference was significant (p ¼
0.02, Kolmogorov-Smirnov test), consistent with previ-
ously reported data.11 Disease duration appeared to differ
between haplotypes encoding Glu200Lys cis 129Met
(n ¼ 42) and Glu200Lys cis 129Val (n ¼ 6) proteins, with
a median duration of 137 versus 331 days respectively
(p ¼ 0.04, Kolmogorov-Smirnov test), although trans
codon 129 information was not available for all of these in-
dividuals, so it is possible that the longer duration among
cis 129Val individuals might be due to higher rates of
codon 129 heterozygosity. Because disease duration was
generally a year or less and our data included age of onset
for some individuals but age of death for others, we
decided to consider age of onset and death interchange-
ably in the anticipation analysis, preferring age of death
when both were available.
Age of Onset or Death and Genotypic Influence
Overall, the mean age of onset or death in affected individ-
uals was 62 5 10 years (5SD, n ¼ 158) and was approxi-
mately normally distributed (p ¼ 0.36, Shapiro-Wilk
normality test; Figure 2A). The median observed age of
onset or death was 63 years (n ¼ 158). The median roseThe Americto 64 years when we included asymptomatic individuals
with the mutation, censored at date of last follow-up or
death due to other causes, and applied a survival analysis
(n ¼ 207). This survival analysis indicated 93% disease
penetrance by age 80, within the range of previously re-
ported estimates,8,9 but we note that this figure is biased
upward by the ascertainment of affected families and
incomplete genotyping of unaffected individuals. To our
knowledge, 64 years is older than any other measure
of central tendency of age of onset for this mutation yet
reported, probably because our use of survival analysis ac-
counts for censoring due to competing risks, whereas other
published estimates have been based simply on observed
ages of onset.3,7,10,47 Even our estimate is likely biased
downward due to incomplete genotyping of unaffected
individuals.
Age of onset or death did not differ by study center (p ¼
0.18, Model I ANOVA, n ¼ 158), sex (p ¼ 0.74, unpaired
t test, n ¼ 132), or mode of ascertainment (direct versus in-
direct, p ¼ 0.66, unpaired t test, n ¼ 158). Among individ-
uals with a haplotype encoding Glu200Lys cis 129Met, age
of onset or death did not differ between trans 129Met (n ¼
46) and trans 129Val (n ¼ 10) genotypes (p ¼ 0.71, two-
tailed unpaired t test; p ¼ 0.39, log rank test, n ¼ 64 Met-
Met versus 17 Met-Val including censored individuals),
consistent with a previous report.48 It was unclear whether
age of onset or death might differ between individuals
with haplotypes encoding Glu200Lys cis 129Met versus
Glu200Lys cis 129Val, because only a weak trend could
be detected whether censored individuals were included
(censored median 64 versus 57 years, p ¼ 0.05, log rank
test, n ¼ 142 Met versus 13 Val) or excluded (mean 63
versus 56 years, p ¼ 0.11, two-tailed unpaired t test, n ¼
105 Met versus 10 Val). Because trans codon 129 did not
influence age of onset or death and because a child’s
cis codon 129 is inherited from the affected parent, we
deemed it unnecessary to consider codon 129 genotype
in our anticipation analyses.
Ascertainment Bias in Glu200Lys Pedigree Data
Excluding asymptomatic individuals, the year of disease
onset or death was known for 94% of directly ascertained
individuals (68 of 72) and 55% of indirectly ascertainedan Journal of Human Genetics 95, 371–382, October 2, 2014 377
Figure 2. Ascertainment Bias and Antici-
pation in Glu200Lys Pedigree Data
(A) Distribution of age of onset or death by
ascertainment mode.
(B) Years of onset or death, when known,
occur overwhelmingly in the 25-year
window since the mutation’s discovery in
1989.
(C) Year of birth and age of onset are
artifactually correlated. This correlation
is strongest in directly ascertained indi-
viduals (black line) but remains highly
significant when indirectly ascertained
individuals (gray points) are included in
addition (dashed black line).
(D) Parent versus child age of onset or
death. Points below the diagonal line indi-
cate pairs in which the child dies younger
than the parent. Directly ascertained pairs
(black points) fall categorically below the
line, pairs with one directly ascertained
member are largely below the line (gray
points), and pairs in which both individ-
uals are indirectly ascertained fall on both
sides (white points).individuals (50 of 91). Year of disease onset or death
occurred between 1989 and 2013 in 92% of all individuals
for whom this variable was known (Figure 2B). This 25-year
window was shorter than the typical difference between
parent and child year of birth, which was 28 5 6 years
(mean 5 SD, n ¼ 150 including unaffected individuals),
thus partially limiting ascertainment to parent-child pairs
in which the child died at least 3 years younger than the
parent. For individuals ascertained directly, year of birth
and age of onset were even more strongly correlated than
in our simulation (slope¼0.79, p< 0.0001, linear regres-
sion, Figure 2C, black line). The correlation weakened
only slightly when indirectly ascertained individuals
were included as well (slope ¼ 0.48, p < 0.0001, linear
regression, Figure 2C, dashed line).
Our simulation (see above) indicated that ascertain-
ment bias could introduce false signals of heritability.
We did not, however, observe any correlation between
parent and child age of onset (p ¼ 0.99, linear regression,
n ¼ 39 pairs) nor in sibling pair ages of onset (p ¼ 0.63,
linear regression, n ¼ 26 pairs). Thus we do not find any
signal, whether real or artifactual, that age of onset in
this disease is heritable. This is not surprising because
our simulation indicated that false signals of heritability
are weaker than false signals of anticipation (Table 1),
and the small size of our data set might also leave us un-
derpowered to detect any true heritability of age of onset
that might exist.378 The American Journal of Human Genetics 95, 371–382, October 2, 2014Strength of Anticipation Signal
Depends upon Degree of
Ascertainment Bias
Because signatures of ascertainment
bias were strongly evident in our
data, we expected to see a differencebetween parent and child age of onset in observed pairs.
On the basis of our simulation results (Table 1), we hypoth-
esized that the strength of the anticipation signal from
naive paired t tests would vary depending on how flexible
we were able to make our ascertainment window, within
the constraints of our available data. When we considered
only pairs in which both parent and child were ascertained
directly, we observed 28 years of anticipation (p ¼ 0.002,
two-sided paired t test, n ¼ 4 pairs). When we additionally
included pairs with one indirectly ascertained individual,
this figure dropped to 15 years (p ¼ 0.0002, two-sided
paired t test, n ¼ 20 pairs). When we also included pairs
in which both individuals were ascertained indirectly,
this dropped further to 7 years (p¼ 0.005, two-sided paired
t test, n ¼ 39 pairs). Thus, the number of years of anticipa-
tion observed depends upon how narrow the ascertain-
ment window is and the mechanism of case reporting.
The strength of the anticipation signal also differed by
study center according to the extent of ascertainment
bias in each individual data set. The UCSF data set, which
was the largest and had both the highest percentage of
indirectly ascertained individuals (73%) and the least cor-
relation between year of birth and age of onset or death
(slope ¼ 0.41), showed the least evidence of anticipation
(1 year, p ¼ 0.68, two-sided paired t test). The MRC Prion
Unit showed a marginal paired difference (7 years,
p ¼ 0.10, two-sided paired t test), whereas the Australian
and German cohorts showed larger differences (18 years,
p ¼ 0.05 and 31 years, p ¼ 0.03 respectively, two-sided
paired t test).
Application of Survival Analysis to Glu200Lys
Anticipation
The foregoing analysis indicated that our data exhibited a
nominal signal of anticipation when analyzed with naive
paired t tests. Because this signal depended upon the de-
gree of ascertainment bias, and because our data exhibited
signatures of ascertainment bias similar to what we had
observed in our simulation, we suspected that the anticipa-
tion we observed was an artifact. We next set out to deter-
mine whether a survival analysis including asymptomatic
individuals with the c.598G>A mutation would correct
this artifact. Based on our simulation results (Figure 1E)
and the fact that our ascertainment of asymptomatic
individuals with the mutation was not exhaustive, we ex-
pected that survival analysis would not fully eliminate
the signal of anticipation in our Glu200Lys data. For the
survival analysis, we considered all parent-child pairs in
which both individuals harbored the mutation, regardless
of censored status. To ensure independence of tested pairs
and avoid multiple counting, we randomly selected one
such pair from each pedigree and compared parent and
child survival curves. Across 1,000 iterations, parent and
child survival curve medians differed by an average of 7
years (log rank test p < 0.05 in 82% of iterations). Because
our simulation indicated that more thorough ascertain-
ment of censored individuals reduces artifactual anticipa-
tion signals (Figure 1E), we repeated the same analysis on
only the UCSF and MRC Prion Unit cohorts, which had
the highest proportion of asymptomatic individuals with
the mutation (Table 3). Within these cohorts, the median
difference in parent and child survival curves was only 1
year and was usually not significant (p < 0.05 in only 8%
of 1,000 iterations). This is consistent with the hypothesis
that observed parent-child age of onset differences in
Glu200Lys prion disease are due to incomplete ascertain-
ment and not due to true anticipation.
Anticipation in Age at Death Due to Other, Non-Prion,
Causes
The foregoing analyses suggested that the anticipation we
observed in Glu200Lys families could be attributed entirely
to ascertainment bias. We reasoned that if this were true,
then anticipation in age of death might be observed in
deaths attributable to other causes as well, with these unre-
lated deaths providing a kind of negative control. When
we compared age at death for all parent-child pairs in our
data set in which neither individual had CJD listed as cause
of death, we observed 14 years of anticipation (p ¼ 0.002,
two-sided paired t test, n ¼ 37 pairs). In many cases, the
cause of death was not listed or was ambiguous, so we
could not rule out the possibility that some of those indi-
viduals might actually have died of undiagnosed or unre-
ported prion disease. When we therefore considered only
those pairs in which each individual was known not toThe Americharbor the mutation (see Material and Methods) and/or
died of a known cause clearly distinct from prion disease
(cancer, heart attack, accident, etc.), the anticipation
grew to 35 years (p ¼ 0.001, two-sided paired t test, n ¼ 9
pairs). This set included some individuals who had died
much younger than the typical age of onset for Glu200Lys
prion disease (Figure 2A), introducing a potential new
source of ascertainment bias as individuals who die
young might be counted as children but are unlikely
to ever become parents.14 When we further filtered our
data to include only individuals with age at death greater
than 40, 16 years of anticipation were still observed
(p ¼ 0.002, two-sided paired t test, n ¼ 5 pairs).Discussion
The prediction of age of onset in those carrying mutations
causal of neurodegenerative diseases is important for ge-
netic counseling, clinical trial design,49,50 and understand-
ing of fundamental disease mechanisms. We chose to
investigate bias in a specific genetic prion disease as it
has been reported12,13 that Glu200Lys genetic prion dis-
ease exhibits anticipation, with children succumbing to
disease 7 to 14 years younger than their parents on
average. We approached this claim with skepticism; the
causal mutation is not a repeat expansion and human
prion strains are not transmitted in childbirth or through
casual contact between people,51–53 leaving no obvious
mechanism for anticipation. Such a large decrease in age
of onset in germline transmission ought to lead to juvenile
onset cases within a few generations, as observed in repeat
expansion disorders,15 yet no such cases are observed in
Glu200Lys families (Figure 2A). In the present study, we
considered the possibility that reported evidence of antic-
ipation in Glu200Lys prion disease arises instead from
ascertainment bias.
We tested for anticipation in our data using naive paired
t tests, and we did observe a statistically significant dif-
ference between parent and child age of onset, but four
separate lines of evidence argue that this difference is arti-
factual rather than biological. First, 92% of known years of
onset or death for CJD-affected individuals in our data set
fell within the 25-year window from the mutation’s dis-
covery in 1989 to the time of our study in 2013, whereas
parents were born on average 28 years earlier than their
children. This enriches for pairs in which children die at
least 3 years younger than their affected parent. Pairs in
which children die older than their parents are much less
likely to be observed during this time window. Second,
we observed an artifactual correlation between year of
birth and age of onset reflective of this ‘‘windowing’’ effect
because individuals born later in time are only captured in
this data set if they have earlier onset. The distribution of
ages of onset is therefore shifted older for a parent’s year
of birth (for instance, 1920) than for their child’s year
of birth (for instance, 1950). Third, the strength of thean Journal of Human Genetics 95, 371–382, October 2, 2014 379
anticipation signal we observed depended upon how
strictly the data were limited by the ascertainment win-
dow. When we required that both parent and child had
to be directly observed as patients by the study centers
contributing data, we observed 28 years of anticipation.
When all indirectly ascertained individuals were also
included, this figure dropped to 7 years, and when we per-
formed survival analysis on only the data from two centers
most active in performing predictive genetic testing, we
saw no difference in age of onset at all. Fourth, when using
naive paired t tests, we observed anticipation even among
individuals in our pedigrees who did not harbor the muta-
tion and/or died of causes unrelated to prion disease.
None of the three previous studies reporting Glu200Lys
anticipation12,13 (see also Web Resources) presented data
on the distribution of year of onset, tested for correlation
between year of birth and age of onset, or carried out a
negative control by assessing anticipation in unrelated
deaths as we have done here. One of these studies12 found
a stronger anticipation (14 years rather than 7) when only
directly genotyped individuals were included, similar
to our finding that the strength of anticipation depends
upon the duration of the ascertainment window. We
showed that the stratification analyses, as performed in
one study,13 do not remove the effects of ascertainment
bias. Because anticipation was observed in certain analyses
of our data as well, we consider it likely that the differ-
ences between our study and the previous studies arise
from differences in methodology rather than differences
in whether anticipation is truly present in the study
population.
In assessing the evidence for anticipation in Glu200Lys
prion disease, we have created a simulation model with
relevance to other diseases as well. In contrast to previous
studies of anticipation, we consider ascertainment to be
limited by year of onset, not by age of onset per se. In gen-
eral we find that ascertaining only those individuals with
onset within a restricted time period is sufficient to create
robust false signals of anticipation. This is of general
concern because the genetic causes of many dominant
Mendelian disorders were identified within the past
25 years, leaving a relatively narrow window for ascertain-
ment. Our simulation shows that even high rates of retro-
spective ascertainment are unlikely to completely remove
the resulting false signal of anticipation. Although certain
statistical methods can help to correct for this bias when
ascertainment criteria are consistent or data sets large
enough to allow subsetting, we believe our own data may
be typical of some rare diseases in representing a mixture
of ascertainment modes, with both retrospective and
prospective phenotyping present but nonexhaustive. For
such data sets, we agree with the view54 that statistical tests
alone might be inadequate to discriminate between situa-
tions with and without anticipation. We believe that one
route toward preventing spurious claims of anticipation
such as seen in Glu200Lys genetic prion disease might lie
not in the requirement of more rigorous statistical tests380 The American Journal of Human Genetics 95, 371–382, Octoberbut in an expectation of thorough and transparent assess-
ment of a data set’s degree of bias. Toward that end, we pro-
pose that future studies’ reporting factors that determine
age of onset in adult-onset dominant conditions should
be expected to provide (1) a histogram of year of onset or
death, (2) a test for correlation between year of birth and
age of onset, (3) descriptive statistics on the extent of retro-
spective ascertainment and predictive genetic testing or
prospective follow-up, and (4) a test for anticipation in
deaths of other causes. Our results also have implications
for study design in adult-onset genetic diseases; year
of birth information should be collected, asymptomatic
individuals with a mutation should be tracked, and retro-
spective ascertainment should be as thorough as possible.
These measures will make it easier to quantify and reduce
ascertainment bias.
Though heritability of age of onset was not observed
in our Glu200Lys data, we noticed in our simulation that
windowed ascertainment can also create a false signal
that age of onset is heritable. This false signal could easily
be disproven by including child year of birth as a covariate
in parent-offspring regression. Our result suggests that esti-
mates of the heritability of age of onset in genetic disease
made based on parent-offspring regression ought to be
scrutinized carefully and accepted only if the parent-child
age of onset correlation remains after controlling for year
of birth.
In summary, the phenomenon of anticipation previ-
ously reported in Glu200Lys prion disease is likely an arti-
fact. Ascertainment bias is a pervasive problem in age of
onset in genetic disease but can be reduced through
appropriate data collection methods and recognized with
simple analytical tools.Supplemental Data
Supplemental Data include one table and can be found with this
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drome. Exp. Neurol. 106, 204–206.
5. Goldfarb, L.G., Korczyn, A.D., Brown, P., Chapman, J., and
Gajdusek, D.C. (1990). Mutation in codon 200 of scrapie am-
yloid precursor gene linked to Creutzfeldt-Jakob disease in
Sephardic Jews of Libyan and non-Libyan origin. Lancet
336, 637–638.
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More than 100,000 genetic variants are reported to cause Mendelian disease in humans, but the penetrance—the
probability that a carrier of the purported disease-causing genotype will indeed develop the disease—is generally
unknown. We assess the impact of variants in the prion protein gene (PRNP) on the risk of prion disease by analyzing
16,025 prion disease cases, 60,706 population control exomes, and 531,575 individuals genotyped by 23andMe Inc.
We show that missense variants in PRNP previously reported to be pathogenic are at least 30 times more common in
the population than expected on the basis of genetic prion disease prevalence. Although some of this excess can be
attributed to benign variants falsely assigned as pathogenic, other variants have genuine effects on disease suscep-
tibility but confer lifetime risks ranging from <0.1 to ~100%. We also show that truncating variants in PRNP have
position-dependent effects,with true loss-of-functionalleles found inhealthyolder individuals, a finding that supports
the safety of therapeutic suppression of prion protein expression. on
g/ June 9, 2016INTRODUCTION
The study of pedigrees with Mendelian disease has been tremendously
successful in identifying variants that contribute to severe inherited dis-
orders (1–3). Causal variant discovery is enabled by selective ascertain-
ment of affected individuals and especially of multiplex families.
Although efficient from a gene discovery perspective, the resulting as-
certainment bias confounds efforts to accurately estimate the penetrance—
the probability that a carrier of the purported disease-causing genotype
will indeed develop the disease—of disease-causing variants, with pro-
found implications for genetic counseling (4–7). The development of
large-scale genotyping and sequencing methods has recently made it
tractable to perform unbiased assessments of penetrance in population
controls. In several instances, such studies have suggested that previous-
ly reported Mendelian variants, as a class, are substantially less pene-
trant than had been believed (8–11). To date, however, all of these
studies have been limited to relatively prevalent (>0.1%) diseases, and
point estimates of the penetrance of individual variants have been
limited to large copy number variations (8, 11).
Here, we demonstrate the use of large-scale population data to infer
the penetrance of variants in rare, dominant,monogenic disease using the
example of prion diseases. These invariably fatal neurodegenerative dis-
orders are caused by misfolding of the prion protein [PrP, the product of
the prion protein gene (PRNP)] (12) and have an annual incidence of 1 towww.Scien2 cases per 1million population (13). A small, albeit infamous,minority
of cases (<1% in recent years) (14, 15) are acquired through dietary or
iatrogenic routes. Most of the cases (~85%) are defined as sporadic,
occurring in individuals with twowild-type PRNP alleles and no known
environmental exposures. Finally, ~15%of cases occur in individualswith
rare, typically heterozygous, coding variants in PRNP, includingmissense
variants, truncating variants, and octapeptide repeat insertions or dele-
tions (table S1).Centralized ascertainmentof cases bynational surveillance
centers (Materials and Methods) makes prion disease a good test case
for using reference data sets to assess the penetrance of these variants.
PRNP was conclusively established as a dominant disease gene be-
cause a few variants exhibit clearMendelian segregation with prion dis-
ease (16–18). Yet, ascertainment bias (19), low rates of predictive genetic
testing (20), and frequent lack of family history (21, 22) confound at-
tempts to estimate penetrance by survival analysis (19, 23–26). Mean-
while, the existence of nongenetic etiologies leaves doubt as to whether
new variants are causal or coincidental.
A fully penetrant disease genotype should be no more common in
the population than the disease that it causes. This observation allows us
to leverage two large population control data sets to reevaluate the pen-
etrance of reported disease variants in PRNP. The recently reported
Exome Aggregation Consortium (ExAC) data set (27) contains variant
calls on 60,706 unrelated individuals ascertained for case/control statusceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 1
R E S EARCH ART I C L Efor various common diseases, without any ascertainment on neuro-
degenerative disease. 23andMe’s database contains genotypes on
531,575 customers of its direct-to-consumer genotyping service who
have opted to participate in the research, pruned to remove related in-
dividuals (first cousins or closer, Materials andMethods), preventing en-
richment due to large families with prion disease.D
ow
nloaded fromRESULTS
Disease prevalence and variant frequency
We began by asking whether reportedly pathogenic variants are as rare
as expected in these population control data sets. The proportion of
people alive in the population today who harbor completely penetrant
variants causal for prion disease can be approximated by the product of
three numbers: the annual incidence of prion disease, the proportion of
cases with such a genetic variant, and the life expectancy of individuals
harboring these variants. On the basis of the upper bounds of these
numbers (Fig. 1A), and assuming ascertainment is neutral with respect
to neurodegenerative disease, we would expect no more than ~1.7 such
individuals in the 60,706 exomes in the ExAC data set (27), and ~15
such individuals among the ~530,000 genotyped 23andMe customers
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Through reviews (28–30) and PubMed searches, we identified 63
rare genetic variants reported to cause prion disease (table S2). We re-
viewed ExAC read-level evidence for every rare (<0.1% allele frequency)
variant call in PRNP (Materials and Methods; tables S3 and S4) and
found that 52 individuals in ExAC harbor reportedly pathogenic mis-
sense variants (Fig. 1B), at least a 30-fold excess over expectation if all
such variants were fully penetrant. Similarly, in the 23andMe database,
we observed a total of 141 alleles of 16 reportedly pathogenic variants
genotyped on their platform (table S5).
Individuals with reportedly pathogenic PRNP variants did not
cluster within any cohort within ExAC (table S6), arguing against en-
richment resulting from comorbidity with a common disease ascertained
for in exome sequencing studies. ExAC does include populations such as
SouthAsians, in which prion disease is not closely surveilled, andwe thus
cannot rule out a higher incidence than that reported for developed coun-
tries, yet the individuals with reportedly pathogenic variants in either
ExAC or 23andMe were of diverse inferred ancestry (tables S7 to S9).
These individuals’ ages were consistent with the overall ExAC age
distribution (fig. S1) rather than being shifted toward younger ages, as
would be expected if these individuals were depleted beyond middle
age as a result of prion disease onset.We also examined ExAC genotypes
at the M129V polymorphism, which affects risk, age of onset, disease
duration, and phenotypic presentation in various types of prion disease
(31–33). Codon 129 genotypes were consistent with population allele
frequencies (table S7) rather than enriched for the lower-risk heter-
ozygous genotype. Certain PRNP variants are associated with highly
atypical phenotypes (34, 35), which are mistakable for other demen-
tias and might not be well ascertained by current surveillance efforts.
Most of the variants found in our population control cohorts, how-
ever, have been reported in individuals with a classic, sporadic
Creutzfeldt-Jakob disease phenotype (22, 28, 30, 36–38), arguing that
the discrepancy between observed and expected allele counts does
not result primarily from an underappreciated prevalence of atypical
prion disease.
Assessing penetrance
Having observed a large excess of reportedly pathogenic variants over
expectation in two data sets and having excluded themost obvious con-
founders, we hypothesized that the unexpectedly high frequency of
these variants in controlsmight arise frombenign variants, low-risk var-
iants, or both. We investigated which variants were responsible for the
observed excess (Fig. 2). Variants with the strongest previous evidence
of pathogenicity were absent from ExAC and cumulatively accounted
for five or fewer alleles in 23andMe, consistent with the known rarity of
genetic prion disease. Much of the excess allele frequency in population
controls resulted instead from variants with very weak previous evi-
dence of pathogenicity (Fig. 2 and Supplementary Discussion). For four
variants observed in controls (V180I, R208H, V210I, and M232R),
pathogenicity is controversial (39, 40) or reduced penetrance has been
suggested (41, 42), but quantitative estimates of penetrance have never
been produced, and the variants remain categorized as causes of genetic
Creutzfeldt-Jakob disease (21, 22). Although we cannot prove that any
of the variants we observe in population controls is completely neutral,
the list of reported pathogenic variants likely includes false positives.
Indeed, the observation that 0.4% (236 of 60,706) of ExAC individuals
harbor a rare (<0.1%) missense variant (table S4) suggests that ~4 of
every 1000 sporadic prion disease cases will, by chance, harbor such a
variant, which, inmany cases, will be interpreted and reported as causal,ceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 2
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M232R Reportedly pathogenic variant
Segregation in multiple multigenerational families;
spontaneous disease in mouse models
Fig. 2. Reportedly pathogenic PRNP variants: Mendelian, benign, and
intermediate variants. Previous evidence of pathogenicity is extremely
R208C (eight alleles in 23andMe) and P39L were observed in patients
presenting clinically with other dementias, with prion disease suggestedstrong for four missense variants—P102L, A117V, D178N, and E200K—each
of which has been observed to segregate with disease in multiple multi-
generational families (16–18, 93–97) and to cause spontaneous disease in
mouse models (98–103). These account for >50% of genetic prion disease
cases (table S1), yet are absent from ExAC (table S3) and collectively appear
on five or fewer alleles in 23andMe’s cohort (table S5), indicating allele fre-
quencies sufficiently low to be consistent with the prevalence of genetic pri-
on disease (Fig. 1). Conversely, the variants most common in controls and
rare in cases had categorically weak previous evidence for pathogenicity.www.Scienas an alternative diagnosis solely on the basis of finding a novel PRNP variant
(104, 105). E196A was originally reported in a single patient, with a sporadic
Creutzfeldt-Jakob disease phenotype and no family history (36), and
appeared in only 2 of 790 Chinese prion disease patients in a recent case
series (106), consistent with the ~0.1% allele frequency among Chinese in-
dividuals in ExAC (tables S5 and S8). At least three variants (M232R, V180I,
and V210I) occupy a space inconsistent either with neutrality or with com-
plete penetrance (see main text and Fig. 3). R148H, T188R, V203I, R208H,
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Fig. 1. Frequency of reportedly pathogenic PRNP variants: >30 times
higher in controls than expected on the basis of disease incidence.
(22, 91); we accepted 80, a typical human life expectancy, as an upper
bound for mean age of onset, and to be additionally conservative, we(A and B) Reported prion disease incidence varies with the intensity of surveil-
lance efforts (13), with an apparent upper bound of about two cases per mil-
lion population per year (Materials and Methods). In our surveillance cohorts,
65% of cases underwent PRNP open reading frame sequencing, with 12% of
all cases, or 18% of sequenced cases, having a rare variant (table S1), which is
consistent with an oft-cited estimate that 15% of cases of Creutzfeldt-Jakob
disease are familial (43). Genetic prion diseases typically strike in midlife, with
mean age of onset for different variants ranging from 28 to 77 (table S10)assumed that all individuals in the ExAC and 23andMe data sets were
below any age of onset, even though both contain elderly individuals
(fig. S1) (92). Thus, nomore than~29 people permillion in the general popu-
lation should harbor high-penetrance prion disease–causing variants; at
most ~1.7 people in ExAC (A) and ~15 people in 23andMe would be
expected to harbor such variants. Reportedly pathogenic variants were
observed in 52 ExAC individuals (B) and on 141 alleles in the 23andMe
database (table S5).ceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 3








given the long-standing classification of PRNP as a Mendelian disease
gene.
At least three variants (V180I, V210I, and M232R) failed to cluster
with either the likely benign or likely Mendelian variants (Fig. 2). Be-
cause each of these three appeared primarily in one population (Japa-
nese or Italian) in both cases and controls (tables S1, S5, S7, and S10), we
compared allele frequencies inmatched population groups. Eachhad an
allele frequency in controls that was too high for a fully penetrant, dom-
inant prion disease–causing variant and, yet, far lower than the cor-
responding allele frequency in prion disease cases (Fig. 3). Because
we lacked genome-wide single-nucleotide polymorphism (SNP) data
on cases, we were unable to directly correct for population stratification
or substructure, whereby regional differences in allele frequency within
Italy or Japan might affect our results. Geographical clusters of genetic
prion disease have been recognized for decades (26, 43, 44). For exam-
ple, nearly half of Italian prion disease cases with the V210I variant are
concentrated within two regions of Italy (45), so any nonuniform geo-
graphic sampling in cases versus controls would add some uncertainty
to our penetrance estimates.
Nonetheless, the magnitude of the enrichment of certain variants in
cases over controls in our data sets makes population stratification an
implausible explanation for the entire difference. For V210I to be neu-
tral and, yet, appear with an allele frequency of 8.1% in Italian cases de-
spite an apparent allele frequency of 0.02% in Italian controls, it would
need to be fixed in a subpopulation that comprises 8% of Italy’s popu-
lace. Under this scenario, the subpopulation would need to be virtually
unsampled in any of our control cohorts, and the collection of V210I
prion disease cases would be expected to containmany homozygotes. In
reality, no cases have been reported as homozygous for this variant.
Conversely, if V210I were fully penetrant, then family history would
be positive in most cases, and the variant’s appearance on 13 alleles in
23andMe (table S5) would indicate that this variant alone accounts forwww.Scienthree times the known prevalence of genetic prion disease (Fig. 1A).
Finally, if the low family history rate were caused by many de novo
mutations, then V210I cases would be more uniformly distributed
across populations (table S1). Similar arguments rule out V180I being
either benign or Mendelian. M232R, though clearly not Mendelian,
could still be benign because it exhibits only four- to sixfold enrichment
in cases, an amount that might conceivably be explained by Japanese
population substructure alone. However, because even common var-
iants in PRNP affect prion disease risk with odds ratios of 3 or greater
(46–48), it is plausible that M232R has a similar effect size; indeed, our
data suggest that M232R having this effect on prion disease risk is a
more likely scenario than M232R being neutral.
Satisfied that these three variants are likely neither benign nor
Mendelian, we estimated lifetime risk in heterozygotes (Materials and
Methods). The ~2 in 1 million annual incidence of prion disease trans-
lates into a baseline lifetime risk of ~1 in 5000 in the general population
(Materials and Methods). Because prion diseases are so rare, even the
massive enrichment of heterozygotes in cases (Fig. 3)—implying odds
ratios on the order of 10 to 1000—corresponds to only low penetrance,
with lifetime risks for M232R, V180I, and V210I estimated to be near
0.1, 1, and 10%, respectively. Although our estimates are imperfect be-
cause of population stratification, they accord well with family history
rates (Fig. 3) and explain the unique space that these variants occupy in
the plot of case versus control allele count (Fig. 2). These data indicate
that PRNPmissense variants occupy a risk continuum rather than a di-
chotomy of causal versus benign.
Protein-truncating variants
We asked whether the same was true of protein-truncating variants.
PRNP has only one protein-coding exon, so premature stop codons
are expected to result in truncated polypeptides rather than in
nonsense-mediated decay. Prion diseases are known to arise froma gain on June 9, 2016
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Fig. 3. Variants that confer intermediate amounts of lifetime risk.M232R,
V180I, andV210I showed varying degrees of enrichment in cases over controls,
of E200K penetrance based on survival analysis, which range from~60% to
~90% (19, 23–26). Rates of family history of neurodegenerative disease inindicating a weak tomoderate increase in risk. Best estimates of lifetime risk in
heterozygotes (Materials and Methods) range from ~0.08% for M232R to
~7.8% for V210I and correlate with the proportion of patients with a positive
family history. Allele frequencies for P102L, A117V, D178N, and E200K were
consistentwithup to100%penetrance,withCI includingall reportedestimatesJapanese cases (table S10) and in European populations (21) are shown with
Wilson binomial 95% CIs. *Based on allele counts rounded for privacy
(Materials andMethods). †Gerstmann-Straussler-Scheinker (GSS) disease as-
sociated with variants P102L, A117V, and G131V. ‡Fatal familial insomnia
(FFI) associated with a D178N (cis-129M) haplotype.ceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 4






of function, because neurodegeneration is not seen in mice, cows, or
goats that lack PrP (49–52), and the rate of prion disease progression
is tightly correlated with PrP expression level (53). Yet, heterozygous
C-terminal (residue≥145) truncating variants are known to cause pri-
on disease, sometimes with peripheral amyloidosis (34). Some of these
patients also experience sensorimotor neuropathy phenotypically simi-
lar to that present in homozygous, but not heterozygous, PrP knockout
mice (54); this phenotype has been attributed to amyloid infiltration of
peripheral nerves, rather than loss of PrP function (34).
We identified heterozygous N-terminal (residue ≤131) truncating
variants in four ExAC individuals and were able to obtain Sanger vali-
dation (fig. S2) and limited phenotype data (table S11) for three. These
individuals were free of overt neurological disease at ages 79, 73, and 52,
and report no personal or family history of neurodegeneration or peri-
pheral neuropathy. Therefore, the pathogenicity of protein-truncating
variants appears to be dictated by position within PrP’s amino acid
sequence (Fig. 4). Observing three PRNP nonsense variants in ExAC
was consistent with the expected number (~3.9) based on mutation
rates once we adjusted our model (55) to exclude codons ≥145, where
truncations cause a dominant gain-of-function disease. Thus, we see no
evidence that PRNP is constrained against truncation in its N terminus.
This lack of any evidence of purifying selection againstN-terminal trun-
cating variants, combined with the lack of any obvious phenotype in
individuals harboring these variants, suggests that heterozygous loss




More than 100,000 genetic variants have been reported to cause
Mendelian disease in humans (56, 57). Many such reports do not meet
current standards for assertions of pathogenicity (58, 59), and if all such
reports were believed, the cumulative frequency of these variants in the
population would imply that most people have a genetic disease (27). Itwww.Scienis generally unclear howmuch of the excess burden of purported disease
variants in the population results frombenign variants falsely associated
and how much results from variants with genuine association but
incomplete penetrance.
Here, we leveraged newly available large genomic reference data sets
to reevaluate reported disease associations in a dominant disease gene,
PRNP. We identify some missense variants as likely benign and show
that others span a spectrum from <0.1 to ~100% penetrance. Our analyses
provide quantitative estimates of lifetime risk for hundreds of asymptomatic
individuals who have inherited incompletely penetrant PRNP variants.
Available data sets are only now approaching the size and quality
required for such analyses, resulting in limitations for our study. The
confidence intervals (CIs) on our lifetime risk estimates spanmore than
an order of magnitude, and our inability to perfectly control for popu-
lation stratification injects additional uncertainty.We have been unable
to reclassify those PRNP variants that are very rare both in cases and in
controls (SupplementaryDiscussion).Wehave avoided analysis of large
insertions that are poorly called with short sequencing reads, although
we note that existing literature on these insertions is consistent with a
spectrumof penetrance similar to the spectrum thatwe observe formis-
sense variants (28, 32). Penetrance estimation inMendelian disease will
be improved by the collection of larger case series, particularly with
genome-wide SNP data to allow more accurate population matching.
This, coupled with continued large-scale population control sequencing
and genotyping efforts, should reveal whether the dramatic variation in
penetrance that we observe here is a more general feature of dominant
disease genes.
Because PrP is required for prion pathogenesis and reduction in
gene dosage slows disease progression (53, 60–62), several groups have
sought to therapeutically reduce PrP expression usingRNA interference
(63–65), antisense oligonucleotides (66), or small molecules (67, 68).
Our discovery of heterozygous loss-of-function variants in three healthy
older humans provides the first human genetic data regarding the











prion disease patientsUnknown phenotype
Signal peptide Deleted in susceptible mice GPI signal
Fig. 4. Position-dependent effects of truncating variants in the human
prion protein. Truncating variants reported in prion disease cases in the lit-
most of the protein intact, a combination that mediates gain of function
through mislocalization, which causes this normally cell surface–anchorederature (table S2) and in our cohorts (table S1) cluster exclusively in the C-
terminal region (residue≥145), whereas truncating variants in ExAC aremore
N-terminal (residue ≤131). The ortholog of each residue from 23 to 94 is de-
leted in at least oneprion-susceptible transgenicmouse line (107). C-terminal
truncations abolish PrP’s glycosylphosphatidylinositol (GPI) anchor but leaveprotein to be secreted. Consistent with this model of pathogenicity, mice
that express full-length secreted PrP develop fatal and transmissible prion
disease (108, 109). By contrast, the N-terminal truncating variants that we
observed retain only residues dispensable for prionpropagation and are like-
ly to cause a total loss of protein function.ceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 5
R E S EARCH ART I C L Eof individuals and the depth of available phenotype data are limited, and
lifelong heterozygous inactivation of a gene is an imperfect model of the
effects of pharmacological depletion of the gene product. With those
limitations, our data provide preliminary evidence that a reduction in
PRNP dosage, if achievable in patients, is likely to be tolerated. Increas-
ingly large control sequencing data sets will soon enable researchers to
test whether the same is true of other genes currently being targeted in
substrate-reduction therapeutic approaches for other protein-folding
disorders. Together, our findings highlight the value of large reference
data sets of human genetic variation for informing both genetic










We sought to estimate the penetrance of variants reported to cause ge-
netic prion disease. We reasoned that fully penetrant variants should
not be any more common in the general population than genetic prion
disease is, and that by comparing allele frequencies in cases versus pop-
ulation controls, we could estimate penetrance for individual variants.
This approach does not require controls that are certified to be free of
prion disease, but instead only requires that controls not be enriched for
prion disease. We carried out a retrospective analysis of existing data
from three sources (prion surveillance centers, ExAC, and 23andMe re-
search participants), which are described in detail below.
Prion disease case series
Prion disease is considered a notifiable diagnosis in most developed
countries, withmandatory reporting of all suspect cases to a centralized
surveillance center. Surveillance was carried out broadly according to
established guidelines (69, 70), with specifics as described previously
for Australia (71), France (72), Germany (73–75), Italy (76), Japan
(22), and the Netherlands (77). Sanger sequencing of the PRNP open
reading framewas performed as described (78).We included only prion
disease cases classified as definite (autopsy-confirmed) or probable
(according to published guidelines) (70). Criteria for genetic testing vary
between countries and over the years of data collection, with testing
offered only on indication of family history in some times and places,
and testing of all suspect cases with tissue available in other instances.
Summary statistics on the total number and proportion of cases se-
quenced are presented in table S1.
Exome sequencing and analysis
The ascertainment, sequencing, and joint calling of the ExAC data set
have been described previously (27). We extracted all rare (<0.1%)
coding variant calls in PRNPwith genotype quality (GQ)≥10, alternate
allele depth (AD) ≥3, and alternate allele balance (AB) ≥20%. Read-
level evidence was visualized using Integrative Genomics Viewer
(IGV) (79) for manual review. Because most ExAC exomes were se-
quenced with 76–base pair (bp) reads and the PRNP octapeptide repeat
region (codons 50 to 90 inclusive) is 123 bp long, it was impossible to
determine whether genotype calls in this region were correct, and they
were not considered further. After review of IGV screenshots, 87% of
genotype calls were judged to be correct and were included in table S3.
Of the genotype calls judged to be correct, 99% had GQ≥95, 99% had
AB between 30 and 70%, and 97% had AD ≥10. All participants
provided informed consent for exome sequencing and analysis. Thewww.ScienExAC’s aggregation and release of exome data have been approved by
the Partners Healthcare Institutional Research Board (2013P001339).
ExAC data have been publicly released at http://exac.broadinstitute.org,
and IGVscreenshots of the rarePRNP variants deemed tobe genuine and
included in this study are available at https://github.com/ericminikel/
prnp_penetrance/tree/master/supplement/igv.
23andMe research participants and genotyping
Participants were drawn from the customer base of 23andMe Inc., a
personal genetics company (accessed 6 February 2015). All participants
provided informed consent under a protocol approved by an external
Association for the Accreditation of Human Research Protection
Programs–accredited institutional review board, Ethical & Independent
Review Services. DNA extraction and genotyping were performed on
saliva samples by the National Genetics Institute, a Clinical Laboratory
Improvement Amendments–licensed clinical laboratory and a subsid-
iary of LaboratoryCorporation of America. Samples were genotyped on
one of four Illumina platforms (V1 to V4) as described previously (80).
Of the PRNP SNPs considered, 2 (P105L and E200K) were genotyped
on all four platforms, whereas the other 14 were genotyped only on V3
andV4, resulting in differing numbers of total samples genotyped (table
S5). Genotypes were called with Illumina GenomeStudio. A 98.5% call
rate was required for all samples. As with all 23andMe research parti-
cipants, individuals whose genotyping analyses failed to reach the
desired call rate repeatedly were recontacted to provide additional
samples. Amaximal set of unrelated individuals was chosen on the basis
of segmental identity-by-descent (IBD) estimation (81). Individuals
were defined as related if they shared more than 700-centimorgan
IBD (about the minimal expected sharing between first cousins). Allele
counts between one and five were rounded up to five to protect individ-
ual privacy (table S5). Rounding down to one instead would raise our
estimates of penetrance for V180I to 7.7% (95% CI, 1.2 to 50%) and for
P102L, A117V,D178N, and E200K collectively to 100% (95%CI, 100 to
100%), but the CI would still overlap those based on ExAC allele fre-
quencies, and the overall conclusions of our study would remain un-
changed.
23andMe ancestry composition
Ancestral origins of chromosomal segments were assigned on a
continental level (European, Latino, African, and East Asian) and on
a country level (Japanese) as described by Durand et al. (82). Briefly,
after phasing genotypes using an out-of-sample implementation of
the Beagle algorithm (83), a string kernel support vector machine clas-
sifier assigns tentative ancestry labels to local genomic regions. Then, an
autoregressive pair hidden Markov model was used to simultaneously
correct phasing errors and produce reconciled local ancestry estimates
and confidence scores based on the initial assignment. Finally, isotonic
regression models were used to recalibrate the confidence estimates.
Europeans and East Asians were defined as individuals with more
than 97%of chromosomal segments predicted as being from the respec-
tive ancestries. Because African Americans and Latinos are highly ad-
mixed, no single threshold of genome-wide ancestry is sufficient to
distinguish them. However, segment length distributions of European,
African, and Native American ancestries are different between African
Americans and Latinos, because of the distinct admixture timing in the
two ethnic groups. Thus, a logistic classifier based on segment length of
European, African, and Native American ancestries was used to distin-
guish between African Americans and Latinos.ceTranslationalMedicine.org 20 January 2016 Vol 8 Issue 322 322ra9 6
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At the country level, individuals were classified as Japanese based
on the fraction of the respective local ancestry using a threshold of
90% for classifying Japanese ancestry. This threshold is based on the
average fraction of local ancestry in the reference population (23andMe
research participants with all four grandparents from the reference
country): 94% (5% SD, n = 533) for Japanese. Using the same approach,
we were unable to obtain a confident set of Italian individuals for
analysis of V210I because of extensive admixture. 23andMe research
participants with all four grandparents from Italy only have 66% (18%
SD, n = 2090) Italian ancestry, and only ~60 participants have >90%
Italian ancestry.
ExAC ancestry inference
Wecomputed 10 principal components based on~5800 common SNPs
as described (27, 84). A centroid in eigenvalue-weighted principal
component space was generated for each HapMap population based
on 1000 Genomes individuals in ExAC. The remaining individuals in
ExAC were assigned to the HapMap population with the nearest cen-
troid according to eigenvalue-weighted Euclidean distance. Ancestries
of all individuals, including those with reportedly pathogenic variants,
are summarized in tables S7 and S8.
Prion disease incidence and baseline risk
The reported incidence of prion disease varies between countries and
between years, with much of the variability explained by the intensity
of surveillance, as measured by the number of cases referred to national
surveillance centers (13). Rates of about one case per million population
per year have been reported, for instance, in the United States (85) and
in Japan (22); however, the countries with the most intense surveillance
(greatest number of referrals per capita), such as France and Austria,
observe incidence figures as high as two cases per million population
per year (13). Only in small countries where the statistics are dominated
by a particular genetic prion disease founder mutation, such as Israel
and Slovakia (23, 26), has an incidence higher than two per million been
consistently observed (86). We therefore accepted two cases per million
as an upper bound for the true incidence of prion disease. Assuming an
all-causes death rate of ~10 per 1000 annually (87), this incidence
corresponds to prion disease accounting for ~0.02% of all deaths, which
we accepted as the baseline disease risk in the general population.
Lifetime risk estimation
By Bayes’ theorem, the probability of disease given a genotype [pene-
trance or lifetime risk, P(D|G)] is equal to the proportion of individuals
with the disease who have the genotype [genotype frequency in cases,
P(G|D)] times the prevalence of the disease [baseline lifetime risk
in the general population, P(D)], divided by the frequency of the
genotype in the general population [here, population control allele
frequency, P(G)]. The use of this formula to estimate disease risk
dates back at least to Cornfield’s estimation of the probability of lung
cancer in smokers (88), with later contributions by Woolf (89) and a
synthesis by Li (90) with application to genetics.
We used an allelic rather than a genotypic model, such that lifetime
risk in an individual with one allele is equal to case allele frequency
(based on the number of prion disease cases that underwent PRNP se-
quencing) times baseline risk divided by population control allele fre-
quency, P(D|A) = P(A|D) × P(D)/P(A). Note that we assumed that our
population control data sets include individuals who will later die of
prion disease, thus enabling direct use of the ExAC and 23andMe allelewww.Scienfrequencies as the denominator P(A). Following Kirov et al. (11), we
computed Wilson 95% CI on the binomial proportions P(A|D) and
P(A), and calculated the upper bound of the 95%CI for penetrance using
the upper bound on case allele frequency and the lower bound on pop-
ulation control allele frequency, and vice versa for the lower bound on
penetrance.
Statistical analysis and source code availability
Error bars in Fig. 3 are as described in the previous section. Data pro-
cessing, analysis, and figure generation used custom scripts written in
Python 2.7.6 and R 3.1.2. These scripts, along with vector graphics of all
figures and tab-delimited text versions of all supplementary tables, are
available online at https://github.com/ericminikel/prnp_penetrance and




Table S1. Allele counts of rare PRNP variants in 16,025 definite and probable prion disease
cases in nine countries.
Table S2. Rare PRNP variants reported in peer-reviewed literature to cause prion disease.
Table S3. Allele counts of rare PRNP variants in 60,706 individuals in ExAC.
Table S4. Summary of rare PRNP variants by functional class in ExAC.
Table S5. Allele counts of 16 reportedly pathogenic PRNP variants in >500,000 23andMe re-
search participants.
Table S6. Phenotypes investigated in studies in which ExAC individuals with reportedly path-
ogenic PRNP variants were ascertained.
Table S7. Inferred ancestry and codon 129 genotypes of ExAC individuals with reportedly
pathogenic variants.
Table S8. Inferred ancestry of all ExAC individuals.
Table S9. Inferred ancestry of 23andMe research participants.
Table S10. Details of Japanese prion disease cases.
Table S11. Phenotypes of individuals with N-terminal PrP-truncating variants.
Fig. S1. Age of ExAC individuals with reportedly pathogenic PRNP variants versus all individuals
in ExAC.
Fig. S2. Sanger sequencing results for individuals with N-terminal–truncating variants.
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To determine whether preventive trials in genetic prion disease could be designed to follow
presymptomatic mutation carriers to onset of disease.
Methods
We assembled age at onset or death data from 1,094 individuals with high penetrancemutations
in the prion protein gene (PRNP) in order to generate survival and hazard curves and test for
genetic modifiers of age at onset. We used formulae and simulations to estimate statistical
power for clinical trials.
Results
Genetic prion disease age at onset varies over several decades for the most common mutations
and neither sex, parent's age at onset, nor PRNP codon 129 genotype provided additional
explanatory power to stratify trials. Randomized preventive trials would require hundreds or
thousands of at-risk individuals in order to be statistically powered for an endpoint of clinical
onset, posing prohibitive cost and delay and likely exceeding the number of individuals available
for such trials.
Conclusion
The characterization of biomarkers suitable to serve as surrogate endpoints will be essential for
the prevention of genetic prion disease. Parameters such as longer trial duration, increased
enrollment, and the use of historical controls in a postmarketing study could provide oppor-
tunities for subsequent determination of clinical benefit.
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Regulatory agencies worldwide have created programs to
support drug development in situations where requiring the
gold standard—a placebo-controlled, randomized trial with
a clinical endpoint (a measure of how patients feel or
function)—might unduly delay patient access to potentially
life-saving drugs. Under Accelerated Approval,1 the US Food
and Drug Administration (FDA) “incorporate[s] novel
approaches into the review of surrogate endpoints…espe-
cially…where the low prevalence of a disease renders the
existence or collection of other types of data unlikely or im-
practical.” 2 Here we examine whether genetic prion disease
meets this criterion.
Genetic prion disease (including genetic Creutzfeldt-Jakob dis-
ease, fatal familial insomnia, and Gerstmann-Sträussler-
Scheinker disease) is a fatal, incurable neurodegenerative
disease caused by variants in PRNP,3 some of which are highly
penetrant.4 Trials in prion disease have randomized symptom-
atic patients, mostly with sporadic prion disease, to clinical
endpoints,5–7 but by the time of diagnosis many prion disease
patients are in a state of advanced dementia, and even halting the
disease process might only preserve the patient in a state with
little or no quality of life.8 Meanwhile, several therapies tested
preclinically have increased survival in prion-infected mice by
2–4× when administered long before symptoms, but are less
effective later on and may not be effective at all after symptom
onset.9–12 Thus, it is important to enable preventive trials in
presymptomatic individuals at risk for genetic prion disease.13
The Alzheimer’s Prevention Initiative has randomized
healthy, presymptomatic PSEN1 E280A mutation carriers to
drug or placebo with a cognitive endpoint after 5 years.14 We
sought to determine whether a similar trial design would be
feasible in genetic prion disease.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was performed under ethical approval from
the Partners Healthcare Institutional Research Board
(2014P000226/MGH) and the Broad Institute’s Office of Re-
search Subjects Protection (ORSP-2121 and NHSR-4190).
Written consent was obtained from research participants except
where waived for a subset of deceased participants due to
obligatory case reporting to surveillance centers.
Literature annotation
Some PRNP variants can be identified as highly penetrant by
their extreme enrichment in cases over population controls, but
many variants are too rare in both groups for meaningful
comparison.4 We therefore reviewed primary literature for 70
reportedly pathogenic PRNP variants (table S1, doi.org/10.
5281/zenodo.2535761) to determine which had evidence of at
least one family with at least 3 affected individuals in a pattern
consistent with Mendelian segregation, or had a documented
case with a de novo mutation. We identified 27 such variants,
deemed likely high-penetrance variants. The remainder were
seen in isolated patients with a negative or unknown family
history, or have population allele frequencies inconsistent with
high penetrance.4 These variants will include both benign and
low-risk variants. It is possible that some genuinely high-
penetrance variants may also lack literature evidence for high
penetrance due to missing family history information or an
unavailability of familymemberDNA to confirm de novo status,
but this issue will only affect variants with very low case counts
and thus will have minimal effect on the results reported here.
Data collection
Age at onset data were gathered from 9 study centers (table S2
and supplementary Methods, doi.org/10.5281/zenodo.
2535761) and include both previously reported and newly
identified families and individuals. Age at onset was based on
the earliest date of symptoms, determined by the patient or
witnesses, which subsequently developed into prion disease.
Estimation of the number of individuals
available for trials
The National Prion Disease Pathology Surveillance Center, as
the source of the majority of PRNP gene testing in the United
States, has near exhaustive ascertainment of individuals who have
chosen predictive testing for genetic prion disease in this coun-
try. It provided for this study the number of positive predictive
genetic tests (n = 221) given out for PRNPmutations from 1996
through January 2017 to individuals not known to have de-
veloped disease as of 2017. Privacy concerns prevent publication
of a breakdown of these results by age and specific PRNP mu-
tation, so we multiplied the total (n = 221) by the proportion of
US symptomatic prion disease cases with a rare PRNP variant4
who had a mutation classified here as high penetrance (271/362
[75%]) and by the proportion of individuals in a UK predictive
testing cohort15 who were age 40 or older (37/104 [36%]). This
gives a conservative estimate that 221 × 75% × 36% = ;60
individuals alive in the United States today who meet the criteria
we use in our power calculations. In the supplementary Dis-
cussion (doi.org/10.5281/zenodo.2535761), we consider in
detail several other approaches to estimating the number of
PRNP mutation carriers available for trials.
Statistics, source code, and data availability
Analyses were conducted using custom R 3.5.1 scripts run in
RStudio 1.1.456. We present a public GitHub repository at
github.com/ericminikel/prnp_onset (including figure, tables,
Glossary
AD = Alzheimer disease; FDA = Food and Drug Administration; HR = hazard ratio.
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Discussion, and Methods including the details of power cal-
culations and simulations) (doi.org/10.5281/zenodo.2535761)
as well source code in the R programming language and life
tables for each mutation. These data and code are sufficient to
reproduce most analyses and figures herein. This GitHub re-
pository is permanently archived at doi.org/10.5281/zenodo.
2535761.
Results
Age at onset in genetic prion disease
We reasoned that any preventive trial with a clinical endpoint in
genetic prion disease would derive most of its statistical power
from individuals with high penetrance PRNP variants. Literature
review (see Methods) revealed 27 PRNP variants with evidence
for high penetrance. The top 3—E200K, P102L, and
D178N—collectively explain 85% of high-penetrance cases in
a recent case series4 (figure S1, doi.org/10.5281/zenodo.
2535761). Each of these arises from a CpG transition (a C to T
DNA change where the adjacent base is G), a type of variant that
occurs by spontaneousmutation 10–100×more often than other
mutation types,16,17 explaining the recurrence of these 3 muta-
tions on multiple PRNP haplotypes in families worldwide.4,18,19
Therefore, regardless of the population studied, these 3 variants
are likely to account for a large fraction of genetic prion disease
cases with high-penetrance variants. We focused our analysis
primarily on individuals with these 3 variants, aggregating age at
onset or age at death data on 1,001 individuals from 9 study
centers worldwide (tables 1 and S2 [doi.org/10.5281/zenodo.
2535761]), encompassing both direct clinical reports and family
histories (see Methods), and including censored individuals.
Statistics on 93 individuals with the next 4 mutations most
common in cases—5-OPRI (insertion of 5 extra octapeptide
repeats), 6-OPRI, P105L, and A117V—are included in table S3
(doi.org/10.5281/zenodo.2535761). We used these data to
compile life tables and computed the annual hazard—risk of
onset in each year of life—for each mutation (supplementary life
tables, doi.org/10.5281/zenodo.2535761).
We found wide variability in age at onset (table 1), consistent
with previous reports.20–22 An implication of this variability is
that high lifetime risk arises not from certain onset at a specific
age, but from modest risk in any given year of life, accumu-
lated over many decades of exposure. This poses a challenge
for following presymptomatic individuals to onset in a pre-
ventive clinical trial, as it is difficult to ascertain a group of
individuals for whom onset is imminent. For example, even at
age 57, an E200K individual has only a 5% probability of
disease onset occurring in any given year. This means that 20
person-years of follow-up for E200K individuals around this
age would be expected to result in only one observed disease
onset. Annual hazards do rise with age, but as they reach high
levels, the number of surviving individuals also dwindles
(figure 1). For the 3 most common mutations, the annual
hazard remains below 10% until after the majority of people
have already died (figures 1 and S3 and supplementary life
tables, doi.org/10.5281/zenodo.2535761).
Similarly, the median number of years until onset, condi-
tioned on an individual’s current age, remains ≥5 years until
after the median age at onset has passed (supplementary life
tables, doi.org/10.5281/zenodo.2535761). The next 4 most
common mutations have tighter age at onset distributions,
and so reach higher annual hazards sooner (figure S3, doi.org/
10.5281/zenodo.2535761), but these mutations are also
much rarer, accounting for only 10% of cases with a high-
penetrance variant.4
Power for randomized preapproval trials with
a clinical endpoint
Based on the age-dependent hazards calculated for each
mutation, we set out to determine how many individuals
would need to enroll in order to power prevention trials with
an endpoint of disease onset. While younger individuals or
those with a mutation of modest penetrance might seek to
enroll in trials or take a preventive drug, they would not
contribute much statistical power to an endpoint of clinical
onset. We therefore chose to base our power calculations on
individuals with the 3 most common high-penetrance muta-
tions between age 40 and 80.
We estimated how many individuals in this age range have
high-penetrance PRNP mutations. It is estimated based on
Table 1 Variability in age at onset in genetic prion disease
Mutation
Without censored data Survival curve including censored data
Mean ± SD N Median (IQR) Range N
P102L 53.7 ± 10.6 193 56 (47–60) 22–75 206
D178N 51.3 ± 11.8 256 53 (46–60) 12–89a 289
E200K 61.3 ± 10.0 456 62 (55–68) 31–92 506
Abbreviation: IQR = interquartile range.
Censored data include individuals who were either alive and well at last follow-up or had died of an unrelated cause, and whose genetic status was known
either through predictive testing or due to obligate carrier status. For D178N and E200K, because the majority of individuals have disease duration ≤1 year
(figure S2, doi.org/10.5281/zenodo.2535761), age at death is used where age at onset is unavailable. For P102L, which more often has a longer disease
duration, only age at onset is used. Range indicates highest and lowest observed age at onset, except where a the longest survival is a censored data point.
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disease prevalence that 1–2 people per 100,000 in the general
population harbor high-penetrance PRNPmutations (reference
4 and supplementary Discussion, doi.org/10.5281/zenodo.
2535761), but at present, many remain unaware of their risk due
to underdiagnosis of affected family members,23 and few choose
predictive testing15 as the results are currently considered
medically unactionable. Based on predictive test results, we
estimate there are currently ;60 people in the United States
who are age 40 or older and hold a positive predictive test for
a highly penetrant PRNP variant (see Methods).
We used published formulae24 (see Methods) to calculate
statistical power for a log-rank survival test in randomized
clinical trials (table 2). Across the 3 mutations and weighted
by their prevalence among cases (figure S1, doi.org/10.5281/
zenodo.2535761) and number of surviving individuals at each
age (figure 1), the average annual probability of onset for
individuals aged 40–80 is 4.6%. With this figure as a baseline
hazard, we made the following assumptions: presymptomatic
individuals are randomized half to drug and half to placebo
and followed for 5 years with an endpoint of clinical onset; the
withdrawal rate is 15.2% annually (the median value from 8
prevention trials reviewed, table S4, doi.org/10.5281/zenodo.
2535761); and the trial is designed for 80% power at the p =
0.05 threshold. Events in the first year are ignored as a run-in
period to ensure sufficient drug exposure among individuals
analyzed, because preclinical studies have suggested that drug
treatment close to the symptomatic stage of disease may have
diminished or no efficacy compared to earlier treatment.9–12
We then performed power calculations for such a trial as
a function of the hazard ratio—the ratio of annual risk of
onset in drug-treated individuals to that in placebo-treated
individuals. For context, we also determined the effect size, in
median years of healthy life added, to which each hazard ratio
(HR) corresponds (table 2). The calculations are sensitive to
which mutations are included, the run-in period, the number
of years of follow-up, and the assumed withdrawal rate, but we
explored a range of different assumptions and none supports
a different overall interpretation of the data (table S5, doi.org/
10.5281/zenodo.2535761, and Discussion). In particular, the
assumption of a 15.2% annual withdrawal rate means that only
44% of original participants remain after 5 years, but even
reducing the withdrawal rate to zero only lowers the number
of participants required by one-third (table S5, doi.org/10.
5281/zenodo.2535761).
The above power calculations simplistically assume a uniform
baseline hazard across all participants, regardless of age and
Figure 1 Hazards and survival for the most common PRNP mutations
The hazard, or probability of disease onset, in
each year of life (y axis) is plotted against age (x
axis) with curve thickness representing the
proportion of individuals still living at each age,
which is the product of age-dependent survival
and mutation prevalence. Supplementary
mutations, and conventional survival curves
and hazard plots, are included in figure S3 (doi.
org/10.5281/zenodo.2535761).










0.1 Undefineda 6 101
0.2 21 12 189
0.3 14 22 311
0.4 10 37 498
0.5 7 65 813
0.6 5 120 1,406
0.7 4 247 2,724
0.8 2 631 6,602
0.9 1 2,828 28,204
For example, a hazard ratio (HR) of 0.5 means that placebo-treated indi-
viduals have a 4.6% annual probability of onset, while drug-treated indi-
viduals have only a 2.3% annual probability of onset. If a population of
individuals were treated from an early age with such a drug, themedian age
at onset would be postponed by 7 years. To have 80% power at p = 0.05 to
detect the effect of such a drug, 65 individuals would need to become
symptomatic during the trial—given the 0.5 HR, about two-thirds of these
would occur in the placebo group and one-third would occur in the drug
group. Observing this number of disease onsets would require randomizing
813 people for 5 years (data from the first year would be ignored, and the
remaining 4 years of data would be analyzed).
a For a HR of 0.1, most individuals never become sick, thus, the increase in
median age at onset (the age where 50% of people have had onset) is
undefined.
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PRNPmutation. We also used a simulation to account for the
full shape of the hazard curve and diversity of genetic muta-
tions, but the simulated power results were similar to those in
table 2 (see table S6, doi.org/10.5281/zenodo.2535761).
Stratification by PRNP mutation did not improve power in
our simulations (supplementary discussion, doi.org/10.5281/
zenodo.2535761), perhaps because age at onset distributions
(table 1) are wide and overlapping, such that PRNPmutation
explains only a minority of the overall variance in age at onset
(adjusted R2 = 0.15, linear regression, p < 1 × 10−32).
Statistical power might be improved by stratifying clinical trial
analysis by relevant additional variables, but there are cur-
rently no variables that help to explain age at onset (supple-
mentary Discussion, table S7, and figures S4 and S5, doi.org/
10.5281/zenodo.2535761). For instance, we found no sex
effect, and no evidence that parent and child age at onset are
correlated after controlling for PRNPmutation and for child’s
year of birth, a variable that captures some effects of ascer-
tainment bias25 (table S7, doi.org/10.5281/zenodo.
2535761). A common genetic variant, PRNP M129V, is
known to affect the clinical and pathologic presentation of
many forms of prion disease26 as well as the risk of sporadic
and acquired prion disease.27 This variant has previously been
reported to affect age at onset in some forms of genetic prion
disease but not others.21,25,28,29 We found no evidence that
codon 129 affects age at onset for P102L or E200K individuals
(table S7 and figure S4, doi.org/10.5281/zenodo.2535761).
For D178N, our data are suggestive that a 129VV genotype
may predispose to earlier onset than MM or MV genotypes
(figure S4 and supplementary Discussion, doi.org/10.5281/
zenodo.2535761), but in the overall dataset, codon 129 failed
to explain additional variance in age at onset (supplementary
Discussion, doi.org/10.5281/zenodo.2535761).
Based on this analysis, at present it is not possible to ade-
quately power a randomized preapproval prevention trial with
an endpoint of clinical onset in genetic prion disease. For
example, for a drug that reduces annual risk by half (HR of
0.5), powering such a trial would require 813 participants age
40 or older, many times the;60 currently estimated to exist
in the United States. We next turned our attention to the
possibility that a preventive drug might be developed through
the Accelerated Approval pathway using a surrogate bio-
marker endpoint.
Power for postmarketing studies
We asked whether, if Accelerated Approval were achieved, the
required postmarketing studies to confirm clinical benefit
could be adequately powered by following drug-treated
individuals to clinical onset and comparing their survival to
that of historical controls. Such a trial design could increase
power but also introduce bias; we considered each issue in
turn.
We identified several factors that are likely to decrease the
number of participants required to power such a study com-
pared to its randomized preapproval equivalent: all, rather than
half, of individuals are drug-treated; the number of historical
controls can be large; a longer trial duration could be consid-
ered because the trial would overlap, rather than reduce, the
drug’s effective market exclusivity period (supplementary
Discussion; doi.org/10.5281/zenodo.2535761); and a post-
marketing surveillance program might allow newly drug-
treated individuals to enter the program on a rolling basis,
replacing any who withdraw. The effects of these assumptions
(table 3) are collectively to reduce the number of individuals
required to demonstrate efficacy of a drug with HR of 0.5 from
813 to 37. At the same time, the number of individuals available
for a trial might increase, because an approved drug should
have broader geographic reach than a preapproval trial, being
limited only by the availability of medical personnel capable of
prescribing and administering it rather than by a set number of
trial sites; a treatment might improve awareness and diagnosis
of the disease; and a treatment might stimulate more individ-
uals to pursue predictive genetic testing. For instance, of people
at 50/50 risk for a PRNPmutation, currently only 23% pursue
predictive testing,15 compared to 60% (2.6× higher) for
Table 3 Comparison of power calculations for preapproval and postmarketing studies
Scenario N required Explanation
Randomized preapproval—5-year follow-
up
813 See table 2
Postmarketing with historical controls—5-
year follow-up
229 Increased power because all, rather than half, of individuals are treated, and n = 1,000
historical controls are used for comparison
Postmarketing with historical
controls—15- year follow-up
125 Increased power because longer trial duration may be financially tenable for
postmarketing studies; power is still limited, however, by withdrawal rate, which means




37 Increased power because the withdrawal rate is set to zero, simulating a scenario where
individuals who go on drug can continuously enter the surveillance program, and the
cohort being monitored can maintain its size over time
In each case, the calculation is for a hazard ratio of 0.5, the n indicated is for 80% power at the p = 0.05 threshold, and all assumptions other than those
indicated in the table are the same as for table 2. The number of individuals required for postmarketing studies is determined by simulation (supplementary
Discussion, doi.org/10.5281/zenodo.2535761).
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BRCA1 or BRCA2 mutations,30 which are considered medi-
cally actionable.31 Thus, a postmarketing study could be ade-
quately powered with available numbers of individuals for a HR
of 0.5 (table 3) and, over a range of assumptions, would bring
power requirements into closer alignment with the number of
available individuals (figure S6 and supplementary Discussion,
doi.org/10.5281/zenodo.2535761).
While we conducted tests to ensure that our power simulation
was not itself biased (supplementary Discussion, doi.org/10.
5281/zenodo.2535761), a postmarketing study could still be
biased in real life, if the historical controls used do not accu-
rately estimate the true hazard rates facing the trial partic-
ipants.32 There are no environmental, demographic, or
non-PRNP genetic factors known to affect prion disease risk
or age at onset, although these might nonetheless exist.33,34
Perhaps of greater concern is that most of our historical
controls were collected retrospectively—individuals are only
ascertained if they become sick—and may overestimate the
hazard rates for individuals followed prospectively.25 To as-
sess this possible source of bias, we compared the survival of
the limited number of individuals followed prospectively in
our dataset (n = 24 individuals, with a cumulative 145 person-
years of follow-up), conditioned on their ages at first ascer-
tainment, to those of individuals with no prospective follow-
up. We did not observe a significant difference in hazard (p =
0.59, Cox proportional hazards test) between these 2 groups,
although this could be due to a lack of power (see Discussion).
Discussion
Both our power calculation and simulation indicate that di-
rect demonstration of clinical benefit in a randomized pre-
approval prevention trial would require enrolling a number of
PRNP mutation carriers that is not currently realistic.
Achieving 80% power for a drug that reduces annual risk by
half would require randomizing 813 individuals for 5 years,
while we estimate only ;60 individuals in the United States
fit the age and mutation criteria assumed in this calculation.
Eighty percent power might be barely achievable under the
most wildly optimistic assumptions of an extremely effective
drug (HR of 0.1, reducing annual risk of onset by 10-fold),
along with some increase in predictive testing rates and a very
successful trial recruitment effort. The FDA has cautioned,
however, that rare disease trials should not be designed
around the hope of a huge effect size,35 and even if a drug
were so profoundly effective, it is unlikely that a sponsor
would have sufficient confidence in this a priori to invest in
a trial that is underpowered for more moderate effect sizes.
Key assumptions underpinning this analysis may change with
time: new stratifying variables could help to predict age at
onset, or a first drug for prion disease could improve di-
agnosis and recruitment. However, the insight that ran-
domized preapproval prevention trials with a clinical
endpoint may not be feasible today motivates consideration
of alternative trial designs.
At least 3 factors can explain why a randomized trial design
following presymptomatic individuals to a clinical endpoint was
deemed feasible for early-onset Alzheimer disease (AD), yet
appears unviable for genetic prion disease. First, onset is less
predictable in genetic prion disease. The standard deviation of
age at onset or the 3 PRNP mutations we examined (±10.0 to
±11.8 years) is larger than that for PSEN1 E280A AD (±6.4 to
±8.6 years36,37). In addition, an individual’s age at onset in
genetic AD is reported to be correlated with parental age at
onset,37 and this property has been used to attempt to enrich
for high-hazard individuals in trials,38 whereas we have found
no evidence that parent and child age at onset are correlated in
genetic prion disease (table S7, doi.org/10.5281/zenodo.
2535761, and reference 25). Second, genetic prion disease is
rarer. The PSEN1 preventive trial recruited from a single
pedigree of ;5,000 individuals39 from which 1,065 living
individuals with themutation have been enrolled in a registry.40
There is no known genetic prion disease family this large.
Third, genetic prion disease offers more limited financial
incentives for a pharmaceutical sponsor. The cost of the PSEN1
preventive trial has been estimated at $96 million,38,41 and
while this price may be tenable for sponsors in view of potential
for an expanded AD indication, no similar potential exists for
prion disease. Indeed, even in AD, larger or longer primary
prevention trials are likely to prove challenging for the private
sector and may require public sector investment.42
Preclinical studies of anti-prion agents9,10 suggest that trials in
symptomatic patients could fail to show a benefit that would
have been realizable in preventive treatment. Yet our results here
indicate that it would be difficult or impossible to design a well-
powered randomized preventive trial with a clinical endpoint in
genetic prion disease. Together, these observations argue for the
characterization of biomarkers suitable as endpoints in pre-
symptomatic genetic prion disease, and for their evaluation by
regulatory agencies as surrogate trial endpoints. A route to Ac-
celerated Approval using cerebrospinal fluid prion protein as
a surrogate biomarker endpoint has been proposed.13,43
If provisional approval could be achieved, then a postmarket-
ing study might be required to confirm clinical benefit. We
estimate that a model in which drug-treated individuals are
enrolled in a surveillance program and their survival is com-
pared to that of historical controls could reduce the number of
individuals required for trials by 3- to 20-fold, compared to
randomized preapproval studies. Meanwhile, conditional ap-
proval of a first prion disease drug may alter key measures
such as diagnosis, recruitment, and genetic testing rates, the
last of which alone could increase participant availability by
more than 2-fold. Thus, while power for any trial depends
upon how effective the drug is, there exists a range of
assumptions under which a postmarketing study could be
adequately powered. There may be various formats through
which a postmarketing study could confirm clinical benefit.
Under some assumptions, a postmarketing study might last
a decade or longer and would benefit from following all
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mutation carriers taking the drug. With creative and careful
planning, we propose that these goals could be achieved. In
one model, a postmarketing study might take the form of
a surveillance program, in which treated patients are followed
long-term, perhaps in collaboration with existing prion spe-
cialist clinics and surveillance centers worldwide. In such
a model, drug costs would be reimbursed by payors, in con-
trast to a more traditional sponsor-funded pivotal trial. While
this model would be a departure from the more conventional
design of most postmarketing studies required for recent
Accelerated Approval drugs,44 precedents exist for regulatory
innovation in this area. For example, the FDA’s Risk Evalua-
tion and Mitigation Strategies program for drugs with serious
safety concerns entails indefinite postmarket enrollment and
monitoring of treated patients,45 and postapproval study
requirements for medical devices often include registries or
surveillance efforts and are not always industry-funded.46,47
Our study has several limitations. First, true age at onset dis-
tributions can only be obtained prospectively,48 whereas our data
are largely retrospective. We have included asymptomatic indi-
viduals with pathogenic PRNP variants where possible, but our
ascertainment of them is incomplete due to limited uptake of
predictive testing.15 This bias may tend to make our estimates of
age at onset overly pessimistic.25,49 To the extent that true age at
onset is older, or total lifetime risk lower, than our data suggest,
randomized preventive trials with a clinical endpoint would re-
quire even greater numbers of individuals, and thus further in-
crease our caution around this study design. Second, although
our dataset is, to our knowledge, the largest ever reported for
genetic prion disease age at onset, our statistical power to detect
genetic modifiers, which might aid in age at onset prediction, is
limited. Third, althoughwe have attempted to select a reasonable
set of assumptions for modeling clinical trials, we have by no
means exhaustively sampled the set of possible trial designs and
measures. Fourth, powering a postmarketing study will require
a good historical control dataset to compare to, and our dataset,
which was collected mostly retrospectively, may or may not be
adequate. We found no evidence that our dataset overestimates
the hazards facing prospectively followed individuals, but this
could be due to a lack of power in our analysis. Fifth, the as-
certainment of genetic prion disease by prion surveillance cen-
ters may be biased towards rapidly progressive phenotypes,
meaning that the prevalence of more slowly progressive forms
might be underestimated.
Our findings highlight 2 priorities for the prion field. First, the
discovery and characterization of biomarkers capable of
serving as trial endpoints may be essential to enable near-term
presymptomatic trials in genetic prion disease. Second,
a postapproval surveillance mechanism for age at onset merits
consideration as one option for confirmation of clinical ben-
efit following biomarker-based provisional approval. The
ability to access therapies that can prevent or delay prion
disease, yet which are likely to be less effective or ineffective
after symptom onset, could be greatly enhanced by success in
these areas.
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manuscript. S. Häık has received research support fromMedDay
Pharmaceuticals, LFB Biomedicaments, and Institut de Recher-
che Servier. J. Laplanche, I. Zerr, P. Parchi, S. Capellari, J. Safar, J.
Kenny, J. Fong, L. Takada, C. Ponto, P. Hermann, T. Knipper, C.
Stehmann, T. Kitamoto, R. Ae, T. Hamaguchi, N. Sanjo, and T.
Tsukamoto report no disclosures relevant to the manuscript. H.
Mizusawa has received compensation from Eisai, EA Pharma,
Novartis, Sanofi, TenableMitsubishi Pharma, FP Pharma, Nihon
Pharma, Chugai Igaku Co., Igakushoin Co., and Nankodo Co. S.
Collins, R. Chiesa, I. Roiter, and J. de Pedro-Cuesta report no
disclosures relevant to the manuscript. M. Calero has received
compensation from Raman Health Technologies and Springer
Nature, is a shareholder of RamanHealthTechnologies, Biocross,
and Bio Haptenyc DGR, and has received research support from
AMOPharma, Ltd. M. Geschwind has received research support
fromQuest Diagnostics. M. Yamada and Y. Nakamura report no
disclosures relevant to themanuscript. S.Mead is a shareholder of
GlaxoSmithKline and Ionis Pharmaceuticals and has received
Neurology.org/N Neurology | Volume 93, Number 2 | July 9, 2019 e131
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
research support from Nova Pharmaceuticals. Go to Neurology.
org/N for full disclosures.
Publication history
Received by Neurology November 2, 2018. Accepted in final form
February 21, 2019.
This manuscript was previously posted to bioRxiv (doi.org/10.1101/
401406) on August 29, 2018.
Appendix Authors
































































Inga Zerr University of
Göttingen, Germany






Piero Parchi University of
Bologna, Italy

















Name Location Role Contribution
Jiri Safar Case Western
Reserve University,
Cleveland, OH






Janna Kenny MRC Prion Unit at
UCL, London, UK















































































Ryusuke Ae Jichi Medical
University,
Shimotsuke, Japan


















e132 Neurology | Volume 93, Number 2 | July 9, 2019 Neurology.org/N
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
References
1. New drug, antibiotic, and biological drug product regulations; accelerated approval:
FDA: final rule. Fed Regist 1992;57:58942–58960.
2. Food and Drug Administration Safety and Innovation Act. Public Law 112-114
Section 506(c)(3). July 9, 2012.
3. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363–13383.
4. Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using
large population control cohorts. Sci Transl Med 2016;8:322ra9.
5. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in
patients with CJD: a double-blind study. Neurology 2004;62:714–718.
6. Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic
Creutzfeldt-Jakob disease. Neurology 2013;81:2015–2023.
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Section 4: Human Prion Disease Biomarker Studies 
Across the multifarious neurodegenerative disorders that can cause cognitive decline, when 
patients present with RPD accompanied by myoclonus and gross motor impairment, 
consideration of sCJD as a likely differential diagnostic explanation is relatively straightforward. 
Nonetheless, acknowledging that up to 30% of sCJD can manifest a less typical clinical profile 
and that co-morbidities affecting the brain commonly co-exist in the elderly, it is not infrequent 
that the pre-mortem diagnosis of sCJD can be more challenging. Up to the late 1990s, 
electroencephalography was the principal investigation available to assist with clinical 
evaluation, relying on the presence of generalized periodic complexes recurring at a rate of 1-2 
Hz as a biomarker for sCJD. Although an EEG displaying such features in a patient with RPD 
remains of considerable positive predictive value, the relatively poor sensitivity of this finding 
across the full phenotypic spectrum of sCJD renders reliance on this single investigation 
unsatisfactory. Fortunately, the last 20 years has witnessed meritorious expansion of the 
diagnostic armamentarium for interrogating patients suspected to be manifesting sCJD. I have 
led the Australian participation in all landmark studies validating new biomarkers employed in 
the pre-mortem diagnosis of sCJD, with each of these biomarkers prompting revision of 
surveillance diagnostic criteria to allow their inclusion. This revolution in sCJD diagnostic 
biomarkers started with CSF 14-3-3 protein detection and was then followed by delineation of 
sensitive and specific brain MRI findings, with the most recent achievement confirmation of the 
utility of the protein amplification technology known as the Real-Time Quaking Induced 
Conversion (RT-QUIC) assay. The RT-QUIC assay has been a major advance given specificity 
of close to 100% and the ability to perform the test on both bio-fluids (such as CSF) and tissue 
samples (including from brain, olfactory epithelium and skin). The progressive translational 
incorporation of these diagnostic tests now means that only around 2-3% of sCJD patients do 
not display typical or characteristic findings with at least one of these investigations, thereby 
considerably enhancing our capacity to achieve an accurate clinical diagnosis pre-mortem. 
Despite these advances in pre-mortem diagnostic evaluation, however a diagnosis of “definite” 
CJD still requires neuropathological examination of the brain, preferably through autopsy to 
avoid potential sampling errors and transmission risks posed by brain biopsy.  
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Creutzfeldt-Jakob disease: diagnostic utility of 14Ð3Ð3
protein immunodetection in cerebrospinal fluid
S Collins 1, A Boyd 1, A Fletcher 1, M Gonzales 2, C A McLean 1, K Byron 3, CL Masters 1
1The Australian Creutzfeldt-Jakob Disease Registry, Department of Pathology, the University of Melbourne, Victoria, Australia 3010 2Neuropathology Laboratory,
Department of Anatomical Pathology, The Royal Melbourne Hospital, Victoria, Australia 3052  3Molecular Pathology, North Western Health Care Network, Royal
Melbourne Hospital, Victoria, Australia 3052.
Summary With the aim of improving the pre-mortem diagnostic accuracy of sporadic Creutzfeldt-Jakob disease (CJD), there has been
considerable recent interest in the merit of immunodetecting 14–3–3 proteins in the cerebrospinal fluid (CSF) using Western blotting, with
cumulative support for the utility of this technique. As a corollary, during a 20 month period, CSF samples from an unselected prospective
series of 124 patients in whom sporadic CJD was a differential diagnostic possibility were examined by the Australian Creutzfeldt-Jakob
disease Registry (ACJDR) for the presence of 14–3–3 proteins. Follow up to achieve a final diagnosis or clinical outcome was successful in
119. For definite and probable sporadic CJD combined, a positive result was 91.4% sensitive, while the sensitivity for the pathologically
verified group alone was 96.0%. A negative outcome was 92.5% specific with false positive results seen in five patients with diagnoses which
included inflammatory CNS disorders, cerebral ischaemia and dementia with Lewy bodies (DLB). Immunodetectable 14–3–3 proteins were
present in three of four symptomatic patients with prion protein gene (PRNP) mutations. CSF samples containing significant amounts of blood
were confirmed as suboptimal, with weak or qualitatively unusual positive results found in greater than 50% of such specimens, with only one
of 14 such cases ultimately classified as definite or probable CJD. © 2000 Harcourt Publishers Ltd
Keywords : Creutzfeldt-Jakob disease, 14–3–3 proteins, cerebrospinal fluid, prion diseases
Journal of Clinical Neuroscience (2000) 7(3), 203–208
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Creutzfeldt-Jakob disease usually manifests as a clinically dis
tive dementia because of rapid progression accompanied by
bellar ataxia, myoclonus and typical electroencephalogra
(EEG) changes, with the mean age of onset around 60 year
median survival less than 6 months.1 However, less typical, mor
diagnostically challenging CJD subtypes exist, including the 
variant form (vCJD) recently described in the UK, which is pr
ably zoonotically linked to the epidemic of bovine spongifo
encephalopathy.2–4 Although a genetic basis and accidental (usu
iatrogenic) horizontal transmission are both recognised ca
approximately 85% of cases occur without apparent explan
(sporadic).5,6 Kuru, Gerstmann-Sträussler-Scheinker syndro
(GSS), and fatal familial insomnia (FFI) constitute other impor
but less common human transmissible spongiform encephalo
(TSE) phenotypes.7 All are invariably fatal neurodegenerativ
disorders.
Transmissibility and pathogenesis in these disorders are cl
related (and probably causally linked) to an abnormal, prote
resistant, conformational isoform of the constitutively expres
prion protein (PrP).7 Although an excellent, specific diagnos
marker of this group of disorders, at present, protease-resista
(PrPres or PrPsc) cannot be routinely detected in blood or CS
requiring invasive biopsy procedures to procure appropriate t
to facilitate pre-mortem diagnosis. Immunochemical detectio
the PrPres isoform, in combination with standard neuropathologi
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surgical procedures pose inherent risks for both patients and h
care personnel.10,11 Given these considerations, and the relat
low sensitivity of traditional non-invasive diagnostic metho
such as the presence of periodic sharp wave complexes (PSW
the EEG (only approximately 65% overall in sporadic CJD a
never seen in certain, less common subtypes of CJD, inclu
vCJD),3,4,12 interest has focused on developing more sensit
minimally invasive ante-mortem diagnostic methods.
Long repetition time magnetic resonance imaging (MR
sequences can show distinctive heightened signal patterns i
basal ganglia of up to 80% of patients with sporadic CJD,13 and
preliminary reports suggest diffusion weighted imaging (DW
may show even more widespread characteristic abnormalities14–16
Complementing this, a number of CSF proteins have been ass
as non-specific indicators of brain damage and dysfunct
Assessed for this purpose in CJD have been ubiquitin, tau, S-
neuron-specific enolase (NSE), creatine kinase BB isoenz
(CK-BB) and the p130/131 and 14–3–3 proteins.17–27Of these, the
14–3–3 proteins have undergone the greatest scrutiny and a
to be the best (albeit non-specific) premortem CSF marke
sporadic CJD.20,25 They comprise a ubiquitous family of seve
mammalian isoforms involved in a variety of important cellu
functions, including signal transduction and cell cycle regu
tion,28,29and were recently shown to be synonymous with the p
and p131 proteins described on 2-dimensional electrophores
1986 as reliable and specific indicators of CJD.18,23 In patients
eventually classified as manifesting definite and probable spor
CJD, immunodetection of 14–3–3 proteins in the CSF car
sensitivities of 90 to 96% with very good specificity.20,23,25
However, adequate patient evaluation is important as He
simplex encephalitis and recent cerebral infraction are comm
causes of ‘false’ positive results23,25,30 and there appears to b
diminished likelihood of detecting 14–3–3 proteins in vCJD a
genetically determined symptomatic TSEs, perhaps correla
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Iatrogenic (Lyodura recipient) 1
Genetic 3*





Dementia with Lewy bodies 1
Final Clinical Diagnosis
Acute Cerebral Ischaemia/infarct 2***
Non-Herpetic Encephalitis 1
Chronic Lymphocytic Meningitis with Cerebellar Ataxia 1
Overall Total 39
* Prion protein gene T188A, E200K and V210I mutations were present in
three individual patients respectively. ** Includes single patient with an
atypical positive result associated with a suboptimal CSF specimen.
*** Includes one deceased patient.The current report details the ACJDR experience with imm
odetecting 14–3–3 proteins in the CSF of 124 consecutive pa
suspected to be manifesting CJD, with confirmation of the d
nostic utility of the technique. Included were four cases show
harbour mutations in PRNP. In addition, the effects of signific
blood contamination of CSF and the stability of 14–3–3 prot
over an extended time period were assessed as was the suit
of post-mortem CSF for posthumous diagnostic purposes.
METHODS
Patients and classification
Since inauguration in September 1993, the ACJDR has attem
to ascertain all domestic human TSE. Methods of case asce
ment have been described in detail previously33 and the activities
of the ACJDR have ethical approval from the University 
Melbourne. In summary, the three most important methods 
supplied approximately 80% of all registered cases and consi
personal communications from medical practitioners (ma
neurologists and neuropathologists, prompted by semi-an
reply-paid mailouts); systematic searches of state and terr
health department separation coding data bases; and death 
cate searches by the Australian Institute of Health and Wel
Formal collaboration with the New Zealand National Creutzfe
Jakob Disease Register has been ongoing since it comm
activities in July 1996, with data combined annually to gene
Australasian incidence figures.
To aid surveillance and accurate classification, the ACJ
began offering CSF examination for 14–3–3 proteins u
Western immunodetection from November 1997. By the en
September 1999, CSF specimens from 124 patients in wh
spongiform encephalopathy was considered a differential d
nostic possibility had been analysed for the presence of 14
proteins. This included three specimens from New Zealand pa
referred by the New Zealand CJD Registry. The ACJDR was n
actively involved in the management of patients. Salient de
graphic and clinical information was requested on all patie
including the duration and type of presenting symptoms, as we
neurological examination findings. Also sought were results
pertinent investigations such as brain imaging and E
Correspondence and telephone follow up with the managing 
cian (usually neurologist) was undertaken as necessary fo
patients to achieve a final diagnosis or clinical outcome. No atte
was made to correlate 14–3–3 results with illness temporal pro
Classification of spongifrom encephalopathies was accordin
previously published criteria.9 Definite CJD required neuropatholo
ical confirmation of the typical features of spongiform chan
gliosis and neuronal loss either post-mortem or by brain bio
supplemented by immunodetection of PrPres. Probable CJD de
clinically likely cases based on a progressive dementia of less t
years’ duration with an EEG showing PSWC and at least two o
following clinical features: myoclonus, visual or cerebellar sig
pyramidal or extrapyramidal signs, and/or akinetic mutism. Pos
CJD patients are the same as probable cases but without PSW
their EEG. For cases ultimately classified as not manifestin
spongiform encephalopathy, final classification was accordin
autopsy neuropathological findings, or the most accurate cli
diagnosis possible. The latter was based on the best consensu
pretation of all available clinical information and investigat
results, and was almost invariably determined by the mana
physician. In 12 14–3–3 negative patients, specific clinical diagn
were not possible, prompting a more generic descriptive outcom
either: clinically stable, improved or illness duration greater tha
years (11 cases); or progressive neurological illness of less t








































Non-systematic genotyping of the PRNP open reading fr
was undertaken (for varying reasons) on DNA extracted from
blood of 23 patients using the polymerase chain reaction
described previously.34 Four missense mutations were found; th
have been previously described (E200K, V2101 and P105T35) with
one novel mutation (T188A).36
CSF studies
Routine cytological examination and total protein estimation w
requested on all CSF samples prior to assessment for 14
proteins. All CSF specimens were frozen as soon as possible
lumbar puncture and transferred to the ACJDR for storag
–20°C. Macroscopically haemorrhagic specimens underw
centrifugation at 1500 rpm for 10 min prior to analysis of 
supernatant. Detection of CSF 14–3–3 proteins was as desc
previously with some minor modifications.23–25Fifty microlitres of
CSF was added to 10 microlitres of sample buffer (achieving 
concentrations of 5% glycerol, 1% mercaptoethanol, 1% sod
dodecylsulphate and trace bromophenol blue) and boiled fo
min before electrophoretic resolution at 200 volts on a 12% p
acrilamide gel, with 4% stacking component (Novex, San Die
California, USA). As of mid-1998 improved proficiency allowe
us to use half the volumes of CSF and sample buffer with eq
reliable results. Electrophoretic transfer to polyvinylidene difl
ride membranes (Immobilon-P; Millipore, Bedford, Massachus
USA) for 1 h, was followed by overnight blocking at 4°C in Tris-
buffered saline containing 0.5% Tween 20 (Sigma Chem
Company, St Louis, Missouri, USA) and 5% (w/v) skim m
powder. The primary incubation was for 3 h at room tempera
(RT) using a 1:2000 dilution of rabbit polyclonal anti-14–3–β
antibody (K-19; Santa Cruz Biotechnology, Santa Cr
California, USA). Subsequently, anti-rabbit secondary antib
conjugated with horseradish peroxidase (Amersh
Buckinghamshire, UK), was added (1:4000) for one hour at
before detection with enhanced chemiluminescence accordin
the manufacturer’s instructions (Amersham, Buckinghamsh
UK). Molecular weight markers (Rainbow, low molecular weig
Amersham, Buckinghamshire, UK) and a pathologically verif
positive control and negative control were included in every ge
 technically satisfactory slab gel, a typical positive re
consisted of a clear discrete band at 30 kDa, although immu
taining intensities varied (Fig. 1). Weak positive results w
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Table 2 Final Diagnosis/Outcome in 14–3–3 Negative Cases
Creutzfeldt-Jakob disease(CJD)
Pathologically Confirmed 1(1)
Probable (includes single patient with P105T mutation) 2
Possible 1
Pathologically Confirmed not CJD
Alzheimer’s disease 3(1)




Subacute sclerosing panencephalitis 1




Drug reaction or toxicity 6
Alzheimer’s disease 5
Frontal lobe dementia 4
Encephalopathy 2
Corticobasal degeneration 2
Chronic, poorly controlled epilepsy 2
Paraneoplastic limbic encephalitis 2
Wernicke’s encepalopathy 1
Multi-infarct dementia 1
Dementia with Lewy bodies 1
Vasculitis 1
Cerebrovascular accident 1
Normal pressure hydrocephalus 1
Acute disseminated encephalomyelitis 1
Progressive supranuclear palsy 1
Multiple system atrophy 1
Metabolic encephalopathy 1
Cryptoccocal meningitis 1
Progressive non-familial ataxia 1
Sub-cortical dementia 1
Chronic organic brain syndrome 1
Severe depression 1
Sub-total 38
Diagnosis uncertain: illness progressing and <2 years duration 1
Diagnosis uncertain: clinically stable,




Parentheses denote those patients who underwent pre-mortem brain biopsy.
Fig. 1 Western immunodetection of 14–3–3 proteins in the cerebrospinal
fluid (CSF) of patients manifesting Creutzfeldt-Jakob disease (CJD) and non-
CJD neurological disorders. Lane 1, positive control (definite sporadic CJD);
lane 2, patient with recent cerebral infarct; lane 3, definite CJD; lane 4,
patient with probable CJD; lane 5, 30 kDa molecular weight marker; lane 6,
patient thought to have corticobasal degeneration; lane 7, negative control;
lane 8, patient with reversible drug related encephalopathy, lane 9, definite
sporadic CJD.(sensitivity enhancing method).25 Weak positive and atypica
results in the context of significant CSF blood contamination (a
trarily defined as greater than 400 red blood cell/microlitre) w
deemed suboptimal specimens, and these patients were
included in any statistical analyses. A repeat sample was re
mended after 14 days.
For the purposes of assessing 14–3–3 protein stability, suffi
quantities of CSF testing positive and weak positive respectiv
from two definite CJD patients, were thawed, with the posi
specimen examined after storage at RT for 6 days and 4°C for 5
weeks, while the weak positive samples were stored at the 
temperatures and assessed after 7 weeks. To explore the uti
postmortem CSF, nine specimens were obtained from the Nat
Health and Medical Research Council sponsored Brain B
three samples from patients with Alzheimer’s disease, one 
Huntington’s disease, one with alcohol related cerebral atro
and four patients with either no significant pathological change
minor findings such as lipohyalinosis. The post-mortem interv
ranged from 2 to 100 h.
Statistical analyses employed the Exact method to calculat
sensitivity, specificity and predictive values with their 95% con
dence intervals.
RESULTS
Of the 124 patients, 56 were females (age range 22–97 years;
66 years) and 68 males (age range 19–88 years; mean 60 yea
final diagnosis or generic clinical outcome was achieved in 
patients. Mean duration of follow up (or to death) for non-pat
logically examined patients was 4.8 months (range 0.3 to 15.8
As summarised in Table 1, patients testing positive for 14–
proteins totalled 39 (24 female; combined age range 26–85 y
mean 64 years), and excluding non-CJD and iatrogenic case
female:male ratio was 1.5:1. Of these 39 patients, one classifi
probable CJD had an atypical result from a suboptimal (bl
containing) CSF specimen. In the remaining 38, 24 were patho
ically confirmed CJD (two after brain biopsy). One patient w
considered to have contracted CJD iatrogenically through e
sure to a human dura mater (Lyodura) implant, while one eac
three patients had T188A, E200K and V210I mutations in PR
respectively. There were 10 patients who fulfilled criteria for pr
able or possible CJD, including a further iatrogenic case relate
dura mater (Lyodura) exposure.
Five patients positive for 14–3–3 proteins in the CSF had a 
diagnosis that was not CJD. One with pathologically confirm
DLB had an unusually aggressive illness culminating in death 
only 6 months. There was no evidence of a superimposed diso
including a spongiform encephalopathy (negative for PrPres 






















remain alive, with clinical diagnoses of inflammatory CNS dis
ders in two patients (one non-Herpetic encephalitis, the oth
chronic lymphocytic meningitis with slowly progressive cerebe
ataxia) while the third suffered an episode of cerebral ischae
The fourth non-pathologically examined patient died after a c
bral infarct.
Of the 72 patients in which 14–3–3 proteins could not 
detected, 14 underwent neuropathological examination. T
results are summarised in Table 2. Diagnoses in the 13 non
cases include: Alzheimer’s disease (3 cases); inconclusive b
evidence of spongiform encephalopathy (3 cases); heroin leuc
cephalopathy (2 cases); and single cases with amyloid angiop
non-specific encephalitis, hepatic encephalopathy, subacute 
rosing panencephalitis and isolated angitis of the nervous sys
A further patient had CJD confirmed by brain biopsy. In addit
t  this patient with definite CJD, there were three patients w
negative CSF who fulfilled criteria for possible or probable C
One of the probable CJD patients had a positive family his
(first degree relative with pathologically confirmed spongifo
encephalopathy), and died after an 8 month illness consistin
dementia and ataxia. A P105T mutation in PRNP was confirme35
Of the remaining 55 non-pathologically examined patients

















































































































206 Collins et al.The most common clinical diagnoses were drug reaction or 
city (6 cases), Alzheimer’s disease (5 cases) and frontal 
dementia (4 cases). In a further 11 patients, a specific clinical d
nosis was not possible but the patient’s clinical outcome was e
stable or improved, and/or their illness duration exceeded 2 y
making CJD unlikely. There was one patient continuing to dete
rate steadily with an illness duration of less than 2 years who 
be manifesting a spongiform encephalopathy, but there were i
ficient details to establish an alternative clinical diagnosis or fu
CJD classification criteria.
Using all patients with the final classification diagnosis of de
nite and probable CJD, a positive 14–3–3 result was 91.4% s
tive (CI 95%: 76.9–98.2). Including all cases classified 
non-CJD and those with an uncertain diagnosis but unlikel
represent CJD, a negative result carried a specificity of 92.5%
95%: 83.4–97.5). If analysis is confined to only definite C
patients then the detection of 14–3–3 proteins in the CSF
Western immunoblot gives a sensitivity of 96.0% (CI 95
79.6–99.9). Similarly, using only pathologically examined cas
the absence of immunodetectable 14–3–3 proteins in the 
carries a specificity of 92.9% (CI 95%: 66.1–99.8). The posi
predictive value for definite and probable CJD cases was 86
(CI 95%: 71.2–95.5), while the negative predictive value w
95.4% (CI 95%: 87.1–99.0).
Although all CSF specimens were assessed for 14–3–3 pr
content it was confirmed during the course of the study that no
samples were suitable if trying to maintain maximal diagno
utility. Of 16 weak positive results, two showed pleocytosis 
non-Herpetic encephalitis and the other chronic lymphoc
meningitis with progressive cerebellar ataxia), while 10 of 
remaining 14 contained significant amounts of blood. Three a
tional positive CSF specimens were heavily blood stained, f
patients not considered clinically or radiologically to have suffe
an intracranial haemorrhage. Although showing promin
immunostaining at 30 kDa, there was either smearing along
length of the lane (two patients) or additional prominent ba
(not usually evident), rendering the result obviously different fr
the usual single positive band seen with definite CJD cases 
1). As already mentioned, a further patient classified as prob
CJD had an atypical positive result (with additional bands pres
in the context of modest blood contamination of the CSF. He
overall, 14 of 22 blood contaminated CSF specimens showed 
tivity for 14–3–3 proteins with either the qualitative appearanc
the marginal nature of the immunostaining militating against
reliability of the results as far as supporting a diagnosis of spo
form encephalopathy. Illustrating this point, in one of the
patients simultaneous clear and lightly blood stained CSF sp
mens were received, with only the latter showing a weak pos
result.
Providing further support for the unreliability of weak or qua
tatively different positive results from blood stained CSF sp
mens, 11 of these patients are still alive with clinical diagnoses
include single cases of Alzheimer’s disease, paraneoplastic n
logical disorder, dementia with Parkinsonism longer than 2 y
duration, Wernicke’s encephalopathy, lithium toxicity and fron
lobe dementia, and two patients with acute cerebral ischae
One patient had pathologically confirmed encephalitis. In th
patients, all with a stable neurological disorder, a precise clin
diagnosis could not be achieved. Follow up was not possib
one patient. It is unclear why 8 blood stained specimens w
negative with 14–3–3 testing but generally these sam
contained lesser amounts of red blood cells (RBCs). The m
RBC count in these 8 specimens was 1750/µl (range
400–7750/µl), whereas in the 11 positive samples where cou























































Hence, in our experience a significantly blood stained CSF s
imen carries an approximately 64% chance of a weak or aty
positive result with 14–3–3 testing, and in only one of these c
was a diagnosis of probable CJD ultimately conclud
Conversely, the four remaining (of 16) patients with weak posi
results (but without significant CSF blood contamination or pl
cytosis) have all died with a classification status of CJD: two p
able and two pathologically confirmed (Fig. 1, lane 3).
All post-mortem CSF samples appeared strongly positive
14–3–3 proteins (but qualitatively atypical with additional fas
and slower bands), with immunostaining intensity roughly co
lating with the post-mortem interval to specimen procurem
This confirmed our suspicions (based on a single previous pa
that CSF obtained after death is diagnostically unreliable, sho
non-specific strong positive immunostaining.
Our results confirmed good stability of 14–3–3 proteins in C
with positive results not showing any significant alteration 
serial assessments after storage at RT (approximately 20°C) for 6
days and 4°C for 5 weeks, while weak positive results show
only minor loss of signal intensity when tested after 7 week
both storage temperatures (data not shown).
DISCUSSION
The principal findings of this study show good concordance w
those previously reported dealing with the diagnostic utility
detecting 14–3–3 proteins in the CSF of patients with suspe
sporadic CJD. While our total number of patients is similar to
smallest of three prior series,20 the current study had the fewe
patients classified as CJD.20,23,25
Notwithstanding this, for definite CJD we found a sensitivity
96.0%, which correlates well with the reported range of 88–9
as does our sensitivity of 91.4% compared to 90–96% when 
pathologically verified and probable cases are combined.20,23,25Our
specificity of 92.5% also compares favourably with the repo
range of 96–100%.
There were only five misleading positive results, giving a p
tive predictive value of 86.5%, which is somewhat lower th
r ported in previous studies (94.7%–100%).20,25 Given the non-
specific nature of the method, this may relate to the relati
higher proportion of non-CJD patients included in the curr
series. The diagnoses in these five patients were DLB (aut
confirmed), a single patient dying from cerebral infarction a
three patients clinically diagnosed as not-CJD. These latter 
are still alive and include single patients with non-Herpe
encephalitis, chronic lymphocytic meningitis with slowly progre
sive cerebellar ataxia, and acute cerebral ischaemia. The p
suffering from an episode of cerebral ischaemia made an e
tially complete recovery. Encephalitis (particularly of herpe
origin), chronic meningitis with concomitant parenchym
involvement (such as from malignant infiltration or bacterial in
sion) and significant acute cerebral hypoxia (especially suffic
to cause obvious infarction) are all recognised ‘false’ posi
causes of 14–3–3 protein detectability in the CSF.23,25,27,30,31The
finding of immunodetectable 14–3–3 proteins in the CSF
patients with neurodegenerative disorders such as DLB is
typical.20,23,27,30However, positivity in our DLB patient may rela
to their unusually rapid decline. Neurones are abundant in at 
three 14–3–3 isoforms (β, γ and η) which are all detected by th
commercial polyclonal antibody used for Western immunode
tion. Their presence in CSF is thought to reflect acute or ong
significant neuronal destruction from any cause with conseq
non-specific release of the various 14–3–3 isoforms.27 Hence,
other uncommon but recognised causes for false positive re
























































































CJD: diagnostic utility of 14–3–3 protein immunodetection 207sclerosis, intracerebral metastases and Rett’s syndrome.23,25,27It is
the non-specificity of the 14–3–3 proteins as markers of neur
injury or destruction that mandates adequate preliminary inv
gation of patients and underscores the importance of avo
precocious use of this testing method for diagnosing CJD. 
type of approach will ensure optimal utility of this valuable di
nostic technique.
As a corollary, our experience indicates that CSF specim
containing blood have a high (greater than 50%) chance of g
a (usually weak) positive result, with the likelihood appearing
correlate roughly with the amount of RBCs. Consequently, sig
cantly blood contaminated CSF specimens should be regard
suboptimal, with weak and atypical positive results dismisse
unreliable for diagnostic purposes. This is in accord with 
refusal of some groups to examine blood containing CSF sam
for 14–3–3 proteins.27 The explanation for these apparently fa
positive results is unclear but may relate to the concomitant 
ence of platelets which are known to contain 14–3–3 isofo
important in arachidonic acid metabolism and exocytosis.29
The confirmatory role of detecting 14–3–3 proteins in the CS
symptomatic patients manifesting genetic forms of prion disea
still evolving, given the comparatively small total numbers of ca
studied so far. Overall, three of our four genetic cases had 14
proteins immunodetectable during their final neurological illne
Our single patient with an E200K mutation was positive whic
the typical finding in symptomatic carriers of this mutation.20,25,30)
Similarly, the patient carrying the V210I mutation tested posit
which has been reported previously in a single case,25 whereas there
is no published data concerning results with the P105T (negati
the current series) and T188A mutations.
Notwithstanding general optimal laboratory specimen hand
procedures, the results of the current study have shown the 14
proteins to be quite stable in the short term when stored u
different temperature conditions (RT and 4°C). This confirms and
considerably extends the time period of previously repo
stability assessments (from 7 and 12 days, to 7 weeks),20,25 and
additionally refutes prior claims that suboptimal thermal hand
of specimens may have contributed to false negative results.31
To the best of our knowledge this is the first report to objectiv
confirm the predicted unsuitability of post-mortem CSF 
14–3–3 diagnostic testing. All nine patients examined had stro
positive but qualitatively different results, with the degree of p
tivity appearing to crudely correlate with the length of tim
between death and sample procurement. Hence, the likelihoo
positive result was independent of the neuropathological diag
which included Alzheimer’s disease (3 patients), Huntingto
disease (one patient), alcoholic dementia (1 patient), and four
unclear or no detectable abnormalities. None of these maladie
usually associated with a positive result.20,23,25For the purposes o
diagnosis, it is regrettable that posthumous CSF sampling ca
be undertaken as a less invasive (but inferior) substitute to p
logical examination when autopsy is refused. However, the f
ings are entirely consistent with the hypothesis that immed
severe neuronal autolysis post-mortem would release conside
quantities of 14–3–3 and other potentially cross-reacting pro
into the CSF.27
In summary, the present results are in good agreement wit
findings of previous studies, which have shown immunodetec
of 14–3–3 proteins in the CSF to be a worthwhile, minimally in
sive pre-mortem diagnostic marker for sporadic CJD, and at 
some forms of symptomatic genetic prion disease. However
non-specificity of a positive result mandates careful individ
patient evaluation and optimal (non-blood containing) CSF sp
mens to maintain maximal diagnostic utility. Nevertheless, 




















































are usually negative (as outlined in Table 2) attests to the ro
ness and specificity of this method in the appropriate clin
setting. Given the promising recent reports of techniques like
permit detection of PrPres in the blood of manifest TSEs,37,38 the
current high level of interest regarding less invasive diagno
methods for sporadic CJD is likely to be maintained.
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Analysis of EEG and CSF 14-3-3 proteins
as aids to the diagnosis of
Creutzfeldt–Jakob disease
I. Zerr, MD; M. Pocchiari, MD; S. Collins, MD, FRACP; J.P. Brandel, MD; J. de Pedro Cuesta, MD;
R.S.G. Knight, FRCP(E); H. Bernheimer, MD; F. Cardone, PhD; N. Delasnerie-Lauprêtre, MD;
N. Cuadrado Corrales, MD; A. Ladogana, MD; M. Bodemer; A. Fletcher, BSc; T. Awan, MD;
A. Ruiz Bremón, MD; H. Budka, MD; J.L. Laplanche, PhD; R.G. Will, MD; and S. Poser, MD
Article abstract—Objective: To improve diagnostic criteria for sporadic Creutzfeldt–Jakob disease (CJD). Methods:
Pooled data on initial and final diagnostic classification of suspected CJD patients were accumulated, including results of
investigations derived from a coordinated multinational study of CJD. Prospective analysis for a comparison of clinical
and neuropathologic diagnoses and evaluation of the sensitivity and specificity of EEG and 14-3-3 CSF immunoassay were
conducted. Results: Data on 1,003 patients with suspected CJD were collected using a standard questionnaire. After
follow-up was carried out, complete clinical data and neuropathologic diagnoses were available in 805 cases. In these
patients, the sensitivity of the detection of periodic sharp wave complexes in the EEG was 66%, with a specificity of 74%.
The detection of 14-3-3 proteins in the CSF correlated with the clinical diagnosis in 94% (sensitivity). The specificity (84%)
was higher than that of EEG. A combination of both investigations further increased the sensitivity but decreased the
specificity. Conclusions: Incorporation of CSF 14-3-3 analysis in the diagnostic criteria for CJD significantly increases the
sensitivity of case definition. Amended diagnostic criteria for CJD are proposed.
NEUROLOGY 2000;55:811–815
The initial diagnosis of Creutzfeldt–Jakob disease
(CJD) is often based on clinical grounds and is usu-
ally correct in patients with a progressive dementia
extant for , 2 years, with at least two of the follow-
ing neurologic signs: myoclonus, visual or cerebellar
signs, pyramidal or extrapyramidal signs, and aki-
netic mutism.1 Investigations such as EEG,2,3 MRI,4,5
and detection of 14-3-3 proteins in the CSF6,7 support
or weaken the clinical suspicion of the disease, even
if definite diagnosis of CJD still requires postmortem
examination of the brain.8,9 There is an urgent need
for empirical data clarifying the diagnostic utility of
the combined results of the 14-3-3 test in the CSF
and periodic sharp and slow wave complexes (PSWC)
in the EEG for confirming CJD. We analyzed the
value of these two widely used diagnostic tests in
CJD (i.e., EEG and CSF detection of 14-3-3 proteins)
in the context of a prospective multinational study of
CJD.10 The results of these investigations were used
in the classification of suspected CJD cases.
Follow-up was obtained, and the accuracy of the ini-
tial clinical diagnosis based on established criteria2
was evaluated. Finally, the sensitivity and specificity
of new extended diagnostic criteria were analyzed,
after inclusion of 14-3-3 CSF results.
Material and methods. Patients. Patients were re-
cruited from national registries of CJD in Australia, Aus-
tria, France, Germany, Italy, Spain, and the United
Kingdom.10 They were classified as definite, probable, or
possible CJD cases2 based on available clinical and labora-
tory data. A standard questionnaire was used to collect
data from each national center.
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Australia; U360 INSERM, Hôpital de la Salpetriere (Drs. Brandel and Delasnerie-Laupêtre), Paris, France; Department of Applied Epidemiology (Drs. de
Pedro Cuesta and Ruiz Bremón), National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain; CJD Surveillance Unit, Western General
Hospital, Edinburgh, Scotland (Drs. Knight and Will); Klinisches Institut für Neurologie (Drs. Bernheimer and Budka), Universität Wien, Austria; Istituto
Neurologico Nazionale C. Besta, (Dr. Awan), Milan, Italy; Department of Applied Epidemiology, National Centre for Epidemiology, Carlos III Institute of
Health and Research Brain Bank (Dr. Cuadrado Corrales), Medical School, Complutensis University, Madrid, Spain; and Service de Biochimie et Biologie
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Diagnostic criteria for sporadic CJD. We used previ-
ously established criteria to determine the level of diagnos-
tic accuracy in relation to sporadic CJD.2,10 All patients
with spongiform encephalopathy or immunochemical de-
tection of PrPSc in the brain were classified as definite
CJD cases. Patients were classified as probable cases if
they exhibited a rapidly progressive dementia, PSWC on
EEG, and two of the following: myoclonus, visual and cer-
ebellar symptoms or both, pyramidal and extrapyramidal
signs or both, or akinetic mutism. Those fulfilling the
above clinical criteria but without PSWC and a duration of
dementia of , 2 years were classified as “possible CJD.”
Cases that did not fulfill these clinical criteria were classi-
fied as “not CJD.” EEG was used in the initial and
follow-up classification of suspected cases. In contrast, re-
sults of 14-3-3 determination in CSF were used neither in
the initial nor in the follow-up classification of the sus-
pected cases. During follow-up, patients were regularly re-
viewed and reclassified according to these criteria. Cases
with unambiguous clinical improvement or recovery were
classified as “other” even if a definite alternative diagnosis
could not be made and postmortem analysis was not
undertaken.
Analysis of CSF for 14-3-3. CSF samples were ob-
tained by lumbar puncture. CSF was analyzed for the
presence of 14-3-3 proteins as previously described.6,11 The
CSF analysis was carried out in each CJD surveillance
center with minor modifications. Blood-stained CSF sam-
ples were excluded from analysis because contamination of
this type can lead to “false-positive” results. A blinded
comparison of test results from the different centers
showed good reliability and validity. (The detailed analysis
of the comparison will be published elsewhere.)
Results. Patient characteristics. Assessment of CSF 14-
3-3 proteins was performed on 1,003 patients who were
referred to the national CJD registries of Australia (n 5
71), Austria (n 5 31), France (n 5 270), Germany (n 5
351), Italy (n 5 79), Spain (n 5 79), and the United King-
dom (n 5 122). The classification of these patients is re-
ported in table 1. CSF samples of cases classified as “not
CJD” with other neurologic disorders served as controls.
The 14-3-3 proteins were detected in 91% of patients
with definite or probable sporadic CJD, 45% of new variant
CJD (nvCJD) and in 97% of CJD patients with a PRNP
mutation (see table 1). The test was positive in only two
of five Gerstmann–Sträussler–Scheinker (GSS) patients
and was negative in all patients with fatal familial
insomnia (FFI).
Among control subjects, the test was positive in
only ; 9%.
Follow-up. Complete clinical follow-up data were
available in 805 cases (sporadic CJD and control subjects).
In the remainder, no follow-up was possible because of
study design limitations in particular countries. The mean
follow-up time varied from 1.8 to 6.5 months (median)
between the countries, depending on the study design
(range 0.25 to 48 months).
The initial clinical classification of suspected CJD pa-
tients at the time of notification to national registries was
as follows (table 2). Three hundred thirteen patients were
classified as probable CJD cases; among these, 282 had
detectable levels of 14-3-3 in the CSF. Two hundred eleven
patients had a diagnosis of possible CJD, and CSF was posi-
Table 2 Initial and final classification in patients with suspected
sporadic Creutzfeldt-Jakob disease (CJD)
Initial classification Probable Possible Not CJD
14-3-3 in CSF 1 2 1 2 1 2
n 282 31 151 60 22 259
Follow-up
Definite 144 8 61 6 2 1
Probable 135 15 14 — 3 1
Possible — — 72 26 4 —
Not CJD 3* 8† 4‡ 28§ 13¶ 257
* One multiple myeloma, one AD, one frequent seizures.
† Three AD, five unknown.
‡ One anoxia, one stroke, one metabolic encephalopathy, and
one patient with disease duration of .5 years and no final
diagnosis.
§ One AD, 1 Pick’s disease, 10 recovered, 15 not CJD in autopsy,
and 1 patient with disease duration of .2 years and no final
diagnosis.
¶ Three encephalitis, two hypoxic brain damage, one paraneo-
plastic, one suspected possible CJD with duration of .3 years,
one probable CJD with no obvious dementia, remaining cases
no outcome.
Table 1 Occurrence of 14-3-3 proteins in CSF of
Creutzfeldt–Jakob disease (CJD) patients and of patients with
other neurologic diseases (n 5 1,003)
Disease 14-3-3 positive
CJD
Definite or probable CJD, n 5 413 376
Possible CJD, n 5 127 79
New variant CJD, n 5 11 5
Iatrogenic CJD,* n 5 10 6
Genetic/familial patients
P102L,† n 5 5 2
E200K, n 5 13 13
V210I, n 5 15 15
D178N-129M,‡ n 5 15 0
Familial,§ n 5 2 1
Other neurologic diseases, n 5 392 34¶
* Six related to human growth hormone, three dura mater, one
corneal graft.
† Gerstmann–Sträussler–Scheinker disease.
‡ Fatal familial insomnia.
§ Family history, but no genotyping available.
¶ Three AD, three encephalitis, eight vascular disorders (three
anoxia, two stroke, two subarachnoid hemorrhage, one brain-
stem infarction), one each of multiple myeloma, metabolic en-
cephalopathy, lymphohistiocytoma, paraneoplastic
encephalopathy, malignant meningitis, and one patient with
cerebral ischemia whose CSF was taken within a few days of
seizures. In the remaining 14 cases, no final diagnosis could be
made; most of these patients had dementia, but their clinical
features did not fulfill the criteria for classification as CJD.
812 NEUROLOGY 55 September (2 of 2) 2000
tive for 14-3-3 in 151 of them. Two hundred fifty-nine of 281
patients who did not fulfill the criteria for sporadic CJD (“not
CJD”) had no measurable level of 14-3-3 in the CSF.
A further analysis based on the results of follow-up
investigations was carried out for each initial diagnostic
classification subgroup (see below).
Follow-up on probable CJD cases. The diagnostic reli-
ability of “probable CJD” was high. During follow-up, the
diagnosis of CJD was excluded in only 11 patients; about
half of the remaining were confirmed postmortem. In the
remaining patients, there was no change in the diagnostic
classification because either no autopsy of the brain was
performed or the patients were still alive. Of the 11 pa-
tients with a false-positive EEG, 14-3-3 proteins were de-
tectable in the CSF of 3. In one of these, however, there
were high CSF protein levels and hypercalcemia, leading
to a diagnosis of multiple myeloma. In four patients with
AD, the diagnosis was made only after autopsy.
Follow-up on possible CJD cases. The analysis of this
subgroup is of particular practical importance, as a signif-
icant proportion of sporadic CJD patients never develop
typical PSWC. Ninety-three percent of patients in whom
postmortem examination of the brain confirmed CJD or
who developed typical PSWC during follow-up (and were
therefore upgraded to “probable CJD”) had detectable lev-
els of 14-3-3 in the CSF. The 14-3-3 proteins were also
detected in 73% of patients whose diagnosis of “possible
CJD” did not change during the follow-up, either because
autopsy was not done or because the patients were still
alive. The 14-3-3 proteins were detected in only 13% of
patients in whom the diagnosis of CJD was ruled out.
Follow-up on “not CJD” cases. Only a small number of
patients who were initially classified as “not CJD” at the
time of notification turned out to be sporadic CJD cases.
Interestingly, five of seven of them had positive results for
14-3-3.
Comparative diagnostic value of EEG and CSF find-
ings. For the calculation of sensitivity relating to EEG
and 14-3-3 results or both, we used CJD patients who were
clinically diagnosed as “probable” or “possible” cases and
were subsequently confirmed at neuropathologic examina-
tion. Accordingly, for the evaluation of specificity, we used
only “probable” or “possible” CJD patients who were ulti-
mately neuropathologically excluded or who were clinically
recovered (table 3).
A positive 14-3-3 test was more sensitive and more spe-
cific than the presence of PSWC in the EEG. The 14-3-3
test gave a false-positive result in only 7 of 43 cases (1 each
of anoxia, stroke, metabolic encephalopathy, multiple my-
eloma, AD, cerebral ischemia with frequent seizures, and 1
patient with disease duration of . 5 years without definite
diagnosis), whereas PSWC were seen in 11 of 43 “not CJD”
patients (1 each of multiple myeloma and cerebral ische-
mia and frequent seizures, 4 patients with AD, and 5 with
no definite diagnosis neuropathologically).
In patients with PSWC in the EEG and detectable 14-
3-3 levels in the CSF, the clinical diagnosis of CJD was
confirmed at autopsy in all but three cases. The diagnoses
in these three patients were multiple myeloma, AD, and
cerebral ischemia with frequent seizures. In contrast, 28 of
60 patients with a clinical diagnosis of “possible CJD” (no
PSWC in the EEG), who were also negative for 14-3-3,
were ultimately classified “not CJD” (table 2).
Table 3 Comparative diagnostic value of EEG and CSF analysis in cases of Creutzfeldt–Jakob disease (CJD) initially classified as
“probable” or “possible” CJD
Characteristic PSWC in EEG 14-3-3 in CSF
PSWC in EEG or
14-3-3 in CSF*
PSWC in EEG and
14-3-3 in CSF†
CJD 144/219 205/219 213/219 144/219
Not CJD 11/43 7/43 15/43 3/43
Sensitivity, % 66 94 97 66
Specificity, % 74 84 65 93
Positive predictive value, % 93 97 93 98
Negative predictive value, % 30 72 79 35
* Test positive: patients with either periodic sharp wave complexes (PSWC) in EEG or 14-3-3 in CSF. Test negative: patients without
PSWC in EEG and without 14-3-3 in CSF.
† Test positive: only patients who had PSWC in EEG and 14-3-3 in CSF. Test negative: all other patients.
Table 4 Modified diagnostic criteria for sporadic Creutzfeldt-
Jakob disease (CJD)
Definite CJD
● Neuropathologically confirmed and/or
● Abnormal prion protein isoform immunochemically confirmed
by immunocytochemistry or western blot
● Scrapie-associated fibrils
Probable CJD
● Progressive dementia with at least two of four clinical
features:
1. Myoclonus
2. Visual or cerebellar signs
3. Pyramidal or extrapyramidal signs
4. Akinetic mutism
● Periodic sharp and slow wave complexes (PSWC) in EEG
● 14-3-3 proteins in CSF and duration of ,2 years
Possible CJD
● Clinical features as above
● No PSWC in EEG
● No 14-3-3 detection in CSF
● Duration of ,2 years
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The sensitivity of the clinical diagnosis of CJD increases
from 66 to 97% with the inclusion of a positive 14-3-3
result in the diagnostic criteria (table 4). Although this
procedure appears associated with decreased specificity
(from 74 to 65%), it is noteworthy that the majority of
false-positive results were due to the presence of PSWC in
the EEG. The positive predictive value of PSWC in the
EEG was comparable with the detection of 14-3-3 in CSF.
The highest positive predictive value was achieved when
both the EEG and the 14-3-3 proteins were positive:
Ninety-eight percent of these cases were confirmed by neu-
ropathology. The highest predictive value for the absence
of CJD was achieved when both investigations were nega-
tive (negative predictive value 79%).
Discussion. The molecular basis for clinical and
neuropathologic phenotypic variability in CJD has
recently been described.12 Cases of sporadic CJD
with short clinical duration and typical PSWC in the
EEG were identified as a distinct subgroup. How-
ever, the EEG was rarely typical in other CJD sub-
types, leading to the need for improved diagnostic
criteria in these forms of the disease. Detection of
the pathologic isoform PrPSc outside the CNS has not
yet been possible in sporadic CJD in contrast to
nvCJD, in which PrPSc has been detected in lym-
phatic tissues.13,14 Although the postmortem rate in
CJD is relatively high, between 43 and 85%,10 in a
significant proportion of cases, the diagnosis of CJD
still depends on clinical criteria. Such criteria need
to have a high sensitivity and specificity to guaran-
tee an accurate surveillance of the disease and to
ensure a high level of comparability and reliability of
epidemiologic data among different countries.
Several investigations have been proposed to cor-
roborate the clinical diagnosis of CJD. In the criteria
established by Masters et al.,2 the detection of PSWC
in the EEG was used to support the clinical diagno-
sis of CJD in patients with rapidly progressive de-
mentia and various neurologic signs. Increased
levels of neuronal or astrocytic protein have been
investigated in the CSF of CJD patients, namely,
14-3-3 proteins,6,7,11,15-17 neuron-specific enolase, and
S-100.15,18-20 Brain CT does not show specific patterns
in CJD, but brain MRI may be diagnostically useful
in sporadic CJD and nvCJD.4,5,21 Other methods have
been proposed, including somatosensory evoked po-
tentials, retinography, SPECT, and PET,22 but these
methods have not been adequately evaluated in
large numbers of cases.
Data on the sensitivity and specificity of PSWC in
the EEG and 14-3-3 proteins in CSF have been re-
ported in retrospective studies, but they were based
on cases that fulfilled established clinical diagnostic
criteria or were confirmed neuropathologically.6,7
However, the sensitivity and specificity of a test are
best evaluated in a prospective study.
The present prospective study has demonstrated
that the detection of 14-3-3 proteins in the CSF is
sensitive and specific for the diagnosis of sporadic
CJD. In familial CJD patients bearing codon 200 or
codon 210 mutations, the 14-3-3 assay had a similar
diagnostic value. In contrast, 14-3-3 proteins were
not detected at all in FFI and only uncommonly in
GSS. Both these conditions may be difficult to diag-
nose clinically because of an atypical clinical picture,
often with a long disease duration and absence of
PSWC.23 Nevertheless, CSF analysis for 14-3-3 pro-
teins is not useful as a screening test in patients
with dementia, as the protein is only a nonspecific
marker of neuronal damage. However, in the context
of suspected CJD, its presence helps to corroborate
the diagnosis and to differentiate these cases from
cases of AD and other conditions. False-positive find-
ings may occur in patients with cerebral hypoxia,
intracerebral hemorrhage, inflammatory CNS disor-
ders, and blood-stained CSF samples. These condi-
tions can and should be excluded by clinical
evaluation and appropriate investigations such as
CSF analysis and brain imaging.
Follow-up analysis in the “probable CJD” group
demonstrated the high reliability of this clinical clas-
sification. Similar analysis of “possible CJD” cases
allowed three conclusions: 1) The detection of 14-3-3
proteins strongly supports the diagnosis of CJD in
this particular subgroup. 2) The elevation of 14-3-3
proteins in CSF may precede the detection of PSWC
in the EEG. 3) Negative CSF 14-3-3 and no PSWC in
the EEG strongly support an alternative diagnosis.
The analysis in cases who do not fulfill the diagnos-
tic criteria for CJD but who are 14-3-3 positive re-
vealed that careful follow-up is required as this test
may detect disease at a very early stage.
Overall, our results demonstrate a high accuracy
of the clinical diagnosis of CJD. In our analysis, the
14-3-3 test was positive in only 34 of 392 control
subjects, when trying to exclude CJD in patients
with a relatively low clinical likelihood. The utility of
the 14-3-3 test is further enhanced when interpreted
in the clinical context, as many of these “false-
positive” findings were due to diseases that do not
form a differential diagnosis for CJD, such as sub-
arachnoid hemorrhage or inflammatory disease. In
the subgroup of our patients with detailed informa-
tion on follow-up, 297 of 313 patients with a final
diagnosis of “not CJD” were negative for 14-3-3 in
the CSF, giving a high specificity of 94%.
The inclusion of a positive 14-3-3 CSF assay in the
diagnostic criteria leads to a higher sensitivity. In
the framework of this large surveillance study, only
a few definite CJD cases did not show either a char-
acteristic EEG or positive CSF for 14-3-3 proteins.
Moreover, 14-3-3 proteins were detectable in some
patients at an early stage of the disease, preceding
the typical EEG changes, suggesting that they may
be an earlier disease marker than the EEG. Of im-
portance, when both the EEG and CSF were posi-
tive, the highest positive predictive value was
achieved. In 98% of these cases, the clinical diagno-
sis was confirmed by neuropathology (positive pre-
dictive value; table 3). The highest predictive value
for absence of CJD was achieved when both investi-
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gations were negative (negative predictive value
79%), suggesting that in routine clinical practice,
alternative diagnoses should be considered in such
patients.
Although the results of this study demonstrate
worthwhile diagnostic accuracy in patients with
“probable” CJD using established diagnostic criteria,
the sensitivity of the category “probable CJD” is in-
creased by the inclusion of 14-3-3 assay results. Fur-
ther, this study also shows that a significant
proportion of cases classified as “possible CJD” ac-
cording to established criteria (absence of PSWC on
the EEG) do, in fact, suffer from CJD. As cases of
“possible CJD” are often excluded in studies of CJD
because of concerns of diagnostic validity, there is a
particular need to improve the diagnostic accuracy in
this subgroup of cases. It is clearly this group in
which the 14-3-3 CSF test appears to be of most
practical benefit in classifying patients because with-
out autopsy, CJD may not be diagnosed in these
cases. We propose new diagnostic criteria for the
classification of CJD cases.
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To validate the provisional findings of a number of smaller studies and explore additional determinants of
characteristic diagnostic investigation results across the entire clinical spectrum of sporadic Creutzfeldt–Jakob
disease (CJD), an international collaborative study was undertaken comprising 2451 pathologically confirmed
(definite) patients. We assessed the influence of age at disease onset, illness duration, prion protein gene (PRNP)
codon 129 polymorphism (either methionine or valine) and molecular sub-type on the diagnostic sensitivity of
EEG, cerebral MRI and the CSF 14-3-3 immunoassay. For EEG and CSF 14-3-3 protein detection, we also
assessed the influence of the time point in a patient’s illness at which the investigation was performed on the
likelihood of a typical or positive result. Analysis included a large subset of patients (n = 743) in whom molecular
sub-typing had been performed using a combination of the PRNP codon 129 polymorphism and the form of
protease resistant prion protein [type 1 or 2 according to Parchi et al. (Parchi P, Giese A, Capellari S, Brown P,
Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N,
Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. Classification of sporadic Creutzfeldt–Jakob disease
based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224–233.)] present in the
brain. Findings for the whole group paralleled the subset with molecular sub-typing data available, showing that
age at disease onset and disease duration were independent determinants of typical changes on EEG, while
illness duration significantly influenced positive CSF 14-3-3 protein detection; changes on brain MRI were not
influenced by either of these clinical parameters, but overall, imaging data were less complete and consequently
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conclusions are more tentative. In addition to age at disease onset and illness duration, molecular sub-type was
re-affirmed as an important independent determinant of investigation results. In multivariate analyses that
included molecular sub-type, time point of the investigation during a patient’s illness was found not to influence
the occurrence of a typical or positive EEG or CSF 14-3-3 protein result. A typical EEG was most often seen in
MM1 patients and was significantly less likely in the MV1, MV2 and VV2 sub-types, whereas VV2 patients had an
increased likelihood of a typical brain MRI. Overall, the CSF 14-3-3 immunoassay was the most frequently
positive investigation (88.1%) but performed significantly less well in the very uncommon MV2 and MM2 sub-
types. Our findings confirm a number of determinants of principal investigation results in sporadic CJD and
underscore the importance of recognizing these pre-test limitations before accepting the diagnosis excluded or
confirmed. Combinations of investigations offer the best chance of detection, especially for the less common
molecular sub-types such as MV2 and MM2.
Keywords: sporadic CJD; diagnostic investigation results; molecular sub-typing
Abbreviations: CJD = Creutzfeldt–Jakob disease; PrPres = protease-resistant prion protein; PSWC = periodic sharp
wave complexes
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Introduction
Pre-mortem diagnosis of the rare, transmissible neurodegen-
erative disorder, sporadic Creutzfeldt–Jakob disease (CJD),
largely relies on an appropriate clinical profile supported by
characteristic findings on routine investigations such as the
EEG and CSF analysis (Collins et al., 2004). Neuropatholo-
gical examination of the brain remains necessary to achieve a
definite diagnosis. Cerebral MRI may also demonstrate
highly suggestive changes and is assuming a greater role
in CJD evaluation but is not currently included in diagnostic
criteria for surveillance purposes (Collie et al., 2001;
Meissner et al., 2004; Shiga et al., 2004; Tschampa et al.,
2005). Although the diagnostic utility of these investigations
(particularly the EEG and CSF 14-3-3 protein detection) has
been supported by a number of studies (Steinhoff et al.,
1996, 2004; Zerr et al., 2000a), they remain imperfect sur-
rogate markers, with apparent non-uniform sensitivity across
the clinical spectrum of sporadic CJD (Parchi et al., 1999).
Different clinical and pathological sub-types of sporadic
CJD have been linked to polymorphism status at codon 129
of PRNP combined with the type (1 or 2) of protease-
resistant prion protein (PrPres) found in the brain, and
together these probably define different human prion strains
(Parchi et al., 1999; Hill et al., 2003; Korth et al., 2003). The
most widely used scheme distinguishes only two PrPres types
(Parchi et al., 1999), while another commonly employed
nomenclature delineates a greater number (Hill et al.,
2003). Employing this nosology to sub-type sporadic CJD,
the EEG has been shown to vary widely between the specific
molecular sub-types in demonstrating characteristic or typi-
cal changes (Parchi et al., 1999; Zerr et al., 2000b). Generally,
the likelihood of characteristic changes on the EEG was
reported to be highest in MM homozygotes, reduced in
heterozygotes and lowest in VV carriers. Immunoassay for
14-3-3 proteins in CSF, increasingly utilized in the diagnostic
evaluation of patients with suspect CJD (Zerr et al., 2000a),
has also been shown to vary in rates of positivity according to
molecular sub-type, with the likelihood of noticeably
reduced detection rates in heterozygous patients with type
2 PrPres (MV2) (Zerr et al., 2000b; Otto et al., 2002;
Castellani et al., 2004). A notable difficulty with all previous
reports assessing rates of positive diagnostic investigations in
molecular sub-types of sporadic CJD is the small numbers of
patients studied, especially the less common phenotypic sub-
types. Such small patient numbers militate against the relia-
bility of the observations and have precluded multivariate
analyses to assess for covariates and probable confounding
factors. A corollary, unexplored so far, is whether within each
of the molecular subgroups and across the phenotypic spec-
trum of sporadic CJD there are additional independent vari-
ables influencing diagnostic test results. Consequently, there
remains a need to more confidently establish the diagnostic
utility of these investigations across the various molecular
sub-types of sporadic CJD and define further determinants
of their sensitivity and specificity across the entire clinical
range. More clearly defining additional factors influencing
the sensitivity and specificity of these principal investigations
has important practical implications when investigating indi-
vidual patients.
As part of a collaborative multi-national CJD surveillance
program (EUROCJD) initiated in 1993, we assessed the effect
of patient clinical features such as age at onset, illness dura-
tion and PRNP codon 129 polymorphism on the diagnostic
sensitivity of EEG, CSF 14-3-3 immunoassay and cerebral
MRI in a large, population-based sample of 2451 patholo-
gically confirmed (definite) sporadic cases of CJD, employ-
ing harmonized case definitions and data sets. Further,
similar analysis was undertaken in a subset of patients
(n = 743) in whom molecular sub-typing using brain PrPres
isotype and codon 129 polymorphism had been determined.
Inclusion of this data allowed detailed assessment of the
Page 2 of 10 Brain (2006) S. J. Collins et al.
variation in positive test results across the molecular sub-
types, as well as whether patient parameters such as age at
onset, illness duration and the specific time point at which
the investigation was performed during a patient’s illness
were additional independent determinants of investigation
results.
Patients and methods
The present study was undertaken as part of the ongoing activities
of the prospective CJD surveillance programme (EUROCJD) con-
ducted by the European Union and allied countries. In 1993,
national surveillance registers commenced in France, Germany,
Italy, The Netherlands, Slovakia and the UK, with the aim of
ascertaining all patients diagnosed with probable or definite CJD
in the respective countries. The study was extended in 1997 and
again in 1998 to include Australia, Austria, Canada, Spain and
Switzerland. EUROCJD collaborative study methods utilizing
standardized case definitions and centralized harmonized demo-
graphic data sets were as described previously (Pocchiari et al.,
2004; Ladogana et al., 2005a).
The study comprised all patients (n = 2451) with definite spora-
dic CJD who died between 31 December 1992 and 31 December
2002: 136 cases from Australia, 68 from Austria, 146 from Canada,
491 from France, 450 from Germany, 342 from Italy, 100 from The
Netherlands, 438 from the UK, 18 from Slovakia, 183 from Spain
and 79 from Switzerland. A diagnosis of definite sporadic CJD
required neuropathological confirmation most commonly through
post-mortem but occasionally through brain biopsy. Analysis of the
PRNP open reading frame was performed in the majority of patients
to exclude genetic CJD, as clinical differentiation from sporadic CJD
is not always possible (Collins et al., 2000; Ladogana et al., 2005b).
Of the 2451 patients, 746 had their brain PrPres isotype determined,
which in combination with PRNP codon 129 genotyping allowed
molecular sub-typing according to the system of Parchi et al.,
(1999). Whenever possible, PrPres typing was based on analysis
of a number of brain regions, including cerebral cortex, striatum
or thalamus and cerebellum, although the preferred number and
precise location of sampling sites varied between participating
countries.
Whenever possible, all EEGs and MRI brain scans were reviewed
by a member of the surveillance system and scored for the presence
or absence of typical or characteristic diagnostic features. EEG
records were scored positive or characteristic when they fulfilled
validated criteria (Steinhoff et al., 2004): sustained periodic sharp
wave complexes (PSWC) with a variability of <500 ms, with the
periodic complexes (lasting 100–600 ms) demonstrating a bi- or tri-
phasic morphology and seen in a generalized or lateralized distri-
bution. The CSF 14-3-3 immunoassays were performed in each of
the national surveillance centres using western blotting, with con-
formity of testing methods and results interpretation confirmed by
blinded sample exchange programme. On cerebral MRI, high signal
in the putamen and caudate nucleus when using long-repetition
time pulse sequences was considered a positive finding for sporadic
CJD (Collie et al., 2001); however, there was no systematic use of
particular techniques such as fluid attenuated inversion recovery
(FLAIR) or diffusion weighted imaging (DWI).
For assessment of the influence of the timing of the investigation
during a patient’s illness on the test result, data sets were of suffi-
cient size for EEG and CSF 14-3-3 protein detection to allow this
type of analysis. Acknowledging that the median total illness
duration was 5 months, we chose to divide each patient’s sympto-
matic phase into thirds (first, middle and final) rather than into a
greater number of epochs. This was to ensure avoiding the creation
of illness periods of such brevity, especially at the onset of symp-
toms, that they would be unlikely to correspond to a clinically
meaningful phase of a patient’s illness during which investigations
would usually be undertaken, and if undertaken because of the
development of symptoms suggesting neurological dysfunction,
that these features were sufficiently developed that the investigations
had a reasonable likelihood of displaying abnormalities. The median
times (range in months) from the onset of symptoms for the ana-
lyses of each of the first, middle and final thirds of patient’s illnesses
for assessing CSF 14-3-3 protein detection were 1 (0–10), 2.5 (1–17)
and 4 months (1–41), respectively. With respect to EEG findings,
the median times (range in months) from the onset of symptoms
for the analyses of each of the first, middle and final thirds of
patient’s illnesses were 1 (0–18), 2 (1–42) and 4 months (1–41),
respectively.
All data were centralized and analysed collaboratively.
Statistical analysis
Descriptive statistics were calculated for the whole sample and for
every molecular sub-type of the disease. Fisher’s exact and Mann–
Whitney tests were used to assess differences between qualitative
and quantitative variables, respectively. The number of positive
findings (acknowledging that patients may have undergone multiple
tests) over the total number of tested CJD cases for EEG, MRI and
the CSF 14-3-3 immunoassay was determined for each stratum. The
frequency of positive results (number of positive test results in total
number of patients) was then calculated for EEG, MRI and the CSF
14-3-3 test for each stratum.
In order to analyse the independent effect of each factor on
positive test results, taking into account possible confounders, we
fitted two multiple logistic regression models with the test result as
output. Both models included age at onset, and disease duration as
predictors, and included country of origin, year of death and gender
as covariates.
In the first model PRNP codon 129 genotype was entered as a
predictor, while in the second model we used the molecular sub-
type (combination of PRNP codon 129 genotype and PrPres type).
Age at onset was categorized into clinically meaningful groups, with
patients younger than 50 years serving as the reference group.
Disease duration was also categorized with the same criteria into
three groups: duration <6, 6–12 and >12 months. PRNP codon 129
genotype was entered in the model using two dummy variables,
with MM as the reference group; for molecular sub-types we created
eight dummy variables (MM2, MM1/2, MV1, MV2, MV1/2, VV1,
VV2 and VV1/2) with MM1 group as reference. Adjusted odd ratios
(ORs) and 95% confidence intervals (CIs) were generated. All sta-
tistical analyses were performed using SPSS 11.0 for Windows 2000
(SPSS Inc., Chicago, IL).
Results
Table 1 summarizes the salient features of all definite spora-
dic CJD cases. Of the 2451 patients identified, 1329 were
females (54.2%). The median age at death was 68 years
(range: 20–95), while the median disease duration was
5 months (range: 1–81).
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An EEG was performed on 2083 patients (85%). Of
those undergoing EEG, 1216 cases showed typical
PSWCs (58.4%) (Table 1). The codon 129 genotype had a
significant effect on the likelihood of a positive result of the
EEG in sporadic CJD patients (Table 2), which ranged from
73.2% in MM homozygotes to 21.5% in VV homozygotes.
After adjusting for possible confounding variables
(country, sex, year of death, age at onset and disease
duration), the prevalence of PSWC on the EEG was
significantly decreased in heterozygotes (P < 0.001) and
VV homozygotes (P < 0.001). The median age of death of
sporadic CJD patients with a typical EEG was 69.0 (range:
34–92) versus 66 years (range: 20–88) in patients with an
atypical EEG (P < 0.001). The presence of PSWC was
further analysed by age at onset and disease duration
(Table 3). The likelihood of a typical EEG steadily increased
with age (P < 0.001, adjusted for the same variables),
while there was an inverse correlation with disease duration
(P = 0.001).
CSF 14-3-3 protein analysis was performed on 1521 cases
(62.1%) of sporadic CJD. Of these, 1340 cases were positive
(88.1%) (Table 1). Although the frequency of a positive
CSF 14-3-3 immunoassay was high for all three codon
129 genotypes, heterozygotes had a significantly lower rate
(77.0%) in adjusted analyses than VV (P < 0.001) and MM
(P < 0.05) (Table 2). Age at disease onset did not influence
CSF 14-3-3 protein detection but as for the EEG a positive
result was less likely with longer disease duration (Table 3)
(P < 0.001).
MR brain imaging was performed on 1063 patients
(42.3%). Of these patients, 405 patients showed character-
istic changes (39.1%) (Table 1). In contrast with the EEG, the
likelihood of a positive MRI scan was higher in cases with the
MV (P < 0.05) and VV genotypes (P = 0.002) in comparison
to those with an MM genotype (Table 2). MRI results were
not significantly associated with age at onset or disease
duration (Table 3).
Table 1 Summary of clinical features of all patients, including the subset undergoing molecular sub-typing
Clinical feature All patients Patients with molecular
sub-typing
Male (%) 1122 (45.8) 351 (47.2)
Female (%) 1329 (54.2) 392 (52.8)
Median age at onset (range) 67.2 (15.6–94.9) 66.2 (15.6–90.0)
Age at onset < 50 years (%) 116 (5.1) 39 (5.5)
Age at onset 50–59 years (%) 412 (18.2) 141 (19.7)
Age at onset 60–69 years (%) 867 (38.3) 286 (40.0)
Age at onset 70–79 years (%) 729 (32.2) 212 (29.7)
Age at onset > 80 years (%) 137 (6.1) 37 (5.2)
Median duration of illness in months (range) 5 (1–81) 5 (1–62)
Patients with duration < 6 months (%) 1332 (58.8) 404 (56.5)
Patients with duration 6–12 months (%) 611 (27.0) 179 (25.0)
Patients with duration > 12 months (%) 321 (14.2) 132 (18.5)
Codon 129 genotype
Met-Met/total (%) 1061/1604 (66.1) 504/743 (67.8)
Met-Val/total (%) 272/1604 (17.0) 117/743 (15.7)
Val-Val/total (%) 271/1604 (16.9) 122/743 (16.4)
Patients with PRNP gene sequenced (%) 1492 (63.6) 650 (87.5)
PrP isotype
Type 1 495/743 (66.6) 495/743 (66.6)
Type 1 and 2 44/743 (5.9) 44/743 (5.9)
Type 2 204/743 (27.5) 204/743 (27.5)
EEG
Typical/total (%) 1216/2083 (58.4) 371/666 (55.7)
14-3-3 protein in CSF
Positive/total (%) 1340/1521 (88.1) 486/554 (87.7)
MRI
Characteristic findings/total (%) 405/1036 (39.1) 150/387 (38.8)
Table 2 Summary of principal investigation findings for
all patients who underwent PRNP codon 129 genotyping








M/M 710/970 (73.2) 172/474 (36.3) 709/796 (89.1)
M/V 99/245 (40.4) 65/134 (48.5) 147/191 (77.0)
V/V 50/233 (21.5) 71/139 (51.1) 184/196 (93.9)
P-value <0.001 0.004 0.002
Adjusted by age at onset, disease duration, sex, country of origin
and year of death.
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Analysis of sporadic CJD patients
according to molecular sub-type
In 743 patients the codon 129 polymorphism and brain
PrPres isotype were determined allowing molecular
phenotypic sub-stratification (Table 1) (Parchi et al.,
1999). In 87% of these patients the PRNP gene was
sequenced, ruling out pathological mutations associated
with genetic CJD. In comparison to the entire group, the
median age at onset, median disease duration and PRNP
codon 129 polymorphism distributions were similar, and
there were no significant differences in the overall rates
of positive results for each of the investigations. The most
common PrPres isotype was type 1 (67%); type 2 was present
in 27% of the sample, and in 44 cases (6%) there was coex-
istence of both type 1 and 2.
The relative frequency of the various molecular sub-types
is provided in Table 4. There were occasional significant
differences in demographic characteristics between sub-
groups. MM1 patients were the oldest at disease onset (med-
ian: 67.8 years) and VV1 patients were the youngest (median:
47.2 years). The duration of the disease was significantly
shorter in MM1 patients (median: 4 months) in comparison
with the rest, especially the MM2 (median: 12.5 months) and
MV2 (median: 12 months) subgroups, with these groups also
Table 3 Principal investigation findings for all patients according to age at disease onset and duration of illness
EEG MRI 14-3-3 protein in CSF
Typical/total (%) Typical/total (%) Positive/total (%)
Age at onset
Age at onset < 50 years (%) 35/104 (33.7) 18/58 (31.0) 62/77 (80.5)
Age at onset 50–59 years (%) 197/371 (53.1) 83/196 (42.3) 222/260 (85.4)
Age at onset 60–69 years (%) 457/796 (57.4) 166/415 (40.0) 472/545 (86.6)
Age at onset 70–79 years (%) 438/675 (64.9) 126/328 (38.4) 452/492 (91.9)
Age at onset > 80 years (%) 81/124 (65.3) 12/37 (32.4) 73/83 (88.0)
P for trend <0.001 0.3 0.4
Disease duration
Patients with duration < 6 months (%) 814/1228 (66.3) 203/587 (34.6) 779/840 (92.7)
Patients with duration 6–12 months (%) 283/558 (50.7) 125/287 (43.6) 358/408 (87.7)
Patients with duration > 12 months (%) 115/288 (39.9) 77/160 (48.1) 146/211 (69.2)
P for trend 0.001 0.4 <0.001
Adjusted by PRNP codon 129 genotype, sex, country of origin and year of death.
Table 4 Summary of age at disease onset and illness duration for all patients undergoing molecular sub-typing
Sporadic CJD molecular sub-types
MM1 MM2 MM1/2 MV1 MV2 MV1/2 VV1 VV2 VV1/2






















< 50 years (%)
12 (2.8) 5 (16.7)† 1 (3.8) 1 (2.8) 2 (2.9) 0 (0.0) 7 (53.8)† 9 (9.3)† 2 (25.0)†
Age at onset
50–59 years (%)
78 (18.2) 9 (30.0) 3 (11.5) 9 (25.0) 17 (24.6) 1 (14.3) 2 (15.4) 20 (20.6) 2 (25.0)
Age at onset
60–69 years (%)
172 (40.1) 11 (36.7) 12 (46.2) 10 (27.8) 37 (53.6)† 3 (42.9) 3 (23.1) 35 (36.1) 3 (37.5)
Age at onset
70–79 years (%)
143 (33.3) 4 (13.3)* 7 (26.9) 13 (36.1) 12 (17.4)* 3 (42.9) 1 (7.7) 28 (28.9) 1 (12.5)
Age at onset
> 80 years (%)






















< 6 months (%)
307 (71.6) 9 (30.0)* 11 (42.3)* 21 (58.3) 5 (7.2)* 3 (42.9) 4 (30.8)* 40 (41.2)* 4 (50.0)
Duration 6–12
months (%)
78 (18.2) 4 (13.3) 11 (42.3)† 7 (19.4) 28 (40.6)† 0 (0.0) 3 (23.0) 47 (48.5)† 1 (12.5)
Duration
> 12 months (%)
44 (10.3) 17 (56.7)† 4 (15.4) 8 (22.2)† 36 (52.2)† 4 (57.1)† 6 (46.2)† 10 (10.3) 3 (37.5)†
Female (%) 239 (53.8) 15 (48.4) 14 (48.3) 18 (48.6) 35 (47.9) 5 (71.4) 5 (35.7) 56 (56.0) 5 (62.5)
*Significantly lower than MM1 (P < 0.05); †Significantly higher than MM1 (P < 0.05).
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demonstrating a higher percentage of patients with disease
lasting >1 year (57 and 52%, respectively). Of note, albeit the
small patient numbers preclude statistically significant dif-
ferences, patients with co-existence of PrPres types 1 and 2
(MM1/2, VV1/2 and MV1/2) tended to have intermediate
phenotypes but generally aligning more to the most common
molecular PrPres sub-type within each PRNP codon 129
genotype.
Overall, determinants of investigation findings in patients
who underwent molecular sub-typing were the same as for
the entire group. Independent of disease duration and mole-
cular sub-type, age at disease onset correlated significantly
with a positive EEG result (P = 0.007) (Fig. 1). Patients who
developed symptoms <50 years had a lower rate of typical
PSWCs (22%) than patients presenting after 60 years of age.
The median age at onset of the patients with an atypical EEG
was 64 years (range: 16–86), compared with 68 years (range:
31–90) in patients showing the typical findings. CSF 14-3-3
protein immunoassay and MRI results were not significantly
correlated with patient’s age at disease onset.
The duration of disease was independently associated
with the likelihood of PSWCs. Patients with disease duration
<6 months had a significantly higher rate (P = 0.02) of a
typical EEG than patients with duration >12 months (65
versus 35%, respectively). The median disease duration of
patients with an atypical EEG was 6 (range: from 1 to 62)
versus 4 months (range: from 1 to 39) in patients with typical
EEG. Disease duration significantly (P = 0.004) influenced
the likelihood of a positive CSF 14-3-3 test result. Those
patients with disease duration <6 months had a higher
rate of positive test results than those with duration >12
months (91 versus 72%, respectively). On average, patients
with 14-3-3 proteins detectable in their CSF had shorter
disease durations (median: 5 months, range: 1–39) than
patients with a negative test result (median: 11 months,
range: 2–54). MRI results did not correlate with disease
duration (Fig. 2).
Certain molecular sub-types showed significant correla-
tions with investigation results. MM1 patients demonstrated
the highest frequency of positive EEG results (73%) followed
by MV1 patients (53%), although after adjusting for covari-
ates the significance was reduced (P = 0.01). VV2 and MV2
patients had infrequent occurrence of a typical EEG, with a
positive result only observed in 12.8 and 17.5% of the cases,
respectively (Fig. 3). Of the sub-groups with coexistence of
PrPres types, only VV1/2 patients had a significantly lower
frequency compared with the MM1 subgroup. CSF 14-3-3
immunoassay was the most frequently positive investigation,
with an overall positive rate of 88%. However, there were
some significant variations across molecular sub-types, with
the test significantly more often positive (all P-values < 0.05)
for MM1 and VV2 patients (91 and 95%) than for MM2
(61%) and MV2 (71%) (Fig. 3). Of the patient groups with
coexistence of PrPres types, only MM homozygotes had a
significantly lower rate of positive results for this test
(Fig. 3). For MRI, only the VV2 subgroup demonstrated a
significantly increased likelihood of a typical positive result.
Of note, within each molecular sub-type except VV1, occa-
sional patients did not display typical or characteristic find-
ings with any of the three investigations.
Assessment of the influence of the time
point of the investigation during a patient’s
illness on the test result
For both EEG and the detection of CSF 14-3-3 proteins,
sufficient data were available to analyse the influence of
the time point at which the investigation was performed
Fig. 1 The principal investigation results for EEG, brain MRI and CSF 14-3-3 protein analysis were correlated with age at disease onset in
sporadic CJD for all patients undergoing molecular sub-typing. Patients were grouped by age at onset: <50, 50–59, 60–69, 70–79 and
>80 years. Only the EEG showed a significant correlation with age at disease onset. †Significantly higher than in <50 years group (P < 0.05);
adjusted by molecular sub-type, disease duration, sex, country of origin, year of death.





























<6 months 6-12months >12months 
Fig. 2 The principal investigation results for EEG, brain MRI and CSF 14-3-3 protein analysis were correlated with disease duration
in sporadic CJD for all patients undergoing molecular sub-typing. Disease duration was arranged as <6, 6–12 and >12 months.
For both the EEG and CSF 14-3-3 protein detection there was a significant inverse correlation with disease duration >12 months.

















































Typical EEG Typical MRI Positive CSF 14-3-3 test
Fig. 3 The sensitivities of EEG, brain MRI and CSF 14-3-3 protein detection were assessed according to the sporadic CJD molecular
sub-type: MM1, MM2, MM1/2; MV1, MV2, MV1/2; and VV1, VV2 and VV1/2. The MV1, MV2, VV2 and VV1/2 sub-types all showed a
significantly reduced EEG sensitivity, while the VV2 sub-type displayed a significantly higher likelihood of a typical MRI result.
The MM2, MM1/2 and MV2 sub-types all showed significantly reduced rates of CSF 14-3-3 protein positivity. * Significantly lower than MMI
(P < 0.05); †significantly higher than MMI (P < 0.05); adjusted by age at onset, disease duration, sex, country of origin, year of death.
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during the patient’s illness on the likelihood of a typical or
positive result. With the median duration of illness only 5
months, we chose to divide the symptomatic phase into
thirds (first, middle and final) rather than into a greater
number of epochs. This was undertaken to avoid the creation
of illness phases of such brevity, especially at the onset of
symptoms, that they would be unlikely to correspond to a
clinically meaningful period of a patient’s illness during
which investigations would usually be undertaken and
that the test would have a reasonable chance of showing
typical abnormalities.
With respect to EEGs, 2425 recordings with a known time
point in relation to the chronology of the patient’s illness
were available for analysis from 1728 cases. When analysed in
isolation, the likelihood of a typical EEG was significantly less
in the first third of a patient’s illness compared with the last
third (P = 0.02). Multivariate analysis (adjusted by country,
gender, year of death, age at onset, disease duration and
codon 129 polymorphism) also showed that a positive
EEG was significantly more likely in the last third of a
patient’s illness compared with the first third (P = 0.001).
When a patient’s molecular sub-type was substituted for
codon 129 polymorphism in the same regression model,
however, a typical periodic EEG was no longer significantly
more likely in any particular time period of the patient’s
illness. These results are consistent with the specific time
point at which the diagnostic test is undertaken during
the symptomatic period of a patient’s illness not being
independent of molecular sub-type in determining the
likelihood of a positive EEG. With respect to detection of
CSF 14-3-3 proteins, 1032 assays from 985 cases were avail-
able for analysis, showing no significant association between
a positive result and the time point of sampling during a
patient’s illness, regardless of whether assessed in isolation or
in analogous multivariate analyses. For each of the first,
middle and final third time periods of patient’s illnesses,
the CSF 14-3-3 protein sensitivities were 88, 86.4 and
91.3%, respectively.
Discussion
The current study is by far the largest to date to assess the
diagnostic sensitivity of investigations usually employed in
the evaluation of suspected sporadic CJD. By virtue of the
large number of definite sporadic CJD patients comprising
our study we have been able to confidently delineate the
sensitivities of the principal investigation results across the
entire phenotypic spectrum, especially the less common
molecular sub-types, as well as clarify and extend hitherto
uncertain independent determinants of investigation results
(Pocchiari et al., 2004). Analysis of only neuropathologically
confirmed CJD patients has allowed us to avoid the inherent
difficulties that arise from analysis of investigations that also
serve in case definition criteria for probable cases; however, it
is noteworthy that separate analysis of all EUROCJD spora-
dic CJD patients from this time period, that is, inclusion of
clinically probable cases, gave the same results as analysis of
just definite cases (data not shown). Multivariate regression
modelling demonstrated that age at disease onset and disease
duration both act as independent determinants of some
investigation results in sporadic CJD, in addition to the
influence of molecular sub-type. Consequently, in the clinical
evaluation of suspect CJD, our findings reinforce the impor-
tance of fully appreciating the limitations of specific inves-
tigations relative to these salient patient clinical features;
otherwise the heightened likelihood of a negative test result
may be underestimated and incorrectly interpreted as undue
reassurance against the diagnosis. Specifically, the probability
that an EEG will demonstrate PSWCs increases with age and
conversely decreases with disease duration, especially if >12
months. Hence, in a patient <50 years it is most likely that an
EEG will not show typical changes, and even in older
patients, if their illness is >6 months, the probability of
PSWCs is at best only 50%. In contrast to a prior smaller
study (Zerr et al., 2000b) disease duration >12 months was
also observed to significantly lessen the likelihood of a posi-
tive CSF 14-3-3 result. This underscores the importance of
acknowledging illness duration when interpreting a negative
result in an individual patient suspected to be manifesting
sporadic CJD.
The present study re-affirmed that molecular sub-type, in
addition to age at onset and illness duration, is also an
important independent determinant of principal investiga-
tion results (Parchi et al., 1999; Zerr et al., 2000b; Otto et al.,
2002; Hill et al., 2003; Castellani et al., 2004; Meissner et al.,
2004). In contrast to the EEG, where the presence of valine
alleles at codon 129 additively reduces the likelihood of
PSWCs, valine homozygotes (especially VV2 patients)
were significantly more likely to demonstrate a typical
MRI scan than methionine homozygotes (particularly the
MM1 subgroup). These data conform to a pattern whereby
sub-types with ‘classical’ sporadic CJD and predominant
cerebral cortical involvement (MM1 and MV1) are more
likely to manifest PSWCs on EEG, while those with ataxia
and subcortical neuropathological changes (VV2 and MV2)
are more likely to demonstrate characteristic basal ganglia
changes on MRI. However, in contrast to a prior report
suggesting phenotypic homogeneity between the MM1
and MV1 sub-types (Parchi et al., 1999), we found that
the likelihood of a typical EEG was significantly lower and
the average illness duration significantly longer in the MV1
patients. The most likely explanation for this difference in
findings is the much larger sample of MV1 patients available
for analysis in our study.
The CSF 14-3-3 protein immunoassay was the most sen-
sitive investigation across the sporadic CJD phenotypic spec-
trum, but the influence of molecular sub-type was still
evident. Codon 129 heterozygotes, especially the MV2
sub-group, were significantly less likely to be associated
with a positive result [Zerr et al., 2000a, b; Otto et al.,
2002; Castellani et al., 2004], as were the very uncommon
MM2 and MM1/2 subgroups. In comparison with the simple
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demographic features of age at disease onset and illness
duration, the molecular sub-typing profile is much less likely
to be available pre-mortem in individual patients. Neverthe-
less, if this information is available, investigation results
would also need to be interpreted in this specific context
for the most accurate estimation of excluding or confirming
the likelihood of sporadic CJD. Having recognized these
overall limitations and variations across the molecular
sub-types, from a practical clinical perspective it would
appear prudent to utilize all three principal investigations
(brain MRI, CSF 14-3-3 protein analysis and EEG), as, irre-
spective of molecular sub-type, only very uncommonly
(except the rare MM2 sub-group) will all three investigations
not show characteristic findings in an individual patient with
sporadic CJD (Shiga et al., 2004).
Our analyses do not suggest that the time point at which
the investigation is undertaken during a patient’s illness is an
independent determinant of the test result. This was parti-
cularly evident for CSF 14-3-3 protein detection, for which
no association between time point of sampling and a positive
result was found regardless of analytical approach. For EEG,
the apparent reduced likelihood of a typical or periodic
recording in the first third of a patient’s illness compared
with the final period, when examined in isolation or with one
of the multivariate regression models, was no longer evident
when the regression model included molecular sub-type.
Collectively, our findings are consistent with the generally
dominant influence of age at onset, illness duration and
molecular sub-type as the key independent determinants
of investigation results compared with other demographic
variables, including the time point of test sampling during a
patient’s illness.
Although molecular sub-typing of sporadic CJD patients
has proven a useful phenotypic classification system, there
are some difficulties with this approach. Not uncommonly,
more than one PrPres type may be present in the brain of a
patient dying from sporadic CJD (Parchi et al., 1999), and it
is likely that the frequency of occurrence increases with the
number of regions assessed (Puoti et al., 1999; Head et al.,
2004). At present, there is no consensus on how to classify
such patients and whether it is generally better to adopt a
dichotomized approach based on predominance of one type
when several regions are studied or accept classification
based on the analysis of only one or two brain sites. In
our study, patients with more than one PrPres type were a
small minority, but such patients were allowed status as a
separate group within each PRNP genotype without attempt-
ing to adjust for relative abundance of the two PrPres types.
Regardless of PRNP genotype, our patients with simulta-
neous occurrence of both PrPres types tended to present a
different phenotype, sometimes intermediate between those
with a single PrPres isotype and the same codon 129 status,
but often extending beyond the range observed. This suggests
that the simultaneous presence of two PrPres types may evoke
a third or unique phenotype within each codon 129 geno-
type, although our small patient numbers militated against
achieving significance with these observations. Analysis of
investigation results also generally suggests that subgroups
with co-existence of PrPres isotypes tended to appear differ-
ent although not invariably. For CSF 14-3-3 results, the
MM1/2 group behaved more like MM2 patients, and for
the EEG the VV1/2 group were also more like the VV2
patients. The latter is in keeping with the predominant phe-
notypic influence of type 2 PrPres on these investigations or
may simply represent a sampling bias wherein type 2 PrPres
was under-appreciated as the dominant protease resistant
isotype across the brain.
MRI brain imaging is now very commonly employed in
the diagnostic evaluation of suspected sporadic CJD but its
ultimate sensitivity and specificity is still being defined
(Finkenstaedt et al., 1996; Collie et al., 2001; Meissner
et al., 2004; Shiga et al., 2004; Tschampa et al., 2005). For
a number of reasons, our overall sensitivity for typical
changes on MRI scan is lower than that reported in much
smaller studies (Finkenstaedt et al., 1996; Schröter et al.,
2000; Zerr et al., 2000b; Meissner et al., 2004; Shiga et al.,
2004; Tschampa et al., 2005). Importantly, patient MRI
data collected for this study extended over a decade, during
which time this imaging technique was increasingly used
in the evaluation of suspect sporadic CJD, and there were
concurrent improvements in the diagnostic sensitivity of
pulse sequences used for this illness (Collie et al., 2001;
Shiga et al., 2004; Tschampa et al., 2005). Consequently,
the overall number of patients studied with MRI was rela-
tively low (42.3%), and the utilization of optimized MRI
techniques such as DWI and FLAIR mainly occurred only
in the very latter phase of our study epoch and even then was
not uniformly adopted by all neuroimaging services. Further,
during the study period there was progressive appreciation
that increased cerebral cortical signal using the more sensi-
tive techniques of DWI and FLAIR is probably a reasonably
common feature in sporadic CJD (Shiga et al., 2004;
Tschampa et al., 2005). Consequently, another reason for
our low MRI sensitivity relates to our restrictive definition
of what changes we considered characteristic of the diagnosis
(i.e. signal hyperintensity limited to the basal ganglia). Over-
all, this combination of factors has compromised our assess-
ment of the true diagnostic sensitivity and clinical utility of
MRI in the evaluation of sporadic CJD. This sub-optimal
aspect of the present study is being redressed by a further
prospective EUROCJD collaborative project.
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and by a grant from the Academic Trainee Fund Zurich.
United Kingdom: The authors would like to thank the staff
of the National CJD Surveillance Unit, UK, neurologists and
neuropathologists throughout the UK and the families of
patients. Funding to pay the Open Access publication
charges for this article were provided by the ANCJDR.
References
Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, et al. Sensitivity of
14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease.
Neurology 2004; 63: 436–42.
Collie DA, Sellar RJ, Zeidler M, Colchester AC, Knight R, Will RG. MRI of
Creutzfeldt-Jakob disease: imaging features and recommended MRI
protocol. Clin Radiol 2001; 56: 726–39.
Collins S, Boyd A, Fletcher A, Byron K, Harper C, McLean CA, et al. Novel
prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob
disease. Arch Neurol 2000; 57: 1058–63.
Collins SJ, Lawson VA, Masters CL. Transmissible spongiform
encephalopathies. Lancet 2004; 363: 51–61.
Finkenstaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, et al. MR
imaging of Creutzfeldt-Jakob disease. Radiology 1996; 199: 793–8.
Head MW, Bunn TJ, Bishop MT, McLoughlin V, Lowrie S, McKimmie CS,
et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-
Jakob disease: UK cases 1991–2002. Ann Neurol 2004; 55: 851–9.
Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, et al. Molecular
classification of sporadic Creutzfeldt-Jakob disease. Brain 2003;
126: 1333–46.
Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, et al.
Abbreviated incubation times for human prions in mice expressing a
chimeric mouse-human prion protein transgene. Proc Natl Acad Sci USA
2003; 100: 4784–9.
Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al.
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe,
Australia, and Canada. Neurology 2005a; 64: 1586–91.
Ladogana A, Puopolo M, Poleggi A, Almonti S, Mellina V, Equestre M, et al.
High incidence of genetic human transmissible spongiform
encephalopathies in Italy. Neurology 2005b; 64: 1592–7.
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CSF BACE1 activity is




Abstract—To assess the diagnostic utility of CSF BACE1 activity for discrim-
inating Alzheimer disease (AD) from other dementias, particularly
Creutzfeldt–Jakob disease (CJD), the authors studied 26 patients with spo-
radic CJD, 21 patients with AD, and 21 patients with various non-AD, non-
CJD dementias (DCs). CSF BACE1 activity was elevated in AD in comparison
with DC (p  0.01). Unexpectedly, CSF BACE1 activity was also increased in
sporadic CJD (p  0.02).
NEUROLOGY 2006;67:710–712
R.M.D. Holsinger, PhD; J.S. Lee, BSc; A. Boyd, Dip Gen Coun; C.L. Masters, MD;
and S.J. Collins, MD
Alzheimer disease (AD) and Creutzfeldt–Jakob dis-
ease (CJD) can be difficult to differentiate clinically,
and in both diseases, cerebral extracellular mis-
folded protein aggregates are a characteristic neuro-
pathologic finding. In CJD, the plaques consist of
aberrant, protease-resistant conformers (PrPres) of
the ubiquitously expressed prion protein (PrPc),
whereas in AD, the proteinaceous deposits are
formed by the accumulation of -amyloid peptide
(A), an amyloidogenic peptide resulting from the
sequential cleavage of the amyloid precursor protein
by -secretase (BACE1) followed by -secretase.1
Premortem diagnosis is based on a suggestive clini-
cal profile supported by a variety of not entirely spe-
cific laboratory tests. BACE1 protein and catalytic
activity are increased in AD brain in comparison
with age-matched normal and neurologic controls,
including other dementias.2 Further studies demon-
strated increased BACE1 activity in AD CSF vs nor-
mal controls.3 Here, we compare BACE1 activity in
21 patients with AD, 26 patients with sporadic CJD,
and 21 non-CJD, non-AD dementia controls (DCs).
Methods. We conducted this study with ethical approval from
the Human Research Ethics Committee at the University of Mel-
bourne. All CSF samples were from patients initially referred to
the Australian National CJD Registry (ANCJDR) as suspected to
have sporadic CJD. Final diagnoses were based on postmortem
brain examination or made following thorough evaluation of all
available clinical data. Patients included 26 sporadic CJD (23
pathologically verified, definite; 3 clinically probable), 21 AD (16
clinically probable, 5 pathologically confirmed), and 21 DC (of
which 12 were pathologically confirmed) (table). CSF 14-3-3 pro-
tein detection was performed by western blot.4 BACE1 activity
was measured as an in vitro activity assay (TruPoint Assay kit;
Perkin Elmer, Finland)3 and total (nonphosphorylated and nor-
mally phosphorylated) tau protein concentration estimated by
ELISA (Innotest hTAU; Innogenetics, Belgium) according to man-
ufacturer’s instructions. BACE1 activity and total tau protein con-
centration in CSF samples were measured in duplicate. BACE1
activity (absorbance units [AU]/g CSF protein) was measured
every 10 minutes, and data were obtained at 30 minutes as this
point was in the linear phase of BACE1 activity. The median
duration of symptoms at the time of lumbar puncture for sporadic
CJD patients was 2 months, for patients with AD 18 months, and
DC 8 months.
Levels of brain BACE1 protein were determined by western
blot immunoassay.2 BACE1 protein was extracted using Trizol,
with western blot analysis performed on 20 g of total cerebral
cortical protein extract from each sample using BACE C-terminal
antibody 00/6.2 Membranes were stripped and reprobed with an
antibody to -tubulin to assess equivalence of protein loading.
Densitometric comparisons, normalized to the tubulin western
blot signal, were made using the NIH Image 1.60 software pack-
age. Brain samples from six age-matched normal controls were
obtained from the NHMRC Tissue Resource Centre (Melbourne,
Australia) and the Institute of Brain Aging and Dementia Tissue
Repository (Irvine, CA). CJD brain tissue and all CSF samples
were obtained from the ANCJDR (Melbourne, Australia).
Statistical analyses were performed using the SPSS 11.0 soft-
ware package (SPSS, Chicago, IL).
Results. Results are summarized in the table and figure.
A significant difference in both BACE1 activity and tau
protein concentration was observed between the three
patient groups (p  0.024 and p  0.0001; Kruskal–Wallis
test). Mean BACE1 activity was increased in AD vs DC
(p  0.01; Mann–Whitney U test). Unexpectedly, mean
BACE1 activity was also elevated in sporadic CJD com-
pared with DC (p  0.02; Mann–Whitney U test), with
levels comparable with those observed for the AD. Two
patients with sporadic CJD demonstrated coincidental AD
neuropathologic changes: One had BACE1 activity lying
slightly above (24,952 AU/g CSF protein) and one slightly
below (15,393 AU/g CSF protein) the mean CJD BACE1
value (19,712 AU/g CSF protein). The duration of symp-
toms at time of CSF sampling was different between the
three groups (p  0.001; Kruskal–Wallis test), specifically
for sporadic CJD and AD (p  0.0005; Mann–Whitney U
test), but not between AD and DC, showing that duration
of clinical illness at time of lumbar puncture did not deter-
mine BACE1 activity. In agreement with other studies, tau
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protein levels were highest in CJD subjects vs both AD
(p  0.0001; Mann–Whitney U test) and DC (p  0.0001;
Mann–Whitney U test), whereas no difference in tau pro-
tein was observed between the AD and DC groups (p 
0.10; Mann–Whitney U test).
Receiver operating characteristic (ROC) curve analysis
revealed that a BACE1 activity cut-off of 18,845 AU/g
CSF protein was optimal for differentiating AD from DC,
with a sensitivity of 60% and specificity of 86%. Within the
DC group, there were sufficient patients with vascular
disease/multi-infarct dementia (VD/MID; n  5) and de-
mentia with Lewy bodies (DLB; n  7) to allow subgroup
analysis. ROC curve analysis using the same optimized
cut-off (18,845 AU/g CSF protein) revealed a sensitivity
of 60% and specificity of 80% for differentiating VD/MID,
with values of 60 and 86% for DLB. For both VD/MID and
DLB, the CSF BACE1 activities of individual patients
ranged from the lowest through to the highest observed for
the entire DC group.
We also measured BACE1 protein in sporadic CJD
brain (n  6) by western blot analysis2 and compared the
levels with values from age-matched normal controls (n 
6) (not shown). Densitometry failed to reveal a difference
in brain BACE1 levels, normalized to tubulin western blot
signal, between the two groups (p  0.30; Student t test).
Insufficient frozen brain was available from DC patients to
allow meaningful comparison between the three groups,
but in a limited study, patients with AD appeared to have
the highest BACE1 levels (not shown).
Discussion. The reason for, and pathogenic rele-
vance of, the increased CSF BACE1 activity in pa-
tients with sporadic CJD is uncertain and not
intuitively predicted but is the subject of ongoing
investigation. To date, there is no evidence that
BACE1 participates in normal PrPc processing or in
the conversion process to PrPres, and in contrast to
patients with AD, BACE1 protein was not increased
in the brains of a small number of sporadic CJD
patients assessed. Based on brain neuropathologic
examination of approximately 90% of our patients
with sporadic CJD, we are confident that the ob-
served increase in CSF BACE1 activity was not due
to frequent coincidence of AD. However, previous
studies have reported decreases in CSF concentra-
tions of A1-42 in both sporadic CJD and AD when
compared with other forms of dementia and nonde-
mented controls.5,6 In combination with our findings,
these results suggest that A processing is abnormal
in CJD and may be similar to that observed in AD.
In keeping with recent admonitions concerning as-
sessments of the diagnostic utility of CSF markers
Table Tau and 14-3-3 protein levels, as well as BACE1 activity, in the CSF of patients with sporadic Creutzfeldt–Jakob disease (CJD),
Alzheimer disease (AD), and dementia control (DC)
CJD AD DC* p Value
No. of subjects 26 21 21
Gender, M/F 11/15 8/13 16/5
Mean  SEM age, y 65  2 68  3 65  2 0.52‡
BACE activity,† AU/g CSF protein 19,712 19,673 15,145 0.024‡
(12,546–33,536) (10,393–33,329) (6,738–20,166)
Tau,† pg/mL 1,751 289 249 0.0001‡
(228–4,162) (95–735) (34–1,192)
Positive for 14-3-3 protein 22§ 1 3
* The DC group consisted of: vascular disease/multi-infarct dementia (n  5); panencephalitis of uncertain cause (n  1); paraneoplastic or metastatic
cancer-associated neurologic disease (n  2); thalamic dementia (n  1); dementia with Lewy bodies (n  7); frontotemporal dementia (n  2); normal-
pressure hydrocephalus (n  1); idiopathic cerebrocerebellar degeneration (n  1); and neurologic disorders where clinical improvement occurred without
a precise diagnosis achieved (n  1). The single patient with a neuropathologic diagnosis of “thalamic dementia” showed no evidence of spongiform
change and was negative for PrPres on western blots of the thalamic and basal ganglia regions.
† Mean value of BACE1 activity and total tau protein concentration in CSF samples (ranges in parentheses). For BACE1, two sporadic CJD patients and
one AD patient had activities exceeding 40,000 absorbance units (AU)/g CSF protein, which were considered outliers, leaving 24 sporadic CJD and 20
patients with AD who were included for statistical analysis. A single sporadic CJD tau result exceeded the upper limit of the standard curve (4,200 pg/
mL) and was excluded from data analysis.
‡ Kruskal–Wallis test.
§ One weak positive result considered nonsupportive for diagnosis of CJD was omitted.
Figure. Analysis of CSF BACE1 activity in sporadic
Creutzfeldt–Jakob disease (CJD), Alzheimer disease (AD),
and dementia controls (DC). Box plot of CSF BACE1 ac-
tivity (absorbance units [AU]/g CSF protein) showing
the median, interquartile range, and extreme cases of indi-
vidual variables. A difference in CSF BACE1 activity was
observed between the three patient groups (p  0.024;
Kruskal–Wallis test). Two sporadic CJD patients and one
AD patient with BACE1 activity of approximately 40,000
AU/g CSF protein were considered outliers and were
omitted from statistical analyses.
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for dementias,7 we chose to maximize inclusion of
patients with postmortem pathologic confirmation of
their disease and selected patients manifesting de-
mentia as the comparison groups rather than age-
matched normal controls. Numerous studies have
consistently confirmed the ability of CSF markers
such as tau and A1-42 to discriminate AD from non-
demented, age-matched controls,8 whereas their abil-
ity to differentiate AD from dementias of other
causes has proven considerably more limited.9,10 Il-
lustrating this difficulty, the lack of difference in
CSF tau levels between our AD and DC cohorts most
likely reflects the inclusion in the latter group of a
number of patients with frontotemporal dementia,
DLB, and dementia on a vascular basis.9,10 Given the
ongoing development of treatments with efficacy
maximized for, or tailored to, specific dementias such
as AD, our study was aimed at what we believe to be
arguably the greater imperative, the ability to
achieve the most accurate clinical diagnosis in indi-
vidual patients presenting with established cognitive
impairment rather than differentiation of mild de-
mentia from age-matched normalcy.
From a diagnostic perspective, the partial overlap
in the ranges of CSF BACE1 activities observed in
the AD, DC, and CJD groups tends to lessen its
utility when employed in isolation for individual pa-
tients. Nevertheless, an elevated CSF BACE1 activ-
ity would assist the early diagnosis of AD, with a
specificity of at least 80% for differentiation from
other relatively common dementias such as DLB and
VD/MID. Rarely in the evaluation of suspected AD
would sporadic CJD be encountered, and in patients
manifesting more rapidly progressive cognitive de-
cline, recourse to the assessment of other surrogate
biomarkers such as tau or 14-3-3 protein levels
would probably prove useful in helping to distinguish
this type of dementia.
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Background: With respect to sporadic Creutzfeldt–Jakob disease (sCJD), six molecular subtypes
(MM1, MM2, MV1, MV2, VV1, and VV2) have been described, which vary with respect to age at
disease onset, disease duration, early symptoms, and neuropathology. MRI signal alterations
were reported to correlate with distinct Creutzfeldt–Jakob disease (CJD) subtypes. This multi-
center, international study aimed to describe the brain MRI findings associated with each of the
sCJD molecular subtypes.
Methods: Pathologically confirmed sCJD cases with codon 129 genotype (MM, MV, and VV),
PrPSc type, and fluid-attenuated inversion recovery (FLAIR) or diffusion-weighted imaging (DWI)
were collected in seven countries. All MRI scans were assessed for signal changes according to a
standard protocol encompassing seven cortical regions, basal ganglia, thalamus, and cerebellum.
Results: MRI scans were evaluated in 211 CJD patients (98 MM1, 23 MM2, 19 MV1, 30 MV2, 9
VV1, and 32 VV2). Basal ganglia hyperintensities occurred most frequently in MV2, VV2, and
MM1 subtypes (79, 77, and 70%). Wide cerebral cortical signal increase was most common in
VV1, MM2, and MV1 subtypes (86, 77, and 77%). Thalamic hyperintensities occurred most
often in VV2 (45%) and MV2 (43%). The most consistent finding across most subtypes was high
signal in basal ganglia, with these abnormalities found in 63% (FLAIR) and 71% (DWI).
Conclusion: Cortical signal increase and hyperintensities in the basal ganglia and thalamus are
detected by MRI across all molecular sporadic Creutzfeldt–Jakob disease subtypes. Our find-
ings argue that characteristic MRI lesion patterns may occur for each molecular subtype.
Neurology® 2009;72:1994–2001
GLOSSARY
AL  anterolateral; AUC  area under the receiver operating characteristic curve; BG  basal ganglia; CI  confidence
interval; CJD  Creutzfeldt–Jakob disease; DWI  diffusion-weighted imaging; FLAIR  fluid-attenuated inversion recovery;
MD  mediodorsal; OR  odds ratio; ROC  receiver operating characteristic; sCJD  sporadic Creutzfeldt–Jakob disease.
MRI has played a role in the diagnosis of sporadic Creutzfeldt–Jakob disease (sCJD) for many
years, and various signal abnormalities have been reported.1-5
Heterogeneity in sCJD correlates with the codon 129 genotype of the prion protein gene
(PRNP) in combination with the existence either of two distinct types of pathologic prion
protein (PrPSc 1 or 2). Based on these variables, six sCJD subtypes (MM1, MM2, MV1, MV2,
VV1, and VV2) have been defined, and variations in the sensitivities of diagnostic tests for the
different subtypes have been reported.6-11
Although there is now considerable experience with the use of MRI in sCJD, findings in
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are that characteristic MRI lesion patterns
may correspond to a specific Creutzfeldt–
Jakob disease (CJD) subtype.
To address this issue, we undertook a mul-
ticenter, international collaborative study to
describe the MRI lesion patterns across the
entire clinical spectrum of sCJD. All subjects
included in the study had undergone MRI us-
ing the most sensitive pulse sequences, with
systematic regional brain assessment for ab-
normal signal changes.
METHODS Patients. Cases were included from seven coun-
tries (United Kingdom, France, Italy, Belgium, Germany, Can-
ada, and Australia) according to the following criteria:
1. CJD diagnosis confirmed by brain pathology (definite cases)
2. Molecular subtype determined by codon 129 genotyping
(MM, MV, or VV) and Western blot analysis of brain PrPSc
type (1 or 2) (corresponding to MM1, MM2, MV1, MV2,
VV1, or VV2 subtype) and3 fluid-attenuated inversion recov-
ery (FLAIR) or diffusion-weighted imaging (DWI) MRI of
the brain available
All three criteria had to be fulfilled in each case. Genetic CJD
(causal mutations found in PRNP), iatrogenic, and variant CJD
cases were excluded.
Information on CSF (14-3-3 protein) and EEG (periodic
sharp wave complex) findings was acquired and data are displayed in
table e-1 on the Neurology® Web site at www.neurology.org. EEGs
were reviewed by a member of the national surveillance and
scored positive according to the criteria.16 The CSF 14-3-3
immunoassays were performed using Western blotting (con-
formity of testing methods and results interpretation con-
firmed by blinded sample exchange program as reported
previously).17
The study comprised 211 patients who died between March
1996 and February 2006: 92 (44%) from Germany, 38 (18%)
from the United Kingdom, 34 (16%) from Italy, 17 (8%) from
Australia, 15 (7%) from Belgium, 9 (4%) from Canada, and 6
(3%) from France. In 8 patients, mixed PrPSc types were de-
tected, and they were excluded from the article. According to the
study goal of characterizing the single subtypes by MRI, the in-
clusion of MM1 patients as most frequent molecular type was
stopped toward the end of the study because of sufficient patient
numbers.
Molecular subtype classification was performed as published
previously,6 determined by the combination of the codon 129
genotype of the PRNP (MM, MV, or VV) and the pathologic
isotype of the prion protein (PrPSc 1 or 2).
The PrPSc typing was performed according to standard
methods.7 The number of examined brain regions usually in-
cluded the cerebral cortex, basal ganglia or thalamus, and cere-
bellum.8 Codon 129 status was determined either as part of
genotyping of the entire PRNP open reading frame or by restric-
tion fragment length polymorphism analysis.8
MRI data. The magnetic resonance images were acquired at
local sites and obtained from scanners of different manufacturers
and of different magnetic field strengths of 0.5 to 3 tesla (mainly
1.5 tesla).
The majority of the scans were available as hard copy. If
serial MRIs were available, the first examination was used for the
analysis. The scans were assessed for hyperintense signal abnor-
malities by neuroradiologists (K.K., P.S., and D.C.) aware of the
CJD suspicion but not aware of the molecular subtype. The
scans were reviewed by each radiologist individually. All scans
were assessed by a neuroradiologist (K. K.) aware of the suspicion
of sCJD but not aware of the diagnosis or the molecular subtype.
Two further neuroradiologists (P.S. and D.C.) assessed two
separate MRI series for the estimation of the interobserver agree-
ment. With the three raters’ results, we calculated 1) the percent-
age of concordant results and 2) the  statistic, which compares
the agreement against that which might be expected by chance.
Interobserver agreement was moderate between raters 1 and 2
(concordance 76%,   0.45, p  0.001) and high between
raters 1 and 3 (concordance 82%,   0.62, p  0.001). In rare
cases with discrepant findings, a consensus between three radiol-
ogists was sought. A standardized protocol including seven cere-
bral cortex regions (frontal, parietal, temporal, occipital,
cingulate gyrus, insula, and hippocampus), basal ganglia (cau-
date nucleus, putamen, and globus pallidus), thalamus (antero-
lateral nuclei, mediodorsal nuclei, and pulvinar), and cerebellar
cortex was used.18 For the thalamus, the presence of a pulvinar
sign or hockey stick sign was also rated.19 The quality of the
complete MRI examination was graded from 1 to 6 (1  excel-
lent, 6  poor). Scans graded higher than 4 were excluded from
the study (n  6); no later scans were available in these patients.
Statistical analysis. To describe different sCJD MRI pat-
terns, we aimed to select the best radiologic features for molecu-
lar subtype discrimination. We considered a brain region as
affected when a high signal was found in either FLAIR or DWI
MRI sequences.
General data analysis. For the radiologic features selected, we
compared the proportion of patients with a high signal in each
studied region against that same proportion in the rest of pa-
tients not belonging to that particular subtype, and so on for the
six subtypes. Therefore, to test how well the radiologic feature
discriminated each particular subtype, we used six dichotomous
outputs (MM1 vs all others, MM2 vs all others, MV1 vs all
others, MV2 vs all others, VV1 vs all others, and VV2 vs all
others) to fit six binary logistic regression models. Odds ratios
(ORs) were calculated from the logistic regression analyses. First,
we performed univariate or crude analysis showing the increase
or decrease in odds of the subtype-specific diagnosis when each
of the radiologic signs were present. Secondly, we performed
hierarchical cluster analysis to gain more insight about the rela-
tionships among the different radiologic signs. We specifically
were interested to know which radiologic signs grouped together
and therefore tended to appear simultaneously in the same pa-
tients. The hierarchical cluster analysis is an exploratory proce-
dure useful for finding natural groupings and discovering hidden
structures in data. The basic criterion for any clustering is dis-
tance. Objects that are near each other should belong to the same
cluster, and objects that are far from each other should belong to
different clusters. We performed cluster analysis using the overall
sample of sCJD MRI scans. Because our main interest was to
examine relationships between the different radiologic signs, the
objects clustered in our analysis were the brain MRI variables
(regions assessed in the MRI scans), which were all categorical
(high signal [yes/no]), and the study subjects were treated as the
variables of the analysis. We selected between-groups average
linkage as the clustering method for our analysis, and simple
matching coefficient as the measure of distance between vari-
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ables. The information resulting from the cluster analysis helped
us to establish, independently of the molecular subtype of the
patients, which signs could be pooled into composite variables;
e.g., all thalamic nuclei were in the same cluster, so we subse-
quently used “any thalamic nuclei affected” as a new variable to
test for molecular subtype discrimination (figure e-1). Clusters of
variables were pooled to form composite variables when at least
one of the variables included was significantly associated with
subtype discrimination in the crude analysis.
We chose the following radiologic signs as sCJD subtype
predictors: 1) more than three cerebral cortical regions affected,
2) hippocampus affected, 3) any basal ganglia affected, 4) any
thalamic nuclei affected, and 5) cerebellum affected. Multivari-
ate analysis including the five selected predictors was performed,
for each disease subtype (yes/no) separately, to assess them inde-
pendently of each other.
PrPSc type predictive model. We built a PrPSc type predic-
tive model including, together with the MRI data, PRNP codon
129 genotype, and clinical information. The objective of this
analysis was to assess which of these variables better predicted the
type of PrPSc (1 or 2). We fitted a logistic regression model using
the overall sample of sCJD MRI scans. The variable PrPSc type
(1or 2) was the model’s output, and the same five MRI variables
plus age at onset, disease duration, CSF, and EEG results were
included as predictors. We also included sex as a covariate. A
second PrPSc type predictive model was fitted including codon
129 PRNP genotype information as well. The performance of
both models, clinical and clinical plus genetic, were evaluated by
receiver operating characteristic (ROC) curves. We calculated
the area under the ROC curve by the nonparametric method
implemented in SPSS version 15.0 for Windows software.
Ethics. Approvals by local ethical standard committees were
obtained by each national CJD surveillance unit in participating
countries.
RESULTS Patients. Patient characteristics according
to CJD subtype are shown in table e-1.
MRI findings. For all patients, MRI was performed a
median of 3.1 months (range 0–55.3 months) from
the onset of symptoms, corresponding to the second
third of the whole disease duration in the majority of
patients (table e-1). The spectrum of available se-
quences comprised 174 FLAIR and 113 DWI (dis-
tribution of grades given in table e-1).
Basal ganglia signal increase was found in 71%
(DWI) and 63% (FLAIR) of all patients. Wide-
spread signal increase of the cerebral cortex (more
than three regions affected) was found in 66%
(DWI) and 38% (FLAIR) of all patients (table e-1).
MRI findings in sCJD subtypes. DWI detected a
higher percentage of signal alterations than FLAIR.
The frequency of hyperintensities observed for each
subtype on DWI images is given in table e-2.
For MM homozygotes, the frontal and parietal
lobes signal changes were frequent, but in MM2 sub-
jects, the signal increase was more widespread,
commonly including the temporal lobes and hip-
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and cingulate gyri were most affected. However, in
the MV1 subtype, high rates of signal increase were
found in the insular cortex, whereas in MV2 sub-
jects, cerebellar signal increase was observed more fre-
quently in DWI. The cingulate gyri were the most
frequently affected cerebral cortex region in the VV2
subtype. In VV1 subjects, DWI studies were limited,
but FLAIR revealed a higher frequency of hyperinten-
sity in the parietotemporal lobes and particularly the
insular cortex (71% vs 14%) compared with VV2 cases.
Crude analysis and cluster analysis of the raw data.
Based on the ORs and p values obtained by crude
analysis (table 1) and hierarchical cluster analysis of
MRI findings across the spectrum of subtypes, five
MRI criteria were selected as most suitable variables
for discrimination between the subtypes:
1. Cortex: widespread involvement (including more
than three cortex regions)
2. Hippocampus region affected
3. Basal ganglia affected (caudate nucleus or putamen)
4. Thalamus affected (any of the three nuclei)
5. Cerebellar cortex affected
The five selected variables were included in a logistic
regression model for multivariate analysis. Table 2
shows whether the presence (OR 1.0) or absence
(OR 1.0) of the MRI finding was significantly re-
lated to one of the subtypes.
Detailed analysis of individual subtypes. MRI exam-
ples showing characteristic findings of the subtypes
are given in figure 1. The percentages and p values
used for the characterization of the subtypes are dis-
played in tables 1 and 2 and figure 2.
MM1. Basal ganglia signal increase was frequent in
the MM1 subtype, and cerebral cortex involvement
was widespread in half the patients. The frontal
lobes, parietal lobes, and cingulate gyri were most
frequently affected (table e-2). The absence of hip-
pocampal and thalamic signal increase differentiated
this subtype from others.
MM2. No patient was classified as MM2-thalamic
through neuropathologic examination (in 13 of the
23 MM2 patients, no thalamic and brain stem mate-
rial was available). Because MM2-thalamic types
have been previously described as showing no signal
alterations on the MRI,20 we examined the MM2
group for MRI negative cases: all MM2 patients were
found to have signal abnormalities on all available
sequences, making MM2-thalamic less likely.
Figure 1 Characteristic MRI findings in sporadic Creutzfeldt–Jakob disease (sCJD) subtypes
Diffusion-weighted images of six sCJD patients with various molecular subtypes showing basal ganglia signal increase and
signal increase in the frontal, temporal, and insular cortex (MM1); predominant cortical signal increase in the frontal and
parietal lobes (MV1); cortical hyperintensities in the cingulate gyrus, insular cortex, and hippocampus (VV1); basal ganglia
and widespread cortical hyperintensities (MM2); predominant signal increase in the basal ganglia and thalamus (MV2); and
predominant basal ganglia signal increase and signal increase in the cingulate gyrus (VV2). The MV1 image was published in
Am J Neuroradiol 2008;29:1519 –1524 (© 2008 American Society of Neuroradiology; reprinted with permission).22 The
VV1 image was published in Neurology 2005;65:1544 –1550 (© 2005 AAN Enterprises, Inc.; reprinted with permission).15
The MV2 image was published in Am J Neuroradiol 2006;27:1459 –1462 (© 2006 American Society of Neuroradiology;
reprinted with permission).23
1998 Neurology 72 June 9, 2009
Widespread cortical signal increase, which typi-
cally included the temporal lobes, was characteristic
of this subtype. Basal ganglia involvement was rather
limited, and the absence of this finding supported
the diagnosis. In contrast to MM1 patients, thalamic
signal increase and cerebellar signal increase occurred
more frequently in MM2 types.
MV1. In MV1 patients, cerebral cortex and basal
ganglia were both involved often. The cortical signal
increase typically included the insula and the
hippocampus.
MV2. The basal ganglia and the thalamus were char-
acteristically affected in the MV2 subtype. Thalamic
signal increase was most frequently observed in the
pulvinar, followed by the mediodorsal nuclei and the
anterolateral nuclei. A pulvinar sign was present in three
patients, with a hockey stick sign in one. The cerebral
cortex involvement was rather limited and most fre-
quently included the frontal lobes and cingulate gyri.
VV1. The VV1 subtype showed the most frequent
cerebral cortical signal changes, with the most af-
fected cortex region being the cingulate gyri, fol-
lowed by the insula and the temporal lobes (tables 1
and 2). Basal ganglia or thalamic signal increase was
typically absent.
VV2. Across all molecular subtypes, VV2 patients
showed the most frequent involvement of basal gan-
glia and thalamus. Cerebral cortical signal increase
was usually restricted to less than three regions and
most frequently found in the cingulate gyrus (tables
1 and 2).
Predictor analysis. Limited cerebral cortical hyperin-
tensities and the presence of thalamic hyperintensi-
ties were significantly related to PrPSc type 2 (table 3)
as well as valine homozygosity at codon 129, age at
onset, and prolonged disease duration.
DISCUSSION This multicenter collaborative study
has determined the brain MRI findings in a large
number of cases of sCJD with defined molecular
subtype according to the codon 129 genotype and
PrPSc type. Although basal ganglia hyperintensities
on the MRI represented a consistent finding in all
subtypes except VV1, the frequency and location of
cortex hyperintensities as well as the presence or ab-
sence of thalamus involvement varied between the
subtypes.
The most characteristic MRI lesion patterns were
found in MV2 and VV2 showing predominant in-
volvement of thalamus and basal ganglia. Limited
cortical signal increase was significantly related to
PrPSc type 2. A further possible characteristic lesion
pattern was found in VV1 showing widespread corti-
cal hyperintensities and absence of basal ganglia sig-
nal alterations. In the other subtypes, there was a
greater overlap between cortical and subcortical
involvement.
In MV2, we found less basal ganglia and thalamic
involvement than previously reported.5 This discrep-
ancy may be based on the use of only the first MRI
study images in our study and differences in the pa-
tient case-mix. The pulvinar sign according to cur-
rent criteria was identified in the MV2 subtype
only.19 Because of the generally high frequency of
Figure 2 MRI lesion patterns in MM1 and MM2, MV1 and MV2, and VV1 and VV2
*As seen in fluid-attenuated inversion recovery or diffusion-weighted imaging.
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thalamic hyperintensities in MV2, this subtype is the
most likely to be mistaken for variant CJD on MRI.
MRI findings in the VV2 subtype have been re-
ported previously in three cases, demonstrating lim-
ited cerebral cortex involvement associated with
strong subcortical signal increase.14,21 Consistent
with this, we found widespread thalamic involve-
ment in our VV2 patients, with a high degree of the
involvement of the mediodorsal and anterolateral
thalamic nuclei.
VV1 and MM2-cortical subtypes have been pre-
viously described as atypical CJD variants because of
longer disease durations with relatively slowly pro-
gressive dementia and absence of typical EEG
changes. For VV1, basal ganglia hyperintensities are
rare,15 and in MM2-cortical, isolated cerebral cortex
involvement with limited basal ganglia involvement
is characteristic, although normal MRI scans have
been reported.12,13 In our study, 10 patients were
classified as MM2-cortical, and widespread cortical
signal increase represented the main characteristic.
Patients with MM1 and MM2 types, basal gan-
glia and widespread cortex involvement were found
in at least 50% of both patient groups, leading to a
high overlap. However, hippocampus involvement
was more frequently found in MM2-cortical and was
typically absent in MM1.
Previously, the overlap in clinical and neuro-
pathologic findings in some studies has prompted
that MM1 and MV1 patients should be combined as
one phenotype,6 although significant differences in
investigation findings and clinical features have been
noted between these two subtypes.8 Our study offers
additional evidence that MM1 and MV1 might be
considered as separate subtypes, by showing that
MRI lesion profiles differ, with MV1 showing more
frequent cortical and thalamic involvement.
For the premortem diagnostic evaluation, charac-
teristic brain MRI lesion patterns might be helpful in
establishing a diagnosis of sCJD and may help to
identify atypical sporadic disease forms.
Summarizing our data, basal ganglia and cortical
hyperintensities (limited or widespread) represent
the most frequent MRI finding in CJD and are most
typically found in MM1 subjects with a rapid disease
course but also in MV1 individuals. In MM2, the
disease course is more prolonged and widespread cor-
tical hyperintensity on the MRI represents the pre-
dominant finding. Finally, predominant subcortical
signal increase with limited cortical hyperintensities
(mainly in the cingulate gyrus) was seen in the MV2
or VV2 type of CJD.
This is the most comprehensive study on MRI
findings in sCJD to date and, in combination with
previous studies, provides firm evidence of the high
sensitivity of brain MRI in the diagnosis of sCJD.
Some hyperintensity patterns, such as involvement of
more than three cortical areas and hyperintensities in
the basal ganglia, should be further evaluated and
discussed as potential parameters for inclusion into
diagnostic clinical criteria.
Because we intended to study lesion patterns on
the MRI in different disease subtypes, no control
group was included. MRI changes are frequent, and
knowledge about different patterns may help to rec-
ognize specifically atypical disease variants.
Nevertheless, with acknowledgment that MRI
changes in sCJD differ across the subtypes and are
only a surrogate disease marker, any proposed diag-
nostic criteria will need to be rigorously validated
with respect to sensitivity and specificity in a cohort
of patients presenting the differential diagnosis of
rapidly progressive dementia.
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di Sanità (S.A., V.M.), Department of Cell Biology and Neurosciences,
Rome, Italy; Australian National Creutzfeldt-Jakob Disease Registry
(S.J.C., H.R.), Department of Pathology, the University of Melbourne,
Parkville, Australia; Mercy Private Radiology (P.S.), East Melbourne,
Australia; Laboratory of Neurobiology (P.C., B.V.E.), Department of
Neurology, Born Bunge Institute, University of Antwerp, Belgium;
Creutzfeldt-Jakob Disease Surveillance System (G.H.J., M.B.C.), Prion
Diseases Program, Public Health Agency of Canada, Ottawa, Canada;
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Objective: Brain amyloid imaging using positron emission
tomography (PET) is of increasing importance in the
premortem evaluation of dementias, particularly in relation
to Alzheimer disease (AD). The purpose of this study was
to explore the premortem diagnostic utility of 11C-PiB PET
in sporadic Creutzfeldt–Jakob disease (CJD).
Methods: Two patients, 72 and 59 years old, underwent
evaluation for rapidly progressive cognitive decline, dying
after illness durations of 5 and 7 months, respectively. As
part of their comprehensive assessment, 18F-FDG PET and
11C-PiB PET studies were performed approximately 2–
4 weeks prior to death, and the brain regional distribu-
tions compared with those from cohorts of healthy
controls (HC) and AD patients.
Results: Routine investigations, including brain MRI
scans, revealed changes typical of sporadic CJD, with the
diagnosis confirmed at autopsy in both patients. The 18F-
FDG PET showed global hypometabolism in one patient
and thalamic and frontal hypometabolism with unex-
pected hypermetabolism in the dentate nuclei of the
cerebellum in the other. Neither patient displayed cerebral
cortical 11C-PiB PET retention above the levels observed in
HC.
Conclusions: No grey-matter 11C-PiB retention was
observed in two pathologically confirmed cases of typical
sporadic CJD. We speculate that low PrP plaque density
and small plaque size, as well as a relatively low affinity of
the radioligand, explain the absence of 11C-PiB retention.
More studies to validate this hypothesis are warranted.
The spectrum of transmissible human prion
disease, characterised by the presence within the
CNS of conformationally altered, protease-resis-
tant isomers (PrPres) of the normal cellular form of
the prion protein, PrPc,1 2 encompasses
Creutzfeldt–Jakob disease, the variant form
(vCJD) associated with bovine spongiform ence-
phalopathy, kuru and Gerstmann–Straussler–
Scheinker syndrome (GSS).3 4 Despite considerable
improvement in diagnostic accuracy through the
use of CSF biomarker assays5 and brain MRI,6 the
search for additional diagnostic techniques con-
tinues. Neuropathological examination of brain
tissue remains the only definitive method for
diagnostic confirmation.
11C-2-(49-methylamino-phenyl)-6-hydroxy-ben-
zothiazole (11C-PiB) has a high affinity for Ab
fibrils, allowing in vivo quantification of amyloid
deposits in the brain. There is a high correlation
between 11C-PiB retention and Ab concentrations
assessed at postmortem or brain biopsy.7–9 Several
commonly used neuropathological dyes have been
shown to stain prion plaques. Thioflavin T (ThT),
its derivative, 2-(49-methylamino-phenyl)-ben-
zothiazole (BTA-1),10 11 and the Congo Red deriva-
tives BSB10 12 and X0413 bind in vitro and in vivo to
PrPres in mouse and human prion-diseased brains.
To date, however, the use of positron emission
tomography (PET) in the diagnosis of sporadic CJD
has been mainly centred in assessing glucose
metabolism with 18F-FDG.14 15 A previous case
report of two siblings with the same prion protein
gene (PRNP) mutation described differential bind-
ing of two PET amyloid imaging agents (11C-PiB
and 18F-FDDNP).16 Acknowledging that both ThT
and its derivative, BTA-1, bind to PrP plaques, we
explored the diagnostic utility of 11C-PiB in two




PET studies were approved by the Austin Health
Human Research Ethics Committee. Written
informed consent was obtained from the appro-
priate next of kin prior to the scans. A 40–70 min
emission acquisition was performed after injection
of 370 MBq of 11C-PiB. Ten minutes after comple-
tion of the 11C-PiB study, patients were injected
with 185 MBq of 18F-FDG. Forty minutes later, a
20 min emission scan was acquired. Standardised
uptake values (SUV) were obtained from regions of
interest across cortical, subcortical and cerebellar
regions. Acknowledging that PrP plaques are
frequently found in the cerebellar cortex,17 11C-PiB
and 18F-FDG SUV ratios were determined by
normalising the regional SUV to the pons
(SUVRpons). Regional distributions of each radi-
oligand were compared against well-characterised
cohorts of HC and AD patients.
Neuropathological examination and
immunohistochemical detection of PrPres
Brain sections were treated with formic acid prior
to formalin fixation and processing.
Immunostaining for Ab was performed with the
1E8 (1:50) monoclonal antibody, and for PrP with
the 3F4 (1:1000, Covance) and 12F10 (1:2000,
Cayman Chemical) antiprion protein monoclonal
antibodies.18
Determination of prion protein gene codon 129
status and PrPres molecular subtype
Determination of whether the patient was methio-
nine (M) or valine (V) homozygous or MV
heterozygous at codon 129 of the prion protein
gene and characterisation of the PrPres molecular
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subtype by western blot profile were performed as previously
described.18
Statistical evaluations
Statistical analysis was performed through Z scores generated
against 11C-PiB and 18F-FDG regional SUVRpons from cohorts of




Patient 1, a 59-year-old female, initially presented reporting
3 months of dizziness, gait unsteadiness and hearing difficulties,
superimposed on a history of longstanding tinnitus and vertigo.
MRI brain and ENT specialist review prior to neurological
evaluation had not disclosed any abnormalities. One month
later, the patient presented with increasing hearing disturbance
manifesting as difficulty discerning words in conversation.
Emotional lability, poor short-term memory, word-finding
difficulties and prominent ataxia of gait were also evident.
Brain MRI, including T1, T2-weighted, diffusion-weighted
(DWI) and fast fluid-attenuated inversion recovery (FLAIR)
acquisition sequences, reported non-specific small-vessel ischae-
mic changes. CSF examination was unremarkable aside a raised
total protein, and presence of 14-3-3 protein. EEG displayed
generalised slowing but no triphasic waves or periodic dis-
charges. Six months after initial neurological evaluation, the
patient was unable to hold a conversation or reliably name
immediate family members, requiring assistance with feeding,
standing and ambulating. There was a coarse postural tremor in
the upper limbs. Repeat brain MRI revealed restricted diffusion
and T2 hyperintensity in the left and right caudate nuclei and
dorsomedial and pulvinar thalamic regions, with small foci of
restricted diffusion in the left posterior temporal, left frontal
and both occipital cortices. The patient died from respiratory
difficulties approximately 7 months after initial neurological
presentation. No definite myoclonus was ever observed.
Codon 129 genotyping revealed MV heterozygosity, and the
PrPres western blot profile was type 3 (MV3).
PET imaging studies
Visually, the 18F-FDG scan showed hypometabolism of the
thalami and frontal cortices, with hypermetabolism in the
dentate nuclei of the cerebellum (see supplementary fig 1).
There was no cerebral cortical or subcortical 11C-PiB retention
(table 1) with the findings indistinguishable from HC (fig 1).
Neuropathology
Macroscopic examination of the brain was unremarkable.
Microscopic examination showed neuronal loss, gliosis and a
spongiform encephalopathy. No Ab plaques were observed.
There was a fine ‘‘synaptic’’ pattern of PrP immunoreactivity in
the corresponding areas with focal areas of granular PrP
deposition (fig 1). A neuropathological diagnosis of CJD was
made.
Case report 2
Patient 2, a 72-year-old female, was investigated for 4 months of
progressive neurological decline. On hospital admission, dysar-
thria with limited speech output and reduced motor activity
with shuffling gait, but no focal neurological signs nor
myoclonus were observed. Brain MRI revealed increased signal
in the left head of caudate nucleus on both FLAIR and DWI
sequences, not present on a previous MRI 2 months earlier. CSF
examination was unremarkable aside from detection of 14-3-3
proteins, while EEG demonstrated a generally slowed back-
ground with intermittent periodic sharp wave activity. The
patient’s neurological condition inexorably declined, developing
myoclonus and fluctuating consciousness, dying in an akinetic-
mute state approximately 1 month after entering hospital.
Codon 129 genotyping revealed methionine homozygosity,
and the PrPres western blot profile was type 2 (MM2).
PET imaging studies
Visually, the 18F-FDG scan showed global hypometabolism,
more marked in the left frontal and left temporal cortices (see
supplementary fig 1). There was no cerebral cortical or
subcortical 11C-PiB retention, (table 1) with the findings
indistinguishable from HC (fig 1).
Neuropathology
External examination of the brain was unremarkable.
Microscopic examination showed neuronal loss, gliosis and a
spongiform encephalopathy. Occasional (+) Ab diffuse plaques
were observed in the frontal section. 12F10 immunoperoxidase
studies demonstrated a ‘‘synaptic’’ pattern of PrP deposition,
scattered small granular concentrations of PrP in and around
vacuoles in the cortex (fig 1) but no plaque deposition. 3F4
immunohistochemistry additionally showed small plaque-like
PrP deposits within the underlying white matter in frontal
cortical sections and small granular plaques in the thalamus.
There was also quite prominent granular PrP deposition in the
midbrain neuronal areas. A neuropathological diagnosis of CJD
was made.
DISCUSSION
To the best of our knowledge, this is the first report of 11C-PiB
PET imaging in patients with confirmed sporadic CJD.
Although previous studies have shown in vitro and in vivo
binding of BTA-1 (the cognate parent compound of PiB) to PrP
plaques, we found no significant brain retention of 11C-PiB in
our patients. Our observations are in broad agreement with the
findings of a study assessing 11C-PiB in siblings carrying a PRNP
mutation.16
This lack of 11C-PiB binding might be attributed to PrP-plaque
size and density within the brain. Due to the rapid progression
and relatively short duration of symptomatic illness, sporadic
CJD patients do not demonstrate appreciable PrP-plaque
deposition at autopsy, where a positive correlation has been
reported between illness duration and PrP-plaque density.19
Although some sporadic CJD molecular subtypes can manifest
larger kuru-type plaques,20 the most common subtype (MM2, as
in Patient 2) usually demonstrates only very fine ‘‘synaptic’’ and
small perivacuolar deposits.19 20 Among the various molecular
subtypes, MV3 commonly demonstrates PrP plaques, especially
in the cerebellum.20 The lack of detectable 11C-PiB binding in our
patients also concurs with a previous in vitro study of various
forms of human prion disease, which only found BTA-1 binding
to larger PrP plaques and not to smaller synaptic-type deposits.20
It appears possible that a certain threshold of plaque size and/or
density may be required before appreciable 11C-PiB retention can
be detected in vivo using PET. This is also highlighted by the
presence of some Ab diffuse plaques in Patient 2. While there is
a positive correlation between Ab burden as quantified by 11C-
PiB PET and brain Ab at post-mortem or biopsy,7 8 one patient
with a high number of Ab plaques presented with a 11C-PiB
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negative PET scan,9 highlighting the possibility that there might
be certain conformational types of amyloid plaques that 11C-PiB
does not detect in vivo.
The lack of 11C-PiB retention may also relate in part to
reduced blood flow or to the relative affinities of 11C-PiB for
the protein deposits at the concentrations achieved during
PET studies. Despite almost identical PiB-negative scans, the
respective 18F-FDG scans were quite distinct, suggesting blood
flow was unlikely to constitute a significant determinant
factor in 11C-PiB binding. In vitro studies demonstrating
binding of BTA-1 to PrP plaques were performed using 1 mM
BTA-1, while infected mice were injected with 10–30 mg/kg
of BTA-1.10 These concentrations and doses are significantly
greater than the low nanomolar range achieved in the brains
after 0.00006–0.00007 mg/kg is injected into humans for a
11C-PiB PET study. Hence, it is likely that the relatively low
affinity of 11C-PiB for aggregated PrP is translated in
insufficient 11C-PiB concentrations to adequately label PrP
plaques in vivo. This concurs with studies showing that
despite their secondary b-sheet structure, 11C-PiB does not
bind to other misfolded proteins at the concentrations
achieved during PET studies.21 22
Figure 1 Immunohistochemical detection and positron emission tomography imaging of PrP deposits in sporadic CJD and Ab plaques in Dementia
with Lewy Bodies (DLB). The DLB subject was a 78-year-old man with a Mini-Mental State Examination (MMSE) 19 and Clinical Dementia Rating 2.0
who fulfilled criteria for DLB. Cerebral cortical (A and C, respectively) and cerebellar (B and D, respectively) sections from sporadic CJD Patients 1 and 2
were immunostained for PrP (3F4 antibody). Cerebral cortical (E) and cerebellar (F) sections from a patient with DLB were immunostained for Ab (1E8
antibody). Respective 11C-PiB transaxial PET images at the level of the basal ganglia (left column) and cerebellum (right column) of sporadic CJD Patient
1 (I and II, respectively), sporadic CJD Patient 2 (III and IV, respectively) and DLB patient (V and VI, respectively). There is a notable difference in the
plaque size and density observed in sporadic CJD compared with DLB, which probably explains the lack of 11C-PiB retention in the CJD patients.
Conversely, no Ab deposits were detected in the cerebellar cortex of the DLB patient, while PrP deposits were observed in the cerebellar cortex of both
CJD patients, with absence of 11C-PiB retention in the cerebellar cortex further underscoring the lack of 11C-PiB binding to PrP deposits. Magnification:
620 (A–F).
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In conclusion, our observations suggest there might be a
limited diagnostic role for 11C-PiB PET in the clinical evaluation
of sporadic CJD, but it remains possible that other forms of
human prion disease, such as GSS, vCJD and some sporadic CJD
subtypes with higher burdens of larger PrP plaques may
demonstrate significant binding of 11C-PiB. More studies to
validate these hypotheses are warranted.
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Table 1 Regional SUVRpons for
11C-PiB positron emission tomography and 18F-FDG positron emission tomography studies
11C-PiB 18F-FDG
Patient 1 Patient 2 HC (n = 60) AD (n = 60) Patient 1 Patient 2 HC (n = 25) AD (n = 30)
Age/mean age, years (SD) 59 72 72 (7) 73 (10) 59 72 73 (9) 75 (9)
Region of interest
Dorsolateral prefrontal 0.50{ 0.43{ 0.53 (0.07) 1.17 (0.24) 0.96 0.50*{ 1.37 (0.23) 1.15 (0.17)
Ventrolateral prefrontal 0.44{ 0.45{ 0.58 (0.09) 1.29 (0.22) 0.97 0.44*{ 1.43 (0.27) 1.21 (0.17)
Orbitofrontal 0.46{ 0.45{ 0.59 (0.08) 1.27 (0.21) 0.97* 0.46*{ 1.42 (0.19) 1.22 (0.15)
Gyrus rectus 0.51{ 0.51{ 0.63 (0.09) 1.36 (0.25) 1.12 0.51*{ 1.37 (0.15) 1.24 (0.12)
Somatosensory 0.51 0.46{ 0.55 (0.07) 0.95 (0.19) 1.21 0.51*{ 1.33 (0.18) 1.23 (0.18)
Posterior cingulate 0.53{ 0.48{ 0.59 (0.07) 1.35 (0.21) 1.24 0.53*{ 1.61 (0.19) 1.25 (0.19)
Anterior cingulate 0.54{ 0.47{ 0.58 (0.08) 1.27 (0.20) 0.99 0.54*{ 1.36 (0.17) 1.17 (0.14)
Parietal cortex 0.51{ 0.40{ 0.53 (0.07) 1.15 (0.20) 1.11 0.51* 1.36 (0.25) 1.08 (0.24)
Temporal cortex 0.50{ 0.49{ 0.59 (0.08) 1.20 (0.21) 1.12 0.50*{ 1.37 (0.14) 1.09 (0.17)
Occipital cortex 0.53 0.43 0.65 (0.07) 0.99 (0.21) 1.13 0.53*{ 1.44 (0.24) 1.23 (0.21)
Mesial temporal 0.58 0.54{ 0.60 (0.07) 0.82 (0.11) 1.03 0.58*{ 1.04 (0.14) 0.95 (0.11)
Caudate nucleus 0.59{ 0.56{ 0.62 (0.08) 1.36 (0.24) 1.32 0.59*{ 1.59 (0.21) 1.47 (0.19)
Putamen 0.63{ 0.56 0.62 (0.06) 1.16 (0.19) 1.31 0.63*{ 1.65 (0.15) 1.57 (0.15)
Thalamus 0.74 0.60 0.66 (0.09) 0.97 (0.16) 1.03*{ 0.74*{ 1.68 (0.13) 1.49 (0.13)
Midbrain 0.87 0.82 0.89 (0.09) 0.94 (0.08) 1.04 0.87* 1.25 (0.13) 1.16 (0.14)
White matter 0.87 0.86 0.87 (0.09) 0.93 (0.11) 0.62 0.87{ 0.62 (0.12) 0.52 (0.09)
Cerebellum 0.49 0.37{ 0.48 (0.06) 0.52 (0.08) 1.23 0.49*{ 1.32 (0.17) 1.26 (0.15)
*Significantly different from healthy controls (HC) (Z scores .¡2.5).
{Significantly different from Alzheimer disease (AD) (Z scores .¡2.5).
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Several molecular subtypes of sporadic Creutzfeldt–Jakob disease have been identified and electroencephalogram and cere-
brospinal fluid biomarkers have been reported to support clinical diagnosis but with variable utility according to subtype.
In recent years, a series of publications have demonstrated a potentially important role for magnetic resonance imaging in
the pre-mortem diagnosis of sporadic Creutzfeldt–Jakob disease. Magnetic resonance imaging signal alterations correlate with
distinct sporadic Creutzfeldt–Jakob disease molecular subtypes and thus might contribute to the earlier identification of the
whole spectrum of sporadic Creutzfeldt–Jakob disease cases. This multi-centre international study aimed to provide a rationale
for the amendment of the clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Patients with sporadic Creutzfeldt–
Jakob disease and fluid attenuated inversion recovery or diffusion-weight imaging were recruited from 12 countries. Patients
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referred as ‘suspected sporadic Creutzfeldt–Jakob disease’ but with an alternative diagnosis after thorough follow up, were
analysed as controls. All magnetic resonance imaging scans were assessed for signal changes according to a standard protocol
encompassing seven cortical regions, basal ganglia, thalamus and cerebellum. Magnetic resonance imaging scans were eval-
uated in 436 sporadic Creutzfeldt–Jakob disease patients and 141 controls. The pattern of high signal intensity with the best
sensitivity and specificity in the differential diagnosis of sporadic Creutzfeldt–Jakob disease was identified. The optimum
diagnostic accuracy in the differential diagnosis of rapid progressive dementia was obtained when either at least two cortical
regions (temporal, parietal or occipital) or both caudate nucleus and putamen displayed a high signal in fluid attenuated
inversion recovery or diffusion-weight imaging magnetic resonance imaging. Based on our analyses, magnetic resonance
imaging was positive in 83% of cases. In all definite cases, the amended criteria would cover the vast majority of suspected
cases, being positive in 98%. Cerebral cortical signal increase and high signal in caudate nucleus and putamen on fluid
attenuated inversion recovery or diffusion-weight imaging magnetic resonance imaging are useful in the diagnosis of sporadic
Creutzfeldt–Jakob disease. We propose an amendment to the clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease
to include findings from magnetic resonance imaging scans.
Keywords: CJD; MRI; FLAIR; DWI; molecular subtypes; dementia
Abbreviations: CSF = cerebrospinal fluid; DWI = diffusion-weight imaging; EEG = electroencephalography; FLAIR = fluid attenuated
inversion recovery; IgG = immunglobulin G; MRI = magnetic resonance imaging; sCJD = sporadic Creutzfeldt–Jakob disease;
PRNP = prionprotein gene; PrPSc = pathogenic Prion protein; SREAT = steroid responsive encephalitis associated with autoimmune
thyroiditis
Introduction
Sporadic CJD (sCJD) is a transmissible neurodegenerative disorder
with a fatal outcome. Clinical diagnostic criteria for sCJD were first
formulated 30 years ago, using a combination of distinctive clinical
features and best available auxiliary paraclinical investigations,
which at that time was electroencephalography (EEG) (Masters
et al., 1979). In recent years, there has been progress in develop-
ing other specialist investigations, including useful surrogate
biomarkers in the cerebrospinal fluid (CSF), and clinical diagnostic
criteria have been amended (Zerr et al., 2000a; Collins et al.,
2006).
A series of recent publications has dealt with the clinical and
pathological phenotypes and heterogeneity in sCJD (Parchi et al.,
1999; Gambetti et al., 2003; Castellani et al., 2004; Collins et al.,
2006; Sanchez-Juan et al., 2006). It has become apparent that
a multimodal approach may be necessary if detection of the
entire phenotypic spectrum of sCJD is to be achieved (Zerr
et al., 2000b). Whereas some classical molecular subtypes such
as the MM1 subtype frequently display periodic sharp and slow
wave complexes in the EEG, the other five molecular subtypes are
negative with this investigation (Parchi et al., 1999; Castellani et al.,
2004; Collins et al., 2006). Utilizing CSF 14-3-3 protein detection
provides a higher sensitivity, including less typical subtypes of sCJD
such as VV1 and VV2 subtypes (Collins et al., 2006; Sanchez-Juan
et al., 2006; Geschwind et al., 2009). However, even for CSF 14-3-
3 protein detection with an overall sensitivity of 85%–95%,
biological variables modify the test results and cases with longer
duration or younger age at onset may be missed by this investiga-
tion (Castellani et al., 2004; Sanchez-Juan et al., 2006).
Acknowledging the limitations of the clinical criteria, the search
for additional sCJD diagnostic investigations has continued.
Magnetic resonance imaging (MRI) has become increasingly
important in the clinical diagnosis of sCJD. The use of sensitive
fluid attenuated inversion recovery (FLAIR) and diffusion-weight
imaging (DWI) sequences allows the detection of basal ganglia
hyperintensity and signal increase in other brain regions (Satoh
et al., 2007; Tschampa et al., 2007; Fujita et al., 2008;
Galanaud et al., 2008; Meissner et al., 2008). Characteristic MRI
lesion patterns corresponding to individual CJD subtypes have
been reported (Meissner et al., 2009). As MRI findings, even
from early in the illness, are proving valuable in the evaluation
of suspected sCJD patients, both by excluding other disorders
and by demonstrating features considered typical of human
prion disease (Geschwind et al., 2009), we undertook a systematic
multi-centre international collaborative study to analyse the value
of MRI lesion patterns in comparison to CSF biomarker 14-3-3 and




Cases were included from twelve countries (Argentina, Australia,
Belgium, Canada, France, Germany, Italy, Netherlands, Portugal,
Slovenia, Switzerland and United Kingdom) according to the following
criteria: (i) CJD diagnosis confirmed by brain pathology (definite
cases) or fulfilling accepted case definition criteria for ‘probable’ sCJD
(data used for a separate set of analyses); (ii) molecular subtype deter-
mined by codon 129 genotyping (MM, MV or VV) and western blot
analysis of brain pathogenic prion protein (PrPSc) type (1 or 2) (corre-
sponding to MM1, MM2, MV1, MV2, VV1 and VV2 subtype) (Parchi
et al., 1996, 1999); and (iii) available FLAIR or DWI MRI of the brain.
Controls
Controls were included according to the following criteria: (i) cases in
which the diagnosis of sCJD was suspected (patients classified at least as
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probable or possible CJD) but excluded on follow up by clinical investi-
gations (improvement or recovery, inflammatory CSF findings, other
diagnosis) or at autopsy; and (ii) available FLAIR or DWI brain MRI.
Codon 129 status was determined either as part of genotyping of
the entire prion protein gene (PRNP) open reading frame or by restric-
tion fragment length polymorphism analysis (Collins et al., 2006).
Genetic CJD (causal mutations found in prionprotein gene), iatrogenic
and variant CJD cases were excluded.
EEG (periodic sharp wave complexes) findings were also ascertained.
The CSF 14-3-3 immunoassays were performed using western blotting
as previously reported (Zerr et al., 2000a) and the conformity of test
methods and interpretation of results was confirmed by a blinded
sample exchange programme between laboratories (Sanchez-Juan
et al., 2006).
The study comprised 436 sCJD patients who died between April
1998 and March 2007, and 141 controls: 32 (5.5%) from
Argentina, 15 (2.6%) from Australia, 35 (6.1%) from Belgium,
9 (1.6%) from Canada, 16 (2.8%) from France, 328 (56.8%) from
Germany, 32 (5.5%) from Italy, 17 (2.9%) from Netherlands,
7 (1.2%) from Portugal, 4 (0.7%) from Slovenia, 7 (1.2%) from
Switzerland and 75 (13.0%) from UK.
MRI data
The magnetic resonance images were performed as routine clinical
diagnostic studies and were collected from various hospitals in the
framework of epidemiological studies as reported elsewhere
(Meissner et al., 2009).
The majority of the scans were available as hardcopy. If serial MRIs
were available, the first examination was used for the analysis. All
scans were assessed by at least one neuroradiologist (K.K., D.S.,
C.R., P.S. or D.C.) aware that sCJD was a differential diagnostic possi-
bility but blinded to the final diagnosis. All neuroradiologists assessed a
small MRI series for the estimation of the inter-observer agreement.
The intra reader concordance was high: 93.3%, = 0.64 (P50.001).
Inter-rater concordance was 89%, = 0.61 (P50.001) and 82%,
= 0.62 (P50.001) (which is high agreement) or 75.4%, = 0.50
(P50.001) and 76%, = 0.45 (P50.001) (moderate agreement).
A standardized protocol was used which included seven cerebral
cortex regions (specifically the cingulate gyri, insular regions and
hippocampi, as well as the remaining frontal, parietal and temporal
lobes and the occipital lobes), basal ganglia (caudate nucleus, puta-
men, globus pallidus), thalamus (anterolateral nuclei, mediodorsal
nuclei, pulvinar) and cerebellar cortex. For the thalamus, the presence
or absence of a ‘pulvinar sign’ with extension into the antero-medial
thalamus underscoring the ‘hockey stick sign’ was also rated
(hyperintensity of the pulvinar relative to the anterior putamen)
(Collie et al., 2003). The cerebral regions were assessed as hyperin-
tense in relation to isointense cortex areas. As most MRI data were
available as hardcopy only, the grade of hyper-intensity was not
quantified. For each MRI examination, T2-weighted (T2-w) images
were evaluated first, followed by FLAIR and DWI. For further analyses,
only FLAIR and DWI were considered e.g. only the most sensitive
sequences, FLAIR and DWI (Kallenberg et al., 2006), were considered.
Proton-density-weighted scans and apparent diffusion coefficient maps
were less commonly used and not included in this study. Areas of
hyperintensity were scored separately for each sequence. The quality
of the complete MRI examination was graded from 1 to 6 (1 = excel-
lent, 2 = good, 3 = average, 4 = sufficient, 5 = insufficient, 6 = poor).
Scans graded higher than 4 were considered as non-diagnostic
(mainly due to motion artefacts) and excluded from the study.
Statistical analysis
Descriptive statistics were reported for sCJD and control patients;
2-test and the non-parametric Mann–Whitney test were used to
assess differences between categorical and continuous variables.
The goal of our study was to identify the best combination of radi-
ological findings and MRI sequences to discriminate between sCJD and
non-sCJD patients. In order to do this we compared the results of
visual assessments of brain MRI scans in cases and controls. We con-
sidered a brain region as affected when a high signal was found in
either FLAIR or DWI MRI sequences. We calculated sensitivity
[the percentage of scans considered as characteristic (positive) of
sCJD in cases] and specificity [the percentage of scans considered as
not characteristic (negative) of sCJD in controls] for several criteria
patterns involving different combinations of affected regions and
MRI sequences. We also calculated diagnostic odds ratios—the ratio
of the odds of positivity in sCJD cases relative to the odds of positivity
in the controls—to assess which combinations of criteria patterns
yielded better test discriminatory performance; 95% confidence inter-
vals of the diagnostic odds ratios were estimated by the exact method.
Inter-reader agreement for brain MRI scan visual assessment
(normal or affected) was calculated, using Cohen’s  coefficient and
Concordance Index, for all explored areas included in the standardized
protocol. Concordance Index is the percentage of agreement between
readers and the  coefficient shows the difference in agreement, from
chance, between them; thus a -value of 0 means no different from
chance and 1 is perfect agreement.
Ethics
The study was done in accordance with the current revision of the
Declaration of Helsinki and the Good Clinical Practice: Consolidated
Guideline approved by the International Conference on Harmonization
and applicable to national and local laws and regulations. For each
participating site, the study protocol and all amendments were
approved by an institutional review board or independent ethics




In total, MRI scans were available for 436 patients with sCJD and
141 controls.
FLAIR sequences were available in 379 cases and in 128 controls,
DWI in 258 cases and 81 controls. Both sequences were available
in 201 cases and 68 controls. The median time from onset to
MRI was 2.7 months in sCJD cases and 6.7 months in controls.
Patient characteristics are summarized in Table 1.
Definition of the criteria
In the first part of the study, we analysed which FLAIR and/or
DWI MRI lesion pattern was characteristic for sCJD, regardless of
molecular subtype. To achieve this, a stepwise analysis was
performed: (i) selection of the cortical regions; (ii) combination
cortical/subcortical areas; and (iii) definition of the best MRI
sequence (FLAIR/DWI).
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Selection of cortical regions
In this part of the study, we analysed the frequency of high signal
detection in each cortical region for cases and controls and strati-
fied the data by the MRI technique used (FLAIR or DWI, Table 2).
As the result of this analysis, we selected three regions with the
optimum sensitivity and specificity data, irrespective of MRI tech-
nique used. The three areas with the highest values for diagnostic
accuracy were the parietal, occipital and temporal cortical regions.
The other cortical brain regions such as cingulate gyrus, insular
cortex or hippocampus were either non-discriminatory between
cases and controls, had low specificity and, in addition to this,
found low inter reader agreement, as reported before
(Krasnianski et al., 2008).
Combination of cortical and subcortical
areas
Various combinations of high signal intensity were analysed in
the three selected cortical (parietal, occipital and temporal) and
subcortical regions. The results are given in Table 3. For FLAIR
and DWI, the best results were obtained when two or more
regions (either temporal, parietal, occipital) displayed a high
signal in the MRI. The poorest specificity was obtained when
MRI scans were considered positive when only one or more cere-
bral cortical region showed a high signal; therefore, those patterns
were excluded for further analysis. For subcortical areas, the opti-
mum diagnostic accuracy was obtained when a high signal
increase was observed in both the caudate nucleus and putamen
simultaneously. DWI was generally more sensitive than FLAIR with
a similar specificity for both sequences.
Further analyses determined the best possible combination of
various cerebral cortical and subcortical high signal changes.
The highest diagnostic accuracy was obtained by accepting
either a combination of at least two cerebral cortical regions
(temporal, occipital, parietal) showing increased signal or both
the putamen and the caudate nucleus showing high signal inten-
sity (Table 4).
Definition of the MRI sequence
After choosing the combination of either at least two cerebral
cortical regions or both the putamen and caudate nucleus showing
high signal as the optimal radiological pattern, we analysed which
MRI pulse sequence or potential combination of sequences
revealed the highest sensitivity and specificity. Both sequences
achieved high diagnostic accuracy (Table 5). We calculated the
data for other potential combinations, such as FLAIR and DWI
positive, but the sensitivity achieved was only 54%.
In order to estimate the sensitivity and specificity of the combi-
nation FLAIR or DWI, we considered that patients with both pulse
sequences available were most reliable, because including patients
with only one sequence would result in a predominance of the
‘only FLAIR performed’ and a decrease in the sensitivity (Table 5),
since FLAIR is less sensitive than DWI.
False-positive findings in the MRI
According to our criteria, 19 controls had positive findings on the
MRI. Most of these suffered from an infectious or inflammatory
disorder of the central nervous system (n = 9), like lymphocytic
encephalitis, progressive multifocal leucencephalopathy, steroid
responsive encephalitis associated with autoimmune thyroiditis
(SREAT) or encephalitis of unknown origin. In other patients
with a positive MRI, autopsy confirmed Alzheimer’s disease
(n = 2), Dementia with Lewy bodies (n = 2), epilepsy (n = 2),
intravascular lymphomatosis and mitochondrial cytopathy.


























sCJD 436 60.3 55.6 64.0 (35.3–85.0) 6.4 (1.0–56.3) 2.7 195 (62.7) 58 (18.6) 58 (18.6) 379 258
controls 144 39.1 48.8 65.9 (25.9–91.5) 12.0 (0.0–104.0) 6.7 11 (44.0) 8 (32.0) 6 (24.0) 128 81
P-value 0.27 0.2 0.007
Table 2 Selection of cortical areas
Frontal Cinguli Parietal Temporal Occipital Insula Hippocampus
CJD (% positive) FLAIR 48 52 37 32 17 24 20
Control (% negative) FLAIR 75 71 89 82 97 89 76
CJD (% positive) DWI 74 71 65 59 37 52 21































CI = confidence interval.
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Two patients recovered and the diagnosis is not known. No
distinctive MRI pattern could be detected for each disorder and
the frequency of high signal abnormalities in cortical and sub-
cortical areas was similar in all the diagnostic groups mentioned
above.
Modification of clinical criteria for
sCJD
Based on our results, we recommend modifying the current clinical
diagnostic criteria for sCJD to include the detection of either










At least one cortical regiona affected
No (%) 94 (73.4) 190 (50.1) 111 (48.1) 60 (74.1) 57 (22.1) 29 (19.1)
Yes (%) 34 (26.6) 189 (49.9) 120 (51.9) 21 (25.9) 201 (77.9) 123 (80.9)
Diagnostic odds ratio (95% CI) 2.8 (1.5–4.0) 3.0 (1.6–4.4) 10.1 (4.3–15.9) 12.1 (4.4–19.9)
At least two cortical regionsa affected
No (%) 121 (94.5) 278 (73.4) 173 (74.9) 72 (88.9) 115 (44.6) 62 (40.8)
Yes (%) 7 (5.5) 101 (26.6) 58 (25.1) 9 (11.1) 143 (55.4) 90 (59.2)
Diagnostic odds ratio (95% CI) 6.3 (1.3–11.3) 5.8 (1.1–10.5) 10.0 (2.6–17.3) 11.6 (2.7–20.5)
More than three cortical regions affected
No (%) 115 (89.8) 276 (72.8) 163 (70.6) 68 (84.0) 111 (43.0) 57 (37.5)
Yes (%) 13 (10.2) 103 (27.2) 68 (29.4) 13 (16.0) 147 (57.0) 95 (62.5)
Diagnostic odds ratio (95% CI) 3.3 (1.3–5.3) 3.7 (1.3–6.1) 6.9 (2.5–11.4) 8.7 (2.8–14.6)
Putamen or caudatum affected
No (%) 104 (81.3) 147 (38.8) 83 (35.9) 67 (82.7) 83 (32.2) 44 (28.9)
Yes (%) 24 (18.8) 232 (61.2) 148 (64.1) 14 (17.3) 175 (67.8) 108 (71.1)
Diagnostic odds ratio (95% CI) 6.8 (3.5–10.2) 7.7 (3.7–11.7) 10.1 (3.7–16.5) 11.8 (3.8–19.7)
Both putamen and caudatum affected
No (%) 120 (93.8) 223 (58.8) 135 (58.4) 76 (93.8) 133 (51.6) 76 (50.0)
Yes (%) 8 (6.3) 156 (41.2) 96 (41.6) 5 (6.2) 125 (48.4) 76 (50.0)
Diagnostic odds ratio (95% CI) 10.5 (2.7–18.3) 10.7 (2.5–18.8) 14.3 (0.9–27.7) 15.2 (0.6–29.8)
a Parietal–temporal–occipital; CI = confidence interval; s = sCJD cases.










More than three cortical regions OR both Put. and NC affected
No (%) 110 (85.9) 166 (43.8) 94 (40.7) 66 (81.5) 62 (24.0) 32 (21.1)
Yes (%) 18 (14.1) 213 (56.2) 137 (59.3) 15 (18.5) 196 (76.0) 120 (78.9)
Diagnostic odds ratio (95% CI) 7.8 (3.6–12.1) 8.9 (3.9–13.9) 13.9 (5.2-22.7) 16.5 (5.2-27.8)
More than three cortical regions OR Put. OR NC affected
No (%) 99 (77.3) 113 (29.8) 60 (26.0) 61 (75.3) 41 (15.9) 19 (12.5)
Yes (%) 29 (22.7) 266 (70.2) 171 (74.0) 20 (24.7) 217 (84.1) 133 (87.5)
Diagnostic odds ratio (95% CI) 8.0 (4.3–11.8) 9.7 (4.8–14.7) 16.1 (6.4–25.9) 21.4 (6.5–36.2)
At least two cortical regionsa affected OR both Put. and NC affected
No (%) 116 (90.6) 162 (42.7) 97 (42.0) 70 (86.4) 63 (24.4) 33 (21.7)
Yes (%) 12 (9.4) 217 (57.3) 134 (58.0) 11 (13.6) 195 (75.6) 119 (78.3)
Diagnostic odds ratio (95% CI) 13.0 (4.8–21.1) 13.4 (4.7–22.0) 19.7 (6.0–33.4) 23.0 (5.9–40.0)
At least two cortical regionsa affected OR Put. OR NC affected
No (%) 103 (80.5) 106 (28.0) 58 (25.1) 62 (76.5) 42 (16.3) 21 (13.8)
Yes (%) 25 (19.5) 273 (72.0) 173 (74.9) 19 (23.5) 216 (83.7) 131 (86.2)
Diagnostic odds ratio (95% CI) 10.6 (5.4–15.8) 12.3 (5.8–18.8) 16.8 (6.5–27.0) 20.4 (6.3–34.4)
NC = nucleus caudatum; Put. = putamen.
a Parietal–temporal–occipital.
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hyperintensity in the basal ganglia (both caudate nucleus and
putamen) or in at least two cortical regions (from either the
temporal, parietal or occipital cerebral cortices) (Fig. 1). This
implies that the detection of the specified high signal abnormalities
in FLAIR or DWI MRI will be considered at the same level of
diagnostic importance as periodic sharp wave complexes on the
EEG or 14-3-3 protein detection in the CSF.
Comparative analysis of the EEG,
CSF and MRI
In a subgroup of 214 definite CJD patients and 77 definite
non-cases, we analysed the frequency of true-positive results in
cases (sensitivity) and true-negative results in controls (specificity),
in relation to the detection of periodic sharp wave complexes in
the EEG, elevated CSF levels of 14-3-3 protein or MRI abnormal-
ities. Diagnostic MRI abnormalities for sCJD, as defined by our
analyses, were observed in 83% of such patients with a specificity
of 83%. For CSF 14-3-3 protein detection, test sensitivity was
86% but specificity was 68%. EEG had the lowest sensitivity
(44%) and highest specificity (92%). Details on comparative
analyses of current and amended criteria are given in Table 6.
The sensitivity of current criteria is 92%, the specificity 71%.
Thus, 8% of sCJD patients are not covered by the World Health
Figure 1 MRI-CJD Consortium criteria for sporadic Creutzfeldt–Jakob disease.
Table 5 Definition of MRI sequences for the pattern at
least two cortical regions affected (parietal–temporal–








No (%) 64 (94.1) 92 (45.8) 55 (45.8)
Yes (%) 4 (5.9) 109 (54.2) 65 (54.2)
Total (n) 68 201 120
Diagnostic odds
ratio (95%CI)
19.0 (0.9–38.8) 18.9 (1.4–39.2)
FLAIR OR DWI
No (%) 122 (86.5) 133 (30.5) 75 (28.5)
Yes (%) 19 (13.5) 303 (69.5) 188 (71.5)
Total (n) 141 436 263
Diagnostic odds
ratio (95%CI)
14.6 (7.0–22.3) 16.1 (7.2–25.0)
FLAIR OR DWIa
No (%) 56 (82.3) 38 (18.9) 21 (17.5)
Yes (%) 12 (17.6) 163 (81.1) 99 (82.5)
Total (n) 68 201 120
Diagnostic odds
ratio (95%CI)
20.0 (5.7–34.4) 22.0 (4.8–39.2)
a Only cases with both sequences available.
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Organization criteria. By inclusion of the MRI as an additional
parameter for ‘probable’ CJD, the sensitivity of clinical criteria
rises substantially to 98%, but specificity drops marginally.
Value of MRI in identification of
various molecular sCJD subtypes
A comparative analysis of protein 14-3-3, EEG and MRI in a
subset of CJD patients with data on pathogenic prion protein
type and codon 129 genotype available is shown in Table 7.
Currently used criteria improved the recognition of some of the
less typical sCJD subtypes such as VV2. Amended criteria, as
suggested here, are especially helpful for the rare and atypical
subtypes such as MM2, MV1 and MV2. The latter may develop
an atypical clinical syndrome and thus not be properly diagnosed
on clinical grounds (Krasnianski et al., 2006a, b)
Discussion
This multi-centre collaborative study analysed findings from MRI
scans in a large number of sCJD cases and controls; and has
provided evidence that justifies the inclusion of defined MRI
pattern in the clinical diagnostic criteria for sCJD. In a previous
manuscript, we reported characteristic MRI patterns for each
molecular CJD subtype (Meissner et al., 2009) and identified
variables which allowed for the best discrimination between
those subtypes. We chose the following radiological signs as
predictors of sCJD subtypes: high signal in (i) more than three
Table 6 Comparison of new and old criteria
n % Sensitivity Specificity
Current criteria
Definite sporadic CJD cases with both EEG and 14-3-3 tests performed
EEG atypical & 14-3-3 test negative 8 7.8
EEG typical & 14-3-3 test negative 7 6.8
EEG atypical & 14-3-3 test positive 49 47.6
EEG typical & 14-3-3 test positive 39 37.9 92.2
Total 103 100
Controls with both EEG and 14-3-3 tests performed
EEG atypical & 14-3-3 test negative 37 71.2 71.2
EEG typical & 14-3-3 test negative 1 1.9
EEG atypical & 14-3-3 test positive 12 23.1
EEG typical & 14-3-3 test positive 1 1.9
Total 52 100
New criteria
Definite sporadic CJD cases with all three tests performed (EEG, 14-3-3 tests, and MRI FLAIR and DWI, new criteria)
Current criteria negative & MRI negative 1 2.0
Current criteria positive & MRI negative 7 14
Current criteria negative & MRI positive 3 6
Current criteria positive & MRI positive 39 78 98
Total 50 100
Controls with all three tests performed (EEG, 14-3-3 tests, and MRI FLAIR and DWI)
Current criteria negative & MRI negative 17 70.8 70.8
Current criteria positive & MRI negative 5 20.8
Current criteria negative & MRI positive 1 4.2
Current criteria positive & MRI positive 1 4.2
Total 24 100













MM1 33/43 (76.7) 38/42 (90.5) 26/43 (60.5) 100 97.6
MM2 14/15 (93.3) 9/14 (64.3) 3/14 (21.4) 92.3 69.2
MV1 6/6 (100) 5/6 (83.3) 3/6 (50) 100 100
MV2 8/8 (100) 7/8 (87.5) 0/8 (0) 100 87.5
VV1 2/2 (100) 2/2 (100) 1/2 (50) 100 100
VV2 9/15(60) 14/15 (93.3) 0/15 (0) 100 93.3
All 72/89 (80.9) 75/87 (86.2) 33/88 (37.5) 98.8 91.9
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cerebral cortical regions; (ii) hippocampus; (iii) any basal ganglia;
(iv) any thalamic nuclei; and (v) cerebellum. Multivariate analysis,
including the five selected regions, was performed in order to
allow independent assessment of these parameters and a specific
MRI lesion pattern for each molecular disease subtype was identi-
fied (Meissner et al., 2009). Specificity of MRI changes was not
addressed. Since the information on specificity is essential for an
assessment of the true utility of MRI brain scan in the diagnosis of
sCJD, we performed the current study.
In order to assess the sensitivity of MRI in the diagnosis of sCJD,
we developed a set of variables which allowed the optimum dis-
crimination between CJD and controls. In this analysis, we selected
anatomical regions which have been demonstrated to be fre-
quently affected (Meissner et al., 2009). The characteristic MRI
lesion pattern, which allowed for the best discrimination between
sCJD cases and controls was found to be high signal intensity in
FLAIR or DWI in at least two cortical regions, or signal increase in
the caudate nucleus and putamen. Based on these findings, we
propose that the clinical diagnostic criteria for sCJD are amended
to include MRI signal abnormalities as defined above (Fig. 1). The
MRI findings will thus be equivalent to elevated levels of 14-3-3
proteins or periodic sharp and slow wave complexes in the EEG for
the clinical diagnosis of probable sCJD.
With respect to current clinical tests for sCJD, the EEG was the
first in vivo test to be used to support the clinical diagnosis of
sCJD. However, the EEG has been shown to be positive in only a
subset of sCJD patients, usually MM1 or MV1 cases. Typically,
periodic sharp wave complexes are detected late in the disease
and the median time to positive EGG is around 12 weeks. This
corresponds to the terminal stages of the illness (Poser et al.,
1999; Zerr et al., 2000a; Collins et al., 2006). A number of CSF
biomarkers have been reported in sCJD, including 14-3-3, tau,
S100b, neuron-specific enolase, phosphorylated tau and abeta,
with the majority of available data relating to 14-3-3 and tau
proteins (Sanchez-Juan et al., 2006). Both these biomarkers
support the clinical CJD diagnosis with a sensitivity of 92% and
specificity of 71% (Sanchez-Juan et al., 2006). However, a
number of publications have indicated that low levels of these
biomarkers are present in the CSF in some atypical CJD variants
(Castellani et al., 2004; Sanchez-Juan et al., 2006; Gmitterová
et al., 2008). Biological variables such as long disease duration,
young age at onset, type 2 pathogenic prion protein and hetero-
zygosity at codon 129 genotype of the PrP gene are all associated
with low biomarker levels (Parchi et al., 1999; Zerr et al., 2000b;
Castellani et al., 2004; Sanchez-Juan et al., 2006). This is in con-
trast with the results of MRI scans in some atypical and rare
variants of sCJD, such as VV1 and MV2: in VV1 patients there
is high signal in the cortical areas and normal signal in the basal
ganglia, while in MV2 patients characteristic abnormalities are
seen in the basal ganglia, putamen and thalamus (Meissner
et al., 2005; Krasnianski et al., 2006b, 2008). Characteristic
lesion patterns have recently been reported for patients with
other molecular disease subtypes (Meissner et al., 2009) and the
question was raised whether MRI brain scan might contribute to
the improved diagnosis across sCJD subtypes (Tschampa et al.,
2005; Meissner et al., 2009).
Table 7 shows the data on positive tests in a subgroup of
patients with known molecular type. MRI findings are positive in
81% of sCJD patients. Sensitivity of the 14-3-3 test is 86% and
significantly less for the EEG. By combination of all parameters,
sensitivity is 98% and specificity of the criteria is 71%. Although
the frequency and location of high signal intensities vary between
subtypes, by amendment of clinical criteria, most molecular
disease subtypes will be covered, including rare subtypes VV1
and MV2 (Table 7).
Our results indicate a high rate of agreement between identifi-
cation of cortical parietal, temporal and occipital signal and basal
ganglia involvement between five raters, even in a cohort of
patients where MRI scans were acquired at different centres,
with some modifications. These results suggest that MRI is a
robust investigation in sCJD and qualifies as a potential biomarker
for CJD.
A limitation of this study is the high number of sCJD cases as
compared to controls. However, the gold standard for the valida-
tion of the clinical diagnostic criteria was the analysis of the subset
of sCJD cases in which the diagnosis had been confirmed by
neuropathology. In controls, only data from patients in which
the diagnosis of CJD had been definitely excluded by neuropathol-
ogy or in which there was a definite alternative clinical diagnosis,
were used. This group included cases who recovered, cases with
inflammatory CSF findings indicating an alternative diagnosis or a
clinical course which excluded CJD as a diagnosis (Heinemann
et al., 2007). In the context of a multi-centre MRI study on a
rare disorder, achieving a high autopsy rate in non-cases is difficult
and it would take many years to obtain a representative autopsy
sample of non-cases at a similar rate to the sCJD cases.
Epidemiological surveillance studies on rare disorders are person
and cost intensive and a study with selected MRI scans on more
than 300 cases and controls on a solely autoptic sample is unlikely
to be feasible in the near future. However, in this study, we have
achieved neuropathology confirmation in 40% of controls and in
60% of CJD patients.
Our analysis has shown that MRI findings may lead to false
positive diagnosis in a small number of cases. This is an important
issue for the accurate diagnosis of sCJD. Almost 50% of false-
positive findings on the MRI were associated with inflammatory
conditions; the other diagnoses were Alzheimer’s disease and
Dementia with Lewy bodies (HaÏk et al., 2000; Tschampa et al.,
2001). Inflammatory conditions of the brain represent the most
important differential diagnosis as there may be a possibility for
treatment (Chang et al., 2007; Heinemann et al., 2007;
Geschwind et al., 2008). In our patients, diagnoses included
encephalitis of unknown origin and SREAT (Seipelt et al., 1999).
The latter diagnosis has been described previously as an important
treatable condition in the differential diagnosis of CJD. The crucial
question for the clinician is how to avoid the misinterpretation of
tests and how to avoid missing a treatable condition in a patient
with a rapid progressive dementia and focal neurological signs
(Josephs et al., 2009). Thorough analysis of the cerebrospinal
fluid for routine parameters such as cell count, protein and oligo-
clonal bands (which are often positive in SREAT and other inflam-
matory conditions, but usually negative in CJD) may be helpful in
diagnosis (Jacobi et al., 2005; Green et al., 2007). As other tests,
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such as 14-3-3 and EEG, may also show ‘false-positive’ results in
inflammatory conditions of the brain, accurate clinical diagnosis
can be a major challenge. Thus, patients with ‘inflammatory’
abnormalities in the CSF such as pleocytosis, high elevated protein
content and oligoclonal immunglobulin G should enter the
diagnostic pathway for potentially treatable conditions (Vernino
et al., 2007).
The time point at which the clinical diagnosis of sCJD is made
may be very important if treatment strategies become available as
any therapy will probably need to be started early if it is to be
effective. The EEG has been shown to become positive usually
only in the late stages of the disease. CSF biomarkers can
become positive in the early disease stages, as shown in a
cohort of patients with repeated lumbar punctures and multiple
CSF tests (Sanchez-Juan et al., 2007). With MRI the question on
when the typical changes appear is still unresolved because of the
limited number of patients with multiple scans. However, there is
a suggestion from the literature that MRI may become positive
early in the disease (Young et al., 2005; Fujita et al., 2008;
Galanaud et al., 2008; Hoshino et al., 2008). Further work will
be needed to address this question.
In summary, our data show that basal ganglia and cortical
hyperintensities represent the most frequent MRI findings in
sCJD and are present in most cases. Characteristic brain MRI
lesion patterns are helpful in establishing a diagnosis of sCJD
and may help to identify atypical sporadic disease forms. This is
the most comprehensive study on MRI findings in sCJD to date,
and in combination with previous studies, provides firm evidence
that brain MRI has a high sensitivity and specificity in the diag-
nosis of the disease.
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14-3-3 protein detection and
sporadic CJD: the status quo
serves well while awaiting
progress
Steven J Collins,1,2 Amelia McGlade,1,2 Alison Boyd,1,2
C L Masters,1,2 Genevieve M J A Klug1,2
Of the neurodegenerative disorders, prion
diseases pose some unique challenges. The
phenotypic spectrum is sufficiently diverse
that this diagnosis will not infrequently
intrude as a consideration, with the atten-
dant risk of inadvertent disease trans-
mission during healthcare provision adding
concerns not extant in relation to most
neurological diseases, especially disorders
such as Alzheimer ’s disease. Prompt, accu-
rate diagnosis can assist in pre-empting and
thereby minimising transmission risk,
while serving to avoid unhelpful investiga-
tions and treatments, and facilitate more
informed prognostication. Notwith-
standing the acknowledged need to
continue searching for improvements in our
diagnostic capacity, there has fortunately
been major progress over the last
10e15 years in relation to the premortem
diagnosis of sporadic CreutzfeldteJakob
disease (sCJD), the most common form of
human prion disease. In addition to the
more recent contribution of brainMRI,1 the
recognition that 14-3-3 protein detection in
the cerebrospinal fluid (CSF) constituted
a robust surrogate biomarker of sCJD was
a major advance in our clinical diagnostic
armamentarium, far superior to that offered
by EEG.2 Although sometimes vitiated
because of lower sensitivities and specific-
ities described in smaller studies, the large,
long-term study of 579 unselected patients
reported by Chohan et al (see page 1243)3
reconfirms the genuine utility of detection
of CSF surrogate biomarkers, especially
14-3-3 proteins, for supporting a diagnosis
of sCJD.
In their study, based at the UK national
CJD surveillance centre, Chohan et al
evaluated the sensitivity, specificity, posi-
tive and negative predictive values, and
efficiency of detecting 14-3-3 proteins, s
and S100b in the CSF, either alone or
in various combinations, for supporting
a premortem diagnosis of sCJD. As
a single biomarker, 14-3-3 protein detec-
tion was observed to have the highest
overall sensitivity at 86%, remarkably
similar to the findings of two previous
large, collaborative studies in which 85%
of 1531 (probable and definite)4 and 88%
of 1521 (definite)5 sCJD patients returned
positive results. Further, a positive 14-3-3
result was the most sensitive indicator in
less typical cases, such as those less than
50 years at disease onset or those with an
illness duration over 12 months, albeit
with reduced sensitivities of 71% and
56%, respectively. The main limitation of
14-3-3 protein detection used in isolation
was the relatively low specificity of 74%,
particularly in comparison with s (84%)
and S100b (90%). Using combinations of
14-3-3 protein detection with either S100b
or s, or both, improved specificities and
positive predictive values to 88e96%
and 91e95%, respectively, but at the cost
of diminishing sensitivities to 57e75%.
Despite this reduction in sensitivity, the
authors suggest that the best combination
for sCJD is the use of primary 14-3-3
protein detection, followed by the S100b
marker. There was no apparent demo-
graphic profile evincing a greater likeli-
hood of a positive result with 14-3-3
protein detection in comparison with s,
thereby limiting attempts to maximise
complementarity by performing both
simultaneously, and as a corollary both
14-3-3 and s displayed compromised spec-
ificity across the same range of non-CJD
illnesses. Finally, and of considerable
practical importance, in the absence of an
autopsy the use of CSF 14-3-3 protein
detection allowed at least 100 persons to
be classified as sCJD over the 10-year
study period, an outcome that would not
have been otherwise possible given the
absence of an EEG or a non-diagnostic
recording in these persons.
As noted already, an unfortunate
limitation of current CSF biochemical
assays evaluating suspected sCJD is the
non-specificity of the biomarkers, partic-
ularly in relation to the disease-associated
conformations of the prion protein (PrPSc)
directly linked with pathogenesis. It is
anticipated that evolving diagnostic
assays interrogating CSF components
through methods based on the protein
misfolding cyclic amplification assay6 will
have the capacity to directly detect
minuscule amounts of PrPSc even when
applied within a routine clinical context.
Hopefully, such techniques will prove
practicable as stand-alone methods while
delivering optimal sensitivity and speci-
ficity but, if not, could perhaps function as
reliable second-line arbiters to resolve
equivocal, or suspected false-positive,
14-3-3 results.
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The development of technologies for the in vitro amplification 
of abnormal conformations of prion protein (PrPSc) has 
generated the potential for sensitive detection of prions. Here 
we developed a new PrPSc amplification assay, called real-
time quaking-induced conversion (RT-QUIC), which allows 
the detection of ≥1 fg of PrPSc in diluted Creutzfeldt-Jakob 
disease (CJD) brain homogenate. Moreover, we assessed the 
technique first in a series of Japanese subjects and then in a 
blind study of 30 cerebrospinal fluid specimens from Australia, 
which achieved greater than 80% sensitivity and 100% 
specificity. These findings indicate the promising enhanced 
diagnostic capacity of RT-QUIC in the antemortem evaluation 
of suspected CJD.
Transmissible spongiform encephalopathies, or prion diseases, are 
characteristically associated with the accumulation of PrPSc in the 
central nervous system through autocatalytic conversion of normal 
cellular PrP (PrPc) into replicate misfolded isomers1,2. Despite a few 
other reported markers3,4, PrPSc remains the best characterized and 
most reliable marker of prion disease.
Definitive antemortem confirmation of CJD requires the detection 
of PrPSc in biopsy specimens, the practice of which is discouraged 
because it is invasive and poses risks to health care personnel. 
Recently, however, in vitro PrPSc amplification techniques, including 
protein misfolding cyclic amplification5–7, the amyloid seeding assay8 
and QUIC, have been reported to enable the direct and highly sensi-
tive detection of PrPSc in various tissues, including cerebrospinal fluid 
(CSF). QUIC assays involve the use of soluble recombinant PrP 
(rPrP-sen) as a substrate, which is seeded with PrPSc and then 
subjected to intermittent automated shaking. This technique can be 
performed more easily than the protein misfolding cyclic amplifi-
cation, which requires repeated sonication. Previous studies have 
shown that QUIC assays correctly discriminate between normal and 
scrapie-infected CSF samples in both hamster and sheep prion disease 
models9,10. However, ultrasensitive PrPSc detection in CSF from sub-
jects with CJD has not yet been accomplished. Accordingly, we further 
refined the QUIC assay to improve its sensitivity and practicability 
and then applied the technique in a blind pilot study to detect PrPSc 
in CJD CSF specimens.
Given that a correlation between protease-resistant rPrP aggregate 
(rPrP-res) abundance and thioflavin T (ThT) fluorescence had been 
shown previously7, we sought to determine the relative kinetics of 
rPrP-res formation by monitoring levels of ThT fluorescence in the 
QUIC assay. This was intended to minimize the time needed to detect 
rPrP-res. We first tested whether PrPSc-dependent rPrP-res (rPrP-resSc) 
formation could be induced in a microplate reader with intermittent 
shaking. We used human rPrP-sen (rHuPrP-sen) and a 10−7 dilution of 
CJD (molecular subtype MM1) brain homogenate as the substrate and 
seed, respectively. We conducted QUIC reactions at various concen-
trations (0, 0.25, 0.5 and 1.0 M) of guanidine-HCl (GdnHCl), because 
it has been shown that GdnHCl greatly enhances conversion of PrP-
sen to PrP-res in cell-free conversion reactions11. Unexpectedly, we 
observed positive PrPSc-dependent ThT fluorescence within 24 h, 
both in the presence and in the absence of GdnHCl (Fig. 1a). In con-
trast, the negative control reactions without seed and in the absence of 
GdnHCl resulted in no increase in ThT fluorescence over 24 h; how-
ever, de novo formation of rPrP-res (rPrP-resspon) was rapidly induced 
in the presence of GdnHCl when shaking was added (Fig. 1a,b). These 
results indicate that shaking accelerates PrPSc-dependent rPrP-resSc 
formation even without GdnHCl (Supplementary Fig. 1), albeit with 
a lower peak of fluorescence.
Shaking is thought to cause partial unfolding of a portion of 
rPrP-sen by increasing the air-water interface12. Moreover, shaking 
enhances the interaction between rPrP-sen and PrPSc and promotes 
the fragmentation of rPrP-res polymers13. It is generally accepted 
that the energetic barrier of seed-dependent fibril formation and 
 elongation is lower than that of spontaneous fibril formation, which 
first requires nucleation as the rate-limiting step14. The partial 
 unfolding of rPrP-sen by shaking seems to be more heterogeneous 
than that facilitated by a denaturant such as GdnHCl, perhaps because 
the air-water interfaces created by shaking are unequally distributed 
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in solution. We found that the addition of GdnHCl to QUIC reactions 
leads to an increase in the nucleation rate, and increased spontaneous 
fibril formation. The early appearance of rPrP-resspon decreases the 
specificity of QUIC, because ThT fluorescence cannot distinguish 
between rPrP-resSc and rPrP-resspon. Therefore, we chose not to use 
GdnHCl in subsequent analyses.
To further optimize the conditions, we examined the effects of pH, 
as well as of the concentrations of rHuPrP-sen and salt on QUIC 
reactions in GdnHCl-free conditions with shaking (Fig. 1c–e and 
Supplementary Fig. 2). After assessment, we successfully established 
a method for the real-time monitoring of the kinetics of rPrP fibril 
formation seeded with CJD brain homogenate (see Supplementary 
Methods), without the generation of rPrP-resspon and designated the 
assay RT-QUIC.
To determine the minimum amount of PrPSc detectable by RT-
QUIC, we diluted CJD brain homogenate (MM1 and MM2) seri-
ally with artificial CSF (A-CSF) and used these dilutions to seed the 
reactions. We observed increased PrPSc-dependent ThT fluorescence 
within 48 h in more than half the replicates of CJD brain homogenate, 
with dilutions ranging from 10−5 to 10−9 (Fig. 1f and Supplementary 
Table 1). With 10−10 brain homogenate dilutions, we observed a mar-
ginally lower rate of positive reactions, and 10−11 dilutions of the CJD-
brain homogenates produced no ThT fluorescence response (Fig. 1f 
and Supplementary Table 1). The negative controls seeded with 10−5 
and 10−7 dilutions of non-CJD brain homogenate or A-CSF alone 
(no seed) did not produce an increase in the fluorescence (Fig. 1f 
and Supplementary Table 1). The 10−9 dilutions of MM1 and MM2 
CJD brain homogenate contained approximately 0.8 and 1.9 fg of 
PrPSc, respectively, according to our estimation (data not shown). 
Consequently, the results indicate that this assay consistently enables 
us to detect more than or equal to about 1 fg of PrPSc in the diluted 
CJD brain homogenates within 48 h. Moreover, the fact that there was 
no rPrP-resspon formation under the conditions used implies a lower 
and acceptable risk of false-positive reactions. Whether the RT-QUIC 
has the same sensitivity to CJD brain homogenate with 129MV or 
129VV as 129MM remains to be determined.
CSF is routinely used in the evaluation of central nervous system 
disorders and presumably contains more PrPSc and fewer impuri-
ties than blood. This prompted us to compare the RT-QUIC seeding 
activity in CSF samples from subjects with CJD and subjects without 
CJD but with other neurodegenerative diseases. For the pilot study, 
we initially tested CJD CSF samples from 18 definite cases of CJD in 
Japan (Table 1) and 35 non-CJD controls from subjects with other 
neurodegenerative diseases (Supplementary Table 2). We saw a min-
imal ThT fluorescence increase in the controls, with no false positives 
in the assay. In contrast, increased PrPSc-dependent fluorescence was 
seen in at least one of four replicates in 15/18 (83.3%) of the CJD CSF 
samples (Table 1 and Supplementary Table 3).
To further confirm the reliability of RT-QUIC, we conducted a blind 
trial using 30 CSF samples from the Australian National CJD Registry 
and 155 CSF samples containing 25 probable cases of CJD and 130 
cases of other neurological diseases obtained in Japan. In the Australian 
samples, we were able to detect PrPSc in 14/16 (87.5%) definite CJD 
CSF samples, as opposed to 0/14 of the non-CJD controls (Table 1, 
Supplementary Fig. 3 and Supplementary Table 3). It should be 
noted that 3/4 129VV and 2/2 129MV cases were positive by RT-QUIC. 
Figure 1 QUIC reactions induce PrPSc-
dependent rHuPrP-res formation under 
GdnHCl-free conditions. (a,b) The effect  
of the indicated concentration of Gdn-HCl on 
the kinetics of rHuPrP fibril formation with or 
without 10−7 dilution of CJD brain homogenate 
(CJD-BH) (type 1, 129MM). The reaction 
buffer contained 150 mM NaCl, 50 mM  
PIPES, pH 7.0, 1 mM EDTA and 10 µM ThT. 
The concentration of rHuPrP-sen was 0.1 mg ml−1. 
The graphs in a depict one representative  
of triplicates. The maximal fluorescence 
intensity of each single reaction for 24 h is 
plotted in b. (c–e) The effect of pH (c), the 
concentration of rHuPrP-sen (d) and the 
concentration of NaCl (e) were tested with 
the indicated dilutions of CJD-BH (type 1, 
129MM) as seeds. Buffers used in c were  
pH 5 50 mM sodium acetate buffer, pH 6  
50 mM MES, pH 7 50 mM PIPES and  
pH 8 50 mM HEPES. The concentration of 
NaCl in c and d was 150 mM, the pH of the 
buffer in d and e was 7.0 (50 mM PIPES) and 
the rHuPrP-sen concentration in c and e was  
0.1 mg ml−1. Each symbol represents the 
maximal fluorescence intensity from an 
individual reaction for 48 h. (f) Detection limit 
of RT-QUIC with the indicated dilutions of  
CJD-BH (129MM, type 1) and CJD-BH 
(129MM, type 2) as seeds. We used the 
indicated dilutions of non–CJD-BH (dissecting 
aneurysm) or artificial CSF (A-CSF) as negative 
controls. We performed the RT-QUIC reactions 
as described in the Supplementary Methods. The colored curves represent the kinetics of ThT fluorescence from an individual reaction seeded  
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Table 1 Clinical data and RT-QUIC reactions seeded with CSF samples
CSF from 18 definite CJD samples in Japan
Sample Age (years)/sex CJD type Molecular subtypea 14-3-3 (γ-isoform)b RT- QUICc
C1 68/M sCJD MM 1 + + (3/4)
C2 66/F sCJD MM 1 + + (2/4)
C3 71/F sCJD MM 1 + + (1/4)
C4 57/F sCJD MM 2 + + (2/4)
C5 70/M sCJD MM 2 + + (2/4)
C6 66/M sCJD MM 2 + + (2/4)
C7 60/F sCJD MM 2 − − (0/4)
C8 73/F sCJD MM 2 + + (4/4)
C9 74/M sCJD MM 2 + − (0/4)
C10 79/F sCJD MM 2 − + (3/4)
C11 65/F sCJD MM 2 + + (4/4)
C12 69/M sCJD MM 2 + − (0/4)
C13 69/F sCJD MM 2 + + (3/4)
C14 54/F sCJD MM 2 + + (3/4)
C15 76/F sCJD MM 2 − + (2/4)
C16 68/M sCJD MM 2 − + (4/4)
C17 58/F iCJD MM 1 + + (3/4)
C18 79/F iCJD MM 1 − + (3/4)
Blind trial of 30 CSF samples in Australia
Sample Age (years)/sex Diagnosisd Codon 129 Profile of PrPSc 14-3-3 (all isoforms)e RT-QUICg
A1 53/F PN/MC − − (0/4)
A2 59/F PN/ MC − − (0/4)
A3 85/M AD − − (0/4)
A4 60/F ICD + − (0/4)
A5 83/M AD + − (0/4)
A6 73/M sCJD VV 2 + + (2/4)
A7 67/F sCJD MM 1 + + (4/4)
A8 82/F sCJD MM 1 + + (2/4)
A9 67/M sCJD MV 1 − + (2/4)
A10 50/M sCJD MM 1 + + (3/4)
A11 66/M PN/MC − − (0/4)
A12 61/M PN/MC − − (0/4)
A13 84/F sCJD MM 1 + + (3/4)
A14 76/M sCJD MM 1 + + (2/4)
A15 69/M sCJD MV 1 + + (4/4)
A16 67/M AD − − (0/4)
A17 75/F PN/MC + − (0/4)
A18 93/M DLB/PD − − (0/4)
A19 67/F sCJD ND 2 + + (2/4)
A20 53/M DLB/PD − − (0/4)
A21 71/F sCJD VV 2 + − (0/4)
A22 62/F sCJD MM 2 − − (0/4)
A23 90/M sCJD VV ND + + (1/4)
A24 61/F DLB/PD − − (0/4)
A25 74/M sCJD MM ND ±f + (2/4)
A26 74/F AD − − (0/4)
A27 68/F sCJD ND ND + + (2/4)
A28 69/F sCJD VV 2 + + (1/4)
A29 82/M DLB/PD + − (0/4)
A30 70/F sCJD ND 2 + + (4/4)
aCJD can be divided into six molecular subtypes on the basis of whether methionine (M) or valine (V) is present at codon 129 of the gene encoding prion protein combined with the profile of 
PrPSc (type 1 or type 2) as determined by western blotting17. bAmounts of the γ-isoform of 14-3-3 protein in CSF were determined by western blotting with a polyclonal antibody specific for the 
γ-isoform of the 14-3-3 protein18 (+, positive reaction; −, negative reaction). cRT-QUIC was performed as described in the Supplementary Methods. The number of positive reactions over the 
number of replicates is shown in parentheses. Samples with at least one positive reaction were defined as +, representing a positive result in the RT-QUIC. dThe final diagnosis was made by the 
Australian National CJD Registry. eAmounts of 14-3-3 protein (all isoforms) in CSF were determined by western blotting. fAdditional atypical bands were observed. gKinetics graphs are provided 
in Supplementary Figure 3. Subjects or their families agreed with the aims and role of our research and gave appropriate informed consent. The investigation protocol was approved by the Ethics 
Committee of Nagasaki University Hospital (ID: 10042823), and the study was registered with the University Hospital Medical Information Network (ID: UMIN000003301). sCJD, sporadic 
Creutzfeldt-Jakob disease; iCJD, iatrogenic Creutzfeldt-Jakob disease; PN/MC, paraneoplastic/metastatic cancer; ICD, inflammatory central nervous system disorder; DLB/PD, dementia with Lewy 
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These results indicate that RT-QUIC has the ability to discriminate 
CJD CSF samples that include 129MM, 129MV and 129VV cases 
from non-CJD CSF samples. In addition, none of the 130 Japanese 
cases of other neurological diseases were positive, further confirming 
the reliability of this assay (Supplementary Table 4). Collectively, the 
RT-QUIC assays showed more than 80% sensitivity and 100% specifi-
city. The sensitivity was equivalent to and the specificity was much 
higher than that achieved by 14-3-3 (refs. 14,15), a nonspecific marker 
of rapid neuronal damage (Supplementary Table 3).
Although we have never experienced a false-positive reaction 
among the hundreds of non-CJD neurodegenerative disease sam-
ples we have so far tested, it remains possible that certain conditions 
may evoke a positive reaction, and further studies will be required to 
eliminate this possibility. Furthermore, scrupulous attention to the 
conditions of the assay is essential to avoid false positives in the clini-
cal setting. Nevertheless, we believe that the ultrasensitive detection 
of PrPSc in CSF by RT-QUIC represents a valuable new means for the 
early, rapid and specific diagnosis of CJD.
Note: Supplementary information is available on the Nature Medicine website.
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Abstract At present, the testing of 14-3-3 protein in cerebro-
spinal fluid (CSF) is a standard biomarker test in suspected
sporadic Creutzfeldt-Jakob disease (sCJD) diagnosis. Increas-
ing 14-3-3 test referrals in CJD reference laboratories in the
last years have led to an urgent need to improve established
14-3-3 test methods. The main result of our study was the
validation of a commercially available 14-3-3 ELISA next to
the commonly usedWestern blot method as a high-throughput
screening test. Hereby, 14-3-3 protein expression was quanti-
tatively analyzed in CSF of 231 sCJD and 2035 control pa-
tients. We obtained excellent sensitivity/specificity values of
88 and 96 % that are comparable to the established Western
blot method. Since standard protocols and preanalytical sam-
ple handling have become more important in routine diagnos-
tic, we investigated in a further step the reproducibility and
stability of 14-3-3 as a biomarker for human prion diseases.
Ring trial data from 2009 to 2013 revealed an increase of
Fleiss’ kappa from 0.51 to 0.68 indicating an improving reli-
ability of 14-3-3 protein detection. The stability of 14-3-3
protein under short-term and long-term storage conditions at
various temperatures and after repeated freezing/thawing cy-
cles was confirmed. Contamination of CSF samples with
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blood appears likely to be an important factor at a concentra-
tion of more than 2500 erythrocytes/μL. Hemolysis of eryth-
rocytes with significant release of 14-3-3 protein started after
2 days at room temperature. We first define clear standards for
the sample handling, short- and long-term storage of CSF
samples as well as the handling of blood- contaminated sam-
ples which may result in artificially elevated CSF levels of 14-
3-3.
Keywords Biomarker . Cerebrospinal fluid .
Creutzfeldt-Jakob disease . Pre-mortem test . 14-3-3 protein .
Standardization
Introduction
14-3-3 protein belongs to a family of proteins which are con-
served in eukaryotic cells with highest expression in neuronal
synapses. In humans, there are seven genes that encode eight
distinct 14-3-3 isoforms, alpha (α), beta (β), gamma (γ), ep-
silon (ε), zeta (ζ), tau (t), sigma (s), and eta (h).
14-3-3 can bind to more than 200 proteins and plays a role
in cell differentiation, signal transduction and neurotransmis-
sion [1, 2]. The 14-3-3 isoforms alpha/beta and gamma have
been previously reported as specific neuronal biomarkers in
cerebrospinal fluid for the pre-mortem diagnosis of human
prion diseases, in particular sporadic Creutzfeldt-Jakob dis-
ease (sCJD) [3–5]. In most sCJD subtypes, the levels of these
isoforms are elevated compared to patients without prion dis-
ease [5, 6]; however, 14-3-3 protein levels may vary across
different sCJD subtypes [7].
Detection of 14-3-3 protein is usually performed by using a
14-3-3 Western blot, which is prone to methodological and
inter-rater reliability problems. Therefore, the routine use of
14-3-3 protein detection in clinical practice requires standard-
ization of the experimental test protocol, including confine-
ments for the sample handling.
However, there are further factors, which may influence the
concentration of 14-3-3 in CSF. One of these is the contami-
nation of CSF with 14-3-3-containing blood cells, leading to
an artificial increase of 14-3-3 in CSF and to false-positive
results. Another important factor is the CSF pleocytosis due
to an inflammatory process of the central nervous system.
To date, there is a scarcity of studies dealing with the stan-
dardization of 14-3-3 assays as well as a lack of publications
investigating the short- or long-term stability of 14-3-3 protein
in human CSF.
Due to an increase in 14-3-3 test referrals in CJD reference
laboratories, we analyzed a commercial 14-3-3 gamma iso-
form ELISA as a novel test method in sCJD diagnosis and
examined potential variations in comparison to the previously
established immunoblot techniques.
Ring trials were performed to estimate the reproducibility
of 14-3-3 protein in prion disease diagnostic. Finally, short-
and long-term stability of 14-3-3 gamma, as well as the influ-




The present study includes 231 sCJD patients in Germany,
collected between 2009 and 2014. Thirty cases were con-
firmed by neuropathological examination after autopsy; the
others fulfilled the diagnosis of Bprobable CJD^ according
to the WHO diagnostic criteria [5, 6, 8]. Controls were com-
posed of patients with neurodegenerative diseases (n=150):
vascular dementia (n=40), Alzheimer’s disease (n=30),
Parkinson’s disease (n=28), patients with neuroinflammatory
diseases: multiple sclerosis/encephalitis (n=29), patients with
other neurological diseases: epilepsy/tumor (n=11) as well as
non-neurological conditions: depression (n=8) or psychiatric
diseases (n=4). The other control cohort was composed of
1885 prospectively collected samples which were enrolled
from the Neurochemistry Laboratory at the Department of
Neurology in the framework of quality assurance showing
no symptoms for a prion disease. Gender or age-dependent
effects on 14-3-3 level were not observed.
Ethics
The present study was conducted according to the revised
Declaration of Helsinki and Good Clinical Practice guidelines
and has been approved by the local ethics committee in
Göttingen (No. 11/93).
Study Design
1. To validate a commercial 14-3-3 gamma isoform ELISA,
we assessed 231 sCJD patients as well as 2035 control
patients without prion disease. We calculated a cutoff lev-
el and analyzed sensitivity, specificity, and predictive val-
ue levels accordingly.
2. To compare both 14-3-3 protein detection systems, CSF
samples were analyzed in parallel byWestern blot (14-3-3
isoform beta) and ELISA (14-3-3 isoform gamma). Sam-
ples classified according to their Western blot signals (14-
3-3 negative, trace, weak, and positive) were analyzed by
ELISA for the 14-3-3 protein concentration.
3. To analyze the general reliability of CSF 14-3-3 protein
detection, we conducted three ring trials. All laboratories
followed a standard Western blot protocol. Samples ob-
tained from sCJD patients and non-prion disease controls,
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including samples showing atypical Western blot profiles
(additional bands), as well as blood contaminated samples
were examined by different laboratories using the local
protocol for analysis and sample treatment. In 2009, ten
CSF samples derived from one 14-3-3 positive sCJD,
three 14-3-3 negative controls, one atypical positive, three
with a trace of 14-3-3 and two false-positive samples due
to blood contamination were analyzed by nine different
laboratories. In 2011, ten CSF samples encompassing two
14-3-3 positive sCJD, four negative controls, one atypical
positive, and three false-positive samples (two blood con-
taminated and one due to brain trauma) were analyzed by
nine different laboratories. In 2013, six CSF samples
encompassing one positive sCJD and five control patients
were analyzed by 13 different laboratories. The control
panel consisted of two samples which were 14-3-3 nega-
tive, one false-positive due to CNS inflammation, and two
false-positives due to blood-contaminated CSF.
4. To determine the stability of 14-3-3 gamma isoform in
sCJD CSF samples, we investigated the effect of short-
and long-term storage conditions at two different
temperatures.
5. To assess the impact of blood contamination of CSF sam-
ples, CSF from non-prion control donors were spiked
with blood cells and analyzed by 14-3-3 ELISA.
Determination of 14-3-3 Protein Gamma in CSF
by ELISA
Levels of 14-3-3 gamma protein in CSF were determined by
using the CircuLex 14-3-3 gamma ELISA Kit (BIOZOL
Diagnostica Vertrieb GmbH, Eching, Germany). We followed
the manufacturer’s instructions. Briefly, CSF samples were
applied in a dilution of 1:5 in dilution buffer. The level of
14-3-3 gamma were measured in arbitrary units (AU) per
mL (1 AU is almost equal to 1 pg). Samples were incubated
for 1 h at room temperature (25 °C) for capturing. After three
washing steps, 14-3-3 gamma detection antibody and later
horseradish peroxidise-conjugated anti-IgG were added and
incubated for 1 h at room temperature each. We measured
the colorimetric reaction at 450 nm using a 1420 Multilabel
Counter Victor 2 Wallac (PerkinElmer, Massachusetts, USA).
SDS-PAGE and Immunoblotting
ForWestern blot analysis, we followed a protocol as described
previously [9, 10]. A polyclonal 14-3-3 beta antibody, obtain-
ed from Abcam (Milton, GB) diluted 1:2000, was used as
primary antibody. As a secondary antibody, we used a poly-
clonal horseradish peroxidase-conjugated antibody (Jackson
Immuno Research, Leipzig, Saxony, Germany) (diluted
1:7500).
Before being heated for 2 min at 95 C, 10 μL sample
loading buffer (BioRad, München, Bavaria, Germany) were
added to CSF samples (30 μL). Subsequently, the samples
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) (12 % w/v polyacrylamide)
and transferred to polyvinylidene difluoride (PVDF)
hydrobond-P membranes (Amersham, Freiburg, Baden
Württemberg, Germany) using a semidry transblot cell for
70 min at 12 V; for labeling with antibodies, PVDF-
membranes were blocked with 5 % dry milk in PBS and
0.1 % Tween-20 for 1 h at room temperature, and afterward
incubated with the primary antibody overnight at 4 °C. Mem-
branes were rinsed in PBS-Tween and incubated with the cor-
responding horseradish peroxidise-conjugated secondary an-
tibody for 1 h. Protein bands were visualized after immersion
of the membranes in enhanced chemiluminescence (ECL) de-
tection system solution using Chemicon system (Bio-Rad).
Statistical Analysis
In the first part of this study, inter-rater reliability within
ring trials was calculated using Fleiss’ kappa for multiple
readers. In the second part, the 14-3-3 gamma isoform
ELISA was evaluated as a diagnostic test by using
receiver-operating characteristic (ROC) curves. Sensitivity
and specificity were calculated for all potential cutoff
values in a training dataset (n=103 sCJD patients, n=
188 control patients) to establish the best cutoff according
to the Youden index. An external validation of the test was
performed using this cutoff in a different data set includ-
ing 231 sCJD patients and 2035 control patients without
prion disease. Furthermore, the proposed cutoff was also
validated to an extended spectrum of control patients (in-
cluding CNS inflammatory diseases and blood-stained
CSF samples). When comparing 14-3-3 ELISA results
with those of Western blot analysis, we used the ANOVA
test with corresponding Tukey post hoc tests. For analysis
of 14-3-3 gamma isoform stability and blood contamina-
tion, Wilcoxon rank sum tests were applied.
Results
Establishment of 14-3-3 Gamma Isoform ELISA
as a Diagnostic Test for sCJD
14-3-3 protein levels in human CSF samples were measured
by using the CircuLex 14-3-3 gamma ELISA. We aimed to
establish this ELISA as a diagnostic test for CJD diagnosis.
Therefore, we analyzed the diagnostic validity of the
14-3-3 gamma ELISA according to the procedure de-
scribed above. Within the training dataset, the 14-3-3
gamma ELISA showed very good accuracy (AUC=0.9676).
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Using a cutoff of 20,000 AU/mL (the optimum level was
identified by Youden index) (Fig. 1a), a sensitivity of
93 % and a specificity of 96 % could be shown. Within
the validation dataset, we could confirm a high validity of
the 14-3-3 gamma ELISA (sensitivity=88 %; specificity=
96 %, Fig. 1b, c). The specificity of the test decreased
slightly when patients with inflammatory or blood-
stained CSF were included in the analysis (sensitivity=
88 %; specificity=93 %) (Fig. 1c). Predictive values were
not taken directly from the study population as these
values would give biased estimates due to the planned
oversampling of cases. Instead, they were calculated using
the Bayes formula assuming prevalence realistic for the
application setting of the test (1.8 % prevalence of CJD
in CSF samples referred to the German National Refer-
ence Center). The control cohort was composed of pa-
tients with neurodegenerative diseases or patients with
other neurological diseases as well as non-neurological
conditions. When we compared the 14-3-3 level of neu-
rodegenerative diseases and non-neurological disorders,
we obtained no significant difference (Supplement Fig. 1).
Analysis of a Combinative Effect of 14-3-3 with Tau
and S100B Protein
A potential combinative effect of different biomarker proteins
was examined in a patient cohort of 231 sCJD cases and 66
control donors, consisting of 15 patients with PD, 14with AD,
29 with a non-neurodegenerative disease, 4 with encephalitis,
and 4 with a tumor disease. From these patients, amounts of
14-3-3 protein, tau, and S100B were determined. Interesting-
ly, a combination of all three biomarkers resulted in the
highest specificity of 100 % and sensitivity of 94.8 %. The
combination of two biomarkers 14-3-3/tau, 14-3-3/S100B,
and tau/S100B showed a lower sensitivity varying between
92.2 and 93.5 % (Supplement Fig. 2).
Comparison of Western Blot and ELISA Detection
of 14-3-3 Protein
To compare two different detection systems for 14-3-3 pro-
tein, we analyzed the same CSF samples from sCJD patients
and control donors (randomly selected) in parallel by Western
Fig. 1 Determination of sensitivity and specificity of 14-3-3 ELISA de-
tection in CSF. A panel of CJD and non-prion control samples was ana-
lyzed for 14-3-3 gamma via ELISA. a ROC curve of the training dataset
is shown and suggests a cutoff at 20,000 AU/mL. b CSF samples from
sCJD contained a mean concentration of 14-3-3 of approximately
50,000 AU/mL. c 203 of 231 sCJD samples showed a 14-3-3 concentra-
tion higher than 20,000 AU/mL (~sensitivity of 87.9 %). From non-prion
control samples, 1875 samples contained a 14-3-3 concentration lower
than 20,000 AU/mL when inflammatory and blood-contaminated sam-
ples were excluded (specificity of 96.4 %). After inclusion of blood-
contaminated and inflammatory samples, the specificity of the test de-
creases to 92.9 %. The number of stars indicates the significance level:
one star (*) for p<0.05, two (**) for p<0.01 and three (***) for p<0.001
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blot and by ELISA. According to the subjectively determined
signal intensities in Western blot, we divided the samples into
four groups: (1) 14-3-3 negative, n=200; (2) 14-3-3 trace, n=
35; (3) 14-3-3 weak positive (n=35); and (4) 14-3-3 positive,
n=61 (Fig. 2a). Western blot analysis of CSF from sCJD pa-
tients usually showed either a positive or a weak positive 14-
3-3 signal while controls remained negative. In trace positive
classified samples, differentiation between sCJD and controls
was not always possible.
Even though different 14-3-3 isoforms were detected by
the Western blot and ELISA platforms, the relative amounts
of 14-3-3 concurred (Fig. 2a). Samples classified by Western
blot as 14-3-3 negative showed a mean level of 14-3-3 on
ELISA of 5773 AU/mL; trace classified samples 21,
322 AU/mL; weak positive classified samples 42,655 AU/
mL; and positive classified samples at >50,000 AU/mL
(p<0.001, Fig. 2b). Our findings indicate that both methods
deliver comparable results and are suitable for a reliable de-
tection of 14-3-3 protein for sCJD diagnostic purposes.
Reproducibility of 14-3-3 Western Blot Analysis
Across Different Laboratories
To investigate the interlaboratory reproducibility of CSF 14-3-
3 protein detection, we performed three ring trials between
2009 and 2013.
The results of inter laboratory agreement were indicated by
Fleiss’ kappa, a statistical measure for assessing the reliability
of agreement (Fig. 3a). Between 2009 and 2013, we observed
an increase of Fleiss’ kappa from 0.51 (indicating a moderate
agreement) to 0.68, which indicates a rise in agreement in 14-
3-3 protein detection frommoderate to substantial (Fig. 3a, b).
In the earlier ring trials, disagreement was mainly observed
in samples estimated as slightly positive (trace) or atypical
profiles (multiple IgG bands, usually indicating CNS inflam-
mation). In recent years, sample handling, terminology, and
CSF testing protocols for prion diseases have become more
standardized correlating with an increased reliability of 14-3-3
protein analysis.
Stability of the 14-3-3 Protein Concentration
After Long- and Short-Term Storage Conditions
To evaluate the effects of storage conditions (temperature,
duration of storage or freezing and thawing) on the concentra-
tion of 14-3-3 protein in CSF, we stored CSF samples from 10
sCJD patients in polypropylene tubes at room temperature and
4 °C for 8 days. In addition, CSF samples were either stored
for 6 or 12 months at −80 °C or subjected to 10 repeated
freezing and thawing cycles. Finally, we reanalyzed CSF sam-
ples originally classified as 14-3-3 positive and stored for 2–3,
5–6, and 8–9 years at −80 °C.
From each sample, we determined the 14-3-3 protein level
via ELISA and calculated at each time point or cycle the 14-3-
3 levels as percent of control (time point zero), which was
defined as 100 %.
Fig. 2 Comparison of two 14-3-3 detection systems ELISA andWestern
blot. CSF samples were analyzed both via Western blot for 14-3-3 beta
and by 14-3-3 ELISA for 14-3-3 gamma. a Patients analyzed byWestern
blot were separated into four groups according the 14-3-3 level, which
can be negative, trace positive, weak positive, and positive. The
corresponding Western blot signal was shown below. b The average 14-
3-3 concentration was calculated for each group. A strong association
between 14-3-3 Western Blot results and 14-3-3 ELISA results could be
confirmed when grouping Western Blot results in 4 categories (ANOVA
with Tukey post hoc tests, p<0.001 for all pairwise comparisons)
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Our obtained data indicated that the 14-3-3 proteins were
less stable at higher temperatures. After short-term storage
(8 days) at room temperature (~25 °C), we observed an aver-
age decrease of 14-3-3 levels (starting after 2 days) of approx-
imately 20 % after 8 days. At lower temperatures (4 °C), the
14-3-3 concentration was more stable and remained un-
changed for 2 days; afterward (starting from day 4 to day 8),
we obtained a decrease between 10 and 15 % (Fig. 4a, b). Ten
repeated freezing and thawing cycles did not result in a sig-
nificant loss of 14-3-3 protein (Fig. 4c), while long-term stor-
age at −80 °C reduced the level in average by 10–15 % after
6 months and by 15–20 % after 1 year (Fig. 4d). Approxi-
mately 80–85 % of the CSF samples showed elevated (>20,
000 AU/mL) 14-3-3 level after 6-year storage at −80 °C. After
9 years, the number of 14-3-3 positive sCJD samples de-
creased to 70–75 % (Fig. 4e).
Influence of Blood Contamination on 14-3-3 Protein
Levels in CSF
Since erythrocytes and platelets in human blood express 14-3-
3, contamination of CSF with blood may result in false-
positive 14-3-3 protein signals. To estimate the impact of
blood contamination on 14-3-3 protein detection in CSF, we
spiked CSF derived from a non-prion disease control
exhibiting a 14-3-3 protein level below 20,000 AU/mL with
blood. As controls, we used untreated and non-spiked CSF
and defined the 14-3-3 protein level as 100 %. The 14-3-3
protein level of blood-spiked CSF was calculated for each
sample as a percentage of control.
First, we examined whether 14-3-3 protein is measurable
when erythrocytes remained intact. CSF, spiked with 50,000
erythrocytes per μL, was analyzed before and after sonication
Fig. 3 Reproducibility of the 14-
3-3 protein detection by Western
blot. CSF from sCJD patients and
control donors were analyzed by
Western blotting in three different
ring trials between 2009 and
2013. a Results of interlaboratory
agreement were shown as Fleiss’
kappa. b The increase of Fleiss’
kappa from 0.51 to 0.68 in more
recent years correlates with a
more standardized preanalytical
sample handling and testing
protocols
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(5 min in a water bath) via Circulex ELISA for 14-3-3 gamma
isoform. 14-3 3 protein level increased after spiking with
blood, but the elevation was more dramatic after sonication
showing that intact erythrocytes had a lower but still signifi-
cant influence on 14-3-3 detection in the CSF (Fig. 5a).
CSF samples from control donors were spiked with differ-
ent numbers of blood cells, sonicated (to release 14-3-3 pro-
tein), and analyzed by 14-3-3 gamma ELISA. Our results
indicated that a cell number higher than 2500 cells/μL already
showed a significant increase of 14-3-3 protein level, due to
hemolysis of erythrocytes. A contamination of CSF samples
with more than 20,000 erythrocytes/μL can even lead to a
considerable false-positive 14-3-3 signal (Fig. 5b).
Hemolysis and release of 14-3-3 protein were simulated by
incubating CSF samples, spiked with 50,000 erythrocytes per
μL, for 16 days. A significant increase in 14-3-3 protein de-
tection was apparently immediately and becoming marked
after 2 days of incubation (Fig. 5c). For comparison, we used
nonspiked CSF as a control (=100 %).
We summarized the outcome of our study and prepared a
recommendation table for the preanalytical sample handling
and storage in order to improve the standardization of the 14-
3-3 analysis of human CSF samples from CJD patients further
(Table 1).
Discussion
14-3-3 protein detection has already been established as a
useful biomarker in prion disease diagnostic in various studies
[3, 5, 11, 12] (Table 2). However, 14-3-3 protein had been
criticized for being less reliable than other potential markers
(e.g., tau protein) partly due to their usual assessment byWest-
ern blot, since Western blot assessment is less standardized
and interpretation may vary in contrast to other detection as-
says such as ELISA. In addition to problems arising from the
lack of defined standards, for example a consensus validated
cutoff level for CSF 14-3-3 protein level, numerous factors
can influence the concentration of 14-3-3 protein in CSF such
as short- and long-term storage and the release of 14-3-3 pro-
tein from contaminating blood cells. Although recognized as
potentially important contributors to suboptimal specific-
ity, these factors have been relatively under-investigated
to date. Despite these reservations, the reproducibility of
Fig. 4 Effect of short- and long-term storage on 14-3-3 concentration in
human CSF of sCJD patients. We determined 14-3-3 levels by ELISA
and calculated the 14-3-3 level in percent of control (time point 0) which
was set as 100 %. The concentration of 14-3-3 in CSF from 10 different
sCJD patients (n=10) was determined before and after a storage at room
temperature for 8 days, b storage at 4 °C for 8 days, and c 10 repeated
freezing and thawing cycles, and d long-term storage at −80 °C. A sig-
nificant loss of 14-3-3 level could be observed in samples stored at 4 °C
after 4 days and in samples stored at room temperature after 2 days. Long-
term storage for the indicated times revealed a significant decrease of the
number of 14-3-3 positive CSF samples after 9 years. The number of stars
indicates the significance level: one star (*) for p<0.05, two (**) for
p<0.01, and three (***) for p<0.001. Error bars represent standard de-
viations (SD). Statistics were performed by using theWilcoxon rank sum
tests
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14-3-3 protein in Western blot detection assay between
different laboratories (center effect) was demonstrated
by the results of our ring trial studies, which showed
moderate agreement in the earlier trials becoming
substantial in the last trial. Not surprisingly, the
interlaboratory validity improved with more standardized
preanalytical sample handling and testing protocols over
the years in which the ring trials were conducted. Even
CSF samples with a trace level of 14-3-3 protein or
atypical samples (CNS inflammatory samples or those
contaminated with blood cells) still revealed a moderate
agreement.
Over recent years, there has been a marked increase
in 14-3-3 protein test referrals for suspected sCJD cases
across various laboratories [12]. Therefore, despite the
utility of 14-3-3 protein detection by Western blot, a
quantitative, less time-consuming, higher-throughput
screening platform would appear preferable.
Determination of the Diagnostic Accuracy of the 14-3-3
Gamma Isoform Assay
We analyzed 231 sCJD and 2035 control samples without
prion disease. At the cutoff at 20,000 AU/mL (as suggested
from the training dataset), we obtained a specificity of 96 %
and a sensitivity of 88 %.
Even though the detected isoforms are different
because of technical impediments for analysis of the
same isoform, Western blot and ELISA detection of
14-3-3 prote in were largely congruent fur ther
underlining the validity of the assessed 14-3-3 ELIS
A. In the literature, the reported sensitivities and spec-
ificities of 14-3-3 CSF testing in sCJD vary between
100 and 50 % [13, 14]; however, in most studies,
specificity and sensitivity of 14-3-3 protein detection
are higher than 80 % (Table 2) [3, 5, 15–19], similar
to the present study.
Fig. 5 Influence of blood contamination on the 14-3-3-detection. To
analyze the impact of blood contamination, we spiked CSF from
control donors with a defined amount of erythrocytes. The 14-3-3 level
of the spiked CSF samples was calculated in percent of control
(nonspiked) which was set as 100 %. a 14-3-3 levels in CSF, spiked with
erythrocytes, were analyzed before and after sonication in comparison to
nonspiked control CSF. After sonication, 14-3-3 levels were significantly
increased showing that intact erythrocytes have an influence on the 14-3-
3 level in CSF. b Sonication and spiking of CSF with different cell
numbers indicated that cell numbers higher than 2500 cells/μL might
give a significant false-positive 14-3-3 signal (p<0.05). cCSFwas spiked
with 50,000 cells/μL and incubated at room temperature without sonica-
tion for 16 days showing that a significant release of 14-3-3 via hemolysis
started after 2 days. The number of stars indicates the significance level:
one star (*) for p<0.05, two (**) for p<0.01, and three (***) for
p<0.001. Error bars represent standard deviations of the mean (SD).
Statistics were performed by using the Wilcoxon rank sum tests
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A more recent study, which determined 14-3-3 protein in
the CSF quantitatively via ELISA, reported a specificity of
95 % and a sensitivity of 73 % [20]. The reasons for discrep-
ancy with our findings might be (1) detection method, such as
variability in the protocols in each laboratory or different cut-
off points used or (2) the analyzed patient population. It has
been demonstrated that the 14-3-3 protein level is influenced
by the sCJD molecular subtype (variable in different coun-
tries), by the disease duration and the disease stage [7].
A recently developed diagnostic test, based on in vitro ampli-
fication of PrPSc, such as the RT-QuIC assay showed a very high
specificity of almost 100 %, but the average sensitivity for diag-
nostics was around 80 % and comparable to 14-3-3 results
[21–25].
A further possibility to increase the diagnostic accuracy of
prion diseases, in particular the sensitivity, is the combination
of different biomarker proteins such as 14-3-3, tau, and
S100B, which has been suggested in a previous study in a
Canadian sCJD population [26].
In our study, the sensitivity of sCJD diagnostic in-
creased to 94.8 by combining all three biomarker pro-
teins. When combining only two biomarker proteins, the
combination of 14-3-3 with S100B and tau with S100B
showed the highest sensitivity with 93.5 % which is
line with others [27]
Short- and Long-Term Stability of 14-3-3 Protein in CSF
of sCJD Patients
In the present study, we explored factors, which may influence
the CSF protein levels of 14-3-3 and explain interlaboratory
variations. A loss of 14-3-3 protein amount (15–20 %) was
observed when samples were stored for 8 days at room tem-
perature or 1 year at −80 °C. When we analyzed a panel of
arbitrary sCJD samples which were stored between 2 and
9 years at −80 °C, approximately 70–75 % of them exhibited
a 14-3-3 level higher than 20,000 rfu (after 9 years), indicating
that the 14-3-3 protein level is relatively stable.
Storage conditions were reported to markedly influence the
levels of brain-derived proteins in the CSF. For gamma eno-
lase, a marked decrease has been demonstrated when samples
are stored at −80 °C for months or years [28]. In case of Aβ1–
42, a loss of 20 % during the first 2 days independently of
whether CSF samples were stored at 4 °C or at 37 °C and a
Table 1 Recommendations for the standardization and for the
preanalytical treatment of CSF samples for the 14-3-3 analysis in sCJD
diagnostic
Recommendation for a preanalytical sample treatment
of CSF in sCJD diagnostic
1. Tube selection Polypropylene tubes
2. CSF volume 0.5–1.5 mL
3. Blood
contamination
Specimen macroscopically clear and <2500
erythrocytes/μL are acceptable
4. Shipping time Up to 1 week at 4 °C is acceptable
5. After arrival Assessment for blood contamination with visual
inspection supplemented by hemasticks or routine
microscopic quantification obtained from referring
laboratory, centrifugation at 2000×g for 10 min
and immediately freeze at −80 °C
6. Freeze/Thaw
cycles
Stable for at least 10 cycles
7. After analysis If 14-3-3 protein level is elevated, a confirmation by
RT-QuIC assay is recommended
8. Long-term
storage
After 1 year: 80–85 % and after 9 years 70–75 % of
the samples are 14-3-3 positive
Table 2 Comparison of the reported method, sensitivities, and
specificities in different studies about 14-3-3 detection in CSF of sCJD
patients
Study Specificity (1) and
sensitivity (2) in (%)
Number of patients
Zerr et al. [3, 5, 18, 19] 1) 93
2) 94
289 and 1003
Hsich et al. [33] 1) 96
2) 96
162
Beaudry et al. [13] 1) 100
2) 90
129
Lemstra et al. [34] 1) 87
2) 97
112
Kenney et al. [35] 2) 43 147
Collins et al. [36] 1) 67
2) 92
129
Green et al. [16] 1) 97 (94)**
2) 89 (82)
87
Van Everbroeck et al. [37] 1) 92
2) 100
253
Geschwind et al. [14] 2) 56 (43)* 32
Castellani et al. [38] 2) 87 90
Collins et al. [39] 2) 88 743
Sanchez-Juan et al. [27] 2) 85 227
Baldeiras et al. [40] 1) 97
2) 78
71
Matsui et al. [20] 1) 95*
2) 73
223
Begue et al. [41] 1) 92
2) 72
517
Coulthart et al. [26] 1) 88
2) 91
1000
Matsui et al. [20] 1) 95
2) 73
223
Hamlin et al. [42] 2) 68 420
Chohan et al. [43] 1) 74
2) 86
579
Other methods than Western blot are marked. In Western blot, routinely,
14-3-3 alpha/beta and in ELISA, the 14-3-3 isoform gammawas detected.
Controls are usually patients with other diagnosis (a prion disease was
excluded) such as other dementia, inflammatory diseases, psychiatric
disorders, headache, and epilepsy
*for ELISA and **for capture assay)
Mol Neurobiol
low resistance to repeated freezing and thawing cycles is
known [29–31]. In contrast, tau protein is considered to be
relatively stable at lower temperatures (4 °C) and for at least
6 freezing and thawing cycles. However, tau level in CSF
decreases when stored at higher temperature, e.g., 37 °C
[30]. Here, tau may be degradated via proteases, or it may
undergo conformational changes [32]. Compared to these pro-
teins, the stability of 14-3-3 at various storage conditions can
be estimated as good.
Contamination with Blood Cells Results in Elevation
of 14-3-3 Levels in CSF
Lysis of blood cells, such as erythrocytes, may result in artifi-
cially elevated CSF levels of 14-3-3 protein and a false-
positive signal. In routine diagnostic laboratory practice and
depending on the experience of the clinicians who perform the
lumbar puncture between 5 and 10 % of the CSF samples are
contaminated with blood cells during the procedure. There-
fore, there is a need to define clear guidelines to address this
problem. Our data indicate that artificially elevated 14-3-3
protein level can be reduced when blood cells remain intact.
Even though a CSF contamination with 2500 blood cells/μL
already resulted in a moderate elevation of 14-3-3 protein
levels, we consider a CSF contamination with more than 20,
000 cells/μL as critical for prion disease diagnosis. In CSF,
samples (not older than 1 or 2 days after the lumbar puncture),
a centrifugation step before freezing is recommended to re-
move blood cells. After 2 days, the hemolysis of blood cells
was increased to such an extent that no reliable results could
be obtained, and consequently, such samples should be ex-
cluded from further diagnostic procedures.
In conclusion, we standardized a commercial CSF 14-3-3
gamma isoform ELISA as a diagnostic assay for the quantifi-
cation of 14-3-3 protein in sCJD and provide a recommenda-
tion for sample handling in the diagnostic workup in prion
diseases.
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Real-time quaking-induced conversion (RT-QuIC) has
been proposed as a sensitive diagnostic test for spo-
radic Creutzfeldt–Jakob disease; however, before this
assay can be introduced into clinical practice, its reliabil-
ity and reproducibility need to be demonstrated. Two
international ring trials were undertaken in which a set
of 25 cerebrospinal fluid samples were analyzed by a
total of 11 different centers using a range of recombi-
nant prion protein substrates and instrumentation. The
results show almost complete concordance between the
centers and demonstrate that RT-QuIC is a suitably reli-
able and robust technique for clinical practice.
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Creutzfeldt–Jakob disease (CJD) belongs to a familyof fatal neurodegenerative diseases known as trans-
missible spongiform encephalopathies (TSEs). TSEs are
characterized by the post-translational conformational
change of a normally expressed protein called prion pro-
tein (PrP) into a disease-associated form known as PrPSc.
Once formed, PrPSc can induce PrP to undergo a confor-
mational change and produce more PrPSc in a self-
propagating manner. The PrPSc aggregates, becomes pro-
tease resistant, and deposits throughout the brain, leading
to spongiform change and neuronal loss.
Patients with sporadic CJD (sCJD) present with a
rapidly progressing dementia, and death usually occurs
within 6 months. Current diagnostic criteria for sCJD
rely on clinical features, the results of electroencephalog-
raphy and magnetic resonance imaging, and the presence
of 14-3-3 protein in the cerebrospinal fluid (CSF).1,2
These tests are not specific for CJD, and none is able to
detect all forms of CJD.3,4
A new approach to the premortem diagnosis of
sCJD has been to exploit the ability of small amounts of
CSF PrPSc to convert native PrP into PrPSc in a newly
described protein aggregation assay known as real-time
quaking-induced conversion (RT-QuIC). This technique
uses recombinant PrP (rPrP) as a substrate, which is
induced to aggregate by the addition of CSF containing
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PrPSc. Thioflavin T (ThT) in the reaction binds to the
aggregated PrPSc, causing a change in the ThT emission
spectrum, enabling the reaction to be monitored in real
time.5,6
CSF RT-QuIC has been shown to be an accurate
diagnostic test for sCJD, with a high degree of sensitivity
(85–87%) and specificity (99–100%).7,8 An increasing
number of laboratories have established RT-QuIC analy-
sis, and more are interested in doing so. Before RT-
QuIC is fully accepted into clinical practice as a reliable
premortem diagnostic test, studies are required to ensure
that laboratories performing this assay using different
forms of recombinant PrP as a substrate and a variety of
instrumentation are producing comparable results.
This study reports the findings of 2 international
ring trials that were undertaken over a 2-year period.
The initial ring trial comprised European participants,
whereas the second ring trial was wider and included par-
ticipants from Australia, Canada, and Japan.
Materials and Methods
CSF Samples
CSF samples were provided by the National CJD Research &
Surveillance Unit, United Kingdom. These samples are stored
at &minus;80 8C, and consent was obtained from the next of
kin for their use in research (05/MRE00/67). CSF samples
were selected on the basis of having appropriate ethical consent
and sufficient volume to ensure that each participant had an
adequate volume of CSF for analysis. Each set of CSF samples
was sent to each laboratory on dry ice and was analyzed blind
to the final diagnosis. The performance of the RT-QuIC assay
was evaluated in an interlaboratory ring trial, where identical
CSF samples were analyzed by each of the participating labora-
tories. Using this approach, it may be possible to identify ana-
lytical procedures that affect overall assay performance.
Participants
A total of 11 laboratories participated in the ring trials: Depart-
ment of Pathology, University of Melbourne, Melbourne, Aus-
tralia (Aust); Department of Neurology, Antwerp University,
Antwerp, Belgium (Bel); Prion Laboratory Section, Public
Health Agency of Canada, Winnipeg, Canada (Can); Labora-
tory Investigations of Alzheimer’s Disease and Prion Diseases,
Pitie-Salpêtrière Hospital Group, Paris, France (Fra); Depart-
ment of Neurology, University Medical Center and German
Center for Neurodegenerative Diseases, G€ottingen, Germany
(Ger-Goet); Centre for Neuropathology and Prion Research,
Ludwig Maximilian University, Munich, Germany (Ger-Mun);
Department of Neurological Sciences, University of Bologna,
Bologna, Italy (It-Bol); Department of Neurodegenerative Dis-
ease, Carlo Besta Neurological Institute, Milan, Italy (It-Mil);
Department of Neurological Sciences, National Institute of
Health, Rome, Italy (It-Rome); Department of Molecular
Microbiology and Immunology, Nagasaki University, Nagasaki,
Japan (Jpn); and National CJD Research & Surveillance Unit,
University of Edinburgh, Edinburgh, UK (UK).
First Ring Trial
Seven laboratories (UK, It-Rome, It-Mil, It-Bol, Fra, Ger-Mun,
Bel) participated in the first ring trial, and each received 10
CSF samples sent on dry ice. Of these, 1 was from a patient
with neuropathologically confirmed sCJD, 4 were from patients
with probable sCJD, diagnosed according to the World Health
Organization criteria, 2 patients improved and the diagnosis of
sCJD was excluded on clinical grounds, 1 patient had a steroid-
responsive encephalopathy, 1 had no neuropathological evidence
of CJD at postmortem, and 1 had mixed Alzheimer disease and
vascular dementia at postmortem. The age of the patients
ranged from 48 to 86 years and included 5 females and 5
males. The disease duration of the patients with sCJD ranged
from 2 to 12 months, and the CSF samples were taken between
53% and 94% of the disease duration.
Second Ring Trial
Eleven laboratories (UK, It-Rome, It-Mil, It-Bol, Fra, Ger-
Mun, Ger-Goet, Jpn, Aust, Can, and Bel) participated in the
second ring trial, and each received 15 CSF samples sent on
dry ice. One laboratory analyzed the CSF samples twice using a
BMG LABTECH (Ortenberg, Germany) Optima and a BMG
LABTECH Omega. Of the 15 CSF samples, 5 were from
patients with probable sCJD, 3 were from patients with neuro-
pathologically confirmed sCJD, 1 patient improved and the
diagnosis of sCJD was excluded on clinical grounds, 1 had seiz-
ures, 1 had anti-immune encephalopathy, 1 had a psychiatric
disorder, 1 had Huntington disease, 1 had a non-CJD demen-
tia, and 1 had normal pressure hydrocephalus. The age of the
patients ranged from 55 to 87 years and included 6 females
and 9 males. The disease duration of the patients with sCJD
ranged from 1 to 26 months and the CSF samples were taken
between 57% and 90% of the disease duration.
Methodology
Each laboratory performed the RT-QuIC analysis using a stand-
ard 10mM phosphate buffer (pH 7.4), 170mM NaCl (total
400mM including phosphate buffer) containing 0.1mg/ml rPrP,
10 lM ThT, and 10mM ethylenediaminetetraacetic acid tetraso-
dium salt. However, a range of instrumentations, analytical con-
ditions, and types of rPrP were used (Table 1). Most laborato-
ries used either a BMG LABTECH Optima or a BMG
LABTECH Omega, whereas 1 laboratory used a Tecan Infinite
F200PRO (Tecan Group, M€annedorf, Switzerland). Nine labo-
ratories used hamster full-length (23–231) rPrP (supplied by
Bristol Institute of Blood Sciences, Bristol, UK),8,9 2 used
human full-length (23–231) rPrP (produced in-house),7 and 1
used a hamster–sheep chimeric rPrP (hamster 14–126 residues
followed by sheep residues 141-234, produced according to pre-
viously reported conditions).5
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Results
The results of the ring trials are given in Tables 2 and 3.
In the first ring trial 6, of 7 laboratories obtained positive
RT-QuIC responses in the CSF samples from all 5 sCJD
cases; the remaining laboratory obtained positive RT-
QuIC responses in the CSF of 4 of the 5 sCJD cases. A
negative RT-QuIC result was obtained in the CSF of 1
sCJD case, which had a disease duration of 12 months.
This laboratory was using a BMG LABTECH Optima
instrument, with full-length hamster rPrP as substrate
and 30 ml of CSF. These conditions were similar to other
laboratories in the study that obtained positive results for
this particular CSF sample. A limited volume of CSF
was sent to each laboratory, and this meant that repeating
the analysis of this particular CSF by the individual labo-
ratory was not possible.
None of the laboratories obtained positive RT-
QuIC responses in any of the 5 CSF samples from
patients without sCJD. Four of these laboratories used a
BMG LABTECH Optima, and the remaining 3 used a
BMG LABTECH Omega. However, all the laboratories
used the same full-length hamster rPrP.
The second ring trial included a larger number of
laboratories with a wider geographical distribution and
included a wider range of instrumentation and type of
rPrP. Despite this, the results showed complete concord-
ance (see Table 3). Of the 11 laboratories that partici-
pated in this ring trial, 11 obtained positive RT-QuIC










Criteria for Positive Result
UK Omega Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 24,000rfu at 90 h
UK Optima Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 90 h
Germany
(Munich)
Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates





15 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 80 h
Italy (Bologna) Optima Ham FL 15 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 6,000rfu at 90 h
Italy (Milan) Optima Ham FL 30 ml 600rpm 60 s
shake/60 s rest
42 Mean of 2 highest replicates
of 4> 10,000rfu at 90 h
Italy (Rome) Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 32,000rfu at 90 h
France Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 34,345rfu at 90 h
Belgium Omega Ham FL 20 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> 20,000rfu at 90 h
Canada Omega Ham FL 30 ml 900rpm 90 s
shake/30 s rest
42 Mean of 2 highest replicates
of 4> twice baseline
reading at 90 h
Japan Tecan Hum FL 5 ml Max 30 s
shake/30 s rest
37 At least 2 of 6 replicates
> 400rfu at 90 h
Australia Optima Hum FL 5 ml 750rpm 30 s
shake/30 s resta
37 Mean of 2 highest replicates
of 4> 70% of baseline
rfu reading at 90 h
aShaking performed in a Thermomixer Comfort (Eppendorf, Hamburg, Germany) before being read in an Optima instrument.
CSF 5 cerebrospinal fluid; Ham FL 5 hamster full-length PrP (23–231)8,9; Ham-Sh chimeric 5 hamster residues14–128:sheep141–
234
5; Hum FL 5 human full-length (23–231)—codon 129M6; PrP 5 prion protein; rfu 5 relative fluorescence units.
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responses in all 8 CSF samples from sCJD patients. All
11 laboratories obtained a positive RT-QuIC response in
the CSF from the sCJD patient, with a disease duration
of 26 months. This CSF sample was taken 21 months
after the onset of symptoms. The laboratory that failed
to obtain a positive CSF RT-QuIC response in an sCJD
case in the first ring trial correctly identified all sCJD
cases in the second ring trial. None of the analytical
parameters had been changed by the laboratory in ques-
tion. Importantly, the laboratory that used a Tecan Infi-
nite shaker with a human rPrP as a substrate also cor-
rectly identified all sCJD cases. One laboratory analyzed
the ring trial CSF samples using both the BMG LAB-
TECH Optima or a BMG LABTECH Omega and
obtained similar results using both instruments despite
having different cutoff criteria. None of the laboratories
obtained positive RT-QuIC responses in CSF samples
from patients with non-CJD disorders.
Discussion
In the first ring trial, 6 of 7 laboratories correctly identi-
fied all sCJD cases; however, 1 laboratory obtained a
negative CSF RT-QuIC result from an sCJD patient
with a disease duration of 12 months. It has been
reported that CSF samples from sCJD patients with lon-
ger disease durations may have lower seeding efficiency10;
however, this effect was not seen in the second ring trial,
where the CSF from an sCJD patient with a disease
duration of 26 months was identified by RT-QuIC by all
laboratories. All the laboratories that participated in the
first ring trial used the same source and type of rPrP and
either Optima or Omega BMG LABTECH instrumenta-
tion, and demonstrated high levels of accuracy and agree-
ment between laboratories.
The second ring trial took place 18 months later
and was expanded to include other European laboratories
and participants from Australia, Canada, and Japan.
Some of the additional laboratories used alternative types
of rPrP and other forms of instrumentation. This enabled
a more rigorous assessment of the robustness and trans-
ferability of the RT-QuIC technique.
All 11 laboratories accurately identified the 8 CSF
samples from sCJD patients, and none detected a posi-
tive RT-QuIC in any of the non-CJD cases. The agree-
ment between laboratories using different rPrP as a sub-
strate and different forms of instrumentation is
encouraging. The accuracy of the results obtained was
identical for each of the rPrP substrates used. From this


















1 Patient improved M (68) Still alive n/a 0/7 100
2 Steroid-responsive
encephalopathy
M (69) Still alive n/a 0/7 100
3 Neuropathological
evidence of mixed AD
and vascular dementia
M (86) 3 92 0/7 100
4 Psychiatric disorder M (63) Still alive n/a 0/7 100
5 Patient improved F (74) Still alive n/a 0/7 100
6 Definite sCJD—codon
129 MM; PrP type: 1
F (75) 3 83 7/7 100
7 Probable sCJD F (48) 2 77 7/7 100
8 Probable sCJD—codon
129 MM
F (64) 12 94 6/7 83
9 Probable sCJD F (72) 4 76 7/7 100
10 Probable sCJD—codon
129 VV
M (69) 4 53 7/7 100
AD 5 Alzheimer disease; CSF 5 cerebrospinal fluid; F 5 female; LP 5 lumbar puncture; M 5 male; n/a 5 applicable; PrP 5 prion
protein; RT-QuIC 5 real-time quaking-induced conversion; sCJD 5 sporadic Creutzfeldt–Jakob disease.
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limited number of CSF samples, we have achieved an
overall sensitivity of between 85.7% and 100% and a
specificity of 100%. This compares well with a previous
intralaboratory study, which had fewer participants and
reported a sensitivity of 85% and a specificity of 99%.10
The complete concordance between laboratories demon-
strates that CSF RT-QuIC is adaptable to different labo-
ratory instrumentation and different types of rPrP. The
high level of accuracy and agreement between laborato-
ries using CSF RT-QuIC is supportive of this technique
being introduced into clinical practice.
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1 Patient improved F (87) Still alive — 0/12 100
2 Seizures M (56) — — 0/12 100
3 Autoimmune encephalitis F (82) Still alive — 0/12 100
4 Psychiatric disorder M (55) Still alive — 0/12 100
5 Huntington disease F (67) Still alive — 0/12 100
6 Mixed vascular and
Alzheimer dementia
M (80) Still alive — 0/12 100
7 Normal pressure
hydrocephalus
M (78) Still alive — 0/12 100
8 Definite sCJD F (63) 6 90 12/12 100
9 Definite sCJD—codon
129 MM; PrPSc type 1
M (73) 1 71 12/12 100
10 Definite sCJD—codon
129 MM
M (66) 5 57 12/12 100
11 Probable sCJD M (84) No data — 12/12 100
12 Probable sCJD M (66) 3 83 12/12 100
13 Probable sCJD M (69) 3 80 12/12 100
14 Probable sCJD F (65) 26 83 12/12 100
15 Probable sCJD F (67) 8 88 12/12 100
aThe UK laboratory submitted 2 sets of results using 2 sets of instruments: BMG LABTECH Omega and BMG LABTECH
Optima.
CSF 5 cerebrospinal fluid; F 5 female; LP 5 lumbar puncture; M 5 male; PrPSc 5 disease-associated form of prion protein; RT-
QuIC 5 real-time quaking-induced conversion; sCJD 5 sporadic Creutzfeldt–Jakob disease.
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IntroDuctIon
Transmissible spongiform encephalopathies or prion diseases, 
such as Creutzfeldt–Jakob disease (CJD), are fatal neurodegenera-
tive disorders characterized by the accumulation of abnormally 
folded PrPSc in the brain. In humans, sporadic CJD (sCJD) is the 
most common prion disease, followed by genetic CJD (gCJD) and 
transmitted CJD (iatrogenic CJD and variant CJD). For diagno-
sis of sCJD, elevated levels of certain biomarkers for neurode-
generation (such as 14-3-3, total tau, calcium-binding protein B 
(S-100B), neuron-specific enolase, desmoplakin, and α-synu-
clein)1–8, in the CSF in combination with a detailed clinical 
examination, magnetic resonance imaging (MRI) and electro-
encephalogram, are important9,10, although currently a definite 
diagnosis of CJD requires confirmation at autopsy11. However, 
the development of in vitro prion protein conversion assays, such 
as RT-QuIC, to detect misfolded prion protein has, to our knowl-
edge, for the first time led to a test with a specificity close to 100% 
(refs. 12–15) and with high reproducibility across different labora-
tories12,16, arguably making postmortem autopsies less essential.
Development of the protocol
To date, several in vitro protein conversion systems, which are 
directly based on the conversion of cellular prion protein (PrPC) 
to a conformationally altered isoform, PrP scrapie (PrPSc), and 
aggregation of a PrP-amyloid, have been developed. These include 
PMCA17, the amyloid seeding assay18, QuIC19 and RT-QuIC14,19,20. 
These assays are comparable to a PCR for misfolded proteins, 
exploiting the seeded/template-induced assembly and conversion 
of PrPC directly to ordered PrPSc aggregates, thereby amplifying 
miniscule amounts of PrPSc to a detectable level14,17,20,21. Although 
initial aggregation assays used brain material as the source of PrPC 
substrate17, these have subsequently been improved by the use of 
bacterially synthesized recombinant PrPC (recPrPC) substrate19,22.
In RT-QuIC reactions, small amounts of misfolded PrPSc 
act as a seed, recruiting single recPrPC substrate molecules and 
inducing their conversion by integrating them into a growing 
amyloid aggregate concomitant with a conformational change 
of the substrate to a seeding-competent state (Fig. 1). Atarashi 
et al.14 were the first to use a QuIC assay to demonstrate the 
capacity of PrPSc from human CSF samples to seed conver-
sion of recPrPC. During RT-QuIC, the samples are subjected 
to cycles of vigorous shaking, which presumably fragment the 
PrPSc aggregates into additional reactive seeds for conversion. 
With each cycle, consisting of incubation and shaking steps, the 
amyloid reaction product can increase exponentially (Fig. 1). 
The PrPSc-seeded conversion reaction product is enriched in 
β-strand secondary structure, as seen in amyloid, which enhances 
the fluorescence of the thioflavin T (Th-T) dye upon binding. 
Hence, nascent PrPSc can be monitored in real time using a 
temperature-controlled shaking fluorescence plate reader. The 
amplitude and kinetics of fluorescence enhancement can be used 
to evaluate relative seeding activities in test samples. The quantita-
tive parameters were defined as lag phase (time to reach 10,000 
r.f.u. (relative fluorescence units)), area under the curve (AUC)
and maximal signal intensity (Fig. 1). Proteinase K–resistant
PrP (PrPres), generated after amplification by RT-QuIC, can be
detected by western blotting13,14.
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the development and adaption of in vitro misfolded protein amplification systems has been a major innovation in the detection 
of abnormally folded prion protein scrapie (prpsc) in human brain and cerebrospinal fluid (csF) samples. Herein, we describe a 
fast and efficient protein amplification technique, real-time quaking-induced conversion (rt-QuIc), for the detection of a prpsc 
seed in human brain and csF. In contrast to other in vitro misfolded protein amplification assays—such as protein misfolding 
cyclic amplification (pMca)—which are based on sonication, the rt-QuIc technique is based on prion seed–induced misfolding 
and aggregation of recombinant prion protein substrate, accelerated by alternating cycles of shaking and rest in fluorescence 
plate readers. a single rt-QuIc assay typically analyzes up to 32 samples in triplicate, using a 96-well-plate format. From sample 
preparation to analysis of results, the protocol takes ~87 h to complete. In addition to diagnostics, this technique has substantial 
generic analytical applications, including drug screening, prion strain discrimination, biohazard screening (e.g., to reduce 
transmission risk related to prion diseases) and the study of protein misfolding; in addition, it can potentially be used for the 
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The adaptation of the RT-QuIC assay to a 96-well-plate for-
mat14 has the advantage over previous in vitro amplification 
systems of facilitating the automation of the technical proc-
ess, thus enabling the easy detection of PrP aggregates by Th-T; 
these aggregates are considered to be noninfectious. Analysis 
of multiple reactions (96-well plates) also allows the measure-
ment of up to 32 different samples in triplicate in the same 
run. In our 96-well-plate-based RT-QuIC assay12, the signal 
response depends in part on the amount of PrPSc seed. With 
the cutoff threshold set at 10,000 r.f.u., the typical detection 
limit for postmortem sCJD brain tissue for the assay condi-
tions described here is a dilution of ≈10−8, whereas for CSF it 
is a dilution of ≈10−1.2 (Figs. 2a–e and 3a–e, Supplementary 
Tables 1 and 2). Higher dilutions reveal mean positivity rates 
below 50%, even though a positive fluorescence signal can be 
still detected in some reactions (Figs. 2e and 3e). Control samples 
(taken from patients without prion disease) show, independently 
of the dilution, no PrP-seeding reaction (maximal signal below 
cutoff) in the brain or in CSF (Figs. 2f and 3f).
Applications of the method
Being able to analyze RT-QuIC reactions in 96-well plates in an 
automated assay permits the high-throughput analyses of sam-
ples and increases the potential for numerous other applications 
in scientific and industrial fields23,24. Moreover, RT-QuIC assays 
have been developed for most prion strains and many human and 
animal tissues and body fluids15,20,25–28, which makes this method 
applicable for diagnostics, biological science, prescreening for 
potential therapeutics and testing of materials for contamina-
tion with infectious prions. The following paragraphs illustrate 
examples of the manifold applications of the RT-QuIC assays.
Human prion disease diagnostics in CSF and in nasal brushings. 
The RT-QuIC assay was first established as a test for human prion 
disease diagnostics using CSF by Atarashi et al.14. The recent 
experience of different groups underlines the reproducibility of 
RT-QuIC across various CSF storage conditions with remarkable 
sensitivity and specificity, indicating that RT-QuIC is a robust 
diagnostic method12,13,25,29. Currently, although the RT-QuIC 
assay exhibits excellent specificity, it remains contentious whether 
this test can be used for a ‘definite’ diagnosis of prion disease, 
for which confirmation by neuropathological examination is still 
generally required. Given the sensitivity of most reported RT-
QuIC assays, a negative test result cannot generally be interpreted 
as ruling out a CJD diagnosis. Future studies need to assess the 
potential of the method to detect all forms of CJD, including vari-
ant, genetic and atypical cases. To minimize ‘gray-zone’ and/or 
equivocal results but maintain specificity, we recommend testing 
each sample at least in triplicate and defining a sample as positive 
when >50% of the replicate wells show a PrP seeding reaction 
within 80 h. The evidence for this has been published recently12.
Another RT-QuIC application is the detection of PrPSc in the 
olfactory neuroepithelium of prion disease patients15. RT-QuIC 
assays seeded with dilutions of nasal brushing samples were posi-
tive in 42 of 43 sCJD patients (cumulatively from two reports) and 
negative in 43 of 43 control donors, indicating a sensitivity of 97% 
and a specificity of 100% (refs. 15,30). Testing nasal brushings 
elicited stronger and faster RT-QuIC responses (higher seeding 
signal and shorter lag phase) as compared with corresponding 
CSF samples from the same patients. Moreover, as compared with 
lumbar punctures, nasal sampling provides an alternative and less 
invasive tool for collecting diagnostic specimens.
Prion strain typing. In sCJD, different types of PrPSc (type 1 or 2) 
and codon 129 genotypes of the prion protein gene (PRNP) 
determine at least six different molecular sCJD subtypes9,31 that 
show distinct clinicopathological phenotypes and transmission 
characteristics32. A CSF study specifically tested the effects of 
molecular subtypes of prion disease on the RT-QuIC response33 
and found that the type of prion disease (sporadic or genetic), the 



























Figure 1 | Schematic diagram of PrP seed amplification by RT-QuIC assay. 
PrPSc seed derived from brain or CSF and recPrPC (substrate) is mixed and 
incubated, promoting the misfolding and incorporation of recPrPC, and thus 
generating polymers of misfolded β strand–rich recPrPC as found in amyloid. 
The upper part shows how RT-QuIC exploits aspects of the prion replication 
mechanism. PrPSc is used as a seed (prickly dark red balls), which elongates 
through incorporation of recPrPC substrate (green balls). A conformational 
change is induced in the substrate, faithfully adopting some characteristics 
of the initial seed, including PK resistance, β-strand secondary structure and 
the ability to seed PrP amyloid formation (prickly orange balls). The growth 
of the generated β strand–rich PrP polymers can be detected in real time by 
a fluorescent dye. Through periods of shaking (quaking) and rest, these β 
strand–rich PrP polymers can potentially fragment, generating more seeds, 
in turn inducing an exponential amplification of recPrPC conversion. Signal 
quantification occurs according to the seeding parameters of interest, such 
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type affected RT-QuIC responses; e.g., in gCJD forms, samples 
from E200K mutation carriers showed the strongest effect on the 
observed outcome variables. Recent studies by Orrú et al. using 
multiple recPrPC substrates also revealed a correlation of RT-
QuIC responses with different prion strains24,28,34.
Therapeutic drug prescreening. As PrPSc is the main causative 
agent of prion diseases35,36, most potentially therapeutic sub-
stances target PrPSc, the conversion process of PrPC to PrPSc or 
PrPSc aggregation. The RT-QuIC assay can be used to compare the 
efficiency of antiprion compounds in vitro by using PrPSc from 
sCJD brain tissue as seed, providing a screening assay that mimics 
disease-relevant conditions23. However, unlike PMCA, RT-QuIC 
assays do not fully recapitulate infectious PrPSc replication37, and 
thus it may be possible that some inhibitors of PrPSc formation 
might be missed.
However, not all substances that inhibit the conversion process 
of PrP in the RT-QuIC assay are potential therapeutics of prion 
disease; thus, we propose that substances known to interfere with 
Th-T, or with other chemicals from the reaction buffer, to change 
the reaction conditions (such as a change of the pH or digestion 
of the rec PrP substrate) or to show abnormal RT-QuIC seeding 
kinetics should be excluded23.
In addition, the use of suitable controls without prion disease 
is very important in order to exclude the possibility that false-
positive reactions in the RT-QuIC assay could result from the 
replication of a noninfectious amyloid state.
Testing of materials for contamination with infectious pri-
ons. Prions have a particularly high tolerance to inactiva-
tion and can retain infectivity even after undergoing routine 
sterilization processes38,39. Avoiding contamination of reus-
able surgical instruments and medical devices can therefore 
be challenging. The detection of prion infectivity by bioassay 
may take up to 2 weeks in cell-based infectivity assays40 or 
even up to 20 weeks when a rapid mouse bioassay is applied41. 
In contrast, the application of an in vitro amplification assay 
(such as PMCA or RT-QuIC) for assessing prion infectivity 
is less time-consuming and very sensitive20,42,43. In this way, 
the efficiency of existing decontamination procedures can be 
estimated, and novel substances/procedures for disinfection 
can be developed.
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Figure 2 | Influence of serial dilution of brain homogenates on the RT-QuIC response. Serial dilution of brain homogenates, before RT-QuIC analysis, results in 
a decrease of the RT-QuIC response in sCJD samples. (a–e) Brain homogenates (10% (wt/vol)) from sCJD (MM1) patients (n = 6) and from (f) control patients 
(n = 8) (proven free of prion disease, such as those diagnosed with hypoxic encephalopathy, posterior infarct, cerebral amyloid angiopathy or basal ganglion 
infarct) were diluted in the range of 10−3 to 10−14. Diluted samples were analyzed in triplicate by RT-QuIC. Statistical parameters quantifying the RT-QuIC 
response, such as AUC (b), maximal signal intensity (c) and time until the signal reached the cutoff (lag phase (d)), were determined per experimental group 
(dilution). (a) The curves depict the mean kinetics of the RT-QuIC response of six sCJD samples per experimental group (dilution). Fluorescence signal was 
measured every 30 min. Mean values were determined per sample and used to calculate total mean per experimental group (dilution) per measurement  
(time point). Total means were connected by linear interpolation, displaying an averaging line per experimental group (dilution). The cutoff is indicated at 
10,000 r.f.u. This diagram shows aggregated data; therefore, no individual information about AUC, maximal signal intensity or lag phase can be extracted. 
(b–d) The RT-QuIC responses of sCJD samples were quantified by calculating statistical parameters such as area under the curve, maximal signal intensity and 
lag phase. Mean values were determined per sample and used to calculate total mean per experimental group (dilution) and s.e.m. Bar graphs show total mean 
+ s.e.m. per experimental group (dilution). Cutoff is indicated at 10,000 r.f.u. (e) The validity of the RT-QuIC responses from sCJD samples was determined
by calculating the percentage of positive replicates per sample. Mean values were determined per sample and used to calculate total mean per experimental
group (dilution) and (s.e.m. Bar graphs show total mean + s.e.m. per experimental group (dilution). Samples diluted 10−9 to 10−14 showed a mean positivity
rate of <50%. (f) The curves depict the mean kinetics of the RT-QuIC response from control samples per experimental group (dilution). Fluorescence signal
was measured every 30 min. Mean values were determined per sample and used to calculate total mean per experimental group (dilution) per measurement
(time point). Total means were connected by linear interpolation, displaying an averaging line per experimental group (dilution). The cutoff is indicated at
10,000 r.f.u. This diagram shows no seeding of PrP. Therefore, seeding parameters such as AUC, maximal signal intensity and lag phase were not available.
The study conformed to the Code of Ethics of the World Medical Association and informed consent was given by all study participants or their legal next of kin,
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Other protein misfolding diseases. A characteristic feature of 
the major neurodegenerative diseases is the progressive accu-
mulation of protein aggregates in a self-propagating manner, 
with a topographical pattern characteristic of each disease. 
Although the spread of misfolded protein was initially thought 
to have a crucial role only in prion diseases, recent studies have 
identified similar characteristics for amyloid-beta, tau and 
α-synuclein in various other models44–46. The term ‘prion-like’ 
protein propagation in neurodegeneration is now widely used 
to address analogous mechanisms, which might have a role in 
Alzheimer’s disease and α-synucleinopathies, such as Parkinson’s 
disease. The RT-QuIC technique therefore also has considerable 
diagnostic and analytical potential with respect to other misfolded 
proteins (with biomarker potential), such as amyloid-beta, tau 
and α-synuclein46,47.
Comparison with other methods
In comparison with the PCMA, there are technical variances 
between assays. PCMA is based on cyclical sonication of the 
reaction tube, consisting of an incubation and a sonication step 
at 37 °C (refs. 17,48,49). Tubes close to the horn’s wall might 
show lower amplification efficiency compared with those in 
the center50, indicating that quaking might be easier to control. 
There are also a few variations regarding the ingredients of the 
conversion/reaction buffers. The biological tissues in which 
human prion seeding activity has been detected by RT-QuIC 
include CSF, nasal fluid or brain14,51, whereas PMCA can be used 
to detect PrPSc also in blood, urine, spleen, milk, oral secretions 
or liver27,52–55. A more sensitive modification of the RT-QuIC, the 
enhanced QuIC (eQuIC), could, however, be used to detect prion 
seeds in samples with a very low amount of PrPSc (e.g., urine) or 
in samples containing compounds inhibitory for the seeding reac-
tion, such as blood plasma25,27,52–55. This includes a preanalytical 
immunoprecipitation step with beads coated with a PrPSc-specific 
antibody (e.g., 15B3).
RT-QuIC uses bacterially synthesized recPrPC as a substrate 
for the conversion and aggregation of PrP. In contrast, PMCA 
usually uses brain homogenate as a source of PrPC substrate. 
In brain-homogenate-based PMCA reactions, PrPSc is faith-
fully replicated in the presence of necessary cofactors, giving an 
infectious product56. However, in RT-QuIC assays, the amplified 
recPrPC reaction product (PrPres) is seeded by, but not confor-
mationally identical to, PrPSc and lacks infectivity28. This is an 
advantage for prion disease diagnostics because CSF-RT-QuIC 
requires no high biosecurity level and has little potential for cross- 
contamination. A further advantage of RT-QuIC analysis 
compared with PMCA is the multiwell format, which enables 
the analysis of up to 96 samples in the same experiment and the 
ease of signal quantification (detection of Th-T in a fluorescence 
reader, whereas PMCA requires a PK digestion and semiquantita-
tive detection of PrPSc in a western blot).
Limitations
One of the most important preanalytical issues is that con-
tamination with blood cells, such as erythrocytes, may result 
in a false-negative RT-QuIC response. During the lumbar 
puncture, between 5 and 10% of CSF samples are contaminated 
with blood cells, which may disturb the PrP seeding activity. 
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Curves of control samples
Figure 3 | Influence of serial dilution of CSF on the RT-QuIC response.  
Serial dilution of CSF, before RT-QuIC analysis, results in a decrease of the 
RT-QuIC response of sCJD samples. (a–e) CSF samples from sCJD (MM1) 
patients (n = 7) and from (f) control patients (n = 8) (without prion disease 
and with an alternative diagnosis such as headache, psychotic disorder, 
inflammation or another neurodegenerative disorder) were diluted in the 
range of 10−0.6 to 10−2.4. Diluted samples were analyzed in quadruplicate  
by RT-QuIC. Statistical parameters quantifying the RT-QuIC response,  
such as area under the curve (b), maximal signal intensity (c) and time 
until the signal reached the cutoff (lag phase (d)), were determined per 
experimental group (dilution). (a) The curves depict the mean kinetics of 
the RT-QuIC response of sCJD samples per experimental group (dilution). 
Fluorescence signal was measured every 30 min. Mean values were 
determined per sample and used to calculate total mean per experimental 
group (dilution) per measurement (time point). Total means were connected 
by linear interpolation, displaying an averaging line per experimental  
group (dilution). The cutoff is indicated at 10,000 r.f.u. (b–d) The RT-QuIC  
responses of sCJD-samples were quantified by calculating statistical 
parameters, such as AUC, maximal signal intensity and lag phase. Mean 
values were determined per sample and used to calculate total mean per 
experimental group (dilution) and s.e.m. Bar graphs show total mean + 
s.e.m. per experimental group (dilution). Cutoff is indicated at 10,000 
r.f.u. (e) The validity of the RT-QuIC responses from sCJD samples was 
determined by calculating the percentage of positive replicates per sample. 
Mean values were determined per sample and used to calculate total mean 
per experimental group (dilution) and s.e.m. Bar graphs show total mean 
+ s.e.m. per experimental group (dilution). Samples diluted 10−2.4 showed 
a mean positivity rate of <50%. (f) The curves depict the mean kinetics of 
the RT-QuIC response of control samples. Fluorescence signal was measured 
every 30 min. Mean values were determined per sample and used to 
calculate total mean per experimental group (dilution) per measurement 
(time point). Total means were connected by linear interpolation, displaying 
an averaging line per experimental group (dilution). The cutoff is indicated 
at 10,000 r.f.u. This diagram shows no seeding of PrP. Therefore, seeding 
parameters such as AUC, maximal signal intensity and lag phase were not 
available. The study conformed to the Code of Ethics of the World Medical 
Association, and informed consent was given by all study participants or 
their legal next of kin, and the study being approved by the local ethics 
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the RT-QuIC reaction markedly, when all cells are completely 
hemolyzed by sonication12.
Other difficulties currently encountered when comparing 
results of various RT-QuIC assays from different laboratories are 
the variations in samples, reaction conditions and instruments, 
and the lack of standardized criteria for defining positive and 
negative responses. Such criteria will inevitably depend on the 
goals of the type of testing being performed (e.g., whether to 
minimize false positives or false negatives) and the idiosyncrasies 
of individual testing conditions. In the case of using RT-QuIC 
for human prion disease diagnosis using CSF specimens, fur-
ther validation studies are required, although the RT-QuIC assay 
has demonstrated considerable diagnostic utility to date. For the 
protocol described below, a qualitative cutoff at 10,000 r.f.u. is 
suggested on the basis of two previous studies12,33.
The duration of the RT-QuIC assay described below is usu-
ally 4 d. However, a recent study, which requires further validation, 
describes conditions, such as higher temperature (up to 55 °C) and 
addition of 0.002% (wt/vol) SDS and recPrPc substrate (hamster 
90–231), that can reduce assay times to a matter of hours and 
improve sensitivity25.
Although not studied exhaustively, another limitation of 
RT-QuIC assays is that only very few recPrPc substrates, such as 
bank vole recPrPc, are able to amplify and to detect variant CJD 
prions. When using hamster 23–231 recPrPc, no PrP variant CJD 
seeding could be obtained28.
Experimental design
Protocol workflow. In the RT-QuIC, a PrPSc seed is incubated 
with a recPrPC substrate (derived from several species, such as 
human, hamster, hamster–sheep chimera and bank vole; see fur-
ther discussion below)12,13,14,28 and a buffer to induce the con-
version of the substrate and to subsequently amplify miniscule 
amounts of seed up to a detectable limit. Seed (derived from prion-
infected human brain or CSF), substrate (recombinant hamster– 
sheep PrPC (recHaShPrPC)) and buffer are prepared (Steps 4–7), 
combined in a 96-well plate (black 96-well, optical-bottom 
plates; see Steps 8–12) and incubated in a fluorescence plate 
reader (FLUOstar OPTIMA) at 42 °C for 80 h with intermittent 
shaking cycles, consisting of 1 min of double orbital shaking at 
the highest speed (600 r.p.m.) followed by a 1-min incubation 
break (Steps 13–17). Converted PrP is monitored in real time 
by Th-T fluorescent dye analysis. The kinetics of the aggrega-
tion process is determined by measuring the Th-T fluores-
cence signal (450 nm excitation and 480 nm emission) every 
30 min. For data analysis, a quantification of statistical param-
eters, such as lag phase (time to reach the cutoff), AUC and 
maximal signal intensity, using common software programs is 
suggested (Steps 18–21).
Source of recPrPc. recPrPc may derive from various species—i.e., 
human22, hamster13, bank vole24,28—or, as in the present protocol, 
from a hamster–sheep chimera, which, in our experience, pref-
erably shows less spontaneous aggregation and has been evalu-
ated for diagnostic purposes over many years. Some evidence 
for comparability to other PrP substrates (e.g., human recPrPc) 
can be derived from ring trials, in which the data suggest that 
various slightly modified test conditions provide similar test 
sensitivities and positive rates12,16,25,29. A recently described bank 
vole recPrPc has been proven to support the amplification of many 
different PrPSc strains, different Gerstmann–Straussler–Scheinker 
syndrome (GSS) mutations and variant CJD, which cannot be 
detected with hamster recPrPc (refs. 24,28). We propose that 
bank vole recPrPc may become interesting for diagnostics in the 
future; however, an evaluation study on a larger patient cohort is 
still required.
Validation of the protocol: sensitivity and specificity. This 
protocol using the hamster–sheep chimera has been extensively 
validated through the analysis of CSF samples from different 
patient cohorts (within Europe and Japan) consisting of >500 
patients with prion disease and >500 controls. Samples that show 
a seeding reaction (increase of the Th-T fluorescence signal) in 
50% of the replicates are considered to be positive for a prion 
disease. Negative-control patients (without prion disease) show 
no seeding activity of PrP in the RT-QuIC assay after 80 h. A 
test run, in which the positive control remained negative, was 
considered to be a failed test. Under our conditions, we suggest 
a cutoff setting at 10,000 r.f.u. (cutoff may vary in different ref-
erence laboratories depending on the instrumental settings and 
the baseline of the reaction) to obtain a specificity of 99% and a 
sensitivity of 85% for the RT-QuIC assay for all prion diseases12. 
Across different prion diseases, the sensitivity varies from 100% 
for gCJD, 80% for sCJD and 57% for fatal familial insomnia (FFI) 
cases12. Other studies report a specificity of almost 100% and a 
sensitivity between 80 and 96% (refs. 13,14,25). For gCJD cases, 
the following sensitivities for RT-QuIC assays have been reported: 
FFI (100%), gCJD E200K (87%) and gCJD V210I (100%)29. 
Potential reasons for discrepancies in FFI sensitivities across 
studies can be sampling errors due to the low number of patients 
tested (7 versus 22 patients) and methodological differences (e.g., 
use of different PrP substrates)12,29.
Replicates and controls. For diagnostics, each sample is generally 
analyzed in triplicate. A sample is considered as positive for the 
conversion of a competent amyloid (indicating a prion disease) if 
two out of three replicates show a Th-T signal higher than the cut-
off (10,000 r.f.u.). As controls, samples from patients with (posi-
tive control) or without prion disease (negative control) are used. 
Control samples are prepared as described in the Reagent Setup.
False-positive reactions. A potential problem of in vitro amplifi-
cation assays is the occurrence of false-positive reactions, caused 
by spontaneous conversion of the recPrPC. Accordingly, our assay 
components and conditions have been carefully selected to maxi-
mize the kinetic difference between PrPSc-seeded and spontane-
ous, prion-independent responses. This protocol uses chimeric 
recPrPC, composed of the Syrian hamster residues 23–137, fol-
lowed by sheep residues 141–234 (of the R154 Q171 polymor-
phism)26, in conjunction with reaction conditions that greatly 
retard the spontaneous aggregation of recPrPC and thereby the 
occurrence of false-positive signals. A number of other combi-
nations of recPrPC substrate and reaction conditions have also 
been described as being suitable for the detection, and sometimes 
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MaterIals
REAGENTS
Seed (brain homogenates or CSF samples from humans with prion  
diseases) ! cautIon Informed consent must be obtained from all subjects, 
according to the relevant national legislation for the use of human biologi-
cal samples for research. This study conformed to the Code of Ethics of the 
World Medical Association, and informed consent was given by all study 
participants or their legal next of kin, and the study was approved by the 
local ethics committee in Göttingen (no. 24/8/12). ! cautIon This is a 
biological hazard. Biocontainment precautions need to be followed, accord-
ing to the relevant national legislation for the use of biological samples from 
humans with prion diseases. In this study, precautions were taken related to 
biosafety level 3.  crItIcal Stability of the RT-QuIC seed in CSF under 
short- and long-term storage conditions is very high. CSF can be stored at 
room temperature or +4 °C for 8 d and at −80 °C for 9 years12.
Substrate (recombinant hamster–sheep chimeric PrPC (recHaShPrPC))  
 crItIcal Laboratories that do not want to produce their own  
recHaShPrPC (as described in Supplementary Methods) can request  
the protein from Thermo Fisher Scientific using the internal  
cat. no. 7700002 because it is not included in its standard catalog.
Sodium phosphate dibasic (Sigma-Aldrich, cat. no. S7907)
Sodium phosphate monobasic (Sigma-Aldrich, cat. no. S8282)
NaCl (Roth, cat. no. 39571)
Thioflavin-T (Th-T; Sigma-Aldrich, cat. no. T3516)
SDS (Sigma-Aldrich, cat. no. L3771)
Tris–HCl (Sigma-Aldrich, cat. no. T3253)
0.5 M EDTA (Fluka Analytical, cat. no. 06390)
5 M NaCl (SAFC Biosciences, cat. no. 59222C)
PBS (Biochrome, cat. no. L 1825)
50% (wt/vol) NaOH (Roth, cat. no. 8655.1)
EQUIPMENT
Centrifuge (Eppendorf, model no. 5415C)
pH meter (Sartorius, model no. PP-15)
Vortex (Scientific Industries, model no. Genie 2)
Scale (Sartorius, model no. TE313S)
Computer (Dell)
Excitation filter, 450 nm for FLUOstar OPTIMA (BMG Labtech)
Emission filter, 480 nm for FLUOstar OPTIMA (BMG Labtech)
96-Well Optical-Bottom Plate (Nunc, cat. no. 265301)
Sealing tape (Nunc, cat. no. 232702)
Syringe, 5 ml (Ecoject, cat. no. 4676651)
Filter, Millex-GP, 0.22 µM (Merck-Millipore, cat. no. SLGP033RS)
Microtubes, 1.5 and 2.0 ml 
Falcon tubes, 15 ml (VWR, cat. no. 734-0452)
Falcon tubes, 50 ml (Sarstedt, cat. no. 62.547)
REAGENT SETUP 
Homogenization buffer This buffer contains 0.1% (wt/vol) SDS prepared  
in PBS. For a 100-ml preparation, weigh 0.1 g of SDS, add 100 ml of PBS  
and dissolve the SDS by vortexing for 30 s, using a Vortex Genie 2 at level  
10 (or an equivalent). Filter-sterilize the homogenization buffer using a 5-ml 
syringe and a 0.22-µM filter. Keep the buffer stock at 4 °C in 15-ml Falcon 
tubes, and discard after 3 months.
5× PBS, pH 6.9, buffer For a 50-ml preparation, weigh 0.67 g of sodium 
phosphate monobasic, 0.35 g of sodium phosphate dibasic and 1.90 g of 
NaCl and 48 ml of ddH2O. Dissolve the substances by vortexing for 30 s,  
using a Vortex Genie 2 at level 10 (or an equivalent). Adjust the pH to  
6.9, using NaOH (50% (wt/vol)) and a PP-15 pH meter (or an equivalent).  
Dilute 5× PBS, pH 6.9, in 50 ml of ddH2O and mix by vortexing for 30 s,  
using a Vortex Genie 2 at level 10 (or an equivalent). Filter-sterilize 5× PBS, 
pH 6.9, using a 5-ml syringe and a 0.22-µM filter. Keep 5× PBS, pH 6.9, 
buffer stock at −20 °C in 15-ml Falcon tubes, and discard after 3 months.
Basis mix Prepare basis mix by mixing the following components at the  
ratio stated below for five reactions: 167 µl of ddH2O, 100 µl of 5× PBS buffer, 
pH 6.9, 22 µl of NaCl (5 M) and 1 µl of EDTA (0.5 M). The total volume  
of basis mix per reaction is 57.0 µl (285 µl for five reactions). Preparing basis 
mix for multiple reactions in total in one tube is recommended to avoid  
errors in concentration by pipetting small volumes. Mix by vortexing for 30 s, 
using a Vortex Genie 2 at level 10 (or an equivalent). Keep the basis mix stock 



























Th-T solution This solution contains 1 mM Th-T. For a 10-ml preparation of 
10 mM Th-T, dissolve 0.036 g of Th-T in 10 ml of ddH2O and vortex the  
mixture for 30 s, using a Vortex Genie 2 at level 10 (or an equivalent). Filter-
sterilize the 10 mM Th-T solution using a 5-ml syringe and a 0.22-µM filter. 
Keep the 10 mM Th-T buffer stock in the dark at room temperature in a 15-ml 
tube, and discard it after 3 months. For a 10-ml preparation of 1 mM Th-T, 
dilute 1 ml of 10 mM Th-T in 9 ml of ddH2O. Mix by vortexing for 30 s, using a 
Vortex Genie 2 at level 10 (or an equivalent). Keep the 1 mM Th-T buffer stock 
in the dark at room temperature in 2.0-ml tubes, and discard it after 3 months.
Final mix This mix contains 1× PBS, pH 6.9, 170 mM NaCl, 1 mM EDTA, 
10 µM Th-T and 0.1 mg/ml recHaShPrPC. For 1 reaction, mix 57.0 µl 
of basis mix, 1.0 µl of Th-T (1 mM) and 27.0 µl of recHaShPrPC (0.37 
mg/ml). Freshly prepare the final mix for each experiment, and discard  
it after use.
CSF sample preparation Prepare the CSF sample at room temperature (~22 °C). 
Centrifuge the native sample at 720g for 10 min to remove cell debris, using 
a 5415C centrifuge (or an equivalent). Remove the supernatant and discard 
the pellet. Transfer the supernatant to 1.5-ml tubes. Mix the supernatant for 
30 s by using a Vortex Genie 2 at level 10 (or an equivalent). The supernatant 
can be stored at room temperature or 4 °C for up to 8 d, or at −80 °C for up 
to 9 years. ! cautIon This is a biological hazard. Biocontainment precautions 
need to be followed according to the relevant national legislation for the use of 
biological samples from humans with prion diseases. In this study, precautions 
were performed related to biosafety level 3. ! cautIon Informed consent must 
be obtained from all subjects, according to the relevant national legislation  
for the use of human biological samples for research. This study conformed to 
the Code of Ethics of the World Medical Association, and informed consent 
was given by all study participants or their legal next of kin, and the study  
was approved by the local ethics committee in Göttingen (no. 24/8/12).  
 crItIcal Blood contamination may cause false-negative results.
Brain sample preparation Prepare brain sample at room temperature. Weigh 
the native sample using a TE313S scale (or an equivalent), and add 10% 
(wt/vol) homogenization buffer. Homogenize the sample in homogenization 
buffer for 30 s, using a Polytron PT1300D (or an equivalent) at highest speed. 
Centrifuge the homogenized sample at 10,000g for 10 min to remove cell  
debris using a 5415C centrifuge  (or an equivalent). Remove the supernatant 
and discard the pellet. Divide the supernatant into aliquots in 1.5-ml tubes, 
and vortex them for 30 s to mix adequately using a Vortex Genie 2 at level 
10 (or an equivalent). The supernatant can be used immediately, or it can be 
stored at −80 °C. ! cautIon Biological hazard. Biocontainment precautions  
need to be followed, according to the relevant national legislation for the use 
of biological samples from humans with prion diseases. In this study, precau-
tions were performed related to biosafety level 3. ! cautIon Informed consent 
must be obtained from all subjects, according to the relevant national legisla-
tion for the use of human biological samples for research. This study con-
formed to the Code of Ethics of the World Medical Association, and informed 
consent was given by all study participants or their legal next of kin, and the 
study was approved by the local ethics committee in Göttingen (no. 24/8/12).
EQUIPMENT SETUP
FLUOstar OPTIMA This RT-QuIC protocol requires the fluorescence 
reader FLUOstar OPTIMA, a computer and two software programs—i.e., the 
OPTIMA control program and the OPTIMA data analysis program. Both 
programs are provided by BMG Labtech. Using the FLUOStar Optima to run 
the RT-QuIC assay requires two protocols and one script—i.e., the Rocky 
Mtn Read and Rocky Mtn Shake protocols, and the Rocky Mtn Script. These 
can be requested from BMG Labtech. To measure the Th-T fluorescence 
according to this protocol, use two filters for the FLUOstar OPTIMA—i.e., 
an excitation filter at 450 nm and an emission filter at 480 nm. Both can be 
bought from the BMG Labtech Company. Enter the following settings into 
the Rocky Mtn Read protocol, and save the settings: microplate (Nunc 96), 
optic (bottom optic), excitation filter (450 nm), emission filter (480 nm) and 
additional shaking (no shaking). Enter the following settings into the Rocky 
Mtn Shake protocol, and save the settings: shaking mode (double orbital), 
shaking width (600 r.p.m.), additional shaking (before each cycle) and  
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proceDure
operation of the fluorescence reader ● tIMInG 15 min
1| Start the FLUOstar OPTIMA fluorescence reader and the computer.
2| Enter the temperature (42 °C) into the OPTIMA control program, and let the machine heat up.
3| Enter the following settings into the Rocky Mtn Script: target temperature (42 °C), cycle time (1,800 s) and total  
measurement time (80 h).
 pause poInt The fluorescence reader can wait until the start of experiment.
preparation of recHashprpc ● tIMInG 1 h and 15 min
4| Thaw the recHaShPrPC (0.6 mg/ml) at  ≈4 °C.
 crItIcal step Thawing at higher temperatures may induce aggregation of recHaShPrPC.
5| Load 500 µl of recHaShPrPC per 100-kDa filter at room temperature.
6| Centrifuge the loaded filters for 5 min at 1.310g at room temperature to remove possible existing aggregates,  
using a 5415C centrifuge (or an equivalent).
? trouBlesHootInG
7| Discard the filters and proceed with recHaShPrPC filtrate at room temperature.
 crItIcal step Some recHaShPrPC is lost during the filtration process because aggregates are removed; the concentration 
of the filtrate should be ≈0.37 mg/ml.
 pause poInt Filtered recHaShPrPC can be stored at room temperature for up to 30 min.
unification and mixing of the sample at room temperature ● tIMInG variable; ~2 h
8| Optional: thaw the frozen samples at room temperature.
9| Pipette 85 µl of final mix per well into a black 96-well optical-bottom plate.
 crItIcal step Avoid creating bubbles, as they may cause variable results.
10| Vortex the sample for 30 s to mix adequately, using a Vortex Genie 2 at level 10 (or an equivalent).
11| Pipette 15 µl of sample into each well containing final mix from Step 9.
 crItIcal step Avoid creating bubbles, as they may cause variable results.
12| Seal the plate with a sealing tape.
 crItIcal step Make sure that the sealing tape is fixed on the plate without any air bubbles. Air bubbles may connect 
wells and may cause cross-contamination between different wells during the shaking process.
running of the experiment ● tIMInG 80 h and 15 min
13| Open the plate tray of the FLUOstar OPTIMA, and insert the plate from Step 12 into the plate carrier.
14| Declare used wells in the layout of the Rocky Mnt Read protocol.
15| Click the ‘Start’ button.
16| Wait until the temperature is at 42 °C, and confirm that the plate is inserted.
17| Run the machine for 80 h.
? trouBlesHootInG
 pause poInt After the run is completed, the fluorescence reader is ready for the taking of results; the machine stops 
executing the shaking and incubating cycles, but holds the temperature. To reduce the run-time of the machine, it is 
recommended to take the results on the day the run is completed.
examination of results ● tIMInG variable; ~2 h and 15 min
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19| Open the latest run and verify the results. Criteria for a successful run are a complete data set (data for every well  
that should be measured) and valid signals from the controls.
? trouBlesHootInG
20| Discard the used black 96-well optical-bottom plate, or freeze it at −20 °C for further analyses of the product.  
Discard frozen plates after 3 months.
? trouBlesHootInG
21| Analyze the data using the OPTIMA data analysis program according to the manufacturer’s instructions, or export  
the data and analyze in another program—e.g., Microsoft Office Excel or GraphPad Prism.
? trouBlesHootInG
Troubleshooting advice can be found in table 1.
taBle 1 | Troubleshooting table.
step problem possible reason solutions
6 Loss of volume during the  
filtration process
~30% of the volume is usually lost during the 
filtration process, due to aggregation  
of recHaShPrPC
Take this into account in your preparation 
of the final buffer mix
17 Unexpected system shutdown Depending on the computer operating system, 
the system can shut down and restart for 
several reasons and, consequently, stop the 
software executing the fluorescence reader. 
This can be caused by, e.g., software routines 
aimed at saving energy or updating the system
Change the software routines to avoid this
19 Failed test (false-negative  
positive control)
Premature aggregation of recHaShPrPC 
Aggregation of recHaShPrPC may result in a 
loss of amyloid fibrillation potential
Verify storage and handling conditions 
RecHaShPrPC should be stored at −80 °C. 
Thaw recHaShPrPC on ice or at 4 °C and do not 
vortex; gently mix by swinging back and forth
False-positive result Bubbles may cause false-positive results Avoid bubbles in Steps 9 and 11 while 
pipetting
False-negative result Dilution of brain sample might be too high  
CSF sample might be contaminated  
with blood
Choose lower dilutions of the brain sample. 
Dilutions from 10−3 to 10−8 usually work 
Verify the absence of blood contamination. 
Contaminated CSF samples might be rescued 
by centrifugation at 720g for 10 min at 
room temperature12
There are no data for some  
wells, and there are data for wells 
that should not be measured
The plate layout has been changed in the 
Rocky Mnt Shake protocol, instead of the 
Rocky Mnt Read protocol
Verify the plate layout in the Rocky Mtn 
Read protocol
There are data for all wells that 
should be measured, but the  
data do not remotely correspond 
to anticipated results
The plate was accidently rotated by 180 °,  
so the original plate layout and orientation  
of wells no longer fit
Turn the plate layout around by 180°,  
and verify the position of the plate layout 
and anticipated results
Fluorescence curves vary  
vastly between replicates
The software setting for optic is set to  
‘top optic’  
 
The filters have been installed in the  
wrong orientation
Change the software setting from ‘top optic’ 
to ‘bottom optic’ in the Rocky Mnt Read 
protocol  
Check the orientation of the filters
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● tIMInG
Steps 1–3, operation of the fluorescence reader: 15 min
Steps 4–7, preparation of recHaShPrPC: 1 h and 15 min
Steps 8–12, unification and mixing of the sample at room temperature: variable; ~2 h to pipette a 96-well plate
Steps 13–17, running of the experiment: 80 h and 15 min
Steps 18–21, examination of results: ~2 h and 15 min; timing for analysis of the data is variable, depending on the  
experimental setup and analysis software: ~2 h to analyze maximal signal intensity (maximal r.f.u.), AUC and lag phase  
for a complete 96-well plate and compare between experimental groups
antIcIpateD results
This protocol has been used to study the aggregation of misfolded PrP in brain tissue and CSF from prion disease patients33. 
Positive samples showed an increase of seeding activity (>cutoff) within a duration of 80 h (Figs. 2a and 3a). By contrast, 
negative samples (those without prion disease) revealed no PrP seeding in the brain or in CSF (Figs. 2f and 3f). The seeding 
efficiency of PrP, indicated by the Th-T signal, correlated with the dilution. Higher dilutions revealed a decrease of PrP seed-
ing, indicated by a lower AUC, lower maximal signal intensity, longer lag phase and a lower positivity rate (Figs. 2a–e  
and 3a–e; supplementary tables 1 and 2). In addition to prion disease diagnostics12, this methodology can be used for  
a number of different approaches, such as studying protein misfolding in detail, prescreening for compounds inhibiting the  
PrP conversion, testing for prion contaminations or studying other protein misfolding diseases (e.g., Alzheimer’s disease).
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Stability and Reproducibility Underscore Utility of RT-QuIC
for Diagnosis of Creutzfeldt-Jakob Disease
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Abstract Real-time quaking-induced conversion (RT-QuIC)
allows the amplification of miniscule amounts of scrapie prion
protein (PrPSc). Recent studies applied the RT-QuIC methodol-
ogy to cerebrospinal fluid (CSF) for diagnosing human prion
diseases. However, to date, there has not been a formal multi-
centre assessment of the reproducibility, validity and stability of
RT-QuIC in this context, an indispensable step for establish-
ment as a diagnostic test in clinical practice. In the present
study, we analysed CSF from 110 prion disease patients and
400 control patients using the RT-QuIC method under various
conditions. In addition, “blinded” ring trials between different
participating sites were performed to estimate reproducibility.
Using the previously established cut-off of 10,000 relative fluo-
rescence units (rfu), we obtained a sensitivity of 85 % and a
specificity of 99 %. The multi-centre inter-laboratory reproduc-
ibility of RT-QuIC revealed a Fleiss’ kappa value of 0.83 (95%
CI: 0.40–1.00) indicating an almost perfect agreement. More-
over, we investigated the impact of short-term CSF storage at
different temperatures, long-term storage, repeated freezing and
thawing cycles and the contamination of CSFwith blood on the
RT-QuIC seeding response. Our data indicated that the PrPSc
seed in CSF is stable to any type of storage condition but
sensitive to contaminations with blood (>1250 erythrocytes/
μL), which results in a false negative RT-QuIC response. Fresh
blood-contaminated samples (3 days) can be rescued by remov-
al of erythrocytes. The present study underlines the reproduc-
ibility and high stability of RT-QuIC across various CSF stor-
age conditions with a remarkable sensitivity and specificity,
suggesting RT-QuIC as an innovative and robust diagnostic
method.
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Introduction
Transmissible spongiform encephalopathies or prion diseases
are characterized by the aggregation and accumulation of
misfolded scrapie prion protein (PrPSc) in brain tissue. They
can occur spontaneously (sporadic) but also be due to familial
and iatrogenic causes. Sporadic Creutzfeldt-Jakob disease
(sCJD) is the most common prion disease in human, followed
by genetic CJD (gCJD) and iatrogenic CJD (iCJD). Different
molecular sCJD subtypes, which show unique clinicopatho-
logical phenotypes and transmission characteristics [1] and
depend on the codon 129 genotype of the prion protein gene
(PRNP) as well as the type of PrPSc, have been reported [2, 3].
The adaptation of in vitro amplification systems for the
detection of PrPSc in human cerebrospinal fluid (CSF) was
an innovation for the pre-mortem diagnosis. RT-QuIC analysis
uses recombinant prion protein (recPrP) as a substrate to am-
plify very small amounts of PrPSc seed in human CSF to
detectable levels. Time course of conversion can bemonitored
in real-time by a fluorescent dye using a fluorescent reader.
Four previous studies demonstrated the diagnostic potential of
RT-QuIC through amplification of PrPSc from human CSF,
derived from sCJD and gCJD patients [4–7].
However, despite these initial reports, establishing RT-
QuIC as a routine diagnostic test in clinical practice requires
a comprehensive validation and standardization. To date, there
is a lack of studies dealing with inter-laboratory reproducibil-
ity and standardization, assessment of short- and long-term
stability and contamination of CSF samples with potential
inhibitory blood cells of the RT-QuIC seeding response in
human CSF of CJD patients. All of these parameters may lead
to an artificial decrease or increase of PrP seeding activity in
CSF and to false positive or negative results.
The aim of the present study was to further analyse the
applicability of RT-QuIC for routine diagnostic purposes.
Analysis of 110 CSF samples from prion disease patients
and 400 from a control panel consisting of 200 retrospectively
tested patients (diagnoses including Alzheimer’s disease
[AD], Parkinson’s disease [PD], inflammatory [IF] and other
non-prion diseases) and 200 prospectively randomly selected
patients was undertaken to obtain diagnostic data more
aligned to a routine clinical setting. Also, two ring trials were
performed to generate data about the reproducibility of the RT-
QuIC assay. Finally, the influence of different CSF storage
conditions (long- and short-term storage or repeated freezing
and thawing cycles) and the influence of blood contamination
on the RT-QuIC seeding response were examined.
Materials and Methods
Patients
CSF samples were collected through routine activities of the
German National Prion Disease Surveillance Center associat-
ed with the University Medical Center Göttingen. Samples
were derived from 110 prion disease patients, consisting of
64 sCJD, 39 gCJD (33 E200K, 6 V210I mutation carriers)
and 7 FFI (D178N mutation), as well as 400 control patients.
Initial data on the cohort have been published elsewhere [7].
The data were used to calculate the sensitivity and specificity.
All prion disease cases were neuropathologically confirmed.
The 200 retrospectively tested control patients represent
those with either a clinically or pathologically defined alter-
native diagnosis (92 female, 108 male; aged 16–87 years;
mean age 64.1±0.9 years at notification). This control group
consisted of AD patients (rapid progressive and classical
forms), patients with depression, Dementia with Lewy bodies,
PD, psychosis, bipolar disorder, multiple sclerosis, epilepsy,
schizophrenia, inflammatory CNS disease and others. The
200 prospective samples were enrolled from the Neurochem-
istry Laboratory at the Department of Neurology in the frame-
work of quality assurance and were tested blinded for clinical
and personal data. Gender- and age-dependent effects on the
RT-QuIC seeding response were excluded before [7].
CSF Samples
CSF samples were stored at −80 °C prior to analysis.
Haemorrhagic CSF samples were excluded from the study.
Ethical Statement
The study was conformed to the Code of Ethics of the World
Medical Association and informed consent was given by all
study participants or their legal next of kin with the study
being approved by the local ethics committee in Goettingen
(No. 24/8/12). All samples were analysed blinded for at least
personal data.
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RT-QuIC Analysis
The RT-QuIC was performed as described previously [7].
Briefly, 85 μL of reaction buffer were seeded with 15 μL of
freshly thawed and neat CSF to a final volume of 100 μL, with
each CSF sample generally run in triplicate. Prepared plates
were sealed (VWR, Hannover, Germany) and incubated in a
plate reader (FLUOStar OPTIMA, BMG Labtech, Ortenberg,
Germany) at 42 °C for 80 h with intermittent shaking cycles,
consisting of 1 min double orbital shaking at 600 rpm follow-
ed by a 1-min break. Beta-sheet formation kinetic was deter-
mined by measuring the thioflavin T (ThT) fluorescent signal
(450 nm excitation and 480 nm emission) every 30 min in
relative fluorescence units (rfu). When we obtained more than
50 % positive replicates (signal ≥10,000 rfu after 80 h), the
sample was considered as positive. Controls were considered
as negative when more than 50 % of the replicates revealed a
RT-QuIC response after 80 h below 10,000 rfu.
Expression and Purification of Recombinant Sheep-Hamster
PrP
All RT-QuIC experiments were performed using the chimeric
recPrP composed of the Syrian hamster residues 14 to 128
followed by sheep residues 141 to 234 of the R154 Q171 poly-
morphic haplotype as described before [7, 8]. The recPrP was
prepared and its functionality was verified according to the
method described by Wilham et al. [9].
Study Design
The present study was performed in three stages in order to
determine the reproducibility, stability and validity of RT-
QuIC for use as a diagnostic test for human prion diseases:
1. To investigate the reproducibility of the RT-QuIC assay,
we conducted two ring trial studies between different lab-
oratories. Fifty-four CSF samples obtained from sCJD
patients and 32 non-prion disease controls were examined
in two laboratories (UMG, Thermo Fisher Scientific). In a
second ring trial, one sCJD and five controls were inves-
tigated in four laboratories (UMG, Ilsong Institute of Life
Science, Nagasaki University Graduate School of Bio-
medical Sciences, Western General Hospital, and Univer-
sity of Melbourne).
2. To calculate specificity, sensitivity and predictive values
of the RT-QuIC assay, we analysed CSF samples from
110 prion disease patients, as well as from 400 control
patients.
3. To determine the stability of RT-QuIC, sCJD CSF sam-
ples (n=12) and control samples (n=6) were incubated
under short- and long-term storage conditions.
4. To assess the impact of blood contamination of CSF sam-
ples on the RT-QuIC response, we spiked CSF from sCJD
(n=6–8) and control samples (n=6–8) with defined
amounts of blood cells from control patients.
5. To investigate the impact of transportation on blood-
contaminated samples, we spiked CSF from sCJD (n=8)
and control samples (n=8) with a defined amount of
blood cells from control patients and incubated the CSF
samples for 0, 1, 3 and 8 days at room temperature.
Statistical Analysis
In the first part of this study, inter-rater reliability within ring
trials was calculated using the Fleiss’ kappa for multiple
readers. A Fleiss’ kappa value of >0.60 was defined as sub-
stantial agreement, Fleiss’ kappa >0.80 as almost perfect
agreement between raters.
To test the diagnostic validity, we established a training
dataset consisting of 28 CJD patients and nine controls, which
were not part of the present study. A Receiver operating char-
acteristic (ROC) analysis was performed on this dataset, and
the best cut-off value was estimated to be 10,000 rfu based on
the Youden index. We thereby confirmed the analysis of
McGuire et al. [4] in an independent dataset and applied the
cut-off value of 10,000 rfu to this study.
For the analysis of the stability of RT-QuIC, a two-step
approach was performed. First, positivity rates were calculated
(defining a seeding efficiency of ≥10,000 rfu within 80 h as
positive) and were compared between groups using ANOVAs.
Agreement levels and Fleiss’ kappas were calculated in order
to investigate the stability of positivity under different circum-
stances. Then, measurements of seeding efficiency were calcu-
lated for each individual sample defined by relative area under
the curve (rel. AUC) and maximal ThTsignal (maximum), and
groups were compared using paired and unpaired t tests as
appropriate. For graphical illustration, time series plots are pre-
sented at each step of the analysis, displaying means of seeding
activity for each point in time (each measurement) in the re-
spective groups. Thus, these illustrations show aggregated data
for each point in time, but information about means of AUCs
or individual maximums cannot be read out of these plots [7].
Sensitivity, specificity and predictive values of RT-QuIC
were calculated for the entire dataset as well as for distinct
subgroups. All analyses were conducted using Stata 12 soft-
ware (StataCorp, College Town, US) and R 2.15.3 software.
Analysis of CSF by ELISA for 14-3-3
Levels of 14-3-3 protein in CSF were determined by using the
CircuLex 14-3-3 Gamma ELISA Kit (BIOZOL Diagnostica
Vertrieb GmbH, Eching, Germany) according to a previously
established protocol [7].
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Determination of Total Tau Level
CSF levels of total tau protein were measured using a com-
Innogenetics). For the determination of tau levels, we follow-
ed the manufacturer’s instructions.
Results
Reliability of RT-QuIC Assay in Comparison to 14-3-3
and Tau Proteins
To investigate the reproducibility of PrPSc amplification via RT-
QuIC assay, we initiated two ring trial studies and included com-
parison to other biomarker proteins (tau and 14-3-3). Results of
inter-laboratory agreement were indicated as Fleiss’ kappa, which
was calculated in a first ring trial with two partners as 0.75 (95 %
CI: 0.40–1.00) revealing a substantial agreement, comparable to
14-3-3 and tau proteins (Supplement 1). A second ring trial with
four raters showed an almost perfect agreement (Fleiss’ kappa=
0.83 (95 % CI: 0.40–1.00)), proving high reliability and repro-
ducibility of the RT-QuIC assay (Supplement 1).
Determination of the Specificity and Sensitivity of RT-QuIC
Assay
Using a cut-off at 10,000 rfu/80 h (defined by Youden
index[10]), an overall sensitivity of 85 % for all prion diseases
and a specificity of 99 % could be achieved (Fig. 1a–c). Ge-
netic CJD cases showed a sensitivity of 100 %, while analysis
of sCJD and FFI CSF samples revealed a sensitivity of 80 and
57 %, respectively (Fig. 1c). The control cohort consisted of
Fig. 1 Analysis of the sensitivity and specificity of the RT-QuIC assay.
RT-QuIC response was measured in rfu over a period of 80 h. a RT-QuIC
signalling response was evaluated as a diagnostic test by using receiver
operating characteristic (ROC) curves. The ROC curve of the training
dataset is shown suggesting a cut-off at 10,000 rfu. b Prion diseases
exhibited a median RT-QuIC signal of 35,000 rfu, while controls
remained under 10,000 rfu. c Considering >50 % positive RT-QuIC
replicates as positive for prion disease, we obtained a specificity of
99 % and an averaged sensitivity of 85 %. d Two hundred CSF
samples, retrospectively tested by RT-QuIC, are summarized
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mercially available ELISA kit (INNOTEST® hTAU Ag,
200 patients with different diagnoses, e.g. AD, PD, IF etc.
(Fig. 1d) and 200 prospectively tested patients.
However, we obtained two false positive results with a RT-
QuIC response higher than 10,000 rfu in the control samples
(Supplement 2). CSF sample 1 was from a patient originally
clinically diagnosed as AD, while for sample 2, the diagnosis
was still outstanding at the time of RT-QuIC analysis. Sample
1 showed no abnormalities with respect to 14-3-3 and total tau
protein levels, while the second patient exhibited elevated tau
and 14-3-3 levels, as well as a positive MRI, in keeping with
prion disease. For patient 1, autopsy was not available and the
patient has been lost to follow-up.
Stability of the RT-QuIC Seeding Response with Long-
and Short-Term CSF Storage Conditions
CSF samples derived from 12 sCJD and six control patients
were stored in polypropylene tubes at room temperature or 4 °C
for up to 8 days. To estimate the impact of long-term storage on
the stability of RT-QuIC seeding response, we analysed sCJD
(n=12) and control (n=6) samples, which were stored for 2–3,
5–6 or 8–9 years in a −80 °C freezer. Additionally, we subjected
12 sCJD and six control CSF samples to up to 16 repeated
freezing and thawing cycles.
We calculated for each indicated condition the percent of
positive replicates per sample defined as a seeding response of
more than 10,000 rfu (cut-off) in 80 h (3/3=100%, 2/3=66%,
1/3=33 % and 0/3=0 %), which is important for CJD diag-
nostic. Our data indicated that the PrPSc seed in the RT-QuIC
reaction remained stable under the analysed short- and long-
term storage conditions and was resistant to up to 16 repeated
freezing and thawing cycles (Fig. 2a–d). Under short-term
storage conditions, the temperature had no significant influ-
ence on the number of positive replicates.
Subsequently, we analysed the RT-QuIC seeding efficiencies
as a second parameter, which describes the intensity of the RT-
QuIC signal, under the indicated storage conditions. We defined
seeding efficiency as a combination of the following two param-
eters of interest: rel. AUC and the signal maximum of RT-QuIC
response (maximum). Again, we observed that the seeding effi-
ciency of PrPSc was not significantly influenced, neither under
short-term nor under long-term storage conditions or after re-
peated freezing and thawing cycles of CSF samples (Fig. 3a–d).
Control samples without prion disease showed negative
RT-QuIC responses (<10,000 rfu) under these conditions (data
not shown).
Influence of Blood Contamination on RT-QuIC Seeding
Response in CSF
Since erythrocytes and platelets in human blood contamina-
tion of CSF may influence PrPSc seeding activity in the RT-
QuIC assay, we spiked CSF derived from sCJD patients (n=
6–8) and non-CJD controls (n=6–8) with different amounts of
Fig. 2 Effect of various storage
conditions on the RT-QuIC signal
response. RT-QuIC reactions
seeded with CSF from sCJD
patients were analysed under
short-term storage conditions
(8 days) at room temperature (RT)
and 4 °C (a, b), after 16 repeated
freezing and thawing cycles (c)
and after long-term storage (up to
9 years) (d). There was no
significant trend for decreasing
positivity rates over time when a
storing at room temperature (p=
0.337), b storing at 4 °C (p=
0.713) or c after 16 freezing and
thawing cycles (p=0.537) and d
over several years of storage at
−80 °C. Numbers of positive
replicates were calculated for
each sample in percent. Standard
deviation of the mean from n=12
patients per group was indicated
by error bars. For comparison
between groups, we used
ANOVAs
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sonicated red blood cells from control donors (78, 313, 1250,
5000 or 10,000 erythrocytes/μL).
Our results indicated that an erythrocyte concentration
higher than 1250 cells/μL showed a false-negative RT-QuIC
response. Blood contaminations significantly influenced the
number of positive replicates (Fig. 4a) as well as the signal
intensity of the RT-QuIC response (Fig. 4c).
In contrast, erythrocyte concentrations below 1250 cells/
μL are tolerable for diagnostics because they did not show
any significant impact on the number of positive replicates
and the intensity of the RT-QuIC signal (Fig. 4a, c). CSF from
non-prion controls, spiked with blood always revealed a neg-
ative RT-QuIC seeding response (data not shown).
Subsequently, we simulated the impact of transportation on
blood contaminated samples by spiking CSF samples from
sCJD (n=8) and control samples (n=8) with a defined amount
of blood cells (5000 cells/μL) from control patients. After 0, 1,
3 and 8 days, we centrifuged the samples to remove the blood
cells. The haemolysis and release of inhibitory proteins, which
influence the number of positive replicates and the intensity of
the RT-QuIC signal significantly, started after 3 days resulting
in a false-negative RT-QuIC seeding response in sCJD pa-
tients (Fig. 4b, d). For comparison, we used non-spiked CSF
from sCJD patients as a reference.
Discussion
The development of in vitro conversion assays, such as pro-
tein misfolding cyclic amplification (PMCA), enhanced quak-
ing induced conversion (eQuIC) or RT-QuIC, exploit the self-
propagating replication of the abnormally folded PrPSc to am-
plify miniscule amounts of PrPSc to a detectable level. Al-
though these assays initially employed brain material, four
recent studies demonstrated the capacity of RT-QuIC to repli-
cate PrPSc from human CSF [4–7].
Fig. 3 Time course of prion seeding activity in the CSF of sCJD patients
after defined storage conditions. RT-QuIC reactions seeded with CSF
from sCJD patients were analysed under short-term storage conditions
(8 days) at room temperature (RT) and 4 °C (a, b) after long-term storage
(up to 9 years) (c) and after 16 repeated freezing and thawing cycles (d).
The PrPSc seeding efficiency was not significantly changed under these
conditions. Graphically displayed are means of all positive replicates per
group at each point in time. The absolute values for rel. AUC and signal
maximum were shown for each group, and the p values were calculated
for each comparative analysis. p values were obtained using paired or
unpaired t tests for comparisons of maximum values and rel. AUCs
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The use of RT-QuIC in routine CSF diagnostics for prion
diseases requires standardization of sample treatments, defini-
tions of cut-off values by analyzing a high number of samples
and assessments of reproducibility and resistance of the RT-
QuIC response to short- and long-term storage conditions;
until now, only scarce information on these topics is available
in the literature.
Reproducibility of the RT-QuIC Assay Between Different
Study Sites
To evaluate the inter-laboratory reproducibility of the RT-
QuIC assay, we initiated ring trials between different
laboratories. A first RT-QuIC ring trial between two different
partners using a high number of samples (54 sCJD and 32
controls) indicated substantial agreement between raters
(Fleiss’ kappa=0.75 (95 % CI: 0.40–1.00)).
Even though the inter-laboratory agreement was relatively
high, we intended to establish optimal conditions and standard
operating procedures for the RT-QuIC method. The assay pre-
cision depends on various factors including (1) inter-
laboratory variations in staff, protocols and substrates; (2)
sensitivity of the assay to different CSF sample storage and
shipping temperatures and (3) different fluorescent readers.
By minimizing such variations, we achieved in a second ring
trial an almost perfect agreement (Fleiss’ kappa=0.83 (95 %
Fig. 4 Influence of blood contamination on the RT-QuIC seeding
response. CSF from sCJD patients (n=6–8) was spiked with defined
amounts of sonicated red blood cells. a The number of positive
replicates was calculated and revealed that sCJD CSF samples spiked
with more than 1250 cells/μL showed a false-negative RT-QuIC
response. b CSF from sCJD (n=8) patients was spiked with 5000 cells/
μL and incubated at room temperature without sonication for 8 days
showing that a significant inhibition via haemolysis of the RT-QuIC
response started after 3 days. c, d Graphically displayed are means of
all positive replicates per group at each point in time. Absolute values
for rel. AUC and signal maximum were shown for each group, and the
p values were calculated for each comparative analysis. All p values
<0.05 were considered as significant
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CI: 0.40–1.00)) showing a high reproducibility of the RT-
QuIC assay with improved standardization and supporting
the potential of the method for routine diagnostic purposes.
Sensitivity, Specificity and Predictive Values of the RT-QUIC
Assay
We analysed CSF samples from a patient cohort consisting of
110 patients with prion disease (sCJD, gCJD and FFI) and 400
controls. When setting the cut-off at 10,000 rfu, we obtained a
specificity of 99 % and a sensitivity of 85 % for all prion
diseases. Among different prion diseases, the sensitivity var-
ied from 100 % for gCJD, 80 % for sCJD and 57 % for FFI
cases. Our data are in line with two previous studies, which
reported a specificity of almost 100 % and a sensitivity be-
tween 80 and 90 % [4, 5]. For gCJD patients, Sano et al.
reported sensitivities of RT-QUIC as follows: FFI (100 %),
gCJD E200K (87 %) and gCJD V203I (100 %) [6]. Discrep-
ancies for FFI patients may be explained by sampling errors
because of the low number of specimens tested (7 versus 22
per group) and methodological differences [6, 7].
Short- and Long-Term Stability of RT-QuIC Seeding
Response in CSF
A general problem of biomarker-based diagnostics is the sen-
sitivity of biomarker proteins to storage and shipment condi-
tions. During shipment, CSF is subjected for a defined period
of time (between 1 and 8 days) to different temperatures,
which are between 20 and 25 °C. After arrival, CSF is usually
stored at 4 °C before analysis. Samples, which are used for
research, may undergo numerous cycles of freezing and
thawing or will be stored for years at −80 °C.
For simulation of these conditions, we explored the effect
of short-term storage (up to 8 days at room temperature or at
4 °C), long-term storage (up to 8–9 years at −80 °C), as well as
the influence of 16 repeated freezing and thawing cycles on
the RT-QuIC seeding response. Our data demonstrated that the
PrPSc seed in CSF of sCJD patients resisted the variations
posed with across the analysed conditions, and we did not
obtain any loss of sensitivity or specificity or in relation to
the intensity of the RT-QuIC responses.
Compared to other biomarker proteins such as tau or
Aβ42, which become degraded in particular under higher
temperatures during storage [11–13], the proven stability of
RT-QuIC assay is a clear advantage with respect to diagnostic
purposes.
Influence of Blood Contamination on the RT-QuIC Response
in CSF of sCJD Patients
Contamination with blood cells, such as erythrocytes, may
influence the RT-QuIC response. In routine diagnostic
laboratory practice, between 5 and 10 % of the CSF samples
are contaminated with blood cells during the lumbar puncture.
Therefore, there is a need to define clear guidelines for pre-
analytical sample handling. Our data revealed an artificial in-
hibition of the PrPSc seeding activity which resulted in a false-
negative RT-QuIC response in prion disease patients. Our
findings may explain the variable sensitivity of the RT-QuIC
assay (between 80 and 90 %) among different laboratories [4,
5]. The obtained data indicated that a blood cell contamination
higher than 1250 cells/μL may inhibit the RT-QuIC reaction,
when all cells were completely haemolysed by sonication. A
contamination with <1250 cells/μL can be considered as un-
problematic. In CSF samples (not older than 3 days after the
lumbar puncture), a centrifugation step before freezing is rec-
ommended to remove blood cells. After 3 days, haemolysis of
blood cells was increased to such an amount that no reliable
results could be obtained. Therefore, it is strongly suggested to
exclude these samples from further diagnostic analysis.
In conclusion, our data emphasize that RT-QuIC analysis of
CSF is a robust and very useful tool for prion diagnosis and
should become part of the clinical workup in rapidly progres-
sive dementia cases.
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CSFa b s t r a c t
The pre-mortem clinical diagnosis of Creutzfeldt–Jakob disease (CJD) is supported by biomarkers, espe-
cially cerebrospinal fluid (CSF) 14-3-3 and total tau (Tau) protein levels. These CSF biomarkers have pro-
ven the most useful prior to transitioning to powerful next generation diagnostics employing protein
amplification techniques such as the real time quaking-induced conversion (RT-QuIC) assay. To enhance
national diagnostic capacity while transitioning to RT-QuIC assays an optimized CSF Tau cutoff was deter-
mined and shown to usefully supplement 14-3-3 protein detection.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Although CJD can only be definitively confirmed neuropatho-
logically [1] considerable advances in pre-mortem clinical diagnos-
tic capacity have been made over the last 20 years employing brain
MRI and CSF biomarkers [2,3]. Of the CSF biomarkers studied,
14-3-3 and Tau protein levels have proven the most useful prior
to transitioning to powerful next generation diagnostics employing
protein amplification techniques such as the RT-QuIC assay.
RT-QuIC assays, which can be utilized on a range of tissues (eg
brain and nasal brushings) and bodily fluids, when applied to CSF
has been shown to have >80% sensitivity and approximately
100% specificity [4,5]. Consequently, contemporary diagnosis of
‘‘probable CJD” before death can be achieved by application of clin-
ical criteria supported by typical findings on EEG or brain MRI [6,7],
as well as through CSF 14-3-3 protein detection [2,3] or by positive
RT-QuIC amplification of misfolded prion protein (PrPSc) in CSF or
other tissues [4,5].
Similar to 14-3-3 proteins, CSF Tau levels are a non-specific
marker of neuronal injury. The measurement of CSF Tau by ELISAhas been standardized and extensively studied for its utility in sup-
porting a diagnosis of Alzheimer’s disease (AD) when used in con-
junction with amyloid-b1-42 and phospho-tau [8]. In addition, CSF
Tau has demonstrated meritorious sensitivity and specificity for
pre-mortem diagnosis of CJD [9,10] although it is not routinely
included in diagnostic criteria for ‘‘probable CJD” and no interna-
tionally agreed cutoff threshold exists. Nevertheless, to enhance
national diagnostic capacity during our transition to CSF RT-QuIC
assays, we have determined an optimized CSF Tau cutoff based
on pathologically proven sporadic CJD and non-CJD cases, which
offers worthwhile clinical utility supplementary to 14-3-3 protein
detection.2. Methods, results and discussion
We analysed CSF from 130 definite sporadic CJD cases ascer-
tained through routine Australian National CJD Registry (ANCJDR)
surveillance and 124 non-CJD controls (82 referred as ‘‘suspected
CJD” to the ANCJDR with an alternative diagnosis eventually deter-
mined and 42 with abnormal amyloid-b positron emission tomo-
graphic [PET+] scans recruited through the Australian Imaging
Biomarker and Lifestyle (AIBL) study, an important group given
the frequency of neuropathologically confirmed AD in clinically
suspected CJD cases ultimately examined at autopsy [9] (Table 1).
Table 1







Sporadic CJD 130 (130) 109/20 (6#)/1 111/19
Non-CJD 124 (77) 36/84 (13#)/4 22/102
Inflammatory CNS disorder 18 (17) 8/9 (5#)/1 8/10
Drug induced encephalopathy 7 (7) 5/2 (1#) 2/5
AD/amnestic MCI 44* (2) 2/42 1/43
DLB, MND, cerebellar atrophy, hydrocephalus, alcohol encephalopathy 10 (8) 3/6 (1#)/1 1/9
Leucoencephalopathy 10 (10) 2/8 (3#) 3/7
Vascular disease/MID 8 (6) 4/4 3/5
Paraneoplastic/cancer 23 (23) 11/10 (2#)/2 4/19
Disease not defined 4 (4) 1/3 (1#) 0/4
* 42 were amyloid PET+.
# Atypical 14-3-3 positive included in the negative group; TU = technically unsuitable CSF sample and thereby excluded from sensitivity and specificity analysis.
Q.-X. Li et al. / Journal of Clinical Neuroscience 50 (2018) 292–293 293Tau protein was measured using a commercially available assay
(INNOTEST hTAU Ag, Fujirebio, Ghent, Belgium) according to the
manufacturer’s instructions as described previously [8]. CSF
14-3-3 protein detection was through immunoblot [11] allowing
scoring as positive, atypical positive or negative relative to control
CSF. The optimal cutoff level for dichotomizing CSF Tau protein val-
ues was determined using receiver operating characteristics (ROC)
curve analysis, minimizing the difference between the sensitivity
and specificity and maximising accuracy.
CSF Tau levels for sporadic CJD ranged between 86 and 29,484
pg/ml (median 3735 pg/ml and mean 4806 pg/ml) while non-CJD
levels ranged from 22 to 9182 pg/ml (median 399 pg/ml and mean
755 pg/ml), which were significantly different (p < 0.0001 Mann-
Whitney U test). ROC curve analysis defined an optimal cutoff as
1072 pg/ml providing 85% sensitivity and 82% specificity. For
14-3-3 protein detection, analysis based on dichotomised results
gave 89% sensitivity and 66% specificity. Overall sensitivities and
specificities for 14-3-3 and Tau protein detection, as well as for
each of the non-CJD diagnostic groups are provided in the Table 1.
Beyond the superior specificity, CSF Tau was found to be partially
complementary to 14-3-3 protein detection for supporting the
diagnosis of sporadic CJD, with 10 of the 21 CJD cases with either
negative 14-3-3 results or technically unsuitable CSF samples
revealing a Tau above 1072 pg/ml providing a combined sensitivity
of 92%. Of note, sporadic CJD CSF Tau levels correlated with disease
duration being significantly more likely (unpaired t-test with
Welch’s correction, p = 0.003) to be below our optimized cutoff of
1072 pg/ml in longer survival cases (mean 15.62 ± 3.16 months
for negative Tau results) compared to those with positive Tau
results (4.46 ± 0.49 months).
The CSF Tau cutoff we determined for supporting sporadic CJD is
similar to that reported in previous studies, as have the modestly
superior specificity [9,10] and diagnostic complementarity of CSF
Tau in relation to 14-3-3 protein detection [10]. The addition of
CSF Tau to 14-3-3 protein detection as a biomarker for the pre-
mortem evaluation of suspected sporadic CJD offers modestly
enhanced diagnostic capacity while the ANCJDR completes transi-
tion to the clearly superior RT-QuIC protein amplification technique.
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Abstract
Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on
the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and
levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from
different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also
measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic
prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD
and in genetic prion diseases associated with the three most commonmutations E200K, V210I (associated with genetic CJD) and
D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the
Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of
sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in
asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to
all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In
some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease
progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic
biomarker in prion diseases as well as in the evaluation of therapeutic interventions.
Keywords Cerebrospinal fluid . Prion protein . Sporadic Creutzfeldt-Jakob disease . Genetic prion disease . Iatrogenic prion
disease
Introduction
Transmissible spongiform encephalopathies are fatal neurode-
generative disorders characterised by rapid progression and
microvacuolation in the grey matter of the brain. They are also
known as prion diseases relating to the causative agent, which is
the abnormally folded isoform the prion protein scrapie (PrPsc)
that creates insoluble aggregates and accumulate in the brain [1].
Prion diseases affecting humans include sporadic Creutzfeldt-
Jakob disease (sCJD), genetic prion diseases (gPD) and acquired
forms, such as iatrogenic CJD (iCJD) or variant CJD (vCJD).
sCJD is themost prevalent form accounting for about 85–90%of
total cases, followed by hereditary forms (~ 10%). By contrast,
acquired forms only account for at most 2–5% of prion disease
cases [2, 3]. Despite sharing a common pathological agent, prion
diseases present a broad heterogeneity in clinical symptoms and
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disease manifestations. A cause of variability is the polymor-
phism at codon 129 of the PrP encoding gene, PRNP, which
can be methionine (M129) or valine (V129) [4]. In combination
with biochemically characterised conformational variants of
PrPsc, sCJD can be stratified into at least six molecular subtypes,
with MM1/MV1 and VV2 the most prevalent ones (> 80% of
total sCJD cases [5]). gPD are associated with specific mutations
in the PRNP and include familial/genetic Creutzfeldt-Jakob dis-
ease (gCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS-
S) and familial fatal insomnia (FFI). Several PRNP mutations
cause gCJD and GSS-S (reviewed elsewhere [6]), with E200K
and V210I the most prevalent mutations in gCJD and P102L in
GSS-S. In contrast, FFI is associated with a unique haplotype,
D178N-129M (D178N-M) [6, 7]. Acquired human prion dis-
eases develop from exogenous prions and are transmitted from
infected humans (iCJD) or cattle (vCJD). iCJD is caused by
human-to-human transmission during medical treatments, with
dura matter grafts and administration of human growth hormone
the main causes of cross-contamination through surgical and
medical procedures [8].
Clinical diagnosis of prion diseases is supported by cere-
brospinal fluid (CSF) biomarkers. The CSF profile of prion
disease patients is characterised by elevated concentrations of
surrogate protein markers of the pathology such as 14-3-3, tau
and alpha-synuclein [9–11], as well as by the presence of
prion seeding activity [12]. By contrast, the CSF total PrP (t-
PrP) concentrations are decreased in sCJD. The specificity of
this decrease remains unclear as some authors reported re-
duced CSF t-PrP in various neurodegenerative diseases, such
as Alzheimer’s disease (AD), dementia with Lewy bodies and
Parkinson’s disease [13], while others suggested that t-PrP is
specifically reduced in sCJD compared to AD, supporting its
use in the differential diagnostic context [14, 15]. Among
sCJD molecular subtypes, no difference was found in
CSF t-PrP levels between MM1 and VV2 cases [16] and
scant data exist for acquired cases. When CSF t-PrP was
investigated by western blot, no variation appeared in the
truncation or glycosylation state of the protein between
different sCJD subtypes or in comparison with hereditary
prion diseases [17–19]. To date, no further quantification
of CSF t-PrP has been carried out in genetic prion dis-
eases, including a significant number of mutation types.
In addition, few data are available about the relationship of
CSF t-PrP with demographic parameters, as are data on
longitudinal t-PrP CSF levels in prion diseases. A prelim-
inary exploration showed a decrease in t-PrP levels with
disease progression although quantification was lacking
and only six sCJD cases were studied [18].
While age does not influence t-PrP concentration in dis-
eased individuals, low levels are associated with advanced
disease stages [13]. Correlation analysis with other CSF bio-
markers indicated a direct correlation between t-PrP and
amyloid-beta 42 peptide in sCJD [13].
The goal of the present study was to provide complete CSF t-
PrP signatures across the broad spectrum of prion diseases. Thus,
we quantified theCSF t-PrP in a large number of cases that include
sCJD, iCJD, various forms of gPD, and diverse neurological dis-
eases composing our control group. In addition, we also investi-
gated longitudinal CSF t-PrP alterations in serial lumbar punctures
from sCJD cases and asymptomatic PRNP mutant carriers.
Methods
Patients
The study included 561 CSF samples. Samples from patients
with non-primarily neurodegenerative neurological diseases
(ND, n = 147) and sporadic Creutzfeldt-Jakob disease (sCJD,
n = 193) were collected at the Clinical Dementia Center and the
National Reference Center for CJD Surveillance at the
University Medical Center of Göttingen (Germany). The ND
group was composed of cases diagnosed with neurological con-
ditions not associated with neurodegenerative pathology includ-
ing the following diagnostic groups: psychosis, paranoid psycho-
sis, bipolar disorder, schizophrenia, ischemic stroke, multiple ce-
rebral infarcts, epilepsy, meningitis, alcohol abuse, vertigo, acute
or chronic headache, pain syndromes, acute hypoxia,
polyneuropathy, cerebral lymphoma, astrocytoma and
paraneoplasia. ND cases were diagnosed according to acknowl-
edged standard neurologic clinical and para-clinical findings
based on the ICD 10 definitions. The presence of neurodegener-
ative diseases in the ND group was excluded by follow-up eval-
uations. All patients with sCJD were classified as probable or
definite cases according to diagnostic consensus criteria [20, 21].
Iatrogenic (n = 12) and genetic (n= 209) prion diseases were
collected in the following CJD reference centres: (1) Clinical
Dementia Center and the National Reference Center for CJD
Surveillance at the University Medical Center, Göttingen,
Germany, (2) Neurochemistry Laboratory, Neurology
Department of Coimbra University Hospital, Coimbra,
Portugal, (3) Alzheimer’s Disease and Other Cognitive
Disorders Unit, Hospital Clínic, Barcelona, Spain, (4) National
Centre of Microbiology-Carlos III Institute of Health, Madrid,
Spain, (5) Istituto Superiore di Sanità, Rome, Italy, (6) Slovak
Medical University, Bratislava, Slovakia, (7) Australian National
CJD Registry, The Florey Department of Neuroscience and
Mental Health, Melbourne, Australia, and (8) Department of
Neurology, Memory and Aging Center, University of
California, San Francisco (UCSF), USA. The diagnoses of ge-
netic prion diseases were carried out according to surveillance
criteria after prion protein gene (PRNP) analysis [22] and World
Health Organization (WHO) criteria [23]. Iatrogenic CJD was
diagnosed according to established WHO criteria [23]. Eleven




CSF t-PrP was centrally quantified (Clinical Dementia Center-
Göttingen) using a commercially available enzyme-linked im-
munosorbent assay (ELISA) specific for human prion protein
(Analytik Jena AG). Inter- and intra-assay coefficients of var-
iation in our study were below 18 and 12%, respectively. CSF
neurofilament-light (NFL) was quantified using a commer-
cially available ELISA (Uman-Diagnostics). The analysts
were masked to clinical data.
Table 1 Demographic and
biomarkers data from our study
population. Number of cases (n),
age in years (mean values ±
standard deviation), sex (female
(f)/males (m)), codon 129 PRNP
genotype and t-PrP
concentrations (mean values
(mean) ± standard deviation (SD)
in ng/mL), and 95% CI (in ng/
mL) are indicated.Mutation in the
PRNP gene is indicated for




FFI fatal familial insomnia,M
methionine, V valine, NA not
available. Other mutations/
variants refer to cases diagnosed
as prion disease with changes on
the PRNP gene without clear




Age Sex PRNP 129 t-PrP
Mean ± SD
(years)





ND 147 65 ± 11 78/69 0 0 0 147 230 ± 140 207–253
Sporadic prion disease
sCJD 193 65 ± 10 114/79 74 37 45 37 120 ± 83 108–132
Aquired prion disease
iCJD 12 48 ± 10 5/7 9 2 0 1 95 ± 71 50–140
Genetic prion disease
Pathogenic variants associated to gCJD
D178N-V 1 48 1/0 0 0 1 0 29 0
V180l 1 77 0/1 1 0 0 0 300 0
T188A 1 82 1/0 1 0 0 0 142 0
T188K 1 57 1/0 0 1 0 0 173 0
K194E 1 71 0/1 0 1 0 0 232 0
E196K 3 69 ± 4 2/1 1 1 1 0 69 ± 4 59–79
E200K 66 61 ± 11 39/27 45 18 2 1 98 ± 77 78–117
R208H 4 62 ± 7 2/2 3 1 0 0 243 ± 146 10–475
V210l 41 64 ± 10 24/17 31 8 2 0 161 ± 147 114–207
P238S 1 68 1/0 0 1 0 0 52 0
Pathogenic variants associated to GSS-S
P102L 13 53 ± 11 8/4* 11 1 1 0 200 ± 148 111–289
P105T 3 36 ± 17 2/1 0 3 0 0 225 ± 168 0–642
G114V 1 20 0/1 0 1 0 0 114 0
A117V 1 47 1/0 0 0 1 0 95 0
A133V 1 62 1/0 1 0 0 0 68 0
V176G 1 61 1/0 0 0 1 0 31 0
F198S 1 51 0/1 0 1 0 0 47 0
Q217R 1 59 0/1 1 0 0 0 165 0
Y218N 1 NA 1/0 0 1 0 0 254 0
Pathogenic variants associated to FFI
D178N-M 47 50 ± 10 16/31 31 16 0 0 119 ± 94 91–146
Insert mutations
OPRI 14 63 ± 9 8/6 5 4 5 0 105 ± 113 40–171
Nonsense mutations
Q160X 1 27 0/1 1 0 0 0 30 0
Other mutations/variants
Q52P 1 80 1/0 0 1 0 0 141 0
N173K 1 73 0/1 0 1 0 0 203 0
Q212H 1 63 1/0 1 0 0 0 37 0
l215V 1 77 0/1 1 0 0 0 81 0
*Sex unknown in one case
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Genetic Tests
For detection of a prion disease-associated mutation and as-
sessment of codon 129 polymorphism in PRNP, genetic test-
ing was performed as described before [24].
Statistical Analysis
For two group comparisons of biomarker levels, non-
parametric Mann-Whitney U tests were used. For compari-
sons between multiple groups, Kruskal-Wallis tests followed
by Dunn’s post hoc tests were applied. To assess the diagnostic
accuracy of t-PrP, receiver operating characteristic (ROC) curve
analyses were carried out and areas under the curve (AUC)with
95% confidence intervals (95% CI) were calculated. Spearman
rank correlation coefficients were used to assess associations
between continuous biomarker levels. Bootstrap one-tail tests
for paired ROC curves based on the pROC-R package with
boot replicates = 10,000 were used to assess differences in the
diagnostic accuracy between biomarkers [25]. Longitudinal
biomarker data were assessed using a multi-level mixed linear
model. For the analysis of differences on t-PrP concentrations
Fig. 1 Analysis of CSF t-PrP concentrations in sporadic, iatrogenic and
genetic prion diseases. a Whisker and boxplots of CSF t-PrP
concentrations in non-primarily neurodegenerative neurological
diseases (ND), sporadic Creutzfeldt-Jakob disease (sCJD), iatrogenic
Creutzfeldt-Jakob disease (iCJD) and genetic prion diseases (gPD)
associated with mutations in the PRNP gene E200K, V210I, D178N-M
and P102L. Boxes indicate 25th to 75th percentiles and whiskers
minimum to maximum values. Statistical significance was set at *p <
0.05, **p < 0.01, ***p < 0.001. b Receiver operating characteristic
curves for sCJD, iCJD and gPDs associated with mutations E200K,
V210I, D178N-M and P102L versus the ND group are shown. Area
under the curve (AUC) and 95% confidence interval (CI) are shown for
t-PrP analysis
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between different cohorts, only cohorts including enough cases
to perform normality tests were used.
Data Availability The datasets used and/or analysed during the
current study are available from the corresponding author on
reasonable request.
Results
CSF t-PrP in Prion Disease of Different Aetiologies
CSF t-PrP concentrations were assessed in ND, sCJD, iCJD
and gPD cases (Table 1). Compared to ND, mean t-PrP levels
were lower in all types of prion diseases, with the exception of
gPD associated with V180I, K194E and Y218N mutations
(one case of each was available), and the R208H mutation
(four cases available). Other mutations and variants also
displayed similar concentrations to those reported in ND
(P102L, P105L and N173K).
In order to assess if there were differences in t-PrP levels
among diagnostic groups, t-PrP concentrations in ND, sCJD,
iCJD and the four most prevalent forms of genetic prion diseases
(E200K, V210I, D178N-M and P120L mutations) were further
analysed in a multiple comparison test. Compared to ND, t-PrP
was lower in sCJD (p< 0.001), iCJD (p< 0.01) and in gPD as-
sociated with E200K (p< 0.001), V210I (p< 0.01) and D178N-
Mmutations (p< 0.001), but not in P102L cases (Fig. 1a). Lowest
t-PrP concentrations were found in iCJD (95 ± 71 ng/mL) and
E200K (98 ± 77 ng/mL) (Table 1), but no statistical differences
among different forms of prion diseases were detected.
AUCs for the discrimination of sCJD, iCJD and gPD
E200K, V210I and D178N-M from ND ranged from 0.69 to
0.83, indicating moderate potential for a diagnostic test (Fig.
1b). In contrast, t-PrP levels showed no diagnostic value in
distinguishing P102L from ND (AUC = 0.57, p = 0.40)
(Fig. 1b).
CSF from gPD cases was obtained from different countries
(see “Methods”). No differences were found when comparing
t-PrP concentrations from different cohorts for the E200K,
D178N-M and V210 mutations (Suppl. Fig. 1).
Established CSF prion disease biomarkers such as 14-3-
3, tau [26, 27] and RT-QuIC [28] show a high diagnostic
accuracy in the discrimination of non-prion disease cases
from sCJD and gCJD E200K and V210I. However, they
present limited value in the diagnosis of genetic prion dis-
ease associated with D178N-M. We recently reported ele-
vated CSF NFL in D178N-M cases and showed moderate
diagnostic potential for t-PrP in this analysis; therefore, we
explored the ability of NFL/t-PrP ratio for improving the
discrimination of D178N-M from ND. The AUC value in
D178N-M cases using the NFL/t-PrP ratio (AUC = 0.97,
95% CI 0.95–0.99) was superior to that obtained by t-PrP
only (AUC = 0.78, 95% CI 0.70–0.86, p < 0.001), but not
relatively increased when compared to NFL alone (AUC =
0.96, 95% CI 0.93–0.98, p = 0.2).
The presence of octapeptide repeat insertions (OPRI)
in the N-terminal region of the PRNP gene is linked with
genetic prion diseases. High clinical and neuropatholog-
ical heterogeneity in ORPI carriers is associated to the
number of insert mutations (one to nine) [29–31] with
the likelihood that low OPRI numbers are not pathogenic
[32]. Mean t-PrP levels in cases with OPRI mutations
were lower than in ND cases (p = 0.003) (Table 1).
However, no association between CSF t-PrP levels and
number of inserts was detected in our study population
(p = 0.38) (Fig. 2).
Associations of Demographic and Genetic Parameters
with t-PrP Concentrations
In prion diseases, CSF t-PrP levels were associated neither with
age at onset (p = 0.10) (Fig. 3a) nor with sex (p= 0.21) (Fig. 3b).
Lack of associationwith age and sexwas also detected in theND
group (data not shown). CSF t-PrP concentrations were not sta-
tistically different between prion disease cases harbouring
methionine/methionine [MM] (129 ± 107 ng/mL, n = 219),
methionine/valine [MV] (114 ± 88 ng/mL, n = 99) and valine/
valine [VV] (112 ± 85 ng/mL, n = 59) at codon 129 of the
PRNP gene (p= 0.58) (Fig. 2c). Similarly, no differences were
detected between different sCJDmolecular subtypes in the subset
of cases with neuropathological prion disease confirmation and
available prion type (MM1/MV1 110 ± 80 pg/mL, n= 55; MV2
84 ± 61 pg/mL, n = 6; VV2 88 ± 77, n= 16) (p= 0.16) (Fig. 3d).
To investigate whether t-PrP concentrations are associated with
different pathological phenotypes among a mutation type,
D178N-M and E200K cases were stratified according to their
codon 129 PRNP genotype, which influences their clinico-
Fig. 2 Influence of the number of octapeptide repeat insertions (OPRI) in
the prion protein gene (PRNP) on CSF t-PrP concentrations. Association
analysis between t-PrP concentrations and number of OPRI in the PRNP
gene. Spearman rank correlation coefficients were used
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pathological features [33, 34]. t-PrP levels were neither different
between D178-MM and -MV cases (Fig. 3e) nor between
E200K-MM and -MV cases (Fig. 3f).
CSF t-PrP along Disease Stages
t-PrP levels were quantified in sequentially repeated lum-
bar punctures (LPs) obtained from 20 sCJD cases (2 LPs
available in 19 cases and 3 LPs available in 1 case). To
normalise time intervals between LPs, samples were
grouped into three categories according to whether they
underwent LP in the first (time of LP to disease onset/
total duration of the disease < 0.33), second (0.33–0.66)
or third (> 0.66) stage of the disease, as previously report-
ed [35, 36]. In 15 LPs, t-PrP concentrations were lower in
the follow-up LP compared to the initial estimate, while
in 5 LPs, t-PrP concentrations were higher at advanced
disease stages (Fig. 4). Using a multi-level mixed linear
model, a decrease in t-PrP of 24.5 per unit in disease
stages was calculated (95% CI 12.8–48.8, p = 0.005).
Fig. 3 Influence of demographic and PRNP codon 129 genetic factors on
CSF t-PrP concentrations in prion diseases. a Association analysis
between t-PrP concentrations and age at disease onset (in years) in all
prion disease cases (sCJD, iCJD and gPD). Spearman rank correlation
coefficients were used. b t-PrP in prion diseases stratified by sex. c t-PrP
concentrations in prion diseases stratified by prion protein gene (PRNP)
codon 129 polymorphism (M methionine, V valine) in probable and
definite prion disease cases. d t-PrP concentrations in definite sCJD
cases stratified by sCJD molecular subtypes. e t-PrP concentrations in
D178-MM and MV cases. f t-PrP concentrations in E200K-MM and
MV cases. Kruskal-Wallis test followed by Dunn’s post hoc tests
(correction for multiple testing) was applied for multiple comparisons
and Mann-Whitney U test for two group comparisons
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CSF in Pre-Clinical PRNP Mutation Carriers
t-PrP concentrations were analysed in a subset of asymptom-
atic PRNP mutation carriers from the UCSF cohort and were
descriptively compared with symptomatic cases from the
same cohort (symptomatic, UCSF), with the whole population
of cases included in the present study (symptomatic, ALL)
and with the ND cases (Suppl. Fig. 2). For some cases, serial
LPs from the mutation carriers were available.
In E200K, pre-symptomatic carriers (17 LPs from 14
cases) displayed t-PrP concentrations similar to ND controls
(Suppl. Fig. 2) and higher than those detected in symptomatic
cases in the UCSF cohort (1 case) and in the whole cohort of
E200K patients (Fig. 5a). In D178N-M cases, pre-
symptomatic carriers showed similar levels like symptomatic
D178N-M patients from the UCSF and the whole D178N-M
cohort, although only six LPs from three individuals were
available (Fig. 5b), limiting any meaningful conclusions. In
P102L carriers, t-PrP concentrations were similar between
pre-symptomatic (two cases available) and symptomatic pa-
tients, in agreement with the absence of alterations between
ND and symptomatic cases described above (Fig. 5c).
Discussion
In this study, we report the comparative signatures of CSF t-
PrP concentrations across the spectrum of prion diseases.
While decreased t-PrP concentrations are well-reported in
sCJD cases [13–16, 18], data on genetic and iatrogenic cases
have hitherto been quite limited and in most of the cases,
restricted to single case reports. Our study validates previous
observations of decreased CSF t-PrP in sCJD cases compared
to controls and other non-neurodegenerative neurological
conditions evaluated by ELISA [13–16, ] and by immunoblot-
ting techniques [18]. Additionally, although the total number
of samples was relatively low, our data clearly point to the
presence of reduced t-PrP concentrations in iCJD.
Low t-PrP concentrations were observed in genetic prion
diseases associated with mutations E200K, D178N-M and
V210I, but not in P102L cases supporting that among gCJD
and GSS-S-associated mutations, t-PrP levels were not homo-
geneous. Genetic CJD patients with V180I, K194E and
R208H mutations showed normal t-PrP concentrations, while
as did GSS-S patients with P102L, P105L and Y218N muta-
tions. The rest of the mutations displayed decreased or inter-
mediate t-PrP levels. In this regard, well-known disease caus-
ing mutations such as A117V, P102L, E200K and D178N-M
[37] showed diverse t-PrP concentrations, while some muta-
tions with no strong evidence of increased risk for developing
the disease (e.g. A133V, V176G, I215V, P238S) displayed
reduced t-PrP levels. Although these results should be
interpreted with caution due to the low number of cases (sta-
tistical analysis was carried out for the most prevalent forms
only), our data suggest the presence of highly heterogeneous
profiles, which are not associated with disease phenotype.
Indeed, D178N-M cases, displaying a specific clinico-
pathological phenotype compared to sCJD, iCJD and gCJD
E200K and V210I, presented low t-PrP concentrations.
Additionally, no differences on t-PrP levels were detected be-
tween D178N-MM and -MV cases, although both groups
show distinct clinical features and neuropathological profiles
[33, 38].Moreover, similar t-PrP levels were detected between
E200K-MM and -MV cases, despite the presence of different
types of PrP depositions in the brain tissue, with a synaptic
pattern for MM subjects and granules and plaque-like struc-
tures for MV subjects [34].
Overall, the analysis of CSF signatures demonstrated high
variation in t-PrP concentrations across the diagnostic groups.
This, together with a moderate diagnostic accuracy in discrimi-
nating prion disease cases from ND controls (AUC of 0.76 for
sCJD), argues against the use of t-PrP quantification alone as a
diagnostic biomarker for prion diseases in clinical practice.
However, the tentative decrease of t-PrP concentrations along
disease duration observed in serial lumbar punctures from the
same patients indicates that, for a given case, longitudinal alter-
ations on t-PrP levels may have a potential role in the evaluation
of disease progression, as well as in the evaluation of the efficacy
of a potential therapeutic intervention. In this regard, other CSF
prion biomarkers such as tau, alpha-synuclein and NFL have
been able to predict disease duration [36, 39, 40], but show stable
concentrations along disease progression [35, 36, 40]. These
markers reflect pathological alterations associated with the neu-
rodegeneration process such as neuro-axonal degeneration and
white matter involvement. In contrast, decreased t-PrP levels
may reflect primary alterations in the molecular process
Fig. 4 Association between CSF t-PrP levels and disease duration in
sCJD patients. t-PrP concentrations in serial lumbar punctures (LPs) in
sCJD cases at different stages of the disease. Samples were grouped in
three categories according to whether they underwent LP in the first (<
0.33), second (0.33–0.66) or third (> 0.66) stage of an individual’s disease
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associated with the formation of prions. Broadly similar to amy-
loid-beta42 levels in AD, the decrease of CSF t-PrP concentra-
tions in prion cases is speculated to be a consequence of the
misfolding of the cellular prion protein (PrPc) into PrPsc with
consequent “trapping” of the protein in aggregates, limiting the
amount of soluble PrP filtering to the CSF. Based on this hypoth-
esis, it could be assumed that CSF t-PrP levels would be highly
dependent on prion disease aetiology and sCJD subtypes, which
differ with respect to the neuropathological profiles and type of
PrPsc aggregates [16, 21, 34]. For instance, in D178N-M cases,
CSF t-PrP concentrations are decreased despite the reduced
levels of PrPsc in the brain parenchyma, which is usually only
detectable in the entorhinal cortex and in some cases with CJD-
type alterations in the deep regions of the temporal cortex.
Therefore, the absence of differences in CSF t-PrP concentrations
between prion diseases displaying different types of PrP brain
aggregates indicates that additional factors appear to explain the
singular signatures of CSF t-PrP across the spectrum of prion
diseases. Interestingly, decreased PrP expression was found in
the two most prevalent sCJD subtypes (MM1 and VV2) [16],
Fig. 5 CSF t-PrP concentrations
in asymptomatic genetic prion
diseases. CSF t-PrP
concentrations and age of LP in
pre-symptomatic PRNP mutation
carries for the E200K (a),
D178N-M (b) and P102L (c)
mutations from the UCSF cohort.
Black spots indicate a LP. Black
spots connected with a black line
indicating serial LPs from the
same patient. Red lines indicate
mean t-PrP concentrations for
symptomatic cases from all the
cases analysed in the present
study (symptomatic, ALL).
Dashed red lines indicate mean t-
PrP concentrations for
symptomatic cases from the
UCSF cohort (symptomatic,
UCSF). Mean age at onset from
UCSF cohort and from all cases
are indicated with a blue arrow
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as well as in the thalamus and entorhinal cortex of D178N-M
cases [41] causing a reduction of PrP levels in the brain, and
potentially in the CSF. Moreover, the decrease in CSF t-PrP
could be associated with a decrease in proteinase-sensitive inter-
mediate PrP isoforms not detected by the ELISA t-PrP assay.
In pre-symptomatic carriers of the D178N-M mutation, t-PrP
concentrations were similar to those detected in symptomatic
cases and lower than those in ND. This indicates that, at least
in D178N-M, t-PrP could be a potential pre-clinical biomarker of
the pathology. In contrast, pre-symptomatic E200K carriers
harboured t-PrP higher than in clinical cases and similar to values
measured in NDs. Although the low number of cases available
impedes a statistical evaluation and, therefore, results remain
descriptive, several aspects should be underlined. First, the pres-
ence of reduced t-PrP concentrations is not a general observation
for all mutations. Whether these results are associated with
mutation-specific disease duration, low number of cases, data
dispersion and/or confounders such as heterogeneity of age at
onset needs to be further explored in larger cohorts. Therefore,
we cannot exclude t-PrP as a potential pre-clinical biomarker for
other mutation types or prion disease types. Second, despite the
absence of studies addressing the quantification of t-PrP levels in
pre-symptomatic cases, we recently detected lower t-PrP concen-
trations in the CSF of pre-clinical and clinical naturally occurring
scrapie [42], which would support the idea that reduced t-PrP
concentrationsmay happen at pre-clinical and early prion disease
stages.
Conclusions
Herein, we report the largest and most complete study of the
levels of CSF t-PrP across the spectrum of prion diseases,
including multiple cases of gPD associated with a broad range
of PRNP mutations. We have confirmed previous data dem-
onstrating reduced CSF t-PrP in sCJD.
Although the diagnostic potential of CSF t-PrP alone is
perhaps limited, its combination with other biomarkers may
heighten its utility. Importantly, the observed CSF t-PrP de-
cline along disease progression in sCJD and in pre-
symptomatic carriers of certain mutations such as D178N-M
cases deserves further investigation towards potential transla-
tional application in clinical practice.
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Abstract: Human prion diseases are classified into sporadic, genetic, and acquired forms. Within this
last group, iatrogenic Creutzfeldt–Jakob disease (iCJD) is caused by human-to-human transmission
through surgical and medical procedures. After reaching an incidence peak in the 1990s, it is believed
that the iCJD historical period is probably coming to an end, thanks to lessons learnt from past
infection sources that promoted new prion prevention and decontamination protocols. At this point,
we sought to characterise the biomarker profile of iCJD and compare it to that of sporadic CJD (sCJD)
for determining the value of available diagnostic tools in promptly recognising iCJD cases. To that
end, we collected 23 iCJD samples from seven national CJD surveillance centres and analysed the
electroencephalogram and neuroimaging data together with a panel of seven CSF biomarkers: 14-3-3,
total tau, phosphorylated/total tau ratio, alpha-synuclein, neurofilament light, YKL-40, and real-time
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quaking induced conversion of prion protein. Using the cut-off values established for sCJD, we found
the sensitivities of these biomarkers for iCJD to be similar to those described for sCJD. Given the
limited relevant information on this issue to date, the present study validates the use of current sCJD
biomarkers for the diagnosis of future iCJD cases.
Keywords: Iatrogenic Creutzfeldt-Jakob disease; dura matter graft; corneal transplant; growth
hormone; biomarker; cerebrospinal fluid; electroencephalogram; magnetic resonance imaging;
RT-QuIC
1. Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a family of rare
neurodegenerative disorders that affect both humans and animals, caused by the conversion of
the physiological cellular prion protein (PrPc) into a disease-associated isoform (PrPSc). Principal
prion disease neuropathological hallmarks are the presence of spongiform changes in the neuropil
sometimes associated with massive neuronal loss, neuro-inflammation in the form of astrocytic gliosis
and the deposition of aggregated prion protein in the brain parenchyma [1]. In humans, prion diseases
can be classified according to their etiology as sporadic, genetic, and acquired [2]. The sporadic form
of the disease, also known as sporadic Creutzfeldt-Jakob disease (sCJD), accounts for about 85–90%
of all human cases [3]. Some 10–15% of cases are associated with autosomal dominant pathogenic
sequence variations in the prion protein gene (PRNP), while acquired forms are rare and are caused by
the transmission of infective material from human to human (Kuru and iatrogenic Creutzfeldt-Jakob
disease (iCJD)) or from cattle to human (variant CJD) [4]. Iatrogenic transmission of CJD occurs through
particular surgical and medical procedures. The use of contaminated growth hormone and dura mater
grafts derived from human cadavers with undiagnosed sCJD are the principal sources of iCJD [5,6].
Other sources are corneal transplant, treatment with cadaveric pituitary-derived gonadotropin, and the
use of CJD-contaminated electroencephalogram (EEG) depth electrodes and neurosurgical instruments.
Packed red blood cells from variant CJD donors are another source of secondary infection. Iatrogenic
transmission of the CJD agent has been reported in over 490 patients worldwide [7].
iCJD reached its highest incidence in the decade of the 1990s and since then the number of reported
cases has drastically decreased [6]. It is not expected that new iCJD cases will arise in the coming
years except for cases with very long incubation periods. However, the risk of human-to-human prion
disease transmission is still present due to potential new sources of iatrogenic contamination through
humans exposed to zoonotic agents or secondary transmissions [8–10]. Despite the fact that iCJD
diagnosis is based on the presence of a recognized iatrogenic source, unrecognized mechanisms of
human prion disease transmission may occur.
Clinical and neuropathological presentation of iCJD is related to the route of exposure to human
prions, the transmitted CJD strain, and the PRNP genotype of the patient [5,6,11]. Thus, potential
singularities in prion disease biomarkers in different iCJD types might be expected. In this regard, there
is limited information about the accuracy of prion disease biomarkers, including EEG, neuroimaging,
and CSF tests in iCJD. To date, available data in the literature include a limited number of iCJD cases
and/or a reduced number of biomarkers employed [12–16].
In the present study, we characterised the biomarker profiles of iCJD, using a cohort generated
from seven national prion disease surveillance centres and determined their clinical value in reference
to established cut-off points for sCJD.
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2. Materials and Methods
2.1. Patients and CSF Sampling
The study included 23 iCJD cases collected from the following CJD reference centers: 1) Clinical
Dementia Center and the National Reference Center for CJD Surveillance at the University Medical
Center, Göttingen, Germany (n = 11), 2) National Centre of Microbiology-Carlos III Institute of Health,
Madrid, Spain (n = 2), 3) Istituto Superiore di Sanità, Rome, Italy (n = 1), 4) Australian National CJD
Registry, The Florey Department of Neuroscience and Mental Health, Melbourne, Australia (n = 2),
5) Medical University of Vienna, Austria (n = 4), 6) Fondazione IRCCS Istituto Neurologico Carlo
Besta, Milan, Italy (n = 1), and 7) National CJD surveillance center, Beaumont Hospital, Dublin, Ireland
(n = 2). Iatrogenic CJD was diagnosed according to established World Health Organization (WHO)
criteria [17]. Twenty iatrogenic cases were associated with dura matter grafts, two with human growth
hormone, and one with corneal transplantation. Clinical symptoms of the 23 iCJD patients are indicated
in Supplementary Table S1. CSF was collected for diagnostic purposes during regular prospective
surveillance activities of the participating centers and stored in polypropylene tubes at −80 ºC at each
diagnostic centre. For this study, CSF was shipped with dry ice to the University Medical Center of
Göttingen to perform additional CSF biomarker tests.
2.2. CSF Analyses
The presence of 14-3-3 protein in the CSF was determined with western-blot (WB) according
to established CJD diagnostic protocols [18]. Cases with inconclusive outcome (traces of 14-3-3
in the WB) were considered negative. 14-3-3 gamma was quantified using the enzyme-linked
immunosorbent assay (ELISA) 14-3-3 gamma from Circulex (Nagano, Japan). Total-tau (t-tau) and
phosphorylated tau T181 (p-tau) were quantified using the INNOTEST®hTAU-Ag and INNOTEST®
PHOSPHO-TAU(181P) ELISA kits from Fujirebio (Ghent, Belgium), respectively. Neurofilament light
(Nfl) was quantified using the Uman Diagnostics NF-light assay from Uman Diagnostics (Umeå,
Sweden). Alpha-synuclein (a-syn) was quantified using the a-syn ELISA kit from EUROIMMUN as
described before [19]. YKL-40 was quantified using the MicroVue YKL-40 ELISA assay from Quidel
(San Diego, CA, USA). Real-time quaking-induced conversion (RT-QuIC) was performed as described
before [20]. The analysts were blinded to clinical data. CSF biomarkers were centrally quantified
(Clinical Dementia Center—Göttingen) at the time of the present study with the exception of WB
14-3-3, which was locally analysed in each of the participants’ laboratories at the time of diagnosis.
2.3. Electroencephalogram and Magnetic Resonance Imaging
Electroencephalogram (EEG) and magnetic resonance image (MRI) tests were performed as
routine clinical diagnostic studies at each prion diagnostic centre in the framework of epidemiological
studies [21,22]. For the present study, biomarker outcomes were reported as “positive” or “negative”
according to WHO criteria [17], which include high signal abnormalities in the caudate nucleus and/or
putamen on diffusion-weighted imaging (DWI), or fluid attenuated inversion recovery (FLAIR) and
the presence of generalized periodic complexes in the EEG.
2.4. Genetic Test:
Determination of codon 129 polymorphism in the prion protein gene (PRNP) was performed as
described before [23].
2.5. Statistical Analysis
In order to determine associations between biomarkers and age at onset and sex, linear regression
models (for continuous biomarkers) and logistic regression models (for categorical biomarkers)
were used. Disease duration association with other variables was analysed with multivariate Cox
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proportional hazards models for survival analysis. Stratification based on the source of infection was
not considered in any statistical analysis due to the low number of cases in two subgroups. Pearson
correlation coefficients were used to assess associations between continuous biomarkers. All statistical
analyses were conducted in R, except correlations, which were performed in GraphPad Prism 5
(GraphPad Software, San Diego, CA, USA).
2.6. Ethics
The study was conducted according to the revised Declaration of Helsinki and Good Clinical
Practice guidelines, and was approved by local Ethics committees.
3. Results
3.1. Study Population
Of the 23 iCJD cases included in the study, 14 were male and nine were female. Most iCJD cases
(n = 20) were attributed to dura mater grafts, while two were associated with growth hormone therapy,
and one was associated with corneal transplantation. Mean age at disease onset was 51.0 years old and
mean disease duration was 7.9 months. Disease duration was significantly associated with age at onset
and with sex (p < 0.01 in both). The hazard ratios were 1.0526 for the variable age and 4.2121 for the
variable sex, with female patients showing increased disease duration (Figure 1). These association
results with demographic parameters were not significantly altered when only dura matter grafts cases
were considered.
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Most of th cas s (n = 18) were methio ine/methionin (MM) h mozygous at codon 129 of the
PRNP gene, while three were methionine/valine (MV) heterozygous and one was valine/valine (VV)
homozygous (Table 1).
Table 1. Demographic, genetic, and clinical data in iatrogenic CJD. Source of infection, number of cases
(n), sex (female (f)/male (m)), age at onset in years (mean with standard deviation (SD) and minimum
and maximum years), codon 129 genotype (methionine (M), valine (V)), and disease duration in months
(mean and standard deviation (SD), with minimum and maximum months) are indicated. NA: not
available. * For one case, disease duration was not available.
Age (years) Codon 129 PRNP Disease Duration (Months)
Source of Infecti n n Sex(f/m) mean±SD (min-max) MM MV VV NA Mean±SD (min-max)
Dura mater grafts 20 8/12 52 ± 15 (28-76) 16 3 0 1 8.0 ± 7.9 (2-35)
Growth hormone 2 0/2 39.5 ± 0.7 (39-40) 1 0 1 0 3*
Corneal transplant 1 1/0 45 1 0 0 0 11
Total 23 9/14 51 ± 15 (28-76) 18 3 1 1 7.9 ± 7.6 (2-35)
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3.2. EEG and MRI
A positive EEG was recorded in 11 out of 22 cases with available data (sensitivity 50%). MRI
results were recorded in 15 cases, being positive in 10 of them (sensitivity 66.6%). The degree of
agreement between EEG and MRI outcome (number of positive or negative cases in both tests) was
60% (Table 2). EEG and MRI positivity was associated neither with age at onset nor with sex (p > 0.05).
Table 2. Electroencephalogram and magnetic resonance imaging in iatrogenic CJD. Source of infection,
electroencephalogram (EEG), and magnetic resonance imaging (MRI) outcome given as positive (Pos),
negative (Neg), or not available (NA), and sensitivity of the biomarker test (%), are indicated.
EEG MRI
Source of Infection Pos Neg NA Sensitivity (%) Pos Neg NA Sensitivity (%)
Dura mater grafts 9 10 1 47.4 9 4 7 69
Growth hormone 1 1 0 50 1 1 0 50
Corneal transplant 1 0 0 100 0 0 1 NA
Total 11 11 1 50 10 5 8 66.6
3.3. CSF Biomarkers
14-3-3 was measured with WB (n = 23) and ELISA (n = 21). 14-3-3 ELISA quantification
out-performed WB in terms of sensitivity (95.2% vs. 87%) with only one case below the established
cut-off for sCJD (20000 AU/mL, [24]) and mean values of 93,047 AU/mL. t-tau (n = 23) displayed a
sensitivity of 87% based on the established sCJD cut-off of 1300 pg/mL [13], with a mean concentration
of 10,915 pg/mL. The addition to p-tau in the form of p-tau/t-tau ratio (n = 19) increased the sensitivity
achieved by t-tau alone up to 94.7%, with only one case below the p-tau/t-tau cut-off (<0.075, [25]). Mean
p-tau/t-tau ratio was 0.018. a-syn (n = 21) displayed a sensitivity of 90.5% based on the sCJD cut-off
of 3300 pg/mL [26] with a mean concentration of 13,346 pg/mL. Nfl (n = 21) displayed a sensitivity
of 85.7% using a cut-off of 7000 pg/mL [27] with a mean concentration of 12,986 pg/mL. The mean
YKL-40 concentration (n = 21) was 441 ng/mL with a sensitivity of 76.2% based on a sCJD cut-off of
315 ng/mL [28]. Finally, RT-QuIC positive reactions were detected in 18 out of 21 cases (sensitivity of
85.7%) based on a cut-off of 10,000 relative fluorescent units (RFU) for sCJD [20]; mean RFU was 41,129
(Table 3). None of the CSF biomarkers were associated with age at onset or sex (p > 0.05 in all cases).
Disease duration was not associated with any biomarker after controlling for the effects of age and sex.
Biomolecules 2020, 10, 290 6 of 13
Table 3. Cerebrospinal fluid biomarkers in iatrogenic CJD. Cerebrospinal fluid (CSF) biomarker with
cut-off point, source of infection, biomarker outcome given as positive, negative, or not available (NA),
sensitivity of the biomarker test (%) with concentrations (mean with standard deviation (SD)), and
minimum and maximum values are indicated. Data stratification based on infection source are only
disclosed as descriptive information but no subgroup analysis was performed.
CSF Biomarker Source of Infection Positive Negative NA Sensitivity (%) Mean ± SD Min-Max
14-3-3
western-blot Dura mater grafts 17 3 0 85.0 - -
Growth hormone 2 0 0 100.0 - -
Corneal transplant 1 0 0 100.0 - -
Total 20 3 0 87.0 - -
14-3-3 ELISA Dura mater grafts 17 1 2 94.4 94,721±65,638 7677-254,152
(>20,000 AU/mL) Growth hormone 2 0 0 100.0 56,120±36,753 36,753-75,488
Corneal transplant 1 0 0 100.0 136,776 -
Total 20 1 2 95.2 93,047±62,723 7677-254,152
t-tau Dura mater grafts 17 3 0 85.0 10,374±9983 510-35,280
(>1300 pg/mL) Growth hormone 2 0 0 100.0 19,356±22,299 3588-35124
Corneal transplant 1 0 0 100.0 4833.0 -
Total 20 3 0 87.0 10,915±10,822 510-35,280
p-tau/t-tau ratio Dura mater grafts 16 1 3 94.1 0.018±0.025 0.002-0.094
(<0.075) Growth hormone 1 0 1 100.0 0.012 -
Corneal transplant 1 0 0 100.0 0.013 -
Total 18 1 4 94.7 0.018±0.024 0.002-0.094
a-syn Dura mater grafts 16 2 2 88.9 11,884±13,303 2075-45,698
(>3300 pg/ml) Growth hormone 2 0 0 100.0 25,905±24,158 8823-42,987
Corneal transplant 1 0 0 100.0 14,541 -
Total 19 2 2 90.5 13,346±14,049 2075-45,698
Nfl Dura mater grafts 15 3 2 83.3 12,900±7021 5311-29,856
(>7000 pg/mL) Growth hormone 2 0 0 100.0 13,347±8892 7060-19,635
Corneal transplant 1 0 0 100.0 14541 -
Total 18 3 2 85.7 12,986±6776 5311-29,856
YKL-40 Dura mater grafts 13 5 2 72.2 417±205 127-887
(>315 ng/mL) Growth hormone 2 0 0 100.0 630±303 416-845
Corneal transplant 1 0 0 100.0 495.0 -
Total 16 5 2 76.2 441±211 127-887
RT-QuIC Dura mater grafts 16 2 2 88.9 44,180±16,679 10,000-65,000
(>10,000 RFU) Growth hormone 1 1 0 50.0 21,910±16,843 10,000-33,820
Corneal transplant 1 0 0 100.0 24,651 -
Total 18 3 2 85.7 41,129±17,594 10,000-65,000
3.4. Correlation between CSF Biomarkers
Correlations between continuous CSF biomarker data (biomarker concentrations for 14-3-3
(ELISA), t-tau, p-tau/t-tau ratio Nfl, a-syn, YKL-40, and RFU for RT-QuIC assay) were investigated.
WB 14-3-3 data were not included due to the binary outcome of the assay.
Significant correlations were detected between 14-3-3 and t-tau (ρ = 0.57, p = 0.0067), 14-3-3 and
p-tau/t-tau ratio (ρ = −0.52, p = 0.0208), t-tau and p-tau/t-tau ratio (ρ = −0.56, p = 0.0126), t-tau and
a-syn (ρ = 0.70, p < 0.001), t-tau and Nfl (ρ = 0.48, p = 0.0259), t-tau and YKL-40 (ρ = 0.56, p = 0.0079),
a-syn and Nfl (ρ = 0.45, p = 0.0396), a-syn and YKL-40 (ρ = 0.52, p = 0.0148), and Nfl and YKL-40
(ρ = 0.80, p < 0.001). RT-QuIC RFU did not correlate with any of the other biomarkers (p > 0.05 for all
comparisons) (Table 4).
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Table 4. Correlations between cerebrospinal fluid biomarkers. Cerebrospinal fluid (CSF) biomarkers
correlations (biomarkers concentrations for 14-3-3 (ELISA), t-tau, p-tau/t-tau ratio Nfl, a-syn, YKL-40,
and RFU for RT-QuIC assay). Pearson’s correlation coefficients are shown below the diagonal line (-)
and p values are shown above. Statistically significant correlations (p < 0.05) are shown in bold.
14-3-3 t-tau p-tau/t-tau ratio a-syn Nfl YKL-40 RT-QuIC
14-3-3 - 0.0067 0.0208 0.1822 0.8759 0.8064 0.7713
t-tau 0.57 - 0.0126 <0.001 0.0259 0.0079 0.4150
p-tau/t-tau ratio −0.52 −0.56 - 0.0822 0.1938 0.3634 0.9507
a-syn 0.30 0.70 −0.41 - 0.0396 0.0148 0.1822
Nfl 0.04 0.48 −0.31 0.45 - <0.001 0.9358
YKL-40 0.06 0.56 −0.22 0.52 0.80 - 0.1920
RT-QuIC −0.07 −0.19 0.02 −0.29 −0.02 −0.30 -
4. Discussion
The differential diagnosis of human prion diseases can be often challenging due to the phenotypic
heterogeneity of the disease. Prion disease biomarker tests developed in the last two decades allow
the detection of symptomatic sCJD and genetic prion disease cases, with PRNP sequence variations
mimicking the sporadic phenotype (e.g., PRNP-E200K and PRNP-V210I) with high accuracy [27,29–33].
In contrast, very few studies have assessed the accuracy of the same biomarker tests in iCJD. Available
studies described either very small numbers of cases, not necessarily representative of the overall
cohort, or limited biomarker assays, mainly first-generation ones such as CSF 14-3-3 WB, EEG, or
MRI [12,13,16].
Demographic and genetic characteristics of our iCJD cohort were similar to previous studies
reviewing the iCJD outbreak [6]. Methionine homozygosity at codon 129 was over-represented in the
present study (18 out of 22 cases), in agreement with the reported high prevalence of MM genotype in
dura mater cases (80%) [6,11,16], which was indeed the source of infection most represented in our
study population (87% of cases). Similar to other studies [12], mean age at onset in our iCJD cohort (51
years) was below that reported in sCJD (66 years old) [34]. Indeed, in the absence of recognized risk
factors for iatrogenic transmission, iCJD may not be identified as a prion disease due to the significantly
younger age at onset compared to sCJD [11]. We observed an association of disease duration with age
at onset and also with sex, with female patients presenting longer survival times. This finding was
previously described in sCJD and genetic prion diseases [35], as well as in iCJD [36]. Although a longer
survival time in iCJD was also associated with MV heterozygosity at codon 129 and with cases caused
by growth hormone treatment (compared to cases caused by dura mater implants) [36], we could not
validate these findings probably due to the strong imbalance of our cohort regarding these variables.
In our biomarker panel study, we found the accuracy of EEG, MRI, and CSF 14-3-3 WB in iCJD
to be broadly in line with what has been reported for sCJD. This finding is perhaps not surprising
considering the similarity between the iCJD and sCJD clinical phenotypes [11]. When previously
published data are simultaneously explored however, notable differences are observed between studied
cohorts of iCJD. Regarding 14-3-3 detection by WB, a variety of sensitivities have been reported:
43% (n = 14, growth hormone-associated) [12], 75% (n = 20, source not indicated) [13], and 85%
(n = 13, dura mater graft-associated) [16]. Other reports with one [37–39] or two iCJD cases [40]
displayed 14-3-3 WB positivity in all samples. These differences may be related not to only the specific
transmitted sCJD strain and the source of infection, but also to pre-analytical/analytical parameters as
well as demographic/genetic characteristics of the studied cohorts. In our work, 14-3-3 WB sensitivity
(87%) was at the upper range of previous iCJD studies, which is the same value as t-tau sensitivity.
Importantly, 14-3-3 quantification with ELISA (sensitivity 95.2%) out-performed WB, displaying the
highest sensitivity among the biomarkers herein tested. Since the development of the 14-3-3 ELISA,
several studies in large cohorts of sCJD cases have demonstrated superior sensitivity compared to the
WB method [24,40–42], but this is the first study to validate this observation in iCJD.
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The value of EEG and MRI as diagnostic tools in iCJD was previously documented [11,14]. In a
cohort of growth hormone-associated iCJD cases, EEG displayed a sensitivity of 71%, with the presence
of MRI abnormalities in most of the cases [12]. CJD-associated changes on MRI were reported in two
studied growth hormone-associated iCJD cases [43] and in 16 out of 22 (76%) dura matter-associated
iCJD cases [16]. Case reports have also demonstrated the presence of typical abnormalities in growth
hormone-related cases [44,45]. In our study, EEG and MRI displayed lower sensitivities than CSF
biomarkers (50% and 66.6%, respectively) with poor agreement between both tests (60%). The low
sensitivity of CJD-typical EEG findings is in line with other published data from CJD surveillance
centres reporting sCJD cases [1]. In contrast, the herein reported sensitivity of MRI is lower than
in sCJD cases [46–48]. On one side, this might be explained by the fact that most of the cases were
reported to the reference centres before 2009, when standardized MRI criteria had not been established.
On the other side, MRI data were available in only 15 out of the 23 iCJD cases; thus, caution should be
taken when comparing our results with those from larger study cohorts.
Regarding next-generation CSF biomarkers, few data are available in the literature. In the present
work, the addition of p-tau to t-tau quantification in the form of p-tau/t-tau ratio raised the sensitivity
from 87% to 94.7%, which lies within the range of the sensitivities achieved in a large cohort of sCJD
cases [29]. Interestingly, the cut-off utilised in the present study (<0.075) was generated from a cohort
of sCJD and non-CJD cases wherein the control group included neurological controls and non-prion
neurodegenerative diseases [25,29]. In the same cohort, exclusion of non-prion neurodegenerative
diseases from the control group rendered a cut-off of <0.106 [29] that, when applied to the present
iCJD study, boosts sensitivity to 100%.
Recently, CSF a-syn has been demonstrated to be a highly sensitive and specific biomarker for
sCJD [26,30] and for gCJD associated with E200K and V210I mutations [30]. Herein, we also validated
the value of this biomarker in the detection of iCJD cases with a sensitivity of 90.5%, which is only
surpassed by the accuracies obtained for 14-3-3 ELISA and the p-tau/t-tau ratio. In contrast to surrogate
markers of neuro-axonal degeneration such as tau and 14-3-3, a-syn is suggested to reflect synaptic
loss, an early event in the pathology of neurodegeneration. Although synaptic and neuronal damage
are common hallmarks in neurodegenerative diseases, CSF a-syn is highly specific for sCJD [30]. This
is in contrast to CSF Nfl, another non-specific marker of axonal damage that is increased in several
neurological conditions [49]. In our iCJD cohort, Nfl sensitivity (85.7%) was below that reported in
sCJD cases [27,50,51]. YKL-40, a disease-specific marker of neuro- inflammation expressed in astrocytes,
displayed the lowest sensitivity (76.2%) among CSF biomarkers herein tested. Elevated CSF YKL-40
levels are reported in sCJD, gCJD associated with E200K, and V210I mutations, and, to a lesser extent,
in fatal familial insomnia [28]. CSF YKL-40 also appeared to be increased in other neurodegenerative
dementias such as AD and FTD, but not in DLB [28,52,53].
The most recently updated diagnostic criteria for CJD incorporates the RT-QuIC assay as one
of the CSF biomarker tests. This assay detects pathological prion protein in biofluids and has been
reported to be highly sensitive and almost fully specific. We observed 85.7% sensitivity of RT-QuIC
in our iCJD cohort, which is within the range of values described for sCJD [31,54]. Unfortunately,
RT-QuIC results in iCJD are scarce in the literature. One study investigating iCJD reported positive
RT-QuIC signal in two tested patients who received dura matter grafts [40]. Another report mentioned
an RT-QuIC sensitivity of 67% in iCJD patients treated with cadaveric growth hormone although the
data were not disclosed [55].
Investigation of potential associations between biomarkers in iCJD led us to the striking finding
that RT-QuIC results do not correlate with any of the surrogate markers of prion pathology. While it is
possible that RT-QuIC signal does not really reflect the degree of cerebral PrP pathogenesis, it may also
be speculated that PrP seeding capacity for pathological conversion is not linked in a straightforward
manner to neuronal damage and neuro-inflammation. By contrast, positive correlations were observed
between several neuronal damage and neuro-inflammation markers, in line with those previously
detected in sCJD [27,28,30,56,57]. Positive correlation between Nfl and t-tau with YKL-40 suggests
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a pathogenic association between astroglial activation and axonal injury in iCJD. Interestingly, Nfl
vs.YKL-40 and t-tau vs. a-syn correlations were the most significant despite the fact that each pair of
biomarkers is associated with distinct prion disease pathological features. While a positive correlation
between Nfl and YKL-40 was previously detected in AD [58], this has not yet been investigated in
prion diseases.
Limitations of the Study
Due to the rarity of iCJD, a limited number of cases were available. Consequently, diagnostic
accuracies may be partially biased due to case selection. Another important limitation is the impossibility
to perform any subgroup statistical analyses based on infection source because the number of cases
associated to growth hormone and corneal transplant are too low. Thus, data regarding source of
infection remain purely descriptive.
5. Conclusions
In this study, we present the first simultaneous analysis of the available battery of prion disease
biomarkers for iCJD. Among these, CSF biomarkers displayed greater sensitivity than EEG and MRI,
with similar accuracies to those achieved in sCJD and in the most prevalent form of genetic prion disease
(gCJD associated to E200K mutation) using the same cut-off points in the same ethnic populations
(comparisons are summarized in Supplementary Table S2). Utilised CSF biomarkers covered the main
pathological features of prion pathogenesis, including synaptic (a-syn) and neuronal damage (14-3-3,
tau, Nfl), neuro-inflammation (YKL-40), and prion protein seeding and aggregation (RT-QuIC). Our
study validates the use of the conventional panel of sCJD biomarkers for the diagnosis of iCJD. On one
side, this would become useful in the event of the appearance of new iCJD cases (though not likely).
In this regard, there is also the need to obtain data on prion biomarkers for acquired forms through
blood transfusion from variant CJD donors in order to have more comprehensive information in the
event of new iCJD. On the other side, the similarity between iCJD and sCJD in biomarker profiles and
clinical phenotype also unveils the incapacity to distinguish sCJD from iCJD in potential situations of
undiscovered sources of transmissibility, which compels the medical community to keep a strict and
constant vigilance for future cases of iCJD to avoid mis-classification as sCJD.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/2/290/s1,
Table S1: CJD-typical clinical symptoms reported at the time of lumbar puncture for each iCJD case involved in
this study, Table S2: Sensitivities of the studied CSF biomarkers described in the present study for iCJD compared
to the sensitivities of the same biomarkers reported in previous studies for sCJD and for gCJD associated with the
E200K PRNP mutation in the same ethnic populations.
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Biomarkers and diagnostic guidelines for sporadic 
Creutzfeldt-Jakob disease
Peter Hermann, Brian Appleby, Jean-Philippe Brandel, Byron Caughey, Steven Collins, Michael D Geschwind, Alison Green, Stephane Haïk, 
Gabor G Kovacs, Anna Ladogana, Franc Llorens, Simon Mead, Noriyuki Nishida, Suvankar Pal, Piero Parchi, Maurizio Pocchiari, Katsuya Satoh, 
Gianluigi Zanusso, Inga Zerr
Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused by misfolded prion proteins (PrPSc). 
Effective therapeutics are currently not available and accurate diagnosis can be challenging. Clinical diagnostic criteria 
use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and EEG. Supportive 
biomarkers, such as high CSF total tau, could aid the diagnostic process. However, discordant studies have led to 
controversies about the clinical value of some established surrogate biomarkers. Development and clinical application 
of disease-specific protein aggregation and amplification assays, such as real-time quaking induced conversion (RT-
QuIC), have constituted major breakthroughs for the confident pre-mortem diagnosis of sporadic Creutzfeldt-Jakob 
disease. Updated criteria for the diagnosis of sporadic Creutzfeldt-Jakob disease, including application of RT-QuIC, 
should improve early clinical confirmation, surveillance, assessment of PrPSc seeding activity in different tissues, and 
trial monitoring. Moreover, emerging blood-based, prognostic, and potentially pre-symptomatic biomarker candidates 
are under investigation.
Introduction
Sporadic Creutzfeldt-Jakob disease is a rapidly pro gressive 
neuropsychiatric syndrome that is fatal and characterised 
by aggregations of misfolded prion protein Scrapie (PrPSc) 
in the brain. Sporadic Creutzfeldt-Jakob disease is the 
most common form of human prion disease (~90% of 
cases) with an incidence of approximately 1·5–2·0 cases 
per million person-years.1 Different phenotypes of sporadic 
Creutzfeldt-Jakob disease can vary in symptom evolution, 
biomarker profile, and neuropatho logical characteristics. 
They are defined by the polymorphism (Met and Val) at 
codon 129 of the prion protein gene (PRNP) and by the 
molecular mass of PrPSc (glycotype 1 and 2).2 Definite 
diagnosis requires neuropathological confirmation.
The spectrum of possible symptoms is highly hetero-
geneous and includes rapidly progressive dementia, 
cerebellar ataxia, and myoclonus, which means that high-
performing (ie, high sensitivity and specificity)  biomarkers 
are important for making a confident clinical diagnosis. 
In 1998, WHO included a combination of particular 
symptoms, EEG, and detection of CSF 14-3-3 proteins in 
the standard diagnostic criteria.3 Patterns of signal 
alteration on fluid attenuated inversion recovery (FLAIR) 
or diffusion weighted imaging (DWI) sequences, or both, 
of brain MRI were suggested in 2009.4 Another CSF 
protein, total-tau (T-tau), is considered a valuable sup-
portive bio marker.5 Although comparative data on imaging 
markers for sporadic Creutzfeldt-Jakob disease are scarce, 
several studies have evaluated the diag nostic perform ance 
of CSF biomarkers, with occasional discrepancies leading 
to controversy about their clinical utility.6,7
Since 2011, development and clinical application of PrPSc 
amplification assays, such as protein misfolding cyclic 
amplification (PMCA) and real-time quaking induced 
conversion (RT-QuIC),8 have constituted major break-
throughs as aids for an improved pre-mortem diagnosis 
of prion diseases. RT-QuIC has shown excellent diagnostic 
accuracy for sporadic Creutzfeldt-Jakob disease in 
retrospective studies, ring trials (consistency between 
laboratories),9,10 and prospective studies,11,12 which shows its 
high value for an early and accurate diagnosis. Conse-
quently, RT-QuIC (using CSF or other tissue, such as 
olfactory mucosa) was included in diagnostic criteria for 
sporadic Creutzfeldt-Jakob disease of some surveillance 
centers.12,13 However, an important discussion on its clini-
cal utility is needed. Another unmet need is the identi-
fication of blood-based biomarkers for early diagnosis and 
disease progression,14–16 particularly regarding potential 
new therapeutic strategies.
The aim of this Review is to provide an overview of the 
biomarker-based diagnosis of sporadic Creutzfeldt-Jakob 
disease and to suggest guidelines for clinicians to use in 
the differential diagnosis of rapidly progressive dementias. 
Advances of the past 5 years are discussed and put in the 
context of clinical relevance, established biomarkers, and 
epidemiology.
Investigating diagnostic tests
When estimates of diagnostic accuracy are being 
translated into clinical practice, potential selection biases 
of case and control groups should be considered. The 
selection of control groups can be particularly challenging. 
Healthy age-matched controls usually do not reflect the 
population in which a diagnostic biomarker is used. 
However, referral centres often use Creutzfeldt-Jakob 
disease mimics (eg, autoimmune encephalitis) that 
represent the diagnostic challenges but might not reflect 
the routine of a tertiary institution. An example of a 
biased control group was the evaluation of diagnostic 
criteria for sporadic Creutzfeldt-Jakob disease published 
in 2018.12 The control group included many patients 
without Creutzfeldt-Jakob disease who had been further 
investigated because of positive CSF 14-3-3 tests, resulting 
in a weak specificity of this biomarker. In 2017, a study 
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evaluating the use of olfactory mucosa and CSF samples 
in RT-QuIC17 reported a relatively low sensitivity compared 
with some other studies that used RT-QuIC assays. In 
this study, the case group was partly selected from 
samples that had a previous negative first-generation 
RT-QuIC result, leading to a case group selection bias. 
Both examples highlight the importance of interpreting 
all biomarker test results in an adequate clinical context.
Most biomarker studies report the sensitivity and the 
specificity of diagnostic tests. It is debatable whether 
sensitivity and specificity are the most useful measures of 
diagnostic performance as they are not easy to interpret in 
a clinical setting. Predictive values might be more accurate 
to determine the likelihood of a disease, but they are 
associated with disease prevalence. To calculate predictive 
values, the rate of cases and controls in a study has to 
reflect the respective rate in the population or Bayes’ rule 
has to be applied, which requires including disease 
prevalence (proportion) in the calculations.18 In the context 
of an extremely rare disease, such as sporadic Creutzfeldt-
Jakob disease, a sufficient number of controls cannot be 
obtained and applying Bayes’ rule would always lead to 
extremely low positive and extremely high negative 
predictive values. Thus, predictive values are not con-
sidered in this Review. In studies of established biomarkers 
with defined cutoffs, we use test sensitivity and specificity 
as measures for diagnostic accuracy. For experimental 
biomarkers, we report the area under the curve (AUC) 
from receiver operator characteristics.
Advances in biomarker research
Neuropathological investigation and immunostaining of 
PrPSc allow a definite diagnosis of prion diseases.19 For 
definite ante-mortem diagnosis, brain biopsy is required 
but is complicated by infection control concerns, the 
possibility of a false negative result due to sampling error 
in which typical pathology and PrPSc might not be present 
in all cortical regions (eg, sporadic or familial fatal 
insomnia), and issues with tissue quality. Given these 
considerations and the highly invasive nature of the 
procedure, brain biopsy is usually only considered when 
the diagnosis is not clear and potentially treatable 
conditions (eg, encephalitis or lymphoma) are under 
strong considera tion, or a potential contamination of 
medical instruments requires a clear case definition. A 
less invasive procedure, tonsillar or adenoid biopsy, was 
established for the diagnosis of variant Creutzfeldt-Jakob 
disease (prion disease caused by consumption of beef 
from bovines affected by bovine spongiform enceph-
alopathy), but is not helpful for other forms of prion dis-
ease.20 The direct in-vivo detection of PrPSc in sporadic 
Creutzfeldt-Jakob disease using routinely accessible 
biofluids is possible but a pilot study using urine reported 
a poor sensitivity of 40%.21 Given the limitations of tradi-
tional methods (eg, biopsy and direct detection) and 
growing clinical evidence in support of novel PrPSc-seeded 
assays, a shift in clinical diagnosis criteria for sporadic 
Creutzfeldt-Jakob disease is warranted. We describe the 
evidence for these novel assays and the current state of 
established and new diagnostic surro gate biomarkers 
(diagnostic tests that indirectly mark the disease process).
PrPSc-seeded aggregation assays
PMCA
In 2001, PMCA was developed to reproduce and amplify 
PrPSc in microtubes. Brain homogenate provided normal 
prion protein (PrPC) substrate for the reaction and 
sonication fragmented growing PrPSc particles to increase 
their concentration.22 Subsequently, a modified protocol 
introduced the use of recombinant hamster PrPC as sub-
strate to accelerate the reaction and increase its sensitivity 
to detect PrPSc in the CSF of scrapie-infected hamsters.23 
PMCA protocols showed excellent sensitivity for the 
detection of PrPSc in CSF (100%),24 plasma (100%)25,26 and 
urine (93%)27 of patients with variant Creutzfeldt-Jakob 
disease but high sensitivity could not be shown in sporadic 
Creutzfeldt-Jakob disease or other prion diseases seen in 
current clinical practice.
RT-QuIC
A modified multiwell plate-based PrPSc amplification 
technology using quaking to energise the misfolding of 
prion protein coupled to a fluorescent readout was named 
RT-QuIC.8,28 RT-QuIC has shown to be a potential tool not 
only in the diagnosis of prion diseases but also in drug 
screening, prion strain discrimination, and detection 
of other protein misfolding diseases (eg, tauopathies 
and synocleinopathies).29,30 Different protocols concerning 
substrate (eg, recombi nant hamster PrP, hamster–sheep 
chimeric PrP, or bank vole PrP), reaction conditions, and 
the definition of test positivity have been reported.8,29,30 In 
general, each sample is analysed in quadruplicates9 and 
positivity is confirmed when at least two of four replicates 
cross a fluorescence signal cutoff value; similarly, samples 
can be analysed as triplates29 whereby positivity is 
confirmed when at least two of three replicates cross the 
fluorescence threshold. In 2015, the original protocol (first 
generation RT-QuIC) was technically modified by increas-
ing the reaction temperature and using N-terminally 
truncated PrPSen (second generation RT-QuIC) to shorten 
the assay time and to improve the sensitivity.31
CSF RT-QuIC represents a disease-specific biomarker 
and retrospective studies have investigated its diagnostic 
accuracy with test specificity of 99–100%.8–11,17,31–37 Most 
studies, however, did not use control groups consisting 
primarily of cases with rapidly progressive dementias in 
whom Creutzfeldt-Jakob disease was considered as a 
poten tial diagnosis during the disease course. Some false 
positive cases in retrospective studies were speculated to 
possibly represent unrecog nised prion diseases.10 None-
theless, two cases of autopsy-verified non-Creutzfeldt-
Jakob disease showing positive CSF RT-QuIC during the 
diagnostic process have been reported.38,39 One of these 
patients had convulsions caused by steroid-responsive 
Review
www.thelancet.com/neurology   Vol 20   March 2021 237
enceph alitis, which is a potential clinical sporadic 
Creutzfeldt-Jakob disease mimic.38 Prospective studies 
using rapidly pro gres sive dementias as controls and 
mostly neuro pathological confirmed sporadic Creutzfeldt-
Jakob disease cases, were published since 2017 and the 
specificity was also reported as 99–100% (table).11,12,39–42 
Because of its reliability and high diagnostic accuracy, 
CSF RT-QuIC was incorporated in the diagnostic criteria 
for sporadic Creutzfeldt-Jakob disease of several surveil-
lance centres.13,14
Regarding the test sensitivity, figures range from 73%19,33 
to 89%9,12,37 using first generation RT-QuIC, and 92%11 to 
97%35 using second generation RT-QuIC. Molecular sub-
types of sporadic Creutzfeldt-Jakob disease are defined by 
codon 129 polymorphism (M and V) and PrPSc glycotype 
(1 and 2),2 resulting in different subtypes (eg, MM1, MV1). 
The sensitivity is very high in MM1/MV1 and VV2 cases, 
the most common subtypes among sporadic Creutzfeldt-
Jakob disease patients, whereas it is slightly lower in MV2 
cases (75–93%).11,35,36,39,40 Regarding rare subtypes, there are 
few reported cases, hampering the validity of results, but 
sensitivity has been reported to be substantially lower in 
VV1 (range 0–100%)37–39 and MM2 cases (range 44–78%).36,39 
The MM2 subtype is further differentiated into a cortical 
type (MM2C) and a very rare thalamic type (MM2T) 
that show a distinct clinical syndrome called sporadic fatal 
insomnia. Only few known cases of sporadic fatal insomnia 
imply that classic sporadic Creutzfeldt-Jakob disease 
biomarkers and RT-QuIC show poor sensitivity in this con-
dition.39 CSF RT-QuIC showed high sensitivity for genetic 
prion diseases with E200K and V210I mutations but low 
sensitivity for fatal familial insomnia (D178N-129M).10,11,39,40 
Cases Controls Sensitivity Specificity Protocol
n type n type
Retrospective studies
Atarashi et al (2011)*8 34 Definite sporadic Creutzfeldt-Jakob disease 49 Other neurological diseases 85% 100% 1st generation
McGuire et al (2012)9 123 Definite sporadic Creutzfeldt-Jakob disease 103 Rapidly progressive dementia 89% 99% 1st generation
Orrú et al (2014)32 30 Probable and definite sporadic Creutzfeldt-Jakob disease 46 Non-Creutzfeldt-Jakob disease 77% 100% 1st generation
Orrú et al (2015)31 48 Probable and definite sporadic Creutzfeldt-Jakob disease 39 Other neurological diseases 96% 100% 2nd generation
Cramm et al (2016)10 110 Definite sporadic Creutzfeldt-Jakob disease and genetic 
Creutzfeldt-Jakob disease
400 Other neurological diseases 85% 99% 1st generation‡
Groveman et al (2016)†33 113 Probable and definite sporadic Creutzfeldt-Jakob disease 64 Other neurological diseases 73% 100% 1st generation
Groveman et al (2016)†33 113 Probable and definite sporadic Creutzfeldt-Jakob disease 64 Other neurological diseases 94% 100% 2nd generation
Park et al (2016)34 81 Probable and definite sporadic Creutzfeldt-Jakob disease 100 Non-Creutzfeldt-Jakob disease 77% 100% 1st generation
Franceschini et al (2017)35 145 Probable and definite sporadic Creutzfeldt-Jakob disease 
and genetic Creutzfeldt-Jakob disease 
42 Rapidly progressive dementia 97% 100% 2nd generation
Bongianni et al (2017)†17 49 Probable and definite sporadic Creutzfeldt-Jakob disease 71 Other neurological diseases 73% 100% 1st generation
Bongianni et al (2017)†17 22 Probable and definite sporadic Creutzfeldt-Jakob disease 71 Other neurological diseases 86% 100% 2nd generation
Lattanzio et al (2017)36 225 Definite sporadic Creutzfeldt-Jakob disease 348 Rapidly progressive dementia 84% 99% 1st generation
Foutz et al (2017)11 126 Definite sporadic Creutzfeldt-Jakob disease and genetic 
Creutzfeldt-Jakob disease
67 Rapidly progressive dementia 92% 99% 2nd generation
Rudge et al (2018)37 171 Definite sporadic Creutzfeldt-Jakob disease 47 Rapidly progressive dementia 89% 100% 1st generation
Prospective studies
Foutz et al (2017)11 65 Definite sporadic Creutzfeldt-Jakob disease and genetic 
Creutzfeldt-Jakob disease
14 Rapidly progressive dementia 95% 100% 2nd generation
Hermann et al (2018)12 65 Definite sporadic Creutzfeldt-Jakob disease 118 Rapidly progressive dementia 89% 100% 1st generation‡
Abu-Rumeileh et al (2019)†40 65 Definite sporadic Creutzfeldt-Jakob disease and genetic 
Creutzfeldt-Jakob disease
62 Rapidly progressive dementia 82% 100% 1st generation
Abu-Rumeileh et al (2019)†40 65 Definite sporadic Creutzfeldt-Jakob disease and genetic 
Creutzfeldt-Jakob disease
62 Rapidly progressive dementia 96% 100% 2nd generation
Fiorini et al (2020)42 102 Probable and definite sporadic Creutzfeldt-Jakob disease 80 Rapidly progressive dementia 96% 100% 2nd generation
Mammana et al (2020)43 24 Probable and definite sporadic Creutzfeldt-Jakob disease 12 Rapidly progressive dementia 88% 100% 1st generation
Rhoads et al (2020)39 439 Definite sporadic Creutzfeldt-Jakob disease 69 Rapidly progressive dementia 93% 99% 2nd generation
Definite sporadic Creutzfeldt-Jakob disease is defined as neuropathologically confirmed diagnosis. Probable sporadic Creutzfeldt-Jakob disease is defined as clinical diagnosis based on syndrome and biomarkers.4 
Other neurological diseases include dementia syndromes. Non-Creutzfeldt-Jakob disease includes non-neurological disorders, neurological disorders, and dementia syndromes. 1st generation=first generation 
tests.8 2nd generation=second generation tests.31 RT-QuIC=real-time quaking induced conversion. *This study investigated two different cohorts, overall sensitivity and specificity are summarised here. †These 
studies appplied two different protocols and used the same control group for both investigations. ‡This protocol used hamster–sheep chimeric recombinant PrP as substrate (instead of hamster PrP) and test 
positivity was indicated by two out of three positive replicates (instead of two of four).29
Table: Diagnostic accuracy of CSF RT-QuIC in retrospective and prospective studies
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However, supporting data are based on small case 
numbers. RT-QuIC might also aid in the differentiation of 
distinct prion diseases such as sporadic Creutzfeldt-Jakob 
disease, Gerstmann-Sträussler-Scheinker syndrome, and 
fatal familial insomnia and sporadic Creutzfeldt-Jakob 
disease subtypes.30,41
Regarding other tissues, promising studies that applied 
RT-QuIC to olfactory mucosa17,32,42 and skin biopsies43,44 
showed high sensitivities of 89% to 100%, suggesting 
even better diagnostic accuracy than with use of CSF. 
Multiple com ponents of the eye have tested positive by 
RT-QuIC45 post mortem, but the diagnostic value of 




The 14-3-3 proteins are abundantly but not solely expressed 
in the brain. They are located in the cytoplasm, plasma 
membranes, and organelles. Involvement in various 
functions (eg, cell signalling, growth, apoptosis) has 
been identified but not completely clarified.46 Since 
14-3-3 protein detection by western blot became part of 
com monly used clinical diagnostic criteria for sporadic 
Creutzfeldt-Jakob disease,3 several studies evaluated its 
diagnostic performance. In 2012, a structured meta-
analysis reported a sensitivity of 92% and a specificity 
of 80%47 but it was reported that the test sensitivity is 
lower than 92% in early disease stages and differs across 
the spectrum of molecular subtypes. The MV2 and MM2 
subtypes showed lower test sensitivities of between 
60% and 70%.48 Reported specificity ranges between 
40%49 and 92%.50 Such discrepancies might be explained, at 
least partly, by different characteristics of the control 
groups. Over the past 5 years, several studies reported 
a high specificity in the discrim ination of sporadic 
Creutzfeldt-Jakob disease and neurodegenerative diseases 
such as Alzheimer’s disease, dementia with Lewy bodies, 
and fronto-temporal lobar degeneration (appendix p 1).36,50–53 
By contrast, the specificity of CSF 14-3-3 was lowered 
when control groups included acute neuro nal injury 
events and inflammatory and infiltrative neoplastic CNS 
diseases.36,50 Another factor possibly affecting specificity 
could be the execution and rating of 14-3-3 western blot. 
Intermediate results (ie, weak or trace readouts) can 
be difficult to interpret. Comparative evaluations of a new 
14-3-3γ isoform ELISA assay showed a superior diagnostic 
performance by comparison with 14-3-3 western blot.40,54,55 
One study reported a sensitivity of 97% and a speci-
ficity of 94% with an AUC of 0·982 (optimal cutoff 
>14552 AU/mL),54 whereas a larger study (including ring 
trials) reported a sensitivity of 88% and a specificity of 96% 
(cutoff >20 000 AU/mL).55
Tau protein
Tau, a microtubule-associated protein, is expressed in 
neuronal and glial cells.56 Extremely elevated CSF T-tau 
was proposed as a diagnostic biomarker for sporadic 
Creutzfeldt-Jakob disease5 and most studies reported good 
test sensitivity and specificity, each around 90%.36,48,49,57 
However, currently, CSF t-Tau is not formally accepted as 
part of case definition criteria.4 Similar to 14-3-3, reduced 
sensitivity has been shown in MM2 and MV2 subtypes48,58 
and early disease stages.59 Some studies reported relatively 
poor specificities of 67%49 or lower than 50% at vary-
ing optimal diagnostic cut-offs.51–53 Specificity of lower 
than 50% was observed when patients with atypical 
Alzheimer’s disease were used as controls (appendix p 1). 
Some studies, however, have found t-Tau to be a better 
diagnostic marker than 14-3-3,49,60 leading to an ongoing 
discussion and controversy over which biomarker should 
be used primarily. Besides Alzheimer’s disease, inflam-
matory and neoplastic CNS diseases are important 
differential diagnoses of elevated t-Tau concentrations.61 
Unfortunately, there is no general consensus regarding 
the best t-Tau ELISA assay or cut-off that should be used 
to support sporadic Creutzfeldt-Jakob disease (eg, studies 
have suggested either >1072 pg/mL, >1250 pg/mL, 
>1300 pg/mL, or >1400 pg/mL).5,35,62–64 CSF t-Tau can also 
be a predictor of survival time.65,66 The p-Tau/t-Tau (or 
t-Tau/p-Tau) ratio is an important alternative biomarker 
for sporadic Creutzfeldt-Jakob disease.67 It showed a very 
high diagnostic accuracy in the differentiation of spo-
radic Creutzfeldt-Jakob disease from other neurological 
diseases (AUC 0·98), Alzheimer’s disease (AUC 0·99),64 
and rapidly progressive Alzheimer’s disease (AUC 0·99).68 
Several studies that investigated large cohorts rep orted 
a superior diagnostic performance compared with 
t-Tau alone.51,64,68
Neurofilaments
Neurofilaments comprise three subunits: a light (NfL), a 
medium, and a heavy chain. As neuron-specific cyto-
skeleton proteins, their presence in body fluids represents 
neuroaxonal damage.69 Several studies showed an excellent 
diagnostic accuracy in the discrimination of healthy 
individuals and patients with sporadic Creutzfeldt-Jakob 
disease (AUCs >0·99).16,70,71 However, NfL might have 
insufficient specificity for sporadic Creutzfeldt-Jakob 
disease.40 Concerning important differential diagnoses, 
reported AUCs were 0·95 versus patients with other 
neurological diseases (including dementia syndromes),15 
0·77 versus Alzheimer’s disease,16 0·4516 and 0·9070 versus 
other neuro logical diseases with dementia syndrome, 
0·93 versus neurodegenerative dementias,53 and 0·86 to 
0·89 versus rapidly progressive dementia.72 The notable 
differences between these studies might be explained 
by different group selection criteria but this requires 
further clarification. Additionally, different optimal cut-
offs were identified (eg, >5016 pg/ml or >10 500 pg/ml).53,70 
By contrast with 14-3-3 and t-Tau, NfL was shown to be 
markedly elevated in MV2 and VV2 subtypes when 
compared with the MM1 sporadic Creutzfeldt-Jakob dis-
ease subtype.53
See Online for appendix
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Other CSF surrogate biomarkers
Several other CSF biomarkers for sporadic Creutzfeldt-
Jakob disease have been identified over the past two 
decades. Herein, only those that have a high amount of 
supported evidence are considered. CSF S100b has been 
widely studied, but comparative studies showed inferior 
diagnostic perfor mance compared with 14-3-3 and 
t-Tau,48,73 and S100b has not been widely used clinically. 
Total prion protein (t-PrP) is decreased in the CSF of 
patients with sporadic Creutzfeldt-Jakob disease, showing 
moderate diagnostic accuracy.51,74 A study using targeted 
mass spectrometry (instead of the more routinely used 
ELISA) showed that all human PrP domains were 
reduced in the CSF of patients with sporadic Creutzfeldt-
Jakob disease compared with patients with rapidly 
progres sive dementia.75 Additionally, it might have poten-
tial in trial monitoring76 and constitute a valuable part 
of composite biomarker profiles.51,53 α-Synuclein, a 
synaptic protein that aggre gates in synucleinopathies, 
was observed to be massively increased in patients with 
sporadic Creutzfeldt-Jakob disease, possibly related to 
rapid neurodegeneration. A multicentre study showed an 
excellent diagnostic accuracy (AUC >0·99, 98% sensi-
tivity, 97% specificity) in the discrimination of sporadic 
Creutzfeldt-Jakob disease and other neurological diseases 
(including dementia syndromes) at an optimal cut-off of 
820 pg/mL using a commercial ELISA.77,78 Similar results 
were found in an inter-laboratory validation study.79 
Advantages and dis advan tages of common CSF bio-
markers are summarised (appendix p 2); potential CSF 
biomarker candidates evaluated in the past 5 years are 
also noted (appendix p 3).
Blood-based biomarker candidates
Several potential roles might feasibly be fulfilled by 
blood-based biomarkers. Currently, there is no immedi-
ate prospect of a highly specific diagnostic blood test 
comparable to RT-QuIC in CSF samples. Blood assays, 
however, might offer an accessible triage test in primary 
care or first specialist assessment that flags the possibility 
of rapid neuronal damage, and could be useful in case 
prioritisation.
One potential candidate is t-Tau concentration in plasma 
or serum. Studies showed elevated concentrations in 
sporadic Creutzfeldt-Jakob disease compared with healthy 
controls and other neurological diseases.15,16,80 The diag-
nostic accuracy ranged from an AUC of 0·94 versus 
healthy controls to 0·72 versus other neurological dis eases 
that included dementia syndromes (appendix p 4). 
Another investigation showed that the plasma t-Tau 
concentration is a better predictor of survival time in 
sporadic Creutzfeldt-Jakob disease than CSF t-Tau concen-
tration or other fluid biomarkers.66 Another promising 
candidate for a blood-based biomarker is NfL, the most 
soluble subunit of neurofilament. NfL was shown to be an 
effective thera peutic biomarker in CNS disease during 
trials for multiple sclerosis.81 NfL showed similar or 
even better diagnostic accuracy compared with t-Tau in 
the discrimination of sporadic Creutzfeldt-Jakob disease 
from a healthy control population.16,80 By contrast, a study 
that investigated a large cohort of prion diseases and used 
rapidly progressive dementias as controls showed that 
plasma t-Tau had better diagnostic accuracy than NfL 
(appendix p 4). Similar to the CSF counterpart, both 
plasma t-Tau and NfL concentrations were signifi cantly 
associated with the sporadic Creutzfeldt-Jakob disease 
subtype.82
More potential blood-based biomarkers for sporadic 
Creutzfeldt-Jakob disease, such as S100b and others 
(appendix p 4), were elevated in serum or plasma, but few 
available data indicate inferior diagnostic accuracy com-
pared with t-Tau and NfL or these biomarkers still have to 
be validated by other groups. PrP was reported to be 
decreased in the CSF of sporadic Creutzfeldt-Jakob disease 
cases,51,52 although it was reported in another study to be 
increased in plasma.83 The explanation for this dissociation 
has not yet been clarified.
Imaging markers
MRI
MRI is an essential tool in the diagnosis of sporadic 
Creutzfeldt-Jakob disease. It allows the identification of 
important differential diagnoses such as ischaemia, 
encephalitis, and neoplasia. In Creutzfeldt-Jakob disease, 
typical patterns of restricted diffusion on DWI and 
hyperintensities in FLAIR images were suggested to be 
included in the WHO diagnostic criteria in 2009.4 Another 
widely used protocol recommends the use of DWI 
and apparent diffusion coefficient (ADC) maps only.84,85 
Typical Creutzfeldt-Jakob disease MRI displays restricted 
diffusion in at least two cortical regions (ribboning) 
or restricted diffusion predominantly in the caudate 
nucleus, or both, followed by putamen and thalamus 
(figure 1). Involvement of the subcortical white matter 
cannot be observed in visual assessments (DWI, ADC, or 
FLAIR)4,84 but was detected by quantitative diffusion 
tensor imaging.86 Cortical ribboning and involvement of 
the caudate nucleus (of one or both hemispheres, rarely 
perfectly symmetrical) is typically seen in the most 
common MM1 subtype. Involvement of the thalamus 
(aside from the caudate nucleus and putamen) is more 
common in VV2 and MV2 subtypes.87 High signal only on 
FLAIR and DWI in the posterior thalamus brighter than 
in anterior putamen (pulvinar sign) is a strong indicator 
of variant Creutzfeldt-Jakob disease.20
The overall diagnostic accuracy of MRI is possibly 
even superior to CSF 14-3-3 and t-Tau,88,89 but extensive 
comparison data with CSF biomarkers is scarce. Some 
studies showed a sensitivity of around 80%,12,35,40,42 others 
reported 92% to 98%.37,88,89 Similarly, specificity ranges 
from 74%40 to 98%.12 In 2020, a study investigating a large 
cohort with 770 patients with definite sporadic Creutzfeldt-
Jakob disease applied an improved diagnostic index show-
ing 92% sensitivity and 97% specificity.89 The discrep ancies 
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could be caused by different scanners, imag ing and rating 
protocols, a study focus on other biomarkers, or the 
individual experience of image inter preters.90 The future 
possibilities of brain MRI include its application as a 
prognostic marker91 and as a poten tial marker in trial 
monitoring.92,93 Some data suggest that restricted diffusion 
can occur in very early disease stages. Although prospec-
tive studies are not feas ible in sporadic Creutzfeldt-Jakob 
disease, such changes were observed more than one year 
before symptom onset in case reports. 94
Positron emission tomography
Positron emission tomography using ¹⁸F-fluoro-2-deoxy-
d-glucose (FDG-PET) as tracer is able to detect decreased 
glucose metabolism in cortical regions of patients with 
sporadic Creutzfeldt-Jakob disease. However, the value 
of FDG-PET in the differential diagnosis is limited by 
the absence of specific patterns. FDG-PET has potential 
as a marker of early sporadic Creutzfeldt-Jakob disease 
and showed a correlation with clinical symptoms.95 
In the rare MM2T subtype (sporadic fatal insomnia), 
an early-reduced thalamic glucose metabolism is a 
distinctive feature. 96
EEG
Periodic sharp-wave complexes (PSWCs) with a frequency 
of 1 Hz are considered as an EEG pattern typical of 
Creutzfeldt-Jakob disease and have shown a sensitivity 
of 64% and a specificity of 91%.97 The non-convulsive 
status epilepticus is the most common clinical condition 
with Creutzfeldt-Jakob disease EEG.98,99 Over the past 
5 years, CSF biomarker studies reported a substantially 
lower sensitivity (39% to 45%) for EEG.12,34,37,40 Most likely, 
the decreasing sensitivity of EEG is a result of improved 
early recognition of sporadic Creutzfeldt-Jakob disease 
cases. Typical PSWCs occur in late disease stages and are 
less frequent in MV2, VV2, and MM2 cases. However, the 
method is less invasive than CSF sampling, and non-
specific periodic rhythm abnormalities100 and quantita-
tive analysis of frequency alterations101 might have the 
potential to aid diagnosis in early stages and to predict 
disease progression.
Genetic markers
PRNP mutations account for 10–15% of all human prion 
diseases.1 Some cause specific clinical syn dromes (eg, 
Gerstmann–Sträussler–Scheinker syndrome or fatal famil-
ial insomnia), whereas others can mimic clinical presen -
tation and biomarker profiles of sporadic Creutzfeldt-Jakob 
disease (eg, E200K).102 Thus, the sequencing of PRNP is 
an important biomarker that should be considered in the 
differential diagnosis of prion diseases and is crucial in 
atypical cases, and in cases with positive or uninformed 
family history of rapidly progressive dementias. In some 
sporadic Creutzfeldt-Jakob disease subtypes, reduced 
sensitivity of surrogate biomarkers has been observed, 
especially in patients with the MV2 and MM2-types.48,58 
Figure 1: Typical patterns of restricted diffusion on Creutzfeldt-Jakob 
disease MRI
MRI scans were provided by the National Prion Disease Pathology Surveillance 
Center, Case Western Reserve University, Cleveland, OH, USA. (A–C) Brain MRI 
of a patient with sporadic Creutzfeldt-Jakob Disease (MM1 subtype). (A) Restricted 
diffusion in occipital and parietal lobes, green arrows show associated 
hyperintensities on DWI. (B) Hypointensities on ADC maps. (C) Less clear 
hyperintensities on FLAIR images than on DWI. Other patients with MM1 subtypes 
can present additional restricted diffusion in caudate nucleus and putamen, 
a similar pattern (with caudate nucleus and putamen less likely involved) can be 
seen in MM2 and VV1 subtypes. (D–F) Brain MRI of a patient with sporadic 
Creutzfeldt-Jakob Disease (VV2 subtype), restricted diffusion in caudate nucleus, 
putamen and thalamus, predominantly in the pulvinar (less clear than in caudate 
nucleus and putamen) in both hemispheres. (D) Associated hyperintensities on 
DWI. (E) Associated hypointensities on ADC maps. (F) Associated hyperintensities 
on FLAIR images. A similar pattern (with additional cortical involvement) can be 
seen in the MV2 subtype. ADC=apparent diffusion coefficient. DWI=diffusion 







Figure 2: Diagnosis of sporadic Creutzfeldt-Jakob disease
Adapted from National Creutzfeldt-Jakob Disease Research & Surveillance Unit 
criteria13 that were based on the WHO criteria3,4 and amended by including RT-QuIC 
as an additional biomarker. Here, imaging criteria were refined and the need for a 
thorough diagnostic work-up in suspected probable sporadic Creutzfeldt-Jakob 
disease is emphasised. *Generalised periodic sharp or wave complexes. †Restricted 
diffusion in caudate or caudate–putamen or caudate–putamen–thalamus, or at 
least two cortical regions (temporal, parietal, occipital) on MRI brain scan,4 no 
subcortical white matter involvement, no isolated restricted diffusion in the 
thalamus. Characteristic hyperintensities can be seen on fluid attenuated inversion 
recovery images, but diffusion weighted sequences are required to confirm 
Creutzfeldt-Jakob disease-typical restricted diffusion.84,85 
RT-QuIC=real-time quaking induced conversion.
I   




B. Visual or cerebellar disturbance




Progressive neuropsychiatric syndrome and neuropathological or 
immunocytochemical, or biochemical confirmation
Probable:
 I + two of II and typical EEG*
or
 I + two of II and typical brain MRI†
or
 I + two of II and positive CSF 14-3-3
or
progressive neuropsychiatric syndrome 
and positive RT-QuIC in CSF or other 
tissues
+ exclusion of other causes in 
complete diagnostic workup
Possible:
I + two of II + duration <2 years
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The identification of the PrPSc type is only possible in brain 
tissue, but the analysis of codon 129 PRNP might help to 
interpret inconclusive biomarker results.103
Clinical value of RT-QuIC and CSF surrogate 
biomarkers
Over the past 9 years, the evidence suggesting CSF 
RT-QuIC as a major improvement in the clinical 
diagnosis of sporadic Creutzfeldt-Jakob disease has 
accumulated. The test sensitivity is similar to the best 
available surrogate biomarkers and the data display 
superior specificity (table). By contrast with all established 
biomarkers for sporadic Creutzfeldt-Jakob disease and 
other neurodegenerative diseases, RT-QuIC is able to 
detect the protein that was consensually identified to be 
primarily pathogenic (PrPSc). Although different protocols 
and definitions of test positivity have been proposed,9,29,30 
reproducibility of test results has been shown in ring 
trials.10,104 However, RT-QuIC is rather expensive regarding 
its substrate (recombinant PrP) and, although the test is 
less reliant on specialised equipment when compared 
with MRI and PET, the method still has to be established 
in more centres to provide all-encompassing availability. 
There is an ongoing debate on infectivity of the aggre-
gates produced by PrPSc amplification assays. Although 
infectivity was shown in PMCA-replicated PrPSc from 
patients with variant Creutzfeldt-Jakob disease,105 mouse 
models could not show infectivity of the RT-QuIC 
product from sporadic Creutzfeldt-Jakob disease samples 
so far.106
Surrogate CSF biomarkers of sporadic Creutzfeldt-Jakob 
disease are reliable diagnostics but the accuracy might 
differ with respect to the clinical context in which these 
markers are used. They are not disease specific by their 
very nature. Thus, physicians should interpret test results 
with caution. CSF 14-3-3 protein is highly sensitive 
and well validated, but acute brain injury events might 
cause false positive results. CSF 14-3-3 protein is part 
of a widely used clinical diagnostic gold standard3,4 
and estimates of the diagnostic accuracy, especially in 
comparative analyses, might be influenced by verification 
bias.107 A problem with the 14-3-3 western blot method is 
its complex interpreta tion and the presence of borderline 
results (traces). 14-3-3 ELISAs might resolve this problem 
but they have not been widely established. The most 
commonly used alternative CSF biomarker, t-Tau, showed 
improved (but still only moderate) specificity in the 
differentiation of sporadic Creutzfeldt-Jakob disease and 
acute brain injury events or encephalitis,36,50 but there is 
some evidence that t-Tau might not have sufficient 
specificity in the discrim ination of rapidly progressive 
or atypical Alzheimer’s disease and sporadic Creutzfeldt-
Jakob disease (appendix p 1). In a large cohort represent-
ing the full clinical spectrum of a non-specialised 
neurochemical laboratory, sporadic Creutzfeldt-Jakob 
disease accounted for only 18% of patients with highly 
elevated (>1200 pg/mL) CSF t-Tau concentration;61 
therefore, as with other biomarkers, it should not be 
used in general screening but in the proper clinical context 
when suspecting prion disease. Evidence-based consensus 
cut-offs for CSF t-Tau, at best considering different assays, 
differential diagnoses, and supportive information on 
sporadic Creutzfeldt-Jakob disease cases (eg, codon 129 
PRNP polymorphism), would be most helpful and should 
be evaluated through a structured analysis. In conclu-
sion, both markers (t-Tau and 14-3-3) share several 
Panel 1: Historical case studies from the German Creutzfeldt-Jakob Disease 
Surveillance Unit
Case A (typical Creutzfeldt-Jakob disease)
A 63-year-old woman presented with language disturbance (mild amnestic aphasia) that 
had started 2 weeks before hospital admission. 
Neurological and neuropsychiatric examination showed cognitive deficits and ataxia. 
The EEG showed continuous focal epileptiform patterns but enforced antiepileptic 
medication showed no clinical benefit. In the CSF, 14-3-3 proteins (64455 AU/mL, cutoff 
>20 000 AU/mL) and t-Tau (12460 pg/mL, cut-off >1300 pg/mL) were both highly 
increased and RT-QuIC was positive. No signs of CNS inflammation were present. 
MRI showed restricted diffusion in frontal, temporal, and parietal regions, and in caudate 
nucleus, and left putamen. The clinical condition of the patient worsened within 1 week. 
Clinical examination showed severe dementia, pyramidal and extrapyramidal signs, and 
myoclonus. Follow-up EEGs showed periodic sharp-wave complexes (PSWCs) that were 
typical of Creutzfeldt-Jakob disease. Prion protein (PRNP) sequencing showed no 
pathogenic mutation and homozygosity for Met at codon 129. The patient was 
diagnosed with probable sporadic Creutzfeldt-Jakob disease according to common 
criteria,4 supported by positivity of CSF RT-QuIC. 
The patient died after 2 months of disease duration. Brain autopsy showed PrPSc 
depositions with neuropathological characteristics of the most common MM/MV1 
sporadic Creutzfeldt-Jakob disease subtype.
Case B (atypical sporadic Creutzfeldt-Jakob disease)
Family members recognised personality changes and mild cognitive deficits in a 
54-year-old woman, and suspected a disorder. 
After 5 months of symptom duration, a neurologist observed rapidly progressive 
dementia with apraxia. MRI showed restricted diffusion in parietal, occipital, and 
temporal regions with very subtle involvement of caudate nucleus (no other pathological 
findings). EEG showed sporadic triphasic complexes but no PSWCs. The Creutzfeldt-Jakob 
Dsease Surveillance Unit was consulted and recommended further clinical investigations, 
including CSF analyses. The CSF showed no evidence for inflammatory CNS diseases, 
positive 14-3-3 proteins at a relatively low level (21527 AU/mL, cut-off >20 000 AU/mL), 
and positive RT-QuIC. PRNP sequencing revealed no pathogenic mutation and 
homozygosity for Met at codon 129. Although clinical diagnostic criteria4 for sporadic 
Creutzfeldt-Jakob disease were not fulfilled at that time (the patient showed only rapidly 
progressive dementia), the biomarker signature was highly suggestive and no alternative 
diagnoses were revealed. 
The case was classified as probable sporadic Creutzfeldt-Jakob disease according to 
amended surveillance centre criteria12 because of RT-QuIC positivity. Disease course 
(relatively slow progression), MRI results (predominant cortical involvement), and codon 
129 were suggestive for the rare MM2C (cortical) sporadic Creutzfeldt-Jakob disease 
subtype. The patient died after 11 months of disease duration. Brain autopsy revealed 
PrPSc depositions with neuropathological characteristics of the MM/MV2C sporadic 
Creutzfeldt-Jakob disease subtype.
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characteristics, advantages, and dis advantages (appendix 
p 2). The clinical use must be assessed in light of suspected 
differential diagnoses and can be improved by stratification 
of demographic and genetic factors.103
An upcoming issue in the biomarker-based diagnosis of 
sporadic Creutzfeldt-Jakob disease is the use of composites. 
Regarding this issue, the best evidence is available for the 
p-Tau/t-Tau ratio, which was shown to be of superior 
diagnostic accuracy compared with t-Tau alone, especially 
in the differentiation of sporadic Creutzfeldt-Jakob disease 
from Alzheimer’s disease.51,64,68 Proposed ratios combining 
t-Tau, p-Tau, 14-3-3, S100b, t-PrP, or amyloid β showed 
high diagnostic accuracy,48,52,73,108 but have not been estab-
lished in the clinical setting.
Guidelines for biomarker-based diagnosis
Based on WHO criteria,3,4 the studies presented here, 
and previous suggestions that include RT-QuIC,12,13 the 
majority of the authors recommend amended criteria for 
the clinical diagnosis of sporadic Creutzfeldt-Jakob disease 
(figure 2). Because of the outstanding specificity of 
RT-QuIC, positive cases can be classified as probable 
sporadic Creutzfeldt-Jakob disease in early clinical stages, 
even when only one cardinal symptom is present, which 
will improve the early identification of sporadic Creutzfeldt-
Jakob disease.12,39,108
Similar to other diagnostics, as the test becomes widely 
applied, even a false positive rate below 1% will lead to 
some incorrect diagnoses. This likelihood becomes 
particularly concerning if treatable conditions are missed. 
Ability to rely solely on RT-QuIC is further compromised 
by the test’s inability to distinguish accurately between 
different forms of human prion disease and test sensi-
tivities that vary from 73% to 97%. Additionally, RT-QuIC 
is mostly unavailable in countries without major sur-
veillance programmes. Therefore, we recommend that 
clinicians contact national Creutzfeldt-Jakob disease 
surveillance units or referral centres to get information on 
the availability of RT-QuIC and general clinical guidance 
for the diagnosis and management of suspected prion 
disease cases (appendix p 5).
Readily available, economical, and field-tested CSF 
biomarkers such as 14-3-3 and t-Tau, and EEG and MRI 
(preferably DWI including ADC sequences) are still of 
major importance and should be used as routine 
diagnostic tests in cases of suspected sporadic Creutzfeldt-
Jakob disease. These tools have been shown to be effective 
and accurate in the differential diagnosis of sporadic 
Creutzfeldt-Jakob disease, when they are applied and 
interpreted in a reasonable context. In case of ambiguous 
results or uncertain differential diagnoses, the p-Tau/t-Tau 
(or t-Tau/p-Tau) ratio might be considered as a supportive 
biomarker.63,64,68 Genetic analysis of PRNP should be 
considered in all cases of suspected Creutzfeldt-Jakob 
disease to determine the codon 129 polymorphism and to 
exclude pathogenic mutations, which can be present in 
patients with a negative family history.102 Importantly, 
routine blood, CSF, and imaging diagnostics should 
always be done to rule out the most common differential 
diagnoses (appendix p 8, panel 1, panel 2).
Conclusions and future directions
Despite improvements of diagnostic measures for 
sporadic Creutzfeldt-Jakob disease over the past 25 years, 
there are still plenty of challenges. The value of established 
and new biomarkers in the differential diagnosis of 
sporadic Creutzfeldt-Jakob disease subtypes and other 
human prion diseases (eg, iatrogenic Creutzfeldt-Jakob 
disease, variant Creutzfeldt-Jakob disease, and genetic 
Creutzfeldt-Jakob disease) has to be clarified. RT-QuIC 
has to be widely distributed, protocols have to be unified, 
past studies on peripheral tissue have to be validated with 
regard to important differential diagnoses, and more 
candidate tissues have to be evaluated. In this context, the 
potential infectivity of RT-QuIC positive tissues, such as 
olfactory mucosa,106 might be reappraised.
Panel 2: Guidelines for the clinical diagnosis of sporadic Creutzfeldt-Jakob disease
General
The clinical diagnosis of sporadic Creutzfeldt-Jakob disease requires a thorough diagnostic 
investigation, including blood sampling, lumbar puncture, neuroimaging (MRI), and EEG 
at a minimum. Further diagnostics (eg, body CT, PET, specific CSF analyses) can be 
necessary depending on suspected differential diagnoses. 
The diagnostic criteria and its measurements
We recommend amending the established WHO criteria for the clinical diagnosis of 
probable sporadic Creutzfeldt-Jakob disease (figure 2). If available, RT-QuIC should be 
done in every case of suspected prion disease. The 14-3-3 test is the primary CSF 
surrogate biomarker (in some centres, CSF t-Tau is considered as primary CSF surrogate 
biomarker). CSF t-Tau and the p-Tau/t-tau (or t-Tau/p-Tau) ratio are valuable supportive 
biomarkers. All markers need be done in certified laboratories. MRI and EEG are highly 
specific but require experienced interpreters. MRI sequences should include T1 weighted 
images with contrast agent sequences (for differential diagnosis), fluid attenuated 
inversion recovery, and diffusion-weighted images (DWI) with apparent diffusion 
coefficient maps. MRI findings typical of Creutzfeldt-Jakob disease are clearly visible on 
DWI rather than other sequences. All mentioned biomarkers are less sensitive in early 
disease stage and in some molecular subtypes, follow-up investigations can be useful in 
case of negative results. The analysis of codon 129 (PRNP) polymorphism might assist in 
interpreting the results of other biomarker analyses. Diagnosis of possible sporadic 
Creutzfeldt-Jakob disease (ie, the absence of suggestive biomarkers, figure 2) should only 
be made if extensive diagnostics had not revealed alternative explanations for the 
clinical condition.
Important differential diagnoses
Genetic analyses and clinical signs of iatrogenic Creutzfeldt-Jakob disease and variant 
Creutzfeldt-Jakob disease should be considered in all cases with suspected prion disease. 
Rapidly progressive neurodegenerative diseases, (immune-mediated) encephalitis, status 
epilepticus, and cerebral ischaemia are frequent differential diagnoses. Among others, 
these diseases could mimic the clinical syndrome and most surrogate biomarkers of 
sporadic Creutzfeldt-Jakob disease.
Brain biopsy
Brain biopsy is an invasive procedure that can be considered when non-invasive diagnostics 
remain inconclusive and a potentially treatable alternative diagnosis is suspected.
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More potential diagnostic biomarkers are currently 
under investigation. We recommend that new biomarkers 
could be considered in future diagnostic criteria under 
particular conditions. Besides strong clinical evidence (ie, 
validation of cutoffs in independent cohorts, appropriate 
controls), such a biomarker should substantially improve 
the clinical diagnosis of sporadic Creutzfeldt-Jakob disease. 
This improvement can be a biomarker that shows superior 
diagnostic accuracy compared with established markers or 
equal accuracy with reduction of test invasiveness (eg, 
blood-based tests). Although analysis of codon 129 PRNP 
polymorphism, clinical observations, and biomarker 
profiles (especially MRI DWI lesion patterns87) already 
allow conclusions on the sporadic Creutzfeldt-Jakob dis-
ease subtype, new biomarkers should be able to go beyond 
phenotypical variability and disease stage, or at least be 
evaluated in this respect.
Over the past 5 years, some investigations have opened 
the field of prodromal, prognostic, and predictive biomark-
ers for sporadic Creutzfeldt-Jakob disease. One of the 
challenges for clinical trials in sporadic Creutzfeldt-Jakob 
disease is that clinical features are highly heterogeneous 
and it has been difficult to find a suitable single continuous 
measure as an outcome. Therefore, specific Creutzfeldt-
Jakob disease tests, such as RT-QuIC, might be used at 
trial enrolment, and blood-based biomarkers might be 
used repeatedly during a trial to track axonal damage in the 
course of experimental treatment. Further work is required 
to establish variability of biomarkers in the natural history 
of Creutzfeldt-Jakob disease and if biomarkers of neuro-
degeneration can contribute to prognostic or trial models. 
Finally, blood-based biomarkers could have a role in 
preventive trials as a prodromal biomarker for healthy 
individuals who are at-risk of Creutzfeldt-Jakob disease 
because of iatrogenic prion exposure or PRNP mutation. 
Available published work suggests a prodromal bio marker 
window is small or rare in at-risk individuals with 
Search strategy and selection criteria
We searched Google Scholar and PubMed using the terms 
“prion” and “Creutzfeldt-Jakob disease”, each in combination 
with “diagnosis”, “criteria”, “biomarker”, “imaging”, “MRI”, 
“EEG”, and “RT-QuIC”. We included articles published between 
Jan 1, 2015, and Nov 15, 2020, written in English or German, 
on the basis of the scientific merit and contribution to 
developments in biomarker research for sporadic 
Creutzfeldt-Jakob disease (ie, the biomarkers have shown 
potential for a clinical use and results were independently 
validated). However, comprehensive lists of articles (after 
2015, not mentioned in the main text) presenting altered 
biomarkers in sporadic Creutzfeldt-Jakob disease were noted 
(appendix p 3). Older articles (ie, articles published before 
2015) were selected on the basis of author expertise to 
substantiate basic information and evidence of biomarkers 
that are currently being investigated.
pathogenic PRNP mutations,109,110 but this concept is 
currently the focus of many prion researchers.
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Section 5: Clinical Aspects of Human Prion Disease 
Although the principal phenotypes of human prion disease consisting of CJD, GSS, Kuru and 
FFI had been distilled by the early 1990s, the clinical spectrum of human prion disease has 
undergone further refinement and expansion thereafter. Arguably the most significant advance 
has been the delineation of the molecular-genetic sub-types of sCJD according to codon 129 
and PrPSc western blot characteristics, as well as recognition of VPSPr. This improved 
understanding has reinforced the clinical heterogeneity of sCJD and provided a useful albeit 
imperfect objective biomarker framework for diagnostic and sub-type confirmation. Moreover, 
studies related to CJD have also seen the description of further likely forms of genetic prion 
disease.  
Contributing to this enhanced understanding of the likely correlating determinants of human 
prion disease, my research has shown that the molecular-genetic sub-types of sCJD appear to 
occur worldwide, supporting these determinants of clinical disease are independent of 
environment or geographical location. Further studies have allowed: elaboration of diagnostic 
criteria for a less common form of sCJD presenting with Cortico-basal Syndrome; recognition of 
presentations with spastic paraparesis and hyperekplexia; and overlap with autoimmune 
encephalopathy. In addition, my studies have confirmed that sCJD occurs with a similar clinical 
profile and incidence rate in the Indigenous population compared to the non-indigenous 
population. Finally, as part of ongoing strategies to mitigate the risk of health care transmission 
of human prion disease I participated in the development of the current infection control 
guidelines, which were released and announced to the Australian medical community in 2013.   
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Australian sporadic CJD analysis
supports endogenous determinants of
molecular-clinical profiles
V. Lewis, BSc; A.F. Hill, PhD; G.M. Klug, BSc; A. Boyd, Post Grad Dip; C.L. Masters, MD;
and S.J. Collins, MD
Abstract—Objective: To define the protease-resistant prion protein (PrPres) types and associated clinical profiles in
Australian patients with sporadic Creutzfeldt–Jakob disease (CJD) to allow comparison with those reported from other
continents and concomitantly reaffirm absence of variant CJD (vCJD). Methods: Reassessment of available clinical and
neuropathologic data on patients referred to the Australian National Creutzfeldt–Jakob Disease Registry (ANCJDR) who
died between January 1, 1992, and June 30, 2003, was conducted. Molecular classification of PrPres was determined by
immunoblot analysis of available frozen brain tissue. Brain homogenate pH and codon 129 genotype on the prion protein
gene (PRNP) were established. Results: PrPres patterns in 35 of 37 patients with sporadic CJD conformed to one of three
common reported types. Of a range of clinical features assessed, illness duration was the only clinical feature significantly
associated with PrPres type. Two patients displayed coexistence of more than one PrP type, with one displaying a novel
pattern of three PrPres types in a single brain region. The absence of vCJD was reconfirmed, supported by the lack of the
typical PrPres glycoform pattern. Conclusions: Given Australia’s geographic isolation and environmental uniqueness, the
general congruity of these results with those reported from other continents suggests that endogenous factors predomi-
nantly determine sporadic Creutzfeldt–Jakob disease (CJD) phenotypic subtypes or “strains.” These results support a
clinicopathologic classification system whereby both PrPres type and codon 129 genotype are utilized to most accurately
depict phenotypic subtypes or strains of sporadic CJD.
NEUROLOGY 2005;65:113–118
In humans, the most common transmissible spongi-
form encephalopathy (TSE) is sporadic Creutzfeldt–
Jakob disease (CJD), which occurs at a rate of
approximately 1.5 per million per annum and ac-
counts for approximately 85–90% of all human
prion disorders.1 Integral to the pathogenesis and
transmissibility of TSEs is the accumulation of a
protease-resistant abnormal isoform (PrPres) of the
host-encoded cellular prion protein, PrPC.
The existence of distinct “strains” of TSE has been
difficult to reconcile with the protein-only hypothe-
sis, which states that the sole or principal component
of the transmissible agent is PrPres.2 Evidence sug-
gests that different conformers and cognate glyco-
forms of PrPres may encode strain properties.3-5
Experimental data support the concurrent ability of
PrPres to self-propagate and impart its unique strain-
determining structure during a template-directed
conversion of nascent PrPC.4,6 Molecular markers of
TSE strains include the patterns of protease-
resistant PrPres visualized on western immuno-
blots.6,7 A classification system has been proposed
wherein both PrPres type and prion protein gene
(PRNP) codon 129 genotype are utilized to most ac-
curately depict phenotypic subtypes or “strains” of
sporadic CJD.8 Despite competing nomenclatures re-
lating to western blot PrPres profiles6,7 and the re-
ported co-occurrence of different PrPres types within
individual brains,8-11 the epidemiologic and diagnos-
tic utility of PrPres typing as a marker of TSE strains
has been established, particularly by the mainte-
nance of characteristic patterns following transmis-
sion across species. The latter is exemplified by
bovine spongiform encephalopathy (BSE) and vari-
ant CJD (vCJD), with both sharing the same charac-
teristic PrPres (type 4 or 2B) glycoform type.6,7,12
Geographic isolation, environmental uniqueness,
and freedom from indigenous livestock forms of TSE
allow Australia to serve as an important comparison
country for epidemiologic purposes. Previous reports
have suggested that environmental factors such as ru-
ral residence and farm work13,14 and transition metal
concentrations in the soil15 may influence the occur-
rence of sporadic CJD, whereas zoonotic transmission
of BSE has been postulated to masquerade as a specific
PrPres subtype of sporadic human TSE.16,17 To further
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explore the possible influence of environmental factors
in determining human phenotypic subtypes or strains,
we performed, where possible, PrPres analysis in Aus-
tralian patients with sporadic CJD with dates of death
encompassing January 1, 1992, to June 30, 2003, and
correlated molecular types with the clinical and inves-
tigational features to allow comparison with analogous
European and North American studies.8,9 Also, aware
of strong parallels in the travel and migration patterns
between Australia and other countries that have expe-
rienced the occurrence of vCJD in their citizens after
residing for extended periods in the United Kingdom,
all referred patients were specifically reassessed for
this possibility, paying particular attention to the
PrPres glycoform profile distinctive for vCJD.6 Our cor-
relative analyses of PrPres type–phenotype profiles in
Australian patients with sporadic CJD support the
concept that nonenvironmental factors predominate in
determining phenotypic subtypes and strains. Further,
our findings underscore a previously proposed clinico-
pathologic classification system whereby both PrPres
type and codon 129 genotype are needed to most accu-
rately depict phenotypic subtypes or “strains” of spo-
radic CJD.
Methods. Patient selection. There were 365 patients referred
to the Australian National Creutzfeldt–Jakob Disease Registry
(ANCJDR) for evaluation, who died between January 1, 1992, and
June 30, 2003. This cohort includes cases ultimately classified
non-CJD and cases classified as probable or definite CJD (some of
which have been reported previously).1 Operational and surveil-
lance methods of the ANCJDR have been described in detail,1,13
with ethical approval from the University of Melbourne. Clinical
data and available neuropathologic findings were reviewed ac-
cording to published diagnostic criteria.18,19
Codon 129 determination. Permission to genotype the entire
PRNP open reading frame was sought in patients with sporadic
CJD. Codon 129 genotype was determined by either sequencing of
the entire PRNP open reading frame using previously described
methods20 or, when consent was not obtainable, by BbrPI (Roche,
Nutley, NJ) restriction digestion.21
Western immunoblot analysis. Frozen brain specimens were
always from the cerebral cortex, predominantly from the frontal
region. Control samples for typing (representing types 1 to 4 [T1
to T4])6,9 were supplied by the National Institute for Biological
Standards and Control (NIBSC) as part of the World Health Orga-
nization Collaborative Nomenclature Study (2001 to 2002). Brain
homogenates were prepared as 10% (wt/vol) homogenates in
phosphate-buffered saline (pH 7.23). The pH of each homogenate
was determined using a Hanna bench pH meter (U-Lab). Western
immunoblots were performed as described previously6 using a
final proteinase K (PK; Gibco) concentration of 100 g/mL.
Samples were resolved alongside T1 to T3 controls on 16%
Tris-glycine minigels (Novex) and transferred to nitrocellulose
membrane (BioRad). In selected cases, metal-ion chelation using
ethylenediaminetetra-acetate22 (EDTA; final concentration 25
mM) was performed prior to, or deglycosylation with PNGaseF
(Roche)6 subsequent to, PK digestion. Membranes were incubated
with the anti-PrP monoclonal antibody ICSM18 (1:25,000), which
recognizes residues 146 to 159,23,24 overnight at 4 °C and were
visualized using enhanced chemiluminescence (ECL Plus; Amer-
sham) and Biomax MR film (Kodak).
Statistical analysis. The nonparametric Mann–Whitney U
test, based on the ranks of observations rather than actual values,
was used for comparing age at onset, duration of illness, and brain
homogenate pH. Comparisons of the dominant symptom at onset,
EEG, and CSF test results utilized the Fisher exact test, which is
suitable for small sample sizes. The Bonferroni correction method
was performed to assess the significance of multiple comparisons.
Results. Of the 365 patients re-evaluated, 135 were re-
confirmed as non-CJD, 69 following autopsy, and 230 were
reaffirmed as having definite (n  151) or probable (n 
79) sporadic CJD. None of the reassessed cases, including
those originally excluded as manifesting a prion disease,
fulfilled diagnostic criteria for possible, probable, or defi-
nite vCJD.
Forty-three patients underwent western blot analysis
for the presence of PrPres. Three reconfirmed non-CJD
cases were negative for PrPres. In three patients with defi-
nite CJD, PrPres type was not determined: Two had unde-
tectable PrPres levels using conventional western blotting,
with the higher sensitivity method25 not suitable for PrPres
typing; in the third, technical difficulties due to suboptimal
tissue storage prevented analysis. Thirty-seven patients
with pathologically confirmed CJD had their PrPres type
determined (table), of which 35 displayed a profile consis-
tent with previously reported T1, T2, or T3 (figure, A).
These three types all displayed predominance of the mono-
glycosylated band and were distinguished by subtle differ-
ences in the relative mobility of their unglycosylated
isomers: T1 slowest, T2 intermediate, T3 fastest. Glyco-
form T4 (characteristic of vCJD, with predominance of the
diglycosylated band and the nonglycosylated isomer show-
ing a similar mobility to T3) was not observed. In addition,
one of the T1 patients was heterozygous (methionine/
valine [MV]) at codon 129 (see table). This PrPres type–
genotype combination has not previously been described.
Following treatment with EDTA, the unglycosylated
PrPres in this T1 MV patient showed the same shift in
molecular mass (to a cleavage product; see figure, B) as
described for T1 MM and T2 MM cases.22 Neuropathologic
examination of the brain of this patient revealed wide-
spread spongiform degeneration, neuronal loss, and gliosis,
with marked regional variation. The caudate nucleus, cer-
ebellar molecular layer, temporal cortex, and thalamus
were the most severely affected.
In the two remaining CJD patients (both MM homozy-
gotes), there was reproducible co-occurrence of more than
one PrPres type in the sample of brain homogenate (see the
figure, C; frozen tissue was available from only a single
brain region in each patient). One of these patients re-
vealed a novel pattern with three separate faster-
migrating unglycosylated bands, in keeping with the
simultaneous occurrence of T1, T2, and T3. Postmortem
examination of the brain revealed widespread microvacu-
olation, neuronal loss, and gliosis within the basal ganglia
and cerebral cortices, emphasized in the frontal lobes, with
the cerebellum essentially unremarkable. The thalamus
demonstrated selective, severe neuronal loss and gliosis,
largely restricted to the dorsal medial and anterior nuclei.
The other patient displayed banding consistent with coex-
istence of T1 and T3. Autopsy in this patient confirmed
diffuse microvacuolation accompanied by less severe neu-
ronal loss and gliosis throughout the cerebral cortices but
most marked in the temporal lobes, along with subtle
spongiform change in the molecular layer of the cerebel-
lum and basal ganglia. Brain samples from both of these
patients were subject to deglycosylation after protease di-
gestion, revealing in both cases two broad unglycosylated
full-length PrPres bands (data not shown). In the patient
with three PrPres types evident prior to deglycosylation, we
believe that the increased abundance of each of the three
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cognate PrPres types following deglycosylation exceeded
the resolving capacity of the gel to maintain the clear
separation of the subtly different mobilities of the T1 and
T2 bands. This resulted in the T1 and T2 unglycosylated
species appearing together as one broad band, with T3
constituting the other band.
For patients with sporadic CJD undergoing molecular
PrPres typing, the table summarizes their salient clinical
features and diagnostic investigation results. None of the
various clinical symptoms at disease onset (see asterisked
footnote in the table), including cognitive disturbance, gait
or limb ataxia, and visual disturbances, differed signifi-
cantly between the different PrPres types. Of the clinical
features described over the course of illness (see the table),
a significant difference between PrPres types was found
only for duration of illness, precluding meaningful associa-
tion of any one type with a distinctive clinical profile. De-
spite a similar predominance of MM homozygotes in the
T1 and T2 groups, T1 patients manifested the shortest
median illness duration, with (see the table) and without
(data not shown) inclusion of the longest-surviving T2
(MV) patient. Both T1 and T2 patients displayed signifi-
cantly shorter survival than T3 patients. Codon 129 geno-
type also appeared to influence illness duration, most
clearly seen in the T3 group, whereby MV patients dis-
played a significantly longer survival than VV homozy-
gotes (see the table). Also of note, the patient with
simultaneous coexistence of the three PrPres types mani-
fested an unusually long duration of illness (10 months)
compared with other MM homozygotes. The two patients
displaying more than one PrPres type otherwise lacked
clinical distinction, with both cases having cognitive im-
pairment and myoclonus and positive diagnostic investiga-
tion results when tested.
Preliminary evaluation suggested PrPres types were as-
sociated with significant differences in the EEG and 14-3-3
CSF test results (see the table). However, further analysis
demonstrated that codon 129 genotype was also an impor-
tant determinant of these investigation results (see the
table). Regardless of PrPres type, we found significantly
more MM homozygotes (T1 or T2 groups) than heterozy-
gotes (all PrPres types) had an EEG described as character-
istic for sporadic CJD. Greater than 70% of those MM
patients tested manifested a typical EEG, whereas only 1
of the 13 patients carrying at least one valine allele was
reported as having a positive study. Consistent with this
observation, the proportion of characteristic EEGs in T2
patients was significantly greater when compared with T3






























1 6 (14.3) 60 (50–74) 2 (1–2.5) T1 MM (5) 58 (50–74) 2 (1–2.5) 40 (11–79) 100** (39–100)
T1 MV (1) 73 1.5 0 (0–97.5) 100 (2.5–100)
2 18 (51.5) 69 (55–88) 3.5 (1.5–7) T2 MM (17) 69 (55–88) 3.5 (1.5–5.5) 75¶ (49–90) 100†† (73–100)
T2 MV (1) 70 7 0 (0–97.5) 100 (2.5–100)
3 11 (28.6) 68 (40–76) 11 (3.5–22) T3 MV (7) 63 (40–76) 12 (8–22) 0 (0–41) 50** (17–83)
T3 VV (4) 71 (62–75) 4.75 (3.5–11) 25 (3.3–76) 100‡‡ (16–100)
1 and 3 1 (2.8) 64 4 — — — 100 0**
1, 2, 3 1 (2.8) 64 10 — — — 100 100
4 0 — — — — — — —
* Various presenting symptoms (cognitive disturbance, including memory loss, confusion, disorientation, and poor concentration; gait or
limb ataxia; altered personality; visual disturbances; nonmyoclonic dyskinesia, including athetosis and tremor; dizziness, including
“lightheadedness,” vertigo and nonspecific disequilibrium; and insomnia) were assessed and were found not to be significantly differ-
ent between the different PrPres types. In addition, the majority of clinical features manifested during illness (cognitive impairment;
myoclonus; cerebellar dysfunction; extrapyramidal signs, including presence of limb rigidity, dystonia, or gait apraxia; and pyramidal
signs, including unequivocal upper motor neuron signs such as positive Babinski responses, limb spasticity, pathologically brisk ten-
don stretch reflexes) were found not to be significantly different between PrPres types.
† T1 vs T2, (a) p  0.005, (b) p  1; T1 vs T3, (a) p  0.001, (b) p  0.001; T2 vs T3, (a) p  0.001, (b) p  0.001; a  Mann–Whitney
U test; b  Bonferroni correction.
‡ MM vs VV, (a) p  0.05, (b) p  0.5; MM vs MV, (a) p  0.001, (b) p  0.001; T3 MV vs T3 VV, (a) p  0.05, (b) p  0.005; T1 MM vs
T2 MM, (a) p  0.05, (b) p  1; homozygotes vs heterozygotes, (a) p  0.001; a  Mann–Whitney U test; b  Bonferroni correction.
§ Typical EEG  generalized triphasic periodic complexes at approximately 1/s; T2 vs T3, p  0.005; MM vs MV, p  0.005; T2 MM vs
T3 MV, p  0.005 (Fisher exact test).
 T2 vs T3, p  0.05; MM vs MV, p  0.05; T2 MM vs T3 MV, p  0.05 (Fisher exact test).
¶ One case EEG not performed
** One case 14-3-3 CSF testing not done.
†† Five cases 14-3-3 CSF testing not done.
‡‡ Two cases 14-3-3 CSF testing not done.
CJD  Creutzfeldt–Jakob disease; PrP  prion protein; T1  type 1; T2  type 2; T3  type 3; M  methionine; V  valine.
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cases. Reaffirming the diagnostic utility of CSF 14-3-3 pro-
tein testing, we found the overall sensitivity to be 88.5%
(n  26), although there was noticeable variation between
subgroups. Reiterating the influence of the codon 129 ge-
notype, only 50% of results were positive in the T3 MV
subtype, whereas sensitivity was 100% in those tested
with all other PrPres/codon 129 genotype combinations, in-
cluding T3 VV.
The pH of brain homogenates was measured to assess
the recent suggestion that this parameter may influence
PrPres isoform patterns.26,27 Our analysis found no signifi-
cant difference in the pH values of brain homogenates
between any of the three principal PrPres types or codon
129 genotypes, with the brain homogenates from the pa-
tients showing coexistence of multiple types also lying
within the same pH range (data not shown).
Discussion. When allowing for differences in
PrPres typing nomenclature, the current study of
Australian patients with sporadic CJD has demon-
strated considerable similarity in the spectrum of
PrPres type–phenotype profiles to those described for
analogous patients from other continents.8,9 This
overall congruity of molecular subtypes, in combina-
tion with the results of previous epidemiologic stud-
ies of Australian patients with sporadic CJD
compared with patients from different countries,1,28
suggests that environmental factors are unlikely to
be a predominant determinant of the occurrence13,14
and molecular subtypes16,17 of sporadic human TSE.
Contrasting with the considerable geographic and
environmental diversity across reporting continents,
the international conformity of sporadic CJD inci-
dence rates and PrPres type clinical profiles would
appear more in keeping with endogenous determi-
nants of human TSE strains and disease occurrence,
such as stochastic misfolding of PrPC 3 and the con-
sequent PrPres type, although environmental influ-
ences cannot be completely excluded.15 Specifically,
one minor apparent difference between the Austra-
lian and UK9 PrPres typing studies was the relatively
lower number of Australian T2 patients (51.4 vs
64.7%), which is the PrPres molecular subtype of spo-
radic CJD postulated to be possibly zoonotically
linked to BSE.16,17 This difference was due to the
increased numbers of MV and VV T2 patients in the
UK series. It is premature to draw any conclusions
from these preliminary observations, particularly
given that the presence of valine in human PRNP at
codon 129 appears to have a considerable inhibitory
effect on BSE prion transmissibility and correlates
with a T5 rather than T2 PrPres.17
Of all the clinical features we analyzed, only ill-
ness duration was distinctly and significantly associ-
ated with PrPres type. Although it is generally
assumed that PrPres type may be a determinant of
illness duration, it remains possible that the con-
verse is true. In keeping with another study and
using analogous statistical methods,9 our T1 cases
had a significantly shorter symptomatic phase than
PrPres types T2 and T3, despite both the T1 and the
T2 cohorts being almost entirely constituted by MM
homozygotes. However, when correcting for multiple
comparisons, significance was lost between the T1
and T2 groups and maintained for all other analyses.
We attribute this to the small T1 sample size. We are
uncertain as to an explanation for the slightly
shorter illness durations observed for the T1 and T2
cases compared with previous studies.9,22 An unwit-
ting minor selection bias related to availability of
fresh brain tissue and small patient numbers within
each group may be relevant, but a previous collabo-
Figure. Western immunoblots of proteinase K–treated
brain homogenates showing PrPres patterns from represen-
tative Australian National Creutzfeldt–Jakob Disease Reg-
istry (ANCJDR) cases of sporadic CJD. Approximate
molecular masses (kDa) are shown. (A) Sporadic CJD
cases of known PrPres types (lanes 1 to 4, controls from
NIBSC) compared with ANCJDR cases (lanes 5 to 7).
Subtle differences in the mobility (approximately 1 to 2
kd) of the unglycosylated isoforms of PrPres differentiate
the three principal types: T1 (slowest), T2 (intermediate),
and T3 (fastest). T1  lanes 1 (NIBSC) and 5 (ANCJDR);
T2  lanes 2 (NIBSC) and 6 (ANCJDR); T3  lanes 3
(NIBSC) and 7 (ANCJDR), T4  lanes 4 (NIBSC). (B) Ef-
fect of ethylenediaminetetra-acetate (EDTA) (final concen-
tration 25 mM) on novel T1 MV heterozygote compared
with the effect on T1 MM and T2 MM. (C) Australian spo-
radic CJD cases with coexistence of two (lane 2) and three
(lane 3) PrPres types in a single brain homogenate com-
pared with controls, T1 (lane 1), and T2 (lane 4).
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rative study dealing with much larger patient num-
bers did not disclose discrepancies in the clinical
profiles of Australian vs non-Australian patients
with sporadic CJD.28
The importance of PrPres type in determining spo-
radic CJD phenotype and investigation results was
not invariable: Specifically, in accord with previous
reports,8,9 our T3 heterozygotes exhibited a signifi-
cantly longer illness than VV homozygotes. As ob-
served previously,9 we also found a typical EEG
appeared most closely linked to MM homozygosity at
codon 129, and this finding was therefore underrep-
resented in T3 patients. However, caution should be
exercised when analyzing the different PrPres type–
codon 129 genotype combinations, as biases may ex-
ist owing to a lack of independence between these
variables. Therefore, of all our analyses, perhaps the
most reliable comparisons are those within a single
PrPres type or codon 129 genotype. In contrast to
EEG results, CSF 14-3-3 proteins were detected in
all PrPres types, with an overall sensitivity of nearly
90%, although, as observed in another study,29 this
sensitivity was not uniform, with our T3 MV group
positive only 50% of the time.
Our study characterized a single T1 patient as
heterozygous at codon 129 of PRNP, which has not
been described previously.9 The neuropathologic
changes in this patient are different from those pre-
viously reported for T1 MM and T3 MV cases but
appear to have minor overlap with those changes
reported in T2 MV patients.9 In contrast, the clinical
phenotype did not differ noticeably from that of other
T1 patients, aside from the short illness duration in
comparison with other heterozygous patients with
sporadic CJD. Collectively, our data suggest that as
far as phenotype is concerned, PrPres type has a rel-
atively selective but predominant influence over
codon 129 genotype in determining illness duration.
The simultaneous presence of two unglycosylated
PrPres bands in the one brain sample, as observed in
one of our patients, has been reported previously.8-11
The neuropathology of this patient with co-
occurrence of T1 and T3 PrPres appears similar to
that previously reported for T1 MM.9 Our analyses
also revealed a novel pattern, wherein we observed
three distinct unglycosylated bands, corresponding
to T1, T2, and T3, in a single brain region. The
precise frequency of the coexistence of more than one
PrPres type in the brains of patients with sporadic
CJD is unresolved, but studies assessing multiple
sites10,11 suggest it is likely to be higher (around 33%)
than reported in our study (5%) where only single
brain regions were analyzed. Unavailability of addi-
tional frozen brain specimens from other cerebral
cortical and subcortical sites prohibited our ability to
establish the topographic extent of these co-
occurrences, nor, as reported in one study,8 could we
determine whether a single type was present in sub-
cortical regions when various types were found in
the cortex. Whether our novel PrPres pattern repre-
sents a new human sporadic prion strain is uncer-
tain, but the long duration of illness for an MM
homozygote is noteworthy, as are the patient’s neu-
ropathologic features that do not closely conform to
any of the reported PrPres subtypes.9 Further stud-
ies, including bioassay with assessment of incubation
periods and neuropathologic lesion profiles in inbred
strains of mice, may resolve this issue.
Overall, our findings support a previously pro-
posed clinicopathologic classification system whereby
both PrPres type and codon 129 genotype are utilized
to most accurately depict phenotypic subtypes or
“strains” of sporadic CJD. Nevertheless, patients
such as we describe, with multiple PrPres types
within the brain, provoke questions regarding the
relevance of this finding to ultimate determination of
phenotype as well as add complexity in existing clas-
sification systems. Appreciation of these determi-
nants is likely to be of importance in the design of
emerging therapeutic trials.
Variations in the pH of brain homogenates prior
to protease digestion and western blot analysis have
been shown to influence the PrPres glycoform pat-
tern.26,27 The current study, using a single physio-
logic buffer at constant pH, revealed overlapping
variation in the actual pH of the brain homogenates
but did not find significant differences between any
of the PrPres groups or in the two patients with in-
trasample coexistence of multiple types. As we de-
scribe, our PrPres typing showed correlation with a
single distinct clinical feature, and we did not under-
take western blot analysis following deliberate alter-
ation of brain homogenate pH to more acidic and basic
values to explore whether further subtyping with ap-
parent biologic correlates could be achieved.26,27 Our
results suggest that determinants other than brain ho-
mogenate pH promote the different PrPres profiles
observed in vivo and are consistent with an intrinsic,
biologically relevant role in their determination of
phenotype.
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Introduction
Fatal familial insomnia (FFI) is an auto-
somal dominant prion disease character-
ized by rapidly progressive dementia,
dysautonomia, myoclonus and insomnia.
A mutation at position 178 in the prion
protein gene can cause FFI or familial
Creutzfeldt–Jacob disease (fCJD). A non-
pathogenic polymorphism at codon 129
modifies the disease phenotype, with a
methionine residue in cis resulting in an
FFI phenotype and a valine residue in the
fCJD phenotype [1]. We report two cases
of FFI with a novel association between
myelodysplasia (MDS) and syndrome of
inappropriate antidiuretic hormone secre-
tion (SIADH).
Case 1
A 60-year-old Vietnamese man presented
with an 8-month history of insomnia and
dementia, associated with dysautonomia
manifested by hypertension and constipa-
tion. Four months later, he developed
daytime hypersomnolence with oneiric
behaviours, myoclonus and visual hallu-
cinations. On examination, he was ataxic
with hyper-reflexia and extensor plantar
responses with intermittent generalized
myoclonic jerks, not induced by auditory
or tactile stimuli. The patient died
12 months later.
The cerebrospinal fluid (CSF) was acel-
lular and 14-3-3 protein negative. Serial
MRI brain showed subtle hyperintensities
in the white matter. EEG did not show
characteristic patterns suggestive of CJD.
He had macrocytic, normochromic anae-
mia with normal haematinic and negative
haemolysis screen. Bone marrow examina-
tion was consistent with MDS, and cyto-
genetic analysis revealed chromosome 20q
deletion in five of 60 metaphases, with a
normal cell line also present. Serum
sodium, osmolality and urine osmolality
were consistent with SIADH. Sequencing
of the PRNP gene identified a D178N
mutation and homozygous methionine
variant at position 129 consistent with FFI.
His brain autopsy showed mild tha-
lamic atrophy macroscopically. On
microscopic examination, neocortical
areas were unremarkable (Fig. 1a). There
was severe neuronal loss with accompa-
nying spongiform change, gliosis and
microglial activation in the anterior nu-
cleus of the thalamus (Fig. 1b) and infe-
rior olivary nucleus (Fig. 1c, 1d). Similar,
but less pronounced changes were present
throughout other thalamic regions, den-
tate nucleus, dorsal medulla and hypo-
thalamus, particularly the mammillary
bodies, supraoptic and arcuate nuclei. No
specific staining with the prion-specific
antibodies 3F4 or 12F10 could be found in
sections of thalamus and medulla, a find-
ing not uncommon in FFI.
Case 2
His older sister died at the age of 65 years
following 12 months of dementia associ-
ated with myoclonus, visual hallucinations
and dysautonomia. She also had a pro-
found normocytic, normochromic anae-
mia and hyponatraemia from SIADH.
Faecal occult blood, gastroscopy and
colonoscopy were normal. Brain MRI
showed mild atrophy and chronic ischae-
mic changes in the white matter. The CSF
14-3-3 protein was negative. No prion
genetic test or autopsy was performed. She
had extensive other normal investigations
with no explanation for SIADH other
than her neurological picture.
(a) (b)
(d)(c)
Figure 1 Histopathology. Haematoxylin and eosin–stained sections of (a) frontal cortex
and other neocortical areas were unremarkable, whilst sections of anterior thalamic
nucleus (b) and inferior olive (c) reveal prominent neuronal loss with some associated
spongiform change, gliosis and microglial activation. (d) Microglial activation in the
inferior olive is highlighted by HLA-DR immunohistochemistry. Scale bar = 100 lm
(a–d).
 2011 The Author(s)
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Discussion
Phenotypic variability within this condi-
tion suggests both genetic and environ-
mental factors are important in the
expression of D178N mutation [2]. Our
proband had typical clinical manifesta-
tions of FFI, and there are striking simi-
larities with his sisters presentation.
Even though direct genetic testing was
not available for probands sister, she very
likely had a methionine variant in cis at
position 129, given a 97% homozygosity
for this allele in the Han Chinese popula-
tion who share a common ancestry with
the Vietnamese. The anaemia in both
cases appeared of recent onset and con-
current with the neurological deteriora-
tion. In our proband, the karyotypic
abnormality is characteristic of MDS. The
sisters anaemia was attributed to chronic
disease, although a bone marrow biopsy
was never performed. To date, no associ-
ation or underlying mechanism between
MDS and genetic prion disease has been
described.
The 20q deletion associated with MDS
is an acquired disorder, whereas the
mutation for FFI on chromosome 20 is
heritable. DNA fragmentation has been
demonstrated in brains of CJD patients,
perhaps leading to chromosome fragility
and a susceptibility to somatic mutations
[3].
Hyponatraemia because of SIADH has
been reported in cases of sporadic CJD [4],
but to our knowledge is a novel associa-
tion with FFI. In both sporadic and
genetic prion disease, it may be secondary
to generalized seizures or myoclonus.
Alternatively, hypothalamic involvement
as shown in the probands histology may
be one possible explanation.
Further reports of FFI with anaemia
and SIADH are required to clarify the
strength of the association.
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Background: Corticobasal syndrome (CBS), which encompasses cortical sensory loss, alien limb,
bradykinesia, rigidity, limb apraxia and dystonia, is the classic presentation of corticobasal degeneration
(CBD). It may occur in other neurodegenerative disorders including sporadic Creutzfeldt-Jakob disease
(sCJD). Current CBD diagnostic criteria outline features of CBS but fail to distinguish CBD from other
causative pathologies.
Objectives: To characterise the CBS presentation of sCJD (sCJD-CBS) in the context of existing CBD
diagnostic criteria.
Method: Data of two new cases of sCJD-CBS and seven patients identified from the Australian National
Creutzfeldt-Jakob Disease Registry database was reviewed. Additional data from 11 published cases was
incorporated to illustrate the natural history of sCJD-CBS. Comparison was made with pathologically
diagnosed CBD cases with ante-mortem CBS presentation (CBD-CBS).
Results: sCJD-CBS accounts for 1.8% of all Australian sCJD cases. Compared to CBD-CBS, disease
progression is more rapid in sCJD-CBS (median time to diagnosis 48 vs.1.5 months, p < 0.001; and disease
duration until death 68 vs. 5 months, p < 0.001). Although no clinical features separate the two, alien
limb and myoclonus tend to occur early in sCJD-CBS following initial ‘sensory’ disturbance in the affected
limb. Consistent with sCJD, distinctive diffusion weighted imaging (DWI) abnormalities on magnetic
resonance imaging may also occur in sCJD-CBS.
Conclusion: sCJD should be suspected in patients presenting with CBS when clinical progression is rapid
and accompanied by DWI abnormalities, even without cerebrospinal fluid 14-3-3 protein detection and
electroencephalographic periodic sharp wave complexes. We propose the addition of rapid (<12months)
progression to akinetic-mutism or death and DWI abnormalities as exclusions in future CBD diagnostic
criteria.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
The corticobasal syndrome (CBS) is considered the classic
presentation of corticobasal degeneration (CBD), a primaryoscience, Alfred Hospital,
lia. Tel.: þ61 3 9076 2059;
CJD Registry, Level 5, The
f Medicine, The University of
l.: þ61 3 8344 1949; fax: þ61
. Collins), david.williams@
All rights reserved.neurodegenerative disease characterised by widespread neurofi-
brillary tau-pathology affecting the cerebral cortex and basal
ganglia. A CBS presentation comprises variable combinations of
limb apraxia, cortical sensory loss, limb dystonia, focal myoclonus,
alien limb and rigidity and bradykinesia that do not respond to
dopaminergic medications. Since the original description of CBD, it
has become clear that a number of neurodegenerative diseases can
present with CBS such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), progressive supranuclear palsy (PSP), dementia with
Lewy bodies (DLB) and non-CBD frontotemporal dementia (FTD)
pathologies including Pick’s disease [1,2]. Indeed the diagnosis of
CBD made on the basis of presentation with CBS will be correct in
less than 25% of patients [1].
W. Lee et al. / Parkinsonism and Related Disorders 19 (2013) 81e8582Creutzfeldt-Jakob disease (CJD) is characterised by cerebral
deposition of the abnormal protease-resistant prion protein.
Sporadic CJD (sCJD) accounts for the majority of CJD cases and is
another conditionwhere patients may present predominantly with
CBS (sCJD-CBS). This rare clinical subtype adds to the wide clinical
spectrum of sCJD that includes ataxic (Oppenheimer-Brownell),
visual (Heidenhain), thalamic (sporadic fatal insomnia), dyskinetic,
panencephalopathic, posterior cerebral atrophy and even PSP-like
variants [3e6]. Prompted by two recent cases, we sought to
better characterise sCJD-CBS and consider clues that may clinically
separate it from CBD.
2. Methods
We report two new cases of sCJD-CBS and include data collected from the
Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR) and other pub-
lished cases. For this study, CBS was defined by the presence of progressive asym-
metric onset of cortical dysfunction (alien limb, apraxia, cortical sensory loss) and at
least one of the following three movement disorders: akinetic-rigid syndrome, limb
dystonia or myoclonus. The ANCJDR includes all pathologically diagnosed cases of
CJD in Australia, prospectively collected from 1993 and retrospectively identified to
1970. The ANCJDR database was screened using the terms “corticobasal”, “alien
hand”, “alien limb” and “extrapyramidal” and seven patients were identified and
case notes were reviewed. A literature search using PubMed and keywords
“Creutzfeldt-Jakob disease”, “alien hand”, “alien limb” and “corticobasal” in
combinations identified ten English language articles describing cases of
pathologically-proven sCJD-CBS [2,7e15]. From these articles, sufficient clinical data
from 11 cases was available (either published or supplied by the corresponding
authors). In total, we identified twenty patients with sCJD-CBS (two from our clinic,
seven from the ANCJDR database and 11 from published literature).
In addition, we identified pathologically diagnosed cases of CBD presenting with
CBS (CBD-CBS) from the Queen Square Brain Bank for Neurological Disorders in
order to facilitate comparison with cases of sCJD-CBS. Of the 1440 cases collected
over a 20-year period, 19 cases with the pathological diagnosis of CBD were found.
Case notes of these 19 patients were reviewed and five were found to have initially
presented with CBS. The lack of access to raw data for analysis prohibited the use of
additional CBD-CBS cases from published literature.
To identify the characteristics that would be most useful in separating sCJD-CBS
from CBD-CBS, we only considered the clinical features that developed in the first
half of the disease course. This timeframe was chosen as the clinical characteristics
of sCJD-CBS converge with those of classic sCJD as the disease progresses and it is in
this early phase of disease that established sCJD diagnostic criteria are likely to be
least useful. Clinical signs that were not documented were considered absent.
Statistical methods including chi-square, student t-test, Wilcoxon Rank-sum test
were applied as appropriate, to compare clinical features between these groups.
3. Results
3.1. sCJD-CBS: illustrative case
A 71-year old woman presented with two months of right hand
paraesthesia and was referred for neurological consultation. On
examination, she was alert and oriented and was noted to have
dystonia, myoclonus, ideomotor apraxia and involuntary move-
ments consistent with alien limb affecting her right arm. In addi-
tion, there wereword-finding difficulties (Video 1). Initial magnetic
resonance imaging (MRI), including diffusion weighted imaging
(DWI), was normal. The patient went on to develop progressive
visual blurring, dysarthria and walking difficulties over weeks,
leading to hospital admission. On admission, the patient was
unsteady on her feet, found it difficult to stand, was virtually
anarthric and had widespread spontaneous and action myoclonus.
Electroencephalogram (EEG) showed diffuse delta slowing with
frequent non-periodical sharp waves. Repeat brain MRI showed
DWI hyperintensities without fluid attenuation inversion recovery
(FLAIR) changes, involving the right frontal parasagittal, right cal-
carine and bilateral insular cortices, as well as the right caudate,
which appeared hypointense on the apparent diffusion coefficient
(ADC) map. (Fig. 1AeC) Single-photon emission computed tomog-
raphy (SPECT) demonstrated extensive asymmetrical cerebral
cortical and right thalamic hypoperfusion. (Fig. 1D) Cerebrospinalfluid (CSF) 14-3-3 protein was positive. The patient died shortly
afterwards, five months from disease onset.
Supplementary video related to this article can be found at doi:
10.1016/j.parkreldis.2012.07.010.
Post-mortem examination confirmed CJD. No macroscopic
pathology was identified. Sections of the cerebral cortex, basal
ganglia, cerebellar cortex and brain stem showed similar features of
neuronal loss, gliosis and a “synaptic” pattern of prion protein
immunoperoxidase reactivity. (Fig. 1EeF) No cortical post-
ischaemic swollen eosinophilic neurons were seen and there was
no tau immunoreactivity.
3.2. All sCJD-CBS case data
We reviewed case notes of twenty patients with sCJD who
presented with CBS (12 women and 8 men, Table 1A) with a mean
age at disease onset of 66 years (range 50e78) and median time to
present to medical attention of 1.5 months (range 0.25e10). The
median time from disease onset to death was five months (range
1e48). Disease duration was less than 12 months in 80% of cases.
In sCJD-CBS, symptoms began on the non-dominant side in 55%
of patients and themost common signs of cortical dysfunctionwere
limb apraxia (14/20, 70%) and alien limb phenomena (17/20, 85%).
Other features that occurred in the first half of disease included
dysphasia (8/20, 40%), cortical sensory loss (8/20, 40%) and neglect
(3/20, 15%). The most common movement disorders were myoc-
lonus (16/20, 80%) and dystonia (9/20, 45%). Twelve (60%) patients
had rigidity but only five (25%) were documented to have both
rigidity and bradykinesia. Other common features included gait
ataxia (unsteadiness while walking without other specific features)
in 15 patients (75%), pyramidal disturbance (presence of hemi-
paresis, hyper-reflexia or positive Babinski sign) in 13 (65%) and
other cognitive impairment (impairment of memory or specific
cognitive domains) affecting 10 patients (50%). Early visual distur-
bance (25%) and cerebellar signs (20%) were uncommon. (Table 1B).
The most common symptoms reported by patients to their
primary care physicians were sensory disturbances in the affected
limb (10/20, 50%) and limb clumsiness (7/20, 35%). Seventeen
patients (85%) developed alien limb at some stage during the
course of their disease and in these patients the most common
features were purposeless grasping (6/17, 35%), intermanual
conflict (6/17, 35%) and limb levitation (4/17, 24%). (Table 1C and D).
EEG was documented in nineteen patients while CSF 14-3-3
protein assay result was known in seventeen. In 53% of patients (10/
19), typical EEG periodic sharp wave complexes (PSWC) were seen
while CSF 14-3-3 testing (generally available since 1997) was
positive in 59% (10/17). MRI was performed in 17 patients and nine
were documented to be normal. DWI sequence was performed (or
reported) in seven patients, all showing restricted diffusion in the
cerebral cortices and/or basal ganglia. SPECT or positron emission
tomography (PET) was performed in six patients with the universal
finding of widespread asymmetrical cortical hypoperfusion.
Molecular information was unavailable for the majority of identi-
fied cases.
Of the 1440 cases in the Queen Square Brain Bank, 35 patients
(2.4%) either had a final clinical diagnosis of CBS (21/1440, 1.5%) or
pathological diagnosis of CBD (19/1440, 1.3%). Only five patients
had CBD-CBS, therefore constituting 0.3% of all archived cases.
Disease characteristics including gender, age of onset, time to
diagnosis and disease duration in these five cases of CBD-CBS were
compared with sCJD-CBS. (Table 2) The time from disease onset to
final clinical diagnosis was significantly longer in CBD-CBS (median
48 months, range 12e66) than in sCJD-CBS (median 1.5 months,
range 0.25e10, Wilcoxon Rank-sum test, p < 0.001). The duration
from disease onset until death was significantly longer in CBD-CBS
Fig. 1. A. DWI showing hyperintensities involving the right frontal parasagittal, right calcarine and bilateral insular cortices and right caudate. B. ADC map with corresponding right
caudate hypointensity. C. FLAIR showing no corresponding changes. D. SPECT showing moderate left parietal and bilateral frontal and occipital cortical, as well as right thalamic
hypoperfusion. E. Haematoxylin and eosin stain (200 magnification) e Frontal cortex, showing spongiform changes (arrow), neuronal loss and gliosis. F. 12F10 PrP
immunoperoxidase stain (200 magnification) e Frontal cortex, showing synaptic pattern of prion protein deposition (arrow).
W. Lee et al. / Parkinsonism and Related Disorders 19 (2013) 81e85 83(median 68 months, range 58e106) than in sCJD-CBS (5 months,
range 1e48, Wilcoxon Rank-sum test, p < 0.001). Core clinical
features of CBS including alien limb, limb apraxia, dystonia, cortical
sensory loss, myoclonus, pyramidal disturbance and extrapyra-
midal signs were also compared between the two groups. No single
clinical feature was useful in distinguishing sCJD-CBS from
CBD-CBS.Informative epidemiological data was obtained from the
ANCJDR on 387 definite sCJD cases between 1984 and 2010. Based
on a median Australian population of 18 million during this period,
the incidence of sCJD in Australia is in line with reported figures at
0.8 per million persons per year [16]. sCJD-CBS is exceedingly rare
and accounted for 1.8% of all sCJD cases with an estimated incidence
of 0.014 per million persons per year. The true incidence may in fact
Table 2




Sex (M:F) Chi-square 3:2 8:12 0.42










Median ¼ 68.4 Median ¼ 5 <0.001
Extrapyramidal
signs (n/%)
Chi-square 2 (40%) 5 (25%) 0.5
Alien limb (n/%) Chi-square 3 (60%) 17(85%) 0.21
Limb apraxia (n/%) Chi-square 5 (100%) 14 (70%) 0.16
Dystonia (n/%) Chi-square 4 (80%) 9 (45%) 0.16
Cortical sensory
loss (n/%)
Chi-square 4 (80%) 8 (40%) 0.11
Myoclonus (n/%) Chi-square 5 (100%) 16 (80%) 0.28
Pyramidal
disturbance (n/%)
Chi-square 2 (40%) 13 (65%) 0.31
The bold text was to highlight the two items that reached statistical significance.
Table 1
Clinical characteristics of 20 patients with sCJD-CBS. (C. Initial presenting
symptomse Some patients presentedwithmore than one initial symptom. “Others”
includes cognitive decline, gait disturbance, visual loss, limb dystonia.)
A. Disease characteristics
Females (n):Males (n) 12:8
Age at onset in years (Mean/Range) 66 (50e78)
Time to presentation in months (Median/Range) 1.5 (0.25e10)
Disease duration in months (Median/Range) 5 (1e48)
Handedness e Right (n): Left (n): Unknown (n) 14:0:6
Side of onset e Dominant (n): Non-dominant (n):
Unknown (n)
3:11:6
B. Early clinical features
Limb apraxia (n/%) 14 (70%)
Alien limb (n/%) 17 (85%)
Dysphasia (n/%) 8 (40%)
Cortical sensory loss (n/%) 8 (40%)
Neglect (n/%) 3 (15%)
Myoclonus (n/%) 16 (80%)
Dystonia (n/%) 9 (45%)
Rigidity (n/%) 12 (60%)
Bradykinesia (n/%) 5 (25%)
Tremor (n/%) 5 (25%)
Cognitive impairment (n/%) 10 (50%)
Pyramidal disturbance (n/%) 13 (65%)
Other sensory disturbance (n/%) 4 (20%)
Frontal release signs (n/%) 3 (15%)
Cerebellar signs (n/%) 4 (20%)
Gait ataxia (n/%) 15 (75%)
Parkinsonian gait (n/%) 2 (10%)
Visual disturbance (n/%) 5 (25%)
Visual hallucinations (n/%) 2 (10%)
Behavioural disturbance (n/%) 2 (10%)
C. Initial presenting symptoms
Hand/arm clumsiness (n/%) 7 (35%)
Sensory disturbance (n/%) 10 (50%)
Alien limb (n/%) 3 (15%)
Myoclonus (n/%) 2 (10%)
Others (n/%) 4 (20%)
D. Alien hand
Hand e Non-dominant (n):Dominant (n):
Unknown (n)
9:3:5
Intermanual conflict (n/%) 6 (35%)
Grasp (n/%) 6 (35%)
Mirror movements (n/%) 1 (6%)
Limb levitation (n/%) 4 (24%)
Purposeful movements (n/%) 1 (6%)
Wandering (n/%) 2 (12%)
W. Lee et al. / Parkinsonism and Related Disorders 19 (2013) 81e8584be higher as registry case ascertainment prior to 1993 was retro-
spective and most likely incomplete.
The characteristics of patients with sCJD-CBS were comparable
to other sCJD patients in the ANCJDR database in age of onset
(median 67.2 years), disease duration (median 5 months) and
frequency of typical EEG changes (sCJD-CBS 53% vs other sCJD 58%)
but not CSF 14-3-3 protein detection (sCJD-CBS 59% vs other sCJD
88%) [17].4. Discussion
The present study constitutes the largest single reported series
of sCJD patients presenting with CBS. As such, we have been able to
more confidently validate previous anecdotal impressions that
rapidity of disease progression is a valuable salient distinguishing
feature of sCJD-CBS from other neurodegenerative causes of CBS,
including CBD-CBS. Therefore, we believe the presentation of CBS in
the context of sCJD should rarely be confused clinically with CBD
because of the rapid disease progression, particularly when
combined with characteristic MRI and EEG changes. We identified
initial limb sensory disturbance that evolves rapidly to a clumsy
useless arm in association with early myoclonus, as well as limb
dystonia, gait ataxia, pyramidal disturbance and cognitive impair-
ment to be the typical presentation of sCJD-CBS.
The clinical picture of sCJD-CBS can only be differentiated from
CBD-CBS by the rapidity of progression, which correlates with
a significantly shorter time to diagnosis and overall disease
duration. While there are no predictive clinical features, the initial
presenting complaint may provide clues to the diagnosis. Limb
clumsiness is the most common presentation in CBD (67%) [1,18].
Other common initial symptoms in CBD include walking difficul-
ties (28%) while isolated sensory symptoms occurred in only 8%
[18]. On the contrary, limb sensory disturbance was the most
common initial complaint in sCJD-CBS (50%) followed by limb
clumsiness (35%) while gait disturbance was rare (5%). In CBD,
myoclonus and alien hand occurred after one year from disease
onset [18]. In contrast, alien limb phenomena and myoclonus
often occurred early in sCJD-CBS patients and were the first
symptoms in several cases. In addition to these clinical differences,
MRI, particularly DWI sequences, appears to provide helpful
diagnostic clues.
Epidemiological data for CBD-CBS are lacking and CBS is a rare
presentation of PSP and AD, which are both more prevalent than
CBD [1]. Our data suggests that sCJD-CBS is exceedingly rare with
an incidence of 0.014 per million persons per year. To put this into
perspective, in a metropolis of 5 million people, there will be one
case of sCJD-CBS every 14 years based on our calculated
incidence.
This study again reinforces the inadequacy of our current clinical
diagnostic capacity and understanding of CBS and CBD. A number
of diagnostic criteria for CBD have been proposed which focus on
the co-occurrence of movement disorders and cortical signs [19].
These criteria are clearly not useful when applied to non-CBS
presentations of CBD. Only one set of exclusion criteria had been
proposed, which included early dementia, vertical gaze palsy,
severe autonomic disturbance, sustained levodopa response and
lesions on imaging [19]. From our findings, we propose the addition
of rapid disease progression to akinetic-mutism or death in less
than 12 months and brain MRI DWI abnormalities as exclusions in
future CBD diagnostic criteria development.
The main limitations of our study are small patient numbers,
which is not unexpected given the rarity of this form of sCJD, and
the retrospective nature of the study with differing levels of detail
in case note documentation.
W. Lee et al. / Parkinsonism and Related Disorders 19 (2013) 81e85 855. Conclusion
Although sCJD-CBS is exceedingly rare, early recognition is
nonetheless important due to the associated prognostic impli-
cations. sCJD should be considered in a patient presenting with
CBS when progression is rapid, with initial limb sensory distur-
bance and early myoclonus and alien limb, particularly if asym-
metrical cerebral cortical and basal ganglia DWI abnormalities
are present, even without accompanying CSF 14-3-3 protein and
EEG PSWC.
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Editorial
reutzfeldt–Jakob disease (CJD) is a rare neuro-
degenerative disorder which causes the death of
about 25–30 Australians each year, giving an aver-
age mortality rate of 1.2 cases/million/year.1 It is untreat-
able. CJD is the commonest human form of prion disease2
and is a notifiable disease in all Australian states and
territories, with notification to the relevant jurisdictional
health department required for all cases in which a strong
clinical suspicion for CJD exists.
CJD may be acquired through medical intervention
(iatrogenic CJD), for example, from the use of cadaver-
derived pituitary hormones; or it may be inherited in an
autosomal dominant pattern with high penetrance (famil-
ial CJD, occurring in about 10%–15% of cases); but in at
least 85% of cases it occurs sporadically (sporadic CJD),2
with the person having no recognised cause for the dis-
ease. Variant CJD (vCJD) is the form zoonotically linked to
bovine spongiform encephalopathy (mad cow disease),
with a median age at death of around 28 years.2,3
Iatrogenic transmission is generally most likely when
infectious material is placed in direct contact with the
brain.4 CJD is not transmitted through respiratory, casual
or sexual contact, and bloodborne transmission has only
been confirmed for vCJD.5 Whether CJD has been trans-
mitted through surgery not involving the central nervous
system remains debatable.6,7 Worldwide, there have been
two major iatrogenic outbreaks of CJD, one caused by
contaminated pituitary hormone extracts (226 cases),8 and
the other related to dura mater grafts (228 cases),9 mostly
associated with a single brand (Lyodura), when these
products were derived from human cadavers with unrec-
ognised CJD. In Australia, the most recent human-derived
pituitary gonadotrophin-related CJD death occurred in
1991, and the most recent Lyodura-related CJD death
occurred in 2000,1 although new cases were reported
overseas in 2011.
The Communicable Diseases Network Australia has
recently completed a revision of the Australian CJD Infec-
tion Control Guidelines (CJD ICG).10 These guidelines
continue to be primarily aimed at preventing iatrogenic
cases of CJD, and they differ from the previous version by
being considerably more streamlined in order to enhance
useability. They give up-to-date information on diagnosis
(including associated genetic mutations), contain much
more detail on management of surgical instruments, deal-
ing with high- and low-risk people and procedures, and
give new advice on postmortem and funeral industry
practices. The updated guidelines apply a clear risk stratifi-
cation approach to minimise the risk of iatrogenic disease
until a blood test or other screening test for the detection
of preclinical infection becomes available. vCJD has not
occurred in Australia to date,1 with most cases reported in
the United Kingdom, and modelling suggesting that cases
will be unlikely to occur here. Therefore vCJD is not
considered in the scope of the revised guidelines.
We believe the updated CJD ICG will be of interest for
two reasons. First, they serve as a reminder, that despite
the relative rarity of confirmed cases, CJD is not infre-
quently considered in the differential diagnosis of progres-
sive neurological disease in a variety of health care
settings. Second, they contribute to equity in medical care
by aiming to overcome ignorance coupled with suboptimal
implementation of previous CJD ICG, which have some-
times led to discrimination, against not only sufferers of
CJD, but also their family members. To illustrate these
concerns: the family of one suspected CJD patient was told
not to return to a particular general practice, because the
general practitioner did not want “other people at the
practice to become infected”; and numerous asymptomatic
people at above “background” risk of CJD (due to possible
iatrogenic exposure) have been refused routine endoscop-
ies or been told they will have to pay for replacement
colonoscopes, and some have been refused surgery such as
hip replacement. Such occurrences lead to inordinate dis-
tress and, more insidiously, drive some patients to present
to another facility where they conceal risk status in order to
have a procedure performed.
We would like to highlight the information and advice in
these guidelines in the hope that clinicians follow practices
which are based on science and reflect the real and
manageable risks surrounding CJD.
The Australian National CJD Registry (ANCJDR) has
been funded by the federal government since 1993 to
evaluate all suspect and proven cases of prion disease in
Australia. The ANCJDR tries to follow all suspect cases
until the most accurate case classification is achieved, with
brain neuropathological examination being the gold
standard for a definitive diagnosis. Beyond comprehensive
epidemiological surveillance of all cases of prion disease in
the Australian population, the ANCJDR also provides
additional nationwide infection control advice, diagnostic
services, and advice to families and clinicians.
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Stroke care in Australia: why is it still the 
poor cousin of health care?
Stroke prevention and management have changed, but most patients are not 
benefiting from these changes
he National Stroke Foundation’s recent rehabilita-
tion services audit report confirms that only a small
proportion of Australians receive evidence-based
care.1 The gap between best evidence-based and actual
care in many areas of stroke is staggering.
For example, only 44% of patients transferred to rehabil-
itation had been in a stroke unit. This mirrors the acute
care services audit finding that many patients do not
receive dedicated stroke unit care,2 despite overwhelming
evidence of effectiveness.3 Only 7% of ischaemic stroke
patients received thrombolysis treatment,2 yet for every
100 patients who receive it, there are up to 10 extra
independent survivors.4 About 20% of stroke patients are
discharged from hospital without medication (to lower
cholesterol and blood pressure) to prevent recurrent
stroke;2 however, for every 100 people treated with blood-
pressure-lowering medication, three people are saved
from death and/or disability from recurrent stroke and
cardiovascular events.3 Over one-third of patients are put
at risk of complications because their swallowing ability is
not assessed before being given food, drink or oral medica-
tions.2 Despite the contribution of lifestyle risk factors to
secondary stroke risk, almost half (47%) of patients do not
receive lifestyle risk factor modification advice.1 Only 37%
of patients are referred for community rehabilitation,1
although for every 100 people who receive it, six are saved
from death and/or disability.3 For virtually every important
quality indicator, outcomes are better if patients had been
in a stroke unit, or in a hospital treating over 100 stroke
patients per year.
Stroke has been a designated National Health Priority
Area disease since 1996; yet federal budget funding has
never been provided for the implementation of a compre-
hensive stroke strategy. The reasons for this are not clear.
The broader disease category to which stroke belongs
(cardiovascular disease) has received only a tiny proportion
of program funding ($8.6 million) compared with other
conditions ($2.5 billion for cancer, $1.6 billion for diabetes
and $1.4 billion for mental health).5 This is despite the fact
that that cardiovascular disease is Australia’s biggest killer
(with ischaemic heart disease responsible for 15% of all
deaths, and cerebrovascular disease for 8%6), and accounts
for 18% of the overall burden of disease.7
Within cardiovascular disease, there is a large funding
disparity between heart disease and stroke, with stroke
losing out by far. The reasons for this are also unclear.
Perhaps it is because stroke is wrongly assumed by many
to only be a disease of the elderly, perhaps because
lobbying and marketing attempts for heart disease have
been more sustained and effective, or perhaps because the
difference between the two is lost on most — many of the
public think that stroke and heart attack are the same
thing.
Mortality estimates for stroke grossly underestimate the
burden of disease caused by the major acquired disability
in many survivors.8 Stroke impairments can dramatically
impact on function and reduce the psychosocial quality of
life of people with stroke and their carers. Effects can last
for decades, with an estimated yearly cost burden for
stroke in Australia of $2 billion.9
We know about the evidence–practice gaps because
current practice data are available from the National Stroke
Foundation’s National Stroke Audit program (which
includes an organisational audit of over 300 acute and
rehabilitation hospitals and a clinical audit of the stroke
care provided to over 14 000 patients in the past 4 years).
We also know what care Australian stroke patients should
be receiving — in acute care, during rehabilitation and
after discharge. The Clinical guidelines for stroke manage-
ment 2010 endorsed by the National Health and Medical
Research Council clearly highlight effective interventions
that reduce death and disability, and improve quality of
life.3 However, the problems with stroke care are not
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Introduction
Creutzfeldt–Jakob disease (CJD) is a rare
transmissible neurodegenerative disease
related to cerebral accumulation of mis-
folded prion protein. It typically presents
with a rapidly progressive dementia often
associated with myoclonus and ataxia [1].
We describe an unusual presentation of
sporadic CJD with spastic paraparesis,
in the setting of initially preserved
cognition.
Case report
A 55-year-old Asian woman presented
with 3 months of progressively worsening
gait disturbance, accompanied by sensory
disturbance over the right leg, culminat-
ing in overt dysequilibrium. In addition,
the patient reported fatigue and mild
insomnia, with minor dizziness. There
was no sphincter dysfunction. Past medi-
cal history included depression, but no
past neurosurgical procedures or receipt
of human hormone extracts or blood
transfusions. On initial examination, the
patient displayed evidence of gait ataxia,
with lower limb upper motor signs in the
form of spasticity, brisk reflexes and sus-
tained right ankle clonus, right more
than left pyramidal weakness and a right
extensor plantar response. There was no
objective sensory disturbance. Mood and
cognition appeared normal, even to close
relatives.
A right-sided spinal cord lesion was
suspected, but magnetic resonance imag-
ing (MRI) did not reveal any intra-/
extra-axial spinal cord abnormality.
Instead, brain MRI showed a high sig-
nal, cortical ‘ribboning’ pattern on diffu-
sion-weighted sequences diffusely
through the cerebrum. There were no
subcortical hyperintensities. Extensive
investigation for vasculitis, non-vasculitic
auto-immune encephalopathies (e.g.
anti-neuronal autoantibodies and
antibodies to voltage-gated potassium
channels and N-methyl-D-aspartate
receptors) and viral infection were all
normal. Cerebrospinal fluid (CSF) was
unremarkable, and initial 14-3-3 protein
was negative. Computer tomography
chest/abdomen/pelvis and whole body
fludeoxyglucose-positron emission
tomography scan showed no neoplastic
lesion.
Over the next few months, the patient
continued to deteriorate, gradually devel-
oping occasional scintillation in the




Figure 1 Histopathology. Moderate to severe mixed micro- and macrovacuolar spongi-
form change in the occipital, frontal (a) and entorhinal cortices, with accompanying
neuronal loss and gliosis. There was no specific laminar distribution of these changes.
Moderately severe spongiform change was also seen in ventrolateral and dorsomedial
thalamic nuclei (b). There was severe Purkinje cell loss in the cerebellar vermis (d) and
neuronal loss in the thalamus. Milder microvacuolar spongiform change was seen in
other neocortical regions and deep grey nuclei, and 3F4 immunohistochemistry on the
frontal cortex (c) and striatum was positive in a fine synaptic pattern. The brainstem
showed mild spongiform change with some neuronal loss in superior and inferior collicu-
li, and inferior olives. No Kuru-type plaques were seen in any section examined. Western
blot of prion protein from right frontal cortex (e). Lane 1, sporadic CJD Type 2; Lanes
2 and 4, study subject; Lane 3, sporadic CJD Type 1; Lane 5, sporadic CJD Type 3.
© 2013 The Author(s)
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clumsiness of her hands. A severe truncal
ataxia emerged. Neuropsychological test-
ing at this stage revealed severe impair-
ment in verbal learning, marked
constructional apraxia and severe impair-
ment of executive function. Electroen-
cephalogram showed generalized non-
specific slowing. A repeat CSF 14-3-3
protein was positive. The patient contin-
ued to deteriorate, eventually dying 1
year after presentation.
A brain-only post mortem examination
was performed. The fresh brain weight
was 1308 g, and macroscopic examination
revealed mild dilatation of the lateral ven-
tricles only. The microscopic appearances
are illustrated in Fig. 1. Sequencing of
the PRNP open reading frame revealed
no mutations with methionine homozy-
gosity (MM) at codon 129. Western blot
analysis of protease-resistant prion pro-
tein from a single (right frontal) cerebral
cortical site revealed a mixed Type 2/3
pattern with the dominant band T2 [2].
Discussion
Although pyramidal tract degeneration
may be found in the later stages of ill-
ness, presentation of sporadic CJD with
spasticity restricted primarily to the lower
limbs is extremely rare. There have been
two reported patients with the E200K
mutation who have had a similar presen-
tation [3,4]; both were middle-aged
females. Spasticity can also be an early
feature in Gerstmann–Stra}ussler–Schein-
ker syndrome associated with the P102L
mutation [5], and can dominate the
clinical picture in patients with the
P105L mutation [6]. Apparently, there
was no family history in our case of any
prion-like disorder, and PRNP analysis
excluded mutations including E200K,
P105L and P102L.
Co-existing, protease-resistant prion
protein types are less common [2], with
influence on the corresponding pheno-
type incompletely resolved. The Austra-
lian National CJD Registry has classified
one other sporadic CJD as MM Type 2/
3, with their clinical profile unremark-
able, and the authors are not aware of
any additional cases reported of this
molecular subtype [7].
Our case reinforces the variability of
presentations of sporadic CJD, and
highlights that sporadic CJD can also
present with a spastic gait, prior to
other more characteristic features such
as cognitive decline, ataxia and
myoclonus.
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W
e describe a patient with hyperekplexia as the initial presenting symptom in
sporadic Creutzfeldt-Jakob disease (CJD). We also demonstrate the utility
of the sensitive and highly specific new prion protein amplification assay,
real-time quaking-induced conversion (RT-QUIC), which amplifies and
detects misfolded b-sheet–rich conformers of the prion protein (PrPsc), in expediting a con-
fident clinical diagnosis of CJD in an atypical case.
Case report
A 73-year-old man presented with 4 months of an exaggerated startle response (hyperek-
plexia) occasionally but not exclusively associated with myoclonus and without cognitive
decline at onset (video at Neurology.org/cp). The detailed case report is presented in
appendix e-1.
Blood tests revealed mildly low complement and a positive lupus anticoagulant. CSF twice
revealed normal biochemistry and no cells or oligoclonal bands. CSF 14-3-3 protein was not
detected by Western blot. Tremor studies revealed an inconsistent order of myoclonic recruit-
ment and entrainment of tremor to externally paced hand tapping, which alone suggested a




should be considered in the
differential diagnosis of
hyperekplexia.
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preceded clinical myoclonus (figure, A). SPECT imaging demonstrated widespread discrete
areas of hypoperfusion involving the cerebral cortex with a focal area of right frontal hyper-
perfusion (figure, B and C). MRI revealed focal linear cortical T2 hyperintensities (figure,
D–G). A formal cerebral angiogram was normal.
Figure Results of EEG, radiology, and histopathologic investigations
(A) EEG demonstrated intermittent bifrontal and right frontal spikes that often preceded a myoclonic jerk. There was no EEG evidence of a seizure or any pe-
riodic lateralized epileptiform discharges. (B–C) SPECT imaging demonstrated widespread discrete perfusion abnormalities involving the cerebral cortex and
sparing the subcortical regions, with a focal area of increased activity in the right frontal lobe representing a region of hyperperfusion. This right frontal hot
spot (arrow) is visible on both coronal (B) and axial (C) images. (D–G) 3T MRI coronal and axial reformats from a 3D fluid-attenuated inversion recovery
sequence acquired in the sagittal plane revealed small focal ribbons of cortical T2 hyperintensity (coronal, D; axial, F) with associated diffusion restriction
(arrow) (coronal, E; axial, G reformats from a high-resolution diffusion-weighted imaging sequence acquired in the axial plane with a slice thickness of 1.8 mm
and with B0 and B1000); corresponding apparent diffusion coefficient map changes were present (data not shown). (H) Predominantly microvacuolar
spongiform change was present in the cortex, including perineuronal and perivascular vacuolation, with associated mild neuronal loss and reactive gliosis
(hematoxylin & eosin [H&E] stain, magnification 6303). (I) 3F4 immunohistochemistry of the cortex revealed a synaptic staining pattern with globular plaque-
like immunoreactive deposits admixed (3F4 immunohistochemistry, magnification 4003). (J) The cerebellar vermis and lateral hemispheres showed mild
macrovaculoar spongiform change in the molecular layer, Bergmann gliosis (arrow) with Purkinje cell drop out, numerous torpedo-like eosinophilic swellings
(asterisk), and many Kuru-type plaques in the molecular and granular layers (inset) (H&E stain, magnification 6303; inset 12003). (K) Immunostaining for
prion protein in the cerebellar vermis showed intense immunoreactivity of Kuru plaques, small clusters of plaques, and fine synaptic staining mostly restricted
to the granular layer, with occasional plaques seen in the white matter and molecular layer (3F4 immunohistochemistry, magnification 6303).
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Differential diagnoses at this stage included CJD, cerebral vasculitis, and progressive enceph-
alopathy with rigidity and myoclonus. Testing of CSF using the RT-QUIC assay was positive,
strongly supporting a diagnosis of CJD.1
The patient declined, with gait and cognitive impairment plus behavioral changes, and died
13 months following symptom onset. Postmortem brain analysis confirmed CJD with histo-
pathologic features of microvacuolation (spongiform changes) and Kuru-type plaques (figure,
H–K). Sequencing of the entire PrP gene (PRNP) open reading frame was normal, confirm-
ing sporadic CJD with heterozygosity for methionine/valine at codon 129. Glycotyping
revealed type 3 PrPSc.2
DISCUSSION
Sporadic CJD is a prion disease consequent to accumulation of misfolded pathogenic prion
protein in the brain.3 It typically presents with cognitive decline. Clinical heterogeneity
correlates with the molecular subtype, depicted by the combination of the methionine (M)
or valine (V) polymorphism at codon 129 of PRNP and PrPSc glycotype demonstrated though
Western blot analysis of brain homogenates. Postmortem histopathology in this case was
unusual in that there were Kuru-type plaques in the cerebellum, consistent with what is
reported for MV3,4 with immunostaining for PrP also showing PrP-positive plaques in the
cortex and basal ganglia.
This patient’s initial symptom was an exaggerated startle response (hyperekplexia). A
startle reflex is a bilaterally synchronous shocklike set of movements.5 A number of
mutations in the glycine receptor gene and other postsynaptic proteins are associated
with inherited hyperekplexia.5 Acquired forms may be secondary to brainstem or exten-
sive cerebral damage or glycine receptor antibodies.5 Although myoclonus is an estab-
lished clinical feature in CJD, hyperekplexia as the initial symptom of sporadic CJD is
unique.
This case exemplifies the difficulty clinicians may face in the diagnosis of sporadic CJD.
Our case was atypical for sporadic CJD because the patient presented with hyperekplexia,
initially preserved cognition, a longer disease course, and the absence of CSF 14-3-3
protein.
Although CSF 14-3-3 protein detection is a useful confirmatory test for sporadic CJD, it is a
nonspecific marker of neuronal damage, and both its sensitivity and specificity can be subop-
timal. CSF tau levels have been shown to have a higher specificity for the diagnosis of CJD than
14-3-33; however, these results were not available for our patient. In 2011, Atarashi et al.1
described a new amplification assay, RT-QUIC, which allowed for the ultrasensitive detection
of PrPSc in CSF samples with greater than 80% sensitivity and 100% specificity, thus per-
mitting an early, rapid, and highly specific antemortem diagnostic investigation. Further
independent studies have demonstrated a sensitivity of 87% or more in sporadic CJD with
retained high specificity.6 The RT-QUIC assay has also been identified as being more sen-
sitive for the detection of genetic prion disease than biomarkers such as 14-3-3 or tau
protein.7
This case is unique because it highlights hyperekplexia as a possible presenting symptom of
sporadic CJD. It also demonstrates the utility of the highly sensitive and specific RT-QUIC
assay in supporting an antemortem clinical diagnosis of CJD in a case where immunologic find-
ings on blood tests may otherwise have suggested invasive investigation and treatment trials for
possible vasculitis, a recognized differential diagnosis in CJD.
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Objective: To report a rare case of leucine-rich, glioma inactivated 1 (LGI1) antibody–mediated auto-
immune encephalopathy clinically overlapping with pathologically confirmed sporadic Creutzfeldt-
Jakob disease (CJD).
Methods: The patient was investigated with repeated brain MRI, EEG, CSF examination, whole-
body fluorodeoxy-glucose positron emission tomography, genetic analysis of the prion protein
gene (PRNP), and extensive serologic screening for paraneoplastic and autoimmune encephalop-
athy markers. Written informed consent was obtained from the patient’s next of kin for access to
clinical files for research purposes and for publication.
Results: The patient was a 77-year-old man who presented with faciobrachial dystonic seizures
(FBDS) secondary to LGI1 antibody–mediated autoimmune encephalopathy, with suggestive MRI
findings and a complete response to treatment with combinatorial immunosuppression. Stereotactic
biopsy of a nonenhancing T1 hyperintense basal ganglia lesion during the initial FBDS phase, albeit
following immunosuppression, did not disclose evidence of lymphocytic inflammation. Following full
remission of the FBDS, the patient manifested a rapidly progressive dementia associated with gross
motor decline confirmed to be CJD at autopsy (molecular subtype VV3), with no evidence of a path-
ogenic PRNP mutation.
Conclusions: Our patient highlights that these rare diseases are not invariably mutually exclusive
and underscores the benefits of comprehensive neuropathologic examination of the brain to
achieve an accurate diagnosis, especially in complex cases when the clinical trajectory dramati-
cally deviates and a concomitant disease may need to be conscientiously considered to best
explain the new clinical course. Neurol Neuroimmunol Neuroinflamm 2016;3:e248; doi: 10.1212/
NXI.0000000000000248
GLOSSARY
BG 5 basal ganglia; CJD 5 Creutzfeldt-Jakob disease; FBDS 5 faciobrachial dystonic seizures; sCJD 5 sporadic
Creutzfeldt-Jakob disease; VGKC 5 voltage-gated potassium channel; VGKCC-LE 5 voltage-gated potassium channel
complex limbic encephalitis.
A patient presented at age 77 years with a 1-week history of intermittent episodes of left-sided
spasms involving the arm, face, shoulder, or leg, lasting 4–5 seconds, which were accompanied
by recurrent falls but not associated with loss of consciousness. Medical history included type
2 diabetes mellitus managed with metformin and glimepiride; hypertension treated with atenolol
and telmisartan; hypercholesterolemia controlled with simvastatin; and chronic obstructive pulmo-
nary disease, for which salbutamol and tiotropium inhalant therapy were prescribed. There was no
history of neurologic disorders. CT and MRI of the brain, as well as EEG, proved unremarkable.
Neurologic examination results were normal and the patient had apparently normal cognitive
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function by informal assessment. The patient
was commenced on phenytoin (300 mg daily)
following a provisional diagnosis of partial
epilepsy.
Approximately 1 month later, the patient
was admitted to the hospital because of recur-
rence of the left facial and upper limb spasms
of increased frequency, sometimes occurring
every 8–10 minutes, with up to 30 episodes
daily; minor difficulties with cognition were
also apparent. During the admission, repeat
MRI of the brain (figure 1A) showed T1 hy-
perintensity in the right basal ganglia (BG),
which was nonenhancing and appeared asso-
ciated with modest mass effect. Based on the
new imaging findings and concerns about
neoplastic infiltration, anticonvulsant therapy
was changed to carbamazepine 200 mg twice
daily and empirical treatment with oral dexa-
methasone was commenced. Shortly thereaf-
ter, the patient underwent stereotactic biopsy
of the T1 hyperintense lesion, which only
revealed mild, nonspecific, astrocytic gliosis
but no evidence of neoplasia or inflammation.
Routine investigations were unremarkable aside
from a new-onset hyponatremia (122 mM;
normal 135–145 mM). Investigations for an
underlying neoplastic process included CT imag-
ing of the chest-abdomen-pelvis, whole body
fluorodeoxy-glucose positron emission tomog-
raphy with CT correlation (FDG-PET/CT),
and serum paraneoplastic antibody and tumor
marker screening (including anti-Hu and
anti-Yo/Purkinje cell antibodies and carci-
noembryonic antigen CA 19-9), which were
negative. CSF was normal and prolonged scalp
EEG monitoring during episodes of spasms
showed no evidence of focal epileptiform activ-
ity. An autoimmune encephalopathy screen for
anti–NMDA receptor antibodies in both
serum and CSF was negative but anti–volt-
age-gated potassium channel (VGKC) complex
antibodies were positive by radioimmunoassay
at 338 pM (normal,85). Posthumous retesting
of the patient’s serum using indirect immuno-
fluorescence (Euroimmun, Lübeck, Germany)
Figure 1 Prebiopsy and postbiopsy MRI
(A) Immediately prebiopsy, axial brain MRI shows a non–contrast enhancing T1 hyperintensity in the right basal ganglia
juxtaposed to the external capsule (arrows) with modest mass effect; these changes were not evident in a prior MRI study.
Corresponding fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging (DWI) sequences were essen-
tially unremarkable. (B) Postbiopsy axial brain MRI reveals resolution of the right basal ganglia T1 hyperintensity (arrow),
with biopsy artefact (arrow head), with corresponding FLAIR images remaining otherwise unremarkable aside from ongoing
modest mass effect (arrow), while the DWI series displays subtle cerebral cortical signal increase in the posterior cingulate
gyri (right more than left) and right posterior temporal region (arrow).
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confirmed the presence of antibodies to LGI1
but not to contactin-associated protein-like 2.
Based on all the available clinical information
at the time of the anti-VGKC antibody
result, the working diagnosis of faciobrachial
dystonic seizures (FBDS) secondary to anti-
VGKC encephalopathy was made. The patient
was changed from dexamethasone (after approx-
imately 1 month of treatment) to prednisolone
(25 mg daily) and azathioprine (100 mg daily),
with monthly IV immunoglobulin given for
4 months as combinational immunotherapy,
which resulted in complete clinical remission
of his FBDS and partial improvement in cogni-
tion, allowing the patient to be discharged home
with gradual outpatient tapering of maintenance
corticosteroid therapy.
Approximately 4 months after discharge,
despite good ongoing control of the FBDS,
the patient’s cognition began to decline again
(Mini-Mental State Examination 19/30),
with minimal response to escalation of the
prednisolone to 25 mg daily. Cognitive
impairment at that time included amnesia,
executive dysfunction, visuospatial impair-
ment, and poor insight. Repeat brain MRI
confirmed absence of the previous right BG
T1 hyperintensity (with postbiopsy changes
evident) and equivocal cerebral cortical signal
abnormality restricted to the posterior cingu-
late gyri (right more than left) and posterior
right temporal lobe on the diffusion-weighted
series (figure 1B). Repeat EEG showed only
nonspecific generalized slowing consistent
with a moderate encephalopathy. The patient
thereafter manifested inexorable cognitive and
gross motor decline, associated with bulbar
dysfunction and double incontinence, dying
6 months later, spending the final 2 months
of his life in high-level care. The total illness
duration from clinical presentation to death
was 17 months, the first 8 months predomi-
nantly involving autoimmune FBDS and its
management and the next 9 months related
to a rapidly progressing dementia with pro-
found functional decline.
A diagnosis of Creutzfeldt-Jakob disease
(CJD) was confirmed at autopsy, characterized
by widespread spongiform encephalopathy asso-
ciated with neuronal loss and astrocytic gliosis
(figure 2). There was no evidence of any lym-
phocytic inflammatory reaction. Genetic studies
did not reveal any pathogenic variants of the
prion protein gene (PRNP) and the patient was
homozygous valine/valine (VV) at codon 129.
Western blot showed evidence of protease-
resistant prion protein, classified as type 3 ac-
cording to the nomenclature of Collinge et al.1
As follow-up to the brain pathologic findings at
autopsy, formal re-review of the stereotactic
biopsy was undertaken but did not reveal pre-
viously unappreciated spongiform changes and
immunohistochemistry for abnormal prion pro-
tein deposits was negative.
DISCUSSION We propose that the 17-month illness
to the time of death in our patient most likely
comprised 2 overlapping neurologic illnesses: anti-LGI1
autoantibody-mediated encephalopathy predominantly
Figure 2 Neuropathologic diagnosis of Creutzfeldt-Jakob disease (CJD) at postmortem
(A) Cerebellar vermis shows typical changes of CJD including spongiform encephalopathy, gliosis, and neuronal loss (hema-
toxylin and eosin 3 100 actual magnification) and (B) synaptic pattern (PrP) immunoreactivity (12 F10 PrP antibody3 100
actual magnification). Note there is no evidence of any inflammatory cells.
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manifesting as FBDS and inexorable cognitive and
gross motor decline due to VV3 sporadic CJD
(sCJD). While the FBDS was completely responsive
to immunosuppression, the patient’s early cognitive
impairment was only partially responsive, and although
recognized for LGI1 antibody encephalopathy raises the
possibility that at least some of this impairment may
have related to sCJD before more dramatic cognitive
decline and accompanying features were evinced.
Although we consider it unlikely, due to the response
of the FBDS to immunosuppression in the setting of
anti-LGI1 antibodies and typical MRI changes, we
cannot exclude the possibility that the patient’s illness
reflected an atypical CJD phenotype from the time of
first presentation with FBDS.
FBDS is a recently described immunotherapy-
responsive seizure disorder characterized by highly
stereotyped clinical features and the presence of auto-
antibodies to LGI1, a protein component of the
VGKC complex.2–4 Furthermore, FBDS is consid-
ered to be a highly specific phenotype and almost
pathognomonic for LGI1 autoantibody–mediated
disease.5,6 FBDS have also been recognized as a fre-
quent prodromal sign preceding LGI1 antibody lim-
bic encephalitis,5 a neuroinflammatory condition
characterized by a clinical triad of FBDS, cognitive
impairment, and hyponatraemia.6 The absence of
cognitive deficits at presentation with FBDS renders
it more likely that our patient was in the prodromal
phase prior to the onset of limbic encephalitis, which
is consistent with the absence of T2/fluid-attenuated
inversion recovery signal increase in the mesiotempo-
ral lobes typically seen in limbic encephalitis.7 In the
early stage of the illness, MRI demonstrated a non-
enhancing T1 hyperintensity in the right BG, typical
of what is observed in a sizeable proportion of patients
presenting with FBDS secondary to anti–LGI1 anti-
body encephalopathy. In a recent retrospective case
series of 26 patients with FBDS and positive serology
for LGI1 autoantibodies, 10 of these patients had the
novel finding of contralateral BG T1 hyperintensity,
thereby providing evidence for BG T1 hyperintensity
as a useful MRI biomarker of anti-LGI1 autoimmune
FBDS.2 Our patient also developed hyponatremia
(Na 122 mM), a common finding in FBDS and lim-
bic encephalitis.5–7
LGI1 antibody–mediated FBDS and limbic
encephalitis have been reported to show variable
response rates to immunotherapy, with most cases
reporting at least partial improvement of FBDS and
cognitive symptoms. Moreover, early initiation of
immunotherapy at the FBDS stage can prevent pro-
gression to limbic encephalitis.8 Our patient demon-
strated an initial good response of the FBDS to
combination immunotherapy and anticonvulsant
medication, with partial improvement in cognition,
before eventually manifesting inexorable intellectual,
behavioral, and gross motor decline almost certainly
due to co-occurrence of sCJD.
Occasional diagnostic confusion between CJD and
autoimmune encephalopathies is well-recognized.
Although positive VGKC complex (and in retrospect
LGI1) antibodies were present at the early stage of
our patient’s illness, there have been reports of elevated
VGKC complex antibody levels in patients with CJD,
albeit with no symptoms of FBDS or other evidence of
autoimmune encephalopathy, with subsequent uncer-
tainty about the significance of antibody levels in these
clinical situations.9 Further illustrating the diagnostic
challenges that can arise in the evaluation of patients
with neurologic illnesses with positive serology for
autoimmune encephalopathies, previous case series
have discussed autoimmune VGKC complex limbic
encephalitis (VGKCC-LE) as a mimic of CJD,10 with
patients initially thought to have CJD but later con-
firmed to have immunotherapy-responsive VGKCC-
LE, and conversely, CJD has been reported as a mimic
of VGKCC-LE11 and of Morvan syndrome associated
with elevated VGKCC and glycine receptor autoanti-
bodies.12 Our patient was somewhat different from the
usual clinical reports, manifesting a dramatic biphasic
illness punctuated by a period of incomplete recovery,
rather than a predominantly monophasic course, until
an accurate diagnosis was achieved. Development of
refractory cognitive and gross motor decline in our
patient prompted some uncertainty and reconsideration
of the diagnosis but was construed as probably reflecting
treatment-unresponsive LGI1 antibody encephalopathy
rather than representing the development of a second
neurologic illness such as sCJD, especially when there
was no definite objective investigational evidence to
clearly support such an alternative diagnosis.
The absence of inflammation in the brain at biopsy
and autopsy examinations is without definite explana-
tion but we conjecture most likely represents the effects
of immunosuppressant treatment in a patient who ap-
peared to have at least a partially responsive anti–LGI1
antibody encephalopathy. Recent reports of anti–LGI1
antibody encephalopathy are largely devoid of neuro-
pathologic findings.2,3,5,6,11
Our patient underscores the benefits of comprehen-
sive neuropathologic examination of the brain to achieve
an accurate diagnosis, especially in complex cases when
the clinical trajectory dramatically deviates and vigilance
for a concomitant disease is arguably the best approach
to explain the new clinical course. In addition, our
patient exemplifies the utility of recognizing BG T1 hy-
perintensity in patients with brief adventitious face and
limb movements suggestive of FBDS, which should
prompt investigation for VGKC complex antibodies
and in particular anti-LGI1 antibodies, which may be
responsive to immunosuppressive therapy.
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INTRODUCTION 
Creutzfeldt-Jakob disease (CJD) is a rare transmissible, neurodegenerative disorder with an annual 
incidence of approximately 1-2 per million population.1–3 CJD represents the most common 
phenotype of human prion disease,4 which can be sporadic (~85-90%), genetic (~10-15%) or 
acquired (<1%). Sporadic CJD (sCJD) typically presents as a rapidly progressive dementia associated 
with myoclonus and cerebellar ataxia with inexorable clinical decline resulting in death after a 
median survival of ~4-5 months.2–4 In addition to sCJD, the spectrum of human prion disease 
includes Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia. The detection of 
kuru in the 1950s established that prion diseases occur in Indigenous peoples albeit aetiologically 
linked to the culturally peculiar Fore practice of endocannibalism. Epidemiological studies of prion 
disease in specific ethnic groups are limited5 ; however, a global epidemiological survey revealed 
that CJD occurs worldwide,6 including Indigenous peoples from Oman and Papua New Guinea.7,8 
Indigenous Americans and Alaskans were later reported to also develop CJD.5  
Encompassed in the investigation of neurodegenerative disorders occurring in Indigenous Australian 
(Aboriginal and Torres Strait Islander) communities, including Huntington’s disease,9 spinocerebellar 
ataxia10 and early onset dementia,11 is the study of CJD and other forms of human prion disease. 
Systematic epidemiological studies of neurodegenerative disorders in Indigenous Australians can be 
problematic for reasons that include geographical remoteness from clinical services and socio-










cultural attitudes to medical evaluation, including performance of neuropathological studies. Herein, 
we selectively report for the first time, all ANCJDR ascertained cases of CJD in Indigenous 
Australians, highlighting a Western Australian Indigenous person dying from likely prion disease. This 
patient illustrates some of the potential challenges faced in the diagnosis and management of prion 
diseases in Indigenous Australians living in remote communities. Incidence rates, indirect age-
standardised mortality ratios and the clinical phenotype of sCJD in Indigenous Australians are 
compared  to non-Indigenous Australians from the ANCJDR database.12,13  
 
METHODS 
The ascertainment and classification of Indigenous (Aboriginal and Torres Strait Islander) and non-
Indigenous Australians with prion disease occurred as part of routine surveillance activities of the 
ANCJDR, employing updated case classification criteria.13  ANCJDR data and relevant population data 
from the Australian Bureau of Statistics (ABS)14,15 allowed estimation of crude annual incidence rates 
for specific reference years (2006, 2011 and 2016). In addition, indirect age-standardisation of all 
CJD to calculate the standardised mortality ratio (SMR) for the Indigenous Australian population in 
comparison to the all-resident Australian population was undertaken. Indirect age-standardisation 
was performed because case numbers for the Indigenous Australian population for the years 2006 
to 2018 were small rendering age-standardised mortality rates a less robust calculation. Indirect age-
standardised mortality ratios for the Indigenous population for the years 2006 to 2018 in 
comparison to non-Indigenous Australians represents the period during which Indigenous persons 
were diagnosed and classified as dying from sCJD. Due to the lack of resident Aboriginal and Torres 
Strait Islander population data by age group for the years 2017 and 2018, the 2016 estimate was 
used for these years. Indigenous ethnicity was as reported by the patient, family or caring medical 
practitioners. 










The ANCJDR is funded by the Commonwealth Department of Health and is responsible for the 
national surveillance of clinically suspected and confirmed human prion disease in Australia and is 
based at The Florey Institute, The University of Melbourne. ANCJDR surveillance activities are 
approved by The University of Melbourne Human Research Ethics Committee (ID# 1341074) to 
collect and monitor limited personal and health information from Indigenous and non-Indigenous 
Australians in relation to CJD and disseminate de-identified and aggregate data for reporting and 
research purposes; approvals were not obtained from other sources. Written permission to release 
additional data for publication was obtained for the illustrative case report. 
RESULTS 
Illustrative case report 
This patient was a 55-year-old male Indigenous Australian residing in a remote region of Western 
Australia at the time of illness onset. Approximately 6 weeks prior to admission, the patient 
developed progressive unsteadiness of gait associated with blurred vision, tinnitus, short-term 
memory loss and slurred speech.  He was a non-smoker, did not take illicit drugs or alcohol and 
there was no known family history of a neurodegenerative disorder. There was no past surgical 
history nor any history of blood transfusions or treatment with any other medical products. Upon 
admission to hospital gait was impaired but he was able to walk without assistance, his Mini-Mental 
State Examination score was 22/30, and he was intermittently confused with disorientation to year, 
month and day. He had left upper limb dysmetria. Rapid decline in cognition and gross motor 
function continued such that by approximately ten days after admission the patient was only able to 
provide one or two word answers,  was unable to stand independently and could not follow 
commands to allow a detailed neurological examination. Myoclonic jerks became evident in the 
upper limbs.  










A MRI scan revealed increased T2 signal with restricted diffusion in the left caudate nucleus and 
putamen, as well as the posterior cingulate gyrus on both sides, raising the likelihood of CJD. Routine 
CSF parameters were unremarkable with cytology negative for malignant cells; microbiological 
studies were negative for bacteria, viruses and fungi;  14-3-3 protein testing was positive. EEG five 
days after admission showed a non-specific excess of slower frequencies consistent with an 
encephalopathy while a repeat study at 12 days after admission showed diffuse periodic complexes 
at 1 hertz, strongly increasing the likelihood of CJD.  
A working diagnosis of probable sCJD and the attendant poor prognosis was explained to the family.  
It was the family’s preference that the patient be transferred for palliative care at “home and 
country”. The patient died with his family in his local community after an illness duration of 
approximately two months; the patient’s family declined an autopsy. 
Summary of ascertained CJD affecting Indigenous Australians 
As part of comprehensive, national surveillance, eight persons identified as Indigenous Australians 
have been classified as dying from sCJD by the ANCJDR (Table 1). Although dealing with a small 
number of Indigenous Australians with sCJD, basic demographic features are similar to the broader 
Australian population with a median age at death of 61 years (IQR=16 years) and median disease 
duration of 3 months (IQR=1.6 months). Two of the patients were known to share Irish, 
Scandanavian and English ancestry. The patients were geographically, widely dispersed across the 
continent spanning from South Hedland to the eastern seaboard. Definite CJD was confirmed 
through post-mortem neuropathological examination in five persons, while three cases (including 
the illustrative case report from Western Australia) fulfilled classification criteria for probable CJD. 
One patient presented with prominent visual symptoms in keeping with the Heidenhain sub-type of 
sCJD while the others presented with typical sCJD evincing rapidly progressive dementia 
accompanied by myoclonus. There was no family history of similar neurological illness in any of the 










eight Indigenous persons, with genetic testing performed in three patients showing codon 129 
methionine homozygosity and absence of disease-associated prion protein gene (PRNP) mutations. 
CSF 14-3-3 protein was positive in six of the eight patients tested. 
Using data from the ANCJDR and the ABS (populations based on three reference years 2006, 2011 
and 2016), we estimated overall crude annual rates of sCJD in Indigenous Australians compared to 
the remainder of the Australian population (after subtracting the number of Indigenous people): 0–
3.87 per million for Indigenous Australians and 0.94–1.83 per million for the remainder of the 
Australian population (Table 2). In addition, indirect age-standardisation was utilised to estimate a 
standardised mortality ratio for the Indigenous population for the years 2006 to 2018, representing 
the period in which Indigenous persons were diagnosed and classified as dying from sCJD. Using the 
ABS estimated populations for both resident Aboriginal and Torres Strait Islanders (2006-2016)16 and 
all-resident Australians (2006-2018),17 age-specific Australian mortality rates were used to calculate 
the number of Indigenous CJD cases expected if the Indigenous population had the same age-
specific mortality rates as the entire Australian population.  Compared to the eight observed 
Indigenous cases, the overall number of expected CJD cases was calculated to be 5.37, giving a ratio 
of 1.49 (95% CI, 0.75 - 2.98). Although, this suggests a 50% excess of observed cases compared to 
the expected number in the Indigenous Australian population, the wide confidence interval range 
encompassing 1.0 renders this result not statistically significant. 
DISCUSSION 
The present study re-confirms that CJD occurs in Indigenous populations, with the overall features of 
the eight Indigenous Australians in keeping with sCJD, which appears phenotypically in keeping with 
sCJD occurring in non-Indigenous persons with similar geographical dispersion and incidence rates. 
Uniformity of phenotype and rates of occurrence for sCJD is well recognised across non-Indigenous 
populations.18 Our illustrative patient is the first known Indigenous Australian from that particular 










remote region of Western Australia to be diagnosed with probable sCJD, dying approximately two 
months after the onset of symptoms with a typical clinical picture of rapidly progressive dementia, 
ataxia and  myoclonus, positive 14-3-3 protein in the CSF and characteristic MRI and EEG findings. 
Although permission for post-mortem confirmation is commonly sought for persons suspected to be 
manifesting CJD, including in this patient, families not infrequently decline for various reasons 
including cultural, religious and personal preference. This rare neurodegenerative cause of death in 
Indigenous Australians stands in contrast with their much more common causes of death, most of 
which  relate to ischaemic heart disease, diabetes mellitus, chronic lung diseases, lung cancer and 
self-harm.19,20   
Sporadic CJD has also been reported amongst Indigenous North Americans and Alaskans with 12 CJD 
deaths recorded from 1981 until 2002, with an annual age-adjusted mortality rate of 0.47 per million 
population – possibly lower than for Caucasians but close to that reported for African Americans.6 
Potential difficulties with case ascertainment and diagnosis related to remote residence, as well as 
the possibility of problems obtaining autopsy because of cultural and other influences were 
described in relation to these Indigenous populations,5 and these factors may have contributed to 
the absence of confirmed CJD in Indigenous Australians prior to 2006. This year delineates when CJD 
became a notifiable disease across all Australian states and territories. Presumably this or other 
factors mitigated any previous impediments up to around 2006 allowing detection and confirmation 
of CJD in Indigenous Australians at rates broadly comparable to non-Indigenous Australians.  Our 
estimated crude incidence rates and indirect age-standardised mortality ratios for CJD in Indigenous 
Australians since 2006 are equivalent to rates in the non-indigenous population. Overall, and in 
contrast with the findings of Maddox and colleagues suggesting a lower incidence in Indigenous 
North Americans and Alaskans than in Caucasians,21 it appears unlikely there are significant 
differences between the rates of CJD in Indigenous and non-Indigenous Australian populations.  










One important limitation of this study is the small number of patients included. This renders 
incidence rates potentially fragile to the effects of only a small change in detected absolute case 
numbers. As such, although we found the rate of CJD in Indigenous Australians was not different to 
the non-Indigenous population, a small increase in CJD cases could engender a relatively marked 
effect. All Indigenous CJD patients were from regional Australia and under-recognition of Indigenous 
CJD cannot be excluded where it is possible some doctors might not be aware that prion disease 
occurs in Indigenous people and furthermore health workers might not have easy access to 
diagnostic tools such as MRI or CSF biomarker analysis. Of some reassurance however, five out of 
the eight Indigenous patients had autopsy confirmation of CJD, which approximates the proportion 
of definite confirmation in the non-Indigenous population and thereby militates against undue 
concerns regarding difficulties in achieving adequate medical evaluation of suspected CJD in 
Indigenous patients from remote regions. Another limitation of our study was the lack of uniformity 
or consensus regarding the definition of Indigenous, which was based on self, family, or practitioner 
reporting. Given this lack of a definition and our limited understanding of the level of awareness and 
the attitudes of individuals regarding identification as Indigenous or not, our study is at risk of 
potential under- or over-reporting of CJD in Indigenous Australians. These limitations underscore the 
importance of maintaining awareness of CJD amongst practitioners, especially general practitioners 
and general physicians servicing Indigenous Australians in remote regions, to ensure high quality 
national surveillance and accurate incidence rates are achieved. 
In conclusion, we confirm that prion disease in the form of sCJD occurs in geographically dispersed 
Indigenous Australians, with the overall incidence rate and phenotype approximating that observed 
in non-Indigenous Australians. In combination with previous epidemiological studies, it appears 
likely that all human populations, regardless of genetic background and residential location, are 
susceptible to the pathophysiological disturbances culminating in prion disease.22 
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Table 1.  Creutzfeldt-Jakob disease in Indigenous Australians* 
 





ANCJDR Classification CSF 14-3-3 result 
2006 F 67 3 Definite NT 
2006 M 48 8 Definite Positive 
2007 F 61 6 Definite Positive 
2009 M 58 1.3 Definite Positive 
2011 F 80 3.8 Definite Positive 
2011 F 71 3.5 Probable Positive 
2015 M 61 2.3 Probable NT 
2018 M 55 2.2 Probable Positive 
 
 
NT = not tested. 
* Ethics approval was granted from the NH&MRC to collect and disseminate this information.
 










Table 2: Crude annual rates of sporadic Creutzfeldt-Jakob diseases in Indigenous and non-Indigenous Australians. 
 
 INDIGENOUS NON-INDIGENOUS 
Year Population CJD cases CJD rate Population CJD cases CJD rate 
2006 517,043 2 3.87 20,180,837 37 1.83 
2007 549,234 1 1.82 20,478,698 27 1.32 
2008 577,366 0 0.00 20,776,559 34 1.64 
2009 605,499 1 1.65 21,074,421 30 1.42 
2010 633,631 0 0.00 21,372,282 29 1.36 
2011 669,881 2 2.99 21,670,143 36 1.66 
2012 689,895 0 0.00 21,968,004 32 1.46 
2013 718,027 0 0.00 22,265,865 25 1.12 
2014 746,160 0 0.00 22,563,727 27 1.20 
2015 774,292 1 1.29 22,861,588 29 1.27 
2016* 798,365 0 0.00 23,392,542 22 0.94 
2017 830,556 0 0.00 23,690,403 
2018 858,688 2 2.33 23,988,264 
 
* provisional figure
Estimated population based on three referenced years reported by ABS in 2006, 2011 and 2016.
 










Section 6: Prion Disease Treatment Studies 
Without doubt the most important unmet need in relation to human prion diseases is the lack of 
an effective, disease modifying treatment. There is muted excitement in the neurological 
community about the emergence of efficacious therapeutics for some neurodegenerative 
diseases such as Spinal Muscular Atrophy (SMA), Huntington’s Disease (HD) and probably 
Alzheimer’s disease. To date, numerous potential therapeutics have been trialed in pre-clinical, 
including animal, models of prion disease with very limited or no efficacy demonstrated if 
deployed late in the incubation period or around the time of onset of clinical disease. Further, 
there have only been a handful of formal human clinical trials (of varying quality) reported to 
date, involving flupirtine, quinacrine and doxycycline with little or no meaningful benefit 
displayed. A post hoc observational report of pentosan polysulphate utilized in a very small 
vCJD cohort suggested possible benefit of prolonged survival (albeit in a vegetative state) but 
required the onerous delivery mechanism of sustained intra-cerebro-ventricular delivery. 
Despite this rather disappointing history of treatments for prion disease, there is a quietly 
renewed optimism around the prospect of application of the therapeutic approach of ASOs 
successfully utilized in SMA and HD being applied to prion disease, especially for genetic prion 
disease in the first instance.  
As a corollary to the likely role of heightened oxidative stress and the possible contribution from 
transition metal dys-homeostasis to prion pathogenesis, in addition to further exploring the 
therapeutic potential of quinacrine in an in vivo model, my research also assessed an anti-
oxidant and a chelator as candidate therapeutics in our rodent model. Disappointingly, our 
studies added to the literature of little or only marginal efficacy if utilized very early in the 
incubation period, with the latter only of potential clinical relevance therefore to genetic prion 
disease given the only prospect for deployment of therapies in sCJD is after the onset of clinical 
disease.    
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Quinacrine Does Not
Prolong Survival in a
Murine Creutzfeldt-Jakob
Disease Model
Steven J. Collins, MD,1 Victoria Lewis, BSc (Hons),1
Marcus Brazier, BSc (Hons),1 Andrew F. Hill, PhD,1
Ashley Fletcher, BSc,2 and Colin L. Masters, MD1
Paramount among issues relating to the transmissible
spongiform encephalopathies (also known as prion dis-
eases) is the absence of any effective therapy. This need
has been heightened by the substantial European and
emerging global problem of bovine spongiform encepha-
lopathy and consequent variant Creutzfeldt-Jakob dis-
ease. Stimulated by the recent reports of a potent an-
tiprion effect in cell culture–based clearance assays, we
studied the utility of quinacrine in a well-characterized in
vivo model of mouse-adapted transmissible spongiform
encephalopathy. Our results failed to show any evidence
that quinacrine is effective when using the simple but ob-
jective measure of survival prolongation.
Ann Neurol 2002;52:503–506
Creutzfeldt-Jakob disease (CJD) is the most common
human phenotype of the transmissible spongiform en-
cephalopathies (TSEs), a group of invariably fatal neu-
rodegenerative diseases, which also affect animals.1
CJD typically presents as a rapidly progressive demen-
tia, often accompanied by cerebellar ataxia and myoc-
lonus, with inexorable deterioration to death in less
than 1 year. Until recently, TSEs were considered rare,
with comprehensive ascertainment studies of classic
CJD confirming an annual incidence of approximately
one case per million population. The substantial Euro-
pean epidemic, and emerging global problem of bovine
spongiform encephalopathy (BSE) and consequent
variant CJD (vCJD), has necessitated revision of this
attitude. First reported in 1996,2 final case loads of the
vCJD remain uncertain, but despite recent downward
revisions based on modeling studies, total numbers are
still likely to reach several hundreds to thousands over
the coming years.3,4 These developments have under-
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scored several exigencies in relation to prion diseases
not the least of which is the complete absence of clin-
ically appropriate, effective therapy.
A few compounds, including anthracyclines, ampho-
tericin B, polyanions, and cyclic tetrapyrroles, have
been shown in animal studies to have modest antiprion
efficacy by prolonging survival, but only if delivered at
approximately the time of, or exposed to the chemical
from shortly after, inoculation.5–9 Direct application of
these agents to human therapy is quite limited for sev-
eral reasons, including unacceptable toxicity and the
limited ability of the compounds to cross the blood–
brain barrier, although the latter would not preclude
prophylactic use in situations relating to peripheral in-
oculation. Reinforcing the findings of a prior in vitro
study,10 and based on a technique previously used to
examine the antiprion effects of branched polyamines11
and sulfated polyanions,12 interest in the acridine de-
rivative quinacrine recently was strengthened consider-
ably by the report that the lysosomotropic compound
could rapidly eradicate production of the disease-
associated, protease-resistant isoform of the prion pro-
tein (PrPsc) in stably infected murine neuroblastoma
(N2a) cell cultures.13 Quinacrine, an antimalarial drug,
has been used in humans for many years with known
and acceptable biosafety, and the agent also has the
ability to cross the blood–brain barrier.13 Given the
rapidly progressive and invariably fatal outcome of
CJD, it was promptly used on compassionate grounds
in two such patients with initially encouraging results
in at least one patient and a large human treatment
trial of these agents is planned.14
Prompted by these reports, we studied the efficacy of
quinacrine, the most potent antiprion agent in the
neuroblastoma cell culture–based PrPsc clearance as-
says10,13 in a well-characterized in vivo model of
mouse-adapted CJD.
Materials and Methods
Animal handling and killing were in accordance with na-
tional prescribed guidelines, with ethical approval for the
study granted by the University of Melbourne. Three groups
of eight weanling Balb/c female mice were inoculated intra-
cerebrally (into the left parietal region) with 30l of a 101
dilution (final concentration in phosphate-buffered saline) of
brain homogenate pooled from mice confirmed as dying
from a spongiform encephalopathy. The inoculum was pre-
pared by passing through successively higher gauge needles
(to 26 gauge) and was not centrifuged before use. All mice
were gavage fed 5 days per week and received routine hus-
bandry with food and water available ad libitum. Group 1
served as controls and only received deionized water starting
from day 5 postinoculation (PI). Group 2 commenced ga-
vage feeding with quinacrine dihydrochloride (Sigma, St.
Louis, MO), 10mg/kg/day in deionized water, from day 5 PI
(early treatment group), whereas Group 3 received the same
dose of drug from day 65 PI (late treatment group), approx-
imating the midpoint of the incubation period. Groups 2
and 3 both received a loading dose of 20mg/kg of quinacrine
on their first day of gavage feeding. The relatively high but
therapeutically relevant treatment dose of 10mg/kg/day of
quinacrine was chosen to allow the best opportunity to dem-
onstrate any beneficial effects.
Mice were inspected daily for signs of TSE, which in-
cluded apathy, diminished activity, hunched posture, weight
loss, paretic hind legs, and loss of righting reflex and were
killed when persistence and progression of these features were
clearly evident (usually after a few days). Disease transmis-
sion was confirmed by the presence of proteinase K–resistant
PrP in the brains of mice by Western immunoblot and evi-
dence of typical spongiform changes in the cerebrum on rou-
tine histological examination. The log-rank test for equality
of survival was used to compare treatment groups, with p
value less than 0.05 considered significant.
Results
Quinacrine appeared well tolerated by the mice with
the two incidental losses appearing directly related to
the effects of gavage feeding, occurring in Groups 2
and 3, at days 43 and 67 PI, respectively. The brains of
these mice were not examined. The mean survival of
Group 1 was essentially identical to Groups 2 and 3 as
summarized in the Table. The Figure presents an over-
view of survival, with the log-rank test for equality of
survivor functions showing no significant difference be-
tween the treatment groups (p  0.99). In addition,
neuropathological examination and Western immuno-
blots for protease-resistant PrP did not show any con-
sistent intergroup differences between the brains of the
mice (data not shown).
Discussion
Our results therefore failed to show any evidence that
quinacrine offers benefit when using the simple but ob-
jective measure of survival prolongation in an in vivo







Group 1/no treatment 140 
 6.8 8/8
Group 2/early treatment 140 
 7.3 7/7
Group 3/late treatment 140 
 10.8 7/7
SD  standard deviation.
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model of mouse-adapted CJD. This was somewhat un-
expected given that previous studies of Congo
Red,15,16 selected sulfated polyanions,12,17 and certain
tetrapyrroles5,18 have demonstrated reasonably good
concordance between in vitro antiprion potency (using
cell-based assays of the inhibition of PrPsc production
or its enhanced clearance) and their in vivo efficacy in
animal studies. The reasons for such lack of correlation
for quinacrine are unknown but are unlikely to relate
to the inability to penetrate the blood–brain barrier, as
suggested for the poor therapeutic effects of sulfated
polyanions when used late in the incubation phase of
rodent TSE models.12,18 Notwithstanding the good
ability of quinacrine to reach central nervous system
neurons, a speculative explanation for the lack of ther-
apeutic efficacy in our study could relate to the mode
of inoculation, with the possibility that benefit may
have been conferred if a peripheral transmission route
were used.
Although our results do not lend any support for
quinacrine antiprion efficacy in the more complex set-
ting of in vivo treatment, they do not completely pre-
clude the possibility of a positive effect in human trials.
Variations in beneficial effects, apparently correlating
with prion strains, have been reported with in vitro
PrP clearance assays using the branched polyamine
polypropyleneimine,11 and also in animal studies using
the polyene antibiotic amphotericin B.7 Hamsters in-
oculated with the 263K strain of scrapie showed pro-
longed survival when treated with amphotericin B,
whereas these animals and Swiss mice showed no
lengthening of the incubation period if infected with
the 139H strain of scrapie.
Included in our study design were early and late
treatment groups, with the latter starting quinacrine 65
days after inoculation, approximating the midpoint of
the incubation period and more closely simulating the
authentic clinical situation in which treatment is un-
likely to commence until the onset of symptomatic dis-
ease. Even those animal studies demonstrating a bene-
ficial survival effect when compounds were used at, or
from soon after, inoculation have failed to show effi-
cacy when treatment was significantly delayed.5 This
further underscores current therapeutic limitations, be-
cause there are currently no reliable, minimally inva-
sive, preclinical diagnostic screening tests to facilitate
early treatment.
A limitation of the current study is that it did not
address to any extent, potential mechanisms or path-
ways subserving disease pathogenesis, which could have
given greater insights into the failure of quinacrine’s
therapeutic effect, as well as provide possible contrast
with the findings of the in vitro studies. Nonetheless,
correlating with the lack of efficacy seen for survival
prolongation, there was no consistent difference in the
cerebral neuropathological findings or brain PrPsc levels
between the three groups of mice, which stands in clear
contrast with the potent ability of quinacrine to erad-
icate PrPsc from stably infected mouse neuroblastoma
cells. The outcome of trials of quinacrine and chlor-
promazine use in human TSE is awaited with great in-
terest.
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Cree leukoencephalopathy is a rapidly fatal infantile au-
tosomal recessive leukodystrophy of unknown cause ob-
served in the native North American Cree and Chippe-
wayan indigenous population. We found in the brain of
affected individuals the typical foamy cells with the oli-
godendroglial phenotype described in central hypomyeli-
nation syndrome/vanishing white matter, a syndrome re-
lated to mutations in the genes encoding the five
subunits of the eucaryotic translation initiation factor
eIF2B. In three patients of two Cree families, we found a
homozygous missense mutation resulting in a histidine
substitution at arginine 195 of -eIF2B.
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An infantile leukoencephalopathy among the native
Cree and Chippewayan indigenous population in
Northern Quebec and Manitoba was first described in
1988.1 The onset of Cree leukoencephalopathy (CLE)
is between 3 and 9 months of age with death in 100%
by 21 months of age. Hypotonia often is noted in early
infancy followed by relatively sudden onset of seizures,
spasticity, hyperventilation, vomiting, and diarrhea, of-
ten in the setting of a febrile illness. Onset is followed
by developmental regression, lethargy, blindness, and
cessation of head growth seen as flattening of the head
circumference curve.1 Computerized tomography of
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Animal models, and human postmortem studies, of prion disease have demonstrated the presence of
heightened oxidative stress in the brain, with additional findings supporting the likelihood that the normal
isoform of prion protein directly contributes to neuronal antioxidant defences. Although such data are
consistent with the postulate that oxidative stress plays a salient pathogenic role in prion disease, it remains
possible that oxidative damage represents a secondary or relatively less important phenomenon in neurons
already rendered dysfunctional from other primary insults. To provide further insights into the relative
pathogenic importance of oxidative stress, we employed a potent manganese-superoxide dismutase/catalase
mimetic, EUK-189, as a therapeutic in our mouse model of human prion disease. A significant but relatively
modest prolongation of survival in EUK-189-treated mice was observed, which correlated with reductions in
oxidative, especially nitrative, damage to proteins when compared to untreated disease controls. Lesion
profiling also revealed reductions in spongiform change in specific brain regions of terminally sick EUK-189-
treated mice. Our results are consistent with heightened oxidative stress playing a pathogenic role in prion
disease but underscore the need for more biologically potent and, most likely, broader spectrum antioxidant
treatments if more successful amelioration is to be achieved.
© 2008 Elsevier Inc. All rights reserved.
Introduction
Transmissible spongiform encephalopathies (TSE), also known as
prion diseases, are a group of neurodegenerative disorders that affect
humans and animals. Human forms of TSE include Creutzfeldt-Jakob
disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and
fatal familial insomnia while scrapie of sheep and goats, bovine
spongiform encephalopathy and chronic wasting disease of deer, elk,
and moose constitute the main animal forms of the disease. A central
event in the pathogenesis is conversion of the normal or cellular form
of the prionprotein (PrPc), a glycosylphosphatidylinositol-membrane-
anchored glycoprotein, into a β-sheet rich, protease-resistant isoform,
termed PrPres. Typical neuropathological features of TSE consist of
vacuolation of the neuropil, astrocytic gliosis, neuronal loss, and
extracellular deposition of PrPres in the form of plaques (reviewed in
[1]).
Recent data from different laboratories suggest that PrPc may be a
component of cellular antioxidant defence systems, although contra-
dictory findings have been reported [2]. Wong et al. [3] detected a
reduction of total superoxide dismutase (SOD) activity in normal brain
homogenates after immuno-depletion of PrPc while Cu/Zn-SOD and
Mn-SOD activities remained unchanged when compared to nonde-
pleted homogenates. Similarly, brain homogenates from prion protein
knockout (PrP%) mice have been shown to have lower total SOD ac-
tivity, although greater Mn-SOD activity when compared to wild-type
mice [4]. In cell culturemodels, neurons devoid of PrPc expressionhave
been shown to have an increased sensitivity to superoxide anions [5],
hydrogen peroxide [6] and manganese [7] and copper toxicities [8]
when compared to controls. Wong et al. [9] also compared immuno-
purified total PrP from terminal scrapie-infected mouse brains to
controls and found that PrP preparations from controls possessed 10
times the total SOD activity compared with those isolated from
diseased brains. This finding is consistent with PrPc having a SOD-like
function and that the disease-associated conformational change of
PrPc to the PrPres isoform results in the loss of this function, or that
PrPres and/or other cellular changes during infection inhibit the SOD-
like activity of PrPc [10]. At neutral pH, within Cu/Zn-SOD enzymes,
Free Radical Biology & Medicine 45 (2008) 184–192
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copper can oscillate between the +1 and +2 valence states which is an
important component of the catalytic activity during the dismutation
of superoxide molecules. Similarly, the SOD-like activity of recombi-
nant PrPc has been reported to depend on copper [11] and it is note-
worthy that the putative dismutase activity of PrPc has been shown to
decrease contemporaneously with the release of bound copper during
the progress of experimental mouse models of prion disease [12].
Recent studies also suggest that PrPc may influence normal mito-
chondrial, particularly antioxidant, function. Using PrP% mice, Miele
et al. [13] demonstrated diminished brain mitochondria with
abnormal morphology and the mitochondria of these mice were
shown to contain elevated, possibly compensational, levels of Mn-SOD
protein and enzymatic activity. Further, mitochondrial preparations
from transgenic PrPc-overexpressingmice have been demonstrated to
contain decreased Mn-SOD activity [14] supporting the notion that
PrPc may be involved in reciprocal mitochondrial antioxidant acti-
vities. The authors also showed that, as the PrPc-overexpressing mice
age, they develop a spontaneous neurological dysfunction concomi-
tant with an abnormal mitochondrial localization of PrPc when com-
pared to wild-type controls. The precise relevance and relative
importance of all these observations to in vivo TSE pathogenesis is
incompletely resolved but as a corollary there is considerable evidence
for heightened oxidative stress during the course of prion disease
[9,15–21].
Arguably the most consistent alterations observed in rodent mo-
dels of prion disease directly assessing oxidative stress are diminished
SOD (Cu/Zn-SOD or Mn-SOD) or SOD-like activity [9,12,18,21] and
heightened lipid peroxidation [9,15,16,18,21]. Similar changes have
been detected in the brains of patients dying from sporadic CJD [22].
Additional direct support for a relative or absolute insufficiency of SOD
activity in prion disease was shown in the study of Lee et al. [18], with
brains of mice infected with 87V scrapie prions showing a doubling of
the production rate of the superoxide radical compared to control
mice. Although various biochemical mechanisms of lipid peroxidation
are recognised, the presence of this form of oxidative stress suggests
the likelihood of hydroxyl radical generation, and possibly the direct
involvement of transition metal complexes causing decomposition of
preformed lipid hydroperoxides [23]. Less frequently described types
of brain damage in in vivo models and studies of human prion disease
include oxidation of proteins [9,19,22], and nucleic acids [20,24], as
well as changes supporting increased nitrative damage [9,17,19]. The
role of hydrogen peroxide in the oxidative stress of TSE is unclear as
production rates have not been directly assessed; unfavourable
changes in central nervous system (CNS) catalase activity have not
been described [18,21], while brain glutathione peroxidase activity
has been reported to be increased [21], decreased [9], or unchanged
[18]. Collectively, the aforementioned data are consistent with the
principle that increased reactive oxygen and nitrogen species occur in
TSE, probably accompanied by a decrease in antioxidant defences
(including mitochondrial), causing heightened oxidative damage to
the brain, and thereby are a major or significant contributor to patho-
genesis in both prion-infected experimental animals and human
patients.
Eukarion salen-manganese complexes, such as EUK-8, EUK-134,
and EUK-189, have been shown to act as SOD and catalase mimetics,
demonstrating activity against both oxidative and nitrative stresses
[25] with varying levels of antioxidant capacity [26–28]. In addition to
their ability to extend the life span of Caenorhabditis elegans [29], this
group of synthetic catalytic antioxidants has been shown to be
protective in a wide variety of in vitro [30,31] and in vivo models
manifesting heightened oxidative stress [32–40]. Animal models of
multiple sclerosis [32], amyotrophic lateral sclerosis [33], ischemic
brain injury [34], excitotoxic neuronal damage [36], ataxia telangiec-
tasia [37], Parkinson's disease [38], and age-associated cognitive
impairment [39] have all shown benefit from therapeutic adminis-
tration of Eukarion SOD/catalase mimetics, specifically showing re-
duction in protein oxidation [33,39], lipid oxidation [33,37,39], protein
nitration damage [33,36], and oxidative change in nucleic acids [39].
More recently, EUK-189 was shown to reduce cataract incidence in
aging Tg2576 mice which model Alzheimer's disease [40]. Of par-
ticular interest was a study using EUK-189, in which the devel-
opment of brain vacuolation was prevented in a Mn-SOD knockout
(Mn-SOD%) mouse model [28]. When Mn-SOD% mice (a lethal phe-
notype) were treated with a peripherally acting SOD mimetic, man-
ganese 5,10,15,20-tetrakis (Mn-TBAP), they survived beyond 2 weeks
of age but developed a free radical-mediated spongiform encephalo-
pathy [41] reminiscent of the neuropathological changes observed in
TSE. Treatment with EUK-189 from 3 days of age significantly ex-
tended the life span of Mn-TBAP-treated Mn-SOD% mice and was
shown to completely prevent the development of spongiform change.
In all animal models where the therapeutic activity of EUK
antioxidants takes place within the CNS [32–40], it is to be stressed
that the drugs were always administered peripherally attesting to
their ability to effectively cross the blood–brain barrier.
Acknowledging the reported deficiency of SOD and SOD-like
activity in prion disease, as well as the considerable overlap in the
type of oxidative damage observed in TSE and that which is effectively
ameliorated by the Eukarion salen–manganese complexes in other
models, we undertook a study of the therapeutic efficacy of EUK-189
in ourwell characterisedmousemodel of humanprion disease [15]. To
the best of our knowledge, the present study is the first trial of a
primarily antioxidant compound as therapy in an animal model of
prion disease. Daily intraperitoneal (ip) administration of EUK-189
was found to significantly extend the incubation period, reduce
nitrative and oxidative damage to proteins, and selectively reduce the




Animal handling and sacrifice were in accordance with national
prescribed guidelines with ethical approval for the study granted by
the University of Melbourne Animal Ethics Committee. Thirty-five
female weanling Balb/c mice were inoculated with M1000 prions, a
mouse-adapted strain originally isolated from a patient most likely
dying from GSS [42]. Each mouse was inoculated intracerebrally (ic),
as previously described [15,43], with 30 μl of a 0.0001% (w/v in PBS)
diseased mouse brain homogenate (8.9×107 ID50 units/g brain).
Twenty mice were treated with EUK-189 (Proteome Systems, MA)
and 15 served as untreated disease controls. Five EUK-189-treated and
five disease controls were euthanised at 100 days postinoculation
(dpi) to comparatively assess early neuropathological changes, PrPres
levels, and oxidative damage. Remaining mice were euthanised after
displaying persistent symptoms of prion disease, including hind limb
Fig. 1. Chemical structure of manganese (III)-N,N′ ethylenebis-(2-ethoxysalicylidenei-
mine) acetate (EUK-189). EUK-189 contains ethoxy groups at the 3,3′ positions of its
salen rings making it considerably more lipophilic than precursor analogs.
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paresis and loss of righting reflexes. For biochemical assessments of
brain oxidative damage, 8 additional age/sex-matched noninoculated
Balb/c mice, 4 for each time point, were also included, serving as naïve




acetate (EUK-189) (Fig. 1), synthesized as described previously [35],
was stored in a desiccation chamber as a dry powder and solubilised in
deionised water once aweek tomake aweekly working stock of 6 mM
solution, which was stored at 4°C. Mice were administered 200 μl,
equating to 30 mg/kg [28], by ip injection 7 days per week beginning
at 7 dpi.
Biochemical assessments of oxidative damage
For biochemical assays, brain tissue from each of four mice in the
untreated disease control and EUK-189 treatment groups at both
100 dpi and terminal disease, as well as the appropriate age/sex-
matched naïve controls, was individually homogenised to 10% (w/v) in
cold PBS containing 5 mM BHT, and stored at –80°C prior to analysis.
Lipid peroxidation
Aliquots were analysed in duplicate for freemalondialdehyde (MDA)
and hydroxyalkenals (HAE), aldehydic breakdown products of lipid
peroxidation, using theBioxytechLPO586 (Oxis,OR) colorimetric assayas
per the manufacturer's instructions and described previously [15].
Protein nitration
Aliquots of BHT-containing brain homogenates were analysed in
duplicate for protein nitration using the Bioxytech enzyme immu-
noassay for nitrotyrosine (NT) (Oxis). Briefly, antigens were captured
using anti-NT monoclonal antibody-coated 96-well plates and
detected with biotin-labeled polyclonal anti-NT sera and streptavi-
din-conjugated peroxidase. Tetramethylbenzidine was employed as a
chromogen whose yellow activated product was detected by measur-
ing absorbance at 450 nm.
Protein carbonylation
Protein carbonylation (pCO) was assessed using the OxyBlot protein
oxidation detection kit (Chemicon International, CA). Duplicate aliquots
of brain homogenate were denatured in 12% SDS and then protein
carbonyl groups were derivatised with 2,4-dinitrophenylhydrazine to
generate 2,4-dinitrophenylhydrazone (DNP) moities. Homogenates
were then subjected to Western immunoblot and DNP moities were
detected with anti-DNP primary antibody and HRP-conjugated second-
ary antibody. Densitometric quantification of Western blots was
performed using a LAS-3000 (Fujifilm, Tokyo, Japan) and Multi Gauge
software (Fujifilm). To enable comparison of the treatment group and
controls between separate blots, all bands were normalised to an
internal BSA standard with attached DNP residues.
Fig. 2. Survival curves comparing M1000-infected mice treated with EUK-189 to
untreated disease controls. At each time point when mice were euthanised, the
percentage of mice surviving in that group is plotted against days postinoculation (dpi).
The mean survival period of the EUK-189-treated group was significantly longer than
the untreated control group (log-rank test P=0.032; t test P=0.046). □, untreated
disease controls; ♦, EUK-189-treated group.
Fig. 3. Biochemical assays performed to determine the oxidative status of brains of EUK-
189-treated compared to both untreated M1000-inoculated mice at 100 days
postinoculation (dpi) and at the terminal stage of disease, as well as age/sex-matched
uninoculated controls. At 100 dpi, brains from the treated group were demonstrated to
contain nonsignificant reductions in nitrated protein tyrosine (NT) residues (A), protein
carbonyl (pCO) moities (B; expressed as relative arbitrary densitometric units of protein
carbonylation), and aldehydic lipid breakdown products (C) in comparison with the
untreated disease group. For NT (A), levels at the terminal stage of disease in untreated
disease controls were similar to the amounts observed in uninoculated naïve controls
and to those recorded in untreated disease controls at 100 dpi, with this form of
oxidative damage significantly reduced in EUK-189-treated mice at completion of the
experiment in comparison with both untreated disease (⁎P=0.019) and naive controls.
Total pCO (B) was not significantly different between treated and untreated inoculated
mice at the terminal stage of disease, with total pCO in treated mice remaining
significantly above that found in naive controls; however, compared to the total pCO
levels observed in untreated diseased mice at 100 dpi, pCO levels in untreated diseased
animals became significantly higher (P=0.03) by the completion of the experiment,
while total pCO in EUK-189-treated animals did not show a significant further increase.
Free MDA/HAE (C) was not different between disease controls and EUK-189-treated
mice at the terminal stage, with levels similarly reduced in both groups when compared
to those found inmice culled around themid-incubation point, as well as in comparison
to the naïve group. , naïve controls;□, untreated disease controls;■, EUK-189-treated
group.
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Histology and immunohistochemistry
Brains were quickly removed and sagittally hemisectioned with
one half-brain fromeach untreated disease control or EUK-189-treated
mouse immersion fixed in 10% neutral buffered formalin. Fixed tissue
was treatedwith 99% formic acid for 1 h at room temperature to reduce
tissue infectivity before paraffin embedding. Mounted brain sections
from all groups were stained with hematoxylin and eosin (H&E) for
histological analyses with adjacent serial sections utilised for immu-
nohistochemical detection of PrPres plaque burden and astrocytic
gliosis as previously described [15]. The anti-PrPmonoclonal antibody,
ICSM18 (generous gift fromProf J. Collinge), was applied at a dilution of
1:500 and anti-GFAP polyclonal sera (DAKO) was applied at 1:50.
Lesion profiles
To generate lesion profiles [44], sagittal sections of half-brains from
untreated disease control and EUK-189-treated mice were visually
graded for the severity of the various pathological changes including
vacuolation, astrocytic gliosis, and PrPres plaques over eight brain
regions: (1) hippocampus, (2) thalamus, (3) occipital lobe, (4) parietal
lobe, (5) frontal lobe, (6) cerebellum, (7) basis pontis, and (8) caudate/
putamen. Grading of EUK-189-treated (n=6) and untreated disease
control (n=8) tissue sections were performed blinded to the treat-
ment status of themice, with reproducibility of scoring confirmed by a
second blinded scoring examination. Lesion severity was scored using
a 9-point grading system ranging from 0 to 4, the latter representing
the most severe extent of lesion incidence that could be observed at
the terminal stage of disease.
Western immunoblot analysis
For Western immunoblot analysis, half-brains from untreated
disease control and EUK-189-treated mice were quickly frozen and
then stored at -70°C until use. Western immunoblotting for PrPres
was performed as previously described [15] using ICSM-18 mono-
clonal antibody at a 1:25,000 dilution. To assess equivalence of protein
loading across the gel, undigested aliquots of the same brain ho-
mogenates were Western-immunoblotted utilizing anti-β-tubulin
monoclonal antibody (Sigma, Castle Hill, Australia) at a 1:15,000
dilution. Horseradish peroxidase-labeled band quantification was
performed as described above, using a LAS-3000 and Multi Gauge
software. PrPres levels in the two groups (n=3 in each group) were
Fig. 4. Lesion profiles of brain vacuolation inM1000-infectedmice treatedwith EUK-189
compared to untreated disease controls at 100 days postinoculation (dpi; A) and at the
terminal stage of disease (B). Hematoxylin and eosin-stained sagittal sections of half-
brains were visually graded for the severity of spongiform change (vacuolation) in 8
brain regions: (1) hippocampus, (2) thalamus, (3) occipital lobe, (4) parietal lobe,
(5) frontal lobe, (6) cerebellum, (7) basis pontis, and (8) caudate/putamen. Lesion
severitywas scored using a 9-point grading system ranging from 0 to 4 and themeans of
each group plotted for each region. At 100 dpi there were minimal pathological changes
and no difference between EUK-189-treated mice and untreated controls, whereas a
significant reduction in the hippocampus was observed in treated mice at the terminal
stage of disease (P=0.0051). □, untreated disease controls; ♦, EUK-189-treated group.
Fig. 5. Photomicrographs displaying spongiform change in the brains of EUK-189-treated and untreated disease mice. Sagittal brain sections were stained with hematoxylin and eosin
for morphological examination. In M1000-inoculated mice that were euthanised at 100 days postinoculation (dpi), there was only minimal spongiform change regardless of
treatment (A,B,E,F). Mice treated with EUK-189 had significantly less vacuolation in the hippocampus (C) and a clear trend to reduced spongiform change in the thalamus (G) at the
terminal stage of disease when compared to untreated controls (D and H, respectively). Original magnification 200×, arrows highlight vacuoles; asterisks highlight the dentate gyrus.
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compared at both 100 dpi and at terminal disease after adjustment for
protein loading, using separate but duplicated immunoblots.
Statistical analysis
Incubation period data were analysed for statistical significance by
Student t test and log-rank test using GraphPad Prism software
(GraphPad Software CA). Intergroup comparisons of oxidative damage
assay dataweremade utilizing the Student t test while comparisons of
histopathological lesion profiles utilized a Mann-Whitney U test for
nonpaired variants. In all cases the level of significance was set at
Pb0.05.
Results
Diseased control mice survived an average of 169 dpi (SE +/– 3)
while EUK-189-treated mice survived significantly longer, living to a
mean of 177 dpi (SE +/– 3), (t test and log-rank test P=0.046 and 0.032,
respectively). One treated mouse died 97 dpi without displaying any
symptoms of disease and was subsequently omitted from data
analyses; otherwise daily ip administration of EUK-189 was well
tolerated. Fig. 2 depicts the survival curves of both groups of ino-
culated mice where, at each time point when mice were euthanised,
the percentage of mice surviving in that group is plotted against dpi.
All mice succumbed to disease and displayed identical late-stage
symptoms of reduced activity, hunched posture, weight loss, hind-
limb paresis and the loss of righting reflexes.
To assess the specific type andextent of anyattenuation in oxidative
stress in our EUK-189-treated mice, and correlate this to the positive
effects on survival, variousmarkers of oxidative damagewere assessed
biochemically, including lipid peroxidation (specifically the free
aldehydic breakdownproductsMDA andHAEs), protein carbonylation,
and tyrosine nitration. Trends toward reduced oxidative damage were
seen for all markers at 100 dpi in EUK-189-treated mice compared to
untreated disease controls, with average levels equivalent to or below
Fig. 6. Brain lesion profiles based on immunohistochemical detection of PrP in M1000-
infected mice treated with EUK-189 compared to untreated disease controls at 100 days
postinoculation (dpi; A) and at the terminal stage of disease (B). Sagittal sections of half-
brains were immunohistochemically stained as described under Materials and methods
and then visually graded for the degree of PrP positivity in 8 brain regions:
(1) hippocampus, (2) thalamus, (3) occipital lobe, (4) parietal lobe, (5) frontal lobe,
(6) cerebellum, (7) basis pontis, and (8) caudate/putamen. Immuno-positivity was
scored using a 9-point grading system ranging from 0 to 4 and the means of each group
plotted for each region. At 100 dpi there were minimal pathological changes and no
difference between EUK-189-treated mice and untreated controls, whereas significant
differences were observed at the terminal stage of disease in the occipital lobe
(P=0.0024), hippocampus (P=0.027), and the parietal lobe (P=0.036). □, untreated
disease controls; ♦, EUK-189-treated group.
Fig. 7. Photomicrographs showing the degree of brain immunohistochemical PrP positivity in M1000-infected mice treated with EUK-189 compared to untreated disease controls.
Sagittal brain sections were probed with the anti-PrP antibody, ICSM-18, to detect PrP deposits. Overall, minimal PrP positivity was evident in the brains of M1000-inoculated mice
that were euthanised at 100 days postinoculation (dpi), regardless of treatment (A,B,E,F). At the terminal stage of disease, mice treated with EUK-189 had a greater plaque burden in
the hippocampus (C), the occipital lobe (G), and the parietal region (data not shown) when compared to the same regions in untreated controls (hippocampus:D; occipital lobe:H).
Original magnification 200×, arrows highlight PrP deposits; asterisks highlight the dentate gyrus.
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those observed in naive age/sex-matched controls (Fig. 3). For NT,
levels of protein nitration at the terminal stage of disease in untreated
disease controls were similar to the amounts observed in uninoculated
naïve controls and indistinguishable from those recorded in untreated
disease controls at 100 dpi. This form of oxidative damage was
significantly reduced in EUK-189-treated mice at completion of the
experiment in comparison to both untreated disease (P=0.019) and
naive controls (P=0.004; Fig. 3A). In contrast, total pCO was not
significantly different between treated and untreated inoculated mice
at the terminal stage of disease and, although levels were relatively
decreased in EUK-189-treated versus untreated diseased animals, total
pCO in treated mice remained just significantly above that found in
naive age/sex-matched controls (P=0.043; Fig. 3B). However, com-
pared to the total pCO levels observed in untreated diseased mice at
100 dpi, we found pCO levels in untreated diseased animals became
significantly higher (P=0.03) by the completion of the experiment,
while total pCO in EUK-189-treated animals did not show a further
significant increase at the terminal stage of disease. This is consistent
with partial protection against this formof oxidative stress in EUK-189-
treated mice. Free MDA/HAE was not different between disease
controls and EUK-189-treated mice at the terminal stage (Fig. 3C)
with levels similarly reduced in both groups when compared to those
found in mice culled around the mid-incubation point, as well as in
comparison to the naïve group that were age-matched to the terminal
stage of disease.
The temporal evolution and topographical distribution of neuro-
pathological changes are generally characteristic of particular prion
strain–host combinations. Indeed, the pattern of pathological abnorm-
alities across various brain regions is sufficiently stereotyped to define
a “lesion profile,”which is used as one criterion for prion strain typing
[45]. In our mouse model, the hippocampus and thalamus are the first
areas to show vacuolation and abnormal prionprotein deposition from
around the mid-incubation period, although at terminal disease these
changes are widespread, albeit with differential emphasis including
complete sparing of the cerebellum [15].
When the brains of mice were examined at 100 dpi, there were
only minor neuropathological changes evident (Figs. 4A and 6A), with
no difference in vacuolation (Fig. 5), PrP-immunostaining (Fig. 7), or
astrocytic gliosis (data not shown) between EUK-189-treated and
untreated disease controls. At the terminal stage of disease, however,
histological examination of H&E-stained brain sections from mice
treated with EUK-189 revealed that the thalamus and hippocampus
were relatively spared of vacuolar lesions when compared to the
untreated control group (Figs. 4B and 5), with the hippocampus
showing a statistically significant difference (P=0.0051). Scores for the
hippocampus were very consistent but there was greater variation in
the thalamus, with one treated mouse almost devoid of vacuoles. All
other brain regions examined showed considerable abnormalities but
no discernable differences between groups.
In contrast to the regional ameliorating effects observed in relation
to spongiform change, comparative immunohistochemical analyses
showed that the EUK-189-treated group had significantly elevated PrP
positivity in several brain regions (hippocampus P=0.027; parietal
lobe P=0.036) with the most pronounced difference occurring in the
occipital lobe (P=0.0024; Figs. 6B and 7). Western immunoblots of
brain homogenates comparing the amount of PrPres in EUK-189-
treated and untreated diseased animals showed negligible levels at
100 dpi in both groups (Fig. 8A). At the terminal stage of disease,
however, densitometric analysis revealed a trend toward elevated
brain PrPres in the EUK-189-treated group (Figs. 8B and C). Astrocytic
gliosis was not different between EUK-189-treated and untreated
disease controls in any of the brain regions examined at 100 dpi and
terminal disease (data not shown).
Discussion
Irrespective of whether PrPc harbours SOD-like catalytic activity,
numerous reports have documented the presence of oxidative damage
within the CNS in prion disease, suggesting that heightened oxidative
stress may play an important causal role in TSE pathogenesis. Based on
this hypothesis, and in accordwith the approach of a numberof previous
in vivo paradigms wherein oxidative stress has been implicated as an
integral component of pathogenesis [28,33–40], our study offers “proof
of principle” support by demonstrating a significant beneficial treat-
ment effect via use of a manganese-SOD/catalase mimetic, EUK-189.
Through this proof of principle approach, our findings validate and
extend the pathogenetic relevance of previous studies demonstrating
evidence of increased CNS oxidative stress in TSE.
Directly correlatingwith theprolongationof survival in the EUK-189-
treatedmice, we observed significant but selective reduction in the CNS
oxidative damage profile in these mice compared to untreated animals.
The salient finding in the brains of antioxidant-treated mice was a
reduction in NT levels at the terminal stage of disease, with levels
significantly reduced below those observed in uninoculated age/sex-
matched mice. Evidence for increased reactive nitrogen species, and
specifically NT levels, has been reported in TSE models [9,19], as has a
reduction in this type of damage, to levels found in unchallenged control
animals, when manganese-SOD/catalase mimetics were employed in
Fig. 8. Comparative Western immunoblot analysis of brain PrPres levels in EUK-189-treated and untreated M1000-inoculated mice at 100 days postinoculation (dpi) (A) and at the
terminal stage of disease (B). Negligible levels of PrPres were observed at 100 dpi in both EUK-189-treated and untreated disease mice (A; upper image). Although there was some
intragroup variation in brain PrPres levels at the terminal stage of disease (B; upper image), there was no significant difference in the brain PrPres burdens of EUK-189-treated mice
and untreated controls when assessed densitometrically and corrected for protein loading (C; □, untreated disease controls; ■, EUK-189-treated group). Equivalence of protein
loading was assessed by probing for β-tubulin (A and B; lower images) in undigested aliquots of the same brain homogenates. n, normal mouse; PK, proteinase K digestion. Molecular
weight markers are indicated on the right.
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other in vivo paradigms [33,36]. NT is generated by the covalent
substitution of a NO2 moiety at either ortho positioned carbon in the
phenolic ring of tyrosine residues, and although some nonspecificity
exists, it iswidely used as amarker of peroxynitrite (OONO-) production.
This type of protein nitration can lead to deleterious effects on normal
function such as attenuation of inherent catalytic activity or interference
in cellular signaling. Reactive nitrogen species such as nitrogen dioxide
and OONO- are also capable of performing such substitution reactions
within the phenolic rings of other aromatic amino acids such as
tryptophan and phenylalanine. Most commonly, OONO- is formed from
the combination of superoxide and nitric oxide radicals. Under normal
physiological conditions SOD concentrations are around 100-fold
greater than nitric oxide, allowing SOD to outcompete nitric oxide in
reactions with superoxide [46]. Rodent TSE models directly assessing
oxidative stress have revealed diminished SOD (Cu/Zn-SOD orMn-SOD)
or SOD-like activity [9,12,18,21]. Hence, our findings support the
postulate that increases in reactive nitrogen species (particularly
OONO-) play a direct pathogenic role in TSEs and are a priori in keeping
with EUK-189 enhancing SOD-like activity in the brains of treatedmice,
thereby reducing OONO- and consequently the potentially damaging
effects of elevated protein nitration.
In contrast to what was found with total protein carbonylation in
untreated diseasedmice, levels of NTdid not increase further from those
observed at 100 dpi. As outlined, under pathological conditions inwhich
concentrations of SOD and SOD-like activity are diminished, superoxide
in such circumstances could potentially be allowed to bind to the nitric
oxide radical to form reactive OONO-, one of the key generators of NT.
The explanation for the lack of a continuing increase in NT levels in our
untreated diseasedmice is unclear butmay relate to the development of
a new compensatory steady-state equilibrium from around the mid-
incubation period, albeit at a deleteriously higher level, with ongoing
degradation and removal from detection of modified proteins within
neurons containing the highest amounts of NT [47].
Although perturbations to cellular SOD activities are commonly
reported in TSE, there is considerable variation and greater complexity
in the findings. In a previous report assessing SOD and SOD-like
activity over the time course of disease evolution [12], Cu/Zn-SOD
and SOD-like activity decreased from around the mid-incubation
period, while Mn-SOD activity increased. Other reports have des-
cribed reducedMn-SOD activity at terminal disease, either unchanged
or increased Cu/Zn-SOD activity [18,21], or reductions in all three of
Cu/Zn-SOD, Mn-SOD, and SOD-like activities [9]. These divergent
changes may relate to different experimental methodologies, includ-
ing the precise prion strain-host combination utilised, but underscore
the likelihood of a mechanistically complex situation wherein it is not
easy to accurately anticipate consequences. The precise cellular site of
increased superoxide radical generation, shown to occur in TSE
models [18], and the degree and specific location of any protective
cytogenic responses are likely to be among a number of important
factors influencing the ultimate phenotypic outcome.
Protection against other forms of oxidative stress, such as protein
carbonylation and lipid peroxidation, was much less successful. As
similarly reported previously in a TSE mouse model [9], we found
increased levels of total pCO in untreated diseased mice at the
terminal stage of disease. We found some restriction in this form of
oxidative damage in our EUK-189-treated mice, but not the level of
efficacy described in prior experiments employing manganese-SOD/
catalase mimetics in other animal disease models [33,39]. The
superior efficacy (with complete attenuation of age-related increases
in brain total pCO) found in one study may relate to enhanced drug
bioavailability and, therefore, potency through use of continuous
delivery osmotic infusion pumps [39]. In support of this possibility,
sustained release delivery of EUK-189 has been shown to be effective
in rodent models at doses 10- to 100-fold lower than those given by
injection [37–39]. However, drug pharmacokinetics do not appear to
be the obvious explanation in relation to the report of Jung and co-
workers [33]. This group studied a mouse model of genetic motor
neurone disease in which manganese-SOD/catalase mimetics were
delivered three times weekly by ip injection, with the total weekly
SOD units dose given less than half the amount given by the same
route in our study. This outcome alsomakes it unlikely that the limited
efficacy with EUK-189 in our study is simply due to poor access to the
CNS. In models requiring access beyond the blood–brain barrier for
treatment effect, EUK-189 has been found to be more biologically
potent than EUK-134 and other derivatives of at least equal catalytic
activity [28,31]. As a corollary, this particular SOD/catalase mimetic
contains ethoxy groups at the 3,3′ positions of its salen rings (Fig. 1)
making it more lipophilic than other EUK compounds.
No therapeutic effectwas observed in relation to lipid peroxidation.
Congruouswithwhatwe reported previously in our in vivomodel [15],
levels of free aldehydic breakdown products were reduced at terminal
disease compared to around the mid-incubation period, but with
similar levels in both EUK-189-treated anduntreateddiseased animals.
Unexpectedly, however, free MDA/HAE levels were well below those
observed in age/sex-matched naïvemice, with the explanation for this
counterintuitive finding unclear. The biochemical technique employed
measures ongoing lipid peroxidation not cumulative damage. Part of
the explanation may therefore relate to the extended time period of
disease and the inefficacy of this antioxidant, with the progressive loss
of a large number of neuronsmost susceptible to this form of oxidative
damage, such that by the terminal stage of disease only the relatively
resistant neurons remain. Irrespective of this, the lack of any dis-
cernible therapeutic benefit in our study stands in clear contrast to
what has been described in other reports utilizing the same and other
analogous manganese-SOD/catalase mimetics. Once again, although
superior drug delivery through use of continuous osmotic infusion
pumps may explain some of this difference [37,39], pharmacokinetic
factors are unlikely to be the entire explanation. In the study already
cited employing the most comparable model to the one we utilized
(with respect to disease type and treatment method), akin to the
beneficial effects described for pCO these authors found significant
attenuation of lipid peroxidation using less than half the SOD units
dose per week through ip injection [33].
The aforementioned considerations raise the likelihood that TSE
pathogenesis could be consequent to more aggressive oxidative stress
or associated with less successful cellular compensatory responses.
Equally, TSE pathogenesis may involve mechanisms which generate
reactive oxygen and nitrogen species different than those occurring in
other in vivo disease models whereby manganese-SOD/catalase
mimetics aremuch less efficacious. This latter possibility is particularly
relevant to lipid peroxidation, wherein the number of potentially
contributing redox reactions appearmuchmore diverse in comparison
to those generating OONO- and NT. The more biochemically restricted
pathways leading to OONO- production, particularly the more direct
linkage to superoxide radicals, could offer more tractability in relation
to treatment interventions if protein nitration is predominant in
pathogenesis [23]. Additionally, it is possible that relatively subtle,
localized amelioration of oxidative stress occurs in the TSE model, and
that such differences are masked when utilizing total brain prepara-
tions. Supporting this contention, Jung et al. [33] and Rong et al. [36]
showed suppression of localized neuronal staining for NT by EUK-134
treatment, while Liu et al. [39] showed suppression of localized
staining for oxidized nucleic acids in the brain. Analysis of total brain
homogenates might not have revealed such differences. Overall, to
address the limitations of the current study, future in vivo assessments
of antioxidants in TSE should consider methodologies that ensure
optimal drug delivery to the target organ; employ single agents or
antioxidant combinations attenuating a broader range of reactive
oxygen and nitrogen species; and offer brain regional assessments of
oxidative stress. Further, it is recognized that different host–prion
strain combinations can show diversity in pathologic profiles [44] and
in their response to specific therapeutic interventions [48], suggesting
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the likelihood of variability in pathogenesis.We have only investigated
the efficacy of EUK-189 in one model [15,42], and although we believe
it is valid and appropriate for studies of human prion disease, accept
that our findings may not fully represent the entire spectrum of
antioxidant efficacy in prion disease.
Notwithstanding that we observed a significant prolongation of
survival in our study, in parallel with the comparatively limited
attenuation in CNS oxidative damage [33,37,39], the magnitude of the
life-span increase also appears relatively modest. The 4.7% average
increase in survival observed in our study approaches but is clearly
less than the 7.7 and 10.4% mean extensions reported in the most
comparable in vivo study of analogous manganese-SOD/catalase mi-
metic antioxidants employed in a neurodegenerative disease model
[33]. As already stated in relation to the reductions in oxidative
damage reported in this study, the superior prolongation of life span
was achieved delivering less than half the amount of SOD unit doses to
the mice per week [33]. Of greater contrast, are treatment studies
utilising rodent TSE models involving compounds not primarily con-
sidered antioxidants, but also delivered from early after ic inoculation.
Efficacy in such studies has ranged from showing no benefit, such as
with quinacrine [43,49], to dramatically prolonging incubation
periods by up to 160% as observed when using amphotericin B or
pentosan polysulfate [49,50].
The precise molecular pathological mechanisms underlying the
process of vacuolation observed in the neuropil and some neuronal
soma in prion disease are incompletely understood. We observed
topographically restricted reductions in spongiform change, confined
to the hippocampus and thalamus of terminal EUK-189-treated mice,
but not the complete prevention reported in Mn-SOD% mice treated
with the same SOD/catalase mimetic [28]. This observation supports
the likelihood that the vacuolation in Mn-SOD% mice, evidently
arising from splitting of the myelin lamellae of medium sized axons
[41], is probably a direct consequence of heightened oxidative stress,
particularly within mitochondria, whereas other contributing patho-
genic factors may be operating in prion disease. Immunohistochem-
ical analysis revealed a variably higher amount of PrP positivity in
EUK-189-treated mice, emphasised in the hippocampus, occipital
lobe, and parietal lobe, while Western blots of brain homogenates
from treated and untreated animals demonstrated nonsignificant dif-
ferences in amounts of PrPres. Although the increase in immunohis-
tochemical PrP positivity in the EUK-189-treated mice may relate to
their modestly longer survival providing a slightly longer period for
tissue deposition of abnormal PrP, the reason for the disparity in levels
of the abnormal isoform of PrP as detected immunohistochemically in
comparison to levels determined by Western blot is not entirely clear.
Analogous discrepancies in the detection of PrPres across the two
techniques have been reported previously [51–53]. As already
discussed in relation to the results from our biochemical assays,
relatively subtle regional differences observed using immunohisto-
chemistry are likely to be lost through tissue homogenisation.
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Prion diseases are transmissible neurodegenerative disorders,
which include Creutzfeldt-Jakob disease and kuru in humans,
as well as scrapie and bovine spongiform encephalopathy in
animals. In common with Alzheimer’s and Parkinson’s
Diseases, prion diseases are associated with the accumulation
of aberrant conformers of a constitutively expressed cellular
protein; more specifically, in prion disease, pathogenesis
appears linked to the conversion of the normal cellular form
of the prion protein (PrPC) to misfolded, relatively protease-
resistant isoforms (PrPSc), which also appears to constitute
the basic infectious unit (Cohen and Prusiner 1998). Despite
equivalence in primary structure, PrPSc typically exhibits a
number of bio-physical differences in comparison to PrPC
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Abstract
Previous in vitro and in vivo investigations have suggested
manganese (Mn2+) may play a role in pathogenesis through
facilitating refolding of the normal cellular form of the prion
protein into protease resistant, pathogenic isoforms (PrPSc),
as well as the subsequent promotion of higher order aggre-
gation of these abnormal conformers. To further explore the
role of Mn2+ in pathogenesis, we undertook a number of
studies, including an assessment of the disease modifying
effects of chelation therapy in a well-characterized mouse
model of prion disease. The di-sodium, calcium derivative of
the chelator, cyclohexanediaminetetraacetic acid (Na2CaC-
DTA), was administered intraperitoneally to mice inoculated
intra-cerebrally with either high or low-dose inocula, with
treatment beginning early (shortly after inoculation) or late (at
the usual mid-survival point of untreated mice). Analyses by
inductively coupled plasma-mass spectrometry demonstrated
brain Mn2+ levels were selectively reduced by up to 50% in
treated mice compared with untreated controls, with copper,
iron, zinc and cobalt levels unchanged. In mice administered
high-dose inocula, none of the treatment groups displayed an
increase in survival although western blot analyses of early
intensively treated mice showed reduced brain PrPSc levels;
mice infected using low-dose inocula however, showed a
significant prolongation of survival (p = 0.002). Although our
findings support a role for Mn2+ in prion disease, further
studies are required to more precisely delineate the extent of
pathogenic involvement.
Keywords: chelation therapy, cyclohexanediaminetetraace-
tic acid, manganese, neurodegeneration, prion disease,
transmissible spongiform encephalopathy.
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with PrPSc being relatively rich in b-sheet content, more
protease resistant and less soluble in detergents than PrPC.
Prion protein has been shown to bind copper (Cu2+) ions
(Brown et al. 1997; Jackson et al. 2001; Jobling et al. 2001;
Burns et al. 2003; Gaggelli et al. 2005; Thompsett et al.
2005) with a putative role in copper homeostasis suggested
by the rapid endocytosis of PrPC after binding the transition
metal (Pauly and Harris 1998). In addition, PrPC complexed
with Cu2+ has been reported to exhibit superoxide dismutase
(SOD) activity, with this posited function diminished in the
presence of Cu2+ chelators (Brown et al. 1999). Furthermore,
the SOD activity of recombinant PrP is diminished or
nullified when the protein is refolded in the presence of other
transition metals instead of Cu2+ (Brown et al. 2000),
additionally supporting an important role for copper in this
catalytic activity. The reduced catalytic activity in the
presence of manganese may relate in part to conformational
differences, supported by the differential affinities that
monoclonal antibodies have for the two metallated forms
(Thackray et al. 2003).
Transition metals such as iron and copper are typically
associated with aggregated protein deposits and plaques in
neurodegenerative disorders (Allsop et al. 2008), including
Alzheimer’s disease (Barnham et al. 2006) and are likely to
contribute to pathogenesis through the generation of free
radicals and oxidative insults to CNS neurons via mecha-
nisms such as Fenton and Haber–Weiss chemistry (reviewed
in Gaeta and Hider 2005; Lan and Jiang 1997). Several
reports have also shown altered brain transition metal
homeostasis in prion disease, with particular support for a
possible direct pathogenic role for Mn2+. In a mouse model,
by about a third of the way through the incubation period
(and concomitant with the first appearance of PrPSc),
immunopurified PrP was found to be considerably less
associated with Cu2+ while becoming increasingly associated
with Mn2+ (Thackray et al. 2002). The brains of scrapie
infected hamsters have also been shown to harbor increased
Mn2+ levels compared with controls (Kim et al. 2005). Of
direct relevance to human prion disease, Wong et al. (2001)
have shown that the brains of sporadic Creutzfeldt-Jakob
disease patients contain only half the Cu2+ content of age-
matched controls but up to ten-fold the Mn2+ content. From a
molecular mechanistic perspective, Mn2+ is thought to
contribute to pathogenesis through promoting the conforma-
tional transformation of PrPC to PrPSc (Brown et al. 2000;
Treiber et al. 2006; Brazier et al. 2008) and perhaps by
facilitating the formation of large, multimeric complexes of
PrPSc (Thackray et al. 2002; Giese et al. 2004; Tsenkova
et al. 2004; Levin et al. 2005). Contributions from enhanced
oxidative stress through non-homeostatic Mn2+ redox activ-
ity are also likely (Tsenkova et al. 2004). In vitro studies of
recombinant PrP support a direct pro-aggregatory role for
Mn2+, which is inhibited by copper when present prior to
oligomerisation (Giese et al. 2004; Levin et al. 2005; Brazier
et al. 2008), with experimental evidence supporting differ-
ences in the binding mechanisms of Cu2+ and Mn2+ to the
prion protein and cognate peptide fragments (Tsenkova et al.
2004; Gaggelli et al. 2005; Levin et al. 2005). Further
supporting an important pathogenic contribution, using cell
culture assays, Davies and Brown (2009) recently demon-
strated that the infectivity of an infectious cell lysate was
enhanced around 100-fold when recipient cells were cultured
in the presence of Mn2+ and it has been shown (Uppington
and Brown 2008) that recombinant PrP refolded in the
presence of Mn2+ was significantly more toxic to primary
neuronal cultures than the holo-form of the protein.
In response to the increasing recognition of derangements
in brain transition metal content and their likely pathogenic
role in various neurodegenerative disorders, chelators have
been utilized as a therapeutic strategy in experimental animal
models and human trials (Cherny et al. 2001; Youdim et al.
2004; Lannfelt et al. 2008). Indeed, Sigurdsson et al. (2003)
demonstrated that treating prion inoculated mice with the
copper chelator D-penicillamine (D-PEN) prolonged survival
by extending the disease incubation period.
Given the recent data suggesting a pathogenic role for
Mn2+ in prion disease, we undertook a trial of chelation
therapy in our well characterized mouse model of prion
pathogenesis (Brazier et al. 2006). The polyaminocarboxylic
acid, cyclohexanediaminetetraacetic acid (CDTA; Fig. 1),
was chosen as chelator because of its proven efficacy to bind
and remove Mn2+ from the brains of experimental animals
(Tandon and Singh 1975; Tandon 1978) with subsequent
urinary excretion of stable complexes (Khandelwal et al.
1980; Tandon and Khandelwal 1982; Wieczorek and Ober-
dorster 1989; Sanchez et al. 1995). The di-sodium, calcium
salt of CDTA (Na2CaCDTA), employed because it has a
higher LD50 [5396 mg/kg (Sanchez et al. 1995)] than CDTA
[413 mg/kg (Srivastava et al. 1986)], was administered intra-
peritoneally (ip) to mice inoculated intra-cerebrally (ic) with
either high- ( 2 · 105 ID50 units) or low-dose inocula
( 20 ID50 units), with treatment beginning early (shortly
after inoculation) or late (around the usual mid-survival point
of untreated mice). Analyses by inductively coupled plasma-
mass spectrometry demonstrated brain Mn2+ levels were
selectively reduced by 34–50% in treated mice (depending
on the intensity of chelation therapy) compared with
untreated controls, with copper, iron, zinc and cobalt levels
N(CH2CO2H)2
N(CH2CO2H)2
Fig. 1 Chemical structure of cyclohexanediaminetetraacetic acid.
Cyclohexanediaminetetraacetic acid binds manganese via its carboxyl
groups with a log stability constant of 17.4 (Dawson et al. 1986).
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unchanged. In mice administered high-dose inocula, none of
the treatment groups displayed an increase in survival
although brain PrPSc levels were shown to be substantially
reduced by western blot in the most intensively early treated
mice. In contrast, possibly because of the extended period of
pathogenesis, mice infected using low-dose inocula showed a
significant prolongation of survival (p = 0.002) compared
with non-treated controls but no reduction in brain PrPSc
levels.
Methods
Production of the manganese chelator
To reduce the biotoxicity of the chelator, sodium hydroxide (Sigma,
St Louis, MO, USA), calcium hydroxide (Sigma) and CDTA
(Avocado, Ward Hill, MA, USA) were reacted for 2 h at 22C at
molar equivalents of 2 : 1 : 1, respectively in 0.9% saline (Sanchez
et al. 1995) to generate a 0.2 M stock solution of the disodium
calcium salt Na2CaCDTA. The pH of this solution was adjusted to
7.0 before use and aliquots were stored at )20C.
Mouse inoculations and handling
Mouse inoculations and all animal handling procedures such as
culling were performed in accordance with national prescribed
guidelines and ethical approval for the study granted by the
University of Melbourne Animal Experimentation Ethics Commit-
tee. Balb/c weanling mice were ic inoculated with either 1%
normal brain homogenate (sham inoculated controls) or M1000
prions under methoxyfluorane anaesthesia as previously described
(Collins et al. 2002; Brazier et al. 2006). For M1000 inoculations,
mice were inoculated with 30 lL of a diluted brain homogenate
[w/v in phosphate buffered saline (PBS)] made from a terminally
ill mouse, equivalent to a dose of either  2 · 105 ID50 units
(high dose inoculum) or  20 ID50 units (low dose inoculum). All
groups of mice used in the course of these studies are summarized
in Table 1; mice were housed with food and water available ad
libitum. Upon manifesting persisting definite features of prion
disease, these mice and as appropriate, age-matched sham
inoculated controls, were culled by a lethal dose of anaesthetic
(200 lL Nembutal ip; Merial), with selected mice exsanguinated
by transcardial perfusion with PBS containing 2000 IU/L heparin
and 0.028 M sodium nitrite (Clyde Industries, Sydney, Australia)
at 100 mmHg pressure.
In vivo manganese chelation treatment
For a preliminary assessment of brain transition metal changes
occurring as a consequence of prion disease, Balb/c weanling mice
inoculated with high doses ( 2 · 105 ID50 units) of M1000 prions
(Group 1; n = 7) were compared with mice receiving normal brain
homogenate (sham inoculated controls; Group 2; n = 4). To assess
the potential therapeutic effect of Na2CaCDTA, mice were inocu-
lated with either high doses ( 2 · 105 ID50 units) or low doses
( 20 ID50 units) of M1000 prions as outlined in Table 1. The high
dose-inoculated mice were divided into four groups: Group 3
(n = 7), treated ip twice weekly with 200 lL 0.2 M Na2CaCDTA
commencing day 7 post-inoculation; Group 4 (n = 7), treated ip four
times weekly with 200 lL 0.2 M Na2CaCDTA commencing day 7
post-inoculation; Group 5 (n = 7), treated ip four times weekly with
200 lL 0.2 M Na2CaCDTA commencing 75 days post-inoculation
(time chosen to approximate usual mid-survival point of untreated
mice); and an untreated control group (Group 6; n = 6). Low dose-
inoculated mice formed two groups, one treated thrice weekly with
200 lL 0.2 M Na2CaCDTA commencing day 7 post-inoculation
(Group 7; n = 8) and the other untreated serving as controls (Group
8; n = 10). The amount of Na2CaCDTA (200 lL 0.2 M) given each
treatment equates to 1/8 the LD50 for a single dose through this
administration route (Sanchez et al. 1995) and was arbitrarily
chosen to maximize any therapeutic potential without posing undue
toxicity. Treatment with Na2CaCDTA continued until mice mani-
fested persisting, definite features of prion disease at which point
they were culled.
Transition metal analyses
Estimations of brain transition metal content were performed
using inductively coupled plasma-mass spectrometry (Varian, Palo
Alto, CA, USA). Following transcardial perfusion, brains from
M1000 inoculated terminally sick mice and sham inoculated, age
matched controls were immediately removed, with some sagittally
Table 1. Summary of the groups of mice, the inoculation doses used and treatment regimens employed for the study of transition metal changes in
prion disease. Groups 1 and 2 were utilized in the preliminary assessment of transition metal dyshomeostasis in terminal prion disease and groups
3–8 were employed in the study of manganese (Mn2+) chelation as a therapeutic strategy. Groups 7 and 8 were inoculated with a low dose
( 20 ID50 units) of M1000 prions while groups 1 and 3–6 received high dose inoculation ( 2 · 105 ID50 units).
n Mouse strain Inoculum Treatment start Frequency
Group 1 7 Balb/c High dose M1000 n/a
Group 2 4 Balb/c NBH n/a
Group 3 7 Balb/c High dose M1000 Early 2 · weekly
Group 4 7 Balb/c High dose M1000 Early 4 · weekly
Group 5 7 Balb/c High dose M1000 Late 4 · weekly
Group 6 6 Balb/c High dose M1000 Untreated controls
Group 7 8 Balb/c Low dose M1000 Early 3 · weekly
Group 8 10 Balb/c Low dose M1000 Untreated controls
NBH, normal brain homogenate; n/a, not applied.
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hemisectioned, before prompt snap freezing in liquid nitrogen and
storage at )80C until assessment for Cu2+, Mn2+, Co2+, Zn2+ and
Fe2+/3+ content. Samples of brain tissue were weighed (approximate
wet weight) and placed in acid-leached polypropylene tubes. Tissue
samples were hydrolyzed with 700 lL of 70% nitric acid (BDH
Aristar, West Chester, PA, USA) for 46 h before being heated to
80C for 30 min. The acid treated samples were then treated with
600 lL hydrogen peroxide and heated at 70C for 15 min. All
samples were diluted in 1%HNO3 before being assayed. Standards
included multi-element solutions containing 10, 50 and 100 ppb of
the relevant transition metals and National Institute of Standards and
Technology bovine liver (standard reference material 1557B). Each
sample was analyzed in triplicate with the results expressed as lg
metal/g brain wet weight.
Western blot analyses
Brains from mice undergoing high dose inoculation and early
Na2CaCDTA treatment (Groups 3 and 4) or late Na2CaCDTA
treatment (Group 5), as well as untreated mice (Group 6) were
assessed for PrPSc levels by western blotting as described previously
(Brazier et al. 2006). In brief, after thawing, brain samples were
homogenized to 10% (w/v) in PBS and then incubated with 50 U/
mL benzonase nuclease (Merck, VIC, Australia EC number
3.1.30.2) in the presence of 1 mM MgCl2 for 5 min at 37C.
Protease treatment consisted of 100 lg/mL proteinase K (PK;
Sigma; EC number 3.4.21.64) for 1 h at 37C, with the reaction
halted by the addition of an equal volume of 2 · sample buffer
(including 6% b-mercaptoethanol), Pefabloc (8 mM final concen-
tration) and boiling for 10 min. Samples were then briefly
centrifuged at 7500 g prior to loading onto 10% pre-cast tris/
glycine gels (Invitrogen, Carlsbad, CA, USA). Proteins were
resolved at 200 V for 60 min, then electroblot transferred to a
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA,
USA) followed by blocking for 1 h at 22C in PBS-0.05% Tween
20 (Sigma; PBS-T) containing 5% non-fat milk powder. Membranes
were probed with either ICSM18 monoclonal anti-PrP antibody
(White et al. 2003), diluted 1 : 25 000 in PBS-T, or the R-30
polyclonal anti-PrP antibody (gift of Bruce Chesebro [Caughey
et al. 1991]) to control for epitope alteration as a result of chelation
treatment. The ICSM18 epitope is amino acids 143–155, while the
R30 polyclonal anti-PrP antibody is directed against the 89–103
sequence. After extensive washing with PBS-T, bound antibody was
detected using a horseradish peroxidase-conjugated anti-mouse or
anti-rabbit secondary antibody at 1 : 5000 (Dako, Carpinteria, CA,
USA) as appropriate. Visualization was achieved using enhanced
chemiluminescence reagent (ECL; GE Healthcare, Cardiff, UK) and
Kodak Bio-max film, developer and fixative (Sigma), according to
manufacturers’ instructions. Densitometric evaluation for compari-
son of signal intensities was performed using Image J software
(National Institutes of Health, USA).
In vitro manganese chelation assay
Ten percent brain homogenates (w/v in PBS) were prepared from
non-Na2CaCDTA treated, terminally sick (Group 1) mice (n = 7) ic
inoculated with a high dose of M1000 prions, by progressive
passage through 18, 21 and finally 26 gauge needles. To assess
whether Na2CaCDTA could alter the protease resistance of pre-
formed PrPSc present in terminal brains, an equal volume of various
Na2CaCDTA concentrations (0.2 M, 0.1 M, 0.05 M or 0.025 M) or
H2O (untreated control) was added to 50 lL aliquots of the terminal
10% brain homogenate prior to PK digestion. The reaction mixtures
were incubated for either 30 min or 3 h at 37C, with constant
agitation at 450 g on a platform shaker, to assess the effect of
different chelation treatment times. The effect of chelation treat-
ments on protease-resistance of PrPSc was then assessed by
digestion with 100 lg/mL PK (Sigma), with subsequent western
blotting as described above, except that nitrocellulose filters were
digitally imaged the Gene Gnome (Syngene, Cambridge, UK) to
facilitate subsequent assessment of residual levels of PrPSc.
Densitometric analyses of digital images provided relative compar-
isons of the effects of the various Na2CaCDTA treatments on each
individual terminal brain homogenate compared with its untreated
control (adjusted to 100%); relative changes for each Na2CaCDTA
treatment concentration were then pooled from at least five separate
experiments. Pefabloc (Roche Molecular Biochemicals, Indianapo-
lis, IN, USA) was added (to 8 mM final concentration) to some
aliquots prior to chelation treatment to determine the level of
endogenous non-specific serine protease activity during the chela-
tion incubation.
Statistical methods
A log rank test was employed for comparison of mouse survival
periods and Mann–Whitney U-tests were performed on data
pertaining to mouse brain metal content using GraphPad Prism
software (GraphPad Software Inc., San Diego, CA, USA). Other
data comparisons utilized the Student’s t-test. In each case the level
of significance was set at p < 0.05.
Results
Changes in brain transition metal content as a consequence
of M1000 prion infection
Preliminary experiments showed that compared with age-
matched, sham inoculated controls (Group 2), the brains of
terminally sick M1000-inoculated mice (Group 1) showed a
non-significant trend toward less Cu2+ (Fig. 2a and
Table S1). The brains of M1000-inoculated mice (Group 1)
were shown to have significantly higher levels of Mn2+
(p = 0.01) than controls with a mean concentration of 0.390
(± 0.012 SEM) lg Mn2+/g brain wet weight compared with
0.323 (± 0.009 SEM) lg Mn2+/g brain wet weight in controls
(Fig. 2b and Table S1). There was no difference in brain
Co2+ and Fe2+/3+ content between terminally sick M1000-
inoculated mice and sham-inoculated age matched controls,
but Zn2+ was also significantly higher in terminally sick
M1000-inoculated mice (Table S1).
Effect of in vivo Na2CaCDTA chelation treatment on
survival
At the doses used for the period of time given, the chelation
therapy appeared well tolerated with no deleterious effects.
Our initial treatment trial utilized high dose ( 2 · 105 ID50
units)-inoculated mice and there was no significant difference
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in survival between the early (Groups 3 and 4) and late
Na2CaCDTA treated (Group 5) and untreated (Group 6)
control mice, with average incubation periods (± SD) of 147
(± 4.5) days for group 6, 142 (± 8.5) days for group 3, 143
(± 4.7) days for the group 4, and 142 (± 7.4) days for group 5
(Fig. 3a). To further assess therapeutic efficacy we undertook
a second study employing low dose ( 20 ID50 units)-
inoculated mice, and found a significant increase in the
survival period of the Na2CaCDTA treated mice (Group 7).
Control mice (Group 8) survived, on average, 169 (± 2.5)
days whereas the Na2CaCDTA treated group (Group 7)
survived 189 (± 3.8), an approximately 20 day (11.8%)
extension of the control survival period (Fig. 3b). Overall,
two mice died as a direct complication of ip injection and one
Na2CaCDTA treated mouse failed to develop symptoms of
disease after 300 days post-inoculation, which was consid-
ered to be a technical failure with respect to inoculation.
These mice were excluded from data analyses.
Na2CaCDTA chelation treatment selectively reduced brain
manganese levels
Untreated control mice (Groups 6 and 8) displayed a mean
concentration of brain Mn2+ similar to that found in
previously analyzed, terminally sick, M1000-inoculated
(group 1) mice (approximately 0.390 lg Mn2+/g brain wet
weight; Table S1). Given the failure to observe a benefit from
chelation therapy in any of our initially treated, high-dose
inoculated mice, only the brains from groups 4, 5 and 6 mice
were analyzed for transition metal content. In these mice
inoculated with high dose inocula, the chelator Na2CaCDTA
significantly reduced brain manganese levels by around 50%
(to approximately 0.2 lg Mn2+/g brain wet weight) regard-
less of whether chelation treatment was commenced early or
late (Mann–Whitney U-test p < 0.05 for both treatment
groups 4 and 5) (Table S1 and Fig. 4). The level observed






































Fig. 3 Survival curves of Na2CaCDTA treated mice. There was no
difference between Na2CaCDTA treatment groups compared with
untreated controls when mice were inoculated with a high dose
( 2 · 105 ID50 units) inoculum (a; 4 = Group 3, n = 7, r = Group 4,
n = 7, · = Group 5, n = 7, = Group 6, n = 6) whereas there was an
approximately 10% extension to survival because of treatment after a
low dose ( 20 ID50 units) inoculum (b; = Group 7, n = 8,
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Fig. 2 Inductively coupled plasma-mass spectrometry analysis of
brain transition metals in prion infected mice. There is a non-significant
decrease in Cu2+ concentration (a) and a significant increase in Mn2+
concentration (b) in terminally diseased mice brains (Group 1, n = 4)
when compared with age-matched sham inoculated control mice
(Group 2, n = 4; *p < 0.01).
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Mn2+ levels observed in sham-inoculated, age matched
controls (Group 2) (0.323 lg Mn2+/g brain wet weight)
(Table S1; also compare Fig. 2b with Fig. 4). The Cu2+,
Co2+, Zn2+ and Fe2+/3+ concentrations were not different
across the three groups (Table S1 and Fig. 4). Overall, we
observed similar results in our subsequent chelation treat-
ment trial using low dose-inoculated mice (Fig. 5), with the
Mn2+ levels selectively and significantly reduced approxi-
mately 34% (to 0.23 lg Mn2+/g brain wet weight) in Group 7
mice compared with untreated control mice (Group 8). We
attributed this modestly increased mean brain Mn2+ level to
the slightly less intense chelation treatment protocol we
employed in the second trial (because of resource constraints)
wherein Group 7 mice received Na2CaCDTA three times per
week rather four times weekly as undertaken in Groups 4 and
5 mice. Cobalt levels fell below that necessary for meaning-
ful results in low dose-inoculated Groups 7 and 8 mice and
could not be determined.
Assessment of brain PrPSc levels by western blot in high and
low dose M1000 inoculated Na2CaCDTA treated mice
To demonstrate that there were equal amounts of total PrP in
the various early and late treated brains when compared with
the untreated control brain homogenates prior to PK diges-
tion, aliquots of undigested homogenates were run parallel to
their respective PK-digested samples (Fig. 6a). In high dose
inoculated mice, western blots revealed that compared with
the untreated (Group 6 n = 5) mice, the brains of early
Na2CaCDTA treated (Groups 3 and 4) mice appeared to
display less PrPSc after PK digestion, which was borderline
significant (p = 0.052) for Group 3 (n = 3) but highly
significant (p < 0.0005) for Group 4 (n = 3) in comparison
to late treated Group 5 (n = 5) mice; group 5 brain PrPSc
levels appeared similar to the group 6 controls (Fig. 6a and
b). The same results were also obtained when probing with
the R30 polyclonal antibody, showing that the observed
difference in PrPSc signal was not because of an alteration of
antibody epitope (data not shown). In contrast, there was no
significant difference in brain PrPSc levels between the low-
dose inoculation Na2CaCDTA treated Group 7 (n = 3) and
untreated Group 8 (n = 3) mice (Fig. 6c).





















































Fig. 4 Brain transition metal concentrations of Na2CaCDTA treated
mice (high dose inoculum). Mean manganese concentrations are
significantly decreased in the brains of Na2CaCDTA treated M1000
infected mice inoculated with  2 · 105 ID50 units. Metal concentra-
tions in the brains of in vivo Na2CaCDTA treated mice, treated from 7
(early) and 75 days post-inoculation (late) and untreated controls were
determined by inductively coupled plasma-mass spectrometry.
There was a highly significant reduction (**p < 0.005, *p < 0.05) of
manganese in Na2CaCDTA treatment groups whereas the concen-
trations of other metals Co2+, Cu2+, Fe2+/3+ and Zn2+ were unaltered



















































Fig. 5 Brain metal concentrations of Na2CaCDTA treated mice (low
dose inoculum). Manganese concentrations are significantly de-
creased in the brains of Na2CaCDTA treated M1000 infected mice
inoculated with  20 ID50 units. Metal concentrations in the brains of
untreated and Na2CaCDTA -treated mice were determined by in-
ductively coupled plasma-mass spectrometry (IC-PMS). There was a
highly significant reduction (*p < 0.05) of manganese in the Na2CaC-
DTA treatment group whereas the concentrations of other metals
Cu2+, Fe2+/3+ and Zn2+ were unaltered (cobalt was below the detection
limit). h = Group 7, n = 3, = Group 8, n = 4).
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In vitro assessment of Na2CaCDTA does not support
induction of enhanced protease sensitivity of pre-formed
PrPSc
Based on the finding that western blots revealed reduced
PrPSc levels in the brains of early Na2CaCDTA treated mice,
we assessed the in vitro effect of Na2CaCDTA on pre-formed
PrPSc found in the brains of non-treated (Group 1) mice with
terminal prion disease. Aliquots of 10% brain homogenate
from these mice (n = 7) were reacted with differing concen-
trations of Na2CaCDTA for 30 min or 3 h to assess whether
chelation treatment could alter the proteinase resistance of
pre-formed PrPSc. Regardless of the duration of chelation
treatment and Na2CaCDTA concentration employed, there
was no observed alteration in the levels of PrPSc compared
with untreated brain samples (data not shown). Overall, these
results suggest that the reduced PrPSc levels observed in the
brains of early Na2CaCDTA treated mice are more likely to
be on the basis of diminished production rather than
increased PK-sensitivity of mature PrPSc.
Discussion
Conversion of PrPC to PrPSc is considered the principal event
in the pathogenesis of prion disease, although precisely how
this conversion is linked to neurotoxicity is unresolved.
Stimulated by recent data suggesting a possible direct role for
Mn2+ in prion disease, as exemplified by progressive Mn2+
accumulation in the brain as the disease evolves (Wong et al.
2001; Thackray et al. 2002; Kim et al. 2005) and the
apparent facilitation by Mn2+ of the conversion of PrPC to a
protease resistant isoform (Brown et al. 2000; Kim et al.
2005; Treiber et al. 2006), we undertook the present study to
try more accurately to define the pathogenic relevance of
Mn2+ and as a corollary, assess manganese chelation as a
potential therapeutic strategy using our mouse model of prion
disease.
In accordance with previous investigations (Tandon and
Singh 1975; Tandon 1978; Wieczorek and Oberdorster 1989;
Sanchez et al. 1995), we found that Na2CaCDTA is an
effective and relatively selective chelator for the removal of
Mn2+ from the brain. Depending on the intensity of chelation
therapy applied, mice treated for the whole incubation period
and those from approximately the mid-survival point had
approximately 34–50% of their brain Mn2+ removed com-
pared with terminal disease controls, ultimately achieving
levels well below those observed in age-matched, sham-
inoculated animals; the level of other metals assessed were
unchanged. Hence, although in vitro CDTA has high log
stability constants for most transition metals (Dawson et al.
1986; Table S2), the disodium calcium salt of CDTA appears
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Fig. 6 Western blot analyses of the brain scrapie isoform of the prion
protein (PrPSc) in Na2CaCDTA treated mice. Fig. 6a demonstrates
diminished PrPSc signal in the brains of the early intensively
Na2CaCDTA treated (Group 4) mice whereas the brains of the late
treatment (Group 5) mice had a similar level to the untreated (Group 6)
mice. The western blot in Fig. 6a demonstrates that there is similar
total PrP signal in all groups before proteinase K (PK) digestion but
there is a reduced signal in the early treatment (Group 4) mice after PK
digestion (when detected using ICSM-18), and this reduction in signal
was also evident when probing with R30 polyclonal antibody (data not
shown) suggesting that the reduction of signal is not because of an
alteration of epitopes for ICSM-18 monoclonal antibody. Fig. 6b
summarizes densitometric comparisons of western blots of brain
PrPSc from the high dose inoculation treatment groups compared with
the untreated control group. In Fig. 6b, signal from Group 6 mice was
set as 100% (h = Group 4, n = 3; = Group 6, n = 5; = Group 3,
n = 3; = Group 5, n = 5). There was a significant reduction
(***p < 0.0005) in PrPSc signal in the early intensively treated Group 4
mice compared with late treated Group 5 mice, with borderline sig-
nificance (* p = 0.05) for the Group 3 mice. Fig. 6c summarizes den-
sitometric comparisons of western blots of brain PrPSc from low dose
inoculation mice with the treatment Group 7 not significantly different
to the untreated control group 8 (h = Group 7, n = 3; = Group 8,
n = 3).
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highly specific for Mn2+ in vivo. The explanation for this
empirical observation most likely relates to pharmacokinetic
factors and the accessibility of the different metals in vivo
during prion disease. Copper, for example, is highly toxic to
neurons and must therefore be tightly sequestered by other
molecules (Levenson 1998) leaving it much less available to
a chelator, whereas the non-physiological accumulation of
Mn2+ probably occurs mainly in relation to abundant PrPSc
deposits, not primarily for the purpose of sequestration, to
which it is comparatively weakly bound (Brazier et al.
2008). Nevertheless, despite the significant changes in brain
Mn2+ levels we achieved, cognate mice that had been
infected with high dose inocula showed no benefit in terms of
prolongation of their survival, while mice infected using low
dose inocula showed a modest but significant prolongation,
equivalent to approximately 12% of the non-treated, control
survival period.
The explanation for the limited therapeutic efficacy of
Mn2+ chelation despite impressive removal of this transition
metal from the brain, especially as observed in our high dose
inoculated mice, is unclear but a few observations may be
relevant. In in vitro conversion systems, non-manganese
factors have been shown to promote production of abnormal
protease-resistant conformations, with the facilitatory co-
factors including detergents, other transition metals (Kim
et al. 2005; Treiber et al. 2006), non-nucleic acid polyanions
such as heparin sulphate (Deleault et al. 2007), and RNA
(Deleault et al. 2003). The lack of reduction in levels of other
transition metals examined in the brains of our early and late
treated mice may be pertinent. It is possible that inoculation
dose may influence whether Mn2+ plays a greater but non-
exclusive role in the early incubation period, with other
auxiliary factors for PrPC conversion becoming dominant
later, particularly after a sizeable or pathogenic ‘threshold’
amount of PrPSc has been formed. Given the lack of survival
benefit in high dose inoculated mice despite early intensive
Na2CaCDTA treatment, it appears likely that although PrP
Sc
levels were reduced, sufficient conversion, perhaps mainly
non-manganese associated, achieves adequate misfolded
conformers for efficient pathogenesis. In the converse
outcome for low dose inoculated mice, Mn2+-related con-
version may be predominant and rate limiting early, but the
overall prolongation of pathogenesis eventually allows
considerable production of PrPSc through non-Mn2+ related
mechanisms ultimately achieving levels equivalent to those
found in non-treated mice. Detailed, correlative, incubation
period time course studies may provide better insight into
what appears to be an imprecise correlation between overall
survival and brain Mn2+ and PrPSc levels found at terminal
disease.
In addition to the aforementioned, it is possible that in
spite of the impressive reductions in the total brain Mn2+
levels achieved through Na2CaCDTA treatment specific
removal of Mn2+ from PrP conformers poised for conver-
sion was relatively suboptimal, or that enough Mn2+ still
remained in the CNS to generate PrPSc levels above the
threshold required to enable typical pathogenesis. Further, it
is also possible that the most toxic or pathogenically
important conformers of PrPSc are not Mn2+-dependent,
which may be particularly relevant in the setting of high
dose inoculation of prions. The relevance of Mn2+ to
putative non-fibrillar or soluble toxic oligomers of PrPSc
thought to be most critical (Silveira et al. 2005), especially
by analogy to other neurodegenerative disorders such as
Alzheimer’s disease (McLean et al. 1999; Walsh et al.
2002), is largely unexplored, as is the relevance of Mn2+ to
prion disease with minimal or absence of PrPSc (Lasmézas
et al. 1997).
Hypothetically, the reduced brain PrPSc levels depicted by
western blot after early in vivo Na2CaCDTA treatment may
occur through either reducing the production of PrPSc or by
increasing the protease sensitivity of extant misfolded PrP
conformers. In vitro assays have shown D-PEN could
prevent the development of heightened PK-resistance
induced by exogenous copper but could not alter the intrinsic
protease-resistance of pre-formed PrPSc (Sigurdsson et al.
2003). This is similar to the report by Treiber et al. (2006)
demonstrating that copper and manganese-induced protease
resistant PrP was stable in the presence of EDTA, although
more selective Cu1+ chelators could reverse the protease
resistance induced by exogenous copper alone. Even though
CDTA has a much higher affinity for Mn2+ than EDTA (refer
Table 3; Dawson et al. 1986), we also found that mature
PrPSc, made openly accessible through vigorous homogeni-
zation, was not rendered more protease sensitive by
Na2CaCDTA exposure in vitro. Hence, our in vitro and
in vivo data are concordant with previous experimental data
contending that Mn2+ promotes misfolding of PrPC to
isoforms with higher b-sheet content (Brazier et al. 2008),
albeit with an optimal time period exemplified by the first
half of the incubation period. A prominent increase in the
protease sensitivity of pre-formed PrPSc in our in vitro assay
without observing reductions in late Na2CaCDTA treated
mice would have evoked concerns such as whether ineffec-
tive chelator concentrations had been achieved in the brains
of treated mice or possibly poor in situ accessibility to
misfolded PrP. Instead, previous reports and our current data
argue that the most efficient inhibition of PrPSc formation
appears to require the presence of the chelator prior to, or at
least concomitant with, the conversion of PrPC (Sigurdsson
et al. 2003; Kim et al. 2005; Treiber et al. 2006) and this,
coupled to the likelihood that alternative co-factors offer
parallel conversion pathways, may also partly explain why
late treated mice had no discernible reduction in PrPSc levels
despite comparable reductions in brain Mn2+. However, our
results do not completely resolve the mechanism by which
PrPSc levels are reduced in the brains of early Na2CaCDTA
treated mice but, through the paradigms employed, suggest
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the explanation is less likely to be a simple biochemical
enhancement of PrPSc protease sensitivity.
Although we achieved a statistically significant extension
to survival of approximately 12% through Na2CaCDTA
treatment of low-dose inoculated mice, this is a relatively
modest outcome compared with other reported treatments
(Kocisko et al. 2006; Doh-ura et al. 2004; Sethi et al.
2002; Priola et al. 2000; reviewed in Brazier et al. 2009),
especially given our treatment commenced shortly after
inoculation. The M1000 strain is of human origin, and
while the lesion profile (with emphasis of spongiform
change in the hippocampus and thalamus) and the incuba-
tion period (Brazier et al. 2006) are similar to that of
scrapie strains, such as Me7 used in reported animal
treatment models of prion disease showing greater efficacy
(Toupet et al. 2008), it remains to be explored whether
inferior or superior efficacy may occur against other prion
strains or perhaps against the same strain in different hosts.
Further supporting the possibility of strain influences on
pathogenesis and treatment response, for unclear reasons, in
contrast to studies utilizing other prion strains such as
scrapie Rocky Mountain Laboratory (RML), we did not
find that Cu2+ content was significantly reduced in the
brains of our untreated diseased mice (Thackray et al. 2002;
Mitteregger et al. 2009). Of interest, two of the most potent
anti-prion compounds were reported using Tg7 mice
inoculated with 263 K scrapie prions (Doh-ura et al.
2004; Kocisko et al. 2006) suggesting that particular
strain/host combinations may be more inherently amenable
to therapy. There is also great interest in the use of genetic
models of prion disease, for example the A117V mouse
model of GSS (Wenbin et al. 2009), in the study of anti-
prion therapeutics.
We have previously found that  20 ID50 units is the
lowest dose of M1000 prions to result in a 100% attack rate
(Collins et al. 2005). In keeping with previous studies
investigating the therapeutic efficacy of D-PEN (Sigurdsson
et al. 2003) and simvastatin (Mok et al. 2006), an extension
of survival from Na2CaCDTA treatment was achieved only
in mice inoculated with a lower dose of M1000 prions
whereas, for poorly defined reasons, the treatment had no
effect after inoculation with a high dose. As Mn2+ has been
shown to stabilize and increase the survival of infectious
prions (Davies and Brown 2009), it appears possible that our
chelator, at the dose administered, only possessed activity
capable of destabilizing the level of infectivity generated by a
low dose inoculum. Hence, while many drugs have been
shown to have a potent anti-prion effect in mice after high
dose inoculation (Priola et al. 2000; Sethi et al. 2002; Doh-
ura et al. 2004; Kocisko et al. 2006), it appears that high
dose inoculation may initiate transmission and pathogenesis
on too large a scale for less potent drugs such as simvastatin,
D-PEN and Na2CaCDTA to provide benefit. A more
biologically potent manganese chelator may provide superior
hindrance to the production of PrPSc, although as alluded
above, it is conceded that the precise ‘toxic species’ in prion
disease and its relationship to Mn2+ remains uncertain and a
greater reduction in brain Mn2+ increases the potential for
deleterious side effects.
Cumulatively, our findings raise the possibility that Mn2+
may facilitate conversion to PrPSc through pathways that are
largely irrelevant to pathogenesis or that the contribution of
Mn2+ to PrPSc production is dispensable or relatively
superfluous in comparison to the small amount required for
efficient pathogenesis. The progressive and considerable
Mn2+ accumulation in the brain during the incubation period
may therefore possibly represent more of an epiphenomenon
or be simply a consequence of pathogenesis. Our results, in
conjunction with previous related reports (Brown et al. 2000;
Treiber et al. 2006; Brazier et al. 2008), allow us to propose
a mechanism for the involvement of manganese in prion
pathogenesis as follows (Fig. 7). Copper has a stabilizing
effect, with PrPC more readily undergoing conformational
change to a pliable pathological intermediate, perhaps as part
of normal turnover, as it loses bound copper ions. Manganese
may then associate with the metastable intermediate and non-
exclusively facilitate conversion and the acquisition of
proteinase resistance, as well as promote higher order
aggregation of PrP (Thackray et al. 2002; Giese et al.
2004; Tsenkova et al. 2004; Levin et al. 2005) with eventual
deposition as plaques. Copper released from PrPC or a
metastable intermediate conformation of PrP, or Mn2+ bound
to the conformationally altered PrP, may also be able to
participate in oxidative reactions contributing to pathogenesis
through cellular damage and neuronal loss. Hence, to
reconcile the observation that large quantities of Mn2+
accumulate in the brain during the course of prion disease
with our findings, we postulate that Mn2+ is likely to be only
one factor involved in the conformational change of PrPC to














Fig. 7 Proposed mechanism for the involvement of manganese in
prion pathogenesis. As part of normal protein turnover or the template-
driven conformational change, prion protein (PrPC) loses affinity for
Cu2+ generating an infectious toxic intermediate PrP*. This alteration
of PrPC conformation to PrP* then allows Mn2+ (or other cofactors) to
become associated, facilitating the stabilizing conversion to PrPSc with
subsequent aggregation of oligomers and protofibrils into PrP plaques
(Thackray et al. 2002; Giese et al. 2004; Tsenkova et al. 2004; Levin
et al. 2005). Dotted lines represent associated reactions.
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Recent studies utilizing dietary modulation of copper and
manganese during the incubation period of prion disease lend
support for our proposed model of manganese involvement
in PrPSc propagation although some apparent inconsistencies
remain. Kralovicova et al. (2009) have demonstrated that
reduced dietary copper causes decreased in vivo expression
of the neuronal prion protein, considered to be a protective
strategy against infection (Brazier et al. 2009), although mice
fed a low-copper diet prior to and during scrapie incubation
displayed a significantly shortened survival time (Mitteregger
et al. 2009). Also, an elevated dietary copper intake has been
shown to delay the onset of symptoms (Hijazi et al. 2003)
and the terminal stage of scrapie-infection in mice when
compared with controls fed a standard diet (Mitteregger et al.
2009). Studies of the influence that copper and manganese
have on the aggregation of recombinant PrP suggest that,
although copper is able to induce PrP to adopt a PrPSc-like
conformation, this transition metal renders the protein less
prone to aggregation (Giese et al. 2004; Levin et al. 2005;
Brazier et al. 2008). A study by Hortells et al. (2009) has
demonstrated that mice fed on a copper-depleted diet during
scrapie infection displayed significantly more vacuolar
lesions and activated astrocytes in selected regions of the
brain. These pathologic changes are likely because of
heightened oxidative stress resulting from a reduction of
SOD activity.
Kralovicova et al. (2009) also demonstrated that elevated
dietary manganese increases PrPC expression in mice.
Scrapie prion-inoculated mice fed a manganese-enhanced
diet during the incubation period were found to have suffered
more severe neuronal loss and their brains contained
significantly more PrP-containing plaques when compared
with controls (Hortells et al. 2009) although this diet had no
influence on the animals’ incubation periods (Mitteregger
et al. 2009). In accord, our high dose inoculated mice treated
for the entire incubation period with intensive Na2CaCDTA,
which was shown to specifically and significantly remove
brain manganese during the incubation period, displayed
significantly less protease resistant PrPSc when compared
with late-treated and untreated controls. Nevertheless, as
already stated, while Mn2+ is likely to facilitate the
conformational change of PrPC to PrPSc (Giese et al. 2004;
Levin et al. 2005; Brazier et al. 2008), it is conceivable that
the major role for manganese in prion disease is through a
late downstream effect, simply facilitating higher orders of
PrPSc aggregation and perhaps plaque formation (Fig. 7)
which, while serving as a useful disease marker, is mech-
anistically largely unimportant for pathogenesis.
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Section 7: Studies of Human Prion-like Diseases 
Until recently, prion diseases had been construed as biologically unique neurodegenerative 
disorders given a transmissible agent constituted primarily, if not exclusively, by misfolded prion 
protein (PrPSc) free of nucleic acids. Over the last approximately 5-10 years however, numerous 
studies have challenged this unique standing of prion diseases with other misfolded proteins 
such as Abeta, alpha-synuclein and tau appearing to behave in a prion-like manner as far as 
mechanisms of propagation, along with inter-cellular transfer and inter-organismal 
transmissibility. Although many issues remain to be resolved in relation to this blurring of the 
margins between prions and other proteins underscoring non-prion neurodegenerative diseases, 
such as AD (Abetaβand tau) and PDD (alpha-synuclein), there seems little doubt that the 
previous neat biological demarcation of prion diseases from other neurodegenerative disorders 
will stay relegated to history. One of the important issues to resolve is whether subsequent to 
transmission, the propagation and accumulation of non-prion proteins such as Abeta in a new 
host culminate in a disease phenotype or remain sub-clinical. ceVery recent work suggests the 
pendulum is swinging towards the likelihood of eventual overt expression of disease in at least 
some individuals, with the propagated Abeta deposited in cerebral blood vessels as CAA likely to 
be causally associated with spontaneous intra-cranial haemorrhage in relatively young people 
who have undergone treatments (eg dura mater grafts) associated with the deposition of Abetaβ 
proteopathic seeds in or around their brains in early childhood. 
My research further supports this revision of the clear-cut demarcation between prion diseases 
and other neurodegenerative disorders. A large multi-national collaborative study that included 
Australian patients reported a disproportionately high prevalence of Abeta deposited in the brains 
(as both CAA and parenchymal plaques) in persons who developed iatrogenic CJD many years 
following cadaveric pituitary hormone treatments and Lyodura (dura mater) grafts, almost 
certainly due to the concomitant tainting of these therapeutics with both PrPSc and Abeta. 
Moreover, I very recently reported a significant increase of deaths from spontaneous intra-
cerebral haemorrhage amongst Australian recipients of cadaveric pituitary hormones, consistent 
with the hypothesis that such treatments were contaminated by Abeta leading to CAA in the 
absence of PrPSc. 
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Abstract
The presence of pathology related to the deposition of amyloid-β (Aβ) has been recently reported in iatrogenic
Creutzfeldt-Jakob disease (iCJD) acquired from inoculation of growth hormone (GH) extracted from human
cadaveric pituitary gland or use of cadaveric dura mater (DM) grafts.
To investigate this phenomenon further, a cohort of 27 iCJD cases – 21 with adequate number of histopathological
sections – originating from Australia, France, Italy, and the Unites States, were examined by immunohistochemistry,
amyloid staining, and Western blot analysis of the scrapie prion protein (PrPSc), and compared with age-group
matched cases of sporadic CJD (sCJD), Alzheimer disease (AD) or free of neurodegenerative diseases (non-ND).
Cases of iCJD and sCJD shared similar profiles of proteinase K-resistant PrPSc with the exception of iCJD harboring
the “MMi” phenotype. Cerebral amyloid angiopathy (CAA), either associated with, or free of, Thioflavin S-positive
amyloid core plaques (CP), was observed in 52% of 21 cases of iCJD, which comprised 37.5% and 61.5% of the
cases of GH- and DM-iCJD, respectively. If only cases younger than 54 years were considered, Aβ pathology
affected 41%, 2% and 0% of iCJD, sCJD and non-ND, respectively. Despite the patients’ younger age CAA
was more severe in iCJD than sCJD, while Aβ diffuse plaques, in absence of Aβ CP, populated one third of sCJD.
Aβ pathology was by far most severe in AD. Tau pathology was scanty in iCJD and sCJD.
In conclusion, (i) despite the divergences in the use of cadaveric GH and DM products, our cases combined with
previous studies showed remarkably similar iCJD and Aβ phenotypes indicating that the occurrence of Aβ
pathology in iCJD is a widespread phenomenon, (ii) CAA emerges as the hallmark of the Aβ phenotype in iCJD
since it is observed in nearly 90% of all iCJD with Aβ pathology reported to date including ours, and it is shared by
GH- and DM-iCJD, (iii) although the contributions to Aβ pathology of other factors, including GH deficiency, cannot
be discounted, our findings increase the mounting evidence that this pathology is acquired by a mechanism
resembling that of prion diseases.
Keywords: Amyloid-β, Pathology, iCJD, Cerebral amyloid angiopathy, Thioflavin S
* Correspondence: ixc20@case.edu; pxg13@case.edu
1Departments of Pathology, Case Western Reserve University, School of
Medicine, Cleveland, OH 44106, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cali et al. Acta Neuropathologica Communications  (2018) 6:5 
DOI 10.1186/s40478-017-0503-z
Introduction
The key pathogenic event of all prion diseases is the
conversion of a normal or cellular prion protein (PrPc)
into a misfolded and disease-associated isoform com-
monly identified as scrapie prion protein (PrPSc) or
prion. Newly converted PrPSc then propagates and accu-
mulates preferentially in the central nervous system
(CNS) typically accompanied by spongiform degener-
ation, gliosis and neuronal cell death. These pathogen-
etic features apply especially to Creutzfeldt-Jakob disease
(CJD), by far the most common human prion disease.
The pathogenic mechanism based on the conformational
conversion of PrPC into PrPSc, which then acts as a seed,
can conceptually accommodate not only PrPSc accumu-
lation and propagation in the affected subject, but also
the potential transmission of the process from affected
to non-affected subjects. Although the sporadic and
inherited forms account for the majority of human prion
diseases [24], less than 1% of the prion diseases is ac-
quired from animals or humans via an infectious mech-
anism [7]. Within this group, iatrogenic CJD (iCJD) is of
particular interest. More than 492 cases of iCJD have
been reported worldwide [4]. Most cases have been associ-
ated with the administration of growth hormone (GH) ex-
tracted from cadaveric pituitary glands and the application
of cadaveric dura mater (DM) grafts [7]. The existence of
iCJD and experimental evidence have firmly established
the infectious property of prion diseases [18, 26, 27].
The central pathogenic event in Alzheimer’s disease
(AD), the most common cause of dementia, is the de-
position of amyloid β (Aβ), a truncated fragment of the
amyloid precursor protein (APP), which leads to the for-
mation of extracellular Aβ plaques [22, 30]. Deposition
of highly phosphorylated, microtubule-associated tau
protein (p-tau) also occurs [57] and, is believed to be a
downstream event [33]. Most evidence indicates that de-
position of Aβ and p-tau in the affected brain is stereo-
typical and hierarchical [5, 63]. More recently, it has
been pointed out that Aβ and p-tau mimic several major
characteristics of PrPSc including mechanisms of accu-
mulation and propagation and formation of distinct Aβ
and p-tau species that fulfill some of the characteristics
of strains [16, 28, 56, 67, 68]. Like PrPSc, Aβ has been
detected in tissues other than CNS parenchyma includ-
ing dura mater and pituitary glands [35, 43]. Further-
more, Aβ and p-tau pathologies (but not fully developed
AD) have been replicated following Aβ or p-tau intrace-
rebral or peripheral inoculations to transgenic mice that
express human APP harboring AD pathogenic mutations
as well as wild type human APP, indicating that Aβ path-
ology is transmissible [11, 20, 47, 48, 70]. In contrast to
prion diseases, there is no evidence that AD and/or
tauopathy (e.g., frontotemporal lobar degeneration)
transmit from human-to-human.
Five recent studies have independently reported the
presence of significant Aβ pathology in 4 of 8, 18 of 33,
and 1 of 24 cases of iCJD from the United Kingdom
(UK) and France, linked to injections of cadaveric GH
(GH-iCJD) [19, 37, 53], and in 5 of 7 Swiss and Austrian
iCJD and 13 of 16 Japanese iCJD cases who had received
DM grafts (DM-iCJD) [23, 31]. In the most severely af-
fected cases, Aβ amorphous aggregates were also
detected in the pituitary gland and DM [37, 43]. The
concomitant presence of Aβ and PrPSc deposits result-
ing in mixed AD and CJD phenotypes has been re-
ported [8, 25, 50, 65]. However, while the AD-CJD
mixed phenotype has been observed in older CJD-
affected individuals [29, 64], most of the 28 iCJD cases
harboring significant Aβ pathology were under 55 years
of age [19, 23, 37, 53]. A possible explanation for the
higher prevalence of Aβ pathology at a relatively young
age in iCJD-affected subjects is that both Aβ and PrPSc
seeds are transmitted during the iatrogenic procedures
and then accumulate and propagate concurrently. How-
ever, Ritchie and coworkers have also observed brain
Aβ pathology in absence of PrPSc deposition in recipi-
ents of cadaveric GH [53]. This important finding
strongly argues for human-to-human transmission of
an Aβ-related condition independently from the PrPSc
seeding process. Nonetheless, whether the neuroendo-
crine deficiency may favor the Aβ pathology in some
cases is still unknown [21].
To further investigate the iatrogenic seeding of Aβ path-
ology, we examined whether this condition occurs not
only with UK and French GH as previously described but
with receipt of GH produced before 1977 in the United
States (US) as well. All US GH-iCJD patients to date re-
ceived GH made before 1977, when a GH purification
procedure was adopted that reduced or eliminated prion
contamination. We also wanted to further examine the
phenotypes of the DM-iCJD linked to the use of the Lyo-
dura® brand. Out of 27 cases of definite iCJD, we selected
21 which were suitable for detailed histopathological
examination and were provided by national prion surveil-
lance centers of Australia, France, Italy, and the US. Cases
of sporadic CJD (sCJD), non-neurodegenerative disorders
(non-ND), and AD were used as comparison groups. Two
autopsied cases who underwent GH treatment but did not
develop iCJD were also examined. We report that (i) over
50% of iCJD cases harbored significant Aβ pathology,
which included cerebral amyloid angiopathy (CAA) in all
cases; (ii) the prevalence of the Aβ-positive iCJD subset
was significantly higher than that of Aβ-positive sCJD
cases, which were on average 17 years older; (iii) p-tau
pathology was present but did not distinguish Aβ-positive
iCJD cases from the sCJD controls, and seemed to be age-
related; (iv) the phenotypic characteristics of the Aβ
pathology in iCJD were distinct from those of typical AD.
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Materials and methods
Reagents and antibodies
Dulbecco’s Phosphate Buffered Saline (DPBS), NaCl,
Nonidet P-40, Sodium deoxycholate, Tris–HCl, Phenyl-
methanesulfonyl fluoride (PMSF), proteinase K (PK),
Thioflavin S, and Kodak Biomax MR and XAR films
were from Sigma-Aldrich (St. Louis, MO, USA). Tween
20, β–mercaptoethanol, Tris buffered saline (TBS), 2X
Laemmli sample buffer, non-fat dry milk, 15% Criterion
Tris–HCl polyacrylamide precast gels, 30% Acrylamide/
Bis solution, tetramethylethylenediamine (TEMED), 10%
sodium dodecyl sulfate (SDS) and ammonium persul-
phate (APS) were from Bio-Rad Laboratories (Hercules,
CA, USA). Odyssey Blocking Buffer was from LI-COR
Biosciences (Lincoln, NE, USA); polyvinylidene difluor-
ide (PVDF) membrane (Immobilon-FL and Immobilon-
P) was from EMD Millipore (Billerica, MA, USA). The
primary antibodies (Abs) included the AT8 (to human
phospho-tau residues Ser202 and Thr205) from Thermo
Fisher Scientific Inc. (Waltham, MA, USA), 4G8 (to hu-
man Aβ residues 17–24), and 3F4 (to human PrP resi-
dues 106–110) [38, 71] from Richard Kascsak at the
N.Y.S. Institute for Basic Research; 12B2 (to human PrP
residues 89–93) [45] was from the Wageningen Univer-
sity & Research (Lelystad, Netherlands), whereas
Tohoku-2 (to human PrP residues 97–103) [42] was
kindly provided by Dr. Tetsuyuki Kitamoto. Secondary
Abs were the sheep anti-mouse IgG from Life Sciences
(Piscataway, NJ, USA), IRDye 800CW goat anti-mouse
IgG (1 mg/ml) and IRDye 680RD goat anti-rabbit IgG
(1 mg/ml) from LI-COR Biosciences (Lincoln, NE,
USA). Reagents ECL and ECL plus were from GE
Healthcare, Life Sciences (Piscataway, NJ, USA);
Envision Flex Peroxidase Blocking Reagent, Envision
Flex/HRP and Envision Flex DAB were from Dako
(Dako North America Inc., Carpinteria, USA); the Vecta-
shield mounting medium for fluorescence was from
Vector Laboratories Inc. (Burlingame, CA, USA).
Patients
Brain tissue from 27 confirmed iCJD patients was col-
lected in this study. Thirteen of these cases were associ-
ated with cadaveric GH extracted from pituitary glands,
whereas the other 14 cases were associated with cadav-
eric DM graft (Table 1 and Additional file 1: Table S1).
All GH-iCJD were from the US and were treated with
GH under the US National Hormone and Pituitary Pro-
gram and started their treatment between 1969 and
1974. Tissue from 12 of the 13 US GH-iCJD was ob-
tained at autopsy and one at biopsy. Two DM-iCJD were
US cases, but only one -a 26 years old man -had re-
ceived the Lyodura® brand dura (B. Braun Melsungen
AG, Melsungen, Germany) (DML-iCJD) whereas the
other case -a 39 years old woman -had received the
Tutoplast® brand dura (Pfrimmer-Viggo GmbH + Co,
Erlangen, Germany) (DMT-iCJD). An important differ-
ence between these brands of dural graft is that unlike
Tutoplast, Lyodura brand dural grafts were intermingled
with many other dural grafts during the manufacturing
procedure, thereby increasing the risk of cross-
contamination. Other DM-iCJD cases included 1) two
cases from the Australian National CJD Registry
(Melbourne, Australia), 2) six cases from the Réseau
National de Référence de maladies de Creutzfeldt-Jakob
and Centre National de Référence des agents transmissi-
bles non conventionnels (Paris, France), and 3) four
cases from the Istituto Superiore di Sanita’ (Rome, Italy).
With the exception of one French DM-iCJD case, for
which the medical product Lyodura® brand could not be
confirmed, all cases were DML-iCJD. The histopathology
and/or clinical and molecular features have been
published for two US DM-iCJD (cases 1 and 2, Table 1)
[3, 10, 32], three US GH-iCJD (cases 6, 9 and 10, Table 1)
[10], and one Australian DML-iCJD (case 17, Table 1)
[58]. The five distinct comparison groups included 1)
two US non-CJD patients who received the GH between
years 1973–1977 (50 years) or between years 1977–1981
(46 years). The latter case may not have received any of
the pre-1977 produced higher risk US GH material
because 1977 was the transition year when a new
purification procedure of GH extraction was started [1];
2) 67 confirmed sCJD cases from Australia (N = 4),
France (N = 11), Italy (N = 8) and US (N = 44)
(Additional file 1: Tables S1 and S2); 3) 11 US autopsied
cases of non-ND with age at death of 40 ± 12 years
(range, 25–59 years) following diagnosis of blood cancer
(N = 3; 25, 27 and 41 years), intracranial tumors (N = 2;
35 and 44 years), hemoglobin sickle cell disease
(28 years), scrotal abscess and pulmonary embolus
(31 years), type II diabetes mellitus (47 years), gastrointes-
tinal hemorrhage (50 years), systemic lupus erythematosus
(56 years), end stage renal disease and cardiac arrest
(59 years); 4) seven US cases of AD with age at death of
64 ± 8 years, and disease duration of 75 ± 39 months [12].
Disease duration was not available in one AD case. All
sporadic and iatrogenic CJD cases were classified accord-
ing to Parchi and collaborators (1999). Since all Aβ-
positive cases had multiple cortical sections not all of
which were positive, we excluded from the study six Aβ-
negative cases with only one section available.
All of the US iCJD and the two CJD-free recipients of
GH were collected at the National Prion Disease Path-
ology Surveillance Center (NPDPSC) in Cleveland (OH)
in collaboration with the National Institute of Diabetes,
Digestive and Kidney Diseases, NIH, (Bethesda, MD)
and Division of High Consequence Pathogens and
Pathology, CDC, (Atlanta, GA) and Westat Agency
(Rockville, MD). The AD and US sCJD controls were









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cali et al. Acta Neuropathologica Communications  (2018) 6:5 Page 4 of 19
from the NPDPSC whereas the 11 non-ND cases were
collected in the repository of the Department of Path-
ology at Case Western Reserve University. The neuro-
pathological study was carried out either in our
laboratory or in the laboratories of the participating
countries. Neuropathology was reviewed by IC and MC.
Western blot (WB) examination of iCJD cases was per-
formed in our laboratory in Cleveland (cases 2, 6–10, 24,
26 and 27, Table 1), at University of California, San
Francisco (UCSF) (case 5) as well as in France (case 19,
Table 1) and Italy (cases 24, 26 and 27, Table 1).
Histology and immunohistochemistry
Formalin-fixed brain tissue was treated as previously de-
scribed [9]. Briefly, sections were deparaffinized and
rehydrated, immersed in 1X Tris buffered saline-Tween
20 (TBS-T), and endogenous peroxidase blocked after
incubation with the Envision Flex Peroxidase Blocking
Reagent for 10 minutes (min). Sections were washed,
immersed in 1.5 mmol/L hydrochloric acid, microwaved
for 15 min and probed with Abs 3F4 (1:1000), 4G8
(1:3000), and AT8 (1:200) for 1 hour (h). After washing
and incubation with Envision Flex/HRP polymer for
30 min, sections were treated with Envision Flex DAB to
show the immunostaining.
Thioflavin S staining
After deparaffinization, formalin-fixed sections were
stained in Thioflavin S for 7 min, washed three times in
80% alcohol, dehydrated in ethanol, cleared in xylene,
and cover slipped with Vectashield mounting medium
for fluorescence. Sections were kept in the dark at 4 °C
for 30 min before being viewed under the fluorescence
microscope (Olympus IX71).
Evaluation of the histopathological changes associated
with Alzheimer’s disease and Prion disease
Histopathological evaluation was performed in 10 or
more anatomical regions in most cases. Standard brain
locations included the frontal, temporal, parietal,
occipital and entorhinal cortices, hippocampus, stri-
atum, thalamus, midbrain and cerebellar hemispheres
and/or vermis. Histopathological evaluation included 1)
Hematoxylin-eosin (HE) staining, to assess the presence
of spongiform degeneration, gliosis, and amyloid Aβ
cores; 2) Immunostaining with Abs 4G8, AT8 and 3F4
to Aβ, p-tau and PrP, respectively; 3) Staging of Aβ pla-
ques using monoclonal Ab 4G8 and Thioflavin S, ac-
cording to Thal et al. [63]. This method identifies five
major stages or phases of Aβ plaques deposition affect-
ing the neocortex, including frontal, temporal, parietal
and occipital cortices (Phase 1), hippocampus and ento-
rhinal cortex (Phase 2), striatum thalamus and mid-
brain (Phase 3–4), and cerebellum (Phase 5); 4)
Description of the morphology of the Aβ plaques, in-
cluding a) diffuse plaques, b) core plaques (CP) (i.e., a
plaque with a dense core surrounded by a halo and a
corona of lightly stained Aβ), c) neuritc plaques (i.e., a
core plaque surrounded by p-tau dystrophic neurites);
5) Staging of Aβ CAA, according to previous proce-
dures [61] with recognition of three major phases: CAA
affecting the neocortex (Phase 1), hippocampus, ento-
rhinal cortex, cerebellum and midbrain (Phase 2), stri-
atum and thalamus (Phase 3); 6) Typing of CAA,
identified as CAA type 1 or type 2 depending on the
presence or absence of Aβ deposits in the cortical capil-
laries [60]. The criteria for the identification of CAA
type 1 were i) diameter of the vessels ≤ 10 μm, and ii)
deposition of Aβ in the outer basement membrane; 7)
Severity of CAA, based on a modified protocol by Vonsat-
tel and coworkers that uses 4G8-stained sections (with the
addition of Thioflavin S in some cases) instead of Congo
red [66]; 8) Brain distribution of neurofibrillary tangles
(NFT) and neocortical distribution of dystrophic neurites
(DN); 9) Severity of NFT and DN expressed as NFT or
DN density in one microscopic field (area: 1.3 × 1.0 mm2,
using a 10X objective) harboring the highest density of
NFT or DNs in one or more brain regions; severity was
scored as mild (≤ 10 NFT or DN), moderate (> 10 to < 30
NFT or DN) and severe (≥ 30 NFT or DN); 10) Auto-
mated image acquisition and morphometric analysis to as-
sess density (expressed as the percentage of the area of the
cerebral cortex occupied by plaques) and size (diameter)
of Thioflavin S-positive Aβ core plaques as well as size
(perimeter) of the blood vessel; 11) Semiquantitative ana-
lysis of the percentage of 4G8-positive Aβ deposits along
the wall of blood vessels; and 12) Double immunostaining
with 4G8 and 3F4 to rule out the co-localization of PrP
and Aβ [25].
Image acquisition and statistical analysis
Image acquisition was carried out with a Leica DFC 425
digital camera mounted on a Leica DM 2000 microscope.
Images were analyzed by the software Image-Pro Plus 7.0
(Media Cybernetics, Inc.). Cumulative survival curves
were generated by the Kaplan–Meier analysis. Statistical
significance between the survival curves of the individual
groups were determined by the log rank (Mantel-Cox)
test. When comparing different patient groups, P-values
were calculated with Chi-square test, Fisher’s exact test,
Student’s t-test (two-tailed). All the statistical analyses
were performed using GraphPad Prism 6.0.
Preparation of brain homogenates, proteinase K digestion
and Western blot analysis
10% (wt/vol) brain homogenates (BH) prepared in 1X
LB100 buffer (100 mM NaCl, 0.5% Nonidet P-40, 0.5% so-
dium deoxycholate, 10 mM EDTA, 100 mM Tris–HCl,
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pH 6.9 at 37 °C), were centrifuged at 1000 x g for 5 min at
4 °C, pellets discarded and supernatants (S1) collected. S1
aliquots were incubated with 100 U/ml PK at 37 °C for
1 h [PK specific activity was 48 U/mg at 37 °C, with
1 U/ml equal to 20.8 μg/ml PK]. The enzymatic diges-
tion was stopped with PMSF (3 mM final concentra-
tion). Each sample was diluted with an equal volume of
2X Laemmli sample buffer (6% SDS, 20% glycerol,
4 mM EDTA, 5% β –mercaptoethanol, 125 mM Tris–
HCl, pH 6.8) and denatured at 100 °C for 10 min. Proteins
were separated on 15% Criterion™ Tris–HCl Precast Gels
(W x L: 13.3 cm × 8.7 cm) at 120 Volts (V) for 20 min
followed by 150 V for 1 h 45 min, or using 15% Tris–HCl
SDS–polyacrylamide gels (W x L: 20 cm× 20 cm) at
25 mA/gel for 1 h 45 min followed by 35 mA/gel for 6 h
30 min (Bio-Rad PROTEAN® II xi cell system). For near-
infrared WB analysis, proteins were blotted onto the
Immobilon-FL PVDF membrane for 2 h, blocked with the
Blocking Buffer Odyssey for 45 min and incubated with
Abs 3F4 (1:20,000), 12B2 (200 ng/ml) or Tohoku-2
(1:10,000) for 2 h. Membranes were then washed with 1X
DPBS containing 0.1% of Tween 20 (1X DPBS-T) and
incubated with Abs IRDye 800CW goat anti-mouse IgG
(1:15,000) or IRDye 680RD goat anti-rabbit IgG (1:15,000)
for 1 h. After washing in 1X DPBS-T, membranes were
developed with the Odyssey infrared imaging system (LI-
COR Biosciences) as described by the manufacturer. For
chemiluminescence, proteins were blotted onto the
Immobilon-P PVDF membrane, blocked with 5% non-fat
dry milk in 0.1% Tween 20-1X TBS (blocking buffer), and
incubated with primary Abs and horseradish peroxidase-
conjugated goat anti-mouse secondary Ab (1:3000).
Membranes were developed by the enhanced chemilumi-
nesce reaction using ECL and ECL plus reagents, and
signal captured on MR and XAR films.
Clinical evaluation
Medical records were reviewed by a clinician (BSA) and
data were collected on demographics (age at death, gen-
der, and race/ethnicity). Disease onset was defined as the
time at which the first persistent and consistent symp-
tom of prion disease was observed. Data on family his-
tory of dementia as well as past medical and surgical
history were also collected. The mean incubation period
in iCJD was measured from the mid-point of GH ther-
apy or date of receipt of the DM graft to the clinical on-
set of the disease.
Genetic analysis
DNA was extracted from frozen brain tissues and APP,
presenilin 1 (PSEN1), presenilin 2 (PSEN2), and PRNP
gene analysis was performed as previously described using
Illumina and Sanger Sequencing for exons 4 and 5 in
PSEN1 [12]. Sequencing analysis was performed using
Mutation Surveyor Version 4.0.7 (Softgenetics, State Col-
lege, PA). Genotyping of Apolipoprotein E (ApoE) single-
nucleotide polymorphisms was performed by Sanger se-
quencing (Center for Human Genetics, Cleveland, OH).
Results
Demographics, molecular features and histopathological
phenotype of iCJD and controls including sCJD
We examined 27 cases of iCJD linked to cadaveric DM
graft (N = 14) or GH (N = 13), who received the iatro-
genic treatment in Australia, France, Italy and the US
(Table 1). Sixty-seven cases of sCJD obtained from the
same countries as the iCJD cases were used as controls
(Additional file 1: Table S2). The sCJD case population
was selected to be as similar to the age of the iCJD case
population as possible. As expected, the iCJD cases had
a higher percentage of premorbid neurological condi-
tions (including intracranial tumors and head trauma)
and neurosurgery given that these conditions often led
to treatment with GH and/or DM grafts. No statistical
correlations were found when intracranial tumor or
head trauma were tested against either Aβ or tau
pathologies in the iCJD and sCJD populations (Add-
itional file 1: Table S3). Both iCJD and sCJD cohorts
were compared to a seven case group with typical AD
(Tables 2 and 3, and Additional file 2: Table S6). The
iCJD cases were stratified by country of origin, age at
death, disease durations and incubation period (Table 1).
The data stratified according to diagnosis, i.e. all-iCJD,
GH-iCJD, DM-iCJD and sCJD, as well as according to
the age at death, i.e. ≤ 54 years (“young”) and > 54 years
(“old”) are shown in Additional file 1: Table S1 and
Additional file 3: Figure S1. For all the cases combined,
the three iCJD diagnostic groups revealed no significant
difference in mean age at death, disease duration and
median survival, while the incubation period was sig-
nificantly shorter in DM-iCJD than in GH-iCJD (P <
0.0001) (Additional file 1: Table S1 and Additional file 3:
Figure S1). Separation of cases into young and old sub-
sets underscored the younger age of the GH-iCJD
cases, which exclusively populated the young group,
and the wide age range of DM-iCJD (Additional file 1:
Table S1). In the young group, the incubation period
again was significantly shorter in DM-iCJD than GH-
iCJD (P < 0.002). Overall, disease duration and incuba-
tion period were significantly shorter in the older group
(P < 0.0008 and P < 0.03, respectively) (Additional file 1:
Table S1). The sCJD control population was 8 years
older at death than the iCJD population while disease
duration was comparable in the two conditions. Spor-
adic CJD young cases had a mean age at death compar-
able to that of GH-iCJD while disease duration in old
cases matched that of DM-iCJD (Additional file 1:
Table S1).
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With regard to the molecular features, the percent dis-
tribution of the three genotypes (MM, MV, VV) at
codon 129 of the PrP gene in the iCJD population (MM
43%, MV 33%, VV 24%) significantly differed from that
of the sCJD controls (MM 65%, MV 18%, VV 17%) as
well as those reported for unselected sCJD populations
(MM 71%, MV 12%, VV 17%) [15] pointing to an in-
creased relative prevalence of the MV and VV genotypes
at the expense of the MM genotype in our iCJD cohort
(Fig. 1). The iCJD genotype distribution also differed
from those of Western European, Australian and the
North American general populations (MM 37%, MV
51%, VV 12%) [14]. Keeping in mind the limited number
of cases for some of these analyses, 129 genotype distri-
bution also diverged in the GH-iCJD and DM-iCJD
subsets: while the relative representation of the MV geno-
type was increased in both subsets, the DM-iCJD showed
a three times higher representation of the VV genotype
(33% vs. 11%) (Fig. 1). Analyses of the PK-resistant PrPSc
(resPrPSc) type distribution showed that in iCJD the com-
bined representation of types 2 (with unglycosylated
resPrPSc of ~19 kDa), “intermediate” (i; ~20 kDa), i + 2
(~20 + 19 kDa), and 1 + 2 (~21 + 19 kDa) (63%) was much
higher than the representation of combined type 2 and
i + 2 (28%) in sCJD unselected populations [15, 49], as
well as in our sCJD controls, a finding consistent with
the combined prevalence of the MV and VV genotypes
which often are paired with type 2 and i + 2 (Fig. 1).
Next, we compared phenotypic characteristics, such as
disease duration and histopathological features in age-
Table 2 Staging and amyloid presence in Aβ CP from iCJD associated with Aβ pathology along with cases of sCJD and AD used as
controls




PrPSc type Phase 1 Phase 2 Phase 3-4 Phase 5
Neocortex Thiofl Hippoc. Thiofl Subcortical Thiofl Cerebellum Thiofl
iCJD
1 (1)a 26 5 na na +++b,c +d ++ - +e - + -
2 (19) 29 6 MV 1 +++f + + + - nt - nt
3 (8) 44 18 MV i+2 ++++ + ++ - +++ - - -
4 (9) 51 14 MM i - - - - - nt + +
5 (17) 62 2 na na ++++ +g na na na na - -
mean±SD 42±15 9±7 78%h 62.5% 40% 40%
sCJD
1 (57)i 63 3 MV 1 +++f + ++ + ++ nt - nt
2 (59) 71 9 MV 2 +f + - - - nt - nt
3 (65) 71 10 VV 2 + + - nt - nt - nt
4 (67) 79 6 VV 2 +++ + - nt - nt - nt
mean±SD 71±6.5 7±3 57% 25% 17% 0%
P valuej NS NS NS NS
AD
1 56 60 na na ++++ + ++ + +++ + + +
2 56 60 na na ++++ + ++ + +++ + + +
3 59 na na na ++++ + ++ + +++ + + +
4 60 130 na na ++++ + ++ + +++ + + -
5 70 66 na na ++++ + ++ + +++ + + +
6 72 111 na na ++++ + ++ + +++ - + +
7 74 22 na na ++++ + ++ + +++ + + +
mean±SD 64±8 75±39 100% 100% 100% 100%
P valuek < 0.02 < 0.04 < 0.0004 < 0.05
Phases 1 to 5 refer to Aβ plaques deposition in various brain regions reflecting disease progression according to Thal et al [63]; a,iNumbers in parenthesis in the
first column refer to numerals used in aTable 1 and iAdditional file 1: Table S2; bMinus and plus signs indicate absence (-) or presence (+) of Aβ pathology
affecting one (+), two (++), three (+++) or four (++++) of the brain regions that characterize each phase; Phase 1: frontal, temporal, parietal and occipital cortical
regions; Phase 2: hippocampus and entorhinal cortex; Phase 3-4: striatum, thalamus and midbrain; Phase 5: cerebellum; c,eRefers to one iCJD with one or two
missing sections from the cneocortex or esubcortical regions; dThe (+) sign under Thiofl (Thioflavin S) indicates presence of amyloid plaques in at least one brain
region; the (-) sign indicates that all regions tested had Thioflavin S negative staining; fRefers to one iCJD and two sCJD cases with missing parietal cortex;
gPositive staining with Congo red [58]; hPercentage of brain regions with CP; j,kFisher’s exact test comparing iCJD to jsCJD or kAD; Hippoc. hippocampal formation
(hippocampus and entorhinal cortex), y years, durat. duration, mo months, na not available, nt not tested, NS not significant, SD standard deviation
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group matched cases of iCJD and sCJD controls which
shared both 129 genotype and PrPSc type. Iatrogenic
CJD with genotypes 129MM coupled with PrPSc type 1
(iCJDMM1), the only subset with a significant number
of age-group matched cases, showed shorter mean
disease duration than sCJDMM1 (2.7 vs. 5.6 months;
P > 0.05). As for the histopathological features, when
histopathological phenotypes associated with the same
pairing of the 129 genotype and resPrPSc type were
compared, all iCJD phenotypes were found to match









Phase 1 Phase 2 Phase 3 Vstl.a score CAAb type
Neocortex Thiofl Hippoc. Thiofl Crbl Thiofl Midb. Subcort. Thiofl
iCJD
1 (1)c 26 5 na na +++d,e +f ++ + + + na -e - 3 1
2 (19) 29 6 MV 1 +++g + + + + nt + + nt 2 2
3 (16) 32 3.5 MV na +h na - na - na - - na 1 2
4 (8) 44 18 MV i+2 ++++ + ++ - + + - - - 3 2
5 (21) 50 14 MM na +++g + - nt - nt + + nt 1 2
6 (9) 51 14 MM i ++ + - - + + - - - 2 2
7 (10) 54 2 MM 1 + + - - - - - - nt 1 2
8 (17) 62 2 na na ++++ +i na na + +i na na na na na
9 (22) 62 4 VV na ++g - - nt + - + + nt 1 2
10 (23) 71 4 MV na - nt + - + - - - nt 1 2
11 (27) 75 3 VV 2 ++++ - + - + - - - nt 1 2
mean±SD 50.5±17 7±6 69%j 35% 73% 33% 16%
sCJD
1 (55)k 49 4 MM 1 +g - - - - nt - - nt 1 2
2 (56) 63 4 MM 1 +g - ++ - + - + ++ nt 1 2
3 (57) 63 3 MV 1 - - - - + nt - + nt 1 2
4 (44) 64 1 MM 1 ++ + - - - nt - - - 1 2
5 (58) 71 8 VV 2 +++g - ++ - + - - - nt 1 2
6 (66) 74 4.5 VV 2 + - - nt - nt - - nt 1 2
mean±SD 64±9 4±2 38% 33% 50% 17% 25%
P valuel < 0.03 NS NS NS NS = 0.05* NS*
AD
1 56 60 na na ++++ + - - + + + + - 2 2
2 56 60 na na ++++ + - - + + - - - 3 2
3 59 na na na ++++ - - - + + - - - 3 2
4 60 130 na na ++++ - -n - + - - + + 2 2
5 70 66 na na ++++ + + - + + - - - 2 2
6 72 111 na na ++++ + + + + + + + + 3 1
7 74 22 na na +++ - - - + + - + - 3 2
mean±SD 64±8 75±39 96% 15% 100% 29% 29%
P valuem < 0.006 NS NS NS NS < 0.02* NS*
Phases 1 to 3 refer to Aβ CAA deposition in various brain regions, reflecting disease progression according to Thal et al [61]; aVonsattel (Vstl) 0-3 score of Aβ
CAA severity to the highest score in one or more brain locations [66]; bPresence (type 1) or absence (type 2) of Aβ deposits in the cortical capillaries [60];
c,kNumbers in parenthesis in the first column refer to numerals used in cTable 1 and kAdditional file 1: Table S2; dMinus and plus signs indicate absence (-)
or presence (+) of Aβ CAA affecting one (+), two (++), three (+++) or four (++++) brain regions in each phase; Phase 1: frontal, temporal, parietal and occipital
cortical regions; Phase 2: hippocampus, entorhinal cortex, cerebellum and midbrain; Phase 3: striatum, thalamus; eRefers to one iCJD patient with one missing
section from neocortex and subcortical regions; fThe (+) sign under Thiofl (Thioflavin S) indicates presence of positive staining of at least one brain region;
the (-) sign indicates that all regions examined had Thioflavin S negative staining; gRefers to 3 iCJD and 3 sCJD cases with missing parietal cortex; hRefers to
one iCJD with missing frontal cortex; iPositive staining with Congo red [58]; jPercentage of brain regions with Aβ CAA; l,mFisher’s exact test comparing iCJD
to lsCJD or mAD; nRefers to one AD patient with missing entorhinal cortex; y years, mo months Hippoc. hippocampal formation (hippocampus and entorhinal
cortex), Crbl cerebellum, Midb. midbrain, Subcort. subcortical regions (striatum and thalamus), na not available, nt not tested, NS not significant,
SD standard deviation; *Student’s t-test
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the phenotypes of the corresponding sCJD, except for
three cases. Two of these cases (GH-iCJD case 9 and
DM-iCJD case 21), both harboring the 129MM geno-
type, had a phenotype characterized by the presence of
kuru plaques resembling sCJDMV2K phenotype, which
is typically not seen in sCJDMM associated either type 1
or 2 (Table 1). However, both these cases matched the
previously described iCJDMMi phenotype [10, 39–41, 54].
The phenotype of the third case (GH-iCJD, case 5), which
was associated with the 129MM genotype and resPrPSc
type 2, differed in several features from typical phenotype
of sCJDMM2. While spongiform degeneration type mim-
icked that of sCJDMM2, it was limited to the first cortical
layers, rather than being widespread in the cerebral cortex,
and it was accompanied by severe neuronal loss and
astrogliosis while kuru plaques were lacking; furthermore,
PrP immunostaining was punctate rather than forming
coarse granular deposits (Additional file 4: Figure S2).
Western blot profiles of the resPrPSc in iCJD and
matching sCJD controls
The profiles of resPrPSc from 10 iCJD suitable cases
(2, 6–10, 19, 24, 26 and 27, Table 1) were compared
with those of sCJD cases harboring the same 129
genotype and resPrPSc type (Fig. 2). This comparative
study revealed that resPrPSc profiles from nine of the 10
iCJD cases matched those of the corresponding sCJD sub-
types (Fig. 2). Thus, probing with 3F4, all CJDVV2 cases
showed an unglycosylated resPrPSc fragment of ~19 kDa,
which typically identifies type 2, whereas CJDMVi + 2
Fig. 1 Ring doughnut charts visualizing distributions of codon 129 genotypes, resPrPSc types and disease phenotypes among iCJD and sCJD cases
examined. a whole iCJD cohort; inner circle: percent distribution of codon 129 genotype (MM, MV, VV); intermediate circle: distribution of resPrPSc types
(T1, T2, Ti, Ti ± 2, T1 + 2); outer circle: distribution of histopathological phenotype. b GH-iCJD, legend as a; c DM-iCJD, legend as a; d sCJD. T1: type 1; Ti:
type intermediate; T2: type 2; Ti + 2: type i + 2; T1 + 2: type 1 + 2; n: number of cases; na: not available; Atyp.: atypical; Undet.: undetermined. Percentages
refer to the distribution of codon 129 genotype
Cali et al. Acta Neuropathologica Communications  (2018) 6:5 Page 9 of 19
cases showed the type i ~20 kDa fragment in addition to
the unglycosylated resPrPSc of ~19 kDa. In both
iCJDMM1 and sCJDMM1, resPrPSc was characterized by
the type 1 (~21 kDa) fragment as well as a faint band of
~20 kDa (Fig. 2 and Additional file 5: Figure S3).
Conversely, iCJDMMi (case 9, Table 1) showed a promin-
ent fragment matching type i and a faint band of ~21 kDa
possibly representing type 1 (Fig. 2 and Additional file 5:
Figure S3). These findings confirm the presence of type i
in iCJDMMi and CJDMVi + 2 [39, 54], and indicate that
in small amounts, a ~20 kDa fragment matching type i in
mobility may be present also in iCJDMM1 and sCJDMM1
while type 1 may be present in iCJDMMi (Fig. 2 and
Additional file 5: Figure S3). Tissue was not available for a
detailed profile determination of resPrPSc from iCJDMM
case 5 (Table 1), but it was reported to be matching
resPrPSc type 2.
Aβ in iCJD, sCJD, prion disease free GH recipients and
non-ND: Prevalence, clinical molecular and phenotype
features
The presence of Aβ pathology was searched for in all of
the 27 iCJD and 67 sCJD cases. Cases were considered
positive when at least one Aβ CP containing amyloid
(Thioflavin S or Congo red positive) and/or one blood
vessel harboring Aβ deposits consistent with CAA were
identified in at least one histology section of a minimum
of two (Table 1, Fig. 3 and Materials and Methods).
Eleven of 21 iCJD cases (52%) fulfilled these selection
criteria. They comprised three of the eight cases of GH-
iCJD, eight of the 13 cases of DM-iCJD including the
two cases of iCJDMMi (cases 9 and 21 of Table 1, Fig. 4
and Additional file 2: Table S4). Despite the relatively
small size of the Aβ-positive iCJD subset, a trend could
be detected when basic clinical and molecular features
as well as the histopathological phenotypes were com-
paratively analyzed in Aβ-affected and -unaffected
groups and their subsets. Subjects harboring Aβ path-
ology were older in each iCJD subset. Age differentials
varied from ~14 to 17 years, while the incubation period
was ~13 years longer in Aβ-positive GH-iCJD cases
(Fig. 5). Regarding the 129 genotype, the prevalence of
the MV and VV genotypes over the MM genotype
observed in all iCJD cohort was slightly increased in
Aβ-positive iCJD cases (57% vs. 66%) (P > 0.05) (Figs.
1 and 5). Furthermore, histopathological phenotypes
were similarly distributed in the two iCJD groups. In
Aβ-positive iCJD cases (8, 9, 10 and 27 of Table 1)
with available frozen tissue the Illumina and Sanger
sequencing of APP, PSEN1, and PSEN2 genes identi-
fied no novel rare variants nor known mutations. Fur-
thermore, ApoE genotyping available in Aβ-positive
iCJD (8, 9, 10 and 27 of Table 1) and sCJD (65, 66
and 67 of Additional file 1: Table S2) cases under-
lined the lack of ApoE-ε4/4, and the presence of
ApoE-ε3/3 in all CJD cases with the exception of one
iCJD (case 8) that had genotype ApoE-ε2/3.
Fig. 2 WB profile of resPrPSc from iCJD and sCJD controls using high resolution gel electrophoresis. BHs from the frontal cortex (lanes 8 and 9) and
cerebellum (lanes 1–7) treated with 100 U/ml PK (~2000 μg/ml) were probed with 3F4. PrP bands were resolved in a 15% Tris–HCl, 20 cm-long gel,
and visualized with the near-infrared LI-COR system. The resPrPSc profiles from iCJD (lanes 1, 3, 5, 7 and 8) and matching sCJD subtypes (lanes 2, 4 and
6) are similar as shown by the co-migration of the unglycosylated resPrPSc type 2 (19) (lanes 1–4) and type 1 (21) (lanes 6–8). The different thickness of
the type 2 (19) band is within the variability range for this subtype. The unglycosylated resPrPSc band of ~20 kDa, also identified as type i (i), is visible in
GH-iCJDMVi + 2 (lane 3), sCJDMVi + 2 (lane 4) and GH-iCJDMMi case (lane 5); a thin band of ~20 kDa (arrowhead) is also present in CJDMM1. An
~18 kDa fragment (18) is also present in CJDVV2 and CJDMVi + 2
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No Aβ pathology was detected in the two GH recipi-
ents, 46 and 50 years old, free of prion disease. However,
the 50-year old case may not have received the higher
risk US GH produced prior 1977.
Similar Aβ pathology was also present in nine of the 67
(13%) sCJD controls (Fig. 4 and Additional file 2: Table
S4). The Aβ-positive cases were on average 20 years older
than the negative cases (P < 0.0001) and had about half
the disease duration (5.5 vs. 10.4 months) (P = 0.029). As
for 129 genotype and PrPSc type, Aβ-positive sCJD
showed a higher relative representation of the MV and
VV genotypes and PrPSc type 2 than the negative cases, a
trend resembling that of iCJD. However, contrary to iCJD,
the MV2K phenotype was not observed but the VV2
phenotype was better represented in sCJD Aβ-positive
cases. Aβ pathology was also searched for in 11 non-ND
cases (age 40 ± 12 years, range 25–59 years). The two
oldest cases (56- and 59-year-old) were Aβ-positive har-
boring CP one and CAA the other (Fig. 4).
Aβ in iCJD, sCJD and AD: Histopathological phenotype,
severity and staging
All Aβ-positive iCJD cases harbored CAA. However, in
about half of these subjects, CAA was accompanied by
CP (CAA+CP) consistent with the presence of two phe-
notypes: CAA alone and CAA+CP (Additional file 2:
Table S4). The mean age of the subjects harboring CAA+
CP was about 15 years younger than that of the sub-
jects with CAA alone (Tables 2 and 3). Although not
statistically significant, this finding suggests that CP
presence is not age-related, but more consistent with
the existence of two phenotypes. In the sCJD cohort,
the presence of CP alone was observed in three of
the nine Aβ-positive cases along with five cases
Fig. 3 Aβ and tau pathology of iCJD, sCJD and AD. a and b typical Aβ CP (arrows) from the frontal cortex of iCJD (a) and AD (b); inset a: Aβ CP
at higher magnification immunoprobed for Aβ (top) or stained with Thioflavin S (bottom); inset b: Thioflavin S-positive Aβ CP. c diffuse plaques
from the frontal cortex of a case of sCJD; inset: Thioflavin S-negative staining of plaques (dashed rectangle). d co-localization of Aβ (cyan dye)
and PrP (brown dye) immunoreactivity in the same plaque from cerebral (I and III) and cerebellar (II) cortices of iCJD. I: plaque exhibiting a
PrP-positive core surrounded by an Aβ immunoreactive crown; II-III: plaques showing either the immunostaining opposite to that of I, with
Aβ-positive core and a PrP immunoreactive crown (II), or random distribution of PrP- and Aβ-reactive aggregates (III). e-g Aβ deposits (e) and
Thioflavin S-positive staining (f and g) of vessels in frontal cortex (e), hippocampus (f) and cerebellum (g) in iCJD; f: DG, Dentate gyrus; g: asterisk,
Aβ CAA in the subarachnoid space between two cerebellar folia. h Aβ CP predominantly affecting the granular layer (Grl. L) and Purkinje layer of
the cerebellum in iCJD (case 9, Table 1); arrow indicates Aβ CP; large and small insets: enlargements of Aβ CP identified by the dashed rectangle
in the main figure and a Thioflavin S-positive Aβ CP, respectively. i-j hippocampus free of tau pathology in iCJD (i) but severely affected in AD (j).
k Tau-positive DN associated with an Aβ CP in frontal cortex of iCJD (case 8, Table 1) (dashed square); top inset: enlargement of tau reactive DN
identified in dashed square; bottom inset: DN associated with a PrP kuru plaque in iCJD (occipital cortex, case 9, Table 1). l globose NFT (arrow)
and neuropil threads (arrowhead) in the nucleus basalis of Meynert of iCJD (case 6, Table 1); inset: flame-shaped NFT in the temporal neocortex
of the same iCJD case. Abs: 3F4 (d), 4G8 (a-e, h) and AT8 (i-l) to PrP, Aβ and phosphorylated tau, respectively; Thioflavin S to Aβ (a-c, f-h)
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harboring CAA and one CAA + CP (Additional file 2:
Table S4). Contrary to iCJD, sCJD cases harboring CP
were older than those CP-free (71 vs. 64 years), pos-
sibly pointing to a relation to aging. Subpial Aβ de-
position was observed in two DM- and one GH-iCJD
young cases (≤ 54 years; cases 1, 8 and 16, Table 1)
and in two old sCJD (> 54 years; cases 65 and 67,
Additional file 1: Table S2).
As for the structural characteristics, most of the iCJD
CP appeared to contain only Aβ as the only or dominant
component since they reacted exclusively with Abs to
Aβ; occasionally, however, they definitely also contained
PrP either displaying an Aβ immunoreactive core with
PrP reactive crown or the reverse or random mixtures of
Aβ and PrP (Fig. 3). No significant difference was
detected in the presence and brain distribution of Aβ
diffuse (Thioflavin S-negative) plaques between iCJD
(N = 4) and sCJD (N = 21) age-matched cases (Fig. 3
and Additional file 2: Table S5).
Staging of the Aβ pathology, a measure of disease pro-
gression, was carried out in 10 Aβ-positive cases of iCJD
(Tables 2 and 3). Both CAA occurring alone and CAA +
CP had a widespread distribution reaching at least phase
2 in the majority of the cases (82%). The CAA severity
score (0–3) ranged from 1 to 3 with a mean of 1.6, and
with the exception of one case (case 1, Table 3) CAA
was of type 2 (capillaries unaffected) (Table 3 and Fig. 6).
As expected according to the selection criteria, amyloid
was demonstrated in the CP of all five CP-harboring
cases, and in the vascular Aβ deposits of seven of the 10
(70%) CAA cases examined (Tables 2 and 3, and Fig. 3).
In two cases, CP were present in the cerebellum (exclu-
sively or along with other regions) mostly populating the
granule cell layer (Fig. 3). The comparative study of dis-
ease staging in iCJD with those in sCJD and AD revealed
that in the sCJD cohort, only in one third of the cases
Aβ pathology reached phase 2; none harbored CP in the
cerebellum (Tables 2 and 3). The CAA score was 1, 62%
lower than that in iCJD, but the type was exclusively 2
as in most cases of iCJD (Table 3). Amyloid was demon-
strated in one of six (17%) of the CAA-affected
sCJD cases. Contrary to sCJD, Aβ pathology in AD sur-
passed in severity the Aβ pathology observed in iCJD
(Tables 2 and 3). This especially applied to CP distribu-
tion that reached phase 5 in all cases, a level of disease
progression reached only by half of the cases in iCJD. Fur-
thermore, amyloid-positive CAA was observed in all cases.
As for CAA, although the difference in distribution was
less striking, the mean CAA score was 2.57, about 1.6
times greater than in iCJD, but CAA was almost exclu-
sively type 2, as in iCJD.
Morphometric characteristics of amyloid-positive CP
and of blood vessels carrying Aβ deposits in CAA were
compared in iCJD and AD (Additional file 6: Figure S4
and Additional file 7: Figure S5). In iCJD cerebral cortex,
the CP burden was over 4 times lower (P < 0.004) and
CP about 17% smaller than in AD (P < 0.0001). A small
population of large CP in AD were not detected in the
iCJD cohort (Additional file 6: Figure S4). In iCJD CAA-
affected vessels the Aβ deposits occupied a relatively lar-
ger portion of the vessel wall than in AD (P < 0.0001)
(Additional file 7: Figure S5).
Tau pathology in iCJD, sCJD and AD: Lesion type,
prevalence, staging and severity
NFT and DN, two prototypical lesions of tau pathology as-
sociated with typical AD, were found in 48% and 14%, re-
spectively, of all iCJD cases (Additional file 2: Table S4).
The NFT were found regardless of the presence of Aβ
pathology while the DN were present in 3 cases, all har-
boring CP (Figs. 3 and 5). Although the NFT-positive iCJD
subset was 8 years older than the NFT-free, the difference
was not significant. Furthermore, the NFT prevalence in
the entire iCJD cohort did not seem to change significantly
as a function of age also when young (≤ 54 years) and old




Fig. 4 Aβ phenotype and age distribution in Aβ-positive iCJD and
control cases. a: iCJD (N = 11); b: sCJD (N = 9); c: non-ND (N = 2).
Scores for the Aβ phenotype is relative to the presence of either Aβ
CP or CAA (score 1), or combinations of both (score 2). Brackets
below dotted line in the X-axis underline cases of the same age; GH:
growth hormone; DM: dura mater
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Fig. 5 Graphic representation of demographic data, NFT pathology, codon 129 genotype and resPrPSc type in iCJD with (+) and without (−) Aβ
pathology. a-c age, disease duration, incubation period, and NFT pathology relative to All iCJD (a), GH-iCJD (b) and DM-iCJD (c); yrs.: years; mo: months.
d and e ring doughnut charts visualizing genotype frequency at codon 129 (d) and resPrPSc type distribution (e) in iCJD with (iCJD-Aβ+) and without
(iCJD-Aβ−) Aβ pathology; M: methionine; V: valine; T1: type 1; T2: type 2; Ti: type intermediate; Ti + 2: types intermediate +2; T1 + 2: types 1 + 2
Fig. 6 Type 1 or capillary CAA in one iCJD (a and b) and one AD (c and d). a-d Aβ deposits along the basement membrane of capillaries in the
parahippocampal gyrus (a), molecular layer of the cerebellum (b) and hippocampus (c and d). The mean diameter of capillaries in longitudinal
sections resulted from three (a and b) and six (d) measurements along the capillary whereas the diameter of the capillary in cross-section in c is
the mean diameter calculated by the software (Image-Pro Plus)
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vs. 50%). In the Aβ-positive iCJD subset, NFT and DN
were found in 5/11 and 3/11 cases, respectively. The simi-
lar NFT prevalence in the Aβ-positive iCJD population
when compared with that of the general iCJD population
(45.5% vs. 48%) [23] suggests that the presence of Aβ path-
ology does not influence the prevalence of NFT.
In sCJD, prevalences of NFT and DN were 53% and
1.5% respectively, comparable to the 48% prevalence of
NFT in the iCJD cohort, while the DN prevalence in sCJD
compared to iCJD was much lower (Additional file 2:
Table S4). The NFT prevalence appeared to be age-related
given the NFT presence in 41% and 80% of the younger
and older cases, respectively, and the ~ 9.5 years older
age of the NFT-positive compared to the negative cases
(P < 0.0006). Distribution and severity of NFT also were
comparable to those of the corresponding iCJD cohort
and so was the age relation (Additional file 2: Table S6).
Much higher burdens of both NFT and DN with no evi-
dence of age effect were observed in all AD cases. How-
ever, brain distribution was comparable to that of iCJD.
Discussion
We report on 21 cases of iCJD including GH-iCJD and
DM-iCJD subsets collected in Australia, France, Italy
and the US, 11 (52%) of which harbored significant Aβ
pathology. Despite the diversity of their geographic ori-
gin, our iCJD cases were remarkably similar concerning
the 129 genotype and CJD histopathological phenotype
distributions, and the features of the associated Aβ
pathology.
For DM-iCJD, the similarities may reflect the use of
the same Lyodura product in all these countries. In con-
trast, the cases of GH-iCJD were all from the US and
can only be compared with the similar cohorts studied
in the UK and France, where methods of GH production
differed from those in the US (SH and JPB, personal
communication).
Genotype and phenotype distribution in our iCJD co-
hort showed a relatively high prevalence of MV and VV
over MM codon 129 genotypes when compared to sCJD
as also observed in previous studies [54, 55]. Furthermore,
we observed two iCJD with the MMi phenotype that has
been shown to originate from adaptation of sCJDVV2 or
sCJDMV2K to the 129MM background of the recipient
[39, 42, 54, 59]. The finding that this event, initially de-
scribed in Japanese DM-iCJD, is also observed in our
international iCJD cohort as well as the UK cohort, and
thus is widespread, suggests that 129VV and 129MV indi-
viduals may have been preferentially selected as donors in
several countries. Alternatively, subjects with 129MV and
129VV genotypes might be more susceptible to acquire
CJD than the carriers of the 129MM genotype, in whom
the sCJDMM1 phenotype might be difficult to reproduce
requiring strain adaptation [13, 46, 69]. The ~2 times
longer incubation period in GH-iCJD than DM-iCJD cases
resembles the longer incubation period associated with
the peripheral (e.g., in the peritoneal cavity) vs. central
(e.g., intracerebral) inoculations of prions or Aβ seeds in
Tg mouse models for these proteinopathies [20, 36]. Con-
cerning the Aβ pathology, iCJD-affected subjects had
CAA accompanied by parenchymal Aβ CP in five cases
and subpial deposits in three. The Aβ-positive iCJD subset
also had a relatively young age (mean 50.5 years, range
26–75 years) along with the relative severity and wide-
spread distribution of CAA [66]. Furthermore, with only
one exception, CAA was type 2, i.e. did not affect cerebral
capillaries unlike type 1 [66]. Since CAA type 1 has been
directly associated with AD severity, including tau path-
ology, age, and with ApoE-ε4 allele frequency, the pre-
dominance of type 2 CAA in iCJD is not surprising given
the relatively younger age and short duration of this con-
dition [52, 62].
Aβ pathology was examined in age-group matched co-
horts of sCJD and of non-ND used as controls to rule out
the possibility that Aβ deposition in iCJD was either re-
lated to aging or resulted from the concomitant aggrega-
tion of prion or prion-like proteins by a cross-seeding
mechanism. Furthermore, type and severity of the iCJD
Aβ pathology was compared with that of AD. The 13%
prevalence of Aβ pathology in the sCJD cohort (mean age
50 years, range 24–79 years) was 4 times lower than that
in iCJD (52%) even though the Aβ-positive sCJD subset
was 17 years older. In the non-ND cohort (age 40 ±
12 years, range 25–59 years), the 2 (18%) Aβ-positive cases
were 56 and 59 years of age and the oldest of this cohort.
When all Aβ-positive subsets were considered in the 20–
54 years range, the prevalence of Aβ pathology in iCJD,
sCJD and non-ND populations was 41%, 2% and 0%, re-
spectively. Furthermore, the Aβ pathology in iCJD cases
was more severe than sCJD, and showed a significantly
more widespread CP and CAA distribution and a trend to-
ward a significantly higher CAA severity score. On the
contrary, Aβ pathology in AD was dramatically more se-
vere than in Aβ-positive iCJD with regard to number, size
and distribution of CP as well as of CAA in neocortical re-
gions, even though the AD cohort used as control had a
relatively young age (64 ± 8 years). These features clearly
distinguish the Aβ pathology of iCJD from typical AD. Al-
though we cannot rule out that the Aβ pathology might
have evolved toward an AD phenotype had the Aβ positive
iCJD patients lived longer and not died of CJD this possi-
bility is unlikely since no significant differences were found
between the UK GH-iCJD and hGH recipients free of
CJD. Even though we used a different criterion for Aβ
plaque selection, our findings on Aβ pathology do not
significantly differ from those reported in five previous
studies [19, 23, 31, 37, 53], which collectively examined 95
cases of iCJD, including 67 GH-iCJD and 28 DM-iCJD.
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However, the 54% prevalence of the Aβ pathology in UK
GH-iCJD is higher than the 37.5% we observed. Similarly,
the 18 year mean incubation period of UK GH-iCJD is sig-
nificantly shorter than that of US cases (28 years) (P <
0.004). These differences may relate to the relatively high
prevalence of UK GH-iCJD cases (~4.2%) compared to the
1.2% prevalence among US recipients of pre-1977 pro-
duced human GH (hGH) as well as to variations in select-
ing pituitary donors and in protocols of GH purification
[2, 4, 7, 54]. Regardless of the causes, the higher prevalence
of the Aβ pathology, the significantly lower mean incuba-
tion period and the more than a decade younger age differ-
ential of UK Aβ-positive GH-iCJD cases, suggest that GH
used in UK had a higher infectious dose not only of PrPSc
but also of Aβ seeds. Remarkably, despite these differences,
the Aβ phenotype in US and UK was similarly character-
ized by CAA alone or co-existing with CP. The small sub-
set of Aβ-positive GH-iCJD cases harboring parenchymal
Aβ deposits reported by Ritchie and co-workers (2017a)
presumably included diffuse plaques, which may also ac-
count for the higher prevalence of positive Aβ pathology
in UK GH-iCJD. Furthermore, CAA reached similar sever-
ity scores in US (1.6) and UK (2) and type 2 CAA mark-
edly predominated in both countries [37, 53]. The very
low prevalence of the Aβ pathology (4%) in French GH-
iCJD cases compared to the US and UK GH-iCJD cases
has been explained possibly by the few years shorter incu-
bation period in French GH-iCJD and to differences in
GH preparations [19]. The prevalence of the Aβ pathology
in DM-iCJD reported here (61.5%) is similar to that of the
previous studies combined (69%) but differs from the 81%
prevalence reported by Hamaguchi et al. (2016). This dif-
ference may depend on the older age of the Japanese co-
hort compared to those examined by us and Frontzek et
al. (2016) (10 and 16 years, respectively). The co-
occurrence of CAA and Aβ parenchymal deposits was ob-
served in all the cases of Frontzek and co-workers (2016)
but in only half of ours (CAA occurred alone in the
others). This discrepancy along with the aforementioned
discrepancy of UK GH-iCJD cases are likely due to our dif-
ferent criteria of Aβ plaque validation. Unlike the five pre-
vious studies that also accepted diffuse plaques, we
validated only CP (i.e. Aβ plaques that contained amyloid)
to better distinguish Aβ pathology associated with iCJD
from that related to aging [19, 23, 31, 37, 53]. The exclu-
sion of the plaque amyloid requirement would have in-
creased the the Aβ-positive iCJD cases from 11 to 13 and
increased by 9 the number of Aβ-positive sCJD cases
(Additional file 2: Table S5 and data not shown). The CP
requirement in the Aβ pathology of iCJD might establish a
qualitative difference in the Aβ phenotype between iCJD
and sCJD in younger populations. Nonetheless, this and
previous studies show that CAA, with or without CP, is
the distinctive histopathological phenotype of Aβ
deposition in iCJD [19, 23, 31, 37, 53]. Our study taking
advantage of the direct comparison, also shows that the
Aβ phenotype is similar in GH- and DM-iCJD.
Because tau pathology is considered a consistent but
secondary feature of AD, we also searched for the pres-
ence of the two most common tau related lesions, NFT
and DN [33, 34, 57]. NFT were present in Aβ-negative
and Aβ-positive iCJD, as well as in sCJD controls with
similar prevalences (45–53%), and they were age-related.
Occurrence of NFT in absence of Aβ plaques was previ-
ously shown in sCJD and was considered as “primary
age-related tauopathy” in the elderly [17, 44, 51]. Over-
all, the NFT prevalence in cases with less than 52 years
were similar in iCJD (44%) and sCJD (40%) cases, and
did not differ from that reported in a large population of
unselected individuals of similar age (41%) [6]. Neocor-
tical DN were observed in only three iCJD cases and
one case of sCJD where they were occasionally associ-
ated with CP, as previously reported [53]. In contrast,
NFT and DN were consistently present in the AD co-
hort. These findings indicate that tau pathology is (i) a
non-obligatory component of iCJD Aβ phenotype, (ii)
likely develops independently from the Aβ pathology in
iCJD, and (iii) further distinguishes iCJD Aβ pathology
from AD.
Further important questions raised by our and previ-
ous studies are the origin of Aβ seeding, how Aβ seed
reaches the brain, and whether Aβ-seeded diseases are
contagious.
In hGH recipients, Ritchie and colleagues [53] convin-
cingly showed that Aβ deposition occurs in the absence
of prion pathology and the phenotype associated with
the Aβ deposition remains similar to that of Aβ-positive
iCJD cases, suggesting that Aβ deposition is a primary
co-pathology in GH-iCJD and that Aβ and PrPSc seeding
processes occur independently.
Although we occasionally have observed Aβ-PrP
mixed plaques supporting the possibility of co-seeding,
the brunt of the two pathologies were anatomically seg-
regated: Aβ deposition affected mostly vessel walls while
PrPSc affected exclusively the brain parenchyma. More-
over, the fact that Aβ-positive iCJD is associated with
different CJD subtypes argues against cross-seeding of
Aβ by a specific prion strain. Additional support to the
independent seeding of Aβ in DM-iCJD comes from two
other observations. First, Aβ deposits occurred in the
dura graft but not in the patient’s original dura [43], sec-
ondly, the distribution of Aβ deposits is consistent with
the propagation through the brain of Aβ pathology ori-
ginating from the dura graft while the distribution of
PrPSc pathology is uniform [31, 43]. These findings point
to the dura graft as the source of the Aβ seed and to a
different tempo of Aβ and PrPSc propagation further
strengthening the notion that in iCJD PrPSc and Aβ are
Cali et al. Acta Neuropathologica Communications  (2018) 6:5 Page 15 of 19
independent pathologies. In GH-iCJD, the Aβ seed is
likely to propagate from the site of cutaneous injection
to the brain. Experimental data have definitely provided
the proof of principle that human Aβ seed may reach
the brain causing Aβ amyloidosis following systemic in-
oculation [20]. Remarkably, a predominantly vascular
distribution of the Aβ deposits consistent with Aβ-CAA
was noted in these experiments [20].
Conclusions
Although our and previous studies do not rule out
important roles for other factors contributing to Aβ
pathology in iCJD such as hGH deficiency or the DM-
associated neurosurgical procedures, they point to
human-to-human transmission of Aβ with mechanisms
similar to those of PrPSc [19, 23, 31, 37, 53].
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Additional file 3: Figure S1. Kaplan–Meier estimates of iCJD and sCJD
controls. A: survival graphs representing whole iCJD cohort and its
GH- and DM-iCJD subsets as well as sCJD cases. B: survival graphs of 21
iCJD and all sCJD divided into two groups according to age: 54 years or
younger (≤54y), and older than 54 years (> 54y). Median survivals
are indicated on the X-axis in A and B (arrowheads). Significant
differences in median survivals, determined by the log rank (Mantel-Cox),
were found between GH-iCJD and sCJD (P=0.0017) (A) or DM-iCJD ≤ 54y
and sCJD ≤ 54y (P=0.0027) (B). (PDF 2348 kb)
Additional file 4: Figure S2. Histopathology of an atypical US iCJD
(case 5, Table 1). A-C: HE staining. D and E: PrP immunohistochemistry.
A: spongiform degeneration (SD) with large and confluent vacuoles
typical of the sCJDMM2 subtype, but limited to layer II of the frontal
cortex, and severe neuronal loss and gliosis affecting all layers. B: high
magnification of the area highlighted in A showing SD with large
vacuoles. C: severe loss of granule cells and gliosis of the cerebellum; Grl.
L: granular layer; Mol. L: molecular layer. D and E: diffuse or “synaptic” PrP
immunostaining in the frontal cortex (D), and molecular and granular
layers of the cerebellum (E); A-C: HE staining. D and E: PrP
immunohistochemistry with Ab 3F4. (PDF 30981 kb)
Additional file 5: Figure S3. WB profile of resPrPSc from iCJD and sCJD
controls using different WB systems for PrP detection. BHs from the frontal
cortex (lanes 8-10) and cerebellum (lanes 1-7) treated with 100 U/ml PK
(~2000 μg/ml) were probed with indicated Abs. PrP bands were resolved in
15% Tris-HCl, 8.7 cm-long (A-C and E) and 20 cm-long (D) gels, and visualized
with near-infrared LI-COR system (A-D and E(i)) or chemiluminescence (E(ii)
and E(iii)). A: profiles of resPrPSc from CJD obtained with an 8.7 cm-long gel
are similar to those obtained with the 20 cm-long gels in Fig. 2. The
unglycosylated resPrPSc ~21 kDa of type 1 (21), ~20 kDa of type i (i), ~19 kDa
of type 2 (2) and ~18 kDa (18) are indicated. B: the ~20 kDa of type i (i) and
~21 kDa of type 1 (21) (lanes 3-8), but not the ~19 kDa band of type 2,
immunoreact with Ab 12B2. Profile of resPrPSc from iCJDMMi (lane 5) is
indistinguishable from that of CJDMVi+2 (lanes 3 and 4), but differs from
those of iCJDMM1 and sCJDMM1 (lanes 6-8), as the ~21 kDa band
predominates in these three conditions. C: only ~19 kDa (type 2), but not
~21 kDa (type 1) and ~20 kDa (type i) immunoreacted with Tohoku-2 (To-2).
An ~18 kDa (18) band in CJDVV2 and CJDMVi+2, and an unidentified lower
size fragment (large arrow) in all cases harboring type 2 were also detected.
A non-specific band (indicated by three asterisks) was present in all tested
samples. D: high resolution gel electrophoresis in 20-cm long gel revealing
~21 kDa (21) and the ~20 kDa band (i and arrowhead). E(i): enhanced image
of dashed area in A showing the bands ~21 kDa (21), ~20 kDa (i and
arrowhead), and ~19 kDa (19; lane 4). The detection of the resPrPSc ~20 kDa
band in addition to the prominent ~21 kDa fragment in CJDMM1 is most
likely due to our use of a high resolution electrophoretic systems. E(ii):
profiles of unglycosylated resPrPSc from the same cases in E(i) visualized on
film by chemiluminescence. Note that the three CJDMM1 (lanes 6-8) show
only ~21 kDa bands. E(iii): the ~20 kDa and ~21 kDa bands visible in B (lanes
3-5) resolve as a single band of ~21 kDa (lanes 4 and 5) when visualized on
film by chemiluminescence. (PDF 6122 kb)
Additional file 6: Figure S4. Quantitative estimates of Thioflavin
S-positive Aβ CP affecting the cerebral cortex in subjects with iCJD and
sporadic AD (sAD). A: the density of Aβ CP, expressed as the percentage
of cerebral cortex area occupied, was 5 times greater in subjects with
sAD than in iCJD. B: size of Aβ CP (N=500), expressed as diameter, was
greater in patients with sAD than in those with iCJD. C and D:
representative microscopic fields showing fewer and smaller CP (arrows)
in iCJD (C) than sAD (D) where cluster of very large CP (dashed square)
could be detected. Bar graphs are expressed as mean ± standard error of the
mean (SEM) in A or as mean ± standard deviation in B. Student's t-test
(two-tailed). (PDF 3338 kb)
Additional file 7: Figure S5. Size of blood vessels examined and
semiquantitative evaluation of the percentage of the vessel wall
perimeters occupied by Aβ deposits in subjects with iCJD and
sporadic AD (sAD). A: scatter plot showing the similar sizes of the blood
vessels from the subarachnoid spaces of frontal, occipital and cerebellar
regions examined for the semiquantitative determinations made in B;
size of individual vessels is measured as perimeter. B: the percentage of
the blood vessel wall occupied by Aβ was significantly greater in iCJD
than sAD. Bar graphs are expressed as mean±SEM. Student's t-test
(two-tailed). (PDF 228 kb)
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Strokea b s t r a c t
Background and purpose: Recent scientific reports and epidemiological studies have engendered mount-
ing concerns regarding the potential human-to-human transmissibility of non-prion neurodegenerative
and related diseases. This study investigated whether recipients of cadaveric pituitary hormone treat-
ments are at increased risk of death from non-prion neurodegenerative and related diseases.
Methods: A retrospective national cohort study based on death certificates of recipients of the cadaveric
pituitary hormone treatments (n = 184) as part of the Australian Human Pituitary Hormone Program
(AHPHP; n = 2940) 1967–1985. Standardised mortality ratios (SMR) from non-prion neurodegenerative
and other diseases were estimated based on the Australian population.
Results: Allowing for potential diagnostic mis-attributions, there was no significant increase in the SMR
from non-prion central nervous system (CNS) neurodegenerative disease, especially dementia and/or
Alzheimer’s disease (0.47; [95% CI: 0.19, 1.12] P = 0.081). The SMR for intra-cerebral haemorrhage, poten-
tially related to cerebral amyloid angiopathy (CAA), was increased (2.77; [95% CI: 1.12–5.75] P = 0.009),
although accommodation of possible mis-diagnosis through conflation of this category with other stroke
causes of death emphasising likely intra-cranial haemorrhage showed no persisting significant increase
in mortality in cadaveric pituitary hormone recipients, including all deaths recorded as due to intra-
cranial haemorrhage (1.72; [95% CI: 0.80, 3.26] P = 0.123).
Conclusion: In the setting of recent evidence strongly supporting the likelihood of brain-to-brain horizon-
tal transmission and subsequent propagation and deposition of abnormally folded proteins associated
with non-prion neurodegenerative and related disorders, this study offers further tentative support for
deaths directly stemming from transmission of non-prion disease related to cadaveric pituitary hormone
treatment. Acknowledging the limitations of the present study, however, ongoing detailed assessments of
this potential risk are necessary.
 2020 Elsevier Ltd. All rights reserved.1. Introduction
The transmission of human prion disease through various
health care interventions (iatrogenic Creutzfeldt-Jakob disease
[iCJD]), especially treatments involving prion-contaminated cadav-eric pituitary hormones, is well recognised [1]. Numerous scientific
studies support prion-like mechanisms of template-directed pro-
tein propagation, as well as inter-cellular spread, for misfolded iso-
forms associated with non-prion neurodegenerative diseases,
including a-synuclein (related to Parkinson’s disease [PD] and Dif-
fuse Lewy body disease [DLBD]) and amyloid-beta (Ab) and tau (re-
lated to Alzheimer’s disease [AD]) [2–4], including the possibility
that the precise conformation of aberrant proteins may subserve
‘‘strains” determining phenotypic expression and the level of trans-
missibility [5]. Initial circumstantial support for potential human-
S.H. Alnakhli et al. Journal of Clinical Neuroscience 81 (2020) 78–82to-human transmission of Ab from cadaveric adeno/neurohypoph-
ysis to hormone recipients was the immuno-histochemical detec-
tion of Ab (as well as tau and ɑ-synuclein) in the pituitary glands
of donors with non-prion neurodegenerative disease and healthy
persons [6]. This observation was soon followed by case series
cogently supporting the likelihood of human transmission of Ab
causing parenchymal plaques and CAA in the brains of recipients
of cadaveric human pituitary hormones [7–9], including in people
who did not develop iCJD [8], with analogous findings in persons
undergoing neurosurgical procedures that utilised cadaveric dura
mater grafts [9]. Importantly, are recent descriptions of symp-
tomatic intracranial haemorrhage secondary to Ab-related CAA in
younger adults decades after childhood procedures that employed
use of cadaveric dura mater [10], as well as speculation of neuro-
surgical transmission of Ab through contaminated instruments
causing temporally remote CAA-related intracranial haemorrhage
[10]. These cumulative observations underscore the possibility that
misfolded proteins like Ab, especially when derived from cadaveric
dura mater, can be horizontally transmitted and act as prion-like
proteopathic seeds eventually inducing cognate clinical disease
such as CAA-related intra-cranial haemorrhage.
To further assess the potential for inadvertent transmission of
misfolded proteins associated with non-prion neurodegeneration
to induce overt related clinical disease, we assessed specific causes
of death and mortality rates in recipients of cadaveric human pitu-
itary hormones treated under the AHPHP with specific interest in
deaths from dementia, AD, PD, motor neuron disease (MND) and
intracranial haemorrhage (possibly related to CAA). The AHPHP
operated from 1967 to 1985 and analogous to other countries uti-
lised pooled cadaveric pituitary glands to extract growth hormone
(GH) and gonadotrophins (GT) for treatment of short stature and
infertility, respectively. The AHPHP was terminated in 1985 after
the recognition of cases of iCJD in the USA caused by prion contam-
inated GH [11] by which time nearly 3000 Australian patients had
been registered for treatment. To date, four Australians have been
recognised to have most likely died from iCJD related to cadaveric
pituitary hormones [12].2. Materials and methods
The study was undertaken by the Australian National
Creutzfeldt-Jakob Disease Registry (ANCJDR) as part of longstand-
ing national surveillance activities as described previously [13].
Ethical approval for this project was granted by The University of
Melbourne Human Research Ethics Committee (ID#1340151.3),
restricted to anonymised death certificate data only. AHPHP recip-
ient data is held by the Commonwealth Department of Health and
was cross-referenced with death certificate records held on the
Australian Institute of Health and Welfare (AIHW) data base [14].
The AHPHP recipient cohort consisted of 2940 patients with 232
deaths verified by the AIHW up to the end of 2015 and therefore
included for the analysis. Anonymised death certificate data were
reviewed by the ANCJDR with specific interest in listings of demen-
tia, AD, PD, MND and intracranial haemorrhage (possibly related to
CAA) as causes of death.
SMR comparative analysis was utilised as most appropriate
when dealing with groups that contain small numbers, i.e. < 20
observations [15]. The Australian population of 2001 was used as
the reference standard (as recommended by the Australian Bureau
of Statistics [ABS] [16]) because it contains a similar population of
men and women among all age groups and therefore it is more
likely to provide consistent standardised rates [17]. Stata version
15.1 [18] was employed for analyses. stset and stsplit commands
were utilised to declare the dataset for the survival analysis and
to calculate the follow-up time by person-years. The latter was79multiplied by the age-specific mortality rates of the reference stan-
dard population to estimate the expected number of deaths. SMR
was then calculated for each category by dividing the observed
by the expected number of deaths. Openepi.com [19], which is a
freely available online software, was used to generate the corre-
sponding 95% confidence intervals (CI) and the p-values.
To align with ABS data, SMRs were computed based only on the
primary listed cause of death for stroke subtypes, neurodegenera-
tive diseases and two groups of non-neurodegenerative causes of
death. Notably, listings of intra-cerebral haemorrhage as a sec-
ondary cause of death always occurred in association with a pri-
mary cause likely to be an explanation (e.g. acute myeloid
leukaemia). Two non-neurodegenerative causes of death (external
causes of mortality and breast cancer) were arbitrarily chosen to
more fully characterise the causes of death in pituitary hormone
recipients and additionally assess the level of comparability of this
group in relation to the Australian population. The stroke subtypes
we compared emphasised likely or possible intracranial haemor-
rhage including ‘‘subarachnoid haemorrhage” (I60), ‘‘intracerebral
haemorrhage” (I61), ‘‘other non-traumatic intracranial haemor-
rhage” (I62) and ‘‘stroke not specified as haemorrhage or infarc-
tion” (I64), with this last group representing approximately 60%
of all deaths recorded from stroke. Therefore, in addition to the
individual stroke subtypes, we obtained SMRs for three groups of
combined stroke subtypes to allow for the uncertainty in the ABS
data. ‘‘Cerebral infarction” (I63) was excluded from the analysis
as it was deemed less relevant.3. Results
Details concerning the year(s) of pituitary hormone treatment
for individual recipients were not available; however, the median
year of death for recipients was 2003, approximately 27 years from
the mid-point of the period in which the AHPHP operated (1976)
with a potential duration from treatment extending up to approx-
imately 48 years (1967–2015). Of the 2940 persons registered with
the AHPHP, 232 had died up to the end of 2015. Of those decedents,
184 were reported as undergoing cadaveric pituitary hormone
treatment, of whom 65 (35%) were males, with a median age and
standard deviation (SD) of recipient’s deaths 49 (±18) years. Med-
ian ages (±SD) for the various categories of death in addition to the
demographic characteristics of the overall cohort are summarised
in Table 1.
Unexpectedly, the overall mortality rate was significantly lower
in treated pituitary hormone recipients compared to the standard
population (SMR: 0.81; [95% CI: 0.70, 0.93] P = 0.004). Illustrative
of this, the mortality rates of ‘‘external causes of death” and ‘‘breast
cancer” were inexplicably significantly lower than expected com-
pared to the standard population (Table 2). With respect to neu-
rodegenerative diseases, there were no specific listings for deaths
from AD, PD or MND in recipients. To maximise the sensitivity of
our study and ensure potentially mis-attributed deaths from neu-
rodegenerative dementia, especially AD, were not overlooked we
allowed under this rubric, deaths listed as occurring from ‘‘unspec-
ified dementia”, ‘‘unspecified degenerative CNS disease” and ‘‘un-
specified brain or CNS disorder” although there were no primary
listings in the last category. The mortality rate from these com-
bined causes of death in persons who received cadaveric pituitary
hormones was a non-significant 53% lower than expected com-
pared to ‘‘dementia and AD” in the Australian reference population
(SMR: 0.47; [95% CI: 0.19, 1.12] P = 0.081).
Acknowledging the apparent predisposition for transmitted Ab
associated with cadaveric pituitary hormone treatment to cause
CAA within the cerebro-vasculature (with or without associated
CJD) and the recent suggestion that even neurosurgical instru-
Table 1
Demographic characteristics of the AHPHP cohort.
Category (N) Age (years) Year of Death Gender (%) Treated
M, (SD), [R] M, (SD) Male Female n(%)
Death Overall deaths (232) 48, (18), [3–95] 2003, (9) 88(38) 144(62) 184(79)
Treated only (184) 49, (18), [3–87] 2004, (9) 65(35) 119(65) 184(100)
External causes of morbidity and mortality (15) 40, (14), [22–76] 2004, (5) 10(67) 5(33) 12(80)
Breast cancer (11) 58, (10), [41–68] 2003, (6) 0(0) 11(100) 8(73)
Dementia & AD (5) 42, (23), [26–87] 1998, (9) 2(40) 3(60) 5(100)
Intracerebral Haemorrhage (6) 60, (18), [32–75] 2002, (10) 2(33) 4(67) 6(100)
All Stroke (9) 59, (17), [32–75] 2002, (9) 3(33) 6(67) 9(100)
Treatment Location
ACT (13) 47, (12), [27–77] 1993, (-) 10(77) 3(23) 8(62)
NSW (941) 62, (12), [5–95] 2004, (10) 273(29) 668(71) 722(77)
NT (2) 44, (5), [41–48] – 1(50) 1(50) 2(100)
QLD (300) 57, (12), [13–80] 1999, (8) 120(40) 180(60) 219(73)
SA (300) 63, (12), [16–93] 1999, (9) 77(26) 223(74) 260(87)
TAS (129) 64, (10), [33–86] 2004, (6) 23(18) 106(82) 102(79)
VIC (792) 63, (12), [3–88] 2005, (10) 233(29) 559(71) 652(82)
WA (176) 60, (12), [23–87] 2009, (10) 54(31) 122(69) 136(77)
Missing (63) 58, (11), [36–68] 2008, (4) 5(8) 58(92) 62(98)
Type
hGH (688) 48, (10), [3–87] 2000, (10) 482(70) 206(30) 688(100)
hGH_hPG (2) 63, (2), [61–64] – 2(100) 0(0) 2(100)
hPG (1473) 66, (7), [32–93] 2008, (9) 58(4) 1415(96) 1473(100)
M = Mean; SD = Standard deviation; R = Range; Treated = Received a cadaveric pituitary GH treatment.
Table 2
Standardised Mortality Ratios (SMR) for cadaveric pituitary hormone treated patients by cause of death groups.
Cause of Deathe [ICD-10 codes] Observed cases Expected cases SMR [95% CI] P-value
All Causes of Death – 184 227 0.81 [0.70, 0.93] 0.004
Dementia & AD [F01, F03, G30] 5 11 0.47 [0.19, 1.12] 0.081
Stroke
Subarachnoid haemorrhage [I60] 1 2 0.49 [0.02, 2.44] 0.473
Intracerebral haemorrhage [I61] 6 2 2.77 [1.12, 5.75] 0.009
Other nontraumatic intracranial haemorrhage [I62] 1 0 2.10 [0.10, 10.33] 0.449
Stroke, not specified as haemorrhage or infarction [I64] 1 4 0.28 [0.01, 1.39] 0.176
Combined Stroke Group 1 [I60-I61-I62] 8 5 1.72 [0.80, 3.26] 0.123
Combined Stroke Group 2 [I60-I61-I64] 8 8 1.03 [0.48, 1.96] 0.925
Overall Stroke [I60-I61-I62-I64] 9 8 1.10 [0.53, 2.01] 0.784
Other Causes of Death
External causes of morbidity and mortality [V01–Y98] 12 31 0.38 [0.22, 0.67] <0.001
Breast cancer [C50] 8 18 0.43 [0.22, 0.87] 0.015
Follow-up time = 101456.1 person-years.
e Primary cause of death. M = Mean; SD = Standard deviation; CI = Confidence intervals; ICD-10 = The International Statistical Classification of Diseases and Related Health
Problems, (version-10).
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premature symptomatic intra-cranial haemorrhage [10], the mor-
tality rates of various subtypes of intra-cranial haemorrhage, as
well as combined deaths from various types of intra-cranial haem-
orrhage with or without the sizeable group ‘‘stroke not specified as
haemorrhage or infarction‘‘ were analysed (Table 2). Deaths listed
as from ‘‘intra-cerebral haemorrhage” were significantly increased
(SMR: 2.77; [95% CI: 1.12–5.75] P = 0.009) whereas all other haem-
orrhagic stroke groups, including conflated sub-types listed as
related to haemorrhage or containing some deaths from likely
intracranial haemorrhage, were not increased compared to the
standard population (Table 2).
4. Discussion/conclusion
In a medical milieu of growing concerns regarding human-to-
human transmissibility of non-prion neurodegenerative and
related diseases, the present findings offer circumstantial support
for possible CAA related to transmitted Ab associated with cadav-
eric pituitary hormone treatment causing deaths from intra-80cerebral haemorrhage. Although increased deaths from intra-
cerebral haemorrhage plausibly aligns with recognised risks asso-
ciated with premature CAA, as observed in recipients of cadaveric
pituitary hormones [7–9], we found no evidence of increased
deaths from other types of intra-cranial haemorrhage, including
subarachnoid haemorrhage, which is somewhat surprising given
the recognised risks of this type of haemorrhage related to CAA
and the prominent occurrence of CAA in meningeal vessels [7–9].
Further, although the association between CAA related to transmit-
ted Ab and intra-cranial haemorrhage appears sequitur, the report
of a significantly increased risk of haemorrhagic strokes, especially
sub-arachnoid haemorrhage, in people exclusively treated with
recombinant GH for short stature [20] raises the possibility of spe-
cious association and militates against premature conclusions
regarding any causality between transmitted Ab and intra-cranial
haemorrhage.
In contrast to possible deaths related to CAA, we found no evi-
dence to support increased deaths from common, non-prion neu-
rodegenerative diseases such as AD or PD, with these findings
concurring with those of a previous similar study reporting no
S.H. Alnakhli et al. Journal of Clinical Neuroscience 81 (2020) 78–82increased risk of such deaths [6]. This outcome was despite our
conservative approach to potential neurodegenerative death cer-
tificate mis-attributions. In the study by Irwin and colleagues [6]
however, they reported three deaths from Amyotrophic Lateral
Sclerosis in their GH recipient cohort, with our study only finding
a single listing of death from ‘‘CNS paralysis unspecified”, re-
emphasising uncertainties raised by these authors concerning the
explanation and biological significance of their observation of three
deaths from MND in US patients treated with cadaveric pituitary
hormone. Also notable in our recipient cohort and similar to the
findings of the study by Irwin and colleagues [6] was the young
average age at death. Aware of the strong age-dependence of neu-
rodegenerative diseases, especially AD [21], it is arguably not sur-
prising that there would only be few deaths recorded as related to
presumably neurodegenerative dementia and/or un-recognised
AD. Although we were unable to determine the precise length of
time from pituitary hormone treatment to death in members of
our cohort, approximately 27 years had elapsed from the mid-
point of the AHPHP operational period to the mean year of death
for recipients with the period from treatment potentially extend-
ing up to 48 years offering the probability of sufficient time for
overt neurodegenerative disease to develop in at least some per-
sons if these diseases are truly transmissible and able to induce
overt disease. Nonetheless, sporadic AD is recognised to have a
long pre-symptomatic period of neuropathological evolution
before first symptoms appear [22] and given this apparently very
slow pathogenesis related to Ab deposition, a longer period of dis-
ease evolution may be required, particularly in non-genetically
predisposed individuals such as apolipoprotein e4 allele non-
carriers.
Unexpectedly, the SMR for overall deaths was reduced in
patients treated through the AHPHP, exemplified by the signifi-
cantly reduced deaths from ‘‘external causes of morbidity and mor-
tality” and ‘‘breast cancer”. The explanation for the reduced deaths
in patients treated with cadaveric pituitary hormones is unclear
but raises the possibility of the recipient cohort being different to
the broader Australian population such that people treated with
cadaveric pituitary hormones are at diminished risk of developing
neurodegenerative and other serious illnesses.
The present study is acknowledged as harbouring notable limi-
tations, including death certificate causes of death were not inde-
pendently verified and that living persons potentially manifesting
the diseases of interest were not ascertained. As such, our study
cannot exclude the possibility of living recipients manifesting
symptomatic neurodegenerative disease or cases of non-fatal
CAA-related intra-cranial haemorrhage. Importantly however,
death certificate recorded deaths, including those from intra-
cranial haemorrhages and neurodegenerative diseases would be
subject to analogous potential mis-attributions in both the pitu-
itary hormone recipient cohort and the Australian population
[23]. Also, while premature deaths from non-neurodegenerative
causes could possibly pre-emptively camouflage development of
overt neurodegenerative disease related to human-to-human
transmission, this is arguably less likely to be a significant factor
given the overall death SMR was reduced in pituitary hormone
recipients. Nonetheless, the age-dependency of neurodegenerative
diseases with its apparent implications for pathogenesis also
serves to caution against undue reassurance stemming from our
study, as do other methodological considerations such as the
entirely retrospective nature of our study. Consequently, given
the aforementioned limitations, our findings must necessarily be
considered as only tentative and therefore support the need for
ongoing detailed epidemiological studies assessing the risk of
developing overt non-prion neurodegenerative and related dis-
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Section 9: Summary and Future Directions 
This thesis has presented various important, often landmark, contributions to the field of human 
prion disease spanning the diverse spectrum of: normal prion protein cellular biology; prion 
pathogenesis; human prion disease epidemiological studies; human prion disease bio-marker 
studies; clinical aspects of human prion disease; prion disease treatment studies; and studies of 
human prion-like diseases. Across this breadth of these scholastic endeavours, contributions to 
diagnostic bio-markers, epidemiology, normal prion protein cell biology, pathogenesis and the 
potential clinico-biological frequency and significance non-prion protein accumulation in the 
brain contentiously represent the greatest achievements. Despite the meritorious contributions 
described in this thesis, and the prodigious advances more generally to the field of prion 
diseases over the last four decades, considerable gaps in our biological understanding and 
clinical capacity remain to be redressed. 
Pre-mortem diagnostic capabilities for human prion disease are a noteworthy success over the 
last approximately 25 years with this thesis containing most, if not all, seminal contributions that 
have prompted revision of diagnostic criteria and thereby ensured their inclusion. Starting with 
CSF 14-3-3 detection, moving through consolidation of MRI sequences and typical features and 
culminating in the unparalleled advances offered by the RT-QUIC protein amplification 
technology, only a small minority of human prion disease (<2-3%) will currently not display a 
characteristic abnormality on one of these diagnostic tests during pre-mortem evaluation of 
suspected prion disease. A remaining challenge, akin to the threshold being realized in AD, is to 
achieve validated blood tests for human prion disease that offer similar sensitivity and specificity 
to that currently enjoyed with CSF and imaging bio-markers. Application of technologies 
currently demonstrating successful deployment for blood screening in AD (eg single molecule 
array [SIMOA] technology; immunoprecipitation-mass spectrometry) are an avenue for further 
exploration, in addition to further development of protein amplification techniques such as the 
RT-QUIC and protein misfolding cyclic amplification assay (PMCA). Successful delivery of 
sensitive and specific blood tests for human prion disease will clearly simplify screening for 
these maladies, perhaps allowing extant bio-markers to be utilized as orthogonal diagnostic 
confirmation assays.    
Another major achievement described in this thesis is the advancements provided 
epidemiologically. Through large domestic and multi-national studies our epidemiological 
understanding of human prion disease has improved across areas ranging from factors
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influencing annual reported disease incidence, through clarifying determinants of survival and 
diagnostic test results across the clinical sub-types of sporadic CJD, to a better understanding 
of the true biological significance of sequence variations in PRNP. The translational benefits of 
this improved understanding are diverse and impact numerous clinical domains encompassing 
genetic counselling, better stratification of participant cohorts for treatment trials, better 
detection of new sub-types of human prion disease and personalization of optimal diagnostic 
evaluation in suspected prion disease cases. Future studies need to independently verify and 
elaborate these multifarious observations and additionally explore issues such as the incidence 
and phenotype of prion disease in other less studied Indigenous populations. 
Of considerable contemporary clinical and neuro-biological interest are the frequency and 
consequences of transmission and propagation of non-prion proteins (such as Abeta) found in 
other neurodegenerative diseases (such as AD) within the CNS. The investigations provided in 
this thesis add weight to the burgeoning concerns that inadvertent transmission of non-prion 
proteins like Abeta to the brain either alone or accompanying other pathogenic proteins (such as 
PrPSc) leads to their sustained propagation thereafter in an uncertain percentage of exposed 
individuals. Based on cases of iCJD related to cadaveric pituitary hormones and dura mater 
grafts, and even persons treated with cadaveric pituitary hormones who did not develop iCJD, 
the transmission and propagation of Abeta appears potentially relatively common. Moreover, 
there is the likelihood that propagated Abeta may not remain sub-clinical but eventually 
culminate in overt disease. This of particular importance given the prevalence of non-prion 
neurodegenerative diseases, especially in the elderly, and the possibility that inter-individual 
transmission of non-prion proteins through contaminated instruments may occur, culminating in 
manifest serious disease decades later. Future high-quality epidemiological studies are required 
to better define and quantify such risks, with additional investigations required to 
comprehensively and unambiguously determine the efficacy of routine instrument 
decontamination and sterilization practices currently employed in hospitals for destroying non-
prion proteins found in more common neurodegenerative diseases like AD (Abeta and tau) and 
PD (alpha-synuclein). Data of this type would ensure substantial disease risk mitigation through 
adopting validated universal best practice approaches. 
Understanding the factors and cellular pathways contributing to the occurrence of sporadic CJD 
and the bio-physical properties of the neurotoxic form of PrPSc and its early pathophysiological 
effects are likely to facilitate the development of effective disease modifying treatments. Both 
types of contributions are described in this thesis. The largest GWAS undertaken to date has for
      825 
the first time provided unequivocal evidence implicating non-PRNP genetic risk factors 
(syntaxin-6 and galactose-3-O-sulfotransferase-1 genes) in the causation of sporadic CJD. 
Future in vitro and in vivo studies need to elucidate the pathogenetic mechanisms underpinning 
exactly how such non-prion genes lead to disease, with hopefully additional larger GWAS to 
define additional non-PRNP genes contributing to disease risk. These types of studies may 
provide the basis of therapies more specifically targeting corrupted cellular pathways directly 
driving pathogenesis. In addition, studies reported in this thesis have further supported 
enhanced oxidative stress as a key derangement in prion disease and provided mechanistic 
insights into cognate cellular derangements linked to PrPSc propagation; unfortunately 
preliminary studies untilising simple anti-oxidant treatments appear to have negligible effect on 
disease. Future studies are required to better define the contribution that enhanced neuronal 
oxidative stress plays as a driver in the overall pathogenesis of prion disease and to assess 
whether more potent, targeted anti-oxidant therapies may offer enhanced efficacy.  
In addition, this thesis has described studies developing and thereafter utilizing a new 
electrophysiological disease model directly assessing the acute synaptotoxic effects of ex vivo 
PrPSc based on wild-type hippocampal slices. These experiments provided insights into the 
temporal occurrence, the biochemical evolution of, and the bio-physical properties of PrPSc, as 
well as the early deleterious pathophysiological consequences to key synaptic components. 
Future studies utilizing this model could be undertaken to more precisely define the bio-physical 
characteristics of neurotoxic PrPSc and how this contrasts with PrPSc species underscoring 
disease transmission. Moreover, based on the enhanced biological validity of this model, it 
could be employed for low throughput drug screening of promising therapeutic candidates 
selected based on higher throughput, less stringent techniques. 
An important unresolved issue is the primary biological purpose of PrPC, especially in the CNS. 
Studies of the normal cellular biology of PrPC yielded a number of novel insights, suggesting 
PrPC may have more than one principal role, including participation in the regulation of stem cell 
renewal, anti-oxidant effects via the N2 fragment and signal transduction activities. In addition, a 
new endogenous cleavage event denoted as “gamma” was delineated. Future studies would 
ideally pursue all these avenues of potential PrPC function to determine those that are the most 
important biologically, especially whether corruption of such activities contribute to 
pathogenesis. Further studies are also required to more accurately define the site of gamma-
cleavage, as well as determine the biological significance of this constitutive cleavage in both 
normal cellular homeostasis and disease.
826 
Finally, an effective treatment for human prion disease is arguably the most important, extant 
unmet need. Unfortunately, the limited studies interrogating potential treatments described in 
this thesis were all unsuccessful, joining a vast but disappointing list of agents explored in pre-
clinical assessments. Collaborative research described in this thesis however, has clarified that 
the rarity and unpredictability of age of onset of genetic forms of prion disease renders it 
unsuitable for conventional placebo-controlled human therapeutic trials and less conventional, 
innovative approaches are required. Based on the exciting results for other neurological 
diseases, especially SMA type 1, studies will hopefully commence in the very near future to 
assess the efficacy of ASO strategies for human prion disease. In addition, a high affinity, 
humanised, anti-PrP monoclonal antibody has also been developed based on promising pre-
clinical studies but bureaucratic and funding hurdles have delayed transition into formal clinical 
trials although a very limited assessment of safety in a small number of patients has been 
undertaken with an outcome report not yet provided.
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